PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fei, JW; Angel, P; Wei, QX; de Villiers, EM				Fei, J-W; Angel, P.; Wei, Q-X; de Villiers, E-M			TAp63 alpha indirectly regulates a cutaneous HPV promoter through complex formation with Jun family members	ONCOGENE			English	Article						TAp63 alpha; Jun; HPV 20; mtp53 R248W	C-JUN; HUMAN PAPILLOMAVIRUSES; AP-1 SUBUNITS; P53 HOMOLOG; P63; CELL; PROTEINS; DELTA-NP63-ALPHA; FOS; P73	The p63 alpha isoforms of the p53 family have been demonstrated to play a crucial role in the development and differentiation of the skin. We show that expression of the TAp63 alpha isoform leads to an upregulation of the cutaneous papillomavirus HPV 20 promoter, which is increased at least three-fold when c-Jun is co-expressed, in contrast to a minimal increase in activity in the presence of c-Jun alone. Co-expression of TAp63 alpha with JunB or JunD, respectively, and in combination, leads to a reduction in the viral promoter activation measured by the expression of TAp63 alpha alone. JunB and JunD also inhibits the additive effect exerted on the TAp63a activation by c-Jun. Co-immunoprecipitation assays demonstrate a complex formation of c-Jun, JunB and JunD with TAp 63 alpha through the SAM domain mediating protein-protein interactions, which is characteristic for p63 alpha. Co-expression of p53 mutant R248W not only downregulates the differential modulation of the viral promoter by TAp63 alpha alone and in the presence of the Jun family members, but leads to a reduction in the protein levels of the overexpressed c-Jun, JunB, JunD, as well as TAp63 alpha. This model system provides insight into yet unknown pathways through which TAp63 alpha and Jun may cooperate in the pathogenesis of HPV associated cutaneous lesions.	Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	de Villiers, EM (corresponding author), Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	e.devilliers@dkfz.de	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Angel P, 2002, BIOCHEM PHARMACOL, V64, P949, DOI 10.1016/S0006-2952(02)01158-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Fei JW, 2005, CELL CYCLE, V4, P689, DOI 10.4161/cc.4.5.1653; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Green H, 2003, P NATL ACAD SCI USA, V100, P15625, DOI 10.1073/pnas.0307226100; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2004, CELL CYCLE, V3, P411; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; MAJEWSKI S, 1995, ARCH DERMATOL, V131, P1312, DOI 10.1001/archderm.131.11.1312; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3914	3923		10.1038/sj.onc.1209420	http://dx.doi.org/10.1038/sj.onc.1209420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474846				2022-12-25	WOS:000238668800004
J	Akey, D; Martins, A; Aniukwu, J; Glickman, MS; Shuman, S; Berger, JM				Akey, D; Martins, A; Aniukwu, J; Glickman, MS; Shuman, S; Berger, JM			Crystal structure and nonhomologous end-joining function of the ligase component of Mycobacterium DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; PHOSPHODIESTER BOND FORMATION; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; NUCLEOTIDYL TRANSFER; ATOMIC-STRUCTURE; IN-VITRO; DOMAIN; PROTEIN; REPAIR	DNA ligase D ( LigD) is a large polyfunctional enzyme involved in nonhomologous end- joining ( NHEJ) in mycobacteria. LigD consists of a C- terminal ATP- dependent ligase domain fused to upstream polymerase and phosphoesterase modules. Here we report the 2.4 angstrom crystal structure of the ligase domain of Mycobacterium LigD, captured as the covalent ligase- AMP intermediate with a divalent metal in the active site. A chloride anion on the protein surface coordinated by the ribose 3 '- OH and caged by arginine and lysine side chains is a putative mimetic of the 5 '- phosphate at a DNA nick. Structure- guided mutational analysis revealed distinct requirements for the adenylylation and end- sealing reactions catalyzed by LigD. We found that amutation of Mycobacterium LigD that ablates only ligase activity results in decreased fidelity of NHEJ in vivo and a strong bias of mutagenic events toward deletions instead of insertions at the sealed DNA ends. This phenotype contrasts with the increased fidelity of double- strand break repair in Delta ligD cells or in a strain in which only the polymerase function of LigD is defective. We surmise that the signature error- prone quality of bacterial NHEJ in vivo arises from a dynamic balance between the end- remodeling and end- sealing steps.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Div Infect Dis, New York, NY 10021 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California Berkeley	Berger, JM (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	jmberger@berkeley.edu	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497; Glickman, Michael S/0000-0001-7918-5164	NIAID NIH HHS [AI064693, R01 AI064693-03, R01 AI064693] Funding Source: Medline; NIGMS NIH HHS [T32 GM007739, GM62410, GM07739, GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410, T32GM007739, R01GM063611] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; CONG PJ, 1993, J BIOL CHEM, V268, P7256; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Deng JP, 2004, J MOL BIOL, V343, P601, DOI 10.1016/j.jmb.2004.08.041; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; El Omari K, 2006, J BIOL CHEM, V281, P1573, DOI 10.1074/jbc.M509658200; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Gajiwala KS, 2004, STRUCTURE, V12, P1449, DOI 10.1016/j.str.2004.05.017; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; MacDowell AA, 2004, J SYNCHROTRON RADIAT, V11, P447, DOI 10.1107/S0909049504024835; Magnet S, 2004, BIOCHEMISTRY-US, V43, P710, DOI 10.1021/bi0355387; Martin IV, 2002, GENOME BIOL, V3; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Odell M, 2003, NUCLEIC ACIDS RES, V31, P5090, DOI 10.1093/nar/gkg665; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Srivastava SK, 2005, J BIOL CHEM, V280, P30273, DOI 10.1074/jbc.M503780200; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P12137, DOI 10.1074/jbc.M413685200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	63	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13412	13423		10.1074/jbc.M513550200	http://dx.doi.org/10.1074/jbc.M513550200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16476729	hybrid			2022-12-25	WOS:000237336600048
J	Zhao, G; Zhou, XK; Wang, LQ; Li, GT; Kisker, C; Lennarz, WJ; Schindelin, H				Zhao, G; Zhou, XK; Wang, LQ; Li, GT; Kisker, C; Lennarz, WJ; Schindelin, H			Structure of the mouse peptide N-glycanase-HR23 complex suggests co-evolution of the endoplasmic reticulum-associated degradation and DNA repair pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; XPC-BINDING DOMAIN; GROUP-C PROTEIN; ER-ASSOCIATED DEGRADATION; N-GLYCANASE; DAMAGE RECOGNITION; QUALITY-CONTROL; YEAST PEPTIDE; MECHANISM; IDENTIFICATION	Peptide N- glycanase removes N- linked oligosaccharides from mis-folded glycoproteins as part of the endoplasmic reticulum- associated degradation pathway. This process involves the formation of a tight complex of peptide N- glycanase with Rad23 in yeast and the orthologous HR23 proteins in mammals. In addition to its function in endoplasmic reticulum- associated degradation, HR23 is also involved in DNA repair, where it plays an important role in damage recognition in complex with the xeroderma pigmentosum group C protein. To characterize the dual role of HR23, we have determined the high resolution crystal structure of the mouse peptide N- glycanase catalytic core in complex with the xeroderma pigmentosum group C binding domain from HR23B. Peptide N- glycanase features a large cleft between its catalytic cysteine protease core and zinc binding domain. Opposite the zinc binding domain is the HR23B- interacting region, and surprisingly, the complex interface is fundamentally different from the orthologous yeast peptide N- glycanase- Rad23 complex. Different regions on both proteins are involved in complex formation, revealing an amazing degree of divergence in the interaction between two highly homologous proteins. Furthermore, the mouse peptide N- glycanase- HR23B complex mimics the interaction between xeroderma pigmentosum group C and HR23B, thereby providing a first structural model of how the two proteins interact within the nucleotide excision repair cascade in higher eukaryotes. The different interaction interfaces of the xeroderma pigmentosum group C binding domains in yeast and mammals suggest a co- evolution of the endoplasmic reticulum- associated degradation and DNA repair pathways.	SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Biol Struct, D-97078 Wurzburg, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wurzburg; University of Wurzburg	Schindelin, H (corresponding author), SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM70783, GM33814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aloy P, 2004, NAT BIOTECHNOL, V22, P1317, DOI 10.1038/nbt1018; Aloy P, 2003, J MOL BIOL, V332, P989, DOI 10.1016/j.jmb.2003.07.006; Anantharaman V, 2001, HUM MOL GENET, V10, P1627, DOI 10.1093/hmg/10.16.1627; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biswas S, 2004, BIOCHEM BIOPH RES CO, V323, P149, DOI 10.1016/j.bbrc.2004.08.061; Brinda KV, 2005, BIOCHEM J, V391, P1, DOI 10.1042/BJ20050434; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Fu LW, 2003, J CELL BIOL, V160, P157, DOI 10.1083/jcb.200210086; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamionka M, 2004, PROTEIN SCI, V13, P2370, DOI 10.1110/ps.04824304; Katiyar S, 2002, J BIOL CHEM, V277, P12953, DOI 10.1074/jbc.M111383200; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kim B, 2005, FEBS J, V272, P2467, DOI 10.1111/j.1742-4658.2005.04667.x; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; Makarova KS, 1999, PROTEIN SCI, V8, P1714, DOI 10.1110/ps.8.8.1714; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; McCracken AA, 1996, GENETICS, V144, P1355; Misaghi S, 2004, CHEM BIOL, V11, P1677, DOI 10.1016/j.chembiol.2004.11.010; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Ortolan TG, 2004, NUCLEIC ACIDS RES, V32, P6490, DOI 10.1093/nar/gkh987; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Park SY, 2004, P NATL ACAD SCI USA, V101, P11646, DOI 10.1073/pnas.0401038101; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Royer WE, 2001, TRENDS BIOCHEM SCI, V26, P297, DOI 10.1016/S0968-0004(01)01811-4; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sugasawa K, 2002, DNA REPAIR, V1, P95, DOI 10.1016/S1568-7864(01)00008-8; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Suzuki T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0889rev; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9; Xie ZW, 2004, NUCLEIC ACIDS RES, V32, P5981, DOI 10.1093/nar/gkh934; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870	57	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13751	13761		10.1074/jbc.M600137200	http://dx.doi.org/10.1074/jbc.M600137200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16500903	hybrid			2022-12-25	WOS:000237336600086
J	Kanjilal-Kolar, S; Raetz, CRH				Kanjilal-Kolar, S; Raetz, CRH			Dodecaprenyl phosphate-galacturonic acid as a donor substrate for lipopolysaccharide core glycosylation in Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; LIPID-A BIOSYNTHESIS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; EXPRESSION CLONING; O-ANTIGEN; SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; SHIGELLA-FLEXNERI; MASS-SPECTROMETRY; MEMBRANE ENZYME	The lipid A and inner core regions of Rhizobium leguminosarum lipopolysaccharide contain four galacturonic acid ( GalA) residues. Two are attached to the outer unit of the 3-deoxy-D-manno-octulosonic acid (Kdo) disaccharide, one to the mannose residue, and one to the 4'-position of lipid A. The enzymes RgtA and RgtB, described in the accompanying article, catalyze GalA transfer to the Kdo residue, whereas RgtC is responsible for modification of the core mannose unit. Heterologous expression of RgtA in Sinorhizhobium meliloti 1021, a strain that normally lacks GalA modifications on its Kdo disaccharide, resulted in detectable GalA transferase activity in isolated membrane preparations, suggesting that the appropriate GalA donor substrate is available in S. meliloti membranes. In contrast, heterologous expression of RgtA in Escherichia coli yielded inactive membranes. However, RgtA activity was detectable in the E. coli system when total lipids from R. leguminosarum 3841 or S. meliloti 1021 were added. We have now purified and characterized dodecaprenyl (C60) phosphate-GalA as a minor novel lipid of R. leguminosarum 3841 and S. meliloti. This substance is stable to mild base hydrolysis and was purified by DEAE-cellulose column chromatography. Its structure was established by a combination of electrospray ionization mass spectrometry and gas-liquid chromatography. Purified dodecaprenyl phosphate-GalA supports the efficient transfer of GalA to Kdo(2)-1-dephospho-lipid IVA by membranes of E. coli cells expressing RgtA, RgtB, and RgtC. The identification of a polyisoprene phosphate-GalA donor substrate suggests that the active site of RgtA faces the periplasmic side of the inner membrane. This work represents the first definitive characterization of a lipid-linked GalA derivative with the proposed structure dodecaprenyl phosphate-beta-D-GalA.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, R37GM051796, U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069338, R37 GM051796, GM-51796, R37 GM051796-10, R01 GM051796, U54 GM069338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allison GE, 2000, TRENDS MICROBIOL, V8, P17, DOI 10.1016/S0966-842X(99)01646-7; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; Choma A, 2004, EUR J BIOCHEM, V271, P1310, DOI 10.1111/j.1432-1033.2004.04038.x; DO UH, 1980, J LIPID RES, V21, P888; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DOTSON SB, 1995, ARCH BIOCHEM BIOPHYS, V316, P773, DOI 10.1006/abbi.1995.1103; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Guan ZQ, 2005, ANAL BIOCHEM, V345, P336, DOI 10.1016/j.ab.2005.07.002; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; Kanjilal S, 2005, GLYCOBIOLOGY, V15, P1194; Kanjilal-Kolar S, 2006, J BIOL CHEM, V281, P12865, DOI 10.1074/jbc.M513864200; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; Keating DH, 2002, J BACTERIOL, V184, P6681, DOI 10.1128/JB.184.23.6681-6689.2002; Kelleher DJ, 2001, GLYCOBIOLOGY, V11, P321, DOI 10.1093/glycob/11.4.321; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Mavris M, 1997, MOL MICROBIOL, V26, P939, DOI 10.1046/j.1365-2958.1997.6301997.x; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; RUSSOMANDO G, 1992, AN ASOC QUIM ARGENT, V80, P175; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wang XY, 2006, J BIOL CHEM, V281, P9321, DOI 10.1074/jbc.M600435200; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J BIOL CHEM, V270, P20151, DOI 10.1074/jbc.270.34.20151; YOKOYAMA K, 1988, EUR J BIOCHEM, V173, P453, DOI 10.1111/j.1432-1033.1988.tb14020.x	57	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12879	12887		10.1074/jbc.M513865200	http://dx.doi.org/10.1074/jbc.M513865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497671	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000237134700083
J	Yeung, BHY; Huang, DC; Sinicrope, FA				Yeung, BHY; Huang, DC; Sinicrope, FA			PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; CYTOCHROME-C RELEASE; PROTEASOME INHIBITOR; CASPASE-2; ACTIVATION; BAX; DYSFUNCTION; CLEAVAGE; RESISTANCE; EXPRESSION	PS-341 (bortezomib) is a potent and reversible proteosome inhibitor that functions to degrade intracellular polyubiquitinated proteins. PS-341 induces apoptosis and has shown broad antitumor activity with selectivity for transformed cells. We studied the effect of PS-341 on lysosomal and mitochondrial permeabilization, including the role of caspase-2 activation in apoptosis induction in the BxPC-3 human pancreatic carcinoma cell line. PS-341 induced a dose-dependent apoptosis in association with reactive oxygen species generation and cleavage of caspase-2 to its 33- and 14-kDa fragments. PS-341 disrupted lysosomes with redistribution of cathepsin B to the cytosol, as shown using fluorescence confocal microscopy, that was blocked by the free radical scavenger tiron but not by a caspase-2 inhibitor ( benzyloxycarbonyl (Z)-VDVAD-fluoromethyl ketone (FMK)). PS-341-induced caspase-2 activation was attenuated by a selective pharmacological inhibitor of cathepsin B (R-3032), suggesting that cathepsin B release occurs upstream of caspase-2. PS-341-induced mitochondrial depolarization was attenuated by Z-VDVAD-FMK, tiron, and an inhibitor of the mitochondrial permeability transition pore (bongkrekic acid). Regulation of mitochondrial permeability by caspase-2 was confirmed using caspase-2 small interfering RNA. PS-341-induced cytochrome c release and phosphatidylserine externalization were attenuated by Z-VDVAD-FMK and partially by R-3032. PS-341 activated the BH3-only proteins Bik and Bim and down-regulated Bcl-2 and Bcl-x(L) mRNA and protein expression. Taken together, PS-341 induces lysosomal cathepsin B redistribution upstream of caspase-2. Caspase-2 activation regulates PS-341-induced mitochondrial depolarization and apoptosis, suggesting that caspase-2 can serve as a link between lysosomal and mitochondrial permeabilization.	Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Div Oncol, Rochester, MN 55905 USA; Mayo Coll Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Sinicrope, FA (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	sinicrope.frank@mayo.edu						Adams J, 1999, CANCER RES, V59, P2615; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dirsch VM, 2004, ONCOGENE, V23, P1586, DOI 10.1038/sj.onc.1207281; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Hideshima T, 2001, CANCER RES, V61, P3071; Hishita T, 2001, CANCER RES, V61, P2878; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Lassus P, 2004, SCIENCE, V306, P1683; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lebedeva IV, 2003, CANCER RES, V63, P8138; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Ling YH, 2002, MOL CANCER THER, V1, P841; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Nikrad M, 2005, MOL CANCER THER, V4, P443; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paquet C, 2005, LEUKEMIA, V19, P784, DOI 10.1038/sj.leu.2403717; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tatebe S, 2002, INT J CANCER, V97, P21, DOI 10.1002/ijc.1574; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225	52	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11923	11932		10.1074/jbc.M508533200	http://dx.doi.org/10.1074/jbc.M508533200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16446371	hybrid			2022-12-25	WOS:000236988100061
J	Maki, N; Moitra, K; Ghosh, P; Dey, S				Maki, N; Moitra, K; Ghosh, P; Dey, S			Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MULTIDRUG TRANSPORTER; NUCLEOTIDE-BINDING SITES; CATALYTIC CYCLE; ABC TRANSPORTERS; RESISTANCE; INHIBITION; CELLS; PROTEINS; CLEAVAGE; MUTANTS	ATP-dependent drug transport by human P-glycoprotein (Pgp, ABCB1) involves a coordinated communication between its drug-binding site ( substrate site) and the nucleotide binding/hydrolysis domain (ATP sites). It has been demonstrated that the two ATP sites of Pgp play distinct roles within a single catalytic turnover; whereas ATP binding or/and hydrolysis by one drives substrate translocation and dissociation, the hydrolytic activity of the other resets the transporter for the subsequent cycle (Sauna, Z. E., and Ambudkar, S. V. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2515-2520; Sauna, Z. E., and Ambudkar, S. V. (2001) J. Biol. Chem. 276, 11653-11661). Trapping of ADP (or 8-azido-ADP) and vanadate (ADP center dot Vi or 8-azido-ADP center dot Vi) at the catalytic site, following nucleotide hydrolysis, markedly reduces the affinity of Pgp for its transport substrate [I-125]iodoarylazidoprazosin ([I-125]IAAP), resulting in dissociation of the latter. Regeneration of the [I-125] IAAP site requires an additional round of nucleotide hydrolysis. In this study, we demonstrate that certain thioxanthene-based allosteric modulators, such as cis-(Z)-flupentixol and its closely related analogs, induce regeneration of [I-125]IAAP binding to vanadate-trapped (or fluoroaluminate-trapped) Pgp without any further nucleotide hydrolysis. Regeneration was facilitated by dissociation of the trapped nucleotide and vanadate. Once regenerated, the substrate site remains accessible to [I-125] IAAP even after removal of the modulator from the medium, suggesting amodulator-induced relaxation of a constrained transition state conformation. Consistent with this, limited trypsin digestion of vanadate-trapped Pgp shows protection by cis-(Z)-flupentixol of two Pgp fragments (similar to 60 kDa) recognizable by a polyclonal antiserum specific for the NH2-terminal half. No regeneration was observed in the Pgp mutant F983A that is impaired in modulation by flupentixols, indicating involvement of the allosteric modulator site in the phenomenon. In summary, the data demonstrate that in the nucleotide-trapped low affinity state of Pgp, the allosteric site remains accessible and responsive to modulation by flupentixol (and its closely related analogs), which can reset the high affinity state for [I-125]IAAP binding without any further nucleotide hydrolysis.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Dey, S (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	sdey@usuhs.mil			NIGMS NIH HHS [GM067926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Shawi MK, 2003, J BIOL CHEM, V278, P52629, DOI 10.1074/jbc.M308175200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FORD JM, 1990, CANCER RES, V50, P1748; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Loo TW, 2005, BIOCHEMISTRY-US, V44, P10250, DOI 10.1021/bi050705j; Loo TW, 2004, BIOCHEMISTRY-US, V43, P12081, DOI 10.1021/bi049045t; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Maki N, 2003, J BIOL CHEM, V278, P18132, DOI 10.1074/jbc.M210413200; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Nuti SL, 2002, J BIOL CHEM, V277, P29417, DOI 10.1074/jbc.M204054200; Omote H, 2004, BIOCHEMISTRY-US, V43, P3917, DOI 10.1021/bi035365l; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x	41	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10769	10777		10.1074/jbc.M512579200	http://dx.doi.org/10.1074/jbc.M512579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505485	hybrid			2022-12-25	WOS:000236822200016
J	Cauvi, DM; Tian, XF; von Loehneysen, K; Robertson, MW				Cauvi, DM; Tian, XF; von Loehneysen, K; Robertson, MW			Transport of the IgE receptor alpha-chain is controlled by a multicomponent intracellular retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; MAST-CELL; TRANSMEMBRANE DOMAINS; AMINOGLYCOSIDE ANTIBIOTICS; MEMBRANE-PROTEINS; CYTOPLASMIC TAIL	The human high affinity IgE receptor(Fc epsilon RI) is a central component of the allergic response and is expressed as either a trimeric alpha gamma 2 or tetrameric alpha beta gamma 2 complex. It has been previously described that the cytoplasmic domain (CD) of the alpha-chain carries a dilysine motif at positions -3/-7 from the C terminus that functions in intracellular retention prior to assembly with other Fc epsilon RI subunits. In this report we have further explored the role of the -3/-7 dilysine signal in controlling steady-state alpha-chain transport by mutational analysis and found little surface expression of a -3/-7 dialanine alpha-chain mutant but significant Golgi localization. We compared the transport properties of a series of alpha-chain cytoplasmic domain truncation mutants and observed that truncation mutants lacking 23 or more C-terminal residues showed a dramatic increase in steady-state transport suggesting a role for the membrane-proximal CD sequence in alpha-chain retention. By performing alanine-scanning mutagenesis we identified a dilysine sequence (Lys(212)-Lys(216)) proximal to the transmembrane domain (TMD) that is important for both alpha-chain cell-surface expression and intracellular stability. Furthermore, co-mutation of the Lys(212)-Lys(216) residues with the -3/-7 dilysine signal produced a dramatic increase in alpha-chain surface expression that was further increased by co-mutation of the lone charged residue (Asp(192)) in the TMD thereby defining three regions that function to regulate alpha-chain transport and in a highly synergistic manner.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Robertson, MW (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-131,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mwr@scripps.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047238] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 47238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe M, 2004, J CELL SCI, V117, P5687, DOI 10.1242/jcs.01491; Albrecht B, 2000, J IMMUNOL, V165, P5686, DOI 10.4049/jimmunol.165.10.5686; Allam JP, 2004, J INVEST DERMATOL, V123, P676, DOI 10.1111/j.0022-202X.2004.23428.x; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Delgado P, 2005, J EXP MED, V201, P555, DOI 10.1084/jem.20041133; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; Donnadieu E, 2003, IMMUNITY, V18, P665, DOI 10.1016/S1074-7613(03)00115-8; Draper RK, 2001, METHOD ENZYMOL, V329, P372; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fiebiger E, 2005, J EXP MED, V201, P267, DOI 10.1084/jem.20041384; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Gomez G, 2005, J IMMUNOL, V174, P5987, DOI 10.4049/jimmunol.174.10.5987; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GREENE WC, 1985, J CELL SCI, P97; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Nylander S, 1999, J IMMUNOL METHODS, V224, P69, DOI 10.1016/S0022-1759(99)00010-1; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Schroder-Kohne S, 1998, J CELL SCI, V111, P3459; Scott M, 2004, BIOINFORMATICS, V20, P937, DOI 10.1093/bioinformatics/bth010; Seminario MC, 1999, J IMMUNOL, V162, P6893; Smith SJ, 2000, J ALLERGY CLIN IMMUN, V105, P309, DOI 10.1016/S0091-6749(00)90081-2; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Toru H, 1996, INT IMMUNOL, V8, P1367; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	66	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10448	10460		10.1074/jbc.M510751200	http://dx.doi.org/10.1074/jbc.M510751200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459334	hybrid			2022-12-25	WOS:000236594300074
J	Tao, Z; Zhang, Z; Grewer, C				Tao, Z; Zhang, Z; Grewer, C			Neutralization of the aspartic acid residue Asp-367, but not Asp-454, inhibits binding of Na+ to the glutamate-free form and cycling of the glutamate transporter EAAC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FUNCTIONAL-CHARACTERIZATION; ANION CONDUCTANCE; CHLORIDE CHANNEL; GLT-1; CARRIER; EXPRESSION; EXCHANGE; CURRENTS; CLONING	Substrate transport by the plasma membrane glutamate transporter EAAC1 is coupled to cotransport of three sodium ions. One of these Na+ ions binds to the transporter already in the absence of glutamate. Here, we have investigated the possible involvement of two conserved aspartic acid residues in transmembrane segments 7 and 8 of EAAC1, Asp-367 and Asp-454, in Na+ cotransport. To test the effect of charge neutralization mutations in these positions on Na+ binding to the glutamate-free transporter, we recorded the Na+-induced anion leak current to determine the K-m of EAAC1 for Na+. For EAAC1WT, this K-m was determined as 120 mM. When the negative charge of Asp-367 was neutralized by mutagenesis to asparagine, Na+ activated the anion leak current with a K-m of about 2 M, indicating dramatically impaired Na+ binding to the mutant transporter. In contrast, the Na+ affinity of EAAC1(D454N) was virtually unchanged compared with the wild type transporter (K-m = 90 mM). The reduced occupancy of the Na+ binding site of EAAC1(D367N) resulted in a dramatic reduction in glutamate affinity (K-m = 3.6 mM, 140 mM [Na+]), which could be partially overcome by increasing extracellular [Na+]. In addition to impairing Na+ binding, the D367N mutation slowed glutamate transport, as shown by pre-steady-state kinetic analysis of transport currents, by strongly decreasing the rate of a reaction step associated with glutamate translocation. Our data are consistent with a model in which Asp-367, but not Asp-454, is involved in coordinating the bound Na+ in the glutamate-free transporter form.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	University of Miami	Grewer, C (corresponding author), 1600 NW 10th Ave, Miami, FL 33136 USA.	cgrewer@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049335] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS049335-02, R01 NS 049335-02, R01 NS049335] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bergles DE, 2002, J NEUROSCI, V22, P10153; Billups B, 1996, J NEUROSCI, V16, P6722; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Canepari M, 2001, J NEUROSCI METH, V112, P29, DOI 10.1016/S0165-0270(01)00451-4; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grewer C, 2004, J PHYSIOL-LONDON, V557, P747, DOI 10.1113/jphysiol.2004.062521; Grewer C, 2003, J BIOL CHEM, V278, P2585, DOI 10.1074/jbc.M207956200; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KLUGE C, 1993, J BIOL CHEM, V268, P14557; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Melzer N, 2003, J BIOL CHEM, V278, P50112, DOI 10.1074/jbc.M307990200; Otis TS, 2000, J NEUROSCI, V20, P2749; Otis TS, 1998, J NEUROSCI, V18, P7099; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tao Z, 2005, BIOCHEMISTRY-US, V44, P3466, DOI 10.1021/bi047812i; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	40	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10263	10272		10.1074/jbc.M510739200	http://dx.doi.org/10.1074/jbc.M510739200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478724	Green Accepted, hybrid			2022-12-25	WOS:000236594300054
J	Long, XH; Nephew, KP				Long, XH; Nephew, KP			Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; INTERMEDIATE FILAMENT; PURE-ANTIESTROGEN; ER-ALPHA; DEPENDENT DEGRADATION; NUCLEAR RECEPTORS; PROTEASOME; LIGAND; TURNOVER; STABILITY	The antiestrogen fulvestrant (ICI 182,780) causes immobilization of estrogen receptor-alpha(ER alpha) in the nuclear matrix accompanied by rapid degradation by the ubiquitin-proteasome pathway. In this study we tested the hypothesis that fulvestrant induces specific nuclear matrix protein-ER alpha interactions that mediate receptor immobilization and turnover. A glutathione S-transferase (GST)ER alpha-activating function-2 (AF2) fusion protein was used to isolate and purify receptor-interacting proteins in cell lysates prepared from human MCF-7 breast cancer cells. After SDS-PAGE and gel excision, mass spectrometry was used to identify two major ER alpha-interacting proteins, cytokeratins 8 and 18 (CK8 . CK18). We determined, using ER alpha-activating function-2 mutants, that helix 12 (H12) of ER alpha, but not its F domain, is essential for fulvestrant-induced ER alpha-CK8 and CK18 interactions. To investigate the in vivo role of H12 in fulvestrant-induced ER alpha immobilization/degradation, transient transfection assays were performed using wild type ER alpha, ER alpha with amutated H12, and ER alpha with a deleted F domain. Of those, only the ER alpha H12 mutant was resistant to fulvestrant-induced immobilization to the nuclear matrix and protein degradation. Fulvestrant treatment caused ER alpha degradation in CK8 . CK18-positive human breast cancer cells, and CK8 and CK18 depletion by small interference RNAs partially blocked fulvestrant-induced receptor degradation. Furthermore, fulvestrant-induced ER alpha degradation was not observed in CK8 or CK18-negative cancer cells, suggesting that these two intermediate filament proteins are necessary for fulvestrant-induced receptor turnover. Using an ER alpha-green fluorescent protein construct in fluorescence microscopy revealed that fulvestrant-induced cytoplasmic localization of newly synthesized receptor is mediated by its interaction with CK8 and CK18. In summary, this study provides the first direct evidence linking ER alpha immobilization and degradation to the nuclear matrix. We suggest that fulvestrant induces ER alpha to interact with CK8 and CK18, drawing the receptor into close proximity to nuclear matrix-associated proteasomes that facilitate ER alpha turnover.	Indiana Univ, Sch Med, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nephew, KP (corresponding author), Indiana Univ, Sch Med, 302 Jordan Hall,1001 E 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu						Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Arcangeletti C, 2000, EUR J CELL BIOL, V79, P423, DOI 10.1078/0171-9335-00059; Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; BARRACK ER, 1987, J STEROID BIOCHEM, V27, P115, DOI 10.1016/0022-4731(87)90302-5; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fan MY, 2002, MOL ENDOCRINOL, V16, P315, DOI 10.1210/me.16.2.315; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Fuqua SAW, 2000, CANCER RES, V60, P4026; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; GRAHAM ML, 1990, CANCER RES, V50, P6208; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Howell A, 2000, EUR J CANCER, V36, pS87; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Iwaya K, 2003, CANCER SCI, V94, P864, DOI 10.1111/j.1349-7006.2003.tb01368.x; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; McDonnell DP, 2005, CLIN CANCER RES, V11, p871S; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Oesterreich S, 2001, CANCER RES, V61, P5771; OLINKCOUX M, 1994, J CELL SCI, V107, P353; Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Peekhaus NT, 2004, J MOL ENDOCRINOL, V32, P987, DOI 10.1677/jme.0.0320987; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Seo HS, 1998, INT J CANCER, V78, P760, DOI 10.1002/(SICI)1097-0215(19981209)78:6<760::AID-IJC14>3.0.CO;2-U; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014	56	110	114	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9607	9615		10.1074/jbc.M510809200	http://dx.doi.org/10.1074/jbc.M510809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16459337	hybrid			2022-12-25	WOS:000236404700072
J	Reyes, F; Marchant, L; Norambuena, L; Nilo, R; Silva, H; Orellana, A				Reyes, F; Marchant, L; Norambuena, L; Nilo, R; Silva, H; Orellana, A			AtUTr1, a UDP-glucose/UDP-galactose transporter from Arabidopsis thaliana, is located in the endoplasmic reticulum and up-regulated by the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; GLYCOPROTEIN GLUCOSYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; IDENTIFICATION; CALNEXIN; OLIGOSACCHARIDE; PURIFICATION; RECOGNITION; EXPRESSION	The folding of glycoproteins in the endoplasmic reticulum (ER) depends on a quality control mechanism mediated by the calnexin/calreticulin cycle. During this process, continuous glucose trimming and UDP-glucose-dependent re-glucosylation of unfolded glycoproteins takes place. To ensure proper folding, increases in misfolded proteins lead to up-regulation of the components involved in quality control through a process known as the unfolded protein response (UPR). Reglucosylation is catalyzed by the ER lumenal located enzyme UDP-glucose glycoprotein glucosyltransferase, but as UDP-glucose is synthesized in the cytosol, a UDPglucose transporter is required in the calnexin/calreticulin cycle. Even though such a transporter has been hypothesized, no protein playing this role in the ER yet has been identified. Here we provide evidence that AtUTr1, a UDP-galactose/glucose transporter from Arabidopsis thaliana, responds to stimuli that trigger the UPR increasing its expression around 9-fold. The accumulation of AtUTr1 transcript is accompanied by an increase in the level of the AtUTr1 protein. Moreover, subcellular localization studies indicate that AtUTr1 is localized in the ER of plant cells. We reasoned that an impairment in AtUTr1 expression should perturb the calnexin/calreticulin cycle leading to an increase in misfolded protein and triggering the UPR. Toward that end, we analyzed an AtUTr1 insertional mutant and found an up-regulation of the ER chaperones BiP and calnexin, suggesting that these plants may be constitutively activating the UPR. Thus, we propose that in A. thaliana, AtUTr1 is the UDP-glucose transporter involved in quality control in the ER.	Univ Chile, Fac Sci, Plant Cell Biol Millennium Nucleus, Santiago, Chile; Univ Chile, Fac Sci, Grad Sch, Santiago, Chile; Univ Andres Bello, Ctr Plant Biotechnol, Santiago, Chile	Universidad de Chile; Universidad de Chile; Universidad Andres Bello	Orellana, A (corresponding author), Univ Chile, Fac Sci, Plant Cell Biol Millennium Nucleus, Casilla 653, Santiago, Chile.	aorellana@unab.cl	Orellana, Ariel/E-2166-2014; Norambuena, Lorena/I-1248-2013; Poyanco, Ricardo Nilo/AAJ-8006-2021; Silva, Herman P/C-7252-2012; Orellana, Ariel/AAE-4866-2021	Orellana, Ariel/0000-0002-9243-808X; Norambuena, Lorena/0000-0002-6031-2394; Poyanco, Ricardo Nilo/0000-0003-3041-7539; Silva, Herman P/0000-0003-1007-7442; Orellana, Ariel/0000-0002-9243-808X				Baldwin TC, 2001, PLANT CELL, V13, P2283, DOI 10.1105/tpc.13.10.2283; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Boisson M, 2001, EMBO J, V20, P1010, DOI 10.1093/emboj/20.5.1010; BOLLAG DM, 1993, PROTEIN METHODS, P184; BOYCE JM, 1994, PLANT PHYSIOL, V106, P1691, DOI 10.1104/pp.106.4.1691; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; Dhugga KS, 1997, P NATL ACAD SCI USA, V94, P7679, DOI 10.1073/pnas.94.14.7679; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hodges T K, 1974, Methods Enzymol, V32, P392; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; Iwata Y, 2005, P NATL ACAD SCI USA, V102, P5280, DOI 10.1073/pnas.0408941102; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kamauchi S, 2005, FEBS J, V272, P3461, DOI 10.1111/j.1742-4658.2005.04770.x; Kato N, 2002, PLANT PHYSIOL, V129, P931, DOI 10.1104/pp.005496; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Martinez IM, 2003, PLANT CELL, V15, P561, DOI 10.1105/tpc.007609; Munoz P, 1996, PLANT PHYSIOL, V112, P1585, DOI 10.1104/pp.112.4.1585; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; Nelson DE, 1997, PLANT PHYSIOL, V114, P29, DOI 10.1104/pp.114.1.29; Norambuena L, 2005, PLANTA, V222, P521, DOI 10.1007/s00425-005-1557-x; Norambuena L, 2002, J BIOL CHEM, V277, P32923, DOI 10.1074/jbc.M204081200; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Parinov S, 1999, PLANT CELL, V11, P2263, DOI 10.1105/tpc.11.12.2263; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Silva H, 1999, MOL PLANT MICROBE IN, V12, P1053, DOI 10.1094/MPMI.1999.12.12.1053; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; Steinhauser D, 2004, BIOINFORMATICS, V20, P3647, DOI 10.1093/bioinformatics/bth398; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Vanzin GF, 2002, P NATL ACAD SCI USA, V99, P3340, DOI 10.1073/pnas.052450699	46	39	41	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9145	9151		10.1074/jbc.M512210200	http://dx.doi.org/10.1074/jbc.M512210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467298	hybrid			2022-12-25	WOS:000236404700020
J	Ballard, VLT; Sharma, A; Duignan, I; Holm, JM; Chin, A; Choi, R; Hajjar, KA; Wong, SC; Edelberg, JM				Ballard, Victoria L. T.; Sharma, Arti; Duignan, Inga; Holm, Jacquelyne M.; Chin, Andrew; Choi, Ruby; Hajjar, Katherine A.; Wong, Shing-Chiu; Edelberg, Jay M.			Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization	FASEB JOURNAL			English	Article						heart; bone marrow; angiogenesis; EPC	PROGENITOR CELLS; INTEGRIN ALPHA-8-BETA-1; EXTRACELLULAR-MATRIX; ADHESION; EXPRESSION; CARDIOPROTECTION; ANGIOGENESIS; REGENERATION; FIBRONECTIN; IMPAIRMENT	Microenvironmental cues mediate postnatal neovascularization via modulation of endothelial cell and bone marrow-derived endothelial progenitor cell (EPC) activity. Numerous signals regulate the activity of both of these cell types in response to vascular injury, which suggests that parallel mechanisms regulate angiogenesis in the vascular beds of both the heart and bone marrow. To identify mediators of such shared pathways, in vivo bone marrow/cardiac phage display biopanning was performed and led to the identification of tenascin-C as a candidate protein. Functionally, tenascin-C inhibits cardiac endothelial cell spreading and enhances migration in response to angiogenic growth factors. Analysis of human coronary thrombi revealed tenascin-C protein expression colocalized with the endothelial cell/EPC marker Tie-2 in intrathrombi vascular channels. Immunostains in the rodent heart demonstrated that tenascin-C also colocalizes with EPCs homing to sites of cardiac angiogenic induction. To determine the importance of tenascin-C in cardiac neovascularization, we used an established cardiac transplantation model and showed that unlike wild-type mice, tenascin-C-/- mice fail to vascularize cardiac allografts. This demonstrates for the first time that tenascin-C is essential for postnatal cardiac angiogenic function. Together, our data highlight the role of tenascin-C as a microenvironmental regulator of cardiac endothelial/EPC activity.	Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Cornell University; Cornell University	Edelberg, JM (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, 520 E 70th St, New York, NY 10021 USA.	jme2002@med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019738, R03AG020320, R01AG020918] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67839] Funding Source: Medline; NIA NIH HHS [AG19738, AG20918, AG20320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Cai DQ, 2003, AM J PHYSIOL-HEART C, V285, pH463, DOI 10.1152/ajpheart.00144.2003; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Choi K, 1998, DEVELOPMENT, V125, P725; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Edelberg JM, 1998, J CLIN INVEST, V102, P837, DOI 10.1172/JCI3058; Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E; Edelberg JM, 2001, CIRC RES, V89, P117, DOI 10.1161/hh1401.093954; Edelberg JM, 2002, CIRCULATION, V105, P608, DOI 10.1161/hc0502.103672; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Graff J, 2002, J PHARMACOL EXP THER, V300, P952, DOI 10.1124/jpet.300.3.952; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Imanaka-Yoshida K, 2001, LAB INVEST, V81, P1015, DOI 10.1038/labinvest.3780313; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jallo GI, 1997, NEUROSURGERY, V41, P1052, DOI 10.1097/00006123-199711000-00007; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; JOSHI P, 1993, J CELL SCI, V106, P389; Kajiwara K, 2004, CIRC J, V68, P198, DOI 10.1253/circj.68.198; Kale S, 2004, FASEB J, V18, P270, DOI 10.1096/fj.04-1604fje; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kiernan BW, 1996, MOL CELL NEUROSCI, V7, P322, DOI 10.1006/mcne.1996.0024; LAFLEUR DW, 1994, J BIOL CHEM, V269, P20757; Matsuda A, 1999, INVEST OPHTH VIS SCI, V40, P1071; Modarai B, 2005, CIRCULATION, V111, P2645, DOI 10.1161/CIRCULATIONAHA.104.492678; Moldovan NI, 2003, TRENDS CARDIOVAS MED, V13, P265, DOI 10.1016/S1050-1738(03)00108-7; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; Ohta M, 1998, BLOOD, V91, P4074; Paganelli G, 2001, CANCER BIOTHER RADIO, V16, P227, DOI 10.1089/10849780152389410; Paik DC, 2004, EXP MOL MED, V36, P524, DOI 10.1038/emm.2004.67; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Walter DH, 2002, HERZ, V27, P579, DOI 10.1007/s00059-002-2427-y; Whitlon DS, 1999, J COMP NEUROL, V406, P361, DOI 10.1002/(SICI)1096-9861(19990412)406:3<361::AID-CNE5>3.0.CO;2-O; Xaymardan M, 2004, J EXP MED, V199, P797, DOI 10.1084/jem.20031639; Xaymardan M, 2004, CIRC RES, V94, pE39, DOI 10.1161/01.RES.0000122042.51161.B6; Zagzag D, 2002, HISTOL HISTOPATHOL, V17, P301, DOI 10.14670/HH-17.301; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	48	65	79	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					717	+		10.1096/fj.05-5131fje	http://dx.doi.org/10.1096/fj.05-5131fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461331				2022-12-25	WOS:000237698700039
J	Drouineaud, V; Lagrost, L; Klein, A; Desrumaux, C; Le Guern, N; Athias, A; Menetrier, F; Moiroux, P; Sagot, P; Jimenez, C; Masson, D; Deckert, V				Drouineaud, Veronique; Lagrost, Laurent; Klein, Alexis; Desrumaux, Catherine; Le Guern, Naig; Athias, Anne; Menetrier, Franck; Moiroux, Philippe; Sagot, Paul; Jimenez, Clement; Masson, David; Deckert, Valerie			Phospholipid transfer protein (PLTP) deficiency reduces sperm motility and impairs fertility of mouse males.	FASEB JOURNAL			English	Article						alpha-tocopherol; vitamin E; reproductive biology	IN-VITRO FERTILIZATION; ALPHA-TOCOPHEROL; VITAMIN-E; HUMAN SPERMATOZOA; PLASMA; MICE; PATHOPHYSIOLOGY; CHOLESTEROL; INFERTILITY; METABOLISM	Vitamin E was discovered for its implication in reproductive biology, and its transport in mammalian plasma and brain was shown to be governed by plasma phospholipid transfer protein (PLTP). We show that PLTP deficiency is associated with hypofertility of mouse males but not mouse females, and it accounts for a significant decrease in total number of pups produced over a 2-month breeding period of PLTP knocked out mice (-32%, P < 0.03). PLTP is highly expressed in epididymis of mouse males, and alpha-tocopherol, the main vitamin E isomer in vivo, was significantly less abundant in cauda and caput epididymis of PLTP-deficient mice as compared with wild-type counterparts ( caput: -26%, P < 0.05; cauda: -21%, P < 0.05). Mature spermatozoa from PLTP- deficient epididymis were shown to retain an abnormal alpha-tocopherol content. PLTP deficiency tended to reduce sperm motility as shown by a 24% reduction in spermatozoa with progressive motility (P < 0.02), with no change in other sperm parameters as compared with wild-type males. Finally, in vitro fertilization rates of wild-type oocytes with spermatozoa from PLTP- deficient males were markedly reduced as compared with those measured with spermatozoa from wild-type males (-60%, P < 0.05). It is concluded that PLTP is a new, key factor that determines sperm motility and male fertility.	INSERM, U498, Fac Med, F-21079 Dijon, France; EA Genet & Reprod, Lab Biol Reprod, Dijon, France; Fac Med, IFR 100, Dijon, France; Hop Bocage, Serv Gynecol Obstet, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Dijon Bourgogne	Lagrost, L (corresponding author), INSERM, U498, Fac Med, 7 Bd Jeanne Arc,BP87900, F-21079 Dijon, France.	laurent.lagrost@u-bourgogne.fr; valerie.deckert@u-bourgogne.fr	Desrumaux, Catherine/O-1925-2018; Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; DECKERT, Valerie/0000-0001-5728-1710				Agarwal A, 2005, FERTIL STERIL, V84, P228, DOI 10.1016/j.fertnstert.2004.12.057; Agarwal A, 2003, FERTIL STERIL, V79, P829, DOI 10.1016/S0015-0282(02)04948-8; AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Breininger E, 2005, THERIOGENOLOGY, V63, P2126, DOI 10.1016/j.theriogenology.2004.08.016; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Desrumaux C, 1999, FASEB J, V13, P883, DOI 10.1096/fasebj.13.8.883; Desrumaux C, 2004, FASEB J, V18, P296, DOI 10.1096/fj.04-2400fje; ELIASSON R, 1977, FERTIL STERIL, V28, P1257; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; Gatti JL, 2004, ANIM REPROD SCI, V82-3, P321, DOI 10.1016/j.anireprosci.2004.05.011; Geva E, 1996, FERTIL STERIL, V66, P430, DOI 10.1016/S0015-0282(16)58514-8; INGOLD KU, 1987, LIPIDS, V22, P163, DOI 10.1007/BF02537297; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kaempf-Rotzoll DE, 2003, CURR OPIN LIPIDOL, V14, P249, DOI 10.1097/00041433-200306000-00004; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; Keskes-Ammar L, 2003, ARCH ANDROLOGY, V49, P83, DOI 10.1080/713828100; KESSOPOULOU E, 1995, FERTIL STERIL, V64, P825, DOI 10.1016/S0015-0282(16)57861-3; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; LILFORD R, 1994, BMJ-BRIT MED J, V309, P570, DOI 10.1136/bmj.309.6954.570; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Masson D, 2003, MOL HUM REPROD, V9, P457, DOI 10.1093/molehr/gag062; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; Neild DM, 2005, MOL REPROD DEV, V72, P230, DOI 10.1002/mrd.20322; Pena FJ, 2004, ZYGOTE, V12, P117, DOI 10.1017/S096719940400262X; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; Schlitt A, 2005, BBA-MOL CELL BIOL L, V1733, P187, DOI 10.1016/j.bbalip.2004.12.011; Schneider M, 2004, DIABETES, V53, P2633, DOI 10.2337/diabetes.53.10.2633; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Therond P, 1996, MOL HUM REPROD, V2, P739, DOI 10.1093/molehr/2.10.739; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; World Heath Organization (WHO), 2000, WHO LAB MAN EX HUM S; WYROBEK AJ, 1975, P NATL ACAD SCI USA, V72, P4425, DOI 10.1073/pnas.72.11.4425; Xian-Cheng J, 2005, J BIOL CHEM, V280, P18336, DOI 10.1074/jbc.M500007200; Yang XP, 2003, ARTERIOSCL THROM VAS, V23, P1601, DOI 10.1161/01.ATV.0000085841.55248.13	39	15	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					794	+		10.1096/fj.05-5385fje	http://dx.doi.org/10.1096/fj.05-5385fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467369				2022-12-25	WOS:000237698700032
J	Farrar, CA; Zhou, WD; Lin, T; Sacks, SH				Farrar, Conrad A.; Zhou, Wuding; Lin, Tao; Sacks, Steven H.			Local extravascular pool of C3 is a determinant of postischemic acute renal failure	FASEB JOURNAL			English	Article						renal transplant; immune regulation; complement	COMPLEMENT COMPONENT C3; ISCHEMIA-REPERFUSION INJURY; P-SELECTIN; GENE-EXPRESSION; ACUTE REJECTION; FACTOR-B; BIOSYNTHESIS; KIDNEY; IMMUNOLOGY; ACTIVATION	The third complement component (C3) is an acute phase protein that plays a central role in reperfusion injury in several organ models. To investigate the contribution of local synthesis of C3 and distinguish it from that of circulating complement mainly produced by hepatic synthesis, we employed a mouse renal isograft model. Our model demonstrated a close relationship between the extent of intrarenal expression of C3 and cold-ischemia induced injury. Ischemic C3-positive donor kidneys transplanted into C3-positive or C3-negative recipients developed widespread tissue damage and severe acute renal failure. In contrast, ischemic C3-negative isografts exhibited only mild degrees of functional and structural disturbance, even when transplanted into normal C3-positive recipients. Thus local synthesis of C3, mostly identified in the tubular epithelium, was essential for complement-mediated reperfusion damage, whereas circulating C3 had a negligible effect. Our results suggest a two-compartment model for the pathogenic function of C3, in which the extravascular compartment is the domain of local synthesis of C3, and where the role of circulating C3 is redundant. Our data cast new light on the mechanism of complement-mediated tissue injury in nonimmunological disorders, and challenges the longstanding dogma that circulating components are the main complement effectors of extravascular tissue damage.	Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, Sch Med, London SE1 9RT, England; Kings Coll London, Dept Nephrol & Transplantat, Kings Coll Hosp, Sch Med, London SE1 9RT, England; Kings Coll London, Dept Nephrol & Transplantat, St Thomas Hosp, Sch Med, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sacks, SH (corresponding author), Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, Sch Med, 5th Floor,Thomas Guy House, London SE1 9RT, England.	steven.sacks@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095	MRC [G0000771] Funding Source: UKRI; Medical Research Council [G0000771] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bao LH, 2003, J AM SOC NEPHROL, V14, P670, DOI 10.1097/01.ASN.0000051597.27127.A1; BARTOK I, 1995, J IMMUNOL, V154, P5367; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; BOTTO M, 1992, J IMMUNOL, V149, P1348; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; COLTEN HR, 1992, J APPL PHYSIOL, V72, P1; David S, 1997, NEPHROL DIAL TRANSPL, V12, P51, DOI 10.1093/ndt/12.1.51; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Farrar CA, 2004, AM J PATHOL, V164, P133, DOI 10.1016/S0002-9440(10)63104-5; Fischer MB, 1998, J IMMUNOL, V160, P2619; Fischer MB, 1996, J IMMUNOL, V157, P549; Gerritsma JSJ, 1996, MOL IMMUNOL, V33, P847, DOI 10.1016/0161-5890(96)84610-4; Heinzelmann M, 1999, AM J KIDNEY DIS, V34, P384, DOI 10.1016/S0272-6386(99)70375-6; Hoffmann S, 2004, KIDNEY INT, V66, P1686, DOI 10.1111/j.1523-1755.2004.00936.x; Ikai M, 1996, CLIN EXP IMMUNOL, V106, P156, DOI 10.1046/j.1365-2249.1996.d01-817.x; JAESCHKE H, 1993, AM J PHYSIOL, V264, pG801, DOI 10.1152/ajpgi.1993.264.4.G801; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; MCPHADEN AR, 1993, IMMUNOL RES, V12, P213, DOI 10.1007/BF02918254; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; Mulligan MS, 1999, J IMMUNOL, V162, P4952; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pratt JR, 2003, AM J PATHOL, V163, P1457, DOI 10.1016/S0002-9440(10)63503-1; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheerin NS, 1997, KIDNEY INT, V51, P703, DOI 10.1038/ki.1997.101; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Springall T, 2001, NAT MED, V7, P801, DOI 10.1038/89923; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Tang S, 1999, J AM SOC NEPHROL, V10, P69; Tang S, 1999, J IMMUNOL, V162, P4336; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Yasojima K, 1998, CIRC RES, V82, P1224, DOI 10.1161/01.RES.82.11.1224; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621; Zhou WD, 2001, KIDNEY INT, V59, P1227, DOI 10.1046/j.1523-1755.2001.0590041227.x	46	142	146	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					217	226		10.1096/fj.05-4747com	http://dx.doi.org/10.1096/fj.05-4747com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449793				2022-12-25	WOS:000237698700006
J	Maillard, P; Huby, T; Andreo, U; Moreau, M; Chapman, J; Budkowska, A				Maillard, Patrick; Huby, Thierry; Andreo, Ursula; Moreau, Martine; Chapman, John; Budkowska, Agata			The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins	FASEB JOURNAL			English	Article						candidate receptors; VLDL; hepatoma cells	HIGH-DENSITY-LIPOPROTEIN; NEUTRALIZING ANTIBODIES; SR-BI; HYPERVARIABLE REGION-1; CANDIDATE RECEPTOR; ENVELOPE PROTEIN; PARTICLES; ENTRY; INFECTION; BINDING	The possible role of candidate receptors in the cellular penetration of HCV from serum of infected patients remains unclear. SR-BI/Cla1 interacts with plasma HDL, native and modified LDL, and VLDL, and facilitates cellular cholesterol efflux to lipoprotein acceptors. SR-BI/Cla1 binds HCV E2 protein and interacts with HCV pseudotypes via the HVR1 of the E2 envelope glycoprotein. Our data reveal that functional SR-BI/Cla1 expressed on the surface of CHO cells mediates the binding and uptake of HCV from the sera of infected patients. Interaction between HCV and SR-BI/Cla1 is not sensitive to either anti-E2 or anti-HVR1 antibodies but is effectively inhibited by anti-beta lipoprotein antibodies and competed out by apoB-containing lipoproteins and notably by VLDL. We interpret our data to indicate that VLDL associated with or incorporated into HCV plays a critical role in the primary interaction of HCV with SR-BI/Cla1, whereas the HCV E2 protein does not. In addition, our findings in hepatoma cell lines suggest that the interaction of HCV with human hepatocytes is equally mediated, at least in a part, by VLDL, and as such may represent an alternative pathway for infection. The association of HCV with ApoB-containing lipoproteins may promote cellular uptake of this virus in the presence of neutralizing antibodies.	Inst Pasteur, Hepacivirus Unit, F-75724 Paris 15, France; INSERM, U551, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Budkowska, A (corresponding author), Inst Pasteur, Hepacivirus Unit, 25 Rue Dr Roux, F-75724 Paris 15, France.	abudkow@pasteur.fr	HUBY, Thierry/N-4820-2019; Huby, Thierry/E-6768-2017	HUBY, Thierry/0000-0001-6634-551X; Huby, Thierry/0000-0001-6634-551X				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Andre P, 2005, SEMIN LIVER DIS, V25, P93, DOI 10.1055/s-2005-864785; Bartosch B, 2005, J VIROL, V79, P8217, DOI 10.1128/JVI.79.13.8217-8229.2005; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BRADLEY D, 1991, J MED VIROL, V34, P206, DOI 10.1002/jmv.1890340315; BRADLEY DW, 1990, GASTROENTEROLOGY, V99, P1054, DOI 10.1016/0016-5085(90)90626-C; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Germi R, 2002, J MED VIROL, V68, P206, DOI 10.1002/jmv.10196; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Lambot M, 2002, J BIOL CHEM, V277, P20625, DOI 10.1074/jbc.M111020200; Lim SP, 2002, VIROLOGY, V303, P79, DOI 10.1006/viro.2002.1687; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Masciopinto F, 2004, EUR J IMMUNOL, V34, P2834, DOI 10.1002/eji.200424887; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Petit JM, 2003, AM J GASTROENTEROL, V98, P1150, DOI 10.1016/S0002-9270(03)00106-0; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x; Rhainds D, 2004, INT J BIOCHEM CELL B, V36, P39, DOI 10.1016/S1357-2725(03)00173-0; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodriguez E, 1996, J VIROL, V70, P3470; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Serfaty L, 2001, J HEPATOL, V34, P428, DOI 10.1016/S0168-8278(00)00036-2; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Yu MYW, 2004, P NATL ACAD SCI USA, V101, P7705, DOI 10.1073/pnas.0402458101; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	42	117	123	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					735	+		10.1096/fj.05-4728fje	http://dx.doi.org/10.1096/fj.05-4728fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16476701				2022-12-25	WOS:000237698700022
J	Tatebayashi, Y; Planel, E; Chui, DH; Sato, S; Miyasaka, T; Sahara, N; Murayama, M; Kikuchi, N; Yoshioka, K; Rivka, R; Takashima, A				Tatebayashi, Yoshitaka; Planel, Emmanuel; Chui, De-Hua; Sato, Shinji; Miyasaka, Tomohiro; Sahara, Naruhiko; Murayama, Miyuki; Kikuchi, Naomi; Yoshioka, Katsuji; Rivka, Ravid; Takashima, Akihiko			c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis	FASEB JOURNAL			English	Article						frontotemporal dementia and Parkinsonism linked to chromosome 17; glycogen synthase kinase	GLYCOGEN-SYNTHASE KINASE-3-BETA; FAMILIAL PRESENILE-DEMENTIA; MULTIPLE SYSTEM TAUOPATHY; PAIRED HELICAL FILAMENTS; ACTIVATED PROTEIN-KINASE; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; TAU-PROTEIN; FRONTOTEMPORAL DEMENTIA; TRANSGENIC MICE	Tauopathies such as Alzheimer disease ( AD) probably involve a type of phosphorylation imbalance causing the accumulation of abnormally hyperphosphorylated tau in neurons and/or glias. Investigation of R406W tau mutation may provide insight into such abnormal tau hyperphosphorylation, since this mutation causes AD-like dementia and tauopathy in humans and because it has the unique ability to reduce tau phosphorylation in vitro and in cultured cells. Here we show that R406W mutation primarily disrupts tau phosphorylation at Ser404, a priming phosphorylation site of glycogen synthase kinase-3 beta (GSK-3 beta), thereby reducing subsequent GSK-3 beta-mediated phosphorylation at the PHF-1 site (mostly Ser396). In contrast, c-jun N-terminal kinase (JNK) as activated in the mitotic phase directly hyperphosphorylates R406W tau at the PHF-1 site. This was confirmed by PHF-1 hyperphosphorylation of R406W tau in mitotic cells, its association with cytoplasmic JNK activation, and its inhibition by a JNK inhibitor, SP600125. These data unveil the unknown mechanisms of physiological tau phosphorylation at the PHF-1 site and suggest that cytoplasmic JNK activation may play an important role in the abnormal tau hyperphosphorylation associated with R406W tau mutation and in AD.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Alzheimres Dis, Wako, Saitama 3510198, Japan; Psychiat Res Inst Tokyo, Mood Disorder Res Team, Depress Project, Tokyo 156, Japan; NYU, Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, New York, NY USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Lincoln, NE 68583 USA; Univ Tokyo, Fac Med, Dept Neuropathol, Tokyo, Japan; Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa, Japan; Netherlands Brain Bank, Amsterdam, Netherlands; Peking Univ, Neurosci Res Inst, Beijing, Peoples R China	RIKEN; Tokyo Institute of Psychiatry; Nathan Kline Institute for Psychiatric Research; New York University; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Tokyo; Peking University	Takashima, A (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Alzheimres Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.go.jp		Planel, Emmanuel/0000-0001-5128-0565				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Connell JW, 2001, FEBS LETT, V493, P40, DOI 10.1016/S0014-5793(01)02267-0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Herrup K, 2002, J ALZHEIMERS DIS, V4, P243, DOI 10.3233/JAD-2002-4315; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikeda M, 2005, AM J PATHOL, V166, P521, DOI 10.1016/S0002-9440(10)62274-2; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Iqbal K, 1996, ANN NY ACAD SCI, V777, P132, DOI 10.1111/j.1749-6632.1996.tb34411.x; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Ito M, 1999, MOL CELL BIOL, V19, P7539; JORDAN MA, 1992, J CELL SCI, V102, P401; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Miyasaka T, 2001, AM J PATHOL, V158, P373, DOI 10.1016/S0002-9440(10)63979-X; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Passant U, 2004, DEMENT GERIATR COGN, V17, P287, DOI 10.1159/000077156; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; POPE WB, 1994, EXP NEUROL, V126, P185, DOI 10.1006/exnr.1994.1057; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; Sahara N, 2004, J NEUROCHEM, V90, P829, DOI 10.1111/j.1471-4159.2004.02558.x; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; SEHIFF PB, 1980, P NATL ACAD SCI USA, V77, P1561; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tatebayashi Y, 2004, J CELL SCI, V117, P1653, DOI 10.1242/jcs.01018; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhang B, 2004, J NEUROSCI, V24, P4657, DOI 10.1523/JNEUROSCI.0797-04.2004; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	64	32	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					762	+		10.1096/fj.05-4362fje	http://dx.doi.org/10.1096/fj.05-4362fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16478768				2022-12-25	WOS:000237698700019
J	Brun, C; Philip-couderc, P; Raggenbass, M; Roatti, A; Baertschi, AJ				Brun, C; Philip-couderc, P; Raggenbass, M; Roatti, A; Baertschi, AJ			Intracellular targeting of truncated secretory peptides in the mammalian heart and brain	FASEB JOURNAL			English	Article						ANP; atrial myocyte; growth hormone; HL-1; hormones; hypothalamus; mitochondria; NPY; translation initiation	NEUROPEPTIDE-Y; GROWTH-HORMONE; TRANSLATION INITIATION; GRANULE BIOGENESIS; START SITES; PROTEIN; VESICLES; MEMBRANE; NEURONS; ATRIAL	Secretory polypeptides are vital for nervous system function, sleep, reproduction, growth, and metabolism. Ribosomes scanning the 5'-end of mRNA usually detect the first AUG site for initiating translation. The nascent propeptide chain is then directed via a signal-peptide into the endoplasmic reticulum, processed through the Golgi stacks, and packaged into secretory vesicles. By expressing prepropeptide-EGFP fusion proteins, we observed unusual destinations, mitochondria, nucleus, and cytoplasm, of neuropeptide Y (NPY), atrial natriuretic peptide, and growth hormone in living murine cardiac cells and hypothalamic slices. Subcellular expression was modulated by Zn++ or mutations of N-terminal prohormone sequences but was not due to overexpression in the trans-Golgi network. Mitochondrial targeting of NPY also occurred without the EGFP tag, was enhanced by site- directed mutagenesis of the first AUG initiation site, and abolished by mutation of the second AUG. Immunological methods indicated the presence of N-terminal truncated NPY in mitochondria. Imaging studies showed depolarization of NPY-containing mitochondria. P-SORT software correctly predicted the secondary intracellular destinations and suggested such destinations for many neuropeptides and peptide hormones known. Thus, mammalian cells may retarget secretory peptides from extracellular to intracellular sites by skipping the first translation-initiation codon and thereby alter mitochondrial function, gene expression, and secretion.	Ctr Med Univ Geneva, Dept Neurosci, CH-1211 Geneva 4, Switzerland	University of Geneva	Baertschi, AJ (corresponding author), Ctr Med Univ Geneva, Dept Neurosci, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	alex.baertschi@medecine.unige.ch						Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Baertschi AJ, 2001, CIRC RES, V89, pE23, DOI 10.1161/hh1501.095715; Burke NV, 1997, NEURON, V19, P1095, DOI 10.1016/S0896-6273(00)80400-6; CANAFF L, 1993, P NATL ACAD SCI USA, V90, P7799; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2003, FASEB J, V17, P426, DOI 10.1096/fj.02-0732com; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Deloche O, 2004, MOL CELL, V13, P357, DOI 10.1016/S1097-2765(04)00008-5; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; El Meskini R, 2001, ENDOCRINOLOGY, V142, P864, DOI 10.1210/endo.142.2.7929; Fiaschi-Taesch N, 2004, CIRCULATION, V110, P177, DOI 10.1161/01.CIR.0000134483.30849.B7; Guillemin R, 2004, ANN NY ACAD SCI, V1038, P131, DOI 10.1196/annals.1315.021; Gutierrez P, 2002, FEBS LETT, V517, P155, DOI 10.1016/S0014-5793(02)02610-8; Jacques D, 2003, CAN J PHYSIOL PHARM, V81, P288, DOI 10.1139/Y02-165; Kaipio K, 2005, BIOCHEM BIOPH RES CO, V337, P633, DOI 10.1016/j.bbrc.2005.09.093; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; Keeler C, 2004, J MOL NEUROSCI, V22, P43, DOI 10.1385/JMN:22:1-2:43; Kiss J, 2005, EUR J NEUROSCI, V21, P2111, DOI 10.1111/j.1460-9568.2005.04012.x; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kuiper RP, 2000, BIOCHEM CELL BIOL, V78, P289, DOI 10.1139/bcb-78-3-289; Labrador V, 2004, CIRC RES, V95, pE98, DOI 10.1161/01.RES.0000150592.88464.ad; Magoulas C, 2000, ENDOCRINOLOGY, V141, P4681, DOI 10.1210/en.141.12.4681; McGuinness L, 2003, ENDOCRINOLOGY, V144, P720, DOI 10.1210/en.2002-220847; MIFUNE H, 1995, ANAT EMBRYOL, V192, P117; NAKAI K, 1998, P SORT PREDICTION PR; Nguyen MTA, 2001, ENDOCRINOLOGY, V142, P694, DOI 10.1210/en.142.2.694; Nichol H, 2002, INSECT BIOCHEM MOLEC, V32, P1699, DOI 10.1016/S0965-1748(02)00110-8; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; Paquet L, 1996, J NEUROSCI, V16, P964; Pierson PM, 2005, BRAIN RES, V1036, P50, DOI 10.1016/j.brainres.2004.12.020; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rogol AD, 2004, J PEDIATR ENDOCR MET, V17, P1259; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Silva AP, 2005, BIOL CELL, V97, P457, DOI 10.1042/BC20040102; Silva-Filho MC, 2003, CURR OPIN PLANT BIOL, V6, P589, DOI 10.1016/j.pbi.2003.09.008; Swaab DF, 2004, INT REV CYTOL, V240, P305, DOI 10.1016/S0074-7696(04)40003-5; THIBAULT G, 1992, AM J PHYSIOL, V262, pC907, DOI 10.1152/ajpcell.1992.262.4.C907; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Wojewodzka U, 2004, NEUROENDOCRINOL LETT, V25, P78	42	9	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					732	+		10.1096/fj.05-4338fje	http://dx.doi.org/10.1096/fj.05-4338fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16443679				2022-12-25	WOS:000235996000001
J	Stagg, MA; Coppen, SR; Suzuki, K; Varela-Carver, A; Lee, J; Brand, NJ; Fukushima, S; Yacoub, MH; Terracciano, CMN				Stagg, MA; Coppen, SR; Suzuki, K; Varela-Carver, A; Lee, J; Brand, NJ; Fukushima, S; Yacoub, MH; Terracciano, CMN			Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation	FASEB JOURNAL			English	Article						gap junctional conductance; electrophysiology	MYOCARDIAL-INFARCTION; STEM-CELLS; MUSCLE; FIBROBLASTS; EXPRESSION; CHANNELS; REPAIR; CONDUCTANCE	Cell transplantation of skeletal myoblasts (SMs) is one possible treatment for repairing cardiac tissue after myocardial injury. However, inappropriate electrical coupling between grafted SMs and host cardiomyocytes may be responsible for the arrhythmias observed in clinical trials of SM transplantation. Whether functional gap junctions occur between the two cell types remains controversial. We have studied the ability of SMs to electrically couple with isolated adult rat cardiomyocytes (CMs) and assessed whether connexin43 (Cx43) overexpression enhanced gap junctional conductance (G(j)). C2C12 myoblast lines overexpressing Cx43 were generated by gene transfection and clonal selection. CMs were cocultured with either SMs overexpressing Cx43 (CM-SMCx43) or control SMs (CM-SMWT) in vitro. G(j) between pairs of SMs and CMs was quantified with dual whole cell patch clamping. Formation of G(j) occurred between 22% of CM-SMWT pairs (n= 73) and 48% of CM-SMCx43 pairs (n= 71, P < 0.001). The G(j) of CM- SMCx43 pairs (29.7 +/- 4.3 nS, n=21) was greater than that of CM-SMWT pairs (14.8 +/- 2.0 nS, n=12, P < 0.05). The overexpression of Cx43 in SMs increased the formation of electrical communication and the steady-state conductance between SMs and CMs. Enhanced gap junctional conductance may be useful to promote the integration of transplanted SMs into the myocardium.	Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Heart Sci Ctr, Natl Heart & Lung Inst, London UB9 6JH, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Stagg, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Heart Sci Ctr, Natl Heart & Lung Inst, London UB9 6JH, England.	m.stagg@imperial.ac.uk		Stagg, Mark/0000-0003-2306-8326	Medical Research Council [G116/158] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G116/158] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham MR, 2005, CIRC RES, V97, P159, DOI 10.1161/01.RES.0000174794.22491.a0; BEBLO DA, 1995, CIRC RES, V77, P813, DOI 10.1161/01.RES.77.4.813; Camelliti P, 2005, CARDIOVASC RES, V65, P40, DOI 10.1016/j.cardiores.2004.08.020; CARMELIET E, 2002, CELLULAR CARDIAC ELE, P95; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Coppen SR, 1998, CIRC RES, V82, P232; Cottrell GT, 2001, AM J PHYSIOL-CELL PH, V281, pC1559, DOI 10.1152/ajpcell.2001.281.5.C1559; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Formigli L, 2005, AM J PHYSIOL-CELL PH, V288, pC795, DOI 10.1152/ajpcell.00345.2004; Gaudesius G, 2003, CIRC RES, V93, P421, DOI 10.1161/01.RES.0000089258.40661.0C; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Horackova M, 2004, AM J PHYSIOL-HEART C, V287, pH1599, DOI 10.1152/ajpheart.00965.2003; Iijima Y, 2003, FASEB J, V17, P1361, DOI 10.1096/fj.02-1048fje; Kizana E, 2005, CIRCULATION, V111, P394, DOI 10.1161/01.CIR.0000153812.64956.EF; Leobon B, 2003, P NATL ACAD SCI USA, V100, P7808, DOI 10.1073/pnas.1232447100; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Menasche P, 2004, CURR OPIN CARDIOL, V19, P154, DOI 10.1097/00001573-200403000-00016; MORENO AP, 2004, CARDIAC ELECTROPHYSI, P120, DOI DOI 10.1016/B0-7216-0323-8/50017-8; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; Ott HC, 2004, J PHYSIOL-LONDON, V558, P793, DOI 10.1113/jphysiol.2003.060186; Pouly J, 2004, CIRCULATION, V110, P1626, DOI 10.1161/01.CIR.0000142861.55862.15; RASBAND WS, 2005, IMAGEJ; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2004, HUM GENE THER, V15, P627, DOI 10.1089/1043034041361253; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Siminiak T, 2004, AM HEART J, V148, P531, DOI 10.1016/j.ahj.2004.03.043; SRINIVAS M, 2004, CARDIAC ELECTROPHYSI, P158; Suzuki K, 2000, CIRCULATION, V102, P359; Suzuki K, 2001, J THORAC CARDIOV SUR, V122, P759, DOI 10.1067/mtc.2001.116210; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; van den Bos EJ, 2004, J HEART LUNG TRANSPL, V23, P1217, DOI 10.1016/j.healun.2003.10.015; van Veen TAB, 2001, CARDIOVASC RES, V51, P217, DOI 10.1016/S0008-6363(01)00324-8; Veenstra RD, 2001, BIOPHYS J, V80, P2231, DOI 10.1016/S0006-3495(01)76196-6; Yao JA, 2003, CIRC RES, V93, P736, DOI 10.1161/01.RES.0000095977.66660.86; Yao JA, 2003, CIRC RES, V92, P437, DOI 10.1161/01.RES.0000059301.81035.06; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	38	23	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					744	+		10.1096/fj.05-5088fje	http://dx.doi.org/10.1096/fj.05-5088fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16443678				2022-12-25	WOS:000235996000002
J	Ren, Y; Chan, HM; Fan, J; Xie, Y; Chen, YX; Li, W; Jiang, GP; Liu, Q; Meinhardt, A; Tam, PKH				Ren, Y.; Chan, H. M.; Fan, J.; Xie, Y.; Chen, Y. X.; Li, W.; Jiang, G. P.; Liu, Q.; Meinhardt, A.; Tam, P. K. H.			Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma	ONCOGENE			English	Article						MIF; neuroblastoma; antisense; tumor growth and metastasis	SQUAMOUS-CELL CARCINOMA; FACTOR MIF; HEPATOCELLULAR-CARCINOMA; PROSTATIC ADENOCARCINOMA; UP-REGULATION; CANCER CELLS; EXPRESSION; ANGIOGENESIS; INTERLEUKIN-8; MET	Macrophage migration inhibitory factor (MIF) has been defined as a novel oncogene. Our previous results have shown that MIF may contribute to the progression of neuroblastoma by (a) inducing N-Myc expression and (b) upregulating the expression of angiogenic factors. The aim of this study was to test whether tumor growth could be inhibited by reduction of endogenous MIF expression in neuroblastoma and clarify the molecular mechanisms underlying MIF reduction on the control of neuroblastoma growth. We established human neuroblastoma cell lines stably expressing antisense MIF (AS-MIF) cDNA. These stable transfectants were characterized by cell proliferation, gene expression pro. le, tumorigenicity and metastasis in vitro and in vivo. Decreased MIF expression was observed after transfection with AS-MIF in neuroblastoma cells and downregulation of MIF expression significantly correlated with decreased expression of N-Myc, Ras, c-Met and TrkB at protein level. Affymetrix microarray analysis revealed that expression of IL-8 and c-met was inhibited and neuroblastoma-favorable genes such as EPHB6 and BLU were upregulated in MIF reduced cells. Neuroblastoma cell growth exhibited a nearly 80% reduction in AS-MIF transfectants in vitro. Furthermore, mice in which tumors formed after subcutaneous injection of AS-MIF transfectants showed a 90% reduction in tumor growth compared to control. Metastasis in mice was also suppressed dramatically. Our data demonstrate that targeting MIF expression is a promising therapeutic strategy in human neuroblastoma therapy, and also identifies the MIF target genes for further study.	Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, Cleveland, OH 44195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Princeton Univ, Stat Lab, ORFE, Princeton, NJ 08544 USA; Univ Giessen, Dept Anat & Cell Biol, Giessen, Germany	Cleveland Clinic Foundation; University of Hong Kong; Princeton University; Justus Liebig University Giessen	Ren, Y (corresponding author), Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	reny@ccf.org; paultam@hkucc.hku.hk	Meinhardt, Andreas/B-3688-2009; /C-4405-2009	/0000-0001-6231-3035	NIGMS NIH HHS [R01-GM072611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Edsjo A, 2003, LAB INVEST, V83, P813, DOI 10.1097/01.LAB.0000074895.48776.D8; Fan JQ, 2004, P NATL ACAD SCI USA, V101, P1135, DOI 10.1073/pnas.0307557100; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hafner C, 2003, INT J ONCOL, V23, P1553; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahloogi H, 2003, CANCER RES, V63, P4997; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Meyer-Siegler K, 2000, J INTERF CYTOK RES, V20, P769, DOI 10.1089/10799900050151030; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Ren Y, 2003, CLIN CANCER RES, V9, P5996; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Sasaki Y, 2002, INT J MOL MED, V10, P579; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Tang XX, 2004, CLIN CANCER RES, V10, P5837, DOI 10.1158/1078-0432.CCR-04-0395; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; TOMIYASU M, 2000, CLIN CANCER RES, V8, P3755; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	44	56	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3501	3508		10.1038/sj.onc.1209395	http://dx.doi.org/10.1038/sj.onc.1209395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449971				2022-12-25	WOS:000238448200002
J	Nemoda, Z; Sahin-Toth, M				Nemoda, Z; Sahin-Toth, M			Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECREASING FACTOR CALDECRIN; CLEAVAGE SITE MUTATION; HEREDITARY PANCREATITIS; BOVINE PROCARBOXYPEPTIDASE; ENZYMATIC SPECIFICITY; ANIONIC TRYPSINOGEN; MOLECULAR-CLONING; TERNARY COMPLEX; ACTIVATION; PEPTIDE	Trypsin-mediated trypsinogen activation (autoactivation) facilitates digestive zymogen activation in the duodenum but may precipitate pancreatitis if it occurs prematurely in the pancreas. Auto-activation of human cationic trypsinogen is inhibited by a repulsive electrostatic interaction between the unique Asp(218) on the surface of cationic trypsin and the conserved tetra-aspartate (Asp(19-22)) motif in the trypsinogen activation peptide (Nemoda, Z., and Sahin-Toth, M. (2005) J. Biol. Chem. 280, 29645-29652). Here we describe that this interaction is regulated by chymotrypsin C (caldecrin), which can specifically cleave the Phe(18)-Asp(19) peptide bond in the trypsinogen activation peptide and remove the N-terminal tripeptide. In contrast, chymotrypsin B, elastase 2A, or elastase 3A (proteinase E) are ineffective. Autoactivation of N-terminally truncated cationic trypsinogen is stimulated similar to 3-fold, and this effect is dependent on the presence of Asp(218). Because chymotrypsinogen C is activated by trypsin, and chymotrypsin C stimulates trypsinogen activation, these reactions establish a positive feedback mechanism in the digestive enzyme cascade of humans. Furthermore, inappropriate activation of chymotrypsinogen C in the pancreas may contribute to the development of pancreatitis. Consistent with this notion, the pancreatitis-associated mutation A16V in cationic trypsinogen increases the rate of chymotrypsin C-mediated processing of the activation peptide 4-fold and causes accelerated trypsinogen activation in vitro.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Sahin-Toth, M (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA.	miklos@bu.edu		Sahin-Toth, Miklos/0000-0003-4513-9922; Nemoda, Zsofia/0000-0002-9550-7730	NIDDK NIH HHS [R01 DK058088, DK058088] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Applebaum-Shapiro SE, 2001, PANCREATOLOGY, V1, P439, DOI 10.1159/000055844; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Chen JM, 2003, MOL BIOL EVOL, V20, P1767, DOI 10.1093/molbev/msg183; Chen JM, 1999, SCAND J GASTROENTERO, V34, P831; Chen JM, 1999, GASTROENTEROLOGY, V117, P1508, DOI 10.1016/S0016-5085(99)70313-6; CHEN JM, 2003, NATURE ENCY HUMAN GE, P645; FOLK JE, 1965, J BIOL CHEM, V240, P193; FOLK JE, 1965, J BIOL CHEM, V240, P181; GomisRuth FX, 1997, J MOL BIOL, V269, P861, DOI 10.1006/jmbi.1997.1040; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; GUY O, 1978, BIOCHEMISTRY-US, V17, P1669, DOI 10.1021/bi00602a014; Howes N, 2004, CLIN GASTROENTEROL H, V2, P252, DOI 10.1016/S1542-3565(04)00013-8; KEILDLOUHA V, 1972, BIOCHIM BIOPHYS ACTA, V276, P531, DOI 10.1016/0005-2744(72)91013-3; KEIM V, 1992, GASTROENTEROLOGY, V103, P248, DOI 10.1016/0016-5085(92)91120-S; Keim Volker, 2003, JOP, V4, P146; KIRALY O, 2006, PROTEIN EXPR PURIF; Kukor Z, 2003, EUR J BIOCHEM, V270, P2047, DOI 10.1046/j.1432-1033.2003.03581.x; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; Nemoda Z, 2005, J BIOL CHEM, V280, P29645, DOI 10.1074/jbc.M505661200; Otsuki M, 2004, PANCREAS, V28, P200, DOI 10.1097/00006676-200403000-00012; Pasternak A, 1998, BIOCHEMISTRY-US, V37, P16201, DOI 10.1021/bi980951d; PEANASKY RJ, 1969, BIOCHIM BIOPHYS ACTA, V181, P82, DOI 10.1016/0005-2795(69)90229-3; Pfutzer RH, 1999, GASTROENTEROLOGY, V117, P1507, DOI 10.1016/S0016-5085(99)70312-4; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; Szepessy E, 2006, PANCREATOLOGY, V6, P117, DOI 10.1159/000090031; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Teich N, 2002, AM J GASTROENTEROL, V97, P341; TOMOMURA A, 1993, FEBS LETT, V335, P213, DOI 10.1016/0014-5793(93)80732-A; Tomomura A, 2001, FEBS LETT, V508, P454, DOI 10.1016/S0014-5793(01)03107-6; Tomomura A, 1996, FEBS LETT, V386, P26, DOI 10.1016/0014-5793(96)00377-8; Tomomura A, 1995, J BIOL CHEM, V270, P30315, DOI 10.1074/jbc.270.51.30315; TOMOMURA A, 1992, FEBS LETT, V301, P277, DOI 10.1016/0014-5793(92)80256-G; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	38	76	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11879	11886		10.1074/jbc.M600124200	http://dx.doi.org/10.1074/jbc.M600124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505482	Green Accepted, hybrid			2022-12-25	WOS:000236988100055
J	Hata, S; Koyama, S; Kawahara, H; Doi, N; Maeda, T; Toyama-Sorimachi, N; Abe, K; Suzuki, K; Sorimachi, H				Hata, S; Koyama, S; Kawahara, H; Doi, N; Maeda, T; Toyama-Sorimachi, N; Abe, K; Suzuki, K; Sorimachi, H			Stomach-specific calpain, nCL-2, localizes in mucus cells and proteolyzes the beta-subunit of coatomer complex, beta-COP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC CALPAIN; MUSCLE-SPECIFIC CALPAIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; PROTEASE ACTIVITY; ACTIVE-SITE; DOMAIN; GENE; EXPRESSION; APPENDAGE	Calpain is a Ca2+-regulated cytosolic protease. Mammals have 14 calpain genes, half of which are predominantly expressed in specific organ(s); the rest are expressed ubiquitously. A defect in calpains causes lethality/pathogenicity, indicating their physiological indispensability. nCL-2/calpain-8a was identified as a stomach-specific calpain, whose physiological functions are unclear. To elucidate these, we characterized nCL-2 in detail. Unexpectedly, nCL-2 was localized strictly to the surface mucus cells in the gastric epithelium and the mucus-secreting goblet cells in the duodenum. Yeast two-hybrid screening identified several nCL-2-intracting molecules. Of these, the beta-subunit of coatomer complex (beta-COP) occurs in the stomach pit cells and is proteolyzed by nCL-2 in vitro. Furthermore, beta-COP and nCL-2 co-expressed in COS7 cells co-localized in the Golgi, and Ca2+-ionophore stimulation caused the proteolysis of beta-COP near the linker region, resulting in the dissociation of beta-COP from the Golgi. These results strongly suggest novel functions for nCL-2 that involve the membrane trafficking of mucus cells via interactions with coat protein.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol, CREST, Saitama 3320012, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Int Med Ctr Japan, Res Inst, Dept Gastroenterol, Tokyo 1628655, Japan; Toray Industries Ltd, New Frontiers Res Labs, Kanagawa 2488555, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Hokkaido University; Japan Science & Technology Agency (JST); University of Tokyo; National Center for Global Health & Medicine - Japan; Toray Industries, Inc.	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/C-6448-2009; Maeda, Tatsuya/L-5540-2019	Sorimachi, Hiroyuki/0000-0001-9509-6727; 				Amerongen AVN, 1998, BIOL CHEM, V379, P1; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bordone L, 2002, J BIOL CHEM, V277, P26673, DOI 10.1074/jbc.M112037200; Cao Y, 2001, DEV GROWTH DIFFER, V43, P563; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; Duan WR, 2002, BIOCHEM BIOPH RES CO, V295, P261, DOI 10.1016/S0006-291X(02)00655-1; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gotthardt M, 2003, J BIOL CHEM, V278, P6059, DOI 10.1074/jbc.M211723200; Han DS, 2004, NUCLEIC ACIDS RES, V32, P6312, DOI 10.1093/nar/gkh972; Hata S, 2001, J MOL EVOL, V53, P191, DOI 10.1007/s002390010209; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HATTORI T, 1976, CELL TISSUE RES, V175, P49; Hoffman GR, 2003, MOL CELL, V12, P615, DOI 10.1016/j.molcel.2003.08.002; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Karam SM, 2003, STEM CELLS, V21, P322, DOI 10.1634/stemcells.21-3-322; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Kimura E, 2003, BIOSCI BIOTECH BIOCH, V67, P1786, DOI 10.1271/bbb.67.1786; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lid SE, 2005, PLANTA, V221, P339, DOI 10.1007/s00425-004-1448-6; Liu KY, 2000, J BIOL CHEM, V275, P31093, DOI 10.1074/jbc.M005451200; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Morford LA, 2002, BIOCHEM BIOPH RES CO, V295, P540, DOI 10.1016/S0006-291X(02)00676-9; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Ohkawa K, 2000, NEUROREPORT, V11, P4007, DOI 10.1097/00001756-200012180-00021; OLIVER MG, 1991, ANAT REC, V230, P513, DOI 10.1002/ar.1092300410; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Shinozaki K, 1998, INT J MOL MED, V1, P797; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; Watson PJ, 2004, TRAFFIC, V5, P79, DOI 10.1111/j.1600-0854.2004.00158.x; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Xu WJ, 2004, MOL BIOL CELL, V15, P5528, DOI 10.1091/mbc.E04-08-0666; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x	58	24	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11214	11224		10.1074/jbc.M509244200	http://dx.doi.org/10.1074/jbc.M509244200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476741	Green Published, hybrid			2022-12-25	WOS:000236822200065
J	Zhao, TJ; Sun, S; Liu, Y; Liu, JM; Liu, Q; Yan, YB; Zhou, HM				Zhao, TJ; Sun, S; Liu, Y; Liu, JM; Liu, Q; Yan, YB; Zhou, HM			Regulating the drought-responsive element (DRE)-mediated signaling pathway by synergic functions of trans-active and trans-inactive DRE binding factors in Brassica napus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; FREEZING TOLERANCE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; COLD-ACCLIMATION; STRESS TOLERANCE; ABSCISIC-ACID; ARABIDOPSIS; PROTEIN	DREB1/C-repeat binding factor (CBF) is a plant-specific family of transcription factors and plays a crucial role in freeze tolerance. In the present work, two groups of drought-responsive element binding factor (DREB)-like genes were isolated from Brassica napus, named Group I and Group II. The two groups of genes were both induced by low temperature, but the expression of Group I preceded that of Group II. The Group I DREBs could specifically bind with the DRE cis-acting element and activate the expression of downstream genes, but Group II factors were trans-inactive although they still had the ability to bind with DRE, which was confirmed by electrophoretic mobility shift assay. Fluorescence quenching assays indicated that the DRE binding ability of the two groups was similar. Co-expression of Group II could depress the trans-activation activity of Group I DREB in a concentration-dependent manner. These results strongly suggested that the trans-active Group I DREBs were expressed at the early stage of cold stress to open the DRE-mediated signaling pathway in cold stress, whereas the trans-inactive Group II DREBs were expressed at the later stage to close the signal pathway in a competitive manner. The results herein provide a new insight into the regulation mechanisms of the DRE-mediated signaling pathway in response to cold stress.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China; Tsing Hua Univ, Yangtze Delta Reg Inst, Jiaxing 314050, Zhejiang, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Zhao, Tong-Jin/AFH-2915-2022; Yan, Yong-Bin/A-4282-2008	Yan, Yong-Bin/0000-0002-8565-3558				ABELES FB, 1992, ETHYLENE PLANT BIOL, P196; BAKER SS, 1994, PLANT MOL BIOL, V24, P710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chinnusamy V, 2003, GENE DEV, V17, P1043, DOI 10.1101/gad.1077503; *CLONT, 2001, YEAST PROT HDB; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; Gao MJ, 2002, PLANT MOL BIOL, V49, P459, DOI 10.1023/A:1015570308704; Gilmour SJ, 1998, PLANT J, V16, P433, DOI 10.1046/j.1365-313x.1998.00310.x; Gong ZZ, 2002, P NATL ACAD SCI USA, V99, P11507, DOI 10.1073/pnas.172399299; Guo Y, 2002, P NATL ACAD SCI USA, V99, P7786, DOI 10.1073/pnas.112040099; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; Jaglo KR, 2001, PLANT PHYSIOL, V127, P910, DOI 10.1104/pp.010548; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Janssen BJ, 1998, PLANT MOL BIOL, V36, P417, DOI 10.1023/A:1005925508579; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; KELLY RC, 1976, J BIOL CHEM, V251, P7240; Lee H, 2002, EMBO J, V21, P2692, DOI 10.1093/emboj/21.11.2692; Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801; Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.1105/tpc.10.8.1391; Liu Y, 2005, PROTEIN EXPRES PURIF, V44, P155, DOI 10.1016/j.pep.2005.03.030; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medina J, 1999, PLANT PHYSIOL, V119, P463, DOI 10.1104/pp.119.2.463; Novillo F, 2004, P NATL ACAD SCI USA, V101, P3985, DOI 10.1073/pnas.0303029101; Ouellet F, 1998, FEBS LETT, V423, P324, DOI 10.1016/S0014-5793(98)00116-1; Pearce RS, 1999, PLANT GROWTH REGUL, V29, P47, DOI 10.1023/A:1006291330661; Sakuma Y, 2002, BIOCHEM BIOPH RES CO, V290, P998, DOI 10.1006/bbrc.2001.6299; Steponkus PL, 1993, CUR TOP PL, V10, P37; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; Thomashow MF, 1998, PLANT PHYSIOL, V118, P1, DOI 10.1104/pp.118.1.1; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; UEMURA M, 1997, MOL BIOL BIOCH PHYSL, P171; Vazquez-Tello A, 1998, MOL GEN GENET, V257, P157, DOI 10.1007/s004380050635; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	36	84	116	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10752	10759		10.1074/jbc.M510535200	http://dx.doi.org/10.1074/jbc.M510535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497677	hybrid			2022-12-25	WOS:000236822200014
J	Mitaksov, V; Fremont, DH				Mitaksov, V; Fremont, DH			Structural definition of the H-2K(d) peptide-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELLS RECOGNIZE; 3-DIMENSIONAL STRUCTURE; CIRCUMSPOROZOITE PROTEIN; ANTIGENIC PEPTIDES; CRYSTAL-STRUCTURES; VIRAL PEPTIDES; COMPLEX; EPITOPE; IDENTIFICATION	Classic major histocompatibility complex (MHC) proteins associate with antigen- and self-derived peptides in an allele-specific manner. Herein we present the crystal structure of the MHC class I protein H-2K(d) (K-d) expressed by BALB/c mice in complex with an antigenic peptide derived from influenza A/PR/8/34 nucleoprotein ( Flu, residues 147-155, TYQRTRALV). Analysis of our structure in conjunction with the sequences of naturally processed epitopes provides a comprehensive understanding of the dominant K-d peptide-binding motif. We find that Flu residues Tyr(P2), Thr(P5), and Val(P9) are sequestered into the B, C, and F pockets of the K-d groove, respectively. The shape and chemistry of the polymorphic B pocket make it an optimal binding site for the side chain of Tyr(P2) as the dominant anchoring residue of nonameric peptides. The non-polar F pocket limits the amino acid repertoire at P9 to hydrophobic residues such as Ile, Leu, or Val, whereas the C pocket restricts the size of the P5-anchoring side chain. We also show that Flu is accommodated in the complex through an unfavorable kink in the otherwise extended peptide backbone due to the presence of a prominent ridge in the K-d groove. Surprisingly, this backbone conformation is strikingly similar to D-b-presented peptides despite the fact that these proteins employ distinct motif-anchoring strategies. The results presented in this study provide a solid foundation for the understanding of K-d-restricted antigen presentation and recognition events.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Fremont, DH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	fremont@immunology.wustl.edu		Fremont, Daved/0000-0002-8544-2689	NIGMS NIH HHS [GM 62414-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1993, J IMMUNOL, V151, P3569; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; Bhasin M, 2003, BIOINFORMATICS, V19, P665, DOI 10.1093/bioinformatics/btg055; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Ciatto C, 2001, J MOL BIOL, V312, P1059, DOI 10.1006/jmbi.2001.5016; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; EBERL G, 1993, INT IMMUNOL, V5, P1489, DOI 10.1093/intimm/5.11.1489; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; HARDING CV, 1995, J IMMUNOL, V155, P1767; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Ikeda H, 1997, P NATL ACAD SCI USA, V94, P6375, DOI 10.1073/pnas.94.12.6375; Jones EY, 1997, CURR OPIN IMMUNOL, V9, P75, DOI 10.1016/S0952-7915(97)80162-8; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MARYANSKI JL, 1991, INT IMMUNOL, V3, P1035, DOI 10.1093/intimm/3.10.1035; Matsui K, 2003, INT IMMUNOL, V15, P797, DOI 10.1093/intimm/dxg078; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Miley MJ, 2004, J EXP MED, V200, P1445, DOI 10.1084/jem.20040217; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Nagata Y, 1997, J IMMUNOL, V159, P1336; Natarajan K, 1999, Rev Immunogenet, V1, P32; Ostrov DA, 2002, J IMMUNOL, V168, P283, DOI 10.4049/jimmunol.168.1.283; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; QUESNEL A, 1995, PEPTIDE RES, V8, P44; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAITO Y, 1993, J BIOL CHEM, V268, P21309; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; Spaulding AC, 1999, J VIROL, V73, P398, DOI 10.1128/JVI.73.1.398-403.1999; Suri A, 2006, EUR J IMMUNOL, V36, P544, DOI 10.1002/eji.200526235; Tamura M, 1998, J VIROL, V72, P9404, DOI 10.1128/JVI.72.11.9404-9406.1998; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; WALLNY HJ, 1992, INT IMMUNOL, V4, P1085, DOI 10.1093/intimm/4.10.1085; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; Wilson I A, 1993, Semin Immunol, V5, P75, DOI 10.1006/smim.1993.1011; Wong FS, 2002, P NATL ACAD SCI USA, V99, P5551, DOI 10.1073/pnas.072037299; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; YOUNG ACM, 1995, FASEB J, V9, P26, DOI 10.1096/fasebj.9.1.7821756	60	26	28	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10618	10625		10.1074/jbc.M510511200	http://dx.doi.org/10.1074/jbc.M510511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473882	hybrid			2022-12-25	WOS:000236594300094
J	Okuda, T; Tokuda, N; Numata, S; Ito, M; Ohta, M; Kawamura, K; Wiels, J; Urano, T; Tajima, O; Furukawa, K; Furukawa, K				Okuda, T; Tokuda, N; Numata, S; Ito, M; Ohta, M; Kawamura, K; Wiels, J; Urano, T; Tajima, O; Furukawa, K; Furukawa, K			Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to vVerotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC UREMIC SYNDROME; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; VEROTOXIN RECEPTORS; TOXIN-II; BINDING; CELLS; PATHOGENESIS; GLOBOTRIAOSYLCERAMIDE; APOPTOSIS	To examine whether globotriaosylceramide (Gb3/CD77) is a receptor for verotoxins (VTs) in vivo, sensitivity of Gb3/CD77 synthase null mutant mice to VT-2 and VT-1 was analyzed. Although wild-type mice died after administration of 0.02 mu g of VT-2 or 1.0 mu g of VT-1, the mutant mice showed no reaction to doses as much as 100 times that administered to wild types. Expression analysis of Gb3/CD77 in mouse tissues with antibody revealed that low, but definite, levels of Gb3/CD77 were expressed in the microvascular endothelial cells of the brain cortex and pia mater and in renal tubular capillaries. Corresponding to the Gb3/CD77 expression, tissue damage with edema, congestion, and cytopathic changes was observed, indicating that Gb3/CD77 ( and its derivatives) exclusively function as a receptor for VTs in vivo. The lethal kinetics were similar regardless of lipopolysaccharide elimination in VT preparation, suggesting that basal Gb3/CD77 levels are sufficient for lethal effects of VTs.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Microbiol, Showa Ku, Nagoya, Aichi 4660065, Japan; Inst Gustave Roussy, CNRS, Unite Mixte Rech, F-94805 Villejuif, France	Nagoya University; Nagoya University; Nagoya University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okuda, Tetsuya/K-5305-2018; Wiels, Joëlle/AGL-2319-2022	Okuda, Tetsuya/0000-0002-5262-8057; Wiels, Joëlle/0000-0002-3313-2937; Urano, Takeshi/0000-0003-3383-3554				BARRETT TJ, 1989, INFECT IMMUN, V57, P3434, DOI 10.1128/IAI.57.11.3434-3437.1989; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; Devenish J, 1998, CAN J MICROBIOL, V44, P28, DOI 10.1139/cjm-44-1-28; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Iwamura K, 2003, J BIOL CHEM, V278, P44429, DOI 10.1074/jbc.M301609200; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KASAI K, 1985, J IMMUNOGENET, V12, P213; Kitamura M, 1999, BBA-MOL CELL BIOL L, V1441, P1, DOI 10.1016/S1388-1981(99)00140-7; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; Lalli G, 2003, TRENDS MICROBIOL, V11, P431, DOI 10.1016/S0966-842X(03)00210-5; LINGWOOD CA, 1994, NEPHRON, V66, P21, DOI 10.1159/000187761; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; OBRIG TG, 1993, J BIOL CHEM, V268, P15484; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; OOSTERWIJK E, 1991, INT J CANCER, V48, P848, DOI 10.1002/ijc.2910480610; Ren J, 1999, BRAIN RES, V825, P183, DOI 10.1016/S0006-8993(99)01196-8; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rutjes NWP, 2002, KIDNEY INT, V62, P832, DOI 10.1046/j.1523-1755.2002.00502.x; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; Tetaud C, 2003, J BIOL CHEM, V278, P45200, DOI 10.1074/jbc.M303868200; TZIPORI S, 1988, J CLIN PATHOL, V41, P1099, DOI 10.1136/jcp.41.10.1099; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; Wandall HH, 2005, J BIOL CHEM, V280, P4858, DOI 10.1074/jbc.C400571200; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; Zhao YL, 2002, ANTIMICROB AGENTS CH, V46, P1522, DOI 10.1128/AAC.46.5.1522-1528.2002; ZOJA C, 1992, J LAB CLIN MED, V120, P229	32	138	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10230	10235		10.1074/jbc.M600057200	http://dx.doi.org/10.1074/jbc.M600057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476743	hybrid			2022-12-25	WOS:000236594300050
J	Su, M; Lee, D; Ganss, B; Sodek, J				Su, M; Lee, D; Ganss, B; Sodek, J			Stereochemical analysis of the functional significance of the conserved inverted CCAAT and TATA elements in the rat bone sialoprotein gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BOX-BINDING-PROTEIN; FACTOR NF-Y; DNA-BINDING; CRYSTAL-STRUCTURE; MINOR-GROOVE; CBF/NF-Y; TRANSCRIPTION INITIATION; QUATERNARY COMPLEX; IN-VIVO	Basal transcription of the bone sialoprotein gene is mediated by highly conserved inverted CCAAT( ICE; ATTGG) and TATA elements (TTTATA) separated by precisely 21 nucleotides. Here we studied the importance of the relative position and orientation of the CCAAT and TATA elements in the proximal promoter by measuring the transcriptional activity of a series of mutated reporter constructs in transient transfection assays. Whereas inverting the TTTATA( wild type) to a TATAAA ( consensus TATA) sequence increased transcription slightly, transcription was reduced when the flanking dinucleotides were also inverted. In contrast, reversing the ATTGG ( wild type; ICE) to a CCAAT ( RICE) sequence caused a marked reduction in transcription, whereas both transcription and NF-Y binding were progressively increased with the simultaneous inversion of flanking nucleotides (f-RICE-f). Reducing the distance between the ICE and TATA elements produced cyclical changes in transcriptional activity that correlated with progressive alterations in the relative positions of the CCAAT and TATA elements on the face of the DNA helix. Minimal transcription was observed after 5 nucleotides were deleted ( equivalent to approximately one half turn of the helix), whereas transcription was fully restored after deleting 10 nucleotides ( approximately one full turn of the DNA helix), transcriptional activity being progressively lost with deletions beyond 10 nucleotides. In comparison, when deletions were made with the ICE in the reversed (f-RICE-f) orientation transcriptional activity was progressively lost with no recovery. These results show that, although transcription can still occur when the CCAAT box is reversed and/or displaced relative to the TATA box, the activity is dependent upon the flexibility of the intervening DNA helix needed to align the NF-Y complex on the CCAAT box with preinitiation complex proteins that bind to the TATA box. Thus, the precise location and orientation of the CCAAT element is necessary for optimizing basal transcription of the bone sialoprotein gene.	Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	Su, M (corresponding author), Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, 234 FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.su@utoronto.ca						Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 2002, CURR OPIN STRUC BIOL, V12, P225, DOI 10.1016/S0959-440X(02)00314-7; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; Cox JM, 1997, P NATL ACAD SCI USA, V94, P13475, DOI 10.1073/pnas.94.25.13475; Dion V, 2003, J BIOL CHEM, V278, P11495, DOI 10.1074/jbc.M211938200; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kabe Y, 2005, MOL CELL BIOL, V25, P512, DOI 10.1128/MCB.25.1.512-522.2005; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kays AR, 2000, CHEM BIOL, V7, P601, DOI 10.1016/S1074-5521(00)00009-0; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim RH, 1999, CANCER RES, V59, P565; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Lewis DEA, 2002, J BIOL CHEM, V277, P2498, DOI 10.1074/jbc.M108456200; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Liberati C, 1998, FEBS LETT, V433, P174, DOI 10.1016/S0014-5793(98)00905-3; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Miaskiewicz K, 1996, J BIOMOL STRUCT DYN, V13, P593, DOI 10.1080/07391102.1996.10508872; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P6450; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SILVIO A, 1999, NUCLEIC ACIDS RES, V27, P2578; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; Spencer JV, 2002, MOL CELL BIOL, V22, P8744, DOI 10.1128/MCB.22.24.8744-8755.2002; Su M, 2005, J BIOL CHEM, V280, P38365, DOI 10.1074/jbc.M501609200; Suzuki M, 1996, NUCLEIC ACIDS RES, V24, P2767, DOI 10.1093/nar/24.14.2767; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; Tan S, 1998, CURR OPIN STRUC BIOL, V8, P41, DOI 10.1016/S0959-440X(98)80008-0; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	53	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9882	9890		10.1074/jbc.M508364200	http://dx.doi.org/10.1074/jbc.M508364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16495225	hybrid			2022-12-25	WOS:000236594300009
J	Zhang, WW; Patil, S; Chauhan, B; Guo, SD; Powell, DR; Le, J; Klotsas, A; Matika, R; Xiao, XS; Franks, R; Heidenreich, KA; Sajan, MP; Farese, RV; Stolz, DB; Tso, P; Koo, SH; Montminy, M; Unterman, TG				Zhang, WW; Patil, S; Chauhan, B; Guo, SD; Powell, DR; Le, J; Klotsas, A; Matika, R; Xiao, XS; Franks, R; Heidenreich, KA; Sajan, MP; Farese, RV; Stolz, DB; Tso, P; Koo, SH; Montminy, M; Unterman, TG			FoxO1 regulates multiple metabolic pathways in the liver - Effects on gluconeogenic, glycolytic, and lipogenic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; TRANSCRIPTION FACTOR FKHR; GLUCOSE-INDUCED LIPOGENESIS; INSULIN-RESPONSE-SEQUENCE; FATTY-ACID SYNTHESIS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; KINASE-B; PEROXISOME PROLIFERATOR; AQUAPORIN ADIPOSE; SKELETAL-MUSCLE	FoxO transcription factors are important targets of insulin action. To better understand the role of FoxO proteins in the liver, we created transgenic mice expressing constitutively active FoxO1 in the liver using the alpha 1-antitrypsin promoter. Fasting glucose levels are increased, and glucose tolerance is impaired in transgenic (TGN) versus wild type (WT) mice. Interestingly, fasting triglyceride and cholesterol levels are reduced despite hyperinsulinemia, and post-prandial changes in triglyceride levels are markedly suppressed in TGN versus WT mice. Activation of pro-lipogenic signaling pathways (atypical protein kinase C and protein kinase B) and the ability to suppress beta-hydroxybutyrate levels are not impaired in TGN. In contrast, de novo lipogenesis measured with (H2O)-H-3 is suppressed by similar to 70% in the liver of TGN versus WT mice after refeeding. Gene-array studies reveal that the expression of genes involved in gluconeogenesis, glycerol transport, and amino acid catabolism is increased, whereas genes involved in glucose utilization by glycolysis, the pentose phosphate shunt, lipogenesis, and sterol synthesis pathways are suppressed in TGN versus WT. Studies with adenoviral vectors in isolated hepatocytes confirm that FoxO1 stimulates expression of gluconeogenic genes and suppresses expression of genes involved in glycolysis, the shunt pathway, and lipogenesis, including glucokinase and SREBP-1c. Together, these results indicate that FoxO proteins promote hepatic glucose production through multiple mechanisms and contribute to the regulation of other metabolic pathways important in the adaptation to fasting and feeding in the liver, including glycolysis, the pentose phosphate shunt, and lipogenic and sterol synthetic pathways.	Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Coll Med, James A Haley Vet Med Ctr, Res Serv, Tampa, FL 33612 USA; Univ Pittsburgh, Ctr Biol Imaging Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA; Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 440746, South Korea	US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati; Salk Institute; Sungkyunkwan University (SKKU)	Unterman, TG (corresponding author), Jesse Brown Vet Affairs Med Ctr, Room 6229,Med Res Unit MP 151,820 S Damen Ave, Chicago, IL 60612 USA.	Unterman@uic.edu	Farese, Robert/B-3605-2015; Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879	NCI NIH HHS [CA 76541] Funding Source: Medline; NIDDK NIH HHS [DK 41430, R01 DK065969, DK 59630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076541, R01CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041430, R01DK065969, U2CDK059630, U24DK059630, R01DK041430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Churukian CJ, 1999, J HISTOTECHNOL, V22, P309; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Du H, 2001, J LIPID RES, V42, P489; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gan LX, 2005, ENDOCRINOLOGY, V146, P4274, DOI 10.1210/en.2005-0224; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kim S, 2004, DIABETES, V53, pS66, DOI 10.2337/diabetes.53.2007.S66; Kondo H, 2002, EUR J BIOCHEM, V269, P1814, DOI 10.1046/j.1432-1033.2002.02821.x; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Kuriyama H, 2002, DIABETES, V51, P2915, DOI 10.2337/diabetes.51.10.2915; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIANG Y, 1991, J BIOL CHEM, V266, P6999; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Matsumoto M, 2005, CELL METAB, V1, P215, DOI 10.1016/j.cmet.2005.03.008; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Roth U, 2004, J BIOL CHEM, V279, P2623, DOI 10.1074/jbc.M308391200; Rozen S, 2000, BIOINFORMATICS METHO; Sandberg MB, 2005, MOL CELL ENDOCRINOL, V240, P94, DOI 10.1016/j.mce.2005.05.005; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scheimann AO, 2001, HORM METAB RES, V33, P631, DOI 10.1055/s-2001-18687; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Silha JV, 2001, ENDOCRINOLOGY, V142, P4305, DOI 10.1210/en.142.10.4305; Standaert ML, 2004, J BIOL CHEM, V279, P24929, DOI 10.1074/jbc.M402440200; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Towle HC, 2005, TRENDS ENDOCRIN MET, V16, P489, DOI 10.1016/j.tem.2005.10.003; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Valverde AM, 2003, DIABETES, V52, P2239, DOI 10.2337/diabetes.52.9.2239; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; ZHAO X, 2003, BIOCHEM J, V378, P839	78	386	412	0	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10105	10117		10.1074/jbc.M600272200	http://dx.doi.org/10.1074/jbc.M600272200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492665	hybrid			2022-12-25	WOS:000236594300036
J	Hanson, SM; Francis, DJ; Vishnivetskiy, SA; Klug, CS; Gurevich, VV				Hanson, SM; Francis, DJ; Vishnivetskiy, SA; Klug, CS; Gurevich, VV			Visual arrestin binding to microtubules involves a distinct conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; RHODOPSIN; EXPRESSION; MECHANISM; TAU; LOCALIZATION; SELECTIVITY; MUTAGENESIS; ACTIVATION	Recently we found that visual arrestin binds microtubules and that this interaction plays an important role in arrestin localization in photoreceptor cells. Here we use site-directed mutagenesis and spin labeling to explore the molecular mechanism of this novel regulatory interaction. The microtubule binding site maps to the concave sides of the two arrestin domains, overlapping with the rhodopsin binding site, which makes arrestin interactions with rhodopsin and microtubules mutually exclusive. Arrestin interaction with microtubules is enhanced by several "activating mutations" and involves multiple positive charges and hydrophobic elements. The comparable affinity of visual arrestin for microtubules and unpolymerized tubulin (K-D > 40 mu M and > 65 mu M, respectively) suggests that the arrestin binding site is largely localized on the individual alpha beta-dimer. The changes in the spin-spin interaction of a double-labeled arrestin indicate that the conformation of microtubule-bound arrestin differs from that of free arrestin in solution. In sharp contrast to rhodopsin, where tight binding requires an extended interdomain hinge, arrestin binding to microtubules is enhanced by deletions in this region, suggesting that in the process of microtubule binding the domains may move in the opposite direction. Thus, microtubule and rhodopsin binding induce different conformational changes in arrestin, suggesting that arrestin assumes three distinct conformations in the cell, likely with different functional properties.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Medical College of Wisconsin; Vanderbilt University	Gurevich, VV (corresponding author), Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.	vsevolod.gurevich@vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008; Vishnivetskiy, Sergey/AAJ-8661-2020	Gurevich, Vsevolod/0000-0002-3950-5351; 	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097, T32GM007628, R56GM070642, R01GM070642] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011500, R01 EY011500-10, EY11500] Funding Source: Medline; NIAID NIH HHS [R01 AI058024-02, AI58024, R01 AI058024] Funding Source: Medline; NIGMS NIH HHS [GM63097, R56 GM070642, R01 GM063097, R01 GM070642, GM07628, GM70642, R01 GM070642-03, R01 GM063097-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Amos LA, 2000, CURR OPIN STRUC BIOL, V10, P236, DOI 10.1016/S0959-440X(00)00070-1; ARSHAVSKY VY, 2003, SCI STKE, pPE43; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Eckmiller MS, 2000, VISUAL NEUROSCI, V17, P711, DOI 10.1017/S0952523800175054; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 2006, IN PRESS PHARM THER; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hanson SM, 2006, J BIOL CHEM, V281, P3458, DOI 10.1074/jbc.M512148200; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8; Klug Candice S., 2004, V24, P269; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; Nair KS, 2004, J BIOL CHEM, V279, P41240, DOI 10.1074/jbc.M406768200; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Osawa S, 2000, METHOD ENZYMOL, V315, P411; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seitz A, 2002, EMBO J, V21, P4896, DOI 10.1093/emboj/cdf503; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; SMITH WC, 1994, J BIOL CHEM, V269, P15407; Strissel KJ, 2006, J NEUROSCI, V26, P1146, DOI 10.1523/JNEUROSCI.4289-05.2006; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WALLIS KT, 1993, J BIOL CHEM, V268, P15158	47	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9765	9772		10.1074/jbc.M510738200	http://dx.doi.org/10.1074/jbc.M510738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461350	Green Accepted, hybrid			2022-12-25	WOS:000236404700089
J	Jiang, Y; Yan, YB; Zhou, HM				Jiang, Y; Yan, YB; Zhou, HM			Polyvinylpyrrolidone 40 assists the refolding of bovine carbonic anhydrase B by accelerating the refolding of the first molten globule intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE; PROTEIN AGGREGATION; THERMAL-STABILITY; MOLECULAR-WEIGHT; GROWTH-HORMONE; FOLDING AIDS; MECHANISM; DETERGENT; STABILIZATION; DENATURATION	Protecting proteins from aggregation is one of the most important issues in both protein science and protein engineering. In this research, the mechanism of enhancing the refolding of guanidine hydrochloride-denatured carbonic anhydrase B by polyvinylpyrrolidone 40 (PVP40) was studied by both kinetic and equilibrium refolding experiments. The reactivation and refolding kinetics indicated that the rate constant of refolding the first refolding intermediate (I-1) to the second one (I-2) is promoted by the addition of PVP. Fluorescence quenching studies further indicated that PVP could bind to the aggregation-prone species I-1, resulting in the protection of the exposed hydrophobic surface, a minimization of the protein surface, and more importantly, an increase of the refolding rate of I-1. These properties were quite different from those of poly(ethylene glycol) (PEG), which has been shown to have a strong and stoichiometric binding to I-1 and does not interfere with the refolding pathway. Unlike PEG, the binding of PVP to I-1 does not block the aggregation pathway directly but decreases the energy barrier for I-1 to refold to I-2 and thus reduces the accumulation of I-1. These results suggested that PVP works by a quite different mechanism from those well established ones in chaperones and chemical promoters. PVP is more like a folding catalyst rather than a chemical chaperone. The distinct mechanism of enhancing protein aggregation by PVP is expected to facilitate the attempt to develop new chemical compounds as well as new strategies to protect proteins from aggregation.	Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Prot Sci Lab, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Yan, YB (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	ybyan@tsinghua.edu.cn; zhm-dbs@tsinghua.edu.cn	Yan, Yong-Bin/A-4282-2008	Yan, Yong-Bin/0000-0002-8565-3558				Bolen D W, 2001, Methods Mol Biol, V168, P17; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHARMAN SA, 1993, PHARM RES-DORDR, V10, P954, DOI 10.1023/A:1018994102218; Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1992, BIOTECHNOL PROGR, V8, P97, DOI 10.1021/bp00014a002; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; CLELAND JL, 1991, ACS SYM SER, V470, P169; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; Finke JM, 2000, BIOCHEMISTRY-US, V39, P575, DOI 10.1021/bi991518m; GOMBOTZ WR, 1994, PHARMACEUT RES, V11, P624, DOI 10.1023/A:1018903624373; HARRISON RAP, 1988, BIOCHEM J, V252, P875, DOI 10.1042/bj2520875; Jackson C., 1989, J APPL POLYM SCI APP, V43, P99; Jonasson P, 1997, BIOCHEMISTRY-US, V36, P5142, DOI 10.1021/bi961882a; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kurganov BI, 2002, BIOCHEMISTRY-MOSCOW+, V67, P409, DOI 10.1023/A:1015277805345; LEE LLY, 1987, BIOCHEMISTRY-US, V26, P7813, DOI 10.1021/bi00398a042; Li S, 2001, INT J BIOCHEM CELL B, V33, P279, DOI 10.1016/S1357-2725(01)00003-6; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; Maa YF, 1998, J PHARM SCI, V87, P152, DOI 10.1021/js970308x; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Meng FG, 2004, BIOPHYS J, V87, P2247, DOI 10.1529/biophysj.104.044784; Meng FG, 2001, INT J BIOCHEM CELL B, V33, P701, DOI 10.1016/S1357-2725(01)00048-6; Ou WB, 2002, INT J BIOCHEM CELL B, V34, P136, DOI 10.1016/S1357-2725(01)00113-3; Ou WB, 2001, EUR J BIOCHEM, V268, P5901, DOI 10.1046/j.0014-2956.2001.02539.x; Pan JC, 2004, PROTEIN SCI, V13, P1892, DOI 10.1110/ps.03464804; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P20; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; POLSON A, 1964, BIOCHIM BIOPHYS ACTA, V82, P463, DOI 10.1016/0304-4165(64)90438-6; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; Randolph Theodore W, 2002, Pharm Biotechnol, V13, P159; RAVIN HA, 1952, NEW ENGL J MED, V247, P921, DOI 10.1056/NEJM195212112472403; Remmele RL, 1998, PHARMACEUT RES, V15, P200; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; Rozema D, 1996, BIOCHEMISTRY-US, V35, P15760, DOI 10.1021/bi961638j; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; Singh R, 2005, J BIOL CHEM, V280, P11035, DOI 10.1074/jbc.M410716200; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEIN PJ, 1978, J BIOL CHEM, V253, P8016; TANDON S, 1986, J BIOL CHEM, V261, P5615; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; TOWNSEND M W, 1988, Journal of Parenteral Science and Technology, V42, P190; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; VANGELDER P, 1994, EUR J BIOCHEM, V226, P783; VRKLJAN M, 1994, PHARMACEUT RES, V11, P1004, DOI 10.1023/A:1018935420680; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	55	77	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9058	9065		10.1074/jbc.M507874200	http://dx.doi.org/10.1074/jbc.M507874200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16459336	hybrid			2022-12-25	WOS:000236404700010
J	Peterson, JH; Szabady, RL; Bernstein, HD				Peterson, JH; Szabady, RL; Bernstein, HD			An unusual signal peptide extension inhibits the binding of bacterial presecretory proteins to the signal recognition particle, trigger factor, and the SecYEG complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; ESCHERICHIA-COLI; DEPENDENT TRANSLOCATION; TARGETING PATHWAY; 2-PARTNER SECRETION; CRYSTAL-STRUCTURE; NASCENT CHAINS; RIBOSOME; EXPORT; AUTOTRANSPORTER	Considerable evidence indicates that the Escherichia coli signal recognition particle (SRP) selectively targets proteins that contain highly hydrophobic signal peptides to the SecYEG complex cotranslationally. Presecretory proteins that contain only moderately hydrophobic signal peptides typically interact with trigger factor (TF) and are targeted post-translationally. Here we describe a striking exception to this rule that has emerged from the analysis of an unusual 55-amino acid signal peptide associated with the E. coli autotransporter EspP. The EspP signal peptide consists of a C-terminal domain that resembles a classical signal peptide plus an N-terminal extension that is conserved in other autotransporter signal peptides. Although a previous study showed that proteins containing the C-terminal domain of the EspP signal peptide are targeted cotranslationally by SRP, we found that proteins containing the full-length signal peptide were targeted post-translationally via a novel TF-independent mechanism. Mutation of an invariant asparagine residue in the N-terminal extension, however, restored cotranslational targeting. Remarkably, proteins containing extremely hydrophobic derivatives of the EspP signal peptide were also targeted post-translationally. These and other results suggest that the N-terminal extension alters the accessibility of the signal peptide to SRP and TF and promotes post-translational export by reducing the efficiency of the interaction between the signal peptide and the SecYEG complex. Based on data, we propose that the N-terminal extension mediates an interaction with an unidentified cytoplasmic factor or induces the formation of an unusual signal peptide conformation prior to the onset of protein translocation.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 5,Rm 201, Bethesda, MD 20892 USA.	harris_bernstein@nih.gov		Szabady, Rose/0000-0002-1281-7064	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052022, ZIADK052022] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKITA M, 1990, J BIOL CHEM, V265, P8164; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beha D, 2003, J BIOL CHEM, V278, P22161, DOI 10.1074/jbc.M300929200; Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chevalier N, 2004, J MOL MICROB BIOTECH, V8, P7, DOI 10.1159/000082076; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Huber D, 2005, J BACTERIOL, V187, P2983, DOI 10.1128/JB.187.9.2983-2991.2005; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; Karamyshev AL, 2005, J BIOL CHEM, V280, P37930, DOI 10.1074/jbc.M509100200; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; Lee HC, 2002, J BIOL CHEM, V277, P43527, DOI 10.1074/jbc.M205950200; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; Otto BR, 2005, J BIOL CHEM, V280, P17339, DOI 10.1074/jbc.M412885200; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; POGLIANO KJ, 1993, GENETICS, V133, P763; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Qi HY, 2002, J BIOL CHEM, V277, P51077, DOI 10.1074/jbc.M209238200; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Szabady RL, 2005, P NATL ACAD SCI USA, V102, P221, DOI 10.1073/pnas.0406055102; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2	45	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9038	9048		10.1074/jbc.M508681200	http://dx.doi.org/10.1074/jbc.M508681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455668	hybrid			2022-12-25	WOS:000236404700008
J	Yu, ZY; Kuncewicz, T; Dubinsky, WP; Kone, BC				Yu, ZY; Kuncewicz, T; Dubinsky, WP; Kone, BC			Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN S-NITROSYLATION; DNA-BINDING-ACTIVITY; POLY(ADP-RIBOSE) POLYMERASE-1; TRANSCRIPTIONAL ACTIVATION; MESANGIAL CELLS; INHIBITION; INFLAMMATION; INDUCTION; ACETYLATION	Nitric oxide (NO) participates in a variety of physiologic and pathophysiologic processes in diverse tissues, including the kidney. Although mechanisms for cytokine induction of inducible nitric-oxide synthase (iNOS) have been increasingly clarified, the controls for termination of NO production remain unclear. Because excessive NO production can be cytotoxic to host cells, feedback inhibition of iNOS transcription would represent a means of cytoprotection. Many of the cGMP-independent functions of NO are mediated by S-nitrosylation of cysteine thiols of target proteins. We hypothesized that NO-mediated S-nitrosylation of transcription factors might serve to feedback inhibit their trans-activation potential and deactivate iNOS gene transcription. Transient transfection of murine mesangial cells with iNOS promoter deletion-luciferase constructs revealed the region -915 to -849 to be NO sensitive with respect to IL-1 beta-induced promoter activity. In vitro DNase I footprinting identified a footprint at -865/-842 in the absence of NO, but not in the presence of endogenous or exogenously delivered NO. Southwestern blotting using this probe coupled with partial peptide sequencing of the protein bands revealed that poly(ADPribose) polymerase isoform 1 (PARP-1) bound the probe in a sequence-specific manner. Gel shift/supershift experiments and chromatin immunoprecipitation assay analysis confirmed this binding in vitro and in vivo. Functionally, mutation of the -859/-850 site to prevent PARP-1 binding or PARP-1 knockdown by RNA interference relieved the inhibitory effects of NO on iNOS promoter activity. Biotin-switch assays and co-immunoprecipitation with an anti-nitrocysteine antibody indicated that PARP-1 was S-nitrosylated. We conclude that NO feedback inhibits iNOS gene transcription by S-nitrosylating the trans-activator PARP-1 and decreasing its binding and/or action at the iNOS promoter.	Univ Texas, Sch Med, Dept Internal Med, Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Dept Integrat Biol & Pharmacol, Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Brown Fdn Inst Mol Med Prevent Human Dis, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Hlth Sci Ctr, 6431 Fannin,MSB 1-150, Houston, TX 77030 USA.	Bruce.C.Kone@uth.tmc.edu			NIDDK NIH HHS [R01 DK50745] Funding Source: Medline; NIGMS NIH HHS [P50 GM38529] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM038529] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Andreone TL, 2003, J IMMUNOL, V170, P2113, DOI 10.4049/jimmunol.170.4.2113; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Evgenov Oleg V., 2005, Current Vascular Pharmacology, V3, P293, DOI 10.2174/1570161054368580; Gao CJ, 2004, J BIOL CHEM, V279, P11236, DOI 10.1074/jbc.M313385200; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Gupta AK, 2000, KIDNEY INT, V57, P2239, DOI 10.1046/j.1523-1755.2000.00084.x; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kone BC, 1997, AM J KIDNEY DIS, V30, P311, DOI 10.1016/S0272-6386(97)90275-4; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593; Mabley Jon G., 2005, Current Vascular Pharmacology, V3, P247, DOI 10.2174/1570161054368571; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Mohr S, 1996, J BIOL CHEM, V271, P4209; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; NAGELE A, 1995, RADIAT ENVIRON BIOPH, V34, P251, DOI 10.1007/BF01209751; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Szabo C, 2006, NITRIC OXIDE-BIOL CH, V14, P169, DOI 10.1016/j.niox.2005.06.008; van Wijk SJL, 2005, FREE RADICAL BIO MED, V39, P81, DOI 10.1016/j.freeadbiomed.2005.03.021; Veres B, 2004, J PHARMACOL EXP THER, V310, P247, DOI 10.1124/jpet.104.065151; Vossen Christine, 2002, Med Sci Monit, V8, pRA217; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1; Yu ZY, 2006, AM J PHYSIOL-RENAL, V290, pF496, DOI 10.1152/ajprenal.00316.2005; Zhang WZ, 2001, J AM SOC NEPHROL, V12, P2554, DOI 10.1681/ASN.V12122554; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	45	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9101	9109		10.1074/jbc.M511049200	http://dx.doi.org/10.1074/jbc.M511049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464859	hybrid			2022-12-25	WOS:000236404700015
J	Tisdale, EJ; Artalejo, CR				Tisdale, EJ; Artalejo, CR			Src-dependent aprotein kinase C iota/lambda (aPKC iota/lambda) tyrosine phosphorylation is required for aPKC iota/lambda association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; VESICLE FORMATION; IN-VITRO; PROTEIN; INTERACTS; LOCALIZATION; COMPARTMENTS; ACTIVATION	The small GTPase Rab2 is required for membrane transport between the endoplasmic reticulum ( ER) and the Golgi complex. Rab2 associates with pre- Golgi intermediates ( also termed vesicular tubular clusters; VTCs) that sort cargo to the anterograde pathway from recycling proteins retrieved to the ER. Our previous studies have shown that Rab2 stimulates atypical protein kinase C iota/lambda ( aPKC iota/lambda) and glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) recruitment to VTCs. Both aPKC iota/lambda and GAPDH bind directly to Rab2 and aPKC iota/lambda and GAPDH interact. Based on the reports demonstrating aPKC iota- Src interaction and Src activity in the retrograde pathway ( Golgi- ER), studies were initiated to learn whether Rab2 also promoted Src recruitment to VTCs. Using a quantitative membrane binding assay, we found that Rab2- stimulated Src membrane association in a dose- dependent manner. The recruited Src binds to aPKC iota/lambda and GAPDH on the membrane; however, Src does not interact with Rab2. The membrane- associated Src tyrosine phosphorylates aPKC iota/lambda on the VTC. To determine the consequence of aPKC iota/lambda tyrosine phosphorylation, the membrane binding assay was supplemented with the Src- specific tyrosine kinase inhibitor 4- amino- 5-( 4- chlorophenyl)- 7-( t- butyl) pyrazolo( 3,4- d) pyrimidine ( PP2). Although Rab2, Src, and GAPDH recruitment was not affected, the Rab2- PP2- treated membranes contained a negligible amount of aPKC iota/lambda. Since Rab2 requires aPKC iota/lambda for the downstream recruitment of beta- coat protein (beta-COP) to VTCs, the Rab2- PP2- treated membranes were evaluated for the presence of beta-COP. Like aPKC iota/lambda, the membranes contained a negligible amount of beta- COP that was reflected by the drastic reduction in Rab2- dependent vesicle formation. These data suggest that Src- mediated tyrosine phosphorylation of aPKC iota/lambda facilitates aPKC iota/lambda association with Rab2- Src- GAPDH on VTCs, which is ultimately necessary for the downstream recruitment of beta-COP and release of Rab2- mediated retrograde- directed vesicles.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave,6374 Scott Hall, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068813] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK576637, DK58921, R01 DK058921] Funding Source: Medline; NIGMS NIH HHS [GM068813, R01 GM068813, R01 GM068813-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan-Bonnet N, 2004, CURR OPIN CELL BIOL, V16, P364, DOI 10.1016/j.ceb.2004.06.011; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bard F, 2003, J BIOL CHEM, V278, P46601, DOI 10.1074/jbc.M302221200; Bard F, 2002, EUR J CELL BIOL, V81, P26, DOI 10.1078/0171-9335-00217; BECKERS CJ, 1989, CELL, V50, P523; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Ding J, 2003, BIOCHEM BIOPH RES CO, V312, P670, DOI 10.1016/j.bbrc.2003.10.171; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Poole AAW, 2004, TRENDS PHARMACOL SCI, V25, P528, DOI 10.1016/j.tips.2004.08.006; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Tisdale EJ, 2003, J BIOL CHEM, V278, P52524, DOI 10.1074/jbc.M309343200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	32	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8436	8442		10.1074/jbc.M513031200	http://dx.doi.org/10.1074/jbc.M513031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452474	hybrid, Green Accepted			2022-12-25	WOS:000236247100018
J	Glezer, I; Lapointe, A; Rivest, S				Glezer, Isaias; Lapointe, Amelie; Rivest, Serge			Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries	FASEB JOURNAL			English	Article						lipopolysaccharide; toll-like receptor 4; demyelination; Olig bHLH transcription factors; neuroprotection	CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; ETHIDIUM-BROMIDE INJECTION; MULTIPLE-SCLEROSIS; GROWTH-FACTOR; IN-VIVO; INDUCED NEUROTOXICITY; SUBVENTRICULAR ZONE; PRECURSOR CELLS; FACTOR OLIG2	Regarded as a damaging reaction, innate immune response can either improve or worsen brain outcome after injury. Hence, inflammatory molecules might modulate cell susceptibility or healing events. The remyelination that follows brain lesions is dependent on the recruitment of oligodendrocyte progenitor cells (OPCs) and expression of genes controlling differentiation and myelin production, such as Olig1 and Olig2 bHLH transcription factors. We aimed to determine how innate immunity affects these processes. Here we report that lipopolysaccharide (LPS) infusion triggered OPC reactivity. Acute inflammation changed the distribution of Olig1- and Olig2-expressing cells following chemical demyelination, enhanced reappearance of transcription signals linked to remyelination and rapidly cleared myelin debris. Although cells expressing Olig1, Olig2, and proteolipid protein were attracted to demyelinated sites in the course of chronic inflammation, myelin loss was not associated with the effects of inflammation on OPC reactivity. In addition, the beneficial properties of brain immunity are broadened to an aggressive model of injury, wherein LPS through Toll-like receptor 4 (TLR4) reduced surfactant-mediated damage while anti-inflammatory treatment enlarged the lesion. In conclusion, TLR4 activation in microglia is a powerful mechanism for improving repair at the remyelination level and protecting the cerebral tissue in presence of agents with strong cytolytic properties.	Univ Laval, Lab Mol Endocrinol, CHUL Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, Lab Mol Endocrinol, CHUL Res Ctr, 2705,Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	Serge.Rivest@crchul.ulaval.ca	Messier, Claude/A-2322-2008; Glezer, Isaias/D-2867-2013	Messier, Claude/0000-0002-4791-1763; Rivest, Serge/0000-0002-6082-770X; Glezer, Isaias/0000-0002-9799-1933				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Blais V, 2004, J IMMUNOL, V172, P7043, DOI 10.4049/jimmunol.172.11.7043; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; Chen ZJ, 2002, J NEUROCYTOL, V31, P481, DOI 10.1023/A:1025791614468; Cockeran R, 2002, CURR OPIN INFECT DIS, V15, P235, DOI 10.1097/00001432-200206000-00004; Coin PG, 1996, J IMMUNOL, V156, P4797; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Felts PA, 2005, BRAIN, V128, P1649, DOI 10.1093/brain/awh516; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Franklin RJM, 1997, J NEUROSCI RES, V50, P337, DOI 10.1002/(SICI)1097-4547(19971015)50:2<337::AID-JNR21>3.0.CO;2-3; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494; Glezer I, 2003, NEUROPHARMACOLOGY, V45, P1120, DOI 10.1016/S0028-3908(03)00279-X; Glezer I, 2003, J NEUROSCI, V23, P11094; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; GRACA DL, 1986, NEUROPATH APPL NEURO, V12, P593, DOI 10.1111/j.1365-2990.1986.tb00162.x; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jalabi W, 2005, J NEUROSCI, V25, P2885, DOI 10.1523/JNEUROSCI.2748-04.2005; Johnstone RW, 2001, J BIOL CHEM, V276, P16667, DOI 10.1074/jbc.M010774200; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Kuchroo VK, 2002, ANNU REV IMMUNOL, V20, P101, DOI 10.1146/annurev.immunol.20.081701.141316; Laflamme N, 2001, J NEUROCHEM, V79, P648, DOI 10.1046/j.1471-4159.2001.00603.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Lu QR, 2001, NAT NEUROSCI, V4, P973, DOI 10.1038/nn718; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Paxino G, 2001, MOUSE BRAIN STEREOTA; PERRY VH, 1997, IMMUNOLOGY NERVOUS S, P155; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Rowitch DH, 2004, NAT REV NEUROSCI, V5, P409, DOI 10.1038/nrn1389; Schwab JM, 2005, LANCET, V365, P2055, DOI 10.1016/S0140-6736(05)66699-8; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097; Sreedhar AS, 2003, J BIOL CHEM, V278, P35231, DOI 10.1074/jbc.M301371200; Sun T, 2001, CURR BIOL, V11, P1413, DOI 10.1016/S0960-9822(01)00441-9; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; VIGO C, 1985, J BIOL CHEM, V260, P3418; Wolswijk G, 1998, J NEUROSCI, V18, P601; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xin M, 2005, J NEUROSCI, V25, P1354, DOI 10.1523/JNEUROSCI.3034-04.2005; YAJIMA K, 1979, LAB INVEST, V41, P385; Zamvil SS, 2003, NEURON, V38, P685, DOI 10.1016/S0896-6273(03)00326-X; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	70	90	93	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					750	+		10.1096/fj.05-5234fje	http://dx.doi.org/10.1096/fj.05-5234fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464958				2022-12-25	WOS:000237698700035
J	Kobayashi, S; Lackey, T; Huang, Y; Bisping, E; Pu, WT; Boxer, LM; Liang, QR				Kobayashi, Satoru; Lackey, Troy; Huang, Yuan; Bisping, Egbert; Pu, William T.; Boxer, Linda M.; Liang, Qiangrong			Transcription factor GATA4 regulates cardiac BCL2 gene expression in vitro and in vivo	FASEB JOURNAL			English	Article						cardiomyocyte; promoter; doxorubicin; cardiotoxicity	CELL-SURVIVAL; PROMOTER; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; DEATH	The transcription factor GATA-4 protects cardiomyocytes against doxorubicin-induced cardiotoxicity. Here, we report the identification of Bcl2 as a direct target gene of GATA4 that may mediate the prosurvival function of GATA4 in cardiomyocytes. Bcl2 transcript and protein levels were reduced by doxorubicin in neonatal rat ventricular cardiomyocytes (NRVC) and in mouse heart as determined by RT-PCR and Western blot analysis. The reduction in Bcl2 was prevented by overexpression of GATA4 in NRVC and in transgenic mouse heart. Also, expression of GATA4 increased baseline Bcl2 levels by 30% in NRVC and 2.7-fold in transgenic heart, indicating the sufficiency of GATA4 to up-regulate Bcl2 gene expression. GATA4 knockdown by siRNA reduced Bcl2 levels by 48% in NRVC, suggesting that GATA4 is required for Bcl2 constitutive gene expression. Transfection of HEK cells with GATA4 plasmids activated Bcl2 promoter and elevated Bcl2 protein levels. Deletion and mutagenesis analysis revealed that a consensus GATA motif at base -266 on the promoter conserved across multiple species is partially responsible for the promoter activity. Electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrate that GATA4 directly bound to this GATA site. Together, these results indicate that GATA4 positively regulates cardiac Bcl2 gene expression in vitro and in vivo.	Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, Sioux Falls, SD 57105 USA; Childrens Hosp Boston, Dept Cardiol, Boston, MA USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	University of South Dakota; Harvard University; Boston Children's Hospital; Stanford University	Liang, QR (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, 1100 E 21st St, Sioux Falls, SD 57105 USA.	qliang@usd.edu	Pu, William/AAJ-8301-2020	Pu, William/0000-0002-4551-8079	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR-017662] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chagnon F, 2005, CIRC RES, V96, P1095, DOI 10.1161/01.RES.0000168327.22888.4d; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; HEWITT SM, 1995, CANCER RES, V55, P5386; Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Kawamura T, 2004, CIRC RES, V94, P1492, DOI 10.1161/01.RES.0000129701.14494.52; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086; LaVoie HA, 2004, ENDOCRINOLOGY, V145, P3122, DOI 10.1210/en.2003-1719; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Maulik N, 1999, CIRCULATION, V100, P369; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Suzuki YJ, 2004, J MOL CELL CARDIOL, V37, P1195, DOI 10.1016/j.yjmcc.2004.09.009; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101	32	84	91	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					800	+		10.1096/fj.05-5426fje	http://dx.doi.org/10.1096/fj.05-5426fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469847				2022-12-25	WOS:000237698700028
J	Nakamura, N; Kobayashi, K; Nakamoto, M; Kohno, T; Sasaki, H; Matsuno, Y; Yokota, J				Nakamura, N.; Kobayashi, K.; Nakamoto, M.; Kohno, T.; Sasaki, H.; Matsuno, Y.; Yokota, J.			Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinoma; lung epithelial cells; expression pro. le; microdissection; micrometastasis; differential diagnosis	LASER CAPTURE MICRODISSECTION; POLYMERASE-CHAIN-REACTION; CELL 10-KDA PROTEIN; MESSENGER-RNA; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER; CARCINOMAS; CLASSIFICATION	To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14 500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection. Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells. Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells. Sixteen genes were identified as differentiation markers for lung epithelial cells. Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases. Five tumor markers and seven differentiation markers were not expressed in peripheral blood cells. Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Barth PJ, 2000, VIRCHOWS ARCH, V437, P648, DOI 10.1007/s004280000316; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; BROERS JLV, 1992, LAB INVEST, V66, P337; Chhieng DC, 2001, CANCER CYTOPATHOL, V93, P330, DOI 10.1002/cncr.9048; D'Cunha J, 2002, J THORAC CARDIOV SUR, V123, P484, DOI 10.1067/mtc.2002.119883; Egland KA, 2002, MOL CANCER THER, V1, P441; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6; Hosch SB, 2001, SEMIN SURG ONCOL, V20, P278, DOI 10.1002/ssu.1045; Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433; Kufer P, 2002, CANCER RES, V62, P251; Matsunaga H, 2002, INT J CANCER, V100, P592, DOI 10.1002/ijc.10534; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mitas M, 2003, J MOL DIAGN, V5, P237, DOI 10.1016/S1525-1578(10)60480-1; Miura K, 2002, CANCER RES, V62, P3244; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Naruke T, 2001, ANN THORAC SURG, V71, P1759, DOI 10.1016/S0003-4975(00)02609-6; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Player A, 2004, EXPERT REV MOL DIAGN, V4, P831, DOI 10.1586/14737159.4.6.831; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; SOBIN C, 2002, TNM CLASSIFICATION M, P97; Takamochi K, 2004, EUR J CARDIO-THORAC, V25, P877, DOI 10.1016/j.ejcts.2004.01.049; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Travis WD, 1999, HISTOLOGICAL TYPING; VIEAU D, 1991, CLIN ENDOCRINOL, V35, P319, DOI 10.1111/j.1365-2265.1991.tb03543.x; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Zamecnik J, 2002, VIRCHOWS ARCH, V440, P353, DOI 10.1007/s00428-001-0552-2	34	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4245	4255		10.1038/sj.onc.1209442	http://dx.doi.org/10.1038/sj.onc.1209442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491115				2022-12-25	WOS:000239004800013
J	Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND				Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND			Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex	ONCOGENE			English	Article						ataxia telangiectasia mutated and rad3-related (ATR); cell cycle checkpoints; DNA damage and repair	DOUBLE-STRAND BREAKS; EARLY EMBRYONIC LETHALITY; CHECKPOINT KINASE ATR; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; S-PHASE; DEPENDENT PHOSPHORYLATION; REPLICATION CHECKPOINT; GENOTOXIC STRESS; DEFICIENT CELLS	ATM and ATR are two related kinases essential for signalling DNA damage. Although ATM is thought to be the principle kinase responsible for signalling ionising radiation (IR)-induced DNA damage, ATR also contributes to signalling this form of genotoxic stress. However, the molecular basis of differential ATM and ATR activation in response to IR remains unclear. Here, we report that ATR is recruited to sites of IR-induced DNA damage significantly later than activation of ATM. We show that ATR is recruited to IR-induced nuclear foci in G(1) and S phase of the cell cycle, supporting a role for ATR in detecting DNA damage outside of S phase. In addition, we report that recruitment of ATR to sites of IR-induced DNA damage is concomitant with appearance of large tracts of single-stranded DNA (ssDNA) and that this event is dependent on ATM and components of the Mre11/Rad50/Nbs1 (MRN) protein complex.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Lakin, ND (corresponding author), Univ Oxford, Dept Biochem, S Pks Rd, Oxford OX1 3QU, England.	nicholas.lakin@bioch.ox.ac.uk			Cancer Research UK [A5207] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Downs JA, 2003, NATURE, V424, P732, DOI 10.1038/424732a; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nakada D, 2004, MOL CELL BIOL, V24, P10016, DOI 10.1128/MCB.24.22.10016-10025.2004; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	61	117	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	28					3894	3904		10.1038/sj.onc.1209426	http://dx.doi.org/10.1038/sj.onc.1209426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474843	Green Accepted			2022-12-25	WOS:000238668800002
J	Li, Y; Xie, M; Yang, J; Yang, D; Deng, R; Wan, Y; Yan, B				Li, Y.; Xie, M.; Yang, J.; Yang, D.; Deng, R.; Wan, Y.; Yan, B.			The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter	ONCOGENE			English	Article						DEC1; survivin; Sp1 element; transcription activation	WILD-TYPE P53; GENE-EXPRESSION; RESPONSE ELEMENTS; CANCER CELLS; E-BOX; HYPOXIA; STRA13; ACTIVATION; APOPTOSIS; PATHWAY	Human differentially expressed in chondrocytes (DEC), mouse stimulated with retinoic acid and rat split and hairy related proteins constitute a structurally distinct class of the basic helix-loop-helix proteins. DEC1 is abundantly expressed in tumors and protects against apoptosis induced by serum starvation. In this study, we report that DEC1 antiapoptosis is achieved by inducing survivin, an antiapoptotic protein. In paired tumor-normal tissues, survivin and DEC1 exhibited a paralleled expression pattern. Tetracycline-induced expression of DEC1 in stable lines proportionally increased the expression of survivin. In reporter assays, DEC1 trans activated the survivin promoter but repressed the DEC2 promoter. In contrast to the repression, the activation was delayed and varied depending on serum concentrations and cycle blockers. Studies with reporter mutants located, in the survivin promoter, two Sp1 sites that supported DEC1 transactivation. Electrophoretic mobility shift assay and chromatin immunoprecipitation detected the presence of DEC1 in the survivin promoter. These findings establish that the survivin gene is a transcription target of DEC1, and induction of survivin is at least in part responsible for DEC1 antiapoptosis.	Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; Providence Coll, Dept Biol, Providence, RI 02908 USA	University of Rhode Island; Providence College	Yan, B (corresponding author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	byan@uri.edu	Yan, Bingfang/C-7706-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT003019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061988] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05AT003019, F05 AT003019] Funding Source: Medline; NIEHS NIH HHS [R01 ES007965, R01ES07965] Funding Source: Medline; NIGMS NIH HHS [R01 GM061988, R01GM61988] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chakrabarti J, 2004, BRIT J CANCER, V91, P954, DOI 10.1038/sj.bjc.6602059; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Currie MJ, 2004, J CLIN PATHOL, V57, P829, DOI 10.1136/jcp.2003.015644; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halaban R, 2005, CANCER METAST REV, V24, P339, DOI 10.1007/s10555-005-1582-z; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li YX, 2004, BIOCHEM J, V382, P895, DOI 10.1042/BJ20040592; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Song XL, 2004, DRUG METAB DISPOS, V32, P35, DOI 10.1124/dmd.32.1.35; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Turley H, 2004, J PATHOL, V203, P808, DOI 10.1002/path.1585; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Xie MX, 2003, DRUG METAB DISPOS, V31, P21, DOI 10.1124/dmd.31.1.21; Xie MX, 2002, DRUG METAB DISPOS, V30, P541, DOI 10.1124/dmd.30.5.541; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	43	91	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3296	3306		10.1038/sj.onc.1209363	http://dx.doi.org/10.1038/sj.onc.1209363			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462771	Green Accepted			2022-12-25	WOS:000237951200008
J	Fugier, C; Tousaint, JJ; Prieur, X; Plateroti, M; Samarut, J; Delerive, P				Fugier, C; Tousaint, JJ; Prieur, X; Plateroti, M; Samarut, J; Delerive, P			The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOPOIETIN-LIKE PROTEIN-3; RECEPTOR-BETA; CHOLESTEROL-METABOLISM; LIPID-METABOLISM; GENE; ALPHA; LIVER; MICE; IDENTIFICATION; OVEREXPRESSION	Whereas the role of thyroid hormone is clearly established in the regulation of cholesterol homeostasis, its involvement in the control of serum triglyceride ( TG) levels remains largely debated. Angiopoietin-like proteins 3 and 4 have recently been characterized as potent lipoprotein lipase inhibitors and therefore as important components of plasma triglyceride homeostasis. In the present study, the role of thyroid hormone in the regulation of both ANGPTL4 and ANGPTL3 gene expression was investigated. In vivo studies revealed that thyroid hormone down-regulates ANGPTL3 but not ANGPTL4 gene expression in hypothyroid rats. Using thyroid hormone receptor ( TR)-deficient mice, we show that thyroid hormone regulates ANGPTL3 gene expression in a TR beta-dependent manner. Transfection studies revealed that this inhibition occurs at the transcriptional level in a DNA binding-independent fashion and requires the proximal ( -171 to +66) region of the ANGPTL3 gene promoter. Moreover, site-directed mutagenesis experiments indicate that the HNF1 site within this proximal region mediates this TR beta-dependent repression. Finally, co-transfection studies and electrophoretic mobility shift assays suggest that TR beta antagonizes the HNF1 alpha signaling pathway by inhibiting its transcriptional activity without interfering with its DNA-binding capacity. Taken together, our results lead to the identification of ANGPTL3 as a novel TR beta target gene and provide a new potential mechanism to explain the hypotriglyceridemic properties of TR beta agonists in vivo.	GlaxoSmithKline R&D, CVU CEDD, F-91951 Les Ulis, France; Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule,IFR 128, UMR 5161,INRA,UMR 1237, F-69364 Lyon, France	GlaxoSmithKline; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Delerive, P (corresponding author), GlaxoSmithKline R&D, CVU CEDD, 25 Ave Quebec, F-91951 Les Ulis, France.	pxd14884@gsk.com	Samarut, Jacques/AAD-2587-2019; Plateroti, Michelina/F-2928-2017; Prieur, Xavier/D-4760-2015	Prieur, Xavier/0000-0003-0215-5447				ABRAMS JJ, 1981, J LIPID RES, V22, P307; AVIRAM M, 1982, CLIN BIOCHEM, V15, P62, DOI 10.1016/S0009-9120(82)90529-X; Caturla M, 1997, MOL CELL ENDOCRINOL, V135, P139, DOI 10.1016/S0303-7207(97)00196-2; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Dignam D R, 1983, Healthc Financ Manage, V37, P38; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Duntas LH, 2002, THYROID, V12, P287, DOI 10.1089/10507250252949405; ENGELKEN SF, 1981, ATHEROSCLEROSIS, V38, P177, DOI 10.1016/0021-9150(81)90114-3; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Flores-Morales A, 2002, MOL ENDOCRINOL, V16, P1257, DOI 10.1210/me.16.6.1257; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Gauthier K, 2001, MOL CELL BIOL, V21, P4748, DOI 10.1128/MCB.21.14.4748-4760.2001; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Gullberg H, 2002, MOL ENDOCRINOL, V16, P1767, DOI 10.1210/me.2002-0009; HANSSON P, 1983, HORM METAB RES, V15, P449, DOI 10.1055/s-2007-1018751; Hashimoto K, 2006, J BIOL CHEM, V281, P295, DOI 10.1074/jbc.M507877200; Ito M, 2003, CLIN ENDOCRINOL, V58, P621, DOI 10.1046/j.1365-2265.2003.01762.x; Johansson L, 2005, P NATL ACAD SCI USA, V102, P10297, DOI 10.1073/pnas.0504379102; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Kawai K, 2004, ENDOCRINOLOGY, V145, P5515, DOI 10.1210/en.2004-0382; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Korstanje R, 2004, ATHEROSCLEROSIS, V177, P443, DOI 10.1016/j.atherosclerosis.2004.08.006; Koster A, 2005, ENDOCRINOLOGY, V146, P4943, DOI 10.1210/en.2005-0476; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; Moore JMR, 2005, MOL CELL PROTEOMICS, V4, P475, DOI 10.1074/mcp.R500001-MCP200; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; NIKKILA EA, 1972, J CLIN INVEST, V51, P2103, DOI 10.1172/JCI107017; OIKE Y, 2005, TRENDS MOL MED; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Prieur X, 2005, J BIOL CHEM, V280, P27533, DOI 10.1074/jbc.M503139200; Roberts CGP, 2004, LANCET, V363, P793, DOI 10.1016/S0140-6736(04)15696-1; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; Staton JM, 1998, ENDOCRINOLOGY, V139, P1093, DOI 10.1210/en.139.3.1093; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Taylor AH, 1997, MOL PHARMACOL, V52, P542, DOI 10.1124/mol.52.3.542; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Wu YF, 2000, TRENDS ENDOCRIN MET, V11, P207, DOI 10.1016/S1043-2760(00)00263-0; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200; Yu XX, 2005, P NATL ACAD SCI USA, V102, P1767, DOI 10.1073/pnas.0409564102	53	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11553	11559		10.1074/jbc.M512554200	http://dx.doi.org/10.1074/jbc.M512554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505486	hybrid, Green Published			2022-12-25	WOS:000236988100017
J	Birmingham, CL; Smith, AC; Bakowski, MA; Yoshimori, T; Brumell, JH				Birmingham, CL; Smith, AC; Bakowski, MA; Yoshimori, T; Brumell, JH			Autophagy controls Salmonella infection in response to damage to the Salmonella-containing vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; LATE ENDOCYTIC COMPARTMENTS; PROTEIN SECRETION SYSTEM; EPITHELIAL-CELLS; MAMMALIAN-CELLS; HOST-CELL; INTRACELLULAR SALMONELLA; LEGIONELLA-PNEUMOPHILA; FILAMENTOUS STRUCTURES	Salmonella enterica serovar Typhimurium ( S. Typhimurium) is a facultative intracellular pathogen that causes disease in a variety of hosts. S. Typhimurium actively invade host cells and typically reside within a membrane-bound compartment called the Salmonella-containing vacuole (SCV). The bacteria modify the fate of the SCV using two independent type III secretion systems(TTSS). TTSS are known to damage eukaryotic cell membranes and S. Typhimurium has been suggested to damage the SCV using its Salmonella pathogenicity island (SPI)-1 encoded TTSS. Here we show that this damage gives rise to an intracellular bacterial population targeted by the autophagy system during in vitro infection. Approximately 20% of intracellular S. Typhimurium colocalized with the autophagy marker GFP-LC3 at 1 h postinfection. Autophagy of S. Typhimurium was dependent upon the SPI-1 TTSS and bacterial protein synthesis. Bacteria targeted by the autophagy system were often associated with ubiquitinated proteins, indicating their exposure to the cytosol. Surprisingly, these bacteria also colocalized with SCV markers. Autophagy-deficient (atg5(-/-)) cells were more permissive for intracellular growth by S. Typhimurium than normal cells, allowing increased bacterial growth in the cytosol. We propose a model in which the host autophagy system targets bacteria in SCVs damaged by the SPI-1 TTSS. This serves to retain intracellular S. Typhimurium within vacuoles early after infection to protect the cytosol from bacterial colonization. Our findings support a role for autophagy in innate immunity and demonstrate that Salmonella infection is a powerful model to study the autophagy process.	Hosp Sick Children, Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Natl Inst Genet, Dept Cell Genet, Shizuoka 4118540, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Brumell, JH (corresponding author), Hosp Sick Children, Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	john.brumell@sickkids.ca	Birmingham, Cheryl/AAF-6649-2020					Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Birmingham CL, 2005, INFECT IMMUN, V73, P1204, DOI 10.1128/IAI.73.2.1204-1208.2005; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Brumell JH, 2003, TRAFFIC, V4, P36, DOI 10.1034/j.1600-0854.2003.40106.x; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Brumell JH, 2002, INFECT IMMUN, V70, P3264, DOI 10.1128/IAI.70.6.3264-3270.2002; Brumell JH, 2004, CURR OPIN MICROBIOL, V7, P78, DOI 10.1016/j.mib.2003.12.005; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chakravortty D, 2002, J EXP MED, V195, P1155, DOI 10.1084/jem.20011547; CIECHANOVER A, 1991, BIOMED BIOCHIM ACTA, V50, P321; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; Dorn BR, 2001, INFECT IMMUN, V69, P5698, DOI 10.1128/IAI.69.9.5698-5708.2001; Drecktrah D, 2005, CELL MICROBIOL, V7, P105, DOI 10.1111/j.1462-5822.2004.00436.x; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Gallois A, 2001, J IMMUNOL, V166, P5741, DOI 10.4049/jimmunol.166.9.5741; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hernandez LD, 2003, J CELL BIOL, V163, P1123, DOI 10.1083/jcb.200309161; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Holden DW, 2002, TRAFFIC, V3, P161, DOI 10.1034/j.1600-0854.2002.030301.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Martens S, 2005, PLOS PATHOG, V1, P187, DOI 10.1371/journal.ppat.0010024; Mastroeni P, 2004, MICROBES INFECT, V6, P398, DOI 10.1016/j.micinf.2003.12.009; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P5711; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; RIKIHISA Y, 1984, ANAT REC, V208, P319, DOI 10.1002/ar.1092080302; Roy D, 2004, SCIENCE, V304, P1515, DOI 10.1126/science.1098371; Salcedo SP, 2001, CELL MICROBIOL, V3, P587, DOI 10.1046/j.1462-5822.2001.00137.x; Smith AC, 2005, J BIOL CHEM, V280, P24634, DOI 10.1074/jbc.M500358200; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tsolis RM, 1999, ADV EXP MED BIOL, V473, P261; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Walker DH, 1997, LAB INVEST, V76, P129; Wood MW, 1998, MOL MICROBIOL, V29, P883, DOI 10.1046/j.1365-2958.1998.00984.x; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	73	505	517	0	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11374	11383		10.1074/jbc.M509157200	http://dx.doi.org/10.1074/jbc.M509157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495224	hybrid			2022-12-25	WOS:000236822200080
J	Salas, A; Shimaoka, M; Phan, U; Kim, M; Springer, TA				Salas, A; Shimaoka, M; Phan, U; Kim, M; Springer, TA			Transition from rolling to firm adhesion can be mimicked by extension of integrin alpha(L)beta(2) in an intermediate affinity state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; I-LIKE DOMAIN; DISULFIDE BOND; CONFORMATION; REVEALS; LFA-1; FLOW; ALPHA-L-BETA-2; ADHESIVENESS; ANTAGONISTS	alpha(L)beta(2) affinity for intercellular adhesion molecule-1 (ICAM-1) is regulated by the conformation of the alpha(L) I domain, which is in turn controlled by the conformation and orientation of other adjacent domains. Additionally, overall integrin conformation (bent versus straightened) influences the orientation of the I domain and access to its ligands, influencing adhesive efficiency. The open or high affinity I domain conformation supports strong adhesion, whereas the closed, low affinity conformation mediates weak interactions or rolling. We have previously suggested that alpha(L)beta(2) can also exist on the cell surface in an intermediate affinity state. Here we have studied the adhesive properties of integrin alpha(L)beta(2) containing mutant I domains with intermediate affinities for ICAM-1. In an overall bent conformation, the intermediate affinity state of alpha(L)beta(2) is hardly detected by conventional adhesion assays, but robust adhesion is seen when an extended conformation is induced by a small molecule alpha/beta I allo-steric antagonist. Intermediate affinity alpha(L)beta(2) supports more stable rolling than wild-type alpha(L)beta(2) under shear conditions. Moreover, antagonist-induced extension transforms rolling adhesion into firm adhesion in a manner reminiscent of chemokine activation of integrin alpha(L)beta(2). These findings suggest the relevance of intermediate affinity states of alpha(L)beta(2) to the transition between inactive and active states and demonstrate the importance of both I domain affinity and overall integrin conformation for cell adhesion.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Salas, Azucena/AAN-7035-2020	Salas, Azucena/0000-0003-4572-2907	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798, R01 CA031798, R37 CA031798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	25	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10876	10882		10.1074/jbc.M512472200	http://dx.doi.org/10.1074/jbc.M512472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505487	Green Accepted, hybrid			2022-12-25	WOS:000236822200027
J	Zhang, H; Schmidt, BZ; Sun, F; Condliffe, SB; Butterworth, MB; Youker, RT; Brodsky, JL; Aridor, M; Frizzell, RA				Zhang, H; Schmidt, BZ; Sun, F; Condliffe, SB; Butterworth, MB; Youker, RT; Brodsky, JL; Aridor, M; Frizzell, RA			Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE T; DELTA F508 MUTATION; HEAT-SHOCK-PROTEIN; QUALITY-CONTROL; KINASE-A; CHAPERONE; CFTR; EXOCYTOSIS; COPII; HSP70	We examined the role of the cysteine string protein (Csp) in cystic fibrosis transmembrane conductance regulator ( CFTR) biogenesis in relation to another J-domain protein, Hdj-2, a recognized CFTR cochaperone. Increased expression of Csp produced a dose-dependent reduction in mature(band C) CFTR and an increase in immature( band B) CFTR. Exogenous expression of Hdj-2 also increased CFTR band B, but unlike Csp, Hdj-2 increased band C as well. The Csp-induced block of CFTR maturation required Hsp70, because a J-domain mutant (H43Q) that interferes with the ability of Csp to stimulate Hsp70 ATPase activity relieved the Csp-induced block of CFTR maturation. Nevertheless, Csp H43Q still increased immature CFTR. Csp-induced band B CFTR was found adjacent to the nucleus, co-localizing with calnexin, and it remained detergent-soluble. These data indicate that Csp did not block CFTR maturation by promoting the aggregation or degradation of immature CFTR. Csp knockdown by RNA interference produced a 5-fold increase in mature CFTR and augmented cAMP-stimulated CFTR currents. Thus, the production of mature CFTR is inversely related to the expression level of Csp. Both Csp and Hdj-2 associated with the CFTR R-domain in vitro, and Hdj-2 binding was displaced by Csp, suggesting common interaction sites. Combined expression of Csp and Hdj-2 mimicked the effect of Csp alone, a block of CFTR maturation. But together, Csp and Hdj-2 produced additive increases in CFTR band B, and this did not depend on their interactions with Hsp70, consistent with direct chaperone actions of these proteins. Like Hdj-2, Csp reduced the aggregation of NBD1 in vitro in the absence of Hsp70. Our data suggest that both Csp and Hdj-2 facilitate the biosynthesis of immature CFTR, acting as direct CFTR chaperones, but in addition, Csp is positioned later in the CFTR biogenesis cascade where it regulates the production of mature CFTR by limiting its exit from the endoplasmic reticulum.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu	Youker, Robert/AAP-8725-2021	Schmidt, Bela Z/0000-0003-1085-9372; Youker, Robert/0000-0002-3986-1655; Butterworth, Michael/0000-0002-2173-8333	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062318, R21DK060835, P30DK072506, R56DK062318, R01DK068196] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62318, DK68196, DK60835, R01 DK062318, DK72506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Aridor M, 1996, NATURE, V383, P220, DOI 10.1038/383220a0; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Barlowe C, 2003, CELL, V114, P395, DOI 10.1016/S0092-8674(03)00650-0; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Butterworth MB, 2005, AM J PHYSIOL-RENAL, V289, pF969, DOI 10.1152/ajprenal.00390.2003; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Eberle KK, 1998, CELL TISSUE RES, V294, P203, DOI 10.1007/s004410051170; Evans GJO, 2003, BIOCHEM SOC T, V31, P824, DOI 10.1042/bst0310824; Evans GJO, 2003, TRAFFIC, V4, P653, DOI 10.1034/j.1600-0854.2003.00127.x; Fewell SW, 2004, J BIOL CHEM, V279, P51131, DOI 10.1074/jbc.M404857200; Fewell SW, 2002, P NATL ACAD SCI USA, V99, P2002, DOI 10.1073/pnas.042670999; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Mancias JD, 2005, TRAFFIC, V6, P278, DOI 10.1111/j.1600-0854.2005.00279.x; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Sakisaka T, 2002, EMBO J, V21, P6125, DOI 10.1093/emboj/cdf603; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Smith GB, 2005, J BIOL CHEM, V280, P32669, DOI 10.1074/jbc.M501806200; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhu KM, 1998, CANCER CAUSE CONTROL, V9, P77, DOI 10.1023/A:1008853421083; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	61	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11312	11321		10.1074/jbc.M512013200	http://dx.doi.org/10.1074/jbc.M512013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16469739	Green Published, hybrid			2022-12-25	WOS:000236822200074
J	Jiang, N; Wang, XX; Jhanwar-Uniyal, M; Darzynkiewicz, Z; Dai, W				Jiang, N; Wang, XX; Jhanwar-Uniyal, M; Darzynkiewicz, Z; Dai, W			Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC5; CELL-CYCLE ARREST; SERINE/THREONINE KINASE; PHOSPHORYLATION; PROGRESSION; INHIBITION; MECHANISM; DOCKING; CANCER; PART	Polo-like kinase 3 (Plk3), an immediate early response gene product, plays an important role in the regulation of mitosis, DNA damage checkpoint activation, and Golgi dynamics. Similar to other members of the Plk family, Plk3 has a conserved kinase domain at the N terminus and a Polo box domain consisting of two Polo boxes at the C terminus. In this study, we demonstrate that the Polo box domain of Plk3 is sufficient for subcellular localization of this kinase to the centrosomes, the spindle poles, and the midbody when ectopically expressed in HeLa and U2OS cells. Both Polo boxes are required for the subcellular localization. Overexpression of the Polo box domain, not the kinase domain, of Plk3 causes significant cell cycle arrest and cytokinesis defects, eventually leading to mitotic catastrophe/apoptosis. Interestingly, the Polo box domain of Plk3 is more potent in inhibiting cell proliferation and inducing apoptosis than that of Plk1, suggesting that this domain can provide an additional structural basis for discovery of new anticancer drugs given the current emphasis on Plk1 as a therapeutic target.	New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Dept Neurosurg, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Brander Canc Inst, Div Mol Carcinogenesis, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Basic Sci Bldg,Rm A22, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA074229, R01CA028704] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704, R01 CA028704-27, CA 74229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2005, ONCOGENE, V24, P214, DOI 10.1038/sj.onc.1208270; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; JULIAN M, 1993, J CELL SCI, V105, P145; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Levitzki A, 2002, EUR J CANCER, V38, pS11, DOI 10.1016/S0959-8049(02)80598-6; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yuan JP, 2002, CANCER RES, V62, P4186; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	34	49	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10577	10582		10.1074/jbc.M513156200	http://dx.doi.org/10.1074/jbc.M513156200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478733	hybrid			2022-12-25	WOS:000236594300089
J	Loriot, A; De Plaen, E; Boon, T; De Smet, C				Loriot, A; De Plaen, E; Boon, T; De Smet, C			Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; HUMAN CANCER-CELLS; DNA METHYLATION; CPG ISLANDS; DEPENDENT MECHANISM; MOUSE EMBRYO; GERM LINE; GENE; EXPRESSION	MAGE-A1 belongs to a group of germ line-specific genes that rely primarily on DNA methylation for repression in somatic tissues. In many types of tumors, the promoter of these genes becomes demethylated and transcription becomes activated. We showed previously that, although MZ2-MEL melanoma cells contain an active unmethylated MAGE-A1 gene, they lack the ability to induce demethylation of newly integrated MAGE-A1 transgenes that were methylated in vitro before transfection. In the same cells, unmethylated MAGE-A1 transgenes were protected against remethylation, and this appeared to depend on the level of transcriptional activity. We therefore proposed that hypomethylation of MAGE-A1 in tumors relies on a past demethylation event and on the presence of appropriate transcription factors that maintain the promoter unmethylated. Here, we tested this hypothesis further by examining whether induction of a transient demethylation phase in MZ2-MEL would suffice to convert a previously methylated MAGE-A1 transgene into a permanently hypomethylated and active one. For induction of the demethylation phase, we used antisense oligonucleotides targeting the three known human DNA methyltransferases. We found that down-regulation of DNMT1, but not of DNMT3A and DNMT3B, induces activation of the MAGE-A1 transgene, suggesting that DNMT1 has a predominant role for methylation maintenance in MZ2-MEL cells. By using a selectable MAGE-A1 transgene construct, we were able to isolate a cell population in which DNMT1 depletion had resulted in transgene activation. The promoter region of the transgene was almost completely unmethylated in these cells, and this active and unmethylated state was maintained for over 60 days after restoration of normal DNMT1 expression.	Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; Catholic Univ Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	De Smet, C (corresponding author), Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, 74 Ave Hippocrate, B-1200 Brussels, Belgium.	charles.desmet@bru.licr.org						ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Conway KE, 2000, CANCER RES, V60, P6236; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; FLATAU E, 1984, MOL CELL BIOL, V4, P2098, DOI 10.1128/MCB.4.10.2098; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girault I, 2003, CLIN CANCER RES, V9, P4415; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hattori N, 2004, GENOME RES, V14, P1733, DOI 10.1101/gr.2431504; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lin CH, 2001, CANCER RES, V61, P4238; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; MONK M, 1987, DEVELOPMENT, V99, P371; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Shi HD, 2003, CANCER RES, V63, P2164; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WEYNANTS P, 1994, INT J CANCER, V56, P826, DOI 10.1002/ijc.2910560612; WILSON VL, 1983, SCIENCE, V220, P1054; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	52	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10118	10126		10.1074/jbc.M510469200	http://dx.doi.org/10.1074/jbc.M510469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16497664	hybrid			2022-12-25	WOS:000236594300037
J	Kovacevic, S; Anderson, D; Morita, YS; Patterson, J; Haites, R; McMillan, BNI; Coppel, R; McConville, MJ; Billman-Jacobe, H				Kovacevic, S; Anderson, D; Morita, YS; Patterson, J; Haites, R; McMillan, BNI; Coppel, R; McConville, MJ; Billman-Jacobe, H			Identification of a novel protein with a role in lipoarabinomannan biosynthesis in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMEGMATIS; PHOSPHATIDYLINOSITOL; TUBERCULOSIS; BIOGENESIS; GENE	All species of Mycobacteria synthesize distinctive cell walls that are rich in phosphatidylinositol mannosides (PIMs), lipomannan (LM), and lipoarabinomannan (LAM). PIM glycolipids, having 2-4 mannose residues, can either be channeled into polar PIM species (with 6 Man residues) or hypermannosylated to form LM and LAM. In this study, we have identified a Mycobacterium smegmatis gene, termed lpqW, that is required for the conversion of PIMs to LAM and is highly conserved in all mycobacteria. A transposon mutant, Myco481, containing an insertion near the 3' end of lpqW exhibited altered colony morphology on complex agar medium. This mutant was unstable and was consistently overgrown by a second mutant, represented by Myco481.1, that had normal growth and colony characteristics. Biochemical analysis and metabolic labeling studies showed that Myco481 synthesized the complete spectrum of apolar and polar PIMs but was unable to make LAM. LAM biosynthesis was restored to near wild type levels in Myco481.1. However, this mutant was unable to synthesize the major polar PIM (AcPIM6) and accumulated a smaller intermediate, AcPIM4. Targeted disruption of the lpqW gene and complementation of the initial Myco481 mutant with the wild type gene confirmed that the phenotype of this mutant was due to loss of LpqW. These studies suggest that LpqW has a role in regulating the flux of early PIM intermediates into polar PIM or LAM biosynthesis. They also suggest that AcPIM4 is the likely branch point intermediate in polar PIM and LAM biosynthesis.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Bio21 Inst Mol Sci & Biotechnol, Parkville, Vic 3010, Australia; Monash Univ, Dept Microbiol, ARC Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia	University of Melbourne; University of Melbourne; Monash University	Billman-Jacobe, H (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.	hbj@unimelb.edu.au	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124; Billman-Jacobe, Helen/0000-0001-5713-4657; Morita, Yasu/0000-0002-4514-9242				Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 1997, BIOCHEM SOC T, V25, P188, DOI 10.1042/bst0250188; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; GUILHOT C, 1994, J BACTERIOL, V176, P535, DOI 10.1128/JB.176.2.535-539.1994; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; HENRY RJ, 1983, J CHROMATOGR, V256, P419, DOI 10.1016/S0021-9673(01)88259-5; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; Jeevarajah D, 2004, J BACTERIOL, V186, P6792, DOI 10.1128/JB.186.20.6792-6799.2004; KORDULAKOVA J, 2002, J BIOL CHEM, V14, P14; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Prod'hom G, 1998, FEMS MICROBIOL LETT, V158, P75, DOI 10.1111/j.1574-6968.1998.tb12803.x; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Rawat M, 2003, MICROBIOL-SGM, V149, P1341, DOI 10.1099/mic.0.26084-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sauton B., 1912, CR HEBD ACAD SCI, V92, P85; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	31	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9011	9017		10.1074/jbc.M511709200	http://dx.doi.org/10.1074/jbc.M511709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455649	hybrid			2022-12-25	WOS:000236404700005
J	Xu, Y; Huang, S; Liu, ZG; Han, JH				Xu, Y; Huang, S; Liu, ZG; Han, JH			Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; APOPTOSIS-INDUCING FACTOR; RECEPTOR-INTERACTING PROTEIN; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; DNA-DAMAGE; PATHWAY; BCL-2; RIP	Poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation-induced necrosis has been implicated in several pathophysiological conditions. Although mitochondrial dysfunction and apoptosis-inducing factor translocation from the mitochondria to the nucleus have been suggested to play very important roles in PARP-1-mediated cell death, the signaling events downstream of PARP-1 activation in initiating mitochondria dysfunction are not clear. Here we used the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine, a potent PARP-1 activator, to study PARP-1 activation-mediated cell death. We found, based on genetic knockouts and pharmacological inhibition, that c-Jun N-terminal kinase (JNK), especially JNK1, but not the other groups of mitogen-activated protein kinase, is required for PARP-1-induced mitochondrial dysfunction, apoptosis-inducing factor translocation, and subsequent cell death. We reveal that receptor-interacting protein 1 (RIP1) and tumor necrosis factor receptor-associated factor 2 (TRAF2), are upstream of JNK in PARP-1 hyperactivated cells, because PARP-1-induced JNK activation was attenuated in RIP1-/- and TRAF2-/- mouse embryonic fibroblast cells. Consistently, knockouts of RIP1 and TRAF2 caused a resistance to PARP-1-induced cell death. Therefore, our study uncovers that RIP1, TRAF2, and JNK comprise a pathway to mediate the signaling from PARP-1 overactivation to mitochondrial dysfunction.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, Y (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mcbxuyue@scripps.edu	Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637, R01AI054796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067101, P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054796, AI41637] Funding Source: Medline; NIGMS NIH HHS [GM67101, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Bajenova O, 2004, APOPTOSIS, V9, P561, DOI 10.1023/B:APPT.0000038030.47068.49; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanduc D, 2002, INT J ONCOL, V21, P165; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004; Shrivastava P, 2004, MOL CELL BIOL, V24, P6763, DOI 10.1128/MCB.24.15.6763-6772.2004; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	89	93	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8788	8795		10.1074/jbc.M508135200	http://dx.doi.org/10.1074/jbc.M508135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446354	hybrid			2022-12-25	WOS:000236247100058
J	Maezawa, I; Nivison, M; Montine, KS; Maeda, N; Montine, TJ				Maezawa, Izumi; Nivison, Mary; Montine, Kathleen S.; Maeda, Nobuyo; Montine, Thomas J.			Neurotoxicity from innate immune response is greatest with targeted replacement of epsilon 4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK	FASEB JOURNAL			English	Article						APOE; neurodegeneration	ACTIVATED PROTEIN-KINASE; NEURONAL OXIDATIVE DAMAGE; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; BRAIN INFLAMMATION; IN-VIVO; LIPOPOLYSACCHARIDE; RECEPTOR; APOE; ALLELE	Inheritance of APOE alleles is associated with varying clinical outcomes in several neurodegenerative diseases that are associated with innate immune response in brain. We tested the hypothesis that inheritance of different APOE alleles would significantly modulate neurotoxicity arising from glial innate immune response. We first used dissociated cultures of wild-type (wt) murine neurons and glia derived from mice with targeted replacement (TR) of the epsilon 2, epsilon 3, or, epsilon 4 APOE allele. Our results showed that the vast majority of bystander damage to wt neurons derived from microglia was greatest with TR APOE4 glia, intermediate from TR APOE3 glia, and least from TR APOE2 glia and preceded detectable NO secretion. Microglial p38MAPK-dependent cytokine secretion followed a similar pattern of TR APOE dependence. In hippocampal slice cultures, innate immune activation had a similar pattern of TR APOE-dependence and produced postsynaptic neuronal damage in TR APOE4 and TR APOE3 but not TR APOE2 cultures that was p38MAPK dependent. These findings suggest a new mechanism by which inheritance of different APOE alleles may influence the outcome of neurodegenerative diseases associated with microglial innate immune response.	Univ Washington, Dept Pathol, Seattle, WA 98104 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	Montine, TJ (corresponding author), Univ Washington, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Montine, Kathleen/0000-0003-2110-8363	NATIONAL INSTITUTE ON AGING [R01AG024011, P50AG005136] Funding Source: NIH RePORTER; NIA NIH HHS [AG-24011, AG-05136] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Bock HH, 2004, J BIOL CHEM, V279, P33471, DOI 10.1074/jbc.M401770200; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brendza RP, 2002, MOL PSYCHIATR, V7, P132, DOI 10.1038/sj.mp.4001006; Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1; Buttini M, 1999, J NEUROSCI, V19, P4867; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Fabrizi C, 2001, J BIOL CHEM, V276, P25692, DOI 10.1074/jbc.M100133200; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Han IO, 2002, NEUROSCI LETT, V325, P9, DOI 10.1016/S0304-3940(02)00218-5; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; John U, 2003, ALCOHOL ALCOHOLISM, V38, P263, DOI 10.1093/alcalc/agg063; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Luk JM, 1995, ANAL BIOCHEM, V232, P217, DOI 10.1006/abio.1995.0010; Maezawa I, 2004, J NEUROCHEM, V91, P1312, DOI 10.1111/j.1471-4159.2004.02818.x; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Milatovic D, 2003, J NEUROCHEM, V87, P1518, DOI 10.1046/j.1471-4159.2003.02120.x; Milatovic D, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-20; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Shie FS, 2005, GLIA, V52, P70, DOI 10.1002/glia.20220; Shie FS, 2005, AM J PATHOL, V166, P1163, DOI 10.1016/S0002-9440(10)62336-X; Stern EL, 2000, J NEUROIMMUNOL, V106, P114, DOI 10.1016/S0165-5728(00)00194-6; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Wenk GL, 2004, J NEUROCHEM, V89, P484, DOI 10.1111/j.1471-4159.2004.02359.x; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8; Xie Z, 2002, J NEUROSCI, V22, P3484; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	61	89	92	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					797	+		10.1096/fj.05-5423fje	http://dx.doi.org/10.1096/fj.05-5423fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16481366				2022-12-25	WOS:000237698700018
J	Wenstrup, RJ; Florer, JB; Davidson, JM; Phillips, CL; Pfeiffer, BJ; Menezes, DW; Chervoneva, I; Birk, DE				Wenstrup, RJ; Florer, JB; Davidson, JM; Phillips, CL; Pfeiffer, BJ; Menezes, DW; Chervoneva, I; Birk, DE			Murine model of the Ehlers-Danlos syndrome - col5a1 haploinsufficiency disrupts collagen fibril assembly at multiple stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPES-I; V COLLAGEN; EXTRACELLULAR COMPARTMENTS; GENE COL5A1; GRAVIS FORM; MUTATION; FIBRILLOGENESIS; SKIN; DEPOSITION; ALPHA-1(V)	The most commonly identified mutations causing Ehlers-Danlos syndrome (EDS) classic type result in haploinsufficiency of pro alpha 1(V) chains of type V collagen, a quantitatively minor collagen that co-assembles with type I collagen as heterotypic fibrils. To determine the role(s) of type I/V collagen interactions in fibrillogenesis and elucidate the mechanism whereby half-reduction of type V collagen causes abnormal connective tissue biogenesis observed in EDS, we analyzed mice heterozygous for a targeted inactivating mutation in col5a1 that caused 50% reduction in col5a1 mRNA and collagen V. Comparable with EDS patients, they had decreased aortic stiffness and tensile strength and hyperextensible skin with decreased tensile strength of both normal and wounded skin. In dermis, 50% fewer fibrils were assembled with two subpopulations: relatively normal fibrils with periodic immunoreactivity for collagen V where type I/V interactions regulate nucleation of fibril assembly and abnormal fibrils, lacking collagen V, generated by unregulated sequestration of type I collagen. The presence of the aberrant fibril subpopulation disrupts the normal linear and lateral growth mediated by fibril fusion. Therefore, abnormal fibril nucleation and dysfunctional fibril growth with potential disruption of cell-directed fibril organization leads to the connective tissue dysfunction associated with EDS.	Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Vanderbilt Univ, Dept Lab Med, Nashville, TN 37232 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Vanderbilt University; University of Missouri System; University of Missouri Columbia; Jefferson University; Jefferson University	Wenstrup, RJ (corresponding author), Childrens Hosp Res Fdn, Div Human Genet, 3333 Burnet Ave,ML 4006, Cincinnati, OH 45229 USA.	richard.wenstrup@cchmc.org	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088; Phillips, Charlotte/0000-0002-7761-3783	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG019475] Funding Source: NIH RePORTER; NEI NIH HHS [EY05129] Funding Source: Medline; NIAMS NIH HHS [AR47054] Funding Source: Medline; NIA NIH HHS [AG19475] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BEIGHTON P, 1992, MCKUSICKS HERITABLE, P189; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1995, DEV DYNAM, V202, P229, DOI 10.1002/aja.1002020303; Birk DE, 1996, MATRIX BIOL, V15, P111, DOI 10.1016/S0945-053X(96)90152-3; BIRK DE, 1984, J CELL BIOL, V99, P2024, DOI 10.1083/jcb.99.6.2024; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; Bouma P, 2001, J BIOL CHEM, V276, P13356, DOI 10.1074/jbc.M011742200; Burrows NP, 1996, J INVEST DERMATOL, V106, P1273, DOI 10.1111/1523-1747.ep12348978; Burrows NP, 1997, CLIN EXP DERMATOL, V22, P174, DOI 10.1046/j.1365-2230.1997.2290654.x; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Chanut-Delalande H, 2004, MOL CELL BIOL, V24, P6049, DOI 10.1128/MCB.24.13.6049-6057.2004; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; CLARK JM, 1985, ARTERIOSCLEROSIS, V5, P19, DOI 10.1161/01.ATV.5.1.19; DePaepe A, 1997, AM J HUM GENET, V60, P547; DOBRIN PB, 1984, ARCH SURG-CHICAGO, V119, P405; Dobrin Philip B., 1997, P69; HAUSSER I, 1994, HUM GENET, V93, P394; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kadler KE, 2000, MATRIX BIOL, V19, P359, DOI 10.1016/S0945-053X(00)00082-2; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LEES JF, 1994, J BIOL CHEM, V269, P24354; Liaw L, 1998, J CLIN INVEST, V101, P1468; Malfait F, 2005, HUM MUTAT, V25, P28, DOI 10.1002/humu.20107; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; PLOETZ C, 1991, J STRUCT BIOL, V106, P73, DOI 10.1016/1047-8477(91)90064-4; Richards AJ, 1998, J MED GENET, V35, P846, DOI 10.1136/jmg.35.10.846; Schwarze U, 2000, AM J HUM GENET, V66, P1757, DOI 10.1086/302933; Segev F, 2006, INVEST OPHTH VIS SCI, V47, P565, DOI 10.1167/iovs.05-0771; Steinmann B., 2002, CONNECTIVE TISSUE IT, P431, DOI DOI 10.1002/0471221929.CH9; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; VOGEL A, 1979, LAB INVEST, V40, P201; Vonesh E.F., 1997, LINEAR NONLINEAR MOD; Vouyouka AG, 2001, J VASC SURG, V33, P1263, DOI 10.1067/mva.2001.113579; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wenstrup RJ, 2004, J CELL BIOCHEM, V92, P113, DOI 10.1002/jcb.20024; Wenstrup RJ, 2002, GENET MED, V4, P112, DOI 10.1097/00125817-200205000-00003; Wenstrup RJ, 2000, AM J HUM GENET, V66, P1766, DOI 10.1086/302930; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200	47	117	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12888	12895		10.1074/jbc.M511528200	http://dx.doi.org/10.1074/jbc.M511528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16492673	hybrid			2022-12-25	WOS:000237134700084
J	Sao-Jose, C; Lhuillier, S; Lurz, R; Melki, R; Lepault, J; Santos, MA; Tavares, P				Sao-Jose, C; Lhuillier, S; Lurz, R; Melki, R; Lepault, J; Santos, MA; Tavares, P			The ectodomain of the viral receptor YueB forms a fiber that triggers ejection of bacteriophage SPP1 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS 168; COILED-COIL STRUCTURE; CELL-WALL; PROTEIN; PHAGE; ADSORPTION; RESOLUTION; MECHANISM; TRANSPORT; RELEASE	The irreversible binding of bacteriophages to their receptor( s) in the host cell surface triggers release of the naked genome from the virion followed by transit of viral DNA to the host cell cytoplasm. We have purified, for the first time, a receptor from a Gram-positive bacterium that is active to trigger viral DNA ejection in vitro. This extracellular region ("ectodomain") of the Bacillus subtilis protein YueB ( YueB780) was a 7 S elongated dimer forming a 36.5-nm-long fiber. YueB780 bound to the tail tip of bacteriophage SPP1. Although a stable receptor-phage interaction occurred between 0 and 37 degrees C, complete blocking of phage DNA release or partial ejection events were observed at temperatures below 15 degrees C. We also showed that the receptor was exposed to the B. subtilis surface. YueB differed structurally from phage receptors from Gram-negative bacteria. Its properties revealed a fiber spanning the full length of the 30-nm-thick peptidoglycan layer. The fiber is predicted to be anchored in the cell membrane through transmembrane segments. These features, highly suitable for a virus receptor in Gram-positive bacteria, are very likely shared by a large number of phage receptors.	CNRS, INRA, UMR 1157,UMR 2472, Unite Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Fac Ciencias Lisboa, Inst Ciencia Aplicada & Tecnol, P-1749016 Lisbon, Portugal; Dept Biol Vegetal, Inst Ciencia Aplicada & Tecnol, P-1749016 Lisbon, Portugal; Inst Federat Rech 115, F-91198 Gif Sur Yvette, France; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universidade de Lisboa; Universidade de Lisboa; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Tavares, P (corresponding author), CNRS, INRA, UMR 1157,UMR 2472, Unite Virol Mol & Struct, Bat 14B,Av Terrasse, F-91198 Gif Sur Yvette, France.	tavares@vmc.cnrs-gif.fr	Sao-Jose, Carlos Jorge/J-6703-2012; iMed.ULisboa, M2B/B-5277-2014; Lepault, Jean/AAN-8859-2020	Sao-Jose, Carlos Jorge/0000-0002-4890-9446; iMed.ULisboa, M2B/0000-0002-1245-3715; Santos, Mario/0000-0002-9447-1553; Tavares, Paulo/0000-0002-2566-4546				Adams MH, 1959, BACTERIOPHAGES; Andrews D, 2005, J BIOL CHEM, V280, P5929, DOI 10.1074/jbc.C400513200; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Davison S, 2005, J BACTERIOL, V187, P6742, DOI 10.1128/JB.187.19.6742-6749.2005; de Frutos M, 2005, EUR PHYS J E, V17, P429, DOI 10.1140/epje/i2005-10019-5; de Frutos M, 2005, BIOPHYS J, V88, P1364, DOI 10.1529/biophysj.104.048785; EFIMOV VP, 1994, J MOL BIOL, V242, P470, DOI 10.1006/jmbi.1994.1595; Evilevitch A, 2003, P NATL ACAD SCI USA, V100, P9292, DOI 10.1073/pnas.1233721100; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GELLER BL, 1993, J BACTERIOL, V175, P5510, DOI 10.1128/JB.175.17.5510-5519.1993; GRAHAM LL, 1994, J BACTERIOL, V176, P1413, DOI 10.1128/jb.176.5.1413-1421.1994; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; JACOBSON ED, 1977, J VIROL, V21, P1223, DOI 10.1128/JVI.21.3.1223-1227.1977; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Kemp P, 2004, MOL MICROBIOL, V53, P1251, DOI 10.1111/j.1365-2958.2004.04204.x; LEPAULT J, 1981, J MOL BIOL, V149, P275, DOI 10.1016/0022-2836(81)90302-8; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lurz R, 2001, J MOL BIOL, V310, P1027, DOI 10.1006/jmbi.2001.4800; MACKAY DJ, 1976, VIROLOGY, V72, P167, DOI 10.1016/0042-6822(76)90321-4; Mangenot S, 2005, CURR BIOL, V15, P430, DOI 10.1016/j.cub.2004.12.080; MONTEVILLE MR, 1994, APPL ENVIRON MICROB, V60, P3204, DOI 10.1128/AEM.60.9.3204-3211.1994; Orlova EV, 2003, EMBO J, V22, P1255, DOI 10.1093/emboj/cdg123; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; Poranen MM, 2002, ANNU REV MICROBIOL, V56, P521, DOI 10.1146/annurev.micro.56.012302.160643; PORTMANN R, 1974, FEBS LETT, V45, P646; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; SANTOS MA, 1983, J GEN MICROBIOL, V129, P3499; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STEVEN AC, 1988, J MOL BIOL, V200, P351, DOI 10.1016/0022-2836(88)90246-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; Vinga I, 2006, BACTERIOPHAGE BIOL B, P165; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8; [No title captured]	39	86	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11464	11470		10.1074/jbc.M513625200	http://dx.doi.org/10.1074/jbc.M513625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16481324	Green Published, hybrid			2022-12-25	WOS:000236988100007
J	Ge, GX; Zhang, Y; Steiglitz, BM; Greenspan, DS				Ge, GX; Zhang, Y; Steiglitz, BM; Greenspan, DS			Mammalian tolloid-like 1 binds procollagen C-proteinase enhancer protein 1 and differs from bone morphogenetic protein 1 in the functional roles of homologous protein domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; TERMINAL PROTEINASE; MOUSE FIBROBLASTS; GENE; DROSOPHILA; IDENTIFICATION; PURIFICATION; BMP-1; METALLOPROTEINASES; EXPRESSION	Bone morphogenetic protein 1 (BMP1) is the prototype of a subgroup of metalloproteinases with manifold roles in morphogenesis. Four mammalian subgroup members exist, including BMP1 and mammalian Tolloid-like 1 (mTLL1). Subgroup members have a conserved protein domain structure: an NH2-terminal astacin-like protease domain, followed by a fixed order of CUB and epidermal growth factor-like protein-protein interaction motifs. Previous structure/function studies have documented those BMP1 protein domains necessary for secretion, and activity against various substrates. Here we demonstrate that, in contradiction to previous reports, the most NH2-terminal CUB domain (CUB1) is not required for BMP1 secretion nor is the next CUB domain (CUB2) required for enzymatic activity. The same is true for mTLL1. In fact, secreted protease domains of BMP1 and mTLL1, devoid of CUB or epidermal growth factor-like domains, have procollagen C-proteinase (pCP) activity and activity for biosynthetic processing of biglycan, the latter with kinetics superior to those of the full-length proteins. Structure-function analyses herein also suggest differences in the functional roles played by some of the homologous domains in BMP1 and mTLL1. Surprisingly, although BMP1 has long been known to be Ca2+-dependent, a property previously assumed to apply to all members of the subgroup, mTLL1 is demonstrated to be independent of Ca-2 levels in its ability to cleave some, but not all, substrates. We also show that pCP activities of only versions of BMP1 and mTLL1 with intact COOH termini are enhanced by the procollagen C-proteinase enhancer 1 (PCOLCE1) and that mTLL1 binds PCOLCE1, thus suggesting reappraisal of the accepted paradigm for how PCOLCE1 enhances pCP activities.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu		Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Clark TG, 1999, DEVELOPMENT, V126, P2631; Dale L, 2002, MECH DEVELOP, V119, P177, DOI 10.1016/S0925-4773(02)00359-3; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Ge GX, 2005, MOL CELL BIOL, V25, P5846, DOI 10.1128/MCB.25.14.5846-5858.2005; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; GREENSPAN DS, 2004, HDB PROTEOLYTIC ENZY, P621; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Lin JJ, 1997, DEV GROWTH DIFFER, V39, P43; Moali C, 2005, J BIOL CHEM, V280, P24188, DOI 10.1074/jbc.M501486200; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Petropoulou V, 2005, J BIOL CHEM, V280, P22616, DOI 10.1074/jbc.M413468200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Serpe M, 2005, DEVELOPMENT, V132, P2645, DOI 10.1242/dev.01838; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200	31	26	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10786	10798		10.1074/jbc.M511111200	http://dx.doi.org/10.1074/jbc.M511111200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16507574	hybrid			2022-12-25	WOS:000236822200018
J	Wesche, J; Malecki, J; Wiedlocha, A; Skjerpen, CS; Claus, P; Olsnes, S				Wesche, J; Malecki, J; Wiedlocha, A; Skjerpen, CS; Claus, P; Olsnes, S			FGF-1 and FGF-2 require the cytosolic chaperone Hsp90 for translocation into the cytosol and the cell nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; PROTEIN TRANSLOCATION; TOXIN; TRANSPORT; RADICICOL; MEMBRANES; MUTANTS; COMPLEX; ENTRY; AFGF	Similarly to many protein toxins, the growth factors fibroblast growth factor 1 (FGF-1) and FGF-2 translocate from endosomes into the cytosol. It was recently found that certain toxins are dependent on cytosolic Hsp90 for efficient translocation across the endosomal membrane. We therefore investigated the requirement for Hsp90 in FGF translocation. We found that low concentrations of the specific Hsp90 inhibitors, geldanamycin and radicicol, completely blocked the translocation of FGF-1 and FGF-2 to the cytosol and the nucleus. The drugs did not interfere with the initial binding of FGF-1 to the growth factor receptors at the cell-surface or with the subsequent internalization of the growth factors into endosomes. The activation of known signaling cascades downstream of the growth factor receptors was also not affected by the drugs. The data indicate that the drugs block translocation from endosomes to the cytosol implying that Hsp90 is required for translocation of FGF-1 and FGF-2 across the endosomal membrane.	Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway; Hannover Med Sch, Dept Neuroanat, D-30625 Hannover, Germany	University of Oslo; Hannover Medical School	Wesche, J (corresponding author), Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.	jorgen.wesche@labmed.uio.no	Claus, Peter/A-7978-2008; Wesche, Jorgen/ABH-7524-2020	Claus, Peter/0000-0003-3824-9445; Malecki, Jedrzej/0000-0003-0825-7962; Wesche, Jorgen/0000-0002-9200-9162				Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Haug G, 2004, INFECT IMMUN, V72, P3066, DOI 10.1128/IAI.72.5.3066-3068.2004; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; Thomas-Mudge RJ, 2004, ONCOGENE, V23, P4771, DOI 10.1038/sj.onc.1207638; Wesche J, 2005, BIOCHEMISTRY-US, V44, P6071, DOI 10.1021/bi047403m; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wesche J, 2000, BIOCHEMISTRY-US, V39, P15091, DOI 10.1021/bi001831k; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 2005, MOL BIOL CELL, V16, P794; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	30	40	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11405	11412		10.1074/jbc.M600477200	http://dx.doi.org/10.1074/jbc.M600477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495214	hybrid			2022-12-25	WOS:000236822200083
J	Zhuang, DZ; Qiu, YL; Kogan, SC; Dong, F				Zhuang, DZ; Qiu, YL; Kogan, SC; Dong, F			Increased CCAAT enhancer-binding protein epsilon(C/EBP epsilon) expression and premature apoptosis in myeloid cells expressing Gfi-1 N382S mutant associated with severe congenital neutropenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING-FACTOR; G-CSF RECEPTOR; ZINC-FINGER PROTEIN; DISTINCT CYTOPLASMIC REGIONS; HEMATOPOIETIC STEM-CELLS; TRANSCRIPTIONAL REPRESSOR; GENE; DIFFERENTIATION; MUTATIONS; LEUKEMIA	Granulocyte-colony-stimulating factor (G-CSF) stimulates the activation of multiple signaling pathways, leading to alterations in the activities of transcription factors. Gfi-1 is a zinc finger transcriptional repressor that is required for granulopoiesis. How Gfi-1 acts in myeloid cells is poorly understood. We show here that the expression of Gfi-1 was up-regulated during G-CSF-induced granulocytic differentiation in myeloid 32D cells. Truncation of the carboxyl terminus of the G-CSF receptor, as seen in patients with acute myeloid leukemia evolving from severe congenital neutropenia, disrupted Gfi-1 up-regulation by G-CSF. Ectopic expression of a dominant negative Gfi-1 mutant, N382S, which was associated with severe congenital neutropenia, resulted in premature apoptosis and reduced proliferation of cells induced to differentiate with G-CSF. The expression of neutrophil elastase (NE) and CCAAT enhancer-binding protein epsilon (C/EBP epsilon) was significantly increased in 32D cells expressing N382S. In contrast, overexpression of wild type Gfi-1 abolished G-CSF-induced up-regulation of C/EBP epsilon but had no apparent effect on NE up-regulation by G-CSF. Notably, G-CSF-dependent proliferation and survival were inhibited upon overexpression of C/EBP epsilon but not NE. These data indicate that Gfi-1 down-regulates C/EBP epsilon expression and suggest that increased expression of C/EBP epsilon as a consequence of loss of Gfi-1 function may be deleterious to the proliferation and survival of early myeloid cells.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University System of Ohio; University of Toledo; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Dong, F (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	fdong@utnet.utoledo.edu		Kogan, Scott/0000-0002-2395-8479	NATIONAL CANCER INSTITUTE [R01CA092172] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA92172, R01 CA092172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbarzadeh S, 2001, VITAM HORM, V63, P159, DOI 10.1016/S0083-6729(01)63006-1; Aprikyan AAG, 2003, EXP HEMATOL, V31, P372, DOI 10.1016/S0301-472X(03)00048-1; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Bellanne-Chantelot C, 2004, BLOOD, V103, P4119, DOI 10.1182/blood-2003-10-3518; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dale DC, 2003, AM J HEMATOL, V72, P82, DOI 10.1002/ajh.10255; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Dong F, 1997, LEUKEMIA, V11, P120, DOI 10.1038/sj.leu.2400537; Dong F, 1998, J IMMUNOL, V161, P6503; Dong F, 1996, EXP HEMATOL, V24, P214; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Horwitz M, 2004, TRENDS MOL MED, V10, P163, DOI 10.1016/j.molmed.2004.02.002; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Massullo P, 2005, BLOOD, V105, P3397, DOI 10.1182/blood-2004-07-2618; Mitsui T, 2003, BLOOD, V101, P2990, DOI 10.1182/blood.V101.8.2990; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Moroy T, 2005, INT J BIOCHEM CELL B, V37, P541, DOI 10.1016/j.biocel.2004.08.011; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Qiu YL, 2005, LEUKEMIA RES, V29, P1153, DOI 10.1016/j.leukres.2005.03.005; SCOTT LM, 1992, BLOOD, V80, P1725; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tidow N, 1997, BLOOD, V89, P2369, DOI 10.1182/blood.V89.7.2369; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5; Zhuang DZ, 2005, J LEUKOCYTE BIOL, V78, P1008, DOI 10.1189/jlb.0105032; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	46	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10745	10751		10.1074/jbc.M510924200	http://dx.doi.org/10.1074/jbc.M510924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500901	hybrid			2022-12-25	WOS:000236822200013
J	Krejci, E; Valenzuela, IMPY; Ameziane, R; Akaaboune, M				Krejci, E; Valenzuela, IMPY; Ameziane, R; Akaaboune, M			Acetylcholinesterase dynamics at the neuromuscular junction of live animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAINS; IN-VIVO; RECEPTOR DENSITY; ANCHORING ACETYLCHOLINESTERASE; ANTICHOLINESTERASE TOXINS; TAIL SUBUNIT; MUSCLE; MICE; BUTYRYLCHOLINESTERASE; NEUROTRANSMITTER	At cholinergic synapses, acetylcholinesterase (AChE) is critical for ensuring normal synaptic transmission. However, little is known about how this enzyme is maintained and regulated in vivo. In this work, we demonstrate that the dissociation of fluorescently-tagged fasciculin 2 ( a specific and selective peptide inhibitor of AChE) from AChE is extremely slow. This fluorescent probe was used to study the removal and insertion of AChE at individual synapses of living adult mice. After a one-time blockade of AChEs with fluorescent fasciculin 2, AChEs are removed from synapses initially at a faster rate (t(1/2) of similar to 3 days) and later at a slower rate (t(1/2) of similar to 12 days). Most of the removed AChEs are replaced by newly inserted AChEs over time. However, when AChEs are continuously blocked with fasciculin 2, the removal rate increases substantially (t(1/2) of similar to 12 h), and most of the lost AChEs are not replaced by newly inserted AChE. Furthermore, complete one-time inactivation of AChE activity significantly increases the removal of postsynaptic nicotinic acetylcholine receptors (AChRs). Finally, time lapse imaging reveals that synaptic AChEs and AChRs that are removed from synapses are co-localized in the same pool after being internalized. These results demonstrate a remarkable AChE dynamism and argue for a potential link between AChE function and postsynaptic receptor lifetime.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; INSERM, U686, F-75006 Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm)	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu	Martinez-Pena y Valenzuela, Isabel/AAI-9845-2020	, Isabel/0000-0002-2196-9297	NINDS NIH HHS [NS 047332] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047332] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler M, 2004, MUSCLE NERVE, V30, P317, DOI 10.1002/mus.20099; Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; Anglister L, 1998, J NEUROSCI METH, V81, P63, DOI 10.1016/S0165-0270(98)00015-6; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BERMAN HA, 1987, DEV BIOL, V120, P154, DOI 10.1016/0012-1606(87)90113-8; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bruneau E, 2005, J NEUROSCI, V25, P9949, DOI 10.1523/JNEUROSCI.3169-05.2005; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Casanueva OI, 1998, J BIOL CHEM, V273, P4258, DOI 10.1074/jbc.273.7.4258; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200; DUXSON MJ, 1982, J NEUROCYTOL, V11, P395, DOI 10.1007/BF01257985; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KARLSSON E, 1985, PHARMACOL THERAPEUT, V30, P259, DOI 10.1016/0163-7258(85)90051-8; KASPRZAK H, 1985, J NEUROSCI, V5, P951; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Katz EJ, 1997, TOXICOL APPL PHARM, V146, P227, DOI 10.1006/taap.1997.8201; Kimbell LM, 2004, J BIOL CHEM, V279, P10997, DOI 10.1074/jbc.M305462200; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; LEONARD JP, 1979, J CELL BIOL, V82, P811, DOI 10.1083/jcb.82.3.811; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; Lin WC, 2005, NEURON, V46, P569, DOI 10.1016/j.neuron.2005.04.002; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Moreno RD, 1998, INT J DEV NEUROSCI, V16, P123, DOI 10.1016/S0736-5748(98)00008-2; Nguyen-Huu T, 2005, ANESTHESIOLOGY, V103, P788, DOI 10.1097/00000542-200510000-00017; Panchuk-Voloshina N, 1999, J HISTOCHEM CYTOCHEM, V47, P1179, DOI 10.1177/002215549904700910; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; Rotundo RL, 2003, J NEUROCYTOL, V32, P743, DOI 10.1023/B:NEUR.0000020621.58197.d4; SALPETER MM, 1978, J CELL BIOL, V78, P274, DOI 10.1083/jcb.78.1.274; SALPETER MM, 1979, J NEUROCYTOL, V8, P95, DOI 10.1007/BF01206461; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; THESLEFF S, 1955, NATURE, V175, P594, DOI 10.1038/175594b0; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; VALENZUELA IMP, 2005, J BIOL CHEM, V280, P31801; ZISKINDCONHAIM L, 1984, DEV BIOL, V103, P369, DOI 10.1016/0012-1606(84)90325-7	46	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10347	10354		10.1074/jbc.M507502200	http://dx.doi.org/10.1074/jbc.M507502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455662	hybrid			2022-12-25	WOS:000236594300063
J	Lu, D; Wolfgang, CD; Hai, T				Lu, D; Wolfgang, CD; Hai, T			Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC FUNCTION; FACTOR ATF3; EMBRYO FIBROBLASTS; LIVER DYSFUNCTION; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; OVER-EXPRESSION; BETA; P53; GROWTH	ATF3 is a stress-inducible gene that encodes a member of the ATF/CREB family of transcription factors. Current literature indicates that ATF3 affects cell death and cell cycle progression. However, controversies exist, because it has been demonstrated to be a negative or positive regulator of these processes. We sought to study the roles of ATF3 in both cell death and cell cycle regulation in the same cell type using mouse fibroblasts. We show that ATF3 promotes apoptosis and cell cycle arrest. Fibroblasts deficient in ATF3 (ATF3(-/-)) were partially protected from UV-induced apoptosis, and fibroblasts ectopically expressing ATF3 under the tet-off system exhibited features characteristic of apoptosis upon ATF3 induction. Furthermore, ATF3(-/-) fibroblasts transitioned from G(1) to S phase more efficiently than the ATF3(+/+) fibroblasts, suggesting a growth arrest role of ATF3. Consistent with the growth arrest and pro-apoptotic roles of ATF3, ATF3(-/-) fibroblasts upon Ras transformation exhibited higher growth rate, produced more colonies in soft agar, and formed larger tumor upon xenograft injection than the ATF3(+/+) counterparts. ATF3(-/-) cells, either with or without Ras transformation, had increased Rb phosphorylation and higher levels of various cyclins. Significantly, ATF3 bound to the cyclin D1 promoter as shown by chromatin immunoprecipitation (ChIP) assay and repressed its transcription by a transcription assay. Taken together, our results indicate that ATF3 promotes cell death and cell arrest, and suppresses Ras-mediated tumorigenesis. Potential explanations for the controversy about the roles of ATF3 in cell cycle and cell death are discussed.	Ohio State Univ, Ohio State Biochem Program, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Ohio State Biochem Program, Dept Mol & Cellular Biochem, Rm 174 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL CANCER INSTITUTE [R01CA118306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA118306] Funding Source: Medline; NIDDK NIH HHS [DK 59605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Inoue K, 2004, GENES CELLS, V9, P59, DOI 10.1111/j.1356-9597.2004.00707.x; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Pearson AG, 2003, MOL BRAIN RES, V120, P38, DOI 10.1016/j.molbrainres.2003.09.014; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2005, MOL CANCER THER, V4, P233; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200	66	163	170	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10473	10481		10.1074/jbc.M509278200	http://dx.doi.org/10.1074/jbc.M509278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469745	hybrid			2022-12-25	WOS:000236594300076
J	Montagnoli, A; Valsasina, B; Brotherton, D; Troiani, S; Rainoldi, S; Tenca, P; Molinari, A; Santocanale, C				Montagnoli, A; Valsasina, B; Brotherton, D; Troiani, S; Rainoldi, S; Tenca, P; Molinari, A; Santocanale, C			Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC7-RELATED KINASE; DNA-REPLICATION; PROTEINS; COMPLEX; CHECKPOINT; INITIATION; CDC7; CELLS; CYCLE; INHIBITION	Minichromosome maintenance 2 - 7 proteins play a pivotal role in replication of the genome in eukaryotic organisms. Upon entry into S-phase several subunits of the MCM hexameric complex are phosphorylated. It is thought that phosphorylation activates the intrinsic MCM DNA helicase activity, thus allowing formation of active replication forks. Cdc7, Cdk2, and ataxia telangiectasia and Rad3-related kinases regulate S-phase entry and S-phase progression and are known to phosphorylate the Mcm2 subunit. In this work, by in vitro kinase reactions and mass spectrometry analysis of the products, we have mapped phosphorylation sites in the N terminus of Mcm2 by Cdc7, Cdk2, Cdk1, and CK2. We found that Cdc7 phosphorylates Mcm2 in at least three different sites, one of which corresponds to a site also reported to be phosphorylated by ataxia telangiectasia and Rad3-related. Three serine/proline sites were identified for Cdk2 and Cdk1, and a unique site was phosphorylated by CK2. We raised specific anti-phosphopeptide antibodies and found that all the sites identified in vitro are also phosphorylated in cells. Importantly, although all the Cdc7-dependent Mcm2 phosphosites fluctuate during the cell cycle with kinetics similar to Cdc7 kinase activity and Cdc7 protein levels, phosphorylation of Mcm2 in the putative cyclin-dependent kinase (Cdk) consensus sites is constant during the cell cycle. Furthermore, our analysis indicates that the majority of the Mcm2 isoforms phosphorylated by Cdc7 are not stably associated with chromatin. This study forms the basis for understanding how MCM functions are regulated by multiple kinases within the cell cycle and in response to external perturbations.	Nerviano Med Sci Oncol, Dept Biol, I-20014 Nerviano, Italy	Nerviano Medical Sciences S.r.l	Santocanale, C (corresponding author), Nerviano Med Sci Oncol, Dept Biol, Via Pasteur 10, I-20014 Nerviano, Italy.	Corrado.Santocanale@nervianoms.com		Santocanale, Corrado/0000-0003-1337-5656				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Diffley JFX, 2002, J CELL SCI, V115, P869; Dimitrova DS, 2002, J CELL SCI, V115, P51; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Ishimi Y, 2001, J BIOL CHEM, V276, P42744, DOI 10.1074/jbc.M106861200; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kulartz M, 2004, BIOCHEM BIOPH RES CO, V315, P1011, DOI 10.1016/j.bbrc.2004.01.164; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lolli G, 2003, PROTEOMICS, V3, P1287, DOI 10.1002/pmic.200300431; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Rialland M, 2002, J CELL SCI, V115, P1435; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200	29	169	179	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10281	10290		10.1074/jbc.M512921200	http://dx.doi.org/10.1074/jbc.M512921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16446360	hybrid			2022-12-25	WOS:000236594300056
J	Raichaudhuri, A; Bhattacharyya, R; Chaudhuri, S; Chakrabarti, P; DasGupta, M				Raichaudhuri, A; Bhattacharyya, R; Chaudhuri, S; Chakrabarti, P; DasGupta, M			Domain analysis of a groundnut calcium-dependent protein kinase - Nuclear localization sequence in the junction domain is coupled with nonconsensus calcium binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE DOMAIN; IMPORTIN-ALPHA HOMOLOG; INTRAMOLECULAR BINDING; TARGET RECOGNITION; MODULATED PROTEINS; STRUCTURAL BASIS; ACTIVATION; CDPK; EVOLUTION; COMPLEX	The signature of calcium-dependent protein kinases (CDPKs) is a C-terminal calmodulin-like domain (CaMLD) with four consensus calcium-binding sites. A junction domain (JD) joins the kinase with CaMLD and interacts with them through its autoinhibitory and CaMLD binding subdomains, respectively. We noted several CDPKs additionally have a bipartite nuclear localization signal (NLS) sequence as a subdomain in their JD, and this feature is obligatorily coupled with the absence of consensus calcium-binding sites in their respective CaMLDs. These predicted features are substantiated by undertaking investigations on a CDPK (gi: 67479988) isolated from cultured groundnut ( Arachis hypogea) cells. This kinase can bind 3.1 mol of Ca2+ under saturating conditions with a considerably high K-d of 392 mu M as compared with its canonical counterparts. CD spectroscopic analysis, however, indicates the intramolecular structural changes accompanied with calcium binding to be similar to canonical CDPKs. Attesting to the presence of NLS in the JD, the endogenous kinase is localized in the nucleus of osmotically stressed Arachis cells, and in vitro binding assays indicate the NLS in the JD to interact with nuclear transport factors of the importin family. Homology modeling also indicates the feasibility of interaction of importins with the NLS present in the JD of such CDPKs in their activated form. The possible significance of obligatory coupling between the presence of NLS in the junction domain and atypical calcium binding properties of these CDPKs is discussed in the light of the known mechanisms of activation of these kinases.	Univ Calcutta, Dept Biochem, Kolkata 700019, W Bengal, India; Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India; Bose Inst, Bioinformat Ctr, Kolkata 700054, W Bengal, India	University of Calcutta; Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute	DasGupta, M (corresponding author), Univ Calcutta, Dept Biochem, 35 Ballygunge Circular Rd, Kolkata 700019, W Bengal, India.	maitrayee_d@hotmail.com		/0000-0002-7260-3746				Anil VS, 2000, PLANT PHYSIOL, V122, P1035, DOI 10.1104/pp.122.4.1035; Asano T, 2005, PLANT CELL PHYSIOL, V46, P356, DOI 10.1093/pcp/pci035; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; Chaudhuri S, 1999, PLANT PHYSIOL, V120, P859, DOI 10.1104/pp.120.3.859; CHEHAB EW, 2004, PLANT PHYSIOL, V135, P1; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chico JM, 2002, PLANT PHYSIOL, V128, P256, DOI 10.1104/pp.010649; Christodoulou J, 2004, J BIOL CHEM, V279, P29092, DOI 10.1074/jbc.M401297200; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; Dahlquist F W, 1978, Methods Enzymol, V48, P270; Dammann C, 2003, PLANT PHYSIOL, V132, P1840, DOI 10.1104/pp.103.020008; DASGUPTA M, 1994, PLANT PHYSIOL, V104, P961, DOI 10.1104/pp.104.3.961; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drykova D, 2003, PLANT CELL, V15, P465, DOI 10.1105/tpc.007005; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jiang CJ, 2001, J BIOL CHEM, V276, P9322, DOI 10.1074/jbc.M006430200; Jiang CJ, 1998, J BIOL CHEM, V273, P24083, DOI 10.1074/jbc.273.37.24083; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu SX, 2002, PLANT PHYSIOL, V128, P1008, DOI 10.1104/pp.010770; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Nag R, 2006, PLANT CELL TISS ORG, V84, P17, DOI 10.1007/s11240-005-6902-z; Nag R, 2005, PLANT MOL BIOL, V59, P821, DOI 10.1007/s11103-005-1387-z; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Patharkar OR, 2000, PLANT J, V24, P679, DOI 10.1046/j.1365-313x.2000.00912.x; Pazos F, 2002, PROTEINS, V47, P219, DOI 10.1002/prot.10074; PICAL C, 1993, FEBS LETT, V336, P347, DOI 10.1016/0014-5793(93)80835-I; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; Seal A, 2001, PLANT CELL REP, V20, P567, DOI 10.1007/s002990100359; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URAO T, 1994, MOL GEN GENET, V244, P331, DOI 10.1007/BF00286684; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Vitart V, 2000, BIOCHEMISTRY-US, V39, P4004, DOI 10.1021/bi992373m; Weljie AM, 2004, J BIOL CHEM, V279, P35494, DOI 10.1074/jbc.M311520200; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; Zhang XRS, 2001, J MOL EVOL, V53, P214, DOI 10.1007/s002390010211; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031	70	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10399	10409		10.1074/jbc.M511001200	http://dx.doi.org/10.1074/jbc.M511001200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16464867	hybrid			2022-12-25	WOS:000236594300069
J	Rybakova, IN; Humston, JL; Sonnemann, KJ; Ervasti, JM				Rybakova, IN; Humston, JL; Sonnemann, KJ; Ervasti, JM			Dystrophin and utrophin bind actin through distinct modes of contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MDX MICE; SKELETAL-MUSCLE; F-ACTIN; GLYCOPROTEIN COMPLEX; MUSCULAR-DYSTROPHY; FULL-LENGTH; DOMAIN; EXPRESSION; PROTEIN; SARCOLEMMA	This study was designed to define the molecular epitopes of dystrophin-actin interaction and to directly compare the actin binding properties of dystrophin and utrophin. According to our data, dystrophin and utrophin both bound alongside actin filaments with sub-micromolar affinities. However, the molecular epitopes involved in actin binding differed between the two proteins. In utrophin, the amino-terminal domain and an adjacent string of the first 10 spectrin-like repeats more fully recapitulated the activities measured for full-length protein. The homologous region of dystrophin bound actin with low affinity and near 1: 1 stoichiometry as previously measured for the isolated amino-terminal, tandem ( CH) domain. In contrast, a dystrophin construct including a cluster of basic spectrin-like repeats and spanning from the amino terminus through repeat 17, bound actin with properties most similar to full-length dystrophin. Dystrophin and utrophin both stabilized preformed actin filaments from forced depolymerization with similar efficacies but did not appear to compete for binding sites on actin. We also found that dystrophin binding to F-actin was markedly sensitive to increasing ionic strength, although utrophin binding was unaffected. Although dystrophin and utrophin are functionally homologous actin-binding proteins, these results indicate that their respective modes of contact with actin filaments are markedly different. Finally, we reassessed the abundance of dystrophin in striated muscle using full-length protein as the standard and measured greater than 10-fold higher values than previously reported.	Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Serv Mem Inst 127, 1300 Univ Ave, Madison, WI 53706 USA.	ervasti@physiology.wisc.edu	Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [AR 042423] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; BARCHI RL, 1979, J PHYSIOL-LONDON, V295, P383, DOI 10.1113/jphysiol.1979.sp012975; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; CLERK A, 1993, HISTOCHEM J, V25, P554; CLERK A, 1992, DEVELOPMENT, V114, P395; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Ishikawa-Sakurai M, 2004, HUM MOL GENET, V13, P693, DOI 10.1093/hmg/ddh087; Iwata Y, 2004, EUR J CELL BIOL, V83, P555, DOI 10.1078/0171-9335-00415; Iwata Y, 1998, FEBS LETT, V423, P173, DOI 10.1016/S0014-5793(98)00085-4; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; McDearmon EL, 2001, J BIOL CHEM, V276, P35078, DOI 10.1074/jbc.M103843200; Moores CA, 2000, CELL MOTIL CYTOSKEL, V46, P116, DOI 10.1002/1097-0169(200006)46:2<116::AID-CM4>3.0.CO;2-L; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Radojevic V, 2000, CELL TISSUE RES, V300, P447, DOI 10.1007/s004410000213; Renley BA, 1998, CELL MOTIL CYTOSKEL, V41, P264, DOI 10.1002/(SICI)1097-0169(1998)41:3<264::AID-CM7>3.3.CO;2-Q; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Rybakova IN, 2005, J BIOL CHEM, V280, P23018, DOI 10.1074/jbc.M502530200; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 2002, MOL BIOL CELL, V13, P1512, DOI 10.1091/mbc.01-09-0446; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, J CELL SCI, V108, P63	30	75	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9996	10001		10.1074/jbc.M513121200	http://dx.doi.org/10.1074/jbc.M513121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478721	hybrid			2022-12-25	WOS:000236594300022
J	Schneiders, T; Levy, SB				Schneiders, T; Levy, SB			MarA-mediated transcriptional repression of the rob promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; ORGANIC-SOLVENT TOLERANCE; ESCHERICHIA-COLI SOXS; RNA-POLYMERASE; DNA-BINDING; COMPLEX-FORMATION; P-R; PROTEIN; ACTIVATION; EXPRESSION	The Escherichia coli transcriptional regulator MarA affects functions that include antibiotic resistance, persistence, and survival. MarA functions as an activator or repressor of transcription utilizing similar degenerate DNA sequences (marboxes) with three different binding site configurations with respect to the RNA polymerase-binding sites. We demonstrate that MarA down-regulates rob transcripts both in vivo and in vitro via a MarA-binding site within the rob promoter that is positioned between the -10 and -35 hexamers. As for the hdeA and purA promoters, which are repressed by MarA, the rob marbox is also in the "backward" orientation. Protein-DNA interactions show that SoxS and Rob, like MarA, bind the same marbox in the rob promoter. Electrophoretic mobility shift analyses with a MarA-specific antibody demonstrate that MarA and RNA polymerase form a ternary complex with the rob promoter DNA. Transcription experiments in vitro and potassium permanganate footprinting analysis show that MarA affects the RNA polymerase-mediated closed to open complex formation at the rob promoter.	Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Levy, SB (corresponding author), Tufts Univ, Sch Med, Ctr Adaptat Genet & Drug Resistance, 136 Harrison Ave, Boston, MA 02111 USA.	stuart.levy@tufts.edu		Schneiders, Thamarai/0000-0002-7758-7925	NIAID NIH HHS [AI 56021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali Azam T., 1999, J BACTERIOL, V181, P6361; ANSARI AZ, 1995, NATURE, V374, P371; ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; Azam TA, 2000, GENES CELLS, V5, P613, DOI 10.1046/j.1365-2443.2000.00350.x; Bennik MHJ, 2000, J BACTERIOL, V182, P3794, DOI 10.1128/JB.182.13.3794-3801.2000; Dangi B, 2004, MOL MICROBIOL, V54, P45, DOI 10.1111/j.1365-2958.2004.04250.x; Escolar L, 1997, MOL MICROBIOL, V26, P799, DOI 10.1046/j.1365-2958.1997.6211987.x; Gillette WK, 2000, J MOL BIOL, V299, P1245, DOI 10.1006/jmbi.2000.3827; GRALLA JD, 1996, ESCHERICHIA COLI SAL, V1, P1232; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; Griffith KL, 2002, BIOCHEM BIOPH RES CO, V291, P979, DOI 10.1006/bbrc.2002.6559; Griffith KL, 2001, MOL MICROBIOL, V40, P1141, DOI 10.1046/j.1365-2958.2001.02456.x; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; Jair KW, 1996, J BACTERIOL, V178, P2507, DOI 10.1128/jb.178.9.2507-2513.1996; KAKEDA M, 1995, MOL GEN GENET, V248, P629, DOI 10.1007/BF02423459; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Li ZY, 1996, MOL MICROBIOL, V20, P937, DOI 10.1111/j.1365-2958.1996.tb02535.x; Martin RG, 1996, J BACTERIOL, V178, P2216, DOI 10.1128/jb.178.8.2216-2223.1996; Martin RG, 1999, MOL MICROBIOL, V34, P431, DOI 10.1046/j.1365-2958.1999.01599.x; Martin RG, 2002, MOL MICROBIOL, V43, P355, DOI 10.1046/j.1365-2958.2002.02748.x; Martin RG, 2002, MOL MICROBIOL, V44, P1611, DOI 10.1046/j.1365-2958.2002.02985.x; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Michan C, 2002, J BACTERIOL, V184, P4733, DOI 10.1128/JB.184.17.4733-4738.2002; MILLER PF, 1994, ANTIMICROB AGENTS CH, V38, P1773, DOI 10.1128/AAC.38.8.1773; Monsalve M, 1998, J MOL BIOL, V283, P559, DOI 10.1006/jmbi.1998.2084; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; NAKAJIMA H, 1995, APPL ENVIRON MICROB, V61, P2302, DOI 10.1128/AEM.61.6.2302-2307.1995; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Rosenberg EY, 2003, MOL MICROBIOL, V48, P1609, DOI 10.1046/j.1365-2958.2003.03531.x; Rosner JL, 2002, J BACTERIOL, V184, P1407, DOI 10.1128/JB.184.5.1407-1416.2002; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; Savery N. J., 1996, ESSENTIAL TECHNIQUES, P1; Schneiders T, 2004, J BIOL CHEM, V279, P9037, DOI 10.1074/jbc.M313602200; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; White DG, 1997, J BACTERIOL, V179, P6122, DOI 10.1128/jb.179.19.6122-6126.1997; Xu J, 2000, J BACTERIOL, V182, P3165, DOI 10.1128/JB.182.11.3165-3174.2000; Xu J, 2001, J MOL BIOL, V309, P573, DOI 10.1006/jmbi.2001.4702; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x	46	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10049	10055		10.1074/jbc.M512097200	http://dx.doi.org/10.1074/jbc.M512097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478729	hybrid			2022-12-25	WOS:000236594300029
J	van Bloois, E; Haan, GJ; de Gier, JW; Oudega, B; Luirink, J				van Bloois, E; Haan, GJ; de Gier, JW; Oudega, B; Luirink, J			Distinct requirements for translocation of the N-tail and C-tail of the Escherichia coli inner membrane protein CyoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; SYNTHASE SUBUNIT-C; UBIQUINOL OXIDASE; NASCENT MEMBRANE; YIDC; INSERTION; EXPORT; BIOGENESIS; SECY; LIPOPROTEINS	Inner membrane proteins (IMPs) of Escherichia coli use different pathways for membrane targeting and integration. YidC plays an essential but poorly defined role in the integration and folding of IMPs both in conjunction with the Sec translocon and as a Sec-independent insertase. Depletion of YidC only marginally affects the insertion of Sec-dependent IMPs, whereas it blocks the insertion of a subset of Sec-independent IMPs. Substrates of this latter "YidC-only" pathway include the relatively small IMPs M13 procoat, Pf3 coat protein, and subunit c of the F1F0 ATPase. Recently, it has been shown that the steady state level of the larger and more complex CyoA subunit of the cytochrome o oxidase is also severely affected upon depletion of YidC. In the present study we have analyzed the biogenesis of the integral lipoprotein CyoA. Collectively, our data suggest that the first transmembrane segment of CyoA rather than the signal sequence recruits the signal recognition particle for membrane targeting. Membrane integration and assembly appear to occur in two distinct sequential steps. YidC is sufficient to catalyze insertion of the N-terminal domain consisting of the signal sequence, transmembrane segment 1, and the small periplasmic domain in between. Translocation of the large C-terminal periplasmic domain requires the Sec translocon and SecA, suggesting that for this particular IMP the Sec translocon might operate downstream of YidC.	Vrije Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Vrije Universiteit Amsterdam; Stockholm University	Luirink, J (corresponding author), Vrije Univ Amsterdam, Inst Mol Cell Biol, Dept Mol Microbiol, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl	Luirink, Joen/AAB-8658-2021	Luirink, J./0000-0001-8431-0804				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2005, BIOCHEMISTRY-US, V44, P10741, DOI 10.1021/bi047418k; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Funes S, 2004, MOL BIOL CELL, V15, P1853, DOI 10.1091/mbc.e03-11-0789; GIER JW, 2005, ANNU REV MICROBIOL, V59, P329; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LEE JI, 1992, J BIOL CHEM, V267, P938; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Preuss M, 2005, J BIOL CHEM, V280, P13004, DOI 10.1074/jbc.M414093200; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; Tian HP, 2002, J BACTERIOL, V184, P111, DOI 10.1128/JB.184.1.111-118.2002; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; van Bloois E, 2005, J BIOL CHEM, V280, P12996, DOI 10.1074/jbc.M414094200; van Bloois E, 2004, FEBS LETT, V576, P97, DOI 10.1016/j.febslet.2004.08.069; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Yi L, 2004, J BIOL CHEM, V279, P39260, DOI 10.1074/jbc.M405490200; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	46	62	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10002	10009		10.1074/jbc.M511357200	http://dx.doi.org/10.1074/jbc.M511357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481320	hybrid, Green Published			2022-12-25	WOS:000236594300023
J	Liang, MD; Zhang, Y; McDevit, D; Marecki, S; Nikolajczyk, BS				Liang, MD; Zhang, Y; McDevit, D; Marecki, S; Nikolajczyk, BS			The interleukin-1 beta gene is transcribed from a poised promoter architecture in monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; HEMATOPOIETIC STEM-CELLS; NECROSIS-FACTOR-ALPHA; HISTONE ACETYLATION; CHROMATIN ACCESSIBILITY; TRANSCRIPTIONAL REGULATION; IL-1-BETA GENE; PROXIMAL PROMOTER; CUTTING EDGE	Cytokine transcription is usually regulated by transcription factor binding and chromatin remodeling following an inducing signal. By contrast, these data showed the interleukin (IL)-1 beta promoter assembles into a "poised" structure, as evidenced by nuclease accessibility and loss of core histones immediately surrounding the transcription start site. Strikingly, these properties do not change upon transcriptional activation by lipopolysaccharide. Furthermore, association of two key transcriptional activators, PU.1 and C/EBP beta, is robust pre- and post-stimulation indicating the IL-1 beta promoter is packaged into a nontranscribed but poised promoter architecture in cells capable of rapidly inducing IL-1 beta. Monocyte stimulation causes recruitment of a third factor, IRF-4, to the IL-1 beta enhancer. PU.1 phosphorylation at a CK2 kinase consensus element is required for this recruitment. We showed that CK2 phosphorylates PU.1, CK2 inhibitors abrogate IL-1 beta induction, and CK2 inducibly associates with the IL-1 beta enhancer. Taken together, these data indicate a novel two-step mechanism for IL-1 beta transcription: 1) formation of a poised chromatin architecture, and 2) phosphorylation of an enhancer-bound factor that recruits other activators. We propose that this poised structure may generally characterize rapidly activated genes.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Med Ctr, Evans Mem Dept Clin Res, Dept Med, Immunobiol Unit, Boston, MA USA	Boston University; Boston University; Boston Medical Center	Nikolajczyk, BS (corresponding author), Boston Univ, Sch Med, Dept Microbiol, 715 Albany St L516, Boston, MA 02118 USA.	bnikol@bumc.bu.edu			NHLBI NIH HHS [T32 HL07501] Funding Source: Medline; NIAID NIH HHS [R01 AI54611] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054611] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Barthel R, 2003, J IMMUNOL, V171, P3612, DOI 10.4049/jimmunol.171.7.3612; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; BURAS JA, 1994, J IMMUNOL, V152, P4444; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; GODAMBE SA, 1995, MOL CELL BIOL, V15, P112, DOI 10.1128/MCB.15.1.112; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Holloway AF, 2003, J EXP MED, V197, P413, DOI 10.1084/jem.20021039; Im SH, 2004, J BIOL CHEM, V279, P46818, DOI 10.1074/jbc.M401722200; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Kim HG, 2004, BLOOD, V104, P3894, DOI 10.1182/blood-2002-08-2425; Kim HY, 2000, INFECT IMMUN, V68, P3394, DOI 10.1128/IAI.68.6.3394-3402.2000; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Kwan M, 2005, EUR J IMMUNOL, V35, P1267, DOI 10.1002/eji.200425619; Lee JY, 2003, J LEUKOCYTE BIOL, V73, P862, DOI 10.1189/jlb.1202618; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Lucas M, 2005, J IMMUNOL, V175, P469, DOI 10.4049/jimmunol.175.1.469; Marecki S, 2004, MOL IMMUNOL, V40, P723, DOI 10.1016/j.molimm.2003.08.007; Marecki S, 1999, J IMMUNOL, V163, P2713; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCarthy KM, 2003, J BIOL CHEM, V278, P42106, DOI 10.1074/jbc.M308586200; McDevit DC, 2005, J IMMUNOL, V174, P2834, DOI 10.4049/jimmunol.174.5.2834; MONKS BG, 1994, MOL IMMUNOL, V31, P139, DOI 10.1016/0161-5890(94)90086-8; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Vicente R, 2005, J IMMUNOL, V174, P4736, DOI 10.4049/jimmunol.174.8.4736; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Watari K, 1996, J CLIN INVEST, V97, P1666, DOI 10.1172/JCI118593; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	63	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9227	9237		10.1074/jbc.M510700200	http://dx.doi.org/10.1074/jbc.M510700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439360	hybrid			2022-12-25	WOS:000236404700030
J	Wang, Y; Jiang, HB				Wang, Y; Jiang, HB			Interaction of beta-1,3-glucan with its recognition protein activates hemolymph proteinase 14, an initiation enzyme of the prophenoloxidase activation system in Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC REACTIONS; SERINE PROTEINASES; TOBACCO HORNWORM; DROSOPHILA TOLL; INSECT; LECTIN; BACTERIA; DEFENSE; IDENTIFICATION; MELANIZATION	A serine proteinase pathway in insect hemolymph leads to prophenoloxidase activation, an innate immune response against pathogen infection. In the tobacco hornworm Manduca sexta, recombinant hemolymph proteinase 14 precursor (pro-HP14) interacts with peptidoglycan, autoactivates, and initiates the proteinase cascade (Ji, C., Wang, Y., Guo, X., Hartson, S., and Jiang, H. (2004) J. Biol. Chem. 279, 34101-34106). Here, we report the purification and characterization of pro-HP14 from the hemolymph of bacteria-injected M. sexta larvae. The zymogen, consisting of a single polypeptide with a molecular mass of 68.5 kDa, is truncated at the amino terminus. It is converted to a two-chain active form in the presence of beta-1,3-glucan (a fungal cell wall component) and beta-1,3-glucan recognition protein-2. The 45-kDa heavy chain contains four low-density lipoprotein receptor A repeats, one Sushi domain, and one unique cysteine-rich region, whereas the 30-kDa light chain contains a serine proteinase domain, which was labeled by [H-3]diisopropyl fluorophosphate. Pro-HP14 in the plasma strongly binds curdlan, zymosan, and yeast and interacts with peptidoglycan and Micrococcus luteus. Addition of autoactivated HP14 elevated phenoloxidase activity level in the larval plasma. Recombinant M. sexta serpin-1I reduced prophenoloxidase activation by inhibiting HP14. These data are consistent with the current model on initiation and regulation of the prophenoloxidase activation cascade upon recognition of pathogen-associated molecular patterns by specific pattern recognition proteins.	Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Jiang, HB (corresponding author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA.	haobo.jiang@okstate.edu	Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058634] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashida Masaaki, 1998, P135; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; Finehout EJ, 2003, ELECTROPHORESIS, V24, P3508, DOI 10.1002/elps.200305615; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Iwanaga S, 1998, J BIOCHEM, V123, P1; JI C, 2003, PROTEIN EXPRES PURIF, V23, P328; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang HB, 2004, INSECT BIOCHEM MOLEC, V34, P89, DOI 10.1016/j.ibmb.2003.09.006; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; JUNGREIS AM, 1973, J INSECT PHYSIOL, V19, P225, DOI 10.1016/0022-1910(73)90235-7; Kanost MR, 2004, IMMUNOL REV, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; Zou Z, 2005, J BIOL CHEM, V280, P14341, DOI 10.1074/jbc.M500570200	35	76	83	0	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9271	9278		10.1074/jbc.M513797200	http://dx.doi.org/10.1074/jbc.M513797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461344	Green Accepted, hybrid			2022-12-25	WOS:000236404700034
J	Adusumilli, PS; Stiles, BM; Chan, MK; Eisenberg, DP; Yu, ZK; Stanziale, SF; Huq, R; Wong, RJ; Rusch, VW; Fong, YM				Adusumilli, Prasad S.; Stiles, Brendon M.; Chan, Mei-Ki; Eisenberg, David P.; Yu, Zhenkun; Stanziale, Stephen F.; Huq, Rumana; Wong, Richard J.; Rusch, Valerie W.; Fong, Yuman			Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery	FASEB JOURNAL			English	Article						oncolytic viral therapy; gene therapy; HSV; endoscopy	GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRAL THERAPY; LIGHT-EMITTING PROTEINS; GENE-THERAPY; CANCER; VISUALIZATION; BACTERIA; ANIMALS; MICE; CELL	Current efforts on expanding minimally invasive techniques into the realm of oncological surgery are hindered by lack of accurate visualization of tumor margins and failure to detect micro metastases in real time. We used a systemic delivery of a herpes viral vector with cancer-selective infection and replication to precisely differentiate between normal and malignant tissue. NV1066 is a genetically modified, replication-competent herpes simplex virus carrying a transgene for enhanced green fluorescent protein (GFP). We tested the potential of NV1066 in delineating tumor tissue in vitro and in vivo in a wide range of cancers and whether NV1066-induced GFP expression can detect small foci of tumors and metastases in in vivo models using an operating endoscope with fluorescent filters. Our findings indicate that NV1066 can be used for real-time intraoperative imaging and enhanced detection of early cancers and metastases. We demonstrate that a single dose of NV1066, administered either locally (intratumoral or intracavitary) or systemically, will detect loco-regional and distant disease throughout the body. Such cancer selectivity is confirmed in 110 types of cancer cells from 16 different primary organs. Fluorescence-aided minimally invasive endoscopy revealed microscopic tumor deposits unrecognized by conventional laparoscopy/ thoracoscopy. Furthermore, NV1066 ability to transit and infect tumor and metastases is proven in syngenic and transplanted tumors in different animal models, both immunocompetent and immunodeficient. Cancer-selective GFP expression is confirmed by histology, immunohistochemistry, and qRT-PCR. These studies form the basis for real-time, intraoperative diagnostic imaging of tumor and metastases by minimally invasive endoscopic technology.	Mem Sloan Kettering Canc Ctr, Dept Surg, Murray F Brennan Chair Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Murray F Brennan Chair Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org		Rusch, Valerie/0000-0003-2345-6900	NATIONAL CANCER INSTITUTE [R01CA075416, R01CA080982] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075416, R01 CA 75416, R01 CA/DK80982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Adusumilli PS, 2005, ANN THORAC SURG, V80, P409, DOI 10.1016/j.athoracsur.2005.01.048; Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443; Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Buunen M, 2004, SURG ENDOSC, V18, P1022, DOI 10.1007/s00464-003-9169-7; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; D'Angelica M, 2003, ANN SURG ONCOL, V10, P183, DOI 10.1245/ASO.2003.03.091; Everts M, 2004, CURR GENE THER, V4, P337; Green NK, 2002, CANCER GENE THER, V9, P1036, DOI 10.1038/sj.cgt.7700541; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Kooby DA, 1999, FASEB J, V13, P1325, DOI 10.1096/fasebj.13.11.1325; Lal DR, 2005, SURG CLIN N AM, V85, P105, DOI 10.1016/j.suc.2004.09.008; Paquin A, 2001, HUM GENE THER, V12, P13, DOI 10.1089/104303401450924; Paraskeva P A, 2004, Semin Laparosc Surg, V11, P27, DOI 10.1177/107155170401100106; Stanziale SF, 2004, HUM GENE THER, V15, P609, DOI 10.1089/104303404323142051; Stiles BM, 2006, CANCER GENE THER, V13, P53, DOI 10.1038/sj.cgt.7700860; Stiles BM, 2003, SURGERY, V134, P357, DOI 10.1067/msy.2003.244; TSIEN RY, 2003, NAT REV MOL CELL BIO, V4, pSS16; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Wong RJ, 2002, HUM GENE THER, V13, P1213, DOI 10.1089/104303402320138998; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yu YA, 2003, ANAL BIOANAL CHEM, V377, P964, DOI 10.1007/s00216-003-2065-0; Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937	25	41	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					726	+		10.1096/fj.05-5316fje	http://dx.doi.org/10.1096/fj.05-5316fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467372	Green Accepted			2022-12-25	WOS:000237698700031
J	Aguilera, O; Fraga, MF; Ballestar, E; Paz, MF; Herranz, M; Espada, J; Garcia, JM; Munoz, A; Esteller, M; Gonzalez-Sancho, JM				Aguilera, O.; Fraga, M. F.; Ballestar, E.; Paz, M. F.; Herranz, M.; Espada, J.; Garcia, J. M.; Munoz, A.; Esteller, M.; Gonzalez-Sancho, J. M.			Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer	ONCOGENE			English	Article						DICKKOPF-1; Wnt; promoter methylation; colorectal cancer	BETA-CATENIN/TCF; TUMOR-SUPPRESSOR; DNA METHYLATION; MECHANISM; PROTEINS; HYPERMETHYLATION; INHIBITION; TARGET; MODEL	Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/beta-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancercell lines (n = 9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on beta-catenin/T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation- associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).	Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Inst Invest Biomed Alberto Sols, Madrid, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Dept Bioquim, Madrid, Spain; Hosp Univ Puerta Hierro, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Puerta de Hierro-Majadahonda	Esteller, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Fraga, Mario F/H-7824-2017; Munoz, Alberto/O-6393-2014; Ballestar, Esteban/ABG-8561-2020; Herranz, Michel/L-2561-2016; Espada, Jesús/AAA-3198-2019; Esteller, Manel/L-5956-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Fraga, Mario F/0000-0001-8450-2603; Munoz, Alberto/0000-0003-3890-4251; Espada, Jesús/0000-0002-4202-4938; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Maeda K, 2003, ONCOL REP, V10, P935; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Miller JR, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2001-3-1-reviews3001; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Ries LAG, 2003, ONCOLOGIST, V8, P541; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Zou HZ, 2002, CLIN CANCER RES, V8, P188	30	273	294	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4116	4121		10.1038/sj.onc.1209439	http://dx.doi.org/10.1038/sj.onc.1209439			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491118				2022-12-25	WOS:000238802400012
J	Guo, X; Stratton, L; Schrader, JW				Guo, X.; Stratton, L.; Schrader, J. W.			Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells	ONCOGENE			English	Article						M-Ras; hematopoietic stem cells; leukemia; immortalization; mast cell	GROWTH; M-RAS/R-RAS3; INDUCTION; DISTINCT; KINASE; FAMILY; MUTANT; LINE	Cultures of purified hemopoietic stem cells transduced with an activated mutant of M-Ras contained abnormal cells that, despite the presence of only low levels of growth factors, generated large, dense colonies of macrophages and blast cells. Cells from these colonies survived and grew continuously in the absence of growth factors and generated clonal cell-lines that were mainly composed of well-differentiated mast cells, with a low frequency of undifferentiated cells. When transplanted into sublethally irradiated syngeneic mice, four out of four such clones gave rise to a systemic mastocytosis and mast-cell leukemia. However, the donor clones also generated low percentages of cells with the morphological and cell-surface characteristics of erythrocytes, granulocytes, monocytes and T- and B-lymphocytes. These data indicate that signals downstream of activated M-Ras are sufficient to transform hemopoietic stem cells, and while preserving their capacity to generate other cell-lineages in vivo, result in preferential generation of mast cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca						Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Cortez D, 1996, ONCOGENE, V13, P2589; Drachman JG, 2000, CURR OPIN HEMATOL, V7, P183, DOI 10.1097/00062752-200005000-00010; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Guo XC, 2005, ONCOGENE, V24, P2330, DOI 10.1038/sj.onc.1208441; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Hu ZQ, 1997, BLOOD, V89, P526, DOI 10.1182/blood.V89.2.526; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KITAMURA Y, 1979, BLOOD, V53, P492; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Yang J, 2005, CANCER RES, V65, P939; Zhang KX, 2004, MOL CANCER RES, V2, P242	20	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4241	4244		10.1038/sj.onc.1209452	http://dx.doi.org/10.1038/sj.onc.1209452			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501601				2022-12-25	WOS:000239004800012
J	Skoufias, DA; DeBonis, S; Saoudi, Y; Lebeau, L; Crevel, I; Cross, R; Wade, RH; Hackney, D; Kozielski, F				Skoufias, Dimitrios A.; DeBonis, Salvatore; Saoudi, Yasmina; Lebeau, Luc; Crevel, Isabelle; Cross, Robert; Wade, Richard H.; Hackney, David; Kozielski, Frank			S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIONAL-CANCER-INSTITUTE; ANTITUMOR-ACTIVITY; DRUG DISCOVERY; PROTEIN; MOTOR; IDENTIFICATION; MONASTROL; POTENT; MICROTUBULES; EXPRESSION	Human Eg5, responsible for the formation of the bipolar mitotic spindle, has been identified recently as one of the targets of S-trityl-L-cysteine, a potent tumor growth inhibitor in the NCI 60 tumor cell line screen. Here we show that in cell-based assays S-trityl-L-cysteine does not prevent cell cycle progression at the S or G(2) phases but inhibits both separation of the duplicated centrosomes and bipolar spindle formation, thereby blocking cells specifically in the M phase of the cell cycle with monoastral spindles. Following removal of S-trityl-L-cysteine, mitotically arrested cells exit mitosis normally. In vitro, S-trityl-L-cysteine targets the catalytic domain of Eg5 and inhibits Eg5 basal and microtubule- activated ATPase activity as well as mant-ADP release. S-Trityl-L-cysteine is a tight binding inhibitor (estimation of K-i,K-app < 150 nM at 300mM NaCl and 600 nM at 25 mM KCl). S-Trityl-L-cysteine binds more tightly than monastrol because it has both an similar to 8-fold faster association rate and similar to 4-fold slower release rate (6.1 mu M-1 s(-1) and 3.6 s(-1) for S-trityl-L-cysteine versus 0.78 mu M-1 s(-1) and 15 s(-1) for monastrol). S-Trityl-L-cysteine inhibits Eg5-driven microtubule sliding velocity in a reversible fashion with an IC50 of 500 nM. The S and D-enantiomers of S-tritylcysteine are nearly equally potent, indicating that there is no significant stereospecificity. Among nine different human kinesins tested, S-trityl-L-cysteine is specific for Eg5. The results presented here together with the proven effect on human tumor cell line growth make S-trityl-L-cysteine a very attractive starting point for the development of more potent mitotic inhibitors.	CNRS, UJF, Lab Moteurs Mol, Inst Biol Struct, F-38027 Grenoble 01, France; Commiss Energie Atom, INSERM, U336, Lab Cytosquelette, F-38054 Grenoble 9, France; Univ Louis Pasteur Strasbourg 1, Fac Pharm, Inst Gilbert Laustriat, Lab Chim Organ Appl, F-67401 Illkirch Graffenstaden, France; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Marie Curie Res Inst, Oxted RH8 0TL, England	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Carnegie Mellon University	Kozielski, F (corresponding author), 41 Rue Jules Horowitz, F-38027 Grenoble, France.	Frank.kozielski@ibs.fr	saoudi, yasmina/AAW-7354-2020; Lebeau, Luc/M-9964-2019; Skoufias, Dimitrios A/A-5535-2016; Cross, Robert A/F-1798-2011	Cross, Robert A/0000-0002-0004-7832; Lebeau, Luc/0000-0002-3276-6727; Skoufias, Dimitrios/0000-0001-5595-3413				ALLEY MC, 1988, CANCER RES, V48, P589; Andreassen Paul R, 2004, Methods Mol Biol, V281, P213; Bergnes G, 2005, CURR TOP MED CHEM, V5, P127, DOI 10.2174/1568026053507697; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Copeland R.A., 2000, ENZYMES PRACTICAL IN, P305; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DeBonis S, 2004, MOL CANCER THER, V3, P1079; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; Garcia-Saez I, 2004, J MOL BIOL, V340, P1107, DOI 10.1016/j.jmb.2004.05.053; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Goshima G, 2005, CURR BIOL, V15, P1979, DOI 10.1016/j.cub.2005.09.054; GREVER MR, 1992, SEMIN ONCOL, V19, P622; Hackney DD, 2001, METH MOL B, V164, P65; Hotha S, 2003, ANGEW CHEM INT EDIT, V42, P2379, DOI 10.1002/anie.200351173; Kelner MJ, 2002, INVEST NEW DRUG, V20, P271, DOI 10.1023/A:1016201807796; Kim IG, 1997, BBA-MOL CELL RES, V1359, P181, DOI 10.1016/S0167-4889(97)00103-1; Kozielski F, 2001, J BIOL CHEM, V276, P1267, DOI 10.1074/jbc.M007169200; Lai F, 2000, GENE, V248, P117, DOI 10.1016/S0378-1119(00)00135-9; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miyamoto David T, 2003, Prog Cell Cycle Res, V5, P349; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Nakazawa J, 2003, CHEM BIOL, V10, P131, DOI 10.1016/S1074-5521(03)00020-6; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; PAULL KD, 1992, CANCER RES, V52, P3892; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Xiao DH, 2005, MOL CANCER THER, V4, P1388, DOI 10.1158/1535-7163.MCT-05-0152; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	48	184	189	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17559	17569		10.1074/jbc.M511735200	http://dx.doi.org/10.1074/jbc.M511735200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16507573	hybrid			2022-12-25	WOS:000238490300005
J	Ferraro, D; Corso, S; Fasano, E; Panieri, E; Santangelo, R; Borrello, S; Giordano, S; Pani, G; Galeotti, T				Ferraro, D.; Corso, S.; Fasano, E.; Panieri, E.; Santangelo, R.; Borrello, S.; Giordano, S.; Pani, G.; Galeotti, T.			Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)	ONCOGENE			English	Article						signal transduction; c-Met; reactive oxygen species; metastasis; Rac-1	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; REDOX REGULATION; CELL-ADHESION; SUPEROXIDE-DISMUTASE; SCATTER-FACTOR; KINASE; RHO; ACTIVATION; INACTIVATION	Overexpression of the c-Met/hepatocyte growth factor receptor( HGF-R) proto-oncogene and abnormal generation of intracellular oxygen species ( reactive oxygen species ( ROS)) have been linked, by independent lines of evidence, to cell transformation and to malignant growth. By comparing two subpopulations of the B16 mouse melanoma ( B16-F0 and B16-F10) endowed with different lung metastasis capacities ( low and high, respectively) we found that both the expression/phosphorylation of c-Met and the steady-state levels of ROS positively correlated with metastatic growth. shRNA-mediated downregulation of c-Met in F10 cells led to a parallel decrease in the generation of oxygen species and in metastatic capacity, suggesting that oxidants may mediate the pro-metastatic activity of the HGF receptor. c-Met activation by a ligand elicits the formation of oxidant species through the oxidase-coupled small GTPase Rac-1, a relevant downstream target of the HGF-R. Moreover, cell treatment with the catalytic ROS scavengers EUK-134 and EUK-189 attenuates Met signaling to ERKs and inhibits the anchorage-independent growth of F10 cells, consistent with a critical role for oxygen species in HGF signaling and in aggressive cell behavior. Finally, genetic manipulation of the Rac-ROS cascade at different levels demonstrated its crucial role in the pro-metastatic activity of c- Met in vivo. Thus, we have outlined a novel cascade triggered by c- Met and mediated by ROS, linked to metastasis and potentially targetable by new antimetastatic, redox-based therapies.	Catholic Univ, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Oncol,IRCC, Turin, Italy; Catholic Univ, Sch Med, Inst Microbiol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pani, G (corresponding author), Catholic Univ, Sch Med, Inst Gen Pathol, Largo F Vito 1 Largo A Gemelli 1, I-00168 Rome, Italy.	gpani@rm.unicatt.it	Santangelo, Rosaria/AAL-1213-2020; Giordano, Silvia/J-9858-2018; Panieri, Emiliano/AAB-9028-2021; Pani, Giovambattista/AAB-1446-2019	Giordano, Silvia/0000-0003-1854-1086; Panieri, Emiliano/0000-0001-7989-7145; Pani, Giovambattista/0000-0001-7133-8728; Santangelo, Rosaria/0000-0002-8056-218X; CORSO, Simona/0000-0002-5069-1503				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Caplan JF, 2004, J BIOL CHEM, V279, P7740, DOI 10.1074/jbc.M313049200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FIDLER IJ, 1975, CANCER RES, V35, P218; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PONZETTO C, 1991, ONCOGENE, V6, P553; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Ventura A., 2002, SCI STKE, V2002, pPE44; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Wells A, 2000, ADV CANCER RES, V78, P31; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	53	103	107	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3689	3698		10.1038/sj.onc.1209409	http://dx.doi.org/10.1038/sj.onc.1209409			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462764				2022-12-25	WOS:000238448300008
J	Sasaki, M; Sugimoto, K; Tamayose, K; Ando, M; Tanaka, Y; Oshimi, K				Sasaki, M.; Sugimoto, K.; Tamayose, K.; Ando, M.; Tanaka, Y.; Oshimi, K.			Spindle checkpoint protein Bub1 corrects mitotic aberrancy induced by human T-cell leukemia virus type I Tax	ONCOGENE			English	Article						spindle checkpoint; chromosomal instability; Bub1; Tax; mitotic lobulation	MUTATION ANALYSIS; CANCER; GENE; LYMPHOMA; HBUB1; TRANSFORMATION; LOCALIZATION; ONCOPROTEIN; MICRONUCLEI; EXPRESSION	Bub1 is a component of the mitotic spindle checkpoint apparatus. Abnormality of this apparatus is known to cause multinuclei formation, a hallmark of chromosomal instability ( CIN). A549, aneuploid cell line, aberrantly passed through the mitotic phase and became multinuclei morphology in the presence of nocodazole. Time-lapse videomicroscopy showed unreported bizarre morphology, which we named 'mitotic lobulation' in A549 cells just before the exit from mitosis and multinuclei formation. External expression of wild-type Bub1-EGFP clearly suppressed the multinuclei formation by retaining A549 cells at the mitotic phase during 48 h of time-lapse observation. This suppressive effect on mitotic aberrancy should not be mere restoration of normal Bub1 function, because A549 cells express proper amount of Bub1, which distributed cytoplasm during interphase and concentrated at kinetochore in metaphase. Furthermore, external expression of wild-type Bub1-EGFP suppressed multinuclei formation induced by Tax both in A549 and HeLa cells. Tax is known to induce mitotic abnormality by binding and inactivating Mad1. These observations, therefore, suggest functional redundancy between Bub1 and other mitotic checkpoint protein( s) and a possibility of correction of mitotic aberrancy by external Bub1 expression.	Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan; Univ Ryukyus, Grad Sch Med, Dept Immunol, Nishihara, Okinawa, Japan	Juntendo University; University of the Ryukyus	Sugimoto, K (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ksugimot@med.juntendo.ac.jp	Pillay, Nischalan/F-9536-2012					Bahar R, 2002, J BIOL CHEM, V277, P40012, DOI 10.1074/jbc.M205345200; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JG, 2002, CANCER RES, V62, P1935; Hempen PM, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9120; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Isaka T, 2003, J HISTOCHEM CYTOCHEM, V51, P1343, DOI 10.1177/002215540305101011; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA N, 1992, CANCER RES, V52, P1481; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; Tashiro S, 1996, ONCOGENE, V12, P2165; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	33	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3621	3627		10.1038/sj.onc.1209404	http://dx.doi.org/10.1038/sj.onc.1209404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449967				2022-12-25	WOS:000238448300001
J	Fukuda, N; Saitoh, M; Kobayashi, N; Miyazono, K				Fukuda, N.; Saitoh, M.; Kobayashi, N.; Miyazono, K.			Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells	ONCOGENE			English	Article						bMP; apoptosis; p53; ER stress; signal transduction	ENDOPLASMIC-RETICULUM STRESS; BONE MORPHOGENETIC PROTEIN-2; MULTIPLE-MYELOMA; CARCINOMA-CELLS; ACTIVIN-A; ACTIVATION; GROWTH; P53; IDENTIFICATION; INVOLVEMENT	Bone morphogenic protein (BMP)-4 inhibits proliferation and induces the apoptosis of myeloma cells. However, little is known about the molecular mechanisms of how BMP-4 executes this apoptosis. In this report, we investigated the roles of p53 and the endoplasmic reticulum (ER) in BMP-4-induced apoptosis of mouse hybridoma HS-72 cells. We found that 3ng/ml of BMP-4 is sufficient to induce the expression of proapoptotic proteins, puma and bax, in a p53-dependent mechanism, and facilitate Ca2+ release from the ER to the cytosol, resulting in the activation of caspase-12 and ER dysfunction. Similarly to HS-72 cells, multiple myeloma cells with wild-type p53 genes show much higher sensitivity to BMP-4-induced apoptosis than cells without wild-type p53 genes, suggesting that wild-type p53 status is required for dysfunction of the ER during BMP-4-induced apoptosis in ER-enriched cells, such as hybridoma and myeloma cells. These. findings demonstrate that the presence of wild-type p53 genes and enrichment of the ER determines the sensitivity to effective apoptosis by BMP-4, and suggest that ER stress-inducing agents would be valuable in the treatment of multiple myeloma.	Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp		Fukuda, Noboru/0000-0003-0098-054X				BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; Bruno B, 2004, LANCET ONCOL, V5, P430, DOI 10.1016/S1470-2045(04)01511-6; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; CHO HJ, 2005, IN PRESS CANC LETT; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Glozak MA, 2001, EXP CELL RES, V268, P128, DOI 10.1006/excr.2001.5281; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oh SJ, 2000, MOL CELLS, V10, P275; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Phillips DJ, 1999, J ENDOCRINOL, V162, P111, DOI 10.1677/joe.0.1620111; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Shapiro-Shelef M, 2004, CURR OPIN IMMUNOL, V16, P226, DOI 10.1016/j.coi.2004.02.001; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Takuma K, 2005, J PHARMACOL SCI, V97, P312, DOI 10.1254/jphs.CPJ04006X; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yamato K, 2001, ONCOGENE, V20, P4383, DOI 10.1038/sj.onc.1204572; Zipori D, 2001, J LEUKOCYTE BIOL, V69, P867	31	29	30	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3509	3517		10.1038/sj.onc.1209393	http://dx.doi.org/10.1038/sj.onc.1209393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449972				2022-12-25	WOS:000238448200003
J	Liu, Y; Chen, L; Ko, TC; Fields, AP; Thompson, EA				Liu, Y.; Chen, L.; Ko, T. C.; Fields, A. P.; Thompson, E. A.			Evi1 is a survival factor which conveys resistance to both TGFb-beta and taxol-mediated cell death via PI3K/AKT	ONCOGENE			English	Article						apoptosis; carcinogenesis; colon cancer; cell signaling; chemotherapy	KINASE-C-IOTA; INDUCED APOPTOSIS; PROTEIN; GROWTH; GENE; TRANSCRIPTION; AMPLIFICATION; EXPRESSION; ACTIVATION; INHIBITION	In hematopoietic cells the transforming potential of the ecotropic viral integration site 1 (Evi1) oncogene is thought to be dependent upon the ability to inhibit TGF beta signaling. Although Evi1 has recently been implicated in certain epithelial cancers, the effects of Evi1 on transformation and TGF beta signaling in epithelial cells are not completely understood. Herein, we have determined the effects of Evi1 on TGF beta signaling in intestinal epithelial cells. Stable expression of Evi1 in non-transformed intestinal epithelial cells inhibited induction of some Smad3-dependent TGF beta target genes, such as PAI1. However, TGF beta-mediated induction of cellular adhesion signaling components such as integrin1 and paxillin was not inhibited by Evi1; nor did Evi1 inhibit TGF beta-mediated epithelial to mesenchymal transition. Likewise, Evi1 did not inhibit TGF beta-mediated downregulation of cyclin D1 or block TGF beta-mediated growth inhibition. However, Evi1 did inhibit TGF beta-mediated apoptosis by a process that involves phosphoinositide-3-kinase (PI3K) and its downstream effector AKT. The ability of Evi1 to suppress apoptosis is not restricted to TGF beta-mediated cell death, since Evi1 also protects intestinal epithelial cells from taxol-mediated apoptosis. Evi1 is overexpressed in some human colon cancer cell lines, and overexpression is associated with amplification of the Evi1 gene. Knockdown of Evi1 by siRNA inhibited AKT phosphorylation in HT-29 human colon cancer cells and increased their sensitivity to taxol-mediated apoptosis. These data indicate that Evi1 functions as a survival gene in intestinal epithelial cells and colon cancer cells, activating PI3K/AKT and conveying resistance to both physiological and therapeutic apoptotic stimuli.	Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77550 USA	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd,Griffin Canc Res Bldg,RM310, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu; thompson.aubrey@mayo.edu			NCI NIH HHS [R01CA64701] Funding Source: Medline; NIDDK NIH HHS [R01DK060105, P01DK35608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060105, P01DK035608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alliston T, 2005, J BIOL CHEM, V280, P24227, DOI 10.1074/jbc.M414305200; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bergamo NA, 2000, CANCER GENET CYTOGEN, V119, P48, DOI 10.1016/S0165-4608(99)00213-7; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hay ED, 1995, ACTA ANAT, V154, P8; Higashidani Y, 2003, DIS COLON RECTUM, V46, P327, DOI 10.1007/s10350-004-6551-z; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Ogawa S, 1996, ONCOGENE, V13, P183; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARSONS R, 1995, CANCER RES, V55, P5548; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Riggins GJ, 1997, CANCER RES, V57, P2578; Roman C, 2001, MICROSC RES TECHNIQ, V52, P450, DOI 10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	46	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3565	3575		10.1038/sj.onc.1209403	http://dx.doi.org/10.1038/sj.onc.1209403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462766				2022-12-25	WOS:000238448200009
J	Nowis, D; Legat, M; Grzela, T; Niderla, J; Wilczek, E; Wilczynski, GM; Glodkowska, E; Mrowka, P; Issat, T; Dulak, J; Jozkowicz, A; Was, H; Adamek, M; Wrzosek, A; Nazarewski, S; Makowski, M; Stoklosa, T; Jakobisiak, M; Golab, J				Nowis, D.; Legat, M.; Grzela, T.; Niderla, J.; Wilczek, E.; Wilczynski, G. M.; Glodkowska, E.; Mrowka, P.; Issat, T.; Dulak, J.; Jozkowicz, A.; Was, H.; Adamek, M.; Wrzosek, A.; Nazarewski, S.; Makowski, M.; Stoklosa, T.; Jakobisiak, M.; Golab, J.			Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity	ONCOGENE			English	Article						photodynamic therapy; Photofrin; heme oxygenase; cancer	MANGANESE SUPEROXIDE-DISMUTASE; UP-REGULATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GENE-EXPRESSION; CARBON-MONOXIDE; SINGLET OXYGEN; NITRIC-OXIDE; CANCER CELLS; APOPTOSIS	Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.	Warsaw Univ, Ctr Biostruct Res, Dept Immunol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Histol & Embryol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Pathol, PL-02097 Warsaw, Poland; Warsaw Univ, Dept Gen & Vasc Surg & Transplantat, PL-02097 Warsaw, Poland; Jagiellonian Univ, Fac Biotechnol, Dept Med Biotechnol, Krakow, Poland; Silesian Univ, Ctr Laser Diagnost & Therapy, Chair & Clin Internal Dis & Phys Med, Bytom, Poland; M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	University of Warsaw; University of Warsaw; University of Warsaw; University of Warsaw; Jagiellonian University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Golab, J (corresponding author), Warsaw Univ, Ctr Biostruct Res, Dept Immunol, 1A Banacha Str,F Bldg, PL-02097 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Glodkowska-Mrowka, Eliza/AAC-7294-2020; Golab, Jakub/K-6974-2013; Nowis, Dominika/P-6866-2019; Nazarewski, Sławomir D./T-3998-2018; Issat, Tadeusz/AAE-4176-2019; Wrzosek, Antoni/AAE-8070-2021; Nowis, Dominika/P-1213-2017; Glodkowska-Mrowka, Eliza/AAR-8503-2021; Wolinska, Ewa/AAE-4628-2021	Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Golab, Jakub/0000-0002-2830-5100; Nowis, Dominika/0000-0003-2748-9523; Nazarewski, Sławomir D./0000-0003-1195-9252; Issat, Tadeusz/0000-0002-3647-3550; Nowis, Dominika/0000-0003-2748-9523; Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Wilczynski, Grzegorz/0000-0001-6667-0291; Wolinska, Ewa/0000-0001-9592-1301; Wrzosek, Antoni/0000-0001-6376-8816; Stoklosa, Tomasz/0000-0001-6918-5056; Was, Halina/0000-0003-2743-0337				Abels C, 2004, PHOTOCH PHOTOBIO SCI, V3, P765, DOI 10.1039/b314241h; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; BACHOWSKI GJ, 1994, LIPIDS, V29, P449, DOI 10.1007/BF02578241; BALLA G, 1992, J BIOL CHEM, V267, P18148; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; BRESSOUD D, 1992, J PHOTOCH PHOTOBIO B, V14, P311, DOI 10.1016/1011-1344(92)85110-G; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dolgachev V, 2005, BIOCHEM BIOPH RES CO, V332, P411, DOI 10.1016/j.bbrc.2005.04.141; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Dulak J, 2003, ACTA BIOCHIM POL, V50, P31; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Golab J, 2002, CLIN CANCER RES, V8, P1265; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; Granville DJ, 2000, BLOOD, V95, P256; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Grune T, 2001, FREE RADICAL BIO MED, V30, P1243, DOI 10.1016/S0891-5849(01)00515-9; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kliukiene R, 1997, BIOCHEM MOL BIOL INT, V41, P707; Koukourakis MI, 2001, CANCER RES, V61, P1830; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin FB, 1996, CANCER RES, V56, P4636; LUNA MC, 1994, CANCER RES, V54, P1374; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Mcbride G, 2002, J NATL CANCER I, V94, P1740; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Nowis D, 2005, ACTA BIOCHIM POL, V52, P339; Oberdanner CB, 2005, PHOTOCHEM PHOTOBIOL, V81, P609, DOI 10.1562/2004-08-23-RN-284.1; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rasch MH, 1997, PHOTOCHEM PHOTOBIOL, V66, P209, DOI 10.1111/j.1751-1097.1997.tb08645.x; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sahoo SK, 2002, BIOCONJUGATE CHEM, V13, P1031, DOI 10.1021/bc020010k; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Shiraishi F, 2001, ANAL BIOCHEM, V289, P303, DOI 10.1006/abio.2000.4965; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; Verwanger T, 2002, INT J ONCOL, V21, P1353; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1111/j.1751-1097.2004.tb09864.x; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2	61	152	155	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3365	3374		10.1038/sj.onc.1209378	http://dx.doi.org/10.1038/sj.onc.1209378			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462769	Green Accepted			2022-12-25	WOS:000238448100002
J	Duke-Cohan, JS; Kang, H; Liu, H; Rudd, CE				Duke-Cohan, JS; Kang, H; Liu, H; Rudd, CE			Regulation and function of SKAP-55 non-canonical motif binding to the SH3c domain of adhesion and degranulation-promoting adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; SIGNAL-TRANSDUCTION; INTEGRIN ADHESION; FYN; SKAP55; ACTIVATION; RECEPTOR; SLP-76; TRANSCRIPTION; RECOGNITION	The immune cell adaptor adhesion and degranulation promoting adaptor protein ( ADAP) and its binding to T- cell adaptor Src kinase-associated protein of 55 kDa ( SKAP- 55) play a key role in the modulation of T- cell adhesion. While primary binding occurs via SKAP- 55 SH3 domain binding to a proline- rich region in ADAP, a second interaction occurs between the ADAP C- terminal SH3 domain ( ADAP-SH3c) and a non- canonical (RKXXYXXY297)-X-294 motif in SKAP- 55. Increasing numbers of non- canonical SH3 domain binding motifs have been identified in a number of biological systems. The presence of tyrosine residues in the SKAP- 55 RKXXY294XXY297 motif suggested that phosphorylation might influence this unusual SH3 domain interaction. Here, we show that the Src kinase p59(fyn) can induce the in vivo phosphorylation of the motif, and this event blocks ADAP- SH3c domain binding to the peptide motif. The importance of tyrosine phosphorylation was confirmed by plasmon resonance interaction analysis showing that phosphorylation of Tyr(294) residue plays a central role in mediating dissociation, whereas phosphorylation of the second Tyr(297) had no effect. Although loss of this secondary interaction did not result in the disruption of the complex, the Y294F mutation blocked T- cell receptor- induced up- regulation of lymphocyte function- associated antigen- 1- mediated adhesion to intercellular adhesion molecule- 1and interleukin- 2 promoter activity. Our findings identify a RKXXY294 motif in SKAP- 55 that mediates unique ADAP SH3c domain binding and is needed for LFA- 1- mediated adhesion and cytokine production.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Imperial Coll, Mol Immunol Sect, Dept Immunol, Div Invest Sci,Div Med, London W12 0NN, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Imperial College London	Duke-Cohan, JS (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA.	jonathan_duke-cohan@dfci.harvard.edu; c.rudd@imperial.ac.uk	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022; Duke-Cohan, Jonathan/A-5812-2010	Rudd, Christopher E/0000-0001-5295-9019; Duke-Cohan, Jonathan/0000-0002-9478-9609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broome MA, 1997, ONCOGENE, V14, P17, DOI 10.1038/sj.onc.1200798; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Geng LP, 1999, J IMMUNOL, V163, P5753; Geng LP, 2001, BIOCHEM BIOPH RES CO, V289, P1135, DOI 10.1006/bbrc.2001.6117; Geng LP, 2001, P NATL ACAD SCI USA, V98, P11527, DOI 10.1073/pnas.191378198; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Heuer K, 2005, J MOL BIOL, V348, P1025, DOI 10.1016/j.jmb.2005.02.069; Heuer K, 2004, STRUCTURE, V12, P603, DOI 10.1016/j.str.2004.02.021; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; Huang YP, 2005, J BIOL CHEM, V280, P23576, DOI 10.1074/jbc.M413201200; Jo EK, 2005, J EXP MED, V201, P1733, DOI 10.1084/jem.20042577; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kelly AE, 2002, J AM CHEM SOC, V124, P12013, DOI 10.1021/ja026121b; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Wang HY, 2004, J EXP MED, V200, P1063, DOI 10.1084/jem.20040780; Wang HY, 2003, NAT IMMUNOL, V4, P366, DOI 10.1038/ni913	39	25	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13743	13750		10.1074/jbc.M508774200	http://dx.doi.org/10.1074/jbc.M508774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16461356	hybrid			2022-12-25	WOS:000237336600085
J	Gattis, JL; Washington, AV; Chisholm, MM; Quigley, L; Szyk, A; McVicar, DW; Lubkowski, J				Gattis, JL; Washington, AV; Chisholm, MM; Quigley, L; Szyk, A; McVicar, DW; Lubkowski, J			The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INHIBITORY RECEPTOR; TREM-1; PLATELETS; CLUSTER; SYSTEM; NKP44	Triggering receptor expressed on myeloid cells like transcript- 1 ( TLT- 1) is an abundant platelet- specific, type I transmembrane receptor. The extracellular fragment of TLT- 1 consists of a single, immunoglobulin- like domain connected to the platelet cell membrane by a linker region called the stalk. Here we present evidence that a soluble fragment of the TLT- 1extracellular domain is found in serum of humans and mice and that an isoform of similar mass is released from platelets following activation with thrombin. We also report the crystal structure of the immunoglobulin domain of TLT- 1 determined at the resolution of 1.19 angstrom. The structure of TLT- 1 is similar to other immunoglobulin- like variable domains, particularly those of triggering receptor expressed on myeloid cells- 1 ( TREM- 1), the natural killer cell- activating receptor NKp44, and the polymeric immunoglobulin receptor. Particularly interesting is a 17- amino acid segment of TLT- 1, homologous to a fragment of murine TREM- 1, which, in turn, showed activity in blocking the TREM- 1- mediated inflammatory responses in mice. Structural similarity to TREM- 1and polymeric immunoglobulin receptor, and evidence for a naturally occurring soluble fragment of the TLT- 1 extracellular domain, suggest that this immunoglobulin- like domain autonomously plays an as yet unidentified, functional role.	NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, NIH, Ft Detrick,7th St,Bldg 539,POB B,Rm 150, Frederick, MD 21702 USA.	jacek@ncifcrf.gov	McVicar, Daniel/G-1970-2015	McVicar, Daniel/0000-0002-1112-5111	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010300, Z01BC010300] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allcock RJN, 2003, EUR J IMMUNOL, V33, P567, DOI 10.1002/immu.200310033; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantoni C, 2003, STRUCTURE, V11, P725, DOI 10.1016/S0969-2126(03)00095-9; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Gibot S, 2005, INTENS CARE MED, V31, P594, DOI 10.1007/s00134-005-2572-x; Gibot S, 2004, J EXP MED, V200, P1419, DOI 10.1084/jem.20040708; Gibot Sebastien, 2004, Clin Med Res, V2, P181; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hoover DM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e43; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Kelker MS, 2004, J MOL BIOL, V342, P1237, DOI 10.1016/j.jmb.2004.07.089; Kelker MS, 2004, J MOL BIOL, V344, P1175, DOI 10.1016/j.jmb.2004.10.009; KLEYWEGT GJ, 1996, ACTA CRYSTALLOGR A, V47, P110; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Meiler J, 2001, J MOL MODEL, V7, P360, DOI 10.1007/s008940100038; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; *NAT RES COUNC, 1996, NIH PUBL, V8623; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASI JK, 1999, HEMOSTASIS THROMBOSI, P3; Paul SP, 2000, BLOOD, V96, P483; Radaev S, 2003, STRUCTURE, V11, P1527, DOI 10.1016/j.str.2003.11.001; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Washington AV, 2004, BLOOD, V104, P1042, DOI 10.1182/blood-2004-01-0315; Washington AV, 2002, BLOOD, V100, P3822, DOI 10.1182/blood-2002-02-0523; Zhou GF, 1997, PROTEIN SCI, V6, P444	32	42	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13396	13403		10.1074/jbc.M600489200	http://dx.doi.org/10.1074/jbc.M600489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16505478	hybrid			2022-12-25	WOS:000237336600046
J	Glithero, A; Tormo, J; Doering, K; Kojima, M; Jones, EY; Elliott, T				Glithero, A; Tormo, J; Doering, K; Kojima, M; Jones, EY; Elliott, T			The crystal structure of H-2D(b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; T-CELL RECOGNITION; 3-DIMENSIONAL STRUCTURE; MHC; MOLECULES; BINDING; RESOLUTION; EXPRESSION; STABILITY; TAPASIN	In the absence of bound peptide ligands, major histocompatibility complex (MHC) class I molecules are unstable. In an attempt to determine the minimum requirement for peptide-dependent MHC class I stabilization, we have used short synthetic peptides derived from the Sendai virus nucleoprotein epitope ( residues 324-332, (1)FAPGNYPAL(9)) to promote its folding in vitro of H-2D(b). We found that H-2D(b) can be stabilized by the pentapeptide (5)NYPAL(9), which is equivalent to the C-terminal portion of the optimal nonapeptide and includes both the P5 and P9 anchor residues. We have crystallized the complex of the H-2D(b) molecule with the pentamer and determined the structure to show how a quasi-stable MHC class I molecule can be formed by occupancy of a single binding pocket in the peptide-binding groove.	Univ Southampton, Sch Med, Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England; Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 4RU, England	University of Southampton; University of Oxford; University of Oxford	Elliott, T (corresponding author), Univ Southampton, Sch Med, Southampton Gen Hosp, Canc Sci Div, Somers Canc Res Bldg,MP 824, Southampton SO16 6YD, Hants, England.	tje@soton.ac.uk	Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Elliott, Tim/0000-0003-1097-0222	MRC [G9900061] Funding Source: UKRI; Medical Research Council [G9900061] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busch R, 2005, IMMUNOL REV, V207, P242, DOI 10.1111/j.0105-2896.2005.00306.x; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; CATIPOVIC B, 1994, J EXP MED, V180, P1753, DOI 10.1084/jem.180.5.1753; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Gillanders WE, 1997, INT IMMUNOL, V9, P81, DOI 10.1093/intimm/9.1.81; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Hansen TH, 2005, IMMUNOL REV, V207, P100, DOI 10.1111/j.0105-2896.2005.00315.x; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGNEY E, 1998, J BIOL CHEM, P273; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULZ M, 1991, EUR J IMMUNOL, V21, P1181, DOI 10.1002/eji.1830210513; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; Zacharias M, 2004, BIOPHYS J, V87, P2203, DOI 10.1529/biophysj.104.044743	33	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12699	12704		10.1074/jbc.M511683200	http://dx.doi.org/10.1074/jbc.M511683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16478731	hybrid			2022-12-25	WOS:000237134700061
J	Maccarana, M; Olander, B; Malmstrom, J; Tiedemann, K; Aebersold, R; Lindahl, U; Li, JP; Malmstrom, A				Maccarana, M; Olander, B; Malmstrom, J; Tiedemann, K; Aebersold, R; Lindahl, U; Li, JP; Malmstrom, A			Biosynthesis of dermatan sulfate - Chondroitin-glucuronate C5-epimerase is identical to SART2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-REJECTION ANTIGENS; STATISTICAL-MODEL; HEPARIN; PROTEOGLYCANS; EXPRESSION; SUBSTRATE; POLYSACCHARIDE; EPIMERIZATION; SEQUENCES; PEPTIDES	We identified the gene encoding chondroitin-glucuronate C5-epimerase ( EC 5.1.3.19) that converts D-glucuronic acid to L-iduronic acid residues in dermatan sulfate biosynthesis. The enzyme was solubilized from bovine spleen, and an similar to 43,000-fold purified preparation containing a major 89-kDa candidate component was subjected to mass spectrometry analysis of tryptic peptides. SART2 ( squamous cell carcinoma antigen recognized by T cell 2), a protein with unknown function highly expressed in cancer cells and tissues, was identified by 18 peptides covering 26% of the sequence. Transient expression of cDNA resulted in a 22-fold increase in epimerase activity in 293HEK cell lysate. Moreover, overexpressing cells produced dermatan sulfate chains with 20% of iduronic acid-containing disaccharide units, as compared with 5% for mock-transfected cells. The iduronic acid residues were preferentially clustered in blocks, as in naturally occurring dermatan sulfate. Given the discovered identity, we propose to rename SART2 ( Nakao, M., Shichijo, S., Imaizumi, T., Inoue, Y., Matsunaga, K., Yamada, A., Kikuchi, M., Tsuda, N., Ohta, K., Takamori, S., Yamana, H., Fujita, H., and Itoh, K. ( 2000) J. Immunol. 164, 2565-2574) with a functional designation, chondroitin-glucuronate C5-epimerase ( or DS epimerase). DS epimerase activity is ubiquitously present in normal tissues, although with marked quantitative differences. It is highly homologous to part of the NCAG1 protein, encoded by the C18orf4 gene, genetically linked to bipolar disorder. NCAG1 also contains a putative chondroitin sulfate sulfotransferase domain and thus may be involved in dermatan sulfate biosynthesis. The functional relation between dermatan sulfate and cancer is unknown but may involve known iduronic acid-dependent interactions with growth factors, selectins, cytokines, or coagulation inhibitors.	Lund Univ, Dept Expt Med Sci, SE-22184 Lund, Sweden; ETH Honggerberg, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Lund University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Uppsala University	Maccarana, M (corresponding author), Lund Univ, Dept Expt Med Sci, BMC C13, SE-22184 Lund, Sweden.	marco.maccarana@med.lu.se	Malmström, Johan A/B-7660-2009; maccarana, marco/AAB-4764-2021; Tiedemann, one/A-9739-2016	Malmström, Johan A/0000-0002-2889-7169; Malmstrom, Anders/0000-0002-6691-146X; Maccarana, Marco/0000-0003-3549-8921				Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Eklund E, 2000, ARCH BIOCHEM BIOPHYS, V383, P171, DOI 10.1006/abbi.2000.2043; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; FERRO DR, 1990, CARBOHYD RES, V195, P157, DOI 10.1016/0008-6215(90)84164-P; Goossens D, 2003, MOL PSYCHIATR, V8, P83, DOI 10.1038/sj.mp.4001190; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; Hagner-McWhirter A, 2004, J BIOL CHEM, V279, P14631, DOI 10.1074/jbc.M313760200; Hannesson HH, 1996, BIOCHEM J, V313, P589, DOI 10.1042/bj3130589; HOOK M, 1974, J BIOL CHEM, V249, P3908; HOOK M, 1975, J BIOL CHEM, V250, P6065; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Isogai Z, 1996, CANCER RES, V56, P3902; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lee H, 2004, J CHROMATOGR B, V803, P101, DOI 10.1016/j.jchromb.2003.09.005; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1982, BIOCHEM J, V201, P489, DOI 10.1042/bj2010489; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; MALMSTROM L, 2006, IN PRESS BMC BIOINFO; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakao M, 2000, J IMMUNOL, V164, P2565, DOI 10.4049/jimmunol.164.5.2565; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Noguchi M, 2003, PROSTATE, V57, P80, DOI 10.1002/pros.10276; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SARRAZIN S, 2005, IN PRESS BIOCH BIOPH; Sasatomi T, 2002, CANCER, V94, P1636, DOI 10.1002/cncr.10421; Seidler DG, 2002, J BIOL CHEM, V277, P42409, DOI 10.1074/jbc.M208442200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Suzuki N, 2002, INT J CANCER, V98, P45, DOI 10.1002/ijc.10145; Svanem BIG, 2001, J BIOL CHEM, V276, P31542, DOI 10.1074/jbc.M102562200; Tanaka S, 2000, JPN J CANCER RES, V91, P1177, DOI 10.1111/j.1349-7006.2000.tb00902.x; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Tiedemann K, 2005, GLYCOBIOLOGY, V15, P1277, DOI 10.1093/glycob/cwj027; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	50	99	103	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11560	11568		10.1074/jbc.M513373200	http://dx.doi.org/10.1074/jbc.M513373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505484	Green Submitted, hybrid			2022-12-25	WOS:000236988100018
J	Madziva, MT; Birnbaumer, M				Madziva, MT; Birnbaumer, M			A role for ADP-ribosylation factor 6 in the processing of G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V2 VASOPRESSIN RECEPTOR; NEPHROGENIC DIABETES-INSIPIDUS; PLASMA-MEMBRANE; WILD-TYPE; ARF6; CELLS; ENDOCYTOSIS; PHOSPHORYLATION; GLYCOSYLATION; GTPASE	After agonist-induced internalization, the vasopressin V-2 receptor (V2R) does not recycle to the plasma membrane. The ADP-ribosylation factor (ARF) proteins initiate vesicular intracellular traffic by promoting the recruitment of adaptor proteins; thus, we sought to determine whether ARF6 could promote V2R recycling. Neither the agonist-induced internalization nor the recycling of the V2R was regulated by ARF6, but a constitutively active mutant of ARF6 reduced cell-surface V(2)Rs 10-fold in the absence of agonist treatment. Visualization of the ARF6 mutant-expressing cells revealed a vacuolar-staining pattern of the V2R instead of the normal plasma-membrane expression. Analysis of V2R maturation revealed that reduced cell-surface expression was due to the diminished ability of the newly synthesized receptor to migrate from the endoplasmic reticulum to the Golgi network. The same mechanism affected processing of the V1aR and acetylcholine M2 receptors. Therefore, ARF6 controls the exit of the V-2 and other receptors from the endoplasmic reticulum in addition to its established role in the trafficking of plasma-membrane-derived vesicles.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Birnbaumer, M (corresponding author), NIEHS, Lab Signal Transduct, NIH, MD F1-10, Res Triangle Pk, NC 27709 USA.	birnbau2@niehs.nih.gov						BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krause G, 2000, MOL PHARMACOL, V57, P232; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12178	12186		10.1074/jbc.M601357200	http://dx.doi.org/10.1074/jbc.M601357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497672	hybrid			2022-12-25	WOS:000236988100088
J	Marcinkiewicz, A; Gauthier, D; Garcia, A; Brasaemle, DL				Marcinkiewicz, A; Gauthier, D; Garcia, A; Brasaemle, DL			The phosphorylation of serine 492 of perilipin A directs lipid droplet fragmentation and dispersion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DIFFERENTIATION-RELATED PROTEIN; LIPOLYTIC STIMULATION; CHOLESTERYL ESTER; MEDIATED LIPOLYSIS; VESICLE TRANSPORT; TRANSLOCATION; STORAGE; MODULATION; ADIPOCYTES	Perilipin A is a key regulator of triacylglycerol storage and hydrolysis in adipocytes; phosphorylation of perilipin A by protein kinase A facilitates maximal lipolysis. Chronic stimulation of lipolysis in 3T3-L1 adipocytes causes large perinuclear lipid droplets to fragment into myriad dispersed perilipin A-covered microlipid droplets. In cultured fibroblasts stably expressing ectopic perilipin A, clustered lipid droplets disperse throughout the cytoplasm upon incubation of the cells with forskolin and isobutylmethylxanthine (IBMX) to elevate levels of cAMP and activate protein kinase A, mirroring events observed in adipocytes. Furthermore, diethylumbelliferyl phosphate inhibits stimulated lipolysis but not the dispersion of lipid droplets, suggesting that products of lipolysis are not required for this remodeling process. We hypothesized that protein kinase A-mediated phosphorylation of perilipin A triggers the remodeling of lipid droplets. The mutation of serine 492 of perilipin A to alanine prevented the dispersion of clustered lipid droplets in fibroblasts stably expressing the mutated perilipin upon incubation with forskolin and IBMX. In contrast, the substitution of serines 81, 222, 276, or 433 with alanine, either singly or in combinations, did not affect the protein kinase A-mediated remodeling of lipid droplets. Interestingly, substitution of serines 433, 492, and 517 of perilipin A with glutamic acid residues blocked the dispersion of clustered lipid droplets in cells incubated with forskolin and IBMX, indicating that the addition of a negative charge does not mimic a phosphate group. We conclude that protein kinase A-mediated phosphorylation of serine 492 of perilipin A drives the fragmentation and dispersion of lipid droplets.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	Brasaemle@AESOP.Rutgers.edu		Brasaemle, Dawn/0000-0002-8553-8285	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54797] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Clifford GM, 2001, METABOLISM, V50, P1264, DOI 10.1053/meta.2001.27216; Clifford GM, 1997, BIOCHEM SOC T, V25, pS672, DOI 10.1042/bst025s672; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Granneman JG, 2004, AM J PHYSIOL-ENDOC M, V287, pE574, DOI 10.1152/ajpendo.00567.2003; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gross SP, 2000, J CELL BIOL, V148, P945, DOI 10.1083/jcb.148.5.945; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HARRISON EH, 1990, J LIPID RES, V31, P2187; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401; Patel RT, 2005, J BIOL CHEM, V280, P22624, DOI 10.1074/jbc.M413128200; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Welte MA, 2005, CURR BIOL, V15, P1266, DOI 10.1016/j.cub.2005.06.062; Welte MA, 1998, CELL, V92, P547, DOI 10.1016/S0092-8674(00)80947-2; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	55	186	191	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11901	11909		10.1074/jbc.M600171200	http://dx.doi.org/10.1074/jbc.M600171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16488886	hybrid			2022-12-25	WOS:000236988100058
J	Yin, H; Glass, J				Yin, H; Glass, J			In prostate cancer cells the interaction of C/EBP alpha with Ku70, Ku80, and poly(ADP-ribose) polymerase-1 increases sensitivity to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; DOUBLE-STRAND BREAKS; BETA ISOFORM EXPRESSION; GENE-EXPRESSION; 3T3-L1 ADIPOCYTES; MYELOID-LEUKEMIA; GROWTH ARREST; PROLIFERATION; DIFFERENTIATION; REPAIR	Prostate cancer cell lines were examined for proteins that partnered with the transcription factor C/EBP alpha by use of a pull-down assay with S-tagged C/EBP alpha combined with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy analysis. Ku70, Ku80, and poly( ADP-ribose) polymerase-1 ( PARP-1) were identified as proteins that associated with C/EBP alpha. The physical interaction of C/EBP alpha with these partner proteins was further demonstrated by glutathione S-transferase ( GST) pull-downs using purified protein expressed in Escherichia coli. The strongest binding was between C/EBP alpha and PARP-1. Immunoprecipitation of C/EBP alpha expressed in prostate cancer cells co-precipitated Ku70, Ku80, and PARP-1. Deletion analysis of C/EBP alpha indicated that the C terminus of C/EBP alpha was essential for the interaction of C/EBP alpha with Ku70, Ku80, and PARP-1. Functional analysis of the interaction between C/EBP alpha and the Ku proteins as well as PARP-1 showed that cells exhibiting these interactions had increased radiation sensitivity and decreased ability to repair double strand DNA breaks. Deficient DNA repair was dependent on the prostate cancer cell line tested, suggesting a complex process. We conclude that the association of C/EBP alpha with Ku proteins and PARP-1 raises the likelihood that C/EBP alpha-expressing prostate cancer cells may be more sensitive to DNA-damaging agents and may be important in the design of new prostate cancer therapies.	Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Shreveport, LA 71130 USA; Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Yin, H (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, 1501 Kings Highway, Shreveport, LA 71130 USA.	hyin@lsuhsc.edu						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; An MR, 1996, MOL CELL BIOL, V16, P2295; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bertinato J, 2003, GENE, V302, P53, DOI 10.1016/S0378111902010892; Bromfield GP, 2003, PROSTATE CANCER P D, V6, P73, DOI 10.1038/sj.pcan.4500628; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Halmos B, 2002, CANCER RES, V62, P528; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Koike M, 2002, J RADIAT RES, V43, P223, DOI 10.1269/jrr.43.223; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mayeur GL, 2005, J BIOL CHEM, V280, P10827, DOI 10.1074/jbc.M413336200; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Myung K, 2004, MOL CELL BIOL, V24, P5050, DOI 10.1128/MCB.24.11.5050-5059.2004; Noel G, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-7; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pastwa E, 2003, RADIAT RES, V159, P251, DOI 10.1667/0033-7587(2003)159[0251:RORIDD]2.0.CO;2; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; RADTKE K, 1994, BIOCHEM J, V302, P655, DOI 10.1042/bj3020655; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Watkins PJ, 1996, CANCER RES, V56, P1063; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; YIN H, 2003, P 94 ANN M AM ASS CA, V44, P542; Yin Hong, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P115; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	55	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11496	11505		10.1074/jbc.M511138200	http://dx.doi.org/10.1074/jbc.M511138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490787	hybrid			2022-12-25	WOS:000236988100011
J	Besteiro, S; Williams, RAM; Morrison, LS; Coombs, GH; Mottram, JC				Besteiro, S; Williams, RAM; Morrison, LS; Coombs, GH; Mottram, JC			Endosome sorting and autophagy are essential for differentiation and virulence of Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; MULTIVESICULAR-BODY; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; CYSTEINE PROTEINASES; FLAGELLAR POCKET; YEAST; COMPLEX; COMPARTMENT; PATHWAY	Cellular remodeling during differentiation is essential for life-cycle progression of many unicellular eukaryotic pathogens such as Leishmania, but the mechanisms involved are largely uncharacterized. The role of endosomal sorting in differentiation was analyzed in Leishmania major by overexpression of a dominant-negative ATPase, VPS4. VPS4(E235Q) accumulated in vesicles from the endocytic pathway, and the mutant L. major was deficient in endosome sorting. Mutant parasites failed to differentiate to the obligate infective metacyclic promastigote form. Furthermore, the autophagy pathway, monitored via the expression of autophagosome marker GFP-ATG8, and shown to normally peak during initiation of metacyclogenesis, was disrupted in the mutants. The defect in late endosome-autophagosome function in the VPS4(E235Q) parasites made them less able to withstand starvation than wild-type L. major. In addition, a L. major ATG4-deficient mutant was found also to be defective in the ability to differentiate. This finding, that transformation to the infective metacyclic form is dependent on late endosome function and, more directly, autophagy, makes L. major a good model for studying the roles of these processes in differentiation.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland; Univ Glasgow, Glasgow Biomed Res Ctr, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow; University of Glasgow	Mottram, JC (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	jmottram@bio.gla.ac.uk	Besteiro, Sébastien/F-3622-2014; Williams, Roderick/V-4317-2019	Besteiro, Sébastien/0000-0003-1853-1494; Williams, Roderick/0000-0001-5065-9768; Mottram, Jeremy/0000-0001-5574-3766	MRC [G0000508] Funding Source: UKRI; Medical Research Council [G0000508] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alexander J, 1999, J CELL SCI, V112, P2993; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Besteiro S, 2004, MOL MICROBIOL, V54, P1224, DOI 10.1111/j.1365-2958.2004.04355.x; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Conibear E, 2002, MOL CELL, V10, P215, DOI 10.1016/S1097-2765(02)00601-9; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Denny PW, 2002, MOL BIOCHEM PARASIT, V123, P105, DOI 10.1016/S0166-6851(02)00133-0; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; FinkenEigen M, 1997, CURR GENET, V31, P469, DOI 10.1007/s002940050232; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; FRANKE ED, 1985, J IMMUNOL, V134, P2713; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Herman M, 2006, AUTOPHAGY, V2, P107, DOI 10.4161/auto.2.2.2369; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KIDERLEN AF, 1990, J IMMUNOL METHODS, V127, P11, DOI 10.1016/0022-1759(90)90334-R; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2004, AUTOPHAGY; Knuepfer E, 2001, BIOCHEM J, V356, P335, DOI 10.1042/0264-6021:3560335; Krishnamurthy G, 2005, J BIOL CHEM, V280, P5884, DOI 10.1074/jbc.M411845200; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Overath P, 2004, MOL MICROBIOL, V53, P735, DOI 10.1111/j.1365-2958.2004.04224.x; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Shirahama K, 1997, CELL STRUCT FUNCT, V22, P501, DOI 10.1247/csf.22.501; Singh SB, 2003, EMBO J, V22, P5712, DOI 10.1093/emboj/cdg557; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Tetaud E, 2002, MOL BIOCHEM PARASIT, V120, P195, DOI 10.1016/S0166-6851(02)00002-6; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Weise F, 2000, J CELL SCI, V113, P4587; Yang M, 2004, J CELL SCI, V117, P3831, DOI 10.1242/jcs.01237; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	53	167	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11384	11396		10.1074/jbc.M512307200	http://dx.doi.org/10.1074/jbc.M512307200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497676	hybrid			2022-12-25	WOS:000236822200081
J	Devel, L; Rogakos, V; David, A; Makaritis, A; Beau, F; Cuniasse, P; Yiotakis, A; Dive, V				Devel, L; Rogakos, V; David, A; Makaritis, A; Beau, F; Cuniasse, P; Yiotakis, A; Dive, V			Development of selective inhibitors and substrate of matrix metalloproteinase-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABDOMINAL AORTIC-ANEURYSMS; PHOSPHINIC PEPTIDES; MACROPHAGE ELASTASE; DEFICIENT MICE; GELATINASE-A; CANCER; MMP-12; ACTIVATION; EXPRESSION; EMPHYSEMA	Four phosphinic peptide libraries with compounds having the general formula p-Br-Ph-(PO2-CH2)-Xaa'-Yaa'-Zaa'-NH2 have been prepared and screened against 10 matrix metalloproteinases ( MMPs). We identified two phosphinic peptides with K-i values of 0.19 and 4.4 nM toward MMP-12 ( macrophage elastase) that are more than 2 - 3 orders of magnitude less potent toward the other MMPs tested. These highly selective MMP-12 inhibitors contain a Glu-Glu motif in their Yaa'-Zaa' positions. Incorporation of this Glu-Glu motif into the sequence of a nonspecific fluorogenic peptide cleaved by MMPs provides a highly selective substrate for MMP-12. A model of one of these inhibitors interacting with MMP-12 suggests that the selectivity observed might be due, in part, to the presence of two unique polar residues in MMP-12, Thr(239) and Lys(177). These MMP-12-selective inhibitors may have important therapeutic applications to diseases in which MMP-12 has been suggested to play a key role, such as in emphysema, atherosclerosis, and aortic abdominal aneurysm.	Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Univ Athens, Dept Organ Chem, Organ Chem Lab, GR-15771 Athens, Greece	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; National & Kapodistrian University of Athens	Dive, V (corresponding author), Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, Bat 152, F-91191 Gif Sur Yvette, France.	vincent.dive@cea.fr						Bertini I, 2005, P NATL ACAD SCI USA, V102, P5334, DOI 10.1073/pnas.0407106102; Bode W, 2003, BIOCHEM SOC SYMP, V70, P1; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brown S, 2004, CURR TOP MED CHEM, V4, P1227, DOI 10.2174/1568026043387854; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Butler GS, 2004, J BIOL CHEM, V279, P15615, DOI 10.1074/jbc.M312727200; Cook GR, 2004, BIOORG MED CHEM LETT, V14, P4935, DOI 10.1016/j.bmcl.2004.07.023; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cuniasse P, 2005, BIOCHIMIE, V87, P393, DOI 10.1016/j.biochi.2004.09.025; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Daheshia M, 2005, CURR MED RES OPIN, V21, P587, DOI 10.1185/030079905X41417; Dive V, 2004, CELL MOL LIFE SCI, V61, P2010, DOI 10.1007/s00018-004-4050-y; Dollery CM, 2006, CARDIOVASC RES, V69, P625, DOI 10.1016/j.cardiores.2005.11.003; Dublanchet AC, 2005, BIOORG MED CHEM LETT, V15, P3787, DOI 10.1016/j.bmcl.2005.05.079; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engel CK, 2005, CHEM BIOL, V12, P181, DOI 10.1016/j.chembiol.2004.11.014; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Frisch MJ, 2003, GAUSSIAN03; Gall AL, 2001, J MOL BIOL, V307, P577, DOI 10.1006/jmbi.2001.4493; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hofmann HS, 2005, CLIN CANCER RES, V11, P1086; HOROVITZ A, 1987, P NATL ACAD SCI USA, V84, P6654, DOI 10.1073/pnas.84.19.6654; Ikejiri M, 2005, J ORG CHEM, V70, P5709, DOI 10.1021/jo050339+; Johnson JL, 2005, P NATL ACAD SCI USA, V102, P15575, DOI 10.1073/pnas.0506201102; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; Kerkela E, 2001, BONE, V29, P487, DOI 10.1016/S8756-3282(01)00595-6; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Longo GM, 2005, SURGERY, V137, P457, DOI 10.1016/j.surg.2004.12.004; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Makaritis A, 2003, CHEM-EUR J, V9, P2079, DOI 10.1002/chem.200204456; Mannello F, 2005, CURR CANCER DRUG TAR, V5, P285, DOI 10.2174/1568009054064615; Montchamp JL, 2001, J AM CHEM SOC, V123, P510, DOI 10.1021/ja005721c; Morales R, 2004, J MOL BIOL, V341, P1063, DOI 10.1016/j.jmb.2004.06.039; Morgan AR, 2004, STROKE, V35, P1310, DOI 10.1161/01.STR.0000126822.01756.99; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Moy FJ, 2002, J AM CHEM SOC, V124, P12658, DOI 10.1021/ja027391x; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Rosenberg GA, 2005, LANCET, V365, P1291, DOI 10.1016/S0140-6736(05)61008-2; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; STETTER H, 1979, SYNTHESIS-STUTTGART, P29; Tanaka A, 1998, BIOORGAN MED CHEM, V6, P15, DOI 10.1016/S0968-0896(97)10009-8; Tayebjee MH, 2005, CURR MED CHEM, V12, P917, DOI 10.2174/0929867053507270; Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P1259; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Whelan Clifford J, 2004, Curr Opin Investig Drugs, V5, P511; Yiotakis A, 1996, J ORG CHEM, V61, P6601, DOI 10.1021/jo9603439; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	55	130	138	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11152	11160		10.1074/jbc.M600222200	http://dx.doi.org/10.1074/jbc.M600222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481329	hybrid			2022-12-25	WOS:000236822200058
J	Filipeanu, CM; Zhou, F; Lam, ML; Kerut, KE; Claycomb, WC; Wu, GY				Filipeanu, CM; Zhou, F; Lam, ML; Kerut, KE; Claycomb, WC; Wu, GY			Enhancement of the recycling and activation of beta-adrenergic receptor by Rab4 GTPase in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ANGIOTENSIN-II; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; ENDOPLASMIC-RETICULUM; REGULATORY MECHANISMS; HEART-FAILURE; CELL-SURFACE; EXPRESSION; TRAFFICKING	We investigate the role of Rab4, a Ras-like small GTPase coordinating protein transport from the endosome to the plasma membrane, on the recycling and activation of endogenous beta-adrenergic receptor (beta-AR) in HL-1 cardiac myocytes in vitro and transgenic mouse hearts in vivo. beta(1)-AR, the predominant subtype of beta-AR in HL-1 cardiac myocytes, was internalized after stimulation with isoproterenol (ISO) and fully recycled at 4 h upon ISO removal. Transient expression of Rab4 markedly facilitated recycling of internalized beta-AR to the cell surface and enhanced beta-AR signaling as measured by ISO-stimulated cAMP production. Transgenic overexpression of Rab4 in the mouse myocardium significantly increased the number of beta-AR in the plasma membrane and augmented cAMP production at the basal level and in response to ISO stimulation. Rab4 overexpression induced concentric cardiac hypertrophy with a moderate increase in ventricle/body weight ratio and posterior wall thickness and a selective up-regulation of the beta-myosin heavy chain gene. These data provide the first evidence indicating that Rab4 is a rate-limiting factor for the recycling of endogenous beta-AR and augmentation of Rab4-mediated traffic enhances beta-AR function in cardiac myocytes.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu		Filipeanu, Catalin/0000-0002-7298-9327	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076167] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR018766, 1P20RR018766] Funding Source: Medline; NIGMS NIH HHS [R01 GM076167-01, R01 GM076167] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohm SK, 1997, BIOCHEM J, V322, P1; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; Filipeanu CM, 2004, J BIOL CHEM, V279, P41077, DOI 10.1074/jbc.M405988200; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1983, J CELL BIOL, V97, P1538, DOI 10.1083/jcb.97.5.1538; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Mace T, 2005, EMBO J, V24, P3235, DOI 10.1038/sj.emboj.7600799; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Odley A, 2004, P NATL ACAD SCI USA, V101, P7082, DOI 10.1073/pnas.0308335101; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; Post SR, 1999, ANNU REV PHARMACOL, V39, P343, DOI 10.1146/annurev.pharmtox.39.1.343; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sato M, 2004, J BIOL CHEM, V279, P13375, DOI 10.1074/jbc.M312660200; SCHWINGER RHG, 1990, AM HEART J, V119, P899, DOI 10.1016/S0002-8703(05)80329-1; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; vandenHoff MJB, 1997, J MOL CELL CARDIOL, V29, P629, DOI 10.1006/jmcc.1996.0306; Wozniak M, 2002, METHOD ENZYMOL, V343, P530; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206	37	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11097	11103		10.1074/jbc.M511460200	http://dx.doi.org/10.1074/jbc.M511460200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484224	hybrid, Green Accepted			2022-12-25	WOS:000236822200052
J	Ju, DH; Xie, YM				Ju, DH; Xie, YM			Identification of the preferential ubiquitination site and ubiquitin-dependent degradation signal of Rpn4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CELL-CYCLE; SUBSTRATE; MECHANISMS; PROTEOLYSIS; PROTEASOME; EXPRESSION; BINDING; DOMAIN	Lysine selection is a long-standing problem in protein ubiquitination catalyzed by the RING ubiquitin ligases. It is well known that many substrates carry multiple lysines that can be ubiquitinated. However, it has seldom been addressed whether one lysine is preferred for ubiquitin conjugation when all other lysines exist. Here we studied the mechanism underlying ubiquitin-dependent degradation of Rpn4, a transcription activator of the Saccharomyces cerevisiae proteasome genes. We found that the ubiquitin-dependent degradation of Rpn4 can be mediated by six different lysines. Interestingly, we showed through in vivo and in vitro assays that lysine 187 is selected for ubiquitination when all other lysines are available. To the best of our knowledge, this is the first demonstration of a preferential ubiquitination site chosen from a group of lysines susceptible for ubiquitination. We further demonstrated that lysine 187 and a proximal acidic domain constitute a portable degradation signal. The implications of our data are discussed.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Xie, YM (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, 110 E Warren Ave, Detroit, MI 48201 USA.	xiey@karmanos.org						Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; Ju DH, 2004, BIOCHEM BIOPH RES CO, V321, P51, DOI 10.1016/j.bbrc.2004.06.105; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Madura K, 2004, TRENDS BIOCHEM SCI, V29, P637, DOI 10.1016/j.tibs.2004.10.008; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Wang L, 2004, J BIOL CHEM, V279, P55218, DOI 10.1074/jbc.M410085200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298	30	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10657	10662		10.1074/jbc.M513790200	http://dx.doi.org/10.1074/jbc.M513790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492666	hybrid			2022-12-25	WOS:000236822200003
J	Kim, JY; Zhang, XW; Rieger-Christ, KM; Summerhayes, IC; Wazer, DE; Paulson, KE; Yee, AS				Kim, JY; Zhang, XW; Rieger-Christ, KM; Summerhayes, IC; Wazer, DE; Paulson, KE; Yee, AS			Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells - Requirement of the transcriptional repressor HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; C-MYC; BETA-CATENIN; PATHWAY; GENE; TARGET; PROLIFERATION; ACTIVATION; EXPRESSION; MECHANISM	Genetic and biochemical de-regulation of Wnt signaling is correlated with breast and other cancers. Our goal was to identify compounds that block Wnt signaling as a first step toward investigating new strategies for suppression of invasive and other breast cancers. In a limited phytonutrient screen, EGCG ((-)- epigallocatechin 3-gallate), the major phytochemical in green tea, emerged as an intriguing candidate. Epidemiological studies have associated green tea consumption with reduced recurrence of invasive and other breast cancers. Wnt signaling was inhibited by EGCG in a dose-dependent manner in breast cancer cells. The apparent mechanism targeted the HBP1 transcriptional repressor, which we had previously characterized as a suppressor of Wnt signaling. EGCG treatment induced HBP1 transcriptional repressor levels through an increase in HBP1 mRNA stability, but not transcriptional initiation. To test functionality, DNA-based short hairpin RNA (shRNA) was used to knockdown the endogenous HBP1 gene. Consistently, the HBP1 knockdown lines had reduced sensitivity to EGCG in the suppression of Wnt signaling and of a target gene (c-MYC). Because our ongoing studies clinically link abrogation of HBP1 with invasive breast cancer, we tested if EGCG also regulated biological functions associated with de-regulated Wnt signaling and with invasive breast cancer. EGCG reduced both breast cancer cell tumorigenic proliferation and invasiveness in an HBP1-dependent manner. Together, the emerging mechanism is that EGCG blocks Wnt signaling by inducing the HBP1 transcriptional repressor and inhibits aspects of invasive breast cancer. These studies provide a framework for considering future studies in breast cancer treatment and prevention.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Nutr Sci & Policy, Program Cell & Mol Nutr, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Lahey Clin Fdn, Cell & Mol Biol Lab, RE Wise MD Res & Educ Inst, Burlington, MA 01805 USA	Tufts University; Tufts University; Tufts Medical Center; Lahey Hospital & Medical Center	Yee, AS (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	amy.yee@tufts.edu		Kim, Jiyoung/0000-0002-0049-2039	NCI NIH HHS [CA-94187, CA-104236] Funding Source: Medline; NIDDK NIH HHS [1DK59400, P30-DK34928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104236, R01CA094187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059400, P30DK034928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arends JW, 2000, J PATHOL, V190, P412; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Chow HHS, 2003, CLIN CANCER RES, V9, P3312; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harris J.R., 2000, DIS BREAST; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Howe LR, 2003, CANCER RES, V63, P1906; Inoue M, 2001, CANCER LETT, V167, P175, DOI 10.1016/S0304-3835(01)00486-4; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; Musgrove EA, 2004, BREAST CANCER RES, V6, P65, DOI 10.1186/bcr737; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Pisters KMW, 2001, J CLIN ONCOL, V19, P1830, DOI 10.1200/JCO.2001.19.6.1830; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Robanus-Maandag EC, 2003, J PATHOL, V201, P75, DOI 10.1002/path.1385; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Sartippour MR, 2001, NUTR CANCER, V40, P149, DOI 10.1207/S15327914NC402_11; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Wu AH, 2003, INT J CANCER, V106, P574, DOI 10.1002/ijc.11259; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yee AS, 1999, PEDIATR PATHOL MOL M, V18, P275; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	49	154	160	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10865	10875		10.1074/jbc.M513378200	http://dx.doi.org/10.1074/jbc.M513378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495219	hybrid			2022-12-25	WOS:000236822200026
J	Xu, Y; Liu, C; Clark, JC; Whitsett, JA				Xu, Y; Liu, C; Clark, JC; Whitsett, JA			Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR Delta 508 in the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FACTOR-BINDING PROTEIN-3; GROWTH-FACTOR-I; NONSELECTIVE CATION CHANNEL; INDUCIBLE EARLY GENE-1; CHLORIDE CHANNELS; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; MEDIATES APOPTOSIS; ARACHIDONIC-ACID; DELTA-F508 CFTR	Cystic fibrosis (CF), a common lethal pulmonary disorder in Caucasians, is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene ( CFTR) that disturbs fluid homeostasis and host defense in target organs. The effects of CFTR and Delta 508-CFTR were assessed in transgenic mice that 1) lack CFTR expression (Cftr(-/-)); 2) express the human Delta 508 CFTR (CFTR Delta 508); 3) overexpress the normal human CFTR (CFTRtg) in respiratory epithelial cells. Genes were selected from Affymetrix Murine GeneChips analysis and subjected to functional classification, k-means clustering, promoter cis-elements/modules searching, literature mining, and pathway exploring. Genomic responses to Cftr(-/-) were not corrected by expression of CFTR Delta 508. Genes regulating host defense, inflammation, fluid and electrolyte transport were similarly altered in Cftr(-/-) and CFTR Delta 508 mice. CFTR Delta 508 induced a primary disturbance in expression of genes regulating redox and antioxidant systems. Genomic responses to CFTRtg were modest and were not associated with lung pathology. CFTRtg and CFTR Delta 508 induced genes encoding heat shock proteins and other chaperones but did not activate the endoplasmic reticulum-associated degradation pathway. RNAs encoding proteins that directly interact with CFTR were identified in each of the CFTR mouse models, supporting the hypothesis that CFTR functions within amultiprotein complex whose members interact at the level of protein-protein interactions and gene expression. Promoters of genes influenced by CFTR shared common regulatory elements, suggesting that their co-expression may be mediated by shared regulatory mechanisms. Genes and pathways involved in the response to CFTR may be of interest as modifiers of CF.	Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Dept Pediat, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Dept Pediat, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Xu, Y (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yan.xu@cchmc.org		, Yan/0000-0003-2025-027X				Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; BAKER RT, 1992, GENOMICS, V14, P520, DOI 10.1016/S0888-7543(05)80258-7; Barski OA, 2004, GENOMICS, V83, P119, DOI 10.1016/S0888-7543(03)00213-1; Berruyer C, 2004, MOL CELL BIOL, V24, P7214, DOI 10.1128/MCB.24.16.7214-7224.2004; Cai Zhiwei, 2004, J Cyst Fibros, V3 Suppl 2, P141, DOI 10.1016/j.jcf.2004.05.030; Cantin AM, 2004, CURR OPIN PULM MED, V10, P531, DOI 10.1097/01.mcp.0000138997.29276.a1; Cayrol C, 1996, J BIOL CHEM, V271, P31799, DOI 10.1074/jbc.271.50.31799; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clain J, 2005, HUM GENET, V116, P454, DOI 10.1007/s00439-004-1246-z; Clain J, 2005, HUM MUTAT, V25, P360, DOI 10.1002/humu.20156; Corazzari M, 2003, MOL PHARMACOL, V64, P1370, DOI 10.1124/mol.64.6.1370; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; Genter MB, 2003, PHYSIOL GENOMICS, V16, P67, DOI 10.1152/physiolgenomics.00117.2003; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; HARRIS A, 1991, DEVELOPMENT, V113, P305; Hatayama T, 1998, BIOCHEM BIOPH RES CO, V248, P395, DOI 10.1006/bbrc.1998.8979; Hiyama TY, 2004, J NEUROSCI, V24, P9276, DOI 10.1523/JNEUROSCI.2795-04.2004; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; Hudson Valerie M, 2004, Treat Respir Med, V3, P353, DOI 10.2165/00151829-200403060-00003; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Hutton JJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-82; Igase M, 2001, CLIN SCI, V100, P275, DOI 10.1042/CS20000220; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jegga AG, 2005, NUCLEIC ACIDS RES, V33, pW408, DOI 10.1093/nar/gki486; Jiang QS, 1998, EUR J HUM GENET, V6, P12, DOI 10.1038/sj.ejhg.5200158; Johannessen M, 2003, BIOCHEM PHARMACOL, V65, P1317, DOI 10.1016/S0006-2952(03)00071-6; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; KERSTING U, 1993, P NATL ACAD SCI USA, V90, P4047, DOI 10.1073/pnas.90.9.4047; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Kida Y, 2004, NEW ENGL J MED, V350, P2000; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Kutsuwada K, 1999, BBA-GENE STRUCT EXPR, V1444, P92, DOI 10.1016/S0167-4781(98)00269-3; Lebeau C, 2002, PFLUG ARCH EUR J PHY, V444, P722, DOI 10.1007/s00424-002-0880-3; Lebl J, 2001, ACTA PAEDIATR, V90, P868, DOI 10.1080/08035250152509564; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mastruzzo C, 2002, Monaldi Arch Chest Dis, V57, P173; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Miyoshi T, 1999, BIOCHEM BIOPH RES CO, V265, P13, DOI 10.1006/bbrc.1999.1622; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; Mouchel N, 2004, BIOCHEM J, V378, P909, DOI 10.1042/BJ20031157; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Nikitin A, 2003, BIOINFORMATICS, V19, P2155, DOI 10.1093/bioinformatics/btg290; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Novichkova S, 2003, BIOINFORMATICS, V19, P1699, DOI 10.1093/bioinformatics/btg207; Nuthall HN, 1999, BIOCHEM J, V341, P601, DOI 10.1042/0264-6021:3410601; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ozen M, 2004, PEDIATR INT, V46, P429, DOI 10.1111/j.1442-200x.2004.01925.x; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, ANTIOXID REDOX SIGN, V1, P425, DOI 10.1089/ars.1999.1.4-425; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; RIORDAN JR, 1989, SCIENCE, V245, P1066; Ropeleski MJ, 2005, GASTROENTEROLOGY, V129, P170, DOI 10.1053/j.gastro.2005.05.017; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Sashchenko LP, 2004, J BIOL CHEM, V279, P2117, DOI 10.1074/jbc.M307513200; Satoh J, 2000, MOL CELL ENDOCRINOL, V160, P165, DOI 10.1016/S0303-7207(99)00214-2; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schraw TD, 2003, BIOCHEM J, V374, P207, DOI 10.1042/BJ20030610; Smith AN, 1996, J BIOL CHEM, V271, P9947, DOI 10.1074/jbc.271.17.9947; SNOUWAERT JN, 1995, AM J RESP CRIT CARE, V151, pS59, DOI 10.1164/ajrccm/151.3_Pt_2.S59; Steger B, 2004, NEW ENGL J MED, V350, P2000; Strandvik B, 2004, NEW ENGL J MED, V350, P605, DOI 10.1056/NEJMe038217; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang H, 2004, EUR J NEUROSCI, V20, P2049, DOI 10.1111/j.1460-9568.2004.03650.x; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Watanabe E, 2002, NEUROSCI LETT, V330, P109, DOI 10.1016/S0304-3940(02)00708-5; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; Xu Y, 2003, J BIOL CHEM, V278, P7674, DOI 10.1074/jbc.M210277200; Yamagishi N, 2004, J BIOL CHEM, V279, P41727, DOI 10.1074/jbc.M407947200; Yoneda-Kato N, 1999, ONCOGENE, V18, P3716, DOI 10.1038/sj.onc.1202711; ZHOU L, 1994, SCIENCE, V266, P1705, DOI 10.1126/science.7527588	107	26	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11279	11291		10.1074/jbc.M512072200	http://dx.doi.org/10.1074/jbc.M512072200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16455659	hybrid			2022-12-25	WOS:000236822200071
J	Assmann, EM; Alborghetti, MR; Camargo, MER; Kobarg, J				Assmann, EM; Alborghetti, MR; Camargo, MER; Kobarg, J			FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 2-HYBRID SYSTEM; RETINOIC ACID; MOUSE CDNA; COMPLEX; IDENTIFICATION; DOMAIN; SCHIZOPHRENIA; CELLS; GENE	The fasciculation and elongation protein zeta 1 (FEZ1) is a mammalian orthologue of the Caenorhabditis elegans protein UNC-76, which is necessary for axon growth in that nematode. In previous studies FEZ1 has been found to interact with protein kinase C zeta, DISC1, the agnoprotein of the human polyomavirus JC virus, and E4B, a U-box-type ubiquitin-protein isopeptide ligase. We reported previously that FEZ1 and its paralogue FEZ2 are proteins that interact with NEK1, a protein kinase involved in polycystic kidney disease and DNA repair mechanisms at the G(2)/M phase of the cell cycle. Here we report the identification of 16 proteins that interact with human FEZ1-( 221 - 396) in a yeast two-hybrid assay of a human fetal brain cDNA library. The 13 interacting proteins of known functions take part either in transcription regulation and chromatin remodeling ( 6 proteins), the regulation of neuronal cell development ( 2 proteins) and cellular transport mechanisms ( 3 proteins) or participate in apoptosis ( 2 proteins). We were able to confirm eight of the observed interactions by in vitro pull-down assays with recombinant fusion proteins. The confirmed interacting proteins include FEZ1 itself and three transcription controlling proteins (SAP30L, DRAP1, and BAF60a). In mapping studies we found that the C-terminal regions of FEZ1, and especially its coiled-coil region, are involved in its dimerization, its heterodimerization with FEZ2, and in the interaction with 10 of the identified interacting proteins. Our results give further support to the previous speculation of the functional involvement of FEZ1 in neuronal development but suggest further that FEZ1 may also be involved in transcriptional control.	Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, BR-13084970 Campinas, SP, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas	Kobarg, J (corresponding author), Ctr Biol Mol Estrutural, Lab Nacl Luz Sincrotron, Rua Giuseppe Maximo Scolfaro 10-000,CP 6192, BR-13084971 Campinas, SP, Brazil.	jkobarg@lnls.br	Alborghetti, Marcos/K-7547-2012; Kobarg, Jörg/T-4736-2019	Alborghetti, Marcos/0000-0003-4517-5579; Kobarg, Jörg/0000-0002-9419-0145				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Buther K, 2004, BIOCHEM BIOPH RES CO, V317, P703, DOI 10.1016/j.bbrc.2004.03.107; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Clabecq A, 2000, J BIOL CHEM, V275, P31786, DOI 10.1074/jbc.M003705200; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Fujita T, 2004, BIOCHEM BIOPH RES CO, V313, P738, DOI 10.1016/j.bbrc.2003.12.006; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Gindhart JG, 2003, MOL BIOL CELL, V14, P3356, DOI 10.1091/mbc.E02-12-0800; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jung HY, 2005, HEPATOL RES, V31, P143, DOI 10.1016/j.hepres.2004.12.006; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kamiya A, 2005, NAT CELL BIOL, V7, P1167, DOI 10.1038/ncb1328; Kitamura M, 2002, NEPHROL DIAL TRANSPL, V17, P84, DOI 10.1093/ndt/17.suppl_9.84; Kremerskothen J, 2003, BIOCHEM BIOPH RES CO, V300, P862, DOI 10.1016/S0006-291X(02)02945-5; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Lindfors K, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-53; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Naghavi MH, 2005, GENE DEV, V19, P1105, DOI 10.1101/gad.1290005; Oishi H, 1998, J BIOL CHEM, V273, P34580, DOI 10.1074/jbc.273.51.34580; Okumura F, 2004, J BIOL CHEM, V279, P53533, DOI 10.1074/jbc.M402916200; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Park EJ, 1999, NUCLEIC ACIDS RES, V27, P1524, DOI 10.1093/nar/27.6.1524; Quarmby LM, 2005, J CELL SCI, V118, P5161, DOI 10.1242/jcs.02681; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Surpili MJ, 2003, BIOCHEMISTRY-US, V42, P15369, DOI 10.1021/bi034575v; Suzuki T, 2005, J BIOL CHEM, V280, P24948, DOI 10.1074/jbc.M411499200; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	51	37	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9869	9881		10.1074/jbc.M513280200	http://dx.doi.org/10.1074/jbc.M513280200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484223	hybrid			2022-12-25	WOS:000236594300008
J	Han, J; Goldstein, LA; Gastman, BR; Rabinowich, H				Han, J; Goldstein, LA; Gastman, BR; Rabinowich, H			Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GRANZYME-B; T-CELLS; BAX; CLEAVAGE; PROTEINS; DEATH; SMAC/DIABLO; BCL-2; MECHANISMS	The current study demonstrates a novel cross-talk mechanism between the TRAIL receptor death signaling pathway and the mitochondria. This newly identified pathway is regulated at the mitochondrial outer membrane by a complex between the prosurvival Bcl-2 member, Mcl-1 and the BH3-only protein, Bim. Under non-apoptotic conditions, Bim is sequestered by Mcl-1. Direct degradation of Mcl-1 by TRAIL-activated caspase-8 or caspase-3 produces Mcl-1-free Bim that mediates a Bax-dependent apoptotic cascade. Using Mcl-1 or Bim RNAi, we demonstrate that a loss in Mcl-1 expression significantly enhances the mitochondrial apoptotic response to TRAIL that is now mediated by freed Bim. Whereas overexpression of Mcl-1 contributes to the preservation of the mitochondrial membrane potential, Mcl-1 knockdown facilitates the Bim-mediated dissipation of this potential. Loss of Mcl-1 contributes to an increased level of caspase activity downstream of the mitochondrial response to TRAIL. Furthermore, the Mcl-1 expression level at the mitochondrial outer membrane determines the release efficiency for the apoptogenic proteins cytochrome c, Smac, and HtrA2 in response to Bim. These are the first findings to demonstrate the involvement of Bim in the TRAIL-mediated mitochondrial cascade. They also suggest that Mcl-1 may serve as a direct substrate for TRAIL-activated caspases implying the existence of a novel TRAIL/caspase-8/Mcl-1/Bim communication mechanism between the extrinsic and the intrinsic apoptotic pathways.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Plast Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil Rm G17c,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NCI NIH HHS [R01 CA 109285] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Johnson DE, 2000, CANCER RES, V60, P1818; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Ravi R, 2002, CANCER RES, V62, P1583; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200	29	160	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10153	10163		10.1074/jbc.M510349200	http://dx.doi.org/10.1074/jbc.M510349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478725	hybrid			2022-12-25	WOS:000236594300041
J	Liu, YX; Cheng, K; Gong, K; Fu, AKY; Ip, NY				Liu, YX; Cheng, K; Gong, K; Fu, AKY; Ip, NY			Pctaire1 phosphorylates N-ethylmaleimide-sensitive fusion protein - Implications in the regulation of its hexamerization and exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; NEUROTRANSMITTER RELEASE; SYNAPSIN-I; BINDING; CDK5; ATP; FAMILY; DOMAIN; NSF; IDENTIFICATION	Pctaire1, a member of the cyclin-dependent kinase (Cdk)-related family, has recently been shown to be phosphorylated and regulated by Cdk5/p35. Although Pctaire1 is expressed in both neuronal and non-neuronal cells, its precise functions remain elusive. We performed a yeast two-hybrid screen to identify proteins that interact with Pctaire1. N-Ethylmaleimide- sensitive fusion protein (NSF), a crucial factor in vesicular transport and membrane fusion, was identified as one of the Pctaire1 interacting proteins. We demonstrate that the D2 domain of NSF, which is required for the oligomerization of NSF subunits, binds directly to and is phosphorylated by Pctaire1 on serine 569. Mutation of this phosphorylation site on NSF (S569A) augments its ability to oligomerize. Moreover, inhibition of Pctaire1 activity by transfecting its kinase-dead (KD) mutant into COS-7 cells enhances the self-association of NSF. Interestingly, Pctaire1 associates with NSF and synaptic vesicle-associated proteins in adult rat brain. To investigate whether Pctaire1 phosphorylation of NSF is involved in regulation of Ca2+-dependent exocytosis, we examined the effect of expressing Pctaire1 or NSF phosphorylation mutants on the regulated secretion of growth hormone from PC12 cells. Interestingly, expression of either Pctaire1-KD or NSF-S569A in PC12 cells significantly increases high K+-stimulated growth hormone release. Taken together, our findings provide the first demonstration that Pctaire1 phosphorylation of NSF regulates the ability of NSF to oligomerize, implicating an unexpected role of this kinase in modulating exocytosis. These findings open a new avenue of research in studying the functional roles of Pctaire1 in the nervous system.	Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK		Fu, Kit Yu/0000-0003-4085-6201; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Graeser R, 2002, J CELL SCI, V115, P3479; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Matveeva EA, 2001, J BIOL CHEM, V276, P12174, DOI 10.1074/jbc.M007394200; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Morgan A, 2004, CURR BIOL, V14, pR968, DOI 10.1016/j.cub.2004.10.045; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OKUDA T, 1992, ONCOGENE, V7, P2249; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; Schweizer FE, 1998, SCIENCE, V279, P1203, DOI 10.1126/science.279.5354.1203; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Tolar LA, 1998, J NEUROSCI, V18, P10250; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Whiteheart SW, 2004, J STRUCT BIOL, V146, P32, DOI 10.1016/j.jsb.2003.09.015; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	39	49	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9852	9858		10.1074/jbc.M513496200	http://dx.doi.org/10.1074/jbc.M513496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461345	hybrid			2022-12-25	WOS:000236594300006
J	Saitoh, T; Ikegami, T; Nakayama, M; Teshima, K; Akutsu, H; Hase, T				Saitoh, T; Ikegami, T; Nakayama, M; Teshima, K; Akutsu, H; Hase, T			NMR study of the electron transfer complex of plant ferredoxin and sulfite reductase - Mapping the interaction sites of ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; BINDING-SITES; CLONING	Plant ferredoxin serves as the physiological electron donor for sulfite reductase, which catalyzes the reduction of sulfite to sulfide. Ferredoxin and sulfite reductase form an electrostatically stabilized 1:1 complex for the intermolecular electron transfer. The protein-protein interaction between these proteins from maize leaves was analyzed by nuclear magnetic resonance spectroscopy. Chemical shift perturbation and cross-saturation experiments successfully mapped the location of two major interaction sites of ferredoxin: region 1 including Glu-29, Glu-30, and Asp-34 and region 2 including Glu-92, Glu-93, and Glu-94. The importance of these two acidic patches for interaction with sulfite reductase was confirmed by site-specific mutation of acidic ferredoxin residues in regions 1 and 2, separately and in combination, by which the ability of mutant ferredoxins to transfer electrons and bind to sulfite reductase was additively lowered. Taken together, this study gives a clear illustration of the molecular interaction between ferredoxin and sulfite reductase. We also present data showing that this interaction surface of ferredoxin significantly differs from that when ferredoxin-NADP(+) reductase is the interaction partner.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan	Osaka University; Hiroshima University	Saitoh, T (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	enzyme@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013; Ikegami, Takahisa/I-9626-2017	Ikegami, Takahisa/0000-0002-1429-1844; Akutsu, Hideo/0000-0001-7236-5285				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Crowley PB, 2002, J BIOL CHEM, V277, P48685, DOI 10.1074/jbc.M203983200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; Garcia-Sanchez MI, 2000, J BIOL INORG CHEM, V5, P713, DOI 10.1007/s007750000160; HASE T, 1991, PLANT PHYSIOL, V96, P77, DOI 10.1104/pp.96.1.77; Hirasawa M, 2005, PHOTOSYNTH RES, V86, P325, DOI 10.1007/s11120-005-6966-y; HIRASAWA M, 1987, FEBS LETT, V221, P343, DOI 10.1016/0014-5793(87)80953-5; Hirasawa M, 2004, BBA-BIOENERGETICS, V1608, P140, DOI 10.1016/j.bbabio.2003.11.004; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; Knaff D.B., 1996, OXYGENIC PHOTOSYNTHE, V4, P333; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; Nakanishi T, 2002, J MOL BIOL, V318, P245, DOI 10.1016/S0022-2836(02)00018-9; Nakayama M, 2000, J INORG BIOCHEM, V82, P27, DOI 10.1016/S0162-0134(00)00138-0; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Yonekura-Sakakibara K, 2000, PLANT PHYSIOL, V122, P887, DOI 10.1104/pp.122.3.887; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	25	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10482	10488		10.1074/jbc.M510530200	http://dx.doi.org/10.1074/jbc.M510530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469743	hybrid			2022-12-25	WOS:000236594300077
J	Teixeira, M; Viengchareun, S; Butlen, D; Ferreira, C; Cluzeaud, F; Blot-Chabaud, M; Lombes, M; Ferrary, E				Teixeira, M; Viengchareun, S; Butlen, D; Ferreira, C; Cluzeaud, F; Blot-Chabaud, M; Lombes, M; Ferrary, E			Functional I-sK/KvLQT1 potassium channel in a new corticosteroid-sensitive cell line derived from the inner ear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LANGE-NIELSEN-SYNDROME; VESTIBULAR DARK CELLS; HUMAN MINERALOCORTICOID RECEPTOR; TRANSGENIC MOUSE MODELS; STRIAL MARGINAL CELLS; GUINEA-PIG; TARGETED ONCOGENESIS; MENIERES-DISEASE; XENOPUS-OOCYTES; PROTEIN-KINASE	Endolymph, a high K+/low Na+ fluid, participates in mechanoelectrical transduction in inner ear. Molecular mechanisms controlling endolymph ion homeostasis remain elusive, hampered by the lack of appropriate cellular models. We established an inner ear cell line by targeted oncogenesis. The expression of SV40 T antigen was driven by the proximal promoter of the human mineralocorticoid receptor (MR) gene, a receptor expressed in the inner ear. The EC5v cell line, microdissected from the semicircular canal, grew as a monolayer of immortalized epithelial cells forming domes. EC5v cells exhibited on filters of high transepithelial resistance and promoted K+ secretion and Na+ absorption. Functional MR and the 11 beta-hydroxysteroid dehydrogenase type 2, a key enzyme responsible for MR selectivity were identified. Expression of the epithelial sodium channel and serum glucocorticoid-regulated kinase 1 was shown to be up-regulated by aldosterone, indicating that EC5v represents a novel corticosteroid-sensitive cell line. Ionic measurements and Rb-86 transport assays revealed an apical secretion of K+ at least in part through the I-sK/KvLQT1 potassium channel under standard culture conditions. However, when cells were apically exposed to high K+/low Na+ fluid, mimicking endolymph exposure, I-sK/KvLQT1 actually functioned as a strict apical to basolateral K+ channel inhibited by clofilium. Quantitative reverse transcriptase-PCR further demonstrated that expression of KvLQT1 but not of I-sK was down-regulated by high K+ concentration. This first vestibular cellular model thus constitutes a valuable system to further investigate the molecular mechanisms controlling ionic transports in the inner ear and the pathophysiological consequences of their dysfunctions in vertigo and hearing loss.	Univ Paris 07, Fac Med Xavier Bichat, INSERM, EMI U0112, F-75870 Paris 18, France; Univ Paris 07, Fac Med Xavier Bichat, INSERM, U478, F-75870 Paris 18, France; Univ Paris 11, Fac Med Paris Sud, INSERM, U693, F-94276 Le Kremlin Bicetre, France; Univ Paris 07, Inst Federat Rech Claude Bernard, F-75870 Paris 18, France; Fac Pharm Marseille, INSERM, U608, F-13005 Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferrary, E (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM, EMI U0112, 16 Rue Henri Huchard, F-75870 Paris 18, France.	ferrary@bichat.inserm.fr	Lombes, Marc/L-5933-2018; Viengchareun, Say/M-6612-2017; Viengchareun, Say/GOV-6812-2022; Blot-Chabaud, Marcel/D-4064-2017	Lombes, Marc/0000-0003-3189-023X; Ferrary, Evelyne/0000-0003-0066-8556; viengchareun, say/0000-0003-4280-3250; Ferreira, Chrystophe/0000-0002-1990-278X				ACHOUCHE J, 1991, ANN OTO RHINOL LARYN, V100, P999, DOI 10.1177/000348949110001208; Agrup C, 1996, HEARING RES, V102, P155, DOI 10.1016/S0378-5955(96)00156-6; ANNIKO M, 1979, ARCH OTO-RHINO-LARYN, V225, P161, DOI 10.1007/BF00455250; BlotChabaud M, 1996, KIDNEY INT, V50, P367, DOI 10.1038/ki.1996.325; Bosch RF, 2002, CARDIOVASC RES, V56, P393, DOI 10.1016/S0008-6363(02)00601-6; BRIAND P, 1995, KIDNEY INT, V47, P388, DOI 10.1038/ki.1995.51; Couloigner V, 2001, AM J PHYSIOL-RENAL, V280, pF214, DOI 10.1152/ajprenal.2001.280.2.F214; Dunnebier EA, 1997, ACTA OTO-LARYNGOL, V117, P13, DOI 10.3109/00016489709117984; FERRARY E, 1989, AM J PHYSIOL, V257, pF182, DOI 10.1152/ajprenal.1989.257.2.F182; Feunteun J, 1997, HORM RES, V47, P137, DOI 10.1159/000185456; FURUTA H, 1994, HEARING RES, V78, P175, DOI 10.1016/0378-5955(94)90023-X; Kathofer S, 2003, N-S ARCH PHARMACOL, V368, P119, DOI 10.1007/s00210-003-0772-x; Le Menuet D, 2004, MOL CELL ENDOCRINOL, V217, P127, DOI 10.1016/j.mce.2003.10.045; Le Menuet D, 2000, KIDNEY INT, V57, P1299, DOI 10.1046/j.1523-1755.2000.00966.x; Lee JH, 2002, AUDIOL NEURO-OTOL, V7, P100, DOI 10.1159/000057657; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; Mateijsen DJM, 2001, ORL-J OTO-RHIN-LARYN, V63, P280, DOI 10.1159/000055758; MELLON PL, 1991, RECENT PROG HORM RES, V47, P69; Milhaud PG, 1999, PFLUG ARCH EUR J PHY, V437, P823, DOI 10.1007/s004240050851; MIZUTA K, 1995, HEARING RES, V88, P199, DOI 10.1016/0378-5955(95)00113-I; MORI N, 1993, EUR ARCH OTO-RHINO-L, V250, P186; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Nicolas MT, 2001, HEARING RES, V153, P132, DOI 10.1016/S0378-5955(00)00268-9; PAPARELLA MM, 1985, ACTA OTO-LARYNGOL, V99, P445, DOI 10.3109/00016488509108936; PITOVSKI DZ, 1993, HEARING RES, V69, P10, DOI 10.1016/0378-5955(93)90088-I; Pitovski DZ, 1996, ACTA OTO-LARYNGOL, V116, P737, DOI 10.3109/00016489609137916; Pondugula SR, 2004, AM J PHYSIOL-RENAL, V286, pF1127, DOI 10.1152/ajprenal.00387.2003; Potet F, 2001, AM J PHYSIOL-HEART C, V280, pH2038, DOI 10.1152/ajpheart.2001.280.5.H2038; RAREY KE, 1989, HEARING RES, V41, P217, DOI 10.1016/0378-5955(89)90013-0; Rivas A, 2005, OTOL NEUROTOL, V26, P415, DOI 10.1097/01.mao.0000169764.00798.84; Rivolta MN, 2002, J NEUROBIOL, V53, P306, DOI 10.1002/neu.10111; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tadros SF, 2005, AUDIOL NEURO-OTOL, V10, P44, DOI 10.1159/000082307; TENCATE WJF, 1991, ARCH OTOLARYNGOL, V117, P96; Tu TY, 1999, HEARING RES, V127, P149, DOI 10.1016/S0378-5955(98)00192-0; Tu TY, 1999, ACTA OTO-LARYNGOL, V119, P544; Tu TY, 1998, HEARING RES, V123, P97, DOI 10.1016/S0378-5955(98)00101-4; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANGEMANN P, 1995, HEARING RES, V84, P19, DOI 10.1016/0378-5955(95)00009-S; Wangemann P, 1996, HEARING RES, V100, P201, DOI 10.1016/0378-5955(96)00127-X; Wangemann P, 2002, AUDIOL NEURO-OTOL, V7, P199, DOI 10.1159/000063736; WANGEMANN P, 1994, AM J PHYSIOL, V266, pC1046, DOI 10.1152/ajpcell.1994.266.4.C1046; Yao XF, 1996, ACTA OTO-LARYNGOL, V116, P493, DOI 10.3109/00016489609137879; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; [No title captured]	47	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10496	10507		10.1074/jbc.M512254200	http://dx.doi.org/10.1074/jbc.M512254200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478723	hybrid			2022-12-25	WOS:000236594300079
J	Zygadlo, A; Robinson, C; Scheller, HV; Mant, A; Jensen, PE				Zygadlo, A; Robinson, C; Scheller, HV; Mant, A; Jensen, PE			The properties of the positively charged loop region in PSI-G are essential for its "spontaneous" insertion into thylakoids and rapid assembly into the photosystem I complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SEC-INDEPENDENT INSERTION; MEMBRANE-PROTEINS; SUBUNIT; TRANSLOCATION; CONFORMATION; COMPONENT; PEPTIDES; PSBW	The PSI-G subunit of photosystem I (PSI) is an 11-kDa membrane protein that plays an important role in electron transport between plastocyanin and PSI and is involved in the stability of the PSI complex. Within the complex, the PSI-G subunit is bound to PSI-B and is in contact with Lhca1. PSI-G has two transmembrane spans connected by a positively charged stromal loop. The loop is inaccessible to proteases, indicating a tightly bound location within the PSI complex. Here, we have studied the insertion mechanism and assembly of PSI-G. We show that the protein inserts into thylakoids by a direct or "spontaneous" pathway that does not involve the activities of any known chloroplast protein-targeting machinery. Surprisingly, the positively charged stromal loop region plays a major role in this process. Mutagenesis or deletions within this region almost invariably lead to a marked lowering of insertion efficiency, strongly indicating a critical role for the loop in the organization of the transmembrane regions prior to or during membrane insertion. Finally, we have examined the assembly of newly inserted PSI-G into the PSI complex, since very little is known of the assembly pathway for this large multimeric complex. Interestingly, we find that inserted PSI-G can be found within the full PSI complex within the import assay time frame after insertion into thylakoids, strongly suggesting that PSI-G normally associates at the end of the assembly process. This is consistent with its location on the periphery of the complex.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1870 Frederiksberg, Denmark; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Copenhagen; University of Warwick; University of Southampton	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1870 Frederiksberg, Denmark.	peje@kvl.dk	Scheller, Henrik V/A-8106-2008; Jensen, Poul Erik/A-4862-2014; Scheller, Henrik/AAH-4770-2020; Zygadlo Nielsen, Agnieszka/J-4850-2016	Scheller, Henrik V/0000-0002-6702-3560; Jensen, Poul Erik/0000-0001-6524-7723; Scheller, Henrik/0000-0002-6702-3560; Zygadlo Nielsen, Agnieszka/0000-0002-7948-8912; Mant, Alexandra/0000-0001-7169-209X				Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Brambillasca S, 2005, EMBO J, V24, P2533, DOI 10.1038/sj.emboj.7600730; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; CLINE K, 1989, J BIOL CHEM, V264, P14225; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; HOYERHANSEN G, 1988, PLANTA, V173, P12, DOI 10.1007/BF00394481; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Jarvis P, 2004, CURR BIOL, V14, pR1064, DOI 10.1016/j.cub.2004.11.049; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jolley C, 2005, J BIOL CHEM, V280, P33627, DOI 10.1074/jbc.M500937200; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P12189; Nielsen VS, 1996, PHYSIOL PLANTARUM, V98, P637, DOI 10.1111/j.1399-3054.1996.tb05721.x; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Robinson C, 2002, PRACT APPROACH SER, V259, P123; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; Rosgaard L, 2005, FEBS J, V272, P4002, DOI 10.1111/j.1742-4658.2005.04824.x; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Tissier C, 2002, EUR J BIOCHEM, V269, P3131, DOI 10.1046/j.1432-1033.2002.02943.x; Woolhead CA, 2001, J BIOL CHEM, V276, P14607, DOI 10.1074/jbc.M009600200; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Zygadlo A, 2005, BBA-BIOENERGETICS, V1708, P154, DOI 10.1016/j.bbabio.2005.02.003	33	14	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10548	10554		10.1074/jbc.M512687200	http://dx.doi.org/10.1074/jbc.M512687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478728	hybrid			2022-12-25	WOS:000236594300085
J	Ding, J; Li, JX; Chen, JY; Chen, HB; Ouyang, WM; Zhang, RH; Xue, CF; Zhang, DY; Amin, S; Desai, D; Huang, CS				Ding, J; Li, JX; Chen, JY; Chen, HB; Ouyang, WM; Zhang, RH; Xue, CF; Zhang, DY; Amin, S; Desai, D; Huang, CS			Effects of polycyclic aromatic hydrocarbons (PAHs) on vascular endothelial growth factor induction through phosphatidylinositol 3-kinase/AP-1-dependent, HIF-1 alpha-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATOR PROTEIN-1 ACTIVATION; CANCER MUTATIONAL HOTSPOTS; PHOSPHOINOSITIDE 3-KINASE; AP-1 TRANSACTIVATION; CELL-TRANSFORMATION; CATALYTIC SUBUNIT; DIOL-EPOXIDE; FACTOR VEGF; EXPRESSION	Previous studies have demonstrated that exposure to polycyclic aromatic hydrocarbons (PAHs) and its derivatives is associated with an increased risk of skin cancers, and the carcinogenic effect of PAHs is thought to involve both tumor initiation and promotion. Whereas PAH tumor initiation is well characterized, the mechanisms involved in the tumor promotion of PAHs remain elusive. In the present study, we investigated the effects of PAHs on vascular endothelial growth factor (VEGF) expression by comparison of its induction between the active metabolite and its parent compound (B[a]PDE versus B[a]P) or between active compound and its relatively inactive analog (5-MCDE versus CDE). We found that exposure of cells to (+/-)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (B[a]PDE) or (+/-)-anti-5-methylchrysene-1,2-diol-3,4-epoxide (5-MCDE) led to marked induction of VEGF in Cl41 cells, whereas benzo[a]pyrene (B[a]P) or chrysene-1,2-diol-3,4-epoxide (CDE) did not exhibit significant inductive effects. Exposure of cells to B[a]PDE and 5-MCDE did not induce HIF-1 alpha activation, whereas AP-1 was significantly activated. Moreover, overexpression of TAM67 (a dominant-negative mutant c-Jun) dramatically blocked that VEGF induction. Electrophoretic mobility shift assay showed that AP-1 was only able to specifically recognize and bind to its AP-1 potential binding site within -1136 and -1115 of the VEGF promoter region. Site-directed mutation of this AP-1 binding site eliminated the VEGF transcriptional activity induced by B[a]PDE, suggesting that the AP-1 binding site between -1136 and -1115 in the VEGF promoter region is critical for VEGF induction by B[a]PDE. In addition, overexpression of Delta p85 (a dominant-negative mutant PI-3K) impaired B[a]PDE- and 5-MCDE-induced VEGF induction. Considering our previous findings that PI3K is an upstream mediator for c-Jun/AP-1 activation, we conclude that the VEGF induction by B[a]PDE and 5-MCDE is through PI-3K/AP-1-dependent and HIF-1 alpha-independent pathways. These findings may help us to understand the mechanisms involved in PAH carcinogenic effects.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Fourth Mil Med Univ, Dept Etiol, Xian 710032, Shaanxi, Peoples R China; Fourth Mil Med Univ, Dept Occupat & Environm Hlth Sci, Xian 710032, Shaanxi, Peoples R China; Penn State Univ, Sch Med, Dept Pharmacol, Hershey, PA 17033 USA	New York University; Air Force Military Medical University; Air Force Military Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES012451, P42ES010344] Funding Source: NIH RePORTER; NCI NIH HHS [CA094964, CA103180, CA112557] Funding Source: Medline; NIEHS NIH HHS [ES000260, ES012451, ES010344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMIN S, 1985, CANCER RES, V45, P6406; [Anonymous], 1983, IARC Monogr Eval Carcinog Risk Chem Hum, V32, P1; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Brandt HCA, 2003, ANN OCCUP HYG, V47, P349, DOI 10.1093/annhyg/meg052; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CONTI CJ, 2000, CANC THERAPY S3, V7, P4; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Fuh G, 2000, J BIOL CHEM, V275, P26690; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Hecht SS, 2002, CARCINOGENESIS, V23, P907, DOI 10.1093/carcin/23.6.907; HECHT SS, 1998, NAT REV CANCER, V3, P733; Hoffmann D, 1997, PREV MED, V26, P427, DOI 10.1006/pmed.1997.0183; Huang CS, 1998, INT J ONCOL, V13, P711; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1984, IARC MON EV CARC RIS, V34, P37; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAMES EK, 2004, ANN REV PHARM TOXICO, V44, P239; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; JULIANE H, 2000, J CHROMATOGR B, V739, P225; JURGEN G, 2000, J CHROMATOGR B, V738, P47; Jyonouchi H, 1999, CARCINOGENESIS, V20, P139, DOI 10.1093/carcin/20.1.139; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LEVIN W, 1977, CANCER RES, V37, P3356; Li JX, 2004, MOL CARCINOGEN, V40, P104, DOI 10.1002/mc.20020; Li JX, 2004, ONCOGENE, V23, P3932, DOI 10.1038/sj.onc.1207501; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; MATTHIAS S, 2001, ANAL CHEM, V73, P5669; Merimsky O, 1998, CLIN DERMATOL, V16, P585, DOI 10.1016/S0738-081X(98)00043-1; Nesnow S, 1998, ENVIRON HEALTH PERSP, V106, P1337, DOI 10.1289/ehp.98106s61337; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Robinson CJ, 2001, J CELL SCI, V114, P853; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinha R, 2005, CANCER RES, V65, P8034, DOI 10.1158/0008-5472.CAN-04-3429; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Szeliga J, 2000, CHEM-BIOL INTERACT, V128, P159, DOI 10.1016/S0009-2797(00)00184-8; Tannheimer SL, 1998, CARCINOGENESIS, V19, P1291, DOI 10.1093/carcin/19.7.1291; TISCHER E, 1991, J BIOL CHEM, V266, P11947; YOU L, 1994, CARCINOGENESIS, V15, P2613, DOI 10.1093/carcin/15.11.2613	55	24	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9093	9100		10.1074/jbc.M510537200	http://dx.doi.org/10.1074/jbc.M510537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461351	hybrid			2022-12-25	WOS:000236404700014
J	Majumdar, S; Ramachandran, S; Cerione, RA				Majumdar, S; Ramachandran, S; Cerione, RA			New insights into the role of conserved, essential residues in the GTP binding/GTP hydrolytic cycle of large G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL CYCLASE; PITUITARY-TUMORS; EFFECTOR-BINDING; RAS MUTANTS; GAMMA-S; ACTIVATION; MECHANISM; MUTATIONS	The GTP hydrolytic (GTPase) reaction terminates signaling by both large (heterotrimeric) and small (Ras-related) GTP-binding proteins (G proteins). Two residues that are necessary for GTPase activity are an arginine (often called the "arginine finger") found either in the Switch I domains of the alpha subunits of large G proteins or contributed by the GTPase-activating proteins of small G proteins, and a glutamine that is highly conserved in the Switch II domains of G alpha subunits and small G proteins. However, questions still exist regarding the mechanism of the GTPase reaction and the exact role played by the Switch II glutamine. Here, we have characterized the GTP binding and GTPase activities of mutants in which the essential arginine or glutamine residue has been changed within the background of a G alpha chimera (designated alpha(T)*), comprised mainly of the alpha subunit of retinal transducin (alpha(T)) and the Switch III region from the alpha subunit of G(i1). As expected, both the alpha(T)*(R174C) and alpha(T)*(Q200L) mutants exhibited severely compromised GTPase activity. Neither mutant was capable of responding to aluminum fluoride when monitoring changes in the fluorescence of Trp-207 in Switch II, although both stimulated effector activity in the absence of rhodopsin and G beta gamma. Surprisingly, each mutant also showed some capability for being activated by rhodopsin and G beta gamma to undergo GDP-[S-35]GTP gamma S exchange. The ability of the mutants to couple to rhodopsin was not consistent with the assumption that they contained only bound GTP, prompting us to examine their nucleotide-bound states following their expression and purification from Escherichia coli. Indeed, both mutants contained bound GDP as well as GTP, with 35-45% of each mutant being isolated as GDP-P-i complexes. Overall, these findings suggest that the R174C and Q200L mutations reveal G alpha subunit states that occur subsequent to GTP hydrolysis but are still capable of fully stimulating effector activity.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Ramachandran, Sekar/AAP-2287-2020	Ramachandran, Sekar/0000-0002-2243-1368	NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NEI NIH HHS [EY6429] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berghuis AM, 1996, STRUCTURE, V4, P1277, DOI 10.1016/S0969-2126(96)00136-0; BOURNE HR, 1987, NATURE, V330, P517, DOI 10.1038/330517a0; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGEN R, 1992, BIOCHEMISTRY-US, V31, P8691, DOI 10.1021/bi00152a002; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Majumdar S, 2004, J BIOL CHEM, V279, P40137, DOI 10.1074/jbc.M405420200; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Pasqualato S, 2005, STRUCTURE, V13, P533, DOI 10.1016/j.str.2005.01.014; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	34	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9219	9226		10.1074/jbc.M513837200	http://dx.doi.org/10.1074/jbc.M513837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469737	hybrid			2022-12-25	WOS:000236404700029
J	Volovyk, ZM; Wolf, MJ; Prasad, SVN; Rockman, HA				Volovyk, ZM; Wolf, MJ; Prasad, SVN; Rockman, HA			Agonist-stimulated beta-adrenergic receptor internalization requires dynamic cytoskeletal actin turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; MEDIATED ENDOCYTOSIS; MEMBRANE; RECRUITMENT; PHOSPHORYLATION; ORGANIZATION; MODULATION; MECHANISM; BINDING	Stimulation of beta-adrenergic receptors (beta ARs) leads to sequential recruitment of beta-arrestin, AP-2 adaptor protein, clathrin, and dynamin to the receptor complex, resulting in endocytosis. Whether a dynamic actin cytoskeleton is required for beta AR endocytosis is not known. In this study, we have used beta(1)- and beta(2)ARs, two ubiquitously expressed members of the beta AR family, to comprehensively evaluate the requirement of the actin cytoskeleton in receptor internalization. The integrity of the actin cytoskeleton was manipulated with the agent latrunculin B (LB) and mutants of cofilin to depolymerize actin filaments. Treatment of cells with LB resulted in dose-dependent depolymerization of the cortical actin cytoskeleton that was associated with significant attenuation in internalization of beta(2)ARs, beta(1)ARs, and mutants of beta(1)ARs that internalize via either clathrin- or caveolin-dependent pathways. Importantly, LB treatment did not inhibit beta-arrestin translocation or dynamin recruitment to the agonist-stimulated receptor. To unequivocally demonstrate the requirement of the actin cytoskeleton for beta(2)AR endocytosis, we used an actin-binding protein cofilin that biochemically depolymerizes and severs actin filaments. Isoproterenol-mediated internalization of beta(2)AR was completely blocked in the presence of wild type cofilin, which could be rescued by a mutant of cofilin that mimics a constitutive phosphorylated state and leads to normal agonist-stimulated beta(2)AR endocytosis. Finally, treatment with jasplakinolide, an inhibitor of actin turnover, resulted in dose-dependent inhibition of beta(2)AR internalization, suggesting that turnover of actin filaments at the receptor complex is required for endocytosis. Taken together, these data demonstrate that intact and functional dynamic actin cytoskeleton is required for normal beta AR internalization.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, DUMC 3104, Durham, NC 27710 USA.	h.rockman@duke.edu		Wolf, Matthew/0000-0001-8004-4852	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061558] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61558] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Calaghan SC, 2004, PROG BIOPHYS MOL BIO, V84, P29, DOI 10.1016/S0079-6107(03)00057-9; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirasawa A, 1998, BRIT J PHARMACOL, V124, P55, DOI 10.1038/sj.bjp.0701795; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Paavilainen VO, 2004, TRENDS CELL BIOL, V14, P386, DOI 10.1016/j.tcb.2004.05.002; Pendleton A, 2003, J BIOL CHEM, V278, P14394, DOI 10.1074/jbc.M206393200; Perrino C, 2005, CIRCULATION, V111, P2579, DOI 10.1161/CIRCULATIONAHA.104.508796; Prasad SVN, 2005, NAT CELL BIOL, V7, P785, DOI 10.1038/ncb1278; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	29	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9773	9780		10.1074/jbc.M511435200	http://dx.doi.org/10.1074/jbc.M511435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461348	hybrid			2022-12-25	WOS:000236404700090
J	Wewer, UM; Morgelin, M; Holck, P; Jacobsen, J; Lydolph, MC; Johnsen, AH; Kveiborg, M; Albrechtsen, R				Wewer, UM; Morgelin, M; Holck, P; Jacobsen, J; Lydolph, MC; Johnsen, AH; Kveiborg, M; Albrechtsen, R			ADAM12 is a four-leafed clover - The excised prodomain remains bound to the mature enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; CELL; METALLOPROTEASE; DISINTEGRIN; EXPRESSION; BINDING; LOCALIZATION; PROTEASE	The ADAMs (a disintegrin and metalloprotease) comprise a family of multidomain proteins with metalloprotease, cell adhesion, and signaling activities. Human ADAM12, which is implicated in diseases such as cancer, is expressed in two splice forms, the transmembrane ADAM12-L and the shorter and soluble ADAM12-S. ADAM12 is synthesized as a zymogen with the prodomain keeping the metalloprotease inactive through a cysteine-switch mechanism. Maturation and activation of the protease involves the cleavage of the prodomain in the trans-Golgi or possibly at the cell surface by a furin-peptidase. The aim of the present study was to determine the fate of the prodomain following furin cleavage. Here we demonstrate that, following cleavage of the human ADAM12-S prodomain in the trans-Golgi by a furin-peptidase, the prodomain remains non-covalently associated with the mature molecule. Accordingly, both the 68-kDa mature form of ADAM12-S and the 25-kDa prodomain could be detected using domain-specific antisera in immuno-precipitation and Western blot analyses of human serum ADAM12 and purified recombinant human ADAM12. Using electron microscopy after negative staining we have furthermore obtained the first visualization of a full-length ADAM molecule, human ADAM12-S, and report that it appears to be a compact clover composed of four globular domains, one of which is the prodomain. Finally, our data demonstrate that the presence of the metalloprotease domain appears to be sufficient for the prodomain to remain associated with the mature ADAM12-S. Thus, we conclude that the prodomain of human ADAM12-S is an integral domain of the mature molecule and as such might have specific biological functions in the extracellular space.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Lund Univ, BMC, Dept Clin Sci, SE-22184 Lund, Sweden; Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	University of Copenhagen; Lund University; Rigshospitalet; University of Copenhagen	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	ullaw@pai.ku.dk	Kveiborg, Marie/AAM-3019-2020	Kveiborg, Marie/0000-0002-1293-1019; Albrechtsen, Reidar/0000-0003-4180-1827				Andreini C, 2005, J PROTEOME RES, V4, P881, DOI 10.1021/pr0500096; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Laigaard J, 2005, OBSTET GYNECOL, V106, P144, DOI 10.1097/01.AOG.0000165829.65319.65; Laigaard J, 2003, PRENATAL DIAG, V23, P1086, DOI 10.1002/pd.762; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lendeckel U, 2005, J CANCER RES CLIN, V131, P41, DOI 10.1007/s00432-004-0619-y; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; Oh M, 2004, BIOORG MED CHEM LETT, V14, P6071, DOI 10.1016/j.bmcl.2004.09.082; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Thodeti CK, 2005, EXP CELL RES, V309, P438, DOI 10.1016/j.yexcr.2005.06.020; Wewer UM, 2005, PROTEAS BIOL DIS, V4, P123; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	34	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9418	9422		10.1074/jbc.M513580200	http://dx.doi.org/10.1074/jbc.M513580200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455653	hybrid			2022-12-25	WOS:000236404700051
J	Xu, DS; Brumm, K; Zhang, LW				Xu, DS; Brumm, K; Zhang, LW			The latent membrane protein 1 of Epstein-Barr virus (EBV) primes EBV latency cells for type I interferon production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; TREATED HUMAN-CELLS; REGULATORY FACTOR-7; HUMAN CYTOMEGALOVIRUS; ALPHA-INTERFERON; LYMPHOMA-CELLS; SIGNAL TRANSDUCERS; POSITIVE FEEDBACK; ANTIVIRAL STATE; GENE-EXPRESSION	Epstein-Barr virus (EBV) latency has been associated with a variety of human cancers. Latent membrane protein 1 (LMP-1) is one of the key viral proteins required for transformation of primary B cells in vitro and establishment of EBV latency. We have previously shown that LMP-1 induces the expression of several interferon (IFN)-stimulated genes and has antiviral effect (Zhang, J., Das, S. C., Kotalik, C., Pattnaik, A. K., and Zhang, L. (2004) J. Biol. Chem. 279, 46335-46342). In this report, a novel mechanism related to the antiviral effect of LMP-1 is identified. We show that EBV type III latency cells, in which LMP-1 is expressed, are primed to produce robust levels of endogenous IFNs upon infection of Sendai virus. The priming action is due to the expression of LMP-1 but not EBV nuclear antigen 2 (EBNA-2). The signaling events from the C-terminal activator regions of LMP-1 are essential to prime cells for high IFN production. LMP-1-mediated activation of NF-kappa B is apparently necessary and sufficient for LMP-1-mediated priming effect in DG75 cells, a human B cell line. IFN regulatory factor 7 (IRF-7) that can be activated by LMP-1 is also implicated in the priming action. Taken together, these data strongly suggest that LMP-1 may prime EBV latency cells for IFN production and that the antiviral property of LMP-1 may be an intrinsic part of EBV latency program, which may assist the establishment and/or maintenance of viral latency.	Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Zhang, LW (corresponding author), Univ Nebraska, Nebraska Ctr Virol, E141 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	lzhang2@unlnotes.unl.edu			NATIONAL CANCER INSTITUTE [R01CA108951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059132] Funding Source: NIH RePORTER; NCI NIH HHS [CA108951] Funding Source: Medline; NCRR NIH HHS [P20RR15635] Funding Source: Medline; NIAID NIH HHS [U54 AI057160, AI59132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Carter KL, 2002, J VIROL, V76, P10427, DOI 10.1128/JVI.76.20.10427-10436.2002; Cassady KA, 2005, J VIROL, V79, P8707, DOI 10.1128/JVI.79.14.8707-8715.2005; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE PA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P167, DOI 10.1016/0167-4781(90)90161-T; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; FUJITA T, 1979, J GEN VIROL, V45, P301, DOI 10.1099/0022-1317-45-2-301; GHOSH D, 1990, J VIROL, V64, P1855, DOI 10.1128/JVI.64.4.1855-1858.1990; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Gotoh B, 2003, J VIROL, V77, P3360, DOI 10.1128/JVI.77.6.3360-3370.2003; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Hahn AM, 2005, J VIROL, V79, P10040, DOI 10.1128/JVI.79.15.10040-10052.2005; HAVELL EA, 1972, ANTIMICROB AGENTS CH, V2, P476, DOI 10.1128/AAC.2.6.476; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; KIEFF E, 1996, FIELDS VIROLOGY, V3, P2343; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; Komatsu T, 2002, FEBS LETT, V511, P139, DOI 10.1016/S0014-5793(01)03301-4; Krug LT, 2004, J VIROL, V78, P8359, DOI 10.1128/jvi.78.15.8359-8371.2004; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Monini P, 1999, J VIROL, V73, P4029, DOI 10.1128/JVI.73.5.4029-4041.1999; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; NIR U, 1984, NUCLEIC ACIDS RES, V12, P6979, DOI 10.1093/nar/12.18.6979; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; OBERMAN F, 1989, J INTERFERON RES, V9, P563, DOI 10.1089/jir.1989.9.563; OBERMAN F, 1988, J GEN VIROL, V69, P1167, DOI 10.1099/0022-1317-69-6-1167; Pozharskaya VP, 2004, J GEN VIROL, V85, P2779, DOI 10.1099/vir.0.80214-0; Richardson C, 2003, J VIROL, V77, P4439, DOI 10.1128/JVI.77.7.4439-4443.2003; RICKINSON AB, 1996, FIELDS VIROLOGY, V3, P2397; Roberts RM, 1998, J INTERF CYTOK RES, V18, P805, DOI 10.1089/jir.1998.18.805; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SHARP NA, 1989, J GEN VIROL, V70, P2521, DOI 10.1099/0022-1317-70-9-2521; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; Tolo H, 2001, J INTERF CYTOK RES, V21, P913, DOI 10.1089/107999001753289523; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhang J, 2005, J VIROL, V79, P5640, DOI 10.1128/JVI.79.9.5640-5652.2005; Zhang J, 2004, J BIOL CHEM, V279, P46335, DOI 10.1074/jbc.M403966200; ZHANG L, 2000, J VIROL, V74, P5748; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, MOL BIOTECHNOL, V14, P73, DOI 10.1385/MB:14:1:73; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700; Zhang LW, 2001, SEMIN CANCER BIOL, V11, P445, DOI 10.1006/scbi.2001.0411; Zhang LW, 2001, J VIROL, V75, P12393, DOI 10.1128/JVI.75.24.12393-12401.2001; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	71	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9163	9169		10.1074/jbc.M511884200	http://dx.doi.org/10.1074/jbc.M511884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469740	hybrid, Green Published			2022-12-25	WOS:000236404700022
J	Zhang, L; Gao, X; Wen, J; Ning, YH; Chen, YG				Zhang, L; Gao, X; Wen, J; Ning, YH; Chen, YG			Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; IDENTIFICATION; INVOLVEMENT; ACTIVATION; MESODERM; FRODO	Wnt signaling plays pivotal roles in the regulation of embryogenesis and cancer development. Xenopus Dapper (Dpr) was identified as an interacting protein for Dishevelled (Dvl), a Wnt signaling mediator, and modulates Wnt signaling. However, it is largely unclear how Dpr regulates Wnt signaling. Here, we present evidence that human Dpr1, the ortholog of Xenopus Dpr, inhibits Wnt signaling. We have identified the regions responsible for the Dpr-Dvl interaction in both proteins and found that the interaction interface is formed between the DEP ( Dishevelled, Egl-10, and pleckstrin) domain of Dvl and the central and the C-terminal regions of Dpr1. The inhibitory function of human Dpr1 requires both its N and C terminus. Overexpression of the C-terminal region corresponding to the last 225 amino acids of Dpr1, in contrast to wild-type Dpr1, enhances Wnt signaling, suggesting a dominant negative function of this region. Furthermore, we have shown that Dpr1 induces Dvl degradation via a lysosome inhibitor-sensitive and proteasome inhibitor-insensitive mechanism. Knockdown of Dpr1 by RNA interference up-regulates endogenous Dvl2 protein. Taken together, our data indicate that the inhibitory activity of Dpr on Wnt signaling is conserved from Xenopus to human and that Dpr1 antagonizes Wnt signaling by inducing Dvl degradation.	Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University	Chen, YG (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Zhang, Long/AAT-6571-2021; Chen, Ye-Guang/L-6998-2019	Zhang, Long/0000-0001-8139-0474; 				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Gillhouse M, 2004, DEV DYNAM, V230, P403, DOI 10.1002/dvdy.20060; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Katoh M, 2005, INT J MOL MED, V15, P1045; Katoh M, 2003, INT J ONCOL, V22, P907; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Medina A, 2000, DEV DYNAM, V218, P671, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1017>3.0.CO;2-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200	25	123	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8607	8612		10.1074/jbc.M600274200	http://dx.doi.org/10.1074/jbc.M600274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446366	hybrid			2022-12-25	WOS:000236247100037
J	Cho, SJ; Kang, MJ; Homer, RJ; Kang, HR; Zhang, XC; Lee, PJ; Elias, JA; Lee, CG				Cho, SJ; Kang, MJ; Homer, RJ; Kang, HR; Zhang, XC; Lee, PJ; Elias, JA; Lee, CG			Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-13-INDUCED INFLAMMATION; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-TRANSCRIPTION; PULMONARY-FIBROSIS; PATHOGENESIS; IL-13; LUNG; INDUCTION; RECEPTOR; CELLS	IL-13 is an important stimulator of inflammation and tissue remodeling at sites of Th2 inflammation, which plays a key role in the pathogenesis of a variety of human disorders. We hypothesized that the ubiquitous transcription factor, early growth response-1 (Egr-1), plays a key role in IL-13-induced tissue responses. To test this hypothesis we compared the expression of Egr-1 and related moieties in lungs from wild type mice and transgenic mice in which IL-13 was overexpressed in a lung-specific fashion. We simultaneously characterized the effects of a null mutation of Egr-1 on the tissue effects of transgenic IL-13. These studies demonstrate that IL-13 stimulates Egr-1 via an Erk1/2-independent Stat6-dependent pathway(s). They also demonstrate that IL-13 is a potent stimulator of eosinophil- and mononuclear cell-rich inflammation, alveolar remodeling, and tissue fibrosis in mice with wild type Egr-1 loci and that these alterations are ameliorated in the absence of Egr-1. Lastly, they provide insights into the mechanisms of these processes by demonstrating that IL-13 stimulates select CC and CXC chemokines (MIP-1 alpha/CCL-3, MIP-1 beta/CCL-4, MIP-2/CXCL2/3, MCP-1/ CCL-2, MCP-2/CCL-8, MCP-3/CCL-7, MCP-5/CCL-12, KC/CXCL-1, and Lix/CXCL-5), matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and apoptosis regulators(caspase-3,- 6,- 8, and- 9 and Bax) and activates transforming growth factor-beta(1) and pulmonary caspases via Egr-1-dependent pathways. These studies demonstrate that Egr-1 plays a key role in the pathogenesis of IL-13-induced inflammatory and remodeling responses.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University	Lee, CG (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 300 Cedar St,S425A, New Haven, CT 06520 USA.	chungeun.lee@yale.edu	homer, robert/P-3884-2019; Lee, Chun Geun/AAC-2838-2021; zhang, xu/GYE-3558-2022	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658; Zhang, Xuchen/0000-0002-1484-4672	NHLBI NIH HHS [HL-64242, HL-56389, HL-78744, HL-66571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, R01HL066571, R01HL064242, R01HL078744, P01HL056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bahouth SW, 2002, MOL PHARMACOL, V61, P379, DOI 10.1124/mol.61.2.379; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Corry David B, 2002, Am J Respir Med, V1, P185; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; De Sousa LP, 2005, BIOCHEM BIOPH RES CO, V329, P237, DOI 10.1016/j.bbrc.2005.01.123; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hancock A, 1998, AM J RESP CELL MOL, V18, P60, DOI 10.1165/ajrcmb.18.1.2627; Hasegawa M, 1997, J RHEUMATOL, V24, P328; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kane S, 2002, ANTICANCER RES, V22, P1433; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kojima S, 2000, BLOOD, V95, P1309; Kraan TCTMV, 2002, GENES IMMUN, V3, P436, DOI 10.1038/sj.gene.6363896; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lee Y, 2005, MANUSCRIPTA MATH, V116, P173, DOI 10.1007/s00229-004-0530-5; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; Ma B, 2004, J IMMUNOL, V172, P1872, DOI 10.4049/jimmunol.172.3.1872; Nandurkar HH, 1997, BLOOD, V90, P2148; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ohshima K, 2001, HISTOPATHOLOGY, V38, P368, DOI 10.1046/j.1365-2559.2001.01083.x; Okada M, 2002, CIRC RES, V91, P135, DOI 10.1161/01.RES.0000027815.75000.33; Revest JM, 2005, NAT NEUROSCI, V8, P664, DOI 10.1038/nn1441; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sime PJ, 2001, CLIN IMMUNOL, V99, P308, DOI 10.1006/clim.2001.5008; Takahra T, 2004, INT J BIOCHEM CELL B, V36, P353, DOI 10.1016/S1357-2725(03)00260-7; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yu Q, 2000, GENE DEV, V14, P163; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953	47	83	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8161	8168		10.1074/jbc.M506770200	http://dx.doi.org/10.1074/jbc.M506770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439363	hybrid			2022-12-25	WOS:000236031000054
J	Lee, SS; Ayrapetov, MK; Kemble, DJ; Parang, K; Sun, GQ				Lee, SS; Ayrapetov, MK; Kemble, DJ; Parang, K; Sun, GQ			Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, C-terminal Src kinase (Csk)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PEPTIDE; SITE; AUTOPHOSPHORYLATION; DETERMINANTS; SPECIFICITY; EXPRESSION; MOTIF; SH2	Protein tyrosine kinases are key enzymes of mammalian signal transduction. Substrate specificity is a fundamental property that determines the specificity and fidelity of signaling by protein tyrosine kinases. However, how protein tyrosine kinases recognize the protein substrates is not well understood. C-terminal Src kinase (Csk) specifically phosphorylates Src family kinases on a C-terminal Tyr residue, which down-regulates their activities. We have previously determined that Csk recognizes Src using a substrate-docking site away from the active site. In the current study, we identified the docking determinants in Src recognized by the Csk substrate-docking site and demonstrated an interaction between the docking determinants of Src and the Csk substrate-docking site for this recognition. A similar mechanism was confirmed for Csk recognition of another Src family kinase, Yes. Although both Csk and MAP kinases used docking sites for substrate recognition, their docking sites consisted of different substructures in the catalytic domain. These results helped establish a docking-based substrate recognition mechanism for Csk. This model may provide a framework for understanding substrate recognition and specificity of other protein tyrosine kinases.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	University of Rhode Island; University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Sci Bldg,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu	Parang, Keykavous/ABC-1584-2021; Parang, Keykavous/F-9236-2010	Parang, Keykavous/0000-0001-8600-0893; 	NATIONAL CANCER INSTITUTE [R01CA111687] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA111687] Funding Source: Medline; NCRR NIH HHS [1 P20 RR16457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Feuillet V, 2002, ONCOGENE, V21, P7205, DOI 10.1038/sj.onc.1205929; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hunter T, 2000, HARVEY LECT, V94, P81; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; LAM KS, 1995, INT J PEPT PROT RES, V45, P587; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee S, 2002, BIOCHEMISTRY-US, V41, P12107, DOI 10.1021/bi026439g; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lin XF, 2005, BIOCHEMISTRY-US, V44, P1561, DOI 10.1021/bi048142j; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V345, P135, DOI 10.1006/abbi.1997.0236; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	35	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8183	8189		10.1074/jbc.M508120200	http://dx.doi.org/10.1074/jbc.M508120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439366	hybrid, Green Published			2022-12-25	WOS:000236031000057
J	Uemura, N; Kajino, T; Sanjo, H; Sato, S; Akira, S; Matsumoto, K; Ninomiya-Tsuji, J				Uemura, N; Kajino, T; Sanjo, H; Sato, S; Akira, S; Matsumoto, K; Ninomiya-Tsuji, J			TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT MEMBRANE-PROTEIN; IL-1 SIGNALING PATHWAY; IMMUNE-RESPONSES; KINASE TAK1; MEMBRANE-PROTEIN-1; TAB2; TRANSDUCTION; TRAF2; TRANSFORMATION; BINDING	Epstein-Barr virus latent membrane protein 1 (LMP1) activates NF-kappa B and c-Jun N-terminal kinase (JNK), which is essential for LMP1 oncogenic activity. Genetic analysis has revealed that tumor necrosis factor receptor-associated factor 6 (TRAF6) is an indispensable intermediate of LMP1 signaling leading to activation of both NF-kappa B and JNK. However, the mechanism by which LMP1 engages TRAF6 for activation of NF-kappa B and JNK is not well understood. Here we demonstrate that TAK1 mitogen-activated protein kinase kinase kinase and TAK1-binding protein 2 (TAB2), together with TRAF6, are recruited to LMP1 through its N-terminal transmembrane region. The C-terminalcytoplasmicregionofLMP1facilitatestheassemblyofthiscomplex and enhances activation of JNK. In contrast, I kappa B kinase gamma is recruited through the C-terminal cytoplasmic region and this is essential for activation of NF-kappa B. Furthermore, we found that ablation of TAK1 resulted in the loss of LMP1-induced activation of JNK but not of NF-kappa B. These results suggest that an LMP1-associated complex containing TRAF6, TAB2, and TAK1 plays an essential role in the activation of JNK. However, TAK1 is not an exclusive intermediate for NF-kappa B activation in LMP1 signaling.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan; Japan Sci & Technol, Solut Oriented Res Sci & Technol, Tokyo, Japan	University of North Carolina; North Carolina State University; Nagoya University; RIKEN; Osaka University; Japan Science & Technology Agency (JST)	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Akira, Shizuo/C-3134-2009	Ninomiya-Tsuji, Jun/0000-0002-5584-0176; Sato, Shintaro/0000-0001-5156-3354	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050972, R21 AR050972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068812, GM068812] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Coffin WF, 2003, J VIROL, V77, P3749, DOI 10.1128/JVI.77.6.3749-3758.2003; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7863	7872		10.1074/jbc.M509834200	http://dx.doi.org/10.1074/jbc.M509834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16446357	hybrid, Green Accepted			2022-12-25	WOS:000236031000021
J	Desbois-Mouthon, C; Wendum, D; Cadoret, A; Rey, C; Leneuve, P; Blaise, A; Housset, C; Tronche, F; Le Bouc, Y; Holzenberger, M				Desbois-Mouthon, Christele; Wendum, Dominique; Cadoret, Axelle; Rey, Colette; Leneuve, Patricia; Blaise, Annick; Housset, Chantal; Tronche, Francois; Le Bouc, Yves; Holzenberger, Martin			Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout	FASEB JOURNAL			English	Article						cyclin; insulin-like growth factor type 1 receptor; insulin receptor substrate; partial hepatectomy	GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; RAT-BRAIN; EXPRESSION; BINDING; GENE; PHYSIOLOGY; IRS-1; PHOSPHORYLATION; DEGRADATION	Recent evidence indicates that growth hormone (GH) is involved in liver regeneration. To test whether insulin-like growth factor I (IGF-I) mediates this effect, we studied liver regeneration induced by partial hepatectomy in liver-specific IGF type 1 receptor knockout (LIGFREKO) mice. The absence of IGF-1R caused a significant decrease in hepatocyte proliferation in males (-52%), but not in females, as assessed by Ki67 immunohistochemistry. Cyclin D1 and cyclin A protein levels in the livers of LIGFREKO males were only half those in controls, indicating that cyclin induction during liver regeneration is dependent on IGF-1R signaling. Analyzing the signaling cascade initiated by IGF-1R, we observed a lack of IRS-1 induction in LIGFREKO livers. In contrast, the induction of IRS-2 synthesis was similar in LIGFREKO and control groups, suggesting the existence of differential regulation of IRS synthesis during liver regeneration. Regenerating livers from LIGFREKO animals also showed significantly less activated ERKs than controls. Our findings demonstrate that IGF-1R makes a significant contribution to liver regeneration. Using the LIGFREKO model, we provide new evidence that IGF-1R/IRS-1/ERK signaling may be the intracellular pathway controlling the cell cycle via cyclin D1 and cyclin A in the regenerating liver.	Hop St Antoine, INSERM, U515, F-75571 Paris 12, France; Hop St Antoine, INSERM, U680, F-75571 Paris 12, France; Univ Paris 06, Fac Med St Antoine, F-75012 Paris, France; Hop St Antoine, Serv Anatomopathol, F-75571 Paris, France; Coll France, CNRS, UMR 7148, F-75231 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France	Holzenberger, M (corresponding author), Hop St Antoine, INSERM, U515, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	holzenberger@st-antoine.inserm.fr	TRONCHE, François/F-3895-2011; Holzenberger, Martin/N-9732-2018; Cadoret, Axelle/L-2529-2017; Desbois-Mouthon, Christele/M-7076-2017	Cadoret, Axelle/0000-0002-4283-6864; Desbois-Mouthon, Christele/0000-0002-0772-1711; Housset, Chantal/0000-0001-6469-0651; Holzenberger, Martin/0000-0003-4869-725X				Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cadoret A, 2005, INT J CANCER, V114, P668, DOI 10.1002/ijc.20805; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; Carrillo MC, 2001, LIFE SCI, V68, P1417, DOI 10.1016/S0024-3205(01)00936-5; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Giannone PJ, 2004, BBA-GEN SUBJECTS, V1672, P112, DOI 10.1016/j.bbagen.2004.03.003; Hallak H, 2002, HEPATOLOGY, V36, P1509, DOI 10.1053/jhep.2002.37138; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Harada H, 2001, J APPL PHYSIOL, V91, P2816, DOI 10.1152/jappl.2001.91.6.2816; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Holzenberger M, 2000, ENDOCRINOLOGY, V141, P2557, DOI 10.1210/en.141.7.2557; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; LEE JY, 1994, HEPATOLOGY, V19, P656, DOI 10.1002/hep.1840190317; Leneuve P, 2001, BIOTECHNIQUES, V31, P1156, DOI 10.2144/01315rr05; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LORUP C, 1977, CELL TISSUE KINET, V10, P477, DOI 10.1111/j.1365-2184.1977.tb00866.x; Mangnall D, 2003, LIVER INT, V23, P124, DOI 10.1034/j.1600-0676.2003.00812.x; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MCELDUFF A, 1988, ENDOCRINOLOGY, V122, P1933, DOI 10.1210/endo-122-5-1933; Moghaddam AP, 1998, TOXICOLOGY, V130, P95, DOI 10.1016/S0300-483X(98)00095-X; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Paulsen J E, 1990, In Vivo, V4, P235; Pennisi PA, 2004, ENDOCRINOLOGY, V145, P4748, DOI 10.1210/en.2004-0655; Price JA, 2002, HEPATOLOGY, V36, P1089, DOI 10.1053/jhep.2002.36158; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANTOS A, 1994, MOL CELL ENDOCRINOL, V101, P85, DOI 10.1016/0303-7207(94)90222-4; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; von Wichert T, 2005, ONCOGENE, V24, P1284, DOI 10.1038/sj.onc.1208264; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200	45	88	94	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					773	+		10.1096/fj.05-4704fje	http://dx.doi.org/10.1096/fj.05-4704fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16484330	Green Submitted			2022-12-25	WOS:000237698700016
J	Freeman, MW				Freeman, Mason W.			Statins, cholesterol, and the prevention of coronary heart disease	FASEB JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; SIMVASTATIN; PRAVASTATIN; PROTECTION; EVENTS; MEN		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Freeman, MW (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, 55 Fruit St, Boston, MA 02114 USA.	freeman@frodo.mgh.haarvard.edu						BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1932, DOI 10.1161/01.ATV.0000174589.70190.e2; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	13	7	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					200	201		10.1096/fj.06-0202ufm	http://dx.doi.org/10.1096/fj.06-0202ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449790				2022-12-25	WOS:000237698700003
J	Shuto, T; Furuta, T; Oba, M; Xu, HD; Li, JD; Cheung, J; Gruenert, DC; Uehara, A; Suico, MA; Okiyoneda, T; Kai, H				Shuto, Tsuyoshi; Furuta, Takashi; Oba, Mariko; Xu, Haidong; Li, Jian-Dong; Cheung, Judy; Gruenert, Dieter C.; Uehara, Akiko; Suico, Mary Ann; Okiyoneda, Tsukasa; Kai, Hirofumi			Promoter hypomethylation of Toll-like receptor-2 gene is associated with increased proinflammatory response toward bacterial peptidoglycan in cystic fibrosis bronchial epithelial cells	FASEB JOURNAL			English	Article						DNA methylation; chronic inflammation	NF-KAPPA-B; NONTYPABLE HAEMOPHILUS-INFLUENZAE; PSEUDOMONAS-AERUGINOSA; MAP KINASE; EXPRESSION; TRANSCRIPTION; RECOGNITION; ACTIVATION; REGULATOR; PATHOGENS	Cystic fibrosis (CF) is the most common lethal inherited disorder caused by mutation in the gene encoding CF transmembrane regulator (CFTR). The clinical course of CF is characterized by recurrent pulmonary infections and chronic inflammation. Here, we show that toll-like receptor-2 (TLR2) expression and response were strongly enhanced in the human CF bronchial epithelial cell line, CFBE41o-. Treatment of the cells with 5-azacytidine decreased the promoter methylation within TLR2 proximal promoter and increased endogenous expression of TLR2 in non-CF 16HBE14o- cells, suggesting that TLR2 expression is epigenetically regulated by CpG methylation. Moreover, bisulfite sequence analysis revealed that TLR2 promoters were highly demethylated in CFBE41o- cells, implying that decreased methylation of the TLR2 promoter is responsible for CF-related up-regulation of TLR2. Finally, stable expression of WT-CFTR in CFBE41o- cells (CFBE41o-/WT-CFTR cells) reduced TLR2 expression and the response to its ligand peptidoglycan (PGN), implying a causal relationship between CFTR dysfunction and TLR2 up-regulation. Consistent with reduced expression of TLR2 in CFBE41o-/WT-CFTR cells, CpG methylation was increased in CFBE41o-/WT-CFTR cells. Taken together, our results demonstrate that TLR2 expression is epigenetically up-regulated in CF bronchial epithelial cells and suggest that TLR2 overexpression or prolonged activation of TLR2 signaling might be critical in CF pathogenesis.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA USA; Calif Pacific Med Ctr, Inst Res, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Vermont, Dept Med, Burlington, VT USA; Tohoku Univ, Grad Sch Dent, Dept Microbiol & Immunol, Sendai, Miyagi, Japan	Kumamoto University; House Research Institute; University of Southern California; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of Vermont; Tohoku University	Kai, H (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan.	hirokai@gpo.kumamoto-u.ac.jp		Okiyoneda, Tsukasa/0000-0002-5175-2224; Li, Jian-Dong/0000-0002-5593-050X				Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Firoved AM, 2004, INFECT IMMUN, V72, P5012, DOI 10.1128/IAI.72.9.5012-5018.2004; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hornef MW, 2005, J ENDOTOXIN RES, V11, P124, DOI 10.1179/096805105X35224; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; KITAURA Y, 1982, J MED CHEM, V25, P335, DOI 10.1021/jm00346a001; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lei DC, 1996, GENE THER, V3, P427; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Okiyoneda T, 2002, FEBS LETT, V526, P87, DOI 10.1016/S0014-5793(02)03134-4; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pier GB, 2002, CURR OPIN MICROBIOL, V5, P81, DOI 10.1016/S1369-5274(02)00290-4; Ratjen F, 2003, LANCET, V361, P681, DOI 10.1016/S0140-6736(03)12567-6; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Seki Y, 2002, CANCER RES, V62, P6579; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang TY, 2001, J IMMUNOL, V167, P6924, DOI 10.4049/jimmunol.167.12.6924	33	88	93	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					782	+		10.1096/fj.05-4934fje	http://dx.doi.org/10.1096/fj.05-4934fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16478769				2022-12-25	WOS:000237698700020
J	Hashiramoto, A; Mizukami, H; Yamashita, T				Hashiramoto, A.; Mizukami, H.; Yamashita, T.			Ganglioside GM3 promotes cell migration by regulating MAPK and c-Fos/AP-1	ONCOGENE			English	Article						GM3; MAPK; cell cycle; c-Fos; AP-1	SIGNAL-TRANSDUCTION; MICE LACKING; C-FOS; GROWTH; KINASE; EXPRESSION; PROLIFERATION; ACTIVATION; APOPTOSIS; TRANSFORMATION	Gangliosides have been proposed as modulators of transmembrane signaling. Recently, GM3, a glycosphingolipid containing monosaialic acids, is thought to be one of the key molecules of signal transduction in mammalian cells. In this study, we used mouse embryonic fibroblast cell lines (MEFs) established from sialyltransferase-I knockout mice (GM3 synthase KO mice) to evaluate the regulation of mitogenic signals by gangliosides. Cell proliferation assay revealed a higher growth potential of GM3 KO MEFs. Immunoblots showed upregulation of Ras/Raf/MEK/ERK pathway in GM3 KO MEFs, and these signals resulted in enhanced translocation of ERK into the nuclei. Further, both exogenous and endogenous add-back of GM3 decreased the activities of MAPK in GM3 KO MEFs. In addition, GM3 KO MEFs formed foci in high-density culture condition, and analyses of cell cycle modulators revealed the resistance of GM3 KO MEFs for entering cell cycle arrest. Finally, sustained expressions of c-Fos in GM3 KO MEFs were shown to correlate with DNA-binding activity between c-Fos and AP-1. These results demonstrate that the deletion of sialyltransferase-I changes the character of MEFs to a highly activated state of the MAPK pathway, indicating the critical role of GM3 as a regulator of membrane-transmitted signals.	Kobe Univ, Dept Rheumatol, FHS Sch Med, Kobe, Hyogo 6540142, Japan; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 036, Japan; Univ Tokyo, Inst Med Sci, Dept Cell Proc, Tokyo, Japan	Kobe University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Hirosaki University; University of Tokyo	Hashiramoto, A (corresponding author), Kobe Univ, Dept Rheumatol, FHS Sch Med, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.	hash@kobe-u.ac.jp	Mizukami, Hiroki/ABE-7877-2021	Mizukami, Hiroki/0000-0003-2920-582X				Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garofalo T, 2002, J LIPID RES, V43, P971; Gorbacheva VY, 2002, J BIOL CHEM, V277, P6080, DOI 10.1074/jbc.M110542200; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; Groth A, 2005, CELL SIGNAL, V17, P1063, DOI 10.1016/j.cellsig.2004.11.021; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HANAI N, 1988, J BIOL CHEM, V263, P10915; Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO;2-J; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; Li A, 2001, NAT CELL BIOL, V3, pE182, DOI 10.1038/35087119; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakatsuji Y, 2001, J NEUROSCI RES, V66, P487, DOI 10.1002/jnr.1240; NANAI N, 1998, J BIOL CHEM, V263, P10915; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANMEER G, 2000, BIOCHIM BIOPHYS ACTA, V26, P145; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zou YP, 1998, INT J MOL MED, V1, P827	45	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3948	3955		10.1038/sj.onc.1209416	http://dx.doi.org/10.1038/sj.onc.1209416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16491123				2022-12-25	WOS:000238668800008
J	Puranik, M; Weeks, CL; Lahaye, D; Kabil, O; Taoka, S; Nielsen, SB; Groves, JT; Banerjee, R; Spiro, TG				Puranik, M; Weeks, CL; Lahaye, D; Kabil, O; Taoka, S; Nielsen, SB; Groves, JT; Banerjee, R; Spiro, TG			Dynamics of carbon monoxide binding to cystathionine beta-synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX REGULATION; HEME; PROTEIN; ENZYME; MUTATIONS; DOMAIN; MODEL; CO	Cystathionine beta- synthase ( CBS) condenses homocysteine, a toxic metabolite, with serine in a pyridoxal phosphate- dependent reaction. It also contains a heme cofactor to which carbon monoxide ( CO) or nitric oxide can bind, resulting in enzyme inhibition. To understand the mechanism of this regulation, we have investigated the equilibria and kinetics of CO binding to the highly active catalytic core of CBS, which is dimeric. CBS exhibits strong anticooperativity in CO binding with successive association constants of 0.24 and 0.02 mu M-1. Stopped flow measurements reveal slow CO association ( 0.0166 s (-1)) limited by dissociation of the endogenous ligand, Cys- 52. Rebinding of CO and of Cys- 52 following CO photodissociation were independently monitored via time- resolved resonance Raman spectroscopy. The Cys- 52 rebinding rate, 4000 s(-1), is essentially unchanged between pH7.6 and 10.5, indicating that the pK(a) of Cys- 52 is shifted below pH7.6. This effect is attributed to the nearby Arg- 266 residue, which is proposed to form a salt bridge with the dissociated Cys- 52, thereby inhibiting its protonation and slowing rebinding to the Fe. This salt bridge suggests a pathway for enzyme inactivation upon CO binding, because Arg- 266 is located on a helix that connects the heme and pyridoxal phosphate cofactor domains.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	University of Nebraska System; University of Nebraska Lincoln; Princeton University	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu; spiro@princeton.edu	Kabil, Omer/AAJ-1435-2020; Nielsen, Steen Brondsted/G-5844-2016; Groves, John T./GPP-7588-2022	Groves, John T./0000-0002-9944-5899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033576] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058984, HL58984, R01 HL058984-08] Funding Source: Medline; NIGMS NIH HHS [R01 GM033576-40, R01 GM033576, GM33576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R, 2005, ARCH BIOCHEM BIOPHYS, V433, P144, DOI 10.1016/j.abb.2004.08.037; Evande R, 2002, BIOCHEMISTRY-US, V41, P11832, DOI 10.1021/bi026248d; Evande R, 2004, ARCH BIOCHEM BIOPHYS, V427, P188, DOI 10.1016/j.abb.2004.04.027; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Ingi T, 1996, J NEUROSCI, V16, P5621; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Meier M, 2003, BBA-PROTEINS PROTEOM, V1647, P206, DOI 10.1016/S1570-9639(03)00048-7; Miles EW, 2004, J BIOL CHEM, V279, P29871, DOI 10.1074/jbc.R400005200; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Pazicni S, 2004, BIOCHEMISTRY-US, V43, P14684, DOI 10.1021/bi0488496; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2002, BIOCHEMISTRY-US, V41, P10454, DOI 10.1021/bi026052d; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Zhao XJ, 1999, APPL SPECTROSC, V53, P1200, DOI 10.1366/0003702991945669; Zhao XJ, 2000, J RAMAN SPECTROSC, V31, P349, DOI 10.1002/(SICI)1097-4555(200004)31:4<349::AID-JRS548>3.0.CO;2-6	21	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13433	13438		10.1074/jbc.M600246200	http://dx.doi.org/10.1074/jbc.M600246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16505479	Green Accepted, hybrid			2022-12-25	WOS:000237336600050
J	Chen, JY; Park, CS; Tang, SJ				Chen, JY; Park, CS; Tang, SJ			Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; SIGNALING PATHWAY; DENDRITIC SPINES; PREFRONTAL CORTEX; ALZHEIMER-DISEASE; MOUSE DEVELOPMENT; FZD3 GENE; EXPRESSION; SCHIZOPHRENIA; RYK	Wnts are important for various developmental and oncogenic processes. Here we show that Wnt signaling functions at synapses in hippocampal neurons. Tetanic stimulations induce N-methyl-D-aspartate receptor-dependent synaptic Wnt3a release, nuclear beta-catenin accumulations, and the activation of Wnt target genes. Suppression of Wnt signaling impairs long term potentiation. Conversely, activation of Wnt signaling facilitates long term potentiation. These findings suggest that Wnt signaling plays a critical role in regulating synaptic plasticity.	Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Qureshey Res Lab 303, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tang, SJ (corresponding author), Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Qureshey Res Lab 303, Dept Neurobiol & Behav, Irvine, CA 92697 USA.	stang@uci.edu						Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Bamji SX, 2003, NEURON, V40, P719, DOI 10.1016/S0896-6273(03)00718-9; Behrens J, 2003, WNT SIGNALING DEV, P1; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; Dreier L, 2005, NEURON, V46, P51, DOI 10.1016/j.neuron.2004.12.058; DURA JM, 1995, FEBS LETT, V370, P250, DOI 10.1016/0014-5793(95)00847-3; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Fraser PE, 2001, BIOCHEM SOC SYMP, V67, P89, DOI 10.1042/bss0670089; Ftouh S, 2005, J NEUROCHEM, V94, P520, DOI 10.1111/j.1471-4159.2005.03239.x; Fuentealba RA, 2004, BRAIN RES REV, V47, P275, DOI 10.1016/j.brainresrev.2004.07.018; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Galceran J, 2000, DEVELOPMENT, V127, P469; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Grimwood PD, 2001, SYNAPSES, P519; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hering H, 2002, FEBS LETT, V521, P185, DOI 10.1016/S0014-5793(02)02831-4; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017; Kawamura Y, 2001, EUR J BIOCHEM, V268, P3036, DOI 10.1046/j.1432-1327.2001.02197.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2004, J NEURAL TRANSM, V111, P1583, DOI 10.1007/s00702-004-0166-3; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; Liu YB, 2005, NAT NEUROSCI, V8, P1151, DOI 10.1038/nn1520; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Novikova SI, 2005, SYNAPSE, V56, P105, DOI 10.1002/syn.20134; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Schmitt AM, 2006, NATURE, V439, P31, DOI 10.1038/nature04334; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006-3223(03)00291-9; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang YB, 2004, AM J MED GENET B, V129B, P16, DOI 10.1002/ajmg.b.30076; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou CJ, 2004, J NEUROSCI, V24, P121, DOI 10.1523/JNEUROSCI.4071-03.2004; Ziegler S, 2005, FEBS J, V272, P1600, DOI 10.1111/j.1742-4658.2005.04581.x	58	229	237	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11910	11916		10.1074/jbc.M511920200	http://dx.doi.org/10.1074/jbc.M511920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16501258	hybrid			2022-12-25	WOS:000236988100059
J	Maeda, I; Delessert, S; Hasegawa, S; Seto, Y; Zuber, S; Poirier, Y				Maeda, I; Delessert, S; Hasegawa, S; Seto, Y; Zuber, S; Poirier, Y			The peroxisomal acyl-CoA thioesterase pte1p from Saccharomyces cerevisiae is required for efficient degradation of short straight chain and branched chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; MULTIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; LIPID-METABOLISM; YEAST; BIOSYNTHESIS; POLYHYDROXYALKANOATE; PROTEINS	The role of the Saccharomyces cerevisae peroxisomal acyl-coenzyme A (acyl-CoA) thioesterase (Pte1p) in fatty acid beta-oxidation was studied by analyzing the in vitro kinetic activity of the purified protein as well as by measuring the carbon flux through the beta-oxidation cycle in vivo using the synthesis of peroxisomal polyhydroxyalkanoate (PHA) from the polymerization of the 3-hydroxyacyl-CoAs as a marker. The amount of PHA synthesized from the degradation of 10-cis-heptadecenoic, tridecanoic, undecanoic, or nonanoic acids was equivalent or slightly reduced in the pte1 Delta strain compared with wild type. In contrast, a strong reduction in PHA synthesized from heptanoic acid and 8-methyl-nonanoic acid was observed for the pte1 Delta strain compared with wild type. The poor catabolism of 8-methyl-nonanoic acid via beta-oxidation in pte1 Delta negatively impacted the degradation of 10-cis-heptadecenoic acid and reduced the ability of the cells to efficiently grow in medium containing such fatty acids. An increase in the proportion of the short chain 3-hydroxyacid monomers was observed in PHA synthesized in pte1 Delta cells grown on a variety of fatty acids, indicating a reduction in the metabolism of short chain acyl-CoAs in these cells. A purified histidine-tagged Pte1p showed high activity toward short and medium chain length acyl-CoAs, including butyryl-CoA, decanoyl-CoA and 8-methyl-nonanoyl-CoA. The kinetic parameters measured for the purified Pte1p fit well with the implication of this enzyme in the efficient metabolism of short straight and branched chain fatty acyl-CoAs by the beta-oxidation cycle.	Univ Lausanne, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland; Utsunomiya Univ, Fac Agr, Dept Bioprod Sci, Utsunomiya, Tochigi 3218505, Japan	University of Lausanne; Utsunomiya University	Poirier, Y (corresponding author), Univ Lausanne, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland.	yves.poirier@unil.ch		Maeda, Isamu/0000-0003-0723-1752				Bogdawa H, 2005, BBA-MOL CELL BIOL L, V1735, P204, DOI 10.1016/j.bbalip.2005.06.003; GARTON GA, 1985, CHEM IND, V9, P295; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Herbert D, 1996, BIOCHEM J, V318, P997, DOI 10.1042/bj3180997; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Ishizuka M, 2004, EXP CELL RES, V297, P127, DOI 10.1016/j.yexcr.2004.02.029; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; Kal AJ, 2000, CELL BIOCHEM BIOPHYS, V32, P1, DOI 10.1385/CBB:32:1-3:01; KANEDA T, 1991, MICROBIOL REV, V55, P288, DOI 10.1128/MMBR.55.2.288-302.1991; Kurosawa T, 1998, ANAL CHIM ACTA, V365, P249, DOI 10.1016/S0003-2670(97)00601-6; Marchesini S, 2003, APPL ENVIRON MICROB, V69, P6495, DOI 10.1128/AEM.69.11.6495-6499.2003; Marchesini S, 2003, J BIOL CHEM, V278, P32596, DOI 10.1074/jbc.M305574200; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Poirier Y, 2001, APPL ENVIRON MICROB, V67, P5254, DOI 10.1128/AEM.67.11.5254-5260.2001; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Robert J, 2005, BBA-MOL CELL BIOL L, V1734, P169, DOI 10.1016/j.bbalip.2005.02.010; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; Tilton GB, 2004, J BIOL CHEM, V279, P7487, DOI 10.1074/jbc.M309532200	20	26	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11729	11735		10.1074/jbc.M511762200	http://dx.doi.org/10.1074/jbc.M511762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490786	hybrid			2022-12-25	WOS:000236988100037
J	Yano, T; Li, LS; Weinstein, E; Teh, JS; Rubin, H				Yano, T; Li, LS; Weinstein, E; Teh, JS; Rubin, H			Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; IN-VITRO; ACIDIANUS-AMBIVALENS; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; ESCHERICHIA-COLI; DEHYDROGENASE; PURIFICATION; TRIFLUOPERAZINE	Type-II NADH-menaquinone oxidoreductase ( NDH-2) is an essential respiratory enzyme of the pathogenic bacterium Mycobacterium tuberculosis ( Mtb) that plays a pivotal role in its growth. In the present study, we expressed and purified highly active Mtb NDH-2 using a Mycobacterium smegmatis expression system, and the steady-state kinetics and inhibitory actions of phenothiazines were characterized. Purified NDH-2 contains a non-covalently bound flavin adenine dinucleotide cofactor and oxidizes NADH with quinones but does not react with either NADPH or oxygen. Ubiquinone-2 ( Q2) and decylubiquinone showed high electron-accepting activity, and the steady-state kinetics and the NADH-Q2 oxidoreductase reaction were found to operate by a ping-pong reaction mechanism. Phenothiazine analogues, trifluoperazine, Compound 1, and Compound 2 inhibit the NADH-Q2 reductase activity with IC50 = 12, 11, and 13 mu M, respectively. Trifluoperazine inhibition is non-competitive for NADH, whereas the inhibition kinetics is found to be uncompetitive in terms of Q2.	Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rubin, H (corresponding author), Univ Penn, Dept Med, Div Infect Dis, 522 Johnson Pavil,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	rubinh@mail.med.upenn.edu			NIAID NIH HHS [AI43420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amaral L, 1996, J ANTIMICROB CHEMOTH, V38, P1049, DOI 10.1093/jac/38.6.1049; Bandeiras TM, 2003, BBA-BIOENERGETICS, V1557, P13, DOI 10.1016/S0005-2728(02)00374-2; Bandeiras TM, 2002, FEBS LETT, V531, P273, DOI 10.1016/S0014-5793(02)03514-7; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGSMA J, 1982, EUR J BIOCHEM, V128, P151; Bjorklof K, 2000, FEBS LETT, V467, P105, DOI 10.1016/S0014-5793(00)01130-3; Boshoff HIM, 2004, J BIOL CHEM, V279, P40174, DOI 10.1074/jbc.M406796200; COLLINS MD, 1980, J APPL BACTERIOL, V48, P277, DOI 10.1111/j.1365-2672.1980.tb01227.x; Cook SA, 2002, ARCH BIOCHEM BIOPHYS, V398, P32, DOI 10.1006/abbi.2001.2628; CROWLE AJ, 1992, CHEMOTHERAPY, V38, P410, DOI 10.1159/000239036; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Eschemann A, 2005, J BIOL CHEM, V280, P3138, DOI 10.1074/jbc.M411217200; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Fang J, 2003, FREE RADICAL BIO MED, V34, P478, DOI 10.1016/S0891-5849(02)01328-X; Gadre DV, 1998, INT CLIN PSYCHOPHARM, V13, P129, DOI 10.1097/00004850-199805000-00006; Gomes CM, 1998, BIOCHEM BIOPH RES CO, V243, P412, DOI 10.1006/bbrc.1998.8111; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HELTZEL A, 1994, J BACTERIOL, V176, P4790, DOI 10.1128/JB.176.15.4790-4793.1994; Katoch VM, 1998, FEMS IMMUNOL MED MIC, V20, P99, DOI 10.1111/j.1574-695X.1998.tb01115.x; KRISTIANSEN JE, 1986, ACTA PATH MICRO IM B, V94, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee ASG, 2001, ANTIMICROB AGENTS CH, V45, P2157, DOI 10.1128/AAC.45.7.2157-2159.2001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsushita K, 2001, FEMS MICROBIOL LETT, V204, P271, DOI 10.1016/S0378-1097(01)00417-7; McAdam RA, 2002, MICROBIOL-SGM, V148, P2975, DOI 10.1099/00221287-148-10-2975; Melo AMP, 2004, MICROBIOL MOL BIOL R, V68, P603, DOI 10.1128/MMBR.68.4.603-616.2004; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; MOLNAR J, 1977, ZBL BAKT-INT J MED M, V239, P521; Nantapong N, 2005, BIOSCI BIOTECH BIOCH, V69, P149, DOI 10.1271/bbb.69.149; Nantapong N, 2004, APPL MICROBIOL BIOT, V66, P187, DOI 10.1007/s00253-004-1659-6; Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003; RATNAKAR P, 1992, FEMS MICROBIOL LETT, V97, P73; Reddy MV, 1996, J ANTIMICROB CHEMOTH, V37, P196, DOI 10.1093/jac/37.1.196; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102; YOUNG IG, 1978, GENE, V4, P175, DOI 10.1016/0378-1119(78)90029-X	41	112	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11456	11463		10.1074/jbc.M508844200	http://dx.doi.org/10.1074/jbc.M508844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16469750	hybrid			2022-12-25	WOS:000236988100006
J	Chakraborty, G; Rangaswami, H; Jain, S; Kundu, GC				Chakraborty, G; Rangaswami, H; Jain, S; Kundu, GC			Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROMATRIX METALLOPROTEINASE-9 ACTIVATION; PROTEIN-TYROSINE KINASE; CELL-ADHESION; MELANOMA-CELLS; TUMOR-GROWTH; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; PHORBOL ESTER; BLOOD-FLOW	Hypoxia is a key parameter that controls tumor angiogenesis and malignant progression by regulating the expression of several oncogenic molecules. The nonreceptor protein-tyrosine kinases Syk and Lck play crucial roles in the signaling mechanism of various cellular processes. The enhanced expression of Syk in normal breast tissue but not in malignant breast carcinoma has prompted us to investigate its potential role in mammary carcinogenesis. Accordingly, we hypothesized that hypoxia/reoxygenation (H/R) may play an important role in regulating Syk activation, and Lck may be involved in this process. In this study, we have demonstrated that H/R differentially regulates Syk phosphorylation and its subsequent interaction and cross-talk with Lck in MCF-7 cells. Moreover, Syk and Lck play differential roles in regulating Sp1 activation and expressions of melanoma cell adhesion molecule (MelCAM), urokinase-type plasminogen activator (uPA), matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor ( VEGF) in response to H/R. Overexpression of wild type Syk inhibited the H/R-induced uPA, MMP-9, and VEGF expression but up-regulated MelCAM expression. Our data also indicated that MelCAM acts as a tumor suppressor by negatively regulating H/R-induced uPA secretion and MMP-9 activation. The mice xenograft study showed the cross-talk between Syk and Lck regulated H/R-induced breast tumor progression and further correlated with the expressions of MelCAM, uPA, MMP-9, and VEGF. Human clinical specimen analysis supported the in vitro and in vivo findings. To our knowledge, this is first report that the cross-talk between Syk and Lck regulates H/R-induced breast cancer progression and further suggests that Syk may act as potential therapeutic target for the treatment of breast cancer.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Chakraborty, Goutam/U-5559-2019; Chakraborty, Goutam/B-5099-2014; Kundu, Gopal C./ABA-9897-2020					Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Brennan PA, 2005, J ORAL PATHOL MED, V34, P385, DOI 10.1111/j.1600-0714.2005.00335.x; Bussink J, 2003, RADIOTHER ONCOL, V67, P3, DOI 10.1016/S0167-8140(03)00011-2; Chaplin DJ, 1998, SEMIN RADIAT ONCOL, V8, P151, DOI 10.1016/S1053-4296(98)80041-6; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Karlen S, 1999, J INVEST DERMATOL, V113, P711, DOI 10.1046/j.1523-1747.1999.00746.x; Koong AC, 2000, CANCER RES, V60, P883; KOSTER A, 1991, ANTICANCER RES, V11, P193; Kunz M, 2002, BIOCHEM J, V366, P299, DOI 10.1042/BJ20011749; KUNZ M, 2003, MOL CANCER, V2, P1, DOI DOI 10.1186/1476-4598-2-1.PUBMED:12537587; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Lutsenko SV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P286, DOI 10.1023/A:1023002216413; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Natarajan R, 2005, BIOCHEM CELL BIOL, V83, P597, DOI 10.1139/o05-047; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rummel MM, 1996, CANCER RES, V56, P2218; Said HM, 2005, RADIOTHER ONCOL, V76, P200, DOI 10.1016/j.radonc.2005.06.023; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, AM J PATHOL, V151, P745; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004; Vaupel P, 1998, ADV EXP MED BIOL, V454, P591; VAUPEL P, 1989, CANCER RES, V49, P6449; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Xie SH, 1997, CANCER RES, V57, P2295; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S	48	52	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11322	11331		10.1074/jbc.M512546200	http://dx.doi.org/10.1074/jbc.M512546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16474166	hybrid			2022-12-25	WOS:000236822200075
J	Gueorguiev, VD; Cheng, SY; Sabban, EL				Gueorguiev, VD; Cheng, SY; Sabban, EL			Prolonged activation of cAMP-response element-binding protein and ATF-2 needed for nicotine-triggered elevation of tyrosine hydroxylase gene transcription in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE BIOSYNTHETIC-ENZYMES; CREB PHOSPHORYLATION; EXPRESSION; KINASE; INVOLVEMENT; IDENTIFICATION; RECEPTORS; MULTIPLE; CALCIUM; DEPENDENCE	Phosphorylation (P-) of cAMP-response element-binding protein (CREB) by protein kinase A or mitogen-activated protein kinases was implicated in mediating the increased tyrosine hydroxylase (TH) gene expression after prolonged exposure to nicotine in vivo and in cell culture. We examined the time course and signaling pathways for phosphorylation of CREB and possible involvement of ATF-2. Treatment of PC12 cells with 200 mu M nicotine triggered rapid but transient elevation of P- CREB followed by a second sustained rise after 2-5 h of continuous nicotine. In contrast, ERK1/2 was only phosphorylated with short term nicotine exposure. MEK inhibitor U0126 abolished nicotine-induced rise in P-ERK1/2, but not P- CREB, nor did it inhibit nicotine-evoked elevation in TH promoter activity, indicating that ERK1/2 was not needed for induction of TH gene expression by nicotine. In contrast, protein kinase A inhibitor H-89 or Ca2+/calmodulin-activated protein kinase inhibitor KN-93 reduced the nicotine-triggered rise in P- CREB and TH promoter activity. There was a delayed elevation of P-ATF-2 after 1 h of nicotine treatment, accompanied by increased ATF-2 protein. Upstream kinase JNK, but not p38, was phosphorylated especially after 5 min to 2 h of nicotine exposure. To examine the requirement for CREB and ATF-2, cells were transfected with dominant negative forms of ATF-2 or CREB. Both reduced the basal TH promoter activity and the response to nicotine. Knockdown of ATF-2 or CREB with siRNA did not alter basal TH promoter activity or mRNA but greatly attenuated the response to nicotine. The results suggest that both ATF-2 and CREB mediate activation of TH gene transcription by nicotine.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Sabban, EL (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	sabban@nymc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; Anney RJL, 2004, PHARMACOGENETICS, V14, P73, DOI 10.1097/00008571-200402000-00001; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; Brunzell DH, 2003, J NEUROCHEM, V84, P1431, DOI 10.1046/j.1471-4159.2003.01640.x; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Chang KT, 2001, NEURON, V32, P855, DOI 10.1016/S0896-6273(01)00516-5; Cheng SY, 2005, PHARMACOL BIOCHEM BE, V82, P559, DOI 10.1016/j.pbb.2005.10.011; CRAVISO GL, 1992, J NEUROCHEM, V59, P2285; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; Greenberg ME, 2001, SYNAPSES, P357; Gueorguiev VD, 1999, AM J PHYSIOL-CELL PH, V276, pC54, DOI 10.1152/ajpcell.1999.276.1.C54; Gueorguiev VD, 2000, J NEUROCHEM, V75, P1997, DOI 10.1046/j.1471-4159.2000.0751997.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haass M, 1997, CARDIOVASC DRUG THER, V10, P657, DOI 10.1007/BF00053022; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HIREMAGALUR B, 1995, MOL BRAIN RES, V32, P109, DOI 10.1016/0169-328X(95)00068-4; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; Hu M, 2002, MOL CELL NEUROSCI, V21, P616, DOI 10.1006/mcne.2002.1202; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kilaru S, 2001, J AM COLL SURGEONS, V193, P538, DOI 10.1016/S1072-7515(01)01059-6; KIM KS, 1994, J NEUROCHEM, V63, P834; Kim YH, 2002, LIFE SCI, V70, P2915, DOI 10.1016/S0024-3205(02)01539-4; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Lewis-Tuffin LJ, 2004, MOL CELL NEUROSCI, V25, P536, DOI 10.1016/j.mcn.2003.10.010; Lim J, 2000, MOL CELL BIOCHEM, V212, P51, DOI 10.1023/A:1007148719497; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MADHOK TC, 1995, MOL BRAIN RES, V32, P143, DOI 10.1016/0169-328X(95)00073-2; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Menezes A, 1996, J NEUROCHEM, V67, P2316; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Nakashima A, 2003, MOL BRAIN RES, V112, P61, DOI 10.1016/S0169-328X(03)00047-0; Nakayama H, 2006, NEUROSCI LETT, V392, P101, DOI 10.1016/j.neulet.2005.09.003; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Pandey SC, 2001, J NEUROCHEM, V77, P943, DOI 10.1046/j.1471-4159.2001.00309.x; Pearson AG, 2005, NEUROSCIENCE, V133, P437, DOI 10.1016/j.neuroscience.2005.02.029; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I; Serova LI, 2004, BRAIN RES, V1015, P1, DOI 10.1016/j.brainres.2004.04.002; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Suzuki T, 2002, J BIOL CHEM, V277, P40768, DOI 10.1074/jbc.M206043200; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Thiel G, 2005, J NEUROCHEM, V92, P321, DOI 10.1111/j.1471-4159.2004.02882.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Yang CY, 1998, J NEUROCHEM, V71, P1358	53	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10188	10195		10.1074/jbc.M513806200	http://dx.doi.org/10.1074/jbc.M513806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16452470	hybrid			2022-12-25	WOS:000236594300045
J	Negrerie, M; Kruglik, SG; Lambry, JC; Vos, MH; Martin, JL; Franzen, S				Negrerie, M; Kruglik, SG; Lambry, JC; Vos, MH; Martin, JL; Franzen, S			Role of heme iron coordination and protein structure in the dynamics and geminate rebinding of nitric oxide to the H93G myoglobin mutant - Implications for nitric oxide sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; RESONANCE RAMAN-SPECTROSCOPY; PROXIMAL LIGAND; NO RECOMBINATION; ISOTOPE SHIFTS; CAVITY MUTANT; CO BINDING; POCKET; MOLECULES; PHOTODISSOCIATION	The influence of the heme iron coordination on nitric oxide binding dynamics was investigated for the myoglobin mutant H93G (H93G-Mb) by picosecond absorption and resonance Raman time-resolved spectroscopies. In the H93G-Mb, the glycine replacing the proximal histidine does not interact with the heme iron so that exogenous substituents like imidazole may coordinate to the iron at the proximal position. Nitrosylation of H93G-Mb leads to either 6- or 5-coordinate species depending on the imidazole concentration. At high concentrations, ( imidazole)-(NO)-6-coordinate heme is formed, and the photoinduced rebinding kinetics reveal two exponential picosecond phases ( similar to 10 and similar to 100 ps) similar to those of wild type myoglobin. At low concentrations, imidazole is displaced by the trans effect leading to a (NO)-5-coordinate heme, becoming 4-coordinate immediately after photolysis as revealed from the transient Raman spectrum. In this case, NO rebinding kinetics remain bi-exponential with no change in time constant of the fast component whose amplitude increases with respect to the 6- coordinate species. Bi-exponential NO geminate rebinding in 5-coordinate H93G-Mb is in contrast with the single-exponential process reported for nitrosylated soluble guanylate cyclase ( Negrerie, M., Bouzhir, L., Martin, J. L., and Liebl, U. ( 2001) J. Biol. Chem. 276, 46815 - 46821). Thus, our data show that the iron coordination state or the heme iron out-of-plane motion are not at the origin of the bi-exponential kinetics, which depends upon the protein structure, and that the 4-coordinate state favors the fast phase of NO geminate rebinding. Consequently, the heme coordination state together with the energy barriers provided by the protein structure control the dynamics and affinity for NO-binding enzymes.	INSERM, U696, Lab Opt & Biosci, F-91120 Palaiseau, France; CNRS, UMR 7645, F-91120 Palaiseau, France; Ecole Polytech, F-91120 Palaiseau, France; Univ Paris 06, CNRS, UMR 7033, BioMoCeTi, F-91030 Evry, France; N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of North Carolina; North Carolina State University	Negrerie, M (corresponding author), Ecole Polytech, INSERM, U696, Lab Opt & Biosci, F-91128 Palaiseau, France.	michel.negrerie@polytechnique.fr	Negrerie, Michel/L-2283-2018; Kruglik, Sergei/F-7042-2012	Negrerie, Michel/0000-0001-9918-031X; Kruglik, Sergei/0000-0002-2945-3092; Vos, Marten/0000-0003-0493-4831; Franzen, Stefan/0000-0003-2364-2287; Lambry, Jean-Christophe/0000-0001-8264-0391				Andrew CR, 2005, BIOCHEMISTRY-US, V44, P8664, DOI 10.1021/bi050428g; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Becke AD, 1997, J CHEM PHYS, V107, P8554, DOI 10.1063/1.475007; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Cao WX, 2004, BIOCHEMISTRY-US, V43, P11109, DOI 10.1021/bi049077g; Chowdhury PK, 2003, J PHYS CHEM B, V107, P9122, DOI 10.1021/jp030106r; Cianetti S, 2004, J AM CHEM SOC, V126, P13932, DOI 10.1021/ja046442i; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P3925, DOI 10.1021/bi952625t; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452; Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Franzen S, 2000, J PHYS CHEM B, V104, P10359, DOI 10.1021/jp001231v; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; Franzen S, 2002, P NATL ACAD SCI USA, V99, P16754, DOI 10.1073/pnas.252590999; Franzen S, 2002, J PHYS CHEM B, V106, P4533, DOI 10.1021/jp015567w; Franzen S, 2001, BIOPHYS J, V80, P2372, DOI 10.1016/S0006-3495(01)76207-8; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Ionascu D, 2005, J AM CHEM SOC, V127, P16921, DOI 10.1021/ja054249y; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Kim S, 2004, J PHYS CHEM B, V108, P20366, DOI 10.1021/jp0489020; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; Marti MA, 2005, J AM CHEM SOC, V127, P7721, DOI 10.1021/ja042870c; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MITCHELL ML, 1987, J PHYS CHEM-US, V91, P4690, DOI 10.1021/j100302a013; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; NEGRERIE M, 2006, IN PRESS J PHYS CH B; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PRESS WH, 1988, NUMERICAL RECIPES, P59; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Shreve AP, 1999, J PHYS CHEM B, V103, P7969, DOI 10.1021/jp991163g; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; Thomas MR, 2001, BIOCHEMISTRY-US, V40, P15047, DOI 10.1021/bi011440l; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1140, DOI 10.1021/bi00535a005; Wyllie GRA, 2003, INORG CHEM, V42, P5722, DOI 10.1021/ic034473t; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	58	24	24	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10389	10398		10.1074/jbc.M513375200	http://dx.doi.org/10.1074/jbc.M513375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476730	hybrid			2022-12-25	WOS:000236594300068
J	Satoh, T; Sato, K; Kanoh, A; Yamashita, K; Yamada, Y; Igarashi, N; Kato, R; Nakano, A; Wakatsuki, S				Satoh, T; Sato, K; Kanoh, A; Yamashita, K; Yamada, Y; Igarashi, N; Kato, R; Nakano, A; Wakatsuki, S			Structures of the carbohydrate recognition domain of Ca2+-independent cargo receptors Emp46p and Emp47p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTORS V; CRYSTAL-STRUCTURE; LECTIN ERGIC-53; PROTEIN; BINDING; MANNOSE; P58/ERGIC-53; GEOMETRY; HOMOLOG; GLYCANS	Emp46p and Emp47p are type I membrane proteins, which cycle between the endoplasmic reticulum ( ER) and the Golgi apparatus by vesicles coated with coat protein complexes I and II ( COPI and COPII). They are considered to function as cargo receptors for exporting N-linked glycoproteins from the ER. We have determined crystal structures of the carbohydrate recognition domains (CRDs) of Emp46p and Emp47p of Saccharomyces cerevisiae, in the absence and presence of metal ions. Both proteins fold as a beta-sandwich, and resemble that of the mammalian ortholog, p58/ERGIC-53. However, the nature of metal binding is distinct from that of Ca2+-dependent p58/ERGIC-53. Interestingly, the CRD of Emp46p does not bind Ca-2+ ion but instead binds K+ ion at the edge of a concave beta-sheet whose position is distinct from the corresponding site of the Ca2+ ion in p58/ERGIC-53. Binding of K+ ion to Emp46p appears essential for transport of a subset of glycoproteins because the Y131F mutant of Emp46p, which cannot bind K+ ion fails to rescue the transport in disruptants of EMP46 and EMP47 genes. In contrast the CRD of Emp47p binds no metal ions at all. Furthermore, the CRD of Emp46p binds to glycoproteins carrying high mannosetype glycans and the binding is not promoted by the addition of Ca2+ or K+ ion in vitro. These results suggest that Emp46p can be regarded as a Ca2+-independent intracellular lectin at the ER exit sites.	High Energy Accelerator Res Org KEK, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; RIKEN, Discovery Res Inst, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, PRESTO, Wako, Saitama 3510198, Japan; Sasaki Inst, Dept Biochem, Tokyo 1010062, Japan; Japan Sci & Technol Agcy, CREST, Tokyo 1010062, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	High Energy Accelerator Research Organization (KEK); RIKEN; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); University of Tokyo	Wakatsuki, S (corresponding author), High Energy Accelerator Res Org KEK, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan.	soichi.wakatsuki@kek.jp	Nakano, Akihiko/C-6185-2009; Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Satoh, Tadashi/M-5157-2017	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; Igarashi, Noriyuki/0000-0003-2617-3690; Wakatsuki, Soichi/0000-0001-5896-7968; Satoh, Tadashi/0000-0002-4493-4978; Kato, Ryuichi/0000-0003-2087-2896; Yamada, Yusuke/0000-0002-2651-4005				Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; BAENZIGER JU, 1979, J BIOL CHEM, V254, P789; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2002, PYMOL USERS MANUAL; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamiya Y, 2005, J BIOL CHEM, V280, P37178, DOI 10.1074/jbc.M505757200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RINI JM, 1993, J BIOL CHEM, V268, P10126; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Sato K, 2003, MOL BIOL CELL, V14, P3055, DOI 10.1091/mbc.E03-02-0115; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; TAI T, 1975, J BIOL CHEM, V250, P8569; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	46	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10410	10419		10.1074/jbc.M512258200	http://dx.doi.org/10.1074/jbc.M512258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439369	hybrid			2022-12-25	WOS:000236594300070
J	Zhao, J; Kong, HJ; Li, HX; Huang, B; Yang, M; Zhu, C; Bogunovic, M; Zheng, F; Mayer, L; Ozato, K; Unkeless, J; Xiong, HB				Zhao, J; Kong, HJ; Li, HX; Huang, B; Yang, M; Zhu, C; Bogunovic, M; Zheng, F; Mayer, L; Ozato, K; Unkeless, J; Xiong, HB			IRF-8/interferon (IFN) consensus sequence-binding protein is involved in toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-7; IMMUNE-RESPONSES; HOST-DEFENSE; ALPHA GENES; KAPPA-B; ACTIVATION; INDUCTION; MURINE; VIRUS; CELLS	Toll-like receptor (TLR) and interferon-gamma (IFN-gamma) signaling pathways are important for both innate and adaptive immune responses. However, the cross-talk between these two signaling pathways is incompletely understood. Here we show that IFN-gamma and LPS synergistically induce the expression of proinflammatory factors, including interleukin-1 (IL-1), IL-6, IL-12, NO, and tumor necrosis factor-alpha (TNF-alpha). Comparable synergism was observed between IFN-gamma and peptidoglycan (PGN; a TLR2 ligand) and poly(I:C) (a TLR3 ligand) in the induction of IL-12 promoter activity. IFN-gamma enhanced lipopolysaccharide (LPS)-induced ERK and JNK phosphorylation but had no effect on LPS-induced NF-kappa B activation. Interestingly, we found that IRF-8-/- macrophages were impaired in the activation of LPS-induced ERK and JNK and the production of proinflammatory cytokines induced by LPS or IFN-gamma plus LPS. Retroviral transduction of IRF-8 into IRF-8-/- macrophages rescued ERK and JNK activation. Furthermore, co-immunoprecipitation experiments show that IRF-8 physically interacts with TRAF6 at a binding site between amino acid residues 356 and 305 of IRF-8. Transfection of IRF-8 enhanced TRAF6 ubiquitination, which is consistent with a physical interaction of IRF-8 with TRAF6. Taken together, the results suggest that the interaction of IRF-8 with TRAF6 modulates TLR signaling and may contribute to the crosstalk between IFN-gamma and TLR signal pathways.	Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; NICHHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA; Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai	Xiong, HB (corresponding author), Mt Sinai Sch Med, Immunobiol Ctr, Box 1630,1 Gustave L Levy Pl, New York, NY 10029 USA.	Huabao.Xiong@mssm.edu						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Le Page C, 2000, Rev Immunogenet, V2, P374; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200	37	115	120	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10073	10080		10.1074/jbc.M507788200	http://dx.doi.org/10.1074/jbc.M507788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484229	hybrid			2022-12-25	WOS:000236594300032
J	Borghei, A; Ouyang, YB; Westmuckett, AD; Marcello, MR; Landel, CP; Evans, JP; Moore, KL				Borghei, A; Ouyang, YB; Westmuckett, AD; Marcello, MR; Landel, CP; Evans, JP; Moore, KL			Targeted disruption of tyrosylprotein sulfotransferase-2, an enzyme that catalyzes post-translational protein tyrosine O-sulfation, causes male infertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENE-EXPRESSION; SPERM MOTILITY; FERTILIZATION; MICE; TRANSCRIPTOME; CYRITESTIN; INHIBITION; DEFICIENT; HOMOLOG	Tyrosine O-sulfation is a post-translational modification mediated by one of two Golgi tyrosylprotein sulfotransferases (TPST-1 and -2) expressed in all mammalian cells. Tyrosine sulfation plays an important role in the function of some known TPST substrates by enhancing protein-protein interactions. To explore the role of these enzymes in vivo and gain insight into other potential TPST substrates, TPST-2-deficient mice were generated by targeted disruption of the Tpst2 gene. Tpst2(+/-) mice appear normal and, when interbred, yield litters of normal size with a Mendelian distribution of the targeted mutation. Tpst2(-/-) mice have moderately delayed growth but appear healthy and attain normal body weight by 10 weeks of age. In contrast to Tpst1(-/-) males that have normal fertility, Tpst2(-/-) males are infertile. Tpst2(-/-) sperm are normal in number, morphology, and motility in normal media and appear to capacitate and undergo acrosomal exocytosis normally. However, they are severely defective in their motility in viscous media and in their ability to fertilize zona pellucida-intact eggs. Adhesion of Tpst2(-/-) sperm to the egg plasma membrane is reduced compared with wild type sperm, but sperm-egg fusion is similar or even increased. These data strongly suggest that tyrosine sulfation of unidentified substrate(s) play a crucial role in these processes and document for the first time the critical importance of post-translational tyrosine sulfation in male fertility.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jackson Laboratory; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	kevin-moore@omrf.ouhsc.edu	Evans, Janice/Q-8483-2019	Marcello, Matthew/0000-0001-7397-3282	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD045671, R29HD037696, R01HD037696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR009781, P40RR001262] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074015] Funding Source: NIH RePORTER; NCRR NIH HHS [P40 RR009781, P40 RR001262, RR01262, RR09781] Funding Source: Medline; NHLBI NIH HHS [R01 HL074015, HL74015] Funding Source: Medline; NICHD NIH HHS [HD045671, HD037696, R01 HD045671, R29 HD037696, R01 HD037696] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BETTELHEIM FR, 1954, J AM CHEM SOC, V76, P2838, DOI 10.1021/ja01639a073; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Choe H, 2005, MOL MICROBIOL, V55, P1413, DOI 10.1111/j.1365-2958.2004.04478.x; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; EVANS JP, 1995, J CELL SCI, V108, P3267; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Johnston DS, 2005, BIOL REPROD, V73, P404, DOI 10.1095/biolreprod.105.039719; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KALAB P, 1991, BIOL REPROD, V45, P783, DOI 10.1095/biolreprod45.5.783; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Lacourse KA, 1999, AM J PHYSIOL-GASTR L, V276, pG1302, DOI 10.1152/ajpgi.1999.276.5.G1302; McAvey BA, 2002, BIOL REPROD, V67, P1342, DOI 10.1095/biolreprod67.4.1342; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; QUINN P, 1985, FERTIL STERIL, V44, P493; Rehfeld JF, 1998, PHYSIOL REV, V78, P1087, DOI 10.1152/physrev.1998.78.4.1087; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Roberts KP, 2003, BIOL REPROD, V69, P572, DOI 10.1095/biolreprod.102.013771; Seibert C, 2002, P NATL ACAD SCI USA, V99, P11031, DOI 10.1073/pnas.172380899; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880; Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047; Suarez SS, 2003, REPROD DOMEST ANIM, V38, P119, DOI 10.1046/j.1439-0531.2003.00397.x; Suarez SS, 2003, CELL MOL BIOL, V49, P351; Sztein JM, 2000, BIOL REPROD, V63, P1774, DOI 10.1095/biolreprod63.6.1774	38	57	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9423	9431		10.1074/jbc.M513768200	http://dx.doi.org/10.1074/jbc.M513768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469738	Green Accepted, hybrid			2022-12-25	WOS:000236404700052
J	Kaczocha, M; Hermann, A; Glaser, ST; Bojesen, IN; Deutsch, DG				Kaczocha, M; Hermann, A; Glaser, ST; Bojesen, IN; Deutsch, DG			Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; N-ARACHIDONOYLETHANOLAMINE ANANDAMIDE; BOVINE SERUM-ALBUMIN; PROBLEM DRUG-USE; CELLULAR UPTAKE; PROSTAGLANDIN TRANSPORTER; MEMBRANE-TRANSPORT; ENDOCANNABINOID SYSTEM; SELECTIVE-INHIBITION; VANILLOID RECEPTOR	The uptake of arachidonoyl ethanolamide (anandamide, AEA) in rat basophilic leukemia cells (RBL-2H3) has been proposed to occur via a saturable transporter that is blocked by specific inhibitors. Measuring uptake at 25 s, when fatty acid amide hydrolase (FAAH) does not appreciably affect uptake, AEA accumulated via a nonsaturable mechanism at 37 degrees C. Interestingly, saturation was observed when uptake was plotted using unbound AEA at 37 degrees C. Such apparent saturation can be explained by rate-limited delivery of AEA through an unstirred water layer surrounding the cells (1). In support of this, we observed kinetics consistent with rate-limited diffusion at 0 degrees C. Novel transport inhibitors have been synthesized that are either weak FAAH inhibitors or do not inhibit FAAH in vitro (e.g. UCM707, OMDM2, and AM1172). In the current study, none of these purported AEA transporter inhibitors affected uptake at 25 s. Longer incubation times illuminate downstream events that drive AEA uptake. Unlike the situation at 25 s, the efficacy of these inhibitors was unmasked at 5 min with appreciable inhibition of AEA accumulation correlating with partial inhibition of AEA hydrolysis. The uptake and hydrolysis profiles observed with UCM707, VDM11, OMDM2, and AM1172 mirrored two selective and potent FAAH inhibitors CAY10400 and URB597 (at low concentrations), indicating that weak inhibition of FAAH can have a pronounced effect upon AEA uptake. At 5 min, the putative transport inhibitors did not reduce AEA uptake in FAAH chemical knock-out cells. This strongly suggests that the target of UCM707, VDM11, OMDM2, and AM1172 is not a transporter at the plasma membrane but rather FAAH, or an uncharacterized intracellular component that delivers AEA to FAAH. This system is therefore unique among neuro/immune modulators because AEA, an uncharged hydrophobic molecule, diffuses into cells and partial inhibition of FAAH has a pronounced effect upon its uptake.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Brookhaven Natl Lab, Ctr Translat Neuroimaging, Upton, NY 11973 USA; Univ Copenhagen, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Copenhagen	Deutsch, DG (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	DDeutsch@notes.sunysb.edu		Kaczocha, Martin/0000-0002-2527-1398	NIDA NIH HHS [DA16419, DA9374] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016419, R01DA009374] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bojesen IN, 2005, J LIPID RES, V46, P1652, DOI 10.1194/jlr.M400498-JLR200; Bojesen IN, 2006, J LIPID RES, V47, P561, DOI 10.1194/jlr.M500411-JLR200; Bojesen IN, 2003, J LIPID RES, V44, P1790, DOI 10.1194/jlr.M300170-JLR200; Bojesen Inge N, 2004, Biol Proced Online, V6, P226, DOI 10.1251/bpo93; Chi YL, 2006, J PHARMACOL EXP THER, V316, P1346, DOI 10.1124/jpet.105.091975; Chiang KP, 2004, HUM MOL GENET, V13, P2113, DOI 10.1093/hmg/ddh216; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2004, J NEUROBIOL, V61, P149, DOI 10.1002/neu.20080; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cupp D, 2004, BIOCHEMISTRY-US, V43, P4473, DOI 10.1021/bi036335l; Day TA, 2001, MOL PHARMACOL, V59, P1369, DOI 10.1124/mol.59.6.1369; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; Deutsch DG, 2001, J BIOL CHEM, V276, P6967, DOI 10.1074/jbc.M003161200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fasia L, 2003, EUR J BIOCHEM, V270, P3498, DOI 10.1046/j.1432-1033.2003.03724.x; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Fowler CJ, 2004, EUR J PHARMACOL, V492, P1, DOI 10.1016/j.ejphar.2004.03.048; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Giuffrida A, 2001, J PHARMACOL EXP THER, V298, P7; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Glaser ST, 2005, LIFE SCI, V77, P1584, DOI 10.1016/j.lfs.2005.05.007; Goutopoulos A, 2002, PHARMACOL THERAPEUT, V95, P103, DOI 10.1016/S0163-7258(02)00250-4; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hillard CJ, 2003, BRIT J PHARMACOL, V140, P802, DOI 10.1038/sj.bjp.0705468; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hillard CJ, 2005, NEUROPHARMACOLOGY, V48, P1072, DOI 10.1016/j.neuropharm.2004.12.012; Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2; Ibrahimi A, 2002, CURR OPIN CLIN NUTR, V5, P139, DOI 10.1097/00075197-200203000-00004; Jacobsson SOP, 2001, BRIT J PHARMACOL, V132, P1743, DOI 10.1038/sj.bjp.0704029; Jarrahian A, 2000, J NEUROCHEM, V74, P2597, DOI 10.1046/j.1471-4159.2000.0742597.x; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Karlsson M, 2004, EUR J PHARM SCI, V22, P181, DOI 10.1016/j.ejps.2004.03.009; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525-1373.2000.22501.x; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401; Ligresti A, 2004, BIOCHEM J, V380, P265, DOI 10.1042/BJ20031812; Lopez-Rodriguez ML, 2003, J MED CHEM, V46, P1512, DOI 10.1021/jm0210818; Lu R, 1996, J CLIN INVEST, V98, P1142, DOI 10.1172/JCI118897; Maccarrone M, 2000, BIOCHEM BIOPH RES CO, V278, P576, DOI 10.1006/bbrc.2000.3869; McFarland MJ, 2004, J BIOL CHEM, V279, P41991, DOI 10.1074/jbc.M407250200; McFarland MJ, 2004, PHARMACOL THERAPEUT, V104, P117, DOI 10.1016/j.pharmthera.2004.07.008; Mechoulam R, 2005, P NATL ACAD SCI USA, V102, P17541, DOI 10.1073/pnas.0508644102; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Moore SA, 2005, P NATL ACAD SCI USA, V102, P17852, DOI 10.1073/pnas.0507470102; Ortar G, 2003, BIOCHEM PHARMACOL, V65, P1473, DOI 10.1016/S0006-2952(03)00109-6; Ortega-Gutierrez S, 2004, BIOCHEMISTRY-US, V43, P8184, DOI 10.1021/bi049395f; Patricelli MP, 2001, VITAM HORM, V62, P95, DOI 10.1016/S0083-6729(01)62002-8; Price TJ, 2005, NEUROPHARMACOLOGY, V49, P25, DOI 10.1016/j.neuropharm.2005.01.031; Rakhshan F, 2000, J PHARMACOL EXP THER, V292, P960; Rodriguez GJ, 2003, J PHARMACOL EXP THER, V306, P338, DOI 10.1124/jpet.103.048751; Sandberg A, 2005, CHEM PHYS LIPIDS, V134, P131, DOI 10.1016/j.chemphyslip.2004.12.010; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; Schuster VL, 2002, PROSTAG OTH LIPID M, V68-9, P633, DOI 10.1016/S0090-6980(02)00061-8; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vandevoorde S, 2005, BRIT J PHARMACOL, V145, P885, DOI 10.1038/sj.bjp.0706253; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	71	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9066	9075		10.1074/jbc.M509721200	http://dx.doi.org/10.1074/jbc.M509721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461355	hybrid			2022-12-25	WOS:000236404700011
J	Yu, CL; Palumbo, MJ; Lawrence, CE; Morse, RH				Yu, CL; Palumbo, MJ; Lawrence, CE; Morse, RH			Contribution of the histone H3 and H4 amino termini to Gcn4p- and Gcn5p-mediated transcription in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; IN-VIVO; COACTIVATOR COMPLEX; ACTIVATOR PROTEIN; EUKARYOTIC GENOME; ACETYLATION CODE; BUDDING YEAST	Histone amino termini are post-translationally modified by both transcriptional coactivators and corepressors, but the extent to which the relevant histone modifications contribute to gene expression, and the mechanisms by which they do so, are incompletely understood. To address this issue, we have examined the contributions of the histone H3 and H4 amino termini, and of the coactivator and histone acetyltransferase Gcn5p, to activation of a small group of Gcn4p-activated genes. The histone H3 tail exerts a modest ( about 2-fold) but significant effect on activation that correlates with a requirement for Gcn5p and is distributed over multiple lysine residues. The H4 tail also plays a positive role in activation of some of those genes tested, but this does not correlate as closely with Gcn5p coactivation. Microarray experiments did not reveal a close correspondence between those genes activated by Gcn4p and genes requiring the H3 or H4 tail, and analysis of published microarray data indicates that Gcn4p-regulated genes are not in general strongly dependent on Gcn5p. However, a large fraction of genes activated by Gcn4p were found to be repressed by the H3 and H4 amino termini under non-inducing conditions, indicating that one role for Gcn4p is to overcome repression mediated by the histone tails.	New York State Dept Hlth, Wadsworth Ctr, Lab Dev Genet, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Brown University	Morse, RH (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Lab Dev Genet, Albany, NY 12201 USA.	Randall.Morse@wadsworth.org		Morse, Randall/0000-0003-0000-8718				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boorsma A, 2005, NUCLEIC ACIDS RES, V33, pW592, DOI 10.1093/nar/gki484; Conlon EM, 2003, P NATL ACAD SCI USA, V100, P3339, DOI 10.1073/pnas.0630591100; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Larschan E, 2005, MOL CELL BIOL, V25, P114, DOI 10.1128/MCB.25.1.114-123.2005; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Martin AM, 2004, GENETICS, V167, P1123, DOI 10.1534/genetics.104.026674; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Perez-Martin J, 1998, MOL CELL BIOL, V18, P1049, DOI 10.1128/MCB.18.2.1049; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Qiu HF, 2004, MOL CELL BIOL, V24, P4104, DOI 10.1128/MCB.24.10.4104-4117.2004; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sabet N, 2004, MOL CELL BIOL, V24, P8823, DOI 10.1128/MCB.24.20.8823-8833.2004; Sabet N, 2003, P NATL ACAD SCI USA, V100, P4084, DOI 10.1073/pnas.0637524100; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; STADEN R, 1989, COMPUT APPL BIOSCI, V5, P89; Stafford GA, 2001, MOL CELL BIOL, V21, P4568, DOI 10.1128/MCB.21.14.4568-4578.2001; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Swanson MJ, 2003, MOL CELL BIOL, V23, P2800, DOI 10.1128/MCB.23.8.2800-2820.2003; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; Thompson W, 2003, NUCLEIC ACIDS RES, V31, P3580, DOI 10.1093/nar/gkg608; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Yu LN, 1999, MOL CELL BIOL, V19, P5279; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	76	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9755	9764		10.1074/jbc.M513178200	http://dx.doi.org/10.1074/jbc.M513178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461773	hybrid			2022-12-25	WOS:000236404700088
J	Cheon, HM; Shin, SW; Bian, GW; Park, JH; Raikhel, AS				Cheon, HM; Shin, SW; Bian, GW; Park, JH; Raikhel, AS			Regulation of lipid metabolism genes, lipid carrier protein lipophorin, and its receptor during immune challenge in the mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPHORIN-III; FAT-BODY; DROSOPHILA IMMUNITY; GALLERIA-MELLONELLA; ACTIVATION; HEMOLYMPH; PATHWAY; COMMON; LIPOPOLYSACCHARIDE; EXPRESSION	In the mosquito Aedes aegypti, the expression of two fat body genes involved in lipid metabolism, a lipid carrier protein lipophorin ( Lp) and its lipophorin receptor ( LpRfb), was significantly increased after infections with Gram ( +) bacteria and fungi, but not with Gram ( -) bacteria. The expression of these genes was enhanced after the infection with Plasmodium gallinaceum. RNA interference ( RNAi) knockdown of Lp strongly restricted the development of Plasmodium oocysts, reducing their number by 90%. In Vg-Delta REL1- A transgenic mosquitoes, with gain- of- function phenotype of Toll/ REL1 immune pathway activated after blood feeding, both the Lp and LpRfb genes were overexpressed independently of septic injury. The same phenotype was observed in the mosquitoes with RNAi knockdown of Cactus, an I kappa B inhibitor in the Toll/ REL1 pathway. These results showed that, in the mosquito fat body, both Lp and LpRfb gene expression were regulated by the Toll/ REL1 pathway during immune induction by pathogen and parasite infections. Indeed, the proximal region of the LpRfb promoter contained closely linked binding motifs for GATA and NF-kappa B transcription factors. Transfection and in vivo RNAi knockdown experiments showed that the bindings of both GATA and NF-kappa B transcription factors to the corresponding motif were required for the induction of the LpRfb gene. These findings suggest that lipid metabolism is involved in the mosquito systemic immune responses to pathogens and parasites.	Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Bian, Guowu/B-1572-2010	Shin, Sang Woon/0000-0001-9467-0803	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI24716, R01 AI024716, R01-AI052492] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1993, DEVELOPMENT, V119, P623; Ahmed AM, 2001, INSECT MOL BIOL, V10, P347, DOI 10.1046/j.0962-1075.2001.00273.x; Ahmed AM, 1999, INVERTEBR REPROD DEV, V36, P217, DOI 10.1080/07924259.1999.9652703; Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Bansal Devendra, 2005, Lipids Health Dis, V4, P10, DOI 10.1186/1476-511X-4-10; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Brodu V, 2001, DEVELOPMENT, V128, P2593; CAPURRO MD, 1994, COMP BIOCHEM PHYS B, V108, P35, DOI 10.1016/0305-0491(94)90161-9; Cheon HM, 2001, INSECT BIOCHEM MOLEC, V31, P753, DOI 10.1016/S0965-1748(01)00068-6; COODIN S, 1992, J INSECT PHYSIOL, V38, P853, DOI 10.1016/0022-1910(92)90096-V; Dantuma NP, 1999, J LIPID RES, V40, P973; de Bont N, 1999, J LIPID RES, V40, P680; Dettloff M, 2001, J INSECT PHYSIOL, V47, P789, DOI 10.1016/S0022-1910(01)00069-5; Fallon AM, 2001, INSECT BIOCHEM MOLEC, V31, P263, DOI 10.1016/S0965-1748(00)00146-6; FEINGOLD KR, 1995, INFECT IMMUN, V63, P2041, DOI 10.1128/IAI.63.5.2041-2046.1995; HAGEDORN HH, 1977, J INSECT PHYSIOL, V23, P203, DOI 10.1016/0022-1910(77)90030-0; Halwani AE, 2000, J INVERTEBR PATHOL, V76, P233, DOI 10.1006/jipa.2000.4978; Halwani AE, 1999, DEV COMP IMMUNOL, V23, P563, DOI 10.1016/S0145-305X(99)00037-3; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Hurd H, 2005, CURR TOP MICROBIOL, V289, P185; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P539, DOI 10.1016/0965-1748(94)90089-2; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P547, DOI 10.1016/0965-1748(94)90090-6; Kim HJ, 2004, INSECT BIOCHEM MOLEC, V34, P1011, DOI 10.1016/j.ibmb.2004.05.005; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Kutty RK, 1996, J BIOL CHEM, V271, P20641, DOI 10.1074/jbc.271.34.20641; Laskowitz DT, 2000, J LIPID RES, V41, P613; LAW JH, 1989, J BIOL CHEM, V264, P16335; Lee CS, 2003, INSECT BIOCHEM MOLEC, V33, P761, DOI 10.1016/S0965-1748(03)00066-3; Mandato CA, 1996, J INSECT PHYSIOL, V42, P143, DOI 10.1016/0022-1910(95)00091-7; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Mullen L, 2003, INSECT BIOCHEM MOLEC, V33, P661, DOI 10.1016/S0965-1748(03)00045-6; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; Raikhel AS, 2002, INSECT BIOCHEM MOLEC, V32, P1275, DOI 10.1016/S0965-1748(02)00090-5; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Seo SJ, 2003, J BIOL CHEM, V278, P41954, DOI 10.1074/jbc.M308200200; Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun JX, 2000, INSECT BIOCHEM MOLEC, V30, P1161, DOI 10.1016/S0965-1748(00)00093-X; Sundermeyer K, 1996, INSECT BIOCHEM MOLEC, V26, P735, DOI 10.1016/S0965-1748(96)00060-4; van Heusden MC, 1998, INSECT BIOCHEM MOLEC, V28, P733, DOI 10.1016/S0965-1748(98)00068-X; Van Hoof D, 2003, J LIPID RES, V44, P1431, DOI 10.1194/jlr.M300022-JLR200; Van Hoof D, 2002, J CELL SCI, V115, P4001, DOI 10.1242/jcs.00113; VanHeusden MC, 1997, ARCH INSECT BIOCHEM, V34, P301, DOI 10.1002/(SICI)1520-6327(1997)34:3<301::AID-ARCH5>3.0.CO;2-X; Vernick KD, 2005, CURR TOP MICROBIOL, V295, P383; Vlachou D, 2005, CURR BIOL, V15, P1185, DOI 10.1016/j.cub.2005.06.044; Whitten MMA, 2004, J IMMUNOL, V172, P2177, DOI 10.4049/jimmunol.172.4.2177	52	75	76	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8426	8435		10.1074/jbc.M510957200	http://dx.doi.org/10.1074/jbc.M510957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16449228	hybrid			2022-12-25	WOS:000236247100017
J	Chong-Kopera, H; Inoki, K; Li, Y; Zhu, TQ; Garcia-Gonzalo, FR; Rosa, JL; Guan, KL				Chong-Kopera, H; Inoki, K; Li, Y; Zhu, TQ; Garcia-Gonzalo, FR; Rosa, JL; Guan, KL			TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TUMOR-SUPPRESSOR PROTEINS; TUBEROUS-SCLEROSIS; SIGNALING PATHWAY; CELL-GROWTH; REGULATOR RCC1; GIANT PROTEIN; GENE-PRODUCTS; RAB PROTEINS; HAMARTIN	Tuberous sclerosis complex ( TSC) is an autosomal dominant disease characterized by hamartoma formation in various organs. Two genes responsible for the disease, TSC1 and TSC2, have been identified. The TSC1 and TSC2 proteins, also called hamartin and tuberin, respectively, have been shown to regulate cell growth through inhibition of the mammalian target of rapamycin pathway. TSC1 is known to stabilize TSC2 by forming a complex with TSC2, which is a GTPase- activating protein for the Rheb small GTPase. We have identified HERC1 as a TSC2- interacting protein. HERC1 is a 532- kDa protein with an E3 ubiquitin ligase homology to E6AP carboxyl terminus ( HECT) domain. We observed that the interaction of TSC1 with TSC2 appears to exclude TSC2 from interacting with HERC1. Disease mutations in TSC2, which result in its destabilization, allow binding to HERC1 in the presence of TSC1. Our study reveals a potential molecular mechanism of how TSC1 stabilizes TSC2 by excluding the HERC1 ubiquitin ligase from the TSC2 complex. Furthermore, these data reveal a possible biochemical basis of how certain disease mutations inactivate TSC2.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Barcelona, IDIBELL, Dept Ciencies Fisiol 2, Barcelona 08907, Spain	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Guan, KL (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	INOKI, KEN/A-1202-2007; Garcia-Gonzalo, Francesc/W-2639-2017; Rosa, Jose Luis/K-6685-2014	Garcia-Gonzalo, Francesc/0000-0002-9152-2191; Rosa, Jose Luis/0000-0002-6161-5688; Kopera, Huira/0000-0002-8347-5567	NIA NIH HHS [T32 AG00114-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK124709] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garcia-Gonzalo FR, 2005, CELL MOL LIFE SCI, V62, P1826, DOI 10.1007/s00018-005-5119-y; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lu ZM, 2004, J BIOL CHEM, V279, P35664, DOI 10.1074/jbc.M403385200; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Murthy V, 2004, J BIOL CHEM, V279, P1351, DOI 10.1074/jbc.M310208200; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosa JL, 1997, ONCOGENE, V15, P1, DOI 10.1038/sj.onc.1201170; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	30	168	179	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8313	8316		10.1074/jbc.C500451200	http://dx.doi.org/10.1074/jbc.C500451200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16464865	Green Published, hybrid			2022-12-25	WOS:000236247100003
J	Mao, CH; Tai, WC; Bai, Y; Poizat, C; Lee, AS				Mao, CH; Tai, WC; Bai, Y; Poizat, C; Lee, AS			In vivo regulation of Grp78/BiP transcription in the embryonic heart - Role of the endoplasmic reticulum stress response element and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSGENIC MOUSE MODEL; ER STRESS; VENTRAL MORPHOGENESIS; CARDIAC DEVELOPMENT; GENE-EXPRESSION; TUBE FORMATION; MESSENGER-RNA; FACTOR YY1; TFII-I	The transcriptional activation of GRP78, which controls multiple signaling pathways of the unfolded protein response, has been used extensively as an indicator for the onset of endoplasmic reticulum stress in tissue culture systems. Here we investigate the mechanism of Grp78 induction during mouse embryonic development. Our results reveal that in transgenic mouse models, reporter gene activity driven by the Grp78 promoter is strongly activated during early embryonic heart development but subsides in later stages. This activation is strictly dependent on a 100-base pair region of the Grp78 promoter containing the endoplasmic reticulum stress response elements (ERSEs). Previous studies establish that endoplasmic reticulum stress induces in vivo binding of YY1 and the nuclear form of ATF6 to the ERSE. Since the expression of YY1 as well as ATF6 is ubiquitous in the mouse embryo, activation of the Grp78 promoter in the early embryonic heart may involve a specific mechanism. Here we report that GATA-4, a transcription factor essential for heart development, binds to the Grp78 promoter in vivo and activates the ERSE, which does not contain a consensus GATA binding site. GATA-4 cooperatively activates the Grp78 promoter with YY1, and the DNA binding domain of YY1 is necessary and sufficient for this cooperation. In addition, GATA-4 activation of the Grp78 promoter is enhanced by the nuclear form of ATF6, and this synergy is further potentiated by YY1. These results suggest that during early heart organogenesis, Grp78 can be activated through cooperation between the cell type-specific transcription factors and ERSE-binding factors.	Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA	University of Southern California	Lee, AS (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [C06CA062528, R01CA027607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014514, C06RR010600] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA27607, C06 CA62528-01] Funding Source: Medline; NCRR NIH HHS [C06 RR10600-01, C06 RR014514-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abdelrahim M, 2005, J BIOL CHEM, V280, P16508, DOI 10.1074/jbc.C500030200; Barnes JA, 1997, ANAT EMBRYOL, V196, P335, DOI 10.1007/s004290050102; Barnes JA, 1999, CELL STRESS CHAPERON, V4, P250, DOI 10.1379/1466-1268(1999)004<0250:EOGRPG>2.3.CO;2; Barnes JA, 2000, ANAT EMBRYOL, V202, P67, DOI 10.1007/s004290000090; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Dong DZ, 2004, HUM GENE THER, V15, P553, DOI 10.1089/104303404323142006; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Fluck CE, 2004, MOL ENDOCRINOL, V18, P1144, DOI 10.1210/me.2003-0342; GAZIT G, 1995, CANCER RES, V55, P1660; Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200; Hogan B, 1994, MANIPULATING MOUSE E; Hong M, 2005, J BIOL CHEM, V280, P16821, DOI 10.1074/jbc.M413753200; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; KIM KS, 1990, DIFFERENTIATION, V42, P153, DOI 10.1111/j.1432-0436.1990.tb00756.x; KITTEN GT, 1987, ANAT REC, V217, P379, DOI 10.1002/ar.1092170409; KOONG AC, 1994, INT J RADIAT ONCOL, V28, P661, DOI 10.1016/0360-3016(94)90191-0; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Mao CH, 2004, NAT MED, V10, P1013, DOI 10.1038/nm1004-1013; MARKWALD RR, 1990, ANN NY ACAD SCI, V588, P13, DOI 10.1111/j.1749-6632.1990.tb13193.x; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Opie L.H., 1991, HEART PHYSL METABOLI; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97	53	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8877	8887		10.1074/jbc.M505784200	http://dx.doi.org/10.1074/jbc.M505784200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452489	hybrid			2022-12-25	WOS:000236247100068
J	Dickey, CA; Dunmore, J; Lu, BW; Wang, JW; Lee, WC; Kamal, A; Burrows, F; Eckman, C; Hutton, M; Petrucelli, L				Dickey, Chad A.; Dunmore, Judith; Lu, Bingwei; Wang, Ji-Wu; Lee, Wing C.; Kamal, Adeela; Burrows, Francis; Eckman, Christopher; Hutton, Michael; Petrucelli, Leonard			HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites	FASEB JOURNAL			English	Article						neurofibrillary tangles; Alzheimer's disease; proteasome	CELL-SURVIVAL; PROTEIN; DEMENTIA; CHIP; TOXICITY; MISSENSE; MUTATION; GENE	Neurofibrillary tangles (NFTs) are a characteristic neuropathological feature of Alzheimer's disease (AD), and molecular chaperones appear to be involved in the removal of disease-associated hyperphosphorylated tau, a primary component of NFTs. Here, novel HSP90 inhibitors were used to examine the impact of chaperone elevation on clearance of different tau species in transfected cells using a unique quantitative assay. The HSP90 inhibitors reduced levels of tau phosphorylated at proline-directed Ser/Thr sites (pS202/T205, pS396/S404) and conformationally altered ( MC-1) tau species, an epitope that is immeasurable by standard Western blot techniques. The selective clearance of these phospho-tau species and MC-1 tau was mediated via the proteasome, while lysosomal-mediated tau degradation seems to lack specificity for certain tau species, suggesting a more general role in total tau removal. Interestingly, tau phosphorylated at S262/S356 within the tau microtubule binding domain was minimally affected by chaperone induction. Overall, our data show that chaperone induction results in the selective clearance of specific phospho-tau and conformationally altered tau species mediated by the proteasome; however, the apparent stability of pS262/S356 tau may also explain why MARK is able to regulate normal tau function yet still be linked to the initiation of pathogenic tau hyperphosphorylation in AD.	Mayo Clin Jacksonville, Coll Med, Jacksonville, FL 32224 USA; Stanford Univ, Stanford, CA 94305 USA; Conforma Therapeut Corp, San Diego, CA USA	Mayo Clinic; Stanford University	Hutton, M (corresponding author), Mayo Clin Jacksonville, Coll Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	hutton.Michael@mayo.edu	Dickey, Chad A/H-4441-2011	Lee, Chris/0000-0001-9068-5274; Wang, Jiwu/0000-0002-9516-3384; Lu, Bingwei/0000-0002-5807-7014	NIA NIH HHS [P01 AG17216] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017216] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagatell R, 2004, MOL CANCER THER, V3, P1021; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dickey Chad A., 2005, Current Alzheimer Research, V2, P231, DOI 10.2174/1567205053585927; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HYMAN BT, 1988, ANN NEUROL, V23, P371, DOI 10.1002/ana.410230410; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHEN HY, 2005, J BIOL CHEM; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Sun L, 2003, NEUROSCIENCE, V118, P1175, DOI 10.1016/S0306-4522(02)00697-8; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3	21	133	139	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					753	+		10.1096/fj.05-5343fje	http://dx.doi.org/10.1096/fj.05-5343fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464956				2022-12-25	WOS:000237698700036
J	Fecchi, K; Volonte, D; Hezel, MP; Schmeck, K; Galbiati, F				Fecchi, Katia; Volonte, Daniela; Hezel, Michael P.; Schmeck, Kevin; Galbiati, Ferruccio			Spatial and temporal regulation of GLUT4 translocation by flotillin-1 and caveolin-3 in skeletal muscle cells	FASEB JOURNAL			English	Article						caveolae; glucose transporter; insulin signaling; detergent-resistant microdomains	MUSCULAR-DYSTROPHY LGMD-1C; NUCLEOTIDE EXCHANGE FACTOR; RICH MEMBRANE DOMAINS; GLUCOSE-TRANSPORTER; PROTEIN-KINASE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; HETEROOLIGOMERIC COMPLEX; INSULIN-RESISTANCE	Skeletal muscle tissue is one of the main sites where glucose uptake occurs in response to insulin. The glucose transporter type-4 (GLUT4) is primarily responsible for the insulin-stimulated increase in glucose uptake. Upon insulin stimulation, GLUT4 is recruited from intracellular reserves to the plasma membrane. The molecular mechanisms that regulate the translocation of GLUT4 to the sarcolemma remain to be fully identified. Here, we demonstrate that GLUT4 is localized to perinuclear stores that contain flotillin-1, a marker of lipid rafts, in skeletal muscle cells. Stimulation with insulin for 10 min results in the translocation of flotillin1/GLUT4-containing domains to the plasma membrane in a PI3K- and PKC zeta-dependent manner. We also demonstrate that caveolin-3, a marker of caveolae, is required for the insulin receptor-mediated activation of the PI3K- dependent pathway, which occurs 2 min after insulin stimulation. In fact, we demonstrate that lack of caveolin-3 significantly reduces insulin-stimulated glucose uptake in caveolin-3 null myotubes by inhibiting both PI3K and Akt, as well as the movement of GLUT4 to the plasma membrane. Interestingly, caveolin-3 moves away from the plasma membrane toward the cytoplasm 5 min after insulin stimulation and temporarily interacts with flotillin-1/GLUT4-containing domains before they reach the sarcolemma, with the consequent movement of the insulin receptor from caveolin-3-containing domains to flotillin-1-containing domains. Such translocation temporally matches the insulin-stimulated movement of Cbl and CrkII in flotillin-1/GLUT4-containing domains, as well as the activation of the GDP-GTP exchange factor C3G. Disruption of flotillin-1-based domains prevents the activation of C3G, movement of GLUT4 to the sarcolemma, and glucose uptake in response to insulin. Thus, the activation of the Cbl/C3G/TC10-dependent pathway, which occurs before flotillin-1/GLUT4-containing domains reach the plasma membrane, is flotillin-1 mediated and follows the activation of the PI3K- mediated signaling. Taken together, these results indicate that flotillin- 1 and caveolin-3 may regulate muscle energy metabolism through the spatial and temporal segregation of key components of the insulin signaling.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Galbiati, F (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.	feg5@pitt.edu	Galbiati, Ferruccio/AAF-3527-2020; Fecchi, Katia/N-1380-2017	Fecchi, Katia/0000-0003-4397-5783	NATIONAL INSTITUTE ON AGING [R01AG022548] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG022548] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC1317, DOI 10.1152/ajpcell.00489.2004; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; CZECH MP, 1993, J BIOL CHEM, V268, P9187; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EHLER E, 1995, CIRCULATION, V92, P3289, DOI 10.1161/01.CIR.92.11.3289; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1994, J BIOL CHEM, V269, P30745; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Malide D, 2000, J CELL SCI, V113, P4203; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; NOBLE M, 1995, TRANSGENIC RES, V4, P215, DOI 10.1007/BF01969114; OKADA T, 1994, J BIOL CHEM, V269, P3568; Oshikawa J, 2004, P NATL ACAD SCI USA, V101, P12670, DOI 10.1073/pnas.0402053101; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; SATOH S, 1993, J BIOL CHEM, V268, P17820; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VOLDSTEDLUND M, 1993, J MEMBRANE BIOL, V136, P63; Volonte D, 2004, FASEB J, V18, P237, DOI 10.1096/fj.04-2215fje; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	77	89	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					705	+		10.1096/fj.05-4661fje	http://dx.doi.org/10.1096/fj.05-4661fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455755	Green Accepted			2022-12-25	WOS:000237698700043
J	Carujo, S; Estanyol, JM; Ejarque, A; Agell, N; Bachs, O; Pujol, MJ				Carujo, S.; Estanyol, J. M.; Ejarque, A.; Agell, N.; Bachs, O.; Pujol, M. J.			Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity	ONCOGENE			English	Article						SET; GAPDH; cyclin B; cdk1; cell cycle	TANDEM MASS-SPECTROMETRY; ACTIVATING FACTOR-I; GRANZYME-A; PHOSPHATASE 2A; CELL-CYCLE; DNA; IDENTIFICATION; COMPLEX; TRANSCRIPTION; REPLICATION	We report here that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interacts in vitro and in vivo with the protein SET. This interaction is performed through the acidic domain of SET located at the carboxy terminal region. On analysing the functional relevance of SET-GAPDH interaction, we observed that GAPDH reverses in a dose-dependent manner, the inhibition of cyclin B-cdk1 activity produced by SET. Similarly to SET, GAPDH associates with cyclin B, suggesting that the regulation of cyclin B-cdk1 activity might be mediated not only by the interaction of GAPDH with SET but also with cyclin B. To analyse the putative role of GAPDH on cell cycle progression, HCT116 cells were transfected with a GAPDH expression vector. Results indicate that overexpression of GAPDH does not affect the timing of DNA replication but induces an increase in the number of mitosis, an advancement of the peak of cyclin B-cdk1 activity and an acceleration of cell cycle progression. All these results suggest that GAPDH might be involved in cell cycle regulation by modulating cyclin B-cdk1 activity.	Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol & Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Carrascal M, 2002, PROTEOMICS, V2, P455, DOI 10.1002/1615-9861(200204)2:4<455::AID-PROT455>3.0.CO;2-E; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Krynetski EY, 2001, MOL PHARMACOL, V59, P367, DOI 10.1124/mol.59.2.367; Krynetski EY, 2003, CANCER RES, V63, P100; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakagawa T, 2003, J BIOL CHEM, V278, P20395, DOI 10.1074/jbc.M210824200; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Vogel T, 1998, CYTOGENET CELL GENET, V81, P265, DOI 10.1159/000015042; VON LM, 1992, MOL CELL BIOL, V12, P3346; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	47	52	56	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4033	4042		10.1038/sj.onc.1209433	http://dx.doi.org/10.1038/sj.onc.1209433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474839				2022-12-25	WOS:000238802400004
J	Ueno, T; Sasaki, K; Yoshida, S; Kajitani, N; Satsuka, A; Nakamura, H; Sakai, H				Ueno, T.; Sasaki, K.; Yoshida, S.; Kajitani, N.; Satsuka, A.; Nakamura, H.; Sakai, H.			Molecular mechanisms of hyperplasia induction by human papillomavirus E7	ONCOGENE			English	Article						HPV; E7; hyperplasia; pRb; p130; pocket proteins	RETINOBLASTOMA TUMOR-SUPPRESSOR; TYPE-16 E7; E6 ONCOPROTEIN; EPITHELIAL HYPERPLASIA; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; PROTEIN FAMILY; CELLULAR DNA; GENE; DIFFERENTIATION	Infections of human papillomavirus (HPV) induce a variety of benign tumors, such as warts and condylomas. During the process of aberrant cell proliferation, genetic mutations are accumulated in the cells, from which malignant tumor cells arise. The viral oncoproteins E6 and E7 are known to help disrupt the cell cycle checkpoint machinery and accelerate chromosomal instability, events which are critical in malignant conversion. However, the mechanisms involved in the hyperplasia caused by HPV infection have remained unknown. We analysed the effects of regulatory genes of HPV18, a typical high-risk-type HPV, on the formation of the epithelial organ by using an organotypic culture system, and found that E7 had potent activity to induce hyperplasia, to which the disruption of the pRb pathway was well correlated. However, analysis with the E7 variants indicated that other pocket proteins are also involved in the activity.	Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Sakai, H (corresponding author), Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hsakai@virus.kyoto-u.ac.jp						BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CORMACK B, 1987, CURRENT PROTOCOLS MO; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frattini MG, 1996, P NATL ACAD SCI USA, V93, P3062, DOI 10.1073/pnas.93.7.3062; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Majewski S, 2003, EXP DERMATOL, V12, P721, DOI 10.1111/j.0906-6705.2003.00125.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Nakahara T, 2002, J VIROL, V76, P10914, DOI 10.1128/JVI.76.21.10914-10920.2002; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nishimura A, 2000, J VIROL, V74, P3752, DOI 10.1128/JVI.74.8.3752-3760.2000; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	63	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4155	4164		10.1038/sj.onc.1209445	http://dx.doi.org/10.1038/sj.onc.1209445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501608				2022-12-25	WOS:000239004800003
J	Linghu, H; Tsuda, M; Makino, Y; Sakai, M; Watanabe, T; Ichihara, S; Sawa, H; Nagashima, K; Mochizuki, N; Tanaka, S				Linghu, H.; Tsuda, M.; Makino, Y.; Sakai, M.; Watanabe, T.; Ichihara, S.; Sawa, H.; Nagashima, K.; Mochizuki, N.; Tanaka, S.			Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS	ONCOGENE			English	Article						Crk; C3G; Rac; dock180; siRNA; human cancer	V-CRK; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; ACTIVATION; C3G; MIGRATION; COMPLEX; KINASE; MEMBRANE; ADHESION	Signaling adaptor protein Crk regulates cell motility and growth through its targets Dock180 and C3G, those are the guanine-nucleotide exchange factors (GEFs) for small GTPases Rac and Rap, respectively. Recently, overexpression of Crk has been reported in various human cancers. To de. ne the role for Crk in human cancer cells, Crk expression was targeted in the human ovarian cancer cell line MCAS through RNA interference, resulting in the establishment of three Crk knockdown cell lines. These cell lines exhibited disorganized actin fibers, reduced number of focal adhesions, and abolishment of lamellipodia formation. Decreased Rac activity was demonstrated by pull-down assay and FRET-based time-lapse microscopy, in association with suppression of both motility and invasion by phagokinetic track assay and transwell assay in these cells. Furthermore, Crk knockdown cells exhibited slow growth rates in culture and suppressed anchorage-dependent growth in soft agar. Tumor forming potential in nude mice was attenuated, and intraperitoneal dissemination was not observed when Crk knockdown cells were injected into the peritoneal cavity. These results suggest that the Crk is a key component of focal adhesion and involved in cell growth, invasion, and dissemination of human ovarian cancer cell line MCAS.	Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Natl Cardiovasc Ctr Hosp & Res Inst, Osaka, Japan	Hokkaido University; National Cerebral & Cardiovascular Center - Japan	Tanaka, S (corresponding author), Hokkaido Univ, Lab Mol & Cellular Pathol, Sch Med, Kita Ku, N 15,W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; 				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Imaizumi T, 1999, BIOCHEM BIOPH RES CO, V266, P569, DOI 10.1006/bbrc.1999.1869; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu EB, 2000, CANCER RES, V60, P2361; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nishihara H, 2002, BIOCHEM BIOPH RES CO, V296, P716, DOI 10.1016/S0006-291X(02)00931-2; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Nishihara H, 2002, BLOOD, V100, P3968, DOI 10.1182/blood-2001-11-0032; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076	38	49	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3547	3556		10.1038/sj.onc.1209398	http://dx.doi.org/10.1038/sj.onc.1209398			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16491127				2022-12-25	WOS:000238448200007
J	Chattopadhyay, S; Machado-Pinilla, R; Manguan-Garcia, C; Belda-Iniesta, C; Moratilla, C; Cejas, P; Fresno-Vara, JA; de Castro-Carpeno, J; Nistal, M; Gonzalez-Baron, M; Perona, R				Chattopadhyay, S.; Machado-Pinilla, R.; Manguan-Garcia, C.; Belda-Iniesta, C.; Moratilla, C.; Cejas, P.; Fresno-Vara, J. A.; de Castro-Carpeno, J.; Nistal, M.; Gonzalez-Baron, M.; Perona, R.			MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer	ONCOGENE			English	Article						non-small-cell lung cancer; MKP1; CL100; siRNA; Jun kinase; cisplatin	PROTEIN-KINASE PHOSPHATASE-1; N-TERMINAL KINASE; JUN ACTIVATION DOMAIN; C-JUN; MAP KINASE; OVARIAN-CARCINOMA; MKP-1 EXPRESSION; STRESS; APOPTOSIS; SPECIFICITY	Non-small-cell lung cancer (NSCLC) represents the most frequent and therapy-refractive sub-class of lung cancer. Improving apoptosis induction in NSCLC represents a logical way forward in treating this tumor. Cisplatin, a commonly used therapeutic agent in NSCLC, induces activation of N-terminal-c-Jun kinase (JNK) that, in turn, mediates induction of apoptosis. In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei. In the NSCLC-derived cell lines H460 and H-23, we found that MKP1 was constitutively expressed. Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin. A similar response was also observed in H-460 and H-23 cells when treated with the MKP1 expression inhibitor RO-31-8220. Moreover, expression of a siRNA-MKP2, an MKP1-related phosphatase, had no effect on H-460 cell viability response to cisplatin. Tumors induced by H-460 cells expressing MKP1 siRNA grew slower in nu(-)/nu(-) mice and showed more susceptibility to cisplatin than parental cells, and resulted in an impaired growth of the tumor in mice. On the other hand, overexpression of MKP1 in the H-1299 NSCLC-derived cell line resulted in further resistance to cisplatin. Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC. As such, MKP1 can be an attractive target in sensitizing cells to cisplatin to increase the effectiveness of the drug in treating NSCLC.	UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, Madrid 28029, Spain; Hosp La Paz, Med Oncol Serv, Madrid, Spain; Hosp La Paz, Serv Anat Patol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Hospital Universitario La Paz	Perona, R (corresponding author), UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, C-Arturo Duperier 4, Madrid 28029, Spain.	RPerona@iib.uam.es	Vara, Juan Ángel Fresno/Y-9928-2019; Fresno Vara, Juan Angel/F-6702-2010	Vara, Juan Ángel Fresno/0000-0003-1527-1252; Fresno Vara, Juan Angel/0000-0003-1527-1252; Belda Iniesta, Cristobal/0000-0003-3254-7492				Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kim DH, 2003, CANCER RES, V63, P6206; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lim EH, 2003, CLIN CANCER RES, V9, P5980; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SLEBOS RJC, 1989, EUR RESPIR J, V2, P461; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wiest JS, 1997, J CELL BIOCHEM, P64; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200	34	78	83	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3335	3345		10.1038/sj.onc.1209364	http://dx.doi.org/10.1038/sj.onc.1209364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462770				2022-12-25	WOS:000237951200012
J	Thornton, JK; Dalgleish, C; Venables, JP; Sergeant, KA; Ehrmann, IE; Lu, X; Saunders, PTK; Elliott, DJ				Thornton, J. K.; Dalgleish, C.; Venables, J. P.; Sergeant, K. A.; Ehrmann, I. E.; Lu, X.; Saunders, P. T. K.; Elliott, D. J.			The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo	ONCOGENE			English	Article						spermatogenesis; gene expression; tumour suppressor	MESSENGER-RNA EXPRESSION; KH-DOMAIN; FUNCTIONAL INTERACTION; CYCLE PROGRESSION; SAM68; P53; FAMILY; GENE; INTERACTS; MEMBERS	The ASPP1 (Apoptosis Stimulating Protein of p53) protein is an important tumour-suppressor. We have detected a novel protein interaction between the human ASPP1 (hASPP1) protein and the predominantly nuclear adaptor protein SAM68. In the human testis, full-length endogenous hASPP1 protein is located in the nucleus like SAM68, predominantly within meiotic and postmeiotic cells. Mouse ASPP1 (mASPP1) protein is mainly expressed in the brain and testis. The interaction with nuclear SAM68 is likely to be restricted to human germ cells, since endogenous mASPP1 protein is exclusively cytoplasmic. The C-terminal region of hASPP1 efficiently targeted a fused GFP molecule to the nucleus, whereas the N-terminus of hASPP1 targeted GFP to the cytoplasm. In the context of the full-length molecule this cytoplasmic targeting sequence is dominant in HEK293 and Saos-2 cells, since full-length hASPP1-GFP is almost exclusively cytoplasmic. Despite its predominantly cytoplasmic location, we show that ASPP1-GFP expression in HEK293 cells can regulate the ratio of alternative spliced isoforms derived from a pre-mRNA regulated downstream of cytoplasmic signalling pathways, and our data suggest that ASPP1 may operate in this case downstream or parallel to RAS signalling pathways.	Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; UCL, Ludwig Inst Canc Res, London, England; MRC, Ctr Reprod Biol, Human Reprod Sci Unit, Edinburgh, Midlothian, Scotland	Newcastle University - UK; Ludwig Institute for Cancer Research; University of London; University College London	Elliott, DJ (corresponding author), Newcastle Univ, Inst Human Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	david.elliott@ncl.ac.uk	Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Lu, Xin/0000-0002-6587-1152; Elliott, David/0000-0002-6930-0699	MRC [MC_U127685844, MC_U127685841] Funding Source: UKRI; Medical Research Council [MC_U127685841, MC_U127661055, U.1276.00.002(61055), MC_U127685844] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Harlow ED., 1999, USING ANTIBODIES; Hong W, 2002, MOL CANCER RES, V1, P48; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sjoblom T, 1996, ONCOGENE, V12, P2499; Slee EA, 2004, ONCOGENE, V23, P9007, DOI 10.1038/sj.onc.1208088; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Takahashi N, 2004, BIOCHEM BIOPH RES CO, V315, P434, DOI 10.1016/j.bbrc.2004.01.079; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	38	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3104	3112		10.1038/sj.onc.1209341	http://dx.doi.org/10.1038/sj.onc.1209341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16474851				2022-12-25	WOS:000237951000002
J	Hemmler, R; Becker, T; Schleiff, E; Bolter, B; Stahl, T; Soll, J; Gotze, TA; Braams, S; Wagner, R				Hemmler, R; Becker, T; Schleiff, E; Bolter, B; Stahl, T; Soll, J; Gotze, TA; Braams, S; Wagner, R			Molecular properties of Oep21, an ATP-regulated anion-selective solute channel from the outer chloroplast membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT CHANNEL; ENVELOPE MEMBRANES; PEA-CHLOROPLASTS; ION CHANNELS; OEP16; PORIN; RECONSTITUTION; TRANSLOCON; PREDICTION; KINETICS	The flux of phosphorylated carbohydrates, the major export products of chloroplasts, is regulated at the level of the inner and presumably also at the level of the outer membrane. This is achieved through modulation of the outer membrane Oep21 channel currents and tuning of its ion selectivity. Refined analysis of the Oep21 channel properties by biochemical and electrophysiological methods revealed a channel formed by eight beta-strands with a wider pore vestibule of d(vest) similar to 2.4 nm at the intermembrane site and a narrower filter pore of d(restr) similar to 1 nm. The Oep21 pore contains two high affinity sites for ATP, one located at a relative transmembrane electrical distance delta = 0.56 and the second close to the vestibule at the intermembrane site. The ATP-dependent current block and reduction in anion selectivity of the Oep21 channel is relieved by the competitive binding of phosphorylated metabolic intermediates like 3-phosphoglycerate and glycerinaldehyde 3-phosphate. Deletion of a C-terminal putative FX4K binding motif in Oep21 decreased the capability of the channel to tune its ion selectivity by about 50%, whereas current block remained unchanged.	Univ Osnabruck, FB Biol Chem, D-49034 Osnabruck, Germany; LMU Munchen, Dept Biol 1, D-80638 Munich, Germany	University Osnabruck; University of Munich	Wagner, R (corresponding author), Univ Osnabruck, FB Biol Chem, Barbarastr 11, D-49034 Osnabruck, Germany.	wagner@uos.de	Becker, Thomas/AAS-9404-2020; Schleiff, Enrico/C-5105-2017; Goetze, Tom/I-1891-2013	Schleiff, Enrico/0000-0002-0518-3489; 				Bainbridge G, 1998, FEBS LETT, V431, P305, DOI 10.1016/S0014-5793(98)00761-3; Becker T, 2004, MOL BIOL CELL, V15, P5130, DOI 10.1091/mbc.E04-05-0405; Bolter B, 1999, EMBO J, V18, P5505, DOI 10.1093/emboj/18.20.5505; Bolter B, 2001, EMBO J, V20, P935, DOI 10.1093/emboj/20.5.935; Brandt S., 1999, DATENANALYSE, V4; BRUNEN M, 1993, EUR J BIOCHEM, V212, P129, DOI 10.1111/j.1432-1033.1993.tb17642.x; Chen D, 1997, BIOPHYS J, V72, P97, DOI 10.1016/S0006-3495(97)78650-8; ERTEL F, 2000, J BIOL CHEM, V280, P28258; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; HILLE B, 2001, ION CHANNELS EXCITAB, P347; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Linke D, 2004, BIOPHYS J, V86, P1479, DOI 10.1016/S0006-3495(04)74216-2; Linke D, 2000, BIOCHEMISTRY-US, V39, P11050, DOI 10.1021/bi001034m; Mathes A, 1998, J MEMBRANE BIOL, V165, P11, DOI 10.1007/s002329900416; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; Neuhaus HE, 2000, BBA-BIOMEMBRANES, V1465, P307, DOI 10.1016/S0005-2736(00)00146-2; Pohlmeyer K, 1997, P NATL ACAD SCI USA, V94, P9504, DOI 10.1073/pnas.94.17.9504; Pohlmeyer K, 1998, PLANT CELL, V10, P1207, DOI 10.1105/tpc.10.7.1207; Rohl T, 1999, FEBS LETT, V460, P491, DOI 10.1016/S0014-5793(99)01399-X; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; Steinkamp T, 2000, J BIOL CHEM, V275, P11758, DOI 10.1074/jbc.275.16.11758; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Vojta A, 2004, J BIOL CHEM, V279, P21401, DOI 10.1074/jbc.M401968200; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WOODBURY DJ, 1988, BIOPHYS J, V54, P1053, DOI 10.1016/S0006-3495(88)83042-X; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	30	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12020	12029		10.1074/jbc.M513586200	http://dx.doi.org/10.1074/jbc.M513586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16473880	hybrid			2022-12-25	WOS:000236988100072
J	Klco, JM; Nikiforovich, GV; Baranski, TJ				Klco, JM; Nikiforovich, GV; Baranski, TJ			Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; 1ST EXTRACELLULAR LOOP; TRANSMEMBRANE HELICES; MOLECULAR-MECHANISM; BINDING; ACTIVATION; RESIDUES; IDENTIFICATION; RHODOPSIN	The extracellular loops of G protein-coupled receptors (GPCRs) frequently contain binding sites for peptide ligands. However, the mechanism of receptor activation following ligand binding and the influence of the extracellular loops in other aspects of receptor function are poorly understood. Here we report a structure-function analysis of the first and third extracellular loops of the human C5a receptor, a GPCR that binds a 74-amino acid peptide ligand. Amino acid substitutions were randomly incorporated into each loop, and functional receptors were identified in yeast. The first extracellular loop contains a large number of positions that cannot tolerate amino acid substitutions, especially residues within the WXFG motif found in many rhodopsin-like GPCRs, yet disruption of these residues does not alter C5a binding affinity. These results demonstrate an unanticipated role for the first extracellular loop, and the WXFG motif in particular, in ligand-mediated activation of the C5a receptor. This motif likely serves a similar role in other GPCRs. The third extracellular loop, in contrast, contains far fewer preserved residues and appears to play a less essential role in receptor activation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	baranski@wustl.edu	Klco, Jeffery/M-9717-2018	Klco, Jeffery/0000-0003-2961-6960	NIGMS NIH HHS [GM63720-01, GM068460] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720, R01GM068460] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Akal-Strader A, 2002, J BIOL CHEM, V277, P30581, DOI 10.1074/jbc.M204089200; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1989, J BIOL CHEM, V264, P1760; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Huber-Lang MS, 2003, J IMMUNOL, V170, P6115, DOI 10.4049/jimmunol.170.12.6115; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Labrou NE, 2001, J BIOL CHEM, V276, P37944; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; MATSUI H, 1995, MOL PHARMACOL, V47, P88; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Nicastro G, 2003, J PEPT SCI, V9, P229, DOI 10.1002/psc.449; Nikiforovich GV, 2005, BIOPHYS J, V89, P3780, DOI 10.1529/biophysj.105.070722; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unson CG, 2000, J BIOL CHEM, V275, P21631, DOI 10.1074/jbc.M002093200	34	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12010	12019		10.1074/jbc.M600548200	http://dx.doi.org/10.1074/jbc.M600548200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505476	hybrid			2022-12-25	WOS:000236988100071
J	Grosshans, BL; Grotsch, H; Mukhopadhyay, D; Fernandez, IM; Pfannstiel, J; Idrissi, FZ; Lechner, J; Riezman, H; Geli, MI				Grosshans, BL; Grotsch, H; Mukhopadhyay, D; Fernandez, IM; Pfannstiel, J; Idrissi, FZ; Lechner, J; Riezman, H; Geli, MI			TEDS site phosphorylation of the yeast myosins I is required for ligand-induced but not for constitutive endocytosis of the G protein-coupled receptor Ste2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIN CYTOSKELETON ORGANIZATION; SACCHAROMYCES-CEREVISIAE; P21-ACTIVATED KINASE; BUDDING-YEAST; CELL-GROWTH; UNCONVENTIONAL MYOSINS; MEDIATED ENDOCYTOSIS; ASPERGILLUS-NIDULANS; SIGNAL-TRANSDUCTION	The yeast myosins I Myo3p and Myo5p have well established functions in the polarization of the actin cytoskeleton and in the endocytic uptake of the G protein-coupled receptor Ste2p. A number of results suggest that phosphorylation of the conserved TEDS serine of the myosin I motor head by the Cdc42p activated p21-activated kinases Ste20p and Cla4p is required for the organization of the actin cytoskeleton. However, the role of this signaling cascade in the endocytic uptake has not been investigated. Interestingly, we find that Myo5p TEDS site phosphorylation is not required for slow, constitutive endocytosis of Ste2p, but it is essential for rapid, ligand-induced internalization of the receptor. Our results strongly suggest that a kinase activates the myosins I to sustain fast endocytic uptake. Surprisingly, however, despite the fact that only p21-activated kinases are known to phosphorylate the conserved TEDS site, we find that these kinases are not essential for ligand-induced internalization of Ste2p. Our observations indicate that a different signaling cascade, involving the yeast homologues of the mammalian PDK1 (3-phosphoinositide-dependent-protein kinase-1), Phk1p and Pkh2p, and serum and glucocorticoid-induced kinase, Ypk1p and Ypk2p, activate Myo3p and Myo5p for their endocytic function.	CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Dept Biochim, CH-1211 Geneva, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Ruprecht Karls University Heidelberg; University of Geneva	Geli, MI (corresponding author), CSIC, Inst Biol Mol Barcelona, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	mgfbmc@ibmb.csic.es	Geli, Maria Isabel/L-3246-2014; Fernández-Golbano, Isabel M/J-7409-2017; Idrissi Azami, Fatima Zohra/P-5627-2015	Geli, Maria Isabel/0000-0002-3452-6700; Fernández-Golbano, Isabel M/0000-0002-8525-6376; Idrissi Azami, Fatima Zohra/0000-0003-3672-7618; Riezman, Howard/0000-0003-4680-9422; Grotsch, Helga/0000-0003-1948-3922				Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Geli MI, 1998, EMBO J, V17, P635, DOI 10.1093/emboj/17.3.635; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Geli MI, 2000, EMBO J, V19, P4281, DOI 10.1093/emboj/19.16.4281; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gliksman NR, 2001, J BIOL CHEM, V276, P5235, DOI 10.1074/jbc.M008319200; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Idrissi FZ, 2002, MOL BIOL CELL, V13, P4074, DOI 10.1091/mbc.02-04-0052; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu X, 2001, P NATL ACAD SCI USA, V98, P9122, DOI 10.1073/pnas.161285698; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MARUTA H, 1977, J BIOL CHEM, V252, P8329; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Osherov N, 1998, J BIOL CHEM, V273, P27017, DOI 10.1074/jbc.273.41.27017; Ostap EM, 2002, BIOCHEMISTRY-US, V41, P12450, DOI 10.1021/bi0262193; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Pruyne D, 2000, J CELL SCI, V113, P571; Redowicz MJ, 2001, J MUSCLE RES CELL M, V22, P163; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN S, 1974, METHODS YEAST GENETI; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yamashita RA, 1998, J BIOL CHEM, V273, P14644, DOI 10.1074/jbc.273.23.14644; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	67	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11104	11114		10.1074/jbc.M508933200	http://dx.doi.org/10.1074/jbc.M508933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478726	hybrid			2022-12-25	WOS:000236822200053
J	Sutherland, MSK; Sanderson, RJ; Gordon, KA; Andreyka, J; Cerveny, CG; Yu, CP; Lewis, TS; Meyer, DL; Zabinski, RF; Doronina, SO; Senter, PD; Law, CL; Wahl, AF				Sutherland, MSK; Sanderson, RJ; Gordon, KA; Andreyka, J; Cerveny, CG; Yu, CP; Lewis, TS; Meyer, DL; Zabinski, RF; Doronina, SO; Senter, PD; Law, CL; Wahl, AF			Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CARCINOMA; SELECTIVE ANTITUMOR-ACTIVITY; IN-VITRO; MEDIATED ENDOCYTOSIS; LYMPHOMA-CELLS; INTERNALIZATION; IMMUNOCONJUGATE; CANCER; EFFICACY; POTENT	The chimeric anti-CD30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo. These drugs are appended via a valinecitrulline (vc) dipeptide linkage designed for high stability in serum and conditional cleavage and putative release of fully active drugs by lysosomal cathepsins. To characterize the biochemical processes leading to effective drug delivery, we examined the intracellular trafficking, internalization, and metabolism of the parent antibody and two antibody-drug conjugates, cAC10vc-MMAE and cAC10vc-MMAF, following CD30 surface antigen interaction with target cells. Both cAC10 and its conjugates bound to target cells and internalized in a similar manner. Subcellular fractionation and immunofluorescence studies demonstrated that the antibody and antibody-drug conjugates entering target cells migrated to the lysosomes. Trafficking of both species was blocked by inhibitors of clathrin-mediated endocytosis, suggesting that drug conjugation does not alter the fate of antibody-antigen complexes. Incubation of cAC10vc-MMAE or cAC10vc-MMAF with purified cathepsin B or with enriched lysosomal fractions prepared by subcellular fractionation resulted in the release of active, free drug. Cysteine protease inhibitors, but not aspartic or serine protease inhibitors, blocked antibody-drug conjugate metabolism and the ensuing cytotoxicity of target cells and yielded enhanced intracellular levels of the intact conjugates. These findings suggest that in addition to trafficking to the lysosomes, cathepsin B and perhaps other lysosomal cysteine proteases are requisite for drug release and provide a mechanistic basis for developing antibody-drug conjugates cleavable by intracellular proteases for the targeted delivery of anti-cancer therapeutics.	Seattle Genet Inc, Dept Mol Oncol & Immunol, Bothell, WA 98021 USA; Seattle Genet Inc, Dept Chem, Bothell, WA 98021 USA	Seattle Genetics; Seattle Genetics	Wahl, AF (corresponding author), Seattle Genet Inc, Dept Mol Oncol & Immunol, 21823 30th Dr SE, Bothell, WA 98021 USA.	awahl@seagen.com						Afar DEH, 2004, MOL CANCER THER, V3, P921; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; BRASLAWSKY GR, 1991, CANCER IMMUNOL IMMUN, V33, P367, DOI 10.1007/BF01741596; CASTLE JD, 2004, CURRENT PROTOCOLS PR, V1; Chan SY, 2003, CANCER IMMUNOL IMMUN, V52, P243, DOI 10.1007/s00262-002-0343-x; Coffey GP, 2004, J PHARMACOL EXP THER, V310, P896, DOI 10.1124/jpet.104.067611; Davis EC, 1998, MATRIX BIOL, V17, P245, DOI 10.1016/S0945-053X(98)90078-6; Di Paolo C, 2003, CLIN CANCER RES, V9, P2837; Doronina SO, 2006, BIOCONJUGATE CHEM, V17, P114, DOI 10.1021/bc0502917; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j; Durrbach A, 1996, J CELL SCI, V109, P457; Francisco JA, 2003, BLOOD, V102, P1458, DOI 10.1182/blood-2003-01-0039; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Goulet AC, 1997, BLOOD, V90, P2364, DOI 10.1182/blood.V90.6.2364.2364_2364_2375; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Jeitner TM, 2005, BIOCHEM PHARMACOL, V69, P961, DOI 10.1016/j.bcp.2004.12.011; Law CL, 2004, CLIN CANCER RES, V10, P7842, DOI 10.1158/1078-0432.CCR-04-1028; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Omelyanenko V, 1998, INT J CANCER, V75, P600, DOI 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Sapra P, 2002, CANCER RES, V62, P7190; Semac I, 2003, CANCER RES, V63, P534; SHIH LB, 1994, CANCER IMMUNOL IMMUN, V38, P92, DOI 10.1007/BF01526203; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; Sievers EL, 2001, J CLIN ONCOL, V19, P3244, DOI 10.1200/JCO.2001.19.13.3244; Szpaderska AM, 2001, CANCER RES, V61, P3493; Tolcher AW, 2003, J CLIN ONCOL, V21, P211, DOI 10.1200/JCO.2003.05.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wahl AF, 2002, CANCER RES, V62, P3736	37	208	237	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10540	10547		10.1074/jbc.M510026200	http://dx.doi.org/10.1074/jbc.M510026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484228	hybrid			2022-12-25	WOS:000236594300084
J	Monaghan-Benson, E; McKeown-Longo, PJ				Monaghan-Benson, E; McKeown-Longo, PJ			Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; FACTOR EGF RECEPTOR; INTEGRIN ACTIVATION; PLASMA FIBRONECTIN; CELL-MIGRATION; ADHESION; KINASE; PROTEIN; SIGNAL; POLYMERIZATION	Previous studies have indicated that the urokinase-type plasminogen activator receptor ( uPAR) can functionally interact with integrins thereby modulating integrin activity. We have previously demonstrated that treatment of fibroblasts with the uPAR ligand, P25, results in an increase in the activation of the beta 1 integrin and a 35-fold increase in fibronectin matrix assembly ( Monaghan, E., Gueorguiev, V., Wilkins-Port, C., and McKeown-Longo, P. J. ( 2004) J. Biol. Chem. 279, 1400 - 1407). Experiments were conducted to address the mechanism of uPAR regulation of matrix assembly. Treatment of fibroblasts with P25 led to an increase in the activation of the epidermal growth factor receptor ( EGFR) and a colocalization of activated EGFR with beta 1 integrins in cell matrix contacts. The effects of P25 on matrix assembly and beta 1 integrin activation were inhibited by pretreatment with EGFR or Src kinase inhibitors, suggesting a role for both Src and EGFR in integrin activation by uPAR. Phosphorylation of EGFR in response to P25 occurred on Tyr-845, an Src-dependent phosphorylation site and was inhibited by PP2, the Src kinase inhibitor, consistent with Src kinase lying upstream of EGFR and integrin activation. Cells null for Src kinases also showed a loss of P25-induced matrix assembly, integrin activation, and EGFR phosphorylation. These P25-induced effects were restored following Src re-expression. The effects of P25 were specific for uPAR as enhanced matrix assembly by P25 was not seen in uPAR -/- cells, but was restored upon uPAR re-expression. These data provide evidence for a novel pathway of fibronectin matrix assembly through the uPAR-dependent sequential activation of Src kinase, EGFR, and beta 1 integrin.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	McKeown-Longo, PJ (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	mckeowp@mail.amc.edu			NCI NIH HHS [CA-58626] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058626, R56CA058626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Bu XY, 2004, LAB INVEST, V84, P667, DOI 10.1038/labinvest.3700089; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; Christopher RA, 1999, J CELL SCI, V112, P3225; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Darribere T, 2000, BIOL CELL, V92, P5, DOI 10.1016/S0248-4900(00)88760-2; DENO DC, 1983, AM J PHYSIOL, V245, pR564, DOI 10.1152/ajpregu.1983.245.4.R564; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hocking DC, 2003, AM J PHYSIOL-LUNG C, V285, pL169, DOI 10.1152/ajplung.00371.2002; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphries MJ, 2004, BIOCHEM SOC T, V32, P407, DOI 10.1042/BST0320407; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; Monaghan E, 2004, J BIOL CHEM, V279, P1400, DOI 10.1074/jbc.M310374200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; OWENS MR, 1982, BLOOD, V59, P1305; Peyruchaud O, 2000, CELL MOL LIFE SCI, V57, P1109; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Rabbani SA, 2002, CANCER RES, V62, P2390; Rebres RA, 1995, AM J PHYSIOL-GASTR L, V269, pG902, DOI 10.1152/ajpgi.1995.269.6.G902; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2005, MOL BIOL CELL, V16, P757, DOI 10.1091/mbc.e04-08-0672; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; THOMPSON C, 1989, J CLIN INVEST, V84, P1226, DOI 10.1172/JCI114289; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wanaski SP, 2003, BIOCHEMISTRY-US, V42, P42, DOI 10.1021/bi012097n; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wickstrom SA, 2002, CANCER RES, V62, P5580; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WU C, 1995, J BIOL CHEM, V266, P9697; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	68	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9450	9459		10.1074/jbc.M501901200	http://dx.doi.org/10.1074/jbc.M501901200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461772	hybrid			2022-12-25	WOS:000236404700055
J	Schonrock, N; Exner, V; Probst, A; Gruissem, W; Hennig, L				Schonrock, N; Exner, V; Probst, A; Gruissem, W; Hennig, L			Functional genomic analysis of CAF-1 mutants in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN ASSEMBLY FACTOR-1; H3 LYSINE-9 METHYLATION; DNA METHYLATION; FACTOR-I; SEED DEVELOPMENT; P150 SUBUNIT; PROTEIN; HETEROCHROMATIN; MAINTENANCE; CELLS	Duplication of chromatin following DNA replication requires spatial reorganization of chromatin domains assisted by chromatin assembly factor CAF-1. Here, we tested the genomic consequences of CAF-1 loss and the function of chromatin assembly factor CAF-1 in heterochromatin formation. Genes located in heterochromatic regions are usually silent, and we found that this transcriptional repression persists in the absence of CAF-1 in Arabidopsis. However, using microarrays we observed that genes that are active during late S-phase, when heterochromatin is duplicated, were up-regulated in CAF-1 mutants. Arabidopsis CAF-1 mutants also have reduced cytological heterochromatin content; however, DNA methylation of pericentromeric repeats was normal, demonstrating that CAF-1 is not required for maintenance of DNA methylation. Instead, hypomethylation of the genome, which has only mild effects on the development of wild-type plants, completely arrested development of CAF-1 mutants. These results suggest that CAF-1 functions in heterochromatin formation. CAF-1 and DNA methylation, which is also needed for heterochromatin formation, have partially redundant functions that are essential for cell proliferation. Interestingly, transcriptional repression and heterochromatin compaction can be genetically separated, and CAF-1 is required only for the complete compaction of heterochromatin but not to maintain transcriptional repression of heterochromatic genes.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Zurich Basel Plant Sci Ctr, CH-8092 Zurich, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva 4, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Geneva	Hennig, L (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland.	lhennig@ipw.biol.ethz.ch	Gruissem, Wilhelm/H-1752-2013; , Probst/F-2267-2015; Hennig, Lars/G-2081-2011	, Probst/0000-0001-9534-8058; Hennig, Lars/0000-0002-6645-1862; Gruissem, Wilhelm/0000-0002-1872-2998				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ALTMANN T, 2004, GENOMXPRESS, V3, P13; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Donnelly PM, 1999, DEV BIOL, V215, P407, DOI 10.1006/dbio.1999.9443; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fransz P, 2003, CHROMOSOME RES, V11, P227, DOI 10.1023/A:1022835825899; Game JC, 1999, GENETICS, V151, P485; Grandin N, 2003, MOL CELL BIOL, V23, P9162, DOI 10.1128/MCB.23.24.9162-9177.2003; Hennig L, 2003, DEVELOPMENT, V130, P2555, DOI 10.1242/dev.00470; Hennig L, 2004, PLANT PHYSIOL, V135, P1765, DOI 10.1104/pp.104.043182; Hennig L, 2005, TRENDS CELL BIOL, V15, P295, DOI 10.1016/j.tcb.2005.04.004; Hirochika H, 2000, PLANT CELL, V12, P357, DOI 10.1105/tpc.12.3.357; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jasencakova Z, 2003, PLANT J, V33, P471, DOI 10.1046/j.1365-313X.2003.01638.x; Jiao RJ, 2004, MOL CELL BIOL, V24, P4710, DOI 10.1128/MCB.24.11.4710-4719.2004; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Keller C, 2000, J BIOL CHEM, V275, P35512, DOI 10.1074/jbc.M003073200; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; Kohler C, 2003, GENE DEV, V17, P1540, DOI 10.1101/gad.257403; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Menges M, 2003, PLANT MOL BIOL, V53, P423, DOI 10.1023/B:PLAN.0000019059.56489.ca; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Probst AV, 2003, PLANT J, V33, P743, DOI 10.1046/j.1365-313X.2003.01667.x; Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362; Rasmussen LJ, 2000, EXP CELL RES, V257, P127, DOI 10.1006/excr.2000.4865; Reese BE, 2003, MOL CELL BIOL, V23, P3226, DOI 10.1128/MCB.23.9.3226-3236.2003; Reinholz E, 1966, ARAB INF SERV, V3, P19; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Takeda S, 2004, GENE DEV, V18, P782, DOI 10.1101/gad.295404; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Tchenio T, 2001, MOL CELL BIOL, V21, P1953, DOI 10.1128/MCB.21.6.1953-1961.2001; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; WU Z, 2003, TECHNICAL REPORT MOD; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	62	101	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9560	9568		10.1074/jbc.M513426200	http://dx.doi.org/10.1074/jbc.M513426200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452472	hybrid			2022-12-25	WOS:000236404700067
J	Sharon, M; Witt, S; Felderer, K; Rockel, B; Baumeister, W; Robinson, CV				Sharon, M; Witt, S; Felderer, K; Rockel, B; Baumeister, W; Robinson, CV			20S proteasomes have the potential to keep substrates in store for continual degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; THERMOPLASMA-ACIDOPHILUM; PROTEIN-DEGRADATION; ATP HYDROLYSIS; S PROTEASOMES; COMPLEX; DISSOCIATION; STOICHIOMETRY; ARRANGEMENT; ASSEMBLIES	The 20S core of the proteasome, which together with the regulatory particle plays a major role in the degradation of proteins in eukaryotic cells, is traversed by an internal system of cavities, namely two antechambers and one central proteolytic chamber. Little is known about the mechanisms underlying substrate binding and translocation of polypeptide chains into the interior of 20S proteasomes. Specifically, the role of the antechambers is not fully understood, and the number of substrate molecules sequestered within the internal cavities at any one time is unknown. Here we have shown that by applying both electron microscopy and tandem mass spectrometry ( MS) approaches to this multisubunit complex we obtain precise information regarding the stoichiometry and location of substrates within the three chambers. The dissociation pattern in tandem MS allows us to conclude that a maximum of three green fluorescent protein and four cytochrome c substrate molecules are bound within the cavities. Our results also show that > 95% of the population of proteasome molecules contain the maximum number of partially folded substrates. Moreover, we deduce that one green fluorescent protein or two cytochrome c molecules must reside within the central proteolytic chamber while the remaining substrate molecules occupy, singly, both antechambers. The results imply therefore an additional role for 20S proteasomes in the storage of substrates prior to their degradation, specifically in cases where translocation rates are slower than proteolysis. More generally, the ability to locate relatively small protein ligands sequestered within the 28-subunit core particle highlights the tremendous potential of tandem MS for deciphering substrate binding within large macromolecular assemblies.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Dept Mol Struct Biol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Cambridge; Max Planck Society	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk		robinson, carol/0000-0001-7829-5505; Sharon, Michal/0000-0003-3933-0595				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; Chernushevich IV, 2004, ANAL CHEM, V76, P1754, DOI 10.1021/ac035406j; Dolenc I, 1998, FEBS LETT, V434, P357, DOI 10.1016/S0014-5793(98)01010-2; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huffman HA, 2003, BIOCHEMISTRY-US, V42, P8679, DOI 10.1021/bi027310+; Hutschenreiter S, 2004, EMBO J, V23, P2488, DOI 10.1038/sj.emboj.7600262; Jurchen JC, 2003, J AM CHEM SOC, V125, P2817, DOI 10.1021/ja0211508; Kaltashov IA, 2005, ANAL CHEM, V77, P5370, DOI 10.1021/ac050511+; Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Loo JA, 2005, J AM SOC MASS SPECTR, V16, P998, DOI 10.1016/j.jasms.2005.02.017; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luciani F, 2005, BIOPHYS J, V88, P2422, DOI 10.1529/biophysj.104.049221; McCammon MG, 2004, J AM CHEM SOC, V126, P5950, DOI 10.1021/ja0317170; Nettleton EJ, 2000, BIOPHYS J, V79, P1053, DOI 10.1016/S0006-3495(00)76359-4; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Reuter CJ, 2004, J BACTERIOL, V186, P7763, DOI 10.1128/JB.186.22.7763-7772.2004; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH RD, 1992, ORG MASS SPECTROM, V27, P811, DOI 10.1002/oms.1210270709; Sobott F, 2003, INT J MASS SPECTROM, V230, P193, DOI 10.1016/j.ijms.2003.09.008; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Versluis C, 2001, J AM SOC MASS SPECTR, V12, P329, DOI 10.1016/S1044-0305(00)00227-0; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Zwickl P, 1999, PHILOS T R SOC B, V354, P1501, DOI 10.1098/rstb.1999.0494; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	41	57	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9569	9575		10.1074/jbc.M511951200	http://dx.doi.org/10.1074/jbc.M511951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16446364	hybrid			2022-12-25	WOS:000236404700068
J	Yamashita, K; Ollinger, R; McDaid, J; Sakahama, H; Wang, HJ; Tyagi, S; Csizmadia, E; Smith, NR; Soares, MP; Bach, FH				Yamashita, Kenichiro; Oellinger, Robert; McDaid, James; Sakahama, Hideyasu; Wang, Hongjun; Tyagi, Shivraj; Csizmadia, Eva; Smith, Neal R.; Soares, Miguel P.; Bach, Fritz H.			Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs	FASEB JOURNAL			English	Article						T regulatory cells (Tregs); co-stimulation	REGULATORY T-CELLS; CARBON-MONOXIDE; GRAFT-REJECTION; PROTECTIVE GENE; SUPPRESSES; OVEREXPRESSION; PREVENTS; DEATH; FAS; ARTERIOSCLEROSIS	This investigation focused on obtaining a further understanding of the role of heme oxygenase-1 (HO-1) in tolerance induction. Hearts from C57BL/6 (H-2(b)) mice survived long-term when transplanted into BALB/c (H-2(d)) recipients treated with the tolerance-inducing regimen of anti-CD40L antibody (MR-1) plus donor-specific transfusion (DST). Grafts did not, however, survive long-term in (HO-1(-/-)) recipients given the same treatment. Similarly, long-term survival induced by DST was ablated when HO-1 activity was blocked by zinc protoporphyrin IX (ZnPPIX). We further asked whether modulation of HO-1 expression/activity could be used to promote the induction of graft tolerance. DST alone (day 0) failed to promote any prolongation of survival of DBA/2 (H-2(d)) hearts transplanted into B6AF1 (H-2(b,k/d)) recipients. However, long-term survival and (dominant peripheral) tolerance were readily induced when DST was combined with induction of HO-1 expression by cobalt protoporphyrin IX (CoPPIX). HO-1 induction plus DST led to a significant up-regulation of Foxp3, TGF-beta, IL-10, and CTLA4, which suggests a prominent role for CD4+CD25+ regulatory T cells (Tregs). In fact, the tolerogenic effect of HO-1 plus DST was dependent on CD4+CD25+ Tregs as suggested by adoptively transferring these cells into irradiated recipients under various regimens. Taken together, these findings show that expression of HO-1 in a graft recipient can be essential for long-term graft survival and for induction of tolerance and that modulation of HO-1 expression/activity can be used therapeutically to synergize in the generation of graft tolerance.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, Boston, MA 02215 USA; Univ Innsbruck, Dept Surg, Innsbruck, Austria; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA; Inst Culbenkian Ciencia, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Innsbruck; Harvard University; Harvard Medical School; Massachusetts General Hospital	Bach, FH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	fritz_bach@hms.harvard.edu	Öllinger, Robert/D-1538-2009; Soares, Miguel P/G-4188-2011; Wang, Hongjun/AAA-1319-2021	Soares, Miguel/0000-0002-9314-4833; Ollinger, Robert/0000-0002-4499-1673	NHLBI NIH HHS [HL67040, HL58688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067040, R01HL058688] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araujo JA, 2003, J IMMUNOL, V171, P1572, DOI 10.4049/jimmunol.171.3.1572; Baan C, 2004, AM J TRANSPLANT, V4, P811, DOI 10.1111/j.1600-6143.2004.00420.x; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BACH FH, IN PRESS FASEB J; Bachas C, 1997, GAUGE THEORIES, APPLIED SUPERSYMMETRY AND QUANTUM GRAVITY II, P3; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; Braudeau C, 2004, GENE THER, V11, P701, DOI 10.1038/sj.gt.3302208; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Bushell A, 2005, J IMMUNOL, V174, P3290, DOI 10.4049/jimmunol.174.6.3290; Camara NOS, 2005, FREE RADICAL BIO MED, V38, P426, DOI 10.1016/j.freeradbiomed.2004.11.019; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; CHAUVEAU C, 2005, BLOOD; Choi BM, 2004, FREE RADICAL BIO MED, V36, P858, DOI 10.1016/j.freeradbiomed.2004.01.004; Exner M, 2004, TRANSPLANTATION, V77, P538, DOI 10.1097/01.TP.0000113467.36269.F8; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Graca L, 2005, TRENDS IMMUNOL, V26, P130, DOI 10.1016/j.it.2004.12.007; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje; Nikolic B, 1996, J HEART LUNG TRANSPL, V15, P1171; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Pae HO, 2004, J IMMUNOL, V172, P4744, DOI 10.4049/jimmunol.172.8.4744; Pae HO, 2004, MOL PHARMACOL, V66, P122, DOI 10.1124/mol.66.1.122; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Roelen D, 2004, TRANSPLANTATION, V77, pS26, DOI 10.1097/01.TP.0000106469.12073.01; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1999, IMMUNOL TODAY, V20, P434, DOI 10.1016/S0167-5699(99)01530-3; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	43	92	101	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					776	+		10.1096/fj.05-4791fje	http://dx.doi.org/10.1096/fj.05-4791fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473885				2022-12-25	WOS:000237698700023
J	Geserick, C; Tejera, A; Gonzalez-Suarez, E; Klatt, P; Blasco, MA				Geserick, C.; Tejera, A.; Gonzalez-Suarez, E.; Klatt, P.; Blasco, M. A.			Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling	ONCOGENE			English	Article						telomerase; immortalization; proliferation; gene expression profiling; transforming growth factor-beta	KRUPPEL-LIKE FACTOR-4; CATALYTIC SUBUNIT; GENE-EXPRESSION; DOWN-REGULATION; LIFE-SPAN; DIFFERENTIAL REGULATION; TRANSGENIC MICE; CANCER; IDENTIFICATION; SENESCENCE	Here, we show that ectopic expression of the catalytic subunit of mouse telomerase (mTert) confers a growth advantage to primary murine embryonic fibroblasts (MEFs), which have very long telomeres, as well as facilitates their spontaneous immortalization and increases their colony-forming capacity upon activation of oncogenes. We demonstrate that these telomere length-independent growth-promoting effects of mTert overexpression require catalytically active mTert, as well as the formation of mTert/Terc complexes. The gene expression profile of mTert-overexpressing MEFs indicates that telomerase enhances growth in these cells through the repression of growth-inhibiting genes of the transforming growth factor-beta (TGF-beta) signaling network. We functionally validate this result by showing that mTert abrogates the growth-inhibitory effect of TGF-beta in MEFs, thus demonstrating that telomerase increments the proliferative potential of primary mouse embryonic fibroblasts by targeting the TGF-beta pathway.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, Melchor Fernandez Almagro,3, E-28029 Madrid, Spain.	mblasco@cnio.es	Gonzalez-Suarez, Eva/L-6298-2014; Tejera, Agueda M./AAU-2000-2021; Blasco, Maria A./M-1694-2014; Tejera, Agueda/L-1946-2015; Tejera, Agueda/Z-1938-2019	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Blasco, Maria A./0000-0002-4211-233X; Tejera, Agueda M/0000-0002-6703-9466				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Cayuela ML, 2005, EMBO REP, V6, P268, DOI 10.1038/sj.embor.7400359; Chen ZY, 2005, MOL PHARMACOL, V68, P1203, DOI 10.1124/mol.105.014944; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Keeton AB, 2003, ENDOCRINOLOGY, V144, P5402, DOI 10.1210/en.2003-0592; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kopp JB, 1996, LAB INVEST, V74, P991; Krag S, 2000, LAB INVEST, V80, P1855, DOI 10.1038/labinvest.3780196; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liao L, 2005, BIOCHEM BIOPH RES CO, V336, P854, DOI 10.1016/j.bbrc.2005.08.180; Lim JY, 2005, J MOL CELL CARDIOL, V39, P627, DOI 10.1016/j.yjmcc.2005.06.016; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; Liu JH, 2003, AM J PHYSIOL-LUNG C, V285, pL1106, DOI 10.1152/ajplung.00180.2003; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Mulsow JJW, 2005, ANN SURG, V242, P880, DOI 10.1097/01.sla.0000189606.58343.cd; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Ryu MS, 2004, EXP CELL RES, V299, P159, DOI 10.1016/j.yexcr.2004.05.014; Sachsinger J, 2001, CANCER RES, V61, P5580; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2004, J BIOL CHEM, V279, P29286, DOI 10.1074/jbc.M403139200; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Sun LH, 2003, MOL BIOL REP, V30, P249, DOI 10.1023/A:1026370726763; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	74	51	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4310	4319		10.1038/sj.onc.1209465	http://dx.doi.org/10.1038/sj.onc.1209465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501597				2022-12-25	WOS:000239240100006
J	Pretto, D; Barco, R; Rivera, J; Neel, N; Gustavson, MD; Eid, JE				Pretto, D.; Barco, R.; Rivera, J.; Neel, N.; Gustavson, M. D.; Eid, J. E.			The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus andassociates with it in an active complex	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX2; beta-catenin	WNT SIGNALING PATHWAY; SYT-SSX; P120 CATENIN; ACTIVATION; EXPRESSION; GENE; LOCALIZATION; ACCUMULATION; INTERACTS; DOMAINS	Localization of beta-catenin in the cell is a key determinant in its decision to function as a critical mediator of cell adhesion at the surface or a transcription activator in the nucleus. SYT-SSX2 is the fusion product of the chromosomal translocation, t( X; 18)( p11.2; q11.2), which occurs in synovial sarcoma, a soft tissue tumor. SYT-SSX2 is known to associate with chromatin remodeling complexes and is proposed to be involved in controlling gene expression. We report that SYT-SSX2 plays a direct role in b-catenin regulation. When expressed in mammalian cells, SYT-SSX2-induced beta-catenin recruitment to the nucleus. Interestingly, known target genes of canonical Wnt were not activated as a result of SYT-SSX2 expression, nor was the nuclear localization of beta-catenin due to one of the signaling pathways normally implicated in this event. beta-Catenin accumulation in the nucleus led to the formation of a transcriptionally active nuclear complex that contained SYT-SSX2 and beta-catenin. More importantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear beta-catenin signal and a significant decrease in its signaling activity. These results unravel a novel pathway in the control of beta-catenin cellular transport and strongly suggest that SYT-SSX2 contributes to tumor development, in part through beta-catenin signaling.	Vanderbilt Univ, Ctr Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University	Eid, JE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Canc Biol, 23d Ave S Pierce PRB 740, Nashville, TN 37232 USA.	josiane.eid@vanderbilt.edu			NCI NIH HHS [CA68485, CA 15751, R01CA106481-01, K22 CA098008-01] Funding Source: Medline; NIBIB NIH HHS [EB00672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA015751, P30CA068485, R01CA015751, R01CA106481, K22CA098008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000672, R33EB000672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Doucas H, 2005, EUR J CANCER, V41, P365, DOI 10.1016/j.ejca.2004.11.005; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hasegawa T, 2001, HUM PATHOL, V32, P257, DOI 10.1053/hupa.2001.22764; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Xie YT, 2002, CANCER RES, V62, P3861	34	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3661	3669		10.1038/sj.onc.1209413	http://dx.doi.org/10.1038/sj.onc.1209413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462762				2022-12-25	WOS:000238448300005
J	Chou, HYE; Chou, HT; Lee, SC				Chou, Han-Yi E.; Chou, Han Ting; Lee, Sheng-Chung			CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; TANKYRASE; PROTEIN; GENE; IDENTIFICATION; LOCALIZATION; ASSOCIATION; EG5	Proteins of the poly(ADP-ribose) polymerase ( PARP) family play a wide array of functions, covering virtually every aspect of DNA metabolism and function, most notably with the response to DNA damage, transcription, and the maintenance of genomic stability. Here we report the identification and characterization of a novel PARP family member, PARP10 (FLJ14464 or hypothetical protein LOC84875). Overexpression of PARP10 results in loss of cell viability, although down-expression by short hairpin RNA leads to delayed G(1) progression and concomitant cell death. PARP10 exists in both cytoplasm and nucleus, but only nucleolar PARP10 acquires CDK-dependent phosphorylation through late-G1 to S phase, and from prometaphase to cytokinesis in the nucleolar organizing regions. The PARP activity of PARP10 depends on phosphorylation by CDK2-cyclin E in vitro. CDK-phosphorylated PARP10 is absent in growth-arrested cells. These results suggest that PARP10 functions in cell proliferation and may serve as a marker for proliferating cells.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 10617, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan.	slee@ntu.edu.tw						Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Katoh M, 2003, INT J ONCOL, V23, P541; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Liu Y, 2004, MOL CELL BIOL, V24, P5314, DOI 10.1128/MCB.24.12.5314-5323.2004; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Ma Q, 2001, BIOCHEM BIOPH RES CO, V289, P499, DOI 10.1006/bbrc.2001.5987; Matsuo R, 2000, J NEUROCHEM, V74, P2239, DOI 10.1046/j.1471-4159.2000.0742239.x; MENISSIERDEMURC.J, 1999, J BIOL CHEM, V274, P17860; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shall Sydney, 2002, Bioessays, V24, P197, DOI 10.1002/bies.10012; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Yu M, 2005, ONCOGENE, V24, P1982, DOI 10.1038/sj.onc.1208410	26	38	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15201	15207		10.1074/jbc.M506745200	http://dx.doi.org/10.1074/jbc.M506745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16455663	hybrid			2022-12-25	WOS:000237922200023
J	Ecker, M; Deutzmann, R; Lehle, L; Mrsa, V; Tanner, W				Ecker, M; Deutzmann, R; Lehle, L; Mrsa, V; Tanner, W			Pir proteins of Saccharomyces cerevisiae are attached to beta-1,3-glucan by a new protein-carbohydrate linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL WALL; SECRETORY GLYCOPROTEIN; CROSS-LINKING; HEAT-SHOCK; IDENTIFICATION; ARCHITECTURE; BINDING; TRANSGLUTAMINASES; GLYCOSYLATION; MANNOPROTEIN	A family of covalently linked cell wall proteins of Saccharomyces cerevisiae, called Pir proteins, are characterized by up to 10 conserved repeating units. Ccw5/Pir4p contains only one complete repeating sequence and its deletion caused a release of the protein into the medium. The exchange of each of three glutamines ( Gln(69), Gln(74), Gln(76)) as well as one aspartic acid ( Asp(72)) within the repeating unit leads to a loss of the protein from the cell wall. Amino acid sequencing revealed that only Gln(74) is modified. Release of the protein with mild alkali, changed Gln(74) to glutamic acid, suggesting that Gln(74) is involved in the linkage. Analysis by mass spectrometry showed that 5 hexoses are attached to Gln/Glu(74). Sugar analysis revealed glucose as the only constituent. It is suggested that Pir proteins form novel, alkali labile ester linkages between the gamma-carboxyl group of glutamic acids, arising from specific glutamines, with hydroxyl groups of glucoses of beta-1,3-glucan chains. This transglutaminase-type reaction could take place extracellularly and would energetically proceed on the account of amido group elimination.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Biochem, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Tanner, W (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	sekretariat.tanner@biologie.uni-regensburg.de		Mrsa, Vladimir/0000-0002-3989-6938				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; [Anonymous], 1982, METABOLISM GENE EXPR; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Castillo L, 2003, YEAST, V20, P973, DOI 10.1002/yea.1016; De Groot PWJ, 2005, FUNGAL GENET BIOL, V42, P657, DOI 10.1016/j.fgb.2005.04.002; EAMUS D, 1986, WATER FUNGI PLANTS, P27; Ecker M, 2003, EMBO REP, V4, P628, DOI 10.1038/sj.embor.embor864; Esposito C, 2005, FEBS J, V272, P615, DOI 10.1111/j.1742-4658.2004.04476.x; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KOPECKA M, 1974, J CELL BIOL, V62, P66, DOI 10.1083/jcb.62.1.66; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; Molina M, 2000, MICROSC RES TECHNIQ, V51, P601, DOI 10.1002/1097-0029(20001215)51:6<601::AID-JEMT9>3.3.CO;2-9; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Moukadiri I, 1999, J BACTERIOL, V181, P4741, DOI 10.1128/JB.181.16.4741-4745.1999; Mrsa V, 1997, YEAST, V13, P1145; Mrsa V, 1999, YEAST, V15, P813, DOI 10.1002/(SICI)1097-0061(199907)15:10A<813::AID-YEA421>3.0.CO;2-Y; MRSA V, 2001, MOL MECH FUNGAL CELL; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; RUSSO P, 1993, MOL GEN GENET, V239, P273, DOI 10.1007/BF00281628; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sumita T, 2005, EUKARYOT CELL, V4, P1872, DOI 10.1128/EC.4.11.1872-1881.2005; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TOHE A, 1993, YEAST, V9, P481, DOI 10.1002/yea.320090504; VALENTIN E, 1984, J GEN MICROBIOL, V130, P1419; Yin QY, 2005, J BIOL CHEM, V280, P20894, DOI 10.1074/jbc.M500334200; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082	31	128	137	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11523	11529		10.1074/jbc.M600314200	http://dx.doi.org/10.1074/jbc.M600314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495216	hybrid			2022-12-25	WOS:000236988100014
J	Cripps, D; Thomas, SN; Jeng, Y; Yang, F; Davies, P; Yang, AJ				Cripps, D; Thomas, SN; Jeng, Y; Yang, F; Davies, P; Yang, AJ			Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; NEUROFIBRILLARY PATHOLOGY; ABNORMAL PHOSPHORYLATION; STATISTICAL-MODEL; MASS-SPECTROMETRY; BINDING; PROTEASOME; SITES; DOMAINS; TANGLES	One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of paired helical filaments (PHFs) of hyperphosphorylated microtubule-associated protein Tau. Tandem mass spectrometry was employed to examine PHF-Tau post-translational modifications, in particular protein phosphorylation and ubiquitination, to shed light on their role in the early stages of Alzheimer disease. PHF-Tau from Alzheimer disease brain was affinity-purified by MC1 monoclonal antibody to isolate a soluble fraction of PHF-Tau in a conformation unique to human AD brain. A large number of phosphorylation sites were identified by employing a data-dependent neutral loss algorithm to trigger MS3 scans of phosphopeptides. It was found that soluble PHF-Tau is ubiquitinated at its microtubule-binding domain at residues Lys-254, Lys-311, and Lys-353, suggesting that ubiquitination of PHF-Tau may be an earlier pathological event than previously thought and that ubiquitination could play a regulatory role in modulating the integrity of microtubules during the course of AD. Tandem mass spectrometry data for ubiquitin itself indicate that PHF-Tau is modified by three polyubiquitin linkages, at Lys-6, Lys-11, and Lys-48. Relative quantitative analysis indicates that Lys-48-linked polyubiquitination is the primary form of polyubiquitination with a minor portion of ubiquitin linked at Lys-6 and Lys-11. Because modification by Lys-48-linked polyubiquitin chains is known to serve as the essential means of targeting proteins for degradation by the ubiquitin-proteasome system, and it has been reported that modification at Lys-6 inhibits ubiquitin-dependent protein degradation, a failure of the ubiquitin-proteasome system could play a role in initiating the formation of degradation-resistant PHF tangles.	Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Micro Tech Sci Inc, Vista, CA 92081 USA	University of Southern California; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Yang, AJ (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	austiny@usc.edu	Thomas, Stefani/AAF-4212-2021	Thomas, Stefani/0000-0003-1679-5453	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020069, R01MH059786, R01MH038623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025323] Funding Source: NIH RePORTER; NIA NIH HHS [AG25323, R01 AG025323] Funding Source: Medline; NIMH NIH HHS [T32 MH020069, MH59786, R01 MH059786, R01 MH038623] Funding Source: Medline; PHS HHS [38623] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Arrasate M, 2000, NEUROCHEM RES, V25, P43, DOI 10.1023/A:1007583214722; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Fath T, 2002, J NEUROSCI, V22, P9733; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Gong CX, 2005, J NEURAL TRANSM, V112, P813, DOI 10.1007/s00702-004-0221-0; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219-MCP200; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LETERRIER JF, 1982, J CELL BIOL, V95, P982, DOI 10.1083/jcb.95.3.982; Lim JN, 2005, BBA-MOL BASIS DIS, V1739, P311, DOI 10.1016/j.bbadis.2004.10.003; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Mandell JW, 1996, J NEUROSCI, V16, P5727; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Nemes Z, 2004, FASEB J, V18, P1135, DOI 10.1096/fj.04-1493fje; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; REBHAN M, 1995, NEUROREPORT, V6, P429, DOI 10.1097/00001756-199502000-00006; RENDON A, 1990, BIOCHEM J, V269, P555, DOI 10.1042/bj2690555; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200; Uboga NV, 2000, NEUROBIOL AGING, V21, P1, DOI 10.1016/S0197-4580(00)00091-9; Vega IE, 2005, MOL BRAIN RES, V138, P135, DOI 10.1016/j.molbrainres.2005.04.015; Vincent I, 1998, NEUROBIOL AGING, V19, P287, DOI 10.1016/S0197-4580(98)00071-2; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Wischik CM, 2001, NEUROBIOLOGY ALZHEIM, P103; Zhang JY, 2005, J NEURAL TRANSM, V112, P547, DOI 10.1007/s00702-004-0196-x	57	215	223	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10825	10838		10.1074/jbc.M512786200	http://dx.doi.org/10.1074/jbc.M512786200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16443603	hybrid			2022-12-25	WOS:000236822200022
J	Sorrell, AM; Shand, JH; Tonner, E; Gamberoni, M; Accorsi, PA; Beattie, J; Allan, GJ; Flint, DJ				Sorrell, AM; Shand, JH; Tonner, E; Gamberoni, M; Accorsi, PA; Beattie, J; Allan, GJ; Flint, DJ			Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-5; FIBRIN-DEPENDENT ENHANCEMENT; MAMMARY-GLAND; HORMONAL-CONTROL; MEDIATED STIMULATION; AMIDOLYTIC ACTIVITY; TERMINAL DOMAINS; AMINO-ACIDS; CELL-DEATH; IGF	Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.	Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Bologna, Fac Med Vet, Dipartimento Morfofisiol Vet & Prod Anim, I-40064 Ozzano Dell Emilia, BO, Italy	University of Bologna	Flint, DJ (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.	d.flint@hannah.ac.uk						Allan GJ, 2002, ENDOCRINOLOGY, V143, P4310, DOI 10.1210/en.2001-211191; Allan GJ, 2006, ENDOCRINOLOGY, V147, P338, DOI 10.1210/en.2005-0582; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Beattie J, 2005, J MOL ENDOCRINOL, V34, P163, DOI 10.1677/jme.1.01656; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Boutinaud M, 2004, J MOL ENDOCRINOL, V33, P195, DOI 10.1677/jme.0.0330195; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; BUSSO N, 1989, J BIOL CHEM, V264, P7455; CHRISTY JRE, 1989, CARDIOVASC RES, V23, P949, DOI 10.1093/cvr/23.11.949; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Deugnier MA, 1999, J CELL SCI, V112, P1035; FISCHER B, 1990, BIOL CHEM H-S, V371, P1067, DOI 10.1515/bchm3.1990.371.2.1067; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; Flint DJ, 2000, J MAMMARY GLAND BIOL, V5, P65, DOI 10.1023/A:1009567316520; Heegaard CW, 1997, FIBRINOLYSIS PROTEOL, V11, P29, DOI 10.1016/S0268-9499(97)80006-9; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; Lund LR, 1996, DEVELOPMENT, V122, P181; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P988, DOI 10.1016/S0006-291X(02)00569-7; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Phillips K, 2003, J MOL ENDOCRINOL, V31, P197, DOI 10.1677/jme.0.0310197; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Song H, 2000, J MOL ENDOCRINOL, V24, P43, DOI 10.1677/jme.0.0240043; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 2000, J ENDOCRINOL, V167, P265, DOI 10.1677/joe.0.1670265; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10883	10889		10.1074/jbc.M508505200	http://dx.doi.org/10.1074/jbc.M508505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16505491	hybrid			2022-12-25	WOS:000236822200028
J	Miyazaki, K; Takenouchi, M; Kondo, H; Noro, N; Suzuki, M; Tsuda, S				Miyazaki, K; Takenouchi, M; Kondo, H; Noro, N; Suzuki, M; Tsuda, S			Thermal stabilization of Bacillus subtilis family-11 xylanase by directed evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODERMA-REESEI ENDO-1,4-BETA-XYLANASE-II; STRUCTURAL BASIS; PROTEIN; MUTAGENESIS; THERMOSTABILITY; COMBINATION; STABILITY; INCREASES; RESIDUES; PROGRAM	We used directed evolution to enhance the thermostability of glycosyl hydrolase family-11 xylanase from Bacillus subtilis. By combining random point mutagenesis, saturation mutagenesis, and DNA shuffling, a thermostable variant, Xyl(st), was identified which contained three amino acid substitutions: Q7H, N8F, and S179C. The half-inactivation temperature (the midpoint of the melting curves) for the Xyl(st) variant compared with the wild-type enzyme after incubation for 10 min was elevated from 58 to 68 C. At 60 C the wild-type enzyme was inactivated within 5 min, but Xyl(st) retained full activity for at least 2 h. The stabilization was accompanied by evidence of thermophilicity; that is, an increase in the optimal reaction temperature from 55 to 65 C and lower activity at low temperatures and higher activity at higher temperatures relative to wild type. To elucidate the mechanism of thermal stabilization, three-dimensional structures were determined for the wild-type and Xyl(st) enzymes. A cavity was identified around Gln-7/Asn-8 in wild type that was filled with bulky, hydrophobic residues in Xyl(st). This site was not identified by previous approaches, but directed evolution identified the region as a weak point. Formation of an intermolecular disulfide bridge via Cys-179 was observed between monomers in Xyl(st). However, the stability was essentially the same in the presence and absence of a reducing agent, indicating that the increased hydrophobicity around the Cys-179 accounted for the stability.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Genome Based Biofactory, Sapporo, Hokkaido 0628517, Japan; Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Proteom, Suita, Osaka 5650871, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Osaka University; Hokkaido University	Miyazaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	miyazaki-kentaro@aist.go.jp	Miyazaki, Kentaro/F-7022-2010; Tsuda, Sakae/M-2756-2018; Kondo, Hidemasa/M-7465-2018; Suzuki, Mamoru/G-6576-2016	Miyazaki, Kentaro/0000-0002-4349-566X; Tsuda, Sakae/0000-0002-1399-0619; Kondo, Hidemasa/0000-0003-2799-1775; Suzuki, Mamoru/0000-0001-7071-5093				Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; Arnold FH, 1998, NAT BIOTECHNOL, V16, P617, DOI 10.1038/nbt0798-617; Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bajpai P, 2004, CRIT REV BIOTECHNOL, V24, P1, DOI 10.1080/07388550490465817; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; Funahashi J, 2000, BIOCHEMISTRY-US, V39, P14448, DOI 10.1021/bi0015717; Georis J, 2000, PROTEIN SCI, V9, P466; Harris GW, 1997, PROTEINS, V29, P77, DOI 10.1002/(SICI)1097-0134(199709)29:1<77::AID-PROT6>3.3.CO;2-K; Ishikawa K, 1998, J BIOL CHEM, V273, P17726, DOI 10.1074/jbc.273.28.17726; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAICE MG, 1986, ARCH MICROBIOL, V144, P201, DOI 10.1007/BF00410947; Polizeli MLTM, 2005, APPL MICROBIOL BIOT, V67, P577, DOI 10.1007/s00253-005-1904-7; SUNG WL, 1993, PROTEIN EXPRES PURIF, V4, P200, DOI 10.1006/prep.1993.1026; Turunen O, 2002, PROTEIN ENG, V15, P141, DOI 10.1093/protein/15.2.141; Turunen O, 2001, J BIOTECHNOL, V88, P37, DOI 10.1016/S0168-1656(01)00253-X; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDENBURG B, 1994, EUR J BIOCHEM, V220, P981; WAKARCHUK WW, 1994, PROTEIN ENG, V7, P1379, DOI 10.1093/protein/7.11.1379; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WOOD PJ, 1983, J HISTOCHEM CYTOCHEM, V31, P823, DOI 10.1177/31.6.6841974; Xiong HR, 2004, EXTREMOPHILES, V8, P393, DOI 10.1007/s00792-004-0400-9; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	35	98	115	2	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10236	10242		10.1074/jbc.M511948200	http://dx.doi.org/10.1074/jbc.M511948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467302	hybrid			2022-12-25	WOS:000236594300051
J	Fahling, M; Mrowka, R; Steege, A; Martinka, P; Persson, PB; Thiele, BJ				Fahling, M; Mrowka, R; Steege, A; Martinka, P; Persson, PB; Thiele, BJ			Heterogeneous nuclear ribonucleoprotein-A2/B1 modulate collagen prolyl 4-hydroxylase, alpha(I) mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; MICROARRAY ANALYSIS REVEALS; POSTTRANSCRIPTIONAL REGULATION; 3-UNTRANSLATED REGION; RESPONSE ELEMENT; BINDING PROTEIN; NITRIC-OXIDE; HNRNP A2; TRAFFICKING; CELLS	Collagen prolyl 4-hydroxylase (C-P4H) alpha-subunit is of regulatory importance in the assembling of C-P4H tetramers, which are necessary for the hydroxylation of procollagen chains. Change in collagen expression by hypoxia or iron diminishment is a significant issue in extracellular matrix remodeling. It was proposed that C-P4H-alpha (I) is regulated at the posttrancriptional level under these conditions. Here we report that the induction of C-P4H-alpha (I) in human fibrosarcoma cells HT1080 by the iron chelator 2,2-dipyridyl is predominantly caused by an enhancement of mRNA stability. This effect is mediated by an increased synthesis and binding of heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1, which interacts with a (U) 16 element located in the 3'-untranslated region of C-P4H-alpha (I) mRNA. Luciferase reporter gene assays depending on C-P4H-alpha (I) 3'-untranslated region and co-transfection with hnRNP-A2/B1 provide evidence that the (U) 16 element is necessary and sufficient for posttranscriptional control of C-P4H-alpha (I) synthesis under the analyzed conditions. Further indication for the significance of hnRNP-A2/B1 in C-P4H-alpha (I) induction was obtained by micro array experiments. In a data set representing 686 independent physiological conditions, we found a significant positive correlation between hnRNP-A2/B1 and C-P4H-alpha (I) mRNAs.	Univ Med Berlin, Charite, Inst Vegetat Physiol, D-10117 Berlin, Germany; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Fahling, M (corresponding author), Univ Med Berlin, Charite, Inst Vegetat Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	Michael.Faehling@charite.de	Fähling, Michael/E-5018-2011; Mrowka, Ralf/AAW-1480-2021; Steege, Andreas/F-3885-2010	Mrowka, Ralf/0000-0002-0991-3418; Persson, Pontus/0000-0003-0926-2878; Fahling, Michael/0000-0003-1079-5049				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; BERG RA, 1980, BIOCHEM J, V189, P491, DOI 10.1042/bj1890491; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Brooks S A, 2000, Nucleic Acids Res, V28, pE49, DOI 10.1093/nar/28.10.e49; Carson JH, 2005, BIOL CELL, V97, P51; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cuadras MA, 2002, J VIROL, V76, P4467, DOI 10.1128/JVI.76.9.4467-4482.2002; Detweiler CS, 2001, P NATL ACAD SCI USA, V98, P5850, DOI 10.1073/pnas.091110098; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hamilton BJ, 1999, BIOCHEM BIOPH RES CO, V261, P646, DOI 10.1006/bbrc.1999.1040; He YW, 2005, J CELL SCI, V118, P3173, DOI 10.1242/jcs.02448; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LASKO P, 2003, SCI STKE, pRE6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pesole G, 1997, GENE, V205, P95, DOI 10.1016/S0378-1119(97)00407-1; Raghavan A, 2002, NUCLEIC ACIDS RES, V30, P5529, DOI 10.1093/nar/gkf682; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; SIERRA JM, 1994, MOL BIOL REP, V19, P211, DOI 10.1007/BF00986963; Smith R, 2004, NEUROSCIENTIST, V10, P495, DOI 10.1177/1073858404266759; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsukamoto H, 1996, J CLIN INVEST, V97, P2823, DOI 10.1172/JCI118738; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	57	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9279	9286		10.1074/jbc.M510925200	http://dx.doi.org/10.1074/jbc.M510925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464861	hybrid			2022-12-25	WOS:000236404700035
J	Isin, EM; Guengerich, FP				Isin, EM; Guengerich, FP			Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-DRUG INTERACTIONS; ISOTHERMAL TITRATION CALORIMETRY; HUMAN LIVER-MICROSOMES; RATE-LIMITING STEPS; P450 REDUCTASE; ACTIVE-SITE; HETEROTROPIC COOPERATIVITY; ELECTRON-TRANSFER; IN-VITRO; ACTIVATION	Cytochrome P450 (P450) 3A4, the major catalyst involved in human drug oxidation, displays substrate- and reaction-dependent homotropic and heterotropic cooperative behavior. Although several models have been proposed, these mainly rely on steady-state kinetics and do not provide information on the contribution of the individual steps of P450 catalytic cycle to the observed cooperativity. In this work, we focused on the kinetics of substrate binding, and the fluorescent properties of bromocriptine and alpha-naphthoflavone allowed analysis of an initial ligand-P450 3A4 interaction that does not cause a perturbation of the heme spectrum. The binding stoichiometry for bromocriptine was determined to be unity using isothermal titration calorimetry and equilibrium dialysis methods, suggesting that the ligand bound to the peripheral site during the initial encounter dissociates subsequently. A three-step substrate binding model is proposed, based on absorbance and fluorescence stopped-flow kinetic data and equilibrium binding data obtained with bromocriptine, and evaluated using kinetic modeling. The results are consistent with the substrate molecule binding at a site peripheral to the active site and subsequently moving toward the active site to bind to the heme and resulting in a low to high spin iron shift. The last step is attributed to a conformational change in the enzyme active site. The later steps of binding were shown to have rate constants comparable with the subsequent steps of the catalytic cycle. The P450 3A4 binding process is more complex than a two-state system, and the overlap of rates of some of the events with subsequent steps is proposed to underlie the observed cooperativity.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Isin, Emre/0000-0003-3402-7685	NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090426] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BUENING MK, 1978, BIOCHEM BIOPH RES CO, V82, P348, DOI 10.1016/0006-291X(78)90616-2; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CINTI DL, 1979, BIOCHEMISTRY-US, V18, P36, DOI 10.1021/bi00568a006; Cliff MJ, 2003, J MOL RECOGNIT, V16, P383, DOI 10.1002/jmr.648; Cliff MJ, 2004, J MOL RECOGNIT, V17, P513, DOI 10.1002/jmr.714; COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Egnell AC, 2005, J PHARMACOL EXP THER, V312, P926, DOI 10.1124/jpet.104.078519; Ekins S, 1997, PHARMACOGENETICS, V7, P165, DOI 10.1097/00008571-199706000-00001; Ekins S, 1998, INT J CLIN PHARM TH, V36, P642; Fersht A, 1999, STRUCTURE MECH PROTE, P159; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guengerich FP, 2005, ARCH BIOCHEM BIOPHYS, V440, P204, DOI 10.1016/j.abb.2005.06.019; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; Harlow GR, 1997, J BIOL CHEM, V272, P5396, DOI 10.1074/jbc.272.9.5396; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; He YA, 2003, ARCH BIOCHEM BIOPHYS, V409, P92, DOI 10.1016/S0003-9861(02)00484-8; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Houston JB, 2005, ARCH BIOCHEM BIOPHYS, V433, P351, DOI 10.1016/j.abb.2004.09.010; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Hutzler JM, 2002, DRUG METAB DISPOS, V30, P355, DOI 10.1124/dmd.30.4.355; Inaba T, 1997, TOXICOL LETT, V93, P215, DOI 10.1016/S0378-4274(97)00098-2; JOHNSON KA, 2003, KINETIC ANAL MACROMO, V267, P1; KAPITULNIK J, 1977, CLIN PHARMACOL THER, V22, P475; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; Koley AP, 1996, BIOCHIMIE, V78, P706, DOI 10.1016/S0300-9084(97)82528-X; Koley AP, 1997, BIOCHEM PHARMACOL, V53, P455, DOI 10.1016/S0006-2952(96)00836-2; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; Krauser JA, 2005, J BIOL CHEM, V280, P19496, DOI 10.1074/jbc.M501854200; Krauser JA, 2004, EUR J BIOCHEM, V271, P3962, DOI 10.1111/j.1432-1033.2004.04339.x; KUBY SA, 1991, STUDY ENZYMES, V1, P300; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Ladbury JE, 2004, BIOTECHNIQUES, V37, P885, DOI 10.2144/04376TE01; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; Mueller Ernest J., 1995, P83; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ortiz de Montellano P.R., 2005, CYTOCHROME P450 STRU, P183, DOI [10.1007/b139087, DOI 10.1007/B139087]; PALMER G, 1992, J BIOL CHEM, V267, P665; Patil PV, 2000, ANAL BIOCHEM, V286, P187, DOI 10.1006/abio.2000.4802; PATTEN CJ, 1993, CHEM RES TOXICOL, V6, P511, DOI 10.1021/tx00034a019; PEYRONNEAU MA, 1994, EUR J BIOCHEM, V223, P947, DOI 10.1111/j.1432-1033.1994.tb19072.x; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Scott EE, 2005, TRENDS BIOCHEM SCI, V30, P5, DOI 10.1016/j.tibs.2004.11.004; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Shou MG, 2002, METHOD ENZYMOL, V357, P261; Stresser DM, 2000, DRUG METAB DISPOS, V28, P1440; Szklarz GD, 1998, DRUG METAB DISPOS, V26, P1179; Tang W, 2001, CURR DRUG METAB, V2, P185, DOI 10.2174/1389200013338658; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Venkatakrishnan K, 1998, J CLIN PHARMACOL, V38, P112, DOI 10.1002/j.1552-4604.1998.tb04399.x; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Xue LL, 2001, CHEM RES TOXICOL, V14, P483, DOI 10.1021/tx000218z; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zhang QY, 1999, DRUG METAB DISPOS, V27, P804	74	115	117	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9127	9136		10.1074/jbc.M511375200	http://dx.doi.org/10.1074/jbc.M511375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467307	hybrid			2022-12-25	WOS:000236404700018
J	Luo, Y; Nita-Lazar, A; Haltiwanger, RS				Luo, Y; Nita-Lazar, A; Haltiwanger, RS			Two distinct pathways for O-fucosylation of epidermal growth factor-like or thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; FUCOSE GLYCOSYLATION PATHWAY; NOTCH-DELTA INTERACTIONS; FACTOR-LIKE MODULES; HUMAN FACTOR-IX; LINKED FUCOSE; PROTEIN O-FUCOSYL-TRANSFERASE-1; LIGAND-BINDING; PLASMINOGEN-ACTIVATOR; ENZYMATIC ADDITION	Epidermal growth factor-like (EGF) repeats and thrombospondin type 1 repeats (TSRs) are both small cysteine-knot motifs known to be O-fucosylated. The enzyme responsible for the addition of O-fucose to EGF repeats, protein O-fucosyltransferase 1 (POFUT1), has been identified and shown to be essential in Notch signaling. Fringe, an O-fucose beta 1,3-N-acetylglucosaminyltransferase, elongates O-fucose on specific EGF repeats from Notch to form a disaccharide that can be further elongated to a tetrasaccharide. TSRs are found in many extracellular matrix proteins and are involved in protein-protein interactions. The O-fucose moiety on TSRs can be further elongated with glucose to form a disaccharide. The discovery of O-fucose on TSRs raised the question of whether POFUT1, or a different enzyme, adds O-fucose to TSRs. Here we demonstrate the existence of a TSR-specific O-fucosyltransferase distinct from POFUT1. Similar to POFUT1, the novel TSR-specific O-fucosyltransferase is a soluble enzyme that requires a properly folded TSR as an acceptor substrate. In addition, we found that a previously identified fucose-specific beta 1,3-glucosyltransferase adds glucose to O-fucose on TSRs, but it does not modify O-fucose on an EGF repeat. Similarly, Lunatic fringe, Manic fringe, and Radical fringe are all capable of modifying O-fucose on an EGF repeat, but not on a TSR. Taken together, these results suggest that two distinct O-fucosylation pathways exist in cells, one specific for EGF repeat and the other for TSRs.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X	NIGMS NIH HHS [R01 GM061126, GM 61126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; WANG Y, 1996, GLYCOBIOLOGY, V6, P759; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	46	86	88	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9385	9392		10.1074/jbc.M511974200	http://dx.doi.org/10.1074/jbc.M511974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464858	hybrid			2022-12-25	WOS:000236404700047
J	Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB				Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB			BACH1 is a DNA repair protein supporting BRCA1 damage response	ONCOGENE			English	Article						BRCA1; BACH1; FA-J; BRIP1; DNA repair	FANCONI-ANEMIA; HELICASE BRIP1; NUCLEAR FOCI; HISTONE H2AX; PHOSPHORYLATION; PHOSPHOPEPTIDE; TUMORIGENESIS; RECOGNITION; ASSOCIATION; DEFICIENT	The link between defects in BRCA1 and breast cancer development may be best understood by deciphering the role of associated proteins. BRCA1 associated C-terminal helicase (BACH1) interacts directly with the BRCA1 C-terminal BRCT repeats, which are important for BRCA1 DNA repair and are mutated in the majority of BRCA1 familial cancers. Thus, BACH1 is a likely candidate for mediating BRCA1 DNA repair and tumor suppression functions. Although previous evidence using overexpression of a dominant negative BACH1 has suggested that BACH1 is involved in BRCA1-DNA repair function, our results using BACH1 deficient cells provide direct evidence for involvement of BACH1 in DNA repair as well as for localizing BRCA1. Following DNA damage BACH1 is modified by phosphorylation, displays a BRCA1-like nuclear foci pattern and colocalizes with gamma-H2AX. Given that the BACH1/BRCA1 complex is unaltered by DNA damage and the intensity of BRCA1 foci is diminished in BACH1 deficient cells, BACH1 may serve to not only facilitate DNA repair, but also maintain BRCA1 in DNA damage foci.	UMASS Med Sch, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Cantor, SB (corresponding author), UMASS Med Sch, 364 Plantat St LRB 415, Worcester, MA 01605 USA.	Sharon.Cantor@umassmed.edu	Fong, Geoffrey T/H-2810-2014	Fong, Geoffrey T/0000-0001-9098-6472				Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim SS, 2004, MOL CELL BIOL, V24, P9498, DOI 10.1128/MCB.24.21.9498-9507.2004; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Monteiro ANA, 2002, CANCER BIOL THER, V1, P187, DOI 10.4161/cbt.66; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Snouwaert JN, 1999, FASEB J, V13, pA1538; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	68	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2245	2253		10.1038/sj.onc.1209257	http://dx.doi.org/10.1038/sj.onc.1209257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16462773				2022-12-25	WOS:000236581200011
J	Laezza, C; Notarnicola, M; Caruso, MG; Messa, C; Macchia, M; Bertini, S; Minutolo, F; Portella, G; Fiorentino, L; Stingo, S; Bifulco, M				Laezza, Chiara; Notarnicola, Maria; Caruso, Maria Gabriella; Messa, Caterina; Macchia, Marco; Bertini, Simone; Minutolo, Filippo; Portella, Giuseppe; Fiorentino, Laura; Stingo, Stefania; Bifulco, Maurizio			N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation	FASEB JOURNAL			English	Article						cell growth; isoprenoid pathway	THYROID EPITHELIAL-CELLS; PLANT CYTOKININ ANALOGS; HUMAN COLORECTAL-CANCER; FLUORESCENT-PROBES; LEUKEMIA-CELLS; BINDING; GROWTH; THYROTROPIN; APOPTOSIS; ADENOSINE	The physiological effects of a variety of N6-substituted adenine and adenosine derivatives called cytokinins have been documented in plants, but information on their occurrence and function in other biological system is limited. Here we investigated the anti-proliferative effect of N6-isopentenyladenosine (i(6)A), an adenosine and isoprenoid derivative, in a thyroid cell system, FRTL-5 wild-type, and K-ras transformed KiMol cells. Addition of i(6)A to FRTL-5 cells caused a dose-dependent arrest of the G(0)-G(1) cell phase transition associated with a reduction of cells in the S phase that was much more evident in KiMol cells. I(6)A arrested tumor cell proliferation by inhibiting farnesyl diphosphate synthase (FPPS) and protein prenylation. Indeed the addition of farnesol reversed these effects and i(6)A affected protein prenylation, in particular lamin B processing. I(6)A effect was not mediated by the adenosine receptor but was due to a direct modulation of FPPS enzyme activity as a result of its uptake inside the cells. I(6)A inhibited FPPS activity more efficaciously in KiMol cells than in normal FRTL-5. Moreover, the i(6)A anti-proliferative effect was evaluated in vivo in a nude mouse xenograft model, where KiMol cells were implanted subcutaneously. Mice treated with i(6)A showed a drastic reduction in tumor volume. Our findings indicate that this isoprenoid end product might be used for antineoplastic therapy, an application emulating that of the lovastatin and/or farnesyltransferase inhibitors.	Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, Salerno, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Pisa, Dipartimento Sci Farmaceut, I-56100 Pisa, Italy; IRCCS S Bellis Castellana G Bari, Biochim Lab, Bari, Italy; CNR, IEOS, I-00185 Rome, Italy	University of Salerno; University of Naples Federico II; University of Pisa; IRCCS Saverio de Bellis; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Laezza, C (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, Ponte Melillo, I-84084 Fisciano, Salerno, Italy.	maubiful@unina.it	Portella, Giuseppe/AFU-6826-2022; Minutolo, Filippo/A-7480-2011; laez, chi/AAW-4437-2020	Minutolo, Filippo/0000-0002-3312-104X; MACCHIA, MARCO/0000-0002-5565-2044; PORTELLA, Giuseppe/0000-0001-8276-9769; Bifulco, Maurizio/0000-0002-1771-4531; BERTINI, SIMONE/0000-0001-8832-8075				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Aronov AM, 1998, J MED CHEM, V41, P4790, DOI 10.1021/jm9802620; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; Boturyn D, 1997, TETRAHEDRON, V53, P5485, DOI 10.1016/S0040-4020(97)00235-4; BURNS DM, 1976, CANCER BIOCHEM BIOPH, V1, P269; Caruso MG, 2003, SCAND J GASTROENTERO, V38, P80, DOI 10.1080/00365520310000483; CHANG Y, 1982, J PHARM SCI, V71, P328, DOI 10.1002/jps.2600710317; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GALLO RC, 1969, SCIENCE, V165, P400, DOI 10.1126/science.165.3891.400; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Griffey RH, 1996, J MED CHEM, V39, P5100, DOI 10.1021/jm950937o; Gupta SD, 1999, J LIPID RES, V40, P1572; HACKER B, 1983, J PHARM SCI, V72, P902, DOI 10.1002/jps.2600720815; HARGROVE JL, 1982, J CELL PHYSIOL, V111, P232, DOI 10.1002/jcp.1041110303; Ishii Y, 2002, CELL GROWTH DIFFER, V13, P19; KERSTEN H, 1984, PROG NUCLEIC ACID RE, V31, P59, DOI 10.1016/S0079-6603(08)60375-X; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Laezza C, 1997, EXP CELL RES, V234, P178, DOI 10.1006/excr.1997.3610; Laezza C, 1997, FEBS LETT, V413, P260, DOI 10.1016/S0014-5793(97)00924-1; LATEN HM, 1985, P NATL ACAD SCI USA, V82, P1113, DOI 10.1073/pnas.82.4.1113; Macchia M, 1998, BIOORG MED CHEM LETT, V8, P3223, DOI 10.1016/S0960-894X(98)00582-4; Meisel H, 1998, FEBS LETT, V433, P265, DOI 10.1016/S0014-5793(98)00927-2; MITTELMAN A, 1975, ANN NY ACAD SCI, V255, P225, DOI 10.1111/j.1749-6632.1975.tb29228.x; Notarnicola M, 2004, ANTICANCER RES, V24, P3837; Notarnicola M, 2004, ONCOLOGY-BASEL, V67, P351, DOI 10.1159/000082918; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; VANDERPLOEG I, 1992, J NEUROCHEM, V58, P1221; Vermeulen K, 2002, LEUKEMIA, V16, P299, DOI 10.1038/sj.leu.2402378; Vermeulen K, 2002, EXP HEMATOL, V30, P1107, DOI 10.1016/S0301-472X(02)00894-9; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	50	50	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					412	418		10.1096/fj.05-4044lsf	http://dx.doi.org/10.1096/fj.05-4044lsf			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507758				2022-12-25	WOS:000239815100004
J	Liu, XL; Pachori, AS; Ward, CA; Davis, JP; Gnecchi, M; Kong, DL; Zhang, LN; Murduck, J; Yet, SF; Perrella, MA; Pratt, RE; Dzau, VJ; Melo, LG				Liu, Xiaoli; Pachori, Alok S.; Ward, Christopher A.; Davis, J. Paul; Gnecchi, Massimiliano; Kong, Deling; Zhang, Lunan; Murduck, Jared; Yet, Shaw-Fang; Perrella, Mark A.; Pratt, Richard E.; Dzau, Victor J.; Melo, Luis G.			Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function	FASEB JOURNAL			English	Article						echocardiography; gene therapy; ischemia; myocardial infarction; reperfusion; viruses	MYOCARDIAL-INFARCTION; TARGETED DELETION; GENE-EXPRESSION; REPERFUSION; PROLIFERATION; ANTIOXIDANT; BILIRUBIN; PROTECTS; DELIVERY; RUPTURE	We reported previously that predelivery of the anti-oxidant gene heme oxygenase-1 (HO-1) to the heart by adeno associated virus (AAV) markedly reduces injury after acute myocardial infarction (MI). However, the effect of HO-1 gene delivery on postinfarction recovery has not been investigated. In the current study, we assessed the effect of HO-1 gene delivery on post-MI left ventricle (LV) remodeling and function using echocardiographic imaging and histomorphometric approaches. Two groups of Sprague-Dawley rats were injected with 4 x 10(11) particles of AAV-LacZ (control) or AAV-hHO-1 in the LV wall. Eight wk after gene transfer, the animals were subjected to 30 min of ischemia by ligation of left anterior descending artery (LAD) followed by reperfusion. Echocardiographic measurements were obtained in a blinded fashion prior and at 1.5 and 3 months after I/R. Ejection fraction (EF) was reduced by 13% and 40% in the HO-1 and LacZ groups, respectively at 1.5 months after MI. Three months after MI, EF recovered fully in the HO-1, but only partially in the LacZ-treated animals. Post-MI LV dimensions were markedly increased and the anterior wall was markedly thinned in the LacZ-treated animals compared with the HO-1-treated animals. Significant myocardial scarring and fibrosis were observed in the LacZ-group in association with elevated levels of interstitial collagen I and III and MMP-2 activity. Post-MI myofibroblast accumulation was reduced in the HO-1-treated animals, and retroviral overexpression of HO-1 reduced proliferation of isolated cardiac fibroblasts. Our data indicate that rAAV-HO-1 gene transfer markedly reduces fibrosis and ventricular remodeling and restores LV function and chamber dimensions after myocardial infarction.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Brigham & Womens Hosp, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 0W0, Canada	Queens University - Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University; University of Saskatchewan	Melo, LG (corresponding author), Queens Univ, Dept Physiol, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	melol@post.queensu.ca	Yet, Shaw-Fang/B-1067-2010; Gnecchi, Massimiliano/J-8609-2018; Liu, Xiaoli/HGE-7614-2022; Yet, Shaw-Fang/O-8583-2019; Gnecchi, Massimiliano/X-7095-2019	Gnecchi, Massimiliano/0000-0001-7435-4328; Gnecchi, Massimiliano/0000-0001-7435-4328; Liu, Xiaoli/0000-0003-2904-4413; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL 072010, HL 35610, HL 05316, HL 073219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL073219, R01HL072010] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal RS, 2004, GENE THER, V11, P962, DOI 10.1038/sj.gt.3302250; BALLA G, 1992, J BIOL CHEM, V267, P18148; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Guo YR, 2004, AM J PHYSIOL-HEART C, V286, pH1649, DOI 10.1152/ajpheart.00971.2003; Hawkes SP, 2000, METH MOL B, V151, P399, DOI 10.1385/1-59259-046-2:399; Hayashidani S, 2003, AM J PHYSIOL-HEART C, V285, pH1229, DOI 10.1152/ajpheart.00207.2003; Holmes DR, 2003, AM J CARDIOL, V91, p50A; ITO H, 1993, CIRCULATION, V87, P355, DOI 10.1161/01.CIR.87.2.355; JUDGUTT BI, 1996, CIRCULATION, V94, P94; Jugdutt BI, 2003, CIRCULATION, V108, P1395, DOI 10.1161/01.CIR.0000085658.98621.49; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Maulik N, 1996, J MOL CELL CARDIOL, V28, P1261, DOI 10.1006/jmcc.1996.0116; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PACHORI AS, 2004, AAV HO 1 GENE THERAP; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; Snyder R, 1996, CURRENT PROTOCOLS HU; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Volti GL, 2002, BIOCHEM BIOPH RES CO, V296, P1077, DOI 10.1016/S0006-291X(02)02054-5; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	29	89	123	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					207	216		10.1096/fj.05-4435com	http://dx.doi.org/10.1096/fj.05-4435com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449792				2022-12-25	WOS:000237698700005
J	Ma, W; Xia, X; Stafford, LJ; Yu, C; Wang, F; LeSage, G; Liu, M				Ma, W.; Xia, X.; Stafford, L. J.; Yu, C.; Wang, F.; LeSage, G.; Liu, M.			Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis	ONCOGENE			English	Article						GCIP; CCNDBP1; DIP1/HHM; transgenic mouse; hepatocarcinogenesis; diethylnitrosamine; HLH-zipper proteins	LOOP-HELIX PROTEINS; DNA-BINDING PROTEINS; ID PROTEINS; CYCLIN D1; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; MYELOID DIFFERENTIATION; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; GENE-EXPRESSION	Transcription factors with helix-loop-helix (HLH) motif play critical roles in controlling the expression of genes involved in lineage commitment, cell fate determination, proliferation, and tumorigenesis. To examine whether the newly identified HLH protein GCIP/CCNDBP1 modulates cell fate determination and plays a role in hepatocyte growth, proliferation, and hepatocarcinogenesis, we generated transgenic mice with human GCIP gene driven by a liver-specific albumin promoter. We demonstrated that in GCIP transgenic mice, the overall liver growth and regeneration occurred normally after liver injury induced by carbon tetrachloride (CCl4). In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment. Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wildtype mice. Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development.	Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Ctr Canc Biol & Nutr, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Dept Mol & Cellular Med, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Liu, M (corresponding author), Texas A&M Univ, Alkek Inst Biosci & Technol, Syst Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Ma, Wenbin/0000-0001-8774-7593	NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper TA, 2005, CELL, V120, P1, DOI 10.1016/j.cell.2004.12.030; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Deane NG, 2004, CANCER RES, V64, P1315, DOI 10.1158/0008-5472.CAN-03-1772; Deane NG, 2001, CANCER RES, V61, P5389; DIWAN BA, 1976, CANCER LETT, V1, P249; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Hwang SY, 1997, DEV DYNAM, V209, P217, DOI 10.1002/(SICI)1097-0177(199706)209:2<217::AID-AJA7>3.0.CO;2-L; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kee BL, 2000, IMMUNOL REV, V175, P138, DOI 10.1111/j.1600-065X.2000.imr017514.x; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Ledda-Columbano GM, 2002, HEPATOLOGY, V36, P1098, DOI 10.1053/jhep.2002.36159; Lee C, 2005, BRIEF BIOINFORM, V6, P23, DOI 10.1093/bib/6.1.23; Lee GH, 1998, CANCER RES, V58, P1665; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lemmer ER, 2004, CARCINOGENESIS, V25, P1257, DOI 10.1093/carcin/bgh129; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOORE MR, 1981, CANCER RES, V41, P1585; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakatani T, 2001, JPN J CANCER RES, V92, P249, DOI 10.1111/j.1349-7006.2001.tb01089.x; Natrajan R, 2003, CANCER RES, V63, P7657; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; NISHIDA N, 1994, CANCER RES, V54, P3107; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; Sierralta J, 2004, BRAIN RES REV, V47, P105, DOI 10.1016/j.brainresrev.2004.06.002; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; SUGIHARA S, 1992, CANCER, V70, P1488, DOI 10.1002/1097-0142(19920915)70:6<1488::AID-CNCR2820700607>3.0.CO;2-J; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Suzui M, 2002, CANCER RES, V62, P3997; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Theise ND, 2003, HISTOPATHOLOGY, V43, P263, DOI 10.1046/j.1365-2559.2003.01707.x; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; VESSELINOVITCH SD, 1987, TOXICOL PATHOL, V15, P221, DOI 10.1177/019262338701500216; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WROBLEWSKI F, 1959, AM J MED, V27, P911, DOI 10.1016/0002-9343(59)90175-5; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zhao XF, 1999, J BIOL CHEM, V274, P1388, DOI 10.1074/jbc.274.3.1388; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	68	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4207	4216		10.1038/sj.onc.1209450	http://dx.doi.org/10.1038/sj.onc.1209450			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501603				2022-12-25	WOS:000239004800008
J	Ghosh, DK; Holliday, MA; Thomas, C; Weinberg, JB; Smith, SME; Salerno, JC				Ghosh, Dipak K.; Holliday, Michael A.; Thomas, Clayton; Weinberg, J. Brice; Smith, Susan M. E.; Salerno, John C.			Nitric-oxide synthase output state - Design and properties of nitric-oxide synthase oxygenase/FMN domain constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; ELECTRON-TRANSFER; TETRAHYDROBIOPTERIN INTERACTION; CRYSTAL-STRUCTURE; NO SYNTHASE; BINDING; FLAVIN; HEME; CALMODULIN; SUBSTRATE	Mammalian nitric-oxide synthases are large modular enzymes that evolved from independently expressed ancestors. Calmodulin-controlled isoforms are signal generators; calmodulin activates electron transfer from NADPH through three reductase domains to an oxygenase domain. Structures of the reductase unit and its homologs show FMN and FAD in contact but too isolated from the protein surface to permit exit of reducing equivalents. To study states in which FMN/heme electron transfer is feasible, we designed and produced constructs including only oxygenase and FMN binding domains, eliminating strong internal reductase complex interactions. Constructs for all mammalian isoforms were expressed and purified as dimers. All synthesize NO with peroxide as the electron donor at rates comparable with corresponding oxygenase constructs. All bind cofactors nearly stoichiometrically and have native catalytic sites by spectroscopic criteria. Modest differences in electrochemistry versus independently expressed heme and FMN binding domains suggest interdomain interactions. These interactions can be convincingly demonstrated via calmodulin-induced shifts in high spin ferriheme EPR spectra and through mutual broadening of heme and FMNH center dot radical signals in inducible nitric-oxide synthase constructs. Blue neutral FMN semiquinone can be readily observed; potentials of one electron couple ( in inducible nitric-oxide synthase oxygenase FMN, FMN oxidized/semiquione couple = +70 mV, FMN semiquinone/hydroquinone couple = -180 mV, and heme = -180 mV) indicate that FMN is capable of serving as a one electron heme reductant. The construct will serve as the basis for future studies of the output state for NADPH derived reducing equivalents.	Rensselaer Polytech Inst, Dept Biol, Ithaca, NY 14853 USA; Duke Univ, Dept Med, Durham, NC 27705 USA; Vet Affairs Med Ctr, Durham, NC USA	Rensselaer Polytechnic Institute; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ghosh, DK (corresponding author), Rensselaer Polytech Inst, Dept Biol, Ithaca, NY 14853 USA.	dgx@acpub.duke.edu; salerj@rpi.edu	salerno, john c/A-2595-2014					ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2001, BIOCHEM SOC T, V29, P147, DOI 10.1042/0300-5127:0290147; Dutton P L, 1978, Methods Enzymol, V54, P411; Fedorov R, 2004, P NATL ACAD SCI USA, V101, P5892, DOI 10.1073/pnas.0306588101; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gao YT, 2004, J BIOL CHEM, V279, P18759, DOI 10.1074/jbc.M308936200; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Garnaud PE, 2004, BIOCHEMISTRY-US, V43, P11035, DOI 10.1021/bi049312v; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Harris D, 1998, KEIO UNIV SYMP LIFE, V1, P289; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Jones RJ, 2004, J BIOL CHEM, V279, P36876, DOI 10.1074/jbc.M402808200; KWON NS, 1989, J BIOL CHEM, V264, P20496; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sessa WC, 2005, MEM I OSWALDO CRUZ, V100, P15, DOI 10.1590/S0074-02762005000900004; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Smith S. M. E., 2000, Nitric Oxide, V4, P224; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	44	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14173	14183		10.1074/jbc.M509937200	http://dx.doi.org/10.1074/jbc.M509937200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16461329	hybrid			2022-12-25	WOS:000237512300041
J	Agapkina, J; Smolov, M; Barbe, S; Zubin, E; Zatsepin, T; Deprez, E; Le Bret, M; Mouscadet, JF; Gottikh, M				Agapkina, J; Smolov, M; Barbe, S; Zubin, E; Zatsepin, T; Deprez, E; Le Bret, M; Mouscadet, JF; Gottikh, M			Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; METAL-DEPENDENT INHIBITION; ACTIVE-SITE; IN-VITRO; RETROVIRAL INTEGRASES; STRUCTURAL-PROPERTIES; PROTEIN; SEQUENCE; BINDING; RECOGNITION	The specific activity of the human immunodeficiency virus, type 1 ( HIV-1), integrase on the viral long terminal repeat requires the binding of the enzyme to certain sequences located in the U3 and U5 regions at the ends of viral DNA, but the determinants of this specific DNA-protein recognition are not yet completely understood. We synthesized DNA duplexes mimicking the U5 region and containing either 2'-modified nucleosides or 1,3-propanediol insertions and studied their interactions with HIV-1 integrase, using Mn2+ or Mg2+ ions as integrase cofactors. These DNA modifications had no strong effect on integrase binding to the substrate analogs but significantly affected 3'-end processing rate. The effects of nucleoside modifications at positions 5, 6, and especially 3 strongly depended on the cationic cofactor used. These effects were much more pronounced in the presence of Mg2+ than in the presence of Mn2+. Modifications of base pairs 7-9 affected 3'-end processing equally in the presence of both ions. Adenine from the 3rd bp is thought to form at least two hydrogen bonds with integrase that are crucial for specific DNA recognition. The complementary base, thymine, is not important for integrase activity. For other positions, our results suggest that integrase recognizes a fine structure of the sugar-phosphate backbone rather than heterocyclic bases. Integrase interactions with the unprocessed strand at positions 5-8 are more important than interactions with the processed strand for specific substrate recognition. Based on our results, we suggest a model for integrase interaction with the U5 substrate.	Ecole Normale Super, CNRS, LBPA, UMR8113, F-94235 Cachan, France; Moscow MV Lomonosov State Univ, Belozersky Inst Physiochem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Lomonosov Moscow State University	Mouscadet, JF (corresponding author), Ecole Normale Super, CNRS, LBPA, UMR8113, 61 Ave President Wilson, F-94235 Cachan, France.	mouscadet@lbpa.ens-cachan.fr	Zubin, Evgeny/I-3880-2012; Gottikh, Marina/D-7575-2012; Agapkina, Julia/I-5558-2012; Zatsepin, Timofei S/I-2821-2012; Barbe, Sophie/ABD-9530-2020	Zatsepin, Timofei S/0000-0003-0030-9174; Barbe, Sophie/0000-0003-2581-5022				Agapkina J, 2004, EUR J BIOCHEM, V271, P205, DOI 10.1046/j.1432-1033.2003.03921.x; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; Bailly C, 1998, NUCLEIC ACIDS RES, V26, P4309, DOI 10.1093/nar/26.19.4309; Brodin P, 2002, BIOCHEMISTRY-US, V41, P1529, DOI 10.1021/bi015732y; Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Gao K, 2004, J VIROL, V78, P6715, DOI 10.1128/JVI.78.13.6715-6722.2004; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; Gerton JL, 1998, J VIROL, V72, P5046, DOI 10.1128/JVI.72.6.5046-5055.1998; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; HENDRIX C, 1995, NUCLEIC ACIDS RES, V23, P51, DOI 10.1093/nar/23.1.51; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAN LS, 1993, J CHIN CHEM SOC-TAIP, V40, P469, DOI 10.1002/jccs.199300074; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; Katzman M, 1996, J VIROL, V70, P9069, DOI 10.1128/JVI.70.12.9069-9073.1996; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUZNETSOVA LG, 1991, BIOORG KHIM+, V17, P1289; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Neamati N, 2002, J MED CHEM, V45, P5661, DOI 10.1021/jm0201417; Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Renisio JG, 2005, NUCLEIC ACIDS RES, V33, P1970, DOI 10.1093/nar/gki346; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; Venkateswarlu D, 1999, NUCLEIC ACIDS RES, V27, P2189, DOI 10.1093/nar/27.10.2189; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i; Zubin EM, 1998, NUCLEOS NUCLEOT, V17, P425, DOI 10.1080/07328319808005188	50	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11530	11540		10.1074/jbc.M512271200	http://dx.doi.org/10.1074/jbc.M512271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500899	Green Published, hybrid			2022-12-25	WOS:000236988100015
J	Fryer, BH; Wang, CH; Vedantam, S; Zhou, GL; Jin, SH; Fletcher, L; Simon, MC; Field, J				Fryer, BH; Wang, CH; Vedantam, S; Zhou, GL; Jin, SH; Fletcher, L; Simon, MC; Field, J			CGMP-dependent protein kinase phosphorylates p21-activated kinase (Pak) 1, inhibiting Pak/Nck binding and stimulating Pak/vasodilator-stimulated phosphoprotein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; RHO-GTPASES; ACTIN CYTOSKELETON; ENA/VASP PROTEINS; PAK1; ANGIOGENESIS; NCK; SIGNALS; RAS; MECHANISMS	Endothelial cells are normally non-motile and quiescent; however, endothelial cells will become permeable and invade and proliferate to form new blood vessels ( angiogenesis) in response to wounding, cancer, diabetic retinopathy, age-related macular degeneration, or rheumatoid arthritis. p21-activated kinase ( Pak), an effector for the Rho GTPases Rac and Cdc42, is required for angiogenesis and regulates endothelial cell permeability and motility. Although Pak is primarily activated by Rac and Cdc42, there are additional proteins that regulate Pak activity and localization, including three AGC protein kinase family members, Akt-1, PDK-1, and cAMP-dependent protein kinase. We describe phosphorylation and regulation of Pak localization by a fourth AGC kinase family member, cGMP-dependent protein kinase ( PKG). Using in vitro mapping, a phosphospecific antibody, co-transfection assays, and untransfected bovine aortic endothelial cells we determined thatPKGphosphorylates Pak at serine 21. Phosphorylation was accompanied by changes in proteins associated with Pak. The adaptor protein Nck was released, whereas a novel complex with vasodilator-stimulated phosphoprotein was stimulated. Furthermore Ser-21 phosphorylation of Pak appears to be important for regulation of cell morphology. In both human umbilical vein endothelial cells and HeLa cells, activation of PKG in the presence of Pak stimulated tail retraction and cell polarization. However, in cells expressing S21A mutant Pak1, PKG activation or treatment with a peptide that blocks Nck/Pak binding caused aberrant cell morphology, blocked cell retraction, and mislocalized Pak, producing uropod ( tail-like) structures. These data suggest that PKG regulates Pak and that the interaction plays a role in tail retraction.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Field, J (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, John Morgan Bldg,Rm 149, Philadelphia, PA 19104 USA.	field@pharm.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [T32CA009677] Funding Source: NIH RePORTER; NCI NIH HHS [CA09677] Funding Source: Medline; NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fryer BH, 2005, CANCER LETT, V229, P13, DOI 10.1016/j.canlet.2004.12.009; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Mazumdar A, 2003, FEBS LETT, V535, P6, DOI 10.1016/S0014-5793(02)03846-2; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Murthy KS, 2003, AM J PHYSIOL-GASTR L, V284, pG1006, DOI 10.1152/ajpgi.00465.2002; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	37	32	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11487	11495		10.1074/jbc.M600279200	http://dx.doi.org/10.1074/jbc.M600279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16490784	hybrid			2022-12-25	WOS:000236988100010
J	Westphal, AH; Matorin, A; Hink, MA; Borst, JW; van Berkel, WJH; Visser, AJWG				Westphal, AH; Matorin, A; Hink, MA; Borst, JW; van Berkel, WJH; Visser, AJWG			Real-time enzyme dynamics illustrated with fluorescence spectroscopy of p-hydroxybenzoate hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-MOLECULE; PSEUDOMONAS-FLUORESCENS; CONFORMATIONAL DYNAMICS; CRYSTAL-STRUCTURE; ENERGY-TRANSFER; WILD-TYPE; PROTEIN; BINDING; SUBSTRATE; CATALYSIS	We have used the flavoenzyme p-hydroxybenzoate hydroxylase (PHBH) to illustrate that a strongly fluorescent donor label can communicate with the flavin via single-pair Forster resonance energy transfer (spFRET). The accessible Cys-116 of PHBH was labeled with two different fluorescent maleimides with full preservation of enzymatic activity. One of these labels shows overlap between its fluorescence spectrum and the absorption spectrum of the FAD prosthetic group in the oxidized state, while the other fluorescent probe does not have this spectral overlap. The spectral overlap strongly diminished when the flavin becomes reduced during catalysis. The donor fluorescence properties can then be used as a sensitive antenna for the flavin redox state. Time-resolved fluorescence experiments on ensembles of labeled PHBH molecules were carried out in the absence and presence of enzymatic turnover. Distinct changes in fluorescence decays of spFRET-active PHBH can be observed when the enzyme is performing catalysis using both substrates p-hydroxybenzoate and NADPH. Single-molecule fluorescence correlation spectroscopy on spFRET-active PHBH showed the presence of a relaxation process (relaxation time of 23 mu s) that is related to catalysis. In addition, in both labeled PHBH preparations the number of enzyme molecules reversibly increased during enzymatic turnover indicating that the dimer-monomer equilibrium is affected.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Microspect Ctr, NL-6700 ET Wageningen, Netherlands; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, NL-1081 HV Amsterdam, Netherlands	Wageningen University & Research; Vrije Universiteit Amsterdam	Visser, AJWG (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	ton.visser@wur.nl	Borst, Jan Willem/B-1259-2011; van Berkel, Willem J.H./O-2431-2014; Westphal, Adrie Herman/L-3517-2019	van Berkel, Willem J.H./0000-0002-6551-2782; Westphal, Adrie Herman/0000-0003-4264-6267				Antikainen NM, 2005, BIOCHEMISTRY-US, V44, P16835, DOI 10.1021/bi051378i; BASTIAENS PIH, 1992, BIOPHYS J, V63, P839, DOI 10.1016/S0006-3495(92)81659-4; Borst JW, 2005, J FLUORESC, V15, P153, DOI 10.1007/s10895-005-2523-5; Brender JR, 2005, J AM CHEM SOC, V127, P18171, DOI 10.1021/ja055171o; Chattopadhyay K, 2005, P NATL ACAD SCI USA, V102, P2385, DOI 10.1073/pnas.0500127102; Chattopadhyay K, 2002, P NATL ACAD SCI USA, V99, P14171, DOI 10.1073/pnas.172524899; Deniz AA, 2001, ANNU REV PHYS CHEM, V52, P233, DOI 10.1146/annurev.physchem.52.1.233; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Digris AV, 1999, EUR BIOPHYS J BIOPHY, V28, P526, DOI 10.1007/s002490050235; Edman L, 1999, CHEM PHYS, V247, P11, DOI 10.1016/S0301-0104(99)00098-1; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; Entsch B, 2005, ARCH BIOCHEM BIOPHYS, V433, P297, DOI 10.1016/j.abb.2004.09.029; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; Eppink MHM, 1998, J BIOL CHEM, V273, P21031, DOI 10.1074/jbc.273.33.21031; ESCHRICH K, 1990, FEBS LETT, V277, P197, DOI 10.1016/0014-5793(90)80843-8; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Ha T, 2001, METHODS, V25, P78, DOI 10.1006/meth.2001.1217; Ha TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/pnas.96.3.893; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P369, DOI DOI 10.1007/978-1-4757-3061-6; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Michalet X, 2003, ANNU REV BIOPH BIOM, V32, P161, DOI 10.1146/annurev.biophys.32.110601.142525; MULLER F, 1982, EUR J BIOCHEM, V128, P21; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; Shi J, 2004, J AM CHEM SOC, V126, P6914, DOI 10.1021/ja038902y; Skakun VV, 2005, EUR BIOPHYS J BIOPHY, V34, P323, DOI 10.1007/s00249-004-0453-9; SZABO A, 1984, J CHEM PHYS, V81, P150, DOI 10.1063/1.447378; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; van den Berg PAW, 2004, BIOPHYS J, V87, P2577, DOI 10.1529/biophysj.104.040030; Van Den Berg PAW, 2001, SPR S FLUOR, V1, P457; van den Berg PAW, 2001, SPECTROCHIM ACTA A, V57, P2135, DOI 10.1016/S1386-1425(01)00494-2; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; Visser AJWG, 2001, SPRINGER SERIES CHEM, V65, P9; Wang J, 2002, P NATL ACAD SCI USA, V99, P608, DOI 10.1073/pnas.022640199; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009; Xie XS, 1999, J BIOL CHEM, V274, P15967, DOI 10.1074/jbc.274.23.15967; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	50	17	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11074	11081		10.1074/jbc.M600609200	http://dx.doi.org/10.1074/jbc.M600609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492664	hybrid, Green Published			2022-12-25	WOS:000236822200049
J	Wu, WF; Misra, RS; Russell, JQ; Flavell, RA; Rincon, M; Budd, RC				Wu, WF; Misra, RS; Russell, JQ; Flavell, RA; Rincon, M; Budd, RC			Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TH2 CYTOKINE PRODUCTION; CELLULAR FLIP; LONG FORM; GEL-ELECTROPHORESIS; APOPTOSIS; DEATH; PROLIFERATION; TRANSCRIPTION; DIFFERENTIATION; LYMPHOCYTES	The nuclear factor of activated T (NFAT) cell family of transcription factors is important in regulating the expression of a broad array of genes, including cytokines, T cell surface receptors, and other transcription factors. NFATc1 and NFATc2 are two principal NFAT members that are expressed in peripheral T cells. Levels of NFAT expression in T cells are partly transcriptionally regulated, but less is understood regarding their post-transcriptional control. We show here that NFATc1 and NFATc2 are rapidly degraded in apoptotic T cells. NFATc2 is highly sensitive to cleavage by caspase-3, whereas NFATc1 is only weakly sensitive to caspase-3 or caspase-8. Two potential caspase-3 cleavage sites were identified in the N-terminal transactivation domain. These sites were confirmed by in vitro caspase cleavage assays. Abolition of NFATc2 cleavage by mutation of these two cleavage sites resulted in augmented NFAT transcriptional activity. Furthermore, NFAT activity could be augmented in wild-type effector T cells by inhibition of caspase activity. Of particular interest was that non-apoptotic T cells from cellular FLIP long transgenic (c-FLIPL-Tg) mice that manifest elevated caspase activity have greatly reduced levels of NFATc2 protein and NFAT transcriptional activity. Our findings reveal a new post-transcriptional regulation of NFATc2 that operates, not only during apoptosis, but also in non-apoptotic effector T cells.	Univ Vermont, Coll Med, Immunobiol Program, Dept Med, Burlington, VT 05405 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Vermont; Yale University; Howard Hughes Medical Institute	Budd, RC (corresponding author), Univ Vermont, Coll Med, Immunobiol Program, Dept Med, Given Med Bldg,D305,89 Beaumont Dr, Burlington, VT 05405 USA.	ralph.budd@uvm.edu			NIAID NIH HHS [AI36333, AI45666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036333, P01AI045666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dohrman A, 2005, J IMMUNOL, V175, P311, DOI 10.4049/jimmunol.175.1.311; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Liu JQ, 2001, IMMUNITY, V15, P23, DOI 10.1016/S1074-7613(01)00162-5; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Misra RS, 2005, J IMMUNOL, V174, P3999, DOI 10.4049/jimmunol.174.7.3999; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Wu WF, 2004, J IMMUNOL, V172, P4724, DOI 10.4049/jimmunol.172.8.4724; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	39	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10682	10690		10.1074/jbc.M511759200	http://dx.doi.org/10.1074/jbc.M511759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16455648	hybrid			2022-12-25	WOS:000236822200006
J	Krumins, AM; Gilman, AG				Krumins, AM; Gilman, AG			Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; ADENYLATE-CYCLASE; BINDING; EXPRESSION; GAMMA; PURIFICATION; SPECIFICITY; ACTIVATION	Heterotrimeric G protein signaling specificity has been attributed to select combinations of G alpha, beta, and gamma subunits, their interactions with other signaling proteins, and their localization in the cell. With few exceptions, the G protein subunit combinations that exist in vivo and the significance of these specific combinations are largely unknown. We have begun to approach these problems in HeLa cells by: 1) determining the concentrations of G alpha and G beta subunits; 2) examining receptor-dependent activities of two effector systems (adenylyl cyclase and phospholipase C beta); and 3) systematically silencing each of the G alpha and G beta subunits by using small interfering RNA while quantifying resultant changes in effector function and the concentrations of other relevant proteins in the network. HeLa cells express equimolar amounts of total G alpha and G beta subunits. The most prevalent G alpha proteins were one member of each G alpha subfamily (G alpha(s), G alpha(i3), G alpha(11), and G alpha(13)). We substantially abrogated expression of most of the G alpha and G beta proteins expressed in these cells, singly and some in combinations. As expected, agonist-dependent activation of adenylyl cyclase or phospholipase C beta was specifically eliminated following the silencing of G alpha(s) or G alpha(q/11), respectively. We also confirmed that G beta subunits are necessary for stable accumulation of G alpha proteins in vivo. G beta subunits demonstrated little isoform specificity for receptor-dependent modulation of effector activity. We observed compensatory changes in G protein accumulation following silencing of individual genes, as well as an apparent reciprocal relationship between the expression of certain G alpha(q) and G alpha(i) subfamily members. These findings provide a foundation for understanding the mechanisms that regulate the adaptability and remarkable resilience of G protein signaling networks.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), 6001 Forest Pk, Dallas, TX 75390 USA.	Alfred.Gilman@UTSouthwestern.edu			NIGMS NIH HHS [GM 34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GAO B, 1987, J BIOL CHEM, V262, P17254; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; Hwang JI, 2005, P NATL ACAD SCI USA, V102, P9493, DOI 10.1073/pnas.0503503102; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1999, CRC METH SIG TRANS, P23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; ROSS EM, 1977, J BIOL CHEM, V252, P5761; Rosskopf D, 2003, FEBS LETT, V544, P27, DOI 10.1016/S0014-5793(03)00441-1; Ruiz-Velasco V, 2002, PHYSIOL GENOMICS, V8, P41, DOI 10.1152/physiolgenomics.00085.2001; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Steinberg SE, 2004, J MOL CELL CARDIOL, V37, P407, DOI 10.1016/j.yjmcc.2004.04.018; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VANDERVOORN L, 1993, J BIOL CHEM, V268, P5131; Wettschureck N, 2004, PHARMACOL THERAPEUT, V101, P75, DOI 10.1016/j.pharmthera.2003.10.005	34	88	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10250	10262		10.1074/jbc.M511551200	http://dx.doi.org/10.1074/jbc.M511551200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16446365	hybrid			2022-12-25	WOS:000236594300053
J	Lee, EH; Cherednichenko, G; Pessah, IN; Allen, PD				Lee, EH; Cherednichenko, G; Pessah, IN; Allen, PD			Functional coupling between TRPC3 and RyR1 regulates the expressions of key triadic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORE-OPERATED CHANNELS; ACTIVATED CA2+ INFLUX; RYANODINE RECEPTOR; CALCIUM-RELEASE; TRANSIENT RECEPTOR; SKELETAL; CALSEQUESTRIN; ENTRY; CONTRACTION; DEPOLARIZATION	We have shown that TRPC3( transient receptor potential channel canonical type 3) is sharply up-regulated during the early part of myotube differentiation and remains elevated in mature myotubes compared with myoblasts. To examine its functional roles in muscle, TRPC3 was "knocked down" in mouse primary skeletal myoblasts using retroviral-delivered small interference RNAs and single cell cloning. TRPC3 knockdown myoblasts (97.6 +/- 1.9% reduction in mRNA) were differentiated into myotubes ( TRPC3 KD) and subjected to functional and biochemical assays. By measuring rates of Mn2+ influx with Fura-2 and Ca2+ transients with Fluo-4, we found that neither excitation-coupled Ca2+ entry nor thapsigargin-induced store-operated Ca2+ entry was significantly altered in TRPC3 KD, indicating that expression of TRPC3 is not required for engaging either Ca2+ entry mechanism. In Ca2+ imaging experiments, the gain of excitation-contraction coupling and the amplitude of the Ca2+ release seen after direct RyR1 activation with caffeine was significantly reduced in TRPC3 KD. The decreased gain appears to be due to a decrease in RyR1 Ca2+ release channel activity, because sarcoplasmic reticulum (SR) Ca2+ content was not different between TRPC3 KD and wild-type myotubes. Immunoblot analysis demonstrated that TRPC1, calsequestrin, triadin, and junctophilin 1 were up-regulated (1.46 +/- 1.91-, 1.42 +/- 0.08-, 2.99 +/- 0.32-, and 1.91 +/- 0.26-fold, respectively) in TRPC3 KD. Based on these data, we conclude that expression of TRPC3 is tightly regulated during muscle cell differentiation and propose that functional interaction between TRPC3 and RyR1 may regulate the gain of SR Ca2+ release independent of SR Ca2+ load.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Ctr Childrens Environm Hlth, Davis, CA 95616 USA; Catholic Univ Korea, Coll Med, Dept Physiol, Lab Calcium Commun, Seoul 137701, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Davis; University of California System; University of California Davis; Catholic University of Korea	Allen, PD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.	allen@zeus.bwh.harvard.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Lee, Eun Hui/0000-0003-4555-1730	NIAMS NIH HHS [P01 AR 17605] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beard NA, 2004, PROG BIOPHYS MOL BIO, V85, P33, DOI 10.1016/j.pbiomolbio.2003.07.001; Beard NA, 2002, BIOPHYS J, V82, P310, DOI 10.1016/S0006-3495(02)75396-4; BRADY AJ, 1964, ANNU REV PHYSIOL, V26, P341, DOI 10.1146/annurev.ph.26.030164.002013; Cherednichenko G, 2004, P NATL ACAD SCI USA, V101, P15793, DOI 10.1073/pnas.0403485101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COLLINS JH, 1990, BIOCHEM BIOPH RES CO, V167, P189, DOI 10.1016/0006-291X(90)91749-I; Felder E, 2002, BIOPHYS J, V82, P3144, DOI 10.1016/S0006-3495(02)75656-7; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Lee EH, 2004, BIOPHYS J, V86, p61A; Lee EH, 2004, J BIOL CHEM, V279, P26481, DOI 10.1074/jbc.M309574200; Lee EH, 2004, AM J PHYSIOL-CELL PH, V286, pC179, DOI 10.1152/ajpcell.00176.2003; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nishida M, 2003, EMBO J, V22, P4677, DOI 10.1093/emboj/cdg457; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Reading SA, 2005, AM J PHYSIOL-HEART C, V288, pH2055, DOI 10.1152/ajpheart.00861.2004; Rezgui SS, 2005, J BIOL CHEM, V280, P39302, DOI 10.1074/jbc.M506566200; Sampieri A, 2005, J BIOL CHEM, V280, P24804, DOI 10.1074/jbc.M501487200; SANDOW A, 1965, PHARMACOL REV, V17, P265; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Yildirim E, 2005, P NATL ACAD SCI USA, V102, P3307, DOI 10.1073/pnas.0409908102; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	39	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10042	10048		10.1074/jbc.M600981200	http://dx.doi.org/10.1074/jbc.M600981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484216	hybrid			2022-12-25	WOS:000236594300028
J	Varsano, T; Wolf, SG; Pick, U				Varsano, T; Wolf, SG; Pick, U			A chlorophyll a/b-binding protein homolog that is induced by iron deficiency is associated with enlarged photosystem I units in the eucaryotic alga Dunaliella salina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; TRANSFERRIN-LIKE PROTEIN; CHLAMYDOMONAS-REINHARDTII; PLASMA-MEMBRANE; PHOTOSYNTHESIS; ISIA; SUPERCOMPLEXES; ACCUMULATION; FLUORESCENCE; PROTEOMICS	Adaptation of the halotolerant alga Dunaliella salina to iron deprivation involves extensive changes of chloroplast morphology, photosynthetic activities, and induction of a major 45-kDa chloroplast protein termed Tidi. Partial amino acid sequencing of proteolytic peptides suggested that Tidi resembles chlorophyll a/b-binding proteins which compose light-harvesting antenna complexes (LHC) ( Varsano, T., Kaftan, D., and Pick, U. ( 2003) J. Plant Nutr. 26, 2197 - 2210). Here we show that Tidi shares the highest amino acid sequence similarity with light-harvesting I chlorophyll a/b-binding proteins from higher plants but has an extended proline-rich N-terminal domain. The accumulation of Tidi is reversed by iron supplementation, and its level is inversely correlated with photosystem I(PS-I) reaction center proteins. In native gel electrophoresis, Tidi co-migrates with enlarged PS-I-LHC-I super-complexes. Single particle electron microscopy analysis revealed that PS-I units from iron-deficient cells are larger ( 31 and 37 nm in diameter) than PS-I units from control cells ( 22 nm). The 77 K chlorophyll fluorescence emission spectra of isolated complexes suggest that the Tidi-LHC-I antenna are functionally coupled to the reaction centers of PS-I. These findings indicate that Tidi acts as an accessory antenna of PS-I. The enlargement of PS-I antenna in algae and in cyanobacteria under iron deprivation suggests a common limitation that requires rebalancing of the energy distribution between the two photosystems.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Electron Microscopy Unit, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Pick, U (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	uri.pick@weizmann.ac.il	WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				Andrizhiyevskaya EG, 2002, BBA-BIOENERGETICS, V1556, P265, DOI 10.1016/S0005-2728(02)00371-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Bibby TS, 2001, J BIOL CHEM, V276, P43246, DOI 10.1074/jbc.M106541200; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Braun P, 1996, PLANT PHYSIOL, V110, P1405, DOI 10.1104/pp.110.4.1405; Cardol P, 2003, PLANT PHYSIOL, V133, P2010, DOI 10.1104/pp.103.028076; Desquilbet TE, 2003, PLANT CELL PHYSIOL, V44, P1141, DOI 10.1093/pcp/pcg139; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fisher M, 1997, J BIOL CHEM, V272, P1565, DOI 10.1074/jbc.272.3.1565; FISHER M, 1994, PLANT PHYSIOL, V106, P1359, DOI 10.1104/pp.106.4.1359; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; HOHENBERG H, 1994, J MICROSC-OXFORD, V175, P34, DOI 10.1111/j.1365-2818.1994.tb04785.x; Humbel BM, 2001, YEAST, V18, P433, DOI 10.1002/yea.694; Kargul J, 2003, J BIOL CHEM, V278, P16135, DOI 10.1074/jbc.M300262200; KATZ A, 1986, FEBS LETT, V202, P141, DOI 10.1016/0014-5793(86)80665-2; Kouril R, 2005, FEBS LETT, V579, P3253, DOI 10.1016/j.febslet.2005.03.051; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; Liska AJ, 2004, PLANT PHYSIOL, V136, P2806, DOI 10.1104/pp.104.039438; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Morgan-Kiss R, 2002, BBA-BIOMEMBRANES, V1561, P251, DOI 10.1016/S0005-2736(02)00352-8; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Moseley JL, 2002, PLANT CELL, V14, P673, DOI 10.1105/tpc.010420; Murakami A, 1997, PHOTOSYNTH RES, V53, P141, DOI 10.1023/A:1005818317797; Naumann B, 2005, J BIOL CHEM, V280, P20431, DOI 10.1074/jbc.M414486200; Sandstrom S, 2001, PHOTOCHEM PHOTOBIOL, V74, P431, DOI 10.1562/0031-8655(2001)074<0431:CTIGPF>2.0.CO;2; Schwarz M, 2003, BBA-PROTEINS PROTEOM, V1649, P190, DOI 10.1016/S1570-9639(03)00185-7; SEKLER I, 1994, PLANT PHYSIOL, V105, P1125, DOI 10.1104/pp.105.4.1125; SPILLER S, 1980, PLANT PHYSIOL, V65, P121, DOI 10.1104/pp.65.1.121; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Straus N. A., 1994, IRON DEPRIVATION PHY; Strzepek RF, 2004, NATURE, V431, P689, DOI 10.1038/nature02954; Varsano T, 2003, J PLANT NUTR, V26, P2197, DOI 10.1081/PLN-120024275; VASSILIEV IR, 1995, PLANT PHYSIOL, V109, P963, DOI 10.1104/pp.109.3.963; Watson AJ, 2000, NATURE, V407, P730, DOI 10.1038/35037561	40	37	40	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10305	10315		10.1074/jbc.M511057200	http://dx.doi.org/10.1074/jbc.M511057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469742	hybrid			2022-12-25	WOS:000236594300059
J	Camacho, JA; Hensellek, S; Rougier, JS; Blechschmidt, S; Abriel, H; Benndorf, K; Zimmer, T				Camacho, JA; Hensellek, S; Rougier, JS; Blechschmidt, S; Abriel, H; Benndorf, K; Zimmer, T			Modulation of Na(v)1.5 channel function by an alternatively spliced sequence in the DII/DIII linker region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SODIUM-CHANNEL; ISOFORM-SPECIFIC MANNER; DORSAL-ROOT GANGLIA; GATED NA+ CHANNELS; ALPHA-SUBUNIT; BRUGADA-SYNDROME; RAT-BRAIN; CALMODULIN BINDS; XENOPUS OOCYTES; HUMAN HEART	In the present study, we identified a novel splice variant of the human cardiac Na+ channel Na(v)1.5 (Na(v)1.5d), in which a 40-amino acid sequence of the DII/DIII intracellular linker is missing due to a partial deletion of exon 17. Expression of Na(v)1.5d occurred in embryonic and adult hearts of either sex, indicating that the respective alternative splicing is neither age-dependent nor gender-specific. In contrast, Na(v)1.5d was not detected in the mouse heart, indicating that alternative splicing of Na(v)1.5 is species-dependent. In HEK293 cells, splice variant Na(v)1.5d generated voltage-dependent Na+ currents that were markedly reduced compared with wild-type Na(v)1.5. Experiments with mexiletine and 8-bromo-cyclic AMP suggested that the trafficking of Na(v)1.5d channels was not impaired. However, single-channel recordings showed that the whole-cell current reduction was largely due to a significantly reduced open probability. Additionally, steady-state activation and inactivation were shifted to depolarized potentials by 15.9 and 5.1 mV, respectively. Systematic mutagenesis analysis of the spliced region provided evidence that a short amphiphilic region in the DII/DIII linker resembling an S4 voltage sensor of voltage-gated ion channels is an important determinant of Na(v)1.5 channel gating. Moreover, the present study identified novel short sequence motifs within this amphiphilic region that specifically affect the voltage dependence of steady-state activation and inactivation and current amplitude of human Na(v)1.5.	Univ Jena, Inst Physiol 2, D-07740 Jena, Germany; Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Hosp, Serv Cardiol, CH-1005 Lausanne, Switzerland	Friedrich Schiller University of Jena; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Zimmer, T (corresponding author), Univ Jena, Inst Physiol 2, Kollegiengasse 9, D-07743 Jena, Germany.	Thomas.Zimmer@mti.uni-jena.de	Abriel, Hugues/B-9800-2009; Rougier, Jean-Sébastien/AAX-5038-2021	Abriel, Hugues/0000-0003-0465-5138; Benndorf, Klaus/0000-0002-0707-4083; ROUGIER, Jean-Sebastien/0000-0002-8710-0260				AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; Balser JR, 2001, J MOL CELL CARDIOL, V33, P599, DOI 10.1006/jmcc.2000.1346; Bennett ES, 2004, J MEMBRANE BIOL, V197, P155, DOI 10.1007/s00232-004-0650-6; Bennett ES, 2001, J PHYSIOL-LONDON, V535, P371, DOI 10.1111/j.1469-7793.2001.t01-1-00371.x; Chahine M, 1996, AM J PHYSIOL-HEART C, V271, pH498, DOI 10.1152/ajpheart.1996.271.2.H498; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; Deschenes I, 2001, J MEMBRANE BIOL, V183, P103, DOI 10.1007/s00232-001-0058-5; Dib-Hajj SD, 2002, MOL NEUROBIOL, V26, P235, DOI 10.1385/MN:26:2-3:235; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Diss JKJ, 2004, EUR BIOPHYS J BIOPHY, V33, P180, DOI 10.1007/s00249-004-0389-0; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herzog RI, 2003, J NEUROSCI, V23, P8261; Hong K, 2005, J MOL CELL CARDIOL, V38, P555, DOI 10.1016/j.yjmcc.2004.10.015; Keller DI, 2005, CARDIOVASC RES, V67, P510, DOI 10.1016/j.cardiores.2005.03.024; Kerr NCH, 2004, J BIOL CHEM, V279, P24826, DOI 10.1074/jbc.M401281200; Korsgaard MPG, 2001, PFLUG ARCH EUR J PHY, V443, P18, DOI 10.1007/s004240100625; Li RA, 2002, MOL PHARMACOL, V61, P136, DOI 10.1124/mol.61.1.136; Makielski JC, 2003, CIRC RES, V93, P821, DOI 10.1161/01.RES.0000096652.14509.96; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; Mechaly I, 2005, NEUROSCIENCE, V130, P389, DOI 10.1016/j.neuroscience.2004.09.034; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; O'Reilly JP, 1999, J PHYSIOL-LONDON, V515, P61, DOI 10.1111/j.1469-7793.1999.061ad.x; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Probst V, 2003, J AM COLL CARDIOL, V41, P643, DOI 10.1016/S0735-1097(02)02864-4; Raymond CK, 2004, J BIOL CHEM, V279, P46234, DOI 10.1074/jbc.M406387200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; Shang LJL, 2005, J BIOL CHEM, V280, P933, DOI 10.1074/jbc.M409977200; Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a; Valdivia CR, 2004, CARDIOVASC RES, V62, P53, DOI 10.1016/j.cardiores.2004.01.022; van Bemmelen MX, 2004, CIRC RES, V95, P284, DOI 10.1161/01.RES.0000136816.05109.89; Young KA, 2005, J PHYSIOL-LONDON, V565, P349, DOI 10.1113/jphysiol.2004.081422; Zhou JS, 2000, CIRC RES, V87, P33, DOI 10.1161/01.RES.87.1.33; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zimmer T, 2002, J GEN PHYSIOL, V120, P887, DOI 10.1085/jgp.20028703; Zimmer T, 2002, J MEMBRANE BIOL, V186, P1, DOI 10.1007/s00232-001-0130-1; Zimmer T, 2002, AM J PHYSIOL-HEART C, V282, pH1007, DOI 10.1152/ajpheart.00644.2001	44	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9498	9506		10.1074/jbc.M509716200	http://dx.doi.org/10.1074/jbc.M509716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469732	hybrid			2022-12-25	WOS:000236404700060
J	Muhlhauser, U; Zolk, O; Rau, T; Munzel, F; Wieland, T; Eschenhagen, T				Muelhaeuser, Ulrike; Zolk, Oliver; Rau, Thomas; Muenzel, Felix; Wieland, Thomas; Eschenhagen, Thomas			Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits	FASEB JOURNAL			English	Article						statins; receptor pharmacology; cardiac contractile function	HETEROTRIMERIC G-PROTEINS; HMG-COA REDUCTASE; IN-VITRO; RECEPTOR; EXPRESSION; TISSUE; CELLS; LOCALIZATION; ASSOCIATION; PRENYLATION	Statins exert pleiotropic, cholesterol-independent effects by reducing isoprenylation of monomeric GTPases. Here we examined whether statins also reduce isoprenylation of gamma-subunits of heterotrimeric G-proteins and thereby affect beta-adrenergic signaling and regulation of force in cardiac myocytes. Neonatal rat cardiac myocytes (NRCM) were treated with atorvastatin (0.1- 10 mu mol/l; 12-48 h) and examined for adenylyl cyclase regulating G-protein alpha- (G alpha), beta- (G beta), and gamma- (G gamma) subunits and cAMP accumulation. Engineered heart tissue (EHT) from NRCM was used to evaluate contractile consequences. In atorvastatin-treated NRCM, a second band of G gamma 3 with a lower apparent molecular weight appeared in cytosol and particulate fractions that was absent in vehicle-treated NRCM, but also seen after GGTI-298, a geranylgeranyl transferase inhibitor. In parallel, G beta accumulated in the cytosol and total cellular content of Gas was reduced. In atorvastatin-treated NRCM, the cAMP-increasing effect of isoprenaline was reduced. Likewise, the positive inotropic effect of isoprenaline was desensitized and reduced after treatment with atorvastatin. The effects of atorvastatin were abolished by mevalonate and/or geranylgeranyl pyrophosphate, but not by farnesyl pyrophosphate or squalene. Taken together, the results of this study show that atorvastatin desensitizes NRCM to beta-adrenergic stimulation by a mechanism that involves reduced isoprenylation of G gamma and subsequent reductions in the cellular content of G alpha s.	Univ Hamburg, Med Ctr, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Inst Clin Pharmacol, Erlangen, Germany; Heidelberg Univ, Inst Pharmacol & Toxicol Mannheim, D-6800 Mannheim, Germany	University of Hamburg; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Eschenhagen, T (corresponding author), Univ Hamburg, Med Ctr, Inst Expt & Clin Pharmacol, Martinistr 52, D-20246 Hamburg, Germany.	t.eschenhagen@uke.uni-hamburg.de	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Zolk, Oliver/0000-0002-8220-3834				Bohm M, 2005, Z KARDIOL, V94, P223, DOI 10.1007/s00392-005-0210-9; Bountioukos M, 2003, AM J CARDIOL, V92, P613, DOI 10.1016/S0002-9149(03)00737-9; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; CHILOECHES A, 1995, FEBS LETT, V361, P46, DOI 10.1016/0014-5793(95)00139-Z; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; Cilla DD, 1996, CLIN PHARMACOL THER, V60, P687, DOI 10.1016/S0009-9236(96)90218-0; El-Armouche A, 2003, CARDIOVASC RES, V60, P478, DOI 10.1016/j.cardiores.2003.09.014; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ESCHENHAGEN T, 1993, CELL BIOL INT, V17, P723, DOI 10.1006/cbir.1993.1135; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Lee YI, 2003, FEBS LETT, V555, P329, DOI 10.1016/S0014-5793(03)01267-5; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; MCLEISH KR, 1993, BIOCHEM BIOPH RES CO, V197, P763, DOI 10.1006/bbrc.1993.2544; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Murga C, 1997, FEBS LETT, V409, P24, DOI 10.1016/S0014-5793(97)00476-6; Node K, 2003, CIRCULATION, V108, P839, DOI 10.1161/01.CIR.0000084539.58092.DE; Nusse O, 1996, J CELL SCI, V109, P221; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9523, DOI 10.1021/bi963069l; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Qian YM, 1998, BIOORGAN MED CHEM, V6, P293, DOI 10.1016/S0968-0896(97)10040-2; Sari R, 2001, EUR J PHARMACOL, V432, P91, DOI 10.1016/S0014-2999(01)01454-6; Schnabel P, 1996, CELL SIGNAL, V8, P413, DOI 10.1016/S0898-6568(96)00087-3; Schwindinger WF, 2004, MOL CELL BIOL, V24, P7758, DOI 10.1128/MCB.24.17.7758-7768.2004; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Steinberg SF, 1999, CIRC RES, V85, P1101; Stern RH, 2000, J CLIN PHARMACOL, V40, P616, DOI 10.1177/00912700022009396; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zolk O, 2004, AM J PHYSIOL-HEART C, V286, pH1248, DOI 10.1152/ajpheart.00599.2003; Zolk O, 2000, CAN J PHYSIOL PHARM, V78, P187, DOI 10.1139/cjpp-78-3-187	41	55	57	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					785	+		10.1096/fj.05-5067fje	http://dx.doi.org/10.1096/fj.05-5067fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467371				2022-12-25	WOS:000237698700030
J	Hooi, CSF; Blancher, C; Qiu, W; Revet, IM; Williams, LH; Ciavarella, ML; Anderson, RL; Thompson, EW; Connor, A; Phillips, WA; Campbell, IG				Hooi, C. S-F; Blancher, C.; Qiu, W.; Revet, I. M.; Williams, L. H.; Ciavarella, M. L.; Anderson, R. L.; Thompson, E. W.; Connor, A.; Phillips, W. A.; Campbell, I. G.			ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix	ONCOGENE			English	Article						ST7; tumor suppressor; prostate cancer; breast cancer; microarray analysis	SPARC-NULL MICE; FREQUENT LOSS; FUNCTIONAL EVIDENCE; CHROMOSOME 7Q31; ENHANCED GROWTH; POOR-PROGNOSIS; SQUAMOUS-CELL; ST7 GENE; HETEROZYGOSITY; EXPRESSION	Multiple lines of evidence have provided compelling evidence for the existence of a tumor suppressor gene (TSG) on chromosome 7q31.1. ST7 may be the target of this genetic instability but its designation as a TSG is controversial. In this study, we show that, functionally, ST7 behaves as a tumor suppressor in human cancer. ST7 suppressed growth of PC-3 prostate cancer cells inoculated subcutaneously into severe combined immunodeficient mice, and increased the latency of tumor detection from 13 days in control tumors to 23 days. Re-expression of ST7 was also associated with suppression of colony formation under anchorage-independent conditions in MDA-MB-231 breast cancer cells and ST7 mRNA expression was downregulated in 44% of primary breast cancers. Expression pro. ling of PC-3 cells revealed that ST7 predominantly induces changes in genes involved in re-modeling the extracellular matrix such as SPARC, IGFBP5 and several matrix metalloproteinases. These data indicate that ST7 may mediate tumor suppression through modi. cation of the tumor microenvironment.	Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Melbourne, Vic 8006, Australia; Peter MacCallum Canc Ctr, Surg Oncol Res Lab, Melbourne, Vic, Australia; Peter MacCallum Canc Ctr, Canc Biol Lab, Melbourne, Vic, Australia; St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; Univ Melbourne, Dept Surg, St Vincents Hosp, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Campbell, IG (corresponding author), Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Level 2,Locked Bag 1 A Beckett St, Melbourne, Vic 8006, Australia.	ian.campbell@petermac.org	Anderson, Robin/I-2306-2013; Thompson, Erik/GPK-2067-2022; Revet, Ingrid/C-7256-2009; Thompson, Erik W/A-1425-2009; Anderson, Robin/K-6966-2019; Phillips, Wayne A/H-8070-2013; Anderson, Robin/S-1005-2017	Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Phillips, Wayne A/0000-0002-7961-638X; Campbell, Ian/0000-0002-7773-4155; Anderson, Robin/0000-0002-6841-7422				Achille A, 1996, CANCER RES, V56, P3808; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Barker TH, 2005, AM J PATHOL, V166, P923, DOI 10.1016/S0002-9440(10)62312-7; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brown VL, 2002, BRIT J CANCER, V87, P208, DOI 10.1038/sj.bjc.6600418; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Chlenski A, 2004, CANCER RES, V64, P7420, DOI 10.1158/0008-5472.CAN-04-2141; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dong SM, 2002, CLIN CANCER RES, V8, P2939; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Kato Y, 2005, INT J ONCOL, V27, P759; Katoh M, 2002, INT J ONCOL, V20, P1247; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Koukourakis MI, 2003, CANCER RES, V63, P5376; Kruzelock RP, 2000, ONCOGENE, V19, P6277, DOI 10.1038/sj.onc.1204013; Latil A, 1995, CLIN CANCER RES, V1, P1385; Le Bail B, 1999, J PATHOL, V189, P46; Lu C, 2003, WORLD J GASTROENTERO, V9, P2662; Lussier C, 2001, J CELL BIOCHEM, V81, P463, DOI 10.1002/1097-4644(20010601)81:3<463::AID-JCB1060>3.3.CO;2-C; Moschos SJ, 2002, ONCOLOGY-BASEL, V63, P317, DOI 10.1159/000066230; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Paoni NF, 2003, PHYSIOL GENOMICS, V15, P228, DOI 10.1152/physiolgenomics.00078.2003; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vincent JB, 2002, GENOMICS, V80, P283, DOI 10.1006/geno.2002.6835; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zhang JS, 1998, ONCOGENE, V17, P789, DOI 10.1038/sj.onc.1201996	46	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3924	3933		10.1038/sj.onc.1209418	http://dx.doi.org/10.1038/sj.onc.1209418			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474848				2022-12-25	WOS:000238668800005
J	Pan, CQ; Buxton, JM; Yung, SL; Tom, I; Yang, L; Chen, HX; MacDougall, M; Bell, A; Claus, TH; Clairmont, KB; Whelan, JP				Pan, CQ; Buxton, JM; Yung, SL; Tom, I; Yang, L; Chen, HX; MacDougall, M; Bell, A; Claus, TH; Clairmont, KB; Whelan, JP			Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLACEMENT ANALOGS; BIOLOGICAL-ACTIVITIES; EXPRESSION CLONING; LIRAGLUTIDE NN2211; ADENYLATE-CYCLASE; CHARGED RESIDUES; GLYCEMIC CONTROL; IN-VIVO; AMIDE; POTENCY	The closely related peptides glucagon-like peptide (GLP-1) and glucagon have opposing effects on blood glucose. GLP-1 induces glucose-dependent insulin secretion in the pancreas, whereas glucagon stimulates gluconeogenesis and glycogenolysis in the liver. The identification of a hybrid peptide acting as both a GLP-1 agonist and a glucagon antagonist would provide a novel approach for the treatment of type 2 diabetes. Toward this end a series of hybrid peptides made up of glucagon and either GLP-1 or exendin-4, a GLP-1 agonist, was engineered. Several peptides that bind to both the GLP-1 and glucagon receptors were identified. The presence of glucagon sequence at the N terminus removed the dipeptidylpeptidase IV cleavage site and increased plasma stability compared with GLP-1. Targeted mutations were incorporated into the optimal dual-receptor binding peptide to identify a peptide with the highly novel property of functioning as both a GLP-1 receptor agonist and a glucagon receptor antagonist. To overcome the short half-life of this mutant peptide in vivo, while retaining dual GLP-1 agonist and glucagon antagonist activities, site-specific attachment of long chained polyethylene glycol (PEGylation) was pursued. PEGylation at the C terminus retained the in vitro activities of the peptide while dramatically prolonging the duration of action in vivo. Thus, we have generated a novel dual-acting peptide with potential for development as a therapeutic for type 2 diabetes.	Bayer HealthCare, Dept Metab Dis Res, West Haven, CT 06516 USA; Bayer HealthCare, Dept Biotechnol, Berkeley, CA 94701 USA	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Whelan, JP (corresponding author), Bayer HealthCare, Dept Metab Dis Res, 400 Morgan Lane, West Haven, CT 06516 USA.	james.whelan.b@bayer.com	Clairmont, Kevin/ABG-6161-2021	Clairmont, Kevin/0000-0003-4198-2437				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; Azizeh BY, 1997, J MED CHEM, V40, P2555, DOI 10.1021/jm960800d; Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Feinglos MN, 2005, DIABETIC MED, V22, P1016, DOI 10.1111/j.1464-5491.2005.01567.x; GALLWITZ B, 1994, EUR J BIOCHEM, V225, P1151, DOI 10.1111/j.1432-1033.1994.1151b.x; GOKE R, 1993, J BIOL CHEM, V268, P19650; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; GYSIN B, 1986, BIOCHEMISTRY-US, V25, P8278, DOI 10.1021/bi00373a023; GYSIN B, 1987, J MED CHEM, V30, P1409, DOI 10.1021/jm00391a024; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; Hruby V. J., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P199, DOI 10.2174/1568013013359041; HRUBY VJ, 1997, PRINCIPLES MED BIOL, P387; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jiang GQ, 2003, AM J PHYSIOL-ENDOC M, V284, pE671, DOI 10.1152/ajpendo.00492.2002; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; Knudsen LB, 2000, J MED CHEM, V43, P1664, DOI 10.1021/jm9909645; KRSTENANSKY JL, 1986, J AM CHEM SOC, V108, P1696, DOI 10.1021/ja00267a053; Madsbad S, 2004, DIABETES CARE, V27, P1335, DOI 10.2337/diacare.27.6.1335; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; MOJSOV S, 1990, J BIOL CHEM, V265, P8001; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Parker JC, 1998, J PEPT RES, V52, P398; Ribel U, 2002, EUR J PHARMACOL, V451, P217, DOI 10.1016/S0014-2999(02)02189-1; Ritzel U, 1998, J ENDOCRINOL, V159, P93, DOI 10.1677/joe.0.1590093; Roges OA, 2005, EXPERT OPIN INV DRUG, V14, P705, DOI 10.1517/13543784.14.6.705; SMITH RA, 1993, MOL PHARMACOL, V43, P741; Sturm NS, 1998, J MED CHEM, V41, P2693, DOI 10.1021/jm980084a; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; THORNTON K, 1994, BIOCHEMISTRY-US, V33, P3532, DOI 10.1021/bi00178a009; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, BIOCHEMISTRY-US, V33, P6884, DOI 10.1021/bi00188a018; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; Unson CG, 2002, BIOPOLYMERS, V66, P218, DOI 10.1002/bip.10259; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; Unson CG, 1998, J BIOL CHEM, V273, P10308, DOI 10.1074/jbc.273.17.10308; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; Xiao Q, 2001, BIOCHEMISTRY-US, V40, P2860, DOI 10.1021/bi0014498; Ying JF, 2003, BIOCHEMISTRY-US, V42, P2825, DOI 10.1021/bi026629r	45	63	131	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12506	12515		10.1074/jbc.M600127200	http://dx.doi.org/10.1074/jbc.M600127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505481	hybrid			2022-12-25	WOS:000237134700038
J	Kim, BJ; Lee, H				Kim, BJ; Lee, H			Importin-beta mediates Cdc7 nuclear import by binding to the kinase insert II domain, which can be antagonized by importin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; DNA-REPLICATION; S-PHASE; LOCALIZATION SIGNALS; TRANSCRIPTION FACTOR; CDC7P-DBF4P KINASE; G(1)/S TRANSITION; COMPLEX; TRANSPORT	We investigated the nuclear import mechanism of Cdc7, which is essential for the initiation of DNA replication. Here we report that importin-beta binds directly to Cdc7 via the Kinase Insert II domain, promoting its nuclear import. Although both importin-alpha and -beta bind to Cdc7 via the Kinase Insert II domain in a mutually independent manner, the binding affinity of Cdc7 for importin-beta is similar to 10 times higher than for importin-alpha at low protein concentrations of an equimolar ratio. Immunodepletion of importin-beta, but not importin-alpha, abrogates Cdc7 nuclear import, and the addition of importin-beta to the importin-depleted cytosol restores Cdc7 nuclear import. Furthermore, transduction of anti-importin-beta, but not anti-importin-alpha antibodies, into live cells inhibits Cdc7 nuclear import. Unexpectedly, we found that Cdc7 nuclear import is inhibited by competitive binding of importin-alpha to Cdc7. Further studies by site-directed mutagenesis suggest that Lys(306) and Lys(309) within the Kinase Insert II domain are critical for Cdc7 nuclear localization.	Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Sudbury, ON P3E 2C6, Canada; Sudbury Reg Hosp, NE Ontario Reg Canc Program, Tumour Biol Grp, Sudbury, ON P3E 5J1, Canada; No Ontario Sch Med, Dept Med Sci, Sudbury, ON P3E 2C6, Canada	University of Ottawa; Health Sciences North; Northern Ontario School of Medicine	Lee, H (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Sudbury, ON P3E 2C6, Canada.	hlee@hrsrh.on.ca						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guo B, 2001, BIOTECHNIQUES, V31, P314, DOI 10.2144/01312st02; Guo BQ, 1999, SOMAT CELL MOLEC GEN, V25, P159, DOI 10.1023/A:1018841506868; Guo BQ, 2001, GENE, V264, P249, DOI 10.1016/S0378-1119(01)00332-8; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; Kotera I, 2005, EMBO J, V24, P942, DOI 10.1038/sj.emboj.7600587; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; MARX J, 1995, SCIENCE, V270, P1585, DOI 10.1126/science.270.5242.1585; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai Hisao, 1999, Frontiers in Bioscience, V4, pd834, DOI 10.2741/Masai; Merle E, 1999, J CELL BIOCHEM, V74, P628, DOI 10.1002/(SICI)1097-4644(19990915)74:4<628::AID-JCB12>3.0.CO;2-I; Miyamoto Y, 2004, J CELL BIOL, V165, P617, DOI 10.1083/jcb.200312008; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12041	12049		10.1074/jbc.M512630200	http://dx.doi.org/10.1074/jbc.M512630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16492669	hybrid			2022-12-25	WOS:000236988100074
J	Wen, WY; Yang, J; Zhang, MJ				Wen, WY; Yang, J; Zhang, MJ			Structural characterization of the split pleckstrin homology domain in phospholipase C-gamma 1 and its interaction with TRPC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; PH DOMAIN; PHOSPHOINOSITIDE BINDING; PROTEIN STRUCTURES; NMR-SPECTROSCOPY; C-GAMMA-1; PROGRAM; SPECIFICITY; RESOLUTION; DYNAMIN	Phospholipase C ( PLC)-gamma is unique among the PLC enzymes because each PLC-gamma isozyme contains a split pleckstrin homology ( PH) domain with an SH2SH2SH3 tandem repeat insertion ( where SH indicates Src homology domain) in the middle of its sequence. Split PH domains exist in a number of other proteins that play crucial signaling roles. However, little is known about the structure and function of split PH domains. The C-terminal half of the PLC-gamma split PH domain has been implicated to interact directly with the TRPC3 calcium channel, thereby providing a direct coupling mechanism between PLC-gamma and agonist-induced calcium entry. However, this interaction has not been proved by direct biochemical or structural studies. Here we determined the three-dimensional structure of the split PH domain of PLC-gamma 1, and we found that the split PH domain of the enzyme folds into a canonical PH domain fold with high thermostability. The SH2SH2SH3 insertion between the beta 3 and beta 4 strands does not change the structure of the split PH domain. In contrast to the majority of phospholipid-binding PH domains, the PLC-gamma 1 split PH domain lacks the signature lipid-binding motif located between the beta 1 and beta 2 strands. Consistent with this structural feature, the split PH domain of PLC-gamma 1 does not bind to phospholipids. Multiple biochemical and biophysical experiments have argued against a direct interaction between TRPC3 and the C-terminal half of the PLC-gamma 1 split PH domain. Our data pointed to the existence of a yet to be elucidated interaction mechanism between TRPC3 and PLC-gamma 1.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	mzhang@ust.hk		Zhang, Mingjie/0000-0001-9404-0190				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Berg JS, 2000, J CELL SCI, V113, P3439; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cronin TC, 2004, EMBO J, V23, P3711, DOI 10.1038/sj.emboj.7600388; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemmon MA, 2005, CELL, V120, P574, DOI 10.1016/j.cell.2005.02.023; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Yan J, 2005, EMBO J, V24, P3985, DOI 10.1038/sj.emboj.7600858; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	40	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12060	12068		10.1074/jbc.M600336200	http://dx.doi.org/10.1074/jbc.M600336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500902	hybrid			2022-12-25	WOS:000236988100076
J	Giannakis, M; Stappenbeck, TS; Mills, JC; Leip, DG; Lovett, M; Clifton, SW; Ippolito, JE; Glasscock, JI; Arumugam, M; Brent, MR; Gordon, JI				Giannakis, M; Stappenbeck, TS; Mills, JC; Leip, DG; Lovett, M; Clifton, SW; Ippolito, JE; Glasscock, JI; Arumugam, M; Brent, MR; Gordon, JI			Molecular properties of adult mouse gastric and intestinal epithelial progenitors in their niches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL NICHE; INDUCED APOPTOSIS; PARIETAL-CELLS; SELF-RENEWAL; STOMACH; DIFFERENTIATION; DYNAMICS; COLUMNAR; ORIGIN; IMPACT	We have sequenced 36,641 expressed sequence tags from laser capture microdissected adult mouse gastric and small intestinal epithelial progenitors, obtaining 4031 and 3324 unique transcripts, respectively. Using Gene Ontology ( GO) terms, each data set was compared with cDNA libraries from intact adult stomach and small intestine. Genes in GO categories enriched in progenitors were filtered against genes in GO categories represented in hematopoietic, neural, and embryonic stem cell transcriptomes and mapped onto transcription factor networks, plus canonical signal transduction and metabolic pathways. Wnt/beta-catenin, phosphoinositide-3/Akt kinase, insulin-like growth factor-1, vascular endothelial growth factor, integrin, and gamma-aminobutyric acid receptor signaling cascades, plus glycerolipid, fatty acid, and amino acid metabolic pathways are among those prominently represented in adult gut progenitors. The results reveal shared as well as distinctive features of adult gut stem cells when compared with other stem cell populations.	Washington Univ, Ctr Genome Sci, St Louis, MO 63108 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63108 USA; Washington Univ, Dept Pathol & Immunol, St Louis, MO 63108 USA; Washington Univ, Dept Genet, St Louis, MO 63108 USA; Washington Univ, Lab Computat Genom, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Ctr Genome Sci, 4444 Forest Pk Rd,Campus Box 8510, St Louis, MO 63108 USA.	jgordon@wustl.edu	Brent, Michael/AAK-3702-2020; Arumugam, Manimozhiyan/AAJ-2394-2020; Giannakis, Marios/Z-4908-2019; Arumugam, Manimozhiyan/E-1211-2011; Mills, Jason/AAA-6688-2021	Brent, Michael/0000-0002-8689-0299; Arumugam, Manimozhiyan/0000-0002-0886-9101; Arumugam, Manimozhiyan/0000-0002-0886-9101; Mills, Jason/0000-0002-0402-4662	NIDDK NIH HHS [DK63483] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063483] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Bjerknes M, 2002, AM J PHYSIOL-GASTR L, V283, pG767, DOI 10.1152/ajpgi.00415.2001; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CROFT DN, 1973, DIGESTION, V8, P144, DOI 10.1159/000197310; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hawkins RD, 2003, HUM MOL GENET, V12, P1261, DOI 10.1093/hmg/ddg150; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Lin PT, 2000, J NEUROSCI, V20, P9152; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Mills JC, 2002, P NATL ACAD SCI USA, V99, P14819, DOI 10.1073/pnas.192574799; Mills JC, 2003, J BIOL CHEM, V278, P46138, DOI 10.1074/jbc.M308385200; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Syder AJ, 1999, MOL CELL, V3, P263, DOI 10.1016/S1097-2765(00)80454-2; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; ZHONG Z, 2004, APPL BIOINFORMATICS, V3, P261	34	136	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11292	11300		10.1074/jbc.M512118200	http://dx.doi.org/10.1074/jbc.M512118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464855	hybrid			2022-12-25	WOS:000236822200072
J	Shi-Wen, X; Stanton, LA; Kennedy, L; Pala, D; Chen, YL; Howat, SL; Renzoni, EA; Carter, DE; Bou-Gharios, G; Stratton, RJ; Pearson, JD; Beier, F; Lyons, KM; Black, CM; Abraham, DJ; Leask, A				Shi-Wen, X; Stanton, LA; Kennedy, L; Pala, D; Chen, YL; Howat, SL; Renzoni, EA; Carter, DE; Bou-Gharios, G; Stratton, RJ; Pearson, JD; Beier, F; Lyons, KM; Black, CM; Abraham, DJ; Leask, A			CCN2 is necessary for adhesive responses to transforming growth factor-beta 1 in embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; VIABILITY SIGNALING PATHWAY; INTEGRIN-LINKED KINASE; HUMAN SKIN FIBROBLASTS; FACTOR GENE-EXPRESSION; HUMAN MESANGIAL CELLS; I COLLAGEN MATRICES; FACTOR-BETA; SCLERODERMA FIBROBLASTS; TGF-BETA	CCN2 is induced by transforming growth factor-beta (TGF beta) in fibroblasts and is overexpressed in connective tissue disease. CCN2 has been proposed to be a downstream mediator of TGF beta action in fibroblasts; however, the role of CCN2 in regulating this process unclear. By using embryonic fibroblasts isolated from ccn2-/- mice, we showed that CCN2 is required for a subset of responses to TGF beta. Affymetrix genome-wide expression profiling revealed that 942 transcripts were induced by TGF beta greater than 2-fold in ccn2-/- fibroblasts, of which 345 were not induced in ccn2-/- fibroblasts, including pro-adhesive and matrix remodeling genes. Whereas TGF beta properly induced a generic Smad3-responsive promoter in ccn2-/- fibroblasts, TGF beta-induced activation of focal adhesion kinase (FAK) and Akt was reduced in ccn2-/- fibroblasts. Emphasizing the importance of FAK and Akt activation in CCN2-dependent transcriptional responses to TGF beta in fibroblasts, CCN2 dependent transcripts were not induced by TGF beta in fak-/- fibroblasts and were reduced by wortmannin in wild-type fibroblasts. Akt1 overexpression in ccn2-/- fibroblasts rescued the TGF beta-induced transcription of CCN2-dependent mRNA. Finally, induction of TGF beta-induced fibroblast adhesion to fibronectin and type I collagen was significantly diminished in ccn2-/- fibroblasts. Thus in embryonic fibroblasts, CCN2 is a necessary cofactor required for TGF beta to activate the adhesive FAK/Akt/phosphatidylinositol 3-kinase cascade, FAK/Akt-dependent genes, and adhesion to matrix.	Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; UCL, Dept Med, Ctr Rheumatol, London NW3 2PF, England; Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Interstitial Lung Dis Unit, London SW3 6LR, England; Univ Western Ontario, London Reg Genom Ctr, London, ON N6A 5C1, Canada; Imperial Coll London, Dept Med, London W12 0NN, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA	Western University (University of Western Ontario); University of London; University College London; University of London; King's College London; Imperial College London; Royal Brompton Hospital; Western University (University of Western Ontario); Imperial College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leask, A (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.	Andrew.Leask@schulich.uwo.ca	Leask, Andy/ABH-9433-2020; Lyons, Karen M/P-1843-2014; Leask, Andrew/G-5217-2015; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Lyons, Karen M/0000-0001-9420-5813; Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Renzoni, Elisabetta/0000-0002-1118-797X	NIAMS NIH HHS [R01 AR052686] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052686] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; Chen YL, 2005, AM J PATHOL, V167, P1699, DOI 10.1016/S0002-9440(10)61252-7; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dziadzio M, 2005, QJM-INT J MED, V98, P485, DOI 10.1093/qjmed/hci078; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2005, GASTROENTEROLOGY, V129, P1019, DOI 10.1053/j.gastro.2005.06.067; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gao Runping, 2005, Cell Commun Signal, V3, P14; Grashoff C, 2004, CURR OPIN CELL BIOL, V16, P565, DOI 10.1016/j.ceb.2004.07.004; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; HIGLEY H, 1994, ARTHRITIS RHEUM, V37, P278, DOI 10.1002/art.1780370218; Hinz B, 2003, CURR OPIN BIOTECH, V14, P538, DOI 10.1016/j.copbio.2003.08.006; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jun JB, 2005, J INVEST DERMATOL, V124, P298, DOI 10.1111/j.0022-202X.2004.23559.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; LIEN SC, 2005, IN PRESS CELL SIGNAL; MCWHIRTER A, 1994, LAB INVEST, V71, P885; Mimura Y, 2005, J INVEST DERMATOL, V124, P886, DOI 10.1111/j.0022-202X.2005.23701.x; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; Spessotto P, 2003, J BIOL CHEM, V278, P6160, DOI 10.1074/jbc.M208322200; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702	53	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10715	10726		10.1074/jbc.M511343200	http://dx.doi.org/10.1074/jbc.M511343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484225	hybrid			2022-12-25	WOS:000236822200010
J	Hanington, PC; Barreda, DR; Belosevic, M				Hanington, PC; Barreda, DR; Belosevic, M			A novel hematopoietic granulin induces proliferation of goldfish (Carassius auratus L.) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 BETA-HAIRPINS; GROWTH-FACTOR; EPITHELIN PRECURSOR; GENE-EXPRESSION; CELLULAR-LOCALIZATION; EMERGING FAMILY; IN-VITRO; PROGRANULIN; ACROGRANIN; PEPTIDE	Granulins are a group of highly conserved growth factors that have been described from a variety of organisms spanning the metazoa. In this study, goldfish granulin was one of the most commonly identified transcripts in the differential cross-screening of macrophage cDNA libraries and was preferentially expressed in proliferating macrophages. Unlike mammalian granulins, which possess 7.5 repeats of a characteristic signature of 12 cysteine residues, the goldfish granulin encoded a putative peptide possessing only 1.5 cysteine repeats. Northern blot and real-time PCR analyses indicated that goldfish granulin was expressed only in the hematopoietic tissues of the goldfish, specifically the kidney and spleen, and in activated peripheral blood mononuclear cells. We expressed granulin using a prokaryotic expression system and produced an affinity-purified rabbit anti-goldfish granulin IgG. Recombinant goldfish granulin induced a dose-dependent proliferative response of goldfish macrophages that was inversely related to the myeloid differentiation stage of the cells studied. The highest proliferative response was observed in macrophage progenitor cells and monocytes. This proliferative response of macrophages was abrogated by the addition of anti-granulin IgG. These results indicate that goldfish granulin is a growth factor that positively modulates cell proliferation at distinct junctures of macrophage differentiation.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E9, Canada; Univ Penn, Dept Hematol & Oncol, Philadelphia, PA 19104 USA	University of Alberta; University of Alberta; University of Pennsylvania	Belosevic, M (corresponding author), Univ Alberta, Dept Biol Sci, CW-405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	mike.belosevic@ualberta.ca	Belosevic, Miodrag/C-6729-2008; Belosevic, Miodrag/G-9396-2018; Belosevic, Mike/A-2617-2014; Barreda, Daniel/A-2613-2014	Belosevic, Miodrag/0000-0002-6412-8236; Belosevic, Miodrag/0000-0002-6412-8236; Belosevic, Mike/0000-0001-6512-3587; Barreda, Daniel/0000-0003-4630-2840; Hanington, Patrick/0000-0002-3964-5012				ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; Avrova AO, 1999, MOL PLANT MICROBE IN, V12, P1114, DOI 10.1094/MPMI.1999.12.12.1114; BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P727, DOI 10.1016/j.dci.2003.11.005; Barreda DR, 2000, DEV COMP IMMUNOL, V24, P395, DOI 10.1016/S0145-305X(99)00059-2; Barreda DR, 2001, FISH SHELLFISH IMMUN, V11, P169, DOI 10.1006/fsim.2000.0305; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BELCOURT DR, 1995, J LEUKOCYTE BIOL, V57, P94, DOI 10.1002/jlb.57.1.94; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BELOSEVIC M, 1988, J IMMUNOL, V141, P890; BERKS M, 1995, GENOME RES, V5, P99, DOI 10.1101/gr.5.2.99; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; BHANDARI V, 1993, ENDOCRINOLOGY, V133, P2682, DOI 10.1210/en.133.6.2682; Cadieux B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-156; COUTO MA, 1992, INFECT IMMUN, V60, P3065, DOI 10.1128/IAI.60.8.3065-3071.1992; COUTO MA, 1992, INFECT IMMUN, V60, P5042, DOI 10.1128/IAI.60.12.5042-5047.1992; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Deloffre L, 1999, B SOC ZOOL FR, V124, P337; Diaz-Cueto L, 2000, DEV BIOL, V217, P406, DOI 10.1006/dbio.1999.9564; Donald CD, 2001, ANTICANCER RES, V21, P3739; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Hall VJ, 2005, MOL REPROD DEV, V72, P16, DOI 10.1002/mrd.20337; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; He ZH, 2002, CANCER RES, V62, P5590; Hoque M, 2005, J BIOL CHEM, V280, P13648, DOI 10.1074/jbc.M409575200; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Jones MB, 2003, CLIN CANCER RES, V9, P44; Liau LM, 2000, CANCER RES, V60, P1353; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; Nara K, 2004, BBA-GEN SUBJECTS, V1675, P147, DOI 10.1016/j.bbagen.2004.08.016; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P167, DOI 10.1006/fsim.1999.0236; Neumann NF, 2000, FISH SHELLFISH IMMUN, V10, P1, DOI 10.1006/fsim.1999.0221; Neumann NF, 1998, DEV COMP IMMUNOL, V22, P417, DOI 10.1016/S0145-305X(98)00023-8; Neumann NF, 1995, DEV COMP IMMUNOL, V19, P473, DOI 10.1016/0145-305X(95)00032-O; Ong CHP, 2003, HISTOL HISTOPATHOL, V18, P1275, DOI 10.14670/HH-18.1275; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Qin JW, 2005, BIOL REPROD, V73, P434, DOI 10.1095/biolreprod.105.040030; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; Stafford JL, 2003, DEV COMP IMMUNOL, V27, P685, DOI 10.1016/S0145-305X(03)00041-7; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Suzuki M, 2001, NEUROSCI LETT, V297, P199, DOI 10.1016/S0304-3940(00)01699-2; Suzuki M, 2000, PHYSIOL BEHAV, V68, P707, DOI 10.1016/S0031-9384(99)00241-3; Tolkatchev D, 2001, J PEPT RES, V57, P227, DOI 10.1046/j.1397-002X.2000.00828.x; Tolkatchev D, 2000, BIOCHEMISTRY-US, V39, P2878, DOI 10.1021/bi992130u; UESAKA T, 1995, GEN COMP ENDOCR, V99, P298, DOI 10.1006/gcen.1995.1113; Wang WG, 2003, CLIN CANCER RES, V9, P2221; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	60	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9963	9970		10.1074/jbc.M600631200	http://dx.doi.org/10.1074/jbc.M600631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473876	hybrid			2022-12-25	WOS:000236594300018
J	Inoue, Y; Yoneda, M; Zhao, JS; Miyaishi, O; Ohno-Jinno, A; Kataoka, T; Isogai, Z; Kimata, K; Iwaki, M; Zako, M				Inoue, Y; Yoneda, M; Zhao, JS; Miyaishi, O; Ohno-Jinno, A; Kataoka, T; Isogai, Z; Kimata, K; Iwaki, M; Zako, M			Molecular cloning and characterization of chick SPACRCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BOVINE INTERPHOTORECEPTOR MATRIX; PINEAL-GLAND; MOUSE RETINA; PG-M; HYALURONAN; BINDING; PROTEINS; TISSUE; EXPRESSION	MY-174, a monoclonal antibody that reacts with specific sialylated O-linked glycoconjugates of chick SPACR ( sialoprotein associated with cones and rods), also recognizes another molecule of 300 kDa. Here, we verified that this 300-kDa molecule is chick SPACRCAN ( sialoproteoglycan associated with cones and rods), another member of a novel interphotoreceptor matrix molecule family. Screening for chick SPACRCAN was carried out by plaque hybridization using a probe for chick SPACR. Specific polyclonal antibodies raised against chick SPACRCAN were used for the following experiments. To determine whether the 300-kDa molecule detected by MY-174 was identical to 300-kDa chick SPACRCAN, the migrations of these bands were examined after various glycosidase digestions. Furthermore, the expression levels were measured during retinal development and compared with those of chick SPACR. The results demonstrated that the 300-kDa molecule recognized by MY-174 was chick SPACRCAN, and we further identified it as a proteoglycan with chondroitin sulfate chains. SPACRCAN had heavily sialylated N- and O-linked glycoconjugates, and its MY-174 antigenicity was abolished by O-glycanase treatment after neuraminidase treatment, as observed for chick SPACR. During retinal development, the mRNA and core protein expression levels, MY-174 antigenicity, and hyaluronan binding ability of SPACRCAN peaked around embryonic day 17 and then gradually decreased, whereas the corresponding expression levels of SPACR simply increased, but not its hyaluronan binding ability. The MY-174 reactivity of SPACRCAN in the adult retina was decreased compared with that in the newborn retina, whereas that of SPACR was increased. The decreased hyaluronan binding of SPACR was induced by an inhibitory effect of the excess of sialic acids in the adult stage. Thus, with similar core protein structures and specific sialylated glycoconjugates but distinct chondroitin sulfate chains, SPACRCAN and SPACR may have separate roles in the retina due to their differing expression profiles during development.	Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Dept Pathol, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Prefectural Coll Nursing & Hlth, Aichi 4638502, Japan; Natl Ctr Geriatr & Gerontol, Dept Dermatol, Aichi 4748511, Japan	Aichi Medical University; Aichi Medical University; Aichi Medical University; National Center for Geriatrics & Gerontology	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.	zako@aichi-med-u.ac.jp	Isogai, Zenzo/AAD-3690-2022					Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997; Acharya S, 2000, J BIOL CHEM, V275, P6945, DOI 10.1074/jbc.275.10.6945; ADLER AJ, 1982, EXP EYE RES, V34, P423, DOI 10.1016/0014-4835(82)90088-4; ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Chen QY, 2004, J BIOL CHEM, V279, P23142, DOI 10.1074/jbc.M401584200; Chen QY, 2003, EXP EYE RES, V76, P1, DOI 10.1016/S0014-4835(02)00273-7; Foletta VC, 2001, J COMP NEUROL, V435, P354, DOI 10.1002/cne.1035; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369; Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707; Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422; Hollyfield JG, 2001, EXP EYE RES, V72, P49, DOI 10.1006/exer.2000.0922; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Lee JW, 2000, EXP EYE RES, V71, P341, DOI 10.1006/exer.2000.0888; RING C, 1995, DEV BIOL, V168, P11, DOI 10.1006/dbio.1995.1057; Wang C, 1996, GENE, V174, P299, DOI 10.1016/0378-1119(96)00080-7; Wang X, 1996, MOL BRAIN RES, V41, P269, DOI 10.1016/0169-328X(96)00107-6; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 2002, J BIOL CHEM, V277, P25592, DOI 10.1074/jbc.M201279200; Zako M, 1997, J NEUROCHEM, V69, P2155	26	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10381	10388		10.1074/jbc.M508161200	http://dx.doi.org/10.1074/jbc.M508161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469746	hybrid			2022-12-25	WOS:000236594300067
J	Milanesi, E; Costantini, P; Gamblunga, A; Colonna, R; Petronilli, V; Cabrelle, A; Semenzato, G; Cesura, AM; Pinard, E; Bernardi, P				Milanesi, E; Costantini, P; Gamblunga, A; Colonna, R; Petronilli, V; Cabrelle, A; Semenzato, G; Cesura, AM; Pinard, E; Bernardi, P			The mitochondrial effects of small organic ligands of BCL-2 - Sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DEATH; INHIBITOR; RESISTANCE; IDENTIFICATION; MEMBRANE; COMPOUND; LEUKEMIA	We have investigated the mitochondrial effects of BH3I-2', Chelerythrine, and HA14-1, small organic molecules that share the ability to bind the BH3 domain of BCL-2. All compounds displayed a biphasic effect on mitochondrial respiration with uncoupling at low concentrations and respiratory inhibition at higher concentrations, the relative uncoupling potency being BH3I-2' (half-maximal uncoupling at about 80 nM) > Chelerythrine (half-maximal uncoupling at about 2 mu M) > HA14-1 (half-maximal uncoupling at about 20 mu M). At concentrations lower than required for uncoupling all compounds sensitized the permeability transition pore (PTP) to opening both in isolated mitochondria and intact cells. To assess whether the effects on BCL-2 binding, PTP induction and respiration could be due to different structural determinants we have tested a set of HA14-1 analogs from the Hoffmann-La Roche chemical library. We have identified 5-(6-chloro-2,4-dioxo-1,3,4,10-tetrahydro-2H-9-oxa-1,3-diaza-anthracen-10-yl)-pyrimidine-2,4,6-trione (EM20-25) as a molecule devoid of effects on respiration that is able to induce PTP opening, to disrupt the BCL-2/BAX interactions in situ and to activate caspase-9 in BCL-2-overexpressing cells. EM20-25 neutralized the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitized BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine. These results provide a proof of principle that the potentially toxic effects of BCL-2 ligands on mitochondrial respiration are not essential for their antiapoptotic activity and represent an important step forward in the development of tumor-selective drugs acting on BCL-2.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; F Hoffmann La Roche & Co Ltd, Div Pharma, CH-4070 Basel, Switzerland	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Veneto Institute Molecular Medicine; Roche Holding	Bernardi, P (corresponding author), Univ Padua, Dept Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	SEMENZATO, GIANPIETRO C/J-7727-2016; Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	SEMENZATO, GIANPIETRO C/0000-0002-6061-4595; Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cerutti A, 1996, J IMMUNOL, V157, P1854; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; De Marchi U, 2004, J BIOL CHEM, V279, P37415, DOI 10.1074/jbc.M314093200; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Feng WY, 2003, BRIT J HAEMATOL, V121, P332, DOI 10.1046/j.1365-2141.2003.04268.x; FIGUEROAVILLAR JD, 1993, TETRAHEDRON, V49, P2855, DOI 10.1016/S0040-4020(01)80384-7; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TRENTIN L, 1994, BLOOD, V84, P4249, DOI 10.1182/blood.V84.12.4249.bloodjournal84124249; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; YANG J, 1997, SCIENCE, V275, P1132	29	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10066	10072		10.1074/jbc.M513708200	http://dx.doi.org/10.1074/jbc.M513708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481323	hybrid			2022-12-25	WOS:000236594300031
J	Shivaswamy, S; Bhargava, P				Shivaswamy, S; Bhargava, P			Positioned nucleosomes due to sequential remodeling of the yeast U6 small nuclear RNA chromatin are essential for its transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; SNRNA GENE; DNA TRANSLOCATION; IN-VIVO; PROMOTER; CEREVISIAE; TFIIIB; IDENTIFICATION; ACCESSIBILITY; MAINTENANCE	Transcription from the yeast SNR6 (U6 small nuclear RNA) chromatin, a gene transcribed by the enzyme RNA polymerase III, depends on its transcription factor IIIC ( TFIIIC) and the promoter elements ( the intragenic box A and box B located downstream to its terminator) to which TFIIIC binds. The genes transcribed by polymerase III generally lack the upstream promoter elements where TFIIIC is known to recruit the transcription initiation factor TFIIIB. The TFIIIC-dependent chromatin remodeling of the gene in vitro that involves translational positioning of a nucleosome between boxes A and B is found to be essential for its transcriptional activation. We show here that the role of TFIIIC is not limited to the recruitment of TFIIIB on chromatin templates. The pre-binding of TFIIIB to the SNR6 TATA box in the upstream gene region does not alleviate TFIIIC requirement for transcriptional activation of the chromatin. Binding of TFIIIC to an array of pre-positioned nucleosomes results in an upward shift of the single nucleosome between boxes A and B. The similar to 40-bp shift of this nucleosome in the 3' to 5' direction leads to increased nuclease sensitivity of the similar to 40-bp DNA 3' to the upstream TATA box. Further chromatin remodeling accompanies the binding of TFIIIB in the next step. This two-step remodeling mechanism using the basal factors of the gene yields high transcription levels and generates a chromatin structure similar to that reported for the gene in vivo.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Bhargava, P (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	purnima@ccmb.res.in						Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; Bulger M., 1994, METH MOL G, V5, P241; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; CHEN J, 1994, J BIOL CHEM, V269, P12482; CONAWAY RC, 1994, TRANSCRIPTION MECH R, P107; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Gelbart ME, 2005, GENE DEV, V19, P942, DOI 10.1101/gad.1298905; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Pusarla RH, 2005, FEBS J, V272, P5149, DOI 10.1111/j.1742-4658.2005.04930.x; Saha A, 2005, NAT STRUCT MOL BIOL, V12, P747, DOI 10.1038/nsmb973; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Shivaswamy S, 2004, MOL CELL BIOL, V24, P3596, DOI 10.1128/MCB.24.9.3596-3606.2004; Strohner R, 2005, NAT STRUCT MOL BIOL, V12, P683, DOI 10.1038/nsmb966; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	35	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10461	10472		10.1074/jbc.M512425200	http://dx.doi.org/10.1074/jbc.M512425200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461347	hybrid			2022-12-25	WOS:000236594300075
J	Kamp, F; Beyer, K				Kamp, F; Beyer, K			Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PHOSPHOLIPID-VESICLES; PARKINSONS-DISEASE; PHASE-TRANSITION; MEMBRANE; MUTATION; POLARIZATION; PATHOGENESIS; CHOLESTEROL; MECHANISM	The intracellular deposition of fibrillar aggregates of alpha-synuclein is a characteristic feature of Parkinson disease. Alternatively, as a result of its unusual conformational plasticity, alpha-synuclein may fold into an amphipathic helix upon contact with a lipid-water interface. Using spin label ESR and fluorescence spectroscopy, we show here that alpha-synuclein affects the lipid packing in small unilamellar vesicles. The ESR hyperfine splittings of spin-labeled phospholipid probes revealed that alpha-synuclein induces chain ordering at carbon 14 of the acyl chains below the chain melting phase transition temperature but not in the liquid crystalline state of electroneutral vesicle membranes. Binding of alpha-synuclein leads to an increase in the temperature and cooperativity of the phase transition according to the fluorescence anisotropy of the hydrophobic polyene 1,6-diphenylhexatriene and of the fluorescence emission maxima of the amphiphilic probe 6-dodecanoyl-2-dimethylaminonaphthalene. Binding parameters were obtained from the fluorescence anisotropy measurements in combination with our previous determinations by titration calorimetry (Nuscher, B., Kamp, F., Mehnert, T., Odoy, S., Haass, C., Kahle, P. J., and Beyer, K. (2004) J. Biol. Chem. 279, 21966-21975). We also show that alpha-synuclein interacts with vesicle membranes containing sphingomyelin and cholesterol. We propose that the protein is capable of annealing defects in curved vesicle membranes, which may prevent synaptic vesicles from premature fusion.	Univ Munich, Lehrstuhl Stoffwechselbiochim, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Beyer, K (corresponding author), Univ Munich, Lehrstuhl Stoffwechselbiochim, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	kbeyer@med.uni-muenchen.de	Rose, Louise/F-4723-2011; Presneill, Jeffrey J/B-4894-2012	Presneill, Jeffrey J/0000-0001-7177-7667				Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; [Anonymous], 1976, THEORY APPL SPIN LAB; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1976, BIOCHEMISTRY-US, V15, P2441, DOI 10.1021/bi00656a030; Barenholz Y, 1999, CHEM PHYS LIPIDS, V102, P29, DOI 10.1016/S0009-3084(99)00072-9; Barenholz Y., 1984, PHYSL MEMBRANE FLUID, V1, P131; Cabin DE, 2002, J NEUROSCI, V22, P8797; CALHOUN WI, 1979, BIOCHIM BIOPHYS ACTA, V555, P436, DOI 10.1016/0005-2736(79)90397-3; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Collado MI, 2005, BIOCHEMISTRY-US, V44, P4911, DOI 10.1021/bi0474970; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; ESTEP TN, 1980, BIOCHEMISTRY-US, V19, P20, DOI 10.1021/bi00542a004; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; FREDERIK PM, 1991, BIOCHIM BIOPHYS ACTA, V1062, P133, DOI 10.1016/0005-2736(91)90384-K; GABER BP, 1982, BIOCHIM BIOPHYS ACTA, V685, P87, DOI 10.1016/0005-2736(82)90038-4; GAFFNEY BJ, 1974, J MAGN RESON, V16, P1, DOI 10.1016/0022-2364(74)90193-0; Gaffney BJ, 1976, SPIN LABELING THEORY, P567; GRUENEWALD B, 1979, FEBS LETT, V102, P227, DOI 10.1016/0014-5793(79)80006-X; Harris FM, 2002, BBA-BIOMEMBRANES, V1565, P123, DOI 10.1016/S0005-2736(02)00514-X; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hooper NM, 2005, BIOCHEM SOC T, V33, P335, DOI 10.1042/BST0330335; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; KODAMA M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P90; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LAWACZECK R, 1975, NATURE, V256, P584, DOI 10.1038/256584a0; LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G; Marsh D, 1998, BBA-REV BIOMEMBRANES, V1376, P267, DOI 10.1016/S0304-4157(98)00009-4; MARSH D, 1976, BIOCHEMISTRY-US, V15, P3570, DOI 10.1021/bi00661a027; Mehnert T, 2006, BIOPHYS J, V90, P939, DOI 10.1529/biophysj.105.063271; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; PARENTE RA, 1985, BIOCHEMISTRY-US, V24, P6178, DOI 10.1021/bi00343a022; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	59	92	93	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9251	9259		10.1074/jbc.M512292200	http://dx.doi.org/10.1074/jbc.M512292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455667	hybrid			2022-12-25	WOS:000236404700032
J	Marzia, M; Chiusaroli, R; Neff, L; Kim, NY; Chishti, AH; Baron, R; Horne, WC				Marzia, M; Chiusaroli, R; Neff, L; Kim, NY; Chishti, AH; Baron, R; Horne, WC			Calpain is required for normal osteoclast function and is down-regulated by calcitonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; 3,5-CYCLIC ADENOSINE-MONOPHOSPHATE; VIRUS-TRANSFORMED FIBROBLASTS; MU-CALPAIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ALPHA(V)BETA(3) INTEGRIN; ACID-PHOSPHATASE	Osteoclast motility is thought to depend on rapid podosome assembly and disassembly. Both mu-calpain and m-calpain, which promote the formation and disassembly of focal adhesions, were observed in the podosome belt of osteoclasts. Calpain inhibitors disrupted the podosome belt, blocked the constitutive cleavage of the calpain substrates filamin A, talin, and Pyk2, which are enriched in the podosome belt, induced osteoclast retraction, and reduced osteoclast motility and bone resorption. The motility and resorbing activity of mu-calpain(-/-) osteoclast-like cells were also reduced, indicating that mu-calpain is required for normal osteoclast activity. Histomorphometric analysis of tibias from mu-calpain(-/-) mice revealed increased osteoclast numbers and decreased trabecular bone volume that was apparent at 10 weeks but not at 5 weeks of age. In vitro studies suggested that the increased osteoclast number in the mu-calpain(-/-) bones resulted from increased osteoclast survival, not increased osteoclast formation. Calcitonin disrupted the podosome ring, induced osteoclast retraction, and reduced osteoclast motility and bone resorption in a manner similar to the effects of calpain inhibitors and had no further effect on these parameters when added to osteoclasts pretreated with calpain inhibitors. Calcitonin inhibited the constitutive cleavage of a fluorogenic calpain substrate and transiently blocked the constitutive cleavage of filamin A, talin, and Pyk2 by a protein kinase C-dependent mechanism, demonstrating that calcitonin induces the inhibition of calpain in osteoclasts. These results indicate that calpain activity is required for normal osteoclast activity and suggest that calcitonin inhibits osteoclast bone resorbing activity in part by down-regulating calpain activity.	Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02135 USA; Univ Illinois, Coll Med, Dept Pharmacol, Ctr Canc, Chicago, IL 60607 USA	Yale University; Yale University; St. Elizabeth's Medical Center; Tufts University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed & Rehabil, POB 208044, New Haven, CT 06520 USA.	william.horne@yale.edu			NHLBI NIH HHS [R56 HL051445, HL-51445, R01 HL089517, R01 HL051445] Funding Source: Medline; NIAMS NIH HHS [P30 AR046032, R01 AR057769, R56 AR049879, AR-49879, R01 AR049879, AR-46032] Funding Source: Medline; NIDCR NIH HHS [R37 DE004724, R01 DE004724, DE-04724] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL051445, R01HL051445, R01HL089517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049879, R01AR049879, P30AR046032, R01AR057769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Baron R, 2005, TOP BON BIO, V2, P34; Baron Roland, 1993, P445; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012-1606(03)00299-9; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; CONG JY, 1989, J BIOL CHEM, V264, P10096; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; GOLDBERG AF, 1962, NATURE, V195, P297, DOI 10.1038/195297a0; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hayashi M, 1999, ARCH BIOCHEM BIOPHYS, V371, P133, DOI 10.1006/abbi.1999.1427; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; JANCKILA AJ, 1978, AM J CLIN PATHOL, V70, P45; Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1988, BLOOD, V72, P830; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLONI E, 1984, ARCH BIOCHEM BIOPHYS, V232, P513, DOI 10.1016/0003-9861(84)90568-X; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; Murray SS, 1997, EXP CELL RES, V233, P297, DOI 10.1006/excr.1997.3550; Naro F, 1998, ENDOCRINOLOGY, V139, P3241, DOI 10.1210/en.139.7.3241; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Nikki M, 2002, J BIOL CHEM, V277, P11432, DOI 10.1074/jbc.M111753200; OTSUKA Y, 1987, J BIOL CHEM, V262, P5839; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PAVALKO FM, 1989, J CELL SCI, V94, P109; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; Pfaff M, 2001, J CELL SCI, V114, P2775; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Raja S, 1997, J BIOL CHEM, V272, P10941; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SALAMINO F, 1994, BIOCHEM BIOPH RES CO, V202, P1197, DOI 10.1006/bbrc.1994.2057; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Santhanagopal A, 2001, ENDOCRINOLOGY, V142, P4401, DOI 10.1210/en.142.10.4401; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303-7207(96)03870-1; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shiraha H, 1999, J CELL BIOL, V146, P243; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; Wang K K, 1997, Adv Pharmacol, V37, P117; Wong JK, 2003, J NEUROSCI, V23, P4984; Xi XD, 2003, J CELL BIOL, V162, P329, DOI 10.1083/jcb.200303120; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7	89	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9745	9754		10.1074/jbc.M513516200	http://dx.doi.org/10.1074/jbc.M513516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461769	hybrid, Green Accepted			2022-12-25	WOS:000236404700087
J	Tomita, Y; Marchenko, N; Erster, S; Nemajerova, A; Dehner, A; Klein, C; Pan, HG; Kessler, H; Pancoska, P; Moll, UM				Tomita, Y; Marchenko, N; Erster, S; Nemajerova, A; Dehner, A; Klein, C; Pan, HG; Kessler, H; Pancoska, P; Moll, UM			WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; INDUCED APOPTOSIS; X-L; PROTEIN; OVEREXPRESSION; CANCER; PUMA; MICE; LOCALIZATION; ACTIVATION	The induction of apoptosis by p53 in response to cellular stress is its most conserved function and crucial for p53 tumor suppression. We recently reported that p53 directly induces oligomerization of the BH1,2,3 effector protein Bak, leading to outer mitochondrial membrane permeabilization (OMMP) with release of apoptotic activator proteins. One important mechanism by which p53 achieves OMMP is by forming an inhibitory complex with the antiapoptotic BclXL protein. In contrast, the p53 complex with the Bcl2 homolog has not been interrogated. Here we have undertaken a detailed characterization of the p53-Bcl2 interaction using structural, biophysical, and mutational analyses. We have identified the p53 DNA binding domain as the binding interface for Bcl2 using solution NMR. The affinity of the p53-Bcl2 complex was determined by surface plasmon resonance analysis (BIAcore) to have a dominant component K-D 535 +/- 24 nM. Moreover, in contrast to wild type p53, endogenous missense mutants of p53 are unable to form complexes with endogenous Bcl2 in human cancer cells. Functionally, these mutants are all completely or strongly compromised in mediating OMMP, as measured by cytochrome c release from isolated mitochondria. These data implicate p53-Bcl2 complexes in contributing to the direct mitochondrial p53 pathway of apoptosis and further support the notion that the DNA binding domain of p53 is a dual function domain, mediating both its transactivation function and its direct mitochondrial apoptotic function.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Roche Diagnost GmbH, Pharma Res, D-82372 Penzberg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Georgetown University; Roche Holding; Technical University of Munich	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu	Klein, Christian/G-1336-2010; Kessler, Horst/C-1178-2010	Klein, Christian/0000-0001-7594-7280; Pancoska, Petr/0000-0002-6724-8559	NCI NIH HHS [CA060664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060664, R29CA060664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Athanassiadou P, 1998, DIAGN CYTOPATHOL, V19, P255, DOI 10.1002/(SICI)1097-0339(199810)19:4<255::AID-DC5>3.0.CO;2-9; Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.3.CO;2-I; Bonafe M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2004, CELL CYCLE, V3, P429; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Klein C, 2004, BIOL CHEM, V385, P95, DOI 10.1515/BC.2004.012; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mihara Motohiro, 2003, Methods Mol Biol, V234, P203; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PETROS AM, 2004, FEBS LETT, P1; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sasaki M, 2001, MECH AGEING DEV, V122, P1695, DOI 10.1016/S0047-6374(01)00281-0; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	36	193	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8600	8606		10.1074/jbc.M507611200	http://dx.doi.org/10.1074/jbc.M507611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16443602	hybrid			2022-12-25	WOS:000236247100036
J	Dickstein, DL; Biron, KE; Ujiie, M; Pfeifer, CG; Jeffries, AR; Jefferies, WA				Dickstein, Dara L.; Biron, Kaan E.; Ujiie, Maki; Pfeifer, Cheryl G.; Jeffries, Andrew R.; Jefferies, Wilfred A.			A beta peptide immunization restores blood-brain barrier integrity in Alzheimer disease	FASEB JOURNAL			English	Article						brain; microcirculation; vaccination; plaques	CENTRAL-NERVOUS-SYSTEM; VASCULAR ENDOTHELIAL-CELLS; AMYLOID-BETA; MOUSE MODEL; CEREBROSPINAL-FLUID; MEMORY DEFICITS; MICE; DEMENTIA; INFLAMMATION; ACTIVATION	Immunization with amyloid beta (A beta) peptides or passive immunization with antibodies against A beta has been reported to reduce plaque burden, neuritic dystrophy, early Tau pathology, microgliosis as well as reversing learning and memory deficits. This has created a central paradox: how does vaccination in peripheral tissues reduce plaque burden in the brain? No single explanation for these phenomena has yet been presented. To reconcile these observations, we demonstrate that the integrity of the blood-brain barrier (BBB), a structural barrier between the brain and the blood, is compromised in Tg2576 Alzheimer disease (AD) model mice. We immunized Tg2576 mice with A beta before and after the onset of AD-type neuropathology and observed that BBB permeability, amyloid burden, and microgliosis are decreased in immunized mice. It is concluded that the integrity of the BBB is disrupted in AD mice, and after A beta immunization the immune system clears A beta from sources in the brain as it would in peripheral organs lacking barriers. Once A beta is removed, the integrity of the BBB is restored. The data therefore provide an intellectual framework for understanding how the immune system can clear amyloid deposits from AD brains and suggest new strategies for limiting disease progression in amyloidopathies.	Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 E Mall, Vancouver, BC V6T 1Z4, Canada.	wilf@brc.ubc.ca	Dickstein, Dara/AAH-6603-2020; Dickstein, Dara/F-3036-2013	Pfeifer, Cheryl/0000-0001-8584-228X				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blanc EM, 1997, J NEUROCHEM, V68, P1870; Das P, 2003, J NEUROSCI, V23, P8532; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Giri R, 2000, AM J PHYSIOL-CELL PH, V279, pC1772, DOI 10.1152/ajpcell.2000.279.6.C1772; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Guo JT, 2002, J NEUROSCI, V22, P5900; HAMPEL H, 1995, DEMENTIA, V6, P348, DOI 10.1159/000106969; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; KAWAI M, 1990, AM J PATHOL, V137, P1435; Lemere CA, 2003, NEUROBIOL DIS, V14, P10, DOI 10.1016/S0969-9961(03)00044-5; Lemere CA, 2003, NEUROCHEM RES, V28, P1017, DOI 10.1023/A:1023203122036; LEONARDI A, 1985, J NEUROL SCI, V67, P253, DOI 10.1016/0022-510X(85)90121-2; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; MIYAKAWA T, 1982, VIRCHOWS ARCH B, V40, P121, DOI 10.1007/BF02932857; Mohajeri MH, 2004, FEBS LETT, V562, P16, DOI 10.1016/S0014-5793(04)00169-3; Mohajeri MH, 2002, J BIOL CHEM, V277, P33012, DOI 10.1074/jbc.M203193200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mruthinti S, 2004, NEUROBIOL AGING, V25, P1023, DOI 10.1016/j.neurobiolaging.2003.11.001; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Pogue AI, 2004, NEUROREPORT, V15, P1507, DOI 10.1097/01.wnr.0000130539.39937.1d; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Suhara T, 2003, NEUROBIOL AGING, V24, P437, DOI 10.1016/S0197-4580(02)00135-5; Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Uchikado H, 2004, ACTA NEUROPATHOL, V107, P341, DOI 10.1007/s00401-003-0815-x; Ueno M, 2004, HISTOCHEM CELL BIOL, V122, P131, DOI 10.1007/s00418-004-0684-y; Ujiie M, 2003, MICROCIRCULATION, V10, P463, DOI 10.1038/sj.mn.7800212; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Vagnucci AH, 2003, LANCET, V361, P605, DOI 10.1016/S0140-6736(03)12521-4; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Yin KJ, 2002, J NEUROSCI, V22, P9764	50	101	108	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					426	433		10.1096/fj.05-3956com	http://dx.doi.org/10.1096/fj.05-3956com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507760				2022-12-25	WOS:000239815100006
J	Abbott, GW; Butler, MH; Goldstein, SAN				Abbott, Geoffrey W.; Butler, Margaret H.; Goldstein, Steve A. N.			Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis	FASEB JOURNAL			English	Article						KCNE3; periodic paralysis; MiRP2; Kv3.4	LONG-QT SYNDROME; MINK-RELATED PEPTIDES; TO-WORK TRANSITION; CARDIAC-ARRHYTHMIA; SKELETAL-MUSCLE; ENHANCED INACTIVATION; MOLECULAR-BASIS; NERVOUS-SYSTEM; MUTATIONS; EXERCISE	MinK-related peptide 2 (MiRP2) and Kv3.4 subunits assemble in skeletal muscle to create subthreshold, voltage-gated potassium channels. MiRP2 acts on Kv3.4 to shift the voltage dependence of activation, speed recovery from inactivation, suppress cumulative inactivation and increase unitary conductance. We previously found an R83H missense mutation in MiRP2 that segregated with periodic paralysis in two families and diminished the effects of MiRP2 on Kv3.4. Here we show that MiRP2 has a single, functional PKC phosphorylation site at serine 82 and that normal MiRP2- Kv3.4 function requires phosphorylation of the site. The R83H variant does not prevent PKC phosphorylation of neighboring S82; rather, the change shifts the voltage dependence of activation and endows MiRP2- Kv3.4 channels with sensitivity to changes in intracellular pH across the physiological range. Thus, current passed by single R83H channels decreases as internal pH is lowered (pK(a) similar to 7.3, consistent with histidine protonation) whereas wild-type channels are largely insensitive. These findings identify a key regulatory domain in MiRP2 and suggest a mechanistic link between acidosis and episodes of periodic paralysis.	Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Inst Mol Pediat Sci, Chicago, IL 60637 USA; Cornell Univ, Weill Med Coll, Dept Med, Greenberg Div Cardiol, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY USA	University of Chicago; University of Chicago; Cornell University; Cornell University	Goldstein, SAN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Pediat, 5721 S Maryland Ave,MC8000, Chicago, IL 60637 USA.	sangoldstein@uchicago.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Abbott, Geoffrey/0000-0003-4552-496X	NHLBI NIH HHS [R01 HL079275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; ADAMS GR, 1990, J APPL PHYSIOL, V69, P968, DOI 10.1152/jappl.1990.69.3.968; Antz C, 1999, NAT STRUCT BIOL, V6, P146; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BARSTOW TJ, 1994, J APPL PHYSIOL, V77, P1742, DOI 10.1152/jappl.1994.77.4.1742; Bulman DE, 1999, NEUROLOGY, V53, P1932, DOI 10.1212/WNL.53.9.1932; Chuang ML, 1999, J APPL PHYSIOL, V87, P1048, DOI 10.1152/jappl.1999.87.3.1048; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2360, DOI 10.1152/jappl.1987.63.6.2360; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2366, DOI 10.1152/jappl.1987.63.6.2366; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Gamper G, 1998, ACTA MED AUST, V25, P106; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; Gutmann L, 2000, NEUROL CLIN, V18, P195, DOI 10.1016/S0733-8619(05)70185-7; Ikeda K, 2002, INTERNAL MED, V41, P743, DOI 10.2169/internalmedicine.41.743; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Jurkat-Rott K, 2004, NEUROLOGY, V62, P1012, DOI 10.1212/01.WNL.0000119392.29624.88; Jurkat-Rott K, 2000, P NATL ACAD SCI USA, V97, P9549, DOI 10.1073/pnas.97.17.9549; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kowalchuk JM, 2000, J APPL PHYSIOL, V89, P200, DOI 10.1152/jappl.2000.89.1.200; Kuzmenkin A, 2002, BRAIN, V125, P835, DOI 10.1093/brain/awf071; LANDAU EM, 1981, J GEN PHYSIOL, V77, P647, DOI 10.1085/jgp.77.6.647; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; McCracken VJ, 2001, CELL MICROBIOL, V3, P1, DOI 10.1046/j.1462-5822.2001.00090.x; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; PLANT LD, 2005, IN PRESS J CLIN INVE; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Ptacek L, 1998, AM J MED, V105, P58, DOI 10.1016/S0002-9343(98)00123-5; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; Ptacek LJ, 1999, SEMIN NEUROL, V19, P363, DOI 10.1055/s-2008-1040851; Ptacek LJ, 1999, DIGEST DIS SCI, V44, p94S; PTACEK LJ, 1994, CELL, V77, P863; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; STRINGER W, 1994, J APPL PHYSIOL, V76, P1462, DOI 10.1152/jappl.1994.76.4.1462; Tawil R, 2000, ANN NEUROL, V47, P46, DOI 10.1002/1531-8249(200001)47:1<46::AID-ANA9>3.3.CO;2-8; Tengan C H, 1994, Arq Neuropsiquiatr, V52, P501; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Walter G, 1999, J PHYSIOL-LONDON, V519, P901, DOI 10.1111/j.1469-7793.1999.0901n.x; Wasserman K, 1997, J APPL PHYSIOL, V83, P631, DOI 10.1152/jappl.1997.83.2.631	52	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					293	301		10.1096/fj.05-5070com	http://dx.doi.org/10.1096/fj.05-5070com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449802	Green Submitted			2022-12-25	WOS:000237698700015
J	Cardoso, I; Saraiva, MJ				Cardoso, I.; Saraiva, M. J.			Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model	FASEB JOURNAL			English	Article						metalloproteinase-9; serum amyloid P component; amyloid neuropathy; treatment	P-COMPONENT; POLYNEUROPATHY; MATRIX-METALLOPROTEINASE-9; DEPOSITION; FIBRILS; DISEASE; FIBRILLOGENESIS; TETRACYCLINES; AGGREGATION; PROTEOLYSIS	Familial amyloidotic polyneuropathy is an autosomal dominant disorder mainly characterized by the extracellular deposition of transthyretin, with special involvement of the peripheral nerve. Several animal models have been generated, including transgenic mice carrying the most prevalent TTR mutation (TTR Val30Met). TTR-Val30Met mice without endogenous TTR (TTR-Val30Met X TTR-KO) were previously analyzed in our laboratory and similar to 60% of the animals over 1 year of age were found to have deposition as amyloid, i.e., with Congo red (CR) -positive material, constituting a good tool to investigate the effect of drugs on TTR deposition and fibrillogenesis. We recently showed that the drug doxycycline acts in vitro as a TTR fibril disrupter. In the present work we assessed the activity of this drug in vivo in the TTR-Met30Val X TTR-KO mice. Doxycycline was administrated in the drinking water to 23- to 28-month-old mice over a period of 3 months. Immunohistochemistry analyses revealed no differences in nonfibrillar TTR deposition between treated (n = 11) and untreated mice (n = 11). However, CR-positive material was observed only in the control group (untreated) whereas none of the animals treated with doxycycline was CR-positive. Immunohistochemistry for several markers associated with amyloid, such as matrix metalloproteinase-9 (MMP-9) and serum amyloid P component (SAP), was performed. MMP-9 was altered with significantly lower levels in treated animals compared with the control group. Mouse SAP was absent in treated animals, being observed only in untreated animals presenting TTR congophilic deposits. These results indicate that doxycycline is capable of disrupting TTR CR-positive amyloid deposits and decreases standard markers associated with fibrillar deposition, being a potential drug in the treatment of amyloidosis.	IBMC, Mol Neurobiol Unit, P-4150180 Oporto, Portugal; Univ Porto, Inst Biomed Sci Abel Salazar, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Saraiva, MJ (corresponding author), IBMC, Mol Neurobiol Unit, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mjsaraiv@ibmc.up.pt	Saraiva, Maria João/K-3907-2013; Lima, Marta T/C-7042-2009; Cardoso, Isabel/K-3903-2013	Saraiva, Maria João/0000-0002-3360-6899; Cardoso, Isabel/0000-0003-2472-7055				ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; CAMPISTOL JM, 1992, KIDNEY INT, V42, P915, DOI 10.1038/ki.1992.368; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; COIMBRA A, 1971, BRAIN, V94, P199, DOI 10.1093/brain/94.2.199; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Duivenvoorden WCM, 1997, INVAS METAST, V17, P312; Fernandez FG, 2005, AM J TRANSPLANT, V5, P671, DOI 10.1111/j.1600-6143.2005.00751.x; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Gillmore JD, 2000, NUCL MED COMMUN, V21, P735, DOI 10.1097/00006231-200008000-00006; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hughes PM, 2002, NEUROSCIENCE, V113, P273, DOI 10.1016/S0306-4522(02)00183-5; Inoue S, 1998, J STRUCT BIOL, V124, P1, DOI 10.1006/jsbi.1998.4052; Koistinaho M, 2005, J CEREBR BLOOD F MET, V25, P460, DOI 10.1038/sj.jcbfm.9600040; Lee CZ, 2004, STROKE, V35, P1715, DOI 10.1161/01.STR.0000129334.05181.b6; Lee LK, 2003, MED SCI MONITOR, V9, pBR54; Maeda S, 2003, AMYLOID, V10, P17; Pepys MB, 1996, CIBA F SYMP, V199, P73; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; PUCHTLER H, 1965, J HISTOCHEM CYTOCHEM, V13, P693, DOI 10.1177/13.8.693; Saraiva MJ, 2004, J MOL NEUROSCI, V23, P35, DOI 10.1385/JMN:23:1-2:035; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2002, AM J PATHOL, V161, P1935, DOI 10.1016/S0002-9440(10)64469-0; Sousa MM, 2004, FASEB J, V18, P124, DOI 10.1096/fj.04-2022fje; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Stix B, 2001, AM J PATHOL, V159, P561, DOI 10.1016/S0002-9440(10)61727-0; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	35	116	127	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					234	239		10.1096/fj.05-4509com	http://dx.doi.org/10.1096/fj.05-4509com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449795				2022-12-25	WOS:000237698700008
J	Liu, L; Andrews, L; Tollefsbol, TO				Liu, L.; Andrews, L. G.; Tollefsbol, T. O.			Loss of the human polycomb group protein BMI1promotes cancer-specific cell death	ONCOGENE			English	Article						BMI1; cancer stem cells; telomerase; INK4A-ARF; PcG proteins	LIFE-SPAN; SELF-RENEWAL; BMI-1 ONCOPROTEIN; LEUKEMIA-CELLS; MYC; IDENTIFICATION; TRANSFORMATION; PROLIFERATION; TUMORIGENESIS; SENESCENCE	The polycomb group protein BMI1 has been shown to support normal stem cell proliferation via its putative stem cell factor function, but it is not known if BMI1 may also act as a cancer stem cell factor to promote cancer development. To determine the role of human BMI1 in cancer growth and survival, we performed a loss-of-function analysis of BMI1 by RNA interference (RNAi) in both normal and malignant human cells. Our results indicate that BMI1 is crucial for the short-term survival of cancer cells but not of normal cells. We also demonstrated that loss of BMI1 was more effective in suppressing cancer cell growth than retinoid-treatment, and surviving cancer cells showed significantly reduced tumorigenicity. The cancer-specific growth retardation was mediated by an increased level of apoptosis and a delayed cell cycle progression due to the loss of BMI1. By comparison, BMI1 deficiency caused only a moderate inhibition of the cell cycle progression in normal lung cells. In both normal and cancer cells, the loss of BMI1 led to an upregulation of INK4A-ARF, but with no significant effect on the level of telomerase gene expression, suggesting that other BMI1-cooperative factors in addition to INK4A-ARF activation may be involved in the BMI1-dependent cancer-specific growth retardation. Thus, human BMI1 is critical for the short-term survival of cancer cells, and inhibition of BMI1 has minimal effect on the survival of normal cells. These findings provide a foundation for developing a cancer-specific therapy targeting BMI1.	Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Liu, L (corresponding author), Univ Alabama Birmingham, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.	liangliu@uab.edu		Tollefsbol, Trygve/0000-0002-0284-1511	NATIONAL CANCER INSTITUTE [R21CA114019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020375] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA114019, R21 CA114019-02] Funding Source: Medline; NIA NIH HHS [R03 AG020375-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bea S, 2001, CANCER RES, V61, P2409; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Dimri GP, 2002, CANCER RES, V62, P4736; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu L, 2004, MOL CANCER THER, V3, P1003; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Shakhova O, 2005, J MOL MED, V83, P596, DOI 10.1007/s00109-005-0682-0; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.e04-07-0652; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791	28	69	84	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4370	4375		10.1038/sj.onc.1209454	http://dx.doi.org/10.1038/sj.onc.1209454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501599	Green Accepted			2022-12-25	WOS:000239240100012
J	De la Cueva, E; Garcia-Cao, I; Herranz, M; Lopez, P; Garcia-Palencia, P; Flores, JM; Serrano, M; Fernandez-Piqueras, J; Martin-Caballero, J				De la Cueva, E.; Garcia-Cao, I.; Herranz, M.; Lopez, P.; Garcia-Palencia, P.; Flores, J. M.; Serrano, M.; Fernandez-Piqueras, J.; Martin-Caballero, J.			Tumorigenic activity of p21(Waf1/Cip1) in thymic lymphoma	ONCOGENE			English	Article						p21; p53; apoptosis; cell cycle; lymphoma	TUMOR-FORMATION; INHIBITOR P21; SKIN CARCINOGENESIS; MICE LACKING; P21(CIP1); DEFICIENCY; P27(KIP1); RADIATION; APOPTOSIS; P53	The cell cycle inhibitor p21(Waf1/Cip1) is among the most important mediators of the tumor suppressor p53. However, there is increasing evidence indicating that p21 could favor tumorigenesis in specific cell types. In particular, the absence of p21 delays the development of thymic lymphomas induced either by ataxia-telangiectasia mutated deficiency or by ionizing irradiation. Here, we extend these observations to the context of p53-deficient mice. The absence of p21 results in a significant extension of the lifespan of p53-null and p53-haploin sufficient mice, and this effect can be attributed exclusively to a decrease in the incidence of spontaneous thymic lymphomas. Specifically, despite the occurrence of a variety of tumor types in the context of p53 deficiency, the only tumors that were significantly impaired by the absence of p21 were thymic lymphomas. Moreover, the absence of p21 also delays the incidence of radiation-induced thymic lymphomas in p53-deficient mice. Interestingly, p21-deficient lymphomas have a higher apoptotic rate than p21-proficient lymphomas, and this could be on the basis of the delayed incidence of thymic lymphomas in the absence of p21. Together, our results indicate that p21 plays an oncogenic role restricted to thymic lymphomas that is mechanistically independent of p53 and associated to a lower tumor apoptotic rate.	Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Tumor Suppress Grp, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Canc Epigenet Grp, Madrid 28029, Spain; Univ Autonoma Madrid, Human Mol Genet Lab, Madrid, Spain; Univ Complutense Madrid, Sch Vet, Dept Anim Surg & Med, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Herranz, Michel/L-2561-2016; Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; de la Cueva, Ernesto/0000-0001-7078-0901; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARPER JW, 1993, CELL, V75, P805; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	29	58	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4128	4132		10.1038/sj.onc.1209432	http://dx.doi.org/10.1038/sj.onc.1209432			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462758				2022-12-25	WOS:000238802400014
J	Jiang, M; Wei, Q; Wang, J; Du, Q; Yu, J; Zhang, L; Dong, Z				Jiang, M.; Wei, Q.; Wang, J.; Du, Q.; Yu, J.; Zhang, L.; Dong, Z.			Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis	ONCOGENE			English	Article						p53; PUMA; mitochondria; cisplatin; apoptosis; nephrotoxicity	BCL-X-L; COLORECTAL-CANCER CELLS; PROXIMAL TUBULE CELLS; MITOCHONDRIAL DYSFUNCTION; INDUCED NEPHROTOXICITY; DEATH; BAX; PATHWAYS; EXPRESSION; GENE	Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Depending on its concentration, cisplatin induces necrosis or apoptosis of tubular cells in the kidneys, whereas the underlying injury mechanism is unclear. Our recent work has suggested a critical role for p53 in cisplatin-induced tubular cell apoptosis; nevertheless, the apoptotic events triggered by p53 remain elusive. The current study has examined Bcl-2 family proteins, critical regulators of apoptosis that may be subjected to p53 regulation. Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic molecule, was suppressed, while the expression of Bak, a proapoptotic molecule, increased slightly. Of interest, PUMA-alpha, a newly identified p53-responsive proapoptotic Bcl-2 family protein, was drastically induced by cisplatin. PUMA-alpha induction preceded or paralleled the development of apoptosis. Induced PUMA-alpha was localized in mitochondria and appeared to antagonize Bcl-xL via molecular interaction. PUMA-alpha induction during cisplatin treatment was attenuated by pifithrin-alpha, a pharmacological inhibitor of p53, which was accompanied by the amelioration of Bax activation, cytochrome c release and apoptosis. Moreover, PUMA-alpha induction was suppressed by dominant-negative p53. Importantly, cisplatin-induced apoptosis was ameliorated in PUMA-alpha knockout cells. In vivo, cisplatin induced PUMA-alpha in the kidneys, and the inductive response was abrogated in p53-deficient animals. Together, this study has demonstrated the first compelling evidence for the involvement of PUMA-alpha in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA USA; Dept Vet Affairs Med Ctr, Med Res Serv, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd,CB2917, Augusta, GA 30912 USA.	zdong@mail.mcg.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Livingston, Man/0000-0001-8638-0902; Du, Quansheng/0000-0003-4079-8662				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akeshima R, 2001, BRIT J CANCER, V84, P1551, DOI 10.1054/bjoc.2001.1812; Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Chang JS, 2005, LIFE SCI, V76, P1883, DOI 10.1016/j.lfs.2004.11.003; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Fuertes MA, 2003, CURR MED CHEM, V10, P257, DOI 10.2174/0929867033368484; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang M, 2004, AM J PHYSIOL-RENAL, V287, pF1140, DOI 10.1152/ajprenal.00262.2004; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Li SY, 2004, AM J PHYSIOL-RENAL, V287, pF990, DOI 10.1152/ajprenal.00206.2004; Liu H, 2003, KIDNEY INT, V63, P1687, DOI 10.1046/j.1523-1755.2003.00908.x; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; MIYASHITA T, 1995, CELL, V80, P293; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park MS, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134858; Ramesh G, 2002, J CLIN INVEST, V110, P835, DOI 10.1172/JCI200215606; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sheikh-Hamad D, 2004, ARCH TOXICOL, V78, P147, DOI 10.1007/s00204-003-0521-4; Shen ZN, 2005, BIOCHEM BIOPH RES CO, V328, P375, DOI 10.1016/j.bbrc.2004.12.186; Shiraishi F, 2000, AM J PHYSIOL-RENAL, V278, pF726, DOI 10.1152/ajprenal.2000.278.5.F726; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tomasoni S, 2004, CURR GENE THER, V4, P115, DOI 10.2174/1566523044578013; Tomita N, 2004, CURR DRUG TARGETS, V5, P717, DOI 10.2174/1389450043345146; Tsuruya K, 2003, KIDNEY INT, V63, P72, DOI 10.1046/j.1523-1755.2003.00709.x; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei QQ, 2005, AM J NEPHROL, V25, P491, DOI 10.1159/000088171; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yu F, 2005, AM J PHYSIOL-RENAL, V289, pF514, DOI 10.1152/ajprenal.00101.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	167	174	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4056	4066		10.1038/sj.onc.1209440	http://dx.doi.org/10.1038/sj.onc.1209440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491117				2022-12-25	WOS:000238802400006
J	Ellerhorst, JA; Ekmekcioglu, S; Johnson, MK; Cooke, CP; Johnson, MM; Grimm, EA				Ellerhorst, J. A.; Ekmekcioglu, S.; Johnson, M. K.; Cooke, C. P.; Johnson, M. M.; Grimm, E. A.			Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma	ONCOGENE			English	Article						N-Ras; B-Raf; ERK; iNOS; melanoma	NITRIC-OXIDE SYNTHASE; KAPPA-B; RAS MUTATIONS; N-RAS; MELANOCYTIC LESIONS; TUMOR PROGRESSION; GENE-EXPRESSION; BRAF GENE; CANCER; CELLS	Activating mutations of the genes for NRAS and BRAF, components of the p44/42 mitogen-activated protein kinase (MAPK) pathway, are common findings in melanoma. Recent evidence in several nonmelanoma cell systems supports the regulation of the inducible nitric oxide synthase ( iNOS) gene by this pathway. On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma. In the present study, we have shown that inhibition of melanoma iNOS activity by S-methylisothiourea leads to decreased cell proliferation, confirming the importance of iNOS activity for melanoma cell growth. Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference. To explore this regulatory pathway in human tissue, 20 melanoma tumors were examined for NRAS and BRAF mutations, immunohistochemical evidence of ERK phosphorylation, and iNOS expression. A significant association was found among these three features. We conclude that in human melanoma, activating mutations of NRAS and BRAF drive constitutive iNOS expression and, implicitly, nitric oxide production, contributing to the poor survival of these patients.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ellerhorst, JA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 362, Houston, TX 77030 USA.	jaellerh@mdanderson.org	Ekmekcioglu, Suhendan/A-9686-2009		NCI NIH HHS [P50 CA093459, CA16672, R01 CA90282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090282, P30CA016672, P50CA093459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat NR, 2002, BRAIN RES, V948, P93, DOI 10.1016/S0006-8993(02)02953-0; Brose MS, 2002, CANCER RES, V62, P6997; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Ekmekcioglu S, 2003, MOL CANCER THER, V2, P9; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Gay RD, 1998, BBA-GENE STRUCT EXPR, V1443, P315, DOI 10.1016/S0167-4781(98)00234-6; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Gorden A, 2003, CANCER RES, V63, P3955; Guan KL, 2000, J BIOL CHEM, V275, P27354; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; Perrotta C, 2004, CANCER RES, V64, P3767, DOI 10.1158/0008-5472.CAN-04-0668; Salvucci O, 2001, CANCER RES, V61, P318; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 2003, FREE RADICAL BIO MED, V34, P951, DOI 10.1016/S0891-5849(02)01362-X; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Zheng MZ, 2004, MELANOMA RES, V14, P165, DOI 10.1097/01.cmr.0000129374.76399.19	31	35	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3956	3962		10.1038/sj.onc.1209419	http://dx.doi.org/10.1038/sj.onc.1209419			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474847				2022-12-25	WOS:000238668800009
J	Jamburuthugoda, VK; Chugh, P; Kim, B				Jamburuthugoda, VK; Chugh, P; Kim, B			Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; IN-VIVO; CANCER; ADENOVIRUS; FIDELITY; THERAPY; VECTOR; PROCESSIVITY; REPLICATION; REGRESSION	Retroviruses and DNA viruses utilize cellular dNTPs as substrates for their DNA polymerases during viral replication in infected cells. However, because of S phase- dependent dNTP biosynthesis, the availability of cellular dNTPs significantly varies among cell types ( e. g. dividing versus nondividing cells and normal versus tumor cells). Here we tested whether alterations in the dNTP utilization efficiency and dNTP binding affinity of viral DNA polymerases can switch viral infection specificity to cell types with different dNTP concentrations. We employed an HIV- 1 reverse transcriptase ( RT) mutant ( Q151N), which is catalytically active only at high dNTP concentrations because of its reduced dNTP binding affinity. Indeed, the modified HIV- 1 vector harboring the Q151N mutant RT preferentially transduced tumor cells containing higher cellular dNTP concentrations than primary cells ( e. g. human lung fibroblasts ( HLFs) and human keratinocytes). Although the wild type HIV- 1vector transduced both HLFs and tumor cells, the Q151N vector failed to transduce HLFs and keratinocytes but efficiently transduced tumor cells. Pretreatment of HLFs with deoxynucleosides, which increase cellular dNTP pools, enabled the mutant vector to transduce HLFs, suggesting that the transduction failure of the RT mutant vector to primary cells is because of inefficient reverse transcription in low cellular dNTP environments. We also observed that the Q151N vector expressing herpes simplex virus- thymidine kinase renders tumor cells sensitive to gancyclovir. This study validates a novel strategy in which modifications of viral DNA polymerases in various vector systems allow the delivery of target genes exclusively to tumor cells exploiting elevated cellular dNTP concentration as a tumor cell- specific host factor.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049781] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49781] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Baglole CJ, 2005, METH MOLEC MED, V117, P115; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Diamond TL, 2003, J BIOL CHEM, V278, P29913, DOI 10.1074/jbc.M211754200; FULLER SA, 1982, BIOCHEM J, V206, P131, DOI 10.1042/bj2060131; Ghaneh P, 2001, GENE THER, V8, P199, DOI 10.1038/sj.gt.3301394; Gottesman MM, 2003, CANCER GENE THER, V10, P501, DOI 10.1038/sj.cgt.7700602; Hauschka P V, 1973, Methods Cell Biol, V7, P361; Ho IAW, 2004, HUM GENE THER, V15, P495, DOI 10.1089/10430340460745810; Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987; JACKSON RC, 1980, CANCER RES, V40, P1286; Jamburuthugoda VK, 2005, BIOCHEMISTRY-US, V44, P10635, DOI 10.1021/bi050611+; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Kaplitt Michael G., 1996, Methods (Orlando), V10, P343, DOI 10.1006/meth.1996.0112; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Li HH, 2005, GASTROENTEROLOGY, V128, P2029, DOI 10.1053/j.gastro.2005.03.001; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Okada T, 2002, METHODS, V28, P237, DOI 10.1016/S1046-2023(02)00228-1; Putral LN, 2005, MOL PHARMACOL, V68, P1311, DOI 10.1124/mol.105.014191; Renda MJ, 2001, J VIROL, V75, P9671, DOI 10.1128/JVI.75.20.9671-9678.2001; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Skasko M, 2005, J BIOL CHEM, V280, P12190, DOI 10.1074/jbc.M412859200; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Maele B, 2003, J VIROL, V77, P4685, DOI 10.1128/JVI.77.8.4685-4694.2003; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200	35	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13388	13395		10.1074/jbc.M600291200	http://dx.doi.org/10.1074/jbc.M600291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16497663	hybrid			2022-12-25	WOS:000237336600045
J	Imai, M; Mizuno, T; Kawasaki, K				Imai, M; Mizuno, T; Kawasaki, K			Membrane fusion by single influenza hemagglutinin trimers - Kinetic evidence from image analysis of hemagglutinin-reconstituted vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL ENVELOPE PROTEIN; VIRUS HEMAGGLUTININ; CELL-FUSION; RECEPTOR-BINDING; SURFACE-DENSITY; INITIAL-STAGES; FLUORESCENCE; PORE; GLYCOPROTEIN; PH	Influenza hemagglutinin, the receptor-binding and membrane fusion protein of the virus, is a prototypic model for studies of biological membrane fusion in general. To elucidate the minimum number of hemagglutinin trimers needed for fusion, the kinetics of fusion induced by reconstituted vesicles of hemagglutinin was studied by using single-vesicle image analysis. The surface density of hemagglutinin fusion-activity sites on the vesicles was varied, while keeping the surface density of receptor-binding activity sites constant, by co-reconstitution of the fusogenic form of hemagglutinin, HA(1,2), and the non-fusogenic form, HA(0), at various HA(1,2):(HA(1,2) + HA(0)) ratios. The rate of fusion between the hemagglutinin vesicles containing a fluorescent lipid probe, octadecylrhodamine B, and red blood cell ghost membranes was estimated from the time distribution of fusion events of single vesicles observed by fluorescence microscopy. The best fit of a log-log plot of fusion rate versus the surface density of HA(1,2) exhibited a slope of 0.85, strongly supporting the hypothesis that single hemagglutinin trimers are sufficient for fusion. When only HA(1,2) (without HA(0)) was reconstituted on vesicles, the dependence of fusion rate on the surface density of HA(1,2) was distinct from that for the HA(1,2)-HA(0) co-reconstitution. The latter result suggested interference with fusion activity by hemagglutinin-receptor binding, without having to assume a fusion mechanism involving multiple hemagglutinin trimers.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, AIST, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 2080011, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Infectious Diseases (NIID)	Kawasaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, AIST, Tsukuba, Ibaraki 3058566, Japan.	kawasaki.k@aist.go.jp	Kawasaki, Kazunori/L-7007-2018	Kawasaki, Kazunori/0000-0001-8708-2261				ALFORD D, 1994, BIOCHEMISTRY-US, V33, P1977, DOI 10.1021/bi00174a002; Bentz J, 2000, BIOPHYS J, V78, P227, DOI 10.1016/S0006-3495(00)76587-8; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; CLAGUE MJ, 1991, J VIROL, V65, P2402, DOI 10.1128/JVI.65.5.2402-2407.1991; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; EDKERT DM, 2001, ANNU REV BIOCHEM, V70, P777; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GEORGIOU GN, 1989, FEBS LETT, V250, P487, DOI 10.1016/0014-5793(89)80782-3; Gunther-Ausborn S, 2000, J VIROL, V74, P2714, DOI 10.1128/JVI.74.6.2714-2720.2000; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Kanaseki T, 1997, J CELL BIOL, V137, P1041, DOI 10.1083/jcb.137.5.1041; KAWASAKI K, 1983, BIOCHIM BIOPHYS ACTA, V733, P286, DOI 10.1016/0005-2736(83)90534-5; KAWASAKI K, 1992, BIOCHEM BIOPH RES CO, V186, P378, DOI 10.1016/S0006-291X(05)80818-6; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Leikina E, 2000, BIOPHYS J, V79, P1415, DOI 10.1016/S0006-3495(00)76393-4; Lindau M, 2003, BBA-MOL CELL RES, V1641, P167, DOI 10.1016/S0167-4889(03)00085-5; LOWY RJ, 1990, P NATL ACAD SCI USA, V87, P1850, DOI 10.1073/pnas.87.5.1850; LUDWIG K, 1995, EUR BIOPHYS J BIOPHY, V24, P55, DOI 10.1007/BF00211399; MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133; Markosyan RM, 2000, MOL BIOL CELL, V11, P1143, DOI 10.1091/mbc.11.4.1143; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELIKYAN GB, 1995, J GEN PHYSIOL, V106, P783, DOI 10.1085/jgp.106.5.783; Millar BMG, 1999, VIROLOGY, V257, P415, DOI 10.1006/viro.1999.9624; Mittal A, 2001, BIOPHYS J, V81, P1521, DOI 10.1016/S0006-3495(01)75806-7; MIZUNO T, 1992, ANAL BIOCHEM, V207, P208, DOI 10.1016/0003-2697(92)90002-O; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; Ohki S, 1998, BIOCHEMISTRY-US, V37, P7496, DOI 10.1021/bi972016g; Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769; Sakai T, 2006, J VIROL, V80, P2013, DOI 10.1128/JVI.80.4.2013-2018.2006; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; Schoen P, 1996, FEBS LETT, V390, P315, DOI 10.1016/0014-5793(96)00682-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1995, BIOCHEMISTRY-US, V34, P1825, DOI 10.1021/bi00006a002; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VOLSKY DJ, 1978, FEBS LETT, V92, P190, DOI 10.1016/0014-5793(78)80751-0; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005	55	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12729	12735		10.1074/jbc.M600902200	http://dx.doi.org/10.1074/jbc.M600902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505474	hybrid			2022-12-25	WOS:000237134700065
J	Kudo, M; Canfield, WM				Kudo, M; Canfield, WM			Structural requirements for efficient processing and activation of recombinant human UDP-N-acetylglucosamine : Lysosomal-enzyme-N-acetylglucosamine-1-phosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE ALPHA/BETA-SUBUNITS; PSEUDO-HURLER POLYDYSTROPHY; MUCOLIPIDOSIS-II; PURIFICATION; MUTATIONS; OLIGOSACCHARIDES; IDENTIFICATION; ENDOPROTEASE; PROTEINS	Mannose 6-phosphate-modified N-glycans are the determinant for intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome. The enzyme responsible for the initial step in the synthesis of mannose 6-phosphate is UDP-N-acetylglucosamine: lysosomalenzyme-N- acetylglucosmine-1-phosphotransferase(GlcNAc-phosphotransferase). GlcNAc-phosphotransferase is a multisubunit enzyme with an alpha(2)beta(2)gamma(2) arrangement that requires a detergent for solubilization. Recent cloning of cDNAs and genes encoding these subunits revealed that the alpha- and beta-subunits are encoded by a single gene as a precursor, whereas the gamma-subunit is encoded by a second gene. The hydropathy plots of the deduced amino acid sequences suggested that the alpha- and beta-subunits but not the gamma-subunit contain transmembrane domains. Access to these cDNAs allowed us to express a soluble form of human recombinant GlcNAc-phosphotransferase by removing the putative transmembrane and cytoplasmic domains from the alpha- and beta-subunits. Because this modification prevented precursor processing to mature alpha- and beta-subunits, the native cleavage sequence was replaced by a cleavage site for furin. When the modified alpha/beta-subunits (alpha'/beta'-subunits) precursor and wild type gamma-subunit cDNAs were co-expressed in 293T or CHO-K1 cells, a furin-like protease activity in these cells cleaved the precursor and produced an active and processed soluble GlcNAc-phosphotransferase with an alpha'(2)beta'(2)gamma(2)-subunits arrangement. Recombinant soluble GlcNAc-phosphotransferase exhibited specific activity and substrate preferences similar to the wild type bovine GlcNAc-phosphotransferase and was able to phosphorylate a lysosomal hydrolase, acid alpha-glucosidase in vitro.	Genzyme Corp, Oklahoma City, OK 73104 USA	Sanofi-Aventis; Genzyme Corporation	Canfield, WM (corresponding author), Genzyme Corp, 800 Res Pkwy,Suite 200, Oklahoma City, OK 73104 USA.	William.Canfield@genzyme.com						Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; Do H, 2002, J BIOL CHEM, V277, P29737, DOI 10.1074/jbc.M202369200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kudo M, 2006, AM J HUM GENET, V78, P451, DOI 10.1086/500849; Kudo M, 2005, J BIOL CHEM, V280, P36141, DOI 10.1074/jbc.m509008200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Paik KH, 2005, HUM MUTAT, V26, P308, DOI 10.1002/humu.20205; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Tiede S, 2005, NAT MED, V11, P1109, DOI 10.1038/nm1305; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1980, J BIOL CHEM, V255, P847; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717	24	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11761	11768		10.1074/jbc.M513717200	http://dx.doi.org/10.1074/jbc.M513717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507578	hybrid			2022-12-25	WOS:000236988100041
J	Kumari, K; Baggenstoss, BA; Parker, AL; Weigel, PH				Kumari, K; Baggenstoss, BA; Parker, AL; Weigel, PH			Mutation of two intramembrane polar residues conserved within the hyaluronan synthase family alters hyaluronan product size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; MOLECULAR-CLONING; EXPRESSION; GENE; BIOSYNTHESIS; PROTEINS; IDENTIFICATION; ISOFORMS; CELLS; LOOP	We identified two conserved polar amino acids within different membrane domains (MD) of Streptococcus equisimilis hyaluronan synthase (seHAS), Lys(48) in MD2 and Glu(327) in MD4. In eukaryotic HASs, the position of the Glu is very similar and the Lys is replaced by a conserved polar Gln. To assess whether Lys(48) and Glu(327) interact or influence seHAS activity, we investigated the effects of changing Lys(48) to Arg or Glu and Glu(327) to Lys, Asp, or Gln. Mutants, including a double switch variant with Lys(48) and Glu(327) exchanged, were expressed and assayed in Escherichia coli membranes. SeHAS(E327Q) and seHAS(E327K) were expressed at low levels, whereas seHAS(E327D) and the Lys(48) mutants were expressed well. The specific enzyme activities ( relative to wild type) were 17 and 7% for the K48R and K48E mutants and 26 and 38% for the E327Q and E327D mutants, respectively. In contrast, seHAS( E327K) showed only 0.16% of wild-type activity but was rescued over 46-fold by changing Lys(48) to Glu. Expression of the seHAS( E327K, K48E) protein was also rescued to near wild-type levels. Based on size exclusion chromatography coupled to multiangle laser light scattering analysis, all the variants synthesized hyaluronan ( HA) of smaller weight-average molar mass than wild-type enzyme (3.6 MDa); the smallest HA ( similar to 0.6 MDa) was made by seHAS( E327K, K48E) and seHAS( K48E). The results indicate that Glu(327) within MD4 is a critical residue for the stability of seHAS, that it may interact with Lys(48) within MD2, and that these residues are involved in the ability of HAS to synthesize very large HA.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	paul-weigel@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Abramson J, 2004, MOL MEMBR BIOL, V21, P227, DOI 10.1080/09687680410001716862; BAGGENSTOSS BA, 2006, IN PRESS ANAL BIOCH; Bodevin-Authelet S, 2005, J BIOL CHEM, V280, P8813, DOI 10.1074/jbc.M412803200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Heldermon C, 2000, INT CONGR SER, V1196, P41; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; Kumari K, 2005, GLYCOBIOLOGY, V15, P529, DOI 10.1093/glycob/cwi030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Meyer K, 1934, J BIOL CHEM, V107, P629; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Nardini M, 2004, GENE EXPR PATTERNS, V4, P303, DOI 10.1016/j.modgep.2003.10.006; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Tien JYL, 2005, DEV DYNAM, V233, P130, DOI 10.1002/dvdy.20328; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005	44	25	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11755	11760		10.1074/jbc.M600727200	http://dx.doi.org/10.1074/jbc.M600727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505475	hybrid			2022-12-25	WOS:000236988100040
J	Caruso, JA; Mathieu, PA; Joiakim, A; Zhang, H; Reiners, JJ				Caruso, JA; Mathieu, PA; Joiakim, A; Zhang, H; Reiners, JJ			Aryl hydrocarbon receptor modulation of tumor necrosis factor-alpha-induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM STRESS; INDUCED CELL-DEATH; CATHEPSIN-D; TNF-ALPHA; OXIDATIVE STRESS; PHOTOSENSITIZER NPE6; MEDIATED APOPTOSIS; OLIGOMERIZES BAK; LIPID RAFTS	Recent studies suggest that the aryl hydrocarbon receptor (AhR) modulates susceptibilities to some pro-apoptotic agents. AhR-containing murine hepatoma 1c1c7 cultures underwent apoptosis following exposure to tumor necrosis factor-alpha (TNF alpha) + cycloheximide (CHX). In contrast, Tao cells, an AhR-deficient variant of the 1c1c7 line, were refractory to this treatment. AhR sense/antisense transfection studies demonstrated that AhR contents influenced susceptibility to the pro-apoptotic effects of TNF alpha + CHX. 1c1c7 cells and all variants expressed comparable amounts of TNF receptor-1 and TRADD. However, no cell line expressed FADD, and consequently pro-caspase-8 was not activated. AhR content did not influence JNK and NF-kappa B activation. However, Bid and procaspase-9, -3, and -12 processing occurred only in AhR-containing cells. Analyses of cathepsin B and D activities in digitonin-permeabilized cultures and the monitoring of cathepsin B/D co-localization with Lamp-1 indicated that TNF alpha + CHX disrupted late endosomes/lysosomes in only AhR-containing cells. Stabilization of acidic organelles with 3-O-methylsphingomyelin inhibited TNF alpha + CHX-induced apoptosis. The cathepsin D inhibitor pepstatin A suppressed in vitro cleavage of Bid by 1c1c7 lysosomal extracts. It also delayed the induction of apoptosis and partially prevented Bid cleavage and the activation of pro-caspases-3/7 in cultures treated with TNF alpha + CHX. Similar suppressive effects occurred in cultures transfected with murine Bid antisense oligonucleotides. These studies showed that in cells where pro-caspase-8 is not activated, TNF alpha + CHX can initiate apoptosis through lysosomal disruption. Released proteases such as cathepsin D trigger the apoptotic program by activating Bid. Furthermore, in the absence of exogenous ligand, the AhR modulates lysosomal disruption/permeability.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; ISIS Pharmaceut, Gene Trove Div, Carlsbad, CA 92008 USA	Wayne State University; Isis Pharmaceuticals Inc	Reiners, JJ (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave, Detroit, MI 48201 USA.	john.reiners.jr@wayne.edu	Caruso, Joseph A./U-8429-2019	Caruso, Joseph A./0000-0003-2900-3996	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009392, P30ES006639] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES009392, P30 ES06639] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Becattini B, 2004, CHEM BIOL, V11, P1107, DOI 10.1016/j.chembiol.2004.05.022; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boverhof DR, 2005, TOXICOL SCI, V85, P1048, DOI 10.1093/toxsci/kfi162; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Caruso JA, 2005, BIOCHEM J, V392, P325, DOI 10.1042/BJ20050313; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Colell A, 2002, FEBS LETT, V526, P135, DOI 10.1016/S0014-5793(02)03140-X; Dare E, 2001, FREE RADICAL BIO MED, V30, P1347, DOI 10.1016/S0891-5849(01)00526-3; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Harzer K, 2003, FEBS LETT, V537, P177, DOI 10.1016/S0014-5793(03)00100-5; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Ishisaka R, 1998, FEBS LETT, V435, P233, DOI 10.1016/S0014-5793(98)01080-1; ISHISAKA R, 2001, J BIOCHEM-TOKYO, V129, P34; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Joiakim A, 2004, MOL PHARMACOL, V66, P936, DOI 10.1124/mol.66.4.936; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LISTER MD, 1995, BBA-LIPID LIPID MET, V1256, P25, DOI 10.1016/0005-2760(94)00249-X; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Neuzil J, 2002, BIOCHEM J, V362, P709, DOI 10.1042/0264-6021:3620709; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; Park KT, 2005, MOL PHARMACOL, V67, P612, DOI 10.1124/mol.104.005223; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sun YV, 2004, NUCLEIC ACIDS RES, V32, P4512, DOI 10.1093/nar/gkh782; Tardy C, 2004, J BIOL CHEM, V279, P52914, DOI 10.1074/jbc.M408261200; Terman A, 2002, EXP CELL RES, V274, P9, DOI 10.1006/excr.2001.5441; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wei MC, 2000, GENE DEV, V14, P2060; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	70	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10954	10967		10.1074/jbc.M508383200	http://dx.doi.org/10.1074/jbc.M508383200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446372	hybrid			2022-12-25	WOS:000236822200036
J	Ostareck-Lederer, A; Ostareck, DH; Rucknagel, KP; Schierhorn, A; Moritz, B; Huttelmaier, S; Flach, N; Handoko, L; Wahle, E				Ostareck-Lederer, A; Ostareck, DH; Rucknagel, KP; Schierhorn, A; Moritz, B; Huttelmaier, S; Flach, N; Handoko, L; Wahle, E			Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; N-METHYLTRANSFERASE; HNRNP-K; IN-VITRO; ERYTHROID-DIFFERENTIATION; METHYLATION; EXPORT; SUBSTRATE; PRMT1; PHOSPHORYLATION	Arginine methylation is a post-translational modification found in many RNA-binding proteins. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) from HeLa cells was shown, by mass spectrometry and Edman degradation, to contain asymmetric N-G,N-G-dimethylarginine at five positions in its amino acid sequence (Arg(256), Arg(258), Arg(268), Arg(296), and Arg(299)). Whereas these five residues were quantitatively modified, Arg(303) was asymmetrically dimethylated in <33% of hnRNP K and Arg(287) was monomethylated in <10% of the protein. All other arginine residues were unmethylated. Protein-arginine methyltransferase 1 was identified as the only enzyme methylating hnRNP K in vitro and in vivo. An hnRNP K variant in which the five quantitatively modified arginine residues had been substituted was not methylated. Methylation of arginine residues by protein-arginine methyltransferase 1 did not influence the RNA-binding activity, the translation inhibitory function, or the cellular localization of hnRNP K but reduced the interaction of hnRNP K with the tyrosine kinase c-Src. This led to an inhibition of c-Src activation and hnRNP K phosphorylation. These findings support the role of arginine methylation in the regulation of protein-protein interactions.	Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Saale, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Saale, Germany; Univ Halle Wittenberg, ZAMED, D-06120 Halle, Saale, Germany; Univ Wurzburg, Bioctr, Inst Biochem, D-97074 Wurzburg, Germany	Martin Luther University Halle Wittenberg; Max Planck Society; Martin Luther University Halle Wittenberg; University of Wurzburg	Ostareck-Lederer, A (corresponding author), Univ Halle Wittenberg, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.	aostareck@biochemtech.uni-halle.de	Handoko, Lusy/C-3645-2017; Hüttelmaier, Stefan/AAQ-1203-2021	Handoko, Lusy/0000-0001-7989-4243; Ostareck-Lederer, Antje/0000-0003-0733-7071; Ostareck, Dirk/0000-0001-9406-7190; Wahle, Elmar/0000-0003-2504-0677				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen WG, 2004, J IMMUNOL, V172, P6744, DOI 10.4049/jimmunol.172.11.6744; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Hsu IW, 2005, J BIOL CHEM, V280, P34507, DOI 10.1074/jbc.M507658200; Huang HM, 2002, J BIOCHEM, V132, P813, DOI 10.1093/oxfordjournals.jbchem.a003291; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Huttelmaier S, 2001, J CELL BIOL, V155, P775, DOI 10.1083/jcb.200105044; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kuhn U, 2003, J BIOL CHEM, V278, P16916, DOI 10.1074/jbc.M209886200; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; LEE TD, 1990, METHOD ENZYMOL, V193, P361, DOI 10.1016/0076-6879(90)93427-M; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McBride AE, 2005, J BIOL CHEM, V280, P30888, DOI 10.1074/jbc.M505831200; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu C, 2004, MOL CELL BIOL, V24, P10742, DOI 10.1128/MCB.24.24.10742-10756.2004; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6	73	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11115	11125		10.1074/jbc.M513053200	http://dx.doi.org/10.1074/jbc.M513053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492668	hybrid			2022-12-25	WOS:000236822200054
J	Prechtel, AT; Chemnitz, J; Schirmer, S; Ehlers, C; Langbein-Detsch, I; Stulke, J; Dabauvalle, MC; Kehlenbach, RH; Hauber, J				Prechtel, AT; Chemnitz, J; Schirmer, S; Ehlers, C; Langbein-Detsch, I; Stulke, J; Dabauvalle, MC; Kehlenbach, RH; Hauber, J			Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BINDING PROTEIN HUR; IMMUNODEFICIENCY-VIRUS REV; DEPENDENT MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; EXPORT RECEPTOR CRM1; NUCLEAR-PORE COMPLEX; DENDRITIC CELLS; GENE-EXPRESSION; NUCLEOCYTOPLASMIC TRANSPORT	Dendritic cells are the most potent of the antigen-presenting cells and are characterized by surface expression of CD83. Here, we show that the coding region of CD83 mRNA contains a novel cis-acting structured RNA element that binds to HuR, a member of the ELAV family of AU-rich element RNA-binding proteins. Transient transfection of mammalian cells demonstrated that this CD83 mRNA-derived element acts as a post-transcriptional regulatory element in cells over-expressing HuR. Notably, binding of HuR to the CD83 post-transcriptional regulatory element did not affect mRNA stability. Using RNA interference, we show that HuR mediated efficient expression of CD83. In particular, HuR was required for cytoplasmic accumulation of CD83 transcripts. Likewise, inhibition of the CRM1 nuclear export pathway by leptomycin B or overexpression of a defective form of the nucleoporin Nup214/CAN diminished cytoplasmic CD83 mRNA levels. In summary, the data presented demonstrate that the HuR-CRM1 axis affects the nucleocytoplasmic translocation of CD83 mRNA under regular physiological conditions.	Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Erlangen Nurnberg, Inst Microbiol Biochem & Genet, D-91054 Erlangen, Germany; Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Univ Wurzburg, Bioctr, Dept Cell & Dev Biol, D-97074 Wurzburg, Germany; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37073 Gottingen, Germany	Heinrich Pette Institute; University of Erlangen Nuremberg; University of Gottingen; University of Wurzburg; University of Gottingen	Hauber, J (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	joachim.hauber@hpi.uni-hamburg.de	Stülke, Jörg/AAD-1600-2021	Stulke, Jorg/0000-0001-5881-5390; Kehlenbach, Ralph/0000-0003-4920-9916				Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Berchtold S, 2002, IMMUNOBIOLOGY, V205, P231, DOI 10.1078/0171-2985-00128; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fan XHC, 1997, GENE DEV, V11, P2557, DOI 10.1101/gad.11.19.2557; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Hieronymus H, 2004, GENE DEV, V18, P2845, DOI 10.1101/gad.1256904; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kimura T, 2004, J CELL SCI, V117, P2259, DOI 10.1242/jcs.01076; KING PH, 1994, J NEUROSCI, V14, P1943; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZLOW EJ, 1993, BLOOD, V81, P454, DOI 10.1182/blood.V81.2.454.454; Kruse M, 2000, J VIROL, V74, P7127, DOI 10.1128/JVI.74.15.7127-7136.2000; Kruse M, 2000, J EXP MED, V191, P1581, DOI 10.1084/jem.191.9.1581; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Lechmann M, 2002, INT ARCH ALLERGY IMM, V129, P113, DOI 10.1159/000065883; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lewis T, 1998, J BIOL CHEM, V273, P13781, DOI 10.1074/jbc.273.22.13781; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; Quinn JG, 2001, ANAL BIOCHEM, V290, P36, DOI 10.1006/abio.2000.4919; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rosorius O, 1999, J CELL SCI, V112, P2369; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Sarkar B, 2003, J BIOL CHEM, V278, P20700, DOI 10.1074/jbc.M301176200; Scholler N, 2002, J IMMUNOL, V168, P2599, DOI 10.4049/jimmunol.168.6.2599; SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; ZHOU LJ, 1992, J IMMUNOL, V149, P735; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	96	63	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10912	10925		10.1074/jbc.M510306200	http://dx.doi.org/10.1074/jbc.M510306200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484227	hybrid			2022-12-25	WOS:000236822200032
J	Song, F; Zhuang, ZH; Finci, L; Dunaway-Mariano, D; Kniewel, R; Buglino, JA; Solorzano, V; Wu, J; Lima, CD				Song, F; Zhuang, ZH; Finci, L; Dunaway-Mariano, D; Kniewel, R; Buglino, JA; Solorzano, V; Wu, J; Lima, CD			Structure, function, and mechanism of the phenylacetate pathway hot dog-fold thioesterase PaaI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC BENZOATE METABOLISM; PSEUDOMONAS-PUTIDA U; CATABOLIC PATHWAY; 4-HYDROXYBENZOYL-COA THIOESTERASE; MOLECULAR CHARACTERIZATION; AROMATIC-HYDROCARBONS; ESCHERICHIA-COLI; AZOARCUS-EVANSII; BETA-OXIDATION; ACID	The structure and biochemical function of the hot dog-fold thioesterase PaaI operative in the aerobic phenylacetate degradation pathway are examined. PaaI showed modest activity with phenylacetyl-coenzyme A, suggestive of a role in coenzyme A release from this pathway intermediate in the event of limiting downstream pathway enzymes. Minimal activity was observed with aliphatic acyl-coenzyme A thioesters, which ruled out PaaI function in the lower phenylacetate pathway. PaaI was most active with ring-hydroxylated phenylacetyl-coenzyme A thioesters. The x-ray crystal structure of the Escherichia coli thioesterase is reported and analyzed to define the structural basis of substrate recognition and catalysis. The contributions of catalytic and substrate binding residues, thus, identified were examined through steady-state kinetic analysis of site-directed mutant proteins.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	University of New Mexico; Memorial Sloan Kettering Cancer Center; Cornell University	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu		Kniewel, Ryan/0000-0003-3462-6450; Lima, Christopher/0000-0002-9163-6092	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, P50GM062529] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28688, 1P50GM62529] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MJ, 1988, J ANTIBIOT, V41, P1074, DOI 10.7164/antibiotics.41.1074; Alonso S, 2003, GENE, V319, P71, DOI 10.1016/S0378-1119(03)00794-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartolome-Martin D, 2004, GENE, V341, P167, DOI 10.1016/j.gene.2004.06.042; Boyd DR, 2005, CHEM COMMUN, P3989, DOI 10.1039/b506944k; Boyd DR, 2005, ORG BIOMOL CHEM, V3, P1953, DOI 10.1039/b502009c; Boyd DR, 2004, ORG BIOMOL CHEM, V2, P2530, DOI 10.1039/b409149c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAUDHRY GR, 1991, MICROBIOL REV, V55, P59, DOI 10.1128/MMBR.55.1.59-79.1991; D'Annibale A, 2005, BIOTECHNOL BIOENG, V90, P723, DOI 10.1002/bit.20461; DeLano WL, 2002, PYMOL USERS MANUAL; Diaz E, 2004, INT MICROBIOL, V7, P173; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; Dillon SC, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-109; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; ERLICH HA, 1991, PCR TECHNOLOGY PRINC; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; FERSHT A, 1990, STRUCTURE MECH PROTE, P164; Garcia B, 2000, APPL ENVIRON MICROB, V66, P4575, DOI 10.1128/AEM.66.10.4575-4578.2000; Gescher J, 2005, MOL MICROBIOL, V56, P1586, DOI 10.1111/j.1365-2958.2005.04637.x; Gescher J, 2002, J BACTERIOL, V184, P6301, DOI 10.1128/JB.184.22.6301-6315.2002; Gibson J, 2002, ANNU REV MICROBIOL, V56, P345, DOI 10.1146/annurev.micro.56.012302.160749; HAGGBLOM MM, 1992, FEMS MICROBIOL LETT, V103, P29; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Ismail W, 2003, EUR J BIOCHEM, V270, P3047, DOI 10.1046/j.1432-1033.2003.03683.x; Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x; Johnson GR, 2003, APPL MICROBIOL BIOT, V62, P110, DOI 10.1007/s00253-003-1341-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komives T, 2005, Z NATURFORSCH C, V60, P179; Kunishima N, 2005, J MOL BIOL, V352, P212, DOI 10.1016/j.jmb.2005.07.008; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MERKEL SM, 1989, J BACTERIOL, V171, P1; Mohamed ME, 2000, J BACTERIOL, V182, P286, DOI 10.1128/JB.182.2.286-294.2000; Mohamed MES, 2002, ARCH MICROBIOL, V178, P180, DOI 10.1007/s00203-002-0438-y; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parales RE, 2004, CURR OPIN BIOTECH, V15, P374, DOI 10.1016/j.copbio.2004.06.003; Peres C M, 2000, Biotechnol Annu Rev, V6, P197, DOI 10.1016/S1387-2656(00)06023-3; Poppe L, 2005, ANGEW CHEM INT EDIT, V44, P3668, DOI 10.1002/anie.200461377; Ramos JL, 2005, CURR OPIN BIOTECH, V16, P275, DOI 10.1016/j.copbio.2005.03.010; Ren Y, 2004, J BIOL CHEM, V279, P11042, DOI 10.1074/jbc.M310032200; Rost R, 2002, MOL GENET GENOMICS, V267, P656, DOI 10.1007/s00438-002-0699-9; Samanta SK, 2002, TRENDS BIOTECHNOL, V20, P243, DOI 10.1016/S0167-7799(02)01943-1; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THEILACKER W, 1950, LIEBIGS ANN CHEM, V570, P15; Thoden JB, 2003, J BIOL CHEM, V278, P43709, DOI 10.1074/jbc.M308198200; Thoden JB, 2002, J BIOL CHEM, V277, P27468, DOI 10.1074/jbc.M203904200; Yu WF, 2004, J BIOL CHEM, V279, P52160, DOI 10.1074/jbc.M409640200; Zaar A, 2004, MOL MICROBIOL, V54, P223, DOI 10.1111/j.1365-2958.2004.04263.x; Zaar A, 2001, J BIOL CHEM, V276, P24997, DOI 10.1074/jbc.M100291200; Zhang CL, 2005, APPL MICROBIOL BIOT, V67, P600, DOI 10.1007/s00253-004-1864-3; ZHUANG Z, 2003, THESIS U NEW MEXICO; Zhuang ZH, 2004, J BACTERIOL, V186, P393, DOI 10.1128/JB.186.2.393-399.2004; Zhuang ZH, 2003, APPL ENVIRON MICROB, V69, P2707, DOI 10.1128/AEM.69.5.2707-2711.2003; Zhuang ZH, 2002, BIOCHEMISTRY-US, V41, P11152, DOI 10.1021/bi0262303	69	54	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11028	11038		10.1074/jbc.M513896200	http://dx.doi.org/10.1074/jbc.M513896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464851	hybrid			2022-12-25	WOS:000236822200044
J	Wijewickrama, GT; Kim, JH; Kim, YJ; Abraham, A; Oh, YS; Ananthanarayanan, B; Kwatia, M; Ackerman, SJ; Cho, W				Wijewickrama, GT; Kim, JH; Kim, YJ; Abraham, A; Oh, YS; Ananthanarayanan, B; Kwatia, M; Ackerman, SJ; Cho, W			Systematic evaluation of transcellular activities of secretory phospholipases A(2) - High activity of group V phospholipases A(2) to induce eicosanoid biosynthesis in neighboring inflammatory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN GROUP-IIA; HUMAN NEUTROPHILS; LEUKOTRIENE BIOSYNTHESIS; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; GROUP-IV; BINDING; EOSINOPHIL; GENERATION	The mechanisms by which secretory phospholipase A(2) (PLA(2)) exerts cellular effects are not fully understood. To elucidate these mechanisms, we systematically and quantitatively assessed the activities of human group IIA, V, and X PLA(2)s on originating and neighboring cells using orthogonal fluorogenic substrates in various mixed cell systems. When HEK293 cells stably expressing each of these PLA(2)s were mixed with non-transfected HEK293 cells, group V and X PLA(2)s showed strong transcellular lipolytic activity, whereas group IIA PLA(2) exhibited much lower transcellular activity. The transcellular activity of group V PLA(2) was highly dependent on the presence of cell surface heparan sulfate proteoglycans of acceptor cells. Activation of RBL-2H3 and DLD-1 cells that express endogenous group V PLA(2) led to the secretion of group V PLA(2) and its transcellular action on neighboring human neutrophils and eosinophils, respectively. Similarly, activation of human bronchial epithelial cells, BEAS-2B, caused large increases in arachidonic acid and leukotriene C-4 release from neighboring human eosinophils. Collectively, these studies show that group V and X PLA(2)s can act transcellularly on mammalian cells and suggest that group V PLA(2) released from neighboring cells may function in triggering the activation of inflammatory cells under physiological conditions.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NCRR NIH HHS [M01-RR-13987] Funding Source: Medline; NIAID NIH HHS [AI25230] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Jawien J, 2002, J PHYSIOL PHARMACOL, V53, P127; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2000, HYBRIDOMA, V19, P171, DOI 10.1089/02724570050031220; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Munoz NM, 2002, J IMMUNOL METHODS, V262, P41, DOI 10.1016/S0022-1759(01)00573-7; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Murakami M, 1997, FEBS LETT, V413, P249, DOI 10.1016/S0014-5793(97)00916-2; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Sato M, 1997, INT ARCH ALLERGY IMM, V113, P203, DOI 10.1159/000237547; Sexton DW, 2002, CLIN EXP ALLERGY, V32, P811, DOI 10.1046/j.1365-2745.2002.01428.x; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1986, LAB INVEST, V55, P391; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	47	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10935	10944		10.1074/jbc.M512657200	http://dx.doi.org/10.1074/jbc.M512657200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476735	hybrid			2022-12-25	WOS:000236822200034
J	Aglipay, JA; Martin, SA; Tawara, H; Lee, SW; Ouchi, T				Aglipay, JA; Martin, SA; Tawara, H; Lee, SW; Ouchi, T			ATM activation by ionizing radiation requires BRCA1-associated BAAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TELANGIECTASIA MUTATED ATM; DNA-DAMAGE RESPONSE; BRCA1 PHOSPHORYLATION; OVARIAN-CANCER; DEPENDENT PHOSPHORYLATION; GENE BRCA1; PROTEIN; COMPLEX; KINASE	ATM ( ataxia telangiectasia mutated) is required for the early response to DNA-damaging agents such as ionizing radiation (IR) that induce DNA double-strand breaks. Cells deficient in ATM are extremely sensitive to IR. It has been shown that IR induces immediate phosphorylation of ATM at Ser(1981), leading to catalytic activation of the protein. We recently isolated a novel BRCA1-associated protein, BAAT1 (BRCA1-associated protein required for ATM activation-1), by yeast two-hybrid screening and found that BAAT1 also binds to ATM, localizes to double-strand breaks, and is required for Ser(1981) phosphorylation of ATM. Small interfering RNA-mediated stable or transient reduction of BAAT1 resulted in decreased phosphorylation of both ATM at Ser(1981) and CHK2 at Thr(68). Treatment of BAAT1-depleted cells with okadaic acid greatly restored phosphorylation of ATM at Ser(1981), suggesting that BAAT1 is involved in the regulation of ATM phosphatase. Protein phosphatase 2A-mediated dephosphorylation of ATM was partially blocked by purified BAAT1 in vitro. Significantly, acute loss of BAAT1 resulted in increased p53, leading to apoptosis. These results demonstrate that DNA damage-induced ATM activation requires a coordinated assembly of BRCA1, BAAT1, and ATM.	NYU, Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Massachusetts General Hospital	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,POB 1130, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu		Martin, Sarah/0000-0003-3321-6601	NATIONAL CANCER INSTITUTE [R01CA090631, R01CA079892, P01CA080058, R01CA078356, R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM064148] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79892, R01 CA08568, R01 CA078356, R01CA90631, P01 CA80058, R24CA095823] Funding Source: Medline; NIGMS NIH HHS [F31 GM64148-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CHAMBERLAIN JS, 1993, AM J HUM GENET, V52, P792; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Chun HH, 2004, BIOCHEM BIOPH RES CO, V322, P74, DOI 10.1016/j.bbrc.2004.07.085; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mochan TA, 2003, CANCER RES, V63, P8586; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Venkitaraman AR, 2004, NAT REV CANCER, V4, P266, DOI 10.1038/nrc1321; WU X, 1999, NAT GENET, V22, P37; Xu B, 2002, CANCER RES, V62, P4588	41	34	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9710	9718		10.1074/jbc.M510332200	http://dx.doi.org/10.1074/jbc.M510332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452482	hybrid			2022-12-25	WOS:000236404700083
J	da Costa, CA; Dunys, J; Brau, F; Wilk, S; Cappai, R; Checler, F				da Costa, CA; Dunys, J; Brau, F; Wilk, S; Cappai, R; Checler, F			6-hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; DOPAMINERGIC NEURONAL DEATH; INCLUSION-BODY FORMATION; PARKINSONS-DISEASE; CELL-DEATH; WILD-TYPE; MOLECULAR PATHWAYS; PROTECTS; MUTATION; MICE	We established previously that alpha-synuclein displayed a protective anti-apoptotic phenotype in neurons, mainly by down-regulating p53-dependent caspase-3 activation (Alves da Costa, C., Ancolio, K., and Checler, F. ( 2000) J. Biol. Chem. 275, 24065 - 24069; Alves da Costa, C., Paitel, E., Vincent, B., and Checler, F. ( 2002) J. Biol. Chem. 277, 50980 50984). This function was abolished by Parkinson disease-linked pathogenic mutations and by the dopaminergic toxin, 6-hydroxydopamine (6OH-DOPA)( Alves da Costa, C., Paitel, E., Vincent, B., and Checler, F. ( 2002) J. Biol. Chem. 277, 50980 - 50984). However, the mechanisms by which 6OH-DOPA interfered with alpha-synuclein function remained unclear. Here we showed that 6OH-DOPA prevents alpha-synuclein-mediated anti-apoptotic function by altering its degradation. Thus, 6OH-DOPA-treatment of TSM1 neurons and SH-SY5Y neuroblastoma cells enhances endogenous alpha-synuclein-like immunoreactivity and inhibits the catabolism of endogenous and recombinant alpha-synucleins by purified 20 S proteasome. Furthermore, we demonstrated that 6OH-DOPA directly inhibits endogenous proteasomal activity in TSM1 and SH-SY5Y cells and also blocks purified proteasome activity in vitro. This inhibitory effect can be prevented by the anti-oxidant phenyl-N-butylnitrone. We also established that 6OH-DOPA triggers the aggregation of recombinant alpha-synuclein in vitro. Therefore, we conclude that 6OH-DOPA abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation, thereby increasing its intracellular concentration and potential propensity to aggregation, the latter phenomenon being directly exacerbated by 6OH-DOPA itself. Interestingly, 1-methyl-4-phenylpyridinium (MPP+), another toxin inducer of Parkinson disease-like pathology, does not affect alpha-synuclein protective function and fails to trigger aggregation of recombinant alpha-synuclein. Furthermore, MPP+ does not alter cellular proteasomal activity, and only high concentrations of the toxin affect purified 20 S proteasome by a mechanism that remains insensitive to phenyl-N-butylnitrone. The drastically distinct effects of 6OH-DOPA and MPP+ on alpha-synuclein function are discussed with respect to Parkinson disease pathology and animal models mimicking this pathology.	CNRS, IPMC, UMR6097, Equipe Labellisee FRM, F-06560 Valbonne, France; CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Univ Melbourne, Ctr Neurosci, Dept Pathol, Parkville, Vic 3010, Australia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Melbourne	da Costa, CA (corresponding author), CNRS, IPMC, UMR6097, Equipe Labellisee FRM, 660 Route Lucioles, F-06560 Valbonne, France.	acosta@ipmc.cnrs.fr; checler@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011; Cappai, Roberto/B-3347-2010	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X; Cappai, Roberto/0000-0002-9505-8496				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Biasini E, 2004, J NEUROCHEM, V88, P545, DOI 10.1046/j.1471-4159.2003.02152.x; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; Bradbury J, 2003, LANCET NEUROL, V2, P715, DOI 10.1016/S1474-4422(03)00601-X; Cappai R, 2005, FASEB J, V19, P1377, DOI 10.1096/fj.04-3437fje; Carr J, 2003, PARKINSONISM RELAT D, V9, P201, DOI 10.1016/S1353-8020(02)00048-2; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Checler F., 1993, TEC BEHAV N 2, P375; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirata H, 1997, J NEUROCHEM, V69, P780; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x; Kaul S, 2005, MOL BRAIN RES, V139, P137, DOI 10.1016/j.molbrainres.2005.05.022; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li WX, 2005, J NEUROCHEM, V93, P1542, DOI 10.1111/j.1471-4159.2005.03146.x; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 1999, J NEUROSCI, V19, P1284; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nicotra A, 2000, TOXICOLOGY, V153, P157, DOI 10.1016/S0300-483X(00)00311-5; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Serra PA, 2002, J BIOL CHEM, V277, P34451, DOI 10.1074/jbc.M202099200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; WILK S, 2001, CURRENT PROTOCOLS PR; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	67	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9824	9831		10.1074/jbc.M513903200	http://dx.doi.org/10.1074/jbc.M513903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464850	hybrid			2022-12-25	WOS:000236404700095
J	Lee, I; Hong, WJ				Lee, Ian; Hong, Wanjin			Diverse membrane-associated proteins contain a novel SMP domain	FASEB JOURNAL			English	Article						PROBE; chaperones; signaling; eukaryotic; complexes	MITOCHONDRIAL-MEMBRANES; HOMOLOGY DOMAINS; COMPLEXES; DATABASE; FOLD	We have analyzed the sequence of a mitochondrial integral membrane protein, Mdm12, and found that it forms the prototype for a novel domain, designated the SMP domain, that is common to an extended family of membrane-associated proteins. Comprehensive sequence searches using protein alignment models of SMP proteins were cross-validated by statistical resampling; providing strong support for these relationships. No consensus of 3-dimensional structure was reached upon threading sequences through known folds. SMP proteins are widespread amongst eukaryotic species with a particular enrichment in plants and features suggestive of species-specific functional variations. Members of 2 SMP families, the mitochore and tricalbin proteins, are essential components of protein complexes involved in mitochondrial inheritance and receptor endocytosis while a third SMP protein family, HT008, is associated with the Rvs161-Rvs167 complex, a known regulator of sphingolipid metabolism. In addition, HT008 and PDZK8 SMP proteins possess additional protein-protein interaction domains in domain architectures that are typical of protein scaffolds and adaptors. We therefore predict that the SMP domain is an important link between these distinct membrane-associated proteins and a key regulatory hub for unidentified global regulators.	Inst Mol & Cell Biol, Computat Mol Biol Programme, Singapore 138673, Singapore; Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lee, I (corresponding author), Inst Mol & Cell Biol, Computat Mol Biol Programme, 61 Biopolis Dr, Singapore 138673, Singapore.	leehh@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Creutz CE, 2004, CELL MOL LIFE SCI, V61, P1208, DOI 10.1007/s00018-004-4029-8; Germann M, 2005, J BIOL CHEM, V280, P4270, DOI 10.1074/jbc.M412454200; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Hurley JH, 1997, PROTEIN SCI, V6, P477; JONES DT, 1995, PROTEINS, V23, P387, DOI 10.1002/prot.340230312; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; Lee SY, 2003, P NATL ACAD SCI USA, V100, P2651, DOI 10.1073/pnas.0437972100; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Neuwald AF, 1999, GENOME RES, V9, P27; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; RANGANATHAN R, 1997, CURR BIOL, V7, P770; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schulz TA, 2004, BIOCHEMISTRY-US, V43, P3987, DOI 10.1021/bi036082w; Soti C, 2005, CURR OPIN CELL BIOL, V17, P210, DOI 10.1016/j.ceb.2005.02.012	20	66	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					202	206		10.1096/fj.05-4581hyp	http://dx.doi.org/10.1096/fj.05-4581hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449791				2022-12-25	WOS:000237698700004
J	Petrosillo, G; Di Venosa, N; Pistolese, M; Casanova, G; Tiravanti, E; Colantuono, G; Federici, A; Paradies, G; Ruggiero, FM				Petrosillo, G.; Di Venosa, N.; Pistolese, M.; Casanova, G.; Tiravanti, E.; Colantuono, G.; Federici, A.; Paradies, G.; Ruggiero, F. M.			Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin	FASEB JOURNAL			English	Article						ROS; mitochondria; MPT	CYTOCHROME-C-OXIDASE; OXYGEN RADICAL GENERATION; RAT-HEART MITOCHONDRIA; PERMEABILITY TRANSITION; MYOCARDIAL REPERFUSION; LIVER-MITOCHONDRIA; RESPIRATORY-CHAIN; COMPLEX-I; HYDROGEN-PEROXIDE; OXIDATIVE STRESS	Reactive oxygen species (ROS) are considered an important factor in ischemia/reperfusion injury to cardiac myocytes. Mitochondrial respiration, mainly at the level of complex I and III, is an important source of ROS generation and hence a potential contributor of cardiac reperfusion injury. Appropriate antioxidant strategies could be particularly useful to limit this ROS generation and associated mitochondrial dysfunction. Melatonin has been shown to effectively protect against ischemic-reperfusion myocardial damage. The mechanism by which melatonin exerts this cardioprotective effect is not well established. In the present study we examined the effects of melatonin on various parameters of mitochondrial bioenergetics in a Langerdoff isolated perfused rat heart model. After isolation of mitochondria from control, ischemic-reperfused and melatonin-treated ischemic-reperfused rat heart, various bioenergetic parameters were evaluated such as rates of mitochondrial oxygen consumption, complex I and complex III activity, H2O2 production as well as the degree of lipid peroxidation, cardiolipin content, and cardiolipin oxidation. We found that reperfusion significantly altered all these mitochondrial parameters, while melatonin treatment had strong protective effect attenuating these alterations. This effect appears to be due, at least in part, to the preservation, by ROS attack, of the content and integrity of cardiolipin molecules which play a pivotal role in mitochondrial bioenergetics. Protection of mitochondrial dysfunction was associated with an improvement of post-ischemic hemodynamic function of the heart. Melatonin had also strong protective effect against oxidative alterations to complex I and III as well as to cardiolipin in isolated mitochondria.	Univ Bari, Dept Biochem & Mol Biol, Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, Bari, Italy; Univ Bari, Dept Emergency & Transplantat, Bari, Italy; Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368; federici, antonio/0000-0001-5102-9995				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Buege J A, 1978, Methods Enzymol, V52, P302; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Das DK, 1994, ANN NY ACAD SCI, V723, P116; Dobsak P, 2003, Pathophysiology, V9, P179, DOI 10.1016/S0928-4680(02)00080-9; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; FRY M, 1981, J BIOL CHEM, V256, P1874; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Kaneko S, 2000, LIFE SCI, V67, P101, DOI 10.1016/S0024-3205(00)00607-X; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lagneux C, 2000, LIFE SCI, V66, P503, DOI 10.1016/S0024-3205(99)00620-7; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lesnefsky EJ, 2004, J BIOL CHEM, V279, P47961, DOI 10.1074/jbc.M409720200; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Martin M, 2000, FASEB J, V14, P1677; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; Okatani Y, 2003, EUR J PHARMACOL, V469, P145, DOI 10.1016/S0014-2999(03)01643-1; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; PARINANDI NL, 1988, CHEM PHYS LIPIDS, V49, P215, DOI 10.1016/0009-3084(88)90009-6; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; PETROSILLO G, 2003, FASEB J, V17, P714, DOI DOI 10.1096/fj.02-0729fje; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Salie R, 2001, J MOL CELL CARDIOL, V33, P343, DOI 10.1006/jmcc.2000.1306; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P207, DOI 10.1016/S0005-2760(97)00119-7; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; Tan DX, 1998, J PINEAL RES, V25, P184, DOI 10.1111/j.1600-079X.1998.tb00558.x; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	57	101	122	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					269	276		10.1096/fj.05-4692com	http://dx.doi.org/10.1096/fj.05-4692com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449799				2022-12-25	WOS:000237698700012
J	Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB				Egwuagu, CE; Li, W; Yu, CR; Lin, MCM; Chan, CC; Nakamura, T; Chepelinsky, AB			Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors	ONCOGENE			English	Article						IFN gamma; epithelial cell carcinoma; SV40 T-antigen; IRF-1; ICSBP; apoptosis	SEQUENCE-BINDING-PROTEIN; REGULATORY FACTOR-I; HUMAN-PAPILLOMAVIRUS INFECTION; FAS-MEDIATED APOPTOSIS; LARGE T-ANTIGEN; TRANSGENIC MICE; IFN-GAMMA; MAMMALIAN LENS; RISK FACTOR; EXPRESSION	We have developed an epithelial cell carcinoma model for studying efficacy of IFN gamma gene therapy and have identified components of IFN gamma-signaling pathway responsible for its direct anti-tumor actions. The tumor results from ectopic expression of SV40 Large T-Antigen ( SV40 T-Ag) oncogene in lens of transgenic mouse ( alpha T3) and complete regression of the tumor is induced by targeting expression of IFN gamma into malignant lens cells. In. ammatory cells are absent in lens of aT3 or DT ( co-expressing IFN gamma and SV40-T-Antigen) mice and the transformed lens cells are non-immunogenic, suggesting non- involvement of immunologic cells. We show that IFN gamma has direct growth-inhibitory effects on tumor cells, induces death of tumor cells by apoptosis and that these effects are mediated by two transcription factors, IRF-1 ( interferon-regulatory factor-1) and ICSBP ( interferon-consensus sequence-binding protein) induced by IFN gamma. Furthermore, stable transfection with ICSBP or IRF-1 construct inhibits lens carcinoma cell growth by upregulating Caspase-1, p21(WAF1) and p27 expression. In contrast, tumor progression in aT3 lens correlates with inhibition of IRF-1 and ICSBP expression. Our results suggest that IFN gamma gene therapy maybe effective in malignant diseases for which DNA tumor viruses are etiologic agents and that antitumor actions of IRF-1/ICSBP can be exploited therapeutically to circumvent adverse clinical effects associated with IFN therapy.	NEI, Lab Immunol Mol, Immunol Sect, NIH, Bethesda, MD 20892 USA; Mol & Dev Biol Natl Eye Inst, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, Lab Immunol Mol, Immunol Sect, NIH, Bldg 10,Room 10N116,10 Ctr Dr, Bethesda, MD 20892 USA.	egwuaguc@nei.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000315, Z01EY000253, ZIAEY000315, ZIAEY000222] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Asamoto M, 2001, CANCER RES, V61, P4693; Awasthi N, 2004, INVEST OPHTH VIS SCI, V45, P222, DOI 10.1167/iovs.03-0571; Bjorge T, 2002, BRIT J CANCER, V87, P61, DOI 10.1038/sj.bjc.6600350; BOULTWOOD J, 1993, BLOOD, V82, P2611; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; CHEPELINSKY AB, 1987, ENVIRON HEALTH PERSP, V75, P17, DOI 10.2307/3430571; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Vita VT, 2001, CANC PRINCIPLES PRAC; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Duan WM, 2005, ONCOGENE, V24, P1510, DOI 10.1038/sj.onc.1208229; Ebong S, 2004, MOL VIS, V10, P122; Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03-0311; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Egwuagu CE, 1999, CLIN IMMUNOL, V91, P196, DOI 10.1006/clim.1999.4701; Egwuagu CE, 1999, J IMMUNOL, V162, P510; Gabril MY, 2005, MOL THER, V11, P348, DOI 10.1016/j.ymthe.2004.12.005; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Garson K, 2003, J SOC GYNECOL INVEST, V10, P244, DOI 10.1016/S1071-5576(03)00073-X; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Horiuchi M, 1999, HYPERTENSION, V33, P162, DOI 10.1161/01.HYP.33.1.162; Hughes RS, 2005, AM J MED SCI, V329, P29; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jin M, 2004, J MED VIROL, V74, P668, DOI 10.1002/jmv.20219; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Lai JC, 1998, INVEST OPHTH VIS SCI, V39, P2049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Li WM, 1999, J BIOL CHEM, V274, P9686, DOI 10.1074/jbc.274.14.9686; Li WM, 1999, DEV BIOL, V210, P44, DOI 10.1006/dbio.1999.9267; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Pfeffer LM, 1998, CANCER RES, V58, P2489; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Schaeffer AJ, 2004, CANCER RES, V64, P538, DOI 10.1158/0008-5472.CAN-03-0124; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Sharf R, 1997, J BIOL CHEM, V272, P9785; Tagliaferri P, 2005, CANCER IMMUNOL IMMUN, V54, P1, DOI 10.1007/s00262-004-0549-1; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; YE XH, 1994, P NATL ACAD SCI USA, V91, P3916, DOI 10.1073/pnas.91.9.3916; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu CR, 2003, J BIOL CHEM, V278, P29752, DOI 10.1074/jbc.M300489200	54	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3670	3679		10.1038/sj.onc.1209402	http://dx.doi.org/10.1038/sj.onc.1209402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462767				2022-12-25	WOS:000238448300006
J	Wang, P; Greiner, TC; Lushnikova, T; Eischen, CM				Wang, P.; Greiner, T. C.; Lushnikova, T.; Eischen, C. M.			Decreased Mdm2 expression inhibits tumor development induced by loss of ARF	ONCOGENE			English	Article						Mdm2; ARF; p53; transformation; tumor	MYC-INDUCED LYMPHOMAGENESIS; CELL-CYCLE ARREST; P53-INDEPENDENT FUNCTIONS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SUPPRESSOR PROTEIN; DEFICIENT MICE; DNA-DAMAGE; P53; P19(ARF)	The tumor suppressor p14/p19(ARF) regulates Mdm2, which is known for controlling the p53 tumor suppressor. Here we report that loss of one allele of Mdm2 in cells that lack ARF resulted in a decreased rate of proliferation, fewer chromosomal aberrations, and suppression of Ras-induced transformation. Moreover, a haploinsufficiency of Mdm2 inhibited spontaneous tumor development in ARF-null mice. Remarkably, Mdm2(+/-) ARF(-/-) mice survived an average of 6 months longer than Mdm2(+/-) ARF(-/-) mice. The spectrum of tumors that arose in Mdm2(+/-) ARF(-/-) mice did not significantly differ from those that developed in mice lacking only ARF. However, the extended tumor latency allowed for the emergence of multiple primary tumors in a third of the Mdm2(+/-) ARF(-/-) mice, as compared to the single tumor type that arose in ARF null only mic e. Therefore, a decrease in Mdm2 levels restored regulation of critical cellular processes that are altered during transformation and that occur in the absence of ARF. Our findings also indicate that Mdm2 can function independently from ARF and imply that targeting Mdm2 in tumors that lack ARF expression should be an effective therapeutic approach.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Ctr Med, Dept Pathol & Microbiol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 600 S 42nd St, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2002, CANCER RES, V62, P2184; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Matheu A, 2004, GENE DEV, V18, P2736, DOI 10.1101/gad.310304; MAYR GA, 1995, CANCER RES, V55, P2410; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3708	3718		10.1038/sj.onc.1209411	http://dx.doi.org/10.1038/sj.onc.1209411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491126				2022-12-25	WOS:000238448300010
J	Gu, Y; Siefring, JE; Wang, L; Chae, HD; Bailey, JR; Zheng, Y				Gu, Y.; Siefring, J. E.; Wang, L.; Chae, H-D; Bailey, J. R.; Zheng, Y.			Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation	ONCOGENE			English	Article						Vav1 proto-oncogene; Rac GTPase; hematopoietic progenitor cell; proliferation; apoptosis	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; RHO GTPASE; T-CELLS; ACTIVATION; PROTOONCOGENE; EXPRESSION; SURVIVAL; GENE; MEMBER	Vav1 is an hematopoietic-specific Rho guanine nucleotide exchange factor coupling tyrosine kinase receptors and Rac GTPases, and has been implicated in transformation of fibroblasts and pancreas. To determine the biologic effect and oncogenic potential of Vav1 in hematopoietic lineages, we stably express oncogenic mutant of Vav1 in primary bone marrow cells using retrovirus-mediated gene transfer. Contrary to the growth stimulatory effects observed in. broblasts, oncogenic Vav1 inhibits hematopoietic stem cell/progenitor engraftment in vivo and progenitor cell expansion in vitro via inducing apoptosis. The oncogenic Vav1-induced apoptosis is associated with reduced expression of Bcl-2 and Bcl-xL proteins and effectively suppressed by transgenic overexpression of Bcl-2, suggesting Vav1-mediated signaling via Bcl-2 in apoptosis. Also, oncogenic Vav1 stimulates sustained activation of Rac GTPases and the biologic effects of oncogenic Vav1 are Rac-dependent. Further, when expressed in the p53-deficient cells, which express elevated Bcl-2 and Bcl-xL and are resistant to the apoptosis, oncogenic Vav1 enhances both proliferation and self-renewal of hematopoietic progenitor cells. These results demonstrate clear phenotypic differences between wild-type and p53(-/-) hematopoietic cells expressing oncogenic Vav1, and suggest oncogenic potential of Vav1-mediated pathways in primary hematopoietic cell when they collaborate with additional genetic hits that affect the p53 pathway.	Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Gu, Y (corresponding author), Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, 3333 Burnet Ave,Mail Locat 7013, Cincinnati, OH 45229 USA.	yi.gu@cchmc.org	Chae, Hee-Don/D-2620-2011; Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL CANCER INSTITUTE [K01CA107110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA107110] Funding Source: Medline; NIGMS NIH HHS [R01 GM53943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ALAI M, 1992, J BIOL CHEM, V267, P18021; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betz R, 2003, NEUROSCI LETT, V339, P37, DOI 10.1016/S0304-3940(02)01457-X; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166; Gu Y, 2005, BLOOD, V105, P1467, DOI 10.1182/blood-2004-04-1604; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NAKAHATA T, 1982, J CELL PHYSIOL, V111, P239, DOI 10.1002/jcp.1041110304; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang XW, 1999, ANTICANCER RES, V19, P4759; Williams DA, 2000, BLOOD, V96, P1646; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZMUIDZINAS A, 1995, EMBO J, V14, P1	47	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3963	3972		10.1038/sj.onc.1209427	http://dx.doi.org/10.1038/sj.onc.1209427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474842				2022-12-25	WOS:000238668800010
J	Kanjilal-Kolar, S; Basu, SS; Kanipes, MI; Guan, ZQ; Garrett, TA; Raetz, CRH				Kanjilal-Kolar, S; Basu, SS; Kanipes, MI; Guan, ZQ; Garrett, TA; Raetz, CRH			Expression cloning of three Rhizobium leguminosarum lipopolysaccharide core galacturonosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTURONIC ACID; ESCHERICHIA-COLI; LIPID-A; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; SURFACE POLYSACCHARIDES; SALMONELLA-TYPHIMURIUM; MEMBRANE ENZYME; INNER MEMBRANE; COG DATABASE; GENE	The lipid A and core regions of the lipopolysaccharide in Rhizobium leguminosarum, a nitrogen-fixing plant endosymbiont, are strikingly different from those of Escherichia coli. In R. leguminosarum lipopolysaccharide, the inner core is modified with three galacturonic acid ( GalA) moieties, two on the distal 3-deoxy-D-manno-octulosonic acid (Kdo) unit and one on the mannose residue. Here we describe the expression cloning of three novel GalA transferases from a 22-kb R. leguminosarum genomic DNA insert-containing cosmid (pSGAT). Two of these enzymes modify the substrate, Kdo2-[4'-P-32] lipid IVA and its 1-dephosphorylated derivative on the distal Kdo residue, as indicated by mild acid hydrolysis. The third enzyme modifies the mannose unit of the substrate mannosyl-Kdo(2)-1-dephospho-[4'-P-32] lipid IVA. Sequencing of a 7-kb subclone derived from pSGAT revealed three putative membrane-bound glycosyltransferases, now designated RgtA, RgtB, and RgtC. Transfer by tri-parental mating of these genes into Sinorhizobium meliloti 1021, a strain that lacks these particular GalA residues, results in the heterologous expression of the GalA transferase activities seen in membranes of cells expressing pSGAT. Reconstitution experiments with the individual genes demonstrated that the activity of RgtA precedes and is necessary for the subsequent activity of RgtB, which is followed by the activity of RgtC. Electrospray ionization-tandem mass spectrometry and gas-liquid chromatography of the product generated in vitro by RgtA confirmed the presence of a GalA moiety. No in vitro activity was detected when RgtA was expressed in Escherichia coli unless Rhizobiaceae membranes were also included.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu	Guan, Ziqiang/AAE-5110-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796, R37-GM-51796, U54 GM069338, GM-069338, R37 GM051796-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P927; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; Carlson R. W., 1992, Plant biotechnology and development., P33; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; Choma A, 2004, EUR J BIOCHEM, V271, P1310, DOI 10.1111/j.1432-1033.2004.04038.x; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DJORDJEVIC SP, 1987, J BACTERIOL, V169, P53, DOI 10.1128/jb.169.1.53-60.1987; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; Kanjilal-Kolar S, 2006, J BIOL CHEM, V281, P12879, DOI 10.1074/jbc.M513865200; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; Keating DH, 2002, J BACTERIOL, V184, P6681, DOI 10.1128/JB.184.23.6681-6689.2002; Laus MC, 2004, J BACTERIOL, V186, P6617, DOI 10.1128/JB.186.19.6617-6625.2004; Mohnen D, 1993, Semin Cell Biol, V4, P93, DOI 10.1006/scel.1993.1012; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Niehaus K, 1998, Subcell Biochem, V29, P73; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P498; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; ROANTREE RJ, 1967, ANNU REV MICROBIOL, V21, P443, DOI 10.1146/annurev.mi.21.100167.002303; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; RUSSOMANDO G, 1992, AN ASOC QUIM ARGENT, V80, P175; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	70	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12865	12878		10.1074/jbc.M513864200	http://dx.doi.org/10.1074/jbc.M513864200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497674	Green Accepted, hybrid			2022-12-25	WOS:000237134700082
J	Rava, P; Ojakian, GK; Shelness, GS; Hussain, MM				Rava, P; Ojakian, GK; Shelness, GS; Hussain, MM			Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; CARBOXYL-TERMINAL TRUNCATION; ESTER TRANSFER PROTEIN; DISULFIDE-ISOMERASE; LIVER-MICROSOMES; LIPID TRANSPORT; SREBP PATHWAY; CELL-LINES; ABETALIPOPROTEINEMIA; MICE	Human microsomal triacylglycerol transfer protein (hMTP) is essential for apolipoprotein B (apoB)-lipoprotein assembly and secretion and is known to transfer triacylglycerols, cholesterol esters, and phospholipids. To understand the relative importance of each lipid transfer activity, we compared the ability of hMTP and its Drosophila ortholog (dMTP) to assemble apoB lipoproteins and to transfer various lipids. apoB48 secretion was induced when co-expressed with either hMTP or dMTP in COS cells, and oleic acid supplementation further augmented secretion without altering particle density. C-terminal epitope-tagged dMTP (dMTP-FLAG) facilitated the secretion of apoB polypeptides in the range of apoB48 to apoB72 but was similar to 50% as efficient as hMTP-FLAG. Comparison of lipid transfer activities revealed that although phospholipid transfer was similar in both orthologs, dMTP was unable to transfer neutral lipids. We conclude that the phospholipid transfer activity of MTP is sufficient for the assembly and secretion of primordial apoB lipoproteins and may represent its earliest function evolved for the mobilization of lipid in invertebrates. Identification of MTP inhibitors, which selectively affect transfer of a specific lipid class, may have therapeutic potential.	SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Wake Forest University	Hussain, MM (corresponding author), SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA.	Mahmood.Hussain@downstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64272, HL49373] Funding Source: Medline; NIDDK NIH HHS [DK46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; ATZEL A, 1994, BIOCHEMISTRY-US, V33, P15382, DOI 10.1021/bi00255a019; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chang G, 2002, CURR OPIN DRUG DISC, V5, P562; Crooke RM, 2005, J LIPID RES, V46, P872, DOI 10.1194/jlr.M400492-JLR200; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Lieu HD, 2003, CIRCULATION, V107, P1315, DOI 10.1161/01.CIR.0000054781.50889.0C; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; Ohashi K, 2000, J LIPID RES, V41, P1199; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Sellers JA, 2005, J BIOL CHEM, V280, P13902, DOI 10.1074/jbc.M500769200; Sellers JA, 2003, J BIOL CHEM, V278, P20367, DOI 10.1074/jbc.M300271200; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; Vance JE, 2005, J BIOL CHEM, V280, P10877, DOI 10.1074/jbc.R400038200; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863	50	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11019	11027		10.1074/jbc.M512823200	http://dx.doi.org/10.1074/jbc.M512823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478722	hybrid			2022-12-25	WOS:000236822200043
J	Sazinsky, MH; Mandal, AK; Arguello, JM; Rosenzweig, AC				Sazinsky, MH; Mandal, AK; Arguello, JM; Rosenzweig, AC			Structure of the ATP binding domain from the Archaeoglobus fulgidus Cu+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSONS-DISEASE PROTEIN; P-TYPE ATPASES; HEAVY-METAL TRANSPORT; N-TERMINAL DOMAIN; ESCHERICHIA-COLI; CYTOPLASMIC LOOP; MENKES-DISEASE; CALCIUM-PUMP; COPPER; IDENTIFICATION	The P-type ATPases translocate cations across membranes using the energy provided by ATP hydrolysis. CopA from Archaeoglobus fulgidus is a hyperthermophilic ATPase responsible for the cellular export of Cu+ and is a member of the heavy metal P-1B-type ATPase subfamily, which includes the related Wilson and Menkes diseases proteins. The Cu+-ATPases are distinct from their P-type counterparts in ion binding sequences, membrane topology, and the presence of cytoplasmic metal binding domains, suggesting that they employ alternate forms of regulation and novel mechanisms of ion transport. To gain insight into Cu+-ATPase function, the structure of the CopA ATP binding domain (ATPBD) was determined to 2.3 angstrom resolution. Similar to other P-type ATPases, the ATPBD includes nucleotide binding (N-domain) and phosphorylation ( P-domain) domains. The ATPBD adopts a closed conformation similar to the nucleotide-bound forms of the Ca2+-ATPase. The CopA ATPBD is much smaller and more compact, however, revealing the minimal elements required for ATP binding, hydrolysis, and enzyme phosphorylation. Structural comparisons to the AMP-PMP-bound form of the Escherichia coli K+-transporting Kdp-ATPase and to the Wilson disease protein N-domain indicate that the five conserved N-domain residues found in P-1B-type ATPases, but not in the other families, most likely participate in ATP binding. By contrast, the P-domain includes several residues conserved among all P-type ATPases. Finally, the CopA ATPBD structure provides a basis for understanding the likely structural and functional effects of various mutations that lead to Wilson and Menkes diseases.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA; Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol & Chem, Evanston, IL 60208 USA	Worcester Polytechnic Institute; Northwestern University; Northwestern University; Northwestern University	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA.	arguello@wpi.edu; amyr@northwestern.edu	Johnson, Michael D. L./B-4352-2012; Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NIGMS NIH HHS [GM073457, GM58518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518, F32GM073457] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P12289, DOI 10.1021/bi048727d; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; Haupt M, 2004, J MOL BIOL, V342, P1547, DOI 10.1016/j.jmb.2004.07.060; Kim BE, 2002, J BIOL CHEM, V277, P44079, DOI 10.1074/jbc.M208737200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lutsenko S, 2003, ANN NY ACAD SCI, V986, P204, DOI 10.1111/j.1749-6632.2003.tb07161.x; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; Okkeri J, 2004, BIOCHEM J, V377, P95, DOI 10.1042/BJ20030740; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POST RL, 1972, J BIOL CHEM, V247, P6530; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4	46	77	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11161	11166		10.1074/jbc.M510708200	http://dx.doi.org/10.1074/jbc.M510708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495228	hybrid			2022-12-25	WOS:000236822200059
J	Waga, S; Zembutsu, A				Waga, S; Zembutsu, A			Dynamics of DNA binding of replication initiation proteins during de novo formation of pre-replicative complexes in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; MINICHROMOSOME MAINTENANCE PROTEINS; LICENSING SYSTEM; CHROMOSOMAL DNA; ATP HYDROLYSIS; CELL-CYCLE; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MULTIPROTEIN COMPLEX	We investigated the dynamics of DNA binding of replication initiation proteins during formation of the pre-replicative complex (pre-RC) on plasmids in Xenopus egg extracts. The pre-RC was efficiently formed on plasmids at 23 degrees C, with one or a few origin recognition complex (ORC) molecules and similar to 10-20 mini-chromosome maintenance 2 (MCM2) molecules loaded onto each plasmid. Although geminin inhibited MCM loading, MCM interacted weakly but stoichiometrically with the plasmid in an ORC-dependent manner, even in the presence of geminin (with similar to 10 MCM2 molecules per plasmid). Interestingly, DNA binding of ORC, CDC6, and CDT1 was significantly stabilized in the presence of geminin, under which conditions similar to 10-20 molecules each of ORC and CDC6 were bound. Moreover, a similarly stable ORC-CDC6-CDT1 complex rapidly formed on DNA at lower temperature (0 degrees C) without geminin, with similar to 10-20 molecules each of ORC and CDC6 bound to the plasmid, but almost no binding of MCM. However, upon shifting the temperature to 23 degrees C, most ORC, CDC6, and CDT1 molecules were displaced from the DNA, leaving about one ORC molecule on the plasmid, whereas similar to 10 MCM2 molecules were loaded onto each plasmid. Furthermore, it was possible to load MCM onto DNA when the isolated ORC-CDC6-CDT1-DNA complex was mixed with purified MCM proteins. These results suggest that an ORC-CDC6-CDT1 complex pre-formed on DNA is directly involved in MCM loading and imply that each DNA-bound ORC molecule loads only one or a few MCM2-7 complexes during metazoan pre-RC formation.	Osaka Univ, Grad Sch Frontier Biosci, Lab Biomol Network, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Osaka University; Osaka University	Waga, S (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Lab Biomol Network, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	swaga@fbs.osaka-u.ac.jp		Waga, Shou/0000-0003-4986-8735				Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chong JPJ, 1997, METHOD ENZYMOL, V283, P549; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Crowe AJ, 1999, METHOD ENZYMOL, V304, P63; Davey MJ, 2003, CURR BIOL, V13, pR594, DOI 10.1016/S0960-9822(03)00523-2; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Frolova NS, 2002, MOL BIOL CELL, V13, P1298, DOI 10.1091/mbc.01-08-0382; Furukohri A, 2003, J BIOCHEM, V134, P447, DOI 10.1093/jb/mvg163; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Harvey KJ, 2003, J BIOL CHEM, V278, P48524, DOI 10.1074/jbc.M307661200; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; Kong DC, 2003, EMBO J, V22, P3441, DOI 10.1093/emboj/cdg319; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McNairn AJ, 2005, EXP CELL RES, V308, P345, DOI 10.1016/j.yexcr.2005.05.009; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Neuwald AF, 1999, GENOME RES, V9, P27; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Ray-Gallet D, 2004, METHOD ENZYMOL, V375, P117; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; Takahashi N, 2002, J BIOL CHEM, V277, P16033, DOI 10.1074/jbc.M108615200; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda DY, 2005, GENE DEV, V19, P2827, DOI 10.1101/gad.1369805; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; You ZY, 1999, MOL CELL BIOL, V19, P8003	67	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10926	10934		10.1074/jbc.M600299200	http://dx.doi.org/10.1074/jbc.M600299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497662	hybrid			2022-12-25	WOS:000236822200033
J	Itoh, R; Fujiki, Y				Itoh, R; Fujiki, Y			Functional domains and dynamic assembly of the peroxin Pex14p, the entry site of matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; OVARY CELL MUTANTS; TARGETING SIGNALS; RECEPTOR DOCKING; COMPLEMENTATION GROUP; BIOGENESIS DISORDERS; IMPORT MACHINERY; POTENTIAL ROLE; CDNA CLONING; YEAST PEX14P	The 41-kDa membrane-anchored peroxin Pex14p functions as the peroxisome targeting signal (PTS) receptor-mediated, initial import site for matrix proteins. We here identify the functional domains of Pex14p involved in the assembly of import site subcomplexes. The minimal region of Pex14p required for restoring impaired protein import in pex14 Chinese hamster ovary cell mutant lies at residues 21-260 in the primary sequence. A highly conserved N-terminal region, encompassing residues 21-70, interacts with the PTS1 receptor Pex5p, Pex13p, and Pex19p that is essential for membrane biogenesis. N-terminal residues 21-140, including a hydrophobic segment at 110-138, function as a topogenic sequence. Site-directed mutagenesis, size fractionation, and chemical cross-linking analyses demonstrate that the coiled-coil domain at residues 156-197 regulates homodimerization of Pex14p. Moreover, AXXXA and GXXXG motifs in the transmembrane segment mediate homomeric oligomerization of Pex14p, giving rise to assembly of high molecular mass complexes and thereby assuring Pex13p-dependent localization of Pex14p to peroxisomes. Pex5p, Pex13p, and Pex19p bind to Pex14p homo-oligomers with different molecular masses, whereas cargo-unloaded Pex5p apparently disassembles Pex14p homo-oligomers. Thus, Pex14p most likely forms several distinct peroxin complexes involved in peroxisomal matrix protein import.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp						Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BAJAJ M, 1984, ANNU REV BIOPHYS BIO, V13, P453; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Choe J, 2003, BIOCHEMISTRY-US, V42, P10915, DOI 10.1021/bi034248n; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Madrid KP, 2005, BIOCHEM J, V391, P105, DOI 10.1042/BJ20050328; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsuzono Y, 2006, J BIOL CHEM, V281, P36, DOI 10.1074/jbc.M509819200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Niederhoff K, 2005, J BIOL CHEM, V280, P35571, DOI 10.1074/jbc.M502460200; Nito K, 2002, PLANT CELL PHYSIOL, V43, P355, DOI 10.1093/pcp/pcf057; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2001, J BIOL CHEM, V276, P2858, DOI 10.1074/jbc.M007730200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; Platta HW, 2005, NAT CELL BIOL, V7, P817, DOI 10.1038/ncb1281; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yan MD, 2005, CURR OPIN CELL BIOL, V17, P376, DOI 10.1016/j.ceb.2005.06.003	48	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10196	10205		10.1074/jbc.M600158200	http://dx.doi.org/10.1074/jbc.M600158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459329	hybrid			2022-12-25	WOS:000236594300046
J	Xu, J; Gong, NL; Bondi, I; Aronow, BJ; Backx, PH; Molkentin, JD				Xu, J; Gong, NL; Bondi, I; Aronow, BJ; Backx, PH; Molkentin, JD			Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; MUSCLE FIBER-TYPE; PROTEIN-KINASE-C; ACTION-POTENTIAL REPOLARIZATION; II HISTONE DEACETYLASES; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; IN-VIVO; NUCLEAR EXPORT; TARGETED INHIBITION	Cardiac hypertrophy and dilation are mediated by neuroendocrine factors and/or mitogens as well as through internal stretch- and stress-sensitive signaling pathways, which in turn transduce alterations in cardiac gene expression through specific signaling pathways. The transcription factor family known as myocyte enhancer factor 2( MEF2) has been implicated as a signal-responsive mediator of the cardiac transcriptional program. For example, known hypertrophic signaling pathways that utilize calcineurin, calmodulin-dependent protein kinase, and MAPKs can each affect MEF2 activity. Here we demonstrate that MEF2 transcription factors induced dilated cardiomyopathy and lengthening of myocytes. Specifically, multiple transgenic mouse lines with cardiac-specific overexpression of MEF2A or MEF2C presented with cardiomyopathy at base line or were predisposed to more fulminant disease following pressure overload stimulation. The cardiomyopathic response associated with MEF2A and MEF2C was not further altered by activated calcineurin, suggesting that MEF2 functions independently of calcineurin in this response. In cultured cardiomyocytes, MEF2A, MEF2C, and MEF2-VP16 overexpression induced sarcomeric disorganization and focal elongation. Mechanistically, MEF2A and MEF2C each programmed similar profiles of altered gene expression in the heart that included extracellular matrix remodeling, ion handling, and metabolic genes. Indeed, adenoviral transfection of cultured cardiomyocytes with MEF2A or of myocytes from the hearts of MEF2A transgenic adult mice showed reduced transient outward K+ currents, consistent with the alterations in gene expression observed in transgenic mice and partially suggesting a proximal mechanism underlying MEF2-dependent cardiomyopathy.	Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Dept Pharmacol, Cincinnati Childrens Hosp, Cincinnati, OH 45229 USA; Univ Toronto, Div Cardiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Heart & Stroke Richard Lewar Ctr, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3E2, Canada	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Molkentin, JD (corresponding author), Univ Cincinnati, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Xu, Jian/AAE-1415-2019; Aronow, Bruce J/F-8438-2012	Molkentin, Jeffery/0000-0002-3558-6529				Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Harris DM, 2005, CIRC RES, V96, P543, DOI 10.1161/01.RES.0000158966.58380.37; Karasseva N, 2003, MOL CELL BIOL, V23, P5143, DOI 10.1128/MCB.23.15.5143-5164.2003; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kassiri Z, 2002, CIRC RES, V90, P578, DOI 10.1161/01.RES.0000012223.86441.A1; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Lebeche D, 2004, CIRCULATION, V110, P3435, DOI 10.1161/01.CIR.0000148176.33730.3F; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Nishida K, 2004, MOL CELL BIOL, V24, P10611, DOI 10.1128/MCB.24.24.10611-10620.2004; Notterman DA, 2001, CANCER RES, V61, P3124; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Pan F, 2004, J BIOL CHEM, V279, P14477, DOI 10.1074/jbc.C300487200; Parsons SA, 2004, J BIOL CHEM, V279, P26192, DOI 10.1074/jbc.M313800200; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Rao S, 1998, J BIOL CHEM, V273, P26123, DOI 10.1074/jbc.273.40.26123; Sah R, 2003, J PHYSIOL-LONDON, V546, P5, DOI 10.1113/jphysiol.2002.026468; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang SS, 2003, J CLIN INVEST, V111, P833, DOI 10.1172/JCI200316290; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zobel C, 2002, CIRCULATION, V106, P2385, DOI 10.1161/01.CIR.0000033970.22130.93	70	150	157	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9152	9162		10.1074/jbc.M510217200	http://dx.doi.org/10.1074/jbc.M510217200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469744	hybrid			2022-12-25	WOS:000236404700021
J	Yan, WS; Chen, XB				Yan, WS; Chen, XB			GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL GLUTATHIONE-PEROXIDASE; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; P53 FAMILY; GI-GPX; FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; CANCER; P21; P73	The p53 family consists of p53, p63, and p73, each of which has multiple isoforms due to transcription at two separate promoters and alternative splicing. Although p53 is a bona fide tumor suppressor, p63 appears to have a Janus-faced function as a tumor suppressor and an oncogene. To address the two opposing functions of p63, we analyzed its target genes. Here, we found that GPX2, which encodes a glutathione peroxidase, is up-regulated by p63 but not p53. Accordingly, a unique responsive element was found in the promoter of the GPX2 gene that can be activated and bound by p63 but not p53. We also found that upon overexpression, GPX2 alleviates the apoptotic response of MCF7 cells to oxidative stresses. Interestingly, the protective function of GPX2 is p53 dependent. Likewise, we showed that a deficiency in GPX2 renders MCF7 cells susceptible to oxidative stress-induced apoptosis. Given that the Delta N isoform of p63 is frequently overexpressed in tumor cells, the observations here provide an insight into the mechanism by which some isoforms of p63 serve as a pro-survival factor by up-regulating GPX2 to reduce the p53-dependent oxidative stress-induced apoptotic response.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NATIONAL CANCER INSTITUTE [R29CA076069, R01CA102188, R01CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102188, CA076069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banning A, 2005, MOL CELL BIOL, V25, P4914, DOI 10.1128/MCB.25.12.4914-4923.2005; Brigelius-Flohe R, 2001, BIOFACTORS, V14, P101, DOI 10.1002/biof.5520140114; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; CHEN XB, 1995, CANCER RES, V55, P4257; Chu FF, 2004, FREE RADICAL BIO MED, V36, P1481, DOI 10.1016/j.freeradbiomed.2004.04.010; CHU FF, 1993, J BIOL CHEM, V268, P2571; Chu FF, 1999, J NUTR, V129, P1846, DOI 10.1093/jn/129.10.1846; Chu FF, 2004, CANCER RES, V64, P962, DOI 10.1158/0008-5472.CAN-03-2272; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dohn Michael, 2003, Methods Mol Biol, V223, P221; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Florian S, 2001, FREE RADICAL RES, V35, P655, DOI 10.1080/10715760100301181; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Mork H, 2003, INT J CANCER, V105, P300, DOI 10.1002/ijc.11087; Mork H, 2000, NUTR CANCER, V37, P108, DOI 10.1207/S15327914NC3701_14; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Serewko MM, 2002, CANCER RES, V62, P3759; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	42	123	126	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7856	7862		10.1074/jbc.M512655200	http://dx.doi.org/10.1074/jbc.M512655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16446369	hybrid			2022-12-25	WOS:000236031000020
J	Gudi, R; Barkinge, J; Hawkins, S; Chu, F; Manicassamy, S; Sun, Z; Duke-Cohan, JS; Prasad, KVS				Gudi, R.; Barkinge, J.; Hawkins, S.; Chu, F.; Manicassamy, S.; Sun, Z.; Duke-Cohan, J. S.; Prasad, K. V. S.			Siva-1 negatively regulates NF-kappa B activity: effect on T-cell receptor-mediated activation-induced cell death (AICD)	ONCOGENE			English	Article						TCR; apoptosis; NF-kappa B; Bcl-xL; c-FLIP; AICD	APOPTOSIS; INTERACTS; PATHWAY; BINDING; FAMILY; MEMBER; CD27	Ligation of TCRs on stimulated T cells leads to activation-induced cell death (AICD) resulting in the downregulation of immune responses, a process essential for T-cell homeostasis. In this study, using transformed T-cell lines such as Jurkat and Do11.10 as cellular models of TCR-mediated AICD, we have demonstrated that the proapoptotic protein Siva-1 is required for TCR-induced apoptosis. Knockdown of Siva-1 rendered T cells specifically resistant to anti-CD3 but not Fas-induced apoptosis. Further, we observed that in Siva-1 knockout Jurkat cells, TCR-mediated activation of the canonical and non-canonical limbs of the NF-kappa B pathway are significantly enhanced as reflected by elevated nuclear levels of p65 and RelB, respectively. In addition, loss of endogenous Siva-1 also resulted in the enhanced expression of NF-kappa B-responsive anti-apoptotic genes such as Bcl-xL and c-FLIP. Interestingly, the c-FLIPshort was detected only in TCR-ligated Siva-1 knockdown Jurkat cells. These results demonstrate a significant role for endogenous Siva-1, through its inhibitory effect on NF-kappa B activity, in TCR-mediated AICD with implications in peripheral tolerance, T-cell homeostasis and cancer.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Prasad, KVS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, 835 S Wolcott Ave,Room 820, Chicago, IL 60612 USA.	kanteti@uic.edu	Duke-Cohan, Jonathan/A-5812-2010	Duke-Cohan, Jonathan/0000-0002-9478-9609				Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chu F, 2005, CANCER RES, V65, P5301, DOI 10.1158/0008-5472.CAN-04-3270; Chu F, 2004, APOPTOSIS, V9, P83, DOI 10.1023/B:APPT.0000012125.01799.4c; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Li YQ, 2005, J BIOL CHEM, V280, P1217, DOI 10.1074/jbc.M409492200; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; XIAO N, 2005, LYMPHOMA J INVEST DE, V124, P741; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Yoon Y, 1999, ONCOGENE, V18, P7174, DOI 10.1038/sj.onc.1203144	20	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3458	3462		10.1038/sj.onc.1209381	http://dx.doi.org/10.1038/sj.onc.1209381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16491128				2022-12-25	WOS:000238448100010
J	Sensi, M; Nicolini, G; Petti, C; Bersani, I; Lozupone, F; Molla, A; Vegetti, C; Nonaka, D; Mortarini, R; Parmiani, G; Fais, S; Anichini, A				Sensi, M.; Nicolini, G.; Petti, C.; Bersani, I.; Lozupone, F.; Molla, A.; Vegetti, C.; Nonaka, D.; Mortarini, R.; Parmiani, G.; Fais, S.; Anichini, A.			Mutually exclusive NRAS(Q61R) and BRAF(V600E) mutations at the single-cell level in the same human melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; MASA-PCR; SCID	N-RAS MUTATIONS; B-RAF; BRAF MUTATIONS; COLORECTAL TUMORS; K-RAS; EXPRESSION; KINASE; GROWTH; GENE; ACTIVATION	BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour. This suggests that BRAF and NRAS 'double mutants' may not provide advantage for tumour growth, or may even be selected against during tumorigenesis. However, by applying mutant-allele-specific-amplification-PCR method to short-term melanoma lines, one out of 14 tumours was found to harbour both BRAF(V600E) and the activating NRAS(Q61R) mutations. On the other hand, analysis of 21 melanoma clones isolated by growth in soft agar from this tumour indicated that 16/21 clones harboured a BRAF(V600E), but were wild-type for NRAS, whereas the remaining had the opposite genotype (NRAS(Q61R)/wild-type BRAF). When compared to BRAF(V600E) clones, NRAS(Q61R) clones displayed reduced growth in soft agar, but higher proliferative ability in vitro in liquid medium and even in vivo after grafting into SCID/SCID mice. These data suggest that NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level. Moreover, the presence of NRAS(Q61R) or BRAF(V600E) is associated with distinct in vitro and in vivo growth properties of neoplastic cells.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Super Sanita, Dept Drug Res & Evaluat Pharmacogenet, Drug Resistance & Expt Therapeut Sect, I-00161 Rome, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumors, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Sensi, M (corresponding author), Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy.	marialuisa.sensi@istitutotumori.mi.it	Mortarini, Roberta/C-9483-2017; Fais, Stefano/J-8638-2016; Lozupone, Francesco/H-2998-2016; Sensi, Marialuisa/K-5631-2014; Anichini, Andrea/K-1434-2016	Mortarini, Roberta/0000-0001-7732-0561; Fais, Stefano/0000-0001-9060-2766; Lozupone, Francesco/0000-0002-4959-9400; Sensi, Marialuisa/0000-0002-7643-0248; Anichini, Andrea/0000-0001-5096-5538				ANICHINI A, 1989, J IMMUNOL, V142, P3692; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Brose MS, 2002, CANCER RES, V62, P6997; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Lilleberg SL, 2004, ANN NY ACAD SCI, V1022, P250, DOI 10.1196/annals.1318.039; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Loewe R, 2004, J INVEST DERMATOL, V123, P733, DOI 10.1111/j.0022-202X.2004.23402.x; Lozupone F, 2004, CANCER RES, V64, P378, DOI 10.1158/0008-5472.CAN-03-1501; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rak J, 2004, SEMIN CANCER BIOL, V14, P93, DOI 10.1016/j.semcancer.2003.09.014; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sivertsson A, 2002, CLIN CHEM, V48, P2164; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xu XL, 2003, CANCER RES, V63, P4561	39	134	136	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3357	3364		10.1038/sj.onc.1209379	http://dx.doi.org/10.1038/sj.onc.1209379			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462768				2022-12-25	WOS:000238448100001
J	Choi, S; Kim, JH; Roh, EJ; Ko, MJ; Jung, JE; Kim, HJ				Choi, S; Kim, JH; Roh, EJ; Ko, MJ; Jung, JE; Kim, HJ			Nuclear factor-kappa B activated by capacitative Ca2+ entry enhances muscarinic receptor-mediated soluble amyloid precursor protein (sAPP alpha) release in SH-SY5Y cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; POTENT INHIBITORS; CALCIUM; KINASE; SURVIVAL; NEURONS; COMPLEX; FORM; PHOSPHORYLATION	Gq/11 protein-coupled muscarinic receptors are known to regulate the release of soluble amyloid precursor protein (sAPP alpha) produced by alpha-secretase processing; however, their signaling mechanisms remain to be elucidated. It has been reported that a muscarinic agonist activates nuclear factor (NF)-kappa B, a transcription factor that has been shown to play an important role in the Alzheimer disease brain, and that NF-kappa B activation is regulated by intracellular Ca2+ level. In the present study, we investigated whether NF-kappa B activation plays a role in muscarinic receptor-mediated sAPP alpha release enhancement and contributes to a changed capacitative Ca2+ entry (CCE), which was suggested to be involved in the muscarinic receptor-mediated stimulation of sAPP alpha release. Muscarinic receptor-mediated NF-kappa B activation was confirmed by observing the translocation of the active subunit (p65) of NF-kappa B to the nucleus by the muscarinic agonist, oxotremorine M (oxoM), in SH-SY5Y neuroblastoma cells expressing muscarinic receptors that are predominantly of the M3 subtype. NF-kappa B activation and sAPP alpha release enhancement induced by oxoM were inhibited by NF-kappa B inhibitors, such as an NF-kappa B peptide inhibitor (SN50), an I kappa B alpha kinase inhibitor (BAY11-7085), a proteasome inhibitor (MG132), the inhibitor of proteasome activity and I kappa B phosphorylation, pyrrolidine dithiocarbamate, the novel NF-kappa B activation inhibitor (6-amino-4-(4-phenoxyphenylethylamino) quinazoline), and by an intracellular Ca2+ chelator (TMB-8). Furthermore, both oxoM-induced NF-kappa B activation and sAPP alpha release were antagonized by CCE inhibitors (gadolinium or SKF96365) but not by voltage-gated Ca2+-channel blockers. On the other hand, treatment of cells with NF-kappa B inhibitors (SN50, BAY11-7085, MG132, or pyrrolidine dithiocarbamate) did not inhibit muscarinic receptor-mediated CCE. These findings provide evidence for the involvement of NF-kappa B regulated by CCE in muscarinic receptor-mediated sAPP alpha release enhancement.	Ewha Womans Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 120750, South Korea	Ewha Womans University	Kim, HJ (corresponding author), Ewha Womans Univ, Coll Pharm, Pharmaceut Sci Res Inst, 11-1 Daehyun Dong, Seoul 120750, South Korea.	hjkim@ewha.ac.kr						Barger SW, 1996, MOL BRAIN RES, V40, P116; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Camandola S, 2005, J BIOL CHEM, V280, P22287, DOI 10.1074/jbc.M410923200; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Daniel KG, 2005, BREAST CANCER RES, V7, pR897, DOI 10.1186/bcr1322; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FERNANDO KC, 1994, BBA-MOL CELL RES, V1222, P383, DOI 10.1016/0167-4889(94)90044-2; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kim JH, 2006, J NEUROCHEM, V97, P245, DOI 10.1111/j.1471-4159.2006.03734.x; Kim Y, 2004, BIOCHEM BIOPH RES CO, V314, P695, DOI 10.1016/j.bbrc.2003.12.153; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Li XH, 1996, J NEUROSCI, V16, P5914; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MASON MJ, 1993, AM J PHYSIOL, V264, pC564; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Okamura H, 2001, CURR OPIN CELL BIOL, V13, P239, DOI 10.1016/S0955-0674(00)00203-9; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Petegnief V, 2004, NEUROCHEM INT, V44, P287, DOI 10.1016/S0197-0186(03)00136-0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Stein TD, 2002, J NEUROSCI, V22, P7380; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Todisco A, 1999, BIOCHEM BIOPH RES CO, V261, P877, DOI 10.1006/bbrc.1999.1141; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; UNLAP T, 1995, NEUROSCI LETT, V198, P41, DOI 10.1016/0304-3940(95)11963-W; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	53	31	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12722	12728		10.1074/jbc.M601018200	http://dx.doi.org/10.1074/jbc.M601018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16490783	hybrid			2022-12-25	WOS:000237134700064
J	Zhang, K; Zang, TZ; Yang, W; Sun, Y; Mu, Y; Liu, JQ; Shen, JC; Luo, GM				Zhang, K; Zang, TZ; Yang, W; Sun, Y; Mu, Y; Liu, JQ; Shen, JC; Luo, GM			Single chain antibody displays glutathione S-transferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM-CONTAINING ABZYME; HIGH CATALYTIC EFFICIENCY; PEROXIDASE; MECHANISM; MIMICS; CONJUGATION; GENERATION; EVOLUTION; KINETICS	Substrate binding and the subsequent reaction are the two principal phenomena that underlie the activity of enzymes, and many enzyme-like catalysts were generated based on the phenomena. The single chain variable region fragment of antibody 2F3 (scFv2F3) was elicited against hapten GSH-S-DN(2)phBu, a conjugate of glutathione (GSH), butyl alcohol, and 1-chloro-2,4-dinitrobenzene ( CDNB); it can therefore bind both GSH and CDNB, the substrates of native glutathione S-transferases (GSTs). It was shown previously that there is a serine residue that is the catalytic group of GST in the CDR regions of scFv2F3 close to the sulfhydryl of GSH. Thus, we anticipated that scFv2F3 will display GST activity. The experimental results showed that scFv2F3 indeed displayed GST activity that is equivalent to the rat theta-class GST T-2-2 and exhibited pH-and temperature-dependent catalytic activity. Steady-state kinetic studies showed that the Km values for the substrates are close to those of native GSTs, indicating that scFv2F3 has strong affinities for the substrates. Compared with some other GSTs, its k(cat) value was found to be low, which could be caused by the similarity between the GSH-S-DN2phBu and the reaction product of GSH and CDNB. These results showed that our approach to imitating enzymes is correct, which is that an active site may catalyze a chemical reaction when a catalytic group locates beside a substrate-binding site of a receptor. It is important to consider product inhibition in hapten design in order to obtain a mimic with a high catalytic efficiency.	Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China	Jilin University	Luo, GM (corresponding author), Jilin Univ, Key Lab Mol Enzymol & Engn, Minist Educ, 2519 Jiefeng Rd, Changchun 130023, Peoples R China.	luogm@jlu.edu.cn	Zhang, Kun/K-1218-2015	Sun, Ye/0000-0002-7674-9056				Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins JF, 2000, NATURE, V407, P463, DOI 10.1038/35035189; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Gallagher EP, 2000, ENVIRON TOXICOL CHEM, V19, P319, DOI 10.1002/etc.5620190211; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Habig W H, 1981, Methods Enzymol, V77, P398; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hoarau P, 2002, EUR J BIOCHEM, V269, P4359, DOI 10.1046/j.1432-1033.2002.03141.x; Jiang ZH, 2002, ACTA BIOCH BIOPH SIN, V34, P395; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; Liu JQ, 2004, ANAL CHIM ACTA, V504, P185, DOI 10.1016/S0003-2670(03)00763-3; Liu JQ, 1999, MAT SCI ENG C-BIO S, V10, P131, DOI 10.1016/S0928-4931(99)00095-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo GM, 1998, ANN NY ACAD SCI, V864, P136, DOI 10.1111/j.1749-6632.1998.tb10296.x; LUO GM, 1994, BIOCHEM BIOPH RES CO, V198, P1240, DOI 10.1006/bbrc.1994.1175; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Ren XJ, 2002, CHEM BIOL, V9, P789, DOI 10.1016/S1074-5521(02)00167-9; Ren XJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P250, DOI 10.1006/abbi.2000.2238; Ren XJ, 2001, BIOCHEM J, V359, P369, DOI 10.1042/0264-6021:3590369; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Singh SP, 2001, EUR J BIOCHEM, V268, P2912, DOI 10.1046/j.1432-1327.2001.02179.x; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Su D, 2001, ARCH BIOCHEM BIOPHYS, V395, P177, DOI 10.1006/abbi.2001.2551; Su D, 2001, BIOCHEM BIOPH RES CO, V285, P702, DOI 10.1006/bbrc.2001.5183; Sun Y, 2004, J BIOL CHEM, V279, P37235, DOI 10.1074/jbc.M403032200; Thanbichler M, 2002, METHOD ENZYMOL, V347, P3; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; Zhang K, 2003, CHINESE J CATAL+, V24, P97; Zhang Y, 2005, BBA-PROTEINS PROTEOM, V1747, P27, DOI 10.1016/j.bbapap.2004.09.022	34	12	12	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12516	12520		10.1074/jbc.M513596200	http://dx.doi.org/10.1074/jbc.M513596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507568	hybrid			2022-12-25	WOS:000237134700039
J	Alfalah, M; Krahn, MP; Wetzel, G; von Horsten, S; Wolke, C; Hooper, N; Kalinski, T; Krueger, S; Naim, HY; Lendeckel, U				Alfalah, M; Krahn, MP; Wetzel, G; von Horsten, S; Wolke, C; Hooper, N; Kalinski, T; Krueger, S; Naim, HY; Lendeckel, U			A mutation in aminopeptidase N (CD13) isolated from a patient suffering from leukemia leads to an arrest in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; VASOACTIVE PEPTIDES; CYTOMEGALOVIRUS-INFECTION; METHIONINE-ENKEPHALIN; ALANYL AMINOPEPTIDASE; CYSTIC-FIBROSIS; MOLECULAR-BASIS; EXPRESSION; METABOLISM; DEGRADATION	Human aminopeptidase N (APN) is used as a routine marker for myelomonocytic cells in hematopoietic malignant disorders. Its gene and surface expressions are increased in cases of malignant transformation, inflammation, or T cell activation, whereas normal B and resting T cells lack detectable APN protein expression. In this study we elucidated the intracellular distribution, expression pattern, and enzymatic activity of a naturally occurring mutation in the coding region of the APN gene. At physiological temperatures the mutant protein is enzymatically inactive, persists as a mannose-rich polypeptide in the endoplasmic reticulum, and is ultimately degraded by an endoplasmic reticulum-associated degradation pathway. It shows in part the distinct behavior of a temperature-sensitive mutant with a permissive temperature of 32 degrees C, leading to correct sorting of the Golgi compartment accompanied by the acquisition of proper glycosylation but without reaching the cell-surface membrane and without regaining its enzymatic activity. Because the patient bearing this mutation suffered from leukemia, possible links to the pathogenesis of leukemia are discussed.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Hannover Med Sch, Dept Funct & Appl Anat, D-30625 Hannover, Germany; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany	University of Veterinary Medicine Hannover, Foundation; Hannover Medical School; Otto von Guericke University; University of Leeds; Otto von Guericke University	Alfalah, M (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.	Marwan.Alfalah@tiho-hannover.de	Lendeckel, Uwe/Q-6922-2016; von Hörsten, Stephan/G-9005-2015; Al Falah, Dr. Marwan/C-6281-2011; Krahn, Michael/AAD-4476-2022	Lendeckel, Uwe/0000-0002-0684-9959; von Hörsten, Stephan/0000-0001-6409-0664; Krahn, Michael/0000-0001-7718-9890; Hooper, Nigel/0000-0002-5811-3484				AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; Barnes K, 1997, J NEUROCHEM, V68, P570; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; BNAK U, 2006, IN PRESS ADV EXP MED, V575; Chansel D, 1998, AM J PHYSIOL-RENAL, V275, pF535, DOI 10.1152/ajprenal.1998.275.4.F535; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DELMAS B, 1993, ADV EXP MED BIOL, V342, P293; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dong X, 2000, J IMMUNOL, V164, P129, DOI 10.4049/jimmunol.164.1.129; DREXLER HG, 1991, LEUKEMIA, V5, P637; Esapa CT, 2005, HUM MOL GENET, V14, P295, DOI 10.1093/hmg/ddi026; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Firla B, 2002, FREE RADICAL BIO MED, V32, P584, DOI 10.1016/S0891-5849(01)00827-9; FUJII H, 1995, CLIN EXP METASTAS, V13, P337; FURUHASHI M, 1988, EXP CLIN ENDOCRINOL, V92, P235, DOI 10.1055/s-0029-1210807; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GIROS B, 1986, MOL PHARMACOL, V29, P281; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; Ino K, 1995, ANTICANCER RES, V15, P2081; IWAHASHI M, 1994, ANTICANCER RES, V14, P1563; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1994, J BIOL CHEM, V269, P2712; KANAYAMA N, 1995, J LEUKOCYTE BIOL, V57, P129, DOI 10.1002/jlb.57.1.129; Kasman LM, 2005, VIROLOGY, V334, P1, DOI 10.1016/j.virol.2005.01.028; Kowalski Jan, 1995, Archivum Immunologiae et Therapiae Experimentalis, V43, P265; Krueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200; Larsen SL, 1996, J EXP MED, V184, P183, DOI 10.1084/jem.184.1.183; Larsson S, 1998, TRANSPLANTATION, V65, P411, DOI 10.1097/00007890-199802150-00021; Lendeckel U, 1999, INT J MOL MED, V4, P17; LENDECKEL U, 1994, CELL IMMUNOL, V153, P214, DOI 10.1006/cimm.1994.1019; Lendeckel U, 1996, BIOCHEM J, V319, P817, DOI 10.1042/bj3190817; LUCIUS R, 1995, J NEUROCHEM, V64, P1841; Mathe G, 1987, Cancer Detect Prev Suppl, V1, P445; MATSUSHITA A, 1994, INT J HEMATOL, V60, P157; MILLER BC, 1994, REGUL PEPTIDES, V50, P87, DOI 10.1016/0167-0115(94)90194-5; MILLER BC, 1994, ARCH BIOCHEM BIOPHYS, V311, P174, DOI 10.1006/abbi.1994.1223; Mina-Osorio P, 2005, J LEUKOCYTE BIOL, V77, P1008, DOI 10.1189/jlb.1204714; MIZUTANI S, 1993, RES COMMUN CHEM PATH, V82, P65; Moffatt S, 2005, HUM GENE THER, V16, P57, DOI 10.1089/hum.2005.16.57; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; OKAMURA T, 1992, ACTA HAEMATOL-BASEL, V87, P94; PALMIERI FE, 1985, BIOCHEM PHARMACOL, V34, P2309, DOI 10.1016/0006-2952(85)90787-7; PALMIERI FE, 1989, BIOCHEM PHARMACOL, V38, P173, DOI 10.1016/0006-2952(89)90165-2; PINTO A, 1991, ANN ONCOL, V2, P107, DOI 10.1093/annonc/2.suppl_2.107; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; Ron I, 2005, HUM MOL GENET, V14, P2387, DOI 10.1093/hmg/ddi240; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Sakuraya M, 2000, J INT MED RES, V28, P214, DOI 10.1177/147323000002800503; Sato Y, 2004, BIOL PHARM BULL, V27, P772, DOI 10.1248/bpb.27.772; Sawafuji K, 2003, LEUKEMIA LYMPHOMA, V44, P1987, DOI 10.1080/1042819031000122033; Shen S, 2004, VIROLOGY, V326, P288, DOI 10.1016/j.virol.2004.06.016; SHIBANOKI S, 1991, REGUL PEPTIDES, V32, P267, DOI 10.1016/0167-0115(91)90020-H; SHIMAMURA M, 1988, BRAIN RES, V445, P350, DOI 10.1016/0006-8993(88)91197-3; SHIMAMURA M, 1991, J BIOCHEM-TOKYO, V109, P492, DOI 10.1093/oxfordjournals.jbchem.a123409; SODERBERG C, 1993, J VIROL, V67, P6576; WARD PE, 1990, BIOCHEM PHARMACOL, V40, P1725, DOI 10.1016/0006-2952(90)90348-O; Woodhead VE, 2000, INT IMMUNOL, V12, P1051, DOI 10.1093/intimm/12.7.1051; YAMAGISHI H, 1991, BIOMED PHARMACOTHER, V45, P117, DOI 10.1016/0753-3322(91)90131-C; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; [No title captured]	62	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11894	11900		10.1074/jbc.M511364200	http://dx.doi.org/10.1074/jbc.M511364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16469741	hybrid			2022-12-25	WOS:000236988100057
J	Dominguez-Cuevas, P; Gonzalez-Pastor, JE; Marques, S; Ramos, JL; de Lorenzo, V				Dominguez-Cuevas, P; Gonzalez-Pastor, JE; Marques, S; Ramos, JL; de Lorenzo, V			Transcriptional tradeoff between metabolic and stress-response programs in Pseudomonas putida KT2440 cells exposed to toluene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOL PLASMID PWW0; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI K-12; PATHWAY OPERON; RNA-POLYMERASE; EFFLUX PUMPS; PM PROMOTER; CRITICAL NUCLEOTIDES; SOLVENT TOLERANCE; OXIDATIVE STRESS	When Pseudomonas putida KT2440 cells encounter toluene in the growth medium, they perceive it simultaneously as a potential nutrient to be metabolized, as a membrane-damaging toxic drug to be extruded, and as a macromolecule-disrupting agent from which to protect proteins. Each of these inputs requires a dedicated transcriptional response that involves a large number of genes. We used DNA array technology to decipher the interplay between these responses in P. putida KT2440 subjected to a short challenge ( 15 min) with toluene. We then compared the results with those in cells exposed to o-xylene ( a non-biodegradable toluene counterpart) and 3-methylbenzoate ( a specific substrate of the lower TOL pathway of the P. putida pWW0 plasmid). The resulting expression profiles suggest that the bulk of the available transcriptional machinery is reassigned to endure general stress, whereas only a small share of the available machinery is redirected to the degradation of the aromatic compounds. Specifically, both toluene and o-xylene induce the TOL pathways and a dedicated but not always productive metabolic program. Similarly, 3-methylbenzoate induces the expression not only of the lower meta pathway but also of the non-productive and potentially deleterious genes for the metabolism of (nonsubstituted) benzoate. In addition, toluene ( and to a lesser extent o-xylene) inhibit motility functions as an unequivocal response to aromatic toxicity. We argue that toluene is sensed by P. putida KT2440 as a stressor rather than as a nutrient and that the inhibition by the aromatic compounds of many functions we tested is the tradeoff for activating stress tolerance genes at a minimal cost in terms of energy.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain; CSIC, Inst Nacl Tecn Aeroesp, Ctr Astrobiol, E-28850 Madrid, Spain; CSIC, Dept Microbiol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Ramos, JL (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Profesor Albareda 1, E-18008 Granada, Spain.	jlramos@eez.csic.es	González-Pastor, José/I-2118-2015; Marqués, Silvia/B-8079-2012; Dominguez-Cuevas, Patricia/D-6608-2017	González-Pastor, José/0000-0002-7615-7042; Marqués, Silvia/0000-0002-6289-3348; Dominguez-Cuevas, Patricia/0000-0002-9343-091X; Ramos, Juan L./0000-0002-8731-7435; de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; Allocati N, 2003, BIOCHEM J, V373, P305, DOI 10.1042/BJ20030184; Buege J A, 1978, Methods Enzymol, V52, P302; Cases I, 2005, NAT REV MICROBIOL, V3, P105, DOI 10.1038/nrmicro1084; Cowles CE, 2000, J BACTERIOL, V182, P6339, DOI 10.1128/JB.182.22.6339-6346.2000; Dominguez-Cuevas P, 2005, J BIOL CHEM, V280, P41315, DOI 10.1074/jbc.M505415200; DUETZ WA, 1991, J GEN MICROBIOL, V137, P1369, DOI 10.1099/00221287-137-6-1369; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fawcett J, 2000, SCIENCE, V290, P725, DOI 10.1126/science.290.5492.725; Gonzalez-Perez MM, 1999, J BIOL CHEM, V274, P2286, DOI 10.1074/jbc.274.4.2286; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; Greated A, 2002, ENVIRON MICROBIOL, V4, P856, DOI 10.1046/j.1462-2920.2002.00305.x; Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jimenez JI, 2004, PSEUDOMONAS, VOL 3: BIOSYNTHESIS OF MACROMOLECULES AND MOLECULAR METABOLISM, P425; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Junker F, 1999, J BACTERIOL, V181, P5693, DOI 10.1128/JB.181.18.5693-5700.1999; KESSLER B, 1994, J BACTERIOL, V176, P5578, DOI 10.1128/JB.176.17.5578-5582.1994; Kieboom J, 1998, J BACTERIOL, V180, P6769, DOI 10.1128/JB.180.24.6769-6772.1998; Kim K, 1998, J BACTERIOL, V180, P3692, DOI 10.1128/JB.180.14.3692-3696.1998; LI CY, 1993, J BACTERIOL, V175, P2229, DOI 10.1128/JB.175.8.2229-2235.1993; Liu YQ, 2005, J BACTERIOL, V187, P2501, DOI 10.1128/JB.187.7.2501-2507.2005; Marnett LJ, 2002, TOXICOLOGY, V181, P219, DOI 10.1016/S0300-483X(02)00448-1; Marques S, 1999, MOL MICROBIOL, V31, P1105, DOI 10.1046/j.1365-2958.1999.01249.x; MARQUES S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P227, DOI 10.1016/0167-4781(93)90149-8; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; Miller JH., 1972, EXPT MOL GENETICS; Mosqueda G, 2000, J BACTERIOL, V182, P937, DOI 10.1128/JB.182.4.937-943.2000; Munoz-Rojas J, 2006, APPL ENVIRON MICROB, V72, P472, DOI 10.1128/AEM.72.1.472-477.2006; Nakazawa T, 2002, ENVIRON MICROBIOL, V4, P782, DOI 10.1046/j.1462-2920.2002.00310.x; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Ochsner UA, 2000, J BACTERIOL, V182, P4533, DOI 10.1128/JB.182.16.4533-4544.2000; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; Ramos JL, 1997, J BIOL CHEM, V272, P3887, DOI 10.1074/jbc.272.7.3887; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Ramos JL, 2001, CURR OPIN MICROBIOL, V4, P166, DOI 10.1016/S1369-5274(00)00183-1; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; ROJO F, 1987, SCIENCE, V238, P1395, DOI 10.1126/science.3479842; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Ruberg S, 2003, J BIOTECHNOL, V106, P255, DOI 10.1016/j.jbiotec.2003.08.005; Santos PM, 2004, PROTEOMICS, V4, P2640, DOI 10.1002/pmic.200300793; Segura A, 2005, J BACTERIOL, V187, P5937, DOI 10.1128/JB.187.17.5937-5945.2005; SEGURA A, 2004, PSEUDOMONAS, V2, P479; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; Velazquez F, 2005, MOL MICROBIOL, V57, P1557, DOI 10.1111/j.1365-2958.2005.04787.x; von Wallbrunn A, 2003, J BACTERIOL, V185, P1730, DOI 10.1128/JB.185.5.1730-1733.2003; Wen Y, 2003, INFECT IMMUN, V71, P5921, DOI 10.1128/IAI.71.10.5921-5939.2003; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7; Yuste L, 2006, ENVIRON MICROBIOL, V8, P165, DOI 10.1111/j.1462-2920.2005.00890.x	59	154	157	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11981	11991		10.1074/jbc.M509848200	http://dx.doi.org/10.1074/jbc.M509848200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495222	hybrid			2022-12-25	WOS:000236988100068
J	Miller, AG; Smith, DG; Bhat, M; Nagaraj, RH				Miller, AG; Smith, DG; Bhat, M; Nagaraj, RH			Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; METHYLGLYOXAL INDUCES APOPTOSIS; GLYCATION END-PRODUCTS; DIABETIC-RETINOPATHY; NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HIGH GLUCOSE; CANCER-CHEMOTHERAPY; MAILLARD REACTION	Retinal capillary pericytes undergo premature death, possibly by apoptosis, during the early stages of diabetic retinopathy. The alpha-oxoaldehyde, methylglyoxal (MGO), has been implicated as a cause of cell damage in diabetes. We have investigated the role of MGO and its metabolizing enzyme, glyoxalase I, in high glucose-induced apoptosis ( annexin V binding) of human retinal pericyte (HRP). HRP incubated with high glucose ( 30 mM D-glucose) for 7 days did not undergo apoptosis despite accumulation of MGO. However, treatment with a combination of high glucose and S-p-bromobenzylglutathione cyclopentyl diester, a competitive inhibitor of glyoxalase I, resulted in apoptosis along with a dramatic increase in MGO. Overexpression of glyoxalase I in HRP protected against S-p-bromobenzylglutathione cyclopentyl diester-induced apoptosis under high glucose conditions. Incubation of HRP with high concentrations of MGO resulted in an increase of apoptosis relative to untreated controls. We found an elevation of nitric oxide (NOcenter dot) in HRP that was incubated with high glucose when compared with those incubated with either the L-glucose or untreated controls. When HRP were incubated with an NOcenter dot donor, DETANONOATE ((Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-1-ium-1,2- diolate), we observed both decreased glyoxalase I expression and activity relative to untreated control cells. Further studies showed that HRP underwent apoptosis when incubated with DETANONOATE and that apoptosis increased further on co-incubation with high glucose. Our findings indicate that glyoxalase I is critical for pericyte survival under hyperglycemic conditions, and its inactivation and/or down-regulation by NOcenter dot may contribute to pericyte death by apoptosis during the early stages of diabetic retinopathy.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Visual Sci Res Ctr, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Wearn Bldg,Rm 653, Cleveland, OH 44106 USA.	ram.nagaraj@case.edu			NATIONAL EYE INSTITUTE [R01EY016219, P30EY011373, R01EY009912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068045] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY-016219, P30EY-11373, R01EY-09912] Funding Source: Medline; NIDDK NIH HHS [R21DK-068045] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADDISON DJ, 1970, BRIT MED J, V1, P264, DOI 10.1136/bmj.1.5691.264; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Beisswenger PJ, 2003, BBA-MOL BASIS DIS, V1637, P98, DOI 10.1016/S09254439(02)00219-3; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Creighton DJ, 2003, BIOCHEM SOC T, V31, P1378; Dagher Z, 2004, DIABETES, V53, P2404, DOI 10.2337/diabetes.53.9.2404; Davidson SD, 2002, UROL RES, V30, P116, DOI 10.1007/s00240-002-0244-7; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53; Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kasper M, 2000, AM J RESP CELL MOL, V23, P485, DOI 10.1165/ajrcmb.23.4.4117; Kern TS, 2000, INVEST OPHTH VIS SCI, V41, P3972; Kim J, 2005, EXP EYE RES, V81, P65, DOI 10.1016/j.exer.2005.01.010; Kim J, 2004, J KOREAN MED SCI, V19, P95, DOI 10.3346/jkms.2004.19.1.95; Kowluru RA, 2005, LIFE SCI, V76, P1051, DOI 10.1016/j.lfs.2004.10.017; Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353; Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572; Kusner LL, 2004, INVEST OPHTH VIS SCI, V45, P1553, DOI 10.1167/iovs.03-1294; Li WY, 1999, CELL MOL BIOL, V45, P59; Liu BF, 2004, INVEST OPHTH VIS SCI, V45, P1983, DOI 10.1167/iovs.03-0995; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mitsumoto A, 2000, J BIOCHEM, V128, P647, DOI 10.1093/oxfordjournals.jbchem.a022797; Mitsumoto A, 1999, BIOCHEM J, V344, P837, DOI 10.1042/0264-6021:3440837; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; Morgan PE, 2002, ARCH BIOCHEM BIOPHYS, V403, P259, DOI 10.1016/S0003-9861(02)00222-9; MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Padayatti PS, 2001, CURR EYE RES, V23, P106, DOI 10.1076/ceyr.23.2.106.5472; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478; Rulli A, 2001, BREAST CANCER RES TR, V66, P67, DOI 10.1023/A:1010632919129; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Santilli F, 2004, HORM METAB RES, V36, P319, DOI 10.1055/s-2004-814489; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, BIOCHEM PHARMACOL, V51, P1365, DOI 10.1016/0006-2952(96)00059-7; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372, DOI 10.1042/BST0311372; Yamagishi S, 2005, FEBS LETT, V579, P4265, DOI 10.1016/j.febslet.2005.06.058; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010	58	91	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11864	11871		10.1074/jbc.M513813200	http://dx.doi.org/10.1074/jbc.M513813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505483	hybrid			2022-12-25	WOS:000236988100053
J	Syeda, F; Grosjean, J; Houliston, RA; Keogh, RJ; Carter, TD; Paleolog, E; Wheeler-Jones, CPD				Syeda, F; Grosjean, J; Houliston, RA; Keogh, RJ; Carter, TD; Paleolog, E; Wheeler-Jones, CPD			Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappa B pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; THROMBIN; EXPRESSION; PHOSPHORYLATION; TRANSACTIVATION; TRANSCRIPTION; INHIBITION; SIGNAL; BETA	The functional significance of protease-activated receptors (PARs) in endothelial cells is largely undefined, and the intracellular consequences of their activation are poorly understood. Here, we show that the serine protease thrombin, a PAR-1-selective peptide (TFLLRN), and SLIGKV ( PAR-2-selective peptide) induce cyclooxygenase-2 (COX-2) protein and mRNA expression in human endothelial cells without modifying COX-1 expression. COX-2 induction was accompanied by sustained production of 6-keto-PGF(1 alpha), the stable hydrolysis product of prostacyclin, and this was inhibited by indomethacin and the COX-2-selective inhibitor NS398. PAR-1 and PAR-2 stimulation rapidly activated both ERK1/2 and p38(MAPK), and pharmacological blockade of MEK with either PD98059 or U0126 or of p38(MAPK) by SB203580 or SB202190 strongly inhibited thrombin- and SLIGKV-induced COX-2 expression and 6-keto-PGF(1 alpha) formation. Thrombin and peptide agonists of PAR-1 and PAR-2 increased luciferase activity in human umbilical vein endothelial cells infected with an NF-kappa B-dependent luciferase reporter adenovirus, and this, as well as PAR-induced 6-keto-PGF(1 alpha) synthesis, was inhibited by co-infection with adenovirus encoding wild-type or mutated (Y42F) I kappa B alpha. Thrombin- and SLIGKV-induced COX-2 expression and 6-keto-PGF(1 alpha) generation were markedly attenuated by the NF-kappa B inhibitor PG490 and partially inhibited by the proteasome pathway inhibitor MG-132. Activation of PAR-1 or PAR-2 promoted nuclear translocation and phosphorylation of p65-NF-kappa B, and thrombin- induced but not PAR-2-induced p65-NF-kappa B phosphorylation was reduced by inhibition of MEK or p38MAPK. Activation of PAR-4 by AYPGKF increased phosphorylation of ERK1/2 and p38MAPK without modifying NF-kappa B activation or COX-2 induction. Our data show that PAR-1 and PAR-2, but not PAR-4, are coupled with COX-2 expression and sustained endothelial production of vasculoprotective prostacyclin by mechanisms that depend on ERK1/2, p38(MAPK), and I kappa B alpha-dependent NF-kappa B activation.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, London W6 8LH, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Surg Oncol Reprod Biol & Anaesthet, London W6 8LH, England; Natl Inst Med Res, London NW7 1AA, England	University of London; University of London Royal Veterinary College; Imperial College London; University of Oxford; Imperial College London; MRC National Institute for Medical Research	Wheeler-Jones, CPD (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 0TU, England.	cwheeler@rvc.ac.uk	Carter, Tom/E-5035-2016	Carter, Tom/0000-0002-6248-7278	Medical Research Council [MC_U117573808] Funding Source: Medline; MRC [MC_U117573808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Bretschneider E, 1999, BRIT J PHARMACOL, V126, P1735, DOI 10.1038/sj.bjp.0702509; Bretschneider E, 1997, BIOCHEM BIOPH RES CO, V235, P365, DOI 10.1006/bbrc.1997.6788; Brown M, 2005, AM J PHYSIOL-HEART C, V289, pH466, DOI 10.1152/ajpheart.00170.2004; Brueckmann M, 2005, THROMB HAEMOSTASIS, V93, P743, DOI 10.1160/TH04-08-0511; CARAMORI G, 2004, CURR OPIN INVESTIG D, V11, P1141; Chen J, 2005, J BIOL CHEM, V280, P16354, DOI 10.1074/jbc.M411134200; Chung A, 2005, J THORAC CARDIOV SUR, V129, P782, DOI 10.1016/j.jtcvs.2004.06.049; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Fitzpatrick FA, 2004, CURR PHARM DESIGN, V10, P577, DOI 10.2174/1381612043453144; Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hollenberg MD, 2005, J PHARMACOL SCI, V97, P8, DOI 10.1254/jphs.FMJ04005X2; Holzhausen M, 2005, J DENT RES, V84, P154, DOI 10.1177/154405910508400209; Houliston RA, 2002, THROMB HAEMOSTASIS, V88, P321; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Kataoka H, 2003, BLOOD, V102, P3224, DOI 10.1182/blood-2003-04-1130; Kawabata A, 2004, J PHARMACOL EXP THER, V309, P1098, DOI 10.1124/jpet.103.061010; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Lin CC, 2004, J BIOMED SCI, V11, P377, DOI 10.1159/000077107; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; May MJ, 1998, AM J PHYSIOL-CELL PH, V274, pC789, DOI 10.1152/ajpcell.1998.274.3.C789; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Misra A, 2003, CIRCULATION, V108, P3075, DOI 10.1161/01.CIR.0000108929.93074.0B; Monaco C, 2004, CARDIOVASC RES, V61, P671, DOI 10.1016/j.cardiores.2003.11.038; Nadjar A, 2005, J CEREBR BLOOD F MET, V25, P1047, DOI 10.1038/sj.jcbfm.9600106; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pru James K, 2003, Reprod Biol Endocrinol, V1, P17, DOI 10.1186/1477-7827-1-17; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Rudic RD, 2005, CIRC RES, V96, P1240, DOI 10.1161/01.RES.0000170888.11669.28; Sabri A, 2003, J BIOL CHEM, V278, P11714, DOI 10.1074/jbc.M213091200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Sato T, 1999, J PHARMACOL TOX MET, V41, P173, DOI 10.1016/S1056-8719(99)00039-8; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SHIROTANI M, 1991, PROSTAG OTH LIPID M, V41, P97, DOI 10.1016/0090-6980(91)90023-9; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tang H, 2005, BLOOD, V105, P1977, DOI 10.1182/blood-2004-08-3308; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang Y, 2004, CIRC RES, V95, P84, DOI 10.1161/01.RES.0000133679.38825.a6; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9	56	87	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11792	11804		10.1074/jbc.M509292200	http://dx.doi.org/10.1074/jbc.M509292200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16467309	Green Published, hybrid			2022-12-25	WOS:000236988100045
J	da Silva, GFZ; Reuille, RL; Ming, LJ; Livingston, BT				da Silva, GFZ; Reuille, RL; Ming, LJ; Livingston, BT			Overexpression and mechanistic characterization of blastula protease 10, a metalloprotease involved in sea urchin embryogenesis and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; ZINC-ENDOPEPTIDASE; CRYSTAL-STRUCTURE; LYSYL OXIDASE; ASTACIN; ACTIVATION; EXPRESSION; COLLAGEN; MATRIX; DERIVATIVES	Blastula protease 10 (BP10) is a metalloenzyme involved in sea urchin embryogenesis, which has been assigned to the astacin family of zinc-dependent endopeptidases. It shows greatest homology with the mammalian tolloid-like genes and contains conserved structural motifs consistent with astacin, tolloid, and bone morphogenetic protein 1. Astacin, a crustacean digestive enzyme, has been proposed to carry out hydrolysis via a metal-centered mechanism that involves a metal-coordinated "tyrosine switch." It has not been determined if the more structurally complex members of this family involved in eukaryotic development share this mechanism. The recombinant BP10 has been overexpressed in Escherichia coli, its metalloenzyme nature has been confirmed, and its catalytic properties have been characterized through kinetic studies. BP10 shows significant hydrolysis toward gelatin both in its native zinc-containing form and copper derivative. The copper derivative of BP10 shows a remarkable 960% rate acceleration toward the hydrolysis of the synthetic substrate N-benzoyl-arginine-p-nitroanilide when compared with the zinc form. The enzyme also shows calcium-dependent activation. These are the first thorough mechanistic studies reported on BP10 as a representative of the more structurally complex members of astacin-type enzymes in deuterostomes, which can add supporting data to corroborate the metal-centered mechanism proposed for astacin and the role of the coordinated Tyr. We have demonstrated the first mechanistic study of a tolloid-related metalloenzyme involved in sea urchin embryogenesis.	Univ S Florida, Dept Biol, Tampa, FL 33620 USA; Univ S Florida, Dept Chem, Tampa, FL 33620 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ming, LJ (corresponding author), Univ S Florida, Dept Biol, 4202 E Fowler Ave, Tampa, FL 33620 USA.	ming@shell.cas.usf.edu; blivings@cas.usf.edu						APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Bertini I., 1994, BIOINORG CHEM, P37; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; CALLOWAY C, 2003, BIOCHIM BIOPHYS ACTA, V1621, P67; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Frey ST, 1997, INORG CHEM, V36, P956, DOI 10.1021/ic961439o; Friedman M, 2004, J AGR FOOD CHEM, V52, P385, DOI 10.1021/jf030490p; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; GRUBB JD, 1994, METHOD ENZYMOL, V235, P602; Hanafy AI, 2005, INORG CHIM ACTA, V358, P1247, DOI 10.1016/j.ica.2004.10.024; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HEGG EL, 2005, COORDIN CHEM REV, V173, P133; HOOPER NM, 1996, ZINC METALLOPROTEASE, P23; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; KARAKIULAKIS G, 1993, J CELL BIOCHEM, V52, P92, DOI 10.1002/jcb.240520113; Kimura E, 1997, ADV INORG CHEM, V44, P229; KIMURA E, 1994, PROG INORG CHEM, V41, P443, DOI 10.1002/9780470166420.ch6; LEPAE T, 1996, EUR J BIOCHEM, V238, P744; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mayne J, 1998, J CELL BIOCHEM, V71, P546, DOI 10.1002/(SICI)1097-4644(19981215)71:4<546::AID-JCB9>3.0.CO;2-Y; Mohrlen F, 2003, EUR J BIOCHEM, V270, P4909, DOI 10.1046/j.1432-1033.2003.03891.x; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Park HI, 1998, J INORG BIOCHEM, V72, P57, DOI 10.1016/S0162-0134(98)10063-6; Park HI, 2002, J BIOL INORG CHEM, V7, P600, DOI 10.1007/s00775-002-0338-2; QUIGLEY JP, 1993, DIFFERENTIATION, V54, P19, DOI 10.1111/j.1432-0436.1993.tb00655.x; Sharpe C, 2001, BIOCHEM CELL BIOL, V79, P461; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOCKER W, 1995, PROTEIN SCI, V4, P823; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VAFA O, 1995, MOL REPROD DEV, V40, P36, DOI 10.1002/mrd.1080400106; Wardle FC, 1999, DEV BIOL, V206, P63, DOI 10.1006/dbio.1998.9127; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5	44	11	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10737	10744		10.1074/jbc.M510707200	http://dx.doi.org/10.1074/jbc.M510707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492671	hybrid			2022-12-25	WOS:000236822200012
J	Hashemy, SI; Ungerstedt, JS; Avval, FZ; Holmgren, A				Hashemy, SI; Ungerstedt, JS; Avval, FZ; Holmgren, A			Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHOLE-BRAIN RADIATION; MAMMALIAN THIOREDOXIN; IONIZING-RADIATION; RECOMBINANT MOUSE; INDUCED APOPTOSIS; ESCHERICHIA-COLI; ACTIVE-SITE; CELL-LINES; SELENOCYSTEINE; MECHANISM	Motexafin gadolinium (MGd) is a chemotherapeutic drug that selectively targets tumor cells and mediates redox reactions generating reactive oxygen species. Thioredoxin (Trx), NADPH, and thioredoxin reductase (TrxR) of the cytosol/nucleus or mitochondria are major thiol-dependent reductases with many functions in cell growth, defense against oxidative stress, and apoptosis. Mammalian TrxRs are selenocysteine-containing flavoenzymes; MGd was an NADPH-oxidizing substrate for human or rat TrxR1 with a K-m value of 8.65 mu M (k(cat)/K-m of 4.86 x 10(4) M-1 s(-1)). The reaction involved redox cycling of MGd by oxygen producing superoxide and hydrogen peroxide. MGd acted as a non-competitive inhibitor (IC50 of 6 mu M) for rat TrxR. In contrast, direct reaction between MGd and reduced human Trx was negligible. The corresponding reaction with reduced Escherichia coli Trx was also negligible, but MGd was a better substrate (k(cat)/K-m of 2.23 x 10(5) M-1 s(-1)) for TrxR from E. coli and a strong inhibitor of Trx-dependent protein disulfide reduction. Ribonucleotide reductase (RNR), a 1:1 complex of the non-identical R1- and R2-subunits, catalyzes the essential de novo synthesis of deoxyribonucleotides for DNA synthesis using electrons from Trx and TrxR. MGd inhibited recombinant mouse RNR activity with either 3 mu M reduced human Trx (IC50 2 mu M) or 4 mM dithiothreitol (IC50 6 mu M) as electron donors. Our results demonstrate MGd-induced enzymatic generation of reactive oxygen species by TrxR plus a powerful inhibition of RNR. This may explain the effects of the drug on cancer cells, which often overproduce TrxR and have induced RNR for replication and repair.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@mbb.ki.se	Ungerstedt, Johanna/C-7004-2014; Hashemy, Seyed Isaac/A-2693-2017	Hashemy, Seyed Isaac/0000-0002-1323-5250; Zahedi Avval, Farnaz/0000-0001-8915-3596				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Berggren M, 1996, ANTICANCER RES, V16, P3459; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Donnelly ET, 2004, INT J RADIAT ONCOL, V58, P1570, DOI 10.1016/j.ijrobp.2003.12.017; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Evens AM, 2005, BLOOD, V105, P1265, DOI 10.1182/blood-2004-03-0964; Evens Andrew M, 2005, Curr Treat Options Oncol, V6, P289, DOI 10.1007/s11864-005-0033-y; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 2003, SIGNAL TRANSDUCTION, P33; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kahlos K, 2001, INT J CANCER, V95, P198, DOI 10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F; Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007; Magda D, 2005, CANCER RES, V65, P3837, DOI 10.1158/0008-5472.CAN-04-4099; Magda D, 2002, EUR J CANCER, V38, pS26; Magda D, 2001, INT J RADIAT ONCOL, V51, P1025, DOI 10.1016/S0360-3016(01)01810-7; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Mehta MP, 2002, J CLIN ONCOL, V20, P3445, DOI 10.1200/JCO.2002.07.500; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Miller FJ, 2002, METHOD ENZYMOL, V353, P220; Miller RA, 2001, CLIN CANCER RES, V7, P3215; Nilsson J, 2000, BLOOD, V95, P1420, DOI 10.1182/blood.V95.4.1420.004k12_1420_1426; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Sessler JL, 2000, BIOCHEM PHARMACOL, V59, P733, DOI 10.1016/S0006-2952(99)00314-7; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Xu S, 2001, INT J RADIAT ONCOL, V49, P1381, DOI 10.1016/S0360-3016(00)01566-2; Young SW, 1996, P NATL ACAD SCI USA, V93, P6610, DOI 10.1073/pnas.93.13.6610; ZAWIRSKA B, 1979, NEOPLASMA, V26, P223; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	48	136	151	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10691	10697		10.1074/jbc.M511373200	http://dx.doi.org/10.1074/jbc.M511373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481328	hybrid			2022-12-25	WOS:000236822200007
J	Takahashi, K; Kimura, Y; Kioka, N; Matsuo, M; Ueda, K				Takahashi, K; Kimura, Y; Kioka, N; Matsuo, M; Ueda, K			Purification and ATPase activity of human ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; APOLIPOPROTEIN-A-I; MULTIDRUG-RESISTANCE PROTEINS; HIGH-DENSITY-LIPOPROTEIN; P-GLYCOPROTEIN; NUCLEOTIDE-BINDING; EXTRACELLULAR DOMAIN; PHOSPHOLIPID EFFLUX; INORGANIC-PHOSPHATE; CHOLESTEROL EFFLUX	ATP-binding cassette protein A1 (ABCA1) plays a major role in cholesterol homeostasis and high density lipoprotein metabolism. Apolipoprotein A-I binds to ABCA1 and cellular cholesterol and phospholipids, mainly phosphatidylcholine, are loaded onto apoA-I to form pre-beta high density lipoprotein (HDL). It is proposed that ABCA1 translocates phospholipids and cholesterol directly or indirectly to form pre-beta HDL. To explore the mechanism of ABCA1-mediated pre-beta HDL formation, we expressed human ABCA1 in insect Sf9 cells and purified it. Trypsin limited-digestion of purified ABCA1 in the detergent-soluble form suggested that it retained conformation similar to ABCA1 expressed in the membranes of human fibroblast WI-38 cells. Purified ABCA1 showed robust ATPase activity when reconstituted in liposomes made of synthetic phosphatidylcholine. ABCA1 showed lower ATPase activity when reconstituted in liposomes containing phosphatidylserine, phosphatidylethanolamine, or phosphatidylglycerol and also showed weak specificity in acyl chain species. ATPase activity was reduced by the addition of cholesterol and decreased by 25% in the presence of 20% cholesterol. beta-Sitosterol and campesterol showed similar inhibitory effects but stigmasterol did not, suggesting structure-specific interaction between ABCA1 and sterols. Glibenclamide suppressed ABCA1 ATPase, suggesting that it inhibits apoA-I-dependent cellular cholesterol efflux by suppressing ABCA1 ATPase activity. These results suggest that the ATPase activity of ABCA1 is stimulated preferentially by phospholipids with choline head groups, phosphatidylcholine and sphingomyelin. This study with purified human ABCA1 provides the first biochemical basis of the mechanism for HDL formation mediated by ABCA1.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Kimura, Yasuhisa/0000-0001-6466-1324; Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DRUECKES P, 1995, ANAL BIOCHEM, V230, P173, DOI 10.1006/abio.1995.1453; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Francone OL, 2003, BIOCHEMISTRY-US, V42, P8569, DOI 10.1021/bi034540v; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hayashi M, 2005, J LIPID RES, V46, P1703, DOI 10.1194/jlr.M500092-JLR200; Julien M, 2000, BIOCHEMISTRY-US, V39, P75, DOI 10.1021/bi991726e; Kimura Y, 2004, ANAL BIOCHEM, V326, P262, DOI 10.1016/j.ab.2003.12.012; Kimura Y, 2004, CURR DRUG METAB, V5, P1, DOI 10.2174/1389200043489090; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Roosbeek S, 2004, J BIOL CHEM, V279, P37779, DOI 10.1074/jbc.M401821200; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7215; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	43	78	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10760	10768		10.1074/jbc.M513783200	http://dx.doi.org/10.1074/jbc.M513783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500904	hybrid			2022-12-25	WOS:000236822200015
J	Yamada, T; Ohtani, S; Sakurai, T; Tsuji, T; Kunieda, T; Yanagisawa, M				Yamada, T; Ohtani, S; Sakurai, T; Tsuji, T; Kunieda, T; Yanagisawa, M			Reduced expression of the endothelin receptor type B gene in piebald mice caused by insertion of a retroposon-like element in intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; NEURAL CREST DEVELOPMENT; 9-CIS RETINOIC ACID; AGANGLIONIC MEGACOLON; MOLECULAR-BIOLOGY; LEADER SEQUENCE; COAT COLOR; MOUSE; CELLS; MUTATIONS	Mice carrying the piebald mutation exhibit white coat spotting due to the regional absence of neural crest-derived melanocytes. We reported previously that the piebald locus encodes the Ednrb gene and that piebald mice express low levels of structurally intact Ednrb mRNA and EDNRB protein (Hosoda, K., Hammer, R. E., Richardson, J. A., Baynash, A. G., Cheung, J. C., Giaid, A., and Yanagisawa, M. (1994) Cell 79, 1267-1276). Here, we report that both the life span of the Ednrb mRNA and the promoter activity of the Ednrb gene are indistinguishable between wild-type and piebald mice. Introns 2-6 of the Ednrb gene in piebald mice were correctly excised with an efficiency indistinguishable from those in wild-type mice in exon trapping experiments. We found that the piebald allele of the Ednrb gene has a 5.5-kb retroposon-like element in intron 1 possessing canonical sequences of a polyadenylation signal and a splice acceptor site. Abnormal hybrid transcripts carrying exon 1 of the Ednrb gene and a portion of the 5.5-kb element are expressed in piebald mice. The insertion of the 5.5-kb element into a heterologous intron in a mammalian expression vector markedly reduced the expression of the reporter gene. Premature termination and aberrant splicing of the Ednrb transcript caused by the retroposon-like element in intron 1 lead to a reduced level of the normal Ednrb transcript, which is responsible for the partial loss-of-function phenotype of piebald mice.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Okayama University	Yamada, T (corresponding author), Kyoto Univ, Grad Sch Agr, Lab Anim Breeding & Genet, Sakyo Ku, Kyoto 6068502, Japan.	tyamada@kais.kyoto-u.ac.jp						ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; Baust C, 2003, J VIROL, V77, P11448, DOI 10.1128/JVI.77.21.11448-11458.2003; Baust C, 2002, MAMM GENOME, V13, P423, DOI 10.1007/s00335-002-2178-3; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Berg DE, 1989, MOBILE DNA; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Gariepy CE, 1996, P NATL ACAD SCI USA, V93, P867, DOI 10.1073/pnas.93.2.867; Gitler AD, 2002, COLD SPRING HARB SYM, V67, P57, DOI 10.1101/sqb.2002.67.57; HARRISON GP, 1995, J VIROL, V69, P2175, DOI 10.1128/JVI.69.4.2175-2186.1995; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hertz L., 1989, DISSECTION TISSUE CU, P105; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMOKAWA G, 1982, CANCER RES, V42, P1994; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; Kurihara H, 1999, CELL MOL BIOL, V45, P639; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; Le Douarin NM, 1999, NEURAL CREST, V2; Lee HO, 2003, DEV BIOL, V259, P162, DOI 10.1016/S0012-1606(03)00160-X; Leong WL, 2000, MAMM GENOME, V11, P97, DOI 10.1007/s003350010020; LIM R, 1990, CELL CULTURE, V2, P47; Lyon M., 1989, GENETIC VARIANTS STR; Mager DL, 2000, J VIROL, V74, P7221, DOI 10.1128/JVI.74.16.7221-7229.2000; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; Maschhoff KL, 2000, AM J MED GENET, V97, P280, DOI 10.1002/1096-8628(200024)97:4<280::AID-AJMG1278>3.0.CO;2-N; Peterfy M, 1998, GENE, V216, P225, DOI 10.1016/S0378-1119(98)00321-7; Pla P, 2003, INT J DEV BIOL, V47, P315; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; UEHARA H, 1990, GENETICS, V126, P1093; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	52	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10799	10807		10.1074/jbc.M512618200	http://dx.doi.org/10.1074/jbc.M512618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16500897	hybrid			2022-12-25	WOS:000236822200019
J	Calipel, A; Mouriaux, F; Glotin, AL; Malecaze, F; Faussat, AM; Mascarelli, F				Calipel, A; Mouriaux, F; Glotin, AL; Malecaze, F; Faussat, AM; Mascarelli, F			Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE BRAF; B-RAF; MAP KINASE; MALIGNANT MELANOMAS; TUMOR PROGRESSION; MUTATIONS; CAMP; MELANOCYTES; ACTIVATION; GROWTH	Mutated B-Raf-mediated constitutive activation of ERK1/2 is involved in about 66% of cutaneous melanoma. By contrast, activating mutations in B-RAF are rare in ocular melanoma. This study aimed to determine the role of wild-type B-Raf (B-WT-Raf) in uveal melanoma cell growth. We used cell lines derived from primary tumors of uveal melanoma to assess the role of B-WT-Raf in cell proliferation and to characterize its upstream regulators and downstream effectors. Melanoma cell lines expressing B-WT-Raf and (WT)Ras grew with similar proliferation rates, showed constitutive activation of ERK1/2, and had similar levels of B-Raf expression and B-Raf kinase activity as melanoma cell lines expressing the activating V600E mutation (B-V600E-Raf). They were equally as sensitive to pharmacological inhibition of MEK1/2 for cell proliferation and transformation as (EB)-E-V600-Raf cells. siRNA-mediated depletion of Raf-1 did not affect either ERK1/2 activation, whereas siRNA-mediated depletion of B-Raf reduced cell proliferation by up to 65% through the inhibition of ERK1/2 activation, irrespective of the mutational status of B-Raf. Pharmacological inhibition of cAMP-dependent protein kinase (PKA) and siRNA-mediated depletion of PKA greatly reduced B-Raf activity, ERK1/2 activation, and cell proliferation in B-WT-Raf cells, whereas it did not affect B-V600E-Raf cells, demonstrating a key role of PKA in mediating B-WT-Raf/ERK signaling for uveal melanoma cell growth. Moreover, inactivation or depletion of PKA did not affect Rap-1 activity, and Rap-1 depletion did not affect either B-Raf activity or ERK1/2 activation. This ruled out a role for Rap1 in the PKA-mediated B-Raf/ERK activation in B-WT-Raf cells. Finally, we demonstrated the importance of cyclin D1 in mediating PKA/B-WT-Raf signaling for cell proliferation. Altogether, our results suggest that the PKA/B-Raf pathway is a potential target for therapeutic strategies against B-WT-Raf-expressing uveal melanoma.	INSERM, Inst Biomed Cordeliers, U598, F-75006 Paris, France; CHU Caen, Serv Ophtalmol, F-14000 Caen, France; Hop Purpan, CHRU, Serv Ophthalmol, F-31000 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Toulouse	Mascarelli, F (corresponding author), INSERM, Inst Biomed Cordeliers, U598, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mouriaux, Frederic/T-1440-2019; Mascarelli, Frederic/L-8916-2018					BECKER D, 1990, ONCOGENE, V5, P1133; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Crepieux P, 2001, ONCOGENE, V20, P4696, DOI 10.1038/sj.onc.1204632; Cruz F, 2003, CANCER RES, V63, P5761; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gear J, 2004, INVEST OPHTH VIS SCI, V45, P2484, DOI 10.1167/iovs.04-0093; Hingorani SR, 2003, CANCER RES, V63, P5198; Hu DN, 2000, EXP EYE RES, V70, P113, DOI 10.1006/exer.1999.0760; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kilic E, 2004, MELANOMA RES, V14, P203, DOI 10.1097/cmr.0000130006.46885.a0; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Lou TF, 2003, OLIGONUCLEOTIDES, V13, P313, DOI 10.1089/154545703322616998; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; Mouriaux F, 2001, EXP EYE RES, V73, P151, DOI 10.1006/exer.2001.1017; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Rimoldi D, 2003, CANCER RES, V63, P5712; Saavedra AP, 2002, ONCOGENE, V21, P778, DOI 10.1038/sj.onc.1205123; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Spendlove HE, 2004, MELANOMA RES, V14, P449, DOI 10.1097/00008390-200412000-00003; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	49	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9238	9250		10.1074/jbc.M600228200	http://dx.doi.org/10.1074/jbc.M600228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452469	hybrid			2022-12-25	WOS:000236404700031
J	Yang, JM; O'Neill, P; Jin, W; Foty, R; Medina, DJ; Xu, ZD; Lomas, M; Arndt, GM; Tang, Y; Nakada, M; Yan, L; Hait, WN				Yang, JM; O'Neill, P; Jin, W; Foty, R; Medina, DJ; Xu, ZD; Lomas, M; Arndt, GM; Tang, Y; Nakada, M; Yan, L; Hait, WN			Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; FOCAL ADHESION KINASE; TUMOR PROGRESSION; GROWTH-FACTOR; EXPRESSION; APOPTOSIS; EMMPRIN; PROTEIN; FIBRONECTIN; METASTASIS	Overexpression of extracellular matrix metalloproteinase inducer ( EMMPRIN or CD147), a member of the immunoglobulin family and a glycoprotein enriched on the surface of tumor cells, promotes invasion, metastasis, and growth and survival of malignant cells and confers resistance to some chemotherapeutic drugs. However, the molecular mechanisms underlying the actions of EMMPRIN are not fully understood. In this study we sought to determine whether EMMPRIN contributes to the malignant phenotype of breast cancer by inhibiting anoikis, a form of apoptosis induced by loss or alteration of cell-cell or cell-matrix anchorage, and to explore the signaling pathways involved. We found that in the absence of attachment, human breast carcinoma cells expressing high levels of EMMPRIN formed less compact aggregates with larger surface area and less fibronectin matrix assembly, had higher viability, and were resistant to anoikis. Knockdown of EMMPRIN expression by RNA interference ( small interfering RNA or short hairpin RNA) sensitized cancer cells to anoikis, as demonstrated by activation of caspase-3, increased DNA fragmentation, and decreased cellular viability. Furthermore, we observed that the accumulation of Bim, a proapoptotic BH3-only protein, was reduced in EMMPRIN-expressing cells and that silencing of EMMPRIN expression elevated Bim protein levels and enhanced cellular sensitivity to anoikis. Treatment of cells with a MEK inhibitor (U0126) or proteasome inhibitor ( epoxomicin) also up-regulated Bim accumulation and rendered cells more sensitive to anoikis. These results indicated that expression of EMMPRIN protects cancer cells from anoikis and that this effect is mediated at least in part by a MAP kinase-dependent reduction of Bim. Because anoikis deficiency is a key feature of neoplastic transformation and invasive growth of epithelial cancer cells, our study on the role of EMMPRIN in anoikis resistance and the mechanism involved underscores the potential of EMMPRIN expression as a prognostic marker and novel target for cancer therapy.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Centocor Inc, Oncol Res, Malvern, PA 19355 USA; Johnson & Johnson Res, Sydney, NSW 1430, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson	Yang, JM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08901 USA.	jyang@umdnj.edu; haitwn@umdnj.edu	Medina, Daniel/B-8196-2013	Medina, Daniel/0000-0003-4830-6941	NCI NIH HHS [CA 66077, CA 72720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066077, P30CA072720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Curtin KD, 2005, J CELL SCI, V118, P2649, DOI 10.1242/jcs.02408; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Davidson B, 2004, CLIN CANCER RES, V10, P7335, DOI 10.1158/1078-0432.CCR-04-0183; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Marieb EA, 2004, CANCER RES, V64, P1229, DOI 10.1158/0008-5472.CAN-03-2832; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Reimers N, 2004, CLIN CANCER RES, V10, P3422, DOI 10.1158/1078-0432.CCR-03-0610; Robinson EE, 2004, MOL BIOL CELL, V15, P973, DOI 10.1091/mbc.E03-07-0528; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tang Y, 2004, MOL CANCER RES, V2, P73; Toole BP, 2003, CURR TOP DEV BIOL, V54, P371, DOI 10.1016/S0070-2153(03)54015-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Yang JM, 2003, MOL CANCER RES, V1, P420; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847; Zhang Y, 2004, J BIOL CHEM, V279, P48342, DOI 10.1074/jbc.M407953200; Zhivotovsky B, 2003, ESSAYS BIOCHEM, V39, P25, DOI 10.1042/bse0390025; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	37	93	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9719	9727		10.1074/jbc.M508421200	http://dx.doi.org/10.1074/jbc.M508421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16443928	hybrid			2022-12-25	WOS:000236404700084
J	Santucci, L; Mencarelli, A; Renga, B; Pasut, G; Veronese, F; Zacheo, A; Germani, A; Fiorucci, S				Santucci, Luca; Mencarelli, Andrea; Renga, Barbara; Pasut, Gianfranco; Veronese, Francesco; Zacheo, Antonella; Germani, Antonia; Fiorucci, Stefano			Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin	FASEB JOURNAL			English	Article						anthracycline-induced miocardiopathy; cell apoptosis; HUVEC; mitochondrial membrane depolarization; colon cancer cells	DOXORUBICIN INDUCES APOPTOSIS; CANCER CELLS; MITOCHONDRIAL DYSFUNCTION; ANTIINFLAMMATORY DRUGS; ENDOTHELIAL-CELLS; GROWTH-INHIBITION; CARDIOTOXICITY; SURVIVIN; GENE; CARDIOMYOCYTE	The use of the anthracycline epirubicin (EPI) is limited by the risk of a dilatory congestive heart failure that develops as a consequence of induction of a mitochondrial-dependent cardiomyocyte and endothelial cell apoptosis. Nitric oxide ( NO) increases the antitumoral activity of several chemotherapics, while it provides protection against apoptosis induced by oxidative stress both in endothelial cells and cardiomyocytes. The aim of the present study was to investigate whether the addition of an NO-releasing moiety to a pegylated derivative of EPI (p-EPI-NO) confers to the drug a different cytotoxic profile against tumoral and normal cells. The cytotoxic profile of the drugs was investigated in Caco-2 cell line, in embryonic rat heart-derived myoblasts (H9c2), in adult cardiomyocytes, and in endothelial cells (HUVEC). p-EPI-NO was more efficient than EPI in inducing Caco-2 cell apoptosis, while it spared HUVEC, H9c2 cells and adult cardiomyocytes from EPI-induced toxicity. Exposure of cells to p-EPI-NO resulted in a NO-mediated inhibition of cellular respiration followed by mitochondrial membrane depolarization and cell death in Caco-2 cells but not in HUVEC and H9c2 cells in which mitochondrial membrane polarization was maintained at the expense of glycolytically generated ATP. These findings indicate that addition of an NO-releasing moiety to p-EPI increases the anti-neoplastic activity of the drug, while it reduces its cytotoxicity against nonneoplastic cells.	Univ Perugia, Dept Clin & Expt Med, Clin Gastroenterol & Epatol, I-06122 Perugia, Italy; Univ Padua, Dept Pharmaceut Sci, Padua, Italy; Ist Ricovero & Cura Carattere Sci, Lab Patol Vasc, Ist Dermopat Immacolata, Rome, Italy; Ist Ricovero & Cura Carattere Sci, Lab Biol Vasc & Terapia Gen, Ctr Cardiol Fdn Monzino, Rome, Italy	University of Perugia; University of Padua; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Santucci, L (corresponding author), Univ Perugia, Dept Clin & Expt Med, Clin Gastroenterol & Epatol, Via Enrico Pozzo, I-06122 Perugia, Italy.	lsant@unipg.it	Pasut, Gianfranco/I-5944-2012; Zacheo, Antonella/AAI-1422-2020; Fiorucci, Stefano/I-1251-2012	Pasut, Gianfranco/0000-0002-8754-0899; 				Adams DJ, 2001, LEUKEMIA, V15, P1852, DOI 10.1038/sj.leu.2402291; Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arola OJ, 2000, CANCER RES, V60, P1789; Bellarosa D, 2001, J PHARMACOL EXP THER, V296, P276; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Chan EM, 1996, CAN J PHYSIOL PHARM, V74, P904, DOI 10.1139/cjpp-74-8-904; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; Chang Q, 2004, WORLD J GASTROENTERO, V10, P415; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Childs AC, 2002, CANCER RES, V62, P4592; Chung P, 2003, NITRIC OXIDE-BIOL CH, V8, P119, DOI 10.1016/S1089-8603(02)00147-7; Cook JA, 1997, BRIT J CANCER, V76, P325, DOI 10.1038/bjc.1997.386; Cook T, 2004, CANCER RES, V64, P8015, DOI 10.1158/0008-5472.CAN-04-2212; Delikouras A, 2001, TRANSPLANTATION, V71, P599, DOI 10.1097/00007890-200103150-00004; Evig CB, 2004, NITRIC OXIDE-BIOL CH, V10, P119, DOI 10.1016/j.niox.2004.03.006; Fiorucci S, 2004, J IMMUNOL, V173, P874, DOI 10.4049/jimmunol.173.2.874; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Gupta S, 1998, CANCER RES, V58, P1785; Huguenin S, 2004, PROSTATE, V61, P132, DOI 10.1002/pros.20081; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jensen BV, 2002, ANN ONCOL, V13, P699, DOI 10.1093/annonc/mdf132; Kelso EJ, 1997, J MOL CELL CARDIOL, V29, P3385, DOI 10.1006/jmcc.1997.0563; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; Lavagna C, 2003, CURR CANCER DRUG TAR, V3, P407, DOI 10.2174/1568009033481750; Leri A, 1999, CIRC RES, V84, P752; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LLESUY SF, 1990, FREE RADICAL BIO MED, V8, P259, DOI 10.1016/0891-5849(90)90071-P; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Mitchell JB, 1996, BRIT J CANCER, V74, pS181; Monastyrskaya E, 2002, NITRIC OXIDE-BIOL CH, V7, P127, DOI 10.1016/S1089-8603(02)00107-6; Morpurgo Margherita, 2004, Methods Mol Biol, V283, P45; NIELSEN D, 1990, J CLIN ONCOL, V8, P1806, DOI 10.1200/JCO.1990.8.11.1806; Pai VB, 2000, DRUG SAFETY, V22, P263, DOI 10.2165/00002018-200022040-00002; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; RHODEN W, 1993, BRIT HEART J, V70, P499; Riganti C, 2005, CANCER RES, V65, P516; Ryberg M, 1998, J CLIN ONCOL, V16, P3502, DOI 10.1200/JCO.1998.16.11.3502; Sacco G, 2003, BRIT J PHARMACOL, V139, P641, DOI 10.1038/sj.bjp.0705270; Santucci L, 2005, GASTROENTEROLOGY, V128, P1243, DOI 10.1053/j.gastro.2005.01.051; SEYMOUR LW, 1994, BRIT J CANCER, V70, P636, DOI 10.1038/bjc.1994.363; Spallarossa P, 2004, J MOL CELL CARDIOL, V37, P837, DOI 10.1016/j.yjmcc.2004.05.024; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407; Tsang WP, 2003, LIFE SCI, V73, P2047, DOI 10.1016/S0024-3205(03)00566-6; Walford G, 2003, J THROMB HAEMOST, V1, P2112, DOI 10.1046/j.1538-7836.2003.00345.x; Wallace KB, 2003, PHARMACOL TOXICOL, V93, P105, DOI 10.1034/j.1600-0773.2003.930301.x; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992; Wink DA, 1997, NITRIC OXIDE-BIOL CH, V1, P88, DOI 10.1006/niox.1996.0108; Working PK, 1999, J PHARMACOL EXP THER, V289, P1128; Wu S, 2002, J MOL CELL CARDIOL, V34, P1595, DOI 10.1006/jmcc.2002.2110; Yeh RK, 2004, BIOCHEM PHARMACOL, V67, P2197, DOI 10.1016/j.bcp.2004.02.027; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	56	39	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					765	+		10.1096/fj.05-4452fje	http://dx.doi.org/10.1096/fj.05-4452fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455756				2022-12-25	WOS:000237698700042
J	Glaviano, A; Nayak, V; Cabuy, E; Baird, DM; Yin, Z; Newson, R; Ladon, D; Rubio, MA; Slijepcevic, P; Lyng, F; Mothersill, C; Case, CP				Glaviano, A.; Nayak, V.; Cabuy, E.; Baird, D. M.; Yin, Z.; Newson, R.; Ladon, D.; Rubio, M. A.; Slijepcevic, P.; Lyng, F.; Mothersill, C.; Case, C. P.			Effects of hTERT on metal ion-induced genomic instability	ONCOGENE			English	Article						chromium; vanadium; hTERT; genomic instability; carcinogenesis	TELOMERE LENGTH; CHROMOSOMAL INSTABILITY; GENE-EXPRESSION; HUMAN-CELLS; IONIZING-RADIATION; CELLULAR-RESPONSE; HUMAN FIBROBLASTS; LETHAL MUTATIONS; MAMMALIAN-CELLS; ANEUPLOID CELLS	There is currently a great interest in delayed chromosomal and other damaging effects of low-dose exposure to a variety of pollutants which appear collectively to act through induction of stress-response pathways related to oxidative stress and ageing. These have been studied mostly in the radiation field but evidence is accumulating that the mechanisms can also be triggered by chemicals, especially heavy metals. Humans are exposed to metals, including chromium (Cr) (VI) and vanadium (V) (V), from the environment, industry and surgical implants. Thus, the impact of low-dose stress responses may be larger than expected from individual toxicity projections. In this study, a short (24 h) exposure of human fibroblasts to low doses of Cr (VI) and V (V) caused both acute chromosome damage and genomic instability in the progeny of exposed cells for at least 30 days after exposure. Acutely, Cr (VI) caused chromatid breaks without aneuploidy while V (V) caused aneuploidy without chromatid breaks. The longer-term genomic instability was similar but depended on hTERT positivity. In telomerase-negative hTERT - cells, Cr (VI) and V (V) caused a long lasting and transmissible induction of dicentric chromosomes, nucleoplasmic bridges, micronuclei and aneuploidy. There was also a long term and transmissible reduction of clonogenic survival, with an increased beta-galactosidase staining and apoptosis. This instability was not present in telomerase-positive hTERT+ cells. In contrast, in hTERT+ cells the metals caused a persistent induction of tetraploidy, which was not noted in hTERT - cells. The growth and survival of both metal-exposed hTERT+ and hTERT+ cells differed if they were cultured at subconfluent levels or plated out as colonies. Genomic instability is considered to be a driving force towards cancer. This study suggests that the type of genomic instability in human cells may depend critically on whether they are telomerase-positive or - negative and that their sensitivities to metals could depend on whether they are clustered or diffuse.	Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England; Dublin Inst Technol, Radiat & Environm Sci Ctr, Dublin 8, Ireland; Brunel Univ, Uxbridge UB8 3PH, Middx, England; Cardiff Univ, Dept Pathol, Sch Med, Cardiff, S Glam, Wales; Kings Coll London, Dept Publ Hlth Serv, London WC2R 2LS, England; Netherlands Canc Inst, Amsterdam, Netherlands	University of Bristol; Technological University Dublin; Brunel University; Cardiff University; University of London; King's College London; Netherlands Cancer Institute	Case, CP (corresponding author), Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England.	cpcase@hotmail.com	Baird, Duncan M/C-9671-2011; Lyng, Fiona/AAD-2842-2020	Baird, Duncan M/0000-0001-8408-5467; Lyng, Fiona/0000-0002-9876-963X				Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cabuy E, 2004, CYTOM PART A, V62A, P150, DOI 10.1002/cyto.a.20096; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Cheng RYS, 2003, TOXICOL APPL PHARM, V191, P22, DOI 10.1016/S0041-008X(03)00228-X; Coen N, 2003, BRIT J CANCER, V88, P548, DOI 10.1038/sj.bjc.6600758; Coen N, 2001, J PATHOL, V195, P293; CORINNA M, 2003, CARCINOGENESIS, V24, P1183; Cui W, 2002, J BIOL CHEM, V277, P38531, DOI 10.1074/jbc.M205981200; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Ha LN, 2004, CARCINOGENESIS, V25, P2265, DOI 10.1093/carcin/bgh242; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HARDIN J, 2001, COLLEGE STATION; Henegariu O, 2001, CYTOMETRY, V43, P101, DOI 10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8; IARC, 1990, MON EV CARC RISK HUM; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P25, DOI 10.1016/S1383-5718(02)00138-9; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Koizumi S, 2003, J OCCUP HEALTH, V45, P331, DOI 10.1539/joh.45.331; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Luther MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE502, DOI 10.1152/ajpendo.00424.2004; McClintock B, 1941, GENETICS, V26, P234; McIlrath J, 2001, CANCER RES, V61, P912; Mese H, 2001, CHEMOTHERAPY, V47, P136, DOI 10.1159/000048513; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, MUTAT RES-FUND MOL M, V568, P121, DOI 10.1016/j.mrfmmm.2004.06.050; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; NIOSH (National Institute for Occupational Safety and Health), 1997, NIOSH POCK GUID CHEM; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; O'Brien TJ, 2003, MUTAT RES-FUND MOL M, V533, P3, DOI 10.1016/j.mrfmmm.2003.09.006; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pritchard DE, 2001, CELL GROWTH DIFFER, V12, P487; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Risques RA, 2003, CANCER RES, V63, P7206; Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; SABATIER L, 1994, INT J RADIAT BIOL, V66, P611, DOI 10.1080/09553009414551701; Sciandrello G, 2004, CARCINOGENESIS, V25, P413, DOI 10.1093/carcin/bgh029; SEONE AI, 2001, MUTAT RES, V490, P99; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; SMORGORZEWSKA A, 2002, CURR BIOL, V12, P1635; Sorensen M, 2005, CANCER EPIDEM BIOMAR, V14, P1340, DOI 10.1158/1055-9965.EPI-04-0899; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sugden Kent D., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P215; Thomas P, 2003, MUTAGENESIS, V18, P187, DOI 10.1093/mutage/18.2.187; TSUNETA Y, 1980, THORAX, V35, P294, DOI 10.1136/thx.35.4.294; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; World Health Organization (WHO), 2001, VAN PENT OTH IN VAN; Zhang Y, 2005, EUR J PHARMACOL, V516, P1, DOI 10.1016/j.ejphar.2005.04.022	76	30	30	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3424	3435		10.1038/sj.onc.1209399	http://dx.doi.org/10.1038/sj.onc.1209399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449970	Bronze			2022-12-25	WOS:000238448100007
J	Bampi, C; Bibillo, A; Wendeler, M; Divita, G; Gorelick, RJ; Le Grice, SFJ; Darlix, JL				Bampi, C; Bibillo, A; Wendeler, M; Divita, G; Gorelick, RJ; Le Grice, SFJ; Darlix, JL			Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA STRAND TRANSFER; RNASE-H ACTIVITY; IN-VITRO; VIRAL-DNA; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; CDNA INTEGRATION; MUTATION-RATE; LIFE-CYCLE; HOT-SPOT	During HIV replication, reverse transcriptase (RT), assisted by the nucleocapsid protein (NC), converts the genomic RNA into proviral DNA. This process appears to be the major source of genetic variability, as RT can misincorporate nucleotides during minus and plus strand DNA synthesis. To investigate nucleotide addition or substitution by RT, we set up in vitro models containing HIV-1 RNA, cDNA, NC, and various RTs. We used the wild type RT and azidothymidine- and didanosine-resistant RTs, because they represent the major forms of resistant RTs selected in patients undergoing therapies. Results show that all RTs can add nucleotides in a non-template fashion at the cDNA 3'end, a reaction stimulated by NC. Nucleotide substitutions were examined using in vitro systems where 3'-mutated cDNAs were extended by RT on an HIV-1 RNA template. With NC, RT extension of the mutated cDNAs was efficient, and surprisingly, mutations were frequently corrected. These results suggest for the first time that RT has excision-repair activity that is triggered by NC. Chaperoning of RT by NC might be explained by the fact that NC stabilizes an RT-DNA binary complex. In conclusion, RT-NC interactions appear to play critical roles in HIV-1 variability.	Ecole Normale Super Lyon, LaboRetro, INSERM, U412,Unite Virol Humaine,Inst Federat Rech 128, F-69364 Lyon 07, France; NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA; Ctr Rech Biochim Macromol, CNRS, Format Rech Evolut 2593, F-36293 Montpellier 05, France; NCI, AIDS Vaccine Program, Sci Applicat Int Corp Frederick Inc, NIH, Frederick, MD 21702 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Darlix, JL (corresponding author), Ecole Normale Super Lyon, LaboRetro, INSERM, U412,Unite Virol Humaine,Inst Federat Rech 128, 46 Allee Italie, F-69364 Lyon 07, France.	Jean-Luc.Darlix@ens-lyon.fr	LUC, DARLIX JEAN/AAE-9268-2020	Wendeler, Michaela/0000-0001-7503-5257	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BATTULA N, 1976, J BIOL CHEM, V251, P982; Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008; Darlix J L, 2000, Adv Pharmacol, V48, P345; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DeStefano JJ, 2000, VIROLOGY, V276, P7, DOI 10.1006/viro.2000.0533; Diaz L, 2000, ARCH VIROL, V145, P1117, DOI 10.1007/s007050070113; Diaz L, 1996, NUCLEIC ACIDS RES, V24, P3086, DOI 10.1093/nar/24.15.3086; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003; Golinelli MP, 2002, BIOCHEMISTRY-US, V41, P5894, DOI 10.1021/bi0160415; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Julias JG, 1997, J VIROL, V71, P4254, DOI 10.1128/JVI.71.6.4254-4263.1997; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Mansky LM, 2000, J VIROL, V74, P9532, DOI 10.1128/JVI.74.20.9532-9539.2000; Marchand B, 2004, INT J BIOCHEM CELL B, V36, P1823, DOI 10.1016/j.biocel.2004.02.029; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Oulton R, 2004, MOL BIOL CELL, V15, P3244, DOI 10.1091/mbc.E04-03-0178; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Poljak L, 2003, J MOL BIOL, V329, P411, DOI 10.1016/S0022-2836(03)00472-8; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; YU H, 1992, J BIOL CHEM, V267, P10888; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	50	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11736	11743		10.1074/jbc.M600290200	http://dx.doi.org/10.1074/jbc.M600290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500895	hybrid			2022-12-25	WOS:000236988100038
J	Bunker, JM; Kamath, K; Wilson, L; Jordan, MA; Feinstein, SC				Bunker, JM; Kamath, K; Wilson, L; Jordan, MA; Feinstein, SC			FTDP-17 mutations compromise the ability of Tau to regulate microtubule dynamics in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL MICROTUBULES; FRONTOTEMPORAL DEMENTIA; PROTEIN; GENE; PHOSPHORYLATION; INSTABILITY; MODULATION; TUBULIN; BINDING; MISSENSE	The neural microtubule-associated protein Tau binds directly to microtubules and regulates their dynamic behavior. In addition to being required for normal development, maintenance, and function of the nervous system, Tau is associated with several neurodegenerative diseases, including Alzheimer disease. One group of neurodegenerative dementias known as FTDP-17 ( frontotemporal dementia with Parkinsonism linked to chromosome 17) is directly linked genetically to mutations in the tau gene, demonstrating that Tau misfunction can cause neuronal cell death and dementia. These mutations result either in amino acid substitutions in Tau or in altered Tau mRNA splicing that skews the expression ratio of wild-type 3-repeat and 4-repeat Tau isoforms. Because wild-type Tau regulates microtubule dynamics, one possible mechanism underlying Tau-mediated neurodegeneration is aberrant regulation of microtubule behavior. In this study, we microinjected normal and mutated Tau protein into cultured cells expressing fluorescent tubulin and measured the effects on the dynamic instability of individual microtubules. We found that the FTDP-17 amino acid substitutions G272V ( in both 3-repeat and 4-repeat Tau contexts), Delta K280, and P301L all exhibited markedly reduced abilities to regulate dynamic instability relative to wild-type Tau. In contrast, the FTDP-17 R406W mutation ( which maps in a regulatory region outside the microtubule binding domain of Tau) did not significantly alter the ability of 3-repeat or 4-repeat Tau to regulate microtubule dynamics. Overall, these data are consistent with a loss-of-function model in which both amino acid substitutions and altered mRNA splicing in Tau lead to neurodegeneration by diminishing the ability of Tau to properly regulate microtubule dynamics.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Bldg 571,Rm 6129, Santa Barbara, CA 93106 USA.	feinstei@lifesci.ucsb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035010, R01NS013560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35010, NS13560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Delobel P, 2002, J BIOL CHEM, V277, P9199, DOI 10.1074/jbc.M107716200; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Goedert M, 1999, NAT MED, V5, P454, DOI 10.1038/7454; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 2006, IN PRESS MICROTUBULE; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; Lamb NJC, 1997, METHOD ENZYMOL, V283, P72; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Luduena RF, 1998, INT REV CYTOL, V178, P207; Machesky LM, 2003, CURR OPIN CELL BIOL, V15, P2, DOI 10.1016/S0955-0674(02)00016-9; Maiato H, 2004, INT REV CYTOL, V241, P53, DOI 10.1016/S0074-7696(04)41002-X; Nakao C, 2004, J BIOL CHEM, V279, P23014, DOI 10.1074/jbc.M313693200; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Popov AV, 2003, TRENDS CELL BIOL, V13, P547, DOI 10.1016/j.tcb.2003.09.006; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; ROSE GG, 1958, J BIOPHYS BIOCHEM CY, V4, P761, DOI 10.1083/jcb.4.6.761; Ruiz-Canada C, 2004, NEURON, V42, P567, DOI 10.1016/S0896-6273(04)00255-7; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; ZHAI Y, 1994, J CELL SCI, V107, P881; Zhou FQ, 2005, SCIENCE, V308, P211, DOI 10.1126/science.1110301; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569	58	77	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11856	11863		10.1074/jbc.M509420200	http://dx.doi.org/10.1074/jbc.M509420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495230	Green Published, hybrid			2022-12-25	WOS:000236988100052
J	Kinlough, CL; McMahan, RJ; Poland, PA; Bruns, JB; Harkleroad, KL; Stremple, RJ; Kashlan, OB; Weixel, KM; Weisz, OA; Hughey, RP				Kinlough, CL; McMahan, RJ; Poland, PA; Bruns, JB; Harkleroad, KL; Stremple, RJ; Kashlan, OB; Weixel, KM; Weisz, OA; Hughey, RP			Recycling of MUC1 is dependent on its palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; ACYL-PROTEIN THIOESTERASE-1; TRANS-GOLGI NETWORK; BETA-CATENIN; MEDIATED ENDOCYTOSIS; BREAST-CARCINOMA; CYTOPLASMIC TAIL; COLON-CARCINOMA	MUC1 is a mucin-like transmembrane protein expressed on the apical surface of epithelia, where it protects the cell surface. The cytoplasmic domain has numerous sites for phosphorylation and docking of proteins involved in signal transduction. In a previous study, we showed that the cytoplasmic YXX phi motif (YHPM)-H-20 and the tyrosine-phosphorylated (YTNP)-T-60 motif are required for MUC1 clathrin-mediated endocytosis through binding AP-2 and Grb2, respectively ( Kinlough, C. L., Poland, P. A., Bruns, J. B., Harkleroad, K. L., and Hughey, R. P. ( 2004) J. Biol. Chem. 279, 53071-53077). Palmitoylation of transmembrane proteins can affect their membrane trafficking, and the MUC1 sequence CQC(3)RRK at the boundary of the transmembrane and cytoplasmic domains mimics reported site( s) of S-palmitoylation. [ H-3] Palmitate labeling of Chinese hamster ovary cells expressing MUC1 with mutations in CQC3RRK revealed that MUC1 is dually palmitoylated at the CQC motif independent of RRK. Lack of palmitoylation did not affect the cold detergent solubility profile of a chimera ( Tac ectodomain and MUC1 transmembrane and cytoplasmic domains), the rate of chimera delivery to the cell surface, or its half-life. Calculation of rate constants for membrane trafficking of wild-type and mutant Tac-MUC1 indicated that the lack of palmitoylation blocked recycling, but not endocytosis, and caused the chimera to accumulate in a EGFP-Rab11-positive endosomal compartment. Mutations CQC/AQA and Y20N inhibited Tac-MUC1 co-immunoprecipitation with AP-1, although mutant Y20N had reduced rates of both endocytosis and recycling, but a normal subcellular distribution. The double mutant chimera AQA+Y20N had reduced endocytosis and recycling rates and accumulated in EGFP-Rab11-positive endosomes, indicating that palmitoylation is the dominant feature modulating MUC1 recycling from endosomes back to the plasma membrane.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, 933 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hughey@dom.pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK078734, T32DK061296, R01DK054787, P50DK056490, R01DK054407] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA9044] Funding Source: Medline; NIDDK NIH HHS [K01 DK078734, DK054787, P50-DK056490, T32-DK061296, DK054407] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; ARCASOY SM, 1998, AM J RESP CRIT CARE, V157, pA582; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bhattacharya J, 2004, J VIROL, V78, P5500, DOI 10.1128/JVI.78.10.5500-5506.2004; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Cheung JC, 2004, BIOCHEM J, V378, P1015, DOI 10.1042/BJ20030847; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Dietrich LEP, 2004, EMBO REP, V5, P1053, DOI 10.1038/sj.embor.7400277; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dolganiuc V, 2003, J VIROL, V77, P12968, DOI 10.1128/JVI.77.24.12968-12979.2003; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Duncan JA, 2002, J BIOL CHEM, V277, P31740, DOI 10.1074/jbc.M202505200; Engelmann K, 2005, GLYCOBIOLOGY, V15, P1111, DOI 10.1093/glycob/cwi099; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gubitosi-Klug RA, 2005, P NATL ACAD SCI USA, V102, P5964, DOI 10.1073/pnas.0501999102; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HANSKI C, 1995, CANCER RES, V55, P928; Herincs Z, 2005, J CELL SCI, V118, P1687, DOI 10.1242/jcs.02296; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; HILKENS J, 1988, J BIOL CHEM, V263, P4215; Hudson MJH, 1996, AM J PATHOL, V148, P951; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hull S R, 1989, Cancer Commun, V1, P261; JING SQ, 1990, J BIOL CHEM, V265, P11555; Julian J, 2002, BIOCHEM BIOPH RES CO, V293, P1183, DOI 10.1016/S0006-291X(02)00352-2; Kalinina EV, 2003, J BIOL CHEM, V278, P9244, DOI 10.1074/jbc.M209379200; Katzman RB, 2004, J VIROL, V78, P10878, DOI 10.1128/JVI.78.20.10878-10887.2004; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Lillehoj EP, 2002, AM J PHYSIOL-LUNG C, V282, pL751, DOI 10.1152/ajplung.00383.2001; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MANNORI G, 1995, CANCER RES, V55, P4425; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; Muller L, 1997, J BIOL CHEM, V272, P3669, DOI 10.1074/jbc.272.6.3749; Mulugeta S, 2003, J BIOL CHEM, V278, P47979, DOI 10.1074/jbc.M308210200; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; Pagano A, 2004, MOL BIOL CELL, V15, P4990, DOI 10.1091/mbc.E04-04-0355; Pemberton LF, 1996, J BIOL CHEM, V271, P2332, DOI 10.1074/jbc.271.4.2332; Poland PA, 1997, GLYCOCONJUGATE J, V14, P89, DOI 10.1023/A:1018569100438; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Rathenberg J, 2004, MOL CELL NEUROSCI, V26, P251, DOI 10.1016/j.mcn.2004.01.012; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Shmulevitz M, 2003, J VIROL, V77, P9769, DOI 10.1128/JVI.77.18.9769-9779.2003; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; van't Hof W, 2002, J VIROL, V76, P6382, DOI 10.1128/JVI.76.12.6382-6386.2002; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Veit M, 2001, VIROLOGY, V288, P89, DOI 10.1006/viro.2001.1063; Wagner R, 2005, J VIROL, V79, P6449, DOI 10.1128/JVI.79.10.6449-6458.2005; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	113	51	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12112	12122		10.1074/jbc.M512996200	http://dx.doi.org/10.1074/jbc.M512996200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507569	hybrid			2022-12-25	WOS:000236988100081
J	Takeuchi, R; Ruike, T; Nakamura, R; Shimanouchi, K; Kanai, Y; Abe, Y; Ihara, A; Sakaguchi, K				Takeuchi, R; Ruike, T; Nakamura, R; Shimanouchi, K; Kanai, Y; Abe, Y; Ihara, A; Sakaguchi, K			Drosophila DNA polymerase zeta interacts with recombination repair protein 1, the Drosophila homologue of human abasic endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; EXPRESSING ANTISENSE RNA; CATALYTIC SUBUNIT; EMBRYONIC LETHALITY; QUALITY-CONTROL; SOMATIC HYPERMUTATION; DECREASED FREQUENCY; POLY(A) POLYMERASE; REV1 PROTEIN	Abasic ( AP) sites are a threat to cellular viability and genomic integrity, since they impede transcription and DNA replication. In mammalian cells, DNA polymerase ( pol) beta plays an important role in the repair of AP sites. However, it is known that many organisms, including Drosophila melanogaster, do not have a pol beta homologue, and it is unclear how they repair AP sites. Here, we screened for DNA polymerases that interact with the Drosophila AP endonuclease 1 homologue, Rrp1 ( recombination repair protein 1), and found that Drosophila pol zeta ( Dmpol zeta), DmREV3 and DmREV7 bound to Rrp1 in a protein affinity column. Rrp1 directly interacted with DmREV7 in vitro and in vivo but not with DmREV3. These findings suggest that the DNA polymerase partner for Rrp1 is Dmpol zeta and that this interaction occurs through DmREV7. Interestingly, DmREV7 bound to the N-terminal region of Rrp1, which has no known protein homologue, suggesting that this binding is a species-specific event. Moreover, DmREV7 could stimulate the AP endonuclease activity of Rrp1, but not the 3'-exonuclease activity, and form a homomultimer. DmREV3 could not incorporate nucleotides at the 5'-incised tetrahydrofran sites but did show strand displacement activity for one-nucleotide-gapped DNA, which was not influenced by either DmREV7 or Rrp1. Methyl methanesulfonate and hydrogen peroxide treatments increased mRNA levels of DmREV3 and DmREV7. On the basis of the direct interaction between DmREV7 and Rrp1, we suggest that Dmpol zeta may be involved in the repair pathway of AP sites in DNA.	Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan	Tokyo University of Science	Sakaguchi, K (corresponding author), Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	kengo@rs.noda.tus.ac.jp						Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; Diaz M, 2003, MOL CANCER RES, V1, P836; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Eeken JCJ, 2001, MUTAT RES-DNA REPAIR, V485, P237, DOI 10.1016/S0921-8777(01)00062-3; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; HARRIS PV, 1987, MUTAT RES, V183, P53, DOI 10.1016/0167-8817(87)90045-9; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kajiwara K, 2001, GENES CELLS, V6, P99, DOI 10.1046/j.1365-2443.2001.00410.x; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; Li ZQ, 2002, MUTAT RES-FUND MOL M, V510, P71, DOI 10.1016/S0027-5107(02)00253-1; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Reardon BJ, 1998, J BIOL CHEM, V273, P33991, DOI 10.1074/jbc.273.51.33991; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Szakmary A, 1996, P NATL ACAD SCI USA, V93, P1607, DOI 10.1073/pnas.93.4.1607; Takeuchi R, 2004, BIOCHEM J, V382, P535, DOI 10.1042/BJ20031833; Uchiyama Y, 2004, EUR J BIOCHEM, V271, P2799, DOI 10.1111/j.1432-1033.2004.04214.x; Van Sloun PPH, 1999, MUTAT RES-DNA REPAIR, V433, P109, DOI 10.1016/S0921-8777(98)00067-6; Vanacova S, 2005, PLOS BIOL, V3, P986, DOI 10.1371/journal.pbio.0030189; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9; Wong D, 2003, J BIOL CHEM, V278, P36242, DOI 10.1074/jbc.M306065200; Wyers F, 2005, CELL, V121, P725, DOI 10.1016/j.cell.2005.04.030; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X	40	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11577	11585		10.1074/jbc.M512959200	http://dx.doi.org/10.1074/jbc.M512959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507570	hybrid			2022-12-25	WOS:000236988100020
J	Bugyi, B; Papp, G; Hild, G; Lorinczy, D; Nevalainen, EM; Lappalainen, P; Somogyi, B; Nyitrai, M				Bugyi, B; Papp, G; Hild, G; Lorinczy, D; Nevalainen, EM; Lappalainen, P; Somogyi, B; Nyitrai, M			Formins regulate actin filament flexibility through long range allosteric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DIAPHANOUS-RELATED FORMINS; F-ACTIN; INORGANIC-PHOSPHATE; HOMOLOGY-2 DOMAIN; DIVALENT-CATIONS; ATP HYDROLYSIS; FISSION YEAST; CELL-GROWTH; PROTEIN	The members of the formin family nucleate actin polymerization and play essential roles in the regulation of the actin cytoskeleton during a wide range of cellular and developmental processes. In the present work, we describe the effects of mDia1-FH2 on the conformation of actin filaments by using a temperature-dependent fluorescence resonance energy transfer method. Our results revealed that actin filaments were more flexible in the presence than in the absence of formin. The effect strongly depends on the mDia1-FH2 concentration in a way that indicates that more than one mechanism is responsible for the formin effect. In accordance with the more flexible filament structure, the thermal stability of actin decreased and the rate of phosphate dissociation from actin filaments increased in the presence of formin. The interpretation of the results supports a model in which formin binding to barbed ends makes filaments more flexible through long range allosteric interactions, whereas binding of formin to the sides of the filaments stabilizes the protomer-protomer interactions. These results suggest that formins can regulate the conformation of actin filaments and may thus also modulate the affinity of actin-binding proteins to filaments nucleated/capped by formins.	Univ Pecs, Fac Med, Dept Biophys, Res Grp Fluorescence Spect,Off Acad Res Grp Attac, H-7624 Pecs, Hungary; Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland	University of Pecs; University of Helsinki	Nyitrai, M (corresponding author), Univ Pecs, Fac Med, Dept Biophys, Res Grp Fluorescence Spect,Off Acad Res Grp Attac, Szigeti Str 12, H-7624 Pecs, Hungary.	miklos.nyitrai@aok.pte.hu		Nyitrai, Miklos/0000-0002-6229-4337; Lappalainen, Pekka/0000-0001-6227-0354	Wellcome Trust [079003] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hild G, 2002, EUR J BIOCHEM, V269, P842, DOI 10.1046/j.0014-2956.2001.02716.x; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nyitrai M, 2000, EUR J BIOCHEM, V267, P4334, DOI 10.1046/j.1432-1327.2000.01461.x; Nyitrai M, 1997, BIOPHYS J, V73, P2023, DOI 10.1016/S0006-3495(97)78232-8; Nyitrai M, 1999, J BIOL CHEM, V274, P12996, DOI 10.1074/jbc.274.19.12996; Nyitrai M, 2000, J BIOL CHEM, V275, P41143, DOI 10.1074/jbc.M004146200; Oosawa F, 1972, Nihon Seirigaku Zasshi, V34, P96; Orlova A, 2004, P NATL ACAD SCI USA, V101, P17664, DOI 10.1073/pnas.0407525102; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Prochniewicz E, 1996, J MOL BIOL, V260, P756, DOI 10.1006/jmbi.1996.0435; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Pruyne D, 2000, J CELL SCI, V113, P571; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; SOMOGYI B, 1984, BIOCHEMISTRY-US, V23, P3403, DOI 10.1021/bi00310a004; Somogyi B, 2000, J PHOTOCH PHOTOBIO B, V59, P26, DOI 10.1016/S1011-1344(00)00130-5; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Visegrady B, 2004, FEBS LETT, V565, P163, DOI 10.1016/j.febslet.2004.03.096; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000	60	53	55	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10727	10736		10.1074/jbc.M510252200	http://dx.doi.org/10.1074/jbc.M510252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490788	hybrid, Green Accepted			2022-12-25	WOS:000236822200011
J	Cariou, B; van Harmelen, K; Duran-Sandoval, D; van Dijk, TH; Grefhorst, A; Abdelkarim, M; Caron, S; Torpier, G; Fruchart, JC; Gonzalez, FJ; Kuipers, F; Staels, B				Cariou, B; van Harmelen, K; Duran-Sandoval, D; van Dijk, TH; Grefhorst, A; Abdelkarim, M; Caron, S; Torpier, G; Fruchart, JC; Gonzalez, FJ; Kuipers, F; Staels, B			The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; HEPATIC CARBOHYDRATE-METABOLISM; BILE-ACID; DIABETES-MELLITUS; 3T3-L1 ADIPOCYTES; DEFICIENT MICE; FXR; ACTIVATION; RESISTANCE; EXPRESSION	The farnesoid X receptor (FXR) is a bile acid (BA)-activated nuclear receptor that plays a major role in the regulation of BA and lipid metabolism. Recently, several studies have suggested a potential role of FXR in the control of hepatic carbohydrate metabolism, but its contribution to the maintenance of peripheral glucose homeostasis remains to be established. FXR-deficient mice display decreased adipose tissue mass, lower serum leptin concentrations, and elevated plasma free fatty acid levels. Glucose and insulin tolerance tests revealed that FXR deficiency is associated with impaired glucose tolerance and insulin resistance. Moreover, whole-body glucose disposal during a hyperinsulinemic euglycemic clamp is decreased in FXR-deficient mice. In parallel, FXR deficiency alters distal insulin signaling, as reflected by decreased insulin-dependent Akt phosphorylation in both white adipose tissue and skeletal muscle. Whereas FXR is not expressed in skeletal muscle, it was detected at a low level in white adipose tissue in vivo and induced during adipocyte differentiation in vitro. Moreover, mouse embryonic fibroblasts derived from FXR-deficient mice displayed impaired adipocyte differentiation, identifying a direct role for FXR in adipocyte function. Treatment of differentiated 3T3-L1 adipocytes with the FXR-specific synthetic agonist GW4064 enhanced insulin signaling and insulin-stimulated glucose uptake. Finally, treatment with GW4064 improved insulin resistance in genetically obese ob/ob mice in vivo. Although the underlying molecular mechanisms remain to be unraveled, these results clearly identify a novel role of FXR in the regulation of peripheral insulin sensitivity and adipocyte function. This unexpected function of FXR opens new perspectives for the treatment of type 2 diabetes.	Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; INSERM, U545, F-59019 Lille, France; Univ Lille 2, F-59006 Lille, France; Univ Groningen, Med Ctr, Pediat Lab, Ctr Liver Digest & Metab Dis, NL-9700 RB Groningen, Netherlands; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Staels, Bart/N-9497-2016; CARON, Sandrine/R-6624-2018	Staels, Bart/0000-0002-3784-1503; CARON, Sandrine/0000-0002-4660-7436; Abdelkarim, Mouaadh/0000-0003-3538-2566; Cariou, Bertrand/0000-0002-1580-8040; Kuipers, Folkert/0000-0003-2518-737X				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cariou B, 2005, ENDOCRINOLOGY, V146, P981, DOI 10.1210/en.2004-1595; Cariou B, 2005, FEBS LETT, V579, P4076, DOI 10.1016/j.febslet.2005.06.033; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200; Duran-Sandoval D, 2004, DIABETES, V53, P890, DOI 10.2337/diabetes.53.4.890; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Kuipers F, 2004, REV ENDOCR METAB DIS, V5, P319, DOI 10.1023/B:REMD.0000045103.00467.9a; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Li JL, 2005, J BIOL CHEM, V280, P7427, DOI 10.1074/jbc.M411473200; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; RANDLE PJ, 1963, LANCET, V1, P785; Rosen ED, 2000, GENE DEV, V14, P1293; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	39	413	453	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11039	11049		10.1074/jbc.M510258200	http://dx.doi.org/10.1074/jbc.M510258200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446356	hybrid			2022-12-25	WOS:000236822200045
J	He, L; Simmen, FA; Mehendale, HM; Ronis, MJJ; Badger, TM				He, L; Simmen, FA; Mehendale, HM; Ronis, MJJ; Badger, TM			Chronic ethanol intake impairs insulin signaling in rats by disrupting akt association with the cell membrane - Role of TRB3 in inhibition of Akt/protein kinase B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I ALCOHOL-DEHYDROGENASE; GLYCOGEN-SYNTHASE KINASE-3; TYROSINE PHOSPHORYLATION; BINDING-PROTEINS; POTENTIAL ROLE; LIVER; RESISTANCE; IDENTIFICATION; CONSUMPTION; PHOSPHATASE	Chronic and excessive alcohol consumption is an important and modifiable risk factor for type 2 diabetes. We previously reported elevations in hepatic Class 1 alcohol dehydrogenase (ADH) expression in ethanol-fed rats correspondent with reduced levels of mature, nuclear sterol-regulatory element-binding protein-1 (SREBP-1), an insulin-induced transcriptional repressor of the ADH gene. In this report, we have studied the effects of insulin and ethanol on ADH gene expression in a highly differentiated rat hepatoma cell line (FGC-4), as well as the in vivo effects of chronic intake of an ethanol-containing diet on hepatic insulin signaling. Insulin inhibited ADH gene expression, and this was abolished by LY294002 ( a phosphatidylinositol 3-kinase inhibitor) and small interfering RNA knockdown of SREBP-1. Chronic ethanol intake led to decreased phosphorylation of Akt ( protein kinase B) at Thr(308), increased phosphorylation of Akt at Ser(473), and decreased phosphorylation of glycogen synthase kinase-3 beta ( a downstream effector of Akt). Hepatic membrane-associated Akt content was decreased and cytosolic Akt content was increased in rats fed an ethanol-containing diet. Thus, disruptive effects of ethanol on insulin signaling occurred via impaired phosphorylation of Akt at Thr(308). TRB3, a negative regulator of Akt, was induced in liver of ethanol-fed rats. In ethanol-treated FGC-4 cells, small interfering RNA knockdown of TRB3 increased membrane-associated Akt and the phosphorylation of Akt at Thr(308). Our results suggest that ethanol induces TRB3, which, through binding to the pleckstrin homology domain of Akt, prevents its plasma membrane association, Akt-Thr(308) phosphorylation, and subsequent Akt-mediated signaling. Ethanol inhibition of insulin signaling reduces nuclear SREBP accumulation and results in disinhibition of Class 1 ADH transcription.	Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72202 USA; Univ Louisiana, Dept Toxicol, Monroe, LA 71209 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Louisiana System; University of Louisiana Monroe	Badger, TM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, 1120 Marshall St, Little Rock, AR 72202 USA.	badgerthomasm@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008645] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA008645] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Atkinson KJ, 2001, AM J PHYSIOL-GASTR L, V280, pG1280, DOI 10.1152/ajpgi.2001.280.6.G1280; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P438; Badger TM, 2000, BIOCHEM BIOPH RES CO, V274, P684, DOI 10.1006/bbrc.2000.3186; Bell DSH, 1996, DIABETES CARE, V19, P509, DOI 10.2337/diacare.19.5.509; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CRABB DW, 1986, ALCOHOL CLIN EXP RES, V10, P77, DOI 10.1111/j.1530-0277.1986.tb05619.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; He L, 2004, J BIOL CHEM, V279, P28113, DOI 10.1074/jbc.M400906200; He L, 2002, J BIOL CHEM, V277, P43572, DOI 10.1074/jbc.M204535200; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Kao WHL, 2001, AM J EPIDEMIOL, V154, P748, DOI 10.1093/aje/154.8.748; Kim KH, 2004, J BIOL CHEM, V279, P51999, DOI 10.1074/jbc.M405522200; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sawant SP, 2004, J PHARMACOL EXP THER, V308, P694, DOI 10.1124/jpet.103.058834; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wannamethee SG, 2002, J EPIDEMIOL COMMUN H, V56, P542, DOI 10.1136/jech.56.7.542; Wei M, 2000, DIABETES CARE, V23, P18, DOI 10.2337/diacare.23.1.18; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yeon JE, 2003, HEPATOLOGY, V38, P703, DOI 10.1053/jhep.2003.50368	36	86	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11126	11134		10.1074/jbc.M510724200	http://dx.doi.org/10.1074/jbc.M510724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16452480	hybrid			2022-12-25	WOS:000236822200055
J	Park, JH; Attardo, GM; Hansen, IA; Raikhel, AS				Park, JH; Attardo, GM; Hansen, IA; Raikhel, AS			GATA factor translation is the final downstream step in the amino acid/target-of-rapamycin-mediated vitellogenin gene expression in the anautogenous mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; DNA-BINDING; FAT-BODY; TOR; SERPENT; FAMILY; LINK; ACTIVATION; CULICIDAE; HIERARCHY	Ingestion of blood is required for vector mosquitoes to initiate reproductive cycles determining their role as vectors of devastating human diseases. Nutritional signaling plays a pivotal role in regulating mosquito reproduction. Transcription of yolk protein precursor genes is repressed until mosquitoes take blood. Previously, we have shown that to signal the presence of blood in the gut, mosquitoes utilize the target-of-rapamycin ( TOR) pathway. The TOR signaling pathway transduces the amino acid signal activating the major yolk protein precursor gene, vitellogenin (Vg). Here we report the identification of a GATA factor (AaGATAa) that is synthesized after a blood meal and acts as a transcriptional activator of Vg. We showed that AaGATAa bound specifically to GATA-binding sites present in the proximal promoter region of the Vg gene and positively regulated Vg expression in transfection assays. RNA interference-mediated knock down of AaGATAa transcript resulted in a significant inhibition of Vg expression in both fat-body tissue culture and blood-fed mosquitoes. AaGATAa mRNA accumulated in the fat body prior to blood feeding. However, translation of GATA was activated by blood feeding because the GATA protein increased dramatically in the fat body of blood-fed mosquitoes. This increase was also reproduced in the fat-body culture stimulated with amino acids. GATA translation was inhibited by rapamycin and cycloheximide as well as by RNA interference-mediated knock down of S6 kinase. These experiments have revealed that the TOR signaling pathway induced by nutritional signaling regulates the translation of a GATA factor, which is the specific transcriptional activator of the Vg gene.	Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Ctr Dis Vector Res, 3401 Watkins Dr, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Attardo, Geoffrey Michael/I-3320-2019	Attardo, Geoffrey Michael/0000-0001-6265-2969	NIAID NIH HHS [R01 AI024716, 5R37AI24716] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1993, DEVELOPMENT, V119, P623; Attardo GM, 2003, P NATL ACAD SCI USA, V100, P13374, DOI 10.1073/pnas.2235649100; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bell A, 2000, OBES RES, V8, P249, DOI 10.1038/oby.2000.29; Brodu V, 2001, DEVELOPMENT, V128, P2593; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carney GE, 2000, GENETICS, V154, P1203; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Chen L, 2004, J MOL ENDOCRINOL, V33, P743, DOI 10.1677/jme.1.01531; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Fossett N, 2003, P NATL ACAD SCI USA, V100, P11451, DOI 10.1073/pnas.1635050100; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; Kokoza VA, 2001, GENE, V274, P47, DOI 10.1016/S0378-1119(01)00602-3; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Martin D, 2001, MOL CELL ENDOCRINOL, V173, P75, DOI 10.1016/S0303-7207(00)00413-5; Miura K, 1999, MOL CELL ENDOCRINOL, V156, P111, DOI 10.1016/S0303-7207(99)00136-7; ORKIN SH, 1992, BLOOD, V80, P575; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Petersen UM, 1999, EMBO J, V18, P4013, DOI 10.1093/emboj/18.14.4013; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Raikhel A. S., 1997, The molecular biology of insect disease vectors: a methods manual., P507; Raikhel AS, 2002, INSECT BIOCHEM MOLEC, V32, P1275, DOI 10.1016/S0965-1748(02)00090-5; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Sun GQ, 2004, MOL CELL ENDOCRINOL, V218, P95, DOI 10.1016/j.mce.2003.12.014; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; UCHIDA K, 1990, J MED ENTOMOL, V27, P302, DOI 10.1093/jmedent/27.3.302; Uchida K, 2001, J MED ENTOMOL, V38, P572, DOI 10.1603/0022-2585-38.4.572; Waltzer L, 2002, EMBO J, V21, P5477, DOI 10.1093/emboj/cdf545; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wang SF, 2005, REPRO BIOL, V12, P69	39	78	85	4	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11167	11176		10.1074/jbc.M601517200	http://dx.doi.org/10.1074/jbc.M601517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490782	hybrid			2022-12-25	WOS:000236822200060
J	Berry, FB; Mirzayans, F; Walter, MA				Berry, FB; Mirzayans, F; Walter, MA			Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD/WINGED-HELIX GENE; MUTATION CONGENITAL-HYDROCEPHALUS; CELL-DEATH; GLAUCOMA; PHOSPHORYLATION; DEGRADATION; MF1; PHENOTYPES; FKHL7; MAP	Mutations in the FOXC1 transcription factor gene result in Axenfeld Rieger malformations, a disorder that affects the anterior segment of the eye, the teeth, and craniofacial structures. Individuals with this disorder possess an elevated risk for developing glaucoma. Previous work in our laboratory has indicated that FOXC1 transcriptional activity may be regulated by phosphorylation. We report here that FOXC1 is a short-lived protein (t(1/2) <30 min), and serine 272 is a critical residue in maintaining proper stability of FOXC1. Furthermore, we have demonstrated that activation of the ERK1/2 mitogen-activated protein kinase through epidermal growth factor stimulation is required for maximal FOXC1 transcriptional activation and stability. Finally, we have demonstrated that FOXC1 is targeted to the ubiquitin 26 S proteasomal degradation pathway and that amino acid residues 367-553, which include the C-terminal transactivation domain of FOXC1, are essential for ubiquitin incorporation and proteolysis. These results indicate that FOXC1 protein levels and activity are tightly regulated by post-translational modifications.	Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berry, FB (corresponding author), Univ Alberta, Dept Ophthalmol, Edmonton, AB T6G 2H7, Canada.	fberry@ualberta.ca						Berry FB, 2005, MOL CELL BIOL, V25, P1415, DOI 10.1128/MCB.25.4.1415-1424.2005; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Charles I, 2005, INVEST OPHTH VIS SCI, V46, P1330, DOI 10.1167/iovs.04-0363; Hong HK, 1999, HUM MOL GENET, V8, P625, DOI 10.1093/hmg/8.4.625; Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314; Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Lehmann OJ, 2000, AM J HUM GENET, V67, P1129; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nickells RW, 1996, J GLAUCOMA, V5, P345; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012-1606(03)00355-5; Saleem RA, 2001, AM J HUM GENET, V68, P627, DOI 10.1086/318792; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shields M B, 1983, Trans Am Ophthalmol Soc, V81, P736; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860	29	37	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10098	10104		10.1074/jbc.M513629200	http://dx.doi.org/10.1074/jbc.M513629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492674	hybrid			2022-12-25	WOS:000236594300035
J	Dahm, CC; Moore, K; Murphy, MP				Dahm, CC; Moore, K; Murphy, MP			Persistent S-nitrosation of complex I and other mitochondrial membrane proteins by S-nitrosothiols but not nitric oxide or peroxynitrite - Implications for the interaction of nitric oxide with mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; MEDIATED OXIDATION; RADICAL PRODUCTION; IRON-NITROSYLS; SUPEROXIDE; INHIBITION; OXYGEN; RESPIRATION; SYNTHASE; THIOLS	S-Nitrosation of mitochondrial proteins has been proposed to contribute to the pathophysiological interactions of nitric oxide (NO) and its derivatives with mitochondria but has not been shown directly. Furthermore, little is known about the mechanism of formation or the fate of these putative S-nitrosothiols. Here we have determined whether mitochondrial membrane protein thiols can be S-nitrosated on exposure to free NO from 3,3-bis(aminoethyl)1-hydroxy-2-oxo-1-triazene (DETA-NONOate) by interaction with S-nitrosoglutathione or S-nitroso-N-acetylpenicillamine (SNAP) and by the NO derivative peroxynitrite. S-Nitrosation of protein thiols was measured directly by chemiluminescence detection. S-Nitrosoglutathione and S-nitroso-N-acetylpenicillamine led to extensive protein thiol oxidation, with about 30% of the modified protein thiols persistently S-nitrosated. In contrast, there was no protein thiol oxidation or S-nitrosation on exposure to 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene. Peroxynitrite extensively oxidized protein thiols but produced negligible amounts of S-nitrosothiols. Therefore, mitochondrial membrane protein thiols are S-nitrosated by preformed S-nitrosothiols but not by NO or by peroxynitrite. These S-nitrosated protein thiols were readily reduced by glutathione, so S-nitrosation will only persist when the mitochondrial glutathione pool is oxidized. Respiratory chain complex I was S-nitrosated by S-nitrosothiols, consistent with it being an important target for S-nitrosation during nitrosative stress. The S-nitrosation of complex I correlated with a significant loss of activity that was reversed by thiol reductants. S-Nitrosation was also associated with increased superoxide production from complex I. These findings point to a significant role for complex I S-nitrosation and consequent dysfunction during nitrosative stress in disorders such as Parkinson disease and sepsis.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; UCL, Dept Med, London NW3 2PF, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of London; University College London	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Dahm, Christina C/G-9787-2014; Murphy, Michael P/C-2120-2009	Dahm, Christina C/0000-0003-0481-2893; Murphy, Michael P/0000-0003-1115-9618	MRC [MC_U105663142] Funding Source: UKRI; Medical Research Council [MC_U105663142] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BUTLER AR, 1995, TRENDS PHARMACOL SCI, V16, P18, DOI 10.1016/S0165-6147(00)88968-3; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cornwell TL, 2003, AM J PHYSIOL-CELL PH, V284, pC1516, DOI 10.1152/ajpcell.00268.2002; Costa NJ, 2003, ANTIOXID REDOX SIGN, V5, P291, DOI 10.1089/152308603322110878; Di Iorio E E, 1981, Methods Enzymol, V76, P57; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Hsu M, 2005, J NEUROCHEM, V92, P1091, DOI 10.1111/j.1471-4159.2004.02929.x; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; Kindig CA, 2002, RESP PHYSIOL NEUROBI, V132, P169, DOI 10.1016/S1569-9048(02)00068-X; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; LUCAS M, 1992, ANAL BIOCHEM, V206, P273, DOI 10.1016/0003-2697(92)90366-F; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Packer MA, 1996, BIOCHEM MOL BIOL INT, V40, P527; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Rogers SC, 2005, J BIOL CHEM, V280, P26720, DOI 10.1074/jbc.M501179200; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x; Shiva S, 2004, BIOCHEM J, V379, P359, DOI 10.1042/BJ20031758; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P874, DOI 10.1016/j.freeradbiomed.2004.12.012	75	160	166	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10056	10065		10.1074/jbc.M512203200	http://dx.doi.org/10.1074/jbc.M512203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481325	hybrid			2022-12-25	WOS:000236594300030
J	English, JL; Kassiri, Z; Koskivirta, I; Atkinson, SJ; Di Grappa, M; Soloway, PD; Nagase, H; Vuorio, E; Murphy, G; Khokha, R				English, JL; Kassiri, Z; Koskivirta, I; Atkinson, SJ; Di Grappa, M; Soloway, PD; Nagase, H; Vuorio, E; Murphy, G; Khokha, R			Individual Timp deficiencies differentially impact pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; HUMAN TISSUE INHIBITOR; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; GELATINASE-A; TUMOR INVASION; CELL-SURFACE; 1-MATRIX METALLOPROTEINASE; EFFICIENT ACTIVATION; EXPRESSION SYSTEM	Membrane-type matrix metalloproteinases (MT-MMPs) have emerged as key enzymes in tumor cell biology. The importance of MT1-MMP, in particular, is highlighted by its ability to activate pro-MMP-2 at the cell surface through the formation of a trimolecular complex comprised of MT1-MMP/tissue inhibitor of metalloproteinase-2 (TIMP-2)/pro-MMP-2. TIMPs1-4 are physiological MMP inhibitors with distinct roles in the regulation of pro-MMP-2 processing. Here, we have shown that individual Timp deficiencies differentially affect MMP-2 processing using primary mouse embryonic fibroblasts (MEFs). Timp-3 deficiency accelerated pro-MMP-2 activation in response to both cytochalasin D and concanavalin A. Exogenous TIMP-2 and N-TIMP-3 inhibited this activation, whereas TIMP-3 containing matrix from wild-type MEFs did not rescue the enhanced MMP-2 activation in Timp-3(-/-) cells. Increased processing of MMP-2 did not arise from increased expression of MT1-MMP, MT2-MMP, or MT3-MMP or altered expression of TIMP-2 and MMP-2. To test whether increased MMP-2 processing in Timp-3(-/-) MEFs is dependent on TIMP-2, double deficient Timp-2(-/-)/-3(-/-) MEFs were used. In these double deficient cells, the cleavage of pro-MMP-2 to its intermediate form was substantially increased, but the subsequent cleavage of intermediate-MMP-2 to fully active form, although absent in Timp-2(-/-) MEFs, was detectable with combined Timp-2(-/-)/-3(-/-) deficiency. TIMP-4 associates with MMP-2 and MT1-MMP in a manner similar to TIMP-3, but its deletion had no effect on pro-MMP-2 processing. Thus, TIMP-3 provides an inherent regulation over the kinetics of pro-MMP-2 processing, serving at a level distinct from that of TIMP-2 and TIMP-4.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Turku, Dept Med Biochem & Mol Biol, FI-20520 Turku, Finland; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, London W6 8LH, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turku; University of Cambridge; Cornell University; Imperial College London; University of Oxford	Khokha, R (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Soloway, Paul/T-8243-2019	Vuorio, Eero/0000-0003-3404-2439; Soloway, Paul/0000-0003-1967-0437; Khokha, Rama/0000-0002-6028-1524	MRC [G0400637] Funding Source: UKRI; Medical Research Council [G0400637] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ailenberg M, 1996, BIOCHEM J, V313, P879, DOI 10.1042/bj3130879; Atkinson SJ, 2004, FEBS LETT, V566, P65, DOI 10.1016/j.febslet.2004.04.040; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Lafleur MA, 2003, FEBS LETT, V553, P457, DOI 10.1016/S0014-5793(03)01094-9; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Llano E, 1999, CANCER RES, V59, P2570; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mohammed FF, 2003, ANN RHEUM DIS, V62, P43; Monea S, 2002, J CELL PHYSIOL, V192, P160, DOI 10.1002/jcp.10126; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nabeshima K, 2000, CANCER RES, V60, P3364; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Peterson JT, 2001, CIRCULATION, V103, P2303; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Soloway PD, 1996, ONCOGENE, V13, P2307; STASKUS PW, 1991, J BIOL CHEM, V266, P449; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Velasco G, 2000, CANCER RES, V60, P877; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200	68	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10337	10346		10.1074/jbc.M512009200	http://dx.doi.org/10.1074/jbc.M512009200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469749	hybrid			2022-12-25	WOS:000236594300062
J	Iavarone, C; Acunzo, M; Carlomagno, F; Catania, A; Melillo, RM; Carlomagno, SM; Santoro, M; Chiariello, M				Iavarone, C; Acunzo, M; Carlomagno, F; Catania, A; Melillo, RM; Carlomagno, SM; Santoro, M; Chiariello, M			Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; C-JUN PROMOTER; CELLULAR-RESPONSE; FAMILY; ABL; DISEASE; SRC; EXPRESSION; INHIBITOR; MUTATIONS	Mitogen-activated protein (MAP) kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation, and apoptosis. Extracellular signal- regulated kinase 8 (Erk8) is a large MAP kinase whose activity is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate Erk8, and we demonstrate that such MAP kinase participated in RET/PTC3-dependent stimulation of the c-jun promoter. By using RET/PTC3 molecules mutated in specific tyrosine autophosphorylation sites, we characterized Tyr(981), a known binding site for c-Src, as a major determinant of RET/PTC3-induced Erk8 activation, although, surprisingly, the underlying mechanism did not strictly depend on the activity of Src. In contrast, we present evidence that RET/PTC3 acts on Erk8 through Tyr(981)-mediated activation of c-Abl. Furthermore, we localized the region responsible for the modulation of Erk8 activity by the RET/PTC3 and Abl oncogenes in the Erk8 C-terminal domain. Altogether, these results support a role for Erk8 as a novel effector of RET/PTC3 and, therefore, RET biological functions.	CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Chiariello, M (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	chiariel@unina.it	Chiariello, Mario/O-3642-2014; melillo, rosa marina/O-5255-2015; Acunzo, Mario/ABE-1739-2020	Chiariello, Mario/0000-0001-8434-5177; Acunzo, Mario/0000-0002-3942-9061; MELILLO, Rosa Marina/0000-0002-9233-5275				Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810; Carlomagno F, 2002, CANCER RES, V62, P1077; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1331, DOI 10.1016/0006-291X(91)91719-S; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; Lobo VJSA, 2005, BIOCHEM J, V387, P231, DOI 10.1042/BJ20040927; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16	32	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10567	10576		10.1074/jbc.M513397200	http://dx.doi.org/10.1074/jbc.M513397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484222	hybrid			2022-12-25	WOS:000236594300088
J	Buwitt-Beckmann, U; Heine, H; Wiesmuller, KH; Jung, G; Brock, R; Akira, S; Ulmer, AJ				Buwitt-Beckmann, U; Heine, H; Wiesmuller, KH; Jung, G; Brock, R; Akira, S; Ulmer, AJ			TLR1- and TLR6-independent recognition of bacterial lipopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; INNATE IMMUNE-SYSTEM; CELL WALL COMPONENTS; CUTTING EDGE; DIACYLATED LIPOPEPTIDES; PATTERN-RECOGNITION; ESCHERICHIA-COLI; LIPOPROTEINS; ACTIVATION; PATHWAYS	Bacterial cell walls contain lipoproteins/peptides, which are strong modulators of the innate immune system. Triacylated lipopeptides are assumed to be recognized by TLR2/TLR1-, whereas diacylated lipopeptides use TLR2/TLR6 heteromers for signaling. Following our initial discovery of TLR6-independent diacylated lipopeptides, we could now characterize di- and triacylated lipopeptides (e.g. Pam(2)C-SK4, Pam(3)C-GNNDESNISFKEK), which have stimulatory activity in TLR1- and in TLR6-deficient mice. Furthermore, for the first time, we present triacylated lipopeptides with short length ester-bound fatty acids (like PamOct(2)C-SSNASK(4)), which induce no response in TLR1- deficient cells. No differences in the phosphorylation of MAP kinases by lipopeptide analogs having different TLR2-coreceptor usage were observed. Blocking experiments indicated that different TLR2 heteromers recognize their specific lipopeptide ligands independently from each other. In summary, a triacylation pattern is necessary but not sufficient to render a lipopeptide TLR1- dependent, and a diacylation pattern is necessary but not sufficient to render a lipopeptide TLR6-dependent. Contrary to the current model, distinct lipopeptides are recognized by TLR2 in a TLR1- and TLR6-independent manner.	Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; EMC Microcollect GmbH, D-72070 Tubingen, Germany; Univ Tubingen, Inst Cell Biol, D-72076 Tubingen, Germany; Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Forschungszentrum Borstel; Eberhard Karls University of Tubingen; EMC Microcollections GmbH; Eberhard Karls University of Tubingen; Osaka University	Ulmer, AJ (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Pk Allee 22, D-23845 Borstel, Germany.	ajulmer@fz-borstel.de	Brock, Roland/O-9411-2019; Heine, Holger/H-4552-2012; Brock, Roland/K-2590-2012; Akira, Shizuo/C-3134-2009	Heine, Holger/0000-0001-8128-5068; Brock, Roland/0000-0003-1395-6127; 				Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Boncheva M, 1996, LANGMUIR, V12, P5636, DOI 10.1021/la9605753; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; Buwitt-Beckmann U, 2005, FEBS J, V272, P6354, DOI 10.1111/j.1742-4658.2005.05029.x; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Into T, 2004, CELL MICROBIOL, V6, P187, DOI 10.1046/j.1462-5822.2003.00356.x; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; METZGER J, 1991, INT J PEPT PROT RES, V37, P46; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; METZGER JW, 1993, BIOCHIM BIOPHYS ACTA, V1149, P29, DOI 10.1016/0005-2736(93)90021-Q; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Omueti KO, 2005, J BIOL CHEM, V280, P36616, DOI 10.1074/jbc.M504320200; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; PRASS W, 1987, BIOCHIM BIOPHYS ACTA, V900, P116, DOI 10.1016/0005-2736(87)90283-5; Reichel F, 1999, J AM CHEM SOC, V121, P7989, DOI 10.1021/ja991319q; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Reschner A, 2003, EUR J IMMUNOL, V33, P2044, DOI 10.1002/eji.200323776; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Spohn R, 2004, VACCINE, V22, P2494, DOI 10.1016/j.vaccine.2003.11.074; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; ULMER AJ, 1992, INFECT IMMUN, V60, P3309, DOI 10.1128/IAI.60.8.3309-3314.1992; WIESMULLER KH, 1992, INT J PEPT PROT RES, V40, P255; Yoshimura A, 1999, J IMMUNOL, V163, P1	40	198	203	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9049	9057		10.1074/jbc.M512525200	http://dx.doi.org/10.1074/jbc.M512525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455646	hybrid, Green Published			2022-12-25	WOS:000236404700009
J	Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A				Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A			Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta 1 production	ONCOGENE			English	Article						SOCS; STAT; TGF-beta 1; liver fibrosis	GROWTH-FACTOR-BETA; PHYSIOLOGICAL NEGATIVE REGULATOR; HUMAN HEPATOCELLULAR-CARCINOMA; GP130 MUTANT MICE; TGF-BETA; CYTOKINE SIGNALING-3; IMMUNE-RESPONSES; CELL-GROWTH; HEPATITIS-C; IN-VIVO	Recently, DNA methylation and reduced expression of the suppressor of the cytokine signaling-3 (SOCS3) gene in human hepatocellular carcinoma (HCC) patients have been reported. However, the roles of SOCS3 in HCC development in vivo have not been clarified. Using RT-PCR analysis and Western blotting, we confirmed that SOCS3 expression was reduced in HCC patients. However, reduced expression of SOCS3 occurred not only in HCC but also in nontumor regions, and this reduction was stronger as the fibrosis grade increased. Furthermore, SOCS3 levels were inversely correlated with signal transducers and activators of transcription-3 (STAT3) activation as well as transforming growth factor (TGF)-beta 1 levels in the non-HCC region. To de. ne the molecular consequences of SOCS3 silencing/STAT3 hyperactivation and liver fibrosis, we examined liver-specific SOCS3-deficient mice. We demonstrated that SOCS3 deletion in the liver resulted in hyperactivation of STAT3 and promoted ConA- and chemical-induced liver fibrosis. The expression of TGF-beta 1, a mediator of fibrosis, was enhanced by SOCS3 gene deletion, but suppressed by the overexpression of a dominant-negative STAT3 or SOCS3 both in vivo and in vitro. These data suggest that TGF-beta 1 is a target gene of STAT3 and could be one of the mechanisms for enhanced fibrosis in SOCS3-deficient mice. Thus, our present study provides a novel role of SOCS3 and STAT3 in HCC development: in addition to the previously characterized oncogenic potentials, STAT3 enhances hepatic fibrosis through the upregulation of TGF-beta 1 expression, and SOCS3 prevents this process.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Japan	Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790; Takaesu, Giichi/0000-0002-1581-1055				Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Factor VM, 1997, CANCER RES, V57, P2089; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Huang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014-5793(03)01297-3; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Natsume M, 1999, J LEUKOCYTE BIOL, V66, P601, DOI 10.1002/jlb.66.4.601; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Theiss AL, 2005, GASTROENTEROLOGY, V129, P204, DOI 10.1053/j.gastro.2005.05.019; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741	42	192	205	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2520	2530		10.1038/sj.onc.1209281	http://dx.doi.org/10.1038/sj.onc.1209281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16474852				2022-12-25	WOS:000236948000010
J	Acker, MG; Shin, BS; Dever, TE; Lorsch, JR				Acker, MG; Shin, BS; Dever, TE; Lorsch, JR			Interaction between eukaryotic initiation factors 1A and 5B is required for efficient ribosomal subunit joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START-SITE SELECTION; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; TRANSFER-RNA; FACTOR IF2; FACTOR-II; IN-VIVO; BINDING; COMPLEX	Eukaryotic initiation factor 5B ( eIF5B) is aGTPase that facilitates joining of the 60 S ribosomal subunit to the 40 S ribosomal subunit during translation initiation. Formation of the resulting 80 S initiation complex triggers eIF5B to hydrolyze its bound GTP, reducing the affinity of the factor for the complex and allowing it to dissociate. Here we present a kinetic analysis of GTP hydrolysis by eIF5B in the context of the translation initiation pathway. Our data indicate that stimulation of GTP hydrolysis by eIF5B requires the completion of early steps in translation initiation, including the eIF1- and eIF1A- dependent delivery of initiator methionyl- tRNA to the 40 S ribosomal subunit and subsequent GTP hydrolysis by eIF2. Full activation of GTP hydrolysis by eIF5B requires the extreme C terminus of eIF1A, which has previously been shown to interact with the C terminus of eIF5B. Disruption of either isoleucine residue in the eIF1A C- terminal sequence DIDDI reduces the rate constant for GTP hydrolysis by similar to 20- fold, whereas changing the aspartic acid residues has no effect. Changing the isoleucines in the C terminus of eIF1A also disrupts the ability of eIF5B to facilitate subunit joining. These data indicate that the interaction of the C terminus of eIF1A with eIF5B promotes ribosomal subunit joining and possibly provides a checkpoint for correct complex formation, allowing full activation of GTP hydrolysis only upon formation of a properly organized 80 S initiation complex.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lorsch, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	jlorsch@jhmi.edu	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Lorsch, Jon/0000-0002-4521-4999; Acker, Michael/0000-0002-3565-9601	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Algire MA, 2005, MOL CELL, V20, P251, DOI 10.1016/j.molcel.2005.09.008; Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Allen GS, 2005, CELL, V121, P703, DOI 10.1016/j.cell.2005.03.023; Antoun A, 2003, EMBO J, V22, P5593, DOI 10.1093/emboj/cdg525; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; BOILEAU G, 1983, BIOCHEMISTRY-US, V22, P3162, DOI 10.1021/bi00282a020; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; Choi SK, 2000, MOL CELL BIOL, V20, P7183, DOI 10.1128/MCB.20.19.7183-7191.2000; FAKUNDING JL, 1973, J BIOL CHEM, V248, P4206; Fekete CA, 2005, EMBO J, V24, P3588, DOI 10.1038/sj.emboj.7600821; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guillon L, 2005, BIOCHEMISTRY-US, V44, P15594, DOI 10.1021/bi051514j; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kapp LD, 2004, J MOL BIOL, V335, P923, DOI 10.1016/j.jmb.2003.11.025; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Lee JH, 2002, P NATL ACAD SCI USA, V99, P16689, DOI 10.1073/pnas.262569399; Lomakin IB, 2006, EMBO J, V25, P196, DOI 10.1038/sj.emboj.7600904; Lomakin IB, 2003, GENE DEV, V17, P2786, DOI 10.1101/gad.1141803; Lorsch JR, 1999, EMBO J, V18, P6705, DOI 10.1093/emboj/18.23.6705; Maag D, 2006, J MOL BIOL, V356, P724, DOI 10.1016/j.jmb.2005.11.083; Maag D, 2005, MOL CELL, V17, P265, DOI 10.1016/j.molcel.2004.11.051; Maag D, 2003, J MOL BIOL, V330, P917, DOI 10.1016/S0022-2836(03)00665-X; Marintchev A, 2004, Q REV BIOPHYS, V37, P197, DOI 10.1017/S0033583505004026; Marintchev A, 2003, P NATL ACAD SCI USA, V100, P1535, DOI 10.1073/pnas.0437845100; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; Myasnikov AG, 2005, NAT STRUCT MOL BIOL, V12, P1145, DOI 10.1038/nsmb1012; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Shin BS, 2002, CELL, V111, P1015, DOI 10.1016/S0092-8674(02)01171-6; WAKAO H, 1989, J BIOL CHEM, V264, P20363	34	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8469	8475		10.1074/jbc.M600210200	http://dx.doi.org/10.1074/jbc.M600210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16461768	hybrid			2022-12-25	WOS:000236247100022
J	Heinemann, S; Biesinger, B; Fleckenstein, B; Albrecht, JC				Heinemann, S; Biesinger, B; Fleckenstein, B; Albrecht, JC			NF kappa B signaling is induced by the oncoprotein tio through direct interaction with TRAF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; RECEPTOR-ASSOCIATED FACTORS; LATENT MEMBRANE-PROTEIN; HUMAN T-CELLS; HERPESVIRUS SAIMIRI STP; LCK-BINDING ELEMENTS; GROWTH TRANSFORMATION; TRANSCRIPTION FACTORS; LYMPHOCYTE-TRANSFORMATION; GENE-EXPRESSION	The transcription factor NF kappa B is a major regulator of genes involved in inflammation and oncogenesis. NF kappa B is induced upon stimulation of cellular receptors coupled to different intracellular signaling molecules. Further downstream, TRAF6 links at least two receptor pathways to take control of I kappa B, the administrator of NF kappa B activity. Here we report on a strong NF kappa B activation by Tio, a unique herpesviral oncoprotein promoting transformation of human T cells in a Src-kinase-dependent manner. NF kappa B induction by Tio is independent of Src-kinase interaction and tyrosine phosphorylation of Tio. Mutation of a glutamic acid-rich motif at the N terminus of Tio, corresponding to a TRAF6 consensus binding motif, completely abrogated NF kappa B activation. Cotransfection of a dominant negative TRAF6 construct led to a decrease in NF kappa B activation. Furthermore, we provide evidence that TRAF6 directly binds to the Tio oncoprotein. Identification of TRAF6 as the direct target of Tio describes a novel mechanism for the constitutive activation of NF kappa B through an oncoprotein.	Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Heinemann, S (corresponding author), Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	stefanie.heinemann@viro.med.uni-erlangen.de						AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Albrecht JC, 2005, J VIROL, V79, P10507, DOI 10.1128/JVI.79.16.10507-10513.2005; Albrecht JC, 2004, J VIROL, V78, P9814, DOI 10.1128/JVI.78.18.9814-9819.2004; Albrecht JC, 1999, J VIROL, V73, P4631, DOI 10.1128/JVI.73.6.4631-4639.1999; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bauer F, 2004, BIOCHEMISTRY-US, V43, P14932, DOI 10.1021/bi0485068; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Choi JK, 2000, J VIROL, V74, P8102, DOI 10.1128/JVI.74.17.8102-8110.2000; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; FALK L, 1974, INT J CANCER, V14, P244, DOI 10.1002/ijc.2910140213; FALK L, 1978, INT J CANCER, V21, P652, DOI 10.1002/ijc.2910210517; FALK LA, 1974, INT J CANCER, V14, P473, DOI 10.1002/ijc.2910140407; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; Heck E, 2005, J VIROL, V79, P5713, DOI 10.1128/JVI.79.9.5713-5720.2005; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Izumi KM, 2004, PROG MOL SUBCELL BIO, V36, P269; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jung JU, 1999, SEMIN CANCER BIOL, V9, P231, DOI 10.1006/scbi.1998.0115; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YQ, 2005, J BIOL CHEM, V280, P1217, DOI 10.1074/jbc.M409492200; Li ZW, 2004, MOL IMMUNOL, V41, P701, DOI 10.1016/j.molimm.2004.04.012; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Rincon M, 1996, MOL CELL BIOL, V16, P1074; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; TSAN MF, 2005, SEMIN CANC BIOL; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wehner LE, 2001, DNA CELL BIOL, V20, P81, DOI 10.1089/104454901750070283; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	72	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8565	8572		10.1074/jbc.M510891200	http://dx.doi.org/10.1074/jbc.M510891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452479	hybrid			2022-12-25	WOS:000236247100032
J	Robertson, A; Pattishall, SR; Matson, SW				Robertson, A; Pattishall, SR; Matson, SW			The DNA binding activity of MutL is required for methyl-directed mismatch repair in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HELICASE-II; GENE-PRODUCT; D(GATC) SEQUENCES; DEPENDENT MANNER; IN-VIVO; UVRD; RECOMBINATION; MUTATIONS; PROTEINS	The DNA binding properties of the mismatch repair protein MutL and their importance in the repair process have been controversial for nearly two decades. We have addressed this issue using a point mutant of MutL ( MutL- R266E). The biochemical and genetic data suggest that DNA binding by MutL is required for dam methylation-directed mismatch repair. We demonstrate that purified MutL- R266E retains wild- type biochemical properties that do not depend on DNA binding, such as basal ATP hydrolysis in the absence of DNA and the ability to interact with other mismatch repair proteins. However, purified MutL- R266E binds DNA poorly in vitro as compared with MutL, and consistent with this observation, its DNA- dependent biochemical activities, like DNA- stimulated ATP hydrolysis and helicase II stimulation, are severely compromised. In addition, there is a modest effect on stimulation of MutH- catalyzed nicking. Finally, genetic assays show that MutLR-266E has a strong mutator phenotype, demonstrating that the mutant is unable to function in dam methylation- directed mismatch repair in vivo.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@bio.unc.edu						Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FEINSTEIN SI, 1986, GENETICS, V113, P13; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Giron-Monzon L, 2004, J BIOL CHEM, V279, P49338, DOI 10.1074/jbc.M409307200; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 2003, NUCLEIC ACIDS RES, V31, P2025, DOI 10.1093/nar/gkg324; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Kosinski J, 2005, J MOL BIOL, V351, P895, DOI 10.1016/j.jmb.2005.06.044; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Luria SE, 1943, GENETICS, V28, P491; MATSON SW, 1986, J BIOL CHEM, V261, P169; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICKOLOFF JA, 1998, DNA DAMAGE REPAIR, P205; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	48	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8399	8408		10.1074/jbc.M509184200	http://dx.doi.org/10.1074/jbc.M509184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446358	hybrid			2022-12-25	WOS:000236247100014
J	Hsieh, CC; Papaconstantinou, J				Hsieh, Ching-Chyuan; Papaconstantinou, John			Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 MAPK pathway activity in livers of aged and long-lived Snell dwarf mice	FASEB JOURNAL			English	Article						rotenone; MKK3 kinase; MKP-1 levels; MAPK signaling	OXIDATIVE STRESS-RESPONSE; LIFE-SPAN; POSTTRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; NUCLEAR EXPORT; KINASE; ACTIVATION; EXTENSION; APOPTOSIS; RESISTANCE	We have proposed that the age-associated increase of reactive oxygen species (ROS) by electron transport chain (ETC) dysfunction may cause the elevated basal level of p38 MAPK stress response pathway activity. However, the mechanism by which ROS activates this pathway is not clear. Here we propose that activation of the p38 MAPK pathway by complex I (CI) generated ROS, in response to rotenone (ROT) treatment, is based on the ability of reduced Trx to bind to and inhibit ASK 1 and its release from the complex upon oxidation. This balance of free vs. bound ASK1 regulates the level of p38 MAPK pathway activity. To support this mechanism we demonstrate that the production of ROS by ROT treated AML12 hepatocyte cells dissociates the Trx-ASK1 complex, thereby increasing p38 MAPK pathway activity. This mechanism is supported by the ability of N-acetyl cysteine (NAC) to prevent dissociation of Trx-ASK1 and activation of the p38 MAPK pathway. We also demonstrated that the ratio of ASK1/Trx-ASK1 increases in aged mouse livers and that this correlates with the increased basal activity of the p38 MAPK pathway. The longevity of Snell dwarf mice has been attributed to their resistance to oxidative stress. A comparison of the levels of Tx-ASK1 in young and aged dwarfs showed a higher abundance of the complex than in their age-matched controls. These results, which are indicative of a decreased level of oxidative stress, suggest that increased ROS production in aged liver may alter the ratio of ASK1 and Trx-ASK1, thereby increasing the age-associated basal level of p38 MAPK pathway activity.	Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Papaconstantinou, J (corresponding author), Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.	jpapacon@utmb.edu	Papaconstantinou, John/E-3312-2010		NATIONAL INSTITUTE ON AGING [P01AG021830, P30AG024832] Funding Source: NIH RePORTER; NIA NIH HHS [1P01 AG 021830-01, P30 AG024832, P01 AG021830] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1993, ONCOGENE, V8, P2015; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; An MR, 1996, MOL CELL BIOL, V16, P2295; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bonilla E, 2002, EXP GERONTOL, V37, P629, DOI 10.1016/S0531-5565(01)00229-7; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FLEMING JE, 1992, MUTAT RES, V275, P267, DOI 10.1016/0921-8734(92)90031-J; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; Hsieh CC, 2004, MECH AGEING DEV, V125, P785, DOI 10.1016/j.mad.2004.07.008; Hsieh CC, 2003, MECH AGEING DEV, V124, P733, DOI 10.1016/S0047-6374(03)00083-6; Hsieh CC, 2002, MECH AGEING DEV, V123, P1423, DOI 10.1016/S0047-6374(02)00084-2; Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Madsen MA, 2004, BIOCHEM BIOPH RES CO, V318, P998, DOI 10.1016/j.bbrc.2004.04.126; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sampayo JN, 2003, AGING CELL, V2, P319, DOI 10.1046/j.1474-9728.2003.00063.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Suh YS, 2001, MECH AGEING DEV, V122, P1797, DOI 10.1016/S0047-6374(01)00301-3; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7	50	157	168	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					259	268		10.1096/fj.05-4376com	http://dx.doi.org/10.1096/fj.05-4376com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449798	Green Accepted			2022-12-25	WOS:000237698700011
J	Marques, C; Guo, WM; Pereira, P; Taylor, A; Patterson, C; Evans, PC; Shang, F				Marques, Carla; Guo, Weimin; Pereira, Paulo; Taylor, Allen; Patterson, Cam; Evans, Paul C.; Shang, Fu			The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones	FASEB JOURNAL			English	Article						CHIP; heat shock proteins; isopeptidase; luciferase	AMYOTROPHIC-LATERAL-SCLEROSIS; HEAT-SHOCK PROTEINS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CU/ZN SUPEROXIDE-DISMUTASE; LENS EPITHELIAL-CELLS; ABNORMAL PROTEINS; QUALITY-CONTROL; DEPENDENT DEGRADATION; ACTIVATING ENZYME; OXIDATIVE STRESS	Accumulation of damaged proteins is causally related to many age-related diseases. The ubiquitin-proteasome pathway (UPP) plays a role in selective degradation of damaged proteins, whereas molecular chaperones, such as heat shock proteins, are involved in refolding denatured proteins. This work demonstrates for the first time that the UPP and molecular chaperones work in a competitive manner and that the fates of denatured proteins are determined by the relative activities of the UPP and molecular chaperones. Enhanced UPP activity suppresses the refolding of denatured proteins whereas elevated chaperone activity inhibits the degradation of denatured proteins. CHIP, a co-chaperone with E3 activity, plays a pivotal role in determining the fates of the damaged proteins. The delicate balance between UPP-mediated degradation and refolding of denatured proteins is governed by relative levels of CHIP and other molecular chaperones. Isopeptidases, the enzymes that reverse the actions of CHIP, also play an important role in determining the fate of denatured proteins.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Univ Coimbra, Fac Med, Ctr Ophthalmol, IBILI, Coimbra, Portugal; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA; Imperial Coll London, BHF Cardiovasc Med, London, England	Tufts University; United States Department of Agriculture (USDA); Universidade de Coimbra; University of North Carolina; University of North Carolina Chapel Hill; Imperial College London	Shang, F (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	fu.shang@tufts.edu	Pereira, Paulo/AAD-8375-2022; Guo, Weimin/B-3155-2009; Marques, Carla/AAC-9838-2019	Pereira, Paulo/0000-0002-9908-2290; Guo, Weimin/0000-0003-4318-7154; Marques, Carla/0000-0002-1817-4813; Evans, Paul/0000-0001-7975-681X	NATIONAL EYE INSTITUTE [P30EY013078, R29EY011717, R01EY011717, R01EY013250] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY013078, R01 EY011717-08, EY11717, R01 EY011717-07, R01 EY011717-06A1, R01 EY011717, EY13078, EY13250, R29 EY011717, R01 EY013250] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Cyr DM, 1997, J BIOENERG BIOMEMBR, V29, P29, DOI 10.1023/A:1022455621111; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Hungness ES, 2002, BIOCHEM BIOPH RES CO, V290, P469, DOI 10.1006/bbrc.2001.6168; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Liu CW, 2002, J BIOL CHEM, V277, P26815, DOI 10.1074/jbc.M201782200; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shang F, 2001, EXP EYE RES, V73, P827, DOI 10.1006/exer.2001.1091; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	60	85	90	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					741	+		10.1096/fj.05-5080fje	http://dx.doi.org/10.1096/fj.05-5080fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469848	Green Submitted, Green Accepted			2022-12-25	WOS:000237698700027
J	Seo, J; Barhoumi, R; Johnson, AE; Lupton, JR; Chapkin, RS				Seo, Jeongmin; Barhoumi, Rola; Johnson, Arthur E.; Lupton, Joanne R.; Chapkin, Robert S.			Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins	FASEB JOURNAL			English	Article						intracellular trafficking; subcellular localization	POLYUNSATURATED FATTY-ACIDS; H-RAS; N-RAS; ACYL-CHAIN; K-RAS; PHOSPHOLIPID-BILAYERS; ENDOPLASMIC-RETICULUM; TYROSINE KINASES; EXOCYTIC PATHWAY; MOLECULAR ORDER	Membrane localization of lipidated cytosolic signaling proteins is mediated by interactions between specific lipid anchors and membranes, but little is known about the regulatory role of membrane composition in lipidated protein membrane targeting. Here, using green fluorescent protein (GFP) chimeras and quantitative fluorescence microscopy in living mouse colonocytes, we show that docosahexaenoic acid (DHA), a dietary polyunsaturated fatty acid (PUFA) with membrane lipid-modifying properties, selectively inhibits plasma membrane (PM) targeting and increases the endomembrane localization of lipidated proteins that are cytoplasmic cargo in the exocytic pathway, without affecting the exocytic pathway itself. DHA selectivity seems to be dictated by the protein trafficking route, independent of the functional state of proteins and the location and composition of membrane anchors. DHA enrichment in cell membranes was required to elicit the inhibitory effect. These data reveal that membrane lipid composition influences cell signaling by modulating intracellular trafficking and localization of membrane proteins, providing a potential molecular mechanism for the documented health benefits of DHA.	Texas A&M Univ, Fac Nutr, Dept Nutr & Food Sci, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem Med, College Stn, TX 77843 USA; Texas A&M Univ, Dept Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Chapkin, RS (corresponding author), Texas A&M Univ, Fac Nutr, Dept Nutr & Food Sci, TAMU 2253, College Stn, TX 77843 USA.	r-chapkin@tamu.edu	Johnson, Arthur E/G-3457-2012	Chapkin, Robert/0000-0002-6515-3898	NCI NIH HHS [R01 CA059034, CA-59034] Funding Source: Medline; NIEHS NIH HHS [P30ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Babia T, 1999, J CELL SCI, V112, P477; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; Bijlmakers MJJE, 1999, J CELL BIOL, V145, P457, DOI 10.1083/jcb.145.3.457; BOS JL, 1989, CANCER RES, V49, P4682; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Davidson LA, 1999, CARCINOGENESIS, V20, P785, DOI 10.1093/carcin/20.5.785; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; EHRINGER W, 1990, CHEM PHYS LIPIDS, V54, P79, DOI 10.1016/0009-3084(90)90063-W; Gawrisch K, 2003, LIPIDS, V38, P445, DOI 10.1007/s11745-003-1082-0; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HOLTE LL, 1995, BIOPHYS J, V68, P2396, DOI 10.1016/S0006-3495(95)80422-4; Huster D, 1997, BIOPHYS J, V73, P855, DOI 10.1016/S0006-3495(97)78118-9; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Janecki AJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1479, DOI 10.1177/002215540004801105; Kamens J S, 2001, Curr Opin Investig Drugs, V2, P1213; Kim K, 1997, INT J CANCER, V71, P767, DOI 10.1002/(SICI)1097-0215(19970529)71:5<767::AID-IJC13>3.0.CO;2-5; Kloog Y, 2000, MOL MED TODAY, V6, P398, DOI 10.1016/S1357-4310(00)01789-5; Koenig BW, 1997, BIOPHYS J, V73, P1954, DOI 10.1016/S0006-3495(97)78226-2; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Ma DWL, 2004, FASEB J, V18, P1040, DOI 10.1096/fj.03-1430fje; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Perez de Castro I, 2003, CANCER RES, V63, P1615; Pinheiro J, 2001, MIXED EFFECTS MODELS; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Shaikh SR, 2004, BIOPHYS J, V87, P1752, DOI 10.1529/biophysj.104.044552; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stulnig TM, 2003, INT ARCH ALLERGY IMM, V132, P310, DOI 10.1159/000074898; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Talbot WA, 1997, BIOCHEMISTRY-US, V36, P5827, DOI 10.1021/bi962437i; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wong WSF, 2004, BBA-PROTEINS PROTEOM, V1697, P53, DOI 10.1016/j.bbapap.2003.11.013; Yu Calvin C K, 2003, Curr Dir Autoimmun, V6, P61; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0	64	51	56	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					770	+		10.1096/fj.05-4683fje	http://dx.doi.org/10.1096/fj.05-4683fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469846				2022-12-25	WOS:000237698700026
J	Tarsitano, M; De Falco, S; Colonna, V; McGhee, JD; Persico, MG				Tarsitano, Marina; De Falco, Sandro; Colonna, Vincenza; McGhee, James D.; Persico, M. Graziella			The C. elegans pvf-1 gene encodes a PDGF/VEGF-like factor able to bind mammalian VEGF receptors and to induce angiogenesis	FASEB JOURNAL			English	Article						growth factors; evolutionary conservation; Flt-1/KDR	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE-KINASE RECEPTORS; CAENORHABDITIS-ELEGANS; FACTOR DETERMINANTS; CELL-MIGRATION; EXPRESSION; IDENTIFICATION; GLYCOSYLATION; NEUROPILIN-1	Members of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family have been implicated in a variety of functions in vertebrates, especially angiogenesis. Here we identify and characterize a PDGF/VEGF-like factor (named PVF-1) from the nematode C. elegans. We show that PVF-1 has biochemical properties similar to vertebrate PDGF/VEGF growth factors. More important, PVF-1 binds to the human receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and is able to induce angiogenesis in two model systems derived from vertebrates. Our results highlight the widespread evolutionary conservation of this important class of growth factors and raise the possibility that C. elegans can provide a simple experimental system in which to investigate how these factors function.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; Univ Calgary, Dept Biochem & Mol Biol, Genes & Dev Res Grp, Calgary, AB T2N 4N1, Canada	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Calgary	Persico, MG (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via Pietro Castellino 111, I-80131 Naples, Italy.	persico@igb.cnr.it	De Falco, Sandro/P-6724-2015; Colonna, Vincenza/H-2021-2014	De Falco, Sandro/0000-0002-6501-1697; Colonna, Vincenza/0000-0002-3966-0474; McGhee, James/0000-0001-7266-7275				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Fukushige T, 1996, DEV BIOL, V178, P276, DOI 10.1006/dbio.1996.0218; Heino TI, 2001, MECH DEVELOP, V109, P69, DOI 10.1016/S0925-4773(01)00510-X; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Macias A, 2004, INT J DEV BIOL, V48, P1087, DOI 10.1387/ijdb.041859am; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; MELLO C, 1996, METHODS CELL BIOL; Munier AI, 2002, EMBO REP, V3, P1195, DOI 10.1093/embo-reports/kvf242; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Popovici C, 1999, GENOME RES, V9, P1026, DOI 10.1101/gr.9.11.1026; Popovici C, 2002, NEUROSCI LETT, V329, P116, DOI 10.1016/S0304-3940(02)00595-5; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rosin D, 2004, DEVELOPMENT, V131, P1939, DOI 10.1242/dev.01101; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Schachter H, 2004, CURR OPIN STRUC BIOL, V14, P607, DOI 10.1016/j.sbi.2004.09.005; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Uutela M, 2001, CIRCULATION, V103, P2242; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wood WB, 1988, NEMATODE CAENORHABDI; Ziche M, 1997, LAB INVEST, V76, P517	32	41	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					227	233		10.1096/fj.05-4147com	http://dx.doi.org/10.1096/fj.05-4147com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449794				2022-12-25	WOS:000237698700007
J	Phillips, A; Darley, M; Blaydes, J				Phillips, A.; Darley, M.; Blaydes, J. P.			GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis	ONCOGENE			English	Article						Hdm2; Mdm2; transcription; mRNA export; promoter	SINGLE NUCLEOTIDE POLYMORPHISM; OPEN READING FRAMES; MESSENGER-RNA; MDM2 EXPRESSION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; P53; GENE; ACTIVATION	The primary role of the Hdm2/Mdm2 oncoprotein is to regulate the levels and activity of the transcription factor p53. Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition. To further de. ne mechanisms regulating Hdm2 expression, we have investigated the effects of the GC-selective DNA-binding drug, Mithramycin A ( MA) on hdm2 mRNA transcription, trafficking, and translation. Firstly we show that the constitutive hdm2-P1 promoter is inhibited by MA. We de. ne, for the first time, the minimal sequence elements that are required for P1-promoter activity and identify those which confer MA sensitivity. Secondly, MA induces p53-dependent transcription from the hdm2-P2 promoter. Thirdly, and critically, MA also inhibits Hdm2 synthesis at the post-transcriptional level, with negative effects on hdm2 mRNA nuclear export and translation. This study highlights the complex interplay between the pathways that regulate Hdm2 protein synthesis in cancer cells, and furthermore emphasizes the export of hdm2 mRNA from the nucleus to the cytoplasm as a key point of control in this process.	Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Somers Canc Res Bldg,MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Landers JE, 1997, CANCER RES, V57, P3562; LUNA RMD, 1995, NATURE, V378, P203; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Qi JS, 1999, MOL CELL BIOL, V19, P864; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	56	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4183	4193		10.1038/sj.onc.1209451	http://dx.doi.org/10.1038/sj.onc.1209451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501602	Green Accepted			2022-12-25	WOS:000239004800006
J	Armishaw, CJ; Daly, NL; Nevin, ST; Adams, DJ; Craik, DJ; Alewood, PF				Armishaw, Christopher J.; Daly, Norelle L.; Nevin, Simon T.; Adams, David J.; Craik, David J.; Alewood, Paul F.			alpha-selenoconotoxins, a new class of potent alpha(7) neuronal nicotinic receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE CHEMICAL LIGATION; SOLID-PHASE SYNTHESIS; CONOTOXIN-IMI; THIOREDOXIN REDUCTASE; ACETYLCHOLINE-RECEPTORS; BIOLOGICAL-ACTIVITIES; STRUCTURAL STABILITY; CONTAINING PEPTIDE; CYCLIC-PEPTIDES; SELENOCYSTEINE	Disulfide bonds are important structural motifs that play an essential role in maintaining the conformational stability of many bioactive peptides. Of particular importance are the conotoxins, which selectively target a wide range of ion channels that are implicated in numerous disease states. Despite the enormous potential of conotoxins as therapeutics, their multiple disulfide bond frameworks are inherently unstable under reducing conditions. Reduction or scrambling by thiol-containing molecules such as glutathione or serum albumin in intracellular or extracellular environments such as blood plasma can decrease their effectiveness as drugs. To address this issue, we describe a new class of selenoconotoxins where cysteine residues are replaced by selenocysteine to form isosteric and non-reducible diselenide bonds. Three isoforms of alpha-conotoxin ImI were synthesized by t-butoxycarbonyl chemistry with systematic replacement of one([ Sec(2,8)] ImI or [Sec(3,12)] ImI), or both([Sec(2,3,8,12)] ImI) disulfide bonds with a diselenide bond. Each analogue demonstrated remarkable stability to reduction or scrambling under a range of chemical and biological reducing conditions. Three-dimensional structural characterization by NMR and CD spectroscopy indicates conformational preferences that are very similar to those of native ImI, suggesting fully isomorphic structures. Additionally, full bioactivity was retained at the alpha(7) nicotinic acetylcholine receptor, with each seleno-analogue exhibiting a dose-response curve that overlaps with wild-type ImI, thus further supporting an isomorphic structure. These results demonstrate that selenoconotoxins can be used as highly stable scaffolds for the design of new drugs.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Alewood, PF (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	P.Alewood@imb.uq.edu.au	Adams, David John/K-3578-2019; Adams, David/J-9125-2014; Daly, Norelle L/D-4302-2013; Alewood, Paul F/J-2412-2014; Nevin, Simon/B-2663-2014; Craik, David/B-1695-2010	Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Daly, Norelle L/0000-0002-4697-6602; Craik, David/0000-0003-0007-6796				Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Armishaw CJ, 2005, CURR PROTEIN PEPT SC, V6, P221, DOI 10.2174/1389203054065437; Besse D, 1997, ANGEW CHEM INT EDIT, V36, P883, DOI 10.1002/anie.199708831; Besse D, 1997, J PEPT SCI, V3, P442, DOI 10.1002/(SICI)1099-1387(199711)3:6<442::AID-PSC122>3.0.CO;2-2; Bondebjerg J, 2003, CHEMBIOCHEM, V4, P186, DOI 10.1002/cbic.200390030; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOCAT P, 1985, ANAL BIOCHEM, V148, P485, DOI 10.1016/0003-2697(85)90256-8; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; DRYLAND A, 1986, J CHEM SOC P1, V1, P125; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gehrmann J, 1999, J MED CHEM, V42, P2364, DOI 10.1021/jm990114p; Gieselman MD, 2001, ORG LETT, V3, P1331, DOI 10.1021/ol015712o; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hargittai B, 2000, J MED CHEM, V43, P4787, DOI 10.1021/jm990635c; HARTRODT B, 1980, TETRAHEDRON LETT, V21, P2393, DOI 10.1016/S0040-4039(00)93158-7; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hondal RJ, 2001, J AM CHEM SOC, V123, P5140, DOI 10.1021/ja005885t; HOUSE KL, 1992, J AM CHEM SOC, V114, P8573, DOI 10.1021/ja00048a033; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; KOIDE T, 1993, CHEM PHARM BULL, V41, P1596; LARSEN BD, 1994, INT J PEPT PROT RES, V43, P1; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LIPINSKI B, 1992, BIOORG MED CHEM LETT, V2, P919, DOI 10.1016/S0960-894X(00)80588-0; LIVE DH, 1977, J ORG CHEM, V42, P3556, DOI 10.1021/jo00442a025; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moroder L, 2005, BIOPOLYMERS, V80, P85, DOI 10.1002/bip.20174; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; NUTT RF, 1980, J AM CHEM SOC, V102, P6539, DOI 10.1021/ja00541a025; OIKAWA T, 1991, P NATL ACAD SCI USA, V88, P3057, DOI 10.1073/pnas.88.8.3057; OTAKA A, 1991, TETRAHEDRON LETT, V32, P1223, DOI 10.1016/S0040-4039(00)92050-1; Pegoraro S, 1998, J MOL BIOL, V284, P779, DOI 10.1006/jmbi.1998.2189; Pegoraro S, 1999, PROTEIN SCI, V8, P1605, DOI 10.1110/ps.8.8.1605; Quaderer R, 2001, HELV CHIM ACTA, V84, P1197, DOI 10.1002/1522-2675(20010516)84:5<1197::AID-HLCA1197>3.0.CO;2-#; Quinlan GJ, 2005, HEPATOLOGY, V41, P1211, DOI 10.1002/hep.20720; Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SIEBER P, 1980, HELV CHIM ACTA, V63, P2358, DOI 10.1002/hlca.19800630826; Singh RR, 2003, BBA-PROTEINS PROTEOM, V1651, P85, DOI 10.1016/S1570-9639(03)00238-3; Stadtman TC, 2002, ANNU REV BIOCHEM, V71, P1, DOI 10.1146/annurev.biochem.71.083101.134224; Stymiest JL, 2003, ORG LETT, V5, P47, DOI 10.1021/ol027160v; WALTER R, 1965, J AM CHEM SOC, V87, P4192, DOI 10.1021/ja01096a036; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	54	146	152	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14136	14143		10.1074/jbc.M512419200	http://dx.doi.org/10.1074/jbc.M512419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16500898	hybrid			2022-12-25	WOS:000237512300037
J	Jeltsch, M; Karpanen, T; Strandin, T; Aho, K; Lankinen, H; Alitalo, K				Jeltsch, M; Karpanen, T; Strandin, T; Aho, K; Lankinen, H; Alitalo, K			Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR VEGF; FACTOR-C; ANGSTROM RESOLUTION; KINASE DOMAIN; LYMPHANGIOGENESIS; ANGIOGENESIS; PROMOTES; ACTIVATION; VARIANTS	Vascular endothelial growth factors (VEGFs) and their receptors play key roles in angiogenesis and lymphangiogenesis. VEGF activates VEGF receptor-1 (VEGFR-1) and VEGFR-2, whereas VEGF-C activates VEGFR-2 and VEGFR-3. We have created a library of VEGF/VEGF-C mosaic molecules that contains factors with novel receptor binding profiles, notably proteins binding to all three VEGF receptors ("super-VEGFs"). The analyzed super-VEGFs show both angiogenic and lymphangiogenic effects in vivo, although weaker than the parental molecules. The composition of the VEGFR-3 binding molecules and scanning mutagenesis revealed determinants of receptor binding and specificity. VEGFR-2 and VEGFR-3 showed striking differences in their requirements for VEGF-C binding; extracellular domain 2 of VEGFR-2 was sufficient, whereas in VEGFR-3, both domains 1 and 2 were necessary.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomedicum Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, Peptide & Prot Lab, FIN-00014 Helsinki, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Alitalo, Kari K/J-5013-2014; Jeltsch, Michael/I-5340-2012; Strandin, Tomas/K-5322-2019	Alitalo, Kari K/0000-0002-7331-0902; Jeltsch, Michael/0000-0003-2890-7790; Strandin, Tomas/0000-0002-2454-7479; Karpanen, Terhi/0000-0002-2803-083X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075183] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 R01 HL075183-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; Eichmann A, 1998, DEVELOPMENT, V125, P743; Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joern JM, 2002, J MOL BIOL, V316, P643, DOI 10.1006/jmbi.2001.5349; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, CANCER RES, V61, P1786; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kiba A, 2003, J BIOL CHEM, V278, P13453, DOI 10.1074/jbc.M210931200; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MARAGOUDAKIS ME, 1995, MICROVASC RES, V50, P215, DOI 10.1006/mvre.1995.1054; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yamaguchi S, 2002, BIOCHEM BIOPH RES CO, V291, P554, DOI 10.1006/bbrc.2002.6478	51	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12187	12195		10.1074/jbc.M511593200	http://dx.doi.org/10.1074/jbc.M511593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505489	hybrid			2022-12-25	WOS:000236988100089
J	Longhurst, DM; Watanabe, M; Rothstein, JD; Jackson, M				Longhurst, DM; Watanabe, M; Rothstein, JD; Jackson, M			Interaction of PDZRhoGEF with microtubule-associated protein 1 light chains - Link between microtubules, actin cytoskeleton, and neuronal polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; LEUKEMIA-ASSOCIATED RHO; NEURITE RETRACTION; STRESS FIBERS; PDZ DOMAIN; FOCAL ADHESIONS; CELL POLARITY; AXON GUIDANCE; KINASE-C; BINDING	Rat (r) PDZRhoGEF, initially identified as a glutamate transporter EAAT4-associated protein, is a member of a novel RhoGEF subfamily. The N terminus of the protein contains a PDZ and a proline-rich domain, two motifs known to be involved in protein-protein interactions. By using the yeast two-hybrid approach, we screened for proteins that interact with the N terminus of rPDZRhoGEF. The light chain 2 of microtubule-associated protein 1 (LC2) was the only protein identified from the screen that does not contain a type I PDZ-binding motif at its extreme C terminus (-(S/T) X phi-COOH, where phi is a hydrophobic amino acid). However, the C terminus does conform to a type II-binding motif (-phi X phi). We report here that rPDZRhoGEF interacts with LC2 via the PDZ domain, and the interaction is abolished by mutations in the carboxylate-binding loop. The specificity of the interaction was confirmed using GST fusion protein pull-down assays and coimmunoprecipitations. Expression of rPDZRhoGEF mutants that are unable to interact with proteins via the carboxylate-binding loop induced changes in cell morphology and actin organization. These mutants alter the activation of RhoGTPases, and coexpression of dominant-negative RhoGTPases prevent the morphological changes. Furthermore, in cells expressing wild type rPDZRhoGEF, drug-induced microtubule depolymerization produces changes in cell morphology that are similar to those induced by rPDZRhoGEF mutants. These results indicate that modulation of the guanine nucleotide exchange activity of rPDZRhoGEF through interaction with microtubule-associated protein light chains may coordinate microtubule integrity and the reorganization of actin cytoskeleton. This coordinated action of the actin and microtubular cytoskeletons is essential for the development and maintenance of neuronal polarity.	Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland; Gunma Univ, Grad Sch Med, Dept Neurol, Maebashi, Gumma 3718511, Japan; Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21287 USA	University of Edinburgh; Gunma University; Johns Hopkins University	Jackson, M (corresponding author), Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland.	Mandy.Jackson@ed.ac.uk	rothstein, jeffrey d/C-9470-2013					Barac A, 2004, J BIOL CHEM, V279, P6182, DOI 10.1074/jbc.M309579200; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; Dev KK, 2004, J BIOL CHEM, V279, P41393, DOI 10.1074/jbc.M404499200; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Franz CM, 2004, J BIOL CHEM, V279, P6588, DOI 10.1074/jbc.M312812200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kaufmann N, 1998, DEVELOPMENT, V125, P453; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1997, J CELL SCI, V110, P2417; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12030	12040		10.1074/jbc.M513756200	http://dx.doi.org/10.1074/jbc.M513756200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16478718	hybrid			2022-12-25	WOS:000236988100073
J	Malhi, H; Bronk, SF; Werneburg, NW; Gores, GJ				Malhi, H; Bronk, SF; Werneburg, NW; Gores, GJ			Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; OXIDATIVE STRESS; NONALCOHOLIC STEATOHEPATITIS; SYMPATHETIC NEURONS; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DIRECT ACTIVATION; RAT HEPATOCYTES	Elevated serum free fatty acids ( FFAs) and hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease. However, the mechanism by which FFAs mediate lipoapoptosis is unclear. Because JNK activation is pivotal in both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis, we examined the role of JNK activation in FFA-induced lipoapoptosis. Multiple hepatocyte cell lines and primary mouse hepatocytes were treated in culture with monounsaturated fatty acids and saturated fatty acids. Despite equal cellular steatosis, apoptosis and JNK activation were greater during exposure to saturated versus monounsaturated FFAs. Inhibition of JNK, pharmacologically as well as genetically, reduced saturated FFA-mediated hepatocyte lipoapoptosis. Cell death was caspase-dependent and associated with mitochondrial membrane depolarization and cytochrome c release indicating activation of the mitochondrial pathway of apoptosis. JNK-dependent lipoapoptosis was associated with activation of Bax, a known mediator of mitochondrial dysfunction. As JNK can activate Bim, a BH3 domain-only protein capable of binding to and activating Bax, its role in lipoapoptosis was also examined. Small interfering RNA-targeted knock-down of Bim attenuated both Bax activation and cell death. Collectively the data indicate that saturated FFAs induce JNK-dependent hepatocyte lipoapoptosis by activating the proapoptotic Bcl-2 proteins Bim and Bax, which trigger the mitochondrial apoptotic pathway.	Mayo Clin Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu			NIDDK NIH HHS [DK41876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041876, R01DK041876, R29DK041876] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Bruckner SR, 2002, J NEUROSCI RES, V70, P665, DOI 10.1002/jnr.10437; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; DASHTI N, 1987, J LIPID RES, V28, P423; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feldstein AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Keramaris E, 2005, J BIOL CHEM, V280, P1132, DOI 10.1074/jbc.M410127200; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Nanji AA, 2004, ALCOHOL, V34, P21, DOI 10.1016/j.alcohol.2004.08.005; Oh SH, 2003, ARCH TOXICOL, V77, P110, DOI 10.1007/s00204-002-0415-x; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zu K, 2005, MOL CANCER THER, V4, P43	50	527	563	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12093	12101		10.1074/jbc.M510660200	http://dx.doi.org/10.1074/jbc.M510660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505490	hybrid			2022-12-25	WOS:000236988100079
J	Shi, JX; Koeppe, JR; Komives, EA; Taylor, P				Shi, JX; Koeppe, JR; Komives, EA; Taylor, P			Ligand-induced conformational changes in the acetylcholine-binding protein analyzed by hydrogen-deuterium exchange mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRYPTOPHAN FLUORESCENCE; SOLVENT ACCESSIBILITY; NICOTINIC RECEPTORS; ACHBP; REVEALS; INTERFACES; COMPLEX; DOMAIN; IDENTIFICATION	Recent x-ray crystallographic studies of the acetylcholine-binding protein( AChBP) suggest that loop C, found at the circumference of the pentameric molecule, shows distinctive conformational changes upon antagonist and agonist occupation. We have employed hydrogen-deuterium exchange mass spectrometry to examine the influence of bound ligands on solvent exposure of AChBP. Quantitative measurements of deuterium incorporation are possible for similar to 56% of the Lymnaea AChBP sequence, covering primarily the outer surface of AChBP. In the apoprotein, two regions flanking the ligand occupation site at the subunit interface, loop C( residues 175 - 193) and loop F( residues 164 171), show greater extents of solvent exchange than other regions of the protein including the N- and C-terminal regions. Occupation by nicotinic agonists, epibatidine and lobeline, and nicotinic antagonists, methyllycaconitine, alpha-bungarotoxin, and alpha-cobratoxin, markedly restricts the exchange of loop C amide protons, influencing both the rates and degrees of exchange. Solvent exposure of loop C and its protection by ligand suggest that in the apoprotein, loop C exhibits rapid fluctuations in an open conformation. Bound agonists restrict solvent exposure through loop closure, whereas the larger antagonists restrict solvent exposure largely through occlusion of solvent. Loop F, found on the complementary subunit surface at the interface, also reveals ligand selective changes in amide proton exchange rates. Agonists do not affect solvent accessibility of loop F, whereas certain antagonists cause subtle accessibility changes. These results reveal dynamic states and fluctuating movements in the vicinity of the binding site for unligated AChBP that can be influenced selectively by ligands.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Mass Spectrometry Facil, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42-ES10337] Funding Source: Medline; NIGMS NIH HHS [R37-GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Henchman RH, 2005, BIOPHYS J, V88, P2564, DOI 10.1529/biophysj.104.053934; Hibbs RE, 2005, BIOCHEMISTRY-US, V44, P16602, DOI 10.1021/bi051735p; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523; Karlin A., 1969, J GEN PHYSIOL, V54, P245; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Mandell JG, 1998, ANAL CHEM, V70, P3987, DOI 10.1021/ac980553g; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	23	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12170	12177		10.1074/jbc.M600154200	http://dx.doi.org/10.1074/jbc.M600154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16484218	hybrid			2022-12-25	WOS:000236988100087
J	Zetterberg, H; Campbell, WA; Yang, HW; Xia, WM				Zetterberg, H; Campbell, WA; Yang, HW; Xia, WM			The cytosolic loop of the gamma-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVITY; FAS LIGAND; RELA P65; PRESENILIN; PEN-2; ACTIVATION; COMPLEX; NOTCH; EXPRESSION	The gamma-secretase complex, composed of presenilin, presenilin enhancer 2 (Pen-2), nicastrin, and Aph-1, catalyzes the final cleavage of amyloid precursor protein to generate the toxic amyloid beta protein, the major component of plaques in the brains of Alzheimer disease patients. To understand the in vivo function of Pen- 2, we used morphant technology available in zebrafish and transiently knocked down the expression of endogenous Pen- 2 by injecting the morpholino (MO) against Pen- 2. Two truncated Pen- 2 proteins lacking either the cytosolic or the C-terminal domain were expressed in MO-injected embryos. This deletion analysis demonstrated that the Pen- 2 cytosolic loop is essential for protecting developing embryos from caspase-dependent apoptosis caused by the reduction of Pen- 2. Twelve amino acids in the C terminus of Pen- 2 were dispensable and could not rescue the Pen- 2 knockdown-induced apoptotic phenotype. Surprisingly, double knockdown of Pen- 2 and nuclear factor kappa B component p65 abrogated the single Pen- 2 MO-induced caspase activation, indicating that a previously reported pro-apoptotic role of NF-kappa B in some cell types could be manifested in a whole animal and that knockdown of Pen- 2 may trigger pro-apoptotic activation of NF-kappa B.	Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Xia, WM (corresponding author), Harvard Univ, Inst Med, Ctr Neurol Dis, Brigham & Womens Hosp,Sch Med, HIM 616,77 Ave Louis Pasteur, Boston, MA 02115 USA.	wxia@rics.bwh.harvard.edu	xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER; NIA NIH HHS [AG015379] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Campbell WA, 2006, J NEUROCHEM, V96, P1423, DOI 10.1111/j.1471-4159.2006.03648.x; Chen XF, 2003, CANCER RES, V63, P1059; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Correa RG, 2004, MOL CELL BIOL, V24, P5257, DOI 10.1128/MCB.24.12.5257-5268.2004; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fortini ME, 2001, CURR OPIN CELL BIOL, V13, P627, DOI 10.1016/S0955-0674(00)00261-1; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Hasegawa H, 2004, J BIOL CHEM, V279, P46455, DOI 10.1074/jbc.M406289200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Key Brian, 2003, Methods in Cell Science, V25, P1; Kim SH, 2005, J BIOL CHEM, V280, P1992, DOI 10.1074/jbc.M412404200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Matsui K, 1998, J IMMUNOL, V161, P3469; Negron JF, 2004, DEV DYNAM, V231, P161, DOI 10.1002/dvdy.20124; Prokop S, 2005, J NEUROCHEM, V94, P57, DOI 10.1111/j.1471-4159.2005.03165.x; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Westerfield M, 1994, ZEBRAFISH BOOK; Xia W, 2001, Curr Neurol Neurosci Rep, V1, P422, DOI 10.1007/s11910-001-0101-z; XIA W, 2004, AMYLOID PRECURSOR PR, P9; Xia Weiming, 2003, Curr Opin Investig Drugs, V4, P55; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	50	26	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11933	11939		10.1074/jbc.M512521200	http://dx.doi.org/10.1074/jbc.M512521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507571	hybrid			2022-12-25	WOS:000236988100062
J	Blumberg, JM; Tzameli, I; Astapova, I; Lam, FS; Flier, JS; Hollenberg, AN				Blumberg, JM; Tzameli, I; Astapova, I; Lam, FS; Flier, JS; Hollenberg, AN			Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTOR; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; C/EBP-BETA; NEGATIVE REGULATION; BINDING PROTEINS; CO-REPRESSOR; N-COR	The vitamin D receptor (VDR) and its ligand 1,25-OH2-VD3 (calcitriol) play an essential role in mineral homeostasis in mammals. Interestingly, the VDR is expressed very early in adipogenesis in 3T3-L1 cells, suggesting that the VDR signaling pathway may play a role in adipocyte biology and function. Indeed, it has been known for a number of years that calcitriol is a potent inhibitor of adipogenesis in this model but with no clear mechanism identified. In this study, we have further defined the molecular mechanism by which the unliganded VDR and calcitriol-liganded VDR regulate adipogenesis. In the presence of calcitriol, the VDR blocks adipogenesis by down-regulating both C/EBP beta mRNA expression and C/EBP beta nuclear protein levels at a critical stage of differentiation. In addition, calcitriol allows for the up-regulation of the recently described C/EBP beta corerepressor, ETO, which would further inhibit the action of any remaining C/EBP beta, whose action is required for adipogenesis. In contrast, in the absence of calcitriol, the unliganded VDR appears necessary for lipid accumulation, since knock-down of the VDR using siRNA both delays and prevents this process. Taken together, these data support the notion that the intracellular concentrations of calcitriol can play an important role in either promoting or inhibiting adipogenesis via the VDR and the transcriptional pathways that it targets. Further examination of this hypothesis in vivo may shed new light on the biology of adipogenesis.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hollenberg, AN (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, 330 Brookline Ave, Boston, MA 02215 USA.	thollenb@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DK056123, R37DK28081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056123, R01DK056123, R01DK028081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Dhawan P, 2005, MOL CELL BIOL, V25, P472, DOI 10.1128/MCB.25.1.472-487.2005; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsieh JC, 2003, J BIOL CHEM, V278, P38665, DOI 10.1074/jbc.M304886200; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KAMEI Y, 1993, BIOCHEM BIOPH RES CO, V193, P948, DOI 10.1006/bbrc.1993.1717; KAWADA T, 1996, INT J OBESITY, V20, P52; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KONG J, 2005, IN PRESS AM J PHYSL; KRISHNAN AV, 1992, MOL ENDOCRINOL, V6, P198, DOI 10.1210/me.6.2.198; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lee S, 2005, MOL ENDOCRINOL, V19, P399, DOI 10.1210/me.2004-0324; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SATO M, 1988, J CELL PHYSIOL, V135, P545, DOI 10.1002/jcp.1041350326; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	49	160	169	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11205	11213		10.1074/jbc.M510343200	http://dx.doi.org/10.1074/jbc.M510343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16467308	hybrid			2022-12-25	WOS:000236822200064
J	Croucher, D; Saunders, DN; Ranson, M				Croucher, D; Saunders, DN; Ranson, M			The urokinase/PAI-2 complex - A new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; MEDIATES ENDOCYTOSIS; BOUND UROKINASE; BINDING-SITE; INTERNALIZATION; DEGRADATION; SURFACE; PROUROKINASE; CATABOLISM; EXPRESSION	The efficient inactivation of urokinase plasminogen activator (uPA) by plasminogen activator inhibitor type 2 (PAI-2) at the surface of carcinoma cells is followed by rapid endocytosis of the uPA-PAI-2 complex. We now show that one pathway of this receptor-mediated endocytosis is mediated via the low density lipoprotein receptor-related protein (LRP) in prostate cancer cells. Detailed biochemical analyses using ligand binding assays and surface plasmon resonance revealed a novel and distinct interaction mechanism between native, human LRP and uPA-PAI-2. As reported previously for PAI-1, inhibition of uPA by PAI-2 significantly increased the affinity of the complex for LRP (K-D of 36 nM for uPA-PAI-2 versus 200 nM for uPA). This interaction was maintained in the presence of uPAR, confirming the validity of this interaction at the cell surface. However, unlike PAI-1, no interaction was observed between LRP and PAI-2 in either the stressed or the relaxed conformation. This suggests that the uPA-PAI-2-LRP interaction is mediated by site(s) within the uPA molecule alone. Thus, as inhibition of uPA by PAI-2 resulted in accelerated clearance of uPA from the cell surface possibly via its increased affinity for LRP, this represents a mechanism through which PAI-2 can clear proteolytic activity from the cell surface. Furthermore, lack of a direct interaction between PAI-2 and LRP implies that downstream signaling events initiated by PAI-1 may not be activated by PAI-2.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University of Wollongong; Garvan Institute of Medical Research	Ranson, M (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mranson@uow.edu.Au	Ranson, Marie/AAC-4468-2019; Ranson, Marie/GRO-5792-2022; Saunders, Darren/B-7677-2008; Ranson, Marie/A-6324-2008	Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Croucher, David/0000-0003-4965-8674; Saunders, Darren/0000-0003-0924-0513	Wellcome Trust [052458] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; Allen BJ, 2003, BRIT J CANCER, V88, P944, DOI 10.1038/sj.bjc.6600838; Allen BJ, 2001, CRIT REV ONCOL HEMAT, V39, P139, DOI 10.1016/S1040-8428(01)00113-5; Andersen OM, 2001, BIOCHEM J, V357, P289, DOI 10.1042/0264-6021:3570289; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andronicos NM, 2001, BRIT J CANCER, V85, P909, DOI 10.1054/bjoc.2001.2022; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FOEKENS JA, 1995, CANCER RES, V55, P1423; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; Li Y, 2002, BRIT J CANCER, V86, P1197, DOI 10.1038/sj/bjc/6600179; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; Ranson M, 2003, FRONT BIOSCI, V8, pS294, DOI 10.2741/1044; Ranson M, 2002, BREAST CANCER RES TR, V71, P149, DOI 10.1023/A:1013850107791; Ranson M, 1998, BRIT J CANCER, V77, P1586, DOI 10.1038/bjc.1998.261; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; Rodenburg KW, 1998, BIOCHEM J, V329, P55; Saunders DN, 1998, J BIOL CHEM, V273, P10965, DOI 10.1074/jbc.273.18.10965; Saunders DN, 2001, J BIOL CHEM, V276, P43383, DOI 10.1074/jbc.M103123200; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Wang SX, 2004, J CELL BIOCHEM, V91, P766, DOI 10.1002/jcb.10781; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	54	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10206	10213		10.1074/jbc.M513645200	http://dx.doi.org/10.1074/jbc.M513645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459332	hybrid			2022-12-25	WOS:000236594300047
J	Holger, S; Kurtzer, R; Eisenreich, W; Schwab, W				Holger, S; Kurtzer, R; Eisenreich, W; Schwab, W			The carotenase AtCCD1 from Arabidopsis thaliana is a dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; PSEUDOMONAS-PAUCIMOBILIS TMY1009; CLEAVAGE DIOXYGENASE; BETA-CAROTENE; OXYGENASE; FLOWERS; PLANTS; GENE; IDENTIFICATION; METABOLISM	Apocarotenoids resulting from the oxidative cleavage of carotenoids serve as important signaling and accessory molecules in a variety of biological processes. The enzymes catalyzing these reactions are referred to as carotenases or carotenoid oxygenases. Whether they act according to a monooxygenase mechanism, requiring two oxygens from different sources, or a dioxygenase mechanism is still a topic of controversy. In this study, we utilized the readily available beta-apo-8'-carotenal as a substrate for the heterologously expressed AtCCD1 protein from Arabidopsis thaliana to investigate the oxidative cleavage mechanism of the 9,10 double bond of carotenoids. beta-Ionone and a C-17-dialdehyde were detected as products by gas and liquid chromatography-mass spectrometry as well as NMR analysis. Labeling experiments using H-2 O-18 or O-18(2) showed that the oxygen in the keto-group of beta-ionone is derived solely from molecular dioxygen. When experiments were performed in an O-18(2)-enriched atmosphere, a substantial fraction of the C-17-dialdehyde contained labeled oxygen. The results unambiguously demonstrate a dioxygenase mechanism for the carotenase AtCCD1 from A. thaliana.	Tech Univ Munich, Fdn Biomol Food Technol, D-84354 Freising Weihenstephan, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich; Technical University of Munich	Holger, S (corresponding author), Tech Univ Munich, Fdn Biomol Food Technol, Lise Meitner Str 34, D-84354 Freising Weihenstephan, Germany.	holger.schmidt@mytum.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2005, TRENDS PLANT SCI, V10, P187, DOI 10.1016/j.tplants.2005.02.007; Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; BYRN M, 1966, J AM CHEM SOC, V88, P1916, DOI 10.1021/ja00961a013; Camara B, 2004, ARCH BIOCHEM BIOPHYS, V430, P16, DOI 10.1016/j.abb.2004.06.028; Cao YR, 2005, PLANT GROWTH REGUL, V46, P61, DOI 10.1007/s10725-005-5667-z; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; CREELMAN RA, 1984, PLANT PHYSIOL, V75, P166, DOI 10.1104/pp.75.1.166; CREELMAN RA, 1987, PLANT PHYSIOL, V85, P726, DOI 10.1104/pp.85.3.726; During A, 2004, ARCH BIOCHEM BIOPHYS, V430, P77, DOI 10.1016/j.abb.2004.03.024; Gessler NN, 2002, APPL BIOCHEM MICRO+, V38, P536, DOI 10.1023/A:1020770426304; Giuliano G, 2003, TRENDS PLANT SCI, V8, P145, DOI 10.1016/S1360-1385(03)00053-0; Gomez E, 1997, J SCI FOOD AGR, V74, P541, DOI [10.1002/(SICI)1097-0010(199708)74:4<541::AID-JSFA851>3.3.CO;2-4, 10.1002/(SICI)1097-0010(199708)74:4&lt;541::AID-JSFA851&gt;3.0.CO;2-D]; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; JUTTNER F, 1985, ARCH MICROBIOL, V141, P337, DOI 10.1007/BF00428846; KAISER R, 2002, CAROTENOID DERIVED A; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1866, DOI 10.1271/bbb.59.1866; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; LI Y, 1990, PLANT PHYSIOL, V92, P551, DOI 10.1104/pp.92.3.551; Maia JGS, 2000, J ESSENT OIL RES, V12, P322, DOI 10.1080/10412905.2000.9699526; Mathieu S, 2005, J EXP BOT, V56, P2721, DOI 10.1093/jxb/eri265; Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Reeder MR, 1999, TETRAHEDRON LETT, V40, P3115, DOI 10.1016/S0040-4039(99)00454-2; ROBERTSON GW, 1995, PHYTOCHEMISTRY, V38, P1175, DOI 10.1016/0031-9422(94)00782-O; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Simkin AJ, 2004, PLANT PHYSIOL, V136, P3504, DOI 10.1104/pp.104.049718; Svensson S, 1996, FEBS LETT, V394, P217, DOI 10.1016/0014-5793(96)00954-4; Vartapetian B B, 1966, Biokhimiia, V31, P881; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WILLOWS RD, 1992, PHYTOCHEMISTRY, V31, P2649, DOI 10.1016/0031-9422(92)83604-W; Wise KJ, 2002, TRENDS BIOTECHNOL, V20, P387, DOI 10.1016/S0167-7799(02)02023-1; ZEEVAART JAD, 1989, PLANT PHYSIOL, V91, P1594, DOI 10.1104/pp.91.4.1594	40	102	110	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9845	9851		10.1074/jbc.M511668200	http://dx.doi.org/10.1074/jbc.M511668200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459333	hybrid			2022-12-25	WOS:000236594300005
J	Oka, M; Rodic, N; Graddy, J; Chang, LJ; Terada, N				Oka, M; Rodic, N; Graddy, J; Chang, LJ; Terada, N			CpG sites preferentially methylated by Dnmt3a in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; FIBROBLAST GROWTH-FACTORS; DNA CYTOSINE-5 METHYLTRANSFERASES; DE-NOVO; PWWP DOMAIN; DIFFERENTIAL EXPRESSION; MAMMALIAN DEVELOPMENT; MESSENGER-RNA; TRANSCRIPTION; MAINTENANCE	Dnmt3a and Dnmt3b are two major de novo DNA methyltransferases essential for embryonic development in mammals. It has been shown that Dnmt3a and Dnmt3b have distinct substrate preferences for certain genomic loci, including major and minor satellite repeats. However, the exact target CpG sites where Dnmt3a and Dnmt3b catalyze DNA methylation remains largely unknown. To identify a CpG site that is specifically methylated by Dnmt3a or Dnmt3b, we screened methylated genomic loci by methylation sensitive restriction fingerprinting using genomic DNA from wildtype, Dnmt3a null, Dnmt3b null, and Dnmt3a-Dnmt3b double null ES cells. Interestingly, one of the CpG sites was preferentially methylated in wild-type and Dnmt3b null ES cells but not in Dnmt3a null or Dnmt3a-Dnmt3b double null ES cells, suggesting that the site-specific methylation was Dnmt3a-dependent. Sequencing results revealed that the isolated CpG site is located within the 1st exon of the G isoform of fibroblast growth factor (Fgf-1.G) on mouse chromosome 18. Exogenous expression of Dnmt3a but not Dnmt3b in the double null ES cells restored DNA methylation of this CpG site. When we examined alternative transcription initiation sites, we determined that another CpG site in the 5'-flanking region of the Fgf-1. A isoform was also methylated specifically by Dnmt3a. Using chimeric constructs between Dnmt3a and Dnmt3b, we further determined that the NH2-terminal regulatory domain of Dnmt3a was responsible for establishing its substrate specificity. These results indicate that certain CpG sites within the Fgf-1 gene locus are preferentially methylated by Dnmt3a but not by Dnmt3b. Selective methylation by a specific member of Dnmt3 may therefore play a role in the orchestration of gene expression during embryonic development.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu			NCRR NIH HHS [RR 17001] Funding Source: Medline; NIDDK NIH HHS [DK 59699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR017001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Handa V, 2005, J MOL BIOL, V348, P1103, DOI 10.1016/j.jmb.2005.02.044; Hattori N, 2004, GENOME RES, V14, P1733, DOI 10.1101/gr.2431504; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Huang THM, 1997, CANCER RES, V57, P1030; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin IG, 2002, MOL CELL BIOL, V22, P704, DOI 10.1128/MCB.22.3.704-723.2002; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; MYERS RL, 1993, ONCOGENE, V8, P341; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540; Oka M, 2002, MOL BIOL CELL, V13, P1274, DOI 10.1091/mbc.02-01-0600; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; RYDEL RE, 1987, J NEUROSCI, V7, P3639; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhang YX, 2001, BBA-GENE STRUCT EXPR, V1521, P45, DOI 10.1016/S0167-4781(01)00282-2	37	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9901	9908		10.1074/jbc.M511100200	http://dx.doi.org/10.1074/jbc.M511100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439359	hybrid			2022-12-25	WOS:000236594300011
J	Hasan, Z; Renirie, R; Kerkman, R; Ruijssenaars, HJ; Hartog, AF; Wever, R				Hasan, Z; Renirie, R; Kerkman, R; Ruijssenaars, HJ; Hartog, AF; Wever, R			Laboratory-evolved vanadium chloroperoxidase exhibits 100-fold higher halogenating activity at alkaline pH - Catalytic effects from first and second coordination sphere mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS CURVULARIA-INAEQUALIS; CONTAINING ENZYME CHLOROPEROXIDASE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; SITE MUTANTS; BROMOPEROXIDASE; HALOPEROXIDASE; MECHANISM; INACTIVATION; PURIFICATION	Directed evolution was performed on vanadium chloroperoxidase from the fungus Curvularia inaequalis to increase its brominating activity at a mildly alkaline pH for industrial and synthetic applications and to further understand its mechanism. After successful expression of the enzyme in Escherichia coli, two rounds of screening and selection, saturation mutagenesis of a "hot spot," and rational recombination, a triple mutant (P395D/L241V/T343A) was obtained that showed a 100-fold increase in activity at pH 8 (k(cat) = 100 s(-1)). The increased K-m values for Br- (3.1 mM) and H2O2 (16 mu M) are smaller than those found for vanadium bromoperoxidases that are reasonably active at this pH. In addition the brominating activity at pH 5 was increased by a factor of 6 (k(cat) = 575 s(-1)), and the chlorinating activity at pH 5 was increased by a factor of 2 (k(cat) = 36 s(-1)), yielding the "best" vanadium haloperoxidase known thus far. The mutations are in the first and second coordination sphere of the vanadate cofactor, and the catalytic effects suggest that fine tuning of residues Lys-353 and Phe-397, along with addition of negative charge or removal of positive charge near one of the vanadate oxygens, is very important. Lys-353 and Phe-397 were previously assigned to be essential in peroxide activation and halide binding. Analysis of the catalytic parameters of the mutant vanadium bromoperoxidase from the seaweed Ascophyllum nodosum also adds fuel to the discussion regarding factors governing the halide specificity of vanadium haloperoxidases. This study presents the first example of directed evolution of a vanadium enzyme.	Univ Amsterdam, Vant Hoff Inst Mol Sci, NL-1018 WS Amsterdam, Netherlands; Dutch States Mines Antiinfect BV, Delft, Netherlands	University of Amsterdam	Wever, R (corresponding author), Univ Amsterdam, Vant Hoff Inst Mol Sci, Nieuwe Achtergracht 129, NL-1018 WS Amsterdam, Netherlands.	rwever@science.uva.nl	Wever, Ron/AAM-4520-2020					Brochardt SA, 2001, APPL ENVIRON MICROB, V67, P3174, DOI 10.1128/AEM.67.7.3174-3179.2001; CABRI W, 1995, ACCOUNTS CHEM RES, V28, P2, DOI 10.1021/ar00049a001; Carter JN, 2002, J INORG BIOCHEM, V91, P59, DOI 10.1016/S0162-0134(02)00400-2; CHASTEEN ND, 1983, STRUCT BOND, V53, P105; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DEBOER E, 1988, J BIOL CHEM, V263, P12326; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V872, P104, DOI 10.1016/0167-4838(86)90153-6; DEBOER E, 1987, BIOTECHNOL BIOENG, V30, P607, DOI 10.1002/bit.260300504; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dembitsky VM, 2003, TETRAHEDRON, V59, P4701, DOI 10.1016/S0040-4020(03)00701-4; Hansen EH, 2005, J APPL MICROBIOL, V98, P581, DOI 10.1111/j.1365-2672.2004.02491.x; Hansen EH, 2003, APPL ENVIRON MICROB, V69, P4611, DOI 10.1128/AEM.69.8.4611-4617.2003; HECK RF, 1972, J ORG CHEM, V37, P2320, DOI 10.1021/jo00979a024; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; JOHANSEN C, 1999, Patent No. 9908531; Leung DW, 1989, TECHNIQUE, V1, P11; Littlechild J, 1999, CURR OPIN CHEM BIOL, V3, P28, DOI 10.1016/S1367-5931(99)80006-4; Littlechild J, 2003, COORDIN CHEM REV, V237, P65, DOI 10.1016/S0010-8545(02)00226-6; Littlechild J, 2002, J MOL RECOGNIT, V15, P291, DOI 10.1002/jmr.590; Macedo-Ribeiro S, 1999, J BIOL INORG CHEM, V4, P209, DOI 10.1007/s007750050306; Messerschmidt A, 1997, BIOL CHEM, V378, P309, DOI 10.1515/bchm.1997.378.3-4.309; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; Ohshiro T, 2004, PROTEIN SCI, V13, P1566, DOI 10.1110/ps.03496004; Ortiz-Bermudez P, 2003, APPL ENVIRON MICROB, V69, P5015, DOI 10.1128/AEM.69.8.5015-5018.2003; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Renirie R, 2003, ADV SYNTH CATAL, V345, P849, DOI 10.1002/adsc.200303008; RILEY JP, 1971, INTRO MARINE CHEM, P60; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Shimonishi M, 1998, FEBS LETT, V428, P105, DOI 10.1016/S0014-5793(98)00500-6; SOEDJAK HS, 1995, BIOCHEMISTRY-US, V34, P12689, DOI 10.1021/bi00039a027; SVENDSEN A, 2002, Patent No. 6372465; Tanaka N, 2004, J INORG BIOCHEM, V98, P625, DOI 10.1016/j.jinorgbio.2004.02.001; Tanaka N, 2003, INORG CHIM ACTA, V356, P288, DOI 10.1016/S0020-1693(03)00476-6; VANSCHIJNDEL JWPM, 1994, EUR J BIOCHEM, V225, P151; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WEVER R, 1991, ENVIRON SCI TECHNOL, V25, P446, DOI 10.1021/es00015a010; Wever R., 2001, HDB METALLOPROTEINS, P1417; WEVER R, 1995, Patent No. 9527009; Zampella G, 2005, J AM CHEM SOC, V127, P953, DOI 10.1021/ja046016x	40	63	64	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9738	9744		10.1074/jbc.M512166200	http://dx.doi.org/10.1074/jbc.M512166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455658	hybrid			2022-12-25	WOS:000236404700086
J	Lee, DY; Northrop, JP; Kuo, MH; Stallcup, MR				Lee, DY; Northrop, JP; Kuo, MH; Stallcup, MR			Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN METHYLTRANSFERASE; P160 COACTIVATORS; METHYLATION; ACTIVATION; CHROMATIN; DOMAINS; ACETYLTRANSFERASE; RECRUITS; COMPLEX; PRMT1	Methylation of Lys- 9 of histone H3 has been associated with repression of transcription. G9a is a histone H3 Lys- 9 methyltransferase localized in euchromatin and acts as a corepressor for specific transcription factors. Here we demonstrate that G9a also functions as a coactivator for nuclear receptors, cooperating synergistically with nuclear receptor coactivators glucocorticoid receptor interacting protein 1, coactivator- associated arginine methyltransferase 1 ( CARM1), and p300 in transient transfection assays. This synergy depends strongly on the arginine- specific protein methyltransferase activity of CARM1 but does not absolutely require the enzymatic activity of G9a and is specific to CARM1 and G9a among various protein methyltransferases. Reduction of endogenous G9a diminished hormonal activation of an endogenous target gene by the androgen receptor, and G9a associated with regulatory regions of this same gene. G9a fused to Gal4 DNA binding domain can repress transcription in a lysine methyltransferase- dependent manner; however, the histone modifications associated with transcriptional activation can inhibit the methyltransferase activity of G9a. These findings suggest a link between histone arginine and lysine methylation and a mechanism for controlling whether G9a functions as a corepressor or coactivator.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Southern California; Michigan State University	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 1333 San Pablo St,MCA-51A, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE007211, DE07211] Funding Source: Medline; NIDDK NIH HHS [R37 DK055274, R01 DK055274, DK55274] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen YH, 2005, MOL CELL BIOL, V25, P5965, DOI 10.1128/MCB.25.14.5965-5972.2005; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Ma H, 2003, METHOD ENZYMOL, V364, P284; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507	33	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8476	8485		10.1074/jbc.M511093200	http://dx.doi.org/10.1074/jbc.M511093200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16461774	hybrid, Green Accepted			2022-12-25	WOS:000236247100023
J	Lee, YK; Choi, YH; Chua, S; Park, YJ; Moore, DM				Lee, YK; Choi, YH; Chua, S; Park, YJ; Moore, DM			Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BILE-ACID SYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; FEEDBACK-REGULATION; ESTROGEN-RECEPTOR; REGULATES EXPRESSION; COACTIVATOR ACTIVITY; UP-REGULATION	The nuclear receptor LRH-1 (NR5A2) functions to regulate expression of a number of genes associated with bile acid homeostasis and other liver functions, but mechanisms that modulate its activity remain unclear. We have found that mitogenic stimuli, including treatment with phorbol myristate (PMA), increase LRH-1 transactivation. This response maps to the hinge and ligand binding domains of LRH-1 and is blocked by the mitogen-activated protein kinase ERK1/2 inhibitor U0126. LRH-1 is a phosphoprotein and hinge domain serine residues at 238 and 243 are required for effective phosphorylation, both in vitro and in cells. Preventing phosphorylation of these residues by mutating both to alanine decreases PMA-dependent LRH-1 transactivation and mimicking phosphorylation by mutation to positively charged aspartate residues increases basal transactivation. Although serine phosphorylation of the hinge of SF-1 (NR5A1), the closest relative of LRH-1, confers a similar response, the specific targets differ in the two closely related orphan receptors. These results define a novel pathway for the modulation of LRH-1 transactivation and identify specific LRH-1 residues as downstream targets of mitogenic stimuli. This pathway may contribute to recently described proliferative functions of LRH-1.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Lee, YK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	ylee@bcm.tmc.edu	Park, Young Joo/J-4161-2012	Park, Young Joo/0000-0002-3671-6364	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068804] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK068804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Broadus J, 1999, MOL CELL, V3, P143, DOI 10.1016/S1097-2765(00)80305-6; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Crestani M, 1996, BIOCHEM BIOPH RES CO, V225, P585, DOI 10.1006/bbrc.1996.1215; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Feingold KR, 1996, J LIPID RES, V37, P223; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; Parker KL, 1998, MOL CELL ENDOCRINOL, V145, P15, DOI 10.1016/S0303-7207(98)00164-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; Stroup D, 2005, FRONT BIOSCI-LANDMRK, V10, P1678, DOI 10.2741/1652; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang W, 2005, P NATL ACAD SCI USA, V102, P7505, DOI 10.1073/pnas.0409482102; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu PL, 2004, MOL ENDOCRINOL, V18, P1887, DOI 10.1210/me.2003-0334; Yu FQ, 2005, J ENDOCRINOL, V186, P85, DOI 10.1677/joe.1.05955	52	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7850	7855		10.1074/jbc.M509115200	http://dx.doi.org/10.1074/jbc.M509115200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439367	hybrid			2022-12-25	WOS:000236031000019
J	Langhorst, MF; Reuter, A; Luxenhofer, G; Boneberg, EM; Legler, DF; Plattner, H; Stuermer, CAO				Langhorst, Matthias F.; Reuter, Alexander; Luxenhofer, Georg; Boneberg, Eva-Maria; Legler, Daniel F.; Plattner, Helmut; Stuermer, Claudia A. O.			Preformed reggie/flotillin caps: stable priming platforms for macrodomain assembly in T cells	FASEB JOURNAL			English	Article						lipid rafts; signal transduction; T cell activation; actin cytoskeleton; raft clustering	ENRICHED MEMBRANE DOMAINS; LIPID RAFTS; ANCHORED PROTEINS; PLASMA-MEMBRANE; ANTIGEN RECEPTOR; IMMUNE SYNAPSE; RHO-FAMILY; VAV; LCK; REORGANIZATION	T cell activation after contact with an antigen-presenting cell depends on the regulated assembly of the T cell receptor signaling complex, which involves the polarized assembly of a stable, raft-like macrodomain surrounding engaged T cell receptors. Here we show that the preformed reggie/flotillin caps present in resting T cells act as priming platforms for macrodomain assembly. Preformed reggie-1/flotillin-2 caps are exceptionally stable, as shown by fluorescence recovery after photobleaching (FRAP). Upon T cell stimulation, signaling molecules are recruited to the stable reggie/flotillin caps. Importantly, a trans-negative reggie-1/flotillin-2 deletion mutant, which interferes with assembly of the preformed reggie/ flotillin cap, impairs raft polarization and macrodomain formation after T cell activation. Accordingly, expression of the trans-negative reggie-1 mutant leads to the incorrect positioning of the guanine nucleotide exchange factor Vav, resulting in defects in cytoskeletal reorganization. Thus, the preformed reggie/ flotillin caps are stable priming platforms for the assembly of multiprotein complexes controlling actin reorganization during T cell activation.	Univ Konstanz, Dev Neurobiol Grp, Dept Biol, D-7750 Constance, Germany; Univ Konstanz, Biotechnol Inst Thurgau, Tagerwilen, Switzerland	University of Konstanz	Langhorst, MF (corresponding author), Univ Str 10, D-78457 Constance, Germany.			Legler, Daniel F./0000-0001-8610-4764				Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Filipp D, 2004, J IMMUNOL, V172, P4266, DOI 10.4049/jimmunol.172.7.4266; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gordy C, 2004, J IMMUNOL, V172, P2030, DOI 10.4049/jimmunol.172.4.2030; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hazarika P, 1999, J CELL BIOCHEM, V75, P147, DOI 10.1002/(SICI)1097-4644(19991001)75:1<147::AID-JCB15>3.0.CO;2-D; He HT, 2005, SEMIN IMMUNOL, V17, P23, DOI 10.1016/j.smim.2004.09.001; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Huang JY, 2000, P NATL ACAD SCI USA, V97, P10923, DOI 10.1073/pnas.97.20.10923; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; KWON G, 1994, CELL SIGNAL, V6, P663, DOI 10.1016/0898-6568(94)90049-3; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Mittelbrunn M, 2002, J IMMUNOL, V169, P6691, DOI 10.4049/jimmunol.169.12.6691; Morgan MM, 2001, J IMMUNOL, V167, P5708, DOI 10.4049/jimmunol.167.10.5708; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Petersson K, 2004, SCAND J IMMUNOL, V59, P345, DOI 10.1111/j.0300-9475.2004.01404.x; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Rodgers W, 2005, TRENDS IMMUNOL, V26, P97, DOI 10.1016/j.it.2004.11.016; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slaughter N, 2003, CLIN IMMUNOL, V108, P138, DOI 10.1016/S1521-6616(03)00097-4; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Tu XL, 2004, J PROTEOME RES, V3, P445, DOI 10.1021/pr0340779; Valensin S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Weber I, 2003, METHOD ENZYMOL, V361, P34; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	56	47	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					711	+		10.1096/fj.05-4760fje	http://dx.doi.org/10.1096/fj.05-4760fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16452278	Green Published			2022-12-25	WOS:000237698700044
J	Moore, LR; Fujioka, H; Williams, PS; Chalmers, JJ; Grimberg, B; Zimmerman, PA; Zborowski, M				Moore, Lee R.; Fujioka, Hisashi; Williams, P. Stephen; Chalmers, Jeffrey J.; Grimberg, Brian; Zimmerman, Peter A.; Zborowski, Maciej			Hemoglobin degradation in malaria-infected erythrocytes determined from live cell magnetophoresis	FASEB JOURNAL			English	Article						erythrocyte magnetic susceptibility; Plasmodium falciparum; hemozoin; ferriheme; heme; toxicity	INTRAERYTHROCYTIC PLASMODIUM-FALCIPARUM; MAGNETIC-SUSCEPTIBILITY; BETA-HEMATIN; WHOLE-BLOOD; RED-CELLS; IN-VITRO; PARASITE; HEME; CHLOROQUINE; SEPARATION	During intra-erythrocytic development, malaria trophozoites digest hemoglobin, which leads to parasite growth and asexual replication while accumulating toxic heme. To avoid death, the parasite synthesizes insoluble hemozoin crystals in the digestive vacuole through polymerization of beta-hematin dimers. In the process, the heme is converted to a high-spin ferriheme whose magnetic properties were studied as early as 1936 by Pauling et al. Here, by magnetophoretic cell motion analysis, we provide evidence for a graduated increase of live cell magnetic susceptibility with developing blood-stage parasites, compatible with the increase in hemozoin content and the mechanism used by P. falciparum to avoid heme toxicity. The measured magnetophoretic mobility of the erythrocyte infected with a late-stage schizont form was m = 2.94 x 10(-6) mm(3) s/kg, corresponding to the net volume magnetic susceptibility ( relative to water) of Delta(X) = 1.80 x 10(-6), significantly higher than that of the oxygenated erythrocyte (-0.18 x 10(-6)) but lower than that of the fully deoxygenated erythrocyte (3.33 x 10(-6)). The corresponding fraction of hemoglobin converted to hemozoin, calculated based on the known magnetic susceptibilities of hemoglobin heme and hemozoin ferriheme, was 0.50, in agreement with the published biochemical and crystallography data. Magnetophoretic analysis of live erythrocytes could become significant for antimalarial drug susceptibility and resistance determination.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA; Case Western Reserve Univ, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; University System of Ohio; Ohio State University; Case Western Reserve University	Zborowski, M (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	zborowm@ccf.org	Grimberg, Brian/I-1251-2013; Williams, Philip/C-2774-2008	Grimberg, Brian/0000-0002-6015-4912; Williams, Philip/0000-0002-5951-2612	NCI NIH HHS [CA-062349, R01 CA062349] Funding Source: Medline; NIAID NIH HHS [R01 AI052312, AI-523213, R01 AI046919] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052312, R01AI046919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bartoszek M, 2001, PHYSICA B, V307, P217, DOI 10.1016/S0921-4526(01)00630-5; Bazylinski DA, 2004, NAT REV MICROBIOL, V2, P217, DOI 10.1038/nrmicro842; Becker K, 2004, INT J PARASITOL, V34, P163, DOI 10.1016/j.ijpara.2003.09.011; Becker R., 1982, ELECTROMAGNETIC FIEL; BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; Bohle DS, 1998, J AM CHEM SOC, V120, P8255, DOI 10.1021/ja980962u; Carpino F, 2005, J MAGN MAGN MATER, V293, P546, DOI 10.1016/j.jmmm.2005.01.071; Carter V, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-35; CERDONIO M, 1978, P NATL ACAD SCI USA, V75, P4916, DOI 10.1073/pnas.75.10.4916; CERDONIO M, 1985, P NATL ACAD SCI USA, V82, P102, DOI 10.1073/pnas.82.1.102; Coryell CD, 1937, J AM CHEM SOC, V59, P633, DOI 10.1021/ja01283a012; Cranmer SL, 1997, T ROY SOC TROP MED H, V91, P363, DOI 10.1016/S0035-9203(97)90110-3; Dunin-Borkowski RE, 1998, SCIENCE, V282, P1868, DOI 10.1126/science.282.5395.1868; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Egan TJ, 2002, J INORG BIOCHEM, V91, P19, DOI 10.1016/S0162-0134(02)00372-0; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; FABRY ME, 1983, BIOCHEMISTRY-US, V22, P4119, DOI 10.1021/bi00286a020; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; GUTIERREZ Y, 2000, DIAGNOSTIC PATHOLOGY, V2, P235; HEDELBERGER M, 1946, J IMMUNOL, V52, P325; KROGSTAD DF, 2001, ESSENTIALS TROPICAL, P341; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lelievre J, 2005, EXP PARASITOL, V109, P195, DOI 10.1016/j.exppara.2004.11.012; McCloskey KE, 2003, ANAL CHEM, V75, P6868, DOI 10.1021/ac034315j; MELVILLE D, 1975, NATURE, V255, P706, DOI 10.1038/255706a0; Miller JC., 1992, STAT ANAL CHEM; Moore LR, 2004, ANAL CHEM, V76, P3899, DOI 10.1021/ac049910f; Noland GS, 2003, MOL BIOCHEM PARASIT, V130, P91, DOI 10.1016/S0166-6851(03)00163-4; ORJIH AU, 1993, BIOCHIM BIOPHYS ACTA, V1157, P270, DOI 10.1016/0304-4165(93)90109-L; ORJIH AU, 1994, EXPERIENTIA, V50, P34, DOI 10.1007/BF01992046; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; PAUL F, 1981, LANCET, V2, P70; PAULING L, 1977, P NATL ACAD SCI USA, V74, P2612, DOI 10.1073/pnas.74.7.2612; Plyavin' Yu. A., 1983, Magnetohydrodynamics, V19, P349; Recktenwald D., 1998, CELL SEPARATION METH; Ridley RG, 2003, NATURE, V424, P887, DOI 10.1038/424887a; SAVICKI JP, 1984, P NATL ACAD SCI-BIOL, V81, P5417, DOI 10.1073/pnas.81.17.5417; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAYLOR TE, 2000, HUNTERS TROPICAL MED, P614; Tripathi AK, 2004, ANAL BIOCHEM, V325, P85, DOI 10.1016/j.ab.2003.10.016; UHLEMANN AC, 2000, MACS MORE, V4, P7; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Zborowski M, 2003, BIOPHYS J, V84, P2638, DOI 10.1016/S0006-3495(03)75069-3; Zborowski Maciej, 2005, Methods Mol Biol, V295, P291; Zhang JM, 1999, MOL BIOCHEM PARASIT, V99, P129, DOI 10.1016/S0166-6851(99)00008-0	53	72	75	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					747	+		10.1096/fj.05-5122fje	http://dx.doi.org/10.1096/fj.05-5122fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461330	Green Accepted			2022-12-25	WOS:000237698700038
J	Leduc, C; Claverie, P; Eymin, B; Col, E; Khochbin, S; Brambilla, E; Gazzeri, S				Leduc, C.; Claverie, P.; Eymin, B.; Col, E.; Khochbin, S.; Brambilla, E.; Gazzeri, S.			p14(ARF) promotes RB accumulation through inhibition of its Tip60-dependent acetylation	ONCOGENE			English	Article						p14(ARF); RB; acetylation; Tip60; DNA damage	DEGRADATION; P53; PROTEIN; MDM2; DIFFERENTIATION; PATHWAY; TUMORS; DEATH; TIP60; E2F1	p14(ARF) is a tumour suppressor which plays a critical role in p53-dependent or -independent cell growth control. Several studies have recently provided evidence that p14(ARF) can also interfere either directly or indirectly with some components of the RB signalling pathway to mediate its antiproliferative activity. The aim of this study was to explore the existence of direct relationships between p14(ARF) and RB proteins. We show that p14(ARF) promotes the accumulation of a hypoacetylated RB protein, when it is upregulated in a model of stable-inducible clones or physiologically induced following cell exposure to cytotoxic agents. Looking for the mechanisms involved in this process, we demonstrate that the histone acetyl transferase Tip60 directly interacts with RB and stimulates its degradation by the proteasome through acetylation of its C-terminus. Furthermore, and consistent with p14(ARF)-induced RB accumulation, we provide evidence that p14(ARF) prevents Tip60-mediated RB acetylation, therefore precluding its proteasomal degradation. Overall, our results identify a novel mechanism by which p14(ARF) controls the RB pathway to trigger its antiproliferative function.	Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France; Univ Grenoble 1, INSERM, U309, Inst Albert Bonniot,Lab Biol Mol & Cellulaire Dif, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Univ Grenoble 1, INSERM, U578,Grp Rech Canc Poumon, Inst Albert Bonniot,Fac Med, F-38706 La Tronche, France.	sylvie.gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; Khochbin, Saadi/M-8090-2013; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019	eymin, beatrice/0000-0002-7311-3810; Khochbin, Saadi/0000-0002-0455-0857; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486	23	48	52	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4147	4154		10.1038/sj.onc.1209446	http://dx.doi.org/10.1038/sj.onc.1209446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501607				2022-12-25	WOS:000239004800002
J	Moretti, S; Macchiarulo, A; De Falco, V; Avenia, N; Barbi, F; Carta, C; Cavaliere, A; Melillo, RM; Passeri, L; Santeusanio, F; Tartaglia, M; Santoro, M; Puxeddu, E				Moretti, S.; Macchiarulo, A.; De Falco, V.; Avenia, N.; Barbi, F.; Carta, C.; Cavaliere, A.; Melillo, R. M.; Passeri, L.; Santeusanio, F.; Tartaglia, M.; Santoro, M.; Puxeddu, E.			Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma	ONCOGENE			English	Article						papillary thyroid carcinoma; BRAF mutation; kinase assay; molecular dynamic simulation	BRAF MUTATIONS; ACTIVATION; CANCER; GENE; PREVALENCE; MECHANISM; PATHWAY	Activating mutations of the BRAF gene are the most common genetic alterations in papillary thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF(V600E), appeared virtually unique in this cancer type. Here, we report on the identification in a classic PTC of a novel BRAF mutation, namely a 1795GTT insertion, resulting in BRAF(V599Ins), and describe its biochemical and molecular characterization. Kinase assays carried out on BRAF(V599Ins) and BRAF(V600E) revealed a three- to five-fold increase in the enzymatic activity of both mutants with respect to BRAF(WT). Similarly, evaluation of BRAF-induced phosphorylation of MEK, MAPK and RSK revealed a significant MAPK cascade activation in cells expressing BRAF(V599Ins) or BRAF(V600E), but not in cells expressing BRAF(WT). Molecular dynamic simulations showed a destabilization of the inactive conformation of the enzyme in both BRAF(V599Ins) and BRAF(V600E) mutants, but not in BRAF(WT). The analysis of the interaction energies inside the catalytic site allowed to demonstrate the presence of repulsive electrostatic forces acting on the activation loop and moving from inward to outward of the mutant enzymes. Finally, focus assays in NIH-3T3 cells confirmed a high transformation rate in the cells transfected either with BRAF(V599Ins) or BRAF(V600E). In conclusion, this study demonstrated that BRAF(V599Ins), as BRAF(V600E), is a 'gain of function' mutation, characterized by a constitutive catalytic activation, which accounts for its causative role in the studied PTC.	Univ Perugia, Dipartimento Med Interna, Sez MISEM, I-06126 Perugia, Italy; Univ Perugia, Dipartimento Chim & Tecnol Farm, I-06126 Perugia, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Perugia, Ctr Riferimento Reg Endocrinochirurg, I-06126 Perugia, Italy; Ist Super Sanita, Dipartimento Biol Cellulare & Neurosci, I-00161 Rome, Italy; Univ Perugia, Ist Anat Patol, I-06126 Perugia, Italy	University of Perugia; University of Perugia; University of Naples Federico II; University of Perugia; Istituto Superiore di Sanita (ISS); University of Perugia	Puxeddu, E (corresponding author), Univ Perugia, Dipartimento Med Interna, Sez MISEM, Via Enrico dal Pozzo, I-06126 Perugia, Italy.	efisio@dimisem.med.unipg.it	Puxeddu, Efisio/I-8188-2012; Macchiarulo, Antonio/L-2846-2017; DE FALCO, VALENTINA/C-2061-2015; Carta, Claudio/A-7305-2013; Avenia, Nicola/AAL-4546-2021; melillo, rosa marina/O-5255-2015; Tartaglia, Marco/K-2955-2018	Macchiarulo, Antonio/0000-0001-9535-4183; DE FALCO, VALENTINA/0000-0002-8972-7921; Carta, Claudio/0000-0003-3545-198X; Tartaglia, Marco/0000-0001-7736-9672; MELILLO, Rosa Marina/0000-0002-9233-5275				Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carta C, 2006, CLIN ENDOCRINOL, V64, P105, DOI 10.1111/j.1365-2265.2005.02401.x; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Greene F, 2002, AJCC CANC STAGING MA, P77; GRUBMULLER H, 1996, SOLVATE V10 THEORETI; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Oler G, 2005, CLIN ENDOCRINOL, V62, P509, DOI 10.1111/j.1365-2265.2005.02235.x; Puxeddu E, 2004, J CLIN ENDOCR METAB, V89, P2414, DOI 10.1210/jc.2003-031425; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Trovisco V, 2005, VIRCHOWS ARCH, V446, P589, DOI 10.1007/s00428-005-1236-0; Trovisco V, 2005, HUM PATHOL, V36, P694, DOI 10.1016/j.humpath.2005.04.011; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978	23	46	47	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4235	4240		10.1038/sj.onc.1209448	http://dx.doi.org/10.1038/sj.onc.1209448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501605				2022-12-25	WOS:000239004800011
J	Lynch, CJ; Milner, J				Lynch, C. J.; Milner, J.			Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency	ONCOGENE			English	Article						p53; haplo-insufficiency; Li-Fraumeni; survivin; SIRT1; mRNA	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENES; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; HUMAN CANCERS; IN-VIVO; MODEL; TRANSCRIPTION; ACTIVATION	A haploid genotype may be insufficient to support normal wild-type function. Such haplo-insufficiency has recently been documented for numerous tumour suppressor genes. p53 is a crucial tumour suppressor governing DNA repair, cell cycle arrest and apoptosis via its role as a stress-responsive transcription factor. p53 haplo-insufficiency has been observed in vivo with human familial cancer in Li-Fraumeni Syndrome (LFS) and in mouse p53-knockout models of LFS. The increased tumorigenesis associated with loss of one p53 allele has been attributed to reduced p53-dependent stress responses. However, the underlying biochemical basis for such attenuated responses in p53(+/-) cells remains unclear. Here we have determined basal p53 messenger RNA ( mRNA) and protein levels, and compared the p53 stress response in p53+/+, p53+/- and p53-/- isogenic clones derived from HCT116 cells. Basal expression of p53 in p53+/- cells was 25% relative to p53+/+ cells, and this differential was maintained following oncogenic stress. This deficiency was manifested at both p53 mRNA and protein levels and resulted in attenuated p53 stress responses, in particular for p21(waf1) upregulation and survivin downregulation, and reduced G1 arrest and apoptosis. These observations identify a molecular basis for wild-type p53 haplo-insufficiency, which may explain the attenuated tumour-suppressive phenotype observed in cells with a single wild-type p53 allele and in humans with LFS.	Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Lynch, CJ (corresponding author), Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, Zone 14, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk	Lynch, Christopher J./E-6875-2010; Lynch, Cian/AIC-5510-2022; Stoklosa, Tomasz A/I-8825-2017; Lynch, Cian J/K-2191-2017	Lynch, Christopher J./0000-0003-2453-5838; Lynch, Cian/0000-0003-0187-3527; Lynch, Cian J/0000-0003-0187-3527				Allison SJ, 2003, CANCER RES, V63, P6674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FOFO T, 2002, DRUG RESIST UPDAT, V50, P209; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GENG L, 2004, NAT GENET, V36, P63; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mirzayans R, 2003, ONCOGENE, V22, P5562, DOI 10.1038/sj.onc.1206514; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637	49	46	49	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3463	3470		10.1038/sj.onc.1209387	http://dx.doi.org/10.1038/sj.onc.1209387			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449974				2022-12-25	WOS:000238448100011
J	Yang, X; Chen, MW; Terry, S; Vacherot, F; Bemis, DL; Capodice, J; Kitajewski, J; de la Taille, A; Benson, MC; Guo, Y; Buttyan, R				Yang, X.; Chen, M. -W.; Terry, S.; Vacherot, F.; Bemis, D. L.; Capodice, J.; Kitajewski, J.; de la Taille, A.; Benson, M. C.; Guo, Y.; Buttyan, R.			Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Wnt signaling; beta-catenin; PCDH-PC; Akt; MDM2	BETA-CATENIN MUTATIONS; GENE; TRANSCRIPTION; PROGRESSION; ACTIVATION; AKT; PHOSPHORYLATION; PATHWAY; GROWTH; ALPHA	beta-Catenin, a component of the Wnt signaling pathway, is a coactivator of human androgen receptor (hAR) transcriptional activity. Here, we show that Wnt signaling also influences androgen-mediated signaling through its ability to regulate hAR mRNA and protein in prostate cancer (PCa) cells. Three functional LEF-1/TCF binding sites lie within the promoter of the hAR gene as shown by CHIP assays that captured beta-catenin-bound chromatin from Wnt-activated LNCaP cells. Chimeric reporter vectors that use the hAR gene promoter to drive luciferase expression confirmed that these LEF-1/TCF binding elements are able to confer robust upregulation of luciferase expression when stimulated by Wnt-1 or by transfection with beta-catenin and that dominant-negative TCF or mutations within the dominant TCF-binding element abrogated the response. Semi-quantitative and real time RT-PCR assays confirmed that Wnt activation upregulates hAR mRNA in PCa cells. In contrast, hAR protein expression was strongly suppressed by Wnt activation. The reduction of hAR protein is consistent with evidence that Wnt signaling increased phosphorylation of Akt and its downstream target, MDM2 that promotes degradation of hAR protein through a proteasomal pathway. These data indicate that the hAR gene is a direct target of LEF-1/TCF transcriptional regulation in PCa cells but also show that the expression of the hAR protein is suppressed by a degradation pathway regulated by cross-talk of Wnt to Akt that is likely mediated by Wnt-directed degradation of the B regulatory subunit of protein phosphatase, PP2A.	Columbia Univ, Dept Urol, Med Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA; Univ Paris 12, AP HP, CHU Henri Mondor, INSERM,E03 37, Creteil, France; Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China	Columbia University; Columbia University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Peking University	Buttyan, R (corresponding author), Columbia Univ, Dept Urol, Med Ctr, Irving Pavilion-11,161 Ft Washington Ave, New York, NY 10032 USA.	rb46@columbia.edu	Vacherot, Francis/R-6588-2018; Terry, Stephane/K-5351-2013; de la taille, Alex/ABE-8422-2021	Vacherot, Francis/0000-0002-3677-1267; Terry, Stephane/0000-0003-3089-7886; 	NATIONAL CANCER INSTITUTE [R01CA111618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111618-04, R01 CA111618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Barker N, 2000, BIOESSAYS, V22, P961; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHEN G, 2004, CANCER, V10, P1345; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Craft N, 1999, CANCER RES, V59, P5030; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Latil A, 2001, CANCER RES, V61, P1919; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Ohigashi T, 2005, PROSTATE, V62, P61, DOI 10.1002/pros.20117; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; STACK S, 2004, J BIOL CHEM, V279, P47732; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Voeller HJ, 1998, CANCER RES, V58, P2520; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	37	87	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3436	3444		10.1038/sj.onc.1209366	http://dx.doi.org/10.1038/sj.onc.1209366			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16474850	Green Accepted			2022-12-25	WOS:000238448100008
J	Liu, ZP; Li, HB; Derouet, M; Berezkin, A; Sasazuki, T; Shirasawa, S; Rosen, K				Liu, Zaiping; Li, Hongbing; Derouet, Mathieu; Berezkin, Alexander; Sasazuki, Takehiko; Shirasawa, Senji; Rosen, Kirill			Oncogenic Ras inhibits anoikis of intestinal epithelial cells by preventing the release of a mitochondrial pro-apoptotic protein Omi/HtrA2 into the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SERINE-PROTEASE; DOWN-REGULATION; BCL-X; INDUCED TRANSFORMATION; EXTRACELLULAR-MATRIX; BCL-X(L) EXPRESSION; HUMAN KERATINOCYTES; PROMOTES APOPTOSIS; CASPASE ACTIVATION	Resistance of cancer cells to anoikis, apoptosis induced by cell detachment from the extracellular matrix, is thought to represent a critical feature of the malignant phenotype. Mechanisms that control anoikis of normal and cancer cells are understood only in part. Previously we found that anoikis of non-malignant intestinal epithelial cells is driven by detachment-induced down-regulation of Bcl-X-L, a protein that blocks apoptosis through preventing the release of death-promoting factors from the mitochondria. Mitochondrial proteins the release of which causes anoikis are presently unknown. Similar to what was previously observed by others for keratinocytes and fibroblasts, we show here that anoikis of intestinal epithelial cells does not involve caspase-9, a target of a mitochondrial protein cytochrome c. Furthermore, Smac/Diablo, another mitochondrial pro-apoptotic factor, does not appear to play a role in detachment-dependent apoptosis of these cells either. Instead, anoikis of intestinal epithelial cells is triggered by the release of a mitochondrial protein Omi/HtrA2, an event driven by detachment-induced down-regulation of Bcl-XL. Moreover, we established that oncogenic ras inhibits anoikis by preventing the release of Omi/HtrA2. This effect of ras required ras-induced down-regulation of a pro-apoptotic protein Bak and could be blocked by an inhibitor of phosphoinositide 3-kinase, a target of Ras that was previously implicated by us in the down-regulation of Bak and blockade of anoikis. We conclude that Omi/HtrA2 is an inducer of anoikis and an important regulator of ras-induced transformation.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Int Med Ctr Japan, Dept Pathol, Res Inst, Shinjyuku Ku, Tokyo 1628655, Japan	Dalhousie University; Dalhousie University; National Center for Global Health & Medicine - Japan	Rosen, K (corresponding author), CRC, Rm C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	Kirill.Rosen@Dal.Ca		Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Bian X, 2004, J BIOL CHEM, V279, P4663, DOI 10.1074/jbc.M306905200; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; FILMUS J, 1993, ONCOGENE, V8, P1017; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krajewska M, 1996, CANCER RES, V56, P2422; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lebowitz PF, 1997, CANCER RES, V57, P708; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyazaki T, 2004, J BIOL CHEM, V279, P44667, DOI 10.1074/jbc.M408101200; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Ozoren N, 2000, CANCER RES, V60, P6259; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sevignani C, 1999, CANCER RES, V59, P5882; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang J, 2000, J CELL SCI, V113, P753; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	73	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14738	14747		10.1074/jbc.M508664200	http://dx.doi.org/10.1074/jbc.M508664200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16461771	hybrid			2022-12-25	WOS:000237671300027
J	Chen, L; Shen, YH; Wang, XW; Wang, J; Gan, YH; Chen, NY; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL				Chen, L; Shen, YH; Wang, XW; Wang, J; Gan, YH; Chen, NY; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL			Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream stimulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; HUMAN TROPHOBLAST DIFFERENTIATION; FAMILIAL COMBINED HYPERLIPIDEMIA; PROLYL 4-HYDROXYLASE ISOENZYME; DISULFIDE-ISOMERASE SUBUNIT; AMERICAN-HEART-ASSOCIATION; BINDING PROTEIN-1 GENE; SMOOTH-MUSCLE-CELLS; ACID SYNTHASE GENE; COLLAGEN-SYNTHESIS	Prolyl-4-hydroxylase alpha(I) (P4H alpha(I)) is the rate-limiting subunit for P4H enzyme activity, which is essential for procollagen hydroxylation and secretion. In the current study, we have characterized the human P4H alpha(I) promoter for transcription factors and DNA elements regulating P4H alpha(I) expression. Using a progressive deletion cloning approach, we have constructed pGL3-P4H alpha(I) recombinant plasmids. We have identified a positive regulatory region at the positions of bp -184 to -97 responsible for similar to 80% of the P4H alpha(I) promoter efficiency. Three E-boxes were located within this region, and the E-box at position bp -135 explains most of the regulatory capacity. Upstream stimulatory factors (USF1/USF2) were shown to bind on the E-box using chromatin immunoprecipitation assay. Suppression of USF1 and/or USF2 using specific short interference RNA resulted in a significant reduction in P4H alpha(I) promoter activity, and overexpressed USF1 or USF2 increased P4H alpha(I) promoter activity significantly. Although transforming growth factor beta 1 increased the USF1/USF2-E-box binding and P4H alpha(I) promoter activity, this up-regulatory effect can be largely prevented by USF1/USF2-specific short interference RNA. On the other hand, cigarette smoking extracts, which have been shown to suppress P4H alpha(I) expression, inhibited the binding between the USF1/USF2 and E-box, resulting in a reduced P4H alpha(I) promoter activity. Furthermore, the E-box on the P4H alpha(I) promoter appeared to indiscriminately bind with either USF1 or USF2, with a similar outcome on the promoter efficiency. In conclusion, our study shows that USF1/USF2 plays a critical role in basal P4H alpha(I) expression, and both positive (transforming growth factor beta 1) and negative (cigarette smoking extract) regulators appear to influence the USF-E-box interaction and affect P4H alpha(I) expression.	Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiothorac Serv, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute; University of Texas System; UTMD Anderson Cancer Center	Wang, XL (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA.	xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022	LeMaire, Scott/0000-0002-8736-4266	NHLBI NIH HHS [R01 HL066053, HL066053, K08 HL080085-02, R01 HL071608, HL71608, K08 HL080085] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071608, R01HL066053, K08HL080085] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bengtsson SHM, 2002, BIOCHEM J, V365, P481, DOI 10.1042/BJ20020223; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; Coulson JM, 2003, BIOCHEM J, V369, P549, DOI 10.1042/BJ20021176; Crissey MAS, 1999, HEPATOLOGY, V30, P1187, DOI 10.1002/hep.510300520; Fabunmi RP, 1998, CIRC RES, V83, P270, DOI 10.1161/01.RES.83.3.270; Gao EW, 2003, AM J PHYSIOL-LUNG C, V284, pL1027, DOI 10.1152/ajplung.00219.2002; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Harris AN, 1998, MOL ENDOCRINOL, V12, P714, DOI 10.1210/me.12.5.714; HIRAMATSU M, 1982, ENDOCRINOLOGY, V111, P1810, DOI 10.1210/endo-111-6-1810; Jiang B, 2005, MOL CELL BIOL, V25, P8824, DOI 10.1128/MCB.25.20.8824-8833.2005; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; John DCA, 1999, NAT BIOTECHNOL, V17, P385, DOI 10.1038/7945; Kato Y, 1996, J GASTROENTEROL, V31, P565, DOI 10.1007/BF02355058; KAWAGUCHI Y, 1992, J RHEUMATOL, V19, P1195; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kyriacou CP, 2000, J BIOL RHYTHM, V15, P483, DOI 10.1177/074873000129001594; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Luo X, 1996, MOL CELL BIOL, V16, P1367; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; Mizutani K, 2000, BIOCHEM BIOPH RES CO, V274, P61, DOI 10.1006/bbrc.2000.3097; Muguerza B, 2001, BBA-MOL BASIS DIS, V1536, P185, DOI 10.1016/S0925-4439(01)00045-X; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Pajukanta P, 2004, NAT GENET, V36, P371, DOI 10.1038/ng1320; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Raveendran M, 2005, FEBS LETT, V579, P733, DOI 10.1016/j.febslet.2004.12.052; Raveendran M, 2004, BIOCHEM BIOPH RES CO, V323, P592, DOI 10.1016/j.bbrc.2004.08.129; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Rodriguez CI, 2003, J BIOL CHEM, V278, P43135, DOI 10.1074/jbc.M300053200; ROUSSEAU GG, 1992, HORM RES, V37, P88, DOI 10.1159/000182407; Sasaki Tetsuo, 1992, Journal of Dermatology (Tokyo), V19, P664; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Schweizer M, 2002, BIOCHEM SOC T, V30, P1070, DOI 10.1042/BST0301070; Sellak H, 2005, J BIOL CHEM, V280, P18425, DOI 10.1074/jbc.M500775200; Shoulders CC, 2004, TRENDS MOL MED, V10, P362, DOI 10.1016/j.molmed.2004.06.011; Shoulders CC, 2004, NAT GENET, V36, P322, DOI 10.1038/ng0404-322; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Takahashi S, 2002, BBA-GENE STRUCT EXPR, V1574, P354, DOI 10.1016/S0167-4781(01)00360-8; Takahashi Y, 2001, DRUG METAB REV, V33, P37, DOI 10.1081/DMR-100000139; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Weigert C, 2004, J BIOL CHEM, V279, P15908, DOI 10.1074/jbc.M313524200; Yan SQ, 2004, GENE, V337, P199, DOI 10.1016/j.gene.2004.05.005; Zhu YQ, 2005, DIABETES, V54, P1976, DOI 10.2337/diabetes.54.7.1976	60	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10849	10855		10.1074/jbc.M511237200	http://dx.doi.org/10.1074/jbc.M511237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488890	hybrid, Green Accepted			2022-12-25	WOS:000236822200024
J	Kamiyama, S; Sasaki, N; Goda, E; Ui-Tei, K; Saigo, K; Narimatsu, H; Jigami, Y; Kannagi, R; Irimura, T; Nishihara, S				Kamiyama, S; Sasaki, N; Goda, E; Ui-Tei, K; Saigo, K; Narimatsu, H; Jigami, Y; Kannagi, R; Irimura, T; Nishihara, S			Molecular cloning and characterization of a novel 3 '-phosphoadenosine 5 '-phosphosulfate transporter, PAPST2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SUGAR TRANSPORTER; HIGH ENDOTHELIAL VENULES; L-SELECTIN LIGAND; SIALYL-LEWIS-X; N-ACETYLGLUCOSAMINE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; HUMAN COLONIC SULFOMUCIN; SULFATE-TRANSPORTER; MONOCLONAL-ANTIBODY; HEPARAN-SULFATE	Sulfation is an important posttranslational modification associated with a variety of molecules. It requires the involvement of the high energy form of the universal sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS). Recently, we identified a PAPS transporter gene in both humans and Drosophila. Although human colonic epithelial tissues express many sulfated glycoconjugates, PAPST1 expression in the colon is trace. In the present study, we identified a novel human PAPS transporter gene that is closely related to human PAPST1. This gene, called PAPST2, is predominantly expressed in human colon tissues. The PAPST2 protein is localized on the Golgi apparatus in a manner similar to the PAPST1 protein. By using yeast expression studies, PAPST2 protein was shown to have PAPS transport activity with an apparent Km value of 2.2 mu M, which is comparable with that of PAPST1 (0.8 mu M). Overexpression of either the PAPST1 or PAPST2 gene increased PAPS transport activity in human colon cancer HCT116 cells. The RNA interference of the PAPST2 gene in the HCT116 cells significantly reduced the reactivity of G72 antibody directed against the sialyl 6-sulfo N-acetyllactosamine epitope and total sulfate incorporation into cellular proteins. These findings indicate that PAPST2 is a PAPS transporter gene involved in the synthesis of sulfated glycoconjugates in the colon.	Soka Univ, Dept Bioinformat, Cell Biol Lab, Tokyo 1928577, Japan; Res Assoc Biotechnol, Minato Ku, Tokyo 1050003, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058586, Japan; Aichi Canc Ctr, Program Mol Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan	Soka University; Japan Science & Technology Agency (JST); University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Aichi Cancer Center; University of Tokyo	Nishihara, S (corresponding author), Soka Univ, Dept Bioinformat, Cell Biol Lab, 1-236 Tangi Cho, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp	Kannagi, Reiji/Q-6459-2018; Narimatsu, Hisashi/M-4757-2018	Kannagi, Reiji/0000-0003-4202-2921; Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Antalis TM, 1998, CLIN CANCER RES, V4, P1857; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BAUERLE PA, 1987, J CELL BIOL, V105, P2655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; FLEISCHER B, 1974, J BIOL CHEM, V249, P5995; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; IMAI Y, 1993, NATURE, V361, P555; IRIMURA T, 1991, CANCER RES, V51, P5728; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 2004, PFLUG ARCH EUR J PHY, V447, P768, DOI 10.1007/s00424-003-1093-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izawa M, 2000, CANCER RES, V60, P1410; Kamiyama S, 2004, TRENDS GLYCOSCI GLYC, V16, P109, DOI 10.4052/tigg.16.109; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kannagi R, 1999, TRENDS GLYCOSCI GLYC, V11, P329, DOI 10.4052/tigg.11.329; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kumamoto K, 2001, CANCER RES, V61, P4620; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LANE N, 1964, J CELL BIOL, V21, P339, DOI 10.1083/jcb.21.3.339; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; MATSUSHITA Y, 1995, JPN J CANCER RES, V86, P1060, DOI 10.1111/j.1349-7006.1995.tb03021.x; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; NAKAYAMA T, 1995, CANCER, V75, P2051, DOI 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Seko A, 2000, GLYCOBIOLOGY, V10, P919, DOI 10.1093/glycob/10.9.919; Seko A, 2002, JPN J CANCER RES, V93, P507, DOI 10.1111/j.1349-7006.2002.tb01285.x; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; Superti-Furga A, 1999, J MED GENET, V36, P621; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tsuiji H, 1998, JPN J CANCER RES, V89, P1267, DOI 10.1111/j.1349-7006.1998.tb00523.x; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; UEMURA M, 1992, CANCER RES, V52, P6153; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Yamachika T, 1997, VIRCHOWS ARCH, V431, P25, DOI 10.1007/s004280050065; YAMORI T, 1989, CANCER RES, V49, P887; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	55	54	57	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10945	10953		10.1074/jbc.M508991200	http://dx.doi.org/10.1074/jbc.M508991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492677	hybrid			2022-12-25	WOS:000236822200035
J	Yang, LM; Rinke, R; Korbmacher, C				Yang, LM; Rinke, R; Korbmacher, C			Stimulation of the epithelial sodium channel (ENaC) by cAMP involves putative ERK phosphorylation sites in the C termini of the channel's beta- and gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE INHIBITORS; CORTICAL COLLECTING DUCT; CELL-SURFACE EXPRESSION; NA+-CHANNEL; LIDDLES-SYNDROME; XENOPUS OOCYTES; DOWN-REGULATION; ALPHA-SUBUNIT; BREFELDIN-A; ACTIVATION	The mechanisms involved in the regulation of the epithelial sodium channel ( ENaC) via the cAMP pathway are not yet completely understood. The aim of the present study was to investigate cAMP-mediated ENaC regulation in Xenopus laevis oocytes heterologously expressing the three subunits (alpha beta gamma) of rat ENaC and to determine the ENaC regions important for mediating the stimulatory effect of cAMP. In oocytes treated for about 24 h with 1 mM 3-isobutyl-1-methylxanthine ( IBMX) and 1 mu M forskolin (FSK) so as to increase intracellular cAMP, the amiloride-sensitive whole cell current (Delta I-Ami) was on average 10-fold larger than Delta I-Ami in matched control oocytes. This effect on Delta I-Ami was paralleled by an increase in ENaC surface expression caused by a reduced rate of ENaC retrieval. In addition, IBMX/FSK also enhanced ENaC open probability from about 0.2 to 0.5. The stimulatory effect of IBMX/FSK was dependent on the presence of intact PY motifs in the C termini of the channel. Mutagenesis of putative protein kinase A and CK-2 consensus motifs in the cytosolic domains of the channel did not reveal critical sites involved in mediating the stimulatory effect of IBMX/FSK. In contrast, site-directed mutagenesis of two putative ERK-consensus motifs (T613A in beta ENaC and T623A in gamma ENaC) largely reduced the stimulatory effect of IBMX/FSK. Phosphorylation of these ERK sites has previously been reported to enhance the interaction of ENaC and Nedd4 (Shi, H., Asher, C., Chigaev, A., Yung, Y., Reuveny, E., Seger, R., and Garty, H. ( 2002) J. Biol. Chem. 277, 13539 - 13547). Using co-expression experiments we demonstrated that mutating the two ERK sites attenuates the inhibitory effect of Nedd4-2 on ENaC currents. We conclude that an increase in intracellular cAMP favors the dephosphorylation of the two ERK sites, which reduces channel retrieval and increases PO by modulating ENaC/Nedd4 interaction. This defines a novel regulatory pathway likely to be relevant for cAMP-induced stimulation of ENaC in vivo.	Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Korbmacher, C (corresponding author), Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de						Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bankir L, 2005, J AM SOC NEPHROL, V16, P1920, DOI 10.1681/ASN.2004121079; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Diakov A, 2004, J BIOL CHEM, V279, P38134, DOI 10.1074/jbc.M403260200; Dinudom A, 2004, P NATL ACAD SCI USA, V101, P11886, DOI 10.1073/pnas.0402178101; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; Falin R, 2005, AM J PHYSIOL-CELL PH, V288, pC1003, DOI 10.1152/ajpcell.00213.2004; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grossmann C, 2004, AM J PHYSIOL-RENAL, V286, pF1226, DOI 10.1152/ajprenal.00378.2003; Kansy JW, 2004, J NEUROCHEM, V91, P374, DOI 10.1111/j.1471-4159.2004.02723.x; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Michlig S, 2005, J BIOL CHEM, V280, P38264, DOI 10.1074/jbc.M506308200; Michlig S, 2004, J BIOL CHEM, V279, P51002, DOI 10.1074/jbc.M405674200; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Pearce D, 2003, CELL PHYSIOL BIOCHEM, V13, P13, DOI 10.1159/000070245; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Soundararajan R, 2005, J BIOL CHEM, V280, P39970, DOI 10.1074/jbc.M508658200; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stevenson-Lindert LM, 2003, J BIOL CHEM, V278, P50956, DOI 10.1074/jbc.M306546200; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047; Volk T, 2004, PFLUG ARCH EUR J PHY, V447, P884, DOI 10.1007/s00424-003-1193-x; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang YH, 2005, AM J PHYSIOL-CELL PH, V288, pC141, DOI 10.1152/ajpcell.00343.2004	60	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9859	9868		10.1074/jbc.M512046200	http://dx.doi.org/10.1074/jbc.M512046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476738	hybrid			2022-12-25	WOS:000236594300007
J	Yu, G; Mao, JN; Wu, YL; Luo, HY; Wu, JP				Yu, G; Mao, JN; Wu, YL; Luo, HY; Wu, JP			Ephrin-B1 is critical in T-cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; THYMUS ORGAN-CULTURE; POSITIVE SELECTION; EPH RECEPTORS; NEGATIVE SELECTION; CROSS-LINKING; EXPRESSION; ACTIVATION; LIGANDS; FAMILY	Eph kinases are the largest family of receptor tyrosine kinases, and their ligands, ephrins (EFNs), are also cell surface molecules. In this study, we investigated the role of EFNB1 and the Ephs it interacts with (collectively called EFNB1 receptors) in mouse T-cell development. In the thymus, CD8 single positive (SP) and CD4CD8 double positive (DP) cells expressed high levels of EFNB1 and EFNB1 receptors, whereas CD4 SP cells had moderate expression of both. Soluble EFNB1-Fc in fetal thymus organ culture caused significant subpopulation ratio skew, with increased CD4 SP and CD8 SP and decreased DP percentage, while the cellularity of the thymus remained constant. Moreover, in EFNB1-treated fetal thymus organ culture, CD117(+), CD25(+), DP, CD4 SP, and CD8 SP cells all had significantly enhanced proliferation history, according to bromodeoxyuridine uptake. In vitro culture of isolated thymocytes revealed that EFNB1-Fc on solid-phase protected thymocytes from anti-CD3-induced apoptosis, with concomitant augmentation of several antiapoptotic factors, particularly in CD4 SP and CD8 SP cells; on the other hand, soluble EFNB1-Fc promoted anti-CD3-induced apoptosis, as was the case in vivo. This study reveals that EFNB1 and EFNB1 receptors are critical in thymocyte development.	CHUM, Notre Dame Hosp, Res Ctr, Immunol Lab, Montreal, PQ H2L 4M1, Canada; CHUM, Notre Dame Hosp, Serv Nephrol, Montreal, PQ H2L 4M1, Canada; Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou 310009, Peoples R China	Universite de Montreal; Universite de Montreal; Zhejiang University	Luo, HY (corresponding author), CHUM, Notre Dame Hosp, Res Ctr, Immunol Lab, Pavil DeSeve,Rm Y-5616,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	hongyu.luo@umontreal.ca	mao, jianning/A-4254-2011					Amsen D, 1998, IMMUNOL REV, V165, P209, DOI 10.1111/j.1600-065X.1998.tb01241.x; Anderson G, 1997, IMMUNOL TODAY, V18, P363; ANDRES AC, 1994, ONCOGENE, V9, P1461; Baldwin KK, 1999, J IMMUNOL, V163, P689; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; CIOSSEK T, 1995, ONCOGENE, V11, P2085; DELUCA D, 1995, J IMMUNOL METHODS, V178, P13, DOI 10.1016/0022-1759(94)00236-P; Dravis C, 2004, DEV BIOL, V271, P272, DOI 10.1016/j.ydbio.2004.03.027; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Germain RN, 2003, IMMUNOL RES, V27, P277, DOI 10.1385/IR:27:2-3:277; Gurniak CB, 1996, ONCOGENE, V13, P777; Hare KJ, 1999, J IMMUNOL, V162, P3978; Hare KJ, 2001, CELL MOL BIOL, V47, P119; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Lickliter JD, 1996, P NATL ACAD SCI USA, V93, P145, DOI 10.1073/pnas.93.1.145; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Luo HY, 2004, J CLIN INVEST, V114, P1762, DOI 10.1172/JCI200421846; Middlebrook AJ, 2002, J IMMUNOL, V169, P2915, DOI 10.4049/jimmunol.169.6.2915; Munoz JJ, 2002, J IMMUNOL, V169, P177, DOI 10.4049/jimmunol.169.1.177; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ober BT, 2000, INT IMMUNOL, V12, P1353, DOI 10.1093/intimm/12.9.1353; Prevost N, 2004, BLOOD, V103, P1348, DOI 10.1182/blood-2003-06-1781; SCOLLAY R, 1995, IMMUNOL TODAY, V16, P273; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Stefanski HE, 2001, J IMMUNOL, V166, P6602, DOI 10.4049/jimmunol.166.11.6602; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vergara-Silva Andrea, 2002, Gene Expression Patterns, V2, P261, DOI 10.1016/S1567-133X(02)00054-6; Viret C, 1999, Rev Immunogenet, V1, P91; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Yu G, 2003, J IMMUNOL, V171, P106, DOI 10.4049/jimmunol.171.1.106; Yu G, 2004, J BIOL CHEM, V279, P55531, DOI 10.1074/jbc.M410814200; Yu G, 2003, J BIOL CHEM, V278, P47209, DOI 10.1074/jbc.M306659200	43	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10222	10229		10.1074/jbc.M510320200	http://dx.doi.org/10.1074/jbc.M510320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476740	hybrid			2022-12-25	WOS:000236594300049
J	Zhao, KH; Su, P; Li, J; Tu, JM; Zhou, M; Bubenzer, C; Scheer, H				Zhao, KH; Su, P; Li, J; Tu, JM; Zhou, M; Bubenzer, C; Scheer, H			Chromophore attachment to phycobiliprotein beta-subunits - Phycocyanobilin : Cysteine-beta 84 phycobiliprotein lyase activity of CpeS-like protein from Anabaena sp PCC7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLO-ALPHA SUBUNIT; MASTIGOCLADUS-LAMINOSUS; C-PHYCOCYANIN; PHYCOVIOLOBILIN CHROMOPHORE; PHYCOERYTHROCYANIN OPERON; REVERSIBLE PHOTOCHEMISTRY; PHYCOBILISOME STRUCTURE; INVITRO ATTACHMENT; SP PCC-7120; CYANOBACTERIUM	The gene alr0617, from the cyanobacterium Anabaena sp. PCC7120, which is homologous to cpeS from Gloeobacter violaceus PCC 7421, Fremyella diplosiphon (Calothrix PCC7601), and Synechococcus sp. WH8102, and to cpcS from Synechococcus sp. PCC7002, was overexpressed in Escherichia coli. CpeS acts as a phycocyanobilin: Cys-beta 84-phycobiliprotein lyase that can attach, in vitro and in vivo, phycocyanobilin (PCB) to cysteine-beta 84 of the apo-beta-subunits of C-phycocyanin (CpcB) and phycoerythrocyanin (PecB). We found the following: ( a) In vitro, CpeS attaches PCB to native CpcB and PecB, and to their C155 I-mutants, but not to the C84S mutants. Under optimal conditions (150 mM NaCl and 500 mM potassium phosphate, 37 degrees C, and pH 7.5), no cofactors are required, and the lyase had a K-m(PCB) = 2.7 and 2.3 mu M, and a k(cat) = 1.7 x 10(-5) and 1.1 x 10(-5) s(-1) for PCB attachment to CpcB (C155I) and PecB (C155I), respectively; (b) Reconstitution products had absorption maxima at 619 and 602 nm and fluorescence emission maxima at 643 and 629 nm, respectively; and (c) PCB-CpcB(C155I) and PCB-PecB(C155I), with the same absorption and fluorescence maxima, were also biosynthesized heterologously in vivo, when cpeS was introduced into E. coli with cpcB( C155I) or pecB( C155I), respectively, together with genes ho1 ( encoding heme oxygenase) and pcyA ( encoding PCB: ferredoxin oxidoreductase), thereby further proving the lyase function of CpeS.	Huazhong Univ Sci & Technol, Coll Environm Sci & Engn, Wuhan 430074, Peoples R China; Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Munich	Scheer, H (corresponding author), Huazhong Univ Sci & Technol, Coll Environm Sci & Engn, Wuhan 430074, Peoples R China.	hugo.scheer@lmu.de						ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; Beale S. I., 1994, MOL BIOL CYANOBACTER, P519; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BHALERAO RP, 1994, PHYSIOL PLANTARUM, V90, P187; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai YA, 2001, ANAL BIOCHEM, V290, P186, DOI 10.1006/abio.2000.4979; Cobley JG, 2002, MOL MICROBIOL, V44, P1517, DOI 10.1046/j.1365-2958.2002.02966.x; COLE WJ, 1968, BIOCHEMISTRY-US, V7, P2929, DOI 10.1021/bi00848a033; DEBRECZENY MP, 1995, J PHYS CHEM-US, V99, P8412, DOI 10.1021/j100020a080; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; Ducret A, 1996, EUR J BIOCHEM, V236, P1010, DOI 10.1111/j.1432-1033.1996.01010.x; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; FRANKENBERG N, 2002, PORPHYRIN HDB, P211; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Gantt E., 2003, LIGHT HARVESTING ANT, P307, DOI DOI 10.1007/978-94-017-2087-8_10; GLAUSER M, 1992, EUR J BIOCHEM, V205, P907, DOI 10.1111/j.1432-1033.1992.tb16857.x; Glazer A. N, 1994, ADV MOL CELL BIOL, V10, P119; GLAZER AN, 1973, J BIOL CHEM, V248, P659; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Landgraf FT, 2001, FEBS LETT, V508, P459, DOI 10.1016/S0014-5793(01)02988-X; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; MacColl R, 1998, J STRUCT BIOL, V124, P311, DOI 10.1006/jsbi.1998.4062; NAGY JO, 1985, J BIOL CHEM, V260, P4864; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Parbel A, 1997, PHOTOSYNTH RES, V54, P25, DOI 10.1023/A:1005877531271; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUER K, 1988, BIOCHIM BIOPHYS ACTA, V936, P157, DOI 10.1016/0005-2728(88)90232-0; Scheer H., 1982, LIGHT REACTION PATH, P7; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; Schluchter W.M., 2002, HEME CHLOROPHYLL BIL, P311, DOI DOI 10.1385/1-59259-243-0:311; Schluchter W. M., 1999, PHOTOTROPHIC PROKARY, P83; Shen G., 2004, PS 2004 LIGHT HARV S, P14; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Six C, 2005, J BACTERIOL, V187, P1685, DOI 10.1128/JB.187.5.1685-1694.2005; Storf M, 2001, BIOCHEMISTRY-US, V40, P12444, DOI 10.1021/bi010776s; STORF M, 2004, THESIS L MAXIMILIANS; SWANSON RV, 1992, J BACTERIOL, V174, P2640, DOI 10.1128/jb.174.8.2640-2647.1992; Terauchi K, 2004, MOL MICROBIOL, V51, P567, DOI 10.1046/j.1365-2958.2003.03853.x; Tooley AJ, 2002, J BACTERIOL, V184, P4666, DOI 10.1128/JB.184.17.4666-4671.2002; Tooley AJ, 2001, P NATL ACAD SCI USA, V98, P10560, DOI 10.1073/pnas.181340998; Willows RD, 2000, PLANT MOL BIOL, V43, P113, DOI 10.1023/A:1006489129449; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Zhao KH, 2005, BIOCHEMISTRY-US, V44, P8126, DOI 10.1021/bi0500168; Zhao KH, 2005, BBA-BIOENERGETICS, V1706, P81, DOI 10.1016/j.bbabio.2004.09.008; Zhao KH, 2004, BIOCHEMISTRY-US, V43, P11576, DOI 10.1021/bi0491548; Zhao KH, 2004, BBA-BIOENERGETICS, V1657, P131, DOI 10.1016/j.bbabio.2004.04.010; Zhao KH, 2002, EUR J BIOCHEM, V269, P4542, DOI 10.1046/j.1432-1033.2002.03148.x; ZHAO KH, 1995, BBA-BIOENERGETICS, V1228, P244, DOI 10.1016/0005-2728(94)00180-D; ZHAO KH, 1995, BBA-BIOENERGETICS, V1228, P235, DOI 10.1016/0005-2728(94)00181-4; Zhao KH, 2000, FEBS LETT, V469, P9, DOI 10.1016/S0014-5793(00)01245-X; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	60	58	76	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8573	8581		10.1074/jbc.M513796200	http://dx.doi.org/10.1074/jbc.M513796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452471	hybrid			2022-12-25	WOS:000236247100033
J	Rasmussen, BB; Fujita, S; Wolfe, RR; Mittendorfer, B; Roy, M; Rowe, VL; Volpi, E				Rasmussen, Blake B.; Fujita, Satoshi; Wolfe, Robert R.; Mittendorfer, Bettina; Roy, Mona; Rowe, Vincent L.; Volpi, Elena			Insulin resistance of muscle protein metabolism in aging	FASEB JOURNAL			English	Article						skeletal muscle; hyperinsulinemia; leg blood flow; phenylalanine	SKELETAL-MUSCLE; AMINO-ACIDS; NITRIC-OXIDE; WHOLE-BODY; PHYSIOLOGICAL HYPERINSULINEMIA; EUGLYCEMIC HYPERINSULINEMIA; SYSTEMIC HYPERINSULINEMIA; VASCULAR-TONE; BLOOD-FLOW; YOUNG	A reduced response of older skeletal muscle to anabolic stimuli may contribute to the development of sarcopenia. We hypothesized that muscle proteins are resistant to the anabolic action of insulin in the elderly. We examined the effects of hyperinsulinemia on muscle protein metabolism in young (25 +/- 2 year) and older (68 +/- 1 year) healthy subjects using stable isotope tracer techniques. Leg blood flow was higher in the young at baseline and increased during hyperinsulinemia, whereas it did not change in the elderly. Glucose concentrations and muscle uptake were not different between groups at baseline and during hyperinsulinemia. Leg phenylalanine net balance was not different at baseline and significantly increased in both groups with hyperinsulinemia (P < 0.05) but to a greater extent in the young (P < 0.05). Muscle protein synthesis increased only in the young during hyperinsulinemia. Muscle protein breakdown did not significantly change in either group, although it tended to decrease in the elderly. Changes in muscle protein synthesis were correlated with changes in leg amino acid delivery (R= 0.89; P= 0.0001) and blood flow (R= 0.90; P < 0.0001). In conclusion, skeletal muscle protein synthesis is resistant to the anabolic action of insulin in older subjects, which may be an important contributor to the development of sarcopenia.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ So Calif, Dept Kinesiol, Los Angeles, CA USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Med, Los Angeles, CA USA; Univ So Calif, Dept Surg, Los Angeles, CA USA	University of Texas System; University of Texas Medical Branch Galveston; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Volpi, E (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Geriatr Med, 301 Univ Blvd, Galveston, TX 77555 USA.	evolpi@utmb.edu	Volpi, Elena/I-4459-2012	Rasmussen, Blake/0000-0001-7854-5375; Volpi, Elena/0000-0001-8776-0384	NCRR NIH HHS [M01 RR000043-450887, M01 RR00073, M01 RR000073-438733, M01 RR000043, S10 RR16650, M01 RR000073, S10 RR016650-01, M01 RR00043] Funding Source: Medline; NIA NIH HHS [R01 AG018311, P30 AG024832, R01 AG018311-05, R01 AG18311, P30 AG17231, P60 AG017231, P30 AG024832-039004] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043, M01RR000073, S10RR016650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832, R01AG018311, P60AG017231] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; Baron AD, 2000, DIABETES, V49, P768, DOI 10.2337/diabetes.49.5.768; Bell JA, 2005, AM J PHYSIOL-ENDOC M, V289, pE999, DOI 10.1152/ajpendo.00170.2005; BENNET WM, 1989, CLIN SCI, V76, P447, DOI 10.1042/cs0760447; BENNET WM, 1990, AM J PHYSIOL, V259, pE185, DOI 10.1152/ajpendo.1990.259.2.E185; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE75, DOI 10.1152/ajpendo.1995.268.1.E75; BIOLO G, 1995, J CLIN INVEST, V95, P811, DOI 10.1172/JCI117731; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CALDER AG, 1992, RAPID COMMUN MASS SP, V6, P421, DOI 10.1002/rcm.1290060704; Cardillo CM, 2000, HYPERTENSION, V35, P1237, DOI 10.1161/01.HYP.35.6.1237; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Dardevet D, 2002, J NUTR, V132, P95, DOI 10.1093/jn/132.1.95; DEFEO P, 1993, DIABETES, V42, P995, DOI 10.2337/diabetes.42.7.995; DENNE SC, 1991, AM J PHYSIOL, V261, pE809, DOI 10.1152/ajpendo.1991.261.6.E809; DUTTA C, 1995, J GERONTOL A-BIOL, V50, P1, DOI 10.1093/gerona/50A.Special_Issue.1; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; GELFAND RA, 1987, J CLIN INVEST, V80, P1, DOI 10.1172/JCI113033; Guillet C, 2004, FASEB J, V18, P1586, DOI 10.1096/fj.03-1341fje; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; HESLIN MJ, 1992, AM J PHYSIOL, V262, pE911, DOI 10.1152/ajpendo.1992.262.6.E911; Hillier TA, 1998, AM J PHYSIOL-ENDOC M, V274, pE1067, DOI 10.1152/ajpendo.1998.274.6.E1067; JORFELDT L, 1978, METABOLISM, V27, P97, DOI 10.1016/0026-0495(78)90128-2; JORFELDT L, 1971, CLIN SCI, V41, P459, DOI 10.1042/cs0410459; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; LOUARD RJ, 1992, J CLIN INVEST, V90, P2348, DOI 10.1172/JCI116124; Mather KJ, 2004, DIABETES, V53, P2060, DOI 10.2337/diabetes.53.8.2060; MENEILLY GS, 1995, J CLIN ENDOCR METAB, V80, P1899, DOI 10.1210/jc.80.6.1899; Miller AW, 2002, HYPERTENSION, V40, P78, DOI 10.1161/01.HYP.0000022806.87281.62; MOLLERLOSWICK AC, 1994, AM J PHYSIOL, V266, pE645, DOI 10.1152/ajpendo.1994.266.4.E645; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; NEWMAN E, 1994, METABOLISM, V43, P70, DOI 10.1016/0026-0495(94)90159-7; Nygren J, 2003, DIABETES, V52, P1377, DOI 10.2337/diabetes.52.6.1377; Paddon-Jones D, 2004, AM J PHYSIOL-ENDOC M, V286, pE321, DOI 10.1152/ajpendo.00368.2003; Rasmussen B B, 2002, J Nutr Health Aging, V6, P358; Rasmussen BB, 2000, J APPL PHYSIOL, V88, P386, DOI 10.1152/jappl.2000.88.2.386; Roubenoff R, 2001, JAMA-J AM MED ASSOC, V286, P1230, DOI 10.1001/jama.286.10.1230; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; TESSARI P, 1991, J CLIN INVEST, V88, P27, DOI 10.1172/JCI115287; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Volpi E, 2003, AM J CLIN NUTR, V78, P250, DOI 10.1093/ajcn/78.2.250; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422; WELLE S, 1990, AM J PHYSIOL, V258, pE990, DOI 10.1152/ajpendo.1990.258.6.E990; WOLF RF, 1992, SURGERY, V112, P284; Wolfe RR, 1992, RADIOACTIVE STABLE I; WOLFE RR, 1992, RADIOACTIVE STABLE I, P167; WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210	58	246	249	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					768	+		10.1096/fj.05-4607fje	http://dx.doi.org/10.1096/fj.05-4607fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464955	Green Accepted			2022-12-25	WOS:000237698700033
J	Shen, JB; Pappano, AJ; Liang, BT				Shen, Jian-Bing; Pappano, Achilles J.; Liang, Bruce T.			Extracellular ATP-stimulated current in wild-type and P2X(4) receptor transgenic mouse ventricular myocytes: implications for a cardiac physiologic role of P2X(4) receptors	FASEB JOURNAL			English	Article						ion channels; membrane current; mouse; heart	PHARMACOLOGICAL PROFILE; CALCIUM CURRENT; RAT; CHANNELS; COPPER; ZINC; OVEREXPRESSION; CONTRACTILITY; PURINOCEPTORS; ACTIVATION	P2X receptors, activated by extracellular ATP, may be important in regulating cardiac function. The objective of the present study was to characterize the electrophysiologic actions of P2X(4) receptors in cardiac myocytes and to determine whether they are involved in mediating the effect of extracellular ATP. Membrane currents under voltage clamp were determined in myocytes from both wild-type (WT) and P2X(4) receptor-overexpressing transgenic (TG) mice. The P2X agonist 2-meSATP induced an inward current at -100 mV that was greater in magnitude (2-fold) in TG than in WT ventricular cells. In the presence of the P2X(4) receptor-selective allosteric enhancer ivermectin (3 mu M), the 2-meSATP-stimulated current increased significantly in both WT and TG ventricular cells, consistent with an important role of P2X(4) receptors in mediating the ATP current not only in TG but also WT myocytes. That the current in both WT and TG cells showed similar voltage-dependence and reverse potential (similar to 0 mV) further suggests a role for this receptor in the normal electrophysiological action of ATP in WT murine cardiac myocytes. The P2X antagonist suramin was only able to block partially the 2-meSATP-stimulated current in WT cells, implying that both P2X(4) receptor and another yet-to-be-identified P2X receptor mediate this current.	Univ Connecticut, Ctr Hlth, Pat & Jim Calhoun Cardiol Ctr, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Liang, BT (corresponding author), Univ Connecticut, Ctr Hlth, Pat & Jim Calhoun Cardiol Ctr, MC-3946,263 Farmington Ave, Farmington, CT 06030 USA.	bliang@uchc.edu	Shen, Jianbing/U-8796-2019	Shen, Jianbing/0000-0002-4109-8353	NHLBI NIH HHS [R01-HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acuna-Castillo C, 2000, J NEUROCHEM, V74, P1529, DOI 10.1046/j.1471-4159.2000.0741529.x; Bo XN, 2003, CELL TISSUE RES, V313, P159, DOI 10.1007/s00441-003-0758-5; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Coddou C, 2003, EUR J PHARMACOL, V472, P49, DOI 10.1016/S0014-2999(03)01864-8; Heubach JF, 1999, CARDIOVASC RES, V42, P173, DOI 10.1016/S0008-6363(98)00262-4; Hille B., 2001, ION CHANNELS EXCITAB; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Jones CA, 2000, BRIT J PHARMACOL, V129, P388, DOI 10.1038/sj.bjp.0703059; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Mei QB, 2001, AM J PHYSIOL-HEART C, V281, pH334, DOI 10.1152/ajpheart.2001.281.1.H334; Michel AD, 1997, MOL PHARMACOL, V51, P524; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PARKER KE, 1995, AM J PHYSIOL-HEART C, V269, pH789, DOI 10.1152/ajpheart.1995.269.3.H789; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCAMPS F, 1994, BRIT J PHARMACOL, V113, P982, DOI 10.1111/j.1476-5381.1994.tb17089.x; Shen JB, 2005, FASEB J, V19, pA517; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; Xiong KM, 1999, J NEUROPHYSIOL, V81, P2088, DOI 10.1152/jn.1999.81.5.2088; Yang A, 2004, AM J PHYSIOL-HEART C, V287, pH1096, DOI 10.1152/ajpheart.00079.2004	24	37	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					277	284		10.1096/fj.05-4749com	http://dx.doi.org/10.1096/fj.05-4749com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449800				2022-12-25	WOS:000237698700013
J	Baraz, L; Haupt, Y; Elkin, M; Peretz, T; Vlodavsky, I				Baraz, L.; Haupt, Y.; Elkin, M.; Peretz, T.; Vlodavsky, I.			Tumor suppressor p53 regulates heparanase gene expression	ONCOGENE			English	Article						heparanase; p53; gene expression; promoter activity	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN HEPARANASE; TRANSCRIPTIONAL REPRESSION; EXTRACELLULAR-MATRIX; MEDIATED DEGRADATION; MOLECULAR-PROPERTIES; BASEMENT-MEMBRANES; HUMAN FIBROBLASTS; CANCER	Mammalian heparanase degrades heparan sulfate, the most prominent polysaccharide of the extracellular matrix. Causal involvement of heparanase in tumor progression is well documented. Little is known, however, about mechanisms that regulate heparanase gene expression. Mutational inactivation of tumor suppressor p53 is the most frequent genetic alteration in human tumors. p53 is a transcription factor that regulates a wide variety of cellular promoters. In this study, we demonstrate that wild-type (wt) p53 binds to heparanase promoter and inhibits its activity, whereas mutant p53 variants failed to exert an inhibitory effect. Moreover, p53-H175R mutant even activated heparanase promoter activity. Elimination or inhibition of p53 in several cell types resulted in a significant increase in heparanase gene expression and enzymatic activity. Trichostatin A abolished the inhibitory effect of wt p53, suggesting the involvement of histone deacetylation in negative regulation of the heparanase promoter. Altogether, our results indicate that the heparanase gene is regulated by p53 under normal conditions, while mutational inactivation of p53 during cancer development leads to induction of heparanase expression, providing a possible explanation for the frequent increase of heparanase levels observed in the course of tumorigenesis.	Hadassah Univ, Med Ctr, Dept Oncol, Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Jerusalem, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01 CA 106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allison SJ, 2004, CARCINOGENESIS, V25, P1551, DOI 10.1093/carcin/bgh212; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkin M, 2003, CANCER RES, V63, P8821; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; Haupt S, 2004, CELL CYCLE, V3, P912; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1999, J SURG RES, V81, P42, DOI 10.1006/jsre.1998.5519; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2005, DIABETES, V54, P2172, DOI 10.2337/diabetes.54.7.2172; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milyavsky M, 2003, CANCER RES, V63, P7147; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nadav L, 2002, J CELL SCI, V115, P2179; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zcharia E, 2005, AM J PATHOL, V166, P999, DOI 10.1016/S0002-9440(10)62321-8; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	55	78	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3939	3947		10.1038/sj.onc.1209425	http://dx.doi.org/10.1038/sj.onc.1209425			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474844				2022-12-25	WOS:000238668800007
J	Miao, J; Fang, SS; Bae, Y; Kemper, JK				Miao, Ji; Fang, Sungsoon; Bae, Yangjin; Kemper, Jongsook Kim			Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CARBOXYKINASE GENE-TRANSCRIPTION; GAMMA COACTIVATOR-1-ALPHA; XENOBIOTIC INDUCTION; ACCESSORY FACTORS; FACTOR 4-ALPHA; CAR; CHOLESTEROL; GLUCONEOGENESIS; ACTIVATION	The role of the constitutive androstane receptor (CAR) in xenobiotic metabolism by inducing expression of cytochromes P450 is well known, but CAR has also been implicated in the down-regulation of key genes involved in bile acid synthesis, gluconeogenesis, and fatty acid beta-oxidation by largely unknown mechanisms. Because a key hepatic factor, hepatic nuclear factor-4 (HNF-4), is crucial for the expression of many of these genes, we examined whether CAR could suppress HNF-4 transactivation. Expression of CAR inhibited HNF-4 transactivation of CYP7A1, a key gene in bile acid synthesis, in HepG2 cells, and mutation of the DNA binding domain of CAR impaired this inhibition. Gel shift assays revealed that CAR competes with HNF-4 for binding to the DR1 motif in the CYP7A1 promoter. TCPOBOP, a CAR agonist that increases the interaction of CAR with coactivators, potentiated CAR inhibition of HNF-4 transactivation. Furthermore, inhibition by CAR was reversed by expression of increasing amounts of GRIP-1 or PGC-1 alpha, indicating that CAR competes with HNF-4 for these coactivators. Treatment of mice with phenobarbital or TCPOBOP resulted in decreased hepatic mRNA levels of the reported genes down-regulated by CAR, including Cyp7a1 and Pepck. In vivo recruitment of endogenous CAR to the promoters of Cyp7a1 and Pepck was detected in mouse liver after phenobarbital treatment, whereas association of HNF-4 and coactivators, GRIP-1, p300, and PGC-1 alpha, with these promoters was significantly decreased. Our data suggest that CAR inhibits HNF-4 activity by competing with HNF-4 for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1 alpha, which may be a general mechanism by which CAR down-regulates key genes in hepatic lipid and glucose metabolism.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, JK (corresponding author), Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA.	jongsook@uiuc.edu	Bae, Yangjin/AAO-1866-2021; Miao, Ji/F-9398-2015	Bae, Yangjin/0000-0003-2397-0192; Miao, Ji/0000-0003-0869-4492	NIDDK NIH HHS [DK 062777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062777, R01DK062777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; Bae YJ, 2004, DNA CELL BIOL, V23, P81, DOI 10.1089/104454904322759894; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Cancado ELR, 1998, AM J GASTROENTEROL, V93, P1510, DOI 10.1111/j.1572-0241.1998.00472.x; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Eloranta JJ, 2005, ARCH BIOCHEM BIOPHYS, V433, P397, DOI 10.1016/j.abb.2004.09.019; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004-0211; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; Marrapodi M, 2000, J LIPID RES, V41, P514; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rencurel F, 2005, J BIOL CHEM, V280, P4367, DOI 10.1074/jbc.M412711200; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Stroup D, 1997, J BIOL CHEM, V272, P9833; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Wang DP, 1996, J LIPID RES, V37, P1831; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	52	150	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14537	14546		10.1074/jbc.M510713200	http://dx.doi.org/10.1074/jbc.M510713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16492670	hybrid			2022-12-25	WOS:000237671300004
J	Li, DWC; Liu, JP; Schmid, PC; Schlosser, R; Feng, H; Liu, WB; Yan, Q; Gong, L; Sun, SM; Deng, M; Liu, Y				Li, D. W-C; Liu, J-P; Schmid, P. C.; Schlosser, R.; Feng, H.; Liu, W-B; Yan, Q.; Gong, L.; Sun, S-M; Deng, M.; Liu, Y.			Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities	ONCOGENE			English	Review						p53; PP-1; dephosphorylation; apoptosis; RNAi; phosphorylation and signal transduction	TUMOR-SUPPRESSOR P53; EPITHELIAL-CELL APOPTOSIS; DAMAGE-INDUCED PHOSPHORYLATION; JUN NH2-TERMINAL KINASE; DNA-BINDING FUNCTION; ALPHA-B-CRYSTALLIN; LARGE-T-ANTIGEN; OKADAIC ACID; P53-DEPENDENT APOPTOSIS; IN-VITRO	We have previously demonstrated that the serine/threonine protein phosphatase-1 (PP-1) plays an important role in promoting cell survival. However, the molecular mechanisms by which PP-1 promotes survival remain largely unknown. In the present study, we provide evidence to show that PP-1 can directly dephosphorylate a master regulator of apoptosis, p53, to negatively modulate its transcriptional and apoptotic activities, and thus to promote cell survival. As a transcriptional factor, the function of p53 can be greatly regulated by phosphorylation and dephosphorylation. While the kinases responsible for phosphorylation of the 17 serine/threonine sites have been identified, the dephosphorylation of these sites remains largely unknown. In the present study, we demonstrate that PP-1 can dephosphorylate p53 at Ser-15 and Ser-37 through co-immunoprecipitation, in vitro and in vivo dephosphorylation assays, overexpression and silence of the gene encoding the catalytic subunit for PP-1. We further show that mutations mimicking constitutive dephosphorylation or phosphorylation of p53 at these sites attenuate or enhance its transcriptional activity, respectively. As a result of the changed p53 activity, expression of the downstream apoptosis-related genes such as bcl-2 and bax is accordingly altered and the apoptotic events are either largely abrogated or enhanced. Thus, our results demonstrate that PP-1 directly dephosphorylates p53, and dephosphorylation of p53 has as important impact on its functions as phosphorylation does. In addition, our results reveal that one of the molecular mechanisms by which PP-1 promotes cell survival is to dephosphorylate p53, and thus negatively regulate p53-dependent death pathway.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China	University of Minnesota System; Hunan Normal University	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Gong, Lili/F-8452-2014; Yan, Qin/F-5161-2012; Yan, Qin/K-3539-2013; Deng, Mi/K-8699-2012; Li, David/AAN-9205-2021	Gong, Lili/0000-0002-6533-5333; Yan, Qin/0000-0002-6344-6398; Deng, Mi/0000-0003-4291-0144; 	NEI NIH HHS [EY15765, R01 EY015765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bastians H, 1996, J CELL SCI, V109, P2865; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DEPAOLIROACH AA, 2003, HDB CELLULAR SIGNALI, V1, P613; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haneda M, 2004, FEBS LETT, V567, P171, DOI 10.1016/j.febslet.2004.04.066; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; KAIGHN ME, 1979, INVEST UROL, V17, P16; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LASSUS P, 2002, SCI STKE, V147, pPL13; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI DWC, 2004, INVEST OPHTHALMOL  S, V45, pE401; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li WC, 1996, FREE RADICAL BIO MED, V20, P301, DOI 10.1016/0891-5849(96)02050-3; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Long X, 2002, APOPTOSIS, V7, P31, DOI 10.1023/A:1013508811252; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; NEVINS JR, 1992, SCIENCE, V258, P424; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PARK IK, 1994, J BIOL CHEM, V269, P944; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALTER G, 2003, HDB CELL SIGNALING, V1, P621; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wen-Schaub LB, 1995, MOL CELL BIOL, V15, P3032; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	133	80	87	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3006	3022		10.1038/sj.onc.1209334	http://dx.doi.org/10.1038/sj.onc.1209334			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501611	Bronze			2022-12-25	WOS:000237950800005
J	Maeda, K; Das, D; Ogata-Aoki, H; Nakata, H; Miyakawa, T; Tojo, Y; Norman, R; Takaoka, Y; Ding, JP; Arnold, GF; Arnold, E; Mitsuya, H				Maeda, K; Das, D; Ogata-Aoki, H; Nakata, H; Miyakawa, T; Tojo, Y; Norman, R; Takaoka, Y; Ding, JP; Arnold, GF; Arnold, E; Mitsuya, H			Structural and molecular interactions of CCR5 inhibitors with CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; ACCURATE DOCKING; HIV-1 INFECTION; GP120 BINDING; IN-VITRO; CORECEPTOR; POTENT; ANTAGONIST; RANTES	We have characterized the structural and molecular interactions of CC-chemokine receptor 5 (CCR5) with three CCR5 inhibitors active against R5 human immunodeficiency virus type 1 (HIV-1) including the potent in vitro and in vivo CCR5 inhibitor aplaviroc (AVC). The data obtained with saturation binding assays and structural analyses delineated the key interactions responsible for the binding of CCR5 inhibitors with CCR5 and illustrated that their binding site is located in a predominantly lipophilic pocket in the interface of extracellular loops and within the upper transmembrane (TM) domain of CCR5. Mutations in the CCR5 binding sites of AVC decreased gp120 binding to CCR5 and the susceptibility to HIV-1 infection, although mutations in TM4 and TM5 that also decreased gp120 binding and HIV-1 infectivity had less effects on the binding of CC-chemokines, suggesting that CCR5 inhibition targeting appropriate regions might render the inhibition highly HIV-1-specific while preserving the CC chemokine-CCR5 interactions. The present data delineating residue by residue interactions of CCR5 with CCR5 inhibitors should not only help design more potent and more HIV-1-specific CCR5 inhibitors, but also give new insights into the dynamics of CC-chemokine-CCR5 interactions and the mechanisms of CCR5 involvement in the process of cellular entry of HIV-1.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan; NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; Ono Pharmaceut Co Ltd, Minase Res Inst, Osaka 6188585, Japan; Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Kumamoto University; Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ono Pharmaceutical Co Ltd; Rutgers State University New Brunswick	Mitsuya, H (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan.	hmitsuya@helix.nih.gov	Maeda, Kenji/B-7708-2019	Maeda, Kenji/0000-0002-9424-1491; ding, jian ping/0000-0001-7029-7346; Arnold, Gail/0000-0002-3335-6965	NATIONAL CANCER INSTITUTE [ZIASC006738, Z01SC006738] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; *DHHS, 2005, GUID US ANT AG HIV 1; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; EVANS EA, 1974, TRITIUM ITS COMPOUND, P271; Exner T, 1998, J MOL MODEL, V4, P340, DOI 10.1007/s008940050091; Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; GRIBBLE GW, 1975, J CHEM SOC CHEM COMM, P535, DOI 10.1039/c39750000535; Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; LALEZARI J, 2005, 44 INT C ANT AG CHEM; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; Maeda Y, 2000, J VIROL, V74, P1787, DOI 10.1128/JVI.74.4.1787-1793.2000; Mitsuya H, 1999, TXB AIDS MED, P751; Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005; Navenot JM, 2001, J MOL BIOL, V313, P1181, DOI 10.1006/jmbi.2001.5086; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; Sarafianos SG, 2004, CURR OPIN STRUC BIOL, V14, P716, DOI 10.1016/j.sbi.2004.10.013; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; SPARKS S, 2005, 12 C RETR OPP INF BO; Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003; VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xiang ZX, 2001, J MOL BIOL, V311, P421, DOI 10.1006/jmbi.2001.4865	38	143	150	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12688	12698		10.1074/jbc.M512688200	http://dx.doi.org/10.1074/jbc.M512688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16476734	hybrid			2022-12-25	WOS:000237134700060
J	Toth, J; Gombos, L; Simon, Z; Medveczky, P; Szilagyi, L; Graf, L; Malnasi-Csizmadia, A				Toth, J; Gombos, L; Simon, Z; Medveczky, P; Szilagyi, L; Graf, L; Malnasi-Csizmadia, A			Thermodynamic analysis reveals structural rearrangement during the acylation step in human trypsin 4 on 4-methylumbelliferyl 4-guanidinobenzoate substrate analogue Jbc. m512301200	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; TETRAHEDRAL INTERMEDIATE; PLASMINOGEN-ACTIVATOR; INHIBITOR RESISTANCE; ALPHA-CHYMOTRYPSIN; HUMAN MESOTRYPSIN; TRANSITION-STATE; MECHANISM; CATALYSIS; ENZYMES	Human trypsin 4 is an unconventional serine protease that possesses an arginine at position 193 in place of the highly conserved glycine. Although this single amino acid substitution does not affect steady-state activity on small synthetic substrates, it has dramatic effects on zymogen activation, interaction with canonical inhibitors, and substrate specificity toward macromolecular substrates. To study the effect of a non-glycine residue at position 193 on the mechanism of the individual enzymatic reaction steps, we expressed wild type human trypsin 4 and its R193G mutant. 4-Methylumbelliferyl 4-guanidinobenzoate has been chosen as a substrate analogue, where deacylation is rate-limiting, and transient kinetic methods were used to monitor the reactions. This experimental system allows for the separation of the individual reaction steps during substrate hydrolysis and the determination of their rate constants dependably. We suggest a refined model for the reaction mechanism, in which acylation is preceded by the reversible formation of the first tetrahedral intermediate. Furthermore, the thermodynamics of these steps were also investigated. The formation of the first tetrahedral intermediate is highly exothermic and accompanied by a large entropy decrease for the wild type enzyme, whereas the signs of the enthalpy and entropy changes are opposite and smaller for the R193G mutant. This difference in the energetic profiles indicates much more extended structural and/or dynamic rearrangements in the equilibrium step of the first tetrahedral intermediate formation in wild type human trypsin 4 than in the R193G mutant enzyme, which may contribute to the biological function of this protease.	Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary	Eotvos Lorand University	Malnasi-Csizmadia, A (corresponding author), Eotvos Lorand Univ, Dept Biochem, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.	amc26@le.ac.uk	Csizmadia, András Málnási/K-7632-2018	Csizmadia, András Málnási/0000-0002-2430-8398; Medveczky, Peter/0000-0002-1798-2595				BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; Bernardi F, 1996, HUM MUTAT, V8, P108; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Bott RR, 2003, BIOCHEMISTRY-US, V42, P10545, DOI 10.1021/bi034773m; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; ESTELL DA, 1980, BIOCHEMISTRY-US, V19, P124, DOI 10.1021/bi00542a019; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GRAF L, 1995, NATURAL SCI HUMAN TH, P139; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HIROHARA H, 1974, P NATL ACAD SCI USA, V71, P1643, DOI 10.1073/pnas.71.5.1643; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUNKAPILLER MW, 1976, BIOCHEMISTRY-US, V15, P5581, DOI 10.1021/bi00670a024; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KELETI T, 1983, BIOCHEM J, V209, P277, DOI 10.1042/bj2090277; KUROMIZU K, 1985, ANAL BIOCHEM, V151, P534, DOI 10.1016/0003-2697(85)90216-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGEL WF, 1990, BIOCHEMISTRY-US, V29, P8351, DOI 10.1021/bi00488a022; Medveczky P, 2006, FEBS LETT, V580, P545, DOI 10.1016/j.febslet.2005.12.067; MEDVECZKY P, 2003, PROTEIN STRUCTURE FU, P41; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; Payne MA, 1996, BIOCHEMISTRY-US, V35, P7100, DOI 10.1021/bi9529770; POLGAR L, 1969, P NATL ACAD SCI USA, V64, P1335, DOI 10.1073/pnas.64.4.1335; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Rowen L, 2005, MOL BIOL EVOL, V22, P1712, DOI 10.1093/molbev/msi166; RYAN TJ, 1976, BIOCHEMISTRY-US, V15, P1337, DOI 10.1021/bi00651a026; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmidt AE, 2004, J BIOL CHEM, V279, P29485, DOI 10.1074/jbc.M402971200; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; VAJDA T, 1988, ACTA BIOCHIM BIOPHYS, V23, P195; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246; ZIVELIN A, 2001, THROMB HAEMOSTASIS S	37	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12596	12602		10.1074/jbc.M512301200	http://dx.doi.org/10.1074/jbc.M512301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16492676	hybrid			2022-12-25	WOS:000237134700049
J	Li, ZR; Benard, O; Margolskee, RF				Li, ZR; Benard, O; Margolskee, RF			G gamma 13 interacts with PDZ domain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERIC G-PROTEINS; GAMMA-SUBUNIT; BETA-GAMMA; MEMBRANE LOCALIZATION; NMDA RECEPTOR; COMPLEX; CELLS; ASSOCIATION; PRENYLATION; FAMILY	The G protein gamma 13 subunit (G gamma 13) is expressed in taste and retinal and neuronal tissues and plays a key role in taste transduction. We identified PSD95, Veli-2, and other PDZ domain-containing proteins as binding partners for G gamma 13 by yeast two-hybrid and pull-down assays. In two-hybrid assays, G gamma 13 interacted specifically with the third PDZ domain of PSD95, the sole PDZ domain of Veli-2, and the third PDZ domain of SAP97, a PSD95-related protein. G gamma 13 did not interact with the other PDZ domains of PSD95. Coexpression of G gamma 13 with its G beta 1 partner did not interfere with these two-hybrid interactions. The physical interaction of G gamma 13 with PSD95 in the cellular milieu was confirmed in pull-down assays following heterologous expression in HEK293 cells. The interaction of G gamma 13 with the PDZ domain of PSD95 was via the C-terminal CAAX tail of G gamma 13 (where AA indicates the aliphatic amino acid); alanine substitution of the CTAL sequence at the C terminus of G gamma 13 abolished its interactions with PSD95 in two-hybrid and pull-down assays. Veli-2 and SAP97 were identified in taste tissue and in G gamma 13-expressing taste cells. Coimmunoprecipitation of G gamma 13 and PSD95 from brain and of G gamma 13 and SAP97 from taste tissue indicates that G gamma 13 interacts with these proteins endogenously. This is the first demonstration that PDZ domain proteins interact with heterotrimeric G proteins via the CAAX tail of G gamma subunits. The interaction of G gamma 13 with PDZ domain-containing proteins may provide a means to target particular G beta gamma subunits to specific subcellular locations and/or macromolecular complexes involved in signaling pathways.	CUNY Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Margolskee, RF (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurosurg, 1425 Madison Ave,Box 1065, New York, NY 10029 USA.	robert.margolskee@mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NIDCD NIH HHS [DC003055, DC003155] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155, R01DC003055] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P51; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Harris BZ, 2001, J CELL SCI, V114, P3219; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Huang LQ, 2003, J COMP NEUROL, V455, P1, DOI 10.1002/cne.10396; Huber A, 2001, EUR J NEUROSCI, V14, P769, DOI 10.1046/j.0953-816x.2001.01704.x; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; James P, 1996, GENETICS, V144, P1425; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koulen P, 1999, EUR J NEUROSCI, V11, P2007, DOI 10.1046/j.1460-9568.1999.00622.x; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11066	11073		10.1074/jbc.M600113200	http://dx.doi.org/10.1074/jbc.M600113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473877	hybrid			2022-12-25	WOS:000236822200048
J	Marinissen, MJ; Tanos, T; Bolos, M; de Sagarra, MR; Coso, OA; Cuadrado, A				Marinissen, MJ; Tanos, T; Bolos, M; de Sagarra, MR; Coso, OA; Cuadrado, A			Inhibition of heme oxygenase-1 interferes with the transforming activity of the Kaposi sarcoma herpesvirus-encoded G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CARBON-MONOXIDE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; VASCULAR-PERMEABILITY; BILIVERDIN REDUCTASE; CHEMOKINE RECEPTOR; TIN-PROTOPORPHYRIN; OXIDATIVE STRESS; VEGF SYNTHESIS; C-JUN	Heme oxygenase-1 (HO-1), the inducible enzyme responsible for the rate-limiting step in the heme catabolism, is expressed in AIDS-Kaposi sarcoma (KS) lesions. Its expression is up-regulated by the Kaposi sarcoma-associated herpesvirus ( KSHV) in endothelial cells, but the mechanisms underlying KSHV-induced HO-1 expression are still unknown. In this study we investigated whether the oncogenic G protein-coupled receptor (KSHV-GPCR or vGPCR), one of the key KSHV genes involved in KS development, activated HO-1 expression. Here we show that vGPCR induces HO-1 mRNA and protein levels in fibroblasts and endothelial cells. Moreover, targeted knock-down gene expression of HO-1 by small hairpin RNA and chemical inhibition of HO-1 enzymatic activity by tin protoporphyrin IX ( SnPP), impaired vGPCR-induced survival, proliferation, transformation, and vascular endothelial growth factor (VEGF)-A expression. vGPCR-expressing cells implanted in the dorsal flank of nude mice developed tumors with elevated HO-1 expression and activity. Chronic administration of SnPP to the implanted mice, under conditions that effectively blocked HO-1 activity and VEGF-A expression in the transplanted cells, strikingly reduced tumor growth, without apparent side effects. On the contrary, administration of the HO-1 inducer cobalt protoporphyrin (CoPP) further enhanced vGPCR-induced tumor growth. These data postulate HO-1 as an important mediator of vGPCR-induced tumor growth and suggest that inhibition of intratumoral HO-1 activity by SnPP may be a potential therapeutic strategy.	Univ Autonoma Madrid, Inst Invest Biomed A Sols, CSIC,Dept Bioquim,, Fac Med,Lab C11, E-28029 Madrid, Spain; Univ Buenos Aires, Dept Fisiol Biol Mol Celular, Fac Ciencias Exactas Nat,Inst Fisiol Biol M, Consejo Nacl Invest Cient Tecn, RA-1428 Buenos Aires, DF, Argentina	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Marinissen, MJ (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed A Sols, CSIC,Dept Bioquim,, Fac Med,Lab C11, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	mjmarinissen@iib.uam.es	Bolos Jurado, Marta/J-7620-2014	Bolos Jurado, Marta/0000-0003-2652-8607; Cuadrado, Antonio/0000-0002-4039-7140; Tanos, Tamara/0000-0002-3217-3104; Cuadrado, Antonio/0000-0002-3444-9012				ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Alam J, 2004, ANTIOXID REDOX SIGN, V6, P924, DOI 10.1089/1523086041798114; Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; ANDERSON KE, 1984, J PHARMACOL EXP THER, V228, P327; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Burger M, 2005, ONCOGENE, V24, P2067, DOI 10.1038/SJ.ONC.1208442; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Cornali E, 1996, AM J PATHOL, V149, P1851; CORNELIUS CE, 1984, PEDIATR RES, V18, P728, DOI 10.1203/00006450-198408000-00010; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Devesa I, 2005, ARTHRITIS RHEUM-US, V52, P3230, DOI 10.1002/art.21356; Doi K, 1999, BRIT J CANCER, V80, P1945, DOI 10.1038/sj.bjc.6690624; Drummond GS, 2004, SEMIN PERINATOL, V28, P365, DOI 10.1053/j.semperi.2004.09.004; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Fang J, 2003, CANCER RES, V63, P3567; Fang J, 2004, APOPTOSIS, V9, P27, DOI 10.1023/B:APPT.0000012119.83734.4e; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; Jozkowicz A, 2002, ANTIOXID REDOX SIGN, V4, P577, DOI 10.1089/15230860260220076; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Kappas A, 2001, PEDIATRICS, V108, P25, DOI 10.1542/peds.108.1.25; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kreiser D, 2002, LAB INVEST, V82, P687, DOI 10.1097/01.LAB.0000017167.26718.F2; Kushida T, 2002, BIOCHEM BIOPH RES CO, V291, P68, DOI 10.1006/bbrc.2002.6403; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Lam CW, 2005, J IMMUNOL, V174, P2297, DOI 10.4049/jimmunol.174.4.2297; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; Loboda A, 2005, CELL MOL BIOL, V51, P347, DOI 10.1170/T637; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Malaguarnera L, 2004, J CELL BIOCHEM, V93, P197, DOI 10.1002/jcb.20167; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; McAllister SC, 2004, BLOOD, V103, P3465, DOI 10.1182/blood-2003-08-2781; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785; Nicholas J, 2003, J BIOMED SCI, V10, P475, DOI 10.1159/000072375; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Reeve VE, 1999, P NATL ACAD SCI USA, V96, P9317, DOI 10.1073/pnas.96.16.9317; Sacerdoti D, 2005, CELL MOL BIOL, V51, P363, DOI 10.1170/T639; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Sodhi A, 2000, CANCER RES, V60, P4873; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tang Rui-Fang, 2005, Hepatobiliary Pancreat Dis Int, V4, P460; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Volti GL, 2005, ANTIOXID REDOX SIGN, V7, P704, DOI 10.1089/ars.2005.7.704; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	72	64	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11332	11346		10.1074/jbc.M512199200	http://dx.doi.org/10.1074/jbc.M512199200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476737	Green Published, hybrid			2022-12-25	WOS:000236822200076
J	Metz, RP; Kwak, HI; Gustafson, T; Laffin, B; Porter, WW				Metz, RP; Kwak, HI; Gustafson, T; Laffin, B; Porter, WW			Differential transcriptional regulation by mouse single-minded 2s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-THERAPY TARGET; MURINE HOMOLOG; GENE; REPRESSION; RECEPTOR; EXPRESSION; ARNT; TRANSACTIVATION; IDENTIFICATION; CLONING	Single-minded 1 and 2 are unique members of the basic helix-loop-helix Per-Arnt-Sim family as they are transcriptional repressors. Here we report the identification and transcriptional characterization of mouse Sim2s, a splice variant of Sim2, which is missing the carboxyl Pro/Ala-rich repressive domain. Sim2s is expressed at high levels in kidney and skeletal muscle; however, the ratio of Sim2 to Sim2s mRNA differs between these tissues. Similar to full-length Sim2, Sim2s interacts with Arnt and to a lesser extent, Arnt2. The effects of Sim2s on transcriptional regulation through hypoxia, dioxin, and central midline response elements are different than that of full-length Sim2. Specifically, Sim2s exerts a less repressive effect on hypoxia-induced gene expression than full-length Sim2, but is just as effective as Sim2 at repressing TCDD-induced gene expression from a dioxin response element. Interestingly, Sim2s bind to and activates expression from a central midline response element-controlled reporter through an Arnt transactivation domain-dependent mechanism. The differences in expression pattern, protein interactions, and transcriptional activities between Sim2 and Sim2s may reflect differential roles each isoform plays during development or in tissue-specific effects on other protein-mediated pathways.	Texas A&M Univ, Coll Vet Med, Dept Integrated Biosci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Integrated Biosci, MS 4458, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu		Metz, Richard/0000-0002-9876-3385	NATIONAL CANCER INSTITUTE [R01CA111551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA111551] Funding Source: Medline; NIEHS NIH HHS [P30ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chrast R, 1997, GENOME RES, V7, P615, DOI 10.1101/gr.7.6.615; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Ema M, 1996, BIOCHEM BIOPH RES CO, V218, P588, DOI 10.1006/bbrc.1996.0104; Estes P, 2001, DEV BIOL, V232, P157, DOI 10.1006/dbio.2001.0174; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; McKay LM, 1999, NUCLEIC ACIDS RES, V27, P3064, DOI 10.1093/nar/27.15.3064; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; Moffett P, 1996, GENOMICS, V35, P144, DOI 10.1006/geno.1996.0333; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Moffett P, 2000, FEBS LETT, V466, P80, DOI 10.1016/S0014-5793(99)01750-0; Morrow D, 2004, J STEROID BIOCHEM, V88, P27, DOI 10.1016/j.jsbmb.2003.10.005; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200	22	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10839	10848		10.1074/jbc.M508858200	http://dx.doi.org/10.1074/jbc.M508858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484282	hybrid			2022-12-25	WOS:000236822200023
J	Tsuruma, K; Nakagawa, T; Morimoto, N; Minami, M; Hara, H; Uehara, T; Nomura, Y				Tsuruma, K; Nakagawa, T; Morimoto, N; Minami, M; Hara, H; Uehara, T; Nomura, Y			Glucocorticoid modulatory element-binding protein 1 binds to initiator procaspases and inhibits ischemia-induced apoptosis and neuronal injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; KAPPA-B ACTIVATION; CELL-DEATH; DISULFIDE ISOMERASE; PROTEASE; STRESS; INTERLEUKIN-1-BETA; INVOLVEMENT; CASPASE-9; KINASE	Caspases are divided into two classes: initiator caspases, which include caspase-8 and - 9 and possess long prodomains, and effector caspases, which include caspase-3 and - 7 and possess short prodomains. Recently, we demonstrated that glucocorticoid modulatory element-binding protein 1( GMEB1) interacts with the prodomain of procaspase-2, thereby disrupting its autoactivation and the induction of apoptosis. Here we show that GMEB1 is also capable of binding to procaspase-8 and - 9. GMEB1 attenuated the Fas-mediated activation of these caspases and the subsequent apoptosis. The knockdown of endogenous GMEB1 using RNA interference revealed that cells with decreased GMEB1 expression are more sensitive to stress and undergo accelerated apoptosis. Transgenic mice expressing a neurospecific GMEB1 had smaller cerebral infarcts and less brain swelling than wildtype mice in response to transient focal ischemia. These results suggest that GMEB1 is an endogenous regulator that selectively binds to initiator procaspases and inhibits caspase-induced apoptosis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan; Gifu Pharmaceut Univ, Dept Biofunct Mol, Gifu 5028585, Japan	Hokkaido University; Gifu Pharmaceutical University	Uehara, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, N12W6, Sapporo, Hokkaido 0600812, Japan.	uehara@pharm.hokudai.ac.jp; nomura@pharm.hokudai.ac.jp	Minami, Masabumi/A-3883-2012	Minami, Masabumi/0000-0002-0144-0679; Uehara, Takashi/0000-0002-8545-4006				Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen J, 2002, J BIOL CHEM, V277, P22053, DOI 10.1074/jbc.M202311200; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Furuta Y, 2003, J CEREBR BLOOD F MET, V23, P962, DOI 10.1097/01.WCB.0000073948.29308.F8; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Ko HS, 2004, FEBS LETT, V566, P110, DOI 10.1016/j.febslet.2004.04.031; Ko HS, 2002, J BIOL CHEM, V277, P35386, DOI 10.1074/jbc.M203412200; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Moriya R, 2000, FEBS LETT, V484, P253, DOI 10.1016/S0014-5793(00)02167-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ogino S, 2004, MOL PHARMACOL, V65, P1344, DOI 10.1124/mol.65.6.1344; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu T, 2004, J NEUROCHEM, V91, P167, DOI 10.1111/j.1471-4159.2004.02702.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Theriault JR, 1999, FEBS LETT, V452, P170, DOI 10.1016/S0014-5793(99)00634-1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsuruma K, 2004, BIOCHEM BIOPH RES CO, V325, P1246, DOI 10.1016/j.bbrc.2004.10.145; Uehara T, 1999, J BIOL CHEM, V274, P15875, DOI 10.1074/jbc.274.22.15875; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11397	11404		10.1074/jbc.M510597200	http://dx.doi.org/10.1074/jbc.M510597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497673	Green Published, hybrid			2022-12-25	WOS:000236822200082
J	Banchio, C; Lingrell, S; Vance, DE				Banchio, C; Lingrell, S; Vance, DE			Role of histone deacetylase in the expression of CTP : Phosphocholine cytidylyltransferase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; CELL-CYCLE; S-PHASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; REPRESS TRANSCRIPTION; E2F; PROMOTER; GENE; PROTEIN; REQUIREMENT	Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in cell-specific expression of CTP: phosphocholine cytidylyltransferase alpha (CT alpha) are not fully understood. In this study, we investigated whether or not histone deacetylation is involved in repression of CT alpha expression in quiescent C3H10T1/2 mouse embryo fibroblasts. We have examined the contributions of the Sp1 and E2F binding sites in the repression of CT alpha gene expression. Immunoprecipitation experiments showed that histone deacetylase 1 (HDAC1) and HDAC activity are associated with Sp1 in serum-starved cells or during serum stimulation. However, HDAC1 association with E2F was only detected in serum-starved cells. By chromatin immunoprecipitation assays, we detected both direct and indirect association of HDAC1 with the CT alpha promoter. Treatment with the HDAC inhibitor trichostatin A induced CT alpha expression. Our data suggest that HDAC1 plays a critical role in CT alpha repression and that Sp1 and E2F may serve as key targets for HDAC1-mediated CT alpha repression in fibroblasts.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst B, RA-2000 Rosario, Santa Fe, Argentina; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; University of Alberta; University of Alberta	Banchio, C (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst B, Suipacha 531,S2002LRK, RA-2000 Rosario, Santa Fe, Argentina.	cbanchio@fbioyf.unr.edu.ar; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Banchio C, 2004, J BIOL CHEM, V279, P40220, DOI 10.1074/jbc.M406468200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; Brehm A, 1999, BRIT J CANCER, V80, P38; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Magnaghi-Jaulin L, 1998, B CANCER, V85, P606; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; Sugimoto H, 2005, J BIOL CHEM, V280, P40857, DOI 10.1074/jbc.M503578200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TERCE F, 1994, J LIPID RES, V35, P2130; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhao SJ, 2003, CANCER RES, V63, P2624	43	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10010	10015		10.1074/jbc.M513503200	http://dx.doi.org/10.1074/jbc.M513503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484221	hybrid			2022-12-25	WOS:000236594300024
J	Shiroishi, M; Kuroki, K; Ose, T; Rasubala, L; Shiratori, I; Arase, H; Tsumoto, K; Kumagai, I; Kohda, D; Maenaka, K				Shiroishi, M; Kuroki, K; Ose, T; Rasubala, L; Shiratori, I; Arase, H; Tsumoto, K; Kumagai, I; Kohda, D; Maenaka, K			Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; FC-ALPHA-RI; CELL-SURFACE; INHIBITORY RECEPTORS; DENDRITIC CELLS; QUALITY-CONTROL; CUTTING EDGE; G MOLECULES; G PROTEIN; T-CELL	HLA-G is a nonclassical major histocompatibility complex class I (MHCI) molecule, which is expressed in trophoblasts and confers immunological tolerance in the maternal-fetal interface by binding to leukocyte Ig-like receptors (LILRs, also called as LIR/ILT/CD85) and CD8. HLA-G is expressed in disulfide-linked dimer form both in solution and at the cell surface. Interestingly, MHCI dimer formations have been involved in pathogenesis and T cell activation. The structure and receptor binding characteristics of MHCI dimers have never been evaluated. Here we performed binding studies showing that the HLA-G dimer exhibited higher overall affinity to LILRB1/2 than the monomer by significant avidity effects. Furthermore, the cell reporter assay demonstrated that the dimer formation remarkably enhanced the LILRB1-mediated signaling at the cellular level. We further determined the crystal structure of the wild-type dimer of HLA-G with the intermolecular Cys(42)-Cys(42) disulfide bond. This dimer structure showed the oblique configuration to expose two LILR/CD8-binding sites upward from the membrane easily accessible for receptors, providing plausible 1: 2 (HLA-G dimer: receptors) complex models. These results indicated that the HLA-G dimer conferred increased avidity in a proper structural orientation to induce efficient LILR signaling, resulting in the dominant immunosuppressive effects. Moreover, structural and functional implications for other MHCI dimers observed in activated T cells and the pathogenic allele, HLA-B27, are discussed.	Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Higashi Ku, Fukuoka 8128582, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Immunochem, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Saitama 3320012, Japan; Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan	Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Tohoku University	Maenaka, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kmaenaka@bioreg.kyushu-u.ac.jp	Kohda, Daisuke/I-4990-2019; Arase, Hisashi/C-8442-2009; Ose, Toyoyuki/AAW-7821-2020; Kuroki, Kimiko/F-6906-2012	Kohda, Daisuke/0000-0001-8234-3776; Arase, Hisashi/0000-0002-1153-3166; Ose, Toyoyuki/0000-0002-2001-9388; Shiroishi, Mitsunori/0000-0002-3133-157X; Shiratori, Ikuo/0000-0003-3713-4910				Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; Brown D, 2004, TISSUE ANTIGENS, V64, P215, DOI 10.1111/j.0001-2815.2004.00290.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Clements CS, 2005, P NATL ACAD SCI USA, V102, P3360, DOI 10.1073/pnas.0409676102; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Damjanovich S, 2002, IMMUNOL LETT, V82, P93, DOI 10.1016/S0165-2478(02)00024-X; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; Diehl M, 1996, CURR BIOL, V6, P305, DOI 10.1016/S0960-9822(02)00481-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; FUJII T, 1994, J IMMUNOL, V153, P5516; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gonen-Gross T, 2003, HUM IMMUNOL, V64, P1011, DOI 10.1016/j.humimm.2003.08.355; Gonen-Gross T, 2005, J IMMUNOL, V175, P4866, DOI 10.4049/jimmunol.175.8.4866; Gonen-Gross T, 2003, J IMMUNOL, V171, P1343, DOI 10.4049/jimmunol.171.3.1343; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Bouteiller P, 2003, PLACENTA, V24, pS10, DOI 10.1053/plac.2002.0931; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; LeMaoult J, 2003, TISSUE ANTIGENS, V62, P273, DOI 10.1034/j.1399-0039.2003.00143.x; Lenfant F, 2003, J GEN VIROL, V84, P307, DOI 10.1099/vir.0.18735-0; Liang SY, 2003, HUM IMMUNOL, V64, P1025, DOI 10.1016/j.humimm.2003.08.348; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; McMichael A, 2002, ARTHRITIS RES THER, V4, pS153, DOI 10.1186/ar571; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morales PJ, 2003, J IMMUNOL, V171, P6215, DOI 10.4049/jimmunol.171.11.6215; O'Callaghan CA, 1998, MOL CELL, V1, P531, DOI 10.1016/S1097-2765(00)80053-2; Ohtsuka M, 2004, P NATL ACAD SCI USA, V101, P8126, DOI 10.1073/pnas.0401119101; Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Santos SG, 2004, J BIOL CHEM, V279, P53062, DOI 10.1074/jbc.M408794200; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Shiroishi M, 2006, BBA-PROTEINS PROTEOM, V1764, P985, DOI 10.1016/j.bbapap.2005.10.006; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961	51	162	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10439	10447		10.1074/jbc.M512305200	http://dx.doi.org/10.1074/jbc.M512305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455647	hybrid			2022-12-25	WOS:000236594300073
J	Edinger, RS; Yospin, J; Perry, C; Kleyman, TR; Johnson, JP				Edinger, RS; Yospin, J; Perry, C; Kleyman, TR; Johnson, JP			Regulation of epithelial Na+ channels (ENaC) by methylation - A novel methyltransferase stimulates ENaC activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNELS; OPEN PROBABILITY; APICAL MEMBRANE; BETA-SUBUNIT; CELL-LINE; ALDOSTERONE; EXPRESSION; TRANSPORT; INCREASES	Aldosterone acts to increase apical membrane permeability by activation of epithelial Na+ channels (ENaC). We have previously shown that aldosterone activates ENaC early in the course of its action by stimulating the methylation of the beta subunit of this heteromeric channel in A6 cells. Aldosterone also stimulates the expression and methylation of k-ras in A6 cells. To determine whether aldosterone-stimulated methylations are seen in mammalian cells, we examined the effect of aldosterone on methylation and ras activation in a continuous line of cultured epithelial cells derived from mouse cortical collecting duct (CCD) and determined that beta mENaC is a substrate for methylation by an enzyme contained in CCD cells. Aldosterone stimulated protein base labile methylation in CCD cells. Aldosterone stimulated Na+ transport in CCD cells within 1 h of addition and without an increase in cellular amount of any ENaC subunits over the first 4 h. Inhibition of methylation, using the inhibitor 3-deaza-adenosine, blocked the stimulation of Na+ transport induced by aldosterone at early time points (1-4 h) without affecting cellular amounts of any ENaC subunits. In contrast to 3-deaza-adenosine (3-DZA), which inhibits all methylation reactions, specific inhibitors of small G-protein methylation or prenylation had no effect on the early aldosterone-induced current. Over expression of isoprenylcysteine carboxylmethyl-transferase (PCMTase), the enzyme that methylates ras, had little effect on basal transport but enhanced aldosterone-stimulated transport in A6 cells. Overexpression of PCMTase in CCD cells had no effect on either basal or aldosterone- stimulated transport. Moreover PCMTase had no effect on ENaC activity when co-expressed in Xenopus oocytes. Aldosterone had no effect on either message or protein levels of k-ras in CCD cells. Searching a mouse kidney library, we identified a methyltransferase that stimulates ENaC activity in Xenopus oocytes without affecting surface expression of ENaC. Our results demonstrate that aldosterone stimulates protein methylation in CCD cells, and this is required for expression of the early transport response. In CCD cells this effect is not mediated via methylation of ras, which is not induced by aldosterone in these cells, and the enzyme that methylates ras has no direct effect on ENaC activity. beta ENaC is a substrate for methylation in CCD cells. A novel methyltransferase that stimulates ENaC directly has been identified in CCD cells.	Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, JP (corresponding author), Univ Pittsburgh, Med Ctr, 935 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.	Johnson@dom.pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057718, R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57718, R01DK47874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Baldawi NF, 2000, AM J PHYSIOL-CELL PH, V279, pC429, DOI 10.1152/ajpcell.2000.279.2.C429; ARIMA S, 2006, IN PRESS STEROIDS; Becchetti A, 2000, J BIOL CHEM, V275, P16550, DOI 10.1074/jbc.M000954200; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TY, 2004, TRENDS ENDOCRIN MET, V15, P353, DOI 10.1016/j.tem.2004.08.002; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Flores SY, 2005, J AM SOC NEPHROL, V16, P2279, DOI 10.1681/ASN.2004100828; Frindt G, 2001, AM J PHYSIOL-RENAL, V280, pF112, DOI 10.1152/ajprenal.2001.280.1.F112; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; JOHNSON JP, 1992, PHARMACOL THERAPEUT, V53, P1, DOI 10.1016/0163-7258(92)90042-X; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LE MC, 2004, CELL MOL BIOL NOISY, V50, P833; Lebowitz J, 2004, J BIOL CHEM, V279, P41985, DOI 10.1074/jbc.M403923200; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McCormick JA, 2005, PHYSIOLOGY, V20, P134, DOI 10.1152/physiol.00053.2004; Mohan S, 2004, J BIOL CHEM, V279, P32071, DOI 10.1074/jbc.M405091200; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Stockand JD, 2000, NEWS PHYSIOL SCI, V15, P161; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 1999, J BIOL CHEM, V274, P3842, DOI 10.1074/jbc.274.6.3842; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZH, 2001, AM J PHYSIOL-CELL PH, V281, pC1118, DOI 10.1152/ajpcell.2001.281.4.C1118	34	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9110	9117		10.1074/jbc.M509232200	http://dx.doi.org/10.1074/jbc.M509232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469734	hybrid			2022-12-25	WOS:000236404700016
J	Lo, KWH; Kan, HM; Pfister, KK				Lo, KWH; Kan, HM; Pfister, KK			Identification of a novel region of the cytoplasmic dynein intermediate chain important for dimerization in the absence of the light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW AXONAL-TRANSPORT; HEAVY-CHAIN; MICROTUBULE MOTOR; DIFFERENTIAL EXPRESSION; SUBUNIT HETEROGENEITY; DYNACTIN COMPLEX; GENETIC-ANALYSIS; BINDING; PHOSPHORYLATION; TCTEX-1	Cytoplasmic dynein is the multisubunit protein complex responsible for many microtubule-based intracellular movements. Its cargo binding domain consists of dimers of five subunits: the intermediate chains, the light intermediate chains, and the Tctex1, Roadblock, and LC8 light chains. The intermediate chains have a key role in the dynein complex. They bind the three light chains and the heavy chains, which contain the motor domains, but little is known about how the two intermediate chains interact. There are six intermediate chain isoforms, and it has been hypothesized that different isoforms may regulate specific dynein functions. However, there are little data on the potential combinations of the intermediate chain isoforms in the dynein complexes. We used co-immunoprecipitation analyses to demonstrate that all combinations of homo- and heterodimers of the six intermediate chains are possible. Therefore the formation of dynein complexes with different combinations of isoforms is not limited by interaction between the various intermediate chains. We further sought to identify the domain necessary for the dimerization of the intermediate chains. Analysis of a series of truncation and deletion mutants showed that a 61-amino-acid region is necessary for dimerization of the intermediate chain. This region does not include the N-terminal coiled-coil, the C-terminal WD repeat domain, or the three different binding sites for the Tctex1, LC8, and Roadblock light chains. Analytical gel filtration and covalent cross-linking of purified recombinant polypeptides further demonstrated that the intermediate chains can dimerize in vitro in the absence of the light chains.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA	University of Virginia; University of Virginia	Pfister, KK (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	kkp9w@virginia.edu						Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Boylan K, 2000, MOL BIOL CELL, V11, P3791, DOI 10.1091/mbc.11.11.3791; Brill LB, 2000, METHODS, V22, P307, DOI 10.1006/meth.2000.1083; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; Dillman JF, 1996, P NATL ACAD SCI USA, V93, P141, DOI 10.1073/pnas.93.1.141; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Dillman JF, 1996, J NEUROSCI, V16, P6742; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Habura A, 1999, J BIOL CHEM, V274, P15447, DOI 10.1074/jbc.274.22.15447; Hendrickson TW, 2004, MOL BIOL CELL, V15, P5431, DOI 10.1091/mbc.E04-08-0694; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 1997, J BIOL CHEM, V272, P19714, DOI 10.1074/jbc.272.32.19714; Liang J, 1999, NAT STRUCT BIOL, V6, P735; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Nikulina K, 2004, CELL MOTIL CYTOSKEL, V57, P233, DOI 10.1002/cm.10172; Nyarko A, 2004, BIOCHEMISTRY-US, V43, P15595, DOI 10.1021/bi048451+; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; Sakato M, 2004, J STRUCT BIOL, V146, P58, DOI 10.1016/j.jsb.2003.09.026; Salata MW, 2001, J NEUROSCI RES, V65, P408, DOI 10.1002/jnr.1168; SOBER HA, 1970, HDB BIOCH, pC10; Song J, 2005, J MOL BIOL, V354, P1043, DOI 10.1016/j.jmb.2005.10.017; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Susalka SJ, 2002, J BIOL CHEM, V277, P32939, DOI 10.1074/jbc.M205510200; Susalka SJ, 2000, J NEUROCYTOL, V29, P819, DOI 10.1023/A:1010995408343; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan PS, 2001, J BIOL CHEM, V276, P26171, DOI 10.1074/jbc.M102649200; Wagner OI, 2004, MOL BIOL CELL, V15, P5092, DOI 10.1091/mbc.E04-05-0401; Wang L, 2004, BIOCHEMISTRY-US, V43, P4611, DOI 10.1021/bi036328x; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Williams JC, 2005, J BIOL CHEM, V280, P21981, DOI 10.1074/jbc.M414643200; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013	51	32	33	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9552	9559		10.1074/jbc.M511721200	http://dx.doi.org/10.1074/jbc.M511721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452477	hybrid			2022-12-25	WOS:000236404700066
J	Ullah, MS; Davies, AJ; Halestrap, AP				Ullah, MS; Davies, AJ; Halestrap, AP			The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1 alpha-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCARBOXYLATE TRANSPORTER; LACTIC-ACID EFFLUX; SKELETAL-MUSCLE; INDUCIBLE FACTOR-1; GENE-EXPRESSION; RAT MUSCLE; FAMILY; CD147; INDUCTION; PROTEIN	The monocarboxylate transporter MCT4 mediates lactic acid efflux from most tissues that are dependent on glycolysis for their ATP production. Here we demonstrate that expression of MCT4 mRNA and protein was increased >3-fold by a 48-h exposure to 1% O-2, whereas MCT1 expression was not increased. The effect was mimicked by CoCl2 (50 mu M), suggesting transcriptional regulation by hypoxia-inducible factor 1 alpha (HIF-1 alpha). The predicted promoters for human MCT1, MCT2, and MCT4 were cloned into the pGL3 vector and shown to be active ( luciferase luminescence) under basal conditions. Only the MCT4 promoter was activated (>2-fold) by hypoxia. No response was found in cells lacking HIF-1 alpha. Four potential hypoxia-response elements were identified, but deletion analysis implicated only two in the hypoxia response. These were just upstream from the transcription start site and also found in the mouse MCT4 promoter. Mutation of site 2 totally abolished the hypoxic response, whereas mutation of site 1 only reduced the response. Gel-shift analysis demonstrated that nuclear extracts of hypoxic but not normoxic HeLa cells contained two transcription factors that bound to DNA probes containing these hypoxia-response elements. The major shifted band was abolished by mutation of site 2, and supershift analysis confirmed that HIF-1 alpha bound to this site. Binding of the second factor was abolished by mutation of site 1. We conclude that MCT4, like other glycolytic enzymes, is up-regulated by hypoxia through a HIF-1 alpha-mediated mechanism. This adaptive response allows the increased lactic acid produced during hypoxia to be rapidly lost from the cell.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	a.halestrap@bristol.ac.uk	Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778				Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Chaudary N, 2002, BIOCHEM CELL BIOL, V80, P655, DOI 10.1139/O02-143; Coles L, 2004, J PHYSIOL-LONDON, V561, P253, DOI 10.1113/jphysiol.2004.073478; Cuff MA, 2002, BIOCHEM BIOPH RES CO, V292, P1048, DOI 10.1006/bbrc.2002.6763; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Grollman EF, 2000, BIOCHEMISTRY-US, V39, P9351, DOI 10.1021/bi000464+; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Moeller LC, 2005, MOL ENDOCRINOL, V19, P2955, DOI 10.1210/me.2004-0542; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; Ord JJ, 2005, BRIT J CANCER, V93, P346, DOI 10.1038/sj.bjc.6602666; Price NT, 1998, BIOCHEM J, V329, P321; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Py G, 2005, METABOLISM, V54, P634, DOI 10.1016/j.metabol.2004.12.007; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; van der Meer DLM, 2005, AM J PHYSIOL-REG I, V289, pR1512, DOI 10.1152/ajpregu.00089.2005; Wang YX, 2003, AM J PHYSIOL-ENDOC M, V285, pE622, DOI 10.1152/ajpendo.00069.2003; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Yoon H, 1998, EXP EYE RES, V67, P417, DOI 10.1006/exer.1998.0533	31	618	643	3	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9030	9037		10.1074/jbc.M511397200	http://dx.doi.org/10.1074/jbc.M511397200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452478	hybrid			2022-12-25	WOS:000236404700007
J	Yamamoto, K; Higashi, S; Kioi, M; Tsunezumi, J; Honke, K; Miyazaki, K				Yamamoto, K; Higashi, S; Kioi, M; Tsunezumi, J; Honke, K; Miyazaki, K			Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane-associated proteolytic action and induction of homotypic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE 7; COLON-CANCER CELLS; CARCINOMA-CELLS; GELATINASE-A; ACTIVATION; INHIBITOR; BETA; ANGIOGENESIS; PRECURSOR; TUMOR	Regulation of cell surface molecules by matrix metalloproteinases (MMPs), as well as MMPs-catalyzed degradation of extracellular matrix, is important for tumor invasion and metastasis. Our previous study (Kioi, M., Yamamoto, K., Higashi, S., Koshikawa, N., Fujita, K., and Miyazaki, K. (2003) Oncogene 22, 8662-8670) demonstrated that active matrilysin specifically binds to the surface of colon cancer cells and induces notable cell aggregation due to processing of the cell membrane protein(s). Furthermore, these aggregated cells showed a dramatically enhanced metastatic potential. To elucidate the mechanism of matrilysin-induced cell aggregation, we attempted to identify the matrilysin-binding substance on the cell surface. Here, we demonstrate that cholesterol sulfate on the cell surface is a major matrilysin-binding substance. We found that active matrilysin bound to the cell membrane and cholesterol sulfate incorporated into liposomes with similar affinities. Treatment of colon cancer cells with beta-cyclodextrin significantly reduced not only matrilysin binding to the cell surface but also matrilysin-dependent proteolysis and cell aggregation. Interestingly, replenishment of cholesterol sulfate, but not cholesterol, neutralized the effects of beta-cyclodextrin. Taken together, it is likely that binding of matrilysin to cholesterol sulfate facilitates the matrilysin-catalyzed modulation of cell surface proteins, thus inducing the cancer cell aggregation.	Yokohama City Univ, Div Cell Biol, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Kochi Univ, Sch Med, Dept Mol Genet, Nankoku, Kochi 7838505, Japan	Yokohama City University; Kochi University	Higashi, S (corresponding author), Yokohama City Univ, Div Cell Biol, Kihara Inst Biol Res, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	shigashi@yokohama-cu.ac.jp	Yamamoto, Kazuhiro/AAD-9650-2019	Kioi, Mitomu/0000-0002-7981-3340				ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; Kihira Y, 1996, Urol Oncol, V2, P20, DOI 10.1016/1078-1439(96)00030-0; Kioi M, 2003, ONCOGENE, V22, P8662, DOI 10.1038/sj.onc.1207181; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; MIYAZAKI K, 1990, CANCER RES, V50, P7758; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Oneda H, 1999, J BIOCHEM-TOKYO, V126, P905, DOI 10.1093/oxfordjournals.jbchem.a022533; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SHIMADA T, 1985, THROMB RES, V38, P21, DOI 10.1016/0049-3848(85)90004-0; Shiomi T, 2005, LAB INVEST, V85, P1489, DOI 10.1038/labinvest.3700351; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Topal B, 2003, J SURG RES, V112, P31, DOI 10.1016/S0022-4804(03)00140-9; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; WANG E, 1991, J BIOL CHEM, V266, P14486; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wu XZ, 2004, INT J CANCER, V110, P504, DOI 10.1002/ijc.20127; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9170	9180		10.1074/jbc.M510377200	http://dx.doi.org/10.1074/jbc.M510377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16476739	hybrid			2022-12-25	WOS:000236404700023
J	Boskovic, J; Arnold, JN; Stilion, R; Gordon, S; Sim, RB; Rivera-Calzada, A; Wienke, D; Isacke, CM; Martinez-Pomares, L; Llorca, O				Boskovic, J; Arnold, JN; Stilion, R; Gordon, S; Sim, RB; Rivera-Calzada, A; Wienke, D; Isacke, CM; Martinez-Pomares, L; Llorca, O			Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PHOSPHOLIPASES A(2); HIGH-AFFINITY BINDING; CYSTEINE-RICH DOMAIN; MEMBRANE-RECEPTOR; LIGAND-BINDING; COLLAGEN; RECOGNITION; IDENTIFICATION; PROTEIN; LECTIN	The mannose receptor family comprises four members in mammals, Endo180 (CD280), DEC-205 (CD205), phospholipase A(2) receptor (PLA2R) and the mannose receptor (MR, CD206), whose extracellular portion contains a similar domain arrangement: an N-terminal cysteine-rich domain (CysR) followed by a single fibronectin type II domain (FNII) and 8-10 C-type lectin-like domains (CTLDs). These proteins mediate diverse functions ranging from extracellular matrix turnover through collagen uptake to homeostasis and immunity based on sugar recognition. Endo180 and the MR are multivalent transmembrane receptors capable of interacting with multiple ligands; in both receptors FNII recognizes collagens, and a single CTLD retains lectin activity (CTLD2 in Endo180 and CTLD4 in MR). It is expected that the overall conformation of these multivalent molecules would deeply influence their function as the availability of their binding sites could be altered under different conditions. However, conflicting reports have been published on the three-dimensional arrangement of these receptors. Here, we have used single particle electron microscopy to elucidate the three-dimensional organization of the MR and Endo180. Strikingly, we have found that both receptors display distinct three-dimensional structures, which are, however, conceptually very similar: a bent and compact conformation built upon interactions of the CysR domain and the lone functional CTLD. Biochemical and electron microscopy experiments indicate that, under a low pH mimicking the endosomal environment, both MR and Endo180 experience large conformational changes. We propose a structural model for the mannose receptor family where at least two conformations exist that may serve to regulate differences in ligand selectivity.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Oxford; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford	Llorca, O (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9,Campus Univ Complutense, Madrid 28040, Spain.	ollorca@cib.csic.es	Arnold, James/ABE-3900-2021; Sim, Bob/A-1354-2008; Llorca, Oscar/K-1144-2014; boskovic, jasminka/L-5117-2018; Rivera-Calzada, Angel/K-3617-2014; Llorca, Oscar/P-2784-2019	Arnold, James/0000-0002-6949-0613; Sim, Bob/0000-0002-2855-7455; Llorca, Oscar/0000-0001-5705-0699; boskovic, jasminka/0000-0001-6135-0686; Rivera-Calzada, Angel/0000-0003-2472-5535; Llorca, Oscar/0000-0001-5705-0699; Martinez-Pomares, Luisa/0000-0002-2331-127X; Isacke, Clare/0000-0002-9222-3345	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; Dube P, 2005, MOL CELL, V20, P867, DOI 10.1016/j.molcel.2005.11.008; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Llorca O, 2005, ACTA PHARMACOL SIN, V26, P1153, DOI 10.1111/j.1745-7254.2005.00203.x; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Martinez-Pomares L, 2003, J LEUKOCYTE BIOL, V73, P604, DOI 10.1189/jlb.0902450; Mould AP, 2004, NATURE, V432, P27, DOI 10.1038/432027a; Napper CE, 2001, J BIOL CHEM, V276, P14759, DOI 10.1074/jbc.M100425200; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rivera-Calzada A, 2003, EMBO REP, V4, P807, DOI 10.1038/sj.embor.embor898; Simpson DZ, 1999, BIOCHEM J, V343, P403, DOI 10.1042/0264-6021:3430403; Sturge J, 2003, J CELL BIOL, V162, P789, DOI 10.1083/jcb.200302124; Su YP, 2005, J BIOL CHEM, V280, P32811, DOI 10.1074/jbc.M503457200; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor PR, 2005, TRENDS IMMUNOL, V26, P104, DOI 10.1016/j.it.2004.12.001; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Thomas EK, 2005, J BIOL CHEM, V280, P22596, DOI 10.1074/jbc.M501155200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; West AP, 2004, IMMUNITY, V20, P601, DOI 10.1016/S1074-7613(04)00113-X; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200	35	61	70	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8780	8787		10.1074/jbc.M513277200	http://dx.doi.org/10.1074/jbc.M513277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452473	Green Published, hybrid			2022-12-25	WOS:000236247100057
J	Darby, S; Sahadevan, K; Khan, MM; Robson, CN; Leung, HY; Gnanapragasam, VJ				Darby, S.; Sahadevan, K.; Khan, M. M.; Robson, C. N.; Leung, H. Y.; Gnanapragasam, V. J.			Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer	ONCOGENE			English	Article						prostate cancer; similar expression to FGF; fibroblast growth factor; metastasis	ISOFORM-B; OVER-EXPRESSION; TUMOR-GROWTH; RECEPTOR; CELLS; FIBROBLAST-GROWTH-FACTOR-8; ACTIVATION; GENE; GBX2	Fibroblast growth factors (FGF), and in particular FGF8, have been strongly implicated in prostate carcinogenesis. This study investigated the expression of Sef, a key inhibitory regulator of FGF signalling, in prostate cancer. In a panel of cell lines, hSef was detected in both androgen-dependent and independent cells but was significantly reduced in highly metastatic derivative clones. hSef expression was not influenced by androgenic stimulation. Forced downregulation of hSef by siRNA increased FGF8b induced cell migration (P = 0.02) and invasion (P = 0.007). Reduced hSef levels also enhanced FGF8b stimulated expression of MMP9 (P = 0.005). mRNA in situ hybridization revealed hSef expression in 80% (8/10) of benign biopsies but in only 69% (23/33) of Gleason sum 4-7 and 35% (10/28) of Gleason sum 8-10 cancer biopsies (P = 0.004). Quantitative PCR of micro-dissected glands confirmed this trend (P = 0.001). hSef was expressed in 69% (27/39) of non-metastatic tumours but in only 18% (2/11) of metastatic tumours (P = 0.004, n = 50). hSef expression was next correlated with earlier data on FGF8b expression in a subgroup of cancers. In this cohort, 86% (19/22) of high-grade cancers expressed FGF8 but only 31% (7/22) expressed hSef. Positive FGF8 expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which co-expressed both FGF8 and hSef (P < 0.001). These results suggest evidence that hSef is downregulated in advanced prostate cancer and might facilitate an enhanced tumorigenic response to FGFs. Further research into the role of hSef in cancer cell signalling and the mechanism of its downregulation may contribute to more effective targeting of growth factors in prostate cancer.	Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Cancer Research UK; Newcastle University - UK; Newcastle University - UK	Gnanapragasam, VJ (corresponding author), Univ Newcastle Upon Tyne, Urol Res Grp, Canc Res UK, No Inst Canc Res,Sch Med, Paul O'Gorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	V.J.Gnanapragasam@ncl.ac.uk		darby, steven/0000-0002-7226-8634; Leung, Hing Y./0000-0002-3933-3975; Sahadevan, Kanagasabai/0000-0002-3141-3276	Medical Research Council [G0100100] Funding Source: Medline; MRC [G0100100] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; DORKIN TJ, 2000, BJU INT, V86, P392; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gao AC, 2000, CLIN CANCER RES, V6, P493; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; KOSLOWSKI J, 1984, CANCER RES, V44, P3522; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Leung HY, 1996, ONCOGENE, V12, P1833; Lin W, 2005, GENESIS, V41, P110, DOI 10.1002/gene.20103; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 2001, CANCER RES, V61, P4229; Song ZG, 2000, CANCER RES, V60, P6730; Song ZG, 2002, CANCER RES, V62, P5096; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; YAN G, 1992, MOL CELL BIOL, V13, P4513; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200	31	42	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4122	4127		10.1038/sj.onc.1209428	http://dx.doi.org/10.1038/sj.onc.1209428			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474841				2022-12-25	WOS:000238802400013
J	Clamp, A; Blackhall, FH; Henrioud, A; Jayson, GC; Javaherian, K; Esko, J; Gallagher, JT; Merry, CLR				Clamp, Andrew; Blackhall, Fiona H.; Henrioud, Audrey; Jayson, Gordon C.; Javaherian, Kashi; Esko, Jeff; Gallagher, John T.; Merry, Catherine L. R.			The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ANGIOGENESIS INHIBITOR ENDOSTATIN; COLLAGEN-XVIII; GLYCOSAMINOGLYCAN BIOSYNTHESIS; NC1/ENDOSTATIN DOMAIN; N-SULFOTRANSFERASE; DERMATAN SULFATE; TUMOR-GROWTH; MUTANT; BINDING	Endostatin has attracted considerable attention because of its ability to inhibit angiogenesis. This property of monomeric endostatin contrasts with that of the trimeric endostatin moiety generated from the intact C-terminal domain of collagen XVIII that induces a promigratory phenotype in endothelial cells. This activity is inhibited by monomeric endostatin. In this study we demonstrate that the effect of oligomeric endostatin can also be inhibited by exogenous glycosaminoglycans in a size-dependent manner, with heparin oligosaccharides containing more than 20 monosaccharide residues having optimal inhibitory activity. Oligomeric endostatin was also found to induce morphological changes in Chinese hamster ovary cells, an epithelial cell line. This novel observation allowed the utilization of a panel of Chinese hamster ovary cell mutants with defined glycosaminoglycan biosynthetic defects. The action of oligomeric endostatin on these cells was shown to be dependent on cell surface glycosaminoglycans, principally heparan sulfate with Nand 6-O-sulfation of glucosamine residues rather than iduronate 2-O-sulfation being important for bioactivity. The responsiveness of a cell line (pgsE-606) with globally reduced heparan sulfate sulfation and shortened S domains, however, indicates that overall heparan sulfate domain patterning is the key determinant of the bioactivity of oligomeric endostatin. Purified heparin-monomeric endostatin constructs generated by zero-length cross-linking techniques were found to be unable to inhibit the action of oligomeric endostatin. This indicates a mechanism for the perturbation of oligomeric endostatin action by its monomeric counterpart via competition for glycosaminoglycan attachment sites at the cell surface.	Canc Res UK, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Cancer Research UK; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California San Diego	Merry, CLR (corresponding author), Canc Res UK, Dept Med Oncol, Manchester M20 4BX, Lancs, England.	cmerry@picr.man.ac.uk	Jayson, Gordon C/O-8224-2015; Blackhall, Fiona/N-2186-2015	Jayson, Gordon C/0000-0002-8515-8944; merry, catherine/0000-0002-3490-2809; Blackhall, Fiona/0000-0001-8716-3395	Medical Research Council [G0601746] Funding Source: Medline; MRC [G0601746] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Javaherian K, 2002, J BIOL CHEM, V277, P45211, DOI 10.1074/jbc.M206358200; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200; Wei G, 2000, J BIOL CHEM, V275, P27733; Wei G, 2004, J BIOL CHEM, V279, P5693, DOI 10.1074/jbc.M311621200; Wen W, 1999, CANCER RES, V59, P6052; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Wilson RF, 2003, ANTICANCER RES, V23, P1289; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14813	14822		10.1074/jbc.M512400200	http://dx.doi.org/10.1074/jbc.M512400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16481316	hybrid			2022-12-25	WOS:000237671300035
J	Suhasini, AN; Sirdeshmukh, R				Suhasini, AN; Sirdeshmukh, R			Transfer RNA cleavages by onconase reveal unusual cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-II TRIAL; CYTOTOXIC RIBONUCLEASES; SELECTIVE DEGRADATION; PROTEIN; RANPIRNASE; INHIBITION; ANGIOGENIN; RESIDUES	Onconase, a protein from amphibian eggs and a homologue of pancreatic ribonuclease (RNase) superfamily, is cytotoxic, exhibits antitumor and antiviral activity, and is in phase III clinical trials. It has been shown to predominantly target cellular tRNA on its entry into mammalian cells (Saxena, S. K., Sirdeshmukh, R., Ardelt, W., Mikulski, S. M., Shogen, K., and Youle, R. J. (2002) J. Biol. Chem. 277, 15142-15146). Cleavage site mapping using natural tRNA substrates, in vitro, revealed predominant cleavage sites at UG and GG residues. Cleavages at UG or the less intense cleavages at CG sites are consistent with the known base specificity of onconase. However, predominance of cleavages at selected G-G bonds is unusual for a homologue of pancreatic RNases. Interestingly, in at least three of the four tRNA substrates studied, the predominant cleavages mapped in the triplet UGG located in the context of the variable loop or the D-arm of the tRNA. The cleavage specificity of onconase observed by us thus indicates another special feature of this enzyme, which may be relevant to its cellular actions.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Sirdeshmukh, R (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	ravi@ccmb.res.in						Ardelt B, 2003, CELL CYCLE, V2, P22, DOI 10.4161/cc.2.1.232; ARDELT W, 1991, J BIOL CHEM, V266, P245; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DLLIAO Y, 2004, PROTEIN SCI, V13, P1802; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; Liao YD, 2003, NUCLEIC ACIDS RES, V31, P5247, DOI 10.1093/nar/gkg746; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; Ogawa T, 1999, SCIENCE, V283, P2097, DOI 10.1126/science.283.5410.2097; Olsnes S, 2001, TOXICON, V39, P1723, DOI 10.1016/S0041-0101(01)00158-1; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Rosenberg HF, 1999, IMMUNOL RES, V20, P261, DOI 10.1007/BF02790409; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; Sambrook J., MOL CLONING LAB MANU; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; Saxena SK, 2002, J BIOL CHEM, V277, P15142, DOI 10.1074/jbc.M108115200; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Vogelzang NJ, 2001, INVEST NEW DRUG, V19, P255, DOI 10.1023/A:1010633004157; Wool I.G., 1997, RIBONUCLEASES STRUCT, P131; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012	33	38	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12201	12209		10.1074/jbc.M504488200	http://dx.doi.org/10.1074/jbc.M504488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16497678	hybrid			2022-12-25	WOS:000237134700002
J	Chen, CL; Huang, SS; Huang, JS				Chen, CL; Huang, SS; Huang, JS			Cellular heparan sulfate negatively modulates transforming growth factor-beta(1) (TGF-beta(1)) responsiveness in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MOLECULAR-WEIGHT RECEPTOR; TGF-BETA; CARCINOMA-CELLS; GLYCOSAMINOGLYCAN CHAINS; ENDOTHELIAL-CELLS; BINDING-PROTEINS; V RECEPTOR; PROTEOGLYCAN; EXPRESSION	Cell-surface proteoglycans have been shown to modulate transforming growth factor ( TGF)-beta responsiveness in epithelial cells and other cell types. However, the proteoglycan ( heparan sulfate or chondroitin sulfate) involved in modulation of TGF-beta responsiveness and the mechanism by which it modulates TGF-beta responsiveness remain unknown. Here we demonstrate that TGF-beta(1) induces transcriptional activation of plasminogen activator inhibitor-1 ( PAI-1) and growth inhibition more potently in CHO cell mutants deficient in heparan sulfate ( CHO-677 cells) than in wild-type CHO-K1 cells. I-125-TGF-beta(1) affinity labeling analysis of cell-surface TGF-beta receptors reveals that CHO-K1 and CHO-677 cells exhibit low (<1) and high (>1) ratios of I-125-TGF-beta(1) binding to T beta R-II and T beta R-I, respectively. Receptor-bound I-125-TGF-beta(1) undergoes nystatin-inhibitable rapid degradation in CHO-K1 cells but not in CHO-677 cells. In Mv1Lu cells ( which, like CHO-K1 cells, exhibit nystatin-inhibitable rapid degradation of receptor-bound I-125-TGF-beta(1)), treatment with heparitinase or a heparan sulfate biosynthesis inhibitor results in a change from a low (< 1) to a high (>1) ratio of I-125-TGF-beta(1) binding to T beta R-II and T beta R-I and enhanced TGF-beta(1)-induced transcriptional activation of PAI-1. Sucrose density gradient analysis indicates that a significant fraction of T beta R-I and T beta R-II is localized in caveolae/lipid-raft fractions in CHO-K1 and Mv1Lu cells whereas the majority of the TGF-beta receptors are localized in non-lipid-raft fractions in CHO-677 cells. These results suggest that heparan sulfate negatively modulates TGF-beta 1 responsiveness by decreasing the ratio of TGF-beta 1 binding to T beta R-II and T beta R-I, facilitating caveolae/lipid-raft-mediated endocytosis and rapid degradation of TGF-beta 1, thus diminishing non-lipid-raft-mediated endocytosis and signaling of TGF-beta 1 in these epithelial cells.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu						Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Huang SS, 2004, FASEB J, V18, P1719, DOI 10.1096/fj.04-1872fje; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Keski-Oja J, 2004, TRENDS CELL BIOL, V14, P657, DOI 10.1016/j.tcb.2004.10.003; Kimura S, 1999, J BIOCHEM-TOKYO, V125, P406, DOI 10.1093/oxfordjournals.jbchem.a022301; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; Mitchell H, 2004, MOL BIOL CELL, V15, P4166, DOI 10.1091/mbc.E04-03-0245; Noble Nancy A., 1992, Progress in Growth Factor Research, V4, P369, DOI 10.1016/0955-2235(92)90017-C; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Riser BL, 1999, KIDNEY INT, V56, P428, DOI 10.1046/j.1523-1755.1999.00600.x; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1993, BIOCHIM BIOPHYS ACTA, V1155, P269, DOI 10.1016/0304-419X(93)90009-2; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Taipale J, 1996, J BIOL CHEM, V271, P4342; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; WEISSMANN G, 1967, J BIOL CHEM, V242, P616; Wells RG, 2004, FEBS LETT, V559, P107, DOI 10.1016/S0014-5793(04)00037-7; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Yokoyama H, 1996, DIABETIC MED, V13, P313, DOI 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.3.CO;2-Z	48	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11506	11514		10.1074/jbc.M512821200	http://dx.doi.org/10.1074/jbc.M512821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16492675	hybrid			2022-12-25	WOS:000236988100012
J	Dejima, K; Seko, A; Yamashita, K; Gengyo-Ando, K; Mitani, S; Izumikawa, T; Kitagawa, H; Sugahara, K; Mizuguchi, S; Nomura, K				Dejima, K; Seko, A; Yamashita, K; Gengyo-Ando, K; Mitani, S; Izumikawa, T; Kitagawa, H; Sugahara, K; Mizuguchi, S; Nomura, K			Essential roles of 3 '-phosphoadenosine 5 '-phoshosulfate synthase in embryonic and larval development of the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRACHYMORPHIC MICE; 5'-PHOSPHOSULFATE TRANSPORTER; GENETIC INTERFERENCE; PAPS SYNTHETASE; CELL-DIVISION; MAST-CELLS; SULFATE; EXPRESSION; RECEPTOR; EMBRYOGENESIS	Sulfation of biomolecules, which is widely observed from bacteria to humans, plays critical roles in many biological processes. All sulfation reactions in all organisms require activated sulfate, 3'-phosphoadenosine 5'-phosphosulfate ( PAPS), as a universal donor. In animals, PAPS is synthesized from ATP and inorganic sulfate by the bifunctional enzyme, PAPS synthase. In mammals, genetic defects in PAPS synthase 2, one of two PAPS synthase isozymes, cause dwarfism disorder, but little is known about the consequences of the complete loss of PAPS synthesis. To define the developmental role of sulfation, we cloned a Caenorhabditis elegans PAPS synthase-homologous gene, pps-1, and depleted expression of its product by isolating the deletion mutant and by RNA-mediated interference. PPS-1 protein exhibits specific activity to form PAPS in vitro, and disruption of the pps-1 gene by RNAi causes pleiotropic developmental defects in muscle patterning and epithelial cell shape changes with a decrease in glycosaminoglycan sulfation. Additionally, the pps-1 null mutant exhibits larval lethality. These data suggest that sulfation is essential for normal growth and integrity of epidermis in C. elegans. Furthermore, reporter analysis showed that pps-1 is expressed in the epidermis and several gland cells but not in neurons and muscles, indicating that PAPS in the neurons and muscles is provided by other cells.	Kyushu Univ 33, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; CREST, Kawaguchi, Saitama 3320012, Japan; Sasaki Inst, Dept Biochem, Tokyo 1010062, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tokyo Women's Medical University; Kobe Pharmaceutical University	Nomura, K (corresponding author), Kyushu Univ 33, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.	knomuscb@mbox.nc.kyushu-u.ac.jp	Gengyo-Ando, Keiko/AAC-4504-2019; Kitagawa, Hiroshi/AAJ-1344-2020; Gengyo-Ando, Keiko/B-2753-2012	Kitagawa, Hiroshi/0000-0002-9307-7079; 				Asahina M, 2000, GENES CELLS, V5, P711, DOI 10.1046/j.1365-2443.2000.00361.x; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Baugh LR, 2003, DEVELOPMENT, V130, P889, DOI 10.1242/dev.00302; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen Z, 2004, MOL CELL BIOL, V24, P7345, DOI 10.1128/MCB.24.17.7345-7358.2004; Costa M, 1997, DEV BIOL, V184, P373, DOI 10.1006/dbio.1997.8530; Edgar LG, 2001, DEV BIOL, V229, P71, DOI 10.1006/dbio.2000.9977; Entchev EV, 2005, SEMIN CELL DEV BIOL, V16, P175, DOI 10.1016/j.semcdb.2005.01.004; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Fuda H, 2002, BIOCHEM J, V365, P497, DOI 10.1042/BJ20020044; GELLER DH, 1987, J BIOL CHEM, V262, P7374; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Johnstone I.J., 1999, C ELEGANS PRACTICAL, P201; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Karabinos A, 2004, EUR J CELL BIOL, V83, P457, DOI 10.1078/0171-9335-00407; Kelly WG, 1997, GENETICS, V146, P227; Kim TH, 2005, FEBS LETT, V579, P53, DOI 10.1016/j.febslet.2004.11.044; Kinnunen T, 2005, P NATL ACAD SCI USA, V102, P1507, DOI 10.1073/pnas.0401591102; Kostrouchova M, 1998, DEVELOPMENT, V125, P1617; Kostrouchova M, 2001, P NATL ACAD SCI USA, V98, P7360, DOI 10.1073/pnas.131171898; Kuervers LM, 2003, MOL GENET GENOMICS, V270, P121, DOI 10.1007/s00438-003-0900-9; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; Lee JS, 2004, NAT REV GENET, V5, P923, DOI 10.1038/nrg1490; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; Mei D, 2004, EXP CELL RES, V301, P84, DOI 10.1016/j.yexcr.2004.08.017; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; ORKIN RW, 1977, J CELL BIOL, V73, P287, DOI 10.1083/jcb.73.2.287; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Rusiniak ME, 1996, MAMM GENOME, V7, P98, DOI 10.1007/s003359900027; SCHWARTZ NB, 1983, LIMB DEV REGENERATIO, P97; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Simske JS, 2001, BIOESSAYS, V23, P12, DOI 10.1002/1521-1878(200101)23:1&lt;12::AID-BIES1003&gt;3.0.CO;2-R; Starich TA, 2003, DEV BIOL, V256, P403, DOI 10.1016/S0012-1606(02)00116-1; Stiernagle T., 1999, C ELEGANS PRACTICAL, P51; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Van Auken K, 2000, P NATL ACAD SCI USA, V97, P4499, DOI 10.1073/pnas.97.9.4499; Venkatachalam KV, 2003, IUBMB LIFE, V55, P1, DOI 10.1080/1521654031000072148; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Xu ZH, 2000, BIOCHEM BIOPH RES CO, V268, P437, DOI 10.1006/bbrc.2000.2123; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	60	23	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11431	11440		10.1074/jbc.M601509200	http://dx.doi.org/10.1074/jbc.M601509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16497669	hybrid			2022-12-25	WOS:000236822200086
J	Koide, T; Nishikawa, Y; Asada, S; Yamazaki, CM; Takahara, Y; Homma, DL; Otaka, A; Ohtani, K; Wakamiya, N; Nagata, K; Kitagawa, K				Koide, T; Nishikawa, Y; Asada, S; Yamazaki, CM; Takahara, Y; Homma, DL; Otaka, A; Ohtani, K; Wakamiya, N; Nagata, K; Kitagawa, K			Specific recognition of the collagen triple helix by chaperone HSP47 II. The HSP47-binding structural motif in collagens and related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; BINDING-SPECIFICITY; PULMONARY-FIBROSIS; PEPTIDES; EXPRESSION; HEAT-SHOCK-PROTEIN-47; REQUIREMENTS; PROCOLLAGEN; STABILITY; COLLECTIN	The endoplasmic reticulum-resident chaperone heat-shock protein 47 (HSP47) plays an essential role in procollagen biosynthesis. The function of HSP47 relies on its specific interaction with correctly folded triple-helical regions comprised of Gly-Xaa-Yaa repeats, and Arg residues at Yaa positions have been shown to be important for this interaction. The amino acid at the Yaa position (Yaa(-3)) in the N-terminal-adjoining triplet containing the critical Arg ( defined as Arg(0)) was also suggested to be directly recognized by HSP47 (Koide, T., Asada, S., Takahara, Y., Nishikawa, Y., Nagata, K., and Kitagawa, K. ( 2006) J. Biol. Chem. 281, 3432 - 3438). Based on this finding, we examined the relationship between the structure of Yaa(-3) and HSP47 binding using synthetic collagenous peptides. The results obtained indicated that the structure of Yaa(-3) determined the binding affinity for HSP47. Maximal binding was observed when Yaa(-3) was Thr. Moreover, the required relative spatial arrangement of these key residues in the triple helix was analyzed by taking advantage of heterotrimeric collagen-model peptides, each of which contains one Thr(-3) and one Arg(0). The results revealed that HSP47 recognizes the Yaa(-3) and Arg(0) residues only when they are on the same peptide strand. Taken together, the data obtained led us to define the HSP47-binding structural epitope in the collagen triple helix and also define the HSP47-binding motif in the primary structure. A motif search against human protein database predicted candidate clients for this molecular chaperone. The search result indicated that not all collagen family proteins require the chaperoning by HSP47.	Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9568603, Japan; Univ Tokushima, Fac Engn, Tokushima 7708506, Japan; Univ Tokushima, Grad Sch Pharmaceut Sci, Tokushima 7708505, Japan; Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068397, Japan	Niigata University; Tokushima University; Tokushima University; Asahikawa Medical College; Kyoto University	Koide, T (corresponding author), Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9568603, Japan.	koi@niigata-pharm.ac.jp						BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Iwashita T, 2000, HUM PATHOL, V31, P1498, DOI 10.1053/hupa.2000.20378; Kakugawa T, 2004, EUR RESPIR J, V24, P57, DOI 10.1183/09031936.04.00120803; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2006, J BIOL CHEM, V281, P3432, DOI 10.1074/jbc.M509707200; Koide T, 2004, BIOORG MED CHEM LETT, V14, P125, DOI 10.1016/j.bmcl.2003.10.005; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Miyazaki M, 2003, CONTRIB NEPHROL, V139, P141; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Ottl J, 1999, J AM CHEM SOC, V121, P653, DOI 10.1021/ja983456d; PETRY F, 1991, J IMMUNOL, V147, P3988; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Razzaque MS, 2005, CONTRIB NEPHROL, V148, P57, DOI 10.1159/000086043; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tasab M, 2002, J BIOL CHEM, V277, P35007, DOI 10.1074/jbc.M202782200; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; Thomson CA, 2005, J MED CHEM, V48, P1680, DOI 10.1021/jm049148+; Thomson CA, 2003, PROTEIN SCI, V12, P1792, DOI 10.1110/ps.0236903; Yokota SI, 2003, BIOCHEM BIOPH RES CO, V303, P413, DOI 10.1016/S0006-291X(03)00352-8	33	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11177	11185		10.1074/jbc.M601369200	http://dx.doi.org/10.1074/jbc.M601369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484215	hybrid			2022-12-25	WOS:000236822200061
J	Shen, JQ; Vil, MD; Jimenez, X; Iacolina, M; Zhang, HF; Zhu, ZP				Shen, JQ; Vil, MD; Jimenez, X; Iacolina, M; Zhang, HF; Zhu, ZP			Single variable domain-IgG fusion - A novel recombinant approach to Fc domain-containing bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PHAGE DISPLAY LIBRARY; HIGH-AFFINITY BINDING; FULLY HUMAN; CRYSTAL-STRUCTURE; FACTOR RECEPTOR-2; EFFICIENT ROUTE; FRAGMENTS; CANCER; INHIBITION	Both laboratory and early clinical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially significant application in cancer therapy. The clinical development of BsAb as therapeutics has been hampered, however, by the difficulty in preparing the materials in sufficient quantity and quality by traditional methods. In recent years, a variety of recombinant methods has been developed for efficient production of BsAb, both as antibody fragments and as full-length IgG-like molecules. Here we describe a novel recombinant approach for the production of an Fc domain-containing, IgG-like tetravalent BsAb, with two antigen-binding sites to each of its target antigens, by genetically fusing a single variable domain antibody to the N terminus of the light chain of a functional IgG antibody of different specificity. A model BsAb was constructed using a single variable domain antibody to mouse platelet-derived growth factor receptor alpha and a conventional IgG antibody to mouse vascular endothelial growth factor receptor 2. The BsAb was expressed in mammalian cells and purified to homogeneity by one-step protein A affinity chromatography. Furthermore, the BsAb retains the antigen binding specificity and the receptor neutralizing activity of both of its parent antibodies. This design and expression of Fc domain-containing, IgG-like BsAb should be applicable to the construction of similar BsAb from antibodies recognizing any pair of antigens.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA	Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.	zhenping.zhu@imclone.com						Atwell S, 1997, J MOL BIOL, V270, P26, DOI 10.1006/jmbi.1997.1116; Baeuerle PA, 2003, CURR OPIN MOL THER, V5, P413; Binz HK, 2005, CURR OPIN BIOTECH, V16, P459, DOI 10.1016/j.copbio.2005.06.005; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; Cai XH, 1996, P NATL ACAD SCI USA, V93, P6280, DOI 10.1073/pnas.93.13.6280; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Chang CH, 2002, MOL CANCER THER, V1, P553; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; Corvalan J R, 1988, Int J Cancer Suppl, V2, P22; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Ferrini S, 2001, METH MOL B, V166, P177; Ford CHJ, 2001, INT J CANCER, V92, P851, DOI 10.1002/ijc.1262; Hoet RM, 2005, NAT BIOTECHNOL, V23, P344, DOI 10.1038/nbt1067; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007; Hu SZ, 1996, CANCER RES, V56, P3055; James ND, 2001, BRIT J CANCER, V85, P152, DOI 10.1054/bjoc.2001.1878; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Jespers L, 2004, J MOL BIOL, V337, P893, DOI 10.1016/j.jmb.2004.02.013; Jimenez X, 2005, MOL CANCER THER, V4, P427; Kabat EA, 1991, SEQUENCES PROTEINS I; Kipriyanov SM, 2004, CURR OPIN DRUG DISC, V7, P233; Kipriyanov SM, 2002, J IMMUNOL, V169, P137, DOI 10.4049/jimmunol.169.1.137; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Lu D, 2005, J BIOL CHEM, V280, P19665, DOI 10.1074/jbc.M500815200; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Lu D, 2002, J IMMUNOL METHODS, V267, P213, DOI 10.1016/S0022-1759(02)00148-5; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Lu D, 2001, CANCER RES, V61, P7002; Lum Lawrence G, 2005, Cancer Chemother Biol Response Modif, V22, P273; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Nuttall SD, 2004, PROTEINS, V55, P187, DOI 10.1002/prot.20005; Parker MH, 2005, PROTEIN ENG DES SEL, V18, P435, DOI 10.1093/protein/gzi050; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Ronnmark J, 2002, EUR J BIOCHEM, V269, P2647, DOI 10.1046/j.1432-1033.2002.02926.x; Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5; Stanfield RL, 2004, SCIENCE, V305, P1770, DOI 10.1126/science.1101148; Tanha J, 2001, J BIOL CHEM, V276, P24774, DOI 10.1074/jbc.M100770200; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Wu AM, 2000, Q J NUCL MED, V44, P268; Xiong DS, 2002, CANCER LETT, V177, P29, DOI 10.1016/S0304-3835(01)00758-3; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	51	43	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10706	10714		10.1074/jbc.M513415200	http://dx.doi.org/10.1074/jbc.M513415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481314	hybrid			2022-12-25	WOS:000236822200009
J	Dogra, C; Changotra, H; Mohan, S; Kumar, A				Dogra, C; Changotra, H; Mohan, S; Kumar, A			Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappa B and degradation of MyoD protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; CELL-CYCLE; MYOBLAST PROLIFERATION; SIGNALING PATHWAYS; MULTIPLE PATHWAYS; TNF SUPERFAMILY; KINASE-ACTIVITY; MESSENGER-RNA; TWEAK; DIFFERENTIATION	In this study we have investigated the effect and the mechanisms by which tumor necrosis factor-like weak inducer of apoptosis ( TWEAK) modulates myogenic differentiation. Treatment of C2C12 myoblasts with TWEAK inhibited their differentiation evident by a decrease in the expression of creatine kinase, myosin heavy chain-fast twitch, myogenin, and the formation of multinucleated myotubes. TWEAK also inhibited the differentiation of mouse primary myoblasts. Conversely, the proliferation of C2C12 myoblasts and the expression of a cell-cycle regulator cyclin D1 were increased in response to TWEAK treatment. Inhibition of cellular proliferation using hydroxyurea only partially reversed the inhibitory effect of TWEAK on myogenic differentiation. Treatment of C2C12 myoblasts with TWEAK resulted in the activation of nuclear factor-kappa B (NF-kappa B), the ( IkappaB) I kappa B kinase (IKK) complex, and the phosphorylation and degradation of I kappa B alpha protein. Inhibition of NF-kappa B activity by overexpression of a dominant negative mutant of I kappa B alpha (I kappa B alpha Delta N) significantly increased the myogenic differentiation in TWEAK-treated C2C12 cultures. Furthermore, overexpression of a dominant negative mutant of IKK beta (IKK beta K44A) but not IKK alpha (IKK alpha K44M) reversed the inhibitory effect of TWEAK onmyogenesis. TWEAK inhibited the expression of myogenic regulatory factors MyoD and myogenin and also induced the degradation of MyoD protein. Finally, inhibition of NF-kappa B activation through overexpression of IKK beta K44A prevented the degradation of MyoD protein. Overall, our data suggest that TWEAK inhibits myogenesis through the activation of NF-kappa B signaling pathway and degradation of MyoD protein.	Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Div Mol Genet, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Div Mol Genet, 11201 Benton St 151, Loma Linda, CA 92357 USA.	Ashok.Kumar2@med.va.gov	Changotra, Harish/H-2105-2011	Changotra, Harish/0000-0002-1465-5257; Kumar, Ashok/0000-0001-8571-2848				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CARUSO M, 1993, ONCOGENE, V8, P267; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Di Marco S, 2005, MOL CELL BIOL, V25, P6533, DOI 10.1128/MCB.25.15.6533-6545.2005; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI [10.1126/sci-ence.289.5488.2363, DOI 10.1126/SCI-ENCE.289.5488.2363, DOI 10.1126/science.289.5488.2363, DOI 10.1126/SCIENCE.289.5488.2363]; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kawakita T, 2005, INT J ONCOL, V26, P87; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kim SH, 2004, CIRC J, V68, P396, DOI 10.1253/circj.68.396; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2003, FASEB J, V17, P1800, DOI 10.1096/fj.02-1148com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Kumar A, 1998, J IMMUNOL, V161, P776; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Masinde Godfred L, 2002, Funct Integr Genomics, V2, P120, DOI 10.1007/s10142-002-0067-1; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Xu HR, 2004, BIOCHEM BIOPH RES CO, V318, P422, DOI 10.1016/j.bbrc.2004.04.036; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	74	128	131	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10327	10336		10.1074/jbc.M511131200	http://dx.doi.org/10.1074/jbc.M511131200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16461349	hybrid			2022-12-25	WOS:000236594300061
J	Kawano, M; Inoue, T; Tsukamoto, H; Takaya, T; Enomoto, T; Takahashi, R; Yokoyama, N; Yamamoto, N; Nakanishi, A; Imai, T; Wada, T; Kataoka, K; Handa, H				Kawano, M; Inoue, T; Tsukamoto, H; Takaya, T; Enomoto, T; Takahashi, R; Yokoyama, N; Yamamoto, N; Nakanishi, A; Imai, T; Wada, T; Kataoka, K; Handa, H			The VP2/VP3 minor capsid protein of simian virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; INSECT CELLS; POLYOMA-VIRUS; SIMIAN VIRUS-40; JC VIRUS; DNA; RESOLUTION; PURIFICATION; EXPRESSION; VIRIONS	The SV40 capsid is composed primarily of 72 pentamers of the VP1 major capsid protein. Although the capsid also contains the minor capsid protein VP2 and its amino-terminally truncated form VP3, their roles in capsid assembly remain unknown. An in vitro assembly system was used to investigate the role of VP2 in the assembly of recombinant VP1 pentamers. Under physiological salt and pH conditions, VP1 alone remained dissociated, and at pH 5.0, it assembled into tubular structures. A stoichiometric amount of VP2 allowed the assembly of VP1 pentamers into spherical particles in a pH range of 7.0 to 4.0. Electron microscopy observation, sucrose gradient sedimentation analysis, and antibody accessibility tests showed that VP2 is incorporated into VP1 particles. The functional domains of VP2 important for VP1 binding and for enhancing VP1 assembly were further explored with a series of VP2 deletion mutants. VP3 also enhanced VP1 assembly, and a region common to VP2 and VP3 (amino acids 119-272) was required to promote VP1 pentamer assembly. These results are relevant for controlling recombinant capsid formation in vitro, which is potentially useful for the in vitro development of SV40 virus vectors.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Natl Inst Longev Sci, Obu 4748522, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300192, Japan	Tokyo Institute of Technology; Nara Institute of Science & Technology	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268503, Japan.	hhanda@bio.titech.ac.jp		Imai, Takeshi/0000-0002-9503-7353; Kawano, Masaaki/0000-0001-8220-4717				ANDERER FA, 1967, VIROLOGY, V32, P511, DOI 10.1016/0042-6822(67)90302-9; BAROUCH DH, 1994, J VIROL, V68, P3982, DOI 10.1128/JVI.68.6.3982-3989.1994; BRADY JN, 1978, J VIROL, V27, P193, DOI 10.1128/JVI.27.1.193-204.1978; BRADY JN, 1977, J VIROL, V23, P717, DOI 10.1128/JVI.23.3.717-724.1977; BRADY JN, 1979, J VIROL, V32, P640, DOI 10.1128/JVI.32.2.640-647.1979; Chang DC, 1997, J GEN VIROL, V78, P1435, DOI 10.1099/0022-1317-78-6-1435; Chen XJS, 1998, EMBO J, V17, P3233, DOI 10.1093/emboj/17.12.3233; Chromy LR, 2003, P NATL ACAD SCI USA, V100, P10477, DOI 10.1073/pnas.1832245100; CLEVER J, 1993, J BIOL CHEM, V268, P20877; COLOMAR MC, 1993, J VIROL, V67, P2779, DOI 10.1128/JVI.67.5.2779-2786.1993; Finnen RL, 2003, J VIROL, V77, P4818, DOI 10.1128/JVI.77.8.4818-4826.2003; FORSTOVA J, 1993, J VIROL, V67, P1405; GARCEA RL, 1987, NATURE, V329, P86, DOI 10.1038/329086a0; Genevaux P, 2003, J VIROL, V77, P10706, DOI 10.1128/JVI.77.19.10706-10713.2003; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8; Gillock ET, 1997, J VIROL, V71, P2857, DOI 10.1128/JVI.71.4.2857-2865.1997; Goldmann C, 1999, J VIROL, V73, P4465, DOI 10.1128/JVI.73.5.4465-4469.1999; Ishizu KI, 2001, J VIROL, V75, P61, DOI 10.1128/JVI.75.1.61-72.2001; Kanesashi SN, 2003, J GEN VIROL, V84, P1899, DOI 10.1099/vir.0.19067-0; KAWANA KH, 1998, J VIROL, V67, P6929; Kimchi-Sarfaty C, 2003, HUM GENE THER, V14, P167, DOI 10.1089/104303403321070865; KOCH MA, 1967, VIROLOGY, V32, P503, DOI 10.1016/0042-6822(67)90302-9; Kosukegawa A, 1996, BBA-GEN SUBJECTS, V1290, P37; LI ML, 1995, P NATL ACAD SCI USA, V92, P5992, DOI 10.1073/pnas.92.13.5992; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Mannova P, 2002, J GEN VIROL, V83, P2309, DOI 10.1099/0022-1317-83-9-2309; Pawlita M, 1996, J VIROL, V70, P7517, DOI 10.1128/JVI.70.11.7517-7526.1996; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Sandalon Z, 1997, VIROLOGY, V237, P414, DOI 10.1006/viro.1997.8796; Stehle T, 1996, STRUCTURE, V4, P165, DOI 10.1016/S0969-2126(96)00020-2; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; WYCHOWSKI C, 1987, J VIROL, V61, P3862, DOI 10.1128/JVI.61.12.3862-3869.1987; Yan YW, 1996, STRUCTURE, V4, P157, DOI 10.1016/S0969-2126(96)00019-6	36	27	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10164	10173		10.1074/jbc.M511261200	http://dx.doi.org/10.1074/jbc.M511261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478732	hybrid			2022-12-25	WOS:000236594300042
J	Matsumi, R; Atomi, H; Imanaka, T				Matsumi, R; Atomi, H; Imanaka, T			Identification of the amino acid residues essential for proteolytic activity in an archaeal signal peptide peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEASE-IV; METHANOCOCCUS-VOLTAE; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; LON PROTEASE; SPPA GENE; SITE; TRANSLOCATION; MEMBRANE	Signal peptide peptidases (SPPs) are enzymes involved in the initial degradation of signal peptides after they are released from the precursor proteins by signal peptidases. In contrast to the eukaryotic enzymes that are aspartate peptidases, the catalytic mechanisms of prokaryotic SPPs had not been known. In this study on the SPP from the hyperthermophilic archaeon Thermococcus koda-karaensis (SppA(Tk)), we have identified amino acid residues that are essential for the peptidase activity of the enzyme. Delta N54SppA(Tk), a truncated protein without the N-terminal 54 residues and putative transmembrane domain, exhibits high peptidase activity, and was used as the wild-type protein. Sixteen residues, highly conserved among archaeal SPP homologue sequences, were selected and replaced by alanine residues. The mutations S162A and K214A were found to abolish peptidase activity of the protein, whereas all other mutant proteins displayed activity to various extents. The results indicated the function of Ser(162) as the nucleophilic serine and that of Lys(214) as the general base, comprising a Ser/Lys catalytic dyad in SppA(Tk). Kinetic analyses indicated that Ser(184), His(191), Lys(209), Asp(215), and Arg(221) supported peptidase activity. Intriguingly, a large number of mutations led to an increase in activity levels of the enzyme. In particular, mutations in Ser(128) and Tyr(165) not only increased activity levels but also broadened the substrate specificity of SppA(Tk), suggesting that these residues may be present to prevent the enzyme from cleaving unintended peptide/protein substrates in the cell. A detailed alignment of prokaryotic SPP sequences strongly suggested that the majority of archaeal enzymes, along with the bacterial enzyme from Bacillus subtilis, adopt the same catalytic mechanism for peptide hydrolysis.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp		Atomi, Haruyuki/0000-0001-9687-6426				Albers SV, 2003, J BACTERIOL, V185, P3918, DOI 10.1128/JB.185.13.3918-3925.2003; Atomi Haruyuki, 2004, Archaea, V1, P263, DOI 10.1155/2004/204953; Bardy SL, 2005, J BACTERIOL, V187, P1188, DOI 10.1128/JB.187.3.1188-1191.2005; Bardy SL, 2003, MOL MICROBIOL, V50, P1339, DOI 10.1046/j.1365-2958.2003.03758.x; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Casso DJ, 2005, GENETICS, V170, P139, DOI 10.1534/genetics.104.039933; Henke E, 2002, ANGEW CHEM INT EDIT, V41, P3211, DOI 10.1002/1521-3773(20020902)41:17<3211::AID-ANIE3211>3.0.CO;2-U; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; ICHIHARA S, 1984, J BIOL CHEM, V259, P9853; Im YJ, 2004, J BIOL CHEM, V279, P53451, DOI 10.1074/jbc.M410437200; Inagaki N, 2001, J BIOL CHEM, V276, P30099, DOI 10.1074/jbc.M102600200; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; Matsumi R, 2005, J BACTERIOL, V187, P7072, DOI 10.1128/JB.187.20.7072-7080.2005; Ng SYM, 2003, J BACTERIOL, V185, P5936, DOI 10.1128/JB.185.20.5936-5942.2003; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; PACAUD M, 1982, J BIOL CHEM, V257, P4333; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Pugsley AP, 2004, MOL MICROBIOL, V52, P3, DOI 10.1111/j.1365-2958.2003.03966.x; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; SUZUKI T, 1987, J BACTERIOL, V169, P2523, DOI 10.1128/jb.169.6.2523-2528.1987; Tanskul S, 2003, BIOCHEM BIOPH RES CO, V309, P547, DOI 10.1016/j.bbrc.2003.08.035; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Yokoyama H, 2005, J BIOL CHEM, V280, P6588, DOI 10.1074/jbc.M411748200	35	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10533	10539		10.1074/jbc.M513754200	http://dx.doi.org/10.1074/jbc.M513754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484219	hybrid			2022-12-25	WOS:000236594300083
J	Williams, MV; Lee, SH; Pollack, M; Blair, IA				Williams, MV; Lee, SH; Pollack, M; Blair, IA			Endogenous lipid hydroperoxide-mediated DNA-adduct formation in min mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; FAMILIAL ADENOMATOUS POLYPOSIS; LIQUID-CHROMATOGRAPHY; HUMAN URINE; MALONDIALDEHYDE-2'-DEOXYGUANOSINE ADDUCT; 1,N-2-ETHENO-2'-DEOXYGUANOSINE ADDUCTS; BIFUNCTIONAL ELECTROPHILES; CYCLOOXYGENASE-2 LEVELS; CIGARETTE-SMOKING; ARACHIDONIC-ACID	Despite intensive research over the last two decades, there are still no specific markers of endogenous lipid hydroperoxide-mediated DNA damage. We recently demonstrated that heptanoneetheno-2'-deoxyguanosine adducts are formed in the DNA of rat intestinal epithelial cells that stably express cyclooxygenase-2. Heptanone-etheno adducts can only arise from the reaction of lipid hydroperoxide-derived 4-oxo-2(E)-nonenal with DNA. This raised the possibility that similar adducts would be formed in vivo in settings where cyclooxygenase-2 expression is increased. Therefore, DNA-adduct formation was studied in C57BL/6JAPC(min) mice, a colorectal cancer mouse model in which cyclooxygenase-2 is up-regulated. 15(S)-Hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid is the major lipid hydroperoxide produced endogenously by cyclooxygenase-2. It undergoes homolytic decomposition to the DNA-reactive bifunctional electrophile4-oxo-2(E)-nonenal, which forms heptanone-etheno adducts with DNA. A quantitative comparison was made of the heptanone-etheno-DNA adducts present in C57BL/6J and C57BL/6JAPC(min) mice. Using highly specific and sensitive methodology based on stable isotope dilution liquid chromatography/tandem mass spectrometry, we have detected the endogenous formation of heptanone-etheno adducts in mammalian tissue DNA for the first time. In addition, we found that there were statistically significant increased levels of the heptanone-etheno-2'- deoxyguanosine and heptanone-etheno-2'-deoxycytidine adducts in the C57BL/6JAPC(min) mice when compared with the control C57BL/6J mice.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 854 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	ian@spirit.gcrc.upenn.edu	Blair, Ian A/B-3320-2010	Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [R01CA091016] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 91016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka S, 1999, CHEM RES TOXICOL, V12, P501, DOI 10.1021/tx980259j; BARBIN A, 1986, CHEM-BIOL INTERACT, V59, P43, DOI 10.1016/S0009-2797(86)80054-0; Barnes CJ, 1998, GASTROENTEROLOGY, V114, P873, DOI 10.1016/S0016-5085(98)70305-1; BOLT HM, 1988, CRIT REV TOXICOL, V18, P299, DOI 10.3109/10408448809037469; Carvalho VM, 2000, CHEM RES TOXICOL, V13, P397, DOI 10.1021/tx9901682; CHANDHARY AK, 1994, BIOL MASS SPECTROM, V23, P457, DOI 10.1002/bms.1200230802; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chen HJC, 2004, CHEM RES TOXICOL, V17, P963, DOI 10.1021/tx0341963; Chen HJC, 2004, CHEM RES TOXICOL, V17, P896, DOI 10.1021/tx0342013; Chen HJC, 2003, TOXICOL SCI, V76, P321, DOI 10.1093/toxsci/kfg219; Chen HJC, 1996, CHEM RES TOXICOL, V9, P306, DOI 10.1021/tx9501389; Chen HJC, 1998, CHEM RES TOXICOL, V11, P1474, DOI 10.1021/tx980107o; Chen HJC, 1999, CHEM RES TOXICOL, V12, P1119, DOI 10.1021/tx990074s; Chulada PC, 2000, CANCER RES, V60, P4705; Doerge DR, 2000, CHEM RES TOXICOL, V13, P1259, DOI 10.1021/tx0001575; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Egner PA, 2003, MUTAT RES-FUND MOL M, V523, P209, DOI 10.1016/S0027-5107(02)00337-8; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gonzalez-Reche LM, 2002, TOXICOL LETT, V134, P71, DOI 10.1016/S0378-4274(02)00165-0; Ham AJL, 2004, DNA REPAIR, V3, P257, DOI 10.1016/j.dnarep.2003.11.003; Ham AJL, 1999, CHEM RES TOXICOL, V12, P1240, DOI 10.1021/tx990150r; HECKER M, 1989, J BIOL CHEM, V264, P141; Hillestrom PR, 2004, FREE RADICAL BIO MED, V36, P1383, DOI 10.1016/j.freeradbiomed.2004.02.068; Hoberg AM, 2004, J MASS SPECTROM, V39, P38, DOI 10.1002/jms.547; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Jian WY, 2005, FREE RADICAL BIO MED, V39, P1162, DOI 10.1016/j.freeradbiomed.2005.06.008; Jian WY, 2005, CHEM RES TOXICOL, V18, P599, DOI 10.1021/tx049693d; Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P698, DOI 10.1016/j.freeradbiomed.2004.09.017; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2005, J BIOL CHEM, V280, P28337, DOI 10.1074/jbc.M504178200; Lee SH, 2005, CHEM RES TOXICOL, V18, P780, DOI 10.1021/tx0497088; Lee SH, 2002, CHEM RES TOXICOL, V15, P300, DOI 10.1021/tx010147j; Levine RL, 2000, CANCER RES, V60, P4098; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Loureiro APM, 2000, CHEM RES TOXICOL, V13, P601, DOI 10.1021/tx000004h; Loureiro APM, 2002, CHEM RES TOXICOL, V15, P1302, DOI 10.1021/tx025554p; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Otteneder M, 2003, ANAL BIOCHEM, V315, P147, DOI 10.1016/S0003-2697(02)00697-8; Petrik MBH, 2000, J NUTR, V130, P1153, DOI 10.1093/jn/130.5.1153; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; Roberts DW, 2001, ANAL CHEM, V73, P303, DOI 10.1021/ac000866n; Rouzer CA, 1997, CHEM RES TOXICOL, V10, P181, DOI 10.1021/tx9601216; Sansom OJ, 2001, CANCER RES, V61, P7060; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Swenberg JA, 1999, IARC SCI PUBL, P29; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams MV, 2005, RAPID COMMUN MASS SP, V19, P849, DOI 10.1002/rcm.1854; Yen TY, 1998, CHEM RES TOXICOL, V11, P810, DOI 10.1021/tx9800194; Zhou XF, 2005, J BIOL CHEM, V280, P25377, DOI 10.1074/jbc.M503079200	65	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10127	10133		10.1074/jbc.M600178200	http://dx.doi.org/10.1074/jbc.M600178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16449227	hybrid			2022-12-25	WOS:000236594300038
J	Atoda, H; Yokota, E; Morita, T				Atoda, H; Yokota, E; Morita, T			Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; CLOTTING FACTOR-IX; BINDING-PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; TRIMERESURUS-FLAVOVIRIDIS; GLA DOMAIN; SITE	Blood coagulation factor IX (FIX) undergoes various post-translational modifications such as gamma-carboxylation and glycosylation. Non-phosphorylated recombinant FIX has been reported to rapidly disappear from plasma, indicating that phosphorylation of FIX plays an important role in the physiological activity of this coagulation factor. In this study, we characterized the human FIX activation peptide (AP) using a monoclonal antibody that recognizes phosphorylated Ser-158 in the AP region. Murine monoclonal antibody B1 against human FIX recognized FIX with an apparent K-d value of 5 nM in the presence of Ca2+ (EC50 = 0.58 mM). B1 bound to the isolated AP of FIX and retained the Ca2+ dependence of binding to the isolated AP. The deglycosylation of AP did not affect the binding of B1 to AP, while B1 failed to bind to recombinant AP expressed in Escherichia coli. MALDI-TOF mass spectrometry showed that the m/z of plasma-derived deglycosylated AP is 82.54 Da greater than that of recombinant AP. The binding ability of B1 to AP was lost by the dephosphorylation of plasma-derived AP. B1 bound to synthetic peptide AP-(5-19), including phosphoserine-13, but not to the non-phosphorylated AP-(5-19) in the presence of Ca2+. These data provide direct evidence that Ser-13 of the plasma-derived FIX AP region (Ser-158 of FIX) is phosphorylated and that B1 recognizes the epitope, which includes Ca2+-bound phosphoserine-158. B1 should be useful in the quality control of biologically active recombinant FIX containing phosphoserine-158.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.	tmorita@my-pharm.ac.jp						AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; Arruda VR, 2001, BLOOD, V97, P130, DOI 10.1182/blood.V97.1.130; ATODA H, 1995, J BIOCHEM-TOKYO, V118, P965, DOI 10.1093/jb/118.5.965; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; Cheung WF, 1996, THROMB RES, V81, P65, DOI 10.1016/0049-3848(95)00214-6; HAMAGUCHI N, 1991, J BIOL CHEM, V266, P15213; Kaufman RJ, 1998, THROMB HAEMOSTASIS, V79, P1068; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; Kurachi S, 1999, SCIENCE, V285, P739, DOI 10.1126/science.285.5428.739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Makino Y, 2000, J BIOCHEM-TOKYO, V128, P175, DOI 10.1093/oxfordjournals.jbchem.a022738; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUEHIRO K, 1989, J BIOL CHEM, V264, P21257; White GC, 1997, THROMB HAEMOSTASIS, V78, P261; Yang LK, 2004, J BIOL CHEM, V279, P38519, DOI 10.1074/jbc.M407304200; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	21	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9314	9320		10.1074/jbc.M512940200	http://dx.doi.org/10.1074/jbc.M512940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467297	hybrid			2022-12-25	WOS:000236404700039
J	Lack, G; Homberger-Zizzari, E; Folkers, G; Scapozza, L; Perozzo, R				Lack, G; Homberger-Zizzari, E; Folkers, G; Scapozza, L; Perozzo, R			Recombinant expression and biochemical characterization of the unique elongating beta-ketoacyl-acyl carrier protein synthase involved in fatty acid biosynthesis of Plasmodium falciparum using natural and artificial substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; GLOBAL DISTRIBUTION; CONDENSING ENZYMES; THIOLACTOMYCIN; MALARIA; SYNTHETASE; CERULENIN; TARGETS; APICOMPLEXAN	The human malaria parasite Plasmodium falciparum synthesizes fatty acids by using a type II synthase that is structurally different from the type I system found in eukaryotes. Because of this difference and the vital role of fatty acids, the enzymes involved in fatty acid biosynthesis of P. falciparum represent interesting targets for the development of new antimalarial drugs. beta-Ketoacyl-acyl carrier protein (ACP) synthase (PfFabBF), being the only elongating beta-ketoacyl-ACP synthase in P. falciparum, is a potential candidate for inhibition. In this study we present the cloning, expression, purification, and characterization of PfFabBF. Soluble protein was obtained when PfFabBF was expressed as a NusA fusion protein in Escherichia coli BL21(DE3)-CodonPlus-RIL cells under conditions of osmotic stress. The fusion protein was purified by affinity and ion exchange chromatography. Various acyl-P. falciparum acyl carrier protein (PfACP) substrates were tested for their specific activities, and their kinetic parameters were determined. Activity of PfFabBF was highest with C-4:0- to C-10:0- acyl-PfACPs and decreased with use of longer chain acyl-PfACPs. Consistent with the fatty acid synthesis profile found in the parasite cell, no activity could be detected with C-16:0- PfACP, indicating that the enzyme is lacking the capability of elongating acyl chains that are longer than 14 carbon atoms. PfFabBF was found to be specific for acyl-PfACPs, and it displayed much lower activities with the corresponding acyl-CoAs. Furthermore, PfFabBF was shown to be sensitive to cerulenin and thiolactomycin, known inhibitors of beta-ketoacyl-ACP synthases. These results represent an important step toward the evaluation of P. falciparum beta-ketoacyl-ACP synthase as a novel antimalaria target.	Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci,Pharmaceut Biochem Grp, Lab Chim Therapeut,Sect Sci Pharmaceut, CH-1211 Geneva 4, Switzerland; Swiss Fed Inst Technol, Dept Chem & Appl BioSci, CH-8057 Zurich, Switzerland; Univ Zurich, Coll Helveticum, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	University of Geneva; University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Perozzo, R (corresponding author), Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci,Pharmaceut Biochem Grp, Lab Chim Therapeut,Sect Sci Pharmaceut, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	remo.perozzo@pharm.unige.ch		Folkers, Gerd/0000-0002-3620-705X; Scapozza, Leonardo/0000-0003-1079-648X				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chopra S, 2002, ACTA CRYSTALLOGR D, V58, P179, DOI 10.1107/S0907444901019874; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; Domergue F, 2000, BIOCHEM SOC T, V28, P610, DOI 10.1042/BST0280610; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; Gornicki P, 2003, INT J PARASITOL, V33, P885, DOI 10.1016/S0020-7519(03)00133-4; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jones AL, 2000, BIOCHEM J, V347, P205, DOI 10.1042/0264-6021:3470205; Jones SM, 2004, BIOORGAN MED CHEM, V12, P683, DOI 10.1016/j.bmc.2003.11.023; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; McGuire KA, 2001, BIOCHEMISTRY-US, V40, P9836, DOI 10.1021/bi0105577; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 2003, ANTIMICROB AGENTS CH, V47, P297, DOI 10.1128/AAC.47.1.297-301.2003; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Waters NC, 2002, MOL BIOCHEM PARASIT, V123, P85, DOI 10.1016/S0166-6851(02)00140-8	43	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9538	9546		10.1074/jbc.M509119200	http://dx.doi.org/10.1074/jbc.M509119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467310	hybrid			2022-12-25	WOS:000236404700064
J	Jones, EM; Surewicz, K; Surewicz, WK				Jones, EM; Surewicz, K; Surewicz, WK			Role of N-terminal familial mutations in prion protein fibrillization and prion amyloid propagation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; VARIANT CJD; CONFORMATIONAL CONVERSION; THERMODYNAMIC STABILITY; POLYMORPHISM; TRANSMISSION; GENERATION; EXPRESSION; MECHANISM; INSERTION	A self-perpetuating conformational conversion of the prion protein (PrP) is believed to underlie pathology and transmission of prion diseases. Here we explore the effects of N-terminal pathogenic mutations (P102L, P105L, A117V) and the residue 129 polymorphism on amyloid fibril formation by the human PrP fragment 23 - 144, an in vitro conversion model that can reproduce certain characteristics of prion replication such as strains and species barriers. We find that these amino acid substitutions neither affect PrP23 - 144 amyloidogenicity nor introduce barriers to cross-seeding of soluble protein. However, the polymorphism strongly influences the conformation of the amyloid fibrils, as determined by infrared spectroscopy. Intriguingly, unlike conformational features governed by the critical amyloidogenic region of PrP23 - 144 ( residues 138 - 139), the structural features distinguishing Met-129 and Val-129 PrP23 - 144 amyloid fibrils are not transmissible by cross-seeding. While based only on in vitro data, these findings provide fundamental insight into the mechanism of prion-based conformational transmission, indicating that only conformational features controlling seeding specificity ( e. g. those in critical intermolecular contact sites of amyloid fibrils) are necessarily transmissible by cross-seeding; conformational traits in other parts of the PrP molecule may not be "heritable" from the amyloid template.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	witold.surewicz@case.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044158] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 44158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Apetri AC, 2005, BIOCHEMISTRY-US, V44, P15880, DOI 10.1021/bi051455+; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Dzwolak W, 2004, PROTEIN SCI, V13, P1927, DOI 10.1110/ps.03607204; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; KAZMIRSKI SL, 1995, CHEM BIOL, V2, P305, DOI 10.1016/1074-5521(95)90049-7; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KITAMOTO T, 1994, PHILOS T R SOC B, V343, P391, DOI 10.1098/rstb.1994.0034; Kong Qingzhong, 2004, VVolume 41, P673; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Mishra RS, 2002, J BIOL CHEM, V277, P24554, DOI 10.1074/jbc.M200213200; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Okimoto N, 2002, BIOPHYS J, V82, P2746, DOI 10.1016/S0006-3495(02)75615-4; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; Priola SA, 2001, ADV PROTEIN CHEM, V57, P1; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Puoti G, 2000, ANN NEUROL, V48, P269, DOI 10.1002/1531-8249(200008)48:2<269::AID-ANA24>3.3.CO;2-M; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Uelhoff A, 2005, J BIOL CHEM, V280, P5137, DOI 10.1074/jbc.C400560200; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Weissmann C, 2005, CELL, V122, P165, DOI 10.1016/j.cell.2005.07.001; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	55	32	32	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8190	8196		10.1074/jbc.M513417200	http://dx.doi.org/10.1074/jbc.M513417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16443601	hybrid			2022-12-25	WOS:000236031000058
J	Shimizu, T; Sekine, H; Yang, J; Isoi, Y; Yamato, M; Kikuchi, A; Kobayashi, E; Okano, T				Shimizu, T; Sekine, H; Yang, J; Isoi, Y; Yamato, M; Kikuchi, A; Kobayashi, E; Okano, T			Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues	FASEB JOURNAL			English	Article						poly(N-isopropylacrylamide); electrophysiology; microsurgery	RESPONSIVE CULTURE DISHES; STEM-CELLS; TRANSPLANTATION; CARTILAGE; SURFACES; HARVEST; SHAPE	Recently, the field of tissue engineering has progressed rapidly, but poor vascularization remains a major obstacle in bioengineering cell-dense tissues, limiting the viable size of constructs due to hypoxia, nutrient insufficiency, and waste accumulation. Therefore, new technologies for fabricating functional tissues with a well-organized vasculature are required. In the present study, neonatal rat cardiomyocytes were harvested as intact sheets from temperature-responsive culture dishes and stacked into cell-dense myocardial tissues. However, the thickness limit for layered cell sheets in subcutaneous tissue was similar to 80 mu m (3 layers). To overcome this limitation, repeated transplantation of triple-layer grafts was performed at 1, 2, or 3 day intervals. The two overlaid grafts completely synchronized and the whole tissues survived without necrosis in the 1 or 2 day interval cases. Multistep transplantation also created similar to 1 mm thick myocardium with a well-organized microvascular network. Furthermore, functional multilayer grafts fabricated over a surgically connectable artery and vein revealed complete graft perfusion via the vessels and ectopic transplantation of the grafts was successfully performed using direct vessel anastomoses. These cultured cell sheet integration methods overcome long-standing barriers to producing thick, vascularized tissues, revealing a possible solution for the clinical repair of various damaged organs, including the impaired myocardium.	Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, Tokyo 1628666, Japan; Jichi Univ, Sch Med, Ctr Mol Med, Div Organ Replacement Res, Kawachi, Tochigi 3290498, Japan	Tokyo Women's Medical University; Jichi Medical University	Okano, T (corresponding author), Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	tokano@abmes.twmu.ac.jp	Tatsuya, Shimizu/AAN-5675-2021; Okano, Teruo/J-4028-2012					BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Harimoto M, 2002, J BIOMED MATER RES, V62, P464, DOI 10.1002/jbm.10228; Hirose M, 2000, BIOMACROMOLECULES, V1, P377, DOI 10.1021/bm0002961; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kirsner RS, 1998, TRENDS BIOTECHNOL, V16, P246, DOI 10.1016/S0167-7799(98)01196-2; Koh CJ, 2004, J AM SOC NEPHROL, V15, P1113, DOI 10.1097/01.ASN.0000119683.59068.F0; Kulig KM, 2004, TRANSPL IMMUNOL, V12, P303, DOI 10.1016/j.trim.2003.12.005; Kushida A, 2000, J BIOMED MATER RES, V51, P216, DOI 10.1002/(SICI)1097-4636(200008)51:2<216::AID-JBM10>3.0.CO;2-K; Kushida A, 1999, J BIOMED MATER RES, V45, P355, DOI 10.1002/(SICI)1097-4636(19990615)45:4<355::AID-JBM10>3.0.CO;2-7; Kushida A, 2001, J BIOMED MATER RES, V54, P37, DOI 10.1002/1097-4636(200101)54:1<37::AID-JBM5>3.0.CO;2-7; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Leor J, 2000, CIRCULATION, V102, P56; Neumann T, 2003, MICROVASC RES, V66, P59, DOI 10.1016/S0026-2862(03)00040-2; Nishida K, 2004, TRANSPLANTATION, V77, P379, DOI 10.1097/01.TP.0000110320.45678.30; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Nugent HM, 2003, CIRC RES, V92, P1068, DOI 10.1161/01.RES.0000073844.41372.38; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Papadaki M, 2001, AM J PHYSIOL-HEART C, V280, pH168, DOI 10.1152/ajpheart.2001.280.1.H168; Sakai T, 2001, J THORAC CARDIOV SUR, V121, P932, DOI 10.1067/mtc.2001.113600; Shimizu T, 2002, CIRC RES, V90, pE40, DOI 10.1161/hh0302.105722; Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; Shimizu T, 2002, J BIOMED MATER RES, V60, P110, DOI 10.1002/jbm.1284; Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142-9612(03)00339-9; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Shiroyanagi Y, 2004, BJU INT, V93, P1069, DOI 10.1111/j.1464-410X.2004.04783.x; Xiu DR, 2001, MICROSURG, V21, P16, DOI 10.1002/1098-2752(2001)21:1<16::AID-MICR1003>3.0.CO;2-B; YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571; Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142-9612(01)00138-7; Zandonella C, 2003, NATURE, V421, P884, DOI 10.1038/421884a; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zimmermann WH, 2002, CIRCULATION, V106, pI151, DOI 10.1161/01.cir.0000032876.55215.10	32	347	366	9	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					708	+		10.1096/fj.05-4715fje	http://dx.doi.org/10.1096/fj.05-4715fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16439619				2022-12-25	WOS:000235996000003
J	Hayashi, T; Kobayashi, Y; Kohsaka, S; Sano, K				Hayashi, T.; Kobayashi, Y.; Kohsaka, S.; Sano, K.			The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2	ONCOGENE			English	Article						LMP2; JAK1; IFN-gamma; uterus; leiomyosarcoma	MHC CLASS-I; NF-KAPPA-B; IFN-GAMMA; EXPRESSION; GENES; COMPLEX; IMMUNOSURVEILLANCE; PATHWAYS; SUBUNITS; TUMORS	The presentation of human leukocyte antigens (HLA) class I requires the coordinated expression of numerous components involved in antigen presentation. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing ( TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2. The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter containing an interferon (IFN)-gamma-response factor element; thus, the IFN-gamma-signal strongly induces both TAP1 and LMP2 expression. Low molecular weight proteins2-deficient mice exhibited the development of uterine leiomyosarcomas. Here, the differential responsiveness to IFN-gamma of the SKN human uterine leiomyosarcomas cell line was investigated. We now identify the G871E mutation in the ATP-binding region of Janus kinases 1, suggesting that the loss of TAP1 and LMP2 induction is a defect in the earliest steps of the IFN-gamma-signal pathway, resulting in the inability of SKN cells to upregulate the antigen-processing pathway. Understanding the mechanisms by which these tumors circumvent cytokine signalling, thereby evading antitumor-specific immunity, would greatly aid the efficacy of immunotherapy for treating uterine leiomyosarcomas.	Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, Nagano 3908621, Japan; Shinshu Univ Hosp, Dept Lab Med, Nagano, Japan	Shinshu University; Shinshu University	Hayashi, T (corresponding author), Shinshu Univ, Sch Med, Dept Immunol & Infect Dis, 3-1-1 Asahi, Nagano 3908621, Japan.	takuma-h@sch.md.shinshu-u.ac.jp						Atkins D, 2004, INT J CANCER, V109, P265, DOI 10.1002/ijc.11681; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; Brucet M, 2004, GENES IMMUN, V5, P26, DOI 10.1038/sj.gene.6364035; Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Dovhey SE, 2000, CANCER RES, V60, P5789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hayashi T, 2002, CANCER RES, V62, P24; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LEISER AL, 2005, GYNECOL ONCOL; Leitao MM, 2004, CANCER-AM CANCER SOC, V101, P1455, DOI 10.1002/cncr.20521; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Miyagi T, 2003, J GASTROEN HEPATOL, V18, P32, DOI 10.1046/j.1440-1746.2003.02921.x; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Raspollini MR, 2005, GYNECOL ONCOL, V98, P334, DOI 10.1016/j.ygyno.2004.09.035; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Sexl V, 2003, BLOOD, V101, P4937, DOI 10.1182/blood-2001-11-0142; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Singal DP, 1996, IMMUNOL LETT, V50, P149, DOI 10.1016/0165-2478(96)02531-X; VAN KL, 1994, IMMUNITY, V1, P533; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459	34	31	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4016	4026		10.1038/sj.onc.1209434	http://dx.doi.org/10.1038/sj.onc.1209434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16474838				2022-12-25	WOS:000238802400002
J	Vogt, M; Butz, K; Dymalla, S; Semzow, J; Hoppe-Seyler, F				Vogt, M.; Butz, K.; Dymalla, S.; Semzow, J.; Hoppe-Seyler, F.			Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein	ONCOGENE			English	Article						cervical cancer; human papillomavirus; apoptosis	P53-INDEPENDENT APOPTOSIS; HUMAN KERATINOCYTES; DOWN-REGULATION; CANCER-CELLS; E7 PROTEIN; TYPE-18 E6; SENESCENCE; EXPRESSION; GENE; P53	Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer in humans. The antiapoptotic viral E6 gene has been identified as a key factor for maintaining the viability of HPV-positive cancer cells. Although E6 has the potential to modulate many apoptosis regulators, the crucial apoptotic pathway blocked by endogenous E6 in cervical cancer cells remained unknown. Using RNA interference (RNAi), here, we show that targeted inhibition of E6 expression in cervical cancer cells leads to the transcriptional stimulation of the PUMA promoter, in a p53-dependent manner. This is linked to the activation and translocation of Bax to the mitochondrial membrane, cytochrome c release into the cytosol, and activation of caspase-3, in a PUMA-dependent manner. Moreover, inhibition of Bax expression by RNAi efficiently reverts the apoptotic phenotype, which results from inhibition of E6 expression. Thus, interference with the p53/PUMA/Bax cascade is crucial for the antiapoptotic function of the viral E6 oncogene in HPV-positive cancer cells.	Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Arbeitsgrp Mol Therapie Virus Assoz Tumore, F065,Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de		Hoppe-Seyler, Felix/0000-0002-1864-300X				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Baldus SE, 2005, ONCOGENE, V24, P810, DOI 10.1038/sj.onc.1208235; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Filippova M, 2004, J BIOL CHEM, V279, P25729, DOI 10.1074/jbc.M401172200; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu J, 2004, ONCOGENE, V23, P1300, DOI 10.1038/sj.onc.1207239; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kong XT, 2001, J BIOL CHEM, V276, P32990, DOI 10.1074/jbc.M103681200; Liu J, 2004, VIROLOGY, V318, P169, DOI 10.1016/j.virol.2003.09.012; Magal SS, 2005, J GEN VIROL, V86, P611, DOI 10.1099/vir.0.80453-0; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan HD, 2005, ONCOGENE, V24, P5069, DOI 10.1038/sj.onc.1208691; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	36	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4009	4015		10.1038/sj.onc.1209429	http://dx.doi.org/10.1038/sj.onc.1209429			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462759				2022-12-25	WOS:000238802400001
J	Suzuki, A; Ogura, T; Esumi, H				Suzuki, Atsushi; Ogura, Tsutomu; Esumi, Hiroyasu			NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; GLUCOSE STARVATION; TUMOR-SUPPRESSOR; DOCKING SITE; PHOSPHORYLATION; TOLERANCE; FAMILY; LKB1; REQUIREMENT	ARK5 is a tumor progression-associated factor that is directly phosphorylated by AKT at serine 600 in the regulatory domain, but phosphorylation at the conserved threonine residue on the active T loop has been found to be required for its full activation. In this study, we identified serine/threonine protein kinase NDR2 as a protein kinase that phosphorylates and activates ARK5 during insulin-like growth factor (IGF)-1 signaling. Upon stimulation with IGF-1, NDR2 was found to directly phosphorylate the conserved threonine 211 on the active T loop of ARK5 and to promote cell survival and invasion of colorectal cancer cell lines through ARK5. During IGF-1 signaling, phosphorylation at three residues (threonine 75, serine 282, and threonine 442) was also found to be required for NDR2 activation. Among these three residues, phosphorylation of serine 282 seemed to be the most important for NDR2 activation (the same as for the mouse homologue) because its aspartic acid-converted mutant (NDR2/S282D) induced ARK5-mediated cell survival and invasion activities even in the absence of IGF-1. As in the mouse homologue, threonine 75 in NDR2 was required for interaction with S100B, and binding was in a calcium ion- and phospholipase C-gamma-dependent manner. We also found that PDK-1 plays an important role in NDR2 activation especially in the phosphorylation of threonine 442. Based on the results of this study, we report here that NDR2 is an upstream kinase of ARK5 that plays an essential role in tumor progression through ARK5.	Natl Canc Ctr, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan; Natl Inst Physiol Sci, Dept Dev Physiol, Div Endocrinol & Metab, Okazaki, Aichi 4448585, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Bioinformat Sci, Kanazawa, Ishikawa 9201181, Japan	National Cancer Center - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Hokuriku University	Esumi, H (corresponding author), Natl Canc Ctr, Res Ctr Innovat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Chattopadhyay A, 2002, J CELL SCI, V115, P2233; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; Fisher JS, 2005, AM J PHYSIOL-ENDOC M, V289, pE986, DOI 10.1152/ajpendo.00335.2004; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Stork O, 2004, J BIOL CHEM, V279, P45773, DOI 10.1074/jbc.M403552200; Suzuki A, 2005, ONCOGENE, V24, P6936, DOI 10.1038/sj.onc.1208844; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, BIOCHEM BIOPH RES CO, V311, P156, DOI 10.1016/j.bbrc.2003.09.184; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	40	24	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13915	13921		10.1074/jbc.M511354200	http://dx.doi.org/10.1074/jbc.M511354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16488889	hybrid			2022-12-25	WOS:000237512300012
J	Quimby, BB; Yong-Gonzalez, V; Anan, T; Strunnikov, AV; Dasso, M				Quimby, B. B.; Yong-Gonzalez, V.; Anan, T.; Strunnikov, A. V.; Dasso, M.			The promyelocytic leukemia protein stimulates SUMO conjugation in yeast	ONCOGENE			English	Article						promyelocytic leukemia protein (PML); SUMO-1; budding yeast; SUMO ligase; PML : RAR alpha	NUCLEAR-BODY; RAR-ALPHA; PML; ENZYME; PATHOGENESIS; HOMOLOG; LIGASE; GENE; RING	The promyelocytic leukemia gene was first identified through its fusion to the gene encoding the retinoic acid receptor alpha (RAR alpha) in acute promyelocytic leukemia (APL) patients. The promyelocytic leukemia gene product (PML) becomes conjugated in vivo to the small ubiquitin-like protein SUMO-1, altering its behavior and capacity to recruit other proteins to PML nuclear bodies (PML-NBs). In the NB4 cell line, which was derived from an APL patient and expresses PML: RARa, we observed a retinoic acid-dependent change in the modi. cation of specific proteins by SUMO-1. To dissect the interaction of PML with the SUMO-1 modi. cation pathway, we used the budding yeast Saccharomyces cerevisiae as a model system through expression of PML and human SUMO-1 (hSUMO-1). We found that PML stimulated hSUMO-1 modi. cation in yeast, in a manner that was dependent upon PML's RING-finger domain. PML: RARa also stimulated hSUMO-1 conjugation in yeast. Interestingly, however, PML and PML: RARa differentially complemented yeast Smt3p conjugation pathway mutants. These findings point toward a potential function of PML and PML: RARa as SUMO E3 enzymes or E3 regulators, and suggest that fusion of RARa to PML may affect this activity.	NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bethesda, MD 20892 USA; NICHD, Unit Chromosome Struct & Funct, Lab Gene Regulat & Dev, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bldg 18T,Room 106,18 Lib Dr, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov		Strunnikov, Alexander/0000-0002-9058-2256; Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902, Z01HD001903] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HD001902-13] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Chen XL, 2005, MOL CELL BIOL, V25, P4311, DOI 10.1128/MCB.25.10.4311-4320.2005; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Duprez E, 1999, J CELL SCI, V112, P381; GODDARD AD, 1992, LEUKEMIA, V6, pS117; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	31	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2999	3005		10.1038/sj.onc.1209335	http://dx.doi.org/10.1038/sj.onc.1209335			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501610				2022-12-25	WOS:000237950800004
J	Bakhrat, A; Baranes, K; Krichevsky, O; Rom, I; Schlenstedt, G; Pietrokovski, S; Raveh, D				Bakhrat, A; Baranes, K; Krichevsky, O; Rom, I; Schlenstedt, G; Pietrokovski, S; Raveh, D			Nuclear import of Ho endonuclease utilizes two nuclear localization signals and four importins of the ribosomal import system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; UBA PROTEIN DDI1; HOMING ENDONUCLEASE; CRYSTAL-STRUCTURE; EVOLUTION; SEQUENCE; INTEIN; GENE; EXPORT; DEGRADATION	Activity of Ho, the yeast mating switch endonuclease, is restricted to a narrow time window of the cell cycle. Ho is unstable and despite being a nuclear protein is exported to the cytoplasm for proteasomal degradation. We report here the molecular basis for the highly efficient nuclear import of Ho and the relation between its short half-life and passage through the nucleus. The Ho nuclear import machinery is functionally redundant, being based on two bipartite nuclear localization signals, recognized by four importins of the ribosomal import system. Ho degradation is regulated by the DNA damage response and Ho retained in the cytoplasm is stabilized, implying that Ho acquires its crucial degradation signals in the nucleus. Ho arose by domestication of a fungal VMA1 intein. A comparison of the primary sequences of Ho and fungal VMA1 inteins shows that the Ho nuclear localization signals are highly conserved in all Ho proteins, but are absent from VMA1 inteins. Thus adoption of a highly efficient import strategy occurred very early in the evolution of Ho. This may have been a crucial factor in establishment of homothallism in yeast, and a key event in the rise of the Saccharomyces sensu stricto.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Phys, IL-84105 Beer Sheva, Israel; Univ Saarland, Dept Med Biochem & Mol Biol, D-66421 Homburg, Germany; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Ben Gurion University; Ben Gurion University; Saarland University; Weizmann Institute of Science	Raveh, D (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	raveh@bgumail.bgu.ac.il	Raveh, Dina/A-7166-2012	Pietrokovski, Shmuel/0000-0001-8573-5863; Krichevsky, Oleg/0000-0002-6856-7551				Bakhrat A, 2004, GENETICS, V166, P721, DOI 10.1534/genetics.166.2.721; BUCHNIK R, 2000, THESIS B GURION U BE; Butler G, 2004, P NATL ACAD SCI USA, V101, P1632, DOI 10.1073/pnas.0304170101; Butler MI, 2005, FUNGAL GENET BIOL, V42, P452, DOI 10.1016/j.fgb.2005.01.011; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Fabre E, 2005, MOL BIOL EVOL, V22, P856, DOI 10.1093/molbev/msi070; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gimble FS, 2001, NUCLEIC ACIDS RES, V29, P4215, DOI 10.1093/nar/29.20.4215; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GU HH, 1993, J BIOL CHEM, V268, P7372; HENIKOFF S, 1995, GENE, V163, P17; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; HOOD JK, 2000, BIOCHIM BIOPHYS ACTA, V1471, P31; Ivantsiv Y, 2006, MOL CELL BIOL, V26, P1579, DOI 10.1128/MCB.26.5.1579-1588.2006; James P, 1996, GENETICS, V144, P1425; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; Kaplun L, 2005, MOL CELL BIOL, V25, P5355, DOI 10.1128/MCB.25.13.5355-5362.2005; Kaplun L, 2003, J BIOL CHEM, V278, P48727, DOI 10.1074/jbc.M308671200; Koufopanou V, 2005, MOL BIOL EVOL, V22, P1535, DOI 10.1093/molbev/msi149; Koufopanou V, 2002, MOL BIOL EVOL, V19, P239, DOI 10.1093/oxfordjournals.molbev.a004077; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Leslie DM, 2004, MOL CELL BIOL, V24, P8487, DOI 10.1128/MCB.24.19.8487-8503.2004; Leslie DM, 2002, MOL CELL BIOL, V22, P2544, DOI 10.1128/MCB.22.8.2544-2555.2002; Leung SW, 2003, J BIOL CHEM, V278, P41947, DOI 10.1074/jbc.M307162200; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Moure CM, 2002, NAT STRUCT BIOL, V9, P764, DOI 10.1038/nsb840; Nagai Y, 2003, MOL CELL BIOL, V23, P1726, DOI 10.1128/MCB.23.5.1726-1736.2003; Nahon E, 1998, NUCLEIC ACIDS RES, V26, P1233, DOI 10.1093/nar/26.5.1233; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Posey KL, 2004, NUCLEIC ACIDS RES, V32, P3947, DOI 10.1093/nar/gkh734; RAVEH D, 1989, MOL GEN GENET, V220, P33; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; Schaper S, 2005, J CELL SCI, V118, P1473, DOI 10.1242/jcs.01739; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Sydorskyy Y, 2003, MOL CELL BIOL, V23, P2042, DOI 10.1128/MCB.23.6.2042-2054.2003; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009	56	13	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12218	12226		10.1074/jbc.M600238200	http://dx.doi.org/10.1074/jbc.M600238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507575	hybrid			2022-12-25	WOS:000237134700004
J	Giaime, E; Sunyach, C; Herrant, M; Grosso, S; Auberger, P; McLean, PJ; Checler, F; da Costa, CA				Giaime, E; Sunyach, C; Herrant, M; Grosso, S; Auberger, P; McLean, PJ; Checler, F; da Costa, CA			Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-SYNUCLEIN AGGREGATION; PARKINSONS-DISEASE; MOLECULAR PATHWAYS; NEURONAL CELLS; LEWY BODIES; WILD-TYPE; APOPTOSIS; MUTATION; DOPAMINE	Parkinson disease is the second most frequent neurodegenerative disorder after Alzheimer disease. A subset of genetic forms of Parkinson disease has been attributed to alpha-synuclein, a synaptic protein with remarkable chaperone properties. Synphilin-1 is a cytoplasmic protein that has been identified as a partner of alpha-synuclein ( Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., Margolis, R. L., Troncoso, J. C., Lanahan, A. A., Worley, P. F., Dawson, V. L., Dawson, T. M., and Ross, C. A. ( 1999) Nat. Gen. 22, 110-114), but its function remains totally unknown. We show here for the first time that synphilin-1 displays an antiapoptotic function in the control of cell death. We have established transient and stable transfectants overexpressing wild-type synphilin-1 in human embryonic kidney 293 cells, telecephalon-specific murine 1 neurons, and SH-SY5Y neuroblastoma cells, and we show that both cell systems display lower responsiveness to staurosporine and 6-hydroxydopamine. Thus, synphilin-1 reduces procaspase-3 hydrolysis and thereby caspase-3 activity and decreases poly( ADP-ribose) polymerase cleavage, two main indicators of apoptotic cell death. Furthermore, we establish that synphilin-1 drastically reduces p53 transcriptional activity and expression and lowers p53 promoter transactivation and mRNA levels. Interestingly, we demonstrate that synphilin-1 catabolism is enhanced by staurosporine and blocked by caspase-3 inhibitors. Accordingly, we show by transcription/translation assay that recombinant caspase-3 and, to a lesser extent, caspase-6 but not caspase-7 hydrolyze synphilin-1. Furthermore, we demonstrate that mutated synphilin-1, in which a consensus caspase-3 target sequence has been disrupted, resists proteolysis by cellular and recombinant caspases and displays drastically reduced antiapoptotic phenotype. We further show that the caspase-3-derived C-terminal fragment of synphilin-1 was probably responsible for the antiapoptotic phenotype elicited by the parent wild-type protein. Altogether, our study is the first demonstration that synphilin-1 harbors a protective function that is controlled by the C-terminal fragment generated by its proteolysis by caspase-3.	Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097,Equipe Labellisee Fdn Rech Med, F-06560 Valbonne, France; INSERM, Fac Med, U526, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; Massachusetts Gen Hosp, Dept Neurol, Alzheimer Dis Res Unit, Charlestown, MA 02129 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Massachusetts General Hospital	Checler, F (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097,Equipe Labellisee Fdn Rech Med, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr; acosta@ipmc.cnrs.fr	Checler, Frederic/C-1241-2009; AUBERGER, Patrick/G-1491-2013; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; AUBERGER, Patrick/0000-0002-2481-8275; da Costa, Cristine Alves/0000-0002-7777-005X; McLean, Pamela/0000-0003-4870-5715				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Gasser T, 2005, CURR OPIN NEUROL, V18, P363, DOI 10.1097/01.wco.0000170951.08924.3d; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Kahns S, 2003, J BIOL CHEM, V278, P23376, DOI 10.1074/jbc.M300495200; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; KHAN NL, 2004, HOSP PHARM, V11, P9; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee SJ, 2003, ANTIOXID REDOX SIGN, V5, P337, DOI 10.1089/152308603322110904; Lev N, 2003, PROG NEURO-PSYCHOPH, V27, P245, DOI 10.1016/S0278-5846(03)00019-8; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Marambaud P, 1998, BIOCHEM BIOPH RES CO, V252, P134, DOI 10.1006/bbrc.1998.9619; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Maruyama Wakako, 2002, Journal of Neurology, V249, P6; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Morris HR, 2005, ANN MED, V37, P86, DOI 10.1080/07853890510007269; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; Pankratz N, 2002, AM J HUM GENET, V71, P124, DOI 10.1086/341282; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajagopalan S, 2001, MECH AGEING DEV, V122, P1499, DOI 10.1016/S0047-6374(01)00283-4; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tanaka K, 2004, BBA-MOL CELL RES, V1695, P235, DOI 10.1016/j.bbamcr.2004.09.026; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Vaux DL, 1999, CELL DEATH DIFFER, V6, P493, DOI 10.1038/sj.cdd.4400523; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	64	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11515	11522		10.1074/jbc.M508619200	http://dx.doi.org/10.1074/jbc.M508619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495229	hybrid			2022-12-25	WOS:000236988100013
J	Schroder, HC; Boreiko, A; Korzhev, M; Tahir, MN; Tremel, W; Eckert, C; Ushijima, H; Muller, IM; Muller, WEG				Schroder, HC; Boreiko, A; Korzhev, M; Tahir, MN; Tremel, W; Eckert, C; Ushijima, H; Muller, IM; Muller, WEG			Co-expression and functional interaction of silicatein with galectin - Matrix-guided formation of siliceous spicules in the marine demosponge Suberites domuncula	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEODIA-CYDONIUM; SPONGE CELLS; EXPRESSION; BIOSILICA; PROTEIN; POLYMERIZATION; PRIMMORPHS; COLLAGENS; INDUCTION; TISSUE	Sponges ( phylum Porifera) of the class of Demospongiae are stabilized by a siliceous skeleton. It is composed of silica needles (spicules), which provide the morphogenetic scaffold of these metazoans. In the center of the spicules there is an axial filament that consists predominantly of silicatein, an enzyme that catalyzes the synthesis of biosilica. By differential display of transcripts we identified additional proteins involved in silica formation. Two genes were isolated from the marine demosponge Suberites domuncula; one codes for a galectin and the other for a fibrillar collagen. The galectin forms aggregates to which silicatein molecules bind. The extent of the silicatein-mediated silica formation strongly increased if associated with the galectin. By applying a new and mild extraction procedure that avoids hydrogen fluoride treatment, native axial filaments were extracted from spicules of S. domuncula. These filaments contained, in addition to silicatein, the galectin and a few other proteins. Immunogold electron microscopic studies underscored the role of these additional proteins, in particular that of galectin, in spiculogenesis. Galectin, in addition to silicatein, presumably forms in the axial canal as well as on the surface of the spicules an organized net-like matrix. In the extraspicular space most of these complexes are arranged concentrically around the spicules. Taken together, these additional proteins, working together with silicatein, may also be relevant for potential ( nano)biotechnological applications of silicatein in the formation of surface coatings. Finally, we propose a scheme that outlines the matrix (galectin/silicatein)-guided appositional growth of spicules through centripetal and centrifugal synthesis and deposition of biosilica.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Anorgan Chem & Analyt Chem, D-55099 Mainz, Germany; Univ Berlin, Museum Naturkunde, Inst Systemat Zool, D-10115 Berlin, Germany; Univ Tokyo, Dept Dev Med Sci, Inst Int Hlth, Grad Sch Med,Bunkyo Ku, Tokyo 1130033, Japan	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Leibniz Institut fur Evolutions und Biodiversitatsforschung; University of Tokyo	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	wmueller@uni-mainz.de	Tremel, Wolfgang/D-8125-2011; Tahir, Muhammad Nawaz/F-2900-2015; Tremel, Wolfgang/AAT-1137-2021; Müller, W. E. G./AAR-8651-2020; Tahir, Muhammad Nawaz/B-2001-2016; tahir, Muhammad Nawaz/B-7650-2011	Tremel, Wolfgang/0000-0002-4536-994X; Müller, W. E. G./0000-0002-8223-3689; Tahir, Muhammad Nawaz/0000-0002-9031-5537; Schroder, Heinz C./0000-0003-0992-6427				[Anonymous], 2004, CURRENT PROTOCOLS MO; Bergquist P.R., 1978, SPONGES; Butschli O, 1901, Z WISS ZOOL ABT A, V69, P235; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Coligan J.E., 2000, CURRENT PROTOCOLS PR; COMPTON SJ, 1985, ANAL BIOCHEM, V151, P369, DOI 10.1016/0003-2697(85)90190-3; CONNES R, 1980, ARCH ZOOL EXP GEN, V121, P213; CROOCKEWIT JH, 1843, LIEBIGS ANN CHEM, V48, P43; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DIEHLSEIFERT B, 1985, J CELL SCI, V79, P271; DIEHLSEIFERT B, 1985, EUR J BIOCHEM, V147, P517; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; Garrone R, 1998, Prog Mol Subcell Biol, V21, P119; Garrone R., 1984, P461; Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002; GROSS J, 1956, J HISTOCHEM CYTOCHEM, V4, P227, DOI 10.1177/4.3.227; Klein SL, 2002, DEV DYNAM, V225, P384, DOI 10.1002/dvdy.10174; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Krasko A, 2002, DNA CELL BIOL, V21, P67, DOI 10.1089/10445490252810320; Krasko A, 2000, EUR J BIOCHEM, V267, P4878, DOI 10.1046/j.1432-1327.2000.01547.x; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; Kruse M, 1999, J CELL SCI, V112, P4305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minchin E. A., 1909, Ergebnisse der Zoologie Jena, V2; MULLER W, 1968, Senckenbergiana Biologica, V49, P469; Muller WEG, 2006, MICRON, V37, P107, DOI 10.1016/j.micron.2005.09.003; Muller WEG, 2005, FEBS J, V272, P3838, DOI 10.1111/j.1742-4658.2005.04795.x; Muller WEG, 2005, CELL TISSUE RES, V321, P285, DOI 10.1007/s00441-005-1141-5; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; Muller WEG, 2002, IMMUNOGENETICS, V54, P48, DOI 10.1007/s00251-002-0441-0; Muller WEG, 1997, TRENDS GLYCOSCI GLYC, V9, P123; MULLER WEG, 2004, Patent No. 1320624; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Schroder HC, 2000, FASEB J, V14, P2022, DOI 10.1096/fj.00-0043com; Schulze F. E., 1887, REPORT SCI RESULTS V, V21, P513; Schulze FE, 1889, BEZEICHNUNG SPONGIEN; Schutze J, 2001, J MOL EVOL, V53, P402, DOI 10.1007/s002390010230; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; Simpson T., 1984, CELL BIOL SPONGES; STANLEY PE, 1990, BIOLUMINESCENCE CHEM; Tahir MN, 2005, CHEM COMMUN, P5533, DOI 10.1039/b510113a; Tahir MN, 2004, CHEM COMMUN, P2848, DOI 10.1039/b410283e; Uriz MJ, 2000, CELL TISSUE RES, V301, P299, DOI 10.1007/s004410000234; Weaver JC, 2003, MICROSC RES TECHNIQ, V62, P356, DOI 10.1002/jemt.10401; Weissenfels N., 1989, BIOL MIKROSKOPISCHE; Wiens M, 2005, J BIOL CHEM, V280, P27949, DOI 10.1074/jbc.M504049200; Wiens M, 2003, J MOL EVOL, V57, pS60, DOI 10.1007/s00239-003-0008-1; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; Yoneda C, 1999, EUR J BIOCHEM, V261, P714, DOI 10.1046/j.1432-1327.1999.00313.x	51	100	107	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12001	12009		10.1074/jbc.M512677200	http://dx.doi.org/10.1074/jbc.M512677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495220	hybrid			2022-12-25	WOS:000236988100070
J	Kaus, S; Castellone, MD; Bedell, VM; Konar, M; Gutkind, JS; Ramchandran, R				Kaus, S; Castellone, MD; Bedell, VM; Konar, M; Gutkind, JS; Ramchandran, R			Robo4 signaling in endothelial cells implies attraction guidance mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGIC ROUNDABOUT; AXON GUIDANCE; RHO-GTPASES; SLIT; ZEBRAFISH; RECEPTORS; MIGRATION; PROTEINS; ANGIOGENESIS; CDC42	Roundabouts (robo) are cell-surface receptors that mediate repulsive signaling mechanisms at the central nervous system midline. However, robos may also mediate attraction mechanisms in the context of vascular development. Here, we have performed structure-function analysis of roundabout4 (Robo4), the predominant robo expressed in embryonic zebrafish vasculature and found by gain of function approaches in vitro that Robo4 activates Cdc42 and Rac1 Rho GTPases in endothelial cells. Indeed, complementary robo4 gene knockdown approaches in zebrafish embryos show lower amounts of active Cdc42 and Rac1 and angioblasts isolated from these knockdown embryos search actively for directionality and guidance cues. Furthermore, Robo4-expressing endothelial cells show morphology and phenotype, characteristic of Rho GTPase activation. Taken together, this study suggests that Robo4 mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance.	NIH, Pathol Lab, NCI, Rockville, MD 20850 USA; NIDCR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ramchandran, R (corresponding author), NIH, Pathol Lab, NCI, Key W Facil,Room 320,9610 Med Ctr Dr, Rockville, MD 20850 USA.	ramchanr@mail.nih.gov	Gutkind, J. Silvio/A-1053-2009; Xiao, Yang/B-5668-2012; Gutkind, J. Silvio/J-1201-2016; Kaur, Sukhbir/ADW-6023-2022	Gutkind, J. Silvio/0000-0002-5150-4482; Kaur, Sukhbir/0000-0003-0513-6225; Bedell, Victoria/0000-0002-8959-6431; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [K22 CA095325-02, K22 CA095325-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010651, K22CA095325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bedell VM, 2005, P NATL ACAD SCI USA, V102, P6373, DOI 10.1073/pnas.0408318102; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Challa AK, 2001, MECH DEVELOP, V101, P249, DOI 10.1016/S0925-4773(00)00570-0; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Englund C, 2002, DEVELOPMENT, V129, P4941; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ghose A, 2002, BIOESSAYS, V24, P401, DOI 10.1002/bies.10080; Gorn M, 2005, LUNG CANCER-J IASLC, V49, P71, DOI 10.1016/j.lungcan.2004.12.005; Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Hu HL, 2005, P NATL ACAD SCI USA, V102, P4613, DOI 10.1073/pnas.0409325102; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hutson LD, 2003, DEV DYNAM, V228, P358, DOI 10.1002/dvdy.10386; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lee JS, 2001, DEV DYNAM, V221, P216, DOI 10.1002/dvdy.1136; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Sang Q, 2002, MOL CELL NEUROSCI, V21, P250, DOI 10.1006/mcne.2002.1156; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Yarar D, 2002, MOL BIOL CELL, V13, P4045, DOI 10.1091/mbc.E02-05-0294; Yeo SY, 2001, DEV BIOL, V230, P1, DOI 10.1006/dbio.2000.0105	36	68	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11347	11356		10.1074/jbc.M508853200	http://dx.doi.org/10.1074/jbc.M508853200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481322	hybrid			2022-12-25	WOS:000236822200077
J	Wu, JS; Katrekar, A; Honigberg, LA; Smith, AM; Conn, MT; Tang, J; Jeffery, D; Mortara, K; Sampang, J; Williams, SR; Buggy, J; Clark, JM				Wu, JS; Katrekar, A; Honigberg, LA; Smith, AM; Conn, MT; Tang, J; Jeffery, D; Mortara, K; Sampang, J; Williams, SR; Buggy, J; Clark, JM			Identification of substrates of human protein-tyrosine phosphatase PTPN22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; GROWTH-FACTOR RECEPTOR; AAA-ATPASE CDC48/P97; T-CELLS; PHOSPHORYLATION SITE; ESCHERICHIA-COLI; TRAPPING MUTANT; KINASE ZAP-70; SH2 DOMAIN; ACTIVATION	Stimulation of mature T cells activates a downstream signaling cascade involving temporally and spatially regulated phosphorylation and dephosphorylation events mediated by protein-tyrosine kinases and phosphatases, respectively. PTPN22 (Lyp), a non-receptor protein-tyrosine phosphatase, is expressed exclusively in cells of hematopoietic origin, notably in T cells where it represses signaling through the T cell receptor. We used substrate trapping coupled with mass spectrometry-based peptide identification in an unbiased approach to identify physiological substrates of PTPN22. Several potential substrates were identified in lysates from pervanadate-stimulated Jurkat cells using PTPN22-D195A/C227S, an optimized substrate trap mutant of PTPN22. These included three novel PTPN22 substrates (Vav, CD3 epsilon, and valosin containing protein) and two known substrates of PEP, the mouse homolog of PTPN22 (Lck and Zap70). T cell antigen receptor (TCR) zeta was also identified as a potential substrate in Jurkat lysates by direct immunoblotting. In vitro experiments with purified recombinant proteins demonstrated that PTPN22-D195A/C227S interacted directly with activated Lck, Zap70, and TCR zeta, confirming the initial substrate trap results. Native PTPN22 dephosphorylated Lck and Zap70 at their activating tyrosine residues Tyr-394 and Tyr-493, respectively, but not at the regulatory tyrosines Tyr-505 (Lck) or Tyr-319 (Zap70). Native PTPN22 also dephosphorylated TCR zeta in vitro and in cells, and its substrate trap variant co-immunoprecipitated with TCR zeta when both were coexpressed in 293T cells, establishing TCR zeta as a direct substrate of PTPN22.	Celera Genom, San Francisco, CA 94080 USA		Wu, JS (corresponding author), 615 John Muir Dr D616, San Francisco, CA 94132 USA.	lakedaly@yahoo.com	Clark, Jeanne/AGG-8199-2022	Clark, Jeanne/0000-0003-1194-0092				Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Di Bartolo V, 1999, J BIOL CHEM, V274, P6285, DOI 10.1074/jbc.274.10.6285; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT NA, 1994, J CELL BIOCHEM, V55, P389, DOI 10.1002/jcb.240550317; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Huang JY, 2000, P NATL ACAD SCI USA, V97, P10923, DOI 10.1073/pnas.97.20.10923; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Kyogoku C, 2004, AM J HUM GENET, V75, P504, DOI 10.1086/423790; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mustelin T, 2004, MOL IMMUNOL, V41, P687, DOI 10.1016/j.molimm.2004.04.015; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sechi AS, 2004, TRENDS IMMUNOL, V25, P257, DOI 10.1016/j.it.2004.03.003; Sozio MS, 2004, J BIOL CHEM, V279, P7760, DOI 10.1074/jbc.M309994200; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; VEILLETTE A, 1992, ONCOGENE, V7, P971; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	184	192	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11002	11010		10.1074/jbc.M600498200	http://dx.doi.org/10.1074/jbc.M600498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16461343	hybrid			2022-12-25	WOS:000236822200041
J	Garcia-Martin, A; Kwa, LG; Strohmann, B; Robert, B; Holzwarth, AR; Braun, P				Garcia-Martin, A; Kwa, LG; Strohmann, B; Robert, B; Holzwarth, AR; Braun, P			Structural role of (bacterio)chlorophyll ligated in the energetically unfavorable beta-position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; BACTERIOCHLOROPHYLL-BINDING-SITE; RHODOBACTER-SPHAEROIDES R-26; MEMBRANE-PROTEINS; CRYSTAL-STRUCTURE; PHOTOSYSTEM-I; DIASTEREOTOPIC LIGATION; TRANSMEMBRANE HELIX; CIRCULAR-DICHROISM; REACTION CENTERS	Chlorophyll is attached to apoprotein in diastereotopically distinct ways, by beta- and alpha-ligation. Both the beta- and alpha-ligated chlorophylls of photosystem I are shown to have ample contacts to apoprotein within their proteinaceous binding sites, in particular, at C-13 of the isocyclic ring. The H-bonding patterns for the C-13(1) oxo groups, however, are clearly distinct for the beta-ligated and alpha-ligated chlorophylls. The beta-ligated chlorophylls frequently employ their C-13(1) oxo in H-bonds to neighboring helices and subunits. In contrast, the C-13(1) oxo of alpha-ligated chlorophylls are significantly less involved in H-bonding interactions, particularly to neighboring helices. Remarkably, in the peripheral antenna, light harvesting complex (LH2) from Rhodobacter sphaeroides, a single mutation in the alpha-subunit, introduced to eliminate H-bonding to the beta-bacteriochlorophyll-B850, which is ligated in the "beta-position," results in significant thermal destabilization of the LH2 in the membrane. In addition, in comparison with wild type LH2, the expression level of the LH2 lacking this H-bond is significantly reduced. These findings show that H-bonding to the C-13(1) keto group of beta-ligated(bacterio)-chlorophyll is a key structural motif and significantly contributes to the stability of bacteriochlorophyll proteins in the native membrane. Our analysis of photosystem I and II suggests that this hitherto unrecognized motif involving H-bonding to beta-ligated chlorophylls may be equally critical for the stable assembly of the inner core antenna of these multicomponent chlorophyll proteins.	Univ Munich, Dept 1, D-80638 Munich, Germany; Ctr Etud Saclay, CEA, DBJC, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Braun, P (corresponding author), Univ Munich, Dept 1, D-80638 Munich, Germany.	paula.braun@lrz.uni-muenchen.de	Robert, Bruno/D-1264-2012; Holzwarth, Alfred R/G-2704-2013; Holzwarth, Alfred/ABE-7424-2020	Robert, Bruno/0000-0001-5999-4538; Holzwarth, Alfred/0000-0002-9562-4873; GARCIA MARTIN, ADELA MARIA/0000-0001-7054-7907				Adamian L, 2003, J MOL BIOL, V327, P251, DOI 10.1016/S0022-2836(03)00041-X; Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; Balaban TS, 2005, PHOTOSYNTH RES, V86, P251, DOI 10.1007/s11120-005-4732-9; Balaban TS, 2002, BBA-BIOENERGETICS, V1556, P197, DOI 10.1016/S0005-2728(02)00363-8; Balaban TS, 2003, FEBS LETT, V545, P97, DOI 10.1016/S0014-5793(03)00531-3; Bandilla M, 1998, BBA-BIOENERGETICS, V1364, P390, DOI 10.1016/S0005-2728(98)00086-3; Barber J, 2000, BBA-BIOENERGETICS, V1459, P239, DOI 10.1016/S0005-2728(00)00158-4; BRAUN P, 1990, BIOCHEMISTRY-US, V29, P10376, DOI 10.1021/bi00497a012; BRAUN P, 1991, BIOCHEMISTRY-US, V30, P5177, DOI 10.1021/bi00235a010; Braun P, 2003, BBA-BIOENERGETICS, V1607, P19, DOI 10.1016/j.bbabio.2003.08.004; Braun P, 2002, J MOL BIOL, V318, P1085, DOI 10.1016/S0022-2836(02)00192-4; Camara-Artigas A, 2003, PHOTOSYNTH RES, V75, P49, DOI 10.1023/A:1022406703110; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CLAYTON RK, 1981, P NATL ACAD SCI-BIOL, V78, P5583, DOI 10.1073/pnas.78.9.5583; COGDELL RJ, 1985, PHOTOCHEM PHOTOBIOL, V42, P669, DOI 10.1111/j.1751-1097.1985.tb01629.x; COLEMAN WJ, 1990, ANNU REV BIOPHYS BIO, V19, P333; DeGrado WF, 2003, PROTEIN SCI, V12, P647, DOI 10.1110/ps.0236503; Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; Encinar JA, 2005, FEBS LETT, V579, P5199, DOI 10.1016/j.febslet.2005.08.038; Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; FOWLER GJS, 1995, J BIOL CHEM, V270, P23875, DOI 10.1074/jbc.270.40.23875; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gall A, 2003, BIOCHEMISTRY-US, V42, P7252, DOI 10.1021/bi0268293; Gall A, 1997, BIOCHEMISTRY-US, V36, P16282, DOI 10.1021/bi9717237; GARCIAMARTIN A, 2005, CHLOROPHYLLS BACTERI; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Ho BK, 2002, J MOL BIOL, V317, P291, DOI 10.1006/jmbi.2001.5385; Ishimura M, 1995, THERMOCHIM ACTA, V266, P355, DOI 10.1016/0040-6031(95)02443-3; Ivancich A, 1998, BIOCHEMISTRY-US, V37, P11812, DOI 10.1021/bi9806908; Janovjak H, 2005, BIOPHYS J, V88, P1423, DOI 10.1529/biophysj.104.052746; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kashiwada A, 1999, CHEM LETT, P1301, DOI 10.1246/cl.1999.1301; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; Koolhaas MHC, 1998, BIOCHEMISTRY-US, V37, P4693, DOI 10.1021/bi973036l; Kwa LG, 2004, J BIOL CHEM, V279, P15067, DOI 10.1074/jbc.M312429200; Lapouge K, 1998, J RAMAN SPECTROSC, V29, P977, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<977::AID-JRS325>3.0.CO;2-K; Liang J, 2002, CURR OPIN CHEM BIOL, V6, P878, DOI 10.1016/S1367-5931(02)00393-9; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liebl U, 1996, PHOTOCHEM PHOTOBIOL, V64, P38, DOI 10.1111/j.1751-1097.1996.tb02419.x; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MATTIOLI TA, 1991, BIOCHEMISTRY-US, V30, P1715, DOI 10.1021/bi00220a038; MATTIOLI TA, 1995, BIOCHEMISTRY-US, V34, P6142, DOI 10.1021/bi00018a017; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MOENNELOCCOZ P, 1990, BIOCHEMISTRY-US, V29, P4740, DOI 10.1021/bi00471a031; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; MOSS GP, 1987, PURE APPL CHEM, V59, P779, DOI 10.1351/pac198759060779; Oba T, 2002, PHOTOSYNTH RES, V74, P1, DOI 10.1023/A:1020816128794; Olsen JD, 1997, BIOCHEMISTRY-US, V36, P12625, DOI 10.1021/bi9710481; Parkes-Loach PS, 2004, BIOCHEMISTRY-US, V43, P7003, DOI 10.1021/bi049798f; POLOZOVA AI, 1995, FEBS LETT, V358, P17, DOI 10.1016/0014-5793(94)01378-E; ROBERT B, 1985, BIOCHIM BIOPHYS ACTA, V807, P10, DOI 10.1016/0005-2728(85)90048-9; Scheer H., 1995, ANOXYGENIC PHOTOSYNT, P649; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; STURGIS JN, 1995, BIOCHEMISTRY-US, V34, P517, DOI 10.1021/bi00002a016; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	66	18	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10626	10634		10.1074/jbc.M510731200	http://dx.doi.org/10.1074/jbc.M510731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484226	hybrid			2022-12-25	WOS:000236594300095
J	McGarrigle, D; Shan, DD; Yang, SY; Huang, XY				McGarrigle, D; Shan, DD; Yang, SY; Huang, XY			Role of tyrosine kinase Csk in G protein-coupled receptor- and receptor tyrosine kinase-induced fibroblast cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE PTP-PEST; SRC FAMILY KINASES; FOCAL ADHESIONS; PHOSPHORYLATED PROTEINS; ACTIVATION; PAXILLIN; INTEGRIN; ASSOCIATION; SIGNALS; GROWTH	Tyrosine kinase Csk is essential for mouse embryonic development. Csk knock-out mice died at early stages of embryogenesis ( around embryonic day 10). The molecular mechanism for this defect is not completely understood. Here we report that Csk deficiency in mouse embryonic fibroblast cells blocked cell migration induced by lysophosphatidic acid through G protein-coupled receptors, by platelet-derived growth factor and epidermal growth factor through receptor tyrosine kinases, and by serum. Re-expression of Csk in these Csk-deficient cells rescued the migratory phenotype. Furthermore, deletion of Csk did not interfere with Rac activation and lamellipodia formation, but impaired the focal adhesions. Our data demonstrate a critical role for Csk in cell migration.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.	xyhuang@med.cornell.edu	Yang, Shengyu/I-9531-2012	Yang, Shengyu/0000-0002-7933-6118	NIA NIH HHS [AG 014563] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Shan DD, 2005, P NATL ACAD SCI USA, V102, P3772, DOI 10.1073/pnas.0500658102; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1995, J CELL SCI, V108, P333; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; Williams DM, 2002, J AM CHEM SOC, V124, P5956, DOI 10.1021/ja025993a; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200	40	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10583	10588		10.1074/jbc.M513002200	http://dx.doi.org/10.1074/jbc.M513002200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16501257	hybrid			2022-12-25	WOS:000236594300090
J	Voigt, P; Dorner, MB; Schaefer, M				Voigt, P; Dorner, MB; Schaefer, M			Characterization of p87(PIKAP), a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; 3-KINASE P110-GAMMA; IN-VIVO; DOMAINS; CELLS; ACTIVATION; PI3K-GAMMA; KINASE; SENSITIVITY; MIGRATION	Phosphoinositide 3- kinase (PI3K) gamma has been implicated in a vast array of physiological settings including the activation of different leukocyte species and the regulation of myocardial contractility. Activation of PI3K gamma is primarily mediated by G beta gamma subunits of heterotrimeric G proteins, which are recognized by a p101 regulatory subunit. Here, we describe the identification and characterization of a novel regulatory subunit of PI3K gamma, which we termed p87(PIKAP) (PI3K gamma adapter protein of 87 kDa). It is homologous to p101 in areas that we have recently shown that they mediate binding to the catalytic p110 gamma subunit and to G beta gamma. Like p101, p87(PIKAP) binds to both p110 gamma and G beta gamma and mediates activation of p110 gamma downstream of G protein-coupled receptors. In contrast to p101, p87(PIKAP) is highly expressed in heart and may therefore be crucial to PI3K gamma cardiac function. Moreover, p87(PIKAP) and p101 are both expressed in dendritic cells, macrophages, and neutrophils, raising the possibility of regulatory subunit-dependent differences in PI3K gamma signaling within the same cell type. We further provide evidence that p87(PIKAP) physically interacts with phosphodiesterase (PDE) 3B, suggesting that p87(PIKAP) is also involved in the recently described noncatalytic scaffolding interaction of p110 gamma with PDE3B. However, coexpression of PDE3B and PI3K gamma subunits was not sufficient to reconstitute the regulatory effect of PI3K gamma on PDE3B activity observed in heart, implying further molecules to be present in the complex regulating PDE3B in heart.	Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Robert Koch Inst, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute	Schaefer, M (corresponding author), Charite Univ Med Berlin, Inst Pharmakol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	m.schaefer@charite.de	Dorner, Martin B/C-5703-2013	Dorner, Martin B/0000-0002-8176-797X; Voigt, Philipp/0000-0003-4366-0490				Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kerchner KR, 2004, J BIOL CHEM, V279, P44554, DOI 10.1074/jbc.M406071200; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Shepherd MC, 2004, BRIT J PHARMACOL, V142, P339, DOI 10.1038/sj.bjp.0705770; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Voigt P, 2005, N-S ARCH PHARMACOL, V371, pR44; Voigt P, 2005, J BIOL CHEM, V280, P5121, DOI 10.1074/jbc.M413104200; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	28	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9977	9986		10.1074/jbc.M512502200	http://dx.doi.org/10.1074/jbc.M512502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476736	hybrid			2022-12-25	WOS:000236594300020
J	Wang, EX; Albritton, L; Ross, SR				Wang, EX; Albritton, L; Ross, SR			Identification of the segments of the mouse transferrin receptor 1 required for mouse mammary tumor virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; HEREDITARY HEMOCHROMATOSIS; CRYSTAL-STRUCTURE; ENVELOPE PROTEIN; BREAST-TUMORS; EXPRESSION; BINDING; GENE; HFE; SEQUENCES	Most enveloped viruses enter cells through binding of virion surface envelope proteins to receptors found on the plasma membrane of the cell. The beta retrovirus mouse mammary tumor virus (MMTV) uses transferrin receptor 1 (TfR1) to enter cells in a pH-dependent mechanism, probably co-trafficking with TfR1 to an acidic compartment where virus entry occurs. We have shown here that, although mouse and rat TfR1 function as entry receptors, cat, dog, hamster, or human TfR1s do not support MMTV infection. We also demonstrated that MMTV entry is independent of transferrin, iron, and the TfR1 cofactor hereditary hematochromatosis HFE protein. Using chimeric mouse/human hybrid TfR1 constructs, we determined the site of interaction with MMTV and found that it maps to two segments physically disparate from the TfR and HFE binding sites. Thus, MMTV has apparently evolved to enter cells independently of the iron status of the host.	Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Ctr, Philadelphia, PA 19104 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Tennessee System; University of Tennessee Health Science Center	Ross, SR (corresponding author), Univ Penn, Dept Microbiol, Rm 313BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	rosss@mail.med.upenn.edu		Ross, Susan R/0000-0002-3094-3769	NCI NIH HHS [R01 CA 73746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISEN P, 2002, INT J BIOCHEM CELL B, V36, P2137; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BREKELMANS P, 1994, CELL IMMUNOL, V159, P331, DOI 10.1006/cimm.1994.1319; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; DUDLEY JP, 1981, J VIROL, V39, P207, DOI 10.1128/JVI.39.1.207-218.1981; Dzuris JL, 1999, VIROLOGY, V263, P418, DOI 10.1006/viro.1999.9967; Etkind PR, 2004, CLIN CANCER RES, V10, P5656, DOI 10.1158/1078-0432.CCR-03-0364; Evans P, 1997, GENE, V199, P123, DOI 10.1016/S0378-1119(97)00356-9; Ford CE, 2003, CLIN CANCER RES, V9, P1118; FRITSCH EF, 1977, J VIROL, V24, P461, DOI 10.1128/JVI.24.2.461-469.1977; FUTRAN J, 1989, J IMMUNOL, V143, P787; Giannetti AM, 2004, J BIOL CHEM, V279, P25866, DOI 10.1074/jbc.M401467200; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUEX N, 1999, IMMUNOL NEWS, V6, P132; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Indik S, 2005, CANCER RES, V65, P6651, DOI 10.1158/0008-5472.CAN-04-2609; Katz RA, 2005, J CELL BIOCHEM, V94, P880, DOI 10.1002/jcb.20358; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCKENNA WR, 1988, INFECT IMMUN, V56, P785, DOI 10.1128/IAI.56.4.785-791.1988; Parkkila S, 2000, HAEMATOLOGICA, V85, P340; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; REDMOND S, 1984, VIROLOGY, V133, P393, DOI 10.1016/0042-6822(84)90405-7; Riegert P, 1998, IMMUNOGENETICS, V47, P174, DOI 10.1007/s002510050344; Ross SR, 2002, P NATL ACAD SCI USA, V99, P12386, DOI 10.1073/pnas.192360099; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHULMAN HM, 1989, BIOCHIM BIOPHYS ACTA, V1010, P1, DOI 10.1016/0167-4889(89)90176-6; SHIMOOKA T, 1986, J CELL PHYSIOL, V126, P341, DOI 10.1002/jcp.1041260304; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tailor CS, 2000, J VIROL, V74, P9797, DOI 10.1128/JVI.74.20.9797-9801.2000; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; Velin D, 1996, J VIROL, V70, P7250, DOI 10.1128/JVI.70.10.7250-7254.1996; WANG Y, 1995, CANCER RES, V55, P5173; Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048; Xu GZ, 2005, MOL CELL PROTEOMICS, V4, P1959, DOI 10.1074/mcp.M500095-MCP200; Xu LZ, 2003, P NATL ACAD SCI USA, V100, P8454, DOI 10.1073/pnas.1433063100; Zhang YM, 2003, J VIROL, V77, P10468, DOI 10.1128/JVI.77.19.10468-10478.2003	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10243	10249		10.1074/jbc.M511572200	http://dx.doi.org/10.1074/jbc.M511572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481319	hybrid			2022-12-25	WOS:000236594300052
J	Borgia, A; Bonivento, D; Travaglini-Allocatelli, C; Di Matteo, A; Brunori, M				Borgia, A; Bonivento, D; Travaglini-Allocatelli, C; Di Matteo, A; Brunori, M			Unveiling a hidden folding intermediate in c-type cytochromes by protein engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-MOLECULES CONTRIBUTE; ON-PATHWAY INTERMEDIATE; PSEUDOMONAS-AERUGINOSA; HYDROGENOBACTER-THERMOPHILUS; TRANSITION-STATES; MECHANISM; STABILITY; C(551); KINETICS; CAVITIES	Several investigators have highlighted a correlation between the basic features of the folding process of a protein and its topology, which dictates the folding pathway. Within this conceptual framework we proposed that different members of the cytochrome c (cyt c) family share the same folding mechanism, involving a consensus partially structured state. Pseudomonas aeruginosa cyt c(551) (Pa cyt c(551)) folds via an apparent two-state mechanism through a high energy intermediate. Here we present kinetic evidence demonstrating that it is possible to switch its folding mechanism from two to three state, stabilizing the high energy intermediate by rational mutagenesis. Characterization of the folding kinetics of one single-site mutant of the Pa cyt c(551) (Phe(7) to Ala) indeed reveals an additional refolding phase and a fast unfolding process which are explained by the accumulation of a partially folded species. Further kinetic analysis highlights the presence of two parallel processes both leading to the native state, suggesting that the above mentioned species is a non obligatory on-pathway intermediate. Determination of the crystallographic structure of F7A shows the presence of an extended internal cavity, which hosts three "bound" water molecules and a H-bond in the N-terminal helix, which is shorter than in the wild type protein. These two features allow us to propose a detailed structural interpretation for the stabilization of the native and especially the intermediate states induced by a single crucial mutation. These results show how protein engineering, x-ray crystallography and state-of-the-art kinetics concur to unveil a folding intermediate and the structural determinants of its stability.	Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim, Ist Biol & Patol Mol, I-00185 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Brunori, M (corresponding author), Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Ple A Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	Borgia, Alessandro/AAF-9203-2019; Di Matteo, Adele/AAC-8338-2019	Borgia, Alessandro/0000-0002-4701-8967; Di Matteo, Adele/0000-0002-5921-7365; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126				Bai YW, 1999, P NATL ACAD SCI USA, V96, P477, DOI 10.1073/pnas.96.2.477; Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Diez J, 2001, J MOL BIOL, V305, P905, DOI 10.1006/jmbi.2000.4203; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERNST JA, 1995, SCIENCE, V267, P1813, DOI 10.1126/science.7892604; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; Friel CT, 2003, J MOL BIOL, V326, P293, DOI 10.1016/S0022-2836(02)01249-4; Gianni S, 2003, J MOL BIOL, V330, P1145, DOI 10.1016/S0022-2836(03)00689-2; Gianni S, 2001, J MOL BIOL, V309, P1177, DOI 10.1006/jmbi.2001.4728; Gorski SA, 2001, J MOL BIOL, V312, P849, DOI 10.1006/jmbi.2001.5001; Griffin S, 2002, ARCH BIOCHEM BIOPHYS, V404, P335, DOI 10.1016/S0003-9861(02)00333-8; Gunasekaran K, 2001, CURR OPIN STRUC BIOL, V11, P83, DOI 10.1016/S0959-440X(00)00173-1; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIEFHABER T, 1992, J MOL BIOL, V224, P217, DOI 10.1016/0022-2836(92)90585-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maity H, 2004, J MOL BIOL, V343, P223, DOI 10.1016/j.jmb.2004.08.005; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oliveberg M, 2001, CURR OPIN STRUC BIOL, V11, P94, DOI 10.1016/S0959-440X(00)00171-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sanchez IE, 2003, J MOL BIOL, V327, P867, DOI 10.1016/S0022-2836(03)00171-2; Sauder JM, 1996, BIOCHEMISTRY-US, V35, P16852, DOI 10.1021/bi961976k; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Takano K, 2003, PROTEIN ENG, V16, P5, DOI 10.1093/proeng/gzg001; Travaglini-Allocatelli C, 1999, J MOL BIOL, V289, P1459, DOI 10.1006/jmbi.1999.2852; Travaglini-Allocatelli C, 2005, J BIOL CHEM, V280, P25729, DOI 10.1074/jbc.M502628200; Travaglini-Allocatelli C, 2004, TRENDS BIOCHEM SCI, V29, P535, DOI 10.1016/j.tibs.2004.08.004; Travaglini-Allocatelli C, 2003, J BIOL CHEM, V278, P41136, DOI 10.1074/jbc.M303990200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; Zarrine-Afsar A, 2005, CURR OPIN STRUC BIOL, V15, P42, DOI 10.1016/j.sbi.2005.01.011	47	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9331	9336		10.1074/jbc.M512127200	http://dx.doi.org/10.1074/jbc.M512127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452476	hybrid			2022-12-25	WOS:000236404700041
J	Higashi, K; Kashiwagi, K; Taniguchi, S; Terui, Y; Yamamoto, K; Ishihama, A; Igarashi, K				Higashi, K; Kashiwagi, K; Taniguchi, S; Terui, Y; Yamamoto, K; Ishihama, A; Igarashi, K			Enhancement of+1 frameshift by polyamines during translation of polypeptide release factor 2 in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							30S RIBOSOMAL-SUBUNIT; ORNITHINE DECARBOXYLASE ANTIZYME; OLIGOPEPTIDE-BINDING PROTEIN; TISSUE-CULTURE CELLS; MESSENGER-RNA; BOVINE LYMPHOCYTES; READING FRAME; FREE SYSTEM; RAT-LIVER; FACTOR-II	Polypeptide release factor 2 (RF2) in Escherichia coli is known to be synthesized by a +1 frameshift at the 26th UGA codon of RF2 mRNA. Polyamines were found to stimulate the +1 frameshift of RF2 synthesis, an effect that was reduced by excess RF2. Polyamine stimulation of +1 frameshift of RF2 synthesis was observed at the early logarithmic phase, which is the important phase in determination of the overall rate of cell growth. A Shine-Dalgarno-like sequence was necessary for an efficient +1 frameshift of RF2 synthesis, but not for polyamine stimulation. Spectinomycin, tetracycline, streptomycin, and neomycin reduced polyamine stimulation of the +1 frameshift of RF2 synthesis. The results suggest that a structural change of the A site on 30 S ribosomal subunits is important for polyamine stimulation of the +1 frameshift. The level of mRNAs of ribosomal proteins and elongation factors having UAA as termination codon was enhanced by polyamines, and OppA synthesis from OppA mRNA having UAA as termination codon was more enhanced by polyamines than that from OppA mRNA having a UGA termination codon. Furthermore, synthesis of ribosomal protein L20 and elongation factor G from the mRNA shaving a UAA termination codon was enhanced by polyamines at the level of translation and transcription. The results suggest that some protein synthesis from mRNAs having a UAA termination codon is enhanced at the level of translation through polyamine stimulation of +1 frameshift of RF2 synthesis. It is concluded that prfB encoding RF2 is a new member of the polyamine modulon.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Kinki Univ, Grad Sch Agr, Nara 6318505, Japan; Nippon Inst Biol Sci, Div Mol Biol, Tokyo 1980024, Japan	Chiba University; Kindai University (Kinki University)	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Higashi, Kyohei/0000-0002-2622-4825; Igarashi, Kazuei/0000-0003-3751-3187				Amarantos I, 2002, NUCLEIC ACIDS RES, V30, P2832, DOI 10.1093/nar/gkf404; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; Hirokawa G, 2005, RNA, V11, P1317, DOI 10.1261/rna.2520405; Hirvonen CA, 2001, J BACTERIOL, V183, P6305, DOI 10.1128/JB.183.21.6305-6314.2001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ICHIBA T, 1995, BBA-GENE STRUCT EXPR, V1262, P83, DOI 10.1016/0167-4781(95)00062-L; IGARASHI K, 1977, J BIOCHEM-TOKYO, V81, P1091, DOI 10.1093/oxfordjournals.jbchem.a131533; Igarashi K, 2006, J BIOCHEM, V139, P11, DOI 10.1093/jb/mvj020; IGARASHI K, 1981, EUR J BIOCHEM, V113, P587, DOI 10.1111/j.1432-1033.1981.tb05103.x; IGARASHI K, 1984, CANCER RES, V44, P5332; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1979, BIOCHEM BIOPH RES CO, V91, P440, DOI 10.1016/0006-291X(79)91541-9; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ITO K, 1990, J BIOL CHEM, V265, P13036; Ito K, 1998, P NATL ACAD SCI USA, V95, P8165, DOI 10.1073/pnas.95.14.8165; ITO K, 1986, EUR J BIOCHEM, V156, P505, DOI 10.1111/j.1432-1033.1986.tb09609.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KAKEGAWA T, 1986, ARCH BIOCHEM BIOPHYS, V251, P413, DOI 10.1016/0003-9861(86)90347-4; KAKEGAWA T, 1986, EUR J BIOCHEM, V158, P265, DOI 10.1111/j.1432-1033.1986.tb09746.x; KALTSCHM.E, 1970, P NATL ACAD SCI USA, V67, P1276, DOI 10.1073/pnas.67.3.1276; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P341; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Marquez V, 2004, CELL, V118, P45, DOI 10.1016/j.cell.2004.06.012; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; Palanimurugan R, 2004, EMBO J, V23, P4857, DOI 10.1038/sj.emboj.7600473; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Recht MI, 1999, EMBO J, V18, P3133, DOI 10.1093/emboj/18.11.3133; Sambrook J, 2001, MOL CLONING LAB MANU; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Yoshida M, 2002, J BIOL CHEM, V277, P37139, DOI 10.1074/jbc.M206668200; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	63	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9527	9537		10.1074/jbc.M513752200	http://dx.doi.org/10.1074/jbc.M513752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16476727	hybrid			2022-12-25	WOS:000236404700063
J	Paul, S; Gable, K; Beaudoin, F; Cahoon, E; Jaworski, J; Napier, JA; Dunn, TM				Paul, S; Gable, K; Beaudoin, F; Cahoon, E; Jaworski, J; Napier, JA; Dunn, TM			Members of the Arabidopsis FAE1-like3-ketoacyl-CoA synthase gene family substitute for the Elop proteins of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ELONGASE; KETOACYL-COA SYNTHASE; FUNCTIONAL-CHARACTERIZATION; CHAIN ELONGATION; FAE1 KCS; REDUCTASE; ENZYME; BIOSYNTHESIS; ENCODES; CLONING	Several 3-keto-synthases have been studied, including the soluble fatty acid synthases, those involved in polyketide synthesis, and the FAE1-like 3-ketoacyl-CoA synthases. All of these condensing enzymes have a common ancestor and an enzymatic mechanism that involves a catalytic triad consisting of Cys, His, and His/Asn. In contrast to the FAE1-like family of enzymes that mediate plant microsomal fatty acid elongation, the condensation step of elongation in animals and in fungi appears to be mediated by the Elop homologs. Curiously these proteins bear no resemblance to the well characterized 3-keto-synthases. There are three ELO genes in yeast that encode the homologous Elo1p, Elo2p, and Elo3p proteins. Elo2p and Elo3p are required for synthesis of the very long-chain fatty acids, and mutants lacking both Elo2p and Elo3p are inviable confirming that the very long-chain fatty acids are essential for cellular functions. In this study we show that heterologous expression of several Arabidopsis FAE1-like genes rescues the lethality of an elo2 Delta elo3 Delta yeast mutant. We further demonstrate that FAE1 acts in conjunction with the 3-keto and trans-2,3-enoyl reductases of the elongase system. These studies indicate that even though the plant-specific FAE1 family of condensing enzymes evolved independently of the Elop family of condensing enzymes, they utilize the same reductases and presumably dehydratase that the Elop proteins rely upon.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Rothamsted Res, Crop Performance & Improvement, Harpenden AL5 2JQ, Herts, England; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; USDA ARS, Plant Genet Res Unit, St Louis, MO 63132 USA	Uniformed Services University of the Health Sciences - USA; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Donald Danforth Plant Science Center; United States Department of Agriculture (USDA)	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil	Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915; Napier, Johnathan/0000-0003-3580-3607; PAUL, SHILPI/0000-0001-5075-2081	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004156] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Agaba M, 2004, MAR BIOTECHNOL, V6, P251, DOI 10.1007/s10126-003-0029-1; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Beaudoin F, 2002, J BIOL CHEM, V277, P11481, DOI 10.1074/jbc.M111441200; Beaudoin F, 2000, BIOCHEM SOC T, V28, P661, DOI 10.1042/BST0280661; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; Blacklock BJ, 2002, EUR J BIOCHEM, V269, P4789, DOI 10.1046/j.1432-1033.2002.03176.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Dietrich CR, 2005, PLANT J, V42, P844, DOI 10.1111/j.1365-313X.2005.02418.x; Dittrich F, 1998, EUR J BIOCHEM, V252, P477, DOI 10.1046/j.1432-1327.1998.2520477.x; Gable K, 2004, J EXP BOT, V55, P543, DOI 10.1093/jxb/erh061; Ghanevati M, 2002, EUR J BIOCHEM, V269, P3531, DOI 10.1046/j.1432-1033.2002.03039.x; Ghanevati M, 2001, BBA-MOL CELL BIOL L, V1530, P77, DOI 10.1016/S1388-1981(00)00168-2; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lassner MW, 1996, PLANT CELL, V8, P281, DOI 10.1105/tpc.8.2.281; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; LESTER RL, 1993, J BIOL CHEM, V268, P845; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Schneiter R, 2000, J BACTERIOL, V182, P3655, DOI 10.1128/JB.182.13.3655-3660.2000; Sherman F., 1986, METHODS YEAST GENETI; Todd J, 1999, PLANT J, V17, P119, DOI 10.1046/j.1365-313X.1999.00352.x; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Trenkamp S, 2004, P NATL ACAD SCI USA, V101, P11903, DOI 10.1073/pnas.0404600101; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Zank TK, 2002, PLANT J, V31, P255, DOI 10.1046/j.1365-313X.2002.01354.x; Zank TK, 2000, BIOCHEM SOC T, V28, P654; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Zheng HQ, 2005, PLANT CELL, V17, P1467, DOI 10.1105/tpc.104.030155	38	104	116	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9018	9029		10.1074/jbc.M507723200	http://dx.doi.org/10.1074/jbc.M507723200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16449229	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000236404700006
J	Wasilenko, J; Fridovich-Keil, JL				Wasilenko, J; Fridovich-Keil, JL			Relationship between UDP-galactose 4 '-epimerase activity and galactose sensitivity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE DEFICIENCY; DIPHOSPHATE GALACTOSE-4-EPIMERASE DEFICIENCY; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; EXPRESSION SYSTEM; LELOIR PATHWAY; 4-EPIMERASE; METABOLISM; PROMOTER	UDP- galactose 4'- epimerase ( GALE) catalyzes the final step of the highly conserved Leloir pathway of galactose metabolism. Loss of GALE in humans results in a variant form of the metabolic disorder, galactosemia. Loss of GALE in yeast results in galactose- dependent growth arrest. Although the role of GALE in galactose metabolism has been recognized for decades, the precise relationship between GALE activity and galactose sensitivity has remained unclear. Here we have explored this relationship by asking the following. 1) Is GALE rate- limiting for galactose metabolism in yeast? 2) What is the relationship between GALE activity and galactose-dependent growth arrest in yeast? 3) What is the relationship between GALE activity and the abnormal accumulation of galactose metabolites in yeast? To answer these questions we engineered a strain of yeast in which GALE was doxycycline- repressible and studied these cells under conditions of intermediate GALE expression. Our results demonstrated a smooth linear relationship between galactose metabolism and GALE activity over a range from 0 to similar to 5% but a steep threshold relationship between growth rate in galactose and GALE activity over the same range. The relationship between abnormal accumulation of metabolites and GALE activity was also linear over the range from 0 to similar to 5%, suggesting that if the abnormal accumulation of metabolites underlies galactose- dependent growth- arrest in GALE- impaired yeast, either the impact of individual metabolites must be synergistic and/ or the threshold of sensitivity must be very steep. Together these data reveal important points of similarity and contrast between the roles of GALE and galactose- 1- phosphate uridylyltransferase in galactose metabolism in yeast and provide a framework for future studies in mammalian systems.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.	jfridov@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046403, R01DK059904, R01DK046403] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403, DK59904] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; [Anonymous], 1991, Methods Enzymol, V194, P1; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; DOUGLAS HC, 1964, GENETICS, V49, P837; GITZELMANN R, 1972, HELV PAEDIATR ACTA, V27, P125; GITZELMANN R, 1977, HELV PAEDIATR ACTA, V31, P441; GITZELMANN R, 1973, HELV PAEDIATR ACTA, V28, P497; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; HOLTON JB, 1981, ARCH DIS CHILD, V56, P885, DOI 10.1136/adc.56.11.885; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; Leslie N, 2005, MOL GENET METAB, V85, P21, DOI 10.1016/j.ymgme.2005.01.004; Leslie ND, 1996, BIOCHEM MOL MED, V59, P7, DOI 10.1006/bmme.1996.0057; Leslie ND, 2001, MOL GENET METAB, V72, P31, DOI 10.1006/mgme.2000.3116; Majumdar S, 2004, EUR J BIOCHEM, V271, P753, DOI 10.1111/j.1432-1033.2003.03974.x; Mehta DV, 1999, BBA-MOL BASIS DIS, V1454, P217, DOI 10.1016/S0925-4439(99)00037-X; Ning C, 2001, MOL GENET METAB, V72, P306, DOI 10.1006/mgme.2001.3152; Ning C, 2000, PEDIATR RES, V48, P211, DOI 10.1203/00006450-200008000-00015; Openo KK, 2006, AM J HUM GENET, V78, P89, DOI 10.1086/498985; Pilauri V, 2005, GENETICS, V169, P1903, DOI 10.1534/genetics.104.036723; PILLER F, 1983, J BIOL CHEM, V258, P774; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Riehman K, 2001, J BIOL CHEM, V276, P10634, DOI 10.1074/jbc.M009583200; Ross KL, 2004, MOL GENET METAB, V83, P103, DOI 10.1016/j.ymgme.2004.07.005; SARDHARWALLA IB, 1988, J INHERIT METAB DIS, V11, P249, DOI 10.1007/BF01804249; SCHULPIS KH, 1993, J INHERIT METAB DIS, V16, P1059, DOI 10.1007/BF00711534; SCHULPIS KH, 1993, J INHERIT METAB DIS, V16, P903, DOI 10.1007/BF00714292; Schulz JM, 2005, J BIOL CHEM, V280, P13493, DOI 10.1074/jbc.M414045200; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; Shin YS, 2000, J INHERIT METAB DIS, V23, P383, DOI 10.1023/A:1005699719068; Thoden JB, 2005, J BIOL CHEM, V280, P21900, DOI 10.1074/jbc.M502411200; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; Walter JH, 1999, ARCH DIS CHILD, V80, P374, DOI 10.1136/adc.80.4.374; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784	37	14	14	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8443	8449		10.1074/jbc.M600778200	http://dx.doi.org/10.1074/jbc.M600778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452467	hybrid			2022-12-25	WOS:000236247100019
J	El-Agnaf, OMA; Salem, SA; Paleologou, KE; Curran, MD; Gibson, MJ; Court, JA; Schlossmacher, MG; Allsop, D				El-Agnaf, Omar M. A.; Salem, Sultan A.; Paleologou, Katerina E.; Curran, Martin D.; Gibson, Mark J.; Court, Jennifer A.; Schlossmacher, Michael G.; Allsop, David			Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease	FASEB JOURNAL			English	Article						CSF; PD; Lewy bodies; alpha-syn fibrils; oligomers	ALZHEIMERS-DISEASE; LOCUS TRIPLICATION; SOLUBLE OLIGOMERS; MOUSE MODEL; LEWY BODY; PATHOGENESIS; MUTATIONS; DEMENTIA; BRAIN; TOXICITY	To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). alpha-Synuclein (alpha-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding alpha-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of alpha-syn into insoluble aggregates. We recently reported the presence of alpha-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether alpha-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric "soluble aggregates" of alpha-syn. Using this ELISA, we report the presence of significantly elevated (P = 0.002) levels of oligomeric forms of alpha-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52% (95% confidence intervals 0.353-0.687) of the PD patients displayed signals > 0.5 OD with our ELISA assay in comparison to only 14.8% ( 95% confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95% confidence intervals 0.662-0.958), sensitivity of 0.529 (95% confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95% confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of alpha-syn.	United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; Univ Lancaster, Dept Biol Sci, Lancaster, England; Belfast City Hosp, No Ireland Reg Histocompatibil & Immunogenet Lab, Belfast BT9 7AD, Antrim, North Ireland; Belfast City Hosp, Movement Disorders Clin, Belfast BT9 7AD, Antrim, North Ireland; Newcastle Gen Hosp, Joint MRC Newcastle Univ Dev Clin Brain Ageing, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	United Arab Emirates University; Lancaster University; Belfast City Hospital; Belfast City Hospital; Newcastle General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	El-Agnaf, OMA (corresponding author), United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, POB 17666, Al Ain, U Arab Emirates.	o.elagnaf@uaeu.ac.ae	Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575; Schlossmacher, Michael/0000-0002-0394-0300	Alzheimers Research UK [ART-PPG2005A-1] Funding Source: researchfish	Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))		Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2004, FASEB J, V18, P1315, DOI 10.1096/fj.03-1346fje; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; LANG AE, 1998, NEW ENGL J MED, V339, P1144; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Li QX, 2002, J ALZHEIMERS DIS, V4, P309, DOI 10.3233/JAD-2002-4406; Martin FL, 2004, PROTEIN PEPTIDE LETT, V11, P229, DOI 10.2174/0929866043407138; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schapira AHV, 1999, BRIT MED J, V318, P311, DOI 10.1136/bmj.318.7179.311; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Silverberg GD, 2003, LANCET NEUROL, V2, P506, DOI 10.1016/S1474-4422(03)00487-3; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	34	533	564	1	77	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					419	425		10.1096/fj.03-1449com	http://dx.doi.org/10.1096/fj.03-1449com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507759				2022-12-25	WOS:000239815100005
J	Shen, JK; Yang, XR; Xiao, WH; Hackett, SF; Sato, Y; Campochiaro, PA				Shen, JiKui; Yang, XiaoRu; Xiao, Wei-Hong; Hackett, Sean F.; Sato, Yasufumi; Campochiaro, Peter A.			Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; autocrine and paracrine regulation; diabetic retinopathy; ischemic retinopathy; negative feedback	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; VASCULAR-PERMEABILITY FACTOR; CHOROIDAL NEOVASCULARIZATION; ANGIOGENESIS; INHIBITION; MODEL; EXPRESSION; GENE; MICE	Vasohibin is a recently identified protein that is up-regulated in cultured vascular endothelial cells by vascular endothelial growth factor and fibroblast growth factor 2. It inhibits endothelial cell migration, proliferation, and tube formation, and suppresses angiogenesis in chick chorioallantoic membrane, after subcutaneous implantation of matrigel, and in a tumor xenograft model. This has led to the hypothesis that vasohibin functions as a negative feedback inhibitor of angiogenesis. In this study, we tested that hypothesis in a well-characterized model of retinal neovascularization. In ischemic retina, increased expression of VEGF was accompanied by elevation of vasohibin mRNA and blocking of the increase in vegf mRNA with vegf siRNA significantly attenuated the rise in vasohibin mRNA. In transgenic mice in which the rhodopsin promoter drives expression of VEGF in the retina, there was also a significant increase in vasohibin mRNA. In mice with ischemic retinopathy, there was increased expression of vasohibin in vascular endothelial cells, and vasohibin knockdown caused an increase in neovascularization. Conversely, intraocular injection of recombinant vasohibin or an adenoviral vector containing a vasohibin expression cassette strongly suppressed retinal neovascularization in mice with ischemic retinopathy. Knockdown of vasohibin mRNA in ischemic retina had no significant effect on vegf or vegf receptor 1 mRNA levels but caused a significant elevation in the level of vegf receptor 2 mRNA. These data support the hypothesis that vasohibin acts as a negative feedback regulator of neovascularization in the retina and suggest that suppression of VEGF receptor 2 may play some role in mediating its activity.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Pulm Dis & Crit Care, Bayview Med Ctr, Baltimore, MD USA; Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Tohoku University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.	pcampo@jhmi.edu	Sato, Yasufumi/AAF-3367-2019		NEI NIH HHS [P30EY1765, EY12609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; MILLER JW, 1994, AM J PATHOL, V145, P574; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Okamoto N, 1997, AM J PATHOL, V151, P281; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073; SHIMIZU K, 1981, OPHTHALMOLOGY, V88, P601; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87	30	80	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					723	+		10.1096/fj.05-5046fje	http://dx.doi.org/10.1096/fj.05-5046fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473886				2022-12-25	WOS:000237698700025
J	Soto-Pena, GA; Luna, AL; Acosta-Saavedra, L; Conde-Moo, P; Lopez-Carrillo, L; Cebrian, ME; Bastida, M; Calderon-Aranda, ES; Vega, L				Soto-Pena, Gerson A.; Luna, Ana L.; Acosta-Saavedra, Leonor; Conde-Moo, Patricia; Lopez-Carrillo, Lizbeth; Cebrian, Mariano E.; Bastida, Mariana; Calderon-Aranda, Emma S.; Vega, Libia			Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic	FASEB JOURNAL			English	Article						cell surface markers; lymphokines; human cells; immunotoxicity	COLONY-STIMULATING FACTOR; CELL-PROLIFERATION; GALLIUM-ARSENIDE; MOUSE SKIN; T-CELLS; GM-CSF; KERATINOCYTES; GROWTH; PROGRESSION; EXPRESSION	Exposure of several human populations to arsenic has been associated with a high incidence of detrimental dermatological and carcinogenic effects. To date, studies examining the immunotoxic effects of arsenic in humans, and specifically in children, are lacking. Therefore, we evaluated several parameters of immunological status in a group of children exposed to arsenic through their drinking water. Peripheral blood mononuclear cells (PBMCs) of 90 children ( 6 to 10 years old) were collected. Proportions of lymphocyte subpopulations, PBMC mitogenic proliferative response, and urinary arsenic levels were evaluated. Increased urine arsenic levels were associated with a reduced proliferative response to phytohemaglutinin (PHA) stimulation (P=0.005), CD4 subpopulation proportion (P=0.092), CD4/CD8 ratio (P=0.056), and IL-2 secretion levels (P=0.003). Increased arsenic exposure was also associated with an increase in GM-CSF secretion by mononucleated cells (P=0.000). We did not observe changes in CD8, B, or NK cell proportions, nor did we observe changes in the secretion of IL-4, IL-10, or IFN-gamma by PHA-activated PBMCs. These data indicate that arsenic exposure could alter the activation processes of T cells, such that an immunosuppression status that favors opportunistic infections and carcinogenesis is produced together with increased GM-CSF secretion that may be associated with chronic inflammation.	CINVESTAV, Secc Externa Toxicol, Mexico City 07360, DF, Mexico; Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; Jurisdicc Sanit 5, Secretaria Salubridad & Asistencia, Zimapan, Hidalgo, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Nacional de Salud Publica	Vega, L (corresponding author), CINVESTAV, Secc Externa Toxicol, Av IPN 2508, Mexico City 07360, DF, Mexico.	lvega@cinvestav.mx	Vega, Libia/C-3391-2013	Vega, Libia/0000-0002-4993-5267; S Calderon Aranda, Emma/0000-0001-8284-2217; Conde, Patricia/0000-0002-9346-305X				Andres A, 2005, CRIT REV ONCOL HEMAT, V56, P71, DOI 10.1016/j.critrevonc.2004.11.010; ANSEL J, 1990, J INVEST DERMATOL, V94, pS101, DOI 10.1111/1523-1747.ep12876053; Armienta MA, 1997, B ENVIRON CONTAM TOX, V59, P583, DOI 10.1007/s001289900519; BRAUNSTEIN S, 1994, J INVEST DERMATOL, V103, P601, DOI 10.1111/1523-1747.ep12396936; BRONFMAN M, 1988, ARCH INVEST MED, V19, P351; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P178; Del Razo LM, 2001, TOXICOL APPL PHARM, V174, P282, DOI 10.1006/taap.2001.9226; Deng JS, 1998, AM J DERMATOPATH, V20, P143, DOI 10.1097/00000372-199804000-00007; *EPA, 1990, EPASABCASAC90002; Germolec DR, 1998, AM J PATHOL, V153, P1775, DOI 10.1016/S0002-9440(10)65692-1; Germolec DR, 1996, TOXICOL APPL PHARM, V141, P308, DOI 10.1016/S0041-008X(96)80037-8; Germolec DR, 1997, MUTAT RES-REV MUTAT, V386, P209, DOI 10.1016/S1383-5742(97)00006-9; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GONSEBATT ME, 1994, MUTAT RES-ENVIR MUTA, V313, P293, DOI 10.1016/0165-1161(94)90059-0; GONSEBATT ME, 1992, MUTAT RES, V283, P91, DOI 10.1016/0165-7992(92)90139-9; Hayashi T, 1997, INTERNAL MED, V36, P822, DOI 10.2169/internalmedicine.36.822; Hernberg M, 1998, MELANOMA RES, V8, P283, DOI 10.1097/00008390-199806000-00013; KOURY MJ, 1983, EMBO J, V2, P1877, DOI 10.1002/j.1460-2075.1983.tb01674.x; Lim Soon Thye, 2005, Curr Infect Dis Rep, V7, P227, DOI 10.1007/s11908-005-0039-4; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; Luna AL, 2003, TOXICOL SCI, V72, P377; McCollum G, 2005, J PHARMACOL EXP THER, V313, P877, DOI 10.1124/jpet.104.080713; McPartlin DW, 1999, INT J CLIN PRACT, V53, P562; Meng ZQ, 2000, CHEMOSPHERE, V41, P115, DOI 10.1016/S0045-6535(99)00397-5; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Patterson R, 2004, TOXICOL APPL PHARM, V198, P434, DOI 10.1016/j.taap.2003.10.012; Rossman TG, 2004, TOXICOL APPL PHARM, V198, P394, DOI 10.1016/j.taap.2003.10.016; SCHOFER H, 1995, HAUTARZT, V46, P632, DOI 10.1007/s001050050310; SIKORSKI EE, 1989, FUND APPL TOXICOL, V13, P843, DOI 10.1016/0272-0590(89)90338-2; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Tseng CH, 2004, TOXICOL APPL PHARM, V197, P67, DOI 10.1016/j.taap.2004.02.009; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VASUNIA KB, 1994, CARCINOGENESIS, V15, P653, DOI 10.1093/carcin/15.4.653; Vega L, 2004, TOXICOLOGY, V199, P121, DOI 10.1016/j.tox.2004.02.012; Vega L, 1999, IMMUNOPHARM IMMUNOT, V21, P203, DOI 10.3109/08923979909052758; Vega L, 2001, TOXICOL APPL PHARM, V172, P225, DOI 10.1006/taap.2001.9152; WIGER K, 2005, IDSSKR NOR LAEGEFORE, V125, P1168; Woo SH, 2005, J CELL BIOCHEM, V95, P120, DOI 10.1002/jcb.20329	40	141	151	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					779	+		10.1096/fj.05-4860fje	http://dx.doi.org/10.1096/fj.05-4860fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461332				2022-12-25	WOS:000237698700037
J	Kanzawa, T; Iwado, E; Aoki, H; Iwamaru, A; Hollingsworth, EF; Sawaya, R; Kondo, S; Kondo, Y				Kanzawa, T.; Iwado, E.; Aoki, H.; Iwamaru, A.; Hollingsworth, E. F.; Sawaya, R.; Kondo, S.; Kondo, Y.			Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via the c-Jun NH2-terminal kinase (JNK) pathway	ONCOGENE			English	Article						neural stem cells; ionizing radiation; JNK; apoptosis; neuronal differentiation	BCL-2 FAMILY-MEMBERS; PROGENITOR CELLS; PRECURSOR CELLS; CYTOCHROME-C; EICOSAPENTAENOIC ACID; GAMMA-IRRADIATION; NERVOUS-SYSTEM; GROWTH-FACTOR; MAP KINASES; ADULT-RAT	A substantial number of neural stem cells ( NSCs) continue to proliferate and generate neurons in the central nervous system throughout life. Ionizing radiation, an important adjuvant therapy for glioma patients, may damage NSCs and cause neuronal deficits, such as cognitive dysfunction and memory impairment. However, the precise mechanism of radiation effects on death and differentiation of NSCs remains largely unknown. Here, we found that radiation induced apoptosis in NSCs via the mitochondrial pathway, upregulating the ratio of Bax to Bcl-2 and releasing cytochrome c into the cytoplasm. Radiation also inhibited neuronal differentiation of NSCs by 50%. Of the three stress-associated mitogen-activated protein kinases ( MAPKs), only c-Jun NH2-terminal kinase ( JNK) was activated in NSCs after radiation. Interestingly, JNK inhibition by the specific inhibitor SP600125 rescued NSCs from apoptosis and improved neuronal differentiation. Furthermore, we examined whether radiation directly inhibits neuronal differentiation or not. Radiation did not affect the promoter activity of NeuroD, a basic helix-loop-helix transcription factor that regulates the expression of neuronal differentiation markers. Radiation induced more apoptosis in NeuroD-positive cells than NeuroD-negative cells. We concluded that radiation activates JNK and induces apoptosis, especially in neural progenitor cells, resulting in the inhibition of neurogenesis. Our findings raise the possibility that JNK inhibition has therapeutic potential in protecting NSCs from the adverse effects of radiation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, BSRB1004, Houston, TX 77030 USA.	yaskondo@mdanderson.org		KANZAWA, TAKAO/0000-0002-8165-5652	NCI NIH HHS [CA088936, CA108558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088936, R01CA108558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Ciccolini F, 1998, J NEUROSCI, V18, P7869; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diez del Corral R, 2001, NAT REV NEUROSCI, V2, P835; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Erlandsson A, 2001, J NEUROSCI, V21, P3483, DOI 10.1523/JNEUROSCI.21-10-03483.2001; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1992, NEUROSURGERY, V30, P506; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Lonergan PE, 2002, J BIOL CHEM, V277, P20804, DOI 10.1074/jbc.M202387200; Lynch AM, 2003, J BIOL CHEM, V278, P51075, DOI 10.1074/jbc.M307970200; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhao WQ, 2003, J NEUROSCI RES, V72, P334, DOI 10.1002/jnr.10591	48	47	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3638	3648		10.1038/sj.onc.1209414	http://dx.doi.org/10.1038/sj.onc.1209414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16491125				2022-12-25	WOS:000238448300003
J	Popov, Y; Patsenker, E; Bauer, M; Niedobitek, E; Schulze-Krebs, A; Schuppan, D				Popov, Yury; Patsenker, Eleonora; Bauer, Michael; Niedobitek, Edith; Schulze-Krebs, Anja; Schuppan, Detlef			Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER FIBROSIS; COLLAGEN-SYNTHESIS; FIBROTIC HUMAN; 3-DIMENSIONAL COLLAGEN; SKIN FIBROBLASTS; BILIARY FIBROSIS; PROTEIN-KINASES; GENE-EXPRESSION; TISSUE-REPAIR; I SYNTHESIS	The semisynthetic plant alkaloid halofuginone (HAL) was reported to prevent and partly reverse experimental liver fibrosis. However, its mechanisms of action are poorly understood. We therefore aimed to determine the antifibrotic potential of HAL and to characterize involved signal transduction pathways in hepatic stellate cells (HSCs). Results were compared with its in vivo effects in a rat model of reversal of established liver fibrosis induced by thioacetamide. In vitro HAL inhibited HSC proliferation and migration dose dependently at submicromolar concentrations. HAL ( 200 nM) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. Procollagen alpha 1(I) and MMP-2 transcript levels were suppressed 2- to 3-fold, whereas expression of other profibrogenic mRNAs remained unaffected. p38 mitogen-activated protein kinase ( p38 MAPK) and nuclear factor kappa B (NF kappa B) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NF kappa B dose dependently inhibited MMP-13 induction. Treatment with HAL did not affect HSC viability, and observed effects were reversible after its removal. In vivo HAL up-regulated MMP-3 and -13 mRNA expression 1.5- and 2- fold, respectively, in cirrhotic rats, whereas tissue inhibitor of metalloproteinase-1 was suppressed by 50%. In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF kappa B. The remarkable induction of MMP-3 and -13 makes HAL a promising agent for antifibrotic combination therapies.	Harvard Univ, Sch Med, Beth Israel Deaconess MC, Div Gastroenterol & Hepatol, Boston, MA 02215 USA; Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Erlangen Nuremberg	Schuppan, D (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess MC, Div Gastroenterol & Hepatol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	dschuppa@bidmc.harvard.edu	Popov, Yury V./A-7781-2008	Popov, Yury V./0000-0001-7973-942X				Benten D, 2005, HEPATOLOGY, V42, P1072, DOI 10.1002/hep.20889; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; Bruck R, 2001, HEPATOLOGY, V33, P379, DOI 10.1053/jhep.2001.21408; Cassiman D, 2002, J HEPATOL, V36, P200, DOI 10.1016/S0168-8278(01)00260-4; Cho JJ, 2000, GASTROENTEROLOGY, V118, P1169, DOI 10.1016/S0016-5085(00)70370-2; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Dufour JF, 1997, ANN INTERN MED, V127, P981, DOI 10.7326/0003-4819-127-11-199712010-00006; Elkin M, 1999, CLIN CANCER RES, V5, P1982; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; GRANOT I, 1991, POULTRY SCI, V70, P1559, DOI 10.3382/ps.0701559; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; GREENWEL P, 1993, LAB INVEST, V69, P210; Halevy O, 1996, BIOCHEM PHARMACOL, V52, P1057, DOI 10.1016/0006-2952(96)00427-3; Hammel P, 2001, NEW ENGL J MED, V344, P418, DOI 10.1056/NEJM200102083440604; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Iimuro Y, 2003, GASTROENTEROLOGY, V124, P445, DOI 10.1053/gast.2003.50063; Knittel T, 1999, HISTOCHEM CELL BIOL, V112, P387, DOI 10.1007/s004180050421; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Lee HS, 2003, J BIOMED SCI, V10, P757, DOI 10.1159/000073963; Lee HS, 2001, HEPATO-GASTROENTEROL, V48, P1114; McCrudden R, 2000, HISTOL HISTOPATHOL, V15, P1159, DOI 10.14670/HH-15.1159; McGaha TL, 2002, ARTHRITIS RHEUM, V46, P2748, DOI 10.1002/art.10549; MILANI S, 1994, AM J PATHOL, V144, P528; Nagler A, 1997, ARTERIOSCL THROM VAS, V17, P194, DOI 10.1161/01.ATV.17.1.194; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Pines A, 2003, BIOL BLOOD MARROW TR, V9, P417, DOI 10.1016/S1083-8791(03)00151-4; Pines M, 1998, GEN PHARMACOL, V30, P445, DOI 10.1016/S0306-3623(97)00307-8; Pinzani M, 1998, LIVER, V18, P2; Popov Y, 2005, J HEPATOL, V43, P1045, DOI 10.1016/j.jhep.2005.06.025; PURUKAWA P, 2003, HEPATOLOGY, V38, P879; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reeves HL, 2000, J HEPATOL, V32, P465, DOI 10.1016/S0168-8278(00)80398-0; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Schaefer B, 2003, AM J PATHOL, V162, P1771, DOI 10.1016/S0002-9440(10)64312-X; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Schulze-Krebs A, 2005, GASTROENTEROLOGY, V129, P246, DOI 10.1053/j.gastro.2005.03.089; Schuppan D, 2003, FALK SYMP, V132, P169; Shiffman ML, 1999, GASTROENTEROLOGY, V117, P1164, DOI 10.1016/S0016-5085(99)70402-6; Siller-Lopez F, 2004, GASTROENTEROLOGY, V126, P1122, DOI 10.1053/j.gastro.2003.12.045; Takahara T, 1997, HEPATOLOGY, V26, P1521; Varela-Rey M, 2002, FEBS LETT, V528, P133, DOI 10.1016/S0014-5793(02)03276-3; Watanabe T, 2000, J HEPATOL, V33, P224, DOI 10.1016/S0168-8278(00)80363-3; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437	53	83	86	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15090	15098		10.1074/jbc.M600030200	http://dx.doi.org/10.1074/jbc.M600030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16489207	hybrid			2022-12-25	WOS:000237922200011
J	Fraser, ME; Hayakawa, K; Hume, MS; Ryan, DG; Brownie, ER				Fraser, ME; Hayakawa, K; Hume, MS; Ryan, DG; Brownie, ER			Interactions of GTP with the ATP-grasp domain of GTP-specific Succinyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-LACTATE LIGASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; RIBONUCLEOTIDE SYNTHETASE; STRUCTURAL CLASSIFICATION; NUCLEOTIDE SPECIFICITY; GLUTATHIONE SYNTHETASE; VANCOMYCIN RESISTANCE; CONFORMATIONAL-CHANGE	Two isoforms of succinyl-CoA synthetase exist in mammals, one specific for ATP and the other for GTP. The GTP-specific form of pig succinyl-CoA synthetase has been crystallized in the presence of GTP and the structure determined to 2.1 angstrom resolution. GTP is bound in the ATP-grasp domain, where interactions of the guanine base with a glutamine residue (Gln-20 beta) and with backbone atoms provide the specificity. The gamma-phosphate interacts with the side chain of an arginine residue (Arg-54 beta) and with backbone amide nitrogen atoms, leading to tight interactions between the gamma-phosphate and the protein. This contrasts with the structures of ATP bound to other members of the family of ATP-grasp proteins where the gamma-phosphate is exposed, free to react with the other substrate. To test if GDP would interact with GTP-specific succinyl-CoA synthetase in the same way that ADP interacts with other members of the family of ATP-grasp proteins, the structure of GDP bound to GTP-specific succinyl-CoA synthetase was also determined. A comparison of the conformations of GTP and GDP shows that the bases adopt the same position but that changes in conformation of the ribose moieties and the alpha- and beta-phosphates allow the gamma-phosphate to interact with the arginine residue and amide nitrogen atoms in GTP, while the beta-phosphate interacts with these residues in GDP. The complex of GTP with succinyl-CoA synthetase shows that the enzyme is able to protect GTP from hydrolysis when the active-site histidine residue is not in position to be phosphorylated.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H1, Canada	University of Calgary; Western University (University of Western Ontario); University of Alberta	Fraser, ME (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	frasm@ucalgary.ca		Fraser, Marie/0000-0001-8501-1494	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Fraser ME, 2002, BIOCHEMISTRY-US, V41, P537, DOI 10.1021/bi011518y; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce MA, 1999, BIOCHEMISTRY-US, V38, P7273, DOI 10.1021/bi990527s; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; KAUFMAN S, 1955, J BIOL CHEM, V216, P141; KAUFMAN S, 1953, J BIOL CHEM, V203, P869; Kuzin AP, 2000, STRUCT FOLD DES, V8, P463, DOI 10.1016/S0969-2126(00)00129-5; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; Lambeth DO, 2004, J BIOL CHEM, V279, P36621, DOI 10.1074/jbc.M406884200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO GX, 1992, J BIOL CHEM, V267, P9516; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURAKAMI K, 1972, J BIOL CHEM, V247, P6247; MURAKAMI Y, 1974, BIOCHIM BIOPHYS ACTA, V336, P252, DOI 10.1016/0005-2795(74)90402-4; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Roper DI, 2000, P NATL ACAD SCI USA, V97, P8921, DOI 10.1073/pnas.150116497; Sakai H, 2003, J MOL BIOL, V332, P729, DOI 10.1016/S0022-2836(03)00946-X; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; SMITH CM, 1974, J BIOL CHEM, V249, P1497; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 2002, J BIOL CHEM, V277, P23898, DOI 10.1074/jbc.M202251200; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	56	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11058	11065		10.1074/jbc.M511785200	http://dx.doi.org/10.1074/jbc.M511785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481318	hybrid			2022-12-25	WOS:000236822200047
J	Richter, K; Moser, S; Hagn, F; Friedrich, R; Hainzl, O; Heller, M; Schlee, S; Kessler, H; Reinstein, J; Buchner, J				Richter, K; Moser, S; Hagn, F; Friedrich, R; Hainzl, O; Heller, M; Schlee, S; Kessler, H; Reinstein, J; Buchner, J			Intrinsic inhibition of the Hsp90 ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; HEAT-SHOCK PROTEINS; GYRASE-B-PROTEIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; CLIENT PROTEIN; IN-VIVO; CONFORMATIONAL-CHANGE; STEROID-RECEPTOR; STRUCTURAL BASIS	The molecular chaperone Hsp90 is required for the folding and activation of a large number of substrate proteins. These are involved in essential cellular processes ranging from signal transduction to viral replication. For the activation of its substrates, Hsp90 binds and hydrolyzes ATP, which is the key driving force for conformational conversions within the dimeric chaperone. Dimerization of Hsp90 is mediated by a C-terminal dimerization site. In addition, there is a transient ATP-induced dimerization of the two N-terminal ATP-binding domains. The resulting ring-like structure is thought to be the ATPase-active conformation. Hsp90 is a slow ATPase with a turnover number of 1 ATP/min for the yeast protein. A key question for understanding the molecular mechanism of Hsp90 is how ATP hydrolysis is regulated and linked to conformational changes. In this study, we analyzed the activation process structurally and biochemically with a view to identify the conformational limitations of the ATPase reaction cycle. We showed that the firs t24 amino acids stabilize the N-terminal domain in a rigid state. Their removal confers flexibility specifically to the region between amino acids 98 and 120. Most surprisingly, the deletion of this structure results in the complete loss of ATPase activity and in increased N-terminal dimerization. Complementation assays using heterodimeric Hsp90 show that this rigid lid acts as an intrinsic kinetic inhibitor of the Hsp90 ATPase cycle preventing N-terminal dimerization in the ground state. On the other hand, this structure acts, in concert with the 24 N-terminal amino acids of the other N-terminal domain, to form an activated ATPase and thus regulates the turnover number of Hsp90.	Tech Univ Munich, Inst Organ Chem & Biochem, Dept Chem, D-85747 Garching, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Hagn, Franz X/N-9553-2016; Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010; Kessler, Horst/C-1178-2010	Hagn, Franz X/0000-0002-1315-459X; Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Cole R, 2003, J BIOMOL NMR, V26, P203, DOI 10.1023/A:1023808801134; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Dehner A, 2003, CHEMBIOCHEM, V4, P870, DOI 10.1002/cbic.200300658; Dollins DE, 2005, J BIOL CHEM, V280, P30438, DOI 10.1074/jbc.M503761200; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GODDARD TD, 2000, SPARKY VERSION 3 110; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Huai Q, 2005, STRUCTURE, V13, P579, DOI 10.1016/j.str.2004.12.018; Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200; JAHNKE W, 1995, J MAGN RESON SER B, V106, P86, DOI 10.1006/jmrb.1995.1015; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Leutner M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Meyer P, 2004, EMBO J, V23, P511, DOI 10.1038/sj.emboj.7600060; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2004, J MOL BIOL, V342, P1403, DOI 10.1016/j.jmb.2004.07.064; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; RICHTER K, 2005, PROTEIN FOLDING HDB, P768; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Salek RM, 2002, J BIOMOL NMR, V23, P327, DOI 10.1023/A:1020268712347; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; Tsai FTF, 1997, PROTEINS, V28, P41; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	57	63	65	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11301	11311		10.1074/jbc.M510142200	http://dx.doi.org/10.1074/jbc.M510142200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16461354	hybrid			2022-12-25	WOS:000236822200073
J	Atteia, A; van Lis, R; Gelius-Dietrich, G; Adrait, A; Garin, J; Joyard, J; Rolland, N; Martin, W				Atteia, A; van Lis, R; Gelius-Dietrich, G; Adrait, A; Garin, J; Joyard, J; Rolland, N; Martin, W			Pyruvate formate-lyase and a novel route of eukaryotic ATP synthesis in Chlamydomonas mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATING ENZYME; RUMINAL BACTERIUM; PROTEIN; REINHARDTII; OXIDOREDUCTASE; DEHYDROGENASE; SEQUENCE; IDENTIFICATION; PURIFICATION	Pyruvate formate-lyase (PFL) catalyzes the non-oxidative conversion of pyruvate to formate and acetyl-CoA.PFL and its activating enzyme (PFL-AE) are common among strict anaerobic and microaerophilic prokaryotes but are very rare among eukaryotes. In a proteome survey of isolated Chlamydomonas reinhardtii mitochondria, we found several PFL-specific peptides leading to the identification of cDNAs for PFL and PFL-AE, establishing the existence of a PFL system in this photosynthetic algae. Anaerobiosis and darkness led to increased PFL transcripts but had little effect on protein levels, as determined with antiserum raised against C. reinhardtii PFL. Protein blots revealed the occurrence of PFL in both chloroplast and mitochondria purified from aerobically grown cells. Mass spectrometry sequencing of C. reinhardtii mitochondrial proteins, furthermore, identified peptides for phosphotransacetylase and acetate kinase. The phosphotransacetylase-acetate kinase pathway is a common route of ATP synthesis or acetate assimilation among prokaryotes but is novel among eukaryotes. In addition to PFL and pyruvate dehydrogenase, the algae also expresses pyruvate: ferredoxin oxidoreductase and bifunctional aldehyde/alcohol dehydrogenase. Among eukaryotes, the oxygen producer C. reinhardtii has the broadest repertoire of pyruvate-, ethanol-, and acetate-metabolizing enzymes described to date, many of which were previously viewed as specific to anaerobic eukaryotic lineages.	Univ Dusseldorf, Inst Bot, D-40225 Dusseldorf, Germany; CEA, INRA, UJF, Lab Physiol Cellulaire Vegetale,CNRS,UMR5168, F-38054 Grenoble, France; CEA, Lab Chim Prot, INSERM, ERM 0201, F-38054 Grenoble, France	Heinrich Heine University Dusseldorf; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Atteia, A (corresponding author), CEA Grenoble, INRA, UJF, Lab Physiol Vegetale,CNRS,UMR5168, 17 Rue Martyrs, F-38054 Grenoble, France.	aatteia@cea.fr	Martin, William F./O-5446-2015; ROLLAND, Norbert/B-4405-2012; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; ROLLAND, Norbert/0000-0003-1959-6636; Adrait, Annie/0000-0002-1565-2859				Akhmanova A, 1999, MOL MICROBIOL, V32, P1103, DOI 10.1046/j.1365-2958.1999.01434.x; Andersson SGE, 1999, CURR OPIN MICROBIOL, V2, P535, DOI 10.1016/S1369-5274(99)00013-2; Asanuma N, 1999, MICROBIOL-UK, V145, P151, DOI 10.1099/13500872-145-1-151; Asanuma N, 2004, ARCH MICROBIOL, V181, P122, DOI 10.1007/s00203-003-0638-0; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; Bollivar DW, 1996, PLANT PHYSIOL, V112, P105, DOI 10.1104/pp.112.1.105; Boxma B, 2005, NATURE, V434, P74, DOI 10.1038/nature03343; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; Dyall SD, 2004, NATURE, V431, P1103, DOI 10.1038/nature02990; ERIKSSON M, 1995, PLANT PHYSIOL, V107, P479, DOI 10.1104/pp.107.2.479; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; FRANZEN LG, 1992, PLANT MOL BIOL, V19, P771, DOI 10.1007/BF00027073; Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Heifetz PB, 2000, PLANT PHYSIOL, V122, P1439, DOI 10.1104/pp.122.4.1439; Himo F, 2005, BBA-BIOENERGETICS, V1707, P24, DOI 10.1016/j.bbabio.2004.04.006; Horner DS, 1999, MOL BIOL EVOL, V16, P1280, DOI 10.1093/oxfordjournals.molbev.a026218; Hrdy I, 2004, NATURE, V432, P618, DOI 10.1038/nature03149; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; KESSLER D, 1992, J BIOL CHEM, V267, P18073; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KREUZBERG K, 1984, PHYSIOL PLANTARUM, V61, P87, DOI 10.1111/j.1399-3054.1984.tb06105.x; KREUZBERG K, 1987, PHYSIOL PLANTARUM, V69, P481, DOI 10.1111/j.1399-3054.1987.tb09229.x; Lehtio L, 2004, PROTEIN ENG DES SEL, V17, P545, DOI 10.1093/protein/gzh059; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Melchiorsen CR, 2000, J BACTERIOL, V182, P4783, DOI 10.1128/JB.182.17.4783-4788.2000; Muller M., 2003, MOL MED PARASITOLOGY, P125, DOI DOI 10.1016/B978-012473346-6/50008-9; PECHER A, 1982, ARCH MICROBIOL, V132, P365, DOI 10.1007/BF00413390; Raynaud C, 2003, P NATL ACAD SCI USA, V100, P5010, DOI 10.1073/pnas.0734105100; RODEL W, 1988, EUR J BIOCHEM, V177, P153, DOI 10.1111/j.1432-1033.1988.tb14356.x; Rotte C, 2001, MOL BIOL EVOL, V18, P710, DOI 10.1093/oxfordjournals.molbev.a003853; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAWERS G, 1988, J BACTERIOL, V170, P5330, DOI 10.1128/jb.170.11.5330-5336.1988; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Zhang WH, 2001, BIOCHEMISTRY-US, V40, P4123, DOI 10.1021/bi002589k	48	96	131	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9909	9918		10.1074/jbc.M507862200	http://dx.doi.org/10.1074/jbc.M507862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16452484	Green Published, hybrid			2022-12-25	WOS:000236594300012
J	Nemoto, S; Combs, CA; French, S; Ahn, BH; Fergusson, MM; Balaban, RS; Finkel, T				Nemoto, S; Combs, CA; French, S; Ahn, BH; Fergusson, MM; Balaban, RS; Finkel, T			The mammalian longevity-associated gene product p66(shc) regulates mitochondrial metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FLUORESCENCE RECOVERY; SYSTEMATIC RNAI SCREEN; PHOTOBLEACHING ED-FRAP; LIFE-SPAN; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; C-ELEGANS; SIGNALING PATHWAY; IN-VITRO; APOPTOSIS	Previous studies have determined that mice with a homozygous deletion in the adapter protein p66(shc) have an extended life span and that cells derived from these mice exhibit lower levels of reactive oxygen species. Here we demonstrate that a fraction of p66(shc) localizes to the mitochondria and that p66(shc-/-) fibroblasts have altered mitochondrial energetics. In particular, despite similar cytochrome content, under basal conditions, the oxygen consumption of spontaneously immortalized p66(shc-/-) mouse embryonic fibroblasts were lower than similarly maintained wild type cells. Differences in oxygen consumption were particularly evident under chemically uncoupled conditions, demonstrating that p66(shc-/-) cells have a reduction in both their resting and maximal oxidative capacity. We further demonstrate that reconstitution of p66(shc) expression in p66(shc-/-) cells increases oxygen consumption. The observed defect in oxidative capacity seen in p66(shc-/-) cells is partially offset by augmented levels of aerobic glycolysis. This metabolic switch is manifested by p66(shc-/-) cells exhibiting an increase in lactate production and a stricter requirement for extracellular glucose in order to maintain intracellular ATP levels. In addition, using an in vivo NADH photobleaching technique, we demonstrate that mitochondrial NADH metabolism is reduced in p66(shc-/-) cells. These results demonstrate that p66(shc) regulates mitochondrial oxidative capacity and suggest that p66(shc) may extend life span by repartitioning metabolic energy conversion away from oxidative and toward glycolytic pathways.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Light Microscopy Facil, Bethesda, MD 20892 USA; NHLBI, Cardiac Energet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@nih.gov	Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005012, ZIAHL004601, Z01HL004601, Z01HL005012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Combs CA, 2004, METHOD ENZYMOL, V385, P257; Combs CA, 2001, BIOPHYS J, V80, P2018, DOI 10.1016/S0006-3495(01)76172-3; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Francia P, 2004, CIRCULATION, V110, P2889, DOI 10.1161/01.CIR.0000147731.24444.4D; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Johnson TE, 2001, EXP GERONTOL, V36, P1609, DOI 10.1016/S0531-5565(01)00144-9; Joubert F, 2004, BIOPHYS J, V86, P629, DOI 10.1016/S0006-3495(04)74141-7; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rea S, 2003, DEV CELL, V5, P197, DOI 10.1016/S1534-5807(03)00242-9; SARIBANSOHRABY S, 1983, CANCER RES, V43, P4662; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751	27	120	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10555	10560		10.1074/jbc.M511626200	http://dx.doi.org/10.1074/jbc.M511626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481327	hybrid			2022-12-25	WOS:000236594300086
J	Han, GS; Wu, WI; Carman, GM				Han, GS; Wu, WI; Carman, GM			The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PROTEIN-KINASE-C; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL-TRANSDUCTION; GENETIC-REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS; 104-KDA FORMS; YEAST	Mg2+-dependent phosphatidate (PA) phosphatase (3-sn-phosphatidate phosphohydrolase, EC3.1.3.4) catalyzes the dephosphorylation of PA to yield diacylglycerol and Pi. In this work, we identified the Saccharomyces cerevisiae PAH1 (previously known as SMP2) gene that encodes Mg2+-dependent PA phosphatase using amino acid sequence information derived from a purified preparation of the enzyme (Lin, Y.-P., and Carman, G. M. (1989) J. Biol. Chem. 264, 8641-8645). Overexpression of PAH1 in S. cerevisiae directed elevated levels of Mg2+-dependent PA phosphatase activity, whereas the pah1 Delta mutation caused reduced levels of enzyme activity. Heterologous expression of PAH1 in Escherichia coli confirmed that Pah1p is a Mg2+-dependent PA phosphatase enzyme and showed that its enzymological properties were very similar to those of the enzyme purified from S. cerevisiae. The PAH1-encoded enzyme activity was associated with both the membrane and cytosolic fractions of the cell, and the membrane-bound form of the enzyme was salt-extractable. Lipid analysis showed that mutants lacking PAH1 accumulated PA and had reduced amounts of diacyl-glycerol and its derivative triacylglycerol. The PAH1-encoded Mg2+-dependent PA phosphatase shows homology to mammalian lipin, a fat-regulating protein whose molecular function is unknown. Heterologous expression of human LPIN1 in E. coli showed that lipin 1 is also a Mg2+-dependent PA phosphatase enzyme.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28140, R37 GM028140, R01 GM028140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BEGGS JD, 1981, GENETIC ENG, P175; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DONAHUE TF, 1981, GENETICS, V98, P491; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P102; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; IRIE K, 1993, MOL GEN GENET, V236, P283, DOI 10.1007/BF00277124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Madera M, 2004, NUCLEIC ACIDS RES, V32, pD235, DOI 10.1093/nar/gkh117; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Oshiro J, 2003, BBA-MOL CELL BIOL L, V1635, P1, DOI 10.1016/j.bbalip.2003.10.002; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2005, DRUG NEWS PERSPECT, V18, P5, DOI 10.1358/dnp.2005.18.1.877165; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; PHAN J, 2005, OBSTET GYNECOL SURV, V60, P652; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SMITH SW, 1957, J BIOL CHEM, V228, P915; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Stukey J, 1997, PROTEIN SCI, V6, P469; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f	80	396	424	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9210	9218		10.1074/jbc.M600425200	http://dx.doi.org/10.1074/jbc.M600425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467296	Green Accepted, hybrid			2022-12-25	WOS:000236404700028
J	Morris, KE; Schang, LM; Brindley, DN				Morris, KE; Schang, LM; Brindley, DN			Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; GROWTH ARREST; CANCER-CELLS; IN-VIVO; ACID; CERAMIDE; PROTEIN; ACTIVATION; INHIBITION; SENESCENCE	Lipid phosphates are potent mediators of cell signaling and control processes including development, cell migration and division, blood vessel formation, wound repair, and tumor progression. Lipid phosphate phosphatases (LPPs) regulate the dephosphorylation of lipid phosphates, thus modulating their signals and producing new bioactive compounds both at the cell surface and in intracellular compartments. Knock-down of endogenous LPP2 in fibroblasts delayed cyclin A accumulation and entry into S-phase of the cell cycle. Conversely, overexpression of LPP2, but not a catalytically inactive mutant, caused premature S-phase entry, accompanied by premature cyclin A accumulation. At high passage, many LPP2 overexpressing cells arrested in G(2)/M and the rate of proliferation declined severely. This was accompanied by changes in proteins and lipids characteristic of senescence. Additionally, arrested LPP2 cells contained decreased lysophosphatidate concentrations and increased ceramide. These effects of LPP2 activity were not reproduced by overexpression or knock-down of LPP1 or LPP3. This work identifies a novel and specific role for LPP2 activity and bioactive lipids in regulating cell cycle progression.	Univ Alberta, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Schang, Luis/F-9576-2012	Schang, Luis Maria/0000-0002-5789-8590				Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Burnett Camilla, 2004, BMC Biochemistry, V5, P2, DOI 10.1186/1471-2091-5-2; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gomez-Munoz A, 2004, J LIPID RES, V45, P99, DOI 10.1194/jlr.M300158-JLR200; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Jaiswal AS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-3; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Long J, 2005, BIOCHEM J, V391, P25, DOI 10.1042/BJ20050342; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Renault AD, 2004, SCIENCE, V305, P1963, DOI 10.1126/science.1102421; Roberts RZ, 2000, BBA-MOL CELL BIOL L, V1487, P33, DOI 10.1016/S1388-1981(00)00081-0; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Song MS, 2003, NEUROPHARMACOLOGY, V45, P1130, DOI 10.1016/S0028-3908(03)00284-3; SULLARDS MC, 2001, SCI STKE, V67, P1; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Tanyi JL, 2003, CANCER RES, V63, P1073; Theocharis S, 2004, CANCER TREAT REV, V30, P545, DOI 10.1016/j.ctrv.2004.04.004; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG J, 1992, ONCOGENE, V7, P1653; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yue JM, 2004, CELL SIGNAL, V16, P385, DOI 10.1016/j.cellsig.2003.08.012; Zhang N, 2002, GENESIS, V33, P21, DOI 10.1002/gene.10081; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181; ZHAO Y, 1999, MOL BIOL CELL, V12, P3601; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160	55	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9297	9306		10.1074/jbc.M511710200	http://dx.doi.org/10.1074/jbc.M511710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467304	hybrid			2022-12-25	WOS:000236404700037
J	Wang, XY; McGrath, SC; Cotter, RJ; Raetz, CRH				Wang, XY; McGrath, SC; Cotter, RJ; Raetz, CRH			Expression cloning and periplasmic orientation of the Francisella novicida lipid A4 '-phosphatase LpxF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MSBB GENE; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; TULARENSIS LIPOPOLYSACCHARIDE; MULTICOPY SUPPRESSOR; RESISTANT MUTANTS; NMR-SPECTROSCOPY; A BIOSYNTHESIS	Francisella tularensis and related intracellular pathogens synthesize lipid A molecules that differ from their Escherichia coli counterparts. Although a functional orthologue of lpxK, the gene encoding the lipid A 4'-kinase, is present in Francisella, no 4'-phosphate moiety is attached to Francisella lipid A. We now demonstrate that a membrane-bound phosphatase present in Francisella novicida U112 selectively removes the 4'-phosphate residue from tetra- and pentaacylated lipid A molecules. A clone that expresses the F. novicida 4'-phosphatase was identified by assaying lysates of E. coli colonies, harboring members of an F. novicida genomic DNA library, for 4'-phosphatase activity. Sequencing of a 2.5-kb F. novicida DNA insert from an active clone located the structural gene for the 4'-phosphatase, designated lpxF. It encodes a protein of 222 amino acid residues with six predicted membrane-spanning segments. Rhizobium leguminosarum and Rhizobium etli contain functional lpxF orthologues, consistent with their lipid A structures. When F. novicida LpxF is expressed in an E. coli LpxM mutant, a strain that synthesizes pentaacylated lipid A, over 90% of the lipid A molecules are dephosphorylated at the 4'-position. Expression of LpxF in wildtype E. coli has no effect, because wild-type hexaacylated lipid A is not a substrate. However, newly synthesized lipid A is not dephosphorylated in LpxM mutants by LpxF when the MsbA flippase is inactivated, indicating that LpxF faces the outer surface of the inner membrane. The availability of the lpxF gene will facilitate re-engineering lipid A structures in diverse bacteria.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796-10, R37 GM051796, GM-54882, R37-GM-51796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ancuta P, 1996, INFECT IMMUN, V64, P2041, DOI 10.1128/IAI.64.6.2041-2046.1996; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Clementz T, 1997, J BIOL CHEM, V272, P10353; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Ellis J, 2002, CLIN MICROBIOL REV, V15, P631, DOI 10.1128/CMR.15.4.631-646.2002; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ishikawa K, 2000, EMBO J, V19, P2412, DOI 10.1093/emboj/19.11.2412; Ismaili J, 2002, J IMMUNOL, V168, P926, DOI 10.4049/jimmunol.168.2.926; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Kieffer TL, 2003, MICROBES INFECT, V5, P397, DOI 10.1016/S1286-4579(03)00052-2; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Larsson P, 2005, NAT GENET, V37, P153, DOI 10.1038/ng1499; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; McDonald MK, 1997, J BACTERIOL, V179, P7638, DOI 10.1128/jb.179.24.7638-7643.1997; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Nano FE, 2004, J BACTERIOL, V186, P6430, DOI 10.1128/JB.186.19.6430-6436.2004; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Phillips NJ, 2004, INFECT IMMUN, V72, P5340, DOI 10.1128/IAI.72.9.5340-5348.2004; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2004, J BIOL CHEM, V279, P25420, DOI 10.1074/jbc.M400598200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J, 2001, MOL CLONING LAB MANU; SANDSTROM G, 1992, FEMS MICROBIOL IMMUN, V105, P201, DOI 10.1111/j.1574-6968.1992.tb05902.x; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; Sjostedt A, 2003, CURR OPIN MICROBIOL, V6, P66, DOI 10.1016/S1369-5274(03)00002-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	70	74	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9321	9330		10.1074/jbc.M600435200	http://dx.doi.org/10.1074/jbc.M600435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467300	Green Accepted, hybrid			2022-12-25	WOS:000236404700040
J	Oh, J; Diaz, T; Wei, B; Chang, H; Noda, M; Stetler-Stevenson, WG				Oh, J.; Diaz, T.; Wei, B.; Chang, H.; Noda, M.; Stetler-Stevenson, W. G.			TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118	ONCOGENE			English	Article						TIMP-2; RECK; Rac1; paxillin; Src	CYSTEINE-RICH PROTEIN; FOCAL ADHESION KINASE; CELL LUNG-CANCER; NBT-II CELLS; TYROSINE PHOSPHORYLATION; CLINICAL-SIGNIFICANCE; TISSUE INHIBITORS; SIGNALING COMPLEX; KAZAL MOTIFS; SRC	We previously demonstrated that TIMP-2 increases the association of Crk with C3G and via subsequent activation of Rap1 enhances the expression of RECK, a membrane-anchored MMP inhibitor. In the present study, we investigate the mechanism of how the TIMP-2 signal is transduced from the alpha 3 beta 1 integrin receptor to the Crk-C3G-Rap1 molecular complex. TIMP-2 treatment of human microvascular endothelial cells (hMVECs) increased the phosphorylation levels of Src at Tyr-527, the negative regulatory site, through enhanced association of Src with Csk. This results in the reduction of Src kinase activity and dephosphorylation of paxillin at Tyr-31/118, the target sites for Src kinase phosphorylation and also the binding sites for the downstream effector Crk. Such TIMP-2 effects accompany the disassembly of paxillin-Crk-DOCK180 molecular complex and, in turn, Rac1 inactivation. On the contrary, levels of paxillin-Crk-C3G complex formation are not reduced, rather slightly increased, which is consistent with our previous finding. Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression.	Korea Univ, Cellular Oncol Lab, Grad Sch Med, Ansan 425707, Gyeonggi Do, South Korea; NCI, Ctr Canc Res, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Kyoto, Japan	Korea University; Korea University Medicine (KU Medicine); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University	Oh, J (corresponding author), Korea Univ, Cellular Oncol Lab, Grad Sch Med, Gojan 1 Dong, Ansan 425707, Gyeonggi Do, South Korea.	ohjs@korea.ac.kr	Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William/0000-0002-5500-5808; Oh, Junseo/0000-0002-0754-4946	Intramural NIH HHS [Z01 SC009179] Funding Source: Medline; NCI NIH HHS [Z01 SC009179-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009179] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn SM, 2004, CANCER LETT, V207, P49, DOI 10.1016/j.canlet.2003.11.025; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Masui T, 2003, CLIN CANCER RES, V9, P1779; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Perez-Martinez L, 2005, J NEUROSCI, V25, P4917, DOI 10.1523/JNEUROSCI.5066-04.2005; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takenaka K, 2005, ANN SURG ONCOL, V12, P817, DOI 10.1245/ASO.2005.09.018; Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; VANDERJAGT MF, 2005, IN PRESS CANC LETT; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	35	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4230	4234		10.1038/sj.onc.1209444	http://dx.doi.org/10.1038/sj.onc.1209444			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491114	Green Accepted, Green Submitted			2022-12-25	WOS:000239004800010
J	Simbulan-Rosenthal, CM; Daher, A; Trabosh, V; Chen, WC; Gerstel, D; Soeda, E; Rosenthal, DS				Simbulan-Rosenthal, C. M.; Daher, A.; Trabosh, V.; Chen, W-C; Gerstel, D.; Soeda, E.; Rosenthal, D. S.			Id3 induces a caspase-3- and -9-dependent apoptosis and mediates UVB sensitization of HPV16 E6/7 immortalized human keratinocytes	ONCOGENE			English	Article						Id proteins; apoptosis; immortalization; caspases	LOOP-HELIX PROTEINS; SOLAR KERATOSES; ULTRAVIOLET-B; CELL-GROWTH; PROTEASE; BAX; IDENTIFICATION; TRANSCRIPTION; DIMERIZATION; EXPRESSION	Inhibitor of differentiation/DNA binding ( Id) proteins comprise a class of helix-loop-helix transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. We have shown that while Id2 is induced by UVB in primary keratinocytes, Id3 is upregulated only in immortalized cells. We have now determined that the consequences of ectopic expression of Id3 protein are strikingly different between immortalized and primary keratinocytes. Overexpression of Id3 induces a significant increase in apoptotic cells as revealed by Annexin V positivity as well as proteolytic processing of caspase-3 in immortalized, but not in primary keratinocytes. Id3-green fluorescent protein ( GFP)-positive cells exhibited a fivefold increase in apoptotic nuclear fragmentation compared to Id3-GFP-negative cells. These apoptotic responses were accompanied by activation of caspase-3, as shown by immunocytochemical staining with antibodies to active caspase-3. Immunostaining with antibodies to the active form of caspase-9 as well as to the active form of Bax further revealed that induction of apoptosis in Id3-overexpressing keratinocytes occurred via a mitochondrial-caspase-9-mediated pathway. Coexpression of dominant-negative caspase-9 with Id3 significantly suppressed apoptotic nuclear fragmentation, indicating that caspase-9 activation is essential for Id3-induced cell death. This response was also markedly attenuated by coexpression with the Bax antagonist antiapoptotic protein Bcl-2, confirming a role for Bax activation in this apoptotic response. Id3-induced Bax activation may result from increased expression of Bax protein. Furthermore, reduction of Id3 expression by small interfering RNAs abrogated the UVB-induced proteolytic activation of caspase- 3 in these cells. These data together suggest that UVB-induced apoptosis of immortalized keratinocytes is at least in part due to Id3 upregulation in these cells.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Room 307,3900 Reservoir Rd WV, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Daher, Ahmad/AAL-4605-2020	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NCI NIH HHS [R01 CA100443-05, R01 CA100443, 1R01 CA100443-01A1, R01 CA100443-01A1, R01 CA100443-03, R01 CA100443-02, R01 CA100443-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Backvall H, 2005, MUTAT RES-FUND MOL M, V571, P65, DOI 10.1016/j.mrfmmm.2004.10.011; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Daher A, 2006, EXP DERMATOL, V15, P23, DOI 10.1111/j.0906-6705.2005.00384.x; Decraene D, 2004, J INVEST DERMATOL, V123, P207, DOI 10.1111/j.0022-202X.2004.22702.x; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Frost C, 2000, J INVEST DERMATOL, V115, P273, DOI 10.1046/j.1523-1747.2000.00048.x; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534; Heisler GM, 2004, PHOTOCHEM PHOTOBIOL, V80, P422, DOI 10.1562/0031-8655(2004)080&lt;0422:SURIUE&gt;2.0.CO;2; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Koyama T, 2004, ANTICANCER RES, V24, P1519; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1995, CELL, V80, P293; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takehara T, 2003, CANCER RES, V63, P3054; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje	40	21	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3649	3660		10.1038/sj.onc.1209407	http://dx.doi.org/10.1038/sj.onc.1209407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449966				2022-12-25	WOS:000238448300004
J	Fang, Y; Liu, T; Wang, X; Yang, YM; Deng, H; Kunicki, J; Traganos, F; Darzynkiewicz, Z; Lu, L; Dai, W				Fang, Y.; Liu, T.; Wang, X.; Yang, Y-M; Deng, H.; Kunicki, J.; Traganos, F.; Darzynkiewicz, Z.; Lu, L.; Dai, W.			BubR1 is involved in regulation of DNA damage responses	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE-1; SPINDLE CHECKPOINT; HUMAN CANCERS; APOPTOSIS; P53; ANEUPLOIDY; MUTATIONS; ARREST	Defective mitotic spindles or an impaired spindle-kinetochore interaction activates the spindle checkpoint. We have previously shown that BubR1 haplo-insufficiency results in enhanced genomic instability and tumorigenesis in mice. Here we report that BubR1 deficiency also leads to a compromised response to DNA damage. Following treatment with doxorubicin, BubR1(+/-) murine fibroblast cells (MEF) were defective in undergoing G(2)/M arrest. Thus, whereas in the presence of DNA damage BubR1(+/+) MEF cells remained arrested in mitosis, BubR1(+/-) MEFs rapidly exited from mitosis and divided. The impaired mitotic arrest of BubR1(+/-) MEFs was associated with low levels of phospho-histone H2AX, p53, and p21 after DNA damage caused by treatment with both doxorubicin and ultraviolet light (UV). The impaired expression of p53 and p21 was also confirmed in human cell lines with BubR1 knockdown via RNA interference. Affinity pull-down coupled with mass spectrometry identified Poly(ADPribose) polymerase 1 (PARP-1) as one of the proteins interacting with BubR1. Reciprocal co-immunoprecipitation analysis confirmed the physical interaction between BubR1 and PARP-1. Our further study revealed that the ability of retaining intact PARP-1 or its cleavage product p89 was compromised in BubR1(+/-) MEFs upon treatment with doxorubicin or UV. Given that PARP-1 mediates DNA damage responses and regulates the activity of p53, our studies suggest that there exists a cross-talk between the spindle checkpoint and the DNA damage checkpoint and that BubR1 may play an important role in mediating the cross-talk.	New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; Rockefeller Univ, Proteom Core Facil, New York, NY 10021 USA; New York Med Coll, Brander Canc Inst, Valhalla, NY 10595 USA; Univ Calif Los Angeles, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA	New York Medical College; Rockefeller University; New York Medical College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Basic Sci Bldg,A22, Valhalla, NY 10595 USA.	wei_dai@nymc.edu	Traganos, Frank/B-8021-2012	Dai, Wei/0000-0003-0169-8327; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA028704, R01CA090658] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704-27, R01-CA90658, R01 CA028704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Hamid T, 2003, HISTOL HISTOPATHOL, V18, P245, DOI 10.14670/HH-18.245; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pirrotta V, 2004, CELL, V119, P735, DOI 10.1016/j.cell.2004.12.002; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Saxena A, 2002, J BIOL CHEM, V277, P26921, DOI 10.1074/jbc.M200620200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	31	58	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3598	3605		10.1038/sj.onc.1209392	http://dx.doi.org/10.1038/sj.onc.1209392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449973				2022-12-25	WOS:000238448200012
J	Veeck, J; Niederacher, D; An, H; Klopocki, E; Wiesmann, F; Betz, B; Galm, O; Camara, O; Durst, M; Kristiansen, G; Huszka, C; Knuchel, R; Dahl, E				Veeck, J.; Niederacher, D.; An, H.; Klopocki, E.; Wiesmann, F.; Betz, B.; Galm, O.; Camara, O.; Duerst, M.; Kristiansen, G.; Huszka, C.; Knuechel, R.; Dahl, E.			Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis	ONCOGENE			English	Article						breast cancer; tumour suppressor gene; Wnt pathway; SFRP1; methylation; epigenetics	TUMOR-SUPPRESSOR; BETA-CATENIN; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BLADDER-CANCER; OVARIAN-CANCER; COMMON EVENT; CYCLIN D1; GENE	The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P < 0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.	Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-4000 Dusseldorf, Germany; Free Univ Berlin, Inst Med Genet, Berlin, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Med Clin 4, D-52074 Aachen, Germany; Univ Jena, Dept Gynecol, D-6900 Jena, Germany; Free Univ Berlin, Inst Pathol, Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine University Dusseldorf; Free University of Berlin; RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin	Dahl, E (corresponding author), Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Klopocki, Eva/B-6823-2017; Veeck, Jürgen/B-9256-2008	Klopocki, Eva/0000-0003-1438-2081; Veeck, Jürgen/0000-0002-2952-6159; An, Han-Xiang/0000-0002-3453-9149				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J NATL CANCER I, V94, P26; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klopocki E, 2004, INT J ONCOL, V25, P641; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Polakis P, 2000, GENE DEV, V14, P1837; REMMELE W, 1987, PATHOLOGE, V8, P138; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447	40	203	217	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3479	3488		10.1038/sj.onc.1209386	http://dx.doi.org/10.1038/sj.onc.1209386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449975				2022-12-25	WOS:000238448100013
J	Doane, AS; Danso, M; Lal, P; Donaton, M; Zhang, L; Hudis, C; Gerald, WL				Doane, A. S.; Danso, M.; Lal, P.; Donaton, M.; Zhang, L.; Hudis, C.; Gerald, W. L.			An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen	ONCOGENE			English	Article						breast cancer; estrogen receptor-negative; androgen responsive; gene expression	POSTMENOPAUSAL WOMEN; PROGESTERONE-RECEPTORS; CELL-PROLIFERATION; CYCLIN D1; EXPRESSION; THERAPY; GROWTH; GENES; MICROARRAY; CARCINOMA	Little is known of the underlying biology of estrogen receptor-negative, progesterone receptor-negative (ER(-)/PR(-)) breast cancer (BC), and few targeted therapies are available. Clinical heterogeneity of ER(-)/ PR(-) tumors suggests that molecular subsets exist. We performed genome-wide expression analysis of 99 primary BC samples and eight BC cell lines in an effort to reveal distinct subsets, provide insight into their biology and potentially identify new therapeutic targets. We identified a subset of ER(-)/PR(-) tumors with paradoxical expression of genes known to be either direct targets of ER, responsive to estrogen, or typically expressed in ER(+) BC. Differentially expressed genes included SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR (P < 0.001). A classification model based on the expression signature of this tumor class identified molecularly similar BCs in an independent human BC data set and among BC cell lines (MDA-MB453). This cell line demonstrated a proliferative response to androgen in an androgen receptor-dependent and ER-independent manner. In addition, the androgen-induced transcriptional program of MDA-MB-453 significantly overlapped the molecular signature of the unique ER(-)/PR(-) subclass of human tumors. This subset of BCs, characterized by a hormonally regulated transcriptional program and response to androgen, suggests the potential for therapeutic strategies targeting the androgen signaling pathway.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gerald, WL (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.	geraldw@mskcc.org	Doane, Ashley/R-4263-2016; Doane, Ashley Stephen/A-6442-2015; Hudis, Clifford/AAW-9482-2021; Doane, Ashley Stephen/B-7027-2008	Doane, Ashley/0000-0002-1489-1786; Doane, Ashley Stephen/0000-0002-1489-1786; Hudis, Clifford/0000-0001-7144-8791; Doane, Ashley Stephen/0000-0002-1489-1786				Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Buchanan G, 2005, CANCER RES, V65, P8487, DOI 10.1158/0008-5472.CAN-04-3077; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Cunliffe HE, 2003, CANCER RES, V63, P7158; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; DeRisi J, 1996, NAT GENET, V14, P457; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gatalica Z, 1997, PATHOL RES PRACT, V193, P753, DOI 10.1016/S0344-0338(97)80053-2; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Greeve MA, 2004, J MOL ENDOCRINOL, V32, P793, DOI 10.1677/jme.0.0320793; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Gruvberger S, 2001, CANCER RES, V61, P5979; Hall RE, 1996, BRIT J CANCER, V74, P1175, DOI 10.1038/bjc.1996.513; HALL RE, 1994, EUR J CANCER, V30A, P484, DOI 10.1016/0959-8049(94)90424-3; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9; LIPPMAN M, 1976, CANCER RES, V36, P4610; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Matsuo Kaneyuki, 2002, Breast Cancer, V9, P43, DOI 10.1007/BF02967546; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; MILLER WR, 1985, BREAST CANCER RES TR, V5, P67, DOI 10.1007/BF01807652; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Nagahata T, 2004, CANCER SCI, V95, P218, DOI 10.1111/j.1349-7006.2004.tb02206.x; Nantermet PV, 2005, ENDOCRINOLOGY, V146, P564, DOI 10.1210/en.2004-1132; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pusztai L, 2003, CLIN CANCER RES, V9, P2406; Rossi S, 2003, MOL CANCER RES, V1, P707; Sapp Michelle, 2003, Breast J, V9, P335, DOI 10.1046/j.1524-4741.2003.09422.x; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Steketee K, 2004, J MOL ENDOCRINOL, V33, P477, DOI 10.1677/jme.1.01478; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Tobias JS, 2004, ANN ONCOL, V15, P1738, DOI 10.1093/annonc/mdh485; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wilson CA, 2004, BREAST CANCER RES, V6, P192, DOI 10.1186/bcr917; Wong YC, 2001, MARC MALPIG SYMP SER, V7, P111; Yakes FM, 2002, CANCER RES, V62, P4132	60	417	441	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3994	4008		10.1038/sj.onc.1209415	http://dx.doi.org/10.1038/sj.onc.1209415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16491124	Bronze			2022-12-25	WOS:000238668800013
J	Hakansson-McReynolds, S; Jiang, SK; Rong, LJ; Caffrey, M				Hakansson-McReynolds, S; Jiang, SK; Rong, LJ; Caffrey, M			Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURE DETERMINATION; SIMIAN IMMUNODEFICIENCY VIRUS; SARS-ASSOCIATED CORONAVIRUS; PROTEIN FUSION CORE; 44 KDA ECTODOMAIN; MEMBRANE-FUSION; SPIKE PROTEIN; CRYSTAL-STRUCTURE; INFLUENZA HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN	The envelope glycoprotein, termed the spike protein, of severe acute respiratory syndrome coronavirus (SARS-CoV) is known to mediate viral entry. Similar to other class 1 viral fusion proteins, the heptad repeat regions of SARS-CoV spike are thought to undergo conformational changes from a prefusion form to a subsequent post-fusion form that enables fusion of the viral and host membranes. Recently, the structure of a post-fusion form of SARS-CoV spike, which consists of isolated domains of heptad repeats 1 and 2 (HR1 and HR2), has been determined by x-ray crystallography. To date there is no structural information for the prefusion conformations of SARS-CoV HR1 and HR2. In this work we present the NMR structure of the HR2 domain ( residues 1141 - 1193) from SARS-CoV ( termed S2-HR2) in the presence of the co-solvent trifluoroethanol. We find that in the absence of HR1, S2-HR2 forms a coiled coil symmetric trimer with a complex molecular mass of 18 kDa. The S2-HR2 structure, which is the first example of the prefusion form of coronavirus envelope, supports the current model of viral membrane fusion and gives insight into the design of structure-based antagonists of SARS.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Caffrey, M (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.	caffrey@uic.edu						BAX A, 1994, METHOD ENZYMOL, V239, P79; Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 2001, BBA-MOL BASIS DIS, V1536, P116, DOI 10.1016/S0925-4439(01)00042-4; Caffrey M, 1997, J MOL BIOL, V271, P819, DOI 10.1006/jmbi.1997.1217; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOUGHERTY WG, 1989, VIROLOGY, V172, P302, DOI 10.1016/0042-6822(89)90132-3; Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008; Huth JR, 1997, PROTEIN SCI, V6, P2359; Hwang TL, 1998, J BIOMOL NMR, V11, P221, DOI 10.1023/A:1008276004875; Jiang SK, 2002, J BIOMOL NMR, V24, P365, DOI 10.1023/A:1021641814058; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Lamb RA, 2006, VIROLOGY, V344, P30, DOI 10.1016/j.virol.2005.09.007; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lindhout DA, 2004, BIOPOLYMERS, V75, P367, DOI 10.1002/bip.20150; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Stuart AC, 1999, J AM CHEM SOC, V121, P5346, DOI 10.1021/ja984172w; Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wishart DS, 2001, METHOD ENZYMOL, V338, P3; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322; Yin HS, 2005, P NATL ACAD SCI USA, V102, P9288, DOI 10.1073/pnas.0503989102; Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141	64	39	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11965	11971		10.1074/jbc.M601174200	http://dx.doi.org/10.1074/jbc.M601174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507566	hybrid, Green Published			2022-12-25	WOS:000236988100066
J	Yao, ZQ; Li, P; Zhang, Q; Schwarz, EM; Keng, P; Arbini, A; Boyce, BF; Xing, LP				Yao, ZQ; Li, P; Zhang, Q; Schwarz, EM; Keng, P; Arbini, A; Boyce, BF; Xing, LP			Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; IN-VIVO; RHEUMATOID-ARTHRITIS; RECEPTOR-ACTIVATOR; JOINT DESTRUCTION; TRANSGENIC MICE; PROGENITOR; CELLS; LIGAND; TRANSCRIPTION	Osteoclasts are essential cells for bone erosion in inflammatory arthritis and are derived from cells in the myeloid lineage. Recently, we reported that tumor necrosis factor-alpha (TNF alpha) increases the blood osteoclast precursor (OCP) numbers in arthritic patients and animals, which are reduced by anti-TNF therapy, implying that circulating OCPs may have an important role in the pathogenesis of erosive arthritis. The aim of this study is to investigate the mechanism by which TNF alpha induces this increase in OCP frequency. We found that TNF alpha stimulated cell division and conversion of CD11b(+)/Gr-1(-/lo)/c-Fms(-) to CD11b(+)/Gr-1(-/lo)/c-Fms(-) cells, which was not blocked by neutralizing macrophage colony-stimulating factor (M-CSF) antibody. Ex vivo analysis of monocytes demonstrated the following: (i) blood CD11b(+)/Gr-1(-/lo) but not CD11b(-)/Gr-1(-) cells give rise to osteoclasts when they were cultured with receptor activator NF-kappa B ligand and M-CSF; and (ii) TNF-transgenic mice have a significant increase in blood CD11b(+)/Gr-1(-/lo) cells and bone marrow proliferating CD11b(+)/Gr-1(-/lo) cells. Administration of TNF alpha to wild type mice induced bone marrow CD11b(+)/Gr-1(-/lo) cell proliferation, which was associated with an increase in CD11b(+)/Gr-1(-/lo) OCPs in the circulation. Thus, TNF alpha directly stimulates bone marrow OCP genesis by enhancing c-Fms expression. This results in progenitor cell proliferation and differentiation in response to M-CSF, leading to an enlargement of the marrow OCP pool. Increased marrow OCPs subsequently egress to the circulation, forming a basis for elevated OCP frequency. Therefore, the first step of TNF-induced osteoclastogenesis is at the level of OCP genesis in the bone marrow, which represents another layer of regulation to control erosive disease.	Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Orthoped, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Canc Res Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Xing, LP (corresponding author), Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Lianping_xing@urmc.rochester.edu		Arbini, Arnaldo/0000-0003-0345-4174	NIAMS NIH HHS [AR43510, AR48697] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048697, R01AR043510] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alford PB, 1997, BIOCHEM BIOPH RES CO, V240, P442, DOI 10.1006/bbrc.1997.7670; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Fan X, 1997, J BONE MINER RES, V12, P1387, DOI 10.1359/jbmr.1997.12.9.1387; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223-002-1049-y; Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Huang W, 2003, ARTHRITIS RES THER, V5, pR49, DOI 10.1186/ar612; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kaplan DL, 1996, J CELL PHYSIOL, V168, P199; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lam J, 2002, ANN RHEUM DIS, V61, P82; Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Xing LP, 2005, CURR RHEUMATOL REV, V1, P21, DOI 10.2174/1573397052954127; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Zhang Q, 2005, ARTHRITIS RHEUM-US, V52, P2708, DOI 10.1002/art.21236	33	155	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11846	11855		10.1074/jbc.M512624200	http://dx.doi.org/10.1074/jbc.M512624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16461346	hybrid			2022-12-25	WOS:000236988100051
J	Kubo, M; Inagaki, S; Yoshioka, S; Uchida, T; Mizutani, Y; Aono, S; Kitagawa, T				Kubo, M; Inagaki, S; Yoshioka, S; Uchida, T; Mizutani, Y; Aono, S; Kitagawa, T			Evidence for displacements of the C-helix by CO Ligation and DNA binding to CooA revealed by UV resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR COOA; PROTEIN SECONDARY STRUCTURE; HEME-BASED SENSORS; RHODOSPIRILLUM-RUBRUM; RECEPTOR PROTEIN; CRYSTAL-STRUCTURE; HISTIDINE 77; SIDE-CHAINS; TRYPTOPHAN; RESOLUTION	The UV and visible resonance Raman spectra are reported for CooA from Rhodospirillum rubrum, which is a transcriptional regulator activated by growth in a CO atmosphere. CO binding to heme in its sensor domain causes rearrangement of its DNA-binding domain, allowing binding of DNA with a specific sequence. The sensor and DNA-binding domains are linked by a hinge region that follows a long C-helix. UV resonance Raman bands arising from Trp-110 in the C-helix revealed local movement around Trp-110 upon CO binding. The indole side chain of Trp-110, which is exposed to solvent in the CO-free ferrous state, becomes buried in the CO-bound state with a slight change in its orientation but maintains a hydrogen bond with a water molecule at the indole nitrogen. This is the first experimental data supporting a previously proposed model involving displacement of the C-helix and heme sliding. The UV resonance Raman spectra for the CooA-DNA complex indicated that binding of DNA to CooA induces a further displacement of the C-helix in the same direction during transition to the complete active conformation. The Fe-CO and C-O stretching bands showed frequency shifts upon DNA binding, but the Fe-His stretching band did not. Moreover, CO-geminate recombination was more efficient in the DNA-bound state. These results suggest that the C-helix displacement in the DNA-bound form causes the CO binding pocket to narrow and become more negative.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 4448585, Japan; Kobe Univ, Mol Photosci Res Ctr, Kobe, Hyogo 6578501, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Kobe University	Kitagawa, T (corresponding author), 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Aono, Shigetoshi/ABD-7618-2020; Mizutani, Yasuhisa/B-3809-2009; Asano, Yasuhisa/K-5898-2016; Uchida, Takeshi/A-6455-2017	Aono, Shigetoshi/0000-0002-2870-3694; Asano, Yasuhisa/0000-0003-3645-3952; Uchida, Takeshi/0000-0001-9270-8329				Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Akiyama S, 2004, J MOL BIOL, V341, P651, DOI 10.1016/j.jmb.2004.06.040; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Asher S.A., 1993, ANAL CHEM, V65, P201; Asher SA, 2001, J AM CHEM SOC, V123, P11775, DOI 10.1021/ja0039738; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; Chi ZH, 1998, BIOCHEMISTRY-US, V37, P2854, DOI 10.1021/bi971160z; Chi ZH, 1998, J PHYS CHEM B, V102, P9595, DOI 10.1021/jp9828336; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Holtz JSW, 1996, APPL SPECTROSC, V50, P1459, DOI 10.1366/0003702963904683; Inagaki S, 2005, J BIOL CHEM, V280, P3269, DOI 10.1074/jbc.M409884200; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Kim JE, 2003, BIOCHEMISTRY-US, V42, P5169, DOI 10.1021/bi030026d; Kitagawa T., 2002, RAMAN SPECTROSCOPY P, V5; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; MIURA T, 1988, BIOCHEMISTRY-US, V27, P88, DOI 10.1021/bi00401a015; Mizutani Y, 2001, CHEM REC, V1, P258, DOI 10.1002/tcr.1012; Mizutani Y, 2001, J PHYS CHEM B, V105, P10992, DOI 10.1021/jp010923w; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Roberts GP, 2005, J INORG BIOCHEM, V99, P280, DOI 10.1016/j.jinorgbio.2004.10.032; Roberts GP, 2004, MICROBIOL MOL BIOL R, V68, P453, DOI 10.1128/MMBR.68.3.453-473.2004; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; Takeuchi H, 2003, BIOPOLYMERS, V72, P305, DOI 10.1002/bip.10440; Takeuchi H., 1986, ADV SPECTROSCOPY SPE, V13, P113; Tsuboi M, 2005, BIOCHEMISTRY-US, V44, P4861, DOI 10.1021/bi0479306; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Uesugi Y, 1997, REV SCI INSTRUM, V68, P4001, DOI 10.1063/1.1148373; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Wen ZQ, 1998, BIOPOLYMERS, V45, P247, DOI 10.1002/(SICI)1097-0282(199803)45:3<247::AID-BIP7>3.0.CO;2-R; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Yamashita T, 2004, J BIOL CHEM, V279, P47320, DOI 10.1074/jbc.M407766200; Youn H, 2005, J BACTERIOL, V187, P2573, DOI 10.1128/JB.187.8.2573-2581.2005; Youn H, 2004, J BACTERIOL, V186, P1320, DOI 10.1128/JB.186.5.1320-1329.2004	56	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11271	11278		10.1074/jbc.M513261200	http://dx.doi.org/10.1074/jbc.M513261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16439368	hybrid			2022-12-25	WOS:000236822200070
J	Fuda, C; Hesek, D; Lee, M; Heilmayer, W; Novak, R; Vakulenko, SB; Mobashery, S				Fuda, C; Hesek, D; Lee, M; Heilmayer, W; Novak, R; Vakulenko, SB; Mobashery, S			Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; BINDING PROTEIN 2A; STREPTOCOCCUS-PNEUMONIAE; KINETICS; CELL; IDENTIFICATION; TRANSPEPTIDASE; INVOLVEMENT; EXPRESSION	Emergence of methicillin-resistant Staphylococcus aureus (MRSA) has created challenges in treatment of nosocomial infections. The recent clinical emergence of vancomycin-resistant MRSA is a new disconcerting chapter in the evolution of these strains. S. aureus normally produces four PBPs, which are susceptible to modification by beta-lactam antibiotics, an event that leads to bacterial death. The gene product of mecA from MRSA is a penicillin-binding protein (PBP) designated PBP 2a. PBP 2a is refractory to the action of all commercially available beta-lactam antibiotics. Furthermore, PBP2a is capable of taking over the functions of the other PBPs of S. aureus in the face of the challenge by beta-lactam antibiotics. Three cephalosporins ( compounds 1 - 3) have been studied herein, which show antibacterial activities against MRSA, including the clinically important vancomycin-resistant strains. These cephalosporins exhibit substantially smaller dissociation constants for the preacylation complex compared with the case of typical cephalosporins, but their pseudo-second-order rate constants for encounter with PBP2a (k(2)/K-s) are not very large (<= 200 M-1 s(-1)). It is documented herein that these cephalosporins facilitate a conformational change in PBP 2a, a process that is enhanced in the presence of a synthetic surrogate for cell wall, resulting in increases in the k(2)/K-s parameter and in more facile enzyme inhibition. These findings argue that the novel cephalosporins are able to co-opt interactions between PBP 2a and the cell wall in gaining access to the active site in the inhibition process, a set of events that leads to effective inhibition of PBP 2a and the attendant killing of the MRSA strains.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Sandoz GmbH, Antibiot Res Inst, A-1235 Vienna, Austria	University of Notre Dame; Novartis; Sandoz	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu	Lee, Mijoon/AFK-1543-2022	Lee, Mijoon/0000-0001-7432-0427	NIAID NIH HHS [N01 AI 95359] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095359] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACAR JF, 1996, ANTIBIOTICS LAB MED, P15; Bartley Judene, 2002, Infect Control Hosp Epidemiol, V23, P480; Bogdanovich T, 2005, ANTIMICROB AGENTS CH, V49, P4210, DOI 10.1128/AAC.49.10.4210-4219.2005; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P931; Chambers HF, 2003, TRENDS MICROBIOL, V11, P145, DOI 10.1016/S0966-842X(03)00046-5; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Fuda C, 2004, J BIOL CHEM, V279, P40802, DOI 10.1074/jbc.M403589200; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Gardete S, 2004, J BACTERIOL, V186, P1705, DOI 10.1128/JB.186.6.1705-1713.2004; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Graves-Woodward K, 1998, BIOCHEM J, V332, P755, DOI 10.1042/bj3320755; Gruebele M, 1999, ANNU REV PHYS CHEM, V50, P485, DOI 10.1146/annurev.physchem.50.1.485; Hujer AM, 2005, ANTIMICROB AGENTS CH, V49, P612, DOI 10.1128/AAC.49.2.612-618.2005; Iizawa Yuji, 2004, Journal of Infection and Chemotherapy, V10, P146; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; Katayama Y, 2004, ANTIMICROB AGENTS CH, V48, P453, DOI 10.1128/AAC.48.2.453-459.2004; Katayama Y, 2003, J BACTERIOL, V185, P5465, DOI 10.1128/JB.185.18.5465-5472.2003; Lee M, 2003, J AM CHEM SOC, V125, P16322, DOI 10.1021/ja038445l; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; Lu WP, 1999, BIOCHEMISTRY-US, V38, P6537, DOI 10.1021/bi990025e; MAZZELLA LJ, 1989, BIOCHEM J, V259, P255, DOI 10.1042/bj2590255; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; *NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L; Osvath S, 2003, J MOL BIOL, V333, P187, DOI 10.1016/j.jmb.2003.08.011; Pagliero E, 2004, ANTIMICROB AGENTS CH, V48, P1848, DOI 10.1128/AAC.48.5.1848-1855.2004; PRATT RF, 1986, J AM CHEM SOC, V108, P5328, DOI 10.1021/ja00277a044; Pucci MJ, 2002, J BACTERIOL, V184, P588, DOI 10.1128/JB.184.2.588-591.2002; Severin A, 2004, J BIOL CHEM, V279, P3398, DOI 10.1074/jbc.M309593200; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Sobral RG, 2003, MICROB DRUG RESIST, V9, P231, DOI 10.1089/107662903322286436; Swinney DC, 2004, NAT REV DRUG DISCOV, V3, P801, DOI 10.1038/nrd1500; Vouillamoz J, 2004, ANTIMICROB AGENTS CH, V48, P4322, DOI 10.1128/AAC.48.11.4322-4327.2004; Yang WY, 2003, J AM CHEM SOC, V125, P16220, DOI 10.1021/ja0360081	37	30	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10035	10041		10.1074/jbc.M508846200	http://dx.doi.org/10.1074/jbc.M508846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16459335	hybrid			2022-12-25	WOS:000236594300027
J	Miyamoto, A; Lau, R; Hein, PW; Shipley, JM; Weinmaster, G				Miyamoto, A; Lau, R; Hein, PW; Shipley, JM; Weinmaster, G			Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMURATI-ENGELMANN-DISEASE; FIBRILLIN-CONTAINING MICROFIBRILS; LATENCY-ASSOCIATED PEPTIDE; SIGNAL-TRANSDUCTION; CELL DIFFERENTIATION; TGF-BETA; LIGAND; GLYCOPROTEIN-2; MUTATIONS; PATHWAY	Unlike most receptors, Notch serves as both the receiver and direct transducer of signaling events. Activation can be mediated by one of five membrane-bound ligands of either the Delta-like (-1, -2, -4) or Jagged/Serrate (-1, -2) families. Alternatively, dissociation of the Notch heterodimer with consequent activation can also be mediated experimentally by calcium chelators or by mutations that destabilize the Notch1 heterodimer, such as in the human disease T cell acute lymphoblastic leukemia. Here we show that MAGP-2, a protein present on microfibrils, can also interact with the EGF-like repeats of Notch1. Co-expression of MAGP-2 with Notch1 leads to both cell surface release of the Notch1 extracellular domain and subsequent activation of Notch signaling. Moreover, we demonstrate that the C-terminal domain of MAGP-2 is required for binding and activation of Notch1. Based on the high level of homology, we predicted and further showed that MAGP-1 can also bind to Notch1, cause the release of the extracellular domain, and activate signaling. Notch1 extracellular domain release induced by MAGP-2 is dependent on formation of the Notch1 heterodimer by a furin-like cleavage, but does not require the subsequent ADAM metalloprotease cleavage necessary for production of the Notch signaling fragment. Together these results demonstrate for the first time that the microfibrillar proteins MAGP-1 and MAGP-2 can function outside of their role in elastic fibers to activate a cellular signaling pathway.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)	Weinmaster, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	gweinmaster@mednet.ucla.edu	Hein, Patrick/F-1180-2015		NINDS NIH HHS [NS 31885] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031885, R37NS031885] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Eiraku M, 2005, NAT NEUROSCI, V8, P873, DOI 10.1038/nn1492; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Hanssen E, 2004, J BIOL CHEM, V279, P29185, DOI 10.1074/jbc.M313672200; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Kielty CM, 2002, J CELL SCI, V115, P2817; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Ladi E, 2005, J CELL BIOL, V170, P983, DOI 10.1083/jcb.200503113; Lemaire R, 2005, ARTHRITIS RHEUM-US, V52, P1812, DOI 10.1002/art.21059; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004; Tan-Pertel HT, 2000, J IMMUNOL, V165, P4428, DOI 10.4049/jimmunol.165.8.4428; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614	45	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10089	10097		10.1074/jbc.M600298200	http://dx.doi.org/10.1074/jbc.M600298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16492672	hybrid			2022-12-25	WOS:000236594300034
J	Song, KH; Li, TG; Chiang, JYL				Song, KH; Li, TG; Chiang, JYL			A prospero-related homeodomain protein is a novel co-regulator of hepatocyte nuclear factor 4 alpha that regulates the cholesterol 7 alpha-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; PROX1 FUNCTION; EXPRESSION; LIVER; GLUCONEOGENESIS; REPRESSION; CYP7A1	Prox1, an early specific marker for developing liver and pancreas in foregut endoderm has recently been shown to interact with alpha-fetoprotein transcription factor and repress cholesterol 7 alpha-hydroxylase (CYP7A1) gene transcription. Using a yeast two-hybrid assay, we found that Prox1 strongly and specifically interacted with hepatocyte nuclear factor (HNF)4 alpha, an important transactivator of the human CYP7A1 gene in bile acid synthesis and phosphoenolpyruvate carboxykinase (PEPCK) gene in gluconeogenesis. A real time PCR assay detected Prox1 mRNA expression in human primary hepatocytes and HepG2 cells. Reporter assay, GST pull-down, co-immunoprecipitation, and yeast two-hybrid assays identified a specific interaction between the N-terminal LXXLL motif of Prox1 and the activation function 2 domain of HNF4 alpha. Prox1 strongly inhibited HNF4 alpha and peroxisome proliferators-activated receptor gamma coactivator-1 alpha co-activation of the CYP7A1 and PEPCK genes. Knock down of the endogenous Prox1 by small interfering RNA resulted in significant increase of CYP7A1 and PEPCK mRNA expression and the rate of bile acid synthesis in HepG2 cells. These results suggest that Prox1 is a novel co-regulator of HNF4 alpha that may play a key role in the regulation of bile acid synthesis and gluconeogenesis in the liver.	Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Chiang, JYL (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Dept Microbiol Immunol & Biochem, 4209 State Route 44,POB 95, Rootstown, OH 44272 USA.	jchiang@neoucom.edu	Chiang, John Y. L./G-2658-2011	Chiang, John Y. L./0000-0001-9360-7650	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058379, R01DK044442, R56DK044442, R37DK058379] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK058379, DK 58379, R01 DK058379, R56 DK044442, R01 DK044442, DK 44442] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; FELDMANN D, 1983, CLIN CHEM, V29, P1694; Glass CK, 2000, GENE DEV, V14, P121; Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li JX, 2000, GENE DEV, V14, P464; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Sladek R, 2000, ADV PHARMACOL, V47, P23; Song KH, 2006, HEPATOLOGY, V43, P117, DOI 10.1002/hep.20919; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Steffensen KR, 2004, EMBO REP, V5, P613, DOI 10.1038/sj.embor.7400147; Stroup D, 2000, J LIPID RES, V41, P1; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392	38	56	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10081	10088		10.1074/jbc.M513420200	http://dx.doi.org/10.1074/jbc.M513420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16488887	Green Accepted, hybrid			2022-12-25	WOS:000236594300033
J	Tan, J; Zhuang, L; Jiang, X; Yang, KK; Karuturi, KM; Yu, Q				Tan, J; Zhuang, L; Jiang, X; Yang, KK; Karuturi, KM; Yu, Q			Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; CELL-CYCLE; GENE-EXPRESSION; P53; INDUCTION; PATHWAYS; P73; RB; IDENTIFICATION; REPLICATION	The oncogenic retinoblastoma protein (Rb)/E2F pathway links cellular proliferation control to apoptosis as a fail-safe mechanism to protect aberrant oncogenic transformation. We have previously shown that histone deacetylase inhibitors (HDACIs) activate the E2F1-Bim apoptotic pathway, leading to efficient cell killing in cancer cells with deregulated E2F1 activity. To identify additional gene cassettes that might contribute HDACI-induced apoptosis upon E2F1 activation, we investigated the apoptotic transcriptional network affected by HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) in cancer cells with inducible E2F1. Data analysis focusing on 220 apoptosis-related genes identified apoptosis signal-regulating kinase 1 (ASK1) as one of a few genes in addition to Bim that are substantially up-regulated by SAHA upon E2F1 activation. We show that ASK1 is directly regulated by E2F1 and that prevention of ASK1 induction by RNA interference decreases SAHA-induced apoptosis. We further show that the role of ASK1 in the SAHA apoptotic response is not associated with its downstream effectors p38 or JNK. Instead, ASK1 knockdown results in reduced E2F1 transcriptional activity, leading to decreased Bim induction by SAHA. Moreover, ASK1 expression reverses the negative effect of Rb on E2F1 activity. These results indicate that ASK1 induction by E2F1 provides positive feedback regulation of E2F1 activity via Rb inhibition, which allows an efficient E2F1-Bim activation. Thus, the concomitant induction of E2F1 targets ASK1 and Bim by HDACIs warrants an effective activation of E2F1-dependent apoptosis in response to SAHA.	Genome Inst Singapore, Mol Pharmacol Lab, Singapore 138672, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Yu, Q (corresponding author), Genome Inst Singapore, Mol Pharmacol Lab, Genome Bldg,02-01,60 Biopolis St, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Marks PA, 2004, CELL CYCLE, V3, P534; MIZUMURA K, 2005, J CELL PHYSL; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	39	61	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10508	10515		10.1074/jbc.M512719200	http://dx.doi.org/10.1074/jbc.M512719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476732	hybrid			2022-12-25	WOS:000236594300080
J	Ueda, T; Postnikov, YV; Bustin, M				Ueda, T; Postnikov, YV; Bustin, M			Distinct domains in high mobility group n variants modulate specific chromatin modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS HMG-14; HISTONE H3; NUCLEOSOME CORES; GENE-REGULATION; PHOSPHORYLATION; ACETYLATION; H1; TRANSCRIPTION; MSK1	We have demonstrated that levels of specific modification in histone H3 are modulated by members of the nucleosome-binding high mobility group N (HMGN) protein family in a variant-specific manner. HMGN1(but not HMGN2) inhibits the phosphorylation of both H3S10 and H3S28, whereas HMGN2 enhances H3K14 acetylation more robustly than HMGN1. Two HMGN domains are necessary for modulating chromatin modifications, a non-modification-specific domain necessary for chromatin binding and a modification-specific domain localized in the C terminus of the HMGNs. Thus, chromatin-binding structural proteins such as HMGNs affect the levels of specific chromatin modifications and therefore may play a role in epigenetic regulation.	NCI, Prot Sect, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bustin, M (corresponding author), NCI, Prot Sect, Lab Metab, NIH, Bldg 37,Rm 3122, Bethesda, MD 20892 USA.	bustin@helix.nih.gov	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [Z01BC004496] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC004496-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BUSTIN M, 1995, SEMIN CELL BIOL, V6, P247, DOI 10.1006/scel.1995.0033; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lim JH, 2005, EMBO J, V24, P3038, DOI 10.1038/sj.emboj.7600768; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Lim JH, 2004, METHOD ENZYMOL, V375, P323; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779	23	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10182	10187		10.1074/jbc.M600821200	http://dx.doi.org/10.1074/jbc.M600821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484217	hybrid			2022-12-25	WOS:000236594300044
J	Zhang, Q; Adiseshaiah, P; Kalvakolanu, DV; Reddy, SP				Zhang, Q; Adiseshaiah, P; Kalvakolanu, DV; Reddy, SP			A phosphatidylinositol 3-kinase-regulated Akt-independent signaling promotes cigarette smoke-induced FRA-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; ALPHA-CONVERTING ENZYME; BREAST-CANCER CELLS; SERUM RESPONSE ELEMENT; PROTEIN-KINASE-B; LUNG-CANCER; C-FOS; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; IN-VITRO	The FRA-1 proto-oncogene is overexpressed in a variety of human tumors and is known to up-regulate the expression of genes involved in tumor progression and invasion. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is also known to regulate these cellular processes. More importantly, respiratory toxicants and carcinogens activate both the PI3K-Akt pathway and FRA-1 expression in human bronchial epithelial (HBE) cells. In this study we investigated a potential link between the PI3K-Akt pathway and the cigarette smoke (CS)-stimulated epidermal growth factor receptor-mediated FRA-1 induction in non-oncogenic HBE cells. Treatment of cells with LY294002, an inhibitor of the PI3K-Akt pathway, completely blocked CS-induced FRA-1 expression. Surprisingly pharmacological inhibition of Akt had no significant effect on CS-induced FRA-1 expression. Likewise the inhibition of protein kinase C zeta, which is a known downstream effector of PI3K, did not alter FRA-1 expression. We found that the PI3K through p21-activated kinase 1 regulates FRA-1 proto-oncogene induction by CS and the subsequent activation of the Elk1 and cAMP-response element-binding protein transcription factors that are bound to the promoter in HBE cells.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Rm E7610,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NCI NIH HHS [CA 105005, CA 78282] Funding Source: Medline; NIEHS NIH HHS [ES 11863] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES011863, R01ES011863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cook SJ, 1999, MOL CELL BIOL, V19, P330; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fiala ES, 2005, CARCINOGENESIS, V26, P605, DOI 10.1093/carcin/bgh341; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Karin M, 2001, IUBMB LIFE, V52, P17; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MATSUI M, 1990, ONCOGENE, V5, P249; Nelson HH, 2002, ONCOGENE, V21, P7284, DOI 10.1038/sj.onc.1205804; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, pA828; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; Shah A, 2005, CLIN CANCER RES, V11, P2930, DOI 10.1158/1078-0432.CCR-04-1385; Shao MXG, 2004, AM J PHYSIOL-LUNG C, V287, pL420, DOI 10.1152/ajplung.00019.2004; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Tiwari G, 2003, MOL CANCER RES, V1, P475; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zhang Q, 2004, AM J PHYSIOL-LUNG C, V286, pL427, DOI 10.1152/ajplung.00221.2003	56	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10174	10181		10.1074/jbc.M513008200	http://dx.doi.org/10.1074/jbc.M513008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16490785	hybrid			2022-12-25	WOS:000236594300043
J	Kino, T; Souvatzoglou, E; Charmandari, E; Ichijo, T; Driggers, P; Mayers, C; Alatsatianos, A; Manoli, I; Westphal, H; Chrousos, GP; Segars, JH; James, HS				Kino, T; Souvatzoglou, E; Charmandari, E; Ichijo, T; Driggers, P; Mayers, C; Alatsatianos, A; Manoli, I; Westphal, H; Chrousos, GP; Segars, JH; James, HS			Rho family guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVITY; NUCLEAR-LOCALIZATION; POLYBASIC REGION; SMALL GTPASES; RECEPTOR; PROTEIN; FKBP51; ACTIVATION; SENSITIVITY	Glucocorticoids regulate many crucial biologic functions through their cytoplasmic/nuclear glucocorticoid receptors (GR). Excess, deficiency, or alteration in tissue sensitivity to glucocorticoids has been associated with major causes of human morbidity and mortality. Brx, a cytoplasmic Rho family guanine nucleotide exchange factor, binds to and influences the activity of several nuclear hormone receptors. We examined the functional and molecular interactions between GR and Brx. The glucocorticoid sensitivity of lymphocytes obtained from mice haplo-insufficient for Brx was significantly decreased. Conversely, GR-mediated transcriptional activity of a glucocorticoid response element (GRE)-mediated glucocorticoid-responsive promoter was enhanced by Brx in a guanine nucleotide exchange factor domain-dependent fashion. Brx interacted with GR, forming a ternary complex with RhoA. In a chromatin immunoprecipitation assay, Brx and RhoA were co-precipitated with GREs only in the presence of ligand-activated GR. Extracellularly administered lysophosphatidic acid, which activates its signaling cascade through a specific membrane GTP-binding protein (G-protein)-coupled receptor in a G-protein alpha(13)-, Brx-, and RhoA-dependent fashion, enhanced GR transcriptional activity, whereas depletion of endogenous Brx attenuated this effect. These findings suggest that glucocorticoid signaling and, hence, the tissue sensitivity to glucocorticoids, may be coupled to extracellular signals via Brx and small G-proteins. Nuclear Brx might act as a local GRE-GR-transcriptosome activator by mediating the effect of small G-proteins on glucocorticoid-regulated genes.	NICHD, Pediat Endocrinol Sect, Reprod Biol & Med Branch, Clin Res Ctr,NIH, Bethesda, MD 20892 USA; NICHD, Natl Ctr Complementary & Alternat Med, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; Univ Athens, Sch Med, Dept Pediat 1, GR-11527 Athens, Greece	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Uniformed Services University of the Health Sciences - USA; Athens Medical School; National & Kapodistrian University of Athens	Kino, T (corresponding author), NICHD, Pediat Endocrinol Sect, Reprod Biol & Med Branch, Clin Res Ctr,NIH, Bldg 10,Rm 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.	kinot@mail.nih.gov	Charmandari, Evangelia/AAF-2038-2019; Charmandari, Evangelia/B-6701-2011	Charmandari, Evangelia/0000-0002-0851-6998; Manoli, Irini/0000-0003-1543-2941	Intramural NIH HHS [Z99 HD999999, Z01 HD008732-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618, Z01HD008737, Z01HD008732, Z01HD000071] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Baughman G, 1997, BIOCHEM BIOPH RES CO, V232, P437, DOI 10.1006/bbrc.1997.6307; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chrousos G.P., 2001, ENDOCRINOLOGY METABO, V4th ed., P609; Chrousos GP, 2004, AM J MED, V117, P204, DOI 10.1016/j.amjmed.2004.05.006; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Colwell JA, 2003, DIABETES CARE, V26, P2181, DOI 10.2337/diacare.26.7.2181; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; Enmark E, 2001, TRENDS PHARMACOL SCI, V22, P611, DOI 10.1016/S0165-6147(00)01859-9; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Ichijo T, 2005, J BIOL CHEM, V280, P42067, DOI 10.1074/jbc.M509338200; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Karl M, 1996, P ASSOC AM PHYSICIAN, V108, P296; Kino T, 2005, J CELL BIOL, V169, P885, DOI 10.1083/jcb.200409150; Kino T, 2003, J STEROID BIOCHEM, V85, P457, DOI 10.1016/S0960-0760(03)00218-8; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Kino T, 2002, J ALLERGY CLIN IMMUN, V109, P609, DOI 10.1067/mai.2002. 123708; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDaniel K, 2004, J SOC GYNECOL INVEST, V11, p199A; Miller WL., 2001, ENDOCRINOLOGY METABO, P387; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vermeer H, 2004, MOL CELL ENDOCRINOL, V218, P49, DOI 10.1016/j.mce.2003.12.011; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6	50	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9118	9126		10.1074/jbc.M509339200	http://dx.doi.org/10.1074/jbc.M509339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469733	Green Accepted, hybrid			2022-12-25	WOS:000236404700017
J	Takatsume, Y; Izawa, S; Inoue, Y				Takatsume, Y; Izawa, S; Inoue, Y			Methylglyoxal as a signal initiator for activation of the stress-activated protein kinase cascade in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PAP1; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; GLYOXALASE-I; OXIDATIVE STRESS; RESPONSE REGULATOR; DIABETES-MELLITUS; PATHWAY; GENES; IDENTIFICATION	Methylglyoxal (MG) is a typical 2-oxoaldehyde derived from glycolysis. We have recently found that MG activates transcription factors such as Yap1 and Msn2, and triggers a Hog1 mitogen-activated protein kinase cascade in Saccharomyces cerevisiae. Regarding the activation of Hog1 by MG, we found that Sln1, an osmosensor possessing histidine kinase activity, functions as a sensor of MG (Maeta, K., Izawa, S., and Inoue, Y. (2005) J. Biol. Chem. 280, 253-260). To gain further insight into the role of MG as a signal initiator, here we analyze the response of Schizosaccharomyces pombe to extracellular MG. Spc1, a stress-activated protein kinase (SAPK), was phosphorylated following the treatment with MG. No phosphorylation was observed in a wis1 Delta mutant. The His-to-Asp phosphorelay system consisting of three histidine kinases (Phk1, Phk2, and Phk3), a phosphorelay protein (Spy1), and a response regulator (Mcs4) exists upstream of the Spc1-SAPK pathway. The phosphorylation of Spc1 following MG treatment was observed in phk1 Delta phk2 Delta phk3 Delta and spy1 Delta cells, but not in mcs4 Delta cells. These results suggest that S. pombe has an alternative module(s) that directs the MG signal to the SAPK pathway via Mcs4. Additionally, we found that the transcription factor Pap1 is concentrated in the nucleus in response to MG, independent of the Spc1-SAPK pathway.	Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Mol Microbiol Lab, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan.	y_inoue@kais.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450; Takatsume, Yoshifumi/0000-0002-9467-2021				Aguilera J, 2005, MOL MICROBIOL, V56, P228, DOI 10.1111/j.1365-2958.2005.04533.x; Aguilera J, 2001, CURR GENET, V39, P273, DOI 10.1007/s002940100213; Ahmed N, 2005, J NEUROCHEM, V92, P255, DOI 10.1111/j.1471-4159.2004.02864.x; Akhand AA, 2001, FREE RADICAL BIO MED, V31, P20, DOI 10.1016/S0891-5849(01)00550-0; Aoyama K, 2001, BIOSCI BIOTECH BIOCH, V65, P2347, DOI 10.1271/bbb.65.2347; Beisswenger PJ, 1999, DIABETES, V48, P198, DOI 10.2337/diabetes.48.1.198; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bito A, 1997, J BIOL CHEM, V272, P21509, DOI 10.1074/jbc.272.34.21509; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Castillo EA, 2003, J BIOL CHEM, V278, P40565, DOI 10.1074/jbc.M305859200; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; Chen CN, 2003, YEAST, V20, P545, DOI 10.1002/yea.979; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Inoue Y, 1999, P JPN ACAD B-PHYS, V75, P127, DOI 10.2183/pjab.75.127; Junaid MA, 2004, AM J MED GENET A, V131A, P11, DOI 10.1002/ajmg.a.30349; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; Maeta K, 2005, FEMS MICROBIOL LETT, V243, P87, DOI 10.1016/j.femsle.2004.11.046; Maeta K, 2005, J BIOL CHEM, V280, P253, DOI 10.1074/jbc.M408061200; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168; Nakamichi N, 2003, BIOSCI BIOTECH BIOCH, V67, P547, DOI 10.1271/bbb.67.547; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; O'Rourke SM, 2002, MOL CELL BIOL, V22, P4739, DOI 10.1128/MCB.22.13.4739-4749.2002; Ohmiya R, 1999, J BIOCHEM, V125, P1061, DOI 10.1093/oxfordjournals.jbchem.a022387; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; Shieh JC, 1998, MOL BIOL CELL, V9, P311, DOI 10.1091/mbc.9.2.311; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; Takatsume Y, 2005, ARCH MICROBIOL, V183, P224, DOI 10.1007/s00203-005-0762-0; Takatsume Y, 2004, ARCH MICROBIOL, V181, P371, DOI 10.1007/s00203-004-0666-4; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; Vivancos AP, 2004, MOL MICROBIOL, V52, P1427, DOI 10.1111/j.1365-2958.2004.04065.x; Zuin A, 2005, J BIOL CHEM, V280, P36708, DOI 10.1074/jbc.M508400200	49	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9086	9092		10.1074/jbc.M511037200	http://dx.doi.org/10.1074/jbc.M511037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464860	hybrid			2022-12-25	WOS:000236404700013
J	Xu, Y; Sengupta, PK; Seto, E; Smith, BD				Xu, Y; Sengupta, PK; Seto, E; Smith, BD			Regulatory factor for X-box family proteins differentially interact with histone deacetylases to repress collagen alpha 2(I) gene (COL1A2) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOXO TRANSCRIPTION FACTORS; TRICHOSTATIN-A; DNA-BINDING; NUCLEOSOME STRUCTURE; MODIFYING ENZYMES; MOUSE ALPHA-2(I); RFX FAMILY; START SITE; 1ST EXON; ACETYLATION	Our studies indicate that the regulatory factor for X-box (RFX) family proteins repress collagen alpha 2(I) gene (COL1A2) expression (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2003) J. Biol. Chem. 278, 49134-49144; Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2004) J. Biol. Chem. 279, 41319-41332). In this study, we examined the mechanism(s) underlying the repression of collagen gene by RFX proteins. Two members of the RFX family, RFX1 and RFX5, associate with distinct sets of co-repressors on the collagen transcription start site in vitro. RFX5 specifically interacts with histone deacetylase 2 (HDAC2) and the mammalian transcriptional repressor (mSin3B), whereas RFX1 preferably interacts with HDAC1 and mSin3A. HDAC2 cooperates with RFX5 to down-regulate collagen promoter activity, whereas HDAC1 enhances inhibition of collagen promoter activity by RFX1. Interferon-gamma promotes the recruitment of RFX5/HDAC2/mSin3B to the collagen transcription start site but decreases the occupancy by RFX1/mSin3A as manifested by chromatin immunoprecipitation assay. RFX1 binds to the methylated collagen sequence with much higher affinity than unmethylated sequence, recruiting more HDAC1 and mSin3A. The DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, which inhibits DNA methylation, reduces RFX1/HDAC1 binding to the collagen transcription start site in chromatin immunoprecipitation assays. Finally, both RFX1 and RFX5 are acetylated in vivo. Trichostatin A stimulates the acetylation of RFX proteins and activates the collagen promoter activity. Collectively, our data strongly indicate two separate pathways for RFX proteins to repress collagen gene expression as follows: one for RFX5/HDAC2 in interferon-gamma-mediated repression, and the other for RFX1/HDAC1 in methylation-mediated collagen silencing.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02118 USA; H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL068094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL068094, P01-HL013262-31, P01 HL013262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; Biade S, 2001, INT J RADIAT BIOL, V77, P1033, DOI 10.1080/09553000110066068; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Chiba T, 2005, EUR J CANCER, V41, P1185, DOI 10.1016/j.ejca.2005.02.014; Chiba T, 2004, ONCOLOGY-BASEL, V66, P481, DOI 10.1159/000079503; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Dangond F, 2001, INT J ONCOL, V19, P773; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang JE, 2005, CELL PHYSIOL BIOCHEM, V16, P23, DOI 10.1159/000087728; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KRIEGER DE, 1974, J BIOL CHEM, V249, P332; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Loury R, 2003, METHODS, V31, P40, DOI 10.1016/S1046-2023(03)00086-0; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Matsumura T, 2005, J BIOL CHEM, V280, P12123, DOI 10.1074/jbc.M410578200; Medugno L, 2005, GENE, V359, P35, DOI 10.1016/j.gene.2005.06.021; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Mudhasani R, 2005, MOL IMMUNOL, V42, P673, DOI 10.1016/j.molimm.2004.09.021; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Rombouts K, 2002, EXP CELL RES, V278, P184, DOI 10.1006/excr.2002.5577; Rombouts K, 2001, ACTA GASTRO-ENT BELG, V64, P239; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; Sengupta PK, 2003, CANCER RES, V63, P1789; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; TISHCHEN.LI, 1971, BIOCHEMISTRY-USSR+, V36, P595; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; You H, 2005, CELL CYCLE, V4, P37, DOI 10.4161/cc.4.1.1401; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhao SJ, 2003, CANCER RES, V63, P2624; Zika E, 2005, CURR OPIN IMMUNOL, V17, P58, DOI 10.1016/j.coi.2004.11.008; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	78	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9260	9270		10.1074/jbc.M511724200	http://dx.doi.org/10.1074/jbc.M511724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464847	Green Accepted, hybrid			2022-12-25	WOS:000236404700033
J	Seymour, KJ; Roberts, LE; Fini, MA; Parmley, LA; Oustitch, TL; Wright, RM				Seymour, KJ; Roberts, LE; Fini, MA; Parmley, LA; Oustitch, TL; Wright, RM			Stress activation of mammary epithelial cell xanthine oxidoreductase is mediated by p38 MAPK and CCAAT/Enhancer-binding protein-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA; CASEIN GENE; DNA-BINDING; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; EXPRESSION; INDUCTION; RECEPTOR; KINASE; SIGNAL	Xanthine oxidoreductase (XOR) catalyzes the formation of uric acid from xanthine and hypoxanthine and is recognized as a source of reactive oxygen and nitrogen species. Unexpectedly, XOR was found to play an essential role in milk secretion in the differentiating mammary gland, where it is an integral component of the milk fat globule. XOR gene expression in both mammary glands and differentiating mammary epithelial cells in culture is regulated by the lactogenic hormones prolactin and cortisol. Expression in mammary epithelial cells is also regulated by inflammatory cytokines and induced by cycloheximide. Cycloheximide was found to stimulate XOR gene expression in differentiating HC11 mouse mammary epithelial cells. Activation of XOR gene expression by both cycloheximide and inflammatory cytokines suggested that XOR may be regulated by stress-activated protein kinases, the MAPKs. We demonstrate here that XOR was induced in HC11 cells by low dose cycloheximide and that expression was blocked by inhibitors of p38 MAPK. Accumulation of phospho-p38 was stimulated by low dose cycloheximide. Low dose cycloheximide stress promoted phosphorylation and nuclear accumulation of the CCAAT/enhancer-binding protein-beta(C/EBP beta) transcription factor, which was blocked by inhibition of p38. Furthermore, C/EBP beta was found to activate the mouse XOR promoter, and XOR promoter-C/EBP beta protein complexes were induced by low dose cycloheximide stress. These data demonstrate, for the first time, that mouse mammary epithelial cell XOR is regulated by p38 MAPK. They identify an essential function of the C/EBP beta transcription factor in mouse XOR expression and suggest a potential role for p38 MAPK activation of C/EBP beta in mammary epithelial cells.	Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pulm Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Bath; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wright, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Campus Box C-322,4200 E 9th Ave, Denver, CO 80262 USA.	richard.m.wright@uchsc.edu			NHLBI NIH HHS [HL45582, HL52509] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045582, R29HL052509] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; Cui TX, 2005, MOL ENDOCRINOL, V19, P2175, DOI 10.1210/me.2004-0502; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lin WW, 2000, CELL SIGNAL, V12, P457, DOI 10.1016/S0898-6568(00)00090-5; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Ma Q, 2002, ARCH BIOCHEM BIOPHYS, V404, P309, DOI 10.1016/S0003-9861(02)00339-9; Marczin N, 1998, BRIT J PHARMACOL, V123, P1000, DOI 10.1038/sj.bjp.0701687; McManaman JL, 2000, ARCH BIOCHEM BIOPHYS, V373, P318, DOI 10.1006/abbi.1999.1573; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; McManaman JL, 1999, ARCH BIOCHEM BIOPHYS, V371, P308, DOI 10.1006/abbi.1999.1432; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Ohtsubo T, 2004, CIRC RES, V95, P1118, DOI 10.1161/01.RES.0000149571.96304.36; Page S, 1998, BBA-GEN SUBJECTS, V1381, P191, DOI 10.1016/S0304-4165(98)00028-2; Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Rosen JM, 1999, ANNU REV NUTR, V19, P407, DOI 10.1146/annurev.nutr.19.1.407; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; Vorbach C, 2003, TRENDS IMMUNOL, V24, P512, DOI 10.1016/S1471-4906(03)00237-0; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wright RM, 2004, AM J RESP CELL MOL, V30, P479, DOI 10.1165/rcmb.2003-0309OC; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; Wright RM, 2000, DNA CELL BIOL, V19, P459, DOI 10.1089/10445490050128395; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228; Xu P, 2000, J BIOL CHEM, V275, P5918, DOI 10.1074/jbc.275.8.5918; Xu P, 2004, J BIOL CHEM, V279, P16057, DOI 10.1074/jbc.M305856200; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	47	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8545	8558		10.1074/jbc.M507349200	http://dx.doi.org/10.1074/jbc.M507349200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452486	hybrid			2022-12-25	WOS:000236247100030
J	Li, Y; Zhou, WH; Tong, YG; He, GQ; Song, WH				Li, Yu; Zhou, Weihui; Tong, Yigang; He, Guiqiong; Song, Weihong			Control of APP processing and A beta generation level by BACE1 enzymatic activity and transcription	FASEB JOURNAL			English	Article						BACE1; secretase; transcription; APP processing; amyloid beta; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; CLEAVING ENZYME; SECRETASE PROTEIN; ASPARTYL PROTEASE; SITE; CLEAVAGE; EXPRESSION; INCREASES; PRESENILIN-1; MATURATION	Deposition of amyloid beta protein (A beta) is one of the characteristic features of Alzheimer's disease (AD) neuropathology. Beta-secretase, a beta-site APP cleaving enzyme 1 (BACE1), is essential for A beta biosynthesis. Although inhibition of BACE1 is considered a valid therapeutic target for AD, the enzymatic dynamics of BACE1 in regulating APP processing and A beta generation has not yet been fully defined. To examine this issue, tightly controlled inducible BACE1 gene expression was established in the neuronal cell line N2ABP1 and the non-neuronal cell line E2BP1 using an ecdysone-inducible system. The BACE1 protein level was increased in a time- and dosage-dependent manner in the inducible BACE1 stable cells by treatment with inducer ponasterone A. The generation of APP CTF beta, the beta-secretase product, increased proportionally with the level of BACE1 protein expression. However, A beta 40/42 production sharply increased to the plateau level with a relatively small increase in BACE1 expression. Although further increasing BACE1 expression increased beta-secretase activity, it had no additional effect on A beta production. Furthermore, we found that BACE1 mRNA levels and BACE1 promoter activity were significantly lower than APP mRNA levels and APP promoter activity. Our data demonstrate that lower BACE transcription is responsible for the minority of APP undergoing the amyloidogenic pathway and relatively lower A beta production in the normal conditions, and that a slight increase in BACE1 can induce a dramatic elevation in A beta production, indicating that the increase in BACE1 can potentially increase neuritic plaque formation in the pathological condition.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Chongqing Univ Med Sci, Dept Pathol, Chongqing, Peoples R China; Chongqing Univ Med Sci, Dept Anat, Chongqing, Peoples R China	University of British Columbia; Chongqing Medical University; Chongqing Medical University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HE W, 2004, NAT MED; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	106	159	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					285	292		10.1096/fj.05-4986com	http://dx.doi.org/10.1096/fj.05-4986com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449801				2022-12-25	WOS:000237698700014
J	Neumann, J; Gunzer, M; Gutzeit, HO; Ullrich, O; Reymann, KG; Dinkel, K				Neumann, Jens; Gunzer, Matthias; Gutzeit, Herwig O.; Ullrich, Oliver; Reymann, Klaus G.; Dinkel, Klaus			Microglia provide neuroprotection after ischemia	FASEB JOURNAL			English	Article						neuroinflammation; stroke; organotypic cultures; two-photon microscopy; CD11a integrin	INTRACEREBROVENTRICULAR INJECTION; SLICE CULTURES; CELLS MIGRATE; RAT; INJURY; INFLAMMATION; MACROPHAGES; STROKE; NEUROTOXICITY; CYTOTOXICITY	Many neurological insults are accompanied by a marked acute inflammatory reaction, involving the activation of microglia. Using a model of exogenous application of fluorescence-labeled BV2 microglia in pathophysiologically relevant concentrations onto organotypic hippocampal slice cultures, we investigated the specific effects of microglia on neuronal damage after ischemic injury. Neuronal cell death after oxygen-glucose deprivation (OGD) was determined by propidium iodide incorporation and Nissl staining. Migration and interaction with neurons were analyzed by time resolved 3-D two-photon microscopy. We show that microglia protect against OGD-induced neuronal damage and engage in close physical cell-cell contact with neurons in the damaged brain area. Neuroprotection and migration of microglia were not seen with integrin regulator CD11a-deficient microglia or HL-60 granulocytes. The induction of migration and neuron-microglia interaction deep inside the slice was markedly increased under OGD conditions. Lipopolysaccharide-prestimulated microglia failed to provide neuroprotection after OGD. Pharmacological interference with microglia function resulted in a reduced neuroprotection. Microglia proved to be neuroprotective even when applied up to 4 h after OGD, thus defining a "protective time window." In acute injury such as trauma or stroke, appropriately activated microglia may primarily have a neuroprotective role. Anti-inflammatory treatment within the protective time window of microglia would therefore be counterintuitive.	FAN gGmbH, Inst Appl Neurosci, D-39120 Magdeburg, Germany; German Res Ctr Biotechnol, Res Grp Immunodynam, D-38124 Braunschweig, Germany; Tech Univ Dresden, Inst Zool, D-8027 Dresden, Germany; Univ Hosp Magdeburg, Inst Immunol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, Project Grp Neuropharmacol, D-39118 Magdeburg, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Technische Universitat Dresden; University Hospital Magdeburg; Leibniz Institut fur Neurobiologie (LIN)	Dinkel, K (corresponding author), Jerini AG, Invalidenstr 130, D-10115 Berlin, Germany.	dinkel@jerini.com	Reymann, Klaus G/J-8507-2013; Gunzer, Matthias/AAW-7026-2021	Gunzer, Matthias/0000-0002-5534-6055				BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOWDING AJ, 1991, GLIA, V4, P345, DOI 10.1002/glia.440040403; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FEUERSTEIN G, 1998, CEREBROVASCULAR DIS; Feuerstein GZ, 2001, ARCH NEUROL-CHICAGO, V58, P672, DOI 10.1001/archneur.58.4.672; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P14663, DOI 10.1073/pnas.0404842101; Kitamura Y, 2005, J PHARMACOL SCI, V97, P289, DOI 10.1254/jphs.SC0040129; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kohl A, 2003, EXP NEUROL, V181, P1, DOI 10.1016/S0014-4886(02)00049-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laskowski A, 2005, BRAIN RES, V1037, P78, DOI 10.1016/j.brainres.2004.12.035; Lee JC, 2005, GLIA, V50, P168, DOI 10.1002/glia.20164; Lu YZ, 2005, NEUROSCI LETT, V373, P159, DOI 10.1016/j.neulet.2004.10.004; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; Mizuno T, 1999, BRAIN RES, V849, P58, DOI 10.1016/S0006-8993(99)01984-8; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Petrault O, 2005, BRIT J PHARMACOL, V144, P1051, DOI 10.1038/sj.bjp.0706124; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; STREIT WJ, 1992, NEUROREPORT, V3, P146, DOI 10.1097/00001756-199202000-00006; THERY C, 1993, CLIN NEUROPATHOL, V12, P288; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	48	216	234	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					714	+		10.1096/fj.05-4882fje	http://dx.doi.org/10.1096/fj.05-4882fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473887				2022-12-25	WOS:000237698700024
J	Muerkoster, SS; Lust, J; Arlt, A; Hasler, R; Witt, M; Sebens, T; Schreiber, S; Folsch, UR; Schafer, H				Mueerkoester, S. Sebens; Lust, J.; Arlt, A.; Haesler, R.; Witt, M.; Sebens, T.; Schreiber, S.; Foelsch, U. R.; Schaefer, H.			Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1 beta and NO lead to inactivation of caspases	ONCOGENE			English	Article						chemoresistance; interleukin-1 beta; pancreatic cancer; nitric oxide	NF-KAPPA-B; NITRIC-OXIDE; APOPTOSIS; CANCER; EXPRESSION; RESISTANCE; CHEMOTHERAPY; PROGRESSION; MECHANISMS; STRATEGIES	Pancreatic cancer exhibits profound chemoresistance resulting either from pre-existing ( intrinsic) mechanisms, or from anticancer drug treatment itself ( acquired chemoresistance). To identify molecular alterations leading to acquired chemoresistance, the chemosensitive pancreatic carcinoma cell line PT45-P1 was exposed to low-dose treatment with etoposide for 6 weeks. Afterwards, these cells (PT45-P1res) were much more resistant to high-dose treatment with anticancer drugs than parental cells. Among several differentially expressed genes in PT45-P1res cells, IL-1 beta was most significantly upregulated, a finding in line with our previous observation that IL-1 beta accounts for intrinsic chemoresistance of pancreatic carcinoma cells. Elevated IL-1 beta expression in PT45-P1res cells was confirmed by real-time PCR and ELISA, and treatment with the IL-1 receptor antagonist restored drug-induced apoptosis. The increased IL-1 beta secretion was accompanied by an elevated formation of nitric oxide ( NO) and a NO-dependent inhibition of the etoposide-induced caspase-3/-7/-8/-9 activity. Caspase activation was restored either by the iNOS inhibitor 1400W, the reducing agent dithiothreitol or the IL-1 receptor antagonist, resulting in greater sensitivity towards anticancer drug treatment. Conversely, IL-1 beta or the NO-donor SNAP decreased caspase activation and apoptosis in etoposide-treated PT45-P1 cells. These data confirm IL-1 beta and NO as determinants of chemoresistance in pancreatic cancer, and indicate that the intrinsic and acquired chemoresistance rely to some extent on common molecular targets beneficial for improved therapeutical strategies.	UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; UKSH, Dept Med 1, Mucosal Immunol Res Grp, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Häsler, Robert/A-4908-2009	Arlt, Alexander/0000-0002-6160-1059; Häsler, Robert/0000-0003-4174-8229				Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Brand Randall E., 1998, Current Opinion in Oncology, V10, P362, DOI 10.1097/00001622-199807000-00014; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kim KM, 2002, J BIOCHEM MOL BIOL, V35, P127; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; KIM R, 2004, CANCER RES, V59, P3505; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Lillemoe K D, 1998, Surg Oncol Clin N Am, V7, P199; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Morisaki T, 2003, CURR MED CHEM, V10, P2517, DOI 10.2174/0929867033456431; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Poppenborg H, 1999, CYTOKINE, V11, P689, DOI 10.1006/cyto.1998.0473; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sreedhar AS, 2004, PHARMACOL THERAPEUT, V101, P227, DOI 10.1016/j.pharmthera.2003.11.004; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Turzanski J, 2004, LEUKEMIA, V18, P1662, DOI 10.1038/sj.leu.2403457; Wang WX, 1999, CLIN CANCER RES, V5, P119; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127	36	40	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3973	3981		10.1038/sj.onc.1209423	http://dx.doi.org/10.1038/sj.onc.1209423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474845				2022-12-25	WOS:000238668800011
J	Shmuel, M; Santy, LC; Frank, S; Avrahami, D; Casanova, JE; Altschuler, Y				Shmuel, M; Santy, LC; Frank, S; Avrahami, D; Casanova, JE; Altschuler, Y			ARNO through its coiled-coil domain regulates endocytosis at the apical surface of polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSYLATION FACTOR 6; NUCLEOTIDE EXCHANGE FACTOR; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; RECEPTOR ENDOCYTOSIS; HOMOLOGY DOMAINS; SORTING SIGNAL; SEC7 DOMAIN; MDCK CELLS	ARNO is a guanine-nucleotide exchange protein for the ARF family of GTPases. Here we show that in polarized epithelial cells, ARNO is localized exclusively to the apical plasma membrane, where it regulates endocytosis. Expression of ARNO stimulates apical endocytosis of the polymeric immunoglobulin receptor, and coexpression of ARF6 with ARNO leads to a synergistic stimulation of apical endocytosis. Expression of a dominant negative ARF6 mutant, ARF6-T27N, antagonizes this stimulatory effect. Deletion of the N-terminal coiled-coil ( CC) domain of ARNO causes the mutant ARNO to localize to both the apical and basolateral plasma membranes. Expression of the CC domain alone abolishes ARNO-induced apical endocytosis as well as co-localization of IgA-receptor complexes with ARNO and clathrin. These results suggest that the CC domain contributes to the specificity of apical localization of ARNO through association with components of the apical plasma membrane. We conclude that ARNO acts together with ARF6 to regulate apical endocytosis.	Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	Hebrew University of Jerusalem; University of Virginia	Altschuler, Y (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yoram11@md.huji.ac.il		Santy, Lorraine/0000-0002-4795-0738				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Austin C, 2002, BIOCHEMISTRY-US, V41, P4669, DOI 10.1021/bi016064j; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Claing A, 2004, BIOCHEM CELL BIOL, V82, P610, DOI 10.1139/O04-113; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Decressac S, 2004, EMBO REP, V5, P1171, DOI 10.1038/sj.embor.7400292; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Hernandez-Deviez DJ, 2004, MOL BIOL CELL, V15, P111, DOI 10.1091/mbc.E03-06-0410; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Hyman T, 2006, MOL BIOL CELL, V17, P427, DOI 10.1091/mbc.E05-05-0420; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lecat S, 2000, J CELL SCI, V113, P2607; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Luton F, 2004, MOL BIOL CELL, V15, P1134, DOI 10.1091/mbc.E03-10-0751; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Mangravite LM, 2001, AM J PHYSIOL-RENAL, V280, pF879, DOI 10.1152/ajprenal.2001.280.5.F879; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Maranda B, 2001, J BIOL CHEM, V276, P18540, DOI 10.1074/jbc.M011577200; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Park JG, 2001, J BIOL CHEM, V276, P47751, DOI 10.1074/jbc.C100524200; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Reich V, 1996, J CELL SCI, V109, P2133; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Song J, 1998, J CELL SCI, V111, P2257; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vitale N, 2002, ANN NY ACAD SCI, V971, P193, DOI 10.1111/j.1749-6632.2002.tb04463.x; Yang CZ, 1999, J BIOL CHEM, V274, P25297, DOI 10.1074/jbc.274.36.25297; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13300	13308		10.1074/jbc.M513723200	http://dx.doi.org/10.1074/jbc.M513723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16484220	hybrid			2022-12-25	WOS:000237336600035
J	Delos Santos, NM; Gardner, LA; White, SW; Bahouth, SW				Delos Santos, NM; Gardner, LA; White, SW; Bahouth, SW			Characterization of the residues in helix 8 of the human beta(1)-adrenergic receptor that are involved in coupling the receptor to G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; LEUKOTRIENE B-4; RHODOPSIN; INTERNALIZATION; DESENSITIZATION; MUTATION; TAIL	Several key amino acids within amphipathic helix 8 of the human beta(1)-adrenergic receptor (beta(1)-AR) were mutagenized to characterize their role in signaling by G protein-coupled receptors. Mutagenesis of phenylalanine at position 383 in the hydrophobic interface to histidine (F383H) prevented the biosynthesis of the receptor, indicating that the orientation of helix 8 is important for receptor biosynthesis. Mutagenesis of aspartic acid at position 382 in the hydrophilic interface to leucine (D382L) reduced the binding and uncoupled the receptor from G protein activation. Mutagenesis of the basic arginine residue at position 384 to glutamine (R384Q) or to glutamic acid (R384E) increased basal and agonist-stimulated adenylyl cyclase activities. R384Q and R384E displayed features associated with constitutively active receptors because inverse agonists markedly reduced their elevated basal adenylyl cyclase activities. Isoproterenol increased the phosphorylation and promoted the desensitization of the Gly389 or Arg389 allelic variants of the wild type beta(1)-AR but failed to produce these effects in R384Q and R384E, because these receptors were maximally phosphorylated and desensitized under basal conditions. In contrast to the membranous distribution of the wild type beta(1)-AR, R384Q and R384E were localized mostly within intracellular punctate structures. Inverse agonists restored the membranous distribution of R384Q and R384E, indicating that they recycled normally when their constitutive internalization was blocked by inverse agonists. These data combined with computer modeling of the putative three-dimensional organization of helix 8 indicated that the amphipathic character of helix 8 and side chain projections of Asp(382) and Arg(384) within the hydrophilic interface might serve as a tethering site for the G protein.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Pediat Nephrol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Bahouth, SW (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	sbahouth@utmem.edu	White, Stephen W/N-8164-2018		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013725] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bahouth SW, 1996, MOL PHARMACOL, V49, P1049; BAHOUTH SW, 1995, BIOCHEM J, V307, P831, DOI 10.1042/bj3070831; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRUNTON LL, 2005, PHARMACOL BASIS THER, P237; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; Christopoulos A, 2004, BIOCHEM SOC T, V32, P873, DOI 10.1042/BST0320873; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Faussner A, 2005, FEBS J, V272, P129, DOI 10.1111/j.1432-1033.2004.04390.x; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gardner LA, 2004, J BIOL CHEM, V279, P21135, DOI 10.1074/jbc.M313652200; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Guthrie CR, 2005, J PHARMACOL EXP THER, V313, P1003, DOI 10.1124/jpet.104.081919; KONG SD, 2002, MOL PHARM, V62, P281; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; May LT, 2003, CURR OPIN PHARMACOL, V3, P551, DOI 10.1016/S1471-4892(03)00107-3; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhong M, 2004, BIOCHEMISTRY-US, V43, P3490, DOI 10.1021/bi035899m	50	57	59	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12896	12907		10.1074/jbc.M508500200	http://dx.doi.org/10.1074/jbc.M508500200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16500896	hybrid			2022-12-25	WOS:000237134700085
J	Ercan, A; Panico, M; Sutton-Smith, M; Dell, A; Morris, HR; Matta, KL; Gay, DF; West, CM				Ercan, A; Panico, M; Sutton-Smith, M; Dell, A; Morris, HR; Matta, KL; Gay, DF; West, CM			Molecular characterization of a novel UDP-galactose : fucoside alpha 3-galactosyltransferase that modifies Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; DISCOIDEUM; HYDROXYPROLINE; GLYCOSYLATION; PURIFICATION; COMPLEX; GENOME; FP21	Skp1 is a nucleocytoplasmic protein that is post-translationally modified by a pentasaccharide, Ga1 alpha 1, Ga1 alpha 1, 3Fuc alpha 1, 2Gal beta 1, 3GlcNAc alpha 1O-, at a 4-hydroxylated derivative of Pro-143 in the amebazoan Dictyostelium discoideum. An enzymatic activity that catalyzes formation of the Ga1 alpha 1, 3Fuc linkage by transfer of Gal from UDP-alpha Gal to Fuc alpha 1, 2Gal beta 1, 3G1cNAc alpha 1O-benzyl, or the corresponding glycoform of Skp1, was described previously in cytosolic extracts of Dictyostelium. A protein GT78 associated with this activity has been purified to chromatographic homogeneity. In-gel tryptic digestion followed by nano-liquid chromatography-mass spectrometry on a quadrupole time-of-flight geometry instrument with data-dependent tandem mass spectrometry acquisition yielded a number of peptide fragmentation spectra, nine of which were manually de novo sequenced and found to map onto a predicted 3-exon gene of unknown function on chromosome 4. GT78 is predicted to comprise 648 amino acids with an N-terminal glycosyltransferase and a C-terminal beta-propeller domain. Overexpression of GT78 with a His(6)-tag resulted in a 120-fold increase in Ga1T-activity in cytosolic extracts, and purified His(6)-GT78 exhibited alpha 3Ga1T-activity toward a synthetic acceptor substrate. Expression of the truncated N-terminal region confirmed the predicted catalytic activity of this domain. Disruption of the GT78 gene led to a loss of enzyme activity in extracts and accumulation of the non-galactosylated isoform of Skp1 in cells. GT78 therefore represents the Skp1 alpha 3Ga1T, and its mechanism conforms to the sequential model of Skp1 glycosylation in the cytoplasm shown for earlier enzymes in the pathway. Informatics studies suggest that related catalytic domains are expressed in the Golgi or cytoplasm of plants, other protozoans, and animals.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AY, England; M SCAN Res & Training Ctr, Ascot SL5 7PZ, Berks, England; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Imperial College London; Roswell Park Cancer Institute	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 937, Oklahoma City, OK 73104 USA.	Cwest2@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NIGMS NIH HHS [R01-GM-37539] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barth C, 1998, PLASMID, V39, P141, DOI 10.1006/plas.1997.1326; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Egelund J, 2004, PLANT PHYSIOL, V136, P2609, DOI 10.1104/pp.104.042978; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Faix J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh136; Greer Fiona M, 2003, Methods Mol Biol, V211, P195; Ketcham C, 2004, J BIOL CHEM, V279, P29050, DOI 10.1074/jbc.M313858200; Kostlanova N, 2005, J BIOL CHEM, V280, P27839, DOI 10.1074/jbc.M505184200; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; Steimle PA, 2001, J BIOL CHEM, V276, P6853, DOI 10.1074/jbc.M008992200; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; van der Wel H, 2005, J BIOL CHEM, V280, P14645, DOI 10.1074/jbc.M500600200; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; West C. M., 2005, DICTYOSTELIUM GENOMI, P235; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2004, BBA-GEN SUBJECTS, V1673, P29, DOI 10.1016/j.bbagen.2004.04.007; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Xue J, 2004, RAPID COMMUN MASS SP, V18, P1947, DOI 10.1002/rcm.1573; Young WW, 2004, J MEMBRANE BIOL, V198, P1, DOI 10.1007/s00232-004-0656-5; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; Zhang YY, 1999, J CELL SCI, V112, P4367; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	26	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12713	12721		10.1074/jbc.M513664200	http://dx.doi.org/10.1074/jbc.M513664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16495217	hybrid			2022-12-25	WOS:000237134700063
J	Yiu, GK; Toker, A				Yiu, GK; Toker, A			NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NUCLEAR FACTOR; COLON-CANCER; MATRIX METALLOPROTEINASE-2; COLORECTAL CARCINOMAS; EXPRESSION; PROSTAGLANDIN; ANGIOGENESIS	The NFAT (nuclear factor of activated T cells) family of transcription factors plays a fundamental role in the transcriptional regulation of the immune response. However, NFATs are ubiquitously expressed, and recent evidence points to their important functions in human epithelial cells and carcinomas. Specifically, NFAT has been shown to be active in human breast and colon carcinoma cells and to promote their invasion through Matrigel. The mechanisms by which NFAT promotes invasion have not been defined. To identify NFAT target genes that induce carcinoma invasion, we have established stable breast cancer cell lines that inducibly express transcriptionally active NFAT. Gene expression profiling by cDNA microarray of cells induced to express NFAT revealed up-regulation of cyclooxygenase-2 (COX-2). Increased NFAT expression and activity induced COX-2 expression as well as prostaglandin E-2 synthesis. This induction was more prominent when NFAT was activated by phorbol 12-myristate 13-acetate and calcium ionophore ionomycin and was blocked by the NFAT antagonist cyclosporin A. Breast cancer cells with elevated COX-2 expression showed increased invasion through Matrigel, and this was reduced in cells treated with COX-2 inhibitors. Conversely, loss of NFAT1 protein expression using small interfering RNA led to a reduction in COX-2 transcription and reduced invasion. Similarly, Matrigel invasion was reduced in cells in which COX-2 expression was reduced using specific siRNA. These findings demonstrate that NFAT promotes breast cancer cell invasion through the induction of COX-2 and the synthesis of prostaglandins.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Toker, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN-237, Boston, MA 02215 USA.	atoker@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA096710] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007893] Funding Source: NIH RePORTER; NCI NIH HHS [CA96710] Funding Source: Medline; NHLBI NIH HHS [T32HL007893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Fujita T, 1998, CANCER RES, V58, P4823; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Half E, 2002, CANCER RES, V62, P1676; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Jacobs EJ, 2005, JNCI-J NATL CANCER I, V97, P975, DOI 10.1093/jnci/dji173; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kawamori T, 1998, CANCER RES, V58, P409; Liu ZM, 2005, J BIOL CHEM, V280, P14700, DOI 10.1074/jbc.M500322200; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Morimoto T, 2001, J BIOL CHEM, V276, P34983, DOI 10.1074/jbc.M005498200; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy BS, 2000, CANCER RES, V60, P293; Richards JA, 2003, J CLIN ENDOCR METAB, V88, P2810, DOI 10.1210/jc.2002-021475; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Sivula A, 2005, BREAST CANCER RES TR, V89, P215, DOI 10.1007/s10549-004-0714-4; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474	57	123	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12210	12217		10.1074/jbc.M600184200	http://dx.doi.org/10.1074/jbc.M600184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16505480	hybrid			2022-12-25	WOS:000237134700003
J	Yang, TTC; Ung, PMU; Rincon, M; Chow, CW; Wing, C				Yang, TTC; Ung, PMU; Rincon, M; Chow, CW; Wing, C			Role of the CCAAT/enhancer-binding protein NFATc2 transcription factor cascade in the induction of secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED T-CELLS; ACUTE-PHASE RESPONSE; NUCLEAR-FACTOR; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; CYCLOSPORINE-A; CYCLOOXYGENASE-2 EXPRESSION; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS	Inflammatory cytokines such as interleukin-1 and tumor necrosis factor-alpha modulate a transcription factor cascade in the liver to induce and sustain an acute and systemic defense against foreign entities. The transcription factors involved include NF-kappa B, STAT, and CCAAT/enhancer-binding protein ( C/EBP). Whether the NFAT group of transcription factors ( which was first characterized as playing an important role in cytokine gene expression in the adaptive response in immune cells) participates in the acute- phase response in hepatocytes is not known. Here, we have investigated whether NFAT is part of the transcription factor cascade in hepatocytes during inflammatory stress. We report that interleukin-1 or tumor necrosis factor-alpha increases expression of and activates NFATc2. C/EBP-mediated NFATc2 induction is temporally required for expression of type IIA secretory phospholipase A(2). NFATc2 is also required for expression of phospholipase D-1 and the calcium-binding protein S100A3. Thus, a C/EBP-NFATc2 transcription factor cascade provides an additional means to modulate the acute-phase response upon stimulation with inflammatory cytokines.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT 05401 USA	Yeshiva University; Albert Einstein College of Medicine; University of Vermont	Chow, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	cchow@aecom.yu.edu	Ung, Peter Man-Un/J-1654-2019	Ung, Peter Man-Un/0000-0002-6849-5252	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI051454, R56AI051454, R01AI051454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063167] Funding Source: NIH RePORTER; NIAID NIH HHS [AI051454] Funding Source: Medline; NIDDK NIH HHS [DK063167, R01 DK063167-04, R01 DK063167-05, R01 DK063167-01A2, R01 DK063167, R01 DK063167-02, R01 DK063167-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; BAK CET, 1991, AGENTS ACTIONS, V34, P81, DOI 10.1007/BF01993244; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Bingham CO, 1999, P ASSOC AM PHYSICIAN, V111, P516, DOI 10.1046/j.1525-1381.1999.99321.x; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Burger D, 2002, ANN NY ACAD SCI, V966, P464, DOI 10.1111/j.1749-6632.2002.tb04248.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cush JJ, 1999, J RHEUMATOL, V26, P1176; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; Gilroy DW, 2004, FASEB J, V18, P489, DOI 10.1096/fj.03-0837com; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Granja AG, 2004, J BIOL CHEM, V279, P53736, DOI 10.1074/jbc.M406620200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holvoet P, 2004, ACTA CARDIOL, V59, P479, DOI 10.2143/AC.59.5.2005219; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jaross W, 2002, EUR J CLIN INVEST, V32, P383, DOI 10.1046/j.1365-2362.2002.01000.x; Jin L, 2003, NAT STRUCT BIOL, V10, P807, DOI 10.1038/nsb975; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kountouras J, 2004, J CELL MOL MED, V8, P317, DOI 10.1111/j.1582-4934.2004.tb00321.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Laye JP, 2003, DRUG DISCOV TODAY, V8, P710, DOI 10.1016/S1359-6446(03)02754-5; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin MKS, 1996, J RHEUMATOL, V23, P1162; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rao A, 2000, BRIT MED BULL, V56, P969, DOI 10.1258/0007142001903634; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Sved P, 2004, CANCER RES, V64, P6934, DOI 10.1158/0008-5472.CAN-03-3018; Svetlov SI, 2002, BBA-MOL CELL BIOL L, V1582, P251, DOI 10.1016/S1388-1981(02)00178-6; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Wendum D, 2003, MODERN PATHOL, V16, P130, DOI 10.1097/01.MP.0000052101.58988.1F; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Yang TTC, 2005, MOL CELL BIOL, V25, P907, DOI 10.1128/MCB.25.3.907-920.2005; Yang TTC, 2003, J BIOL CHEM, V278, P15874, DOI 10.1074/jbc.M211560200; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	91	11	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11541	11552		10.1074/jbc.M511214200	http://dx.doi.org/10.1074/jbc.M511214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16500900	hybrid			2022-12-25	WOS:000236988100016
J	Pagler, TA; Rhode, S; Neuhofer, A; Laggner, H; Strobl, W; Hinterndorfer, C; Volf, I; Pavelka, M; Eckhardt, ERM; van der Westhuyzen, DR; Schutz, GJ; Stangl, H				Pagler, TA; Rhode, S; Neuhofer, A; Laggner, H; Strobl, W; Hinterndorfer, C; Volf, I; Pavelka, M; Eckhardt, ERM; van der Westhuyzen, DR; Schutz, GJ; Stangl, H			SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR-BI; SELECTIVE LIPID UPTAKE; CASSETTE TRANSPORTER 1; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; RETRO-ENDOCYTOSIS; HUMAN-FIBROBLASTS; SKIN FIBROBLASTS; PLASMA-MEMBRANE	The high density lipoprotein (HDL) receptor, scavenger receptor class B, type I (SR-BI), mediates selective cholesteryl ester uptake from lipoproteins into liver and steroidogenic tissues but also cholesterol efflux from macrophages to HDL. Recently, we demonstrated the uptake of HDL particles in SR-BI overexpressing Chinese hamster ovarian cells (ldlA7-SRBI) using ultrasensitive microscopy. In this study we show that this uptake of entire HDL particles is followed by resecretion. After uptake, HDL is localized in endocytic vesicles and organelles en route to the perinuclear area; many HDL-positive compartments were classified as multivesiculated and multilamellated organelles by electron microscopy. By using I-125-labeled HDL, we found that similar to 0.8% of the HDL added to the media is taken up by the ldlA7-SRBI cells within 1 h, and almost all HDL is finally resecreted. I-125-Labeled low density lipoprotein showed a very similar association, uptake, and resecretion pattern in ldlA7-SRBI cells that do not express any low density lipoprotein receptor. Moreover, we demonstrate that the process of HDL cell association, uptake, and resecretion occurs in three physiologically relevant cell systems, the liver cell line HepG2, the adrenal cell line Y1BS1, and phorbol myristate acetate-differentiated THP-1 cells as a model for macrophages. Finally, we present evidence that HDL retroendocytosis represents one of the pathways for cholesterol efflux.	Med Univ Vienna, Dept Med Chem, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Physiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Cell Biol & Ultrastruct Res, Ctr Anat & Cell Biol, A-1090 Vienna, Austria; Johannes Kepler Univ, Inst Biophys, A-4040 Linz, Austria; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Johannes Kepler University Linz; University of Kentucky; University of Kentucky	Stangl, H (corresponding author), Med Univ Vienna, Dept Med Chem, Ctr Physiol & Pathophysiol, Wahringerstr 10, A-1090 Vienna, Austria.	Herbert.Stangl@meduniwien.ac.at	Stangl, Herbert/R-9441-2019; Stangl, Herbert/AAT-4379-2021; Schuetz, Gerhard/B-1243-2008	Stangl, Herbert/0000-0002-7288-7320; Schuetz, Gerhard/0000-0003-1542-1089; Eckhardt, Erik/0000-0002-3015-5180; Neuhofer, Angelika/0000-0002-8989-6207	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063763] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63763] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; Altilia S, 2003, J LIPID RES, V44, P254, DOI 10.1194/jlr.M200248-JLR200; Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409; AULINSKAS TH, 1981, BIOCHIM BIOPHYS ACTA, V664, P255, DOI 10.1016/0005-2760(81)90048-5; AULINSKAS TH, 1985, ARTERIOSCLEROSIS, V5, P45, DOI 10.1161/01.ATV.5.1.45; BADIMON JJ, 1992, CIRCULATION, V86, P86; Barth H, 2005, J VIROL, V79, P5774, DOI 10.1128/JVI.79.9.5774-5785.2005; Bertolini S, 2001, ATHEROSCLEROSIS, V154, P599, DOI 10.1016/S0021-9150(00)00587-6; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; Bocharov AV, 2004, J BIOL CHEM, V279, P36072, DOI 10.1074/jbc.M314264200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BURSTEIN M, 1970, J LIPID RES, V11, P583; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DELAMATRE JG, 1990, J LIPID RES, V31, P191; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; FAUST JR, 1979, ARCH BIOCHEM BIOPHYS, V192, P86, DOI 10.1016/0003-9861(79)90074-2; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENSPAN P, 1984, J BIOL CHEM, V259, P1703; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; Hasty AH, 2005, J LIPID RES, V46, P1433, DOI 10.1194/jlr.M400418-JLR200; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; HO YK, 1977, J EXP MED, V145, P1531, DOI 10.1084/jem.145.6.1531; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Huang ZH, 2002, J LIPID RES, V43, P375; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Pavelka M, 1998, HISTOCHEM CELL BIOL, V109, P555, DOI 10.1007/s004180050255; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Rhode S, 2004, CELL BIOCHEM BIOPHYS, V41, P343, DOI 10.1385/CBB:41:3:343; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; RINNINGER F, 1988, J LIPID RES, V29, P1179; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200	66	102	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11193	11204		10.1074/jbc.M510261200	http://dx.doi.org/10.1074/jbc.M510261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488891	hybrid			2022-12-25	WOS:000236822200063
J	Liu, WS; Konduri, SD; Bansal, S; Nayak, BK; Rajasekaran, SA; Karuppayil, SM; Rajasekaran, AK; Das, GM				Liu, WS; Konduri, SD; Bansal, S; Nayak, BK; Rajasekaran, SA; Karuppayil, SM; Rajasekaran, AK; Das, GM			Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NUCLEAR ANTIGEN GENE; C-TERMINUS; CELLS; EXPRESSION; TRANSCRIPTION; ACTIVATION; TRANSACTIVATION; RESISTANCE; STABILITY	Estrogen receptor-alpha (ER alpha) promotes proliferation of breast cancer cells, whereas tumor suppressor protein p53 impedes proliferation of cells with genomic damage. Whether there is a direct link between these two antagonistic pathways has remained unclear. Here we report that ER alpha binds directly to p53 and represses its function. The activation function-2 (AF-2) domain of ER alpha and the C-terminal regulatory domain of p53 are necessary for the interaction. Knocking down p53 and ER alpha by small interfering RNA elicits opposite effects on p53-target gene expression and cell cycle progression. Remarkably, ionizing radiation that causes genomic damage disrupts the interaction between ER alpha and p53. Ionizing radiation together with ER alpha knock down results in an additive effect on transcription of endogenous p53-target gene p21 (CDKN1) in human breast cancer cells. Our findings reveal a novel mechanism for regulating p53 and suggest that suppressing p53 function is an important component in the proproliferative role of ER alpha.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	Roswell Park Cancer Institute; University of California System; University of California Los Angeles	Das, GM (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	gokul.das@roswellpark.org	Das, Gokul M/A-5772-2013; Bansal, Sanjay/F-5944-2012	Das, Gokul M/0000-0003-2937-8093; Langhans, Sigrid/0000-0003-4695-7468	NCI NIH HHS [CA 79911, R01 CA079911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Clarke RB, 2004, TRENDS ENDOCRIN MET, V15, P316, DOI 10.1016/j.tem.2004.07.004; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Liu GZ, 2000, CANCER RES, V60, P1810; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McDonnell DP, 2004, MATURITAS, V48, pS7, DOI 10.1016/j.maturitas.2004.03.006; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Qin CH, 2002, MOL ENDOCRINOL, V16, P1793, DOI 10.1210/me.2002-0006; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	31	121	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9837	9840		10.1074/jbc.C600001200	http://dx.doi.org/10.1074/jbc.C600001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469747	hybrid			2022-12-25	WOS:000236594300003
J	Zhang, DW; Jeang, KT; Lee, CGL				Zhang, DW; Jeang, KT; Lee, CGL			p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers	ONCOGENE			English	Article						FAT10; diubiquitin; promoter; 5 ' UTR; p53	UBIQUITIN-LIKE PROTEIN; WILD-TYPE P53; MHC CLASS-I; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; HEPATOCELLULAR-CARCINOMA; INTERFERON-GAMMA; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; CHECKPOINT	FAT10 is a member of the ubiquitin-like modi. er family of proteins and has been implicated to play important roles in antigen presentation, cytokine response, apoptosis and mitosis. We have recently demonstrated the upregulation of FAT10 gene expression in 90% of hepatocellular carcinoma patients. Here, we identified and characterized the promoter of the FAT10 gene to elucidate the mechanism of FAT10 gene expression. Notably, we found that the 50 untranslated region (5'UTR), from the transcription start site to 15 bases before the translational start site, displays significant promoter activity. Regions upstream of the 5'UTR (from +26 to -1997) do not confer any promoter activity. Curiously, FAT10 promoter activity and expression is significantly repressed in KB3-1 and HepG2 cells, which have wild-type p53, than in p53-negative Hep3B cells. The role of p53 in regulating FAT10 expression was evident by the significant down-regulation (P < 0.05) of FAT10 mRNA expression and promoter activity when wild-type p53 was transfected into p53-null Hep3B cells. Conversely, inhibiting p53 expression through siRNA against p53 significantly enhanced FAT10 expression and promoter activity. p53 was found to bind in vivo to the 50 half consensus sequence of p53binding site located at the FAT10 promoter. Hence, we propose that FAT10 is a downstream target of p53 and dysregulation of FAT10 expression in p53-defective cells could contribute to carcinogenesis.	Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117548, Singapore; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019; Jeang, Kuan-Teh/A-2424-2008	Lee, Caroline G/0000-0002-4323-3635; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001023, Z01AI001023, ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguiar J, 1999, BIOCHEM BIOPH RES CO, V254, P315, DOI 10.1006/bbrc.1998.9929; Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kumanovics A, 2003, ANNU REV IMMUNOL, V21, P629, DOI 10.1146/annurev.immunol.21.090501.080116; LANE DP, 1992, NATURE, V358, P16; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li GQ, 2003, WORLD J GASTROENTERO, V9, P1972, DOI 10.3748/wjg.v9.i9.1972; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XH, 2002, CANCER RES, V62, P1662; Zhao RB, 2000, GENE DEV, V14, P981	41	63	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2006	25	16					2318	2327		10.1038/sj.onc.1209220	http://dx.doi.org/10.1038/sj.onc.1209220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16501612				2022-12-25	WOS:000236764300004
J	Bartolommei, G; Tadini-Buoninsegni, F; Hua, SM; Moncelli, MR; Inesi, G; Guidelli, R				Bartolommei, G; Tadini-Buoninsegni, F; Hua, SM; Moncelli, MR; Inesi, G; Guidelli, R			Clotrimazole inhibits the Ca2+-ATPase (SERCA) by interfering with Ca2+ binding and favoring the E2 conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID SUPPORTED MEMBRANES; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CHARGE TRANSLOCATION; TRANSPORT MECHANISM; ESCHERICHIA-COLI; MUSCLE DISEASE; ATPASE; PUMP; NA+,K+-ATPASE; THAPSIGARGIN	Clotrimazole (CLT) is an antimycotic imidazole derivative that is known to inhibit cytochrome P-450, ergosterol biosynthesis and proliferation of cells in culture, and to interfere with cellular Ca2+ homeostasis. We found that CLT inhibits the Ca2+-ATPase of rabbit fast-twitch skeletal muscle (SERCA1), and we characterized in detail the effect of CLT on this calcium transport ATPase. We used biochemical methods for characterization of the ATPase and its partial reactions, and we also performed measurements of charge movements following adsorption of sarcoplasmic reticulum vesicles containing the ATPase onto a gold-supported biomimetic membrane. CLT inhibits Ca2+-ATPase and Ca2+ transport with a K-I of 35 mu M. Ca2+ binding in the absence of ATP and phosphoenzyme formation by the utilization of ATP in the presence of Ca2+ are also inhibited within the same CLT concentration range. On the other hand, phosphoenzyme formation by utilization of Pi in the absence of Ca2+ is only minimally inhibited. It is concluded that CLT inhibits primarily Ca2+ binding and, consequently, the Ca2+-dependent reactions of the SERCA cycle. It is suggested that CLT resides within the membrane-bound region of the transport ATPase, thereby interfering with binding and the conformational effects of the activating cation.	Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University of Florence; University System of Maryland; University of Maryland Baltimore	Guidelli, R (corresponding author), Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.	guidelli@unifi.it	Tadini-Buoninsegni, Francesco/CAJ-5745-2022	TADINI-BUONINSEGNI, Francesco/0000-0001-5594-2554	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69830] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; BAMBERG E, 1979, BIOPHYS STRUCT MECH, V5, P277, DOI 10.1007/BF02426663; Bartolommei G, 2004, BIOELECTROCHEMISTRY, V63, P157, DOI 10.1016/j.bioelechem.2003.07.010; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; Berman MC, 2003, BIOCHEMISTRY-US, V42, P3556, DOI 10.1021/bi026071n; Buoninsegni FT, 2004, BIOPHYS J, V86, P3671, DOI 10.1529/biophysj.103.036608; Butscher C, 1999, J MEMBRANE BIOL, V168, P169, DOI 10.1007/s002329900507; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Georgopapadakou NH, 1998, CURR OPIN MICROBIOL, V1, P547, DOI 10.1016/S1369-5274(98)80087-8; Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528; Groll AH, 1998, TRENDS MICROBIOL, V6, P117, DOI 10.1016/S0966-842X(97)01206-7; Hartung K, 1997, BIOPHYS J, V72, P2503, DOI 10.1016/S0006-3495(97)78895-7; Hua SM, 2005, J BIOL CHEM, V280, P17579, DOI 10.1074/jbc.M500472200; INESI G, 1980, J BIOL CHEM, V255, P3025; Jan CR, 2000, LIFE SCI, V66, P2289, DOI 10.1016/S0024-3205(00)00558-0; Kaplan J.H., 2004, HDB ATPASES BIOCH CE, P63; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAUGER P, 1991, ELECTROGENIC ION PUM, P104; Lax A, 2002, AM J PHYSIOL-CELL PH, V283, pC85, DOI 10.1152/ajpcell.00580.2001; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Pintschovius J, 1999, BIOPHYS J, V76, P814, DOI 10.1016/S0006-3495(99)77245-0; Pintschovius J, 1999, BIOPHYS J, V76, P827, DOI 10.1016/S0006-3495(99)77246-2; RAO R, 2004, MEMBRANE TRANSPORTER, P365; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SEIFERT K, 1993, BIOPHYS J, V64, P384, DOI 10.1016/S0006-3495(93)81379-1; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; Sohoel H, 2005, J MED CHEM, V48, P7005, DOI 10.1021/jm058036v; Sumbilla C, 2002, J BIOL CHEM, V277, P13900, DOI 10.1074/jbc.M111155200; Tadini-Buoninsegni F, 2003, BBA-BIOMEMBRANES, V1611, P70, DOI 10.1016/S0005-2736(02)00722-8; Uhlemann AC, 2005, NAT STRUCT MOL BIOL, V12, P628, DOI 10.1038/nsmb947; Zhou A, 2004, J MOL BIOL, V343, P931, DOI 10.1016/j.jmb.2004.09.002	40	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9547	9551		10.1074/jbc.M510550200	http://dx.doi.org/10.1074/jbc.M510550200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452481	hybrid			2022-12-25	WOS:000236404700065
J	Bolin, CM; Basha, R; Cox, D; Zawia, NH; Maloney, B; Lahiri, DK; Cardozo-Pelaez, F				Bolin, Celeste M.; Basha, Riyaz; Cox, David; Zawia, Nasser H.; Maloney, Bryan; Lahiri, Debomoy K.; Cardozo-Pelaez, Fernando			Exposure to lead (Pb) and the developmental origin of oxidative DNA damage in the aging brain	FASEB JOURNAL			English	Article						Alzheimer; epigenetic; free radicals; methylation; Ogg1; oxidative stress	AMYLOID PRECURSOR PROTEIN; IRON-RESPONSIVE ELEMENT; ALZHEIMERS-DISEASE; 5'-UNTRANSLATED REGION; GENE-EXPRESSION; MESSENGER-RNA; BIRTH-WEIGHT; CELL-LINES; RAT-BRAIN; REPAIR	Oxidative damage to DNA has been associated with neurodegenerative diseases. Developmental exposure to lead (Pb) has been shown to elevate the Alzheimer's disease (AD) related beta-amyloid peptide (A beta), which is known to generate reactive oxygen species in the aging brain. This study measures the lifetime cerebral 8-hydroxy-2'-deoxyguanosine (oxo(8)dG) levels and the activity of the DNA repair enzyme 8-oxoguanine DNA glycosylase (Ogg1) in rats developmentally exposed to Pb. Oxo(8)dG was transiently modulated early in life (Postnatal day 5), but was later elevated 20 months after exposure to Pb had ceased, while Ogg1 activity was not altered. Furthermore, an age-dependent loss in the inverse correlation between Ogg1 activity and oxo8dG accumulation was observed. The effect of Pb on oxo8dG levels did not occur if animals were exposed to Pb in old age. These increases in DNA damage occurred in the absence of any Pb-induced changes in copper/zinc-superoxide dismutase (SOD1), manganese-SOD (SOD2), and reduced-form glutathion (GSH). These data suggest that oxidative damage and neurodegeneration in the aging brain could be impacted by the developmental disturbances.	Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res,Lab Mol Neurogenet, Indianapolis, IN 46202 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, NEL, Kingston, RI 02881 USA; Univ Montana, Ctr Environm Hlth Sci, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Rhode Island; University of Montana System; University of Montana	Zawia, NH (corresponding author), Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res,Lab Mol Neurogenet, Indianapolis, IN 46202 USA.	nzawia@uri.edu; dlahiri@iupi.edu	Lahiri, Debomoy/AAZ-3322-2020; Maloney, Bryan J/C-4924-2011	Maloney, Bryan J/0000-0003-2364-9649; Basha, Riyaz/0000-0002-4071-0993	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES013022, R29ES008104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018884, R01AG018379] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16457] Funding Source: Medline; NIA NIH HHS [R01 AG18379, R01 AG18884] Funding Source: Medline; NIEHS NIH HHS [ES013022, ES08104] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARKER DJP, 1989, LANCET, V2, P577; Basha MR, 2003, INT J DEV NEUROSCI, V21, P1, DOI 10.1016/S0736-5748(02)00137-5; Basha MR, 2005, J NEUROSCI, V25, P823, DOI 10.1523/JNEUROSCI.4335-04.2005; Bolin C, 2004, J NEUROSCI METH, V136, P69, DOI 10.1016/j.jneumeth.2003.12.025; Bressler J, 1999, NEUROCHEM RES, V24, P595, DOI 10.1023/A:1022596115897; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cardozo-Pelaez F, 1999, MOVEMENT DISORD, V14, P972, DOI 10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO;2-0; Cardozo-Pelaez F, 1998, NEUROBIOL AGING, V19, P311, DOI 10.1016/S0197-4580(98)00067-0; Cardozo-Pelaez F, 2000, FREE RADICAL BIO MED, V28, P779, DOI 10.1016/S0891-5849(00)00172-6; Dorszewska J, 2004, RESP PHYSIOL NEUROBI, V139, P227, DOI 10.1016/j.resp.2003.10.005; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Ge YW, 2004, J NEUROCHEM, V90, P1432, DOI 10.1111/j.1471-4159.2004.02608.x; Guilarte TR, 2000, MOL BRAIN RES, V76, P299, DOI 10.1016/S0169-328X(00)00010-3; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Lahiri DK, 2005, FASEB J, V19, P653, DOI 10.1096/fj.04-2900fje; Lahiri DK, 1999, ANN NY ACAD SCI, V893, P331, DOI 10.1111/j.1749-6632.1999.tb07848.x; LOCKITCH G, 1993, CLIN BIOCHEM, V26, P371, DOI 10.1016/0009-9120(93)90113-K; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Maloney B, 2004, FASEB J, V18, P1288, DOI 10.1096/fj.03-1703fje; Moreira EG, 2001, TOXICOLOGY, V169, P145, DOI 10.1016/S0300-483X(01)00497-8; OTTO DA, 1993, NEUROTOXICOLOGY, V14, P191; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Sambamurti K, 2004, FASEB J, V18, P1034, DOI 10.1096/fj.03-1378fje; SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; SPARKS DL, 2003, P NATL ACAD SCI USA, V100, P11193; Stedeford T, 2001, FREE RADICAL BIO MED, V31, P1272, DOI 10.1016/S0891-5849(01)00715-8; Toscano CD, 2002, DEV BRAIN RES, V139, P217, DOI 10.1016/S0165-3806(02)00569-2; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Venti A, 2004, ANN NY ACAD SCI, V1035, P34, DOI 10.1196/annals.1332.003; WEISS B, 1991, NEUROTOXICOLOGY, V12, P379; Yarbrough DE, 1998, DIABETES CARE, V21, P1652, DOI 10.2337/diacare.21.10.1652; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6; ZAWIA NH, 1994, INT J DEV NEUROSCI, V12, P25, DOI 10.1016/0736-5748(94)90092-2	38	130	139	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					788	+		10.1096/fj.05-5091fje	http://dx.doi.org/10.1096/fj.05-5091fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16484331				2022-12-25	WOS:000237698700017
J	Glesne, D; Huberman, E				Glesne, D.; Huberman, E.			Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation	ONCOGENE			English	Article						macrophage differentiation; PrKX; Smad6; HL-60; leukemia	GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; MACROPHAGE DIFFERENTIATION; ALPHA(5)BETA(1) INTEGRIN; CATALYTIC SUBUNIT; EXPRESSION; INDUCTION; SEQUENCE; SYSTEM; PRKX	To gain insight into the function of human protein kinase X (PrKX), a signal-transduction protein required for macrophage differentiation, we identified regulatory subunit I alpha of protein kinase A, T54 and Smad6 as partners for this protein using a yeast two-hybrid interaction screen. Interactions between PrKX and these proteins were substantiated by co-immunoprecipitation. Interaction between Smad6 and PrKX was also confirmed in human myeloid HL-60 cells following their phorbol 12-myristate 13-acetate (PMA)-induced differentiation into macrophages. In vitro phosphorylation assays demonstrated that PrKX phosphorylates Smad6 at a serine residue. Mutagenesis of this site resulted in abrogation of PrKX phosphorylation. Both PrKX and Smad6 were shown to be co-localized to the nuclear compartment of HL-60 cells during their macrophage differentiation where PrKX levels are induced and Smad6 protein levels remain relatively constant while levels of serine phosphorylation of Smad6 increase. By using in vitro electrophoretic mobility shift assays and in vivo chromatin immunoprecipitation, we also demonstrate that during macrophage differentiation Smad6 displays an increased binding to the human osteopontin, Id2, and Hex gene promoters, which correlates to an observed increased expression of these genes. Finally, vector-based RNA interference experiments established that both Smad6 and PrKX proteins are required for PMA-induced cell attachment and spreading.	Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Gene Express & Funct Grp, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory	Huberman, E (corresponding author), Argonne Natl Lab, Biosci Div, 9700 S Cass Ave,Bld 202, Argonne, IL 60439 USA.	elih@anl.gov			NATIONAL CANCER INSTITUTE [R01CA080826] Funding Source: NIH RePORTER; NCI NIH HHS [CA80826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson G, 1996, CONNECT TISSUE RES, V35, P163, DOI 10.3109/03008209609029188; Atkins K, 1998, J CELL PHYSIOL, V175, P229, DOI 10.1002/(SICI)1097-4652(199805)175:2<229::AID-JCP13>3.0.CO;2-3; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Blaschke RJ, 2000, GENOMICS, V64, P187, DOI 10.1006/geno.2000.6116; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chiorini JA, 1998, MOL CELL BIOL, V18, P5921, DOI 10.1128/MCB.18.10.5921; COLLART FR, 1990, BLOOD, V75, P570; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Pasquale G, 2003, EMBO J, V22, P1716, DOI 10.1093/emboj/cdg153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Greenbaum L, 2003, ONCOGENE, V22, P5221, DOI 10.1038/sj.onc.1206723; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HUBERMAN E, 1982, CARCINOGENESIS, V3, P111, DOI 10.1093/carcin/3.1.111; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMIJO R, 1990, J IMMUNOL, V144, P1311; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Laouar A, 1999, J IMMUNOL, V162, P407; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; LILJESTROM PL, 1985, NUCLEIC ACIDS RES, V13, P7257, DOI 10.1093/nar/13.20.7257; MELENDEZ A, 1995, GENETICS, V141, P1507; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; NISHIKAWA M, 1994, CANCER RES, V54, P4879; Nunes I, 1996, CANCER RES, V56, P495; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Ribardo DA, 2001, J BIOL CHEM, V276, P5467, DOI 10.1074/jbc.M006690200; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Semizarov D, 1998, P NATL ACAD SCI USA, V95, P15412, DOI 10.1073/pnas.95.26.15412; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Vanegas N, 2003, LEUKEMIA RES, V27, P607, DOI 10.1016/S0145-2126(02)00231-X; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; Zhang WJ, 2002, J BIOL CHEM, V277, P45435, DOI 10.1074/jbc.M208056200; Zhao FP, 2001, J ENDOTOXIN RES, V7, P53, DOI 10.1179/096805101101532549; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100; Zimmermann B, 1999, J BIOL CHEM, V274, P5370, DOI 10.1074/jbc.274.9.5370	56	22	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4086	4098		10.1038/sj.onc.1209436	http://dx.doi.org/10.1038/sj.onc.1209436			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491121				2022-12-25	WOS:000238802400009
J	Scatton, O; Chiappini, F; Riou, P; Marconi, A; Saffroy, R; Bralet, MP; Azoulay, D; Boucheix, C; Debuire, B; Uzan, G; Lemoine, A				Scatton, O.; Chiappini, F.; Riou, P.; Marconi, A.; Saffroy, R.; Bralet, M. -P.; Azoulay, D.; Boucheix, C.; Debuire, B.; Uzan, G.; Lemoine, A.			Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; liver cancer; circulating cells; metastasis; mouse model	FETOPROTEIN MESSENGER-RNA; BONE-MARROW-CELLS; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; HEMATOGENOUS DISSEMINATION; MOLECULAR SIGNATURE; COLORECTAL-CANCER; LIVER RESECTION; GASTRIC-CANCER; LUNG-CANCER	There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (< 1 Mahlavu cell/nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.	Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, F-94804 Villejuif, France; Hop Univ Paul Brousse, Ctr Hepatobiliaire, EA 35 41, Assistance Publ Hop Paris, F-94804 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lemoine, A (corresponding author), Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Chiappini, Franck/AAB-9894-2021; Uzan, Georges/M-8199-2018; Azoulay, Daniel/Q-7887-2018	Uzan, Georges/0000-0002-0178-5386; Boucheix, Claude/0000-0003-4184-7008; SAFFROY, RAPHAEL/0000-0002-9878-3669				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2001, J CLIN ONCOL, V19, P368, DOI 10.1200/JCO.2001.19.2.368; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; DIOGUARDI N, 1992, J HEPATOL, V14, P401; Esumi T, 2003, TRANSPLANTATION, V76, P1543, DOI 10.1097/01.TP.0000081945.23698.5D; Fukutomi M, 2001, EUR J GASTROEN HEPAT, V13, P1083, DOI 10.1097/00042737-200109000-00015; Gerber B, 2001, J CLIN ONCOL, V19, P960, DOI 10.1200/JCO.2001.19.4.960; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Greene AK, 2003, J INVEST SURG, V16, P99, DOI 10.1080/08941930390194424; Gross-Goupil M, 2003, ANN SURG, V238, P241, DOI 10.1097/01.sla.0000080959.95226.be; Guller U, 2002, ANN SURG, V236, P768, DOI 10.1097/00000658-200212000-00009; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Ishikawa H, 2004, GUT, V53, P884, DOI 10.1136/gut.2003.026047; Kienle P, 2000, ARCH SURG-CHICAGO, V135, P213, DOI 10.1001/archsurg.135.2.213; Kushida T, 2001, BLOOD, V97, P3292, DOI 10.1182/blood.V97.10.3292; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; Li QG, 2004, WORLD J GASTROENTERO, V10, P903; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Liu Yang, 2003, Hepatobiliary Pancreat Dis Int, V2, P414; Louha M, 1999, HEPATOLOGY, V29, P879, DOI 10.1002/hep.510290348; Majno PE, 1997, ANN SURG, V226, P688, DOI 10.1097/00000658-199712000-00006; Marx J, 2004, SCIENCE, V306, P1455; MATSUMURA M, 1994, HEPATOLOGY, V20, P1418, DOI 10.1002/hep.1840200607; Minata M, 2001, J GASTROEN HEPATOL, V16, P445, DOI 10.1046/j.1440-1746.2001.02461.x; Osaki T, 2002, J CLIN ONCOL, V20, P2930, DOI 10.1200/JCO.2002.11.011; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; Qin LX, 2002, WORLD J GASTROENTERO, V8, P193; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sell S, 2002, SEMIN CELL DEV BIOL, V13, P419, DOI 10.1016/S1084952102001295; Soeth E, 1997, CANCER RES, V57, P3106; Solakoglu O, 2002, P NATL ACAD SCI USA, V99, P2246, DOI 10.1073/pnas.042372199; Tsavellas G, 2001, BRIT J SURG, V88, P1307, DOI 10.1046/j.0007-1323.2001.01863.x; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Woelfle U, 2003, CANCER RES, V63, P5679	44	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4067	4075		10.1038/sj.onc.1209430	http://dx.doi.org/10.1038/sj.onc.1209430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491122				2022-12-25	WOS:000238802400007
J	Verissimo, F; Silva, E; D Morris, J; Pepperkok, R; Jordan, P				Verissimo, F.; Silva, E.; D Morris, J.; Pepperkok, R.; Jordan, P.			Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathway	ONCOGENE			English	Article						apoptosis; Hsp70; procaspase-3; WNK protein kinases	HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; HEAT-SHOCK PROTEINS; DEATH; HSP70; CHAPERONES; EXPRESSION; SPAK; COTRANSPORTERS; DOWNSTREAM; PROTECTION	The subfamily of WNK (with no K lysine) protein kinases has four human members and germline mutations in the WNK1 and WNK4 genes were recently found to cause pseudohypoaldosteronism type II, a familial hypertension disease. Here, we describe cloning and functional analysis of a further WNK member, human WNK3. Endogenous WNK3 protein is an active protein kinase when immunoprecipitated from cells and its overexpression increases the survival of HeLa cells by delaying the onset of apoptosis. Suppression of endogenous WNK3 protein by RNA interference accelerates the apoptotic response and promotes the activation of caspase-3. The mechanism of WNK3 action involves interaction with procaspase-3 and heat-shock protein 70. These results demonstrate a role for WNK3 in promoting cell survival and suggest a mechanism at the level of procaspase-3 activation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Kings Coll London, Sch Med & Dent, Rayne Inst, London SE5 9NU, England; European Mol Biol Lab, Cell Biophys Programme, Heidelberg, Germany	Instituto Nacional de Saude Dr. Ricardo Jorge; University of London; King's College London; European Molecular Biology Laboratory (EMBL)	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Ave Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211; Pepperkok, Rainer/0000-0002-9762-3583				Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cosulich SC, 1999, CURR BIOL, V9, P147, DOI 10.1016/S0960-9822(99)80068-2; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dmitrieva NI, 2005, MUTAT RES-FUND MOL M, V569, P65, DOI 10.1016/j.mrfmmm.2004.06.053; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gotz R, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-85; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holden S, 2004, GENE, V335, P109, DOI 10.1016/j.gene.2004.03.009; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; Kahle KT, 2005, P NATL ACAD SCI USA, V102, P16783, DOI 10.1073/pnas.0508307102; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kaur J, 2000, INT J CANCER, V85, P1; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Komarova EY, 2004, CELL STRESS CHAPERON, V9, P265, DOI 10.1379/CSC-27R1.1; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nollen EAA, 2002, J CELL SCI, V115, P2809; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Rinehart J, 2005, P NATL ACAD SCI USA, V102, P16777, DOI 10.1073/pnas.0508303102; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	54	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4172	4182		10.1038/sj.onc.1209449	http://dx.doi.org/10.1038/sj.onc.1209449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501604				2022-12-25	WOS:000239004800005
J	Yin, W; Rossin, A; Clifford, JL; Gronemeyer, H				Yin, W.; Rossin, A.; Clifford, J. L.; Gronemeyer, H.			Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM	ONCOGENE			English	Article						retinoic acid; rexinoid; apoptosis; TRAIL; insertion mutagenesis; retrovirus	APOPTOSIS-INDUCING LIGAND; NF-KAPPA-B; TUMOR-SELECTIVE APOPTOSIS; INDUCED-PROXIMITY MODEL; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C; DEATH RECEPTORS; DEFICIENT MICE; CELL-LINES; ACTIVATION	Retinoic acid ( RA), used as first-line therapy for acute promyelocytic leukemia ( APL), exerts its antileukemic activity by inducing blast differentiation and activating tumor-selective TNF-related apoptosis-inducing ligand ( TRAIL) signaling. To identify downstream mediators of RA signaling, we used retrovirus-mediated insertion mutagenesis in PLB985 leukemia cells and established the RA-resistant cell line WY-1. In PLB985, but not WY-1 cells, RA induced TRAIL and its DR4 and DR5 receptors. Knocking down TRAIL expression by RNA interference blocked RA-induced apoptosis. WY-1 cells are defective for RA-induced differentiation, G1 arrest and exhibit coresistance to TRAIL. In WY-1 cells, a single virus copy is integrated into a novel RA-regulated gene termed RAM ( retinoic acid modulator). RAM is expressed in the myelomonocytic lineage and extinguished by RA in PLB985, but not WY-1 cells. Whereas knocking down RAM expression by RNA interference promoted RA-induced differentiation and TRAIL- triggered apoptosis of PLB985 and WY-1 cells, overexpression of the predicted 109 amino-acid RAM open reading frame did not alter RA signaling in PLB985 cells. This indicates that, apart from encoding the putative RAM protein, RAM RNA may exert additional functions that are impaired by the retrovirus insertion. Our study demonstrates that RA induction of the TRAIL pathway is also operative in leukemia cells lacking an RAR alpha oncofusion protein and identifies RAM as a novel RA-dependent modulator of myeloid differentiation and death.	UPL, INSERM, CNRS, IGBMC,Dept Cell Biol & Signal Transduct, Illkirch Graffenstaden, France; CU Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gronemeyer, H (corresponding author), LSUHSC, Dept Biochem & Mol Biol, POB 33932,1501 Kings Highway, Shreveport, LA 71130 USA.	hg@igbmc.u-strasbg.fr	Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Rossin, Aurelie/0000-0002-6110-1249				Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Altucci L, 2004, VITAM HORM, V67, P319; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799; Gavalas A, 2002, TRENDS NEUROSCI, V25, P61, DOI 10.1016/S0166-2236(02)02067-2; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Laudet V., 2002, NUCL RECEPTOR FACTS; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Monczak Y, 1997, BLOOD, V90, P3345, DOI 10.1182/blood.V90.9.3345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TUCKER KA, 1987, BLOOD, V70, P372; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watabe E, 2001, JPN J CANCER RES, V92, P140, DOI 10.1111/j.1349-7006.2001.tb01076.x; Yin WH, 2005, INT J BIOCHEM CELL B, V37, P1696, DOI 10.1016/j.biocel.2005.03.003; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3735	3744		10.1038/sj.onc.1209410	http://dx.doi.org/10.1038/sj.onc.1209410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449964				2022-12-25	WOS:000238448300012
J	Chen, M; Chen, SC; Pallen, CJ				Chen, M; Chen, SC; Pallen, CJ			Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC-FAMILY KINASES; ACTIVATION LOOP PHOSPHORYLATION; PTP-ALPHA; CATALYTIC DOMAINS; AUTOPHOSPHORYLATION; FAK; BINDING; PP60(C-SRC); PP125(FAK)	Protein-tyrosine phosphatase-alpha (PTP alpha) activates Src family kinases (SFKs) to promote the integrin-stimulated early autophosphorylation of focal adhesion kinase (FAK). We report here that integrin stimulation induces tyrosine phosphorylation of PTP alpha. PTP alpha was dephosphorylated upon fibroblast detachment from the substratum and rephosphorylated when cells were plated on the integrin ligand fibronectin. PTP alpha phosphorylation occurred at Tyr(789) and required SFKs ( Src or Fyn/Yes), FAK, and an intact cytoskeleton. It also required active PTP alpha or constitutively active Src. These observations indicate that PTP alpha activates SFKs and that the subsequently activated SFK . FAK tyrosine kinase complex in turn phosphorylates PTP alpha. Reintroduction of wild-type PTP alpha or unphosphorylatable PTP alpha(Y789F) ( but not inactive PTP alpha) into PTP alpha-null fibroblasts restored defective integrin-induced SFK activation, FAK phosphorylation, and paxillin phosphorylation. PTP alpha( Y789F) and inactive PTP alpha could not rescue delayed actin stress fiber assembly and focal adhesion formation or defective cell migration. This study distinguishes two roles of PTP alpha in integrin signaling: an early role as an activator of SFKs and FAK with no requirement for PTP alpha phosphorylation and a later downstream role in cytoskeleton-associated events for which PTP alpha phosphorylation at Tyr(789) is essential.	Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Inst Mol & Cell Biol, Singapore 138673, Singapore; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Child & Family Research Institute; University of British Columbia; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of British Columbia	Pallen, CJ (corresponding author), Univ British Columbia, Dept Pediat, Rm 3102,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	cpallen@interchange.ubc.ca		Pallen, Catherine/0000-0002-3576-5295				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	37	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11972	11980		10.1074/jbc.M600561200	http://dx.doi.org/10.1074/jbc.M600561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507567	hybrid			2022-12-25	WOS:000236988100067
J	Levdikov, VM; Blagova, E; Joseph, P; Sonenshein, AL; Wilkinson, AJ				Levdikov, VM; Blagova, E; Joseph, P; Sonenshein, AL; Wilkinson, AJ			The structure of CodY, a GTP- and isoleucine-responsive regulator of stationary phase and virulence in Gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATOR; CRYSTAL-STRUCTURE; GLOBAL REGULATOR; GAF DOMAINS; PROTEIN; PROMOTER; BINDING; LIGAND; GENES	CodY is a global regulator of transcription in Gram-positive bacteria. It represses during growth genes required for adaptation to nutrient limitation, including virulence genes in some human pathogens. CodY activity is regulated by GTP and branched chain amino acids, metabolites whose intracellular concentrations drop as cells enter stationary phase. Although CodY has a highly conserved sequence, it has no significant similarity to proteins of known structure. Here we report crystal structures of two fragments of CodY from Bacillus subtilis that clearly constitute its cofactor and DNA binding domains and reveal that CodY is a chimera of previously observed folding units. The N-terminal cofactor-binding fragment adopts a fold reminiscent of the GAF domains found in cyclic nucleotide phosphodiesterases and adenylate cyclases. It is a dimer stabilized by an intermolecular six alpha-helical bundle that buries an extensive apolar surface rich in residues invariant in CodY orthologues. The branched chain amino acid ligands reside in hydrophobic pockets of each monomer distal to the dimer-forming surface. The structure of the C-terminal DNA binding domain belongs to the winged helix-turn-helix family. The implications of the structure for DNA binding by CodY and its control by cofactor binding are discussed.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	University of York - UK; Tufts University	Wilkinson, AJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	ajw@ysbl.york.ac.uk	Levdikov, Vladimir/AAA-6139-2022	Levdikov, Vladimir/0000-0003-3041-1049; Wilkinson, Anthony/0000-0003-4577-9479	Biotechnology and Biological Sciences Research Council [BBS/B/1213X] Funding Source: Medline; NIGMS NIH HHS [GM042219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042219] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; AVARIND L, 1997, TRENDS BIOCHEM SCI, V22, P458; Blagova EV, 2003, ACTA CRYSTALLOGR D, V59, P155, DOI 10.1107/S0907444902018358; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guedon E, 2001, MOL MICROBIOL, V40, P1227, DOI 10.1046/j.1365-2958.2001.02470.x; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Joseph P, 2005, J BACTERIOL, V187, P4127, DOI 10.1128/JB.187.12.4127-4139.2005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Molle V, 2003, J BACTERIOL, V185, P1911, DOI 10.1128/JB.185.6.1911-1922.2003; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Petranovic D, 2004, MOL MICROBIOL, V53, P613, DOI 10.1111/j.1365-2958.2004.04136.x; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Ratnayake-Lecamwasam M, 2001, GENE DEV, V15, P1093, DOI 10.1101/gad.874201; Serror P, 1996, MOL MICROBIOL, V20, P843, DOI 10.1111/j.1365-2958.1996.tb02522.x; Shivers RP, 2004, MOL MICROBIOL, V53, P599, DOI 10.1111/j.1365-2958.2004.04135.x; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; Sonenshein AL, 2005, CURR OPIN MICROBIOL, V8, P203, DOI 10.1016/j.mib.2005.01.001; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tani TH, 2002, P NATL ACAD SCI USA, V99, P13471, DOI 10.1073/pnas.212510999; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	35	80	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11366	11373		10.1074/jbc.M513015200	http://dx.doi.org/10.1074/jbc.M513015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16488888	hybrid			2022-12-25	WOS:000236822200079
J	Li, G; Hu, YC; Huo, YY; Liu, ML; Freeman, D; Gao, J; Liu, X; Wu, DC; Wu, H				Li, G; Hu, YC; Huo, YY; Liu, ML; Freeman, D; Gao, J; Liu, X; Wu, DC; Wu, H			PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PROTEIN-TYROSINE-PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; PROSTATE-CANCER; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-SURVIVAL; BETA-CATENIN; ANGIOGENESIS; ACTIVATION	Tumor suppressor gene PTEN is highly mutated in a wide variety of human tumors. To identify unknown targets or signal transduction pathways that are regulated by PTEN, microarray analysis was performed to compare the gene expression profiles of Pten null mouse embryonic fibroblasts (MEFs) cell lines and their isogenic counterparts. Expression of a heparin binding growth factor, pleiotrophin (Ptn), was found to be up-regulated in Pten(-/-) MEFs as well as Pten null mammary tumors. Further experiments revealed that Ptn expression is regulated by the PTEN-PI3K-AKT pathway. Knocking down the expression of Ptn by small interfering RNA resulted in the reduction of Akt and GSK-3 beta phosphorylation and suppression of the growth and the tumorigenicity of Pten null MEFs. Our results suggest that PTN participates in tumorigenesis caused by PTEN loss and PTN may be a potential target for anticancer therapy, especially for those tumors with PTEN deficiencies.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Inst Radiat Med, Beijing 100850, Peoples R China	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, H (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	ligang@nic.bmi.ac.cn; hwu@mednet.ucla.edu	LI, GANG/O-1409-2016	LI, GANG/0000-0003-3203-8567; HUO, YANYING/0000-0003-4747-4951	NCI NIH HHS [R01 CA107166, UO1 CA84128-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107166, U01CA084128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aigner A, 2003, ANN ONCOL, V14, P1525, DOI 10.1093/annonc/mdg416; Bandyopadhyay S, 2004, CANCER RES, V64, P7655, DOI 10.1158/0008-5472.CAN-04-1623; Bernard-Pierrot I, 2001, J BIOL CHEM, V276, P12228, DOI 10.1074/jbc.M010913200; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; CZUBAYKO F, 1995, BREAST CANCER RES TR, V36, P157, DOI 10.1007/BF00666037; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2003, MOL CELL NEUROSCI, V24, P1051, DOI 10.1016/j.mcn.2003.08.010; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Malerczyk C, 2005, GENE THER, V12, P339, DOI 10.1038/sj.gt.3302398; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Satyamoorthy K, 2000, PIGM CELL RES, V13, P87, DOI 10.1034/j.1600-0749.13.s8.16.x; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 2003, CANCER RES, V63, P674; Ulbricht U, 2003, J NEUROPATH EXP NEUR, V62, P1265, DOI 10.1093/jnen/62.12.1265; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Weber D, 2000, CANCER RES, V60, P5284; Xiang CC, 2002, NAT BIOTECHNOL, V20, P738, DOI 10.1038/nb0702-738; Zhong H, 2000, CANCER RES, V60, P1541; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	29	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10663	10668		10.1074/jbc.M512509200	http://dx.doi.org/10.1074/jbc.M512509200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16507572	hybrid			2022-12-25	WOS:000236822200004
J	Gray, P; Dunne, A; Brikos, C; Jefferies, CA; Doyle, SL; O'Neill, LAJ				Gray, P; Dunne, A; Brikos, C; Jefferies, CA; Doyle, SL; O'Neill, LAJ			MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN-CONTAINING ADAPTER; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; CYTOKINE PRODUCTION; INTERFERON-BETA; ACTIVATION; PATHWAY; MOLECULE; PROTEIN	Members of the Toll-like receptor (TLR) family are essential players in activating the host innate immune response against infectious microorganisms. All TLRs signal through Toll/interleukin 1 receptor domain-containing adapter proteins. MyD88 adapter-like (Mal) is one such adapter that specifically is involved in TLR2 and TLR4 signaling. When overexpressed we have found that Mal undergoes tyrosine phosphorylation. Three possible phospho-accepting tyrosines were identified at positions 86, 106, and 187, and two mutant forms of Mal in which tyrosines 86 and 187 were mutated to phenylalanine acted as dominant negative inhibitors of NF-kappa B activation by lipopolysaccharide (LPS). Activation of THP-1 monocytic cells with the TLR4 agonist LPS and the TLR2 agonist macrophage-activating lipopeptide-2 induced phosphorylation of Mal on tyrosine residues. We found that the Bruton's tyrosine kinase (Btk) inhibitor LFM-A13 could block the endogenous phosphorylation of Mal on tyrosine in cells treated with macrophage-activating lipopeptide-2 or LPS. Furthermore, Btk immunoprecipitated from THP-1 cells activated by LPS could phosphorylate Mal. Our study therefore provides the first demonstration of the key role of Mal phosphorylation on tyrosine during signaling by TLR2 and TLR4 and identifies a novel function for Btk as the kinase involved.	Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland	Trinity College Dublin	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland.	laoneill@tcd.ie	Doyle, Sarah/C-1453-2014; Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; dunne, aisling/0000-0002-2342-9518; O'Neill, Luke/0000-0002-4333-2748; Doyle, Sarah/0000-0002-6294-9380				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Chen LY, 2003, AM J PHYSIOL-LUNG C, V284, pL607, DOI 10.1152/ajplung.00116.2002; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; Dunne A, 2005, FEBS LETT, V579, P3330, DOI 10.1016/j.febslet.2005.04.024; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Napolitani G, 2003, EUR J IMMUNOL, V33, P2832, DOI 10.1002/eji.200324073; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	36	165	171	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10489	10495		10.1074/jbc.M508892200	http://dx.doi.org/10.1074/jbc.M508892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16439361	Green Published, hybrid			2022-12-25	WOS:000236594300078
J	McGill, GG; Haq, R; Nishimura, EK; Fisher, DE				McGill, GG; Haq, R; Nishimura, EK; Fisher, DE			c-Met expression is regulated by Mitf in the melanocyte lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MICROPHTHALMIA TRANSCRIPTION FACTOR; MALIGNANT-MELANOMA; NEURAL CREST; STIMULATING HORMONE; SIGNAL-TRANSDUCTION; MUSCLE DEVELOPMENT; HGF RECEPTOR; CELLS	Hepatocyte growth factor (HGF)/c-Met signaling is thought to be a key pathway in both melanocyte development and melanoma metastasis. Here, HGF stimulation of melanocytes was seen to upregulate c-Met expression. In an effort to decipher the mechanism by which HGF up-regulates its receptor, we found that c-Met is a direct transcriptional target of Mitf. This was confirmed with chromatin immunoprecipitation experiments of the human c-Met promoter, as well as by the ability of adenovirally expressed Mitf to modulate endogenous c-Met protein levels in melanocytes. Disruption of Mitf blocked HGF-dependent increases in endogenous c-Met message and protein levels, indicating that HGF regulates its own receptor levels via Mitf. Finally, dominant-negative inhibition of Mitf resulted in profound resistance of melanocytes and melanoma cells to HGF-dependent matrix invasion, suggesting a physiologic role for this pathway in melanocytic development and melanoma.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Johns Hopkins Univ Hosp, Dept Internal Med, Baltimore, MD 21205 USA; Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Creat Res Inst Sousei, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine; Hokkaido University; Hokkaido University	Fisher, DE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu						Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; Chen QY, 1997, HEPATOLOGY, V26, P59; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Goding CR, 2000, GENE DEV, V14, P1712; HALABAN R, 1992, ONCOGENE, V7, P2195; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hendrix MJC, 1998, AM J PATHOL, V152, P855; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; King R, 2001, AM J SURG PATHOL, V25, P51, DOI 10.1097/00000478-200101000-00005; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; LIVANT DL, 1995, CANCER RES, V55, P5085; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Otsuka T, 1998, CANCER RES, V58, P5157; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Rusciano D, 1999, J CELL SCI, V112, P623; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Vetrini F, 2004, MOL CELL BIOL, V24, P6550, DOI 10.1128/mcb.24.15.6550-6559.2004; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Yu YL, 2002, CANCER RES, V62, P2951	55	133	138	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10365	10373		10.1074/jbc.M513094200	http://dx.doi.org/10.1074/jbc.M513094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455654	hybrid			2022-12-25	WOS:000236594300065
J	Zarini, S; Gijon, MA; Folco, G; Murphy, RC				Zarini, S; Gijon, MA; Folco, G; Murphy, RC			Effect of arachidonic acid reacylation on leukotriene biosynthesis in human neutrophils stimulated with granulocyte-macrophage colony-stimulating factor and formyl-methionyl-leucyl-phenylalanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULAR CALCIUM; PROSTANOID SYNTHESIS; REAGENT THIMEROSAL; SULFHYDRYL REAGENT; THIOL REAGENT; CA2+ SPIKES; 5-LIPOXYGENASE; CELLS	Priming of human neutrophils with granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by treatment with formyl-methionyl-leucyl-phenylalanine (fMLP) stimulates cells in a physiologically relevant manner with modest 5-lipoxygenase activation and formation of leukotrienes. However, pretreatment of neutrophils with thimerosal, an organomercury thiosalicylic acid derivative, led to a dramatic increase (>50-fold) in the production of leukotriene B-4 and 5-hydroxyeicosatetraenoic acid, significantly higher than that observed after stimulation with calcium ionophore A23187. Little or no effect was observed with thimerosal alone or in combination with either GM-CSF or fMLP. Elevation of [Ca2+](i) induced by thimerosal in neutrophils stimulated with GM-CSF/fMLP was similar but more sustained compared with samples where thimerosal was absent. However, [Ca2+](i) was significantly lower compared with calcium ionophore-treated cells, suggesting that a sustained calcium rise was necessary but not sufficient to explain the effects of this compound on the GM-CSF/fMLP-stimulated neutrophil. Thimerosal was found to directly inhibit neutrophil lysophospholipid: acyl-CoA acyltransferase activity at the doses that stimulate leukotriene production, and analysis of lysates from neutrophil preparations stimulated in the presence of thimerosal showed a marked increase in free arachidonic acid, supporting the inhibition of the reincorporation of this fatty acid into the membrane phospholipids as a mechanism of action for this compound. The dramatic increase in production of leukotrienes by neutrophils when a physiological stimulus such as GM-CSF/fMLP is employed in the presence of thimerosal suggests a critical regulatory role of arachidonate reacylation that limits leukotriene biosynthesis in concert with 5-lipoxygenase and cytosolic phospholipase A(2)alpha activation.	Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA; Hlth Sci Ctr, Aurora, CO 80045 USA; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Milan	Murphy, RC (corresponding author), Univ Colorado Denver, Dept Pharmacol, Mail Stop 8303,12801 E 17th Ave,POB 6511, Aurora, CO 80045 USA.	robert.murphy@uchsc.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Zarini, Simona/0000-0002-7460-3299	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25785] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Elferink JGR, 1999, GEN PHARMACOL, V33, P1, DOI 10.1016/S0306-3623(98)00258-4; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FANTONE JC, 1982, AM J PATHOL, V107, P397; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HANSCH GM, 1985, J IMMUNOL, V135, P1320; HASLETT C, 1985, AM J PATHOL, V119, P101; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Kaever V, 1988, Eicosanoids, V1, P49; KAEVER V, 1988, PROSTAGLANDINS, V35, P885, DOI 10.1016/0090-6980(88)90114-1; Kerkhoff Claus, 2003, Methods Mol Biol, V228, P111, DOI 10.1385/1-59259-400-X:111; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; LANDS WEM, 1976, ENZYMES BIOL MEMBR, P3; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101; Meloni I, 2002, NAT GENET, V30, P436, DOI 10.1038/ng857; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Peters-Golden M, 2003, PROSTAG LEUKOTR ESS, V69, P99, DOI 10.1016/S0952-3278(03)00070-X; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; STUNING M, 1988, PROSTAG LEUKOTR ESS, V32, P1, DOI 10.1016/0952-3278(88)90086-5; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	44	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10134	10142		10.1074/jbc.M510783200	http://dx.doi.org/10.1074/jbc.M510783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16495221	hybrid			2022-12-25	WOS:000236594300039
J	Benson, LJ; Gu, YL; Yakovleva, T; Tong, K; Barrows, C; Strack, CL; Cook, RG; Mizzen, CA; Annunziato, AT				Benson, LJ; Gu, YL; Yakovleva, T; Tong, K; Barrows, C; Strack, CL; Cook, RG; Mizzen, CA; Annunziato, AT			Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NEWLY SYNTHESIZED HISTONES; DEPOSITION-RELATED ACETYLATION; INACTIVE X-CHROMOSOME; RNA-POLYMERASE-II; DNA-SYNTHESIS; ACTIVE CHROMATIN; HELA-CELLS; IN-VIVO; FUNCTIONALLY DISTINCT; LYSINE-9 METHYLATION	Histone posttranslational modifications that accompany DNA replication, nucleosome assembly, and H2A/H2B exchange were examined in human tissue culture cells. Through microsequencing analysis and chromatin immunoprecipitation, it was found that a subset of newly synthesized H3.2/H3.3 is modified by acetylation and methylation at sites that correlate with transcriptional competence. Immunoprecipitation experiments suggest that cytosolic predeposition complexes purified from cells expressing FLAG-H4 contain H3/H4 dimers, not tetramers. Studies of the deposition of newly synthesized H2A/H2B onto replicating and nonreplicating chromatin demonstrated that H2A/H2B exchange takes place in chromatin regions that contain acetylated H4; however, there is no single pattern of H4 acetylation that accompanies exchange. H2A/H2B exchange is also largely independent of the deposition of replacement histone variant, H3.3. Finally, immunoprecipitation of nucleosomes replicated in the absence of de novo nucleosome assembly showed that histone modifications do not prevent the transfer of parental histones to newly replicated DNA and thus have the potential to serve as means of epigenetic inheritance. Our experiments provide an in-depth analysis of the "histone code" associated with chromatin replication and dynamic histone exchange in human cells.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Boston College; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine	Annunziato, AT (corresponding author), Boston Coll, Dept Biol, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.	anthony.annunziato@bc.edu			NIGMS NIH HHS [GM35837, GM53122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035837] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ALBIG W, 1995, GENOMICS, V30, P264, DOI 10.1006/geno.1995.9878; Albig W, 1997, GENOMICS, V40, P314, DOI 10.1006/geno.1996.4592; ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Annunziato AT, 2005, J BIOL CHEM, V280, P12065, DOI 10.1074/jbc.R400039200; ANNUNZIATO AT, 1981, J BIOL CHEM, V256, P1880; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BONNER WM, 1988, BIOCHEMISTRY-US, V27, P6542, DOI 10.1021/bi00417a052; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Chang L, 1999, METHOD ENZYMOL, V304, P76; Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210/me.2004-0496; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; Choi ES, 2005, NUCLEIC ACIDS RES, V33, P7102, DOI 10.1093/nar/gki1011; Chow CM, 2005, EMBO REP, V6, P354, DOI 10.1038/sj.embor.7400366; COUSENS LS, 1982, J BIOL CHEM, V257, P3945; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; CUSICK ME, 1981, BIOCHEMISTRY-US, V20, P6648, DOI 10.1021/bi00526a020; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FRANKLIN SG, 1977, NATURE, V266, P273, DOI 10.1038/266273a0; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; Hake SB, 2006, J BIOL CHEM, V281, P559, DOI 10.1074/jbc.M509266200; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6921, DOI 10.1021/bi00345a026; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Koessler H, 2003, DNA CELL BIOL, V22, P233, DOI 10.1089/104454903321908629; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; KUMAR S, 1986, BIOCHEMISTRY-US, V25, P2055, DOI 10.1021/bi00356a033; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LEFFAK IM, 1984, NATURE, V307, P82, DOI 10.1038/307082a0; LEFFAK M, 1988, BIOCHEMISTRY-US, V27, P686, DOI 10.1021/bi00402a029; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LU MJ, 1994, CHROMOSOMA, V103, P111; Lucchini R, 2001, EMBO J, V20, P7294, DOI 10.1093/emboj/20.24.7294; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; NADEAU P, 1978, BIOCHEMISTRY-US, V17, P4885, DOI 10.1021/bi00616a005; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; OLIVER D, 1974, BIOCHEMISTRY-US, V13, P746, DOI 10.1021/bi00701a017; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; RUSSEV G, 1981, NUCLEIC ACIDS RES, V9, P4129, DOI 10.1093/nar/9.16.4129; RYAN CA, 1999, CURR PROT MOL BIOL, V21, P1; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schermer UJ, 2005, MOL CELL, V19, P279, DOI 10.1016/j.molcel.2005.05.028; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; SEALE RL, 1978, P NATL ACAD SCI USA, V75, P2717, DOI 10.1073/pnas.75.6.2717; SEALE RL, 1976, CELL, V9, P423, DOI 10.1016/0092-8674(76)90087-8; SEALE RL, 1981, BIOCHEMISTRY-US, V20, P6432, DOI 10.1021/bi00525a023; SEALE RL, 1975, J MOL BIOL, V94, P479, DOI 10.1016/0022-2836(75)90216-8; SEALE RL, 1977, BIOCHEMISTRY-US, V16, P2847, DOI 10.1021/bi00632a007; SEALY L, 1979, ARCH BIOCHEM BIOPHYS, V197, P78, DOI 10.1016/0003-9861(79)90221-2; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200; van Holde K.E., 1988, CHROMATIN; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WEINTRAUB H, 1973, COLD SPRING HARB SYM, V38, P247, DOI 10.1101/SQB.1974.038.01.028; WEINTRAUB H, 1976, CELL, V9, P419, DOI 10.1016/0092-8674(76)90086-6; Wirbelauer C, 2005, GENE DEV, V19, P1761, DOI 10.1101/gad.347705; Witt O, 1996, EXP CELL RES, V229, P301, DOI 10.1006/excr.1996.0375; Wolffe A. P., 1999, CHROMATIN STRUCTURE; WU RS, 1983, BIOCHEMISTRY-US, V22, P3868, DOI 10.1021/bi00285a023; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	110	115	120	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9287	9296		10.1074/jbc.M512956200	http://dx.doi.org/10.1074/jbc.M512956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464854	hybrid			2022-12-25	WOS:000236404700036
J	Clausen, JD; McIntosh, DB; Woolley, DG; Anthonisen, AN; Vilsen, B; Andersen, JP				Clausen, JD; McIntosh, DB; Woolley, DG; Anthonisen, AN; Vilsen, B; Andersen, JP			Asparagine 706 and glutamate 183 at the catalytic site of sarcoplasmic reticulum Ca2+-ATPase play critical but distinct roles in E2 states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED PHOSPHORYLATION LOOP; P-TYPE ATPASE; CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; DEHALOGENASE FOLD; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE	Mutants with alteration to Asn(706) of the highly conserved (701)TGDGVND(707) motif in domain P of sarcoplasmic reticulum Ca2+-ATPase were analyzed for changes in transport cycle kinetics and binding of the inhibitors vanadate, BeF, AlF, and MgF. The fluorides likely mimic the phosphoryl group/P-i in the respective ground, transition, and product states of phosphoenzyme hydrolysis (Danko, S., Yamasaki, K., Daiho, T., and Suzuki, H. ( 2004) J. Biol. Chem. 279, 14991 - 14998). Binding of BeF, AlF, and MgF was also studied for mutant Glu(183) --> Ala, where the glutamate of the (181)TGES(184) motif in domain A is replaced. Mutations of Asn(706) and Glu(183) have in common that they dramatically impede the function of the enzyme in E2 states, but have little effect in E1. Contrary to the Glu(183) mutant, in which E2P slowly accumulates (Clausen, J. D., Vilsen, B., McIntosh, D. B., Einholm, A. P., and Andersen, J. P. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 2776 - 2781), E2P formation was not detectable with the Asn(706) mutants. Differential sensitivities of the mutants to inhibition by AlF, MgF, and BeF made it possible to distinguish different roles of Asn(706) and Glu(183). Hence, Asn(706) is less important than Glu(183) for gaining the transition state during E2P hydrolysis but plays critical roles in stabilization of E2P ground and E2 . P-i product states and in the major conformational changes associated with the Ca(2)E1P --> E2P and E2 --> Ca(2)E1 transitions, which seem to be facilitated by interaction of Asn(706) with domain A.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LEBERER E, 1986, BIOCHEM J, V235, P67, DOI 10.1042/bj2350067; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; McIntosh DB, 2004, J BIOL CHEM, V279, P32515, DOI 10.1074/jbc.M403242200; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6111; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEBER K, 1969, J BIOL CHEM, V244, P4406	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9471	9481		10.1074/jbc.M512371200	http://dx.doi.org/10.1074/jbc.M512371200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16449230	hybrid, Green Published			2022-12-25	WOS:000236404700057
J	Gustafson, B; Smith, U				Gustafson, B; Smith, U			Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; GLYCOGEN-SYNTHASE KINASE-3-BETA; MITOTIC CLONAL EXPANSION; NECROSIS-FACTOR-ALPHA; BINDING PROTEIN-BETA; ADIPOCYTE DIFFERENTIATION; INSULIN-RESISTANCE; C/EBP-ALPHA; ADIPOSE-TISSUE; PPAR-GAMMA	Obesity with enlarged fat cells is associated with high local concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha) in the adipose tissue. We examined the effects of this inflammatory state on 3T3-L1 preadipocyte development and differentiation to mature adipose cells. Both IL-6 and TNF alpha impaired the normal differentiation pattern and lipid accumulation. However, IL-6 allowed a normal early induction of differentiation with inhibition of Wnt10b and Pref-1, whereas expression of CCAAT/ enhancer-binding protein alpha, in contrast to peroxisome proliferator-activated receptor gamma, was markedly reduced. TNF alpha also allowed a normal early induction of differentiation, whereas the terminal differentiation to adipose cells was completely prevented. However, both cytokines induced an inflammatory phenotype of the cells but with different profiles. Remarkably, both IL-6 and TNF alpha maintained and augmented the canonical Wnt signaling associated with low axin and high low density lipoprotein receptor-related protein (LRD), Dishevelled, and beta-catenin levels. TNF alpha, but not IL-6, activated Wnt10b expression, whereas IL-6 increased the apparent phosphorylation of Dishevelled. Thus, both IL-6 and TNF alpha prevent the normal development of preadipocytes to fully differentiated adipose cells and, instead, promote an inflammatory phenotype of the adipocytes. These results provide an explanation as to why obesity and diabetes are associated with both local and systemic inflammation, insulin resistance, and ectopic lipid accumulation.	Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Salgrenska Univ Hosp,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Gothenburg Univ, Sahlgrenska Acad, Dept Internal Med, Salgrenska Univ Hosp,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se						Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471-4914(02)02396-1; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Liu JJ, 2004, J BIOL CHEM, V279, P45020, DOI 10.1074/jbc.M407050200; Liu KN, 2002, MOL CELL ENDOCRINOL, V194, P51, DOI 10.1016/S0303-7207(02)00188-0; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pu YS, 2004, PROSTATE, V60, P120, DOI 10.1002/pros.20057; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sharma C, 2004, J BIOL CHEM, V279, P35583, DOI 10.1074/jbc.M403143200; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	51	195	211	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9507	9516		10.1074/jbc.M512077200	http://dx.doi.org/10.1074/jbc.M512077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464856	hybrid			2022-12-25	WOS:000236404700061
J	Keller, M; Lidington, D; Vogel, L; Peter, BF; Sohn, HY; Pagano, PJ; Pitson, S; Spiegel, S; Pohl, U; Bolz, SS				Keller, Matthias; Lidington, Darcy; Vogel, Lukas; Peter, Bernhard Friedrich; Sohn, Hae-Young; Pagano, Patrick J.; Pitson, Stuart; Spiegel, Sarah; Pohl, Ulrich; Bolz, Steffen-Sebastian			Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries	FASEB JOURNAL			English	Article						smooth muscle; signal transduction; transfection; NADPH oxidase; Ca2+ sensitization	VASCULAR SMOOTH-MUSCLE; RHO-KINASE; CALCIUM SENSITIVITY; MYOGENIC REACTIVITY; NAD(P)H OXIDASE; RHOA/RHO-KINASE; NADPH OXIDASE; ACTIVATION; PATHWAYS; CELLS	Myogenic vasoconstriction, an intrinsic response to elevated transmural pressure (TMP), requires the activation of sphingosine kinase (Sk1) and the generation of reactive oxygen species (ROS). We hypothesized that pressure-induced Sk1 signaling and ROS generation are functionally linked. Using a model of cannulated resistance arteries isolated from the hamster gracilis muscle, we monitored vessel diameter and smooth muscle cell (SMC) Ca-i(2+) (Fura-2) or ROS production (dichlorodihydrofluorescein). Elevation of TMP stimulated the translocation of a GFP- tagged Sk1 fusion protein from the cytosol to the plasma membrane, indicative of enzymatic activation. Concurrently, elevation of TMP initiated a rapid and transient production of ROS, which was enhanced by expression of wild-type Sk1 (hSk(wt)) and inhibited by its dominant-negative mutant (hSk(G82D)). Exogenous sphingosine-1-phosphate (S1P) also stimulated ROS generation is isolated vessels. Chemical (1 mu mol/L DPI), peptide (gp91ds-tat/gp91ds), and genetic (N17Rac) inhibition strategies indicated that NADPH oxidase was the source of the pressure-induced ROS. NADPH oxidase inhibition attenuated myogenic vasoconstriction and reduced the apparent Ca2+ sensitivity of the SMC contractile apparatus, without affecting Ca2+-independent, RhoA-mediated vasoconstriction in response to exogenous S1P. Our results indicate a mandatory role for Sk1/S1P in mediating pressure-induced, NADPH oxidase-derived ROS formation. In turn, ROS generation appears to increase Ca2+ sensitivity, necessary for full myogenic vasoconstriction.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Univ Munich, Dept Cardiol, D-80336 Munich, Germany; Henry Ford Hlth Syst, Div Hypertens, Detroit, MI USA; Henry Ford Hlth Syst, Div Vasc Res, Detroit, MI USA; Inst Med & Vet Sci, Hanson Inst Human Immunol, Adelaide, SA 5000, Australia; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	University of Munich; University of Munich; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Hanson Institute; Institute Medical & Veterinary Science Australia; Virginia Commonwealth University	Bolz, SS (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.	bolz@lmu.de	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Lidington, Darcy/0000-0001-7582-7924				Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bolz SS, 2000, CIRCULATION, V102, P2402, DOI 10.1161/01.CIR.102.19.2402; Bolz SS, 2003, J VASC RES, V40, P399, DOI 10.1159/000072830; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; Gregg D, 2003, AM J PHYSIOL-CELL PH, V285, pC723, DOI 10.1152/ajpcell.00230.2003; Hill MA, 2001, J APPL PHYSIOL, V91, P973, DOI 10.1152/jappl.2001.91.2.973; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL666, DOI 10.1152/ajplung.2001.280.4.L666; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Khan NA, 2003, J NEUROVIROL, V9, P584, DOI 10.1080/714044480; Massett MP, 2002, AM J PHYSIOL-HEART C, V283, pH2282, DOI 10.1152/ajpheart.00544.2002; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nowicki PT, 2001, CIRC RES, V89, P114, DOI 10.1161/hh1401.094367; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Paladugu R, 2003, J VASC SURG, V38, P549, DOI 10.1016/S0741-5214(03)00770-5; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Schubert R, 2002, AM J PHYSIOL-HEART C, V283, pH2288, DOI 10.1152/ajpheart.00549.2002; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Touyz RM, 2004, HISTOCHEM CELL BIOL, V122, P339, DOI 10.1007/s00418-004-0696-7; Touyz RM, 2002, CIRC RES, V90, P1205, DOI 10.1161/01.RES.0000020404.01971.2F; VAN BJ, 1998, J CELL BIOL, V142, P229; WOJCIAKSTOTHARD B, 2004, AM J PHYSL LUNG CELL; Xiao DL, 2004, AM J PHYSIOL-HEART C, V286, pH1615, DOI 10.1152/ajpheart.00981.2003	26	50	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					702	+		10.1096/fj.05-4075fje	http://dx.doi.org/10.1096/fj.05-4075fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16476702				2022-12-25	WOS:000237698700021
J	Niikura, Y; Ohta, S; Vandenbeldt, KJ; Abdulle, R; McEwen, BF; Kitagawa, K				Niikura, Y.; Ohta, S.; Vandenbeldt, K. J.; Abdulle, R.; McEwen, B. F.; Kitagawa, K.			17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation	ONCOGENE			English	Article						kinetochore; centromere; HSP90; SGT1 (SUGT1); 17-AAG	SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST KINETOCHORE; BREAST-CANCER CELLS; SPINDLE CHECKPOINT; ATP BINDING; IN-VIVO; CHROMOSOME CONGRESSION; MOLECULAR CHAPERONE; ANAPHASE TRANSITION; CENTROMERE PROTEIN	The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG), which is currently in clinical trials, is thought to exert antitumor activity by simultaneously targeting several oncogenic signaling pathways. Here we report a novel mechanism by which 17-AAG inhibits cell proliferation, and we provide the first evidence that HSP90 is required for the assembly of kinetochore protein complexes in humans. 17-AAG caused delocalization of several kinetochore proteins including CENP-I and CENP-H but excluding CENP-B and CENP-C. Consistently, 17-AAG induced a mitotic arrest that depends on the spindle checkpoint and induced misalignment of chromosomes and aneuploidy. We found that HSP90 associates with SGT1 (suppressor of G2 allele of skp1; SUGT1) in human cells and that depletion of SGT1 sensitizes HeLa cells to 17-AAG. Overexpression of SGT1 restored the localization of specific kinetochore proteins and chromosome alignment in cells treated with 17-AAG. Biochemical and genetic results suggest that HSP90, through its interaction with SGT1 (SUGT1), is required for kinetochore assembly. Furthermore, time-course experiments revealed that transient treatment with 17-AAG between late S andG2/M phases causes substantial delocalization of CENP-H and CENP-I, a finding that strongly suggests that HSP90 participates in kinetochore assembly in a cell cycle-dependent manner.	St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY USA	St Jude Children's Research Hospital; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Kitagawa, K (corresponding author), St Jude Childrens Hosp, Dept Mol Pharmacol, 332 N Lauderdale St,Mail Stop 230,Rm D3007C, Memphis, TN 38105 USA.	katsumi.kitagawa@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066270, R01GM068418] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM68418, GM066270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen Paul R, 2004, Methods Mol Biol, V281, P213; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Bansal PK, 2004, MOL CELL BIOL, V24, P8069, DOI 10.1128/MCB.24.18.8069-8079.2004; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; DROUIN R, 1988, CYTOBIOS, V56, P107; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hostein I, 2001, CANCER RES, V61, P4003; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lingelbach LB, 2004, MOL CELL BIOL, V24, P8938, DOI 10.1128/MCB.24.20.8938-8950.2004; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; Meraldi P, 2005, EMBO J, V24, P1621, DOI 10.1038/sj.emboj.7600641; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, CLIN CANCER RES, V8, P962; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Piper PW, 2003, GENE, V302, P165, DOI 10.1016/S0378-1119(02)01102-2; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; Solit DB, 2002, CLIN CANCER RES, V8, P986; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steensgaard P, 2004, EMBO REP, V5, P626, DOI 10.1038/sj.embor.7400154; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Taylor SS, 2001, J CELL SCI, V114, P4385; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Workman P, 2003, CURR CANCER DRUG TAR, V3, P297, DOI 10.2174/1568009033481868; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yoda K, 1996, MOL CELL BIOL, V16, P5169	62	55	58	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4133	4146		10.1038/sj.onc.1209461	http://dx.doi.org/10.1038/sj.onc.1209461			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501598				2022-12-25	WOS:000239004800001
J	Canty, EG; Garrigue-Antar, L; Kadler, KE				Canty, EG; Garrigue-Antar, L; Kadler, KE			A complete domain structure of Drosophila tolloid is required for cleavage of short gastrulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; ACTIVITY GRADIENT; FAMILY-MEMBER; EMBRYO; GENE; SOG; RESIDUES; HOMOLOG; PRODUCT	Drosophila tolloid ( TLD) is a member of a family of proteinases that play important roles in development and includes mammalian tolloid ( mTLD) and bone morphogenetic protein ( BMP)-1. TLD accentuates the activity of decapentaplegic ( DPP), a transforming growth factor beta superfamily growth factor, by cleaving its antagonist Short gastrulation ( Sog). Similarly, the activity of BMP-2/4 ( vertebrate homologues of DPP) is augmented by cleavage of chordin. However, whereas TLD is an effective Sogase, mTLD is a poor chordinase and is functionally replaced by its smaller splice variant BMP-1, which lacks the most C-terminal epidermal growth factor ( EGF)-like and CUB domains of mTLD. Moreover, the minimal chordinase activity resides in the N-terminal half of BMP-1. This study showed that the proteolytic activity of TLD is considerably enhanced by Ca2+ and tested the hypothesis that the Sogase activity of TLD resides in the N-terminal half of the proteinase. Unexpectedly, it was found that TLD lacking the CUB4 and CUB5 domains and/or the EGF-like domains was unable to cleave Sog. Loss of function mutations have been reported in the tld gene that result in amino acid substitutions at E835K ( in CUB4), S915L ( in CUB5), and N760I ( in EGF2) in TLD. The CUB mutants were found to be ineffective Sogases, but the activity of the EGF2 mutant was unchanged. The results show that substrate recognition and cleavage by Drosophila tolloid and mTLD are different despite their identical domain structure and homologous functions in patterning. The result that the N760I mutant has full Sogase activity suggests that novel substrates for TLD exist.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr CellMatrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr CellMatrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	Laird, Elizabeth/AAX-7280-2020; KADLER, KARL/ABI-2403-2020	Laird, Elizabeth/0000-0001-5041-1316; KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FINELLI L, 1995, GENETICS, V141, P271; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Petropoulou V, 2005, J BIOL CHEM, V280, P22616, DOI 10.1074/jbc.M413468200; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Serpe M, 2005, DEVELOPMENT, V132, P2645, DOI 10.1242/dev.01838; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Shimmi O, 2003, DEVELOPMENT, V130, P4673, DOI 10.1242/dev.00684; Shimmi O, 2005, CELL, V120, P873, DOI 10.1016/j.cell.2005.02.009; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TAKAHARA K, 1995, GENOMICS, V29, P9, DOI 10.1006/geno.1995.1209; Yu K, 2000, DEVELOPMENT, V127, P2143	34	13	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13258	13267		10.1074/jbc.M510483200	http://dx.doi.org/10.1074/jbc.M510483200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16488892	hybrid			2022-12-25	WOS:000237336600031
J	Feng, J; Che, YS; Milse, J; Yin, YJ; Liu, L; Ruckert, C; Shen, XH; Qi, SW; Kalinowski, J; Liu, SJ				Feng, J; Che, YS; Milse, J; Yin, YJ; Liu, L; Ruckert, C; Shen, XH; Qi, SW; Kalinowski, J; Liu, SJ			The gene ncgl2918 encodes a novel maleylpyruvate isomerase that needs mycothiol as cofactor and links mycothiol biosynthesis and gentisate assimilation in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-SMEGMATIS MUTANTS; COMPLETE GENOME SEQUENCE; STRUCTURAL-ANALYSIS; OVOTHIOL-A; STRAIN U2; PATHWAY; IDENTIFICATION; THIOL; DEGRADATION; METABOLISM	Data mining of the Corynebacterium glutamicum genome identified 4 genes analogous to the mshA, mshB, mshC, and mshD genes that are involved in biosynthesis of mycothiol in Mycobacterium tuberculosis and Mycobacterium smegmatis. Individual deletion of these genes was carried out in this study. Mutants mshC(-) and mshD(-) lost the ability to produce mycothiol, but mutant mshB(-) produced mycothiol as the wild type did. The phenotypes of mutants mshC(-) and mshD(-) were the same as the wild type when grown in LB or BHIS media, but mutants mshC(-) and mshD(-) were not able to grow in mineral medium with gentisate or 3-hydroxybenzoate as carbon sources. C. glutamicum assimilated gentisate and 3-hydroxybenzoate via a glutathione-independent gentisate pathway. In this study it was found that the maleylpyruvate isomerase, which catalyzes the conversion of maleylpyruvate into fumarylpyruvate in the glutathione-independent gentisate pathway, needed mycothiol as a cofactor. This mycothiol-dependent maleylpyruvate isomerase gene (ncgl2918) was cloned, actively expressed, and purified from Escherichia coli. The purified mycothiol-dependent isomerase is a monomer of 34 kDa. The apparent K-m and V-max values for maleylpyruvate were determined to be 148.4 +/- 11.9 mu M and 1520 +/- 57.4 mu mol/min/mg, respectively (mycothiol concentration, 2.5 mu M). Previous studies had shown that mycothiol played roles in detoxification of oxidative chemicals and antibiotics in streptomycetes and mycobacteria. To our knowledge, this is the first demonstration that mycothiol is essential for growth of C. glutamicum with gentisate or 3-hydroxybenzoate as carbon sources and the first characterization of a mycothiol-dependent maleylpyruvate isomerase.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China; Univ Bielefeld, Inst Genomforsch, D-33615 Bielefeld, Germany; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Bielefeld; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Liu, SJ (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China.	liusj@sun.im.ac.cn	Che, Yongsheng/D-9840-2017; Liu, Lei/C-2725-2012	Ruckert-Reed, Christian/0000-0002-9722-4435				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; Eggeling L., 2005, HDB CORYNEBACTERIUM, DOI 10.1201/9781420039696; Fuenmayor SL, 1998, J BACTERIOL, V180, P2522, DOI 10.1128/JB.180.9.2522-2530.1998; GOETZ FE, 1992, FEMS MICROBIOL LETT, V97, P45; GRUND E, 1992, APPL ENVIRON MICROB, V58, P1874, DOI 10.1128/AEM.58.6.1874-1877.1992; HAGEDORN SR, 1985, J BACTERIOL, V163, P640, DOI 10.1128/JB.163.2.640-647.1985; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1; Itoh N, 1996, BIOSCI BIOTECH BIOCH, V60, P1826, DOI 10.1271/bbb.60.1826; Jain RK, 1996, APPL MICROBIOL BIOT, V45, P502, DOI 10.1007/BF00578462; JONES DCN, 1990, ARCH MICROBIOL, V154, P489, DOI 10.1007/BF00245233; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; MissetSmits M, 1997, FEBS LETT, V409, P221, DOI 10.1016/S0014-5793(97)00510-3; MONTICELLO DJ, 1985, APPL ENVIRON MICROB, V49, P761, DOI 10.1128/AEM.49.4.761-764.1985; Newton GL, 2005, J BACTERIOL, V187, P7309, DOI 10.1128/JB.187.21.7309-7316.2005; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; OHMOTO T, 1991, AGR BIOL CHEM TOKYO, V55, P1733, DOI 10.1080/00021369.1991.10870876; POH C L, 1980, Journal of Bacteriology, V143, P59; Rani M, 1996, BIOCHEM BIOPH RES CO, V220, P377, DOI 10.1006/bbrc.1996.0413; Rawat M, 2004, J BACTERIOL, V186, P6050, DOI 10.1128/jb.186.18.6050-6058.2004; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Robson ND, 1996, MICROBIOL-SGM, V142, P2115, DOI 10.1099/13500872-142-8-2115; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Shen X.-H., 2005, MICROB ENV, V20, P160, DOI [10.1264/jsme2.20.160, DOI 10.1264/JSME2.20.160]; Shen XH, 2005, SCI CHINA SER C, V48, P241, DOI 10.1360/062004-32; Shen XH, 2005, APPL ENVIRON MICROB, V71, P3442, DOI 10.1128/AEM.71.7.3442-3452.2005; Shen XH, 2004, BIOTECHNOL LETT, V26, P575; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; STEENKAMP DJ, 1994, EUR J BIOCHEM, V223, P43, DOI 10.1111/j.1432-1033.1994.tb18964.x; Tauch A, 2005, J BACTERIOL, V187, P4671, DOI 10.1128/JB.187.13.4671-4682.2005; Tauch A, 2002, CURR MICROBIOL, V45, P362, DOI 10.1007/s00284-002-3728-3; Werwath J, 1998, J BACTERIOL, V180, P4171, DOI 10.1128/JB.180.16.4171-4176.1998; Zhou NY, 2001, J BACTERIOL, V183, P700, DOI 10.1128/JB.183.2.700-708.2001	43	66	69	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10778	10785		10.1074/jbc.M513192200	http://dx.doi.org/10.1074/jbc.M513192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16481315	hybrid			2022-12-25	WOS:000236822200017
J	Lewthwaite, JC; Bastow, ER; Lamb, KJ; Blenis, J; Wheeler-Jones, CPD; Pitsillides, AA				Lewthwaite, JC; Bastow, ER; Lamb, KJ; Blenis, J; Wheeler-Jones, CPD; Pitsillides, AA			A specific mechanomodulatory role for p38 MAPK in embryonic joint articular surface cell MEK-ERK pathway regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE A(2) CPLA(2); OSTEOBLAST-LIKE CELLS; MECHANICAL STRAIN; INFLAMMATORY CYTOKINES; SIGNALING PATHWAYS; GENE-EXPRESSION; GROWTH-FACTOR; CROSS-TALK; IN-VITRO	Mechanisms regulating cell behavior and extracellular matrix composition in response to mechanical stimuli remain unresolved. Our previous studies have established that the MEK-ERK cascade plays a specific role in the mechano-dependent joint formation process by promoting the assembly of pericellular matrices reliant upon hyaluronan (HA) for their integrity. Here we demonstrate: (i) novel cross-talk between p38 MAPK and MEK-ERK signaling pathways that is specific for mechanical stimuli and (ii) a role for p38 MAPK in facilitating HA production by cells derived from the articular surface of embryonic chick tibiotarsal joints. We find that p38 MAPK blockade restricts pericellular assembly of HA-rich matrices and reduces basal as well as mechanical strain-induced release of HA. p38 MAPK blockers potentiated early strain-induced increases but restricted sustained increases in MEK/ERK phosphorylation at later times; c-Fos hyperphosphorylation at threonine 325 was found to parallel this p38 MAPK-mediated modulation of ERK activation. In contrast, p38 MAPK inhibitors had no detectable effect on the ERK activation induced by fibroblast growth factor 2 or pervanadate, a phosphatase inhibitor, and MEK inhibitors did not influence p38 MAPK phosphorylation, confirming both the specificity and unidirectionality of p38 MAPK-ERK cross-talk. Immunochemical and immunoblotting studies revealed constitutive p38 MAPK activation in cells at, or derived from, developing articular joint surfaces. Unlike the MEK-ERK pathway, however, p38 MAPK was not further stimulated by mechanical stimulation in vitro. Thus, p38 MAPK specifically facilitates ERK activation and downstream signaling in response to mechanical stimuli. These results suggest that constitutively active p38 MAPK serves an essential, permissive role in mechanically induced changes in ERK activation and in the accumulation of HA-rich extracellular matrices that serve a key role in joint development.	Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of London; University of London Royal Veterinary College; Harvard University; Harvard Medical School	Pitsillides, AA (corresponding author), Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 0TU, England.	apitsill@rvc.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S; Bastow ER, 2005, J BIOL CHEM, V280, P11749, DOI 10.1074/jbc.M414495200; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Burlando B, 2003, CELL PHYSIOL BIOCHEM, V13, P147, DOI 10.1159/000071865; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Dong Zigang, 2003, Mol Interv, V3, P306, DOI 10.1124/mi.3.6.306; Dowthwaite GP, 2003, MATRIX BIOL, V22, P311, DOI 10.1016/S0945-053X(03)00037-4; Dowthwaite GP, 1999, MATRIX BIOL, V18, P523, DOI 10.1016/S0945-053X(99)00044-X; DRACHMAN DB, 1962, LANCET, V2, P523; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fell HB, 1934, PROC R SOC SER B-BIO, V116, P316, DOI 10.1098/rspb.1934.0076; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; Houliston RA, 2002, THROMB HAEMOSTASIS, V88, P321; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Jessop HL, 2004, J BONE MINER RES, V19, P938, DOI 10.1359/jbmr.2004.19.6.938; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kurosawa M, 2000, AM J PHYSIOL-CELL PH, V278, pC500, DOI 10.1152/ajpcell.2000.278.3.C500; Lamb KJ, 2003, INT J EXP PATHOL, V84, P55, DOI 10.1046/j.1365-2613.2003.00338.x; Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7; Loveridge N, 2002, BONE, V30, P866, DOI 10.1016/S8756-3282(02)00732-9; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mikic B, 2000, J REHABIL RES DEV, V37, P127; MITROVIC DR, 1977, AM J ANAT, V150, P333, DOI 10.1002/aja.1001500207; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Ohashi R, 2004, AM J PATHOL, V164, P477, DOI 10.1016/S0002-9440(10)63138-0; Osborne A. C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P448; Papakrivopoulou J, 2004, CARDIOVASC RES, V61, P736, DOI 10.1016/j.cardiores.2003.12.018; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; PITSILLIDES AA, 1995, J HISTOCHEM CYTOCHEM, V43, P263, DOI 10.1177/43.3.7868856; Pitsillides AA, 2003, METH MOLEC MED, V80, P399; Pitsillides AA, 2003, CELL BIOCHEM FUNCT, V21, P235, DOI 10.1002/cbf.1079; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; PITSILLIDES AA, 1994, BRIT J RHEUMATOL, V33, P5; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Torocsik B, 2000, EUR J NEUROSCI, V12, P527, DOI 10.1046/j.1460-9568.2000.00933.x; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Wheeler-Jones CPD, 2005, HEART, V91, P1366, DOI 10.1136/hrt.2005.072280; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	63	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11011	11018		10.1074/jbc.M510680200	http://dx.doi.org/10.1074/jbc.M510680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464862	hybrid			2022-12-25	WOS:000236822200042
J	Dong, XH; Xu, F; Gong, YH; Gao, J; Lin, P; Chen, T; Peng, Y; Qiang, BQ; Yuan, JG; Peng, XZ; Rao, ZH				Dong, XH; Xu, F; Gong, YH; Gao, J; Lin, P; Chen, T; Peng, Y; Qiang, BQ; Yuan, JG; Peng, XZ; Rao, ZH			Crystal structure of the v domain of human nectin-like molecule-1/Syncam3/Tsll1/Igsf4b, a neural tissue-specific immunoglobulin-like cell-cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPHILIC ADHESION; PROTEIN STRUCTURES; TRANS-INTERACTS; CONTACT SITES; ENTRY; MIGRATION; AFADIN; MEMBER; DIMERIZATION; SUPERFAMILY	Nectins are Ca2+-independent immunoglobulin (Ig) superfamily proteins that participate in the organization of epithelial and endothelial junctions. Nectins have three Ig-like domains in the extracellular region, and the first one is essential in cell-cell adhesion and plays a central role in the interaction with the envelope glycoprotein D of several viruses. Five Nectin-like molecules (Necl-1 through -5) with similar domain structures to those of Nectins have been identified. Necl-1 is specifically expressed in neural tissue, has Ca2+-independent homophilic and heterophilic cell-cell adhesion activity, and plays an important role in the formation of synapses, axon bundles, and myelinated axons. Here we report the first crystal structure of its N-terminal Ig-like V domain at 2.4 angstrom, providing insight into trans-cellular recognition mediated by Necl-1. The protein crystallized as a dimer, and the dimeric form was confirmed by size-exclusion chromatography and chemical cross-linking experiments, indicating this V domain is sufficient for homophilic interaction. Mutagenesis work demonstrated that Phe(82) is a key residue for the adhesion activity of Necl-1. A model for homophilic adhesion of Necl-1 at synapses is proposed based on its structure and previous studies.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Tsinghua Univ, Tsinghua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China; Peking Union Med Coll, Natl Human Genome Ctr, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Peng, XZ (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.	pengxiaozhong@pumc.edu.cn; raozh@xtal.tsinghua.edu.cn	Lin, P/G-7702-2014; Rao, Zihe/HCH-6944-2022	Gong, Yanhua/0000-0002-2693-0498				Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2001, J VIROL, V75, P7987, DOI 10.1128/JVI.75.17.7987-7994.2001; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fabre-Lafay S, 2005, J BIOL CHEM, V280, P19543, DOI 10.1074/jbc.M410943200; Fukami T, 2003, GENE, V323, P11, DOI 10.1016/j.gene.2003.09.018; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakunaga S, 2005, J CELL SCI, V118, P1267, DOI 10.1242/jcs.01656; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129; Zhou Y, 2005, BBA-BIOMEMBRANES, V1669, P142, DOI 10.1016/j.bbamem.2005.01.013	41	37	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10610	10617		10.1074/jbc.M513459200	http://dx.doi.org/10.1074/jbc.M513459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467305	hybrid			2022-12-25	WOS:000236594300093
J	Yang, CL; Yan, N; Paris, J; Wang, XC; Shi, YG; Xue, D				Yang, CL; Yan, N; Paris, J; Wang, XC; Shi, YG; Xue, D			RNA aptamers targeting the cell death inhibitor CED-9 induce cell killing in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 GENE; PROTEIN; RECOGNITION; APOPTOSIS; MITOCHONDRIA; ANTAGONISTS; REGULATORS; SURVIVAL; FAMILY; BINDS	Bcl-2 family proteins include anti- and proapoptotic factors that play important roles in regulating apoptosis in diverse species. Identification of compounds that can modulate the activities of Bcl-2 family proteins will facilitate development of drugs for treatment of apoptosis-related human diseases. We used an in vitro selection method named systematic evolution of ligands by exponential enrichment (SELEX) to isolate RNA aptamers that bind the Caenorhabditis elegans Bcl-2 homolog CED-9 with high affinity and specificity and tested whether these aptamers modulate programmed cell death in C. elegans. Five CED-9 aptamers were isolated and classified into three groups based on their predicted secondary structures. Biochemical analyses indicated that two of these aptamers, R9-2 and R9-7, and EGL-1, an endogenous CED-9-binding proapoptotic protein, bound to distinct regions of CED-9. However, these two aptamers shared overlapping CED-9 binding sites with CED-4, another CED-9-binding proapoptotic factor. Importantly ectopic expression of these two aptamers in touch receptor neurons induced efficient killing of these neurons largely in a CED-3 caspase-dependent manner. These findings suggest that RNA aptamers can be used to modulate programmed cell death in vivo and can potentially be used to develop drugs to treat human diseases caused by abnormal apoptosis.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Colorado System; University of Colorado Boulder; Princeton University	Xue, D (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	ding.xue@colorado.edu		Shi, Yigong/0000-0003-2030-168X; XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066262] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM66262] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Cassiday LA, 2001, BIOCHEMISTRY-US, V40, P2433, DOI 10.1021/bi002376v; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Fan XC, 2004, P NATL ACAD SCI USA, V101, P6934, DOI 10.1073/pnas.0401523101; Finnegan EJ, 2003, J CELL SCI, V116, P4689, DOI 10.1242/jcs.00838; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X; Ghosh G, 2004, CURR OPIN STRUC BIOL, V14, P21, DOI 10.1016/j.sbi.2004.01.004; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; Jones AK, 2005, NAT REV DRUG DISCOV, V4, P321, DOI 10.1038/nrd1692; Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Mayer G, 2001, P NATL ACAD SCI USA, V98, P4961, DOI 10.1073/pnas.091100698; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023; Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; Shangary S, 2003, LEUKEMIA, V17, P1470, DOI 10.1038/sj.leu.2403029; Shi H, 1999, P NATL ACAD SCI USA, V96, P10033, DOI 10.1073/pnas.96.18.10033; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Theis MG, 2004, P NATL ACAD SCI USA, V101, P11221, DOI 10.1073/pnas.0402901101; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang XD, 2001, GENE DEV, V15, P2922; White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	8	14	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9137	9144		10.1074/jbc.M511742200	http://dx.doi.org/10.1074/jbc.M511742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16467303	hybrid			2022-12-25	WOS:000236404700019
J	Miyakoshi, M; Urata, M; Habe, H; Omori, T; Yamane, H; Nojiri, H				Miyakoshi, M; Urata, M; Habe, H; Omori, T; Yamane, H; Nojiri, H			Differentiation of carbazole catabolic operons by replacement of the regulated promoter via transposition of an insertion sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESINOVORANS STRAIN CA10; COMPLETE NUCLEOTIDE-SEQUENCE; GRAM-NEGATIVE BACTERIA; TRANSCRIPTIONAL REGULATORS; PLASMID PCAR1; PSEUDOMONAS; DEGRADATION; HYDROLASE; FADR; 1,9A-DIOXYGENASE	The carbazole catabolic car operons from Pseudomonas resinovorans CA10 and Janthinobacterium sp. J3 have nearly identical nucleotide sequences in their structural and intergenic regions but not in their flanking regions. Transposition of ISPre1 from the anthranilate catabolic ant operon located an inducible promoter P-ant upstream of the car(CA10) operon, which is regulated by the AraC/ XylS family activator AntR in response to anthranilate. The transposed P-ant drives transcription of the car(CA10) operon, which is composed of the carAaAaBaBbCAcAdDFE(CA10) structural genes. Transcriptional fusion truncating P-ant upstream of carAa(CA10) resulted in constitutive luciferase expression. Primer extension analysis identified a transcription start point of the constitutive mRNA of the car(CA10) operon at 385 nucleotides upstream of the carAa(CA10) translation start point, and the P-carAa promoter was found. On the other hand, a GntR family regulatory gene carR(J3) is divergently located upstream of the car(J3) operon. The P-u13 promoter, required for inducible transcription of the car(J3) operon in the presence of carbazole, was identified in the region upstream of carAa(J3), which had been replaced with the P-ant promoter in the car(CA10) operon. Deletion of carR(J3) from a transcriptional fusion resulted in high level constitutive expression from P-u13. Purified CarR(J3) protein bound at two operator sequences O-I and O-II, showing that CarR(J3) directly represses P-u13 in the absence of its inducer, which was identified as 2- hydroxy- 6- oxo- 6-( 2'- aminophenyl) hexa- 2,4- dienoate, an intermediate of the carbazole degradation pathway.	Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Nojiri, H (corresponding author), Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	anojiri@mail.ecc.u-tokyo.ac.jp	Miyakoshi, Masatoshi/H-5256-2018	Miyakoshi, Masatoshi/0000-0002-4901-2809; Nojiri, Hideaki/0000-0003-3091-8691				Cases I, 2001, EMBO J, V20, P1, DOI 10.1093/emboj/20.1.1; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; Dennis JJ, 2004, J MOL BIOL, V341, P753, DOI 10.1016/j.jmb.2004.06.034; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Dominguez-Cuevas P, 2004, PSEUDOMONAS, VOL 2: VIRULENCE AND GENE REGULATION, P319; Endoh T, 2005, MOL MICROBIOL, V55, P897, DOI 10.1111/j.1365-2958.2004.04431.x; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Habe H, 2003, BIOCHEM BIOPH RES CO, V303, P631, DOI 10.1016/S0006-291X(03)00375-9; HAYAISHI O, 1951, J BACTERIOL, V62, P691, DOI 10.1128/JB.62.6.691-709.1951; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; Inoue K, 2004, BIOSCI BIOTECH BIOCH, V68, P1467, DOI 10.1271/bbb.68.1467; Iwata K, 2003, BIOSCI BIOTECH BIOCH, V67, P300, DOI 10.1271/bbb.67.300; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Li W, 2004, GENE, V336, P231, DOI 10.1016/j.gene.2004.03.027; Maeda K, 2003, J MOL BIOL, V326, P21, DOI 10.1016/S0022-2836(02)01400-6; McAdams HH, 2004, NAT REV GENET, V5, P169, DOI 10.1038/nrg1292; Nojiri H, 2005, J MOL BIOL, V351, P355, DOI 10.1016/j.jmb.2005.05.059; Nojiri H, 2003, BIOSCI BIOTECH BIOCH, V67, P36, DOI 10.1271/bbb.67.36; Nojiri H, 2002, BIOSCI BIOTECH BIOCH, V66, P2001, DOI 10.1271/bbb.66.2001; Nojiri H, 2001, J BACTERIOL, V183, P3663, DOI 10.1128/JB.183.12.3663-3679.2001; OUCHIYAMA N, 1993, BIOSCI BIOTECH BIOCH, V57, P455, DOI 10.1271/bbb.57.455; Rigali S, 2002, J BIOL CHEM, V277, P12507, DOI 10.1074/jbc.M110968200; Rist M, 1998, FEMS MICROBIOL LETT, V169, P179, DOI 10.1111/j.1574-6968.1998.tb13315.x; Sambrook J, 2001, MOL CLONING LAB MANU; Sato S, 1997, J BACTERIOL, V179, P4841, DOI 10.1128/jb.179.15.4841-4849.1997; Sato SI, 1997, J BACTERIOL, V179, P4850, DOI 10.1128/jb.179.15.4850-4858.1997; SERDAR CM, 1989, BIOCHEM BIOPH RES CO, V164, P772, DOI 10.1016/0006-291X(89)91526-X; Top EM, 2003, CURR OPIN BIOTECH, V14, P262, DOI 10.1016/S0958-1669(03)00066-1; Tropel D, 2004, MICROBIOL MOL BIOL R, V68, P474, DOI 10.1128/MMBR.68.3.474-500.2004; Urata M, 2004, J BACTERIOL, V186, P6815, DOI 10.1128/JB.186.20.6815-6823.2004; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200	33	14	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8450	8457		10.1074/jbc.M600234200	http://dx.doi.org/10.1074/jbc.M600234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455652	hybrid			2022-12-25	WOS:000236247100020
J	Muralidhara, BK; Negi, S; Chin, CC; Braun, W; Halpert, JR				Muralidhara, BK; Negi, S; Chin, CC; Braun, W; Halpert, JR			Conformational flexibility of mammalian cytochrome P4502B4 in binding imidazole inhibitors with different ring chemistry and side chains - Solution thermodynamics and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS FLAVODOXIN; RESOLUTION CRYSTAL-STRUCTURE; ACTIVE-SITE; THERMOPHILIC CYTOCHROME-P450; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; FUNCTIONAL-ROLE; MUTAGENESIS; RESIDUES; 3A4	Recent x-ray structures of cytochrome P450 2B4 (CYP2B4) reveal an open form that undergoes a large-scale structural transition to a closed form upon binding to 4-(4-chlorophenyl) imidazole (4-CPI). Here, we report for the first time a complete solution thermodynamic study using isothermal titration calorimetry supported by spectroscopic studies to elucidate the conformational flexibility of CYP2B4 in binding imidazole inhibitors with different ring chemistry and side chains: 4-CPI, 1-benzylimidazole (1-BI), 1-CPI, 4-phenylimidazole (4-PI), 1-(2-(benzyloxy)ethyl) imidazole (BEI), and 1-PI. Each of the inhibitors induced type II spectral changes, and IC50 values for enzyme inhibition ranged from 0.1 to 2.4 mu M, following the order 1-BI<4-CPI<1-CPI<4-PI<BEI<1-PI. Calorimetric titrations using monomeric enzyme yielded a 1:1 binding stoichiometry, with the associated K-D values ranging from 0.3 to 4.8 mu M and following the same rank order as the IC50 values. Changes in enthalpy at 25 degrees C ranged from -6.5 to -8.8 kcal mol(-1). The largest difference in binding entropy (+5.9 versus -4.1 cal mol(-1) K-1) was observed between 4-CPI and BEI, respectively, with a 2- fold difference in heat capacity changes (-604 versus -331 cal mol(-1) K-1), which is inferred to result from the reduction of apolar surface area of the enzyme ensuing from a conformational change upon 4-CPI binding. Accessibility to acrylamide of the only tryptophan (Trp(121)), which is located in helix C, was greatly decreased only in protein bound to 4-CPI. Steric restrictions hindered the perfect docking of only BEI to the closed conformation of the enzyme. The thermodynamic signature obtained for structurally similar inhibitors suggests remarkable plasticity of CYP2B4.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Muralidhara, BK (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	bkmurali@utmb.edu	Braun, Werner/A-6642-2012		NIEHS NIH HHS [ES06676, ES03619] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Coon MJ, 2005, ANNU REV PHARMACOL, V45, P1, DOI 10.1146/annurev.pharmtox.45.120403.100030; Cupp-Vickery JR, 2001, J MOL BIOL, V311, P101, DOI 10.1006/jmbi.2001.4803; DeLano WL, 2004, PYMOL USERS MANUAL; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Edsall JT, 1935, J AM CHEM SOC, V57, P1506, DOI 10.1021/ja01311a501; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HELMS V, 1995, BIOPHYS J, V69, P810, DOI 10.1016/S0006-3495(95)79955-6; Honma W, 2005, ARCH BIOCHEM BIOPHYS, V435, P157, DOI 10.1016/j.abb.2004.12.014; Kemp CA, 2005, ARCH BIOCHEM BIOPHYS, V433, P361, DOI 10.1016/j.abb.2004.08.026; Kennedy MW, 2001, J BIOL CHEM, V276, P35008, DOI 10.1074/jbc.C100301200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lin HL, 2003, J PHARMACOL EXP THER, V306, P744, DOI 10.1124/jpet.103.050260; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Muralidhara BK, 2005, J MOL BIOL, V349, P87, DOI 10.1016/j.jmb.2005.03.054; Muralidhara BK, 2003, BIOCHEMISTRY-US, V42, P13074, DOI 10.1021/bi035073k; Muralidhara BK, 2004, BIOCHEMISTRY-US, V43, P12855, DOI 10.1021/bi048944e; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MURRAY M, 1984, CHEM-BIOL INTERACT, V50, P267, DOI 10.1016/0009-2797(84)90036-X; Ohtaka H, 2002, PROTEIN SCI, V11, P1908, DOI 10.1110/ps.0206402; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; Podust LM, 2003, J BIOL CHEM, V278, P12214, DOI 10.1074/jbc.M212210200; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; Renaud JP, 1996, BIOCHEM J, V319, P675, DOI 10.1042/bj3190675; Schleinkofer K, 2005, EMBO REP, V6, P584, DOI 10.1038/sj.embor.7400420; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; Tsai FTF, 1997, PROTEINS, V28, P41; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; Verras A, 2004, J MED CHEM, V47, P3572, DOI 10.1021/jm030608t; Weber PC, 2003, CURR OPIN STRUC BIOL, V13, P115, DOI 10.1016/S0959-440X(03)00003-4; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; WILKINSON CF, 1974, BIOCHEM PHARMACOL, V23, P2377, DOI 10.1016/0006-2952(74)90227-5; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Winn PJ, 2002, P NATL ACAD SCI USA, V99, P5361, DOI 10.1073/pnas.082522999; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Zhao YH, 2006, J BIOL CHEM, V281, P5973, DOI 10.1074/jbc.M511464200	55	68	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8051	8061		10.1074/jbc.M509696200	http://dx.doi.org/10.1074/jbc.M509696200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439365	hybrid			2022-12-25	WOS:000236031000042
J	Archer, JD; Vargas, CC; Anderson, JE				Archer, Jonathan D.; Vargas, Cinthya C.; Anderson, Judy E.			Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort	FASEB JOURNAL			English	Article						nitric oxide; myf5; exercise; utrophin; muscle regeneration	MUSCLE SATELLITE CELLS; CONTRACTION-INDUCED INJURY; OXIDE SYNTHASE TRANSGENE; SKELETAL-MUSCLE; NITRIC-OXIDE; MOUSE MUSCLE; PRECURSOR REPLICATION; GLYCOPROTEIN COMPLEX; MUSCULAR-DYSTROPHY; MYOGENIC CELLS	Although an increase in nitric oxide (NO) in muscle is reported to improve the outcome of deflazacort treatment for mdx mouse muscular dystrophy, the genetic homologue of Duchenne muscular dystrophy (DMD), the impact such treatment on the functional outcomes of the disease, including fiber susceptibility to exercise-induced injury, is not established. Experiments were designed to test whether treatment with deflazacort and L-arginine (a substrate for NO synthase, NOS) would change the extent of fiber injury induced by 24 h of voluntary exercise. The impact of exercise-related injury to induce a secondary regenerative response by muscle was also examined as corroborating evidence of muscle damage. Dystrophic mdx mice were treated for 3 wk with placebo, deflazacort, or deflazacort plus either L-arginine or N-G-nitro-L-arginine methyl ester (a NOS inhibitor). Deflazacort, especially combined with L-arginine, spared quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise (assessed by Evans blue dye infiltration). Deflazacort alone prevented the typical progressive loss of function (measured as voluntary distance run over 24 h) that was observed 3 months later in placebo-treated mice. Therefore, combined deflazacort plus L-arginine treatment spared mdx dystrophic limb muscle from exercise-induced damage and the need for regeneration and induced a persistent functional improvement in distance run. Results suggest a potential new treatment option for improving the quality of life for boys with DMD.	Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Anderson, JE (corresponding author), Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	janders@ms.umanitoba.ca						Ahmad A, 2000, HUM MOL GENET, V9, P2507, DOI 10.1093/hmg/9.17.2507; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; Anderson J, 2002, NITRIC OXIDE-BIOL CH, V7, P36, DOI 10.1016/S1089-8603(02)00011-3; Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Anderson JE, 2004, CAN J PHYSIOL PHARM, V82, P300, DOI 10.1139/Y04-020; Anderson JE, 2003, NEUROMUSCULAR DISORD, V13, P388, DOI 10.1016/S0960-8966(03)00029-4; Anderson JE, 1998, BIOCHEM CELL BIOL, V76, P13, DOI 10.1139/bcb-76-1-13; Anderson JE, 1998, MUSCLE NERVE, V21, P1153, DOI 10.1002/(SICI)1097-4598(199809)21:9<1153::AID-MUS6>3.0.CO;2-6; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; ANDERSON JE, 2005, PROGR MUSCULAR DYSTR; Biggar WD, 2004, NEUROMUSCULAR DISORD, V14, P476, DOI 10.1016/j.nmd.2004.05.001; Biggar WD, 2001, J PEDIATR-US, V138, P45, DOI 10.1067/mpd.2001.109601; Blaveri K, 1999, DEV DYNAM, V216, P244, DOI 10.1002/(SICI)1097-0177(199911)216:3<244::AID-DVDY3>3.0.CO;2-9; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Chaubourt E, 1999, NEUROBIOL DIS, V6, P499, DOI 10.1006/nbdi.1999.0256; Chaubourt E, 2000, CR ACAD SCI III-VIE, V323, P735, DOI 10.1016/S0764-4469(00)01219-1; Chaubourt E, 2002, J PHYSIOLOGY-PARIS, V96, P43, DOI 10.1016/S0928-4257(01)00079-1; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Cousins JC, 2004, J CELL SCI, V117, P3259, DOI 10.1242/jcs.01161; Crawford GE, 2001, HUM MOL GENET, V10, P2745, DOI 10.1093/hmg/10.24.2745; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Granchelli JA, 1996, RES COMMUN MOL PATH, V91, P287; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; GROUNDS MD, 1989, CELL TISSUE RES, V255, P385; Heslop L, 2000, J CELL SCI, V113, P2299; Kiechle FL, 1996, ANN CLIN LAB SCI, V26, P501; Konhilas JP, 2005, AM J PHYSIOL-HEART C, V289, pH455, DOI 10.1152/ajpheart.00085.2005; Li S, 2005, GENE THER, V12, P1099, DOI 10.1038/sj.gt.3302505; Liu MJ, 2005, MOL THER, V11, P245, DOI 10.1016/j.ymthe.2004.09.013; Lynch GS, 2004, CLIN EXP PHARMACOL P, V31, P557, DOI 10.1111/j.1440-1681.2004.04026.x; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; McCarter GC, 2000, J MEMBRANE BIOL, V176, P169, DOI 10.1007/s002320001086; MCGEACHIE JK, 1987, CELL TISSUE RES, V248, P125, DOI 10.1007/BF01239972; McIntosh L, 1998, NMR BIOMED, V11, P1, DOI 10.1002/(SICI)1099-1492(199802)11:1<1::AID-NBM493>3.0.CO;2-D; MCINTOSH LM, 1995, BIOCHEM CELL BIOL, V73, P181, DOI 10.1139/o95-022; McIntosh LM, 1998, ANAT RECORD, V252, P311, DOI 10.1002/(SICI)1097-0185(199810)252:2<311::AID-AR17>3.0.CO;2-Q; MCINTOSH LM, 1994, MUSCLE NERVE, V17, P444, DOI 10.1002/mus.880170413; Morgan JE, 1996, MUSCLE NERVE, V19, P132, DOI 10.1002/(SICI)1097-4598(199602)19:2<132::AID-MUS2>3.0.CO;2-F; Morrison J, 2000, LAB INVEST, V80, P881, DOI 10.1038/labinvest.3780092; Pagel CN, 1999, J NEUROL SCI, V164, P103, DOI 10.1016/S0022-510X(99)00061-1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Segalat L, 2005, EXP CELL RES, V302, P170, DOI 10.1016/j.yexcr.2004.09.007; Sheehan SM, 2000, MUSCLE NERVE, V23, P239, DOI 10.1002/(SICI)1097-4598(200002)23:2<239::AID-MUS15>3.0.CO;2-U; Shiao T, 2004, HUM MOL GENET, V13, P1873, DOI 10.1093/hmg/ddh204; Squire S, 2002, HUM MOL GENET, V11, P3333, DOI 10.1093/hmg/11.26.3333; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Tatsumi R, 2001, EXP CELL RES, V267, P107, DOI 10.1006/excr.2001.5252; Tidball JG, 2004, MOL GENET METAB, V82, P312, DOI 10.1016/j.ymgme.2004.06.006; Warner LE, 2002, HUM MOL GENET, V11, P1095, DOI 10.1093/hmg/11.9.1095; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; Wehling-Henricks M, 2005, HUM MOL GENET, V14, P1921, DOI 10.1093/hmg/ddi197; Wehling-Henricks M, 2004, NEUROMUSCULAR DISORD, V14, P483, DOI 10.1016/j.nmd.2004.04.008; Wells KE, 2003, NEUROMUSCULAR DISORD, V13, P21, DOI 10.1016/S0960-8966(02)00191-8; Wozniak AC, 2005, MUSCLE NERVE, V31, P283, DOI 10.1002/mus.20263; Wozniak AC, 2003, J HISTOCHEM CYTOCHEM, V51, P1437, DOI 10.1177/002215540305101104; Yablonka-Reuveni Z, 2006, DEV DYNAM, V235, P203, DOI 10.1002/dvdy.20602; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27	67	71	86	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					738	+		10.1096/fj.05-4821fje	http://dx.doi.org/10.1096/fj.05-4821fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464957				2022-12-25	WOS:000237698700034
J	Kwak, HB; Song, W; Lawler, JM				Kwak, Hyo-Bum; Song, Wook; Lawler, John M.			Exercise training attenuates age-induced elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart	FASEB JOURNAL			English	Article						aging; caspase-3; caspase-9	SPONTANEOUSLY HYPERTENSIVE-RATS; CYTOCHROME-C RELEASE; SKELETAL-MUSCLE; CALORIC RESTRICTION; AGING HEART; FAILURE; CELL; MITOCHONDRIA; MYOCARDIUM; EXPRESSION	Aging is characterized by loss of myocytes, remodeling, and impaired contractile function in the heart. The rate of programmed cell death, or "apoptosis," in the left ventricle increases with age, and contributes to a 30% reduction in myocytes. Aging may preferentially target the Bcl-2 pathway of apoptosis in the heart. Exercise can protect cardiac function of the aging heart, although the mechanisms are poorly understood. We tested the hypothesis that 12 wk of exercise training would attenuate age-induced increases in remodeling, apoptosis, and Bax/Bcl-2 ratio in rat left ventricle. We found that exercise training provided significant protection against loss of cardiac myocytes, reduction in number of myonuclei, reactive hypertrophy of remaining myocytes, and increased connective tissue in left ventricle of the aging rat heart. Exercise training significantly attenuated age- induced increases of apoptosis in the left ventricle, as indicated by lower DNA fragmentation, TUNEL-positive staining, and caspase-3 cleavage, when compared with left ventricles from the age- matched sedentary group. Further, exercise training in the aging reduced caspase-9 levels and Bax/ Bcl-2 ratio by lowering Bax protein expression while increasing Bcl-2 levels. These are the first data to demonstrate protective effects of endurance exercise training against elevated apoptosis and remodeling in the aging heart.	Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, College Stn, TX 77843 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Health San Antonio	Lawler, JM (corresponding author), Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.	jml2621@neo.tamu.edu		Kwak, Hyo Bum/0000-0003-0451-4554				Abou-Raya S, 2004, CLIN INVEST MED, V27, P93; Aguila MB, 2001, MECH AGEING DEV, V122, P77, DOI 10.1016/S0047-6374(00)00215-3; Azhar G, 1999, MECH AGEING DEV, V112, P5, DOI 10.1016/S0047-6374(99)00048-2; Bing Oscar H L, 2002, Heart Fail Rev, V7, P71; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027; Burlew Brad S, 2004, Am J Geriatr Cardiol, V13, P29, DOI 10.1111/j.1076-7460.2004.00059.x; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; Centurione L, 2003, MECH AGEING DEV, V124, P957, DOI 10.1016/S0047-6374(03)00168-4; Centurione L, 2002, MECH AGEING DEV, V123, P341, DOI 10.1016/S0047-6374(01)00378-5; Chandrashekhar Y, 2004, J AM COLL CARDIOL, V43, P295, DOI 10.1016/j.jacc.2003.09.026; Csiszar A, 2004, PHYSIOL GENOMICS, V17, P21, DOI 10.1152/physiolgenomics.00136.2003; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; Debessa CRG, 2001, MECH AGEING DEV, V122, P1049; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Ferder L, 1998, AM J HYPERTENS, V11, P1297, DOI 10.1016/S0895-7061(98)00152-6; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; Hagen TM, 2002, ANN NY ACAD SCI, V959, P491, DOI 10.1111/j.1749-6632.2002.tb02119.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Isoyama Shogen, 2002, Heart Fail Rev, V7, P63; Jin HK, 2000, AM J PHYSIOL-HEART C, V279, pH2994, DOI 10.1152/ajpheart.2000.279.6.H2994; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kang PM, 2004, AM J PHYSIOL-HEART C, V287, pH72, DOI 10.1152/ajpheart.00556.2003; Kass DA, 2004, CIRC RES, V94, P1533, DOI 10.1161/01.RES.0000129254.25507.d6; Kemi M, 2000, TOXICOL PATHOL, V28, P285, DOI 10.1177/019262330002800208; Kobayashi N, 2005, ARTERIOSCL THROM VAS, V25, P2114, DOI 10.1161/01.ATV.0000178993.13222.f2; Lajoie C, 2004, PFLUG ARCH EUR J PHY, V449, P26, DOI 10.1007/s00424-004-1307-0; LAWLER JM, 1993, MED SCI SPORT EXER, V25, P1259; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Leeuwenburgh C, 1997, ARCH BIOCHEM BIOPHYS, V346, P74, DOI 10.1006/abbi.1997.0297; Liu JJ, 2000, CARDIOVASC RES, V45, P729, DOI 10.1016/S0008-6363(99)00382-X; Liu LX, 1998, AM J PHYSIOL-REG I, V275, pR315, DOI 10.1152/ajpregu.1998.275.1.R315; Liu PT, 2002, CARDIOVASC RES, V56, P443, DOI 10.1016/S0008-6363(02)00603-X; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, pR423, DOI 10.1152/ajpregu.00296.2001; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; POWERS SK, 1993, AM J PHYSIOL, V265, pH2094, DOI 10.1152/ajpheart.1993.265.6.H2094; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Quindry J, 2005, EXP GERONTOL, V40, P416, DOI 10.1016/j.exger.2005.03.010; Roffe C, 1998, BRIT J BIOMED SCI, V55, P136; Ruetten H, 2001, J AM COLL CARDIOL, V38, P2063, DOI 10.1016/S0735-1097(01)01670-9; Schulman SP, 1996, CIRCULATION, V94, P359, DOI 10.1161/01.CIR.94.3.359; Siu PM, 2005, J APPL PHYSIOL, V99, P204, DOI 10.1152/japplphysiol.00084.2005; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Taylor RP, 2003, ACTA PHYSIOL SCAND, V178, P107, DOI 10.1046/j.1365-201X.2003.01132.x; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wanagat J, 2002, J MOL CELL CARDIOL, V34, P17, DOI 10.1006/jmcc.2001.1483; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9	55	117	124	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					791	+		10.1096/fj.05-5116fje	http://dx.doi.org/10.1096/fj.05-5116fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16459353				2022-12-25	WOS:000237698700040
J	Cao, X; Qin, J; Xie, Y; Khan, O; Dowd, F; Scofield, M; Lin, MF; Tu, Y				Cao, X.; Qin, J.; Xie, Y.; Khan, O.; Dowd, F.; Scofield, M.; Lin, M-F; Tu, Y.			Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells	ONCOGENE			English	Article						RGS2; GPCRs; extracellular signal-regulated; kinases; prostate cancer; androgen receptor; androgen independence	PROTEIN-COUPLED RECEPTOR; LOOP-HELIX PHOSPHOPROTEIN; MESSENGER-RNA; NERVOUS-SYSTEM; ALPHA SUBUNITS; SIGNALING RGS; TARGET GENE; LNCAP CELLS; MAP KINASE; EXPRESSION	Hormones acting through G protein-coupled receptors ( GPCRs) can cause androgen-independent activation of androgen receptor ( AR) in prostate cancer cells. Regulators of G-protein signaling ( RGS) proteins, through their GTPase activating protein ( GAP) activities, inhibit GPCR-mediated signaling by inactivating G proteins. Here, we identified RGS2 as a gene specifically downregulated in androgen-independent prostate cancer cells. Expression of RGS2, but not other RGS proteins, abolished androgen-independent AR activity in androgen-independent LNCaP cells and CWR22Rv1 cells. In LNCaP cells, RGS2 inhibited G(q)-coupled GPCR signaling. Expression of exogenous wild-type RGS2, but not its GAP-deficient mutant, significantly reduced AR activation by constitutively activated G(q)Q209L mutant whereas silencing endogenous RGS2 by siRNA enhanced G(q)Q209L-stimulated AR activity. RGS2 had no effect on RGS-insensitive G(q)Q209L/G188S-induced AR activation. Furthermore, extracellular signal-regulated kinase 1/2 ( ERK1/2) was found to be involved in RGS2-mediated regulation of androgen-independent AR activity. In addition, RGS2 functioned as a growth suppressor for androgen-independent LNCaP cells whereas androgen-sensitive LNCaP cells with RGS2 silencing had a growth advantage under steroid-reduced conditions. Finally, RGS2 expression level was significantly decreased in human prostate tumor specimens. Taken together, our results suggest RGS2 as a novel regulator of AR signaling and its repression may be an important step during prostate tumorigenesis and progression.	Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; Univ Nebraska, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	Creighton University; University of Nebraska System	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Pl, Omaha, NE 68178 USA.	Yat60399@creighton.edu		Khan, Obaid/0000-0002-5596-2122; Scofield, Margaret/0000-0002-9332-1641	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline; NCRR NIH HHS [P20 RR018759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; Bakin RE, 2003, CANCER RES, V63, P1981; Ben-Josef E, 1999, J UROLOGY, V161, P970, DOI 10.1016/S0022-5347(01)61831-7; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Candas B, 2000, PROSTATE, V45, P19; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cunningham JM, 1996, CANCER RES, V56, P4475; DAAKA Y, 2004, SCI STKE, V216, P2; Dai J, 2002, CLIN CANCER RES, V8, P2399; Denmeade SR, 2003, PROSTATE, V54, P249, DOI 10.1002/pros.10199; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gioeli D, 1999, CANCER RES, V59, P279; Gohji K, 2001, J UROLOGY, V165, P1033, DOI 10.1016/S0022-5347(05)66597-4; Grillet N, 2003, J NEUROSCI, V23, P10613; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; GUTKIND JS, 2000, SCI STKE, V40, P1; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hobisch A, 1996, PROSTATE, V28, P129; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ingi T, 1998, J NEUROSCI, V18, P7178; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Karan D, 2001, CLIN CANCER RES, V7, P3472; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lee YF, 2002, CANCER RES, V62, P6039; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Nelson JB, 1996, CANCER RES, V56, P663; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Robinet EA, 2001, NEUROREPORT, V12, P1731, DOI 10.1097/00001756-200106130-00043; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schwable J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood-2004-03-0940; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taub JS, 2003, CANCER RES, V63, P2037; Tepper CG, 2002, CANCER RES, V62, P6606; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Tovey SC, 2004, MOL PHARMACOL, V66, P1453, DOI 10.1124/mol.104.005827; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU HK, 1995, LEUKEMIA, V9, P1291; Xia CZ, 2001, ONCOGENE, V20, P5903, DOI 10.1038/sj.onc.1204803; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu LL, 2000, CANCER RES, V60, P6568; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	78	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3719	3734		10.1038/sj.onc.1209408	http://dx.doi.org/10.1038/sj.onc.1209408			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449965				2022-12-25	WOS:000238448300011
J	Houliston, RS; Endtz, HP; Yuki, N; Li, JJ; Jarrell, HC; Koga, M; van Belkum, A; Karwaski, MF; Wakarchuk, WW; Gilbert, M				Houliston, RS; Endtz, HP; Yuki, N; Li, JJ; Jarrell, HC; Koga, M; van Belkum, A; Karwaski, MF; Wakarchuk, WW; Gilbert, M			Identification of a sialate o-acetyltransferase from Campylobacter jejuni - Demonstration of direct transfer to the C-9 position of terminal alpha-2,8-linked sialic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; DE-ORTHO-ACETYLATION; HUMAN-MELANOMA CELLS; N-LINKED GLYCANS; NEISSERIA-MENINGITIDIS; CORE OLIGOSACCHARIDE; GANGLIOSIDE MIMICS; FORM VARIATION; SEROGROUP-Y; LIPOOLIGOSACCHARIDE	We have identified a sialate O-acetyltransferase in the lipo-oligosaccharide biosynthesis locus of Campylobacter jejuni. Strains possessing this locus are known to produce sialylated outer core structures that mimic host gangliosides, and have been implicated in triggering the onset of Guillain-Barre syndrome. The acetyltransferase, which was cloned and expressed as a fusion construct in Escherichia coli, is soluble and homologous with members of the NodL-LacA-CysE family of O-acetyltransferases. This enzyme catalyzes the transfer of O-acetyl groups onto oligosaccharide-bound sialic acid, with a high specificity for terminal alpha 2,8-linked residues. The modification is directed to C-9 and not C-7 as is believed to occur more commonly in other organisms. Despite their wide prevalence and importance in both eukaryotes and prokaryotes, this is the first report to describe the characterization of a purified sialate O-acetyltransferase.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3015 GD Rotterdam, Netherlands; Dokkyo Univ, Sch Med, Dept Neurol, Tochigi 3210293, Japan	National Research Council Canada; Erasmus University Rotterdam; Erasmus MC; Dokkyo Medical University	Gilbert, M (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	Michel.Gilbert@nrc-cnrc.gc.ca	Wakarchuk, Warren/AAO-2774-2020; Yuki, Nobuhiro/H-3187-2012; Koga, Michiaki/L-4825-2019; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Koga, Michiaki/0000-0002-1356-955X; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1029, DOI 10.1111/j.1432-1033.1993.tb17850.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; Fahr C, 2001, J INVEST DERMATOL, V116, P254, DOI 10.1046/j.1523-1747.2001.01237.x; Gilbert M, 2005, CAMPYLOBACTER: MOLECULAR AND CELLULAR BIOLOGY, P219; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 2002, J BIOL CHEM, V277, P327, DOI 10.1074/jbc.M108452200; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Godschalk PCR, 2004, J CLIN INVEST, V114, P1659, DOI 10.1172/JCI200415707; HARA O, 1992, J BACTERIOL, V174, P5141, DOI 10.1128/JB.174.15.5141-5144.1992; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Iwersen M, 2003, BIOL CHEM, V384, P1035, DOI 10.1515/BC.2003.116; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KNIEP B, 1995, J BIOL CHEM, V270, P30173; Koga M, 2006, J INFECT DIS, V193, P547, DOI 10.1086/499969; Lemercinier X, 1996, CARBOHYD RES, V296, P83, DOI 10.1016/S0008-6215(96)00253-4; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nachamkin I, 1998, CLIN MICROBIOL REV, V11, P555, DOI 10.1128/CMR.11.3.555; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Parker CT, 2005, J CLIN MICROBIOL, V43, P2771, DOI 10.1128/JCM.43.6.2771-2781.2005; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Shen YQ, 2002, BIOL CHEM, V383, P307, DOI 10.1515/BC.2002.033; Shi WX, 1998, GLYCOBIOLOGY, V8, P199, DOI 10.1093/glycob/8.2.199; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; Smits SL, 2005, J BIOL CHEM, V280, P6933, DOI 10.1074/jbc.M409683200; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Vandamme-Feldhaus V, 1998, J BIOCHEM-TOKYO, V124, P111, DOI 10.1093/oxfordjournals.jbchem.a022069; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Wakarchuk Warren W, 2003, Methods Mol Biol, V213, P263; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771	47	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11480	11486		10.1074/jbc.M512183200	http://dx.doi.org/10.1074/jbc.M512183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16481326	hybrid			2022-12-25	WOS:000236988100009
J	Kim, HY; Park, SJ; Joe, EH; Jou, I				Kim, HY; Park, SJ; Joe, EH; Jou, I			Raft-mediated Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP-2) regulation in microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING SOCS; T-CELL-RECEPTOR; TYROSINE PHOSPHATASE; LIPID RAFTS; NEURODEGENERATIVE DISEASES; JAK/STAT PATHWAY; BRAIN MICROGLIA; ACTIVATION; PHOSPHORYLATION; PROTEIN	Janus kinase-signal transducer and activator of transcription (JAK-STAT) signals play important roles in cell proliferation, apoptosis, and inflammation, and they recently have been considered as therapeutic targets for suppressing oncogenesis and inflammatory process. Phosphatases including Src homology 2 domain-containing protein-tyrosine phosphatases (SHPs), are well known as negative regulators of the JAK-STAT pathway, but their precise mechanisms are largely unknown. Based on our previous finding that in cultured rat brain microglia, gangliosides induce rapid and transient activation of the JAK-STAT pathway, we hypothesized that raft-mediated SHP-2 activation is involved in transient activation of JAK-STAT signaling by gangliosides. We first used Western blot analysis to confirm that gangliosides rapidly induce the phosphorylation of SHP-2. This was inhibited by pretreatment with the lipid raft disrupter filipin and was restored following filipin removal. Immunostaining using antibodies directed against p-SHP-2 and flotillin-1 revealed ganglioside-induced clustering and polarization of p-SHP-2 in membrane rafts. Raft-associated regulation of SHP-2 was further demonstrated in fractionation experiments using detergent and detergent-free sucrose gradient ultracentrifugation. Rapid SHP-2 recruitment to detergent-insoluble raft fractions by gangliosides was inhibited by filipin, further indicating the involvement of rafts. We also confirmed by immunoprecipitation that SHP-2 rapidly binds in a raft-dependent manner to JAK2 in response to gangliosides. Our study therefore showed that transient activation of the JAK-STAT pathway by gangliosides is accomplished by SHP-2 in a raft-dependent manner in brain microglia.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea; Ajou Univ, Sch Med, Chron Inflammatory Dis Res Ctr, Suwon 442721, South Korea	Ajou University; Ajou University	Jou, I (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea.	jouilo@ajou.ac.kr						Aldskogius H, 2001, MICROSC RES TECHNIQ, V54, P40, DOI 10.1002/jemt.1119; Arnaud M, 2004, BIOCHEM J, V382, P545, DOI 10.1042/BJ20040103; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Burkart A, 2003, J BIOL CHEM, V278, P18360, DOI 10.1074/jbc.M210701200; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; Fawcett VCJ, 2005, J IMMUNOL, V174, P2849, DOI 10.4049/jimmunol.174.5.2849; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGOOKEY DJ, 1983, J CELL BIOL, V96, P1273, DOI 10.1083/jcb.96.5.1273; Minoo P, 2003, CELL SIGNAL, V15, P319, DOI 10.1016/S0898-6568(02)00122-5; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Pyo H, 1999, J BIOL CHEM, V274, P34584, DOI 10.1074/jbc.274.49.34584; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; ROBINSON JM, 1980, J HISTOCHEM CYTOCHEM, V28, P161, DOI 10.1177/28.2.6766487; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Skwarek M, 2004, ARCH IMMUNOL THER EX, V52, P427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Su MWC, 2001, J IMMUNOL, V166, P3975, DOI 10.4049/jimmunol.166.6.3975; Wang Q, 2005, J BIOL CHEM, V280, P8397, DOI 10.1074/jbc.M410462200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	55	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11872	11878		10.1074/jbc.M511706200	http://dx.doi.org/10.1074/jbc.M511706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507579	hybrid, Green Published			2022-12-25	WOS:000236988100054
J	Lewis, AL; Hensler, ME; Varki, A; Nizet, V				Lewis, AL; Hensler, ME; Varki, A; Nizet, V			The group B streptococcal sialic acid O-acetyltransferase is encoded by neuD, a conserved component of bacterial sialic acid biosynthetic gene clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; N-ACETYLNEURAMINIC ACID; CAPSULAR POLYSACCHARIDE; GUILLAIN-BARRE; SERUM RESISTANCE; PSEUDOMONAS-AERUGINOSA; MOLECULAR-CLONING; SOMATIC ANTIGENS; FORM VARIATION; C3 DEPOSITION	Nearly two dozen microbial pathogens have surface polysaccharides or lipo-oligosaccharides that contain sialic acid (Sia), and several Sia-dependent virulence mechanisms are known to enhance bacterial survival or result in host tissue injury. Some pathogens are also known to O-acetylate their Sias, although the role of this modification in pathogenesis remains unclear. We report that neuD, a gene located within the Group B Streptococcus (GBS) Sia biosynthetic gene cluster, encodes a Sia O-acetyltransferase that is itself required for capsular polysaccharide (CPS) sialylation. Homology modeling and site-directed mutagenesis identified Lys-123 as a critical residue for Sia O-acetyltransferase activity. Moreover, a single nucleotide polymorphism in neuD can determine whether GBS displays a "high" or "low" Sia O-acetylation phenotype. Complementation analysis revealed that Escherichia coli K1 NeuD also functions as a Sia O-acetyltransferase in GBS. In fact, NeuD homologs are commonly found within Sia biosynthetic gene clusters. A bioinformatic approach identified 18 bacterial species with a Sia biosynthetic gene cluster that included neuD. Included in this list are the sialylated human pathogens Legionella pneumophila, Vibrio parahemeolyticus, Pseudomonas aeruginosa, and Campylobacter jejuni, as well as an additional 12 bacterial species never before analyzed for Sia expression. Phylogenetic analysis shows that NeuD homologs of sialylated pathogens share a common evolutionary lineage distinct from the poly-Sia O-acetyltransferase of E. coli K1. These studies define a molecular genetic approach for the selective elimination of GBS Sia O-acetylation without concurrent loss of sialylation, a key to further studies addressing the role(s) of this modification in bacterial virulence.	Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Nizet, V (corresponding author), Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	vnizet@ucsd.edu	Nizet, Victor/AAF-3190-2019	Lewis, Amanda/0000-0001-6195-3030; Nizet, Victor/0000-0003-3847-0422	NHLBI NIH HHS [P01HL57345] Funding Source: Medline; NICHD NIH HHS [R01HD051796] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK07202] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051796] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; ANNUNZIATO PW, 1995, J BACTERIOL, V177, P312, DOI 10.1128/jb.177.2.312-319.1995; Berry DS, 2002, INFECT IMMUN, V70, P3707, DOI 10.1128/IAI.70.7.3707-3713.2002; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; Chaffin DO, 2005, J BACTERIOL, V187, P4615, DOI 10.1128/JB.187.13.4615-4626.2005; Charland N, 1996, FEMS IMMUNOL MED MIC, V14, P195, DOI 10.1111/j.1574-695X.1996.tb00287.x; Chattopadhyay A, 2002, J PEDIATR SURG, V37, P108, DOI 10.1053/jpsu.2002.29439; Daines DA, 2000, FEMS MICROBIOL LETT, V189, P281, DOI 10.1111/j.1574-6968.2000.tb09244.x; Daines DA, 2000, J BACTERIOL, V182, P5267, DOI 10.1128/JB.182.18.5267-5270.2000; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; Doran KS, 2005, J CLIN INVEST, V115, P2499, DOI 10.1172/JCI23829; Edwards MS, 2006, INFECT DIS FETUS NEW, P403; Fattom AI, 1998, INFECT IMMUN, V66, P4588, DOI 10.1128/IAI.66.10.4588-4592.1998; Feng L, 2005, J BACTERIOL, V187, P758, DOI 10.1128/JB.187.2.758-764.2005; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; HAFT RF, 1994, J BACTERIOL, V176, P7372, DOI 10.1128/JB.176.23.7372-7374.1994; HIGA HH, 1988, J BIOL CHEM, V263, P8872; Hitoshi S, 1996, J NEUROIMMUNOL, V66, P95, DOI 10.1016/0165-5728(96)00024-0; Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Jurcisek J, 2005, INFECT IMMUN, V73, P3210, DOI 10.1128/IAI.73.6.3210-3218.2005; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Koga M, 2005, NEUROLOGY, V65, P1376, DOI 10.1212/01.wnl.0000176914.70893.14; Koga M, 1999, J NEUROL SCI, V164, P50, DOI 10.1016/S0022-510X(98)00331-1; Kooistra O, 2001, BIOCHEMISTRY-US, V40, P7630, DOI 10.1021/bi002946r; LEWENDON A, 1995, J BIOL CHEM, V270, P26326, DOI 10.1074/jbc.270.44.26326; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; McNeely TB, 1998, INFECT IMMUN, V66, P3705, DOI 10.1128/IAI.66.8.3705-3710.1998; MORAN AP, 1991, J BACTERIOL, V173, P618, DOI 10.1128/jb.173.2.618-626.1991; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SILVER RP, 1981, NATURE, V289, P696, DOI 10.1038/289696b0; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; Suryanti V, 2003, PROTEIN EXPRES PURIF, V27, P346, DOI 10.1016/S1046-5928(02)00633-2; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Vann WF, 2004, J BACTERIOL, V186, P706, DOI 10.1128/JB.186.3.706-712.2004; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Vogel U, 1997, INFECT IMMUN, V65, P4022, DOI 10.1128/IAI.65.10.4022-4029.1997; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; Zou CH, 1999, J BACTERIOL, V181, P4137, DOI 10.1128/JB.181.13.4137-4141.1999	51	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11186	11192		10.1074/jbc.M513772200	http://dx.doi.org/10.1074/jbc.M513772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16490781	hybrid			2022-12-25	WOS:000236822200062
J	Ugleholdt, R; Poulsen, MLH; Holst, PJ; Irminger, JC; Orskov, C; Pedersen, J; Rosenkilde, MM; Zhu, XR; Steiner, DF; Holst, JJ				Ugleholdt, R; Poulsen, MLH; Holst, PJ; Irminger, JC; Orskov, C; Pedersen, J; Rosenkilde, MM; Zhu, XR; Steiner, DF; Holst, JJ			Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; PROHORMONE CONVERTASE PC2; MICE LACKING; PROPROTEIN CONVERTASES; RECOMBINANT ADENOVIRUS; FUNCTIONAL EXPRESSION; ENDOPROTEASES PC2; PROGLUCAGON; CELLS; GLUCAGON	The physiology of the incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and their role in type 2 diabetes currently attract great interest. Recently we reported an essential role for prohormone convertase (PC)1/3 in the cleavage of intestinal proglucagon, resulting in formation of GLP-1, as demonstrated in PC1/3-deficient mice. However, little is known about the endoproteolytic processing of the GIP precursor. This study investigates the processing of proGIP in PC1/3 and PC2 null mice and in cell lines using adenovirus-mediated overexpression. Supporting a role for PC1/3 in proGIP processing, we found co-localization of GIP and PC1/3 but not PC2 in intestinal sections by immunohistochemistry, and analysis of intestinal extracts from PC1/3-deficient animals demonstrated severely impaired processing to GIP, whereas processing to GIP was unaltered in PC2-deficient mice. Accordingly, overexpression of preproGIP in the neuroendocrine AtT-20 cell line that expresses high levels of endogenous PC1/3 and negligible levels of PC2 resulted in production of GIP. Similar results were obtained after co-expression of preproGIP and PC1/3 in GH(4) cells that express no PC2 and only low levels of PC1/3. In addition, studies in GH(4) cells and the alpha-TC1.9 cell line, expressing PC2 but not PC1/3, indicate that PC2 can mediate processing to GIP but also to other fragments not found in intestinal extracts. Taken together, our data indicate that PC1/3 is essential and sufficient for the production of the intestinal incretin hormone GIP, whereas PC2, although capable of cleaving proGIP, does not participate in intestinal proGIP processing and is not found in intestinal GIP-expressing cells.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Immunol & Med Microbiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Pharmacol, DK-2200 Copenhagen N, Denmark; Ctr Med Univ Geneva, Louis Jeantet Res Labs, CH-1211 Geneva 4, Switzerland; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Geneva; University of Chicago	Holst, JJ (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	holst@mfi.ku.dk	Holst, Jens/AAA-8022-2022	Ugleholdt, Randi/0000-0002-6656-0137; Holst, Peter Johannes/0000-0002-1279-304X; Holst, Jens Juul/0000-0001-6853-3805; Rosenkilde, Mette Marie/0000-0001-9600-3254				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Christensen JP, 2003, J IMMUNOL, V171, P4733, DOI 10.4049/jimmunol.171.9.4733; Damholt AB, 1999, ENDOCRINOLOGY, V140, P4800, DOI 10.1210/en.140.10.4800; Deacon CF, 2000, J CLIN ENDOCR METAB, V85, P3575, DOI 10.1210/jc.85.10.3575; Dey A, 2005, ENDOCRINOLOGY, V146, P713, DOI 10.1210/en.2004-1118; Dey A, 2003, J BIOL CHEM, V278, P15007, DOI 10.1074/jbc.M212128200; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HOLST JJ, 1991, METHODS NEUROSCIENCE, V5, P3, DOI DOI 10.1016/B978-0-12-185259-7.50006-5; Hoy M, 2003, N-S ARCH PHARMACOL, V368, P284, DOI 10.1007/s00210-003-0797-1; Irminger JC, 1996, BIOCHEM J, V320, P11, DOI 10.1042/bj3200011; Kaufmann JE, 1997, DIABETES, V46, P978, DOI 10.2337/diabetes.46.6.978; KRARUP T, 1984, REGUL PEPTIDES, V9, P35, DOI 10.1016/0167-0115(84)90005-3; KRARUP T, 1988, ENDOCR REV, V9, P122, DOI 10.1210/edrv-9-1-122; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Marzban L, 2004, DIABETES, V53, P141, DOI 10.2337/diabetes.53.1.141; MORGAN LM, 1978, ANN CLIN BIOCHEM, V15, P172, DOI 10.1177/000456327801500138; Mortensen K, 2003, REGUL PEPTIDES, V114, P189, DOI 10.1016/S0167-0115(03)00125-3; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; OTTE SC, 1984, DIG DIS SCI S, V29, P63; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Schieldrop PJ, 1996, BBA-GENE STRUCT EXPR, V1308, P111, DOI 10.1016/0167-4781(96)00103-0; SCOPSI L, 1995, J CLIN ENDOCR METAB, V80, P294, DOI 10.1210/jc.80.1.294; SIEGEL EG, 1985, DIABETOLOGIA, V28, P857, DOI 10.1007/BF00291078; TAKEDA J, 1987, P NATL ACAD SCI USA, V84, P7005, DOI 10.1073/pnas.84.20.7005; Tanaka S, 2003, ZOOL SCI, V20, P1183, DOI 10.2108/zsj.20.1183; TSENG CC, 1993, P NATL ACAD SCI USA, V90, P1992, DOI 10.1073/pnas.90.5.1992; Ugleholdt R, 2004, ENDOCRINOLOGY, V145, P1349, DOI 10.1210/en.2003-0801; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	45	75	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11050	11057		10.1074/jbc.M601203200	http://dx.doi.org/10.1074/jbc.M601203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16476726	hybrid			2022-12-25	WOS:000236822200046
J	Zhao, H; Robertson, NB; Jewhurst, SA; Waite, JH				Zhao, H; Robertson, NB; Jewhurst, SA; Waite, JH			Probing the adhesive footprints of Mytilus californianus byssus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-ANALYSIS; PLAQUE PROTEIN; MUSSEL; EXPRESSION; EDULIS; DOPA; HYDROLYSIS; TRYPTOPHAN; SURFACES	California mussels Mytilus californianus owe their tenacity to a holdfast known as the byssus, a fibrous extracellular structure that ends distally in flattened adhesive plaques. The "footprints" of freshly secreted plaques deposited onto glass coverslips were shown by matrix-assisted laser desorption ionization time of flight mass spectrometry to consist chiefly of proteins ranging in mass from 5200 to 6700 Da. These proteins, variants of a family known as mcfp3 ((M.) under bar(c) under bar alifornianus (f) under bar oot (p) under bar rotein 3), were purified from acetic acid/urea extracts of plaques and foot tissue. Mcfp3 appears to sort into fast and slow electrophoretic variants. Both are rich in Gly and Asn and exhibit post-translational hydroxylation of Tyr and Arg to Dopa and 4-hydroxyarginine, respectively, with the fast variant containing more than twice as much Lys+Arg. Both the slow and fast variants were partially sequenced from the N terminus, and the complete sequences of 12 variants were deduced from cDNA using degenerate oligonucleotides, PCR, and rapid amplification of cDNA ends. Mcfp3s are highly polar molecules and contain up to 28 mol% Dopa, which remains intact and may be crucial for adhesion to metal and mineral surfaces.	Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Waite, JH (corresponding author), Univ Calif Santa Barbara, Inst Marine Sci, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	waite@lifesci.ucsb.edu			NIDCR NIH HHS [DE015415] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015415] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson KE, 2000, J EXP BIOL, V203, P3065; Chen BN, 2002, COMB CHEM HIGH T SCR, V5, P409; Chirdon WM, 2003, J BIOMED MATER RES B, V66B, P532, DOI 10.1002/jbm.b.10041; COMYN J, 1981, DEV ADHESIVES, P279; DALSIN, 2005, MAT TODAY, V8, P53; Dalsin JL, 2005, LANGMUIR, V21, P640, DOI 10.1021/la048626g; Deming TJ, 1999, CURR OPIN CHEM BIOL, V3, P100, DOI 10.1016/S1367-5931(99)80018-0; Floriolli RY, 2000, MAR BIOTECHNOL, V2, P352; GARVEY KJ, 1990, VIROLOGY, V175, P391, DOI 10.1016/0042-6822(90)90424-P; Inoue K, 1996, EUR J BIOCHEM, V239, P172, DOI 10.1111/j.1432-1033.1996.0172u.x; ISRAELACHVILI J, 1985, INTERMOLECULAR SURFA, P22; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; PAZ MA, 1991, J BIOL CHEM, V266, P689; PETTIT LD, 1984, PURE APPL CHEM, V56, P247, DOI 10.1351/pac198456020247; PROUDFOOT GM, 1983, AUST J CHEM, V36, P885, DOI 10.1071/CH9830885; Schmitt L, 2000, BIOPHYS J, V78, P3275, DOI 10.1016/S0006-3495(00)76863-9; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WAITE JH, 1990, INT J BIOL MACROMOL, V12, P139, DOI 10.1016/0141-8130(90)90065-I; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; Waite JH, 2002, INTEGR COMP BIOL, V42, P1172, DOI 10.1093/icb/42.6.1172; Waite JH, 2001, BIOCHEMISTRY-US, V40, P2887, DOI 10.1021/bi002718x; WAITE JH, 1984, METHOD ENZYMOL, V107, P397; Warner SC, 1999, MAR BIOL, V134, P729, DOI 10.1007/s002270050589; WITMAN JD, 1984, MAR ECOL PROG SER, V16, P259, DOI 10.3354/meps016259	27	120	132	2	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11090	11096		10.1074/jbc.M510792200	http://dx.doi.org/10.1074/jbc.M510792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495227	hybrid			2022-12-25	WOS:000236822200051
J	An, XL; Guo, XH; Zhang, XH; Baines, AJ; Debnath, G; Moyo, D; Salomao, M; Bhasin, N; Johnson, C; Discher, D; Gratzer, WB; Mohandas, N				An, XL; Guo, XH; Zhang, XH; Baines, AJ; Debnath, G; Moyo, D; Salomao, M; Bhasin, N; Johnson, C; Discher, D; Gratzer, WB; Mohandas, N			Conformational stabilities of the structural repeats of erythroid spectrin and their functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPETITIVE SEGMENTS; HELICAL REPEATS; TANDEM REPEATS; ALPHA-SPECTRIN; PROTEIN; MEMBRANE; FLEXIBILITY; FRAGMENTS; PEPTIDES; INSIGHTS	The two polypeptide chains of the erythroid spectrin heterodimer contain between them 36 structural repeating modules, which can function as independently folding units. We have expressed all 36 and determined their thermal stabilities. These vary widely, with unfolding transition mid-points (T-m) ranging from 21 to 72 C. Eight of the isolated repeats are largely unfolded at physiological temperature. Constructs comprising two or more adjacent repeats show inter-repeat coupling with coupling free energies of several kcal mol(-1). Constructs comprising five successive repeats from the beta-chain displayed cooperativity and strong temperature dependence in forced unfolding by atomic force microscopy. Analysis of aligned sequences and molecular modeling suggests that high stability is conferred by large hydrophobic side chains at position e of the heptad hydrophobic repeats in the first helix of the three-helix bundle that makes up each repeat. This inference was borne out by the properties of mutants in which the critical residues have been replaced. The marginal stability of the tertiary structure at several points in the spectrin chains is moderated by energetic coupling with adjoining structural elements but may be expected to permit adaptation of the membrane to the large distortions that the red cell experiences in the circulation.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Kings Coll London, Randall Ctr Mol Mech Cell Funct, London SE1 1UL, England; Univ Penn, Biophys Engn Lab, Philadelphia, PA 19104 USA	New York Blood Center; University of Kent; University of London; King's College London; University of Pennsylvania	An, XL (corresponding author), New York Blood Ctr, Red Cell Physiol Lab, 310 E 67th St, New York, NY 10021 USA.	xan@nybloodcenter.org		discher, dennis/0000-0001-6163-2229; Salomao, Marcela/0000-0002-3631-2407; Baines, Anthony/0000-0003-3068-7811	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579, R01HL062352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31579, HL 062352] Funding Source: Medline; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; Baines AJ, 2003, CELL MOL BIOL LETT, V8, P195; Batey S, 2005, J MOL BIOL, V349, P1045, DOI 10.1016/j.jmb.2005.04.028; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; DAVIS J, 1983, J BIOL CHEM, V258, P7757; Discher DE, 2001, CELL MOL BIOL LETT, V6, P593; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Kusunoki H, 2004, J MOL BIOL, V344, P495, DOI 10.1016/j.jmb.2004.09.019; Kusunoki H, 2004, STRUCTURE, V12, P645, DOI 10.1016/j.str.2004.02.022; Law R, 2003, BIOPHYS J, V85, P3286, DOI 10.1016/S0006-3495(03)74747-X; Law R, 2003, BIOPHYS J, V84, P533, DOI 10.1016/S0006-3495(03)74872-3; Lecomte MC, 1999, EUR BIOPHYS J BIOPHY, V28, P208, DOI 10.1007/s002490050201; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MacDonald RI, 2004, P NATL ACAD SCI USA, V101, P1502, DOI 10.1073/pnas.0308059100; MacDonald RI, 2001, BIOCHEMISTRY-US, V40, P3974, DOI 10.1021/bi0025159; Menhart N, 1996, J BIOL CHEM, V271, P30410, DOI 10.1074/jbc.271.48.30410; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Muse SV, 1997, J MOL EVOL, V44, P492, DOI 10.1007/PL00006173; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ortiz V, 2005, J MOL BIOL, V349, P638, DOI 10.1016/j.jmb.2005.03.086; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; SHOTTON D, 1979, J MOL BIOL, V131, P302; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZARKOWSKY HS, 1975, BRIT J HAEMATOL, V29, P537, DOI 10.1111/j.1365-2141.1975.tb02740.x	34	58	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10527	10532		10.1074/jbc.M513725200	http://dx.doi.org/10.1074/jbc.M513725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476728	hybrid			2022-12-25	WOS:000236594300082
J	Chartier, FJM; Blais, SP; Couture, M				Chartier, FJM; Blais, SP; Couture, M			A weak Fe-O bond in the oxygenated complex of the nitric-oxide synthase of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN RADICAL FORMATION; HEME-DIOXY REDUCTION; RESONANCE RAMAN; LOW-TEMPERATURE; L-ARGININE; OXYCYTOCHROME P450CAM; CYTOCHROME P450CAM; SINGLE-TURNOVER; PROTEIN; SUBSTRATE	Little is known about the intermediates formed during catalysis by nitric-oxide synthase ( NOS). We report here the characterization by resonance Raman spectroscopy of the oxygenated complex of the NOS from Staphylococcus aureus (saNOS) as well as the kinetics of formation and decay of the complex. An oxygenated complex transiently formed after mixing reduced saNOS with oxygen and decayed to the ferric enzyme with kinetics that were dependent on the substrate L-arginine and the cofactor H4B. The oxygenated complex displayed a Soret absorption band centered at 430 nm. Resonance Raman spectroscopy revealed that it can be described as a ferric superoxide form ((FeO2-)-O-III) with a single nu(O-O) mode at 1135 cm(-1). In the presence of L-arginine, an additional nu(O-O) mode at 1123 cm(-1) was observed, indicating an increased pi back-bonding electron donation to the bound oxygen induced by the substrate. With saNOS, this is the first time that the nu(Fe-O) mode of a NOS has been observed. The low frequency of this mode, at 517 cm(-1), points to an oxygenated complex that differs from that of P450(cam). The electronic structure of the oxygenated complex and the effect of L-arginine are discussed in relation to the kinetic properties of saNOS and other NOS.	Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CREFSIP, Res Ctr, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Couture, M (corresponding author), Univ Laval, Dept Biochem & Microbiol, Pavillon Marchand,Room 4165, Quebec City, PQ G1K 7P4, Canada.	manon.couture@bcm.ulaval.ca	Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055				AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Buddha MR, 2004, J BIOL CHEM, V279, P49567, DOI 10.1074/jbc.C400418200; Chartier FJM, 2004, BIOPHYS J, V87, P1939, DOI 10.1529/biophysj.104.042119; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Couture M, 2001, J BIOL CHEM, V276, P38280; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; HERZBERG G, 1950, MOL SPECTRA MOL STRU, V1, P560; HU SZ, 1991, J AM CHEM SOC, V113, P4815, DOI 10.1021/ja00013a016; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; Macdonald IDG, 1999, J AM CHEM SOC, V121, P376, DOI 10.1021/ja9810383; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; Ohta T, 2004, J AM CHEM SOC, V126, P15000, DOI 10.1021/ja046896f; Ost TWB, 2005, J BIOL CHEM, V280, P965, DOI 10.1074/jbc.M411191200; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Spiro TG, 2001, COORDIN CHEM REV, V219, P923, DOI 10.1016/S0010-8545(01)00384-8; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; TAKAHASHI S, 1995, J BIOL CHEM, V270, P8405, DOI 10.1074/jbc.270.15.8405; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679	48	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9953	9962		10.1074/jbc.M513893200	http://dx.doi.org/10.1074/jbc.M513893200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16473878	hybrid			2022-12-25	WOS:000236594300017
J	Beuning, PJ; Simon, SM; Zemla, A; Barsky, D; Walker, GC				Beuning, PJ; Simon, SM; Zemla, A; Barsky, D; Walker, GC			A non-cleavable UmuD variant that acts as a UmuD ' mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; BETA-PROCESSIVITY CLAMP; RECA-MEDIATED CLEAVAGE; SOS MUTAGENESIS; SLIDING-CLAMP; MOLECULAR-DYNAMICS; COLD SENSITIVITY; INTACT UMUD; PROTEIN; SUBUNIT	UmuD(2) cleaves and removes its N-terminal 24 amino acids to form UmuD'(2), which activates UmuC for its role in UV-induced mutagenesis in Escherichia coli. Cells with a non-cleavable UmuD exhibit essentially no UV-induced mutagenesis and are hypersensitive to killing by UV light. UmuD binds to the beta processivity clamp ("beta") of the replicative DNA polymerase, pol III. A possible beta-binding motif has been predicted in the same region of UmuD shown to be important for its interaction with beta. We performed alanine-scanning mutagenesis of this motif ((TFPLF18)-T-14) in UmuD and found that it has a moderate influence on UV-induced mutagenesis but is required for the cold-sensitive phenotype caused by elevated levels of wild-type UmuD and UmuC. Surprisingly, the wild-type and the beta-binding motif variant bind to beta with similar K-d values as determined by changes in tryptophan fluorescence. However, these data also imply that the single tryptophan in beta is in strikingly different environments in the presence of the wild-type versus the variant UmuD proteins, suggesting a distinct change in some aspect of the interaction with little change in its strength. Despite the fact that this novel UmuD variant is non-cleavable, we find that cells harboring it display phenotypes more consistent with the cleaved form UmuD', such as resistance to killing by UV light and failure to exhibit the cold-sensitive phenotype. Cross-linking and chemical modification experiments indicate that the N-terminal arms of the UmuD variant are less likely to be bound to the globular domain than those of the wild-type, which may be the mechanism by which this UmuD variant acts as a UmuD' mimic.	MIT, Dept Biol, Cambridge, MA 02139 USA; Lawrence Livermore Natl Lab, Computat Directorate, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Biosci Directorate, Livermore, CA 94550 USA	Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Walker, GC (corresponding author), 68-633,77 Massachusetts Ave, Cambridge, MA 02139 USA.	gwalker@mit.edu		/0000-0001-7243-8261	NATIONAL CANCER INSTITUTE [R01CA021615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NCI NIH HHS [CA21615] Funding Source: Medline; NIEHS NIH HHS [P30ES02109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Becherel OJ, 2002, DNA REPAIR, V1, P703, DOI 10.1016/S1568-7864(02)00106-4; Beuning PJ, 2006, METHOD ENZYMOL, V408, P318, DOI 10.1016/S0076-6879(06)08020-7; Beuning PJ, 2006, MOL MICROBIOL, V59, P460, DOI 10.1111/j.1365-2958.2005.04959.x; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Duzen JIM, 2004, DNA REPAIR, V3, P301, DOI 10.1016/j.dnarep.2003.11.008; Ferentz AE, 1997, NAT STRUCT BIOL, V4, P979, DOI 10.1038/nsb1297-979; Ferentz AE, 2001, EMBO J, V20, P4287, DOI 10.1093/emboj/20.15.4287; Friedberg EC, 2005, DNA REPAIR MUTAGENES; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Guzzo A, 1996, J BACTERIOL, V178, P7295, DOI 10.1128/jb.178.24.7295-7303.1996; HARRIS DA, 1996, LIGHT SPECTROSCOPY; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Indiani C, 2005, MOL CELL, V19, P805, DOI 10.1016/j.molcel.2005.08.011; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KULAEVA OI, 1995, J BACTERIOL, V177, P2737, DOI 10.1128/jb.177.10.2737-2743.1995; Lee MH, 1996, J BACTERIOL, V178, P7304, DOI 10.1128/jb.178.24.7304-7307.1996; LEE MH, 1994, J BACTERIOL, V176, P4825, DOI 10.1128/jb.176.16.4825-4837.1994; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; McDonald JP, 1998, P NATL ACAD SCI USA, V95, P1478, DOI 10.1073/pnas.95.4.1478; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Opperman T, 1999, P NATL ACAD SCI USA, V96, P9218, DOI 10.1073/pnas.96.16.9218; Opperman T, 1996, J BACTERIOL, V178, P4400, DOI 10.1128/jb.178.15.4400-4411.1996; Peat TS, 1996, STRUCTURE, V4, P1401, DOI 10.1016/S0969-2126(96)00148-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Shen X, 2003, J BIOL CHEM, V278, P52546, DOI 10.1074/jbc.M310127200; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; Sutton MD, 1999, P NATL ACAD SCI USA, V96, P12373, DOI 10.1073/pnas.96.22.12373; Sutton MD, 2002, DNA REPAIR, V1, P77, DOI 10.1016/S1568-7864(01)00006-4; Sutton MD, 2002, P NATL ACAD SCI USA, V99, P5307, DOI 10.1073/pnas.082322099; Sutton MD, 2001, J BACTERIOL, V183, P2897, DOI 10.1128/JB.183.9.2897-2909.2001; Sutton MD, 2001, J BACTERIOL, V183, P1215, DOI 10.1128/JB.183.4.1215-1224.2001; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Wagner J, 2000, EMBO REP, V1, P484; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wijffels G, 2004, BIOCHEMISTRY-US, V43, P5661, DOI 10.1021/bi036229j; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Yang JS, 2004, P NATL ACAD SCI USA, V101, P8289, DOI 10.1073/pnas.0402625101; Zemla A, 2005, NUCLEIC ACIDS RES, V33, pW111, DOI 10.1093/nar/gki457; Zemla A, 2003, NUCLEIC ACIDS RES, V31, P3370, DOI 10.1093/nar/gkg571	50	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9633	9640		10.1074/jbc.M511101200	http://dx.doi.org/10.1074/jbc.M511101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464848	Green Submitted, hybrid			2022-12-25	WOS:000236404700075
J	Maeda, Y; Hunter, TC; Loudy, DE; Dave, V; Schreiber, V; Whitsett, JA				Maeda, Y; Hunter, TC; Loudy, DE; Dave, V; Schreiber, V; Whitsett, JA			PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; RESPIRATORY EPITHELIAL-CELLS; POLY(ADP-RIBOSE) POLYMERASE-2 PARP-2; FACTOR-KAPPA-B; GENE-EXPRESSION; NUCLEAR-FACTOR; DNA-DAMAGE; FUNCTIONAL INTERACTION; A GENE; LUNG	Thyroid transcription factor 1 (TTF-1/Nkx-2.1) plays a critical role in lung morphogenesis and regulates the expression of lung-specific genes, including the surfactant proteins required for pulmonary function after birth. The activity of TTF-1 is influenced by its interactions with other transcription factors and coactivators, including CBP/p300 and SRC-1. In this study, we have identified poly( ADP-ribose) polymerases (PARP-2 and PARP-1) as TTF-1 interacting proteins that influence its transcriptional activity. Endogenous PARP-2 was coimmunoprecipitated from transformed mouse lung epithelial cell (MLE15) extracts with TTF-1 and was identified by mass spectrometry. PARP-1 and Ku70/Ku80 were also coimmunoprecipitated from the cell extracts with TTF-1. The E domain of PARP-2 interacted via the C-terminal domain of TTF-1. Both PARP-1 and PARP-2 enhanced the activity of the promoter of surfactant protein-B (Sftpb gene) but not other surfactant proteins in vitro. PARP-2 was selectively expressed in epithelial cells of the conducting and peripheral lung tubules of the fetal mouse lung from embryonic day 12.5 and was detected in bronchial epithelial cells in the adult lung at cellular sites consistent with that of surfactant protein B. PARP-2 and PARP-1 interact with TTF-1 and regulate the expression of surfactant protein B, a protein required for lung function.	Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Div Pulm Biol, Cincinnati, OH 45229 USA; Diversa Corp, San Diego, CA 92121 USA; Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR 7175,Lab Convent Avec,CEA, F-67412 Illkirch Graffenstaden, France	Cincinnati Children's Hospital Medical Center; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Div Pulm Biol, 3333 Burnet Ave,MLC 7029, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	Dave, Vrushank/K-5262-2012; Schreiber, Valérie/M-5007-2016	Dave, Vrushank/0000-0003-4044-2658; Schreiber, Valérie/0000-0003-0507-639X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; Dave V, 2004, J BIOL CHEM, V279, P34578, DOI 10.1074/jbc.M404296200; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ertsey R, 2004, AM J RESP CELL MOL, V30, P853, DOI 10.1165/rcmb.2003-0248OC; Fukazawa T, 2004, CANCER RES, V64, P363, DOI 10.1158/0008-5472.CAN-03-2507; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Glass CK, 2000, GENE DEV, V14, P121; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; Idogawa M, 2005, GASTROENTEROLOGY, V128, P1919, DOI 10.1053/j.gastro.2005.03.007; Islam KN, 2002, MOL ENDOCRINOL, V16, P1428, DOI 10.1210/me.16.6.1428; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Li CG, 2002, J BIOL CHEM, V277, P38399, DOI 10.1074/jbc.M203188200; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Mayeur GL, 2005, J BIOL CHEM, V280, P10827, DOI 10.1074/jbc.M413336200; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Yan C, 2002, J BIOL CHEM, V277, P10967, DOI 10.1074/jbc.M109986200; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Yang L, 2004, BIOCHEMISTRY-US, V43, P12489, DOI 10.1021/bi049283o; Yang L, 2003, J BIOL CHEM, V278, P36841, DOI 10.1074/jbc.M304156200; Yang MCW, 2003, EUR RESPIR J, V22, P28, DOI 10.1183/09031936.03.00117702; Yang YS, 2001, AM J RESP CELL MOL, V24, P30, DOI 10.1165/ajrcmb.24.1.4050; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200	63	46	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9600	9606		10.1074/jbc.M510435200	http://dx.doi.org/10.1074/jbc.M510435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461352	hybrid			2022-12-25	WOS:000236404700071
J	Tong, Q; Zhang, WY; Conrad, K; Mostoller, K; Cheung, JY; Peterson, BZ; Miller, BA				Tong, Q; Zhang, WY; Conrad, K; Mostoller, K; Cheung, JY; Peterson, BZ; Miller, BA			Regulation of the transient receptor potential channel TRPM2 by the Ca2(+) sensor calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ADP-RIBOSE; HYDROGEN-PEROXIDE; CA2+ CHANNELS; CALCIUM INFLUX; CELL-DEATH; CA2+-DEPENDENT INACTIVATION; TARGET RECOGNITION; OXIDATIVE STRESS; CATION CHANNELS	TRPM2, a member of the transient receptor potential (TRP) superfamily, is a Ca2+-permeable channel activated by oxidative stress or tumor necrosis factor alpha involved in susceptibility to cell death. TRPM2 activation is dependent on the level of intracellular Ca2+. We explored whether calmodulin (CaM) is the Ca2+ sensor for TRPM2. HEK 293T cells were transfected with TRPM2 and wild type CaM or mutant CaM (CaMMUT) with substitutions of all four EF hands. Treatment of cells expressing TRPM2 with H2O2 or tumor necrosis factor alpha resulted in a significant increase in intracellular calcium ([ Ca2+](i)). This was not affected by coexpression of CaM, suggesting that endogenous CaM levels are sufficient for maximal response. Cotransfection of CaMMUT with TRPM2 dramatically inhibited the increase in [Ca2+](i), demonstrating the requirement for CaM in TRPM2 activation. Immunoprecipitation confirmed direct interaction of CaM and CaMMUT with TRPM2, and the Ca2+ dependence of this association. CaM bound strongly to the TRPM2 N terminus (amino acids 1-730), but weakly to the C terminus (amino acids 1060-1503). CaM binding to an IQ-like motif (amino acids 406-416) in the TRPM2 N terminus was demonstrated utilizing gel shift, immunoprecipitation, biotinylated CaM overlay, and pull-down assays. A substitution mutant of the IQ-like motif of TRPM2 (TRPM2-IQ(MUT1)) reduced but did not eliminate CaM binding to TRPM2, suggesting the presence of at least one other CaM binding site. The functional importance of the TRPM2 IQ-like motif was demonstrated by treatment of TRPM2-IQ(MUT1)-expressing cells with H2O2. The increase in [Ca2+](i) observed with wild type TRPM2 was absent and cell viability was preserved. These data demonstrate the requirement for CaM in TRPM2 activation. They suggest that Ca2+ entering through TRPM2 enhances interaction of CaM with TRPM2 at the IQ-like motif in the N terminus, providing crucial positive feedback for channel activation.	Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Miller, BA (corresponding author), Penn State Univ, Coll Med, Dept Pediat, Hershey, PA 17033 USA.	bmiller3@psu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074854, R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL74854, R01 HL58672] Funding Source: Medline; NIDDK NIH HHS [R01 DK46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; Chu X, 2004, J BIOL CHEM, V279, P10514, DOI 10.1074/jbc.M308478200; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Duncan LM, 1998, CANCER RES, V58, P1515; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; Lambers TT, 2004, J BIOL CHEM, V279, P28855, DOI 10.1074/jbc.M313637200; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Mouton J, 2001, J BIOL CHEM, V276, P22359, DOI 10.1074/jbc.M100755200; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tsavaler L, 2001, CANCER RES, V61, P3760; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Wu YM, 1997, AM J PHYSIOL-HEART C, V273, pH2161, DOI 10.1152/ajpheart.1997.273.5.H2161; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200; ZHANG W, 2006, IN PRESS AM J PHYSL; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200	51	95	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9076	9085		10.1074/jbc.M510422200	http://dx.doi.org/10.1074/jbc.M510422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461353	hybrid			2022-12-25	WOS:000236404700012
J	Westerheide, SD; Kawahara, TLA; Orton, K; Morimoto, RI				Westerheide, SD; Kawahara, TLA; Orton, K; Morimoto, RI			Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; PROTEIN INDUCTION; INDUCED APOPTOSIS; CARCINOMA CELLS; FACTOR-I; ACTIVATION; THERMOTOLERANCE	Molecular chaperones, inducible by heat shock and a variety of other stresses, have critical roles in protein homeostasis, balancing cell stress with adaptation, survival, and cell death mechanisms. In transformed cells and tumors, chaperones are frequently overexpressed, with constitutive activation of the heat shock transcription factor HSF1 implicated in tumor formation. Here, we describe the activity of triptolide, a diterpene triepoxide from the plant Triptergium wilfordii, as an inhibitor of the human heat shock response. Triptolide treatment of human tissue culture cells prevented the inducible expression of heat shock genes, shown by suppression of an HSP70 promoter-reporter construct and by suppression of endogenous HSP70 gene expression. Upon examining the steps in the HSF1 activation pathway, we found that triptolide abrogates the transactivation function of HSF1 without interfering in the early events of trimer formation, hyperphosphorylation, and DNA binding. The ability of triptolide to inhibit the heat shock response renders these cells sensitive to stress-induced cell death, which may be of great relevance to cancer treatments.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu	Longo, Kenneth A/A-5631-2010		NCI NIH HHS [T32 CA70085] Funding Source: Medline; NIGMS NIH HHS [R37 GM038109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Elia G, 1996, J BIOL CHEM, V271, P16111, DOI 10.1074/jbc.271.27.16111; Elia G, 1996, CANCER RES, V56, P210; Hansen RK, 1997, BIOCHEM BIOPH RES CO, V239, P851, DOI 10.1006/bbrc.1997.7572; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; HOSOKAWA N, 1990, CELL STRUCT FUNCT, V15, P393, DOI 10.1247/csf.15.393; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SOLOMON JM, 1991, NEW BIOL, V3, P1106; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Wissing D, 1996, INT J HYPERTHER, V12, P125, DOI 10.3109/02656739609023695; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Yokota S, 2000, CANCER RES, V60, P2942	41	188	205	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9616	9622		10.1074/jbc.M512044200	http://dx.doi.org/10.1074/jbc.M512044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469748	hybrid			2022-12-25	WOS:000236404700073
J	Buytaert, E; Callewaert, G; Hendrickx, N; Scorrano, L; Hartmann, D; Missiaen, L; Vandenheede, JR; Heirman, I; Grooten, J; Agostinis, P				Buytaert, Esther; Callewaert, Geert; Hendrickx, Nico; Scorrano, Luca; Hartmann, Dieter; Missiaen, Ludwig; Vandenheede, Jackie R.; Heirman, Ingeborg; Grooten, Johan; Agostinis, Patrizia			Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy	FASEB JOURNAL			English	Article							THAPSIGARGIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; INTRACELLULAR CA2+; SIGNALING PATHWAYS; HELA-CELLS; BCL-2; CALCIUM; AUTOPHAGY; STORES; ACTIVATION	Both the commitment event and the modality of cell death in photodynamic therapy (PDT) remain poorly defined. We report that PDT with endoplasmic reticulum (ER)-associating hypericin leads to an immediate loss of SERCA2 protein levels, causing disruption of Ca2+ homeostasis and cell death. Protection of SERCA2 protein rescues ER-Ca2+ levels and prevents cell death, suggesting that SERCA2 photodestruction with consequent incapability of the ER to maintain intracellular Ca2+ homeostasis is causal to cell killing. Apoptosis is rapidly initiated after ER-Ca2+ depletion and strictly requires the BAX/BAK gateway at the mitochondria. Bax(-/-)Bak(-/-) double-knockout (DKO) cells are protected from apoptosis but undergo autophagy-associated cell death as revealed by electron microscopy and biochemical analysis. Autophagy inhibitors, but not caspase antagonists, significantly reduce death of DKO cells, suggesting that sustained autophagy is lethal. Thus, following ER photodamage and consequent disruption of Ca2+ homeostasis, BAX and BAK proteins model PDT-mediated cell killing, which is executed through apoptosis in their presence or via an autophagic pathway in their absence.	Catholic Univ Louvain, Dept Mol & Cell Biol, Fac Med, B-1348 Louvain, Belgium; Dulbecco Telethon Inst, Venetian Inst Mol Med, Padua, Italy; Univ Ghent, B-9000 Ghent, Belgium	Universite Catholique Louvain; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; Ghent University	Agostinis, P (corresponding author), Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Patricia.Agostinis@med.kuleuven.ac.be	Agostinis, Patrizia/AAO-2468-2020; Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008; Agostinis, Patrizia/ABI-1177-2020	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928; Agostinis, Patrizia/0000-0003-1314-2115				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Chae HJ, 1999, BONE, V25, P453, DOI 10.1016/S8756-3282(99)00196-9; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Chiu SM, 2003, BRIT J CANCER, V89, P1590, DOI 10.1038/sj.bjc.6601298; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Delaey EM, 1999, INT J ONCOL, V14, P759; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Inanami O, 1999, PHOTOCHEM PHOTOBIOL, V70, P650, DOI 10.1562/0031-8655(1999)070<0650:EOBAAF>2.3.CO;2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaplan P, 2003, MOL CELL BIOCHEM, V248, P41, DOI 10.1023/A:1024145212616; Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MISSIAEN L, 1994, J BIOL CHEM, V269, P5917; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 2004, SCI STKE, V215, pRE1, DOI DOI 10.1126/STKE.2152004RE1; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wei HF, 1998, J NEUROCHEM, V70, P2305; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitacre CM, 2002, CANCER LETT, V179, P43, DOI 10.1016/S0304-3835(01)00853-9; Yamaguchi H, 2003, CANCER RES, V63, P1483; ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	51	188	195	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					756	+		10.1096/fj.05-4305fje	http://dx.doi.org/10.1096/fj.05-4305fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455754	Green Published			2022-12-25	WOS:000237698700041
J	Moll, F; Millet, C; Noel, D; Orsetti, B; Bardin, A; Katsaros, D; Jorgensen, C; Garcia, M; Theillet, C; Pujol, P; Francois, V				Moll, F.; Millet, C.; Noel, D.; Orsetti, B.; Bardin, A.; Katsaros, D.; Jorgensen, C.; Garcia, M.; Theillet, C.; Pujol, P.; Francois, V.			Chordin is underexpressed in ovarian tumors and reduces tumor cell motility	FASEB JOURNAL			English	Article						ovarian carcinoma; BMP antagonist	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-DIFFERENTIATION FACTOR-9; INCREASED OVULATION RATE; SURFACE EPITHELIUM; BREAST-CANCER; GRANULOSA-CELLS; PRIMARY CULTURE; FAMILY-MEMBERS; MYELOMA CELLS; BONE	Ovarian cancers mostly derive from the monolayer epithelium that covers the ovary. There are currently very few molecular clues to the etiology of this cancer. Bone morphogenetic proteins (BMPs) are required for follicular development and female fertility and are expressed in the ovarian surface epithelium (OSE). We previously reported the expression of human chordin (CHRD), a BMP extracellular regulator, in the ovary. Here we show that CHRD is underexpressed in epithelium ovary cancer and epithelial cancer cell lines as compared with normal tissues and OSE, respectively. Besides, we detected BMP expression in all ovarian cell lines analyzed. To determine the functional relevance of the absence of CHRD mRNA in tumors and cancer cell lines, we studied the effects of CHRD on two cancer cell lines, BG1 and PEO14. Migratory and invasive properties were greatly reduced, whereas cell adhesion to the support was enhanced. In addition, we detected chordin (Chrd) expression in OSE of rat ovaries in a pattern similar to that of BMP4. Altogether, these results suggest that CHRD could participate in regulating BMP activity in normal OSE physiology, and that its mis-expression in OSE may facilitate cancer incidence and/or progression.	CNRS, Inst Genet Humaine, UPR 1142, F-34396 Montpellier 5, France; Univ Turin, Sch Med, Gynaecol Oncol & Breast Canc Unit, Turin, Italy; INSERM, U540, Montpellier, France; INSERM, CRLC Val Aurelle, EMI 229, Montpellier, France; INSERM, U475, Montpellier, France; NCI, LCMB, NIH, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-8000 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Max Planck Society	Francois, V (corresponding author), CNRS, Inst Genet Humaine, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.	vincent.francois@igh.cnrs.fr	Theillet, Charles/O-7634-2018; Bardin, Amy/AFW-5158-2022; Noel, Daniele/E-5719-2016	Theillet, Charles/0000-0001-5555-2759; Noel, Daniele/0000-0002-3498-3776				Araujo H, 2003, DEVELOPMENT, V130, P3851, DOI 10.1242/dev.00613; AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Aunoble B, 2000, INT J ONCOL, V16, P567; Bachiller D, 2003, DEVELOPMENT, V130, P3567, DOI 10.1242/dev.00581; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Chen B, 2002, BIOCHEM BIOPH RES CO, V295, P1135, DOI 10.1016/S0006-291X(02)00828-8; Courjal F, 1997, CANCER RES, V57, P4360; Cvetkovic Dusica, 2003, Reprod Biol Endocrinol, V1, P68; Di Pasquale E, 2004, AM J HUM GENET, V75, P106, DOI 10.1086/422103; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; Fuller PJ, 2002, MOL CELL ENDOCRINOL, V191, P89, DOI 10.1016/S0303-7207(02)00059-X; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Glister C, 2005, ENDOCRINOLOGY, V146, P1883, DOI 10.1210/en.2004-1303; Glister C, 2004, REPRODUCTION, V127, P239, DOI 10.1530/rep.1.00090; Guan XY, 2001, CANCER RES, V61, P3806; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008-5472.CAN-04-2251; Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LANGDON SP, 1988, CANCER RES, V48, P6166; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Larrain J, 2003, EMBO REP, V4, P813, DOI 10.1038/sj.embor.embor902; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; OZAKI T, 1995, CANCER RES, V55, P895; Pangas SA, 2004, J BIOL CHEM, V279, P32281, DOI 10.1074/jbc.M403212200; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Rothhammer T, 2005, CANCER RES, V65, P448; Schindl M, 2003, CLIN CANCER RES, V9, P779; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd TG, 2003, ENDOCRINOLOGY, V144, P3306, DOI 10.1210/en.2003-0185; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; Smith M, 1999, HUM GENET, V105, P104, DOI 10.1007/s004390051070; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Souza CJH, 2002, REPRODUCTION, V123, P363, DOI 10.1530/rep.0.1230363; Teixeira FL, 2002, J CLIN ENDOCR METAB, V87, P1337, DOI 10.1210/jc.87.3.1337; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yoshida Y, 2001, INT J ONCOL, V18, P913; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	61	24	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					240	250		10.1096/fj.05-4126com	http://dx.doi.org/10.1096/fj.05-4126com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449796				2022-12-25	WOS:000237698700009
J	To, MD; Gokgoz, N; Doyle, TG; Donoviel, DB; Knight, JA; Hyslop, PS; Bernstein, A; Andrulis, IL				To, M. D.; Gokgoz, N.; Doyle, T. G.; Donoviel, D. B.; Knight, J. A.; Hyslop, P. S.; Bernstein, A.; Andrulis, I. L.			Functional characterization of novel presenilin-2 variants identified in human breast cancers	ONCOGENE			English	Article						presenilins; PS-2; breast cancer; Alzheimer's disease; susceptibility	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; CELL-CYCLE; IN-VIVO; GENE; MUTANT	We identified in breast cancer cases two germline alterations, R62H and R71W, in presenilin-2 (PS-2), a gene involved in familial Alzheimer's disease (FAD). The role of these alleles in FAD is unclear, but neither allele affected A beta(42)/A beta(40) ratio. However, both R62H and R71W alterations compromised PS-2 function in Notch signaling in Caenorhabditis elegans and cell growth inhibition in mouse embryonic fibroblasts, and these effects were dependent on gene dosage. We found that both alterations enhanced the degradation of the PS-2 full-length protein, indicating that they may have a loss-of function effect. The effect of the R71W alteration was noticeably stronger, and we observed an almost threefold higher frequency of this allele in breast cancer cases versus controls, but this difference did not reach statistical significance. Nonetheless, these results collectively suggest that the novel PS-2 alleles described here, especially R71W, affect PS-2 function and may potentially confer a moderate risk of susceptibility to breast cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Ctr Res Neurodegenerat, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Canadian Inst Hth Res, Ottawa, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Columbia University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Andrulis, IL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, 600 Univ Ave,Room 984, Toronto, ON M5G 1X5, Canada.	andrulis@mshri.on.ca	Knight, Julia/R-5617-2019; Knight, Julia/A-6843-2012; Andrulis, Irene L./E-7267-2013	Knight, Julia/0000-0002-7610-7635; St George-Hyslop, Peter/0000-0003-0796-7209	NATIONAL CANCER INSTITUTE [U01CA069467] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA69467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Baumeister R, 1997, Genes Funct, V1, P149; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; Janicki SM, 1999, AM J PATHOL, V155, P135, DOI 10.1016/S0002-9440(10)65108-5; Janicki SM, 2000, NEUROBIOL AGING, V21, P829, DOI 10.1016/S0197-4580(00)00222-0; Jeong SJ, 2000, FASEB J, V14, P2171, DOI 10.1096/fj.99-1068com; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Knight JA, 2002, ANN EPIDEMIOL, V12, P27, DOI 10.1016/S1047-2797(01)00253-8; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takano T, 1997, NEUROSCI LETT, V221, P205, DOI 10.1016/S0304-3940(96)13290-0; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	43	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2006	25	25					3557	3564		10.1038/sj.onc.1209397	http://dx.doi.org/10.1038/sj.onc.1209397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16474849				2022-12-25	WOS:000238448200008
J	Falvella, FS; Manenti, G; Spinola, M; Pignatiello, C; Conti, B; Pastorino, U; Dragani, TA				Falvella, F. S.; Manenti, G.; Spinola, M.; Pignatiello, C.; Conti, B.; Pastorino, U.; Dragani, T. A.			Identification of RASSF8 as a candidate lung tumor suppressor gene	ONCOGENE			English	Article						lung cancer; KRAS; RAS genes; cancer progression	ANCHORAGE-INDEPENDENT GROWTH; K-RAS; METASTASIS; CANCER; ONCOGENE; MUTATIONS; PROTEIN; PATHWAY	The RASSF8 gene, which maps close to the KRAS2 gene, contains a RAS-associated domain and encodes a protein that is evolutionarily conserved from fish to humans. Analysis of the RASSF8 transcript revealed a complex expression pattern of 5'-UTR mRNA isoforms in normal lung and in lung adenocarcinomas (ADCAs), with no apparent differences. However, RASSF8 gene transcript levels were similar to seven-fold-lower in lung ADCAs as compared to normal lung tissue. Expression of RASSF8 protein by transfected lung cancer cells led to inhibition of anchorage-independent growth in soft agar in A549 cells and reduction of clonogenic activity in NCI-H520 cells. These results raise the possibility protein encoded by RASSF8 is a novel tumor suppressor for lung cancer.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Thorac Surg, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Manenti, Giacomo/J-3339-2017; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017	Manenti, Giacomo/0000-0002-4887-4482; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902				Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Nakanishi K, 2002, CANCER RES, V62, P2971; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048	19	41	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3934	3938		10.1038/sj.onc.1209422	http://dx.doi.org/10.1038/sj.onc.1209422			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16462760				2022-12-25	WOS:000238668800006
J	Chen, S; Barbieri, JT				Chen, S; Barbieri, JT			Unique substrate recognition by botulinum neurotoxins serotypes A and E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM; LIGHT-CHAIN; TOXIN PRODUCTION; TETANUS; SNAP-25; INHIBITORS; BINDING; REQUIREMENTS; SPECIFICITY; PROTEOLYSIS	Botulinum neurotoxins (BoNTs) are zinc proteases that cleave SNARE proteins to elicit flaccid paralysis by inhibiting the fusion of neurotransmitter-carrying vesicles to the plasma membrane of peripheral neurons. There are seven serotypes of BoNT, termed A-G. BoNT serotype A and serotype E cleave SNAP25 at residues 197-198 and 180-181, respectively. Unlike other zinc proteases, the BoNTs recognize extended regions of SNAP25 for cleavage. The basis for this extended substrate recognition and specificity is unclear. Saturation mutagenesis and deletion mapping identified residues 156-202 of SNAP25 as the optimal cleavage domain for BoNT/A, whereas the optimal cleavage domain for BoNT/E was shorter, comprising residues 167-186 of SNAP25. Two sub-sites were resolved within each optimal cleavage domain, which included a recognition or active site (AS) domain that contained the site of cleavage and a binding (B) domain, which contributed to substrate affinity. Within the AS domains, the P1', P3, and P5 sites of SNAP25 contributed to scissile bond cleavage by LC/A, whereas the P1' and P2 sites of SNAP25 contributed to scissile bond cleavage by LC/E. These studies provide insight into the development of strategies for small molecule inhibitors of the BoNTs.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu		Chen, Sheng/0000-0003-3526-7808	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057153] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI057153] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal R, 2005, BIOCHEMISTRY-US, V44, P11758, DOI 10.1021/bi0510072; Agarwal R, 2005, BIOCHEMISTRY-US, V44, P8291, DOI 10.1021/bi050253a; Arndt JW, 2005, J MOL BIOL, V346, P1083, DOI 10.1016/j.jmb.2004.12.039; ARNON SS, 1978, LANCET, V1, P1273; Baldwin MR, 2004, PROTEIN EXPRES PURIF, V37, P187, DOI 10.1016/j.pep.2004.05.009; Breidenbach MA, 2005, TRENDS MOL MED, V11, P377, DOI 10.1016/j.molmed.2005.06.012; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Marvaud JC, 2002, CR BIOL, V325, P863, DOI 10.1016/S1631-0691(02)01498-1; Middlebrook JL, 1995, ADV EXP MED BIOL, V383, P93; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Poulain B., 2003, Annales de Readaptation et de Medecine Physique, V46, P265, DOI 10.1016/S0168-6054(03)00114-4; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; Robinson RF, 2003, ANN PHARMACOTHER, V37, P127, DOI 10.1345/aph.1C034; Rupp B, 2001, NAT STRUCT BIOL, V8, P663, DOI 10.1038/90361; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Schmidt JJ, 2005, BIOCHEMISTRY-US, V44, P4067, DOI 10.1021/bi0477642; Schmidt JJ, 1998, FEBS LETT, V435, P61, DOI 10.1016/S0014-5793(98)01041-2; Schmidt JJ, 1997, J PROTEIN CHEM, V16, P19, DOI 10.1023/A:1026386710428; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; SIEGEL LS, 1979, APPL ENVIRON MICROB, V38, P606, DOI 10.1128/AEM.38.4.606-611.1979; Tonello F, 1996, ADV EXP MED BIOL, V389, P251; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8	32	82	90	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10906	10911		10.1074/jbc.M513032200	http://dx.doi.org/10.1074/jbc.M513032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478727	hybrid			2022-12-25	WOS:000236822200031
J	Ren, JW; Kan, A; Leong, SH; Ooi, LLPJ; Jeang, KT; Chong, SS; Kon, OL; Lee, CGL				Ren, JW; Kan, A; Leong, SH; Ooi, LLPJ; Jeang, KT; Chong, SS; Kon, OL; Lee, CGL			FAT10 plays a role in the regulation of chromosomal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; NECROSIS-FACTOR-ALPHA; MITOTIC CHECKPOINT; COLORECTAL-CANCER; MAD2; EXPRESSION; CELLS; GENE; INSTABILITY	Aneuploidy is a key process in tumorigenesis. Dysfunction of the mitotic spindle checkpoint proteins has been implicated as a cause of aneuploidy in cells. We have previously reported that FAT10, a member of the ubiquitin-like modifier family of proteins, is overexpressed in several gastrointestinal and gynecological cancers. Here we show that FAT10 interacts with MAD2, a spindle checkpoint protein, during mitosis. Notably, we show that localization of MAD2 at the kinetochore during the prometaphase stage of the cell cycle was greatly reduced in FAT10-overexpressing cells. Furthermore, compared with parental HCT116 cells, fewer mitotic cells were observed after double thymidine-synchronized FAT10-overexpressing cells were released into nocodazole for more than 4 h. Nonetheless, when these double thymidine-treated cells were released into media, a similar number of G(1) parental and FAT10-overexpressing HCT116 cells was observed throughout the 10-h time course. Additionally, more nocodazole-treated FAT10-overexpressing cells escape mitotic controls and are multinucleate compared with parental cells. Significantly, we observed a higher degree of variability in chromosome number in cells overexpressing FAT10. Hence, our data suggest that high levels of FAT10 protein in cells lead to increased mitotic nondisjunction and chromosome instability, and this effect is mediated by an abbreviated mitotic phase and the reduction in the kinetochore localization of MAD2 during the prometaphase stage of the cell cycle.	Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore; Natl Canc Ctr, Dept Surg Oncol, Singapore 169610, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 117597, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore 117597, Singapore; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA	National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019; Ooi, London Lucien/AGK-1395-2022; Jeang, Kuan-Teh/A-2424-2008; Chong, Samuel S./D-8098-2015	Lee, Caroline G/0000-0002-4323-3635; Chong, Samuel S./0000-0002-1872-5937	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI001023, ZIAAI001023, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; FitzPatrick DR, 2002, HUM MOL GENET, V11, P3249, DOI 10.1093/hmg/11.26.3249; Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAMIHIRA S, 1994, LEUKEMIA RES, V18, P79, DOI 10.1016/0145-2126(94)90122-8; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li GQ, 2003, WORLD J GASTROENTERO, V9, P1972, DOI 10.3748/wjg.v9.i9.1972; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tanaka K, 2001, JPN J CANCER RES, V92, P952, DOI 10.1111/j.1349-7006.2001.tb01186.x; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	35	69	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11413	11421		10.1074/jbc.M507218200	http://dx.doi.org/10.1074/jbc.M507218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495226	hybrid			2022-12-25	WOS:000236822200084
J	Frank, M; Dzikowski, R; Costantini, D; Amulic, B; Berdougo, E; Deitsch, K				Frank, M; Dzikowski, R; Costantini, D; Amulic, B; Berdougo, E; Deitsch, K			Strict pairing of var promoters and introns is required for var gene silencing in the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE-A; ANTIGENIC VARIATION; INFECTED ERYTHROCYTES; DNA-REPLICATION; EXPRESSION; FAMILY; RECOMBINATION; TRANSFORMATION; TRANSCRIPTION; TRANSFECTION	The human malaria parasite, Plasmodium falciparum, maintains a persistent infection altering the proteins expressed on the surface of the infected red blood cells, thus avoiding the host immune response. The primary surface antigen, a protein called PfEMP1, is encoded by amulticopy gene family called var. Each individual parasite only expresses a single var gene at a time, maintaining all other members of the family in a transcriptionally silent state. Previous work using reporter genes in transiently transfected plasmid constructs implicated a conserved intron found in all var genes in the silencing process. Here we have utilized episomal recombination within stably transformed parasites to generate different var promoter and intron arrangements and show that loss of the intron results in var promoter activation. Further, in multicopy plasmid concatamers, each intron could only silence a single promoter, suggesting a one-to-one pairing requirement for silencing. Transcriptionally active, "unpaired" promoters remained active after integration into a chromosome; however, they were not recognized by the pathway that maintains mutually exclusive var gene expression. The data indicate that intron/ promoter pairing is responsible for silencing each individual var gene and that disruption of silencing of one gene does not affect the transcriptional activity of neighboring var promoters. This suggests that silencing is regulated at the level of individual genes rather than by assembly of silent chromatin throughout a chromosomal region, thus providing a possible explanation of how a var gene can be maintained in a silent state while the immediately adjacent var gene is transcriptionally active.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Int Hlth & Infect Dis, New York, NY 10021 USA	Cornell University; Cornell University	Deitsch, K (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave,Box 62, New York, NY 10021 USA.	kwd2001@med.cornell.edu	Dzikowski, Ron/HHZ-2430-2022	Amulic, Borko/0000-0002-8518-8393; si yun, feng/0000-0002-3546-824X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052390] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI052390, AI 52390] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; Calderwood MS, 2003, J BIOL CHEM, V278, P34125, DOI 10.1074/jbc.M213065200; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Gannoun-Zaki L, 2005, EUKARYOT CELL, V4, P490, DOI 10.1128/EC.4.2.490-492.2005; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; Kyes SA, 2003, MOL MICROBIOL, V48, P1339, DOI 10.1046/j.1365-2958.2003.03505.x; Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; O'Donnell RA, 2002, EMBO J, V21, P1231, DOI 10.1093/emboj/21.5.1231; Ralph SA, 2005, P NATL ACAD SCI USA, V102, P5414, DOI 10.1073/pnas.0408883102; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; SAMBROOK J, 1989, MOL CLONING, V2, P9; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Short Robert A, 2005, Am J Nephrol, V25, P36, DOI 10.1159/000084073; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; Williamson DH, 2002, NUCLEIC ACIDS RES, V30, P726, DOI 10.1093/nar/30.3.726; Winter G, 2003, MOL BIOCHEM PARASIT, V127, P179, DOI 10.1016/S0166-6851(03)00004-5; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	40	84	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9942	9952		10.1074/jbc.M513067200	http://dx.doi.org/10.1074/jbc.M513067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455655	hybrid, Green Accepted			2022-12-25	WOS:000236594300016
J	Griffin, BD; Moynagh, PN				Griffin, BD; Moynagh, PN			Persistent interleukin-1 beta signaling causes long term activation of NF kappa B in a promoter-specific manner in human glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; NUCLEAR EXPORT; REL PROTEINS	Nuclear factor-kappa B (NF kappa B) is an inducible transcription factor that plays a key role in regulating the expression of a wide range of immune and inflammatory response genes. The activity of NF kappa B is controlled at multiple levels, including cytoplasmic retention with inhibitor of kappa B (I kappa B) proteins in the basal state. Persistent activation of the transcription factor is seen in numerous chronic inflammatory disease states, and we have previously demonstrated sustained activation of NF kappa B in human glial cells upon stimulation with interleukin (IL)-1 beta. In these cells, NF kappa B retains DNA binding activity for up to 72 h despite the presence of resynthesized I kappa B alpha and in the absence of I kappa B beta. Here we characterized the apparent inability of newly synthesized I kappa B alpha to terminate activation of NF kappa B in glial cells. We showed unexpectedly that newly synthesized I kappa B alpha can enter the nucleus, interact with the NF kappa B subunit p65, and export it to the cytoplasm. However, in vitro analysis of enzyme activity demonstrates that IL-1 beta causes the long term activation of the I kappa B kinase complex leading to chronic phosphorylation of the newly synthesized I kappa B alpha signal response domain and persistent activation of NF kappa B. Such sustained activation of NF kappa B is dependent on the continuous presence and activity of IL-1 beta. Interestingly, the sustained nature of NF kappa B activity is promoter type-specific. Chromatin immunoprecipitation studies revealed that p65 is detected at the promoters of both intercellular adhesion molecule-1 and IL-8 1 h following IL-1 beta stimulation but is only found at the latter at 24 h. The functional significance of this finding is indicated by the transient induction of intercellular adhesion molecule-1 mRNA, but more sustained induction of IL-8 expression, by IL-1 beta. These studies thus demonstrated that persistent IL-1 signaling causes sustained activation of NF kappa B in a promoter-specific manner in human glial cells, leading to prolonged induction of selective pro-inflammatory genes. This is likely to make a key contribution to chronic inflammatory conditions of the brain.	Natl Univ Ireland Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Moynagh, PN (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	P.Moynagh@ucd.ie		Moynagh, Paul/0000-0002-4139-3061				ALOISI F, 1992, J IMMUNOL, V149, P2358; ARCHELOS JJ, 1993, ANN NEUROL, V34, P145, DOI 10.1002/ana.410340209; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOPP JM, 1994, J NEUROIMMUNOL, V54, P129, DOI 10.1016/0165-5728(94)90239-9; ENNIS HL, 1964, SCIENCE, V146, P1474, DOI 10.1126/science.146.3650.1474; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kostulas N, 1998, STROKE, V29, P462, DOI 10.1161/01.STR.29.2.462; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee SJ, 1998, J NEUROIMMUNOL, V92, P196, DOI 10.1016/S0165-5728(98)00209-4; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Sprenger H, 1996, CLIN IMMUNOL IMMUNOP, V80, P155, DOI 10.1006/clin.1996.0109; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	48	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10316	10326		10.1074/jbc.M509973200	http://dx.doi.org/10.1074/jbc.M509973200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16455661	Green Accepted, hybrid			2022-12-25	WOS:000236594300060
J	Jaschke, H; Neumann, S; Moore, S; Thomas, CJ; Colson, AO; Costanzi, S; Kleinau, G; Jiang, JK; Paschke, R; Raaka, BM; Krause, G; Gershengorn, MC				Jaschke, H; Neumann, S; Moore, S; Thomas, CJ; Colson, AO; Costanzi, S; Kleinau, G; Jiang, JK; Paschke, R; Raaka, BM; Krause, G; Gershengorn, MC			A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VIRUS TYPE-1 ENTRY; MODELS; IDENTIFICATION; ACTIVATION; RHODOPSIN; DYNAMICS; LIGAND	Many cognate low molecular weight (LMW) agonists bind to seven transmembrane-spanning receptors within their transmembrane helices (TMHs). The thienopyrimidine org41841 was identified previously as an agonist for the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and suggested to bind within its TMHs because it did not compete for LH binding to the LHCGR ectodomain. Because of its high homology with LHCGR, we predicted that thyroid-stimulating hormone receptor (TSHR) might be activated by org41841 also. We show that org41841 is a partial agonist for TSHR but with lower potency than for LHCGR. Analysis of three-dimensional molecular models of TSHR and LHCGR predicted a binding pocket for org41841 in common clefts between TMHs 3, 4, 5, 6, and 7 and extracellular loop 2 in both receptors. Evidence for this binding pocket was obtained in signaling studies with chimeric receptors that exhibited improved responses to org41841. Furthermore, a key receptor-ligand interaction between the highly conserved negatively charged E3.37 and the amino group of org41841 predicted by docking of the ligand into the three-dimensional TSHR model was experimentally confirmed. These findings provide the first evidence that, in contrast to the ectodomain binding of cognate ligands, a LMW agonist can bind to and activate glycoprotein hormone receptors via interaction with their transmembrane domain.	Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Computat Chem Core Lab, NIH, Bethesda, MD 20892 USA; Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Leipzig University	Jaschke, H (corresponding author), Leibniz Inst Mol Pharmacol, Robert Roessle Str 10, D-13125 Berlin, Germany.	marving@intra.niddk.nih.gov	Neumann, Susanne/GPK-6035-2022; Kleinau, Gunnar/GPX-6330-2022; Costanzi, Stefano/G-8990-2013	Thomas, Craig/0000-0001-9386-9001; Costanzi, Stefano/0000-0003-3183-7332	Intramural NIH HHS [Z01 DK070005-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011006, Z01DK013025, Z01DK070005, Z01DK047045, Z01DK047044] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Case DA, 2002, ACCOUNTS CHEM RES, V35, P325, DOI 10.1021/ar010020l; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; McLachlan SM, 2005, ENDOCR REV, V26, P800, DOI 10.1210/er.2004-0023; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Stenkamp RE, 2005, ARCH PHARM, V338, P209, DOI 10.1002/ardp.200400995; STRADER CD, 1989, J BIOL CHEM, V264, P13572; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; ter Laak AM, 1999, RECEPTOR CHANNEL, V6, P295; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; van Straten NCR, 2005, J MED CHEM, V48, P1697, DOI 10.1021/jm049676l; van Straten NCR, 2002, CHEMBIOCHEM, V3, P1023, DOI 10.1002/1439-7633(20021004)3:10<1023::AID-CBIC1023>3.0.CO;2-9; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Woodmansee WW, 2004, CLIN ENDOCRINOL, V61, P163, DOI 10.1111/j.1365-2265.2004.02025.x	26	73	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9841	9844		10.1074/jbc.C600014200	http://dx.doi.org/10.1074/jbc.C600014200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16488885	hybrid			2022-12-25	WOS:000236594300004
J	Molnar, F; Perakyla, M; Carlberg, C				Molnar, F; Perakyla, M; Carlberg, C			Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIDE-CHAINS; NUCLEAR RECEPTOR; CRYSTAL-STRUCTURE; 20-EPI ANALOGS; DOMAIN; COACTIVATOR; D-3; CONFORMATIONS; ACTIVATION; GEMINI	Existing crystal structure data has indicated that 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) and its analogues bind the ligand-binding pocket (LBP) of the human vitamin D receptor in a very similar fashion. Because docking of a ligand into the LBP is a more flexible process than crystallography can monitor, we analyzed 1 alpha,25(OH)(2)D-3, its 20-epi derivative MC1288, the two side-chain analogues Gemini and Ro43-83582 ( a hexafluoro-derivative) by molecular dynamics simulations in a complex with the vitamin D receptor ligand-binding domain and a co-activator peptide. Superimposition of the structures showed that the side chain of MC1288, the first side chain of the conformation II of Gemini, the second side chain of Ro43-83582 in conformation I and the first side chain of Ro43-83582 in conformation II take the same agonistic position as the side chain of 1 alpha,25(OH)(2)D-3. Compared with the LBP of the natural hormone MC1288 reduced the volume by 17%, and Gemini expanded it by 19%. The shrinking of the LBP of MC1288 and its expansion to accommodate the second side chain of Gemini or Ro43-83582 is the combined result of minor movements of more than 30 residues and major movements of a few critical amino acids. The agonist-selective recognition of anchoring OH groups by the conformational flexible residues Ala-303, Leu-309, and His-397 was confirmed by in vitro assays. In summary, variations in the volume of agonists lead to adaptations in the volume of the LBP and alternative contacts of anchoring OH-groups.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Molnár, Ferdinand/E-2290-2011; Carlberg, Carsten/C-9075-2011	Molnár, Ferdinand/0000-0001-9008-4233; Carlberg, Carsten/0000-0003-2633-0684				BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bury Y, 2001, J CELL BIOCHEM, P179; Carlberg C, 2003, EXPERT OPIN THER PAT, V13, P761; Carlberg C, 2003, J CELL BIOCHEM, V88, P274, DOI 10.1002/jcb.10337; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 2001, STEROIDS, V66, P213, DOI 10.1016/S0039-128X(00)00150-1; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Ciesielski F, 2004, J STEROID BIOCHEM, V89-90, P55, DOI 10.1016/j.jsbmb.2004.03.109; Eelen G, 2005, MOL PHARMACOL, V67, P1566, DOI 10.1124/mol.104.008730; Hansen CM, 2001, FRONT BIOSCI-LANDMRK, V6, pD820, DOI 10.2741/Hansen; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; Jimenez-Lara AM, 1999, J BIOL CHEM, V274, P13503, DOI 10.1074/jbc.274.19.13503; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kohonen T., 1995, SELF ORG MAPS, V30, DOI 10.1007/978-3-642-97610-0; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MACIASGONZALEZ M, 2003, MOL ENDOCRINOL, V17, P2028; Nayeri S, 1996, J CELL BIOCHEM, V62, P325, DOI 10.1002/(SICI)1097-4644(199609)62:3<325::AID-JCB3>3.0.CO;2-T; Norman AW, 2000, J MED CHEM, V43, P2719, DOI 10.1021/jm0000160; ONATE SA, 1995, SCIENCE, V270, P1354; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331; Tocchini-Valentini G, 2004, J MED CHEM, V47, P1956, DOI 10.1021/jm0310582; Tocchini-Valentini G, 2001, P NATL ACAD SCI USA, V98, P5491, DOI 10.1073/pnas.091018698; Vaisanen S, 2003, MOL PHARMACOL, V63, P1230, DOI 10.1124/mol.63.6.1230; Vaisanen S, 2002, MOL PHARMACOL, V62, P788, DOI 10.1124/mol.62.4.788; Vanhooke JL, 2004, BIOCHEMISTRY-US, V43, P4101, DOI 10.1021/bi036056y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weyts FA, 2004, BIOCHEM PHARMACOL, V67, P1327, DOI 10.1016/j.bcp.2003.12.006; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	38	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10516	10526		10.1074/jbc.M513609200	http://dx.doi.org/10.1074/jbc.M513609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16478719	hybrid			2022-12-25	WOS:000236594300081
J	Tanner, DR; Dewey, JD; Miller, MR; Buskirk, AR				Tanner, DR; Dewey, JD; Miller, MR; Buskirk, AR			Genetic analysis of the structure and function of transfer messenger RNA pseudoknot 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TMRNA; TRANSLATION; SEQUENCE; DEGRADATION; UPSTREAM; RIBOSOME; SYSTEM	tmRNA rescues stalled ribosomes in eubacteria by forcing the ribosome to abandon its mRNA template and resume translation with tmRNA itself as a template. Pseudoknot 1 (pk1), immediately upstream of this coding region in tmRNA, is a structural element that is considered essential for tmRNA function based on the analysis of pk1 mutants in vitro. pk1 binds near the ribosomal decoding site and may make base-specific contacts with tmRNA ligands. To study pk1 structure and function in vivo, we have developed a genetic selection that ties the life of Escherichia coli cells to tmRNA activity. Mutation of pk1 at 20% per base and selection for tmRNA activity yielded sequences that retain the same pseudoknot fold. In contrast, selection of active mutants from 106 completely random sequences identified hairpin structures that functionally replace pk1. Rational design of a hairpin with increased stability using an unrelated sequence yielded a tmRNA mutant with nearly wild-type activity. We conclude that the role of pk1 in tmRNA function is purely structural and that it can be replaced with a variety of hairpin structures. Our results demonstrate that in the study of functional RNAs, the inactivity of a mutant designed to destroy a given structure should not be interpreted as proof that the structure is necessary for RNA function. Such mutations may only destabilize a global fold that could be formed equally well by an entirely different, stable structure.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Buskirk, AR (corresponding author), Brigham Young Univ, Dept Chem & Biochem, C203 BNSN, Provo, UT 84602 USA.	buskirk@chem.byu.edu						Aalberts DP, 2005, NUCLEIC ACIDS RES, V33, P2210, DOI 10.1093/nar/gki508; Burks J, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-14; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; de Novoa PG, 2004, NUCLEIC ACIDS RES, V32, pD104, DOI 10.1093/nar/gkh102; Felden B, 1997, RNA, V3, P89; Fong DH, 2002, EMBO J, V21, P2323, DOI 10.1093/emboj/21.10.2323; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; Lim VI, 2005, J MOL BIOL, V346, P395, DOI 10.1016/j.jmb.2004.11.061; Michiels PJA, 2001, J MOL BIOL, V310, P1109, DOI 10.1006/jmbi.2001.4823; Nameki N, 1999, NUCLEIC ACIDS RES, V27, P3667, DOI 10.1093/nar/27.18.3667; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nameki N, 1999, J MOL BIOL, V286, P733, DOI 10.1006/jmbi.1998.2487; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; Reeder J, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-104; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Su L, 1999, NAT STRUCT BIOL, V6, P285, DOI 10.1038/6722; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1996, RNA, V2, P1306; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	25	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10561	10566		10.1074/jbc.M600167200	http://dx.doi.org/10.1074/jbc.M600167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481313	hybrid			2022-12-25	WOS:000236594300087
J	Taurin, S; Sandbo, N; Qin, YM; Browning, D; Dulin, NO				Taurin, S; Sandbo, N; Qin, YM; Browning, D; Dulin, NO			Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; GENE-EXPRESSION; COLON-CANCER; ACTIVATION; INTERACTS; PATHWAY; CELLS; APC; UBIQUITINATION; ACETYLATION	beta-Catenin is a signaling molecule that promotes cell proliferation by the induction of gene transcription through the activation of T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors. The canonical mechanism of the regulation of beta-catenin involves its phosphorylation by casein kinase 1 at the Ser-45 site and by glycogen synthase kinase 3 (GSK3) at the Thr-41, Ser-37, and Ser-33 sites. This phosphorylation targets beta-catenin to ubiquitination and degradation by the proteasome system. Mitogenic factors promote beta-catenin signaling through the inhibition of GSK3, resulting in reduced beta-catenin phosphorylation, its stabilization, and subsequent accumulation in the nucleus, where it stimulates TCF/LEF-dependent gene transcription. In the present study, we have shown that (i) beta-catenin can be phosphorylated by protein kinase A (PKA) in vitro and in intact cells at two novel sites, Ser-552 and Ser-675; (ii) phosphorylation by PKA promotes the transcriptional activity (TCF/LEF transactivation) of beta-catenin; (iii) mutation of Ser-675 attenuates the promoting effect of PKA; (iv) phosphorylation by PKA does not affect the GSK3-dependent phosphorylation of beta-catenin, its stability, or intracellular localization; and ( v) phosphorylation at the Ser-675 site promotes the binding of beta-catenin to its transcriptional coactivator, CREB-binding protein. In conclusion, this study identifies a novel, noncanonical mechanism of modulation of beta-catenin signaling through direct phosphorylation of beta-catenin by PKA, promoting its interaction with CREB-binding protein.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University of Chicago; University System of Georgia; Augusta University	Dulin, NO (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	ndulin@medicine.bsd.uchicago.edu	高, 雨莉/HGU-8187-2022	Browning, Darren/0000-0003-0497-7620; Taurin, Sebastien/0000-0003-2167-5253	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 071755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boucher MJ, 2005, J CELL PHYSIOL, V202, P178, DOI 10.1002/jcp.20104; Davis A, 2003, CELL SIGNAL, V15, P597, DOI 10.1016/S0898-6568(02)00148-1; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hogarth DK, 2004, AM J PHYSIOL-CELL PH, V287, pC449, DOI 10.1152/ajpcell.00547.2003; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Khaled M, 2002, J BIOL CHEM, V277, P33690, DOI 10.1074/jbc.M202939200; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Niu JX, 2002, BIOCHEM J, V365, P677, DOI 10.1042/BJ20020390; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200	34	337	354	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9971	9976		10.1074/jbc.M508778200	http://dx.doi.org/10.1074/jbc.M508778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476742	hybrid			2022-12-25	WOS:000236594300019
J	Cho, HDD; Chen, Y; Varani, G; Weiner, AM				Cho, HDD; Chen, Y; Varani, G; Weiner, AM			A model for C74 addition by CCA-adding enzymes - C74 addition, like C75 and A76 addition, does not involve trna translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SHIBATAE; DNA-POLYMERASE; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; POLY(A) POLYMERASES; PROLINE RESIDUES; STRUCTURAL BASIS; ACTIVE-SITE; POLYMERIZATION; MECHANISM; COMPLEXES	The CCA-adding enzyme adds CCA to the 3'-end of tRNA one nucleotide at a time, using CTP and ATP as substrates. We found previously that tRNA does not rotate or translocate on the enzyme during the addition of C75 and A76. We therefore predicted that the growing 3'-end of tRNA must, upon addition of each nucleotide, refold to reposition the new 3'-hydroxyl equivalently relative to the solitary nucleotidyltransferase motif. Cocrystal structures of the class I archaeal Archaeoglobus fulgidus enzyme, poised for addition of C75 and A76, confirmed this prediction. We have also demonstrated that an evolutionarily flexible beta-turn facilitates progressive refolding of the 3'-terminal C74 and C75 residues during C75 and A76 addition. Although useful cocrystals corresponding to C74 addition have not yet been obtained, we now show experimentally that tRNA does not rotate or translocate during C74 addition. We therefore propose, based on the existing A. fulgidus cocrystal structures, that the same flexible beta-turn functions as a wedge between the discriminator base (N73) and the terminal base pair of the acceptor stem, unstacking and repositioning N73 to attack the incoming CTP. Thus a single flexible beta-turn would orchestrate consecutive addition of all three nucleotides without significant movement of the tRNA on the enzyme surface.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.	amweiner@u.washington.edu			NIGMS NIH HHS [GM064440, GM59804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064440, R01GM059804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cho HD, 2005, J BIOL CHEM, V280, P9555, DOI 10.1074/jbc.M412594200; Cho HD, 2003, RNA, V9, P970, DOI 10.1261/rna.2110903; Cho HDD, 2004, J BIOL CHEM, V279, P40130, DOI 10.1074/jbc.M405518200; Cho HDD, 2002, J BIOL CHEM, V277, P3447, DOI 10.1074/jbc.M109559200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Isaksson J, 2005, BIOCHEMISTRY-US, V44, P5390, DOI 10.1021/bi047414f; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; LI Y, 1999, NUCL ACIDS S SER, V42, P237; Martin G, 2004, RNA, V10, P899, DOI 10.1261/rna.5242304; Okabe M, 2003, EMBO J, V22, P5918, DOI 10.1093/emboj/cdg563; ROMBY P, 1985, J MOL BIOL, V184, P455, DOI 10.1016/0022-2836(85)90294-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Stowasser R, 2002, BIOORG CHEM, V30, P420, DOI 10.1016/S0045-2068(02)00526-6; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	36	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9801	9811		10.1074/jbc.M512603200	http://dx.doi.org/10.1074/jbc.M512603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455665	hybrid			2022-12-25	WOS:000236404700093
J	Luo, Y; Koles, K; Vorndam, W; Haltiwanger, RS; Panin, VM				Luo, Y; Koles, K; Vorndam, W; Haltiwanger, RS; Panin, VM			Protein O-fucosyltransferase 2 adds O-fucose to thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; DROSOPHILA CELL-LINES; N-LINKED GLYCANS; GDP-FUCOSE; CORE FUCOSYLATION; C-MANNOSYLATION; GLYCOSYLATION; FRINGE; TRANSFERASE; GOLGI	O-Fucose is an unusual form of glycosylation found on epidermal growth factor-like (EGF) repeats and thrombospondin type 1 repeats (TSRs) in many secreted and transmembrane proteins. Recently O-fucose on EGF repeats was shown to play important roles in Notch signaling. In contrast, physiological roles for O-fucose on TSRs are unknown. In the accompanying paper (Luo, Y., Nita-Lazar, A., and Haltiwanger, R. S. (2006) J. Biol. Chem. 281, 9385-9392), we demonstrated that an enzyme distinct from protein O-fucosyltransferase 1 adds O-fucose to TSRs. A known homologue of O-fucosyltransferase 1 is putative protein O-fucosyltransferase 2. The cDNA sequence encoding O-fucosyltransferase 2 was originally identified during a data base search for fucosyltransferases in Drosophila. Like O-fucosyltransferase 1, O-fucosyltransferase 2 is conserved from Caenorhabditis elegans to humans. Although O-fucosyltransferase 2 was assumed to be another protein O-fucosyltransferase, no biochemical characterization existed supporting this contention. Here we show that RNAi-mediated reduction of the O-fucosyltransferase 2 message significantly decreased TSR-specific O-fucosyltransferase activity in Drosophila S2 cells. We also found that O-fucosyltransferase 2 is predominantly localized in the endoplasmic reticulum compartment of these cells. Furthermore, we expressed recombinant Drosophila O-fucosyltransferase 2 and showed that it O-fucosylates TSRs but not EGF repeats in vitro. These results demonstrate that O-fucosyltransferase 2 is in fact a TSR-specific O-fucosyltransferase.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Texas A&M University System; Texas A&M University College Station	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.	rhaltiwanger@ms.cc.sunysb.edu; panin@tamu.edu	Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481	NIGMS NIH HHS [GM069952, GM 61126, R01 GM061126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069952, R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2000, DEV DYNAM, V218, P280; Arziman Z, 2005, NUCLEIC ACIDS RES, V33, pW582, DOI 10.1093/nar/gki468; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Correia T, 2003, P NATL ACAD SCI USA, V100, P6404, DOI 10.1073/pnas.1131007100; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Dlugosz KA, 2005, GLYCOBIOLOGY, V15, P1219; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Etzioni A, 2002, AM J MED GENET, V110, P131, DOI 10.1002/ajmg.10423; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Ishikawa HO, 2005, P NATL ACAD SCI USA, V102, P18532, DOI 10.1073/pnas.0504115102; KIRKPATRICK RB, 1995, J BIOL CHEM, V270, P19800, DOI 10.1074/jbc.270.34.19800; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; Menzel O, 2004, GENOMICS, V84, P320, DOI 10.1016/j.ygeno.2004.04.002; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Opalka N, 2000, P NATL ACAD SCI USA, V97, P617, DOI 10.1073/pnas.97.2.617; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Roos C, 2002, J BIOL CHEM, V277, P3168, DOI 10.1074/jbc.m107927200; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200; Sturla L, 2005, GLYCOBIOLOGY, V15, P924, DOI 10.1093/glycob/cwi081; Sturla L, 2001, PEDIATR RES, V49, P537, DOI 10.1203/00006450-200104000-00016; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Wang XC, 2006, J BIOL CHEM, V281, P2572, DOI 10.1074/jbc.M510893200; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200	43	97	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9393	9399		10.1074/jbc.M511975200	http://dx.doi.org/10.1074/jbc.M511975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464857	hybrid			2022-12-25	WOS:000236404700048
J	Rothberg, KG; Burdette, DL; Pfannstiel, J; Jetton, N; Singh, R; Ruben, L				Rothberg, KG; Burdette, DL; Pfannstiel, J; Jetton, N; Singh, R; Ruben, L			The RACK1 homologue from Trypanosoma brucei is required for the onset and progression of cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VARIANT SURFACE GLYCOPROTEIN; CELL-CYCLE PROGRESSION; PROCYCLIC FORM; 80S RIBOSOME; ACTIVATED C-KINASE-1; AFRICAN TRYPANOSOMES; MUTATIONAL ANALYSIS; ANCHORING PROTEIN; RNA INTERFERENCE	The receptor for activated C kinase 1 (RACK1) is a conserved scaffold protein that helps regulate a range of cell activities including cell growth, shape, and protein translation. We report that a homologue of RACK1 is required for cytokinesis in pathogenic Trypanosoma brucei. The protein, referred to as TRACK, is comprised of WD repeat elements and can complement cpc2 null mutants of Schizosaccharomyces pombe. TRACK is expressed throughout the trypanosome life cycle and is distributed predominantly in a perinuclear region and the cytoplasm but not along the endoplasmic reticulum, mitochondrion, or cleavage furrow of dividing cells. When tetracycline-inducible RNA interference (RNAi) is used to deplete the cellular content of TRACK, the cells remain metabolically active, but growth is inhibited. In bloodstream forms, growth arrest is due to a delay in the onset of cytokinesis. By contrast, procyclic forms are able to initiate cytokinesis in the absence of TRACK but arrest midway through cell cleavage. The RNAi cells undergo multiple rounds of partial cytokinesis and accumulate nuclei and cytoplasmic extensions with attached flagella. The TRACK RNAi construct is also inducible within infected mice. Under these conditions parasites are eliminated from peripheral blood within 3 days post-infection. Taken as a whole, these data indicate that trypanosomes utilize a RACK1 homologue to regulate the final stages of mitosis. Moreover, disrupting the interaction between TRACK and its partners might be targeted in the design of novel therapies.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Ruben, L (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	lruben@mail.smu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051531, R01AI024627] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24627, AI051531, R01 AI051531, R01 AI051531-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angenstein F, 2002, J NEUROSCI, V22, P8827; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; DAS A, 1994, J CELL SCI, V107, P3477; Gao HX, 2005, P NATL ACAD SCI USA, V102, P10206, DOI 10.1073/pnas.0500926102; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gerbasi VR, 2004, MOL CELL BIOL, V24, P8276, DOI 10.1128/MCB.24.18.8276-8287.2004; Giavalisco P, 2005, PLANT MOL BIOL, V57, P577, DOI 10.1007/s11103-005-0699-3; Grellier P, 1999, CELL MOTIL CYTOSKEL, V42, P36, DOI 10.1002/(SICI)1097-0169(1999)42:1&lt;36::AID-CM4&gt;3.0.CO;2-G; Hammarton TC, 2005, MOL MICROBIOL, V56, P104, DOI 10.1111/j.1365-2958.2005.04542.x; Hammarton TC, 2004, J BIOL CHEM, V279, P24757, DOI 10.1074/jbc.M401276200; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Inoue M, 2005, J BIOL CHEM, V280, P14085, DOI 10.1074/jbc.M412336200; Kelly BL, 2003, J EXP MED, V198, P1689, DOI 10.1084/jem.20031162; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kilunga KB, 2005, J BIOL CHEM, V280, P26371, DOI 10.1074/jbc.M413884200; Kohl L, 2003, EMBO J, V22, P5336, DOI 10.1093/emboj/cdg518; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; Loreni F, 2005, FEBS LETT, V579, P5517, DOI 10.1016/j.febslet.2005.09.016; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Manuell AL, 2005, J MOL BIOL, V351, P266, DOI 10.1016/j.jmb.2005.06.022; Matthews KR, 1998, MOL BIOCHEM PARASIT, V95, P81, DOI 10.1016/S0166-6851(98)00100-5; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Moreno SNJ, 2003, CURR OPIN MICROBIOL, V6, P359, DOI 10.1016/S1369-5274(03)00091-2; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Ploubidou A, 1999, J CELL SCI, V112, P4641; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RUBEN L, 1991, MOL BIOCHEM PARASIT, V46, P123, DOI 10.1016/0166-6851(91)90206-L; Ruben L, 2003, MOL MED PARASITOLOGY, P241; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Taladriz S, 1999, FEBS LETT, V443, P375, DOI 10.1016/S0014-5793(99)00006-X; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; Traub-Cseko YM, 1998, PARASITOL TODAY, V14, P41, DOI 10.1016/S0169-4758(97)01156-3; Tu XM, 2005, MOL BIOL CELL, V16, P97, DOI 10.1091/mbc.E04-05-0368; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vedrenne C, 2002, MOL BIOL CELL, V13, P1058, DOI 10.1091/mbc.01-06-0298; WANG Z, 2000, J BIOL CHEM, V211, P4998; Welburn SC, 1998, CELL DEATH DIFFER, V5, P615, DOI 10.1038/sj.cdd.4400393; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Won M, 2001, BIOCHEM BIOPH RES CO, V282, P10, DOI 10.1006/bbrc.2001.4535; WOODWARD R, 1990, J CELL SCI, V95, P49	66	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9781	9790		10.1074/jbc.M600133200	http://dx.doi.org/10.1074/jbc.M600133200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16469736	Green Accepted, hybrid			2022-12-25	WOS:000236404700091
J	Wang, XL; Ye, YH; Lencer, W; Hansen, TH				Wang, XL; Ye, YH; Lencer, W; Hansen, TH			The viral E3 ubiquitin ligase mK3 uses the derlin/p97 endoplasmic reticulum-associated degradation pathway to mediate down-regulation of major histocompatibility complex class I proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; PEPTIDE-LOADING COMPLEX; ER-ASSOCIATED DEGRADATION; MEMBRANE-PROTEIN; IMMUNE EVASION; MISFOLDED PROTEINS; AAA-ATPASE; ANTIGEN PRESENTATION; FINGER PROTEIN; HEAVY-CHAINS	Ubiquitin E3 ligases are important cellular components for endoplasmic reticulum (ER)- associated degradation due to their role in substrate-specific ubiquitination, which is required for retrotranslocation ( dislocation) of most unwanted proteins from the ER to the cytosol for proteasome degradation. However, our understanding of the molecular mechanisms of how E3 ligases confer substrate-specific recognition, and their role in substrate retrotranslocation is limited especially in mammalian cells. mK3 is a type III ER membrane protein encoded by murine gamma herpesvirus 68. As conferred by its N-terminal RING-CH domain, mK3 has E3 ubiquitin ligase activity. In its role as an immune evasion protein, mK3 specifically targets nascent major histocompatibility complex class I heavy chains (HC) for rapid degradation. The mechanism by which mK3 extracts HC from the ER membrane into the cytosol for proteasome-mediated degradation is unknown. Evidence is presented here that HC down-regulation by mK3 is dependent on the p97 AAA-ATPase. By contrast, the kK5 protein of Kaposi's sarcoma-associated herpesvirus is p97-independent despite the fact that it is highly homologous to mK3. mK3 protein was also found in physical association with Derlin1, an ER protein recently implicated in the retrotranslocation of HC by immune evasion protein US11, but not US2, of human cytomegalovirus. The mechanistic implications of these findings are discussed.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Childrens Hosp Boston, Boston, MA 02115 USA; Harvard Univ, Ctr Digest Dis, Boston, MA 02115 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Boston Children's Hospital; Harvard University	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	hansen@immunology.wustl.edu		Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019687] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Boname JM, 2004, IMMUNITY, V20, P305, DOI 10.1016/S1074-7613(04)00047-0; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Gewurz BE, 2001, P NATL ACAD SCI USA, V98, P6794, DOI 10.1073/pnas.121172898; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; Hassink G, 2005, BIOCHEM J, V388, P647, DOI 10.1042/BJ20041241; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kothe M, 2005, J BIOL CHEM, V280, P28127, DOI 10.1074/jbc.M503138200; Lehner PJ, 2005, IMMUNOL REV, V207, P112, DOI 10.1111/j.0105-2896.2005.00314.x; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2005, IMMUNOL REV, V207, P126, DOI 10.1111/j.0105-2896.2005.00318.x; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lybarger L, 2005, CURR OPIN IMMUNOL, V17, P71, DOI 10.1016/j.coi.2004.11.009; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Miley MJ, 2003, J IMMUNOL, V170, P6090, DOI 10.4049/jimmunol.170.12.6090; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wang XL, 2005, J VIROL, V79, P4099, DOI 10.1128/JVI.79.7.4099-4108.2005; Wang XL, 2004, J VIROL, V78, P8673, DOI 10.1128/JVI.78.16.8673-8686.2004; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Yu YYL, 2002, J VIROL, V76, P2796, DOI 10.1128/JVI.76.6.2796-2803.2002	51	41	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8636	8644		10.1074/jbc.M513920200	http://dx.doi.org/10.1074/jbc.M513920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16446359	Green Submitted, hybrid			2022-12-25	WOS:000236247100041
J	Bigelow, RLH; Cardelli, JA				Bigelow, RLH; Cardelli, JA			The green tea catechins, (-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells	ONCOGENE			English	Article						green tea; EGCG; HGF; Met; breast cancer	COLON-CARCINOMA CELLS; MET EXPRESSION; SCATTER-FACTOR; IN-VIVO; GROWTH; CANCER; POLYPHENOLS; PHOSPHORYLATION; RECEPTOR; ACTIVATION	The hepatocyte growth factor (HGF) receptor, Met, is a strong prognostic indicator of breast cancer patient outcome and survival, suggesting that therapies targeting Met may have beneficial outcomes in the clinic. (-)Epigallocatechin- 3-gallate ( EGCG), a catechin found in green tea, has been recognized as a potential therapeutic agent. We assessed the ability of EGCG to inhibit HGF signaling in the immortalized, nontumorigenic breast cell line, MCF10A, and the invasive breast carcinoma cell line, MDA-MB-231. HGF treatment in both cell lines induced rapid, sustained activation of Met, ERK and AKT. Pretreatment of cells with concentrations of EGCG as low as 0.3 mu M inhibited HGF-induced Met phosphorylation and downstream activation of AKT and ERK. Treatment with 5.0 mu M EGCG blocked the ability of HGF to induce cell motility and invasion. We assessed the ability of alternative green tea catechins to inhibit HGF induced signaling and motility. (-)-Epicatechin-3-gallate ( ECG) functioned similar to EGCG by completely blocking HGF-induced signaling as low as 0.6 mu M and motility at 5 mu M in MCF10A cells; whereas, (-)- epicatechin (EC) was unable to inhibit HGF-induced events at any concentration tested. (-)- Epigallocatechin ( EGC), however, completely repressed HGF-induced AKT and ERK phosphorylation at concentrations of 10 and 20 mu M, but was incapable of blocking Met activation. Despite these observations, EGC did inhibit HGF-induced motility in MCF10A cells at 10 mu M. These observations suggest that the R1 galloyl and the R2 hydroxyl groups are important in mediating the green tea catechins' inhibitory effect towards HGF/Met signaling. These combined in vitro studies reveal the possible benefits of green tea polyphenols as cancer therapeutic agents to inhibit Met signaling and potentially block invasive cancer growth.	Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Cardelli, JA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, 1501 Kings Highway, Shreveport, LA 71130 USA.	jcarde@lsuhsc.edu			NATIONAL CANCER INSTITUTE [R01CA104242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104242-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Fang MZ, 2003, CANCER RES, V63, P7563; Fujimura Y, 2004, FEBS LETT, V556, P204, DOI 10.1016/S0014-5793(03)01432-7; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Masuda M, 2003, CLIN CANCER RES, V9, P3486; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200; Su LJ, 2002, PUBLIC HEALTH NUTR, V5, P419, DOI 10.1079/PHN2001314; Sun CL, 2002, CARCINOGENESIS, V23, P1497, DOI 10.1093/carcin/23.9.1497; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035	31	111	117	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1922	1930		10.1038/sj.onc.1209227	http://dx.doi.org/10.1038/sj.onc.1209227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16449979				2022-12-25	WOS:000236224800009
J	Archangelo, LF; Glaser, J; Krause, A; Bohlander, SK				Archangelo, L. Froehlich; Glaeser, J.; Krause, A.; Bohlander, S. K.			The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10	ONCOGENE			English	Article						CALM/AF10; PICALM; leukemia; nucleolus	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CALM-AF10 FUSION; LEUCINE-ZIPPER; MOLECULAR CHARACTERIZATION; COATED PITS; CLATHRIN; AF10; GENE; MLL	The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM or PICALM) was first identified as the fusion partner of AF10 in the t(10;11)(p13;q14) translocation, which is observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and malignant lymphoma. The CALM/AF10 fusion protein plays a crucial role in t(10;11)(p13;q14) associated leukemogenesis. Using the N-terminal half of CALM as a bait in a yeast two-hybrid screen, a novel protein named CATS (CALM interacting protein expressed in thymus and spleen) was identified. Multiple tissue Northern blot analysis showed predominant expression of CATS in thymus, spleen and colon. CATS codes for two protein isoforms of 238 and 248 amino acids (aa). The interaction between CALM and CATS could be confirmed using pull down assays, co-immunoprecipitation and colocalization experiments. The CATS interaction domain of CALM was mapped to aa 221-335 of CALM. This domain is contained in the CALM/AF10 fusion protein. CATS localizes to the nucleus and shows a preference for nucleoli. Expression of CATS was able to markedly increase the nuclear localization of CALM and of the leukemogenic fusion protein CALM/AF10. The possible implications of these findings for CALM/AF10-mediated leukemogenesis are discussed.	Univ Munich, Dept Med 3, Grosshadern Hosp, D-81377 Munich, Germany; GSF Munich, Clin Cooperat Grp Leukemia, Munich, Germany; Univ Gottingen, Inst Human Genet, D-3400 Gottingen, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Bohlander, SK (corresponding author), Univ Munich, Dept Med 3, Grosshadern Hosp, Marchioninistr 15, D-81377 Munich, Germany.	sbohlan@gwdg.de	Archangelo, Leticia Fröhlich/P-7048-2015; Krause, Alexandre/K-7221-2013	Archangelo, Leticia Fröhlich/0000-0003-2264-4504; Bohlander, Stefan/0000-0002-2202-9088				Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Asnafi V, 2003, BLOOD, V102, P1000, DOI 10.1182/blood-2002-09-2913; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Chao MM, 2004, BLOOD, V104, p922A, DOI 10.1182/blood.V104.11.3380.3380; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Delabesse E, 2004, BLOOD, V104, p315A; Deshpande A, 2003, BLOOD, V102, p216A; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Evans PR, 2002, CURR OPIN STRUC BIOL, V12, P814, DOI 10.1016/S0959-440X(02)00395-0; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Jones LK, 2001, LEUKEMIA, V15, P910, DOI 10.1038/sj.leu.2402140; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Klebig ML, 2003, P NATL ACAD SCI USA, V100, P8360, DOI 10.1073/pnas.1432634100; Kobayashi H, 1997, GENE CHROMOSOME CANC, V20, P253, DOI 10.1002/(SICI)1098-2264(199711)20:3<253::AID-GCC5>3.0.CO;2-1; Krause A, 2004, BLOOD, V104, p791A, DOI 10.1182/blood.V104.11.2895.2895; Kumon K, 1999, GENE CHROMOSOME CANC, V25, P33, DOI 10.1002/(SICI)1098-2264(199905)25:1<33::AID-GCC5>3.0.CO;2-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakamura F, 2003, AM J HEMATOL, V72, P138, DOI 10.1002/ajh.10265; Narita M, 1999, BRIT J HAEMATOL, V105, P928, DOI 10.1046/j.1365-2141.1999.01433.x; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Perrin L, 2003, MOL CELL BIOL, V23, P119, DOI 10.1128/MCB.23.1.119-130.2003; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Salmon-Nguyen F, 2000, CANCER GENET CYTOGEN, V122, P137, DOI 10.1016/S0165-4608(00)00277-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Silliman CC, 1998, LEUKEMIA, V12, P1404, DOI 10.1038/sj.leu.2401109; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	39	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4099	4109		10.1038/sj.onc.1209438	http://dx.doi.org/10.1038/sj.onc.1209438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491119				2022-12-25	WOS:000238802400010
J	Chini, C; Wood, J; Chen, J				Chini, C. C. S.; Wood, J.; Chen, J.			Chk1 is required to maintain Claspin stability	ONCOGENE			English	Article						claspin; Chk1; protein stability; cell cycle	DNA-REPLICATION; CHECKPOINT; BRCA1; PROTEIN; ATR; PHOSPHORYLATION; UBIQUITINATION; LOCALIZATION; ACTIVATION; EXPRESSION	Claspin is a Chk1-interacting protein that participates in the DNA replication checkpoint. Expression of Claspin fluctuates in a cell cycle-dependent manner, but the mechanisms involved in the regulation of Claspin protein levels have not been explored. In this study, we show that Claspin expression is downregulated by the proteasome-mediated degradation pathway and that Chk1 is required to maintain Claspin stability. Downregulation of Chk1 expression by siRNA or inhibition of Chk1 activity by UCN01 decreases Claspin levels in cells. Conversely, overexpression of Chk1 increases Claspin levels. These data indicate a role of Chk1 in regulating Claspin stability in the cell. Since Claspin has also been shown to participate in Chk1 activation following DNA damage, we further explored the exact role of Claspin during Chk1 activation following replication stress. We observed that while Rad17 is required for early Chk1 activation after hydroxyurea treatment, Claspin is only required to sustain Chk1 activation. Based on these findings, we propose that Claspin functions at late stages of Chk1 activation following DNA damage. Once Chk1 is activated, it stabilizes Claspin, which in turn helps to maintain Chk1 activation during replication stress. In summary, these data indicate that the interaction between Claspin and Chk1 is complex. These proteins regulate each other and thus ensure the proper cell cycle progression and replication checkpoint control.	Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, J (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA092312, R01CA089239, R01CA100109] Funding Source: NIH RePORTER; NCI NIH HHS [CA100109, CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R, 2003, J BIOL CHEM, V278, P45027, DOI 10.1074/jbc.M306783200; Busby EC, 2000, CANCER RES, V60, P2108; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sorensen CS, 2004, CELL CYCLE, V3, P941; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	26	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4165	4171		10.1038/sj.onc.1209447	http://dx.doi.org/10.1038/sj.onc.1209447			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501606				2022-12-25	WOS:000239004800004
J	Siddique, M; Sabapathy, K				Siddique, M.; Sabapathy, K.			Trp53-dependent DNA-repair is affected by the codon 72 polymorphism	ONCOGENE			English	Article						Trp53; codon 72; polymorphism; DNA-repair; target genes	STRAND BREAK REPAIR; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE CHECKPOINT; WILD-TYPE; IN-VITRO; P53 POLYMORPHISM; LACKING P53; EXPRESSION; RADIATION; CANCER	Trp53 is arguably the most critical tumour suppressor gene product that inhibits malignant transformation. Besides mutations that inactivate Trp53 functions, genetic polymorphisms have been suggested to be risk factors for cancer. A polymorphic site at codon 72 in exon 4 encodes either an arginine amino acid (Trp53(72R)) or a proline residue (Trp53(72P)). Previous studies have shown that the Trp53(72R) form is more efficient in apoptosis induction, whereas the Trp53(72P) form was suggested to induce G1 arrest better. Here we report that Trp53(72P) is more efficient than Trp53(72P) in specifically activating several Trp53-dependent DNA-repair target genes in several cellular systems. Moreover, using isogenic cell lines and several DNA-repair assays, we show that Trp53(72P) cells have a significantly higher DNA-repair capacity than the Trp53(72R) cells. Furthermore, Trp53(72P)-expressing cells exhibit reduced micronuclei formation compared to Trp53(72R)-expressing cells, suggesting that genomic instability is reduced in these cells. Together, the data highlight the functional differences between the Trp53 polymorphic variants, and suggest that their expression status may influence cancer risk.	Natl Canc Ctr, Lab Mol Carcinogenesis, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Lab Mol Carcinogenesis, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lahav G, 2004, SCI STKE, V264, P55; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Mallya SM, 1998, INT J RADIAT BIOL, V74, P231, DOI 10.1080/095530098141618; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MATSUOKA A, 1992, MUTAT RES, V272, P223, DOI 10.1016/0165-1161(92)91535-Y; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Olivier Magali, 2004, IARC Sci Publ, P247; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; RAUTH S, 1994, ANTICANCER RES, V14, P2457; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stopper H, 1997, Recent Results Cancer Res, V143, P183; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; THODAY JM, 1951, BRIT J RADIOL, V24, P572, DOI 10.1259/0007-1285-24-286-572; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Toh WH, 2005, J BIOL CHEM, V280, P17329, DOI 10.1074/jbc.M500044200; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wani MA, 2002, CARCINOGENESIS, V23, P403, DOI 10.1093/carcin/23.3.403; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yang WL, 1998, BIOCHEM BIOPH RES CO, V250, P593, DOI 10.1006/bbrc.1998.9366; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	113	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3489	3500		10.1038/sj.onc.1209405	http://dx.doi.org/10.1038/sj.onc.1209405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462765				2022-12-25	WOS:000238448200001
J	Jastrzebska, B; Fotiadis, D; Jang, GF; Stenkamp, RE; Engel, A; Palczewski, K				Jastrzebska, B; Fotiadis, D; Jang, GF; Stenkamp, RE; Engel, A; Palczewski, K			Functional and structural characterization of rhodopsin oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TANDEM MASS-SPECTROMETRY; DRIVEN FRAGMENTATION PROCESSES; ENERGY COLLISIONAL ACTIVATION; FATTY-ACIDS; TRANSDUCIN ACTIVATION; LITHIATED ADDUCTS; DIMERS; SOLUBILIZATION; DISSOCIATION	A major question in G protein-coupled receptor signaling concerns the quaternary structure required for signal transduction. Do these transmembrane receptors function as monomers, dimers, or larger oligomers? We have investigated the oligomeric state of the model G protein-coupled receptor rhodopsin (Rho), which absorbs light and initiates a phototransduction-signaling cascade that forms the basis of vision. In this study, different forms of Rho were isolated using gel filtration techniques in mild detergents, including n-dodecyl-beta-D-maltoside, n-tetradecyl-beta-D-maltoside, and n-hexadecyl-beta-D-maltoside. The quaternary structure of isolated Rho was determined by transmission electron microscopy, demonstrating that in micelles containing n-dodecyl-beta-D-maltoside, Rho exists as a mixture of monomers and dimers whereas in n-tetradecyl-beta-D-maltoside and n-hexadecyl-beta-D-maltoside Rho forms higher ordered structures. Especially in n-hexadecyl-beta-D-maltoside, most of the particles are present in tightly packed rows of dimers. The oligomerization of Rho seems to be important for interaction with its cognate G protein, transducin. Although the activated Rho (Meta II) monomer or dimers are capable of activating the G protein, transducin, the activation process is much faster when Rho exists as organized dimers. Our studies provide direct comparisons between signaling properties of Meta II in different quaternary complexes.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Case Sch Med, Cleveland, OH 44106 USA; Univ Basel, ME Muller Inst Microscopy, Biozentrum, CH-4056 Basel, Switzerland; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA	Case Western Reserve University; University of Basel; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, Case Sch Med, BRB Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu			NATIONAL EYE INSTITUTE [P30EY001730, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; Fanelli F, 2005, CHEM REV, V105, P3297, DOI 10.1021/cr000095n; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Griffiths WJ, 2003, MASS SPECTROM REV, V22, P81, DOI 10.1002/mas.10046; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Herrick-Davis K, 2005, J BIOL CHEM, V280, P40144, DOI 10.1074/jbc.M507396200; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P892, DOI 10.1016/S1044-0305(00)00159-8; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P797, DOI 10.1016/S1044-0305(00)00151-3; Hsu FF, 1999, J AM SOC MASS SPECTR, V10, P600, DOI 10.1016/S1044-0305(99)00041-0; Hsu FF, 2001, J AM SOC MASS SPECTR, V12, P61, DOI 10.1016/S1044-0305(00)00194-X; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P986, DOI 10.1016/S1044-0305(00)00172-0; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; Moritz OL, 2001, J BIOL CHEM, V276, P28242, DOI 10.1074/jbc.M101476200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Park PSH, 2005, P NATL ACAD SCI USA, V102, P8793, DOI 10.1073/pnas.0504016102; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; Pulfer MK, 2004, J AM SOC MASS SPECTR, V15, P194, DOI 10.1016/j.jasms.2003.10.011; STUBBS GW, 1978, BIOCHEMISTRY-US, V17, P215, DOI 10.1021/bi00595a003; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; WHITE DC, 1995, SIGNATURE LIPID BIOM, P255	41	120	124	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11917	11922		10.1074/jbc.M600422200	http://dx.doi.org/10.1074/jbc.M600422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16495215	Green Accepted, hybrid			2022-12-25	WOS:000236988100060
J	Menant, A; Baudouin-Cornu, P; Peyraud, C; Tyers, M; Thomas, D				Menant, A; Baudouin-Cornu, P; Peyraud, C; Tyers, M; Thomas, D			Determinants of the ubiquitin-mediated degradation of the Met4 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SULFUR METABOLISM; GENE-EXPRESSION; PROTEIN; YEAST; ACTIVATION; PROTEOLYSIS; METHIONINE; BIOSYNTHESIS; ASSIMILATION	In yeast, the Met4 transcription factor and its cofactors Cbf1, Met28, Met31, and Met32 control the expression of sulfur metabolism and oxidative stress response genes. Met4 activity is tuned to nutrient and oxidative stress conditions by the SCFMet30 ubiquitin ligase. The mechanism whereby SCFMet30-dependent ubiquitylation of Met4 controls Met4 activity remains contentious. Here, we have demonstrated that intracellular cysteine levels dictate the degradation of Met4 in vivo, as shown by the ability of cysteine, but not methionine or S-adenosylmethionine ( AdoMet), to trigger Met4 degradation in an str4 Delta strain, which lacks the ability to produce cysteine from methionine or AdoMet. Met4 degradation requires its nuclear localization and activity of the 26 S proteasome. Analysis of the regulated degradation of a fully functional Met4-Cbf1 chimera, in which Met4 is fused to the DNA binding domain of Cbf1, demonstrates that elimination of Met4 in vivo can be triggered independently of both its normal protein interactions. Strains that harbor the Met4-Cbf1 fusion as the only source of Cbf1 activity needed for proper kinetochore function exhibit high rates of methionine-dependent chromosomal instability. We suggest that SCFMet30 activity or Met4 utilization as a substrate may be directly regulated by intracellular cysteine concentrations.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Cytom Syst SA, F-91190 Gif Sur Yvette, France; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Thomas, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	dthomas@cytomics.fr	Tyers, Michael/ABE-3194-2021	Baudouin-Cornu, Peggy/0000-0001-7296-099X				BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; Barbey R, 2005, EMBO J, V24, P521, DOI 10.1038/sj.emboj.7600556; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Brunson LE, 2004, J BIOL CHEM, V279, P6674, DOI 10.1074/jbc.M308875200; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHEREST H, 1973, J BACTERIOL, V115, P1084, DOI 10.1128/JB.115.3.1084-1093.1973; CHEREST H, 1992, GENETICS, V130, P51; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jamieson D, 2002, NAT GENET, V31, P228, DOI 10.1038/ng0702-228; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kent NA, 2004, J BIOL CHEM, V279, P27116, DOI 10.1074/jbc.M403818200; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P419; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; Lafaye A, 2005, J BIOL CHEM, V280, P24723, DOI 10.1074/JBC.M502285200; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; MASISON DC, 1993, NUCLEIC ACIDS RES, V21, P4133, DOI 10.1093/nar/21.17.4133; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pocsi I, 2004, ADV MICROB PHYSIOL, V49, P1, DOI 10.1016/S0065-2911(04)49001-8; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Wheeler GL, 2003, J BIOL CHEM, V278, P49920, DOI 10.1074/jbc.M310156200; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Yen JL, 2005, MOL BIOL CELL, V16, P1872, DOI 10.1091/mbc.E04-12-1130	53	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11744	11754		10.1074/jbc.M600037200	http://dx.doi.org/10.1074/jbc.M600037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497670	hybrid			2022-12-25	WOS:000236988100039
J	Gesty-Palmer, D; Chen, MY; Reiter, E; Ahn, S; Nelson, CD; Wang, ST; Eckhardt, AE; Cowan, CL; Spurney, RF; Luttrell, LM; Lefkowitz, RJ				Gesty-Palmer, D; Chen, MY; Reiter, E; Ahn, S; Nelson, CD; Wang, ST; Eckhardt, AE; Cowan, CL; Spurney, RF; Luttrell, LM; Lefkowitz, RJ			Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; COUPLED RECEPTOR; INDEPENDENT FUNCTIONS; ADRENERGIC-RECEPTOR; KIDNEY-CELLS; PEPTIDE; PTH; BONE; DESENSITIZATION; INTERMITTENT	Parathyroid hormone (PTH) regulates calcium homeostasis via the type I PTH/PTH-related peptide (PTH/PTHrP) receptor (PTH1R). The purpose of the present study was to identify the contributions of distinct signaling mechanisms to PTH-stimulated activation of the mitogen-activated protein kinases (MAPK) ERK1/2. In Human embryonic kidney 293 (HEK293) cells transiently transfected with hPTH1R, PTH stimulated a robust increase in ERK activity. The time course of ERK1/2 activation was biphasic with an early peak at 10 min and a later sustained ERK1/2 activation persisting for greater than 60 min. Pretreatment of HEK293 cells with the PKA inhibitor H89 or the PKC inhibitor GF109203X, individually or in combination reduced the early component of PTH-stimulated ERK activity. However, these inhibitors of second messenger dependent kinases had little effect on the later phase of PTH-stimulated ERK1/2 phosphorylation. This later phase of ERK1/2 activation at 30-60 min was blocked by depletion of cellular beta-arrestin 2 and beta-arrestin 1 by small interfering RNA. Furthermore, stimulation of hPTH1R with PTH analogues, [Trp(1)] PTHrp-(1-36) and [D-Trp(12), Tyr(34)] PTH-(7-34), selectively activated G(s)/PKA-mediated ERK1/2 activation or G protein-independent/beta-arrestin-dependent ERK1/2 activation, respectively. It is concluded that PTH stimulates ERK1/2 through several distinct signal transduction pathways: an early G protein-dependent pathway meditated by PKA and PKC and a late pathway independent of G proteins mediated through beta-arrestins. These findings imply the existence of distinct active conformations of the hPTH1R responsible for the two pathways, which can be stimulated by unique ligands. Such ligands may have distinct and valuable therapeutic properties.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA; INRA, F-37380 Nouzilly, France; Xsira Pharmaceut, Morrisville, NC 27709 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; INRAE; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043446] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL070631, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70631, HL16037] Funding Source: Medline; NICHD NIH HHS [HD043446] Funding Source: Medline; NIDDK NIH HHS [DK64353] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004-1282; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; Garcia-Ocana A, 1998, LIFE SCI, V62, P2267, DOI 10.1016/S0024-3205(98)00207-0; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUTKIND JS, 2000, SCI STKE, V40, P11; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Lederer ED, 2000, J AM SOC NEPHROL, V11, P222, DOI 10.1681/ASN.V112222; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Stalheim L, 2005, MOL PHARMACOL, V67, P78, DOI 10.1124/mol.104.006072; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	47	356	368	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10856	10864		10.1074/jbc.M513380200	http://dx.doi.org/10.1074/jbc.M513380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16492667	Green Submitted, hybrid			2022-12-25	WOS:000236822200025
J	Li, CH; Allen, A; Kwagh, J; Doliba, NM; Qin, W; Najafi, H; Collins, HW; Matschinsky, FM; Stanley, CA; Smith, TJ				Li, CH; Allen, A; Kwagh, J; Doliba, NM; Qin, W; Najafi, H; Collins, HW; Matschinsky, FM; Stanley, CA; Smith, TJ			Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERINSULINISM/HYPERAMMONEMIA SYNDROME; REGULATORY MUTATIONS; MECHANISM; METABOLISM; MESSENGER; CHILDREN; LEUCINE; RELEASE	Insulin secretion by pancreatic beta-cells is stimulated by glucose, amino acids, and other metabolic fuels. Glutamate dehydrogenase (GDH) has been shown to play a regulatory role in this process. The importance of GDH was underscored by features of hyperinsulinemia/hyperammonemia syndrome, where a dominant mutation causes the loss of inhibition by GTP and ATP. Here we report the effects of green tea polyphenols on GDH and insulin secretion. Of the four compounds tested, epigallocatechin gallate (EGCG) and epicatechin gallate were found to inhibit GDH with nanomolar ED50 values and were therefore found to be as potent as the physiologically important inhibitor GTP. Furthermore, we have demonstrated that EGCG inhibits BCH-stimulated insulin secretion, a process that is mediated by GDH, under conditions where GDH is no longer inhibited by high energy metabolites. EGCG does not affect glucose-stimulated insulin secretion under high energy conditions where GDH is probably fully inhibited. We have further shown that these compounds act in an allosteric manner independent of their antioxidant activity and that the beta-cell stimulatory effects are directly correlated with glutamine oxidation. These results demonstrate that EGCG, much like the activator of GDH (BCH), can facilitate dissecting the complex regulation of insulin secretion by pharmacologically modulating the effects of GDH.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Childrens Hosp Philadelphia, Abramson Res Ctr, Div Endocrinol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Diabet Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Donald Danforth Plant Science Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Smith, TJ (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	tsmith@danforthcenter.org	Smith, Thomas J/K-9086-2013	Smith, Thomas J/0000-0003-3528-6793; STANLEY, CHARLES/0000-0003-4881-9392	NIDDK NIH HHS [DK 072171, DK 53012, DK 19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053012, R01DK072171, P30DK019525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen A, 2004, BIOCHEMISTRY-US, V43, P14431, DOI 10.1021/bi048817i; Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c; Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189; BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; HAMILTONMILLER JMT, 1995, ANTIMICROB AGENTS CH, V39, P2375, DOI 10.1128/AAC.39.11.2375; Hsu BYL, 2001, J PEDIATR-US, V138, P383, DOI 10.1067/mpd.2001.111818; Katiyar SK, 1996, INT J ONCOL, V8, P221; Konayagi S, 1933, STUDY PHYSL, V10, P449; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Lo LW, 1997, ADV EXP MED BIOL, V428, P651; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MacMullen C, 2001, J CLIN ENDOCR METAB, V86, P1782, DOI 10.1210/jc.86.4.1782; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; PROUGH RA, 1973, J BIOL CHEM, V248, P8528; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Stanley CA, 2000, GENETIC INSIGHTS PAE, P23; Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	29	122	128	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10214	10221		10.1074/jbc.M512792200	http://dx.doi.org/10.1074/jbc.M512792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476731	hybrid			2022-12-25	WOS:000236594300048
J	Mehta, S; Gould, KL				Mehta, S; Gould, KL			Identification of functional domains within the septation initiation network kinase, Cdc7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; SEPTUM FORMATION; PLO1 KINASE; CYTOKINESIS; RESOURCE; ONSET; CELL	The septation initiation network ( SIN) serves to coordinate cytokinesis with mitotic exit in the fission yeast Schizosaccharomyces pombe. SIN components Spg1 and Cdc7 together play a central role in regulating the onset of septation and cytokinesis. Spg1, a Ras-like GTPase, localizes to the spindle pole bodies (SPBs) throughout the cell cycle. It is converted to its GTP-bound ( active) state during mitosis, only to become inactivated at one SPB during anaphase and at both SPBs as cells exit mitosis. Cdc7 functions as an effector kinase for Spg1, binding to Spg1 in its GTP-bound state, and therefore is present at both SPBs during mitosis and asymmetrically at only one during anaphase. Interestingly, the kinase activity of Cdc7 does not vary across the cell cycle, suggesting the possibility that Cdc7 kinase activity is independent of Spg1 binding. Consistent with this, we found that Cdc7 associates with Spg1 only during mitosis. To learn more about the essential role of Cdc7 kinase in the SIN and its regulation, we undertook a structure/function analysis and identified independent functional domains within Cdc7. We found that a region adjacent to the kinase domain is responsible for Spg1 association and identified an overlapping but distinct SPB localization domain. In addition Cdc7 associates with itself and exists as a dimer in vivo.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	kathy.gould@vanderbilt.edu		Gould, Kathleen/0000-0002-3810-4070				Balasubramanian MK, 1998, GENETICS, V149, P1265; Bardin AJ, 2003, MOL CELL BIOL, V23, P5018, DOI 10.1128/MCB.23.14.5018-5030.2003; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Cerutti L, 1999, J CELL SCI, V112, P2313; Chang L, 2000, P NATL ACAD SCI USA, V97, P5249, DOI 10.1073/pnas.97.10.5249; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; James P, 1996, GENETICS, V144, P1425; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Lu YB, 2002, GENES CELLS, V7, P1009, DOI 10.1046/j.1365-2443.2002.00582.x; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morrell JL, 2004, CURR BIOL, V14, P579, DOI 10.1016/j.cub.2004.03.036; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Petretti C, 2005, BIOL CELL, V97, P113, DOI 10.1042/BC20040077; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Salimova E, 2000, J CELL SCI, V113, P1695; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Simanis V, 2003, J CELL SCI, V116, P4263, DOI 10.1242/jcs.00807; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P525, DOI 10.1016/S0079-6107(98)00046-7; Smith CM, 1997, TRENDS BIOCHEM SCI, V22, P444, DOI 10.1016/S0968-0004(97)01131-6; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tomlin GC, 2002, MOL BIOL CELL, V13, P1203, DOI 10.1091/mbc.01-09-0455; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	37	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9935	9941		10.1074/jbc.M600160200	http://dx.doi.org/10.1074/jbc.M600160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16469735	hybrid			2022-12-25	WOS:000236594300015
J	Tanaka, H; Katoh, H; Negishi, M				Tanaka, H; Katoh, H; Negishi, M			Pragmin, a novel effector of Rnd2 GTPase, stimulates RhoA activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; KINASE ROK-ALPHA; PC12 CELLS; NEURITE RETRACTION; FOCAL ADHESIONS; FAMILY GTPASES; REORGANIZATION; OUTGROWTH; RAC	The Rho family of small GTPases has been implicated in the reorganization of actin cytoskeleton and subsequent morphological changes in various cells. Rnd2 is a member of the Rnd subfamily, comprising Rnd1, Rnd2, and Rnd3. In contrast to Rnd1 and Rnd3, displaying an antagonistic action for RhoA signaling, signaling pathways of Rnd2 are not well known. Here we have performed a yeast two-hybrid screen using Rnd2 as bait and identified a novel Rnd2 effector protein, predominantly expressed in neurons, including cortical and hippocampal neurons. We named it Pragmin (pragma of Rnd2). In in vivo and in vitro binding assays, Pragmin specifically binds to Rnd2 among the Rho family GTPases in a GTP-dependent manner. Rnd2-bound Pragmin significantly stimulates RhoA activity and induces cell contraction through RhoA and the Rho-kinase pathway in HeLa cells. In PC12 cells, expressing Pragmin inhibits nerve growth factor-induced neurite outgrowth in response to Rnd2, and knock-down of Pragmin by Pragmin-specific small interfering RNA enhances neurite elongation. Therefore, Rnd2 regulates neurite outgrowth by functioning as the RhoA activator through Pragmin, in contrast to Rnd1 and Rnd3 inhibiting RhoA signaling.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp		Katoh, Hironori/0000-0002-8191-8117	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Decourt B, 2005, DEV BRAIN RES, V159, P36, DOI 10.1016/j.devbrainres.2005.06.013; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harada A, 2005, J BIOL CHEM, V280, P18418, DOI 10.1074/jbc.M411356200; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Leung T, 1996, MOL CELL BIOL, V16, P5313; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	38	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10355	10364		10.1074/jbc.M511314200	http://dx.doi.org/10.1074/jbc.M511314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16481321	hybrid			2022-12-25	WOS:000236594300064
J	Esparza, EM; Lindsten, T; Stockhausen, JM; Arch, RH				Esparza, EM; Lindsten, T; Stockhausen, JM; Arch, RH			Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION; FAMILY; TRAF5; GENE; IDENTIFICATION; SUPERFAMILY; INHIBITOR; INDUCTION; PROTEINS	Tumor necrosis factor receptor ( TNFR) family members such as glucocorticoid-induced TNFR ( GITR) control T cell activation, differentiation, and effector functions. Importantly, GITR functions as a pivotal regulator of physiologic and pathologic immune responses by abrogating the suppressive effects of T regulatory cells and costimulating T effector cells. However, the molecular mechanisms underlying GITR-triggered signal transduction pathways remain unclear. Interestingly, GITR-induced stimulation of TNFR-associated factor ( TRAF) 5-deficient T cells resulted in decreased activation of nuclear factor kappa B as well as the mitogen-activated protein kinases p38 and extracellular signal-regulated protein kinase, whereas activation of c-Jun N-terminal kinase was less affected. Consistent with impaired signaling, costimulatory effects of GITR were diminished in TRAF5(-/-) T cells. In sum, our studies indicate that TRAF5 plays a crucial role in GITR-induced signaling pathways that augment T cell activation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine	Arch, RH (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	arch@wustl.edu.2			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067312] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007317, 5 RO1 HL67312-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Esparza EM, 2006, FRONT BIOSCI-LANDMRK, V11, P1448, DOI 10.2741/1895; Esparza EM, 2005, J IMMUNOL, V174, P7875, DOI 10.4049/jimmunol.174.12.7875; Esparza EM, 2005, J IMMUNOL, V174, P7869, DOI 10.4049/jimmunol.174.12.7869; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443; Kim YS, 2005, MOL CELL BIOL, V25, P2130, DOI 10.1128/MCB.25.6.2130-2137.2005; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Shiels H, 2000, AM J PATHOL, V157, P679, DOI 10.1016/S0002-9440(10)64578-6; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; So T, 2004, J IMMUNOL, V172, P4292, DOI 10.4049/jimmunol.172.7.4292; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Suri A, 2004, EUR J IMMUNOL, V34, P447, DOI 10.1002/eji.200324599; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	29	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8559	8564		10.1074/jbc.M512915200	http://dx.doi.org/10.1074/jbc.M512915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16452475	hybrid			2022-12-25	WOS:000236247100031
J	Mariano, AR; Colombo, E; Luzi, L; Martinelli, P; Volorio, S; Bernard, L; Meani, N; Bergomas, R; Alcalay, M; Pelicci, PG				Mariano, A. R.; Colombo, E.; Luzi, L.; Martinelli, P.; Volorio, S.; Bernard, L.; Meani, N.; Bergomas, R.; Alcalay, M.; Pelicci, P. G.			Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal	ONCOGENE			English	Article						NPM; AML; nucleus-cytoplasmic shuttling; NES; CRM1	ACUTE MYELOGENOUS LEUKEMIA; NORMAL KARYOTYPE; NUCLEOPHOSMIN; PROTEIN; ARF	Nucleophosmin (NPM) is a nucleus-cytoplasmic shuttling protein that is implicated in centrosome duplication, cell cycle progression and stress response. At the steady state, NPM localizes mainly in the nucleolus, where it forms a complex with different cellular proteins. One-third of acute myeloid leukemias (AML) are characterized by aberrant cytoplasmic localization of NPM, due to mutations within its last coding exon (exon 12) that cause a frameshift and the formation of novel C-termini. We report here our investigations on the molecular basis for the aberrant localization of mutated NPM. Alignment of the C-terminus of the various NPM mutants revealed the obligatory presence of four amino-acid residues that match a CRM1-dependent nuclear export signal (NES). Single alanine-substitutions at these sites provoked nuclear re-localization, while fusion of the mutated C-terminus to a heterologous nuclear protein induced CRM1-dependent cytoplasmic localization. Molecular characterization of one exceptional AML carrying cytoplasmic NPM and germ line exon 12 revealed a somatic mutation in the splicing donor site of exon 9 that caused the formation of a functional NES. It appears, therefore, that AMLs are frequently characterized by gain-of-function mutations of NPM that create functional NES, suggesting that alterations of nuclear export might represent a general mechanism of leukemogenesis and a novel target for therapeutic intervention.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM Inst, Milan, Italy; Univ Milan, Dept Med Surg & Dent, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	piergiuseppe.pelicci@ifom-ieo-campus.it	Luzi, Lucilla/K-4350-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Colombo, Emanuela/AAO-8113-2020; Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016	Luzi, Lucilla/0000-0002-8746-4179; Colombo, Emanuela/0000-0003-2079-7398; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Martinelli, Paola/0000-0002-1643-8731				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; COLOMBO E, 2006, IN PRESS CANC RES; den Besten W, 2005, CELL CYCLE, V4, P1593; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Nakagawa M, 2005, NEW ENGL J MED, V352, P1819; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	14	56	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4376	4380		10.1038/sj.onc.1209453	http://dx.doi.org/10.1038/sj.onc.1209453			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501600				2022-12-25	WOS:000239240100013
J	Kommagani, R; Caserta, TM; Kadakia, MP				Kommagani, R.; Caserta, T. M.; Kadakia, M. P.			Identification of vitamin D receptor as a target of p63	ONCOGENE			English	Article						p63 gamma; VDR; p14(ARF); differentiation	FAMILY-MEMBER GENES; P53 HOMOLOG P63; TUMOR-SUPPRESSOR; EPIDERMAL DIFFERENTIATION; PROSTATE-CANCER; DEVELOPMENTAL SYNDROMES; EEC-SYNDROME; EXPRESSION; MUTATIONS; CELLS	p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63 gamma specifically upregulates vitamin D Receptor ( VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63c ( R279H) and p14(ARF), both act in a dominant negative manner to inhibit p63 gamma-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.	Wright State Univ, Dept Biohchem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Ctr Genom Res, Dayton, OH USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Kadakia, MP (corresponding author), Wright State Univ, Dept Biohchem & Mol Biol, 3640 Col Glenn Highway,142 Biol Sci, Dayton, OH 45435 USA.	madhavi.kadakia@wright.edu		Kommagani, Ramakrishna/0000-0003-0403-0971				Banerjee P, 2003, MOL CELL BIOCHEM, V253, P247, DOI 10.1023/A:1026072118217; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barrow LL, 2002, J MED GENET, V39, P559, DOI 10.1136/jmg.39.8.559; Bikle DD, 2004, J NUTR, V134, p3472S, DOI 10.1093/jn/134.12.3472S; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P355, DOI 10.1016/j.jsbmb.2004.03.020; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Bikle DD, 2003, J CELL BIOCHEM, V88, P290, DOI 10.1002/jcb.10339; Blutt SE, 1999, P SOC EXP BIOL MED, V221, P89, DOI 10.1046/j.1525-1373.1999.d01-60.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Feldman D, 2000, ENDOCRINOLOGY, V141, P5, DOI 10.1210/en.141.1.5; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Guzey M, 2004, J CELL BIOCHEM, V93, P271, DOI 10.1002/jcb.20182; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hudson DL, 2004, PROSTATE CANCER P D, V7, P188, DOI 10.1038/sj.pcan.4500745; Kim S, 2004, CANCER RES, V64, P6900, DOI 10.1158/0008-5472.CAN-04-1657; Konety B R, 1999, Semin Urol Oncol, V17, P77; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659; Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x; Miller GJ, 1998, CANCER METAST REV, V17, P353, DOI 10.1023/A:1006102124548; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Shimada A, 1999, CANCER RES, V59, P2781; South AP, 2002, BRIT J DERMATOL, V146, P216, DOI 10.1046/j.1365-2133.2002.04638.x; Spiesbach K, 2005, INT J CANCER, V114, P555, DOI 10.1002/ijc.20766; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Xie ZJ, 2002, J INVEST DERMATOL, V118, P11, DOI 10.1046/j.1523-1747.2002.01644.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	47	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3745	3751		10.1038/sj.onc.1209412	http://dx.doi.org/10.1038/sj.onc.1209412			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462763				2022-12-25	WOS:000238448300013
J	Lapi, E; Iovino, A; Fontemaggi, G; Soliera, AR; Iacovelli, S; Sacchi, A; Rechavi, G; Givol, D; Blandino, G; Strano, S				Lapi, E.; Iovino, A.; Fontemaggi, G.; Soliera, A. R.; Iacovelli, S.; Sacchi, A.; Rechavi, G.; Givol, D.; Blandino, G.; Strano, S.			S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation	ONCOGENE			English	Article						p73; p63; differentiation; transcription; keratinocytes; S100A2	DNA-DAMAGE; P73 GENE; EXPRESSION; P63; PROTEINS; IDENTIFICATION; FAMILY; CELLS; PROLIFERATION; NEUROBLASTOMA	The p53 paralogues p73, p63 and their respective truncated isoforms have been shown to be critical regulators of developmental and differentiation processes. Indeed, both p73- and p63-deficient mice exhibit severe developmental defects. Here, we show that S100A2 gene, whose transcript and protein are induced during keratinocyte differentiation of HaCaT cells, is a direct transcriptional target of p73 beta and Delta Np63 alpha and is required for proper keratinocyte differentiation. Transactivation assays reveal that p73b and DNp63a exert opposite transcriptional effects on S100A2 gene. While DNp63a is found in vivo onto S100A2 regulatory regions predominantly in proliferating cells, p73b is recruited in differentiating cells. Silencing of p73 impairs the induction of S100A2 during the differentiation of HaCaT cells. Moreover, silencing of p73 or S100A2 impairs the proper expression of keratinocyte differentiation markers. Of note, p53 family members do not trigger S100A2 gene expression in response to apoptotic doses of cisplatin and doxorubicin.	Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Rome, Italy; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Hashomer, Israel; Rome Oncogenom Ctr, Rome, Italy; Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Chaim Sheba Medical Center; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Via Messi Oro,156, Rome, Italy.	blandino@ifo.it	strano, sabrina/B-6743-2013; Fontemaggi, Giulia/K-9702-2016; Strano, Sabrina/K-9654-2016; Lapi, Eleonora/ABF-9748-2021; Blandino, Giovanni/B-1137-2013	strano, sabrina/0000-0002-6341-4230; Fontemaggi, Giulia/0000-0001-8332-8842; Lapi, Eleonora/0000-0003-4052-0361; Blandino, Giovanni/0000-0002-6970-2241; iacovelli, stefano/0000-0003-0806-6365	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Attardi LD, 2000, GENE DEV, V14, P704; Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hibi K, 2003, CLIN CANCER RES, V9, P4282; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika AI, 1999, CANCER RES, V59, P3257	40	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3628	3637		10.1038/sj.onc.1209401	http://dx.doi.org/10.1038/sj.onc.1209401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449968				2022-12-25	WOS:000238448300002
J	Qiu, J; Wong, J; Tweardy, DJ; Dong, S				Qiu, J.; Wong, J.; Tweardy, D. J.; Dong, S.			Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta	ONCOGENE			English	Article						AML1; AML1-X; FRAP	ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; GENE; AML1; ETO; ACTIVATION; REPRESSION; OLIGOMERIZATION; TRANSLOCATION; DIMERIZATION	Acute myeloid leukemia 1 (AML1) gene on chromosome 21 is involved in several chromosomal translocations, including t(8; 21) and t(16; 21), that produce chimeric fusion proteins AML1-eight twenty-one (ETO) and AML- myeloid transforming gene chromosome 16 (MTG16), which contribute to leukemogenesis. The molecular basis for the leukemogenic effects of these fusion proteins is incompletely understood. Using gel-shift assay, we showed that AML1-ETO and AML1-MTG16 bound to a series of AML1 consensus DNA-binding sites with different affinities. Using fluorescence recovery after photobleaching (FRAP), we demonstrated that a fusion of AML1 with ETO or MTG16 exhibits reduced intranuclear mobility compared with wild-type AML1 or either fusion partner. The dimerization domain (nervy homology region 2) of ETO is responsible for the reduced mobility of AML1-ETO. Dual FRAP studies revealed that CBF beta colocalized with AML1-ETO within the nucleus, resulting in reduced mobility of CBF beta. Therefore, AML1 fusion proteins may interfere with normal AML1 function due to aberrant nuclear dynamics, which leads to spatial and temporal sequestration of CBF beta and perhaps other coregulators critical for myeloid differentiation.	Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Dong, S (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.	sdong@bcm.tmc.edu	Tweardy, David/L-3929-2019	Wong, Jiemin/0000-0002-5311-842X	NATIONAL CANCER INSTITUTE [R21CA119080] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA119080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Hug BA, 2002, CANCER RES, V62, P2906; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	30	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3982	3993		10.1038/sj.onc.1209431	http://dx.doi.org/10.1038/sj.onc.1209431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474840				2022-12-25	WOS:000238668800012
J	Zhang, XD; Dou, SX; Xie, P; Hu, JS; Wang, PY; Xi, XG				Zhang, XD; Dou, SX; Xie, P; Hu, JS; Wang, PY; Xi, XG			Escherichia coli RecQ is a rapid, efficient, and monomeric helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 DDA HELICASE; TERMINATION FACTOR-RHO; C VIRUS HELICASE; CRYSTAL-STRUCTURE; PCRA HELICASE; REP HELICASE; STEP-SIZE; FLUORESCENCE POLARIZATION; HEXAMERIC HELICASES	RecQ family helicases play a key role in chromosome maintenance. Despite extensive biochemical, biophysical, and structural studies, the mechanism by which helicase unwinds double-stranded DNA remains to be elucidated. Using a wide array of biochemical and biophysical approaches, we have previously shown that the Escherichia coli RecQ helicase functions as a monomer. In this study, we have further characterized the kinetic mechanism of the RecQ-catalyzed unwinding of duplex DNA using the fluorometric stopped-flow method based on fluorescence resonance energy transfer. Our results show that RecQ helicase binds preferentially to 3'-flanking duplex DNA. Under the pre-steady-state conditions, the burst amplitude reveals a 1: 1 ratio between RecQ and DNA substrate, suggesting that an active monomeric form of RecQ helicase is involved in the catalysis. Under the single-turnover conditions, the RecQ-catalyzed unwinding is independent of the 3'-tail length, indicating that functional interactions between RecQ molecules are not implicated in the DNA unwinding. It was further determined that RecQ unwinds DNA rapidly with a step size of 4 bp and a rate of similar to 21 steps/s. These kinetic results not only further support our previous conclusion that E. coli RecQ functions as a monomer but also suggest that some of the Superfamily 2 helicases may function through an "inchworm" mechanism.	Chinese Acad Sci, Inst Phys, Beijing Natl Lab Condensed Matter Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Ctr Biomol Struct & Org, College Pk, MD 20742 USA; ENS, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France	Chinese Academy of Sciences; Institute of Physics, CAS; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Wang, PY (corresponding author), Chinese Acad Sci, Inst Phys, Beijing Natl Lab Condensed Matter Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China.	pywang@aphy.iphy.ac.cn	Xi, Xu Guang/AAK-4511-2020; zhang, xingdong/I-2892-2015; 王, 鹏业/A-9811-2012; Dou, Shi Xue/D-5179-2012	Dou, Shi Xue/0000-0003-3824-7693; Dou, Shuo-Xing/0000-0002-7201-2081; Wang, Peng-Ye/0000-0002-9765-0610				Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dou SX, 2004, J BIOL CHEM, V279, P6354, DOI 10.1074/jbc.M311272200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Levin MK, 2005, NAT STRUCT MOL BIOL, V12, P429, DOI 10.1038/nsmb920; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Liao JC, 2005, J MOL BIOL, V350, P452, DOI 10.1016/j.jmb.2005.04.051; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2004, J MOL BIOL, V339, P731, DOI 10.1016/j.jmb.2004.04.009; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Neuman KC, 2005, J PHYS-CONDENS MAT, V17, pS3811, DOI 10.1088/0953-8984/17/47/012; Norcum MT, 2005, P NATL ACAD SCI USA, V102, P3623, DOI 10.1073/pnas.0500713102; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; von Hippel PH, 2004, NAT STRUCT MOL BIOL, V11, P494, DOI 10.1038/nsmb0604-494; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Zhang XD, 2005, ACTA BIOCH BIOPH SIN, V37, P593, DOI 10.1111/j.1745-7270.2005.00084.x	66	63	69	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12655	12663		10.1074/jbc.M513089200	http://dx.doi.org/10.1074/jbc.M513089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16507576	hybrid			2022-12-25	WOS:000237134700056
J	Zhu, Y; McAvoy, S; Kuhn, R; Smith, DI				Zhu, Y.; McAvoy, S.; Kuhn, R.; Smith, D. I.			RORA, a large common fragile site gene, is involved in cellular stress response	ONCOGENE			English	Article						RORA; breast cancer; common fragile site; stress response	ORPHAN RECEPTOR-ALPHA; N-MYC GENE; CANCER-CELLS; DNA-DAMAGE; FHIT GENE; NUCLEAR RECEPTORS; HUMAN-CHROMOSOMES; STAGGERER MICE; EXPRESSION; FRA16D	Common fragile sites ( CFSs) are large genomic regions present in all individuals that are highly unstable and prone to breakage and rearrangement, especially in cancer cells with genomic instability. Eight of the 90 known CFSs have been precisely defined and five of these span genes that extend from 700 kb to over 1.5Mb of genomic sequence. Although these genes reside within some of the most unstable chromosomal regions in the human genome, they are highly conserved evolutionarily. These genes are targets for large chromosomal deletions and rearrangements in cancer and are frequently inactivated in multiple tumor types. There is also an association between these genes and cellular responses to stress. Based upon the association between large genes and CFSs, we began to systematically test other large genes derived from chromosomal regions that were known to contain a CFS. In this study, we demonstrate that the 730 kb retinoic acid receptor- related orphan receptor alpha ( RORA) gene is derived from the middle of the FRA15A ( 15q22.2) CFS. Although this gene is expressed in normal breast, prostate and ovarian epithelium, it is frequently inactivated in cancers that arise from these organs. RORA was previously shown to be involved in the cellular response to hypoxia and here we demonstrate changes in the amount of RORA message produced in cells exposed to a variety of different cellular stresses. Our results demonstrate that RORA is another very large CFS gene that is inactivated in multiple tumors. In addition, RORA appears to play a critical role in responses to cellular stress, lending further support to the idea that the large CFS genes function as part of a highly conserved stress response network that is uniquely susceptible to genomic instability in cancer cells.	Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Univ Calif Santa Cruz, Dept Biomol Sci & Engn, Santa Cruz, CA 95064 USA	Mayo Clinic; University of California System; University of California Santa Cruz	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu						Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bednarek AK, 2001, CANCER RES, V61, P8068; Broussard DR, 2004, J VIROL, V78, P4943, DOI 10.1128/JVI.78.9.4943-4946.2004; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chauvet C, 2004, BIOCHEM J, V384, P79, DOI 10.1042/BJ20040709; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; Druck T, 1997, CANCER RES, V57, P504; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Gemma A, 1997, CANCER RES, V57, P1435; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gopalakrishnan VK, 2003, PANCREATOLOGY, V3, P293, DOI 10.1159/000071767; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUEBNER K, 1997, BIOCHIM BIOPHYS ACTA, V1332, P65; Ishii H, 2005, MOL CANCER RES, V3, P130, DOI 10.1158/1541-7786.MCR-04-0209; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Jetten Anton M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P395, DOI 10.2174/1568010042634497; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; Littman DR, 1999, COLD SPRING HARB SYM, V64, P373, DOI 10.1101/sqb.1999.64.373; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; MatysiakScholze U, 1997, GENOMICS, V43, P78, DOI 10.1006/geno.1997.4757; Migita H, 2004, FEBS LETT, V557, P269, DOI 10.1016/S0014-5793(03)01502-3; Missbach M, 1996, J BIOL CHEM, V271, P13515, DOI 10.1074/jbc.271.23.13515; Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO;2-6; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pawlikowski M, 1999, ADV EXP MED BIOL, V460, P369; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Smith DI, 1998, INT J ONCOL, V12, P187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020	48	101	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2901	2908		10.1038/sj.onc.1209314	http://dx.doi.org/10.1038/sj.onc.1209314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16462772				2022-12-25	WOS:000237448200008
J	Liu, Y; Belkina, NV; Graham, C; Shaw, S				Liu, Y; Belkina, NV; Graham, C; Shaw, S			Independence of protein kinase C-delta activity from activation loop phosphorylation - Structural basis and altered functions in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; PKC-DELTA; PEPTIDE SPECIFICITY; CRYSTAL-STRUCTURE; CK2; DETERMINANTS; APOPTOSIS; ISOTYPES; SEGMENT; SERINE	Activation loop phosphorylation plays critical regulatory roles for many kinases. Unlike other protein kinase Cs ( PKC), PKC-delta does not require phosphorylation of its activation loop ( Thr-507) for in vitro activity. We investigated the structural basis for this unusual capacity and its relevance to PKC-delta function in intact cells. Mutational analysis demonstrated that activity without Thr- 507 phosphorylation depends on 20 residues N-terminal to the kinase domain and a pair of phenylalanines ( Phe-500/Phe-527) unique to PKC-delta in/near the activation loop. Molecular modeling demonstrated that these elements stabilize the activation loop by forming a hydrophobic chain of interactions from the C-lobe to activation loop to N- terminal ( helical) extension. In cells PKC-delta mediates both apoptosis and transcription regulation. We found that the T507A mutant of the PKC-delta kinase domain resembled the corresponding wild type in mediating apoptosis in transfected HEK293T cells. But the T507A mutant was completely defective in AP-1 and NF-kappa B reporter assays. A novel assay in which the kinase domain of PKC-delta and its substrate ( a fusion protein of PKC substrate peptide with green fluorescent protein) were co-targeted to lipid rafts revealed a major substrate-selective defect of the T507A mutant in phosphorylating the substrate in cells. In vitro analysis showed strong product inhibition on the T507A mutant with particular substrates whose characteristics suggest it contributes to the substrate selective defect of the PKC-delta T507A mutant in cells. Thus, activation loop phosphorylation of PKC-delta may regulate its function in cells in a novel way.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shaw, S (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	sshaw@nih.gov			NATIONAL CANCER INSTITUTE [ZIABC009257, Z01BC009257] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; Breitenlechner C, 2004, BIOCHEMISTRY-US, V43, P7743, DOI 10.1021/bi0362525; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; Holmes JK, 2001, EUR J BIOCHEM, V268, P4647, DOI 10.1046/j.1432-1327.2001.02392.x; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu Y, 2002, BIOCHEM J, V361, P255, DOI 10.1042/bj3610255; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton Alexandra C, 2003, Methods Mol Biol, V233, P3; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; Sarno S, 1998, FEBS LETT, V441, P29, DOI 10.1016/S0014-5793(98)01516-6; Sarno S, 2002, J BIOL CHEM, V277, P22509, DOI 10.1074/jbc.M200486200; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Sowadski JM, 1999, PHARMACOL THERAPEUT, V82, P157, DOI 10.1016/S0163-7258(98)00054-0; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; XIE HJ, 1995, J IMMUNOL, V154, P1717; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	32	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12102	12111		10.1074/jbc.M600508200	http://dx.doi.org/10.1074/jbc.M600508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16505477	hybrid			2022-12-25	WOS:000236988100080
J	Silva, T; Bradley, RH; Gao, YF; Coue, M				Silva, T; Bradley, RH; Gao, YF; Coue, M			Xenopus CDC7/DRF1 complex is required for the initiation of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; MEIOTIC 2ND DIVISION; CDC7 PROTEIN-KINASE; S-PHASE; CELL-CYCLE; MESSENGER-RNAS; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REGULATORY SUBUNIT; CHROMATIN BINDING	The Cdc7 kinase is essential for the initiation of DNA replication in eukaryotes. Two regulatory subunits of the Xenopus Cdc7 kinase have been identified: XDbf4 and XDrf1. In this study we determined the expression pattern of XDbf4 and XDrf1 and examined their involvement in DNA replication. We show that XDrf1 expression is restricted to oogenesis and early embryos, whereas XDbf4 is expressed throughout development. Immunodepletion from Xenopus egg extracts indicated that both proteins are only found in complexes with XCdc7 and there is a 5-fold molar excess of the XCdc7/Drf1 over SCdc7/Dbf4 complexes. Both complexes exhibit kinase activity and are differentially phosphorylated during the cell cycle. Depletion of the XCdc7/Drf1 from egg extracts inhibited DNA replication, whereas depletion of XCdc7/Dbf4 had little effect. Chromatin binding studies indicated that XCdc7/Drf1 is required for pre-replication complex activation but not their assembly. XCdc7/Dbf4 complexes bound to the chromatin in two steps: the first step was independent of pre-replication complex assembly and the second step was dependent on pre-replication complex activation. By contrast, binding of XCdc7/Drf1 complexes was entirely dependent on pre-replication complex assembly. Finally, we present evidence that the association of the two complexes on the chromatin is not regulated by ATR checkpoint pathways that result from DNA replication blocks. These data suggest that Cdc7/Drf1 but not Cdc7/Dbf4 complexes support the initiation of DNA replication in Xenopus egg extracts and during early embryonic development.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Coue, M (corresponding author), 3601 4th St, Lubbock, TX 79430 USA.	martine.coue@ttuhsc.edu						Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Audic Y, 1997, MOL CELL BIOL, V17, P209, DOI 10.1128/MCB.17.1.209; Audic Y, 2001, MOL CELL BIOL, V21, P1662, DOI 10.1128/MCB.21.5.1662-1671.2001; Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Furukohri A, 2003, J BIOCHEM, V134, P447, DOI 10.1093/jb/mvg163; Hodson JA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng134; Jares P, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-5; Jares P, 2000, GENE DEV, V14, P1528; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Legagneux V, 1995, RNA, V1, P1001; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Lucas I, 2001, EMBO J, V20, P6509, DOI 10.1093/emboj/20.22.6509; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Menut S, 1999, ADV MOLEC BIOL, P196; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura T, 2000, GENES CELLS, V5, P463, DOI 10.1046/j.1365-2443.2000.00343.x; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1977, Current Topics Dev Biol, V11, P115, DOI 10.1016/S0070-2153(08)60744-9; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sible JC, 1998, CURR BIOL, V8, P347, DOI 10.1016/S0960-9822(98)70136-8; Takahashi TS, 2005, GENE DEV, V19, P2295, DOI 10.1101/gad.1339805; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Whitmire E, 2002, NATURE, V419, P722, DOI 10.1038/nature01032; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Zhang HJ, 2004, DEVELOPMENT, V131, P2089, DOI 10.1242/dev.01064	43	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11569	11576		10.1074/jbc.M510278200	http://dx.doi.org/10.1074/jbc.M510278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16507577	hybrid			2022-12-25	WOS:000236988100019
J	Dansen, TB; Whitfield, J; Rostker, F; Brown-Swigart, L; Evan, GI				Dansen, TB; Whitfield, J; Rostker, F; Brown-Swigart, L; Evan, GI			Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; C-MYC; ENDOPLASMIC-RETICULUM; PROAPOPTOTIC BAX; DEATH; LYMPHOMAGENESIS; PROLIFERATION; PROTEINS; LEUKEMIA; TARGET	Bax and Bak comprise the mitochondrial gateway for apoptosis induced by diverse stimuli. Loss of both bax and bak is necessary to block cell death induced by such stimuli, indicating a great degree of functional overlap between Bax and Bak. Apoptosis is the major intrinsic pathway that limits the oncogenic potential of Myc. Using a switchable mouse model of Myc-induced apoptosis in pancreatic beta cells, we have shown that Myc induces apoptosis in vivo exclusively through Bax but not Bak. Furthermore, blockade of Myc-induced apoptosis by the inactivation of Bax, but not Bak, eliminates all restraints to the oncogenic potential of Myc, allowing the rapid and synchronous progression of invasive, angiogenic tumors.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Evan, GI (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0128, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Whitfield, Jonathan/N-6690-2014	Whitfield, Jonathan/0000-0002-4925-7283; Dansen, Tobias/0000-0001-5259-8815	NATIONAL CANCER INSTITUTE [R01CA098018] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA98018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Jamerson MH, 2004, BRIT J CANCER, V91, P1372, DOI 10.1038/sj.bjc.6602137; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mitchell KO, 2000, CANCER RES, V60, P6318; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105	26	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10890	10895		10.1074/jbc.M513655200	http://dx.doi.org/10.1074/jbc.M513655200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16464852	hybrid			2022-12-25	WOS:000236822200029
J	Gale, SE; Frolov, A; Han, XL; Bickel, PE; Cao, L; Bowcock, A; Schaffer, JE; Ory, DS				Gale, SE; Frolov, A; Han, XL; Bickel, PE; Cao, L; Bowcock, A; Schaffer, JE; Ory, DS			A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL GENERALIZED LIPODYSTROPHY; EMBRYONIC STEM-CELLS; SHOTGUN LIPIDOMICS; ACID; IDENTIFICATION; LOCALIZATION; INHIBITION; RECEPTOR; ENZYMES; CLONING	Mutations in the 1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2) gene have been identified in individuals affected with congenital generalized lipodystrophy (CGL). AGPAT2 catalyzes acylation of lysophosphatidic acid to phosphatidic acid, a precursor for both triacylglycerol (TAG) and phospholipid synthesis. Recent studies suggest that reduced AGPAT2 enzymatic activity may underlie the CGL clinical phenotype. To gain insight into how altered AGPAT2 activity causes lipodystrophy, we examined the effect of knockdown of AGPAT2 expression in preadipocytes on TAG synthesis and storage, and on adipocyte differentiation. We show that AGPAT2 mRNA expression is induced 30-fold during adipocyte differentiation and that AGPAT2 enzymatic activity is required for TAG mass accumulation in mature adipocytes. We demonstrate that small interference RNA-mediated knockdown of AGPAT2 expression prevents appropriate early induction of C/EBP beta and PPAR gamma, key transcriptional activators of the adipogenic program, and delays expression of multiple adipocyte-related genes. The unexpected finding, that levels of several phospholipid species, including phosphatidic acid (PA), are elevated in TAG-depleted adipocytes with AGPAT2 knockdown, suggests that impaired AGPAT2 activity affects availability of PA for TAG synthesis but not overall PA synthesis nor utilization of PA for phospholipid synthesis. These findings underscore the importance of an AGPAT2-mediated metabolic pathway in adipocyte differentiation.	Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@wustl.edu	Bickel, Perry/Q-9185-2019	Bowcock, Anne/0000-0001-8691-9090	NHLBI NIH HHS [HL67773, HL04482] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-05S2, P30 DK056341, DK059577, P30 DK056341-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067773, K02HL004482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059577, P30DK056341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; Chakraborty TR, 1999, J BIOL CHEM, V274, P29786, DOI 10.1074/jbc.274.42.29786; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gargiulo CE, 1999, J LIPID RES, V40, P881; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Han XL, 2005, EXPERT REV PROTEOMIC, V2, P253, DOI 10.1586/14789450.2.2.253; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; Haque W, 2005, BIOCHEM BIOPH RES CO, V327, P446, DOI 10.1016/j.bbrc.2004.12.024; Kitajima K, 2003, METHOD ENZYMOL, V365, P72; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leung DW, 2001, FRONT BIOSCI, V6, pD944, DOI 10.2741/Leung; Lu B, 2005, BIOCHEM J, V385, P469, DOI 10.1042/BJ20041348; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Schaeffer PJ, 2004, J BIOL CHEM, V279, P39593, DOI 10.1074/jbc.M403649200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Su X, 2004, J BIOL CHEM, V279, P21740, DOI 10.1074/jbc.M314166200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Umeda K, 2004, DEVELOPMENT, V131, P1869, DOI 10.1242/dev.01065; VANCE D, 2002, BIOCH LIPIDS LIPOPRO, P203; VERGNES L, 2006, IN PRESS J LIPID RES; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wolins NE, 2006, J LIPID RES, V47, P450, DOI 10.1194/jlr.D500037-JLR200; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200	35	99	104	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11082	11089		10.1074/jbc.M509612200	http://dx.doi.org/10.1074/jbc.M509612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16495223	hybrid			2022-12-25	WOS:000236822200050
J	Krug, M; Lee, SJ; Diederichs, K; Boos, W; Welte, W				Krug, M; Lee, SJ; Diederichs, K; Boos, W; Welte, W			Crystal structure of the sugar binding domain of the archaeal transcriptional regulator TrmB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; ABC TRANSPORTER; MACROMOLECULAR STRUCTURES; BIOCHEMICAL-ANALYSIS; DIFFRACTION DATA; SYSTEM; SPECIFICITY; REFINEMENT; EXPRESSION	TrmB is an alpha-glucoside-sensing transcriptional regulator controlling two operons encoding maltose/trehalose and maltodextrin ABC transporters of Pyrococcus furiosus. The crystal structure of an N-terminal truncated derivative of TrmB (amino acids 2-109 deleted; TrmB(Delta 2-109)) was solved at 1.5 angstrom resolution. This protein has lost its DNA binding domain but has retained its sugar recognition site. The structure represents a novel sugar-binding fold. TrmB(Delta 2-109) bound maltose, glucose, sucrose, and maltotriose, exhibiting K-d values of 6.8, 25, 34, and 160 mu M, respectively. TrmB(Delta 2-109) behaved as a monomer in dilute buffer solution in contrast to the full-length protein, which is a dimer. Co-crystallization with bound maltose identified a binding site involving seven amino acid residues: Ser(229), Asn(305), Gly(320), Met(321), Val(324), Ile(325), and Glu(326). Six of these residues interact with the nonreducing glucosyl residue of maltose. The nonreducing glucosyl residue is shared by all substrates bound to TrmB, suggesting it as a common recognition motif.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Welte, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de	Lee, Sungjae/AAI-8586-2020	Lee, Sungjae/0000-0002-3997-9020				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 2005, TRENDS MICROBIOL, V13, P262, DOI 10.1016/j.tim.2005.03.015; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; Brinkman AB, 2000, J BIOL CHEM, V275, P38160, DOI 10.1074/jbc.M005916200; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dippel R, 2005, J BACTERIOL, V187, P8322, DOI 10.1128/JB.187.24.8322-8331.2005; DiRuggiero J, 2000, MOL MICROBIOL, V38, P684, DOI 10.1046/j.1365-2958.2000.02161.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evdokimov AG, 2001, J MOL BIOL, V305, P891, DOI 10.1006/jmbi.2000.4202; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greller G, 1999, J BIOL CHEM, V274, P20259, DOI 10.1074/jbc.274.29.20259; Hars U, 1998, PROTEIN SCI, V7, P2511, DOI 10.1002/pro.5560071204; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koning Sonja M., 2002, Archaea, V1, P19, DOI 10.1155/2002/529610; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; Lee SJ, 2005, MOL MICROBIOL, V57, P1797, DOI 10.1111/j.1365-2958.2005.04804.x; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Lie TJ, 2005, J BIOL CHEM, V280, P5236, DOI 10.1074/jbc.M411778200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ouhammouch M, 2004, CURR OPIN GENET DEV, V14, P133, DOI 10.1016/j.gde.2004.01.002; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Qu QH, 2004, J BIOL CHEM, V279, P47890, DOI 10.1074/jbc.M404955200; Qu QH, 2004, EXTREMOPHILES, V8, P301, DOI 10.1007/s00792-004-0392-5; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Reeve JN, 2003, MOL MICROBIOL, V48, P587, DOI 10.1046/j.1365-2958.2003.03439.x; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V742, P16, DOI 10.1016/0167-4838(83)90353-9; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Xie YW, 2005, J BACTERIOL, V187, P6419, DOI 10.1128/JB.187.18.6419-6429.2005	42	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10976	10982		10.1074/jbc.M512809200	http://dx.doi.org/10.1074/jbc.M512809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473881	hybrid, Green Published			2022-12-25	WOS:000236822200038
J	Maklashina, E; Iverson, TM; Sher, Y; Kotlyar, V; Andrell, J; Mirza, O; Hudson, JM; Armstrong, FA; Rothery, RA; Weiner, JH; Cecchini, G				Maklashina, E; Iverson, TM; Sher, Y; Kotlyar, V; Andrell, J; Mirza, O; Hudson, JM; Armstrong, FA; Rothery, RA; Weiner, JH; Cecchini, G			Fumarate reductase and succinate oxidase activity of Escherichia coli complex II homologs are perturbed differently by mutation of the flavin binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; QUINONE OXIDOREDUCTASES; FLAVOCYTOCHROME C(3); ELECTRON-TRANSPORT; CATALYTIC-ACTIVITY; DEHYDROGENASE; SITE; ENZYME; IDENTIFICATION	The Escherichia coli complex II homologues succinate: ubiquinone oxidoreductase (SQR, SdhCDAB) and menaquinol: fumarate oxidoreductase (QFR, FrdABCD) have remarkable structural homology at their dicarboxylate binding sites. Although both SQR and QFR can catalyze the interconversion of fumarate and succinate, QFR is a much better fumarate reductase, and SQR is a better succinate oxidase. An exception to the conservation of amino acids near the dicarboxylate binding sites of the two enzymes is that there is a Glu (FrdA Glu-49) near the covalently bound FAD cofactor in most QFRs, which is replaced with a Gln ( SdhA Gln-50) in SQRs. The role of the amino acid side chain in enzymes with Glu/Gln/Ala substitutions at FrdA Glu-49 and SdhA Gln-50 has been investigated in this study. The data demonstrate that the mutant enzymes with Ala substitutions in either QFR or SQR remain functionally similar to their wild type counterparts. There were, however, dramatic changes in the catalytic properties when Glu and Gln were exchanged for each other in QFR and SQR. The data show that QFR and SQR enzymes are more efficient succinate oxidases when Gln is in the target position and a better fumarate reductase when Glu is present. Overall, structural and catalytic analyses of the FrdA E49Q and SdhA Q50E mutants suggest that coulombic effects and the electronic state of the FAD are critical in dictating the preferred directionality of the succinate/fumarate interconversions catalyzed by the complex II superfamily.	Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci & Technol, Dept Biol Sci, London SW7 2AY, England; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Imperial College London; University of Oxford; University of Alberta	Cecchini, G (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, 151-S,4150 Clement St, San Francisco, CA 94121 USA.	Gary.Cecchini@ucsf.edu		Rothery, Richard/0000-0003-3265-1783; Mirza, Osman Asghar/0000-0001-9435-0690	Biotechnology and Biological Sciences Research Council [B19096] Funding Source: Medline; NIGMS NIH HHS [R01 GM061606, GM61606] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ACKRELL BAC, 1993, FEBS LETT, V326, P92, DOI 10.1016/0014-5793(93)81768-U; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; ACKRELL BAC, 1982, FLAVINS FLAVOPROTEIN, P488; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847; Horsefield R, 2003, ACTA CRYSTALLOGR D, V59, P600, DOI 10.1107/S0907444903002075; Hudson JM, 2005, J AM CHEM SOC, V127, P6977, DOI 10.1021/ja043404q; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leger C, 2001, BIOCHEMISTRY-US, V40, P11234, DOI 10.1021/bi010889b; Leys D, 1999, NAT STRUCT BIOL, V6, P1113; Luna-Chavez C, 2000, PROTEIN EXPRES PURIF, V19, P188, DOI 10.1006/prep.2000.1238; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; Pershad HR, 1999, BBA-BIOENERGETICS, V1412, P262, DOI 10.1016/S0005-2728(99)00066-3; Reid GA, 2000, BBA-BIOENERGETICS, V1459, P310, DOI 10.1016/S0005-2728(00)00166-3; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; Turner KL, 1999, BIOCHEMISTRY-US, V38, P3302, DOI 10.1021/bi9826308; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	50	39	40	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11357	11365		10.1074/jbc.M512544200	http://dx.doi.org/10.1074/jbc.M512544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16484232	hybrid			2022-12-25	WOS:000236822200078
J	Yin, SM; Yu, SL; Li, CY; Wong, P; Chang, BG; Xiao, F; Kang, SC; Yan, HM; Xiao, GF; Grassi, J; Tien, P; Sy, MS				Yin, SM; Yu, SL; Li, CY; Wong, P; Chang, BG; Xiao, F; Kang, SC; Yan, HM; Xiao, GF; Grassi, J; Tien, P; Sy, MS			Prion proteins with insertion mutations have altered N-terminal conformation and increased ligand binding activity and are more susceptible to oxidative attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH; IDENTIFICATION; COPPER; GENE; MICE; PRP; REPLICATION; EXPRESSION; INFECTION; FEATURES	We compared the biochemical properties of a wild type recombinant normal human cellular prion protein, rPrP(c), with a recombinant mutant human prion protein that has three additional octapeptide repeats, rPrP(8OR). Monoclonal antibodies that are specific for the N terminus of rPrP(c) react much better with rPrP(8OR) than rPrP(c), suggesting that the N terminus of rPrP(8OR) is more exposed and hence more available for antibody binding. The N terminus of PrPc contains a glycosaminoglycan binding motif. Accordingly, rPrP(8OR) also binds more glycosaminoglycan than rPrP(c). In addition, the divalent cation copper modulates the conformations of rPrP(c) and rPrP(8OR) differently. When compared with rPrP(c), rPrP(8OR) is also more susceptible to oxidative damage. Furthermore, the abnormalities associated with rPrP(8OR) are recapitulated, but even more profoundly, in another insertion mutant, which has five extra octapeptide repeats, rPrP(10OR). Therefore, insertion mutants appear to share common features, and the degree of abnormality is proportional to the number of insertions. Any of these anomalies may contribute to the pathogenesis of inherited human prion disease.	Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44120 USA; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China; Wuhan Univ, Coll Life Sci, Modern Virol Res Ctr, Wuhan 430072, Hubei, Peoples R China; CEA Saclay, CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Case Western Reserve University; Chinese Academy of Sciences; Institute of Microbiology, CAS; Wuhan University; CEA; UDICE-French Research Universities; Universite Paris Saclay	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, Wolstein Res Bldg,Rm 5131,2103 Cornell Rd, Cleveland, OH 44106 USA.	mxs92@po.cwru.edu	chang, binggong/F-5043-2014	Yan, Huimin/0000-0002-7243-8429	NINDS NIH HHS [NS-045981-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045981] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bonomo RP, 2000, CHEM-EUR J, V6, P4195, DOI 10.1002/1521-3765(20001117)6:22<4195::AID-CHEM4195>3.0.CO;2-2; Brown LR, 2003, J NEUROCHEM, V87, P353, DOI 10.1046/j.1471-4159.2003.01996.x; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; Chevion M, 2000, FREE RADICAL RES, V33, pS99; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Croes EA, 2004, J NEUROL NEUROSUR PS, V75, P1166, DOI 10.1136/jnnp.2003.020198; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Feraudet C, 2005, J BIOL CHEM, V280, P11247, DOI 10.1074/jbc.M407006200; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Frankenfield KN, 2005, PROTEIN SCI, V14, P2154, DOI 10.1110/ps.051434005; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Grasbon-Frodl E, 2004, NEUROGENETICS, V5, P249, DOI 10.1007/s10048-004-0196-x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Hijazi N, 2005, J BIOL CHEM, V280, P17057, DOI 10.1074/jbc.M411314200; Huang Z, 1996, CURR TOP MICROBIOL, V207, P49; Hutter G, 2003, BIOL CHEM, V384, P1279, DOI 10.1515/BC.2003.142; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; OWEN F, 1989, LANCET, V1, P51; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2005, J VIROL, V79, P934, DOI 10.1128/JVI.79.2.934-943.2005; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Wong BS, 2003, CELL MOL LIFE SCI, V60, P1224, DOI 10.1007/s00018-003-3057-0; Wong BS, 2001, J NEUROCHEM, V76, P565, DOI 10.1046/j.1471-4159.2001.00028.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yin SM, 2003, PROTEIN EXPRES PURIF, V32, P104, DOI 10.1016/S1046-5928(03)00195-5; Yu SL, 2004, EUR J HUM GENET, V12, P867, DOI 10.1038/sj.ejhg.5201245; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 2003, J MOL BIOL, V334, P477, DOI 10.1016/j.jmb.2003.09.048; Zanusso G, 2004, J BIOL CHEM, V279, P38936, DOI 10.1074/jbc.M405468200; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	46	36	37	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10698	10705		10.1074/jbc.M511819200	http://dx.doi.org/10.1074/jbc.M511819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16478730	hybrid			2022-12-25	WOS:000236822200008
J	Fukunaga, K; Arita, M; Takahashi, M; Morris, AJ; Pfeffer, M; Levy, BD				Fukunaga, K; Arita, M; Takahashi, M; Morris, AJ; Pfeffer, M; Levy, BD			Identification and functional characterization of a presqualene diphosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE EPOXIDE HYDROLASE; POLYISOPRENYL PHOSPHATES; SPHINGOSINE 1-PHOSPHATE; SQUALENE SYNTHASE; PHOSPHOLIPASE-D; INFLAMMATION; NEUTROPHILS; CONVERSION; PHOSPHOHYDROLASES; PYROPHOSPHATE	Presqualene diphosphate (PSDP) is a bioactive lipid that rapidly remodels to presqualene monophosphate ( PSMP) upon cell activation ( Levy, B. D., Petasis, N. A., and Serhan, C. N. ( 1997) Nature 389, 985 - 990). Here, we have identified and characterized a phosphatase that converts PSDP to PSMP. Unlike the related polyisoprenyl phosphate farnesyl diphosphate (FDP), PSDP was not a substrate for type 2 lipid phosphate phosphohydrolases. PSDP phosphatase activity was identified in activated human neutrophil (PMN) extracts and partially purified in the presence of Nonidet P-40 with gel filtration and anion exchange chromatography. Peptide sequencing of a candidate phosphatase was consistent with phosphatidic acid phosphatase domain containing 2 (PPAPDC2), an uncharacterized protein that contains a lipid phosphate phosphohydrolase consensus motif. Recombinant PPAPDC2 displayed diphosphate phosphatase activity with a substrate preference for PSDP> FDP> phosphatidic acid. PPAPDC2 activity was independent of Mg2+ and optimal at pH 7.0 to 8.0. Incubation of [C-14] FDP with recombinant human squalene synthase led to [C-14] PSDP and [C-14] squalene formation, and in the presence of PPAPDC2, [C-14] PSMP was generated from [C-14] PSDP. PPAPDC2 mRNA was detected in human PMN, and is widely expressed in human tissues. Together, these findings indicate that PPAPDC2 in human PMN is the first lipid phosphate phosphohydrolase identified for PSDP. Regulation of this activity of the enzyme may have important roles for PMN activation in innate immunity.	Brigham & Womens Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Levy, BD (corresponding author), Brigham & Womens Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	blevy@partners.org	Morris, Andrew/B-7869-2010; Takahashi, Minoru/G-4748-2011	Arita, Makoto/0000-0001-9902-0463	NHLBI NIH HHS [R01 HL068669, HL68669] Funding Source: Medline; NIDCR NIH HHS [P50-DE016191] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Drenth JPH, 2001, NEW ENGL J MED, V345, P1748, DOI 10.1056/NEJMra010200; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gu PD, 1998, J BIOL CHEM, V273, P12515, DOI 10.1074/jbc.273.20.12515; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Levy BD, 2000, BIOCHEM BIOPH RES CO, V275, P739, DOI 10.1006/bbrc.2000.3371; Levy BD, 2005, BRIT J PHARMACOL, V146, P344, DOI 10.1038/sj.bjp.0706338; Levy BD, 1999, FASEB J, V13, P903, DOI 10.1096/fasebj.13.8.903; Levy BD, 1997, NATURE, V389, P985, DOI 10.1038/40180; LEVY BD, 2003, CELL MOL LIFE SCI, V59, P1; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Newman JW, 2003, P NATL ACAD SCI USA, V100, P1558, DOI 10.1073/pnas.0437724100; RILLING HC, 1971, J AM CHEM SOC, V93, P1783; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rush JS, 2002, J BIOL CHEM, V277, P45226, DOI 10.1074/jbc.M207076200; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; SHECHTER I, 1980, J LIPID RES, V21, P277; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Stukey J, 1997, PROTEIN SCI, V6, P469; Takada K, 2003, ARTHRITIS RHEUM, V48, P2645, DOI 10.1002/art.11218; TCHEN TT, 1957, J BIOL CHEM, V226, P921; Thompson JF, 1998, ARCH BIOCHEM BIOPHYS, V350, P283, DOI 10.1006/abbi.1997.0502; Tran KL, 2005, BIOCHEMISTRY-US, V44, P12179, DOI 10.1021/bi050842g; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	31	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9490	9497		10.1074/jbc.M512970200	http://dx.doi.org/10.1074/jbc.M512970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464866	hybrid			2022-12-25	WOS:000236404700059
J	Mason, RP; Walter, MF; Day, CA; Jacob, RF				Mason, RP; Walter, MF; Day, CA; Jacob, RF			Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; RANDOMIZED CONTROLLED-TRIAL; CELL PLASMA-MEMBRANES; C-REACTIVE PROTEIN; OXIDATIVE STRESS; ATHEROSCLEROTIC LESIONS; PLAQUE INSTABILITY; MODEL MEMBRANES; ARTERY-DISEASE; STATIN THERAPY	The advanced atherosclerotic lesion is characterized by the formation of microscopic cholesterol crystals that contribute to mechanisms of inflammation and apoptotic cell death. These crystals develop from membrane cholesterol domains, a process that is accelerated under conditions of hyperlipidemia and oxidative stress. In this study, the comparative effects of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on oxidative stress-induced cholesterol domain formation were tested in model membranes containing physiologic levels of cholesterol using small angle x-ray diffraction approaches. In the absence of HMG-CoA reductase, only the atorvastatin active o-hydroxy metabolite (ATM) blocked membrane cholesterol domain formation as a function of oxidative stress. This effect of ATM is attributed to electron donation and proton stabilization mechanisms associated with its phenoxy group located in the membrane hydrocarbon core. ATM inhibited lipid peroxidation in human low density lipoprotein and phospholipid vesicles in a dose-dependent manner, unlike its parent and other statins (pravastatin, rosuvastatin, simvastatin). These findings indicate an atheroprotective effect of ATM on membrane lipid organization through a potent antioxidant mechanism.	Elucida Res, Beverly, MA 01915 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mason, RP (corresponding author), Elucida Res, 100 Cummings Ctr,Ste 135L,POB 7100, Beverly, MA 01915 USA.	rpmason@elucidaresearch.com		Day, Charles A/0000-0001-6277-2004				Aviram M, 1998, ATHEROSCLEROSIS, V138, P271, DOI 10.1016/S0021-9150(98)00032-X; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; CHANG HM, 1995, J MEMBRANE BIOL, V143, P51; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; CHESTER DW, 1987, BIOPHYS J, V52, P1021, DOI 10.1016/S0006-3495(87)83295-2; CRAVEN BM, 1976, NATURE, V260, P727, DOI 10.1038/260727a0; de Planque MRR, 2003, BIOCHEMISTRY-US, V42, P5341, DOI 10.1021/bi027000r; Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955; ELSAADANI M, 1989, J LIPID RES, V30, P627; EMMELOT P, 1977, MAMMALIAN CELL MEMBR, V2, P1; Geng YJ, 2003, BIOCHEM PHARMACOL, V66, P1485, DOI 10.1016/S0006-2952(03)00502-1; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HOUSLAY MD, 1982, DYNAMICS BIOL MEMBRA, P1; Jacob RF, 2005, J BIOL CHEM, V280, P39380, DOI 10.1074/jbc.M507587200; Jacob RF, 1999, J BIOL CHEM, V274, P31613, DOI 10.1074/jbc.274.44.31613; Jialal I, 2003, CIRCULATION, V107, P926, DOI 10.1161/01.CIR.0000048966.26216.4C; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68; MAK IT, 1994, METHOD ENZYMOL, V234, P620; Mason RP, 2004, CIRCULATION, V109, P34, DOI 10.1161/01.CIR.0000129503.62747.03; MASON RP, 1989, BIOPHYS J, V55, P769, DOI 10.1016/S0006-3495(89)82875-9; Micheletta F, 2004, ARTERIOSCL THROM VAS, V24, P136, DOI 10.1161/01.ATV.0000104028.07929.72; Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Phillips JE, 2001, ATHEROSCLEROSIS, V159, P125, DOI 10.1016/S0021-9150(01)00504-4; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; *THOMS PDR, 2005, PHYS DESK REF, P2585; Tsimikas S, 2004, CIRCULATION, V110, P1406, DOI 10.1161/01.CIR.0000141728.23033.B5; Tulenko TN, 1998, J LIPID RES, V39, P947; Walter MF, 2004, J AM COLL CARDIOL, V44, P1996, DOI 10.1016/j.jacc.2004.08.029; Walter MF, 2000, ANAL BIOCHEM, V280, P73, DOI 10.1006/abio.1999.4476	42	72	116	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9337	9345		10.1074/jbc.M513000200	http://dx.doi.org/10.1074/jbc.M513000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464853	hybrid			2022-12-25	WOS:000236404700042
J	Piening, N; Nonno, R; Di Bari, M; Walter, S; Windl, O; Agrimi, U; Kretzschmar, HA; Bertsch, U				Piening, N; Nonno, R; Di Bari, M; Walter, S; Windl, O; Agrimi, U; Kretzschmar, HA; Bertsch, U			Conversion efficiency of bank vole prion protein in vitro is determined by residues 155 and 170, but does not correlate with the high susceptibility of bank voles to sheep scrapie in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; QUANTITATIVE TRAIT LOCI; MICE EXPRESSING HUMAN; TRANSGENIC MICE; SPONGIFORM ENCEPHALOPATHIES; MASS-SPECTROMETRY; SPECIES BARRIER; RESISTANT PRP; NMR STRUCTURE	The misfolded infectious isoform of the prion protein (PrPSc) is thought to replicate in an autocatalytic manner by converting the cellular form (PrPC) into its pathogenic folding variant. The similarity in the amino acid sequence of PrPC and PrPSc influences the conversion efficiency and is considered as the major determinant for the species barrier. We performed in vitro conversion reactions on wild-type and mutated PrPC to determine the role of the primary sequence for the high susceptibility of bank voles to scrapie. Different conversion efficiencies obtained with bank vole and mouse PrPC in reactions with several prion strains were due to differences at amino acid residues 155 and 170. However, the conversion efficiencies obtained with mouse and vole PrPC in reactions with sheep scrapie did not correlate with the susceptibility of the respective species to this prion strain. This discrepancy between in vitro and in vivo data may indicate that at least in the case of scrapie transmission to bank voles additional host factors can strongly modulate the species barrier. Furthermore, in vitro conversion reactions with different prion strains revealed that the degree of alteration of the conversion efficiency induced by amino acid exchanges was varying according to the prion strain. These results support the assumption that the repertoire of conformations adopted by a certain PrPC primary sequence is decisive for its convertibility to the strain-specific PrPSc conformation.	Univ Munich, Zent Neuropathol & Prionforsch, D-81377 Munich, Germany; Ist Super Sanita, I-00161 Rome, Italy; Vet Labs Agcy, TSE Mol Biol Dept, Weybridge KT15 3NB, Surrey, England	University of Munich; Istituto Superiore di Sanita (ISS); Veterinary Laboratories Agency	Bertsch, U (corresponding author), Univ Munich, Zent Neuropathol & Prionforsch, Feodor Lynen Str 23, D-81377 Munich, Germany.	Uwe.Bertsch@med.uni-muenchen.de	Agrimi, Umberto/C-9956-2015; Windl, Otto/C-6760-2011; NONNO, ROMOLO/C-8323-2015; Di Bari, Michele Angelo/C-8327-2015; Di Bari, Michele Angelo/Q-5028-2019	Agrimi, Umberto/0000-0001-7828-0186; NONNO, ROMOLO/0000-0001-7556-1564; Di Bari, Michele Angelo/0000-0003-0943-6823; Di Bari, Michele Angelo/0000-0003-0943-6823				BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bieschke J, 2004, P NATL ACAD SCI USA, V101, P12207, DOI 10.1073/pnas.0404650101; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bruce ME, 2002, J GEN VIROL, V83, P695, DOI 10.1099/0022-1317-83-3-695; Cartoni C, 2005, J CHROMATOGR A, V1081, P122, DOI 10.1016/j.chroma.2005.04.035; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Caughey B, 1999, MOL BIOTECHNOL, V13, P45, DOI 10.1385/MB:13:1:45; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1999, METHOD ENZYMOL, V309, P122; CHANDLER RL, 1971, LANCET, V1, P232; CHANDLER RL, 1972, RES VET SCI, V31, P219, DOI 10.1016/S0034-5288(18)34031-1; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hill AF, 2003, BRIT MED BULL, V66, P161, DOI 10.1093/bmb/66.1.161; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Hornemann S, 2004, EMBO REP, V5, P1159, DOI 10.1038/sj.embor.7400297; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lloyd SE, 2001, P NATL ACAD SCI USA, V98, P6279, DOI 10.1073/pnas.101130398; Masel J, 2000, BIOPHYS CHEM, V88, P47, DOI 10.1016/S0301-4622(00)00197-6; MCCARTHY K, 1963, LANCET, V2, P593; Moreno CR, 2003, GENETICS, V165, P2085; Mulcahy ER, 2004, J BIOL CHEM, V279, P1643, DOI 10.1074/jbc.M307844200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1966, RES VET SCI, V7, P207; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Priola SA, 1999, BIOMED PHARMACOTHER, V53, P27, DOI 10.1016/S0753-3322(99)80057-2; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Race R, 1998, NATURE, V392, P770, DOI 10.1038/33834; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Sabuncu E, 2003, J VIROL, V77, P2696, DOI 10.1128/JVI.77.4.2696-2700.2003; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Steen H, 2005, OECOLOGIA, V143, P357, DOI 10.1007/s00442-004-1792-z; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Windl O, 1999, J GEN VIROL, V80, P15, DOI 10.1099/0022-1317-80-1-15; Xiang W, 2004, J VIROL, V78, P11051, DOI 10.1128/JVI.78.20.11051-11060.2004	61	43	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9373	9384		10.1074/jbc.M512239200	http://dx.doi.org/10.1074/jbc.M512239200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455657	hybrid			2022-12-25	WOS:000236404700046
J	Block, ML; Li, G; Qin, L; Wu, X; Pei, Z; Wang, T; Wilson, B; Yang, J; Hong, JS				Block, M. L.; Li, G.; Qin, L.; Wu, X.; Pei, Z.; Wang, T.; Wilson, B.; Yang, J.; Hong, J. S.			Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin	FASEB JOURNAL			English	Article						microglia; oxidative stress; DA neurotoxicity; superoxide; NADPH oxidase; femtomolar	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; FEMTOMOLAR CONCENTRATIONS; PARKINSONS-DISEASE; NADPH-OXIDASE; INFLAMMATORY DAMAGE; TETRAZOLIUM SALT; ACTIVATION; RAT; CULTURES; NEUROPROTECTION	Unregulated microglial activation has been implicated as a pivotal factor contributing to Parkinson's disease. Using mesencephalic neuron-glia cultures, we address the novel possibility that peptides endogenous to the substantia nigra (SN), substance P and dynorphin (10(-13)-10(-14) M), are opposing mediators of microglial activation and consequent DA neurotoxicity. Here, we identify that substance P (10-(13)-10(-14) M) is selectively toxic to DA neurons in a microglia-dependent manner. Mechanistically, substance P (10(-13)-10(-14) M) activated microglial NADPH oxidase to produce extracellular superoxide and intracellular reactive oxygen species (ROS). Neuron-glia cultures from mice lacking a functional NADPH oxidase complex (PHOX-/-) were insensitive to substance P (10(-13)-10(-14) M) -induced loss of DA neuron function. Mixed glia cultures from (PHOX-/-) mice failed to show a significant increase in intracellular ROS in response to substance P compared with control cultures (PHOX-/-). Further, dynorphin (10(-14) M) inhibited substance P (10(-13) M) -induced loss of [H-3] DA uptake. Here we demonstrate a tightly regulated mechanism governing microglia-derived oxidative stress, where the neuropeptide balance of dynorphin and substance P is critical to DA neuron survival.	NIEHS, Lab Pharmacol & Chem, Neuropharmacol Sect, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Block, ML (corresponding author), NIEHS, Lab Pharmacol & Chem, Neuropharmacol Sect, POB 12233, Res Triangle Pk, NC 27709 USA.	Block@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090082, Z01ES090082] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; Block ML, 2004, FASEB J, V18, P1618, DOI 10.1096/fj.04-1945fje; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BROWNSTEIN MJ, 1976, BRAIN RES, V116, P299, DOI 10.1016/0006-8993(76)90907-0; CALVO CF, 1992, J IMMUNOL, V148, P3498; ChancellorFreeland C, 1995, ANN NY ACAD SCI, V771, P472, DOI 10.1111/j.1749-6632.1995.tb44703.x; DAS KP, 1995, J NEUROIMMUNOL, V62, P9, DOI 10.1016/0165-5728(95)00083-E; Delgado M, 1999, J IMMUNOL, V162, P1200; FAITH RE, 1984, CLIN IMMUNOL IMMUNOP, V31, P412, DOI 10.1016/0090-1229(84)90093-X; Fernandez A, 1996, BRAIN, V119, P823, DOI 10.1093/brain/119.3.823; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GLADYSHEVA TB, 1989, BIOFIZIKA+, V34, P833; Gozes I, 1999, ANN NY ACAD SCI, V897, P125, DOI 10.1111/j.1749-6632.1999.tb07884.x; GRUBER BL, 1995, BLOOD, V86, P2488; HONG JS, 1977, BRAIN RES, V122, P541, DOI 10.1016/0006-8993(77)90464-4; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Kong LY, 2000, J BIOMED SCI, V7, P241; Le YY, 1999, J IMMUNOL, V163, P6777; LEVY R, 1995, EUR J NEUROSCI, V7, P1199, DOI 10.1111/j.1460-9568.1995.tb01110.x; Li GR, 2005, FASEB J, V19, P489, DOI 10.1096/fj.04-2555com; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; Maeda K, 1997, GERONTOLOGY, V43, P11; Marton J, 2003, VALUE HEALTH, V6, P183, DOI 10.1016/S1098-3015(10)63816-8; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MROZ EA, 1977, BRAIN RES, V125, P305, DOI 10.1016/0006-8993(77)90623-0; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Qin IY, 2005, FASEB J, V19, P550, DOI 10.1096/fj.04-2857com; QIN L, IN PRESS FASEB J; Qin LY, 2005, ANN NY ACAD SCI, V1053, P107, DOI 10.1196/annals.1344.009; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Rasley A, 2004, J IMMUNOL, V172, P5707, DOI 10.4049/jimmunol.172.9.5707; Ravati A, 2000, BRAIN RES, V866, P23, DOI 10.1016/S0006-8993(00)02210-1; SERRA MC, 1988, J IMMUNOL, V141, P2118; Sowa G, 1997, BIOCHEM PHARMACOL, V53, P823, DOI 10.1016/S0006-2952(97)00006-3; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; WALSH DT, 1995, BRIT J PHARMACOL, V114, P1343, DOI 10.1111/j.1476-5381.1995.tb13354.x; Wiedermann FJ, 2002, CRIT CARE MED, V30, P1112, DOI 10.1097/00003246-200205000-00025; WILLIAMSON S A, 1987, Brain Behavior and Immunity, V1, P329, DOI 10.1016/0889-1591(87)90035-3; WILLIAMSON SA, 1988, IMMUNOLOGY, V65, P47; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	49	80	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					251	258		10.1096/fj.05-4553com	http://dx.doi.org/10.1096/fj.05-4553com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449797				2022-12-25	WOS:000237698700010
J	Jeong, YH; Park, CH; Yoo, J; Shin, KY; Ahn, SM; Kim, HS; Lee, SH; Emson, PC; Suh, YH				Jeong, Yun Ha; Park, Cheol Hyoung; Yoo, Jongman; Shin, Ki Young; Ahn, Sung-Min; Kim, Hye-Sun; Lee, Sang Hyung; Emson, Piers C.; Suh, Yoo-Hun			Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APP(V717I)-CT100 transgenic mice, an Alzheimer's disease model	FASEB JOURNAL			English	Article						long-term stress; cognitive impairments; amyloid plaque	CARBOXYL-TERMINAL FRAGMENT; RECEPTOR-LIKE IMMUNOREACTIVITY; PRECURSOR PROTEIN; A-BETA; HIPPOCAMPAL-FORMATION; RETROGRADE-AMNESIA; OLFACTORY FUNCTION; APICAL DENDRITES; BRAIN; LESIONS	Although chronic stress is known to be linked with memory and other neurological disorders, little is known about the relationship between chronic stress and the onset or development of Alzheimer's disease ( AD). In this study, we investigated the effects of long-term stress on the onset and severity of cognitive deficits and pathological changes in APP(V717I)-CT100 mice overexpressing human APP-CT100 containing the London mutation (V717I) after exposure to immobilization stress. We found that chronic immobilization stress accelerated cognitive impairments, as accessed by the Passive avoidance and the Social Transfer of Food Preference (STFP) tests. Moreover, the numbers and densities of vascular and extracellular deposits containing amyloid beta peptide (A beta) and carboxyl-terminal fragments of amyloid precursor protein (APP-CTFs), which are pathologic markers of AD, were significantly elevated in stressed animals, especially in the hippocampus. Moreover, stressed animals, also showed highly elevated levels of neurodegeneration and tau phosphorylation and increased intraneuronal A beta and APP-CTFs immunoreactivities in the hippocampus and in the entorhinal and piriform cortex. This study provides the first evidence that chronic stress accelerates the onset and severity of cognitive deficits and that these are highly correlated with pathological changes, which thus indicates that chronic stress may be an important contributor to the onset and development of AD.	Seoul Natl Univ, Dept Pharmacol, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Dept Neurosurg, Coll Med, Seoul 110799, South Korea; Babraham Inst, Neurobiol Programme, Cambridge, England	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Suh, YH (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, 28 Yeongeon Dong, Seoul 110799, South Korea.	yhsuh@snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Lee, Sang Hyung/J-5581-2012; Kim, Hye Sun/J-2752-2012	Jeong, Yun Ha/0000-0001-7703-6659				AHIMA R, 1991, J COMP NEUROL, V313, P522, DOI 10.1002/cne.903130312; AHIMA RS, 1990, NEUROSCIENCE, V39, P579, DOI 10.1016/0306-4522(90)90244-X; Alvarez P, 2002, NEUROBIOL LEARN MEM, V78, P470, DOI 10.1006/nlme.2002.4068; Bach JH, 2001, J NEUROCHEM, V78, P109, DOI 10.1046/j.1471-4159.2001.00370.x; Bacon AW, 1998, ANN NY ACAD SCI, V855, P723, DOI 10.1111/j.1749-6632.1998.tb10651.x; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Bunsey M, 1995, HIPPOCAMPUS, V5, P546, DOI 10.1002/hipo.450050606; Chang KA, 2005, J PHARMACOL SCI, V97, P461, DOI 10.1254/jphs.CR0050014; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Dewachter I, 2002, LANCET NEUROL, V1, P409, DOI 10.1016/S1474-4422(02)00188-6; Dewachter I, 2002, J NEUROSCI, V22, P3445; Figueiredo HF, 2002, ENDOCRINOLOGY, V143, P2534, DOI 10.1210/en.143.7.2534; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gupta A, 2002, MED HYPOTHESES, V59, P727, DOI 10.1016/S0306-9877(02)00321-3; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JACQUELING NC, 2000, LEARNING MEMORY WHAT, P99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kim CM, 2003, VECTOR-BORNE ZOONOT, V3, P17, DOI 10.1089/153036603765627424; Kim HS, 1998, NEUROREPORT, V9, P3875, DOI 10.1097/00001756-199812010-00020; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Kim JH, 2002, J BIOL CHEM, V277, P20256, DOI 10.1074/jbc.M108326200; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kim SH, 1996, J NEUROCHEM, V67, P1172; Koo JW, 2003, FASEB J, V17, P1556, DOI 10.1096/fj.02-1032fje; Lambourne SL, 2005, MOL CELL BIOL, V25, P278, DOI 10.1128/MCB.25.1.278-293.2005; LANDFIELD PW, 1978, SCIENCE, V202, P1098, DOI 10.1126/science.715460; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lordi B, 1997, PHYSIOL BEHAV, V62, P1087, DOI 10.1016/S0031-9384(97)00261-8; Magarinos AM, 1998, BRAIN RES, V809, P314, DOI 10.1016/S0006-8993(98)00882-8; Magarinos AM, 1997, P NATL ACAD SCI USA, V94, P14002, DOI 10.1073/pnas.94.25.14002; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; McEwen BS, 1995, VITAM HORM, V51, P371, DOI 10.1016/S0083-6729(08)61045-6; McEwen BS, 2002, METABOLISM, V51, P2, DOI 10.1053/meta.2002.33183; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Moceri VM, 2001, EPIDEMIOLOGY, V12, P383, DOI 10.1097/00001648-200107000-00007; MORGAN CD, 1995, J CLIN EXP NEUROPSYC, V17, P793, DOI 10.1080/01688639508405168; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; Murphy C, 1999, PHYSIOL BEHAV, V66, P177, DOI 10.1016/S0031-9384(98)00262-5; Nacher J, 2004, NEUROSCIENCE, V126, P503, DOI 10.1016/j.neuroscience.2004.03.038; Nordin S, 1996, NEUROPSYCHOLOGY, V10, P113, DOI 10.1037/0894-4105.10.1.113; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Rah JC, 2001, FASEB J, V15, P1463, DOI 10.1096/fj.00-0724fje; Raiha I, 1998, J NEUROL NEUROSUR PS, V65, P785, DOI 10.1136/jnnp.65.5.785; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; SAPOLSKY RM, 1994, ANN NY ACAD SCI, V746, P294; SELKOE DJ, 1997, NAT MED, V3, P67; Shah ZA, 2003, EUR NEUROPSYCHOPHARM, V13, P321, DOI 10.1016/S0924-977X(03)00005-1; Sousa N, 2000, NEUROSCIENCE, V97, P253, DOI 10.1016/S0306-4522(00)00050-6; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Suh YH, 1997, J NEUROCHEM, V68, P1781; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P241, DOI 10.1023/A:1007754611030; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Weinstock M, 1997, NEUROSCI BIOBEHAV R, V21, P1, DOI 10.1016/S0149-7634(96)00014-0; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; Winocur G, 2001, HIPPOCAMPUS, V11, P18, DOI 10.1002/1098-1063(2001)11:1<18::AID-HIPO1016>3.0.CO;2-5	63	181	186	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					729	+		10.1096/fj.05-4265fje	http://dx.doi.org/10.1096/fj.05-4265fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467370				2022-12-25	WOS:000237698700029
J	Pfister, Y; Gautschi, I; Takeda, AN; van Bemmelen, M; Kellenberger, S; Schild, L				Pfister, Y; Gautschi, I; Takeda, AN; van Bemmelen, M; Kellenberger, S; Schild, L			A gating mutation in the internal pore of ASIC1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; NA+ CHANNEL; ION PERMEATION; SELECTIVITY FILTER; AMILORIDE BLOCK; ALPHA-SUBUNIT; ENAC; IDENTIFICATION; FAMILY	Using a substituted cysteine accessibility scan, we have investigated the structures that form the internal pore of the acid-sensing ion channel 1a. We have identified the amino acid residues Ala-22, Ile-33, and Phe-34 in the amino terminus and Arg-43 in the first transmembrane helix, which when mutated into cysteine, were modified by intracellular application of MTSET, resulting in channel inhibition. The inhibition of the R43C mutant by internal MTSET requires opening of the channel. In addition, binding of Cd2+ ions to R43C slows the channel inactivation. This indicates that the first transmembrane helix undergoes conformational changes during channel inactivation. The effect of Cd2+ on R43C can be obtained with Cd2+ applied at either the extracellular or the intracellular side, indicating that R43C is located in the channel pore. The block of the A22C, I33C, and F34C mutants by MTSET suggests that these residues in the amino terminus of the channel also participate to the internal pore.	Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Schild, L (corresponding author), Univ Lausanne, Fac Biol & Med, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	laurent.Schild@unil.ch	van Bemmelen, Miguel/B-5971-2009; TAKEDA, Armelle-Natsuo/B-6031-2009; van Bemmelen, Miguel Xavier/A-8660-2014	van Bemmelen, Miguel Xavier/0000-0003-2762-6153; Kellenberger, Stephan/0000-0003-1755-6198				Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Kellenberger S, 2005, J BIOL CHEM, V280, P7739, DOI 10.1074/jbc.M409955200; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; Poet M, 2001, EMBO J, V20, P5595, DOI 10.1093/emboj/20.20.5595; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Saugstad JA, 2004, J BIOL CHEM, V279, P55514, DOI 10.1074/jbc.M411849200; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781	24	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11787	11791		10.1074/jbc.M513692200	http://dx.doi.org/10.1074/jbc.M513692200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16497675	hybrid			2022-12-25	WOS:000236988100044
J	Viriyakosol, S; Tobias, PS; Kirkland, TN				Viriyakosol, S; Tobias, PS; Kirkland, TN			Mutational analysis of membrane and soluble forms of human MD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; N-LINKED GLYCOSYLATIONS; CELL-SURFACE; SIGNAL-TRANSDUCTION; RECEPTOR 4-MD-2; BINDING-PROTEIN; TOLL; LPS; TLR4; CD14	Toll-like receptor 4 and MD-2 form a receptor for lipopolysaccharide (LPS), a major constituent of Gram-negative bacteria. MD-2 is a 20 - 25-kDa extracellular glycoprotein that binds to Toll-like receptor 4 (TLR4) and LPS and is a critical part of the LPS receptor. Here we have shown that the level of MD-2 expression regulates TLR4 activation by LPS. Using site-directed mutagenesis, we have found that glycosylation has no effect on MD-2 function as a membrane receptor for LPS. We used alanine-scanning mutagenesis to identify regions of human MD-2 that are important for TLR4 and LPS binding. We found that mutation in the N-terminal 46 amino acids of MD-2 did not substantially diminish LPS activation of Chinese hamster ovary (CHO) cells co-transfected with TLR4 and mutant MD-2. The residues 46 - 50 were important for LPS activation but not LPS binding. The residues 79 - 83, 121 - 124, and 125 129 are identified as important in LPS activation but not surface expression of membrane MD-2. The function of soluble MD-2 is somewhat more sensitive to mutation than membrane MD-2. Our results suggest that the 46 - 50 and 127 - 131 regions of soluble MD-2 bind to TLR4. The region 79 - 120 is not involved in LPS binding but affects monomerization of soluble MD-2 as well as TLR4 binding. We define the LPS binding region of monomeric soluble MD-2 as a cluster of basic residues 125 - 131. Studies on both membrane and soluble MD-2 suggest that domains of MD-2 for TLR4 and LPS binding are separate as well as overlapping. By mapping these regions on a three-dimensional model, we show the likely binding regions of MD-2 to TLR4 and LPS.	Vet Affairs San Diego Healthcare Syst 9151, La Jolla, CA 92161 USA; Univ Calif San Diego, Vet Affairs Med Res Fdn, La Jolla, CA 92161 USA; Univ Calif San Diego, Dept Pathol & Med, La Jolla, CA 92161 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Viriyakosol, S (corresponding author), Vet Affairs San Diego Healthcare Syst 9151, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	sviriyak@ucsd.edu; tkirkland@ucsd.edu	Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Delude RL, 1998, J IMMUNOL, V161, P3001; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Miyake K, 2000, J ENDOTOXIN RES, V6, P389, DOI 10.1179/096805100101532324; Miyake K, 1998, J IMMUNOL, V161, P1348; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Ohnishi T, 2001, J IMMUNOL, V167, P3354, DOI 10.4049/jimmunol.167.6.3354; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11955	11964		10.1074/jbc.M511627200	http://dx.doi.org/10.1074/jbc.M511627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16467306	hybrid			2022-12-25	WOS:000236988100065
J	Gurtan, AM; Stuckert, P; D'Andrea, AD				Gurtan, AM; Stuckert, P; D'Andrea, AD			The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; DNA-DAMAGE RESPONSE; NUCLEAR ACCUMULATION; PROTEINS FANCA; BRCA PATHWAY; RING DOMAIN; GENE; REVEALS; CHROMATIN; INTERACT	Fanconi anemia (FA) is an autosomal recessive disorder characterized by aplastic anemia, cancer susceptibility, and cellular sensitivity to mitomycin C. Eight of the 11 cloned Fanconi anemia gene products (FANCA, -B, -C, -E, -F, -G, -L, and -M) form a multisubunit nuclear complex ( FA core complex) required for monoubiquitination of a downstream FA protein, FANCD2. FANCL, which possesses three WD40 repeats and a plant homeodomain (PHD), is the putative E3 ubiquitin ligase subunit of the FA complex. Here, we demonstrate that the WD40 repeats of FANCL are required for interaction with other subunits of the FA complex. The PHD is dispensable for this interaction, although it is required for FANCD2 mono-ubiquitination. The PHD of FANCL also shares sequence similarity to the canonical RING finger of c-CBL, including a conserved tryptophan required for E2 binding by c-CBL. Mutation of this tryptophan in the FANCL PHD significantly impairs in vivo mono-ubiquitination of FANCD2 and in vitro auto-ubiquitination activity, and partially impairs restoration of mitomycin C resistance. We propose a model in which FANCL, via its WD40 region, binds the FA complex and, via its PHD, recruits an as-yet-unidentified E2 for mono-ubiquitination of FANCD2.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Biol & Biomed Sci Program, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	D'Andrea, AD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,M640, Boston, MA 02115 USA.	Alan_Dandrea@dfci.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052725] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL52725] Funding Source: Medline; PHS HHS [R01KD43889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTER BP, 1995, BLOOD, V85, P1148, DOI 10.1182/blood.V85.4.1148.bloodjournal8541148; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Dodd RB, 2004, J BIOL CHEM, V279, P53840, DOI 10.1074/jbc.M409662200; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gordon SM, 2005, J BIOL CHEM, V280, P36118, DOI 10.1074/jbc.M507758200; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Matsushita N, 2005, MOL CELL, V19, P841, DOI 10.1016/j.molcel.2005.08.018; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Naf D, 1998, MOL CELL BIOL, V18, P5952; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Rooimans MA, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Shimamura A, 2003, BLOOD, V102, P3459, DOI 10.1182/blood-2003-04-1297; Shimamura A, 2002, BLOOD, V100, P4649, DOI 10.1182/blood-2002-05-1399; Siddique MA, 2001, EXP HEMATOL, V29, P1448, DOI 10.1016/S0301-472X(01)00754-8; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tischkowitz MD, 2003, J MED GENET, V40, P1, DOI 10.1136/jmg.40.1.1; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	49	41	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10896	10905		10.1074/jbc.M511411200	http://dx.doi.org/10.1074/jbc.M511411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16474167	hybrid			2022-12-25	WOS:000236822200030
J	Spaziani, A; Alisi, A; Sanna, D; Balsano, C				Spaziani, A; Alisi, A; Sanna, D; Balsano, C			Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; LIVER-REGENERATION; SIGNALING PATHWAY; ACTIVATION; PROLIFERATION; EXPRESSION; PROGRESSION; CHECKPOINT	Some hepatitis C virus (HCV) proteins, including core protein, deregulate the cell cycle of infected cells, thereby playing an important role in the viral pathogenesis of HCC. Thus far, there are only few studies that have deeply investigated in depth the effects of the HCV core protein expression on the progression through the G(1)/S and G(2)/M phases of the cell cycle. To shed light on the molecular mechanisms by which the HCV core protein modulates cell proliferation, we have examined its effects on cell cycle in hepatocarcinoma cells. We show here that HCV core protein perturbs progression through both the G(1)/S and the G(2)/M phases, by modulating the expression and the activity of several cell cycle regulatory proteins. In particular, our data provided evidence that core-dependent deregulation of the G(1)/S phase and its related cyclin-CDK complexes depends upon the ERK1/2 pathway. On the other hand, the viral protein also increases the activity of the cyclin B1-CDK1 complex via the p38 MAPK and JNK pathways. Moreover, we show that HCV core protein promotes nuclear import of cyclin B1, which is affected by the inhibition of both the p38 and the RNA-dependent protein kinase (PKR) activities. The important role of p38 MAPK in regulating G(2)/M phase transition has been previously documented. It is becoming clear that PKR has an important role in regulating both the G(1)/S and the G(2)/M phase, in which it induces M phase arrest. Based on our model, we now show, for the first time, that HCV core expression leads to deregulation of the mitotic checkpoint via a p38/PKR-dependent pathway.	Univ Aquila, Dept Internal Med, Lab Clin Hepatol, I-67100 Laquila, Italy; Ist Ricovery & Cura Carattere Sci SR Pisana, Lab Dev Pathol, I-00163 Rome, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Mol Virol & Oncol, I-00161 Rome, Italy	University of L'Aquila; Sapienza University Rome	Balsano, C (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Mol Virol & Oncol, Clin Med 1,Policlin Umberto I, Viale Policlin N155, I-00161 Rome, Italy.	clara.balsano@uniroma1.it	Alisi, Anna/A-6469-2010; Balsano, Clara/AAK-9870-2020	Alisi, Anna/0000-0001-7241-6329; Balsano, Clara/0000-0002-9615-7031				Alisi A, 2003, LIVER INT, V23, P179, DOI 10.1034/j.1600-0676.2003.00829.x; Alisi A, 2005, J CELL PHYSIOL, V205, P25, DOI 10.1002/jcp.20363; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Cho JW, 2001, LIVER, V21, P137, DOI 10.1034/j.1600-0676.2001.021002137.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dagon Y, 2001, ONCOGENE, V20, P8045, DOI 10.1038/sj.onc.1204945; Donato MF, 2001, HEPATOLOGY, V34, P523, DOI 10.1053/jhep.2001.26820; Duensing S, 2002, CANCER RES, V62, P7075; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; EZAKI T, 1988, CANCER, V61, P1880, DOI 10.1002/1097-0142(19880501)61:9<1880::AID-CNCR2820610926>3.0.CO;2-S; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Huynh H, 2004, INT J ONCOL, V25, P1839; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jeong SJ, 2004, CANCER RES, V64, P8666, DOI 10.1158/0008-5472.CAN-03-3455; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Werling K, 2001, EUR J GASTROEN HEPAT, V13, P489, DOI 10.1097/00042737-200105000-00005; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127	39	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10983	10989		10.1074/jbc.M512536200	http://dx.doi.org/10.1074/jbc.M512536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16446363	hybrid			2022-12-25	WOS:000236822200039
J	Wormald, S; Zhang, JG; Krebes, DL; Mielke, LA; Silver, J; Alexander, WS; Speed, TP; Nicola, NA; Hilton, DJ				Wormald, S; Zhang, JG; Krebes, DL; Mielke, LA; Silver, J; Alexander, WS; Speed, TP; Nicola, NA; Hilton, DJ			The comparative roles of suppressor of cytokine signaling-1 and-3 in the inhibition and desensitization of cytokine signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSIOLOGICAL NEGATIVE REGULATOR; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; STAT FAMILY; IFN-GAMMA; ACTIVATION; RECEPTOR; INTERLEUKIN-6; SOCS3; TRANSCRIPTION	Negative feedback is a mechanism commonly employed in biological processes as a means of maintaining homeostasis. We have investigated the roles of suppressor of cytokine signaling ( SOCS) proteins in regulating the kinetics of negative feedback in response to cytokine signaling. In mouse livers and bone marrow-derived macrophages, both interferon-gamma (IFN gamma) and interleukin-6 (IL-6) rapidly induced the tyrosine phosphorylation of signal transducer and activator of transcription-1 (STAT1) and STAT3. STAT3 tyrosine phosphorylation was bi-phasic in response to continuous IL-6 signaling. In macrophages lacking Socs3, however, continuous IL-6 signaling induced uniformly high levels of STAT3 tyrosine phosphorylation, and early IL-6-inducible genes were inappropriately expressed at intermediate time points. SOCS3 therefore imposes bi-phasic kinetics upon IL-6 signaling. Compared with Socs3 mRNA, Socs1 mRNA was induced relatively slowly, and SOCS1 simply attenuated the duration of IFN gamma signaling. Surprisingly, heightened Socs1 mRNA expression but minimal STAT1 tyrosine phosphorylation was observed after prolonged stimulation with IFN gamma, indicating that STAT1 may not play a large role in inducing Socs1 mRNA during steady-state IFN gamma signaling. We also demonstrate that both SOCS1 and SOCS3 can desensitize primary bone marrow-derived macrophages to IFN gamma and IL-6 signaling, respectively. Consistent with the kinetics with which Socs1 and Socs3 mRNAs were induced, SOCS3 desensitized cells to IL-6 rapidly, whereas SOCS1-mediated desensitization to IFN gamma occurred at later time points. The kinetics with which SOCS proteins are induced by cytokine may therefore be a parameter that is "hard-wired" into specific cytokine signaling pathways as a means of tailoring the kinetics with which cells become desensitized.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Genet & Bioinformat, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Wormald, S (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, 1G Royal Parade, Parkville, Vic 3050, Australia.	wormald@wehi.edu.au	Silver, Jeremy/Y-4174-2019; Speed, Terence P/B-8085-2009; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Silver, Jeremy/0000-0003-1502-6249; Speed, Terence P/0000-0002-5403-7998; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Krebs, Danielle/0000-0002-6522-7308; Mielke, Lisa/0000-0002-9522-9320	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; COWAN DB, 2000, AM J PHYSIOL, V279, pH6719; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HARROCH S, 1994, J BIOL CHEM, V269, P26191; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NICOLA NA, 1994, UIDEBOOK GYTOKINES T; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Reich M, 2004, BIOINFORMATICS, V20, P1797, DOI 10.1093/bioinformatics/bth138; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Steinman RA, 1999, LEUKEMIA, V13, P54, DOI 10.1038/sj.leu.2401253; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	102	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11135	11143		10.1074/jbc.M509595200	http://dx.doi.org/10.1074/jbc.M509595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16473883	hybrid			2022-12-25	WOS:000236822200056
J	Burgess, A; Wigan, M; Giles, N; DePinto, W; Gillespie, P; Stevens, F; Gabrielli, B				Burgess, A; Wigan, M; Giles, N; DePinto, W; Gillespie, P; Stevens, F; Gabrielli, B			Inhibition of S/G(2) phase CDK4 reduces mitotic fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; HELA-CELLS; HUMAN SKIN; CENP-E; CHECKPOINT; KINASE; ACTIVATION; KINETOCHORES; EXPRESSION	Cyclin-dependent kinase 4 (CDK4)/cyclin D has a key role in regulating progression through late G(1) into S phase of the cell cycle. CDK4-cyclin D complexes then persist through the latter phases of the cell cycle, although little is known about their potential roles. We have developed small molecule inhibitors that are highly selective for CDK4 and have used these to define a role for CDK4-cyclin D in G(2) phase. The addition of the CDK4 inhibitor or small interfering RNA knockdown of cyclin D3, the cyclin D partner, delayed progression through G(2) phase and mitosis. The G(2) phase delay was independent of ATM/ATR and p38 MAPK but associated with elevated Wee1. The mitotic delay was because of failure of chromosomes to migrate to the metaphase plate. However, cells eventually exited mitosis, with a resultant increase in cells with multiple or micronuclei. Inhibiting CDK4 delayed the expression of the chromosomal passenger proteins survivin and borealin, although this was unlikely to account for the mitotic phenotype. These data provide evidence for a novel function for CDK4-cyclin D3 activity in S and G(2) phase that is critical for G(2)/M progression and the fidelity of mitosis.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Hoffmann La Roche Inc, Discovery Oncol, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Discovery Chem, Nutley, NJ 07110 USA	University of Queensland; Roche Holding; Roche Holding	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019; Gabrielli, Brian G/B-3655-2011	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651				BATES S, 1994, ONCOGENE, V9, P1633; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castellano M, 1997, CANCER RES, V57, P4868; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Keenan SM, 2004, J BIOL CHEM, V279, P5387, DOI 10.1074/jbc.M310383200; Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Papi M, 2005, NAT CELL BIOL, V7, P1029, DOI 10.1038/ncb1303; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	35	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9987	9995		10.1074/jbc.M512714200	http://dx.doi.org/10.1074/jbc.M512714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16476733	hybrid			2022-12-25	WOS:000236594300021
J	Dorval, V; Fraser, PE				Dorval, V; Fraser, PE			Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; IN-VITRO; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SUMOYLATION; PHOSPHORYLATION; CONJUGATION; IDENTIFICATION; DEGRADATION; ACTIVATION	Sumoylation is an important post-translational modification that provides a rapid and reversible means for controlling the activity, subcellular localization, and stability of target proteins. We have examined the covalent attachment of the small ubiquitin-like modifier ( SUMO) proteins to tau and alpha-synuclein, two natively unfolded proteins that define several neurodegenerative diseases. Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3. Tau contains two SUMO consensus sequences, and mutational analyses identified Lys(340) as the major sumoylation site. Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway. Tau is a microtubule-associated protein, whose ability to bind and stabilize microtubules is negatively regulated by phosphorylation. Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation. This suggests that SUMO modification may preferentially target a free soluble pool of the substrate. These findings revealed a new, possibly regulatory, modification of tau and alpha-synuclein that may also have implications for their pathogenic roles in neurodegenerative diseases.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto	Fraser, PE (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	paul.fraser@utoronto.ca						Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Chung TL, 2004, J BIOL CHEM, V279, P39653, DOI 10.1074/jbc.M405637200; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Gamblin TC, 2005, BBA-MOL BASIS DIS, V1739, P140, DOI 10.1016/j.bbadis.2004.08.013; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hyman BT, 2005, BBA-MOL BASIS DIS, V1739, P150, DOI 10.1016/j.bbadis.2004.06.015; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pountney DL, 2005, NEUROSCI LETT, V381, P74, DOI 10.1016/j.neulet.2005.02.013; Pountney DL, 2003, EXP NEUROL, V184, P436, DOI 10.1016/j.expneurol.2003.07.004; Riley BE, 2005, J BIOL CHEM, V280, P21942, DOI 10.1074/jbc.M501677200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Terashima T, 2002, NEUROREPORT, V13, P2359, DOI 10.1097/00001756-200212030-00038; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Ueda H, 2002, BIOCHEM BIOPH RES CO, V293, P307, DOI 10.1016/S0006-291X(02)00211-5; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	64	214	236	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9919	9924		10.1074/jbc.M510127200	http://dx.doi.org/10.1074/jbc.M510127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16464864	hybrid			2022-12-25	WOS:000236594300013
J	Ruan, X; Bhattacharjee, H; Rosen, BP				Ruan, X; Bhattacharjee, H; Rosen, BP			Cys-113 and Cys-422 form a high affinity metalloid binding site in the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; ESCHERICHIA-COLI; RESISTANCE; DOMAINS; PUMP	The arsRDABC operon of Escherichia coli plasmid R773 encodes the ArsAB extrusion pump for the trivalent metalloids As(III) and Sb(III). ArsA, the catalytic subunit has two homologous halves, A1 and A2. Each half has a consensus signal transduction domain that physically connects the nucleotide-binding domain to the metalloid-binding domain. The relation between metalloid binding by ArsA and transport through ArsB is unclear. In this study, direct metalloid binding to ArsA was examined. The results show that ArsA binds a single Sb( III) with high affinity only in the presence of Mg2+-nucleotide. Mutation of the codons for Cys-113 and Cys-422 eliminated Sb( III) binding to purified ArsA. C113A/ C422A ArsA has basal ATPase activity similar to that of the wild type but lacks metalloid-stimulated activity. Accumulation of metalloid was assayed in intact cells, where reduced uptake results from active extrusion by the ArsAB pump. Cells expressing the arsA(C113A/C422A)B genes had an intermediate level of metalloid resistance and accumulation between those expressing only arsB alone and those expressing wild type arsAB genes. The results indicate that, whereas metalloid stimulation of ArsA activity enhances the ability of the pump to reduce the intracellular concentration of metalloid, high affinity binding of metalloid by ArsA is not obligatory for transport or resistance. Yet, in mixed populations of cells bearing either arsAB or arsA(C113A/C422A)B growing in subtoxic concentrations of arsenite, cells bearing wild type arsAB replaced cells with mutant arsA(C113A/C422A)B in less than 1 week, showing that the metalloid binding site confers an evolutionary advantage.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM 55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; HSU CM, 1989, J BIOL CHEM, V264, P17349; Jia HW, 2003, J BIOL CHEM, V278, P6603, DOI 10.1074/jbc.M211845200; Jiang Y, 2005, J BIOL CHEM, V280, P9921, DOI 10.1074/jbc.M413391200; Kuroda M, 1998, METHOD ENZYMOL, V292, P82; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; Li JX, 2000, MOL MICROBIOL, V35, P361, DOI 10.1046/j.1365-2958.2000.01696.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Walmsley AR, 2001, BIOCHEM J, V360, P589, DOI 10.1042/0264-6021:3600589; WONG MD, 2004, HDB ATPASES, P159; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zhou TQ, 2002, J BIOL CHEM, V277, P23815, DOI 10.1074/jbc.M203432200	22	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9925	9934		10.1074/jbc.M600125200	http://dx.doi.org/10.1074/jbc.M600125200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16467301	hybrid			2022-12-25	WOS:000236594300014
J	Tenchov, B; Vescio, EM; Sprott, GD; Zeidel, ML; Mathai, JC				Tenchov, B; Vescio, EM; Sprott, GD; Zeidel, ML; Mathai, JC			Salt tolerance of archaeal extremely halophilic lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; PHASE-BEHAVIOR; PHOSPHATIDYLETHANOLAMINE DISPERSIONS; HALOBACTERIUM-CUTIRUBRUM; POLAR LIPIDS; MICROORGANISMS; EUBACTERIUM; MECHANISMS; STABILITY; LIPOSOMES	The membranes of extremely halophilic Archaea are characterized by the abundance of a diacidic phospholipid, archaetidylglycerol methylphosphate (PGP-Me), which accounts for 50 - 80 mol% of the polar lipids, and by the absence of phospholipids with choline, ethanolamine, inositol, and serine head groups. These membranes are stable in concentrated 3 - 5 M NaCl solutions, whereas membranes of non-halophilic Archaea, which do not contain PGP-Me, are unstable and leaky under such conditions. By x-ray diffraction and vesicle permeability measurements, we demonstrate that PGP-Me contributes in an essential way to membrane stability in hypersaline environments. Large unilamellar vesicles (LUV) prepared from the polar lipids of extreme halophiles, Halobacterium halobium and Halobacterium salinarum, retain entrapped carboxyfluorescein and resist aggregation in the whole range 0 - 4 M NaCl, similarly to LUV prepared from purified PGP-Me. By contrast, LUV made of polar lipid extracts from moderately halophilic and non-halophilic Archaea ( Methanococcus jannaschii, Methanosarcina mazei, Methanobrevibacter smithii) are leaky and aggregate at high salt concentrations. However, adding PGP-Me to M. mazei lipids results in gradual enhancement of LUV stability, correlating with the PGP-Me content. The LUV data are substantiated by the x-ray results, which show that H. halobium and M. mazei lipids have dissimilar phase behavior and form different structures at high NaCl concentrations. H. halobium lipids maintain an expanded lamellar structure with spacing of 8.5 - 9 nm, which is stable up to at least 100 degrees C in 2 M NaCl and up to similar to 60 degrees C in 4 M NaCl. However, M. mazei lipids form non-lamellar structures, represented by the Pn3m cubic phase and the inverted hexagonal H-II phase. From these data, the forces preventing membrane aggregation in halophilic Archaea appear to be steric repulsion, because of the large head group of PGP-Me, or possibly out-of-plane bilayer undulations, rather than electrostatic repulsion attributed to the doubly charged PGP-Me head group.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; National Research Council Canada	Mathai, JC (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A1222 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	mathaij@dom.pitt.edu	Tenchov, Boris/W-5547-2019		NCRR NIH HHS [RR 08630] Funding Source: Medline; NIDDK NIH HHS [DK 43955] Funding Source: Medline; NIGMS NIH HHS [GM 57305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057305] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYSZEWSKA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P485, DOI 10.1016/0005-2736(88)90381-1; CHOQUET CG, 1994, APPL MICROBIOL BIOT, V42, P375, DOI 10.1007/s002530050266; DEROSA M, 1991, ARCHAEABACTERIA LIPI, P61; FREDRICKSON HL, 1989, BIOMED ENVIRON MASS, V18, P96, DOI 10.1002/bms.1200180203; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Kamekura M, 1999, BIOSCI BIOTECH BIOCH, V63, P969, DOI 10.1271/bbb.63.969; KATES M, 1993, EXPERIENTIA, V49, P1027, DOI 10.1007/BF01929909; KATES M, 1993, BIOCHIM BIOPHYS ACTA, V1169, P46, DOI 10.1016/0005-2760(93)90080-S; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; Koynova R, 1999, COLLOID SURFACE A, V149, P571, DOI 10.1016/S0927-7757(98)00294-5; Koynova R, 1997, EUR BIOPHYS J BIOPHY, V25, P261, DOI 10.1007/s002490050038; Krishnan L, 2000, INFECT IMMUN, V68, P54, DOI 10.1128/IAI.68.1.54-63.2000; LAI MC, 1992, J BACTERIOL, V174, P7474, DOI 10.1128/jb.174.22.7474-7477.1992; Madigan MT, 1997, SCI AM, V276, P82, DOI 10.1038/scientificamerican0497-82; Margesin R, 2001, EXTREMOPHILES, V5, P73, DOI 10.1007/s007920100184; Mathai JC, 2001, J BIOL CHEM, V276, P27266, DOI 10.1074/jbc.M103265200; Oren A, 1999, MICROBIOL MOL BIOL R, V63, P334, DOI 10.1128/MMBR.63.2.334-348.1999; QUINN PJ, 1986, BIOCHIM BIOPHYS ACTA, V863, P213, DOI 10.1016/0005-2736(86)90261-0; SANDERSON PW, 1991, BIOCHIM BIOPHYS ACTA, V1067, P43, DOI 10.1016/0005-2736(91)90024-3; Sprott G. D., 1996, Cells and Materials, V6, P143; Sprott G. Dennis, 2003, Archaea, V1, P151, DOI 10.1155/2003/569283; SPROTT GD, 1991, J BACTERIOL, V173, P3907, DOI 10.1128/JB.173.12.3907-3910.1991; Sprott GD, 1997, CAN J MICROBIOL, V43, P467, DOI 10.1139/m97-066; Sprott GD, 2003, BBA-MOL CELL BIOL L, V1633, P179, DOI 10.1016/j.bbalip.2003.08.001; SPROTT GD, 1994, CAN J MICROBIOL, V40, P837, DOI 10.1139/m94-133; SPROTT GD, 1992, J BIOENERG BIOMEMBR, V24, P555, DOI 10.1007/BF00762348; SUTTON GC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P235, DOI 10.1016/0005-2736(91)90289-K; Tenchov B, 1998, BIOPHYS J, V75, P853, DOI 10.1016/S0006-3495(98)77574-5; TSUJIMOTO K, 1989, J CHEM SOC CHEM COMM, V10, P688; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; van de Vossenberg JLCM, 1999, EXTREMOPHILES, V3, P253, DOI 10.1007/s007920050124; VREELAND RH, 1987, CRIT REV MICROBIOL, V14, P311, DOI 10.3109/10408418709104443; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1110, P171, DOI 10.1016/0005-2736(92)90355-P	34	45	47	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10016	10023		10.1074/jbc.M600369200	http://dx.doi.org/10.1074/jbc.M600369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16484230	hybrid			2022-12-25	WOS:000236594300025
J	Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE				Ahmad, ST; Joyce, MV; Boggess, B; O'Tousa, JE			The role of Drosophila ninaG oxidoreductase in visual pigment chromophore biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECTOPIC EXPRESSION; BETA-CAROTENE; MELANOGASTER; RETINOIDS; PATHWAY; ISOMERIZATION; TRANSDUCTION; RHODOPSINS; OXIDATION; ISOMERS	We previously reported (Sarfare, S., Ahmad, S. T., Joyce, M. V., Boggess, B., and O'Tousa, J. E. (2005) J. Biol. Chem. 280, 11895-11901) that the Drosophila ninaG gene encodes an oxidoreductase involved in the biosynthesis of the (3S)-3-hydroxyretinal serving as chromophore for Rh1 rhodopsin and that ninaG mutant flies expressing Rh4 as the major opsin accumulate large amounts of a different retinoid. Here, we show that this unknown retinoid is 11-cis-3-hydroxyretinol. Reversed phase high performance liquid chromatography coupled with a photodiode array UV-visible absorbance detector and mass spectrometer revealed a major product eluting at a retention time, t(r), of 3.5 min with a lambda(max) of similar to 324 nm and with a base peak in the mass spectrum at m/z 285. These observations are identical with those of the 3-hydroxyretinol standard. The base peak in the electrospray ionization mass spectrum arises from the loss of a water molecule from the protonated molecule at m/z 303 because of fragmentation in the ion source. These results suggest that 11-cis-3-hydroxyretinol is an intermediate required for chromophore biogenesis in Drosophila. We further show that ninaG mutants fed on retinal as the sole source of vitamin A are able to synthesize 3-hydroxyretinoids. Thus, the NinaG oxidoreductase is not responsible for the initial hydroxylation of the retinal ring but rather acts in a subsequent step in chromophore production. These data are used to review chromophore biosynthesis and propose that NinaG acts in the conversion of (3R)-3-hydroxyretinol to the 3S enantiomer.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	jotousa@nd.edu		O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; Cia D, 1999, J CHROMATOGR A, V864, P257, DOI 10.1016/S0021-9673(99)01024-9; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; FEILER R, 1992, J NEUROSCI, V12, P3862; Gu G, 2004, J BIOL CHEM, V279, P18608, DOI 10.1074/jbc.M400323200; Gundersen TE, 2001, J CHROMATOGR A, V935, P13, DOI 10.1016/S0021-9673(01)01043-3; Hsu CD, 2002, VISION RES, V42, P507, DOI 10.1016/S0042-6989(01)00231-0; Kumar JP, 1995, DEVELOPMENT, V121, P4359; NICHOLS R, 1985, DROSOPH INF SERV, V61, P195; Noll GN, 1996, J CHROMATOGR A, V721, P247, DOI 10.1016/0021-9673(95)00789-X; Pak WL, 2003, RECEPTOR CHANNEL, V9, P149, DOI 10.1080/10606820308242; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Salcedo E, 1999, J NEUROSCI, V19, P10716, DOI 10.1523/JNEUROSCI.19-24-10716.1999; Sarfare S, 2005, J BIOL CHEM, V280, P11895, DOI 10.1074/jbc.M412236200; Seki T, 1998, EUR J BIOCHEM, V257, P522, DOI 10.1046/j.1432-1327.1998.2570522.x; SEKI T, 1994, EUR J BIOCHEM, V226, P691, DOI 10.1111/j.1432-1033.1994.tb20097.x; Seki T, 1998, COMP BIOCHEM PHYS B, V119, P53, DOI 10.1016/S0305-0491(97)00322-2; STARK WS, 1990, J COMP PHYSIOL A, V166, P429, DOI 10.1007/BF00192014; vanBreemen RB, 1996, FASEB J, V10, P1098, DOI 10.1096/fasebj.10.9.8801173; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wang T, 2005, J NEUROSCI, V25, P5187, DOI 10.1523/JNEUROSCI.0995-05.2005; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yamashita M, 1998, PROTEIN ENG, V11, P1075, DOI 10.1093/protein/11.11.1075	23	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9205	9209		10.1074/jbc.M510293200	http://dx.doi.org/10.1074/jbc.M510293200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16464863	hybrid			2022-12-25	WOS:000236404700027
J	Berrone, E; Beltramo, E; Solimine, C; Ape, AU; Porta, M				Berrone, E; Beltramo, E; Solimine, C; Ape, AU; Porta, M			Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; DIABETIC COMPLICATIONS; ALDOSE REDUCTASE; ENDOTHELIAL-CELLS; HYPERGLYCEMIC DAMAGE; IN-VITRO; PERICYTES; GLYCOSYLATION; RETINOPATHY; PREVENTION	Hyperglycemia is a causal factor in the development of the vascular complications of diabetes. One of the biochemical mechanisms activated by excess glucose is the polyol pathway, the key enzyme of which, aldose reductase, transforms D-glucose into D-sorbitol, leading to imbalances of intracellular homeostasis. We aimed at verifying the effects of thiamine and benfotiamine on the polyol pathway, transketolase activity, and intracellular glucose in endothelial cells and pericytes under high ambient glucose. Human umbilical vein endothelial cells and bovine retinal pericytes were cultured in normal (5.6 mmol/liter) or high (28 mmol/liter) glucose, with or without thiamine or benfotiamine 50 or 100 mu mol/liter. Transketolase and aldose reductase mRNA expression was determined by reverse transcription-PCR, and their activity was measured spectrophotometrically; sorbitol concentrations were quantified by gas chromatography-mass spectrometry and intracellular glucose concentrations by fluorescent enzyme-linked immunosorbent assay method. Thiamine and benfotiamine reduce aldose reductase mRNA expression, activity, sorbitol concentrations, and intracellular glucose while increasing the expression and activity of transketolase, for which it is a coenzyme, in human endothelial cells and bovine retinal pericytes cultured in high glucose. Thiamine and benfotiamine correct polyol pathway activation induced by high glucose in vascular cells. Activation of transketolase may shift excess glycolytic metabolites into the pentose phosphate cycle, accelerate the glycolytic flux, and reduce intracellular free glucose, thereby preventing its conversion to sorbitol. This effect on the polyol pathway, together with other beneficial effects reported for thiamine in high glucose, could justify testing thiamine as a potential approach to the prevention and/or treatment of diabetic complications.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy	University of Turin	Berrone, E (corresponding author), Univ Turin, Dept Internal Med, Corso AM Dogliotti 14, I-10126 Turin, Italy.	elena.berrone@unito.it	Beltramo, Elena/AAE-4243-2021; Porta, Massimo/G-6146-2011; Berrone, Elena/N-4826-2019	Beltramo, Elena/0000-0002-7868-0988; Berrone, Elena/0000-0002-1731-4810; Porta, Massimo/0000-0002-3407-6017				AIDA K, 1990, DIABETES CARE, V13, P461, DOI 10.2337/diacare.13.5.461; Babaei-Jadidi R, 2003, DIABETES, V52, P2110, DOI 10.2337/diabetes.52.8.2110; Beltramo E, 2004, DIABETES-METAB RES, V20, P330, DOI 10.1002/dmrr.470; Beltramo E, 2003, DIABETOLOGIA, V46, P409, DOI 10.1007/s00125-003-1043-6; Beltramo E, 2002, DIABETOLOGIA, V45, P416, DOI 10.1007/s00125-001-0761-x; BEYER TA, 1986, METABOLISM, V35, P1, DOI 10.1016/0026-0495(86)90178-2; Booth AA, 1996, BIOCHEM BIOPH RES CO, V220, P113, DOI 10.1006/bbrc.1996.0366; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Brignardello E, 1998, J ENDOCRINOL, V158, P21, DOI 10.1677/joe.0.1580021; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Chung SSM, 2003, CURR MED CHEM, V10, P1375, DOI 10.2174/0929867033457322; Crabbe MJC, 1998, PROG RETIN EYE RES, V17, P313, DOI 10.1016/S1350-9462(97)00013-X; Dagher Z, 2004, DIABETES, V53, P2404, DOI 10.2337/diabetes.53.9.2404; Del Corso A, 2000, EXP EYE RES, V71, P515, DOI 10.1006/exer.2000.0906; Dvornik D., 1987, ALDOSE REDUCTASE INH, P221; GORDON OG, 1984, ANAL CHEM, V56, P663; Hamada Y, 1998, DIABETES CARE, V21, P1014, DOI 10.2337/diacare.21.6.1014; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KINOSHITA JH, 1986, AM J OPHTHALMOL, V102, P685, DOI 10.1016/0002-9394(86)90394-6; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LaSelva M, 1996, DIABETOLOGIA, V39, P1263; MCINTOSH LC, 1988, TISSUE CELL, V20, P193, DOI 10.1016/0040-8166(88)90041-9; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NISHIMURA C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P171, DOI 10.1016/0167-4838(91)99006-E; Pomero F, 2001, ACTA DIABETOL, V38, P135, DOI 10.1007/s005920170010; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WONG HC, 1987, INVEST OPHTH VIS SCI, V28, P1767; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21	36	115	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9307	9313		10.1074/jbc.M600418200	http://dx.doi.org/10.1074/jbc.M600418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452468	hybrid			2022-12-25	WOS:000236404700038
J	Humphries, MJ; Limesand, KH; Schneider, JC; Nakayama, KI; Anderson, SM; Reyland, ME				Humphries, MJ; Limesand, KH; Schneider, JC; Nakayama, KI; Anderson, SM; Reyland, ME			Suppression of apoptosis in the protein kinase C delta null mouse in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PKC-DELTA; SALIVARY-GLAND; ACINAR-CELLS; DNA-DAMAGE; PROTEOLYTIC ACTIVATION; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; PRIMARY CULTURE; PROLIFERATION	Protein kinase C (PKC) delta is an essential regulator of mitochondrial dependent apoptosis in epithelial cells. We have used the PKC delta(-/-) mouse to ask if loss of PKC delta protects salivary glands against gamma-irradiation-induced apoptosis in vivo and to explore the mechanism underlying protection from apoptosis. We show that gamma-irradiation in vivo results in a robust induction of apoptosis in the parotid glands of wild type mice, whereas apoptosis is suppressed by greater than 60% in the parotid glands of PKC delta(-/-) mice. Primary parotid cells from PKC delta(-/-) mice are defective in mitochondrial dependent apoptosis as indicated by suppression of etoposide-induced cytochrome c release, poly(ADP-ribose) polymerase cleavage, and caspase-3 activation. Notably, apoptotic responsiveness can be restored by re-introduction of PKC delta by adenoviral transduction. Etoposide and gamma-irradiation-induced activation of p53 is similar in primary parotid cells and parotid glands from PKC delta(+/+) and PKC delta(-/-) mice, indicating that PKC delta functions downstream of the DNA damage response. In contrast, activation of the c-Jun amino-terminal kinase is reduced in primary parotid cells from PKC delta(-/-) cells and in parotid C5 cells, which express a dominant inhibitory mutant of PKC delta. Similarly, c-Jun amino-terminal kinase activation is suppressed in vivo in gamma-irradiated parotid glands from PKC delta(-/-) mice. These studies indicate an essential role for PKC delta downstream of the p53 response and upstream of the c-Jun amino-terminal kinase activation in DNA damage-induced apoptosis in vivo and in vitro.	Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Dent, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Program Cell & Dev Biol, Denver, CO 80262 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyushu University	Reyland, ME (corresponding author), Mailstop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@uchsc.edu			NIDCR NIH HHS [R01 DE015648-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chambers MS, 2004, HEAD NECK-J SCI SPEC, V26, P796, DOI 10.1002/hed.20045; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Eguchi K, 2001, INTERNAL MED, V40, P275, DOI 10.2169/internalmedicine.40.275; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FOX PC, 1987, J AM DENT ASSOC, V115, P581, DOI 10.1016/S0002-8177(87)54012-0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Guchelaar HJ, 1997, SUPPORT CARE CANCER, V5, P281, DOI 10.1007/s005200050075; Ham YM, 2003, J BIOL CHEM, V278, P50330, DOI 10.1074/jbc.M302997200; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Li DW, 2004, MOL CELL BIOL, V24, P3885, DOI 10.1128/MCB.24.9.3885-3893.2004; Li LW, 1999, MOL CELL BIOL, V19, P8547; Limesand KH, 2003, IN VITRO CELL DEV-AN, V39, P170; Limesand KH, 2003, CELL DEATH DIFFER, V10, P345, DOI 10.1038/sj.cdd.4401153; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Muhvic-Urek M, 2006, PHYSIOL RES, V55, P89, DOI 10.33549/physiolres.930739; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; REDMAN RS, 1988, IN VITRO CELL DEV B, V24, P734; REDMAN RS, 1994, IN VITRO CELL DEV, V30, P833; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; STEPHENS LC, 1991, CANCER, V67, P1539, DOI 10.1002/1097-0142(19910315)67:6<1539::AID-CNCR2820670613>3.0.CO;2-Q; Yin YX, 2004, P NATL ACAD SCI USA, V101, P8864, DOI 10.1073/pnas.0403130101; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	51	111	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9728	9737		10.1074/jbc.M507851200	http://dx.doi.org/10.1074/jbc.M507851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16452485	hybrid			2022-12-25	WOS:000236404700085
J	Jiang, JH; Chen, XN; Shen, JL; Wei, YY; Wu, T; Yang, YZ; Wang, HZ; Zong, HL; Yang, JW; Zhang, S; Xie, JH; Kong, XF; Liu, WC; Gu, JX				Jiang, JH; Chen, XN; Shen, JL; Wei, YY; Wu, T; Yang, YZ; Wang, HZ; Zong, HL; Yang, JW; Zhang, S; Xie, JH; Kong, XF; Liu, WC; Gu, JX			beta 1,4-galactosyltransferase V functions as a positive growth regulator in glioma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; OVER-EXPRESSION; BRAIN-TUMORS; CANCER-CELLS; SF-9 CELLS; CYCLIN D3; AKT; ASTROCYTOMA; GENE; TRANSCRIPTION	beta 1,4-galactosyltransferase V ( GalT V; EC 2.4.1.38) can effectively galactosylate the GlcNAc beta 1-->6Man arm of the highly branched N-glycans that are characteristic of glioma. Previously, we have reported that the expression of GalT V is increased in the process of glioma. However, currently little is known about the role of GalT V in this process. In this study, the ectopic expression of GalT V could promote the invasion and survival of glioma cells and transformed astrocytes. Furthermore, decreasing the expression of GalT V in glioma cells promoted apoptosis, inhibited the invasion and migration and the ability of tumor formation in vivo, and reduced the activation of AKT. In addition, the activity of GalT V promoter could be induced by epidermal growth factor, dominant active Ras, ERK1, JNK1, and constitutively active AKT. Taken together, our results suggest that GalT V functioned as a novel glioma growth activator and might represent a novel target in glioma therapy.	Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Minist Educ & Hlth,Key Lab Med Mol Virol, Shanghai 200032, Peoples R China; Shanghai Med Univ, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Minist Educ & Hlth,Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	liu, weicheng/D-4173-2013; zhang, si/AAG-9094-2021; Wang, Hanzhou/G-9814-2012; Zong, Hongliang/F-9366-2013	Wang, Hanzhou/0000-0002-0493-827X; Zong, Hongliang/0000-0002-5855-5733; zhang, Si/0000-0002-5682-4995				ALBINI A, 1987, CANCER RES, V47, P3239; Alemany R, 1999, EXP CELL RES, V252, P1, DOI 10.1006/excr.1999.4623; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; Bacon CL, 2002, J NEUROCHEM, V83, P12, DOI 10.1046/j.1471-4159.2002.01081.x; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; CAVENEE WK, 1992, CANCER, V70, P1788, DOI 10.1002/1097-0142(19920915)70:4+<1788::AID-CNCR2820701621>3.0.CO;2-L; Chen ZP, 1999, CLIN CANCER RES, V5, P4186; Claes P, 2001, BRIT J PHARMACOL, V134, P402, DOI 10.1038/sj.bjp.0704271; Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Hakomori S, 1996, CANCER RES, V56, P5309; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Jetzt A, 2003, CANCER RES, V63, P6697; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Maier D, 1999, CANCER RES, V59, P5479; Nagane M, 1999, JPN J CLIN ONCOL, V29, P527, DOI 10.1093/jjco/29.11.527; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Perkins E, 2003, MOL BRAIN RES, V111, P42, DOI 10.1016/S0169-328X(02)00668-X; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Reuveni H, 2000, J CELL BIOL, V151, P1179, DOI 10.1083/jcb.151.6.1179; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; Sato T, 2004, J BIOL CHEM, V279, P39574, DOI 10.1074/jbc.M405805200; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Sato T, 2001, BIOCHIMIE, V83, P719, DOI 10.1016/S0300-9084(01)01304-9; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xu S, 2002, J EXP CLIN CANC RES, V21, P409; Xu SL, 2001, J CANCER RES CLIN, V127, P502, DOI 10.1007/s004320100246; Yamamoto H, 2000, CANCER RES, V60, P134; Zhu XY, 2003, BIOCHEM BIOPH RES CO, V309, P279, DOI 10.1016/j.bbrc.2003.04.001; Zhu XY, 2005, J BIOL CHEM, V280, P12503, DOI 10.1074/jbc.M413631200	39	30	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9482	9489		10.1074/jbc.M504489200	http://dx.doi.org/10.1074/jbc.M504489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16461357	hybrid			2022-12-25	WOS:000236404700058
J	Pogni, R; Baratto, MC; Teutloff, C; Giansanti, S; Ruiz-Duenas, FJ; Choinowski, T; Piontek, K; Martinez, AT; Lendzian, F; Basosi, R				Pogni, R; Baratto, MC; Teutloff, C; Giansanti, S; Ruiz-Duenas, FJ; Choinowski, T; Piontek, K; Martinez, AT; Lendzian, F; Basosi, R			A tryptophan neutral radical in the oxidized state of versatile peroxidase from Pleurotus eryngii - A combined multifrequency EPR and density functional theory study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FIELD EPR; ELECTRON-PARAMAGNETIC-RESONANCE; I RIBONUCLEOTIDE REDUCTASE; BINDING-SITE MUTANTS; LIGNIN PEROXIDASE; CYTOCHROME-C; MANGANESE PEROXIDASE; CRYSTAL-STRUCTURE; G-TENSOR; PHANEROCHAETE-CHRYSOSPORIUM	Versatile peroxidases are heme enzymes that combine catalytic properties of lignin peroxidases and manganese peroxidases, being able to oxidize Mn2+ as well as phenolic and non-phenolic aromatic compounds in the absence of mediators. The catalytic process ( initiated by hydrogen peroxide) is the same as in classical peroxidases, with the involvement of 2 oxidizing equivalents and the formation of the so-called Compound I. This latter state contains an oxoferryl center and an organic cation radical that can be located on either the porphyrin ring or a protein residue. In this study, a radical intermediate in the reaction of versatile peroxidase from the ligninolytic fungus Pleurotus eryngii with H2O2 has been characterized by multifrequency (9.4 and 94 GHz) EPR and assigned to a tryptophan residue. Comparison of experimental data and density functional theory theoretical results strongly suggests the assignment to a tryptophan neutral radical, excluding the assignment to a tryptophan cation radical or a histidine radical. Based on the experimentally determined side chain orientation and comparison with a high resolution crystal structure, the tryptophan neutral radical can be assigned to Trp(164) as the site involved in long-range electron transfer for aromatic substrate oxidation.	Univ Siena, Dept Chem, I-53100 Siena, Italy; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	University of Siena; Technical University of Berlin; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Swiss Federal Institutes of Technology Domain; ETH Zurich	Pogni, R (corresponding author), Univ Siena, Dept Chem, I-53100 Siena, Italy.	pogni@unisi.it; f.lendzian@tu-berlin.de	Martínez, Angel T/G-7284-2017; Ruiz-Dueñas, Francisco J/L-9837-2015; Basosi, Riccardo/E-7497-2011	Martínez, Angel T/0000-0002-1584-2863; Ruiz-Dueñas, Francisco J/0000-0002-9837-5665; Basosi, Riccardo/0000-0003-1026-7668				Banci L, 2003, J BIOL INORG CHEM, V8, P751, DOI 10.1007/s00775-003-0476-1; Barrows TP, 2004, BIOCHEMISTRY-US, V43, P8826, DOI 10.1021/bi049531g; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; Bleifuss G, 2001, BIOCHEMISTRY-US, V40, P15362, DOI 10.1021/bi010707d; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; Blodig W, 1999, ARCH BIOCHEM BIOPHYS, V370, P86, DOI 10.1006/abbi.1999.1365; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; BRUDVIG GW, 1995, METHOD ENZYMOL, V246, P536; Camarero S, 1996, APPL ENVIRON MICROB, V62, P1070, DOI 10.1128/AEM.62.3.1070-1072.1996; Camarero S, 2000, FEMS MICROBIOL LETT, V191, P37, DOI 10.1111/j.1574-6968.2000.tb09316.x; Camarero S, 1999, J BIOL CHEM, V274, P10324, DOI 10.1074/jbc.274.15.10324; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; Dunford H. B., 1999, HEME PEROXIDASES; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Ehrenberg A., 1967, MAGNETIC RESONANCE B, P221; Engstrom M, 2000, J PHYS CHEM A, V104, P5149, DOI 10.1021/jp0006633; Frisch M.J., 2016, GAUSSIAN 16 REVISION; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; Heinfling A, 1998, FEMS MICROBIOL LETT, V165, P43, DOI 10.1016/S0378-1097(98)00255-9; Heinfling A, 1998, FEBS LETT, V428, P141, DOI 10.1016/S0014-5793(98)00512-2; Heinfling A, 1998, APPL ENVIRON MICROB, V64, P2788; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Johjima T, 1999, P NATL ACAD SCI USA, V96, P1989, DOI 10.1073/pnas.96.5.1989; Kaupp M, 2003, J PHYS CHEM B, V107, P331, DOI 10.1021/jp026596p; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lendzian F, 2005, BBA-BIOENERGETICS, V1707, P67, DOI 10.1016/j.bbabio.2004.02.011; LUBITZ W, 1996, ADV PHOTOSYNTH, V3, P255; MARQUEZ L, 1988, J BIOL CHEM, V263, P10549; Martinez AT, 2002, ENZYME MICROB TECH, V30, P425, DOI 10.1016/S0141-0229(01)00521-X; Martinez MJ, 1996, EUR J BIOCHEM, V237, P424, DOI 10.1111/j.1432-1033.1996.0424k.x; Mester T, 1998, J BIOL CHEM, V273, P15412, DOI 10.1074/jbc.273.25.15412; Mester T, 2001, J BIOL CHEM, V276, P22985, DOI 10.1074/jbc.M010739200; Miller JE, 2003, J AM CHEM SOC, V125, P14220, DOI 10.1021/ja037203i; MOMBOURQUETTE MJ, 1992, J MAGN RESON, V99, P37, DOI 10.1016/0022-2364(92)90153-X; OMalley PJ, 1996, CHEM PHYS LETT, V260, P492, DOI 10.1016/0009-2614(96)00856-1; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Perez-Boada M, 2005, J MOL BIOL, V354, P385, DOI 10.1016/j.jmb.2005.09.047; Perez-Boada M, 2002, ENZYME MICROB TECH, V30, P518, DOI 10.1016/S0141-0229(02)00008-X; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; Pogni R, 2005, BIOCHEMISTRY-US, V44, P4267, DOI 10.1021/bi047474l; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Reece SY, 2005, BBA-BIOENERGETICS, V1706, P232, DOI 10.1016/j.bbabio.2004.11.011; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; Ruiz-Duenas FJ, 1999, MOL MICROBIOL, V31, P223, DOI 10.1046/j.1365-2958.1999.01164.x; Ruiz-Duenas FJ, 2001, BIOCHEM SOC T, V29, P116, DOI 10.1042/BST0290116; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sarkar S, 1997, BBA-PROTEIN STRUCT M, V1339, P23, DOI 10.1016/S0167-4838(96)00201-4; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; Schunemann V, 2004, J BIOL CHEM, V279, P10919, DOI 10.1074/jbc.M307884200; SCHWEIGER A, 1991, ANGEW CHEM INT EDIT, V30, P265, DOI 10.1002/anie.199102651; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Sundaramoorthy M, 1997, J BIOL CHEM, V272, P17574, DOI 10.1074/jbc.272.28.17574; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; Timofeevski SL, 2000, ARCH BIOCHEM BIOPHYS, V373, P147, DOI 10.1006/abbi.1999.1562; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; Villegas JA, 2000, CHEM BIOL, V7, P237, DOI 10.1016/S1074-5521(00)00098-3; Wertz J.E., 1986, ELECT SPIN RESONANCE	75	85	86	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9517	9526		10.1074/jbc.M510424200	http://dx.doi.org/10.1074/jbc.M510424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16443605	hybrid, Green Published			2022-12-25	WOS:000236404700062
J	Shao, BH; Oda, MN; Bergt, C; Fu, XY; Green, PS; Brot, N; Oram, JF; Heinecke, JW				Shao, BH; Oda, MN; Bergt, C; Fu, XY; Green, PS; Brot, N; Oram, JF; Heinecke, JW			Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL; HYPOCHLOROUS ACID; HUMAN NEUTROPHILS; LIPID HYDROPEROXIDES; SULFOXIDE REDUCTASE; HYDROGEN-PEROXIDE; RESIDUES; MECHANISM; SUPEROXIDE	High density lipoprotein (HDL) isolated from human atherosclerotic lesions and the blood of patients with established coronary artery disease contains elevated levels of 3-chlorotyrosine. Myeloperoxidase (MPO) is the only known source of 3-chlorotyrosine in vivo, indicating that MPO oxidizes HDL in humans. We previously reported that Tyr-192 is the major site that is chlorinated in apolipoprotein A-I (apoA-I), the chief protein in HDL, and that chlorinated apoA-I loses its ability to promote cholesterol efflux from cells by the ATP-binding cassette transporter A1 (ABCA1) pathway. However, the pathways that promote the chlorination of specific Tyr residues in apoA-I are controversial, and the mechanism for MPO-mediated loss of ABCA1-dependent cholesterol efflux of apoA-I is unclear. Using site-directed mutagenesis, we now demonstrate that lysine residues direct tyrosine chlorination in apoA-I. Importantly, methionine residues inhibit chlorination, indicating that they can act as local, protein-bound antioxidants. Moreover, we observed near normal cholesterol efflux activity when Tyr-192 of apoA-I was mutated to Phe and the oxidized protein was incubated with methionine sulfoxide reductase. Thus, a combination of Tyr-192 chlorination and methionine oxidation is necessary for depriving apoA-I of its ABCA1-dependent cholesterol transport activity. Our observations suggest that biologically significant oxidative damage of apoA-I involves modification of a limited number of specific amino acids, raising the feasibility of producing oxidation-resistant forms of apoA-I that have enhanced anti-atherogenic activity in vivo.	Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Washington; University of Washington Seattle; Cornell University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu	应, 宁宁/G-9472-2011	Shao, Baohai/0000-0001-8832-2845	NHLBI NIH HHS [HL075381, HL030086] Funding Source: Medline; NIDDK NIH HHS [P30DK017047, DK02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075381, P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROT N, 1984, METHOD ENZYMOL, V107, P352; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Pankhurst G, 2003, J LIPID RES, V44, P349, DOI 10.1194/jlr.M200256-JLR200; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Peng DQ, 2005, J BIOL CHEM, V280, P33775, DOI 10.1074/jbc.M504092200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; SEGREST JP, 1992, J LIPID RES, V33, P141; Shao BH, 2005, J BIOL CHEM, V280, P36386, DOI 10.1074/jbc.M508169200; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	34	168	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9001	9004		10.1074/jbc.C600011200	http://dx.doi.org/10.1074/jbc.C600011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16497665	hybrid			2022-12-25	WOS:000236404700003
J	Wexler-Cohen, Y; Johnson, BT; Puri, A; Blumenthal, R; Shai, Y				Wexler-Cohen, Y; Johnson, BT; Puri, A; Blumenthal, R; Shai, Y			Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SURFACE-PLASMON RESONANCE; MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDE; CELL-FUSION; GP41; AMINO; CONFORMATION; PARDAXIN	Human immunodeficiency virus 1 gp41 folds into a six-helix bundle whereby three C-terminal heptad repeat regions pack in an anti-parallel manner against the coiled-coil formed by three N-terminal heptad repeats (NHR). Peptides that inhibit bundle formation contributed significantly to the understanding of the entry mechanism of the virus. DP178, which partially overlaps C-terminal heptad repeats, prevents bundle formation through an undefined mechanism; additionally it has been suggested to bind other ENV regions and arrest fusion in an unknown manner. We used two structurally altered DP178 peptides; in each, two sequential amino acids were substituted into their D configuration, D-SQ in the hydrophilic N-terminal region and D-LW in the hydrophobic C-terminal. Importantly, we generated an elongated NHR peptide, N54, obtaining the full N-helix docking site for DP178. Interestingly, D-LW retained wild type fusion inhibitory activity, whereas D-SQ exhibited significantly reduced activity. In correlation with the inhibitory data, CD spectroscopy and fluorescence studies revealed that all the DP178 peptides interact with N54, albeit with different stabilities of the bundles. We conclude that strong binding of DP178 N-terminal region to the endogenous NHR, without significant contribution of the C-terminal sequence of DP178 to core formation, is vital for DP178 inhibition. The finding that D-amino acid incorporation in the C terminus did not affect activity or membrane binding as revealed by surface plasmon resonance correlates with an additional membrane binding site, or membrane anchoring role, for the C terminus, which works synergistically with the N terminus to inhibit fusion.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Sect Membrane Struct & Funct, Ctr Canc Res, Nanobiol Program,NIH, Frederick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008303, ZIABC008303] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281, DOI 10.1089/aid.1990.6.1281; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Gerber D, 2004, J BIOL CHEM, V279, P48224, DOI 10.1074/jbc.M403436200; Gerber D, 2004, J MOL BIOL, V339, P243, DOI 10.1016/j.jmb.2004.03.004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LIU S, 2005, J BIOL CHEM; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	33	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9005	9010		10.1074/jbc.M512475200	http://dx.doi.org/10.1074/jbc.M512475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16455666	hybrid			2022-12-25	WOS:000236404700004
J	Ye, H; Abdel-Ghany, SE; Anderson, TD; Pilon-Smits, EAH; Pilon, M				Ye, H; Abdel-Ghany, SE; Anderson, TD; Pilon-Smits, EAH; Pilon, M			CpSufE activates the cysteine desulfurase CpNifS for chloroplastic Fe-S cluster formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; SCAFFOLD PROTEIN; SELENOCYSTEINE LYASE; FERREDOXIN; NIFS; BIOGENESIS; SUFE; GLUTAREDOXIN	CpNifS, a cysteine desulfurase required to supply sulfur for iron-sulfur cluster biogenesis in Arabidopsis thaliana chloroplasts, belongs to a class of NifS-like enzymes with low endogenous cysteine desulfurase activity. Its bacterial homologue SufS is stimulated by SufE. Here we characterize the Arabidopsis chloroplast protein CpSufE, which has an N-terminal SufE-like domain and a C-terminal BolA-like domain unique to higher plants. CpSufE is targeted to the chloroplast stroma, indicated by green fluorescent protein localization and immunoblot experiments. Like CpNifS, CpSufE is expressed in all major tissues, with higher expression in green parts. Its expression is light-dependent and regulated at the mRNA level. The addition of purified recombinant CpSufE increased the V-max for the cysteine desulfurase activity of CpNifS over 40-fold and decreased the K-M toward cysteine from 0.1 to 0.043 mM. In contrast, CpSufE addition decreased the affinity of CpNifS for selenocysteine, as indicated by an increase in the K-M from 2.9 to 4.17 mM, and decreased the V-max for selenocysteine lyase activity by 30%. CpSufE forms dynamic complexes with CpNifS, indicated by gel filtration, native PAGE, and affinity chromatography experiments. A mutant of CpSufE in which the single cysteine was changed to serine was not active in stimulating CpNifS, although it did compete with WT CpSufE. The iron-sulfur cluster reconstitution activity of the CpNifS-CpSufE complex toward apoferredoxin was 20-fold higher than that of CpNifS alone. We conclude that CpNifS and CpSufE together form a cysteine desulfurase required for iron-sulfur cluster formation in chloroplasts.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA	Colorado State University	Pilon, M (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	pilon@lamar.colostate.edu	Pilon-Smits, Elizabeth/AAN-4117-2020	Pilon-Smits, Elizabeth/0000-0003-1205-8798				Abdel-Ghany SE, 2005, PLANT PHYSIOL, V138, P161, DOI 10.1104/pp.104.058602; Alves R, 2004, PROTEINS, V57, P481, DOI 10.1002/prot.20228; Balk J, 2005, TRENDS PLANT SCI, V10, P324, DOI 10.1016/j.tplants.2005.05.002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; Huynen MA, 2005, FEBS LETT, V579, P591, DOI 10.1016/j.febslet.2004.11.111; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; Lezhneva L, 2004, PLANT J, V37, P174, DOI 10.1046/j.1365-313X.2003.01952.x; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; Murashige T., 1962, PHYSIOL PLANTARUM, V15, P437, DOI DOI 10.1111/J.1399-3054.1962.TB08052; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; PILON M, 1995, ADV MOL CELL BIOL, V1, P229; Pilon-Smits EAH, 2002, PLANT PHYSIOL, V130, P1309, DOI [10.1104/pp.102.010280, 10.1104/pp.010280]; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Santos JM, 2002, MOL MICROBIOL, V45, P1729, DOI 10.1046/j.1365-2958.2002.03131.x; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; TAKAHASHI Y, 1991, PLANT PHYSIOL, V95, P97, DOI 10.1104/pp.95.1.97; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; TERRY N, 1986, J PLANT NUTR, V9, P609, DOI 10.1080/01904168609363470; Touraine B, 2004, PLANT J, V40, P101, DOI 10.1111/j.1365-313X.2004.02189.x; Van Hoewyk D, 2005, PLANT PHYSIOL, V139, P1518, DOI 10.1104/pp.105.068684; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Xu XM, 2005, J BIOL CHEM, V280, P6648, DOI 10.1074/jbc.M413082200; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Yabe T, 2004, PLANT CELL, V16, P993, DOI 10.1105/tpc.020511; Ye H, 2005, PLANTA, V220, P602, DOI 10.1007/s00425-004-1388-1; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	43	58	62	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8958	8969		10.1074/jbc.M512737200	http://dx.doi.org/10.1074/jbc.M512737200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16455656	hybrid			2022-12-25	WOS:000236247100076
